<SEC-DOCUMENT>0001655759-25-000139.txt : 20250806
<SEC-HEADER>0001655759-25-000139.hdr.sgml : 20250806
<ACCEPTANCE-DATETIME>20250806171721
ACCESSION NUMBER:		0001655759-25-000139
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250806
DATE AS OF CHANGE:		20250806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		251190685

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arvn-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370,d:b1a91da8aebb40c396ab14e42856cfb2-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:arvn="http://www.arvinas.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-30">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-83" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="f-402">6</ix:nonNumeric><ix:nonNumeric contextRef="c-84" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-403">1</ix:nonNumeric><ix:nonNumeric contextRef="c-85" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-404">1</ix:nonNumeric><ix:nonNumeric contextRef="c-86" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-405">1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>arvn:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>arvn:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2024-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2024-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:RemovalOfCombinationTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentOnFirstAnniversaryOfSigningMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">arvn:StockCompensationAndBonusExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_4"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________ </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________ </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;text-indent:-24.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2025</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38672</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________ </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ARVINAS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________ </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">5 Science Park</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">395 Winchester Ave</ix:nonNumeric>. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Connecticut</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">203</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">535-1456</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________ </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:39.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Nasdaq </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Market LLC</span></ix:nonNumeric></div></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#253;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#253;</ix:nonNumeric></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;1, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">73,417,595</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_16">PART I.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_16">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_22">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_22">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_25">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_25">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.15pt;text-indent:-0.15pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_31">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_31">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_37">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_37">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_40">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_40">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_118">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_118">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_139">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_139">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_139">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_142">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_142">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_142">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_145">PART II.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_145">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_145">42</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_148">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_148">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_148">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_151">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_151">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_151">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_154">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_154">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_154">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_157">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_157">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_154">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_160">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_160">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_160">49</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_163">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib1a91da8aebb40c396ab14e42856cfb2_163">50</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our current and any future clinical trials of vepdegestrant, ARV-393, ARV-102, and ARV-806, including statements regarding the period during which the results of the clinical trials will become available or the forum in which we will present such results;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of, and our ability to obtain, marketing approval of our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to continue market preparations for vepdegestrant and reworking our vepdegestrant collaboration with Pfizer, Inc.;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our belief that ARV-393 can be an attractive combination partner for development of novel therapies for lymphoma;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential receipt of payments based on achievement of milestones under our collaborations, including our collaboration with Pfizer Inc. entered into in July 2021;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential receipt of payments based on the achievement of m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestones related to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> luxdegalutamide</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ARV-766) and future royalties under our license agreement with Novartis Pharma AG; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to pursue research and development of other product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential advantages of our platform technology and our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases and disease targets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential receipt of revenue from future sales of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to manage the transition of a new chief executive officer, once identified;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain arrangements for manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to enter into additional collaborations with third parties;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, and statements regarding our cash, cash equivalents and marketable securities, including their sufficiency to fund planned operating expense and capital expenditure requirements into the second half of 2028;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our belief that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the impact of government laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our competitive position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed on February 11, 2025, and this Quarterly Report on Form 10-Q, particularly in the &#8220;Risk Factors&#8221; sections, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may differ materially from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form 10-Q, references to the &#8220;Company,&#8221; &#8220;Arvinas,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Arvinas, Inc. and its consolidated subsidiaries, except where the context requires otherwise, or any one or more of them as the context may require, and &#8220;board of directors&#8221; refers to the board of directors of Arvinas, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Arvinas name and logo are our trademarks. This Quarterly Report on Form 10-Q contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_19"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_22"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-31">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-32">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-33">746.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-34">938.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-35">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-36">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="f-37">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="f-38">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-39">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-40">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="f-41">889.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-42">1,067.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-43">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-44">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-45">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-46">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-47">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-48">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Assets" scale="6" id="f-49">909.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-50">1,091.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-51">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-52">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-53">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-54">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-55">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-56">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-57">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-58">229.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-59">134.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-60">292.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-61">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-62">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-63">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-64">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-65">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-66">529.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and Contingencies (Note 13)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-68"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-70">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-74">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-77"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-80">73.2</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-82">68.8</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-83">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-84">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-85">1,509.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-86">1,531.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-87">2,118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-88">2,092.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-89">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-90">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-91">609.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-92">561.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="f-93">909.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-94">1,091.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-95">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-96">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-97">211.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-98">101.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-99">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-100">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-101">159.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-102">178.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-103">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-104">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-105">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-106">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-107">93.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-108">125.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-109">211.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-110">233.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-111">71.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-112">48.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-113">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-114">131.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-115">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-116">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-117">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-118">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-119">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-120">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-121">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-122">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-123">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-124">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-125">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-126">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net (loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-127">61.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-128">35.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-129">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-130">104.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-131">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-132">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-133">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-134">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-135">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-136">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-137">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-138">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(Loss) earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-139">0.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-140">0.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-141">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142">1.46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-143">0.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-144">0.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-145">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-146">1.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-147">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-148">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-149">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-150">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-151">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-152">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-153">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-154">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_28"></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Comprehensive (Loss) Income</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-155">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-156">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-157">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-158">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized (loss) gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-159">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-160">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-162">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-163">61.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-164">34.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-165">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-166">105.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.027%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated <br/>Other <br/>Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Total <br/>Stockholders' <br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:115%">For the Three Months Ended June 30, 2025 and 2024</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-167">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-168">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-169">1,448.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-170">2,107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-171">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-172">660.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-173">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-174">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-175">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-176">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-177">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-178">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-179">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-180">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-181">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of June&#160;30, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-182">73.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-183">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-184">1,509.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-185">2,118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-186">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-187">609.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-188">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-189">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-190">1,402.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-191">2,016.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-192">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-193">609.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-194">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-195">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-196">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-197">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-198">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-199">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-200">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-201">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-202">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of June&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-203">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-204">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-205">1,437.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-206">2,041.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-207">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-208">600.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.028%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated <br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Additional <br/>Paid-in <br/>Capital </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated <br/>Other <br/>Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Total <br/>Stockholders' <br/>Equity </span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:115%">For the Six Months Ended June 30, 2025 and 2024</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-209">68.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-210">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-211">1,531.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-212">2,092.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-213">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-214">561.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-215">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-216">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-217">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-218">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-219">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-220">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-221">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of common stock for pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="arvn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="6" id="f-222">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of June&#160;30, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-223">73.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-224">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-225">1,509.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-226">2,118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-227">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-228">609.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-229">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-230">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-231">1,332.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-232">1,995.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-233">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-234">660.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-235">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-236">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-237">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-238">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-239">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-240">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-241">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:21.22pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-242">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-243">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of June&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-244">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-245">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-246">1,437.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-247">2,041.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-248">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-249">600.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-250">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-251">104.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-252">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-253">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net accretion of bond discounts/premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-254">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-255">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-256">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-257">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="f-258">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="f-259">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-260">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-261">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-262">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="6" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="f-264">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="f-265">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-266">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-267">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-269">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-270">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-271">13.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-272">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-273">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-274">211.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-275">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-276">184.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-277">47.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-278">237.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-279">440.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="f-280">437.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="f-281">326.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-282">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-283">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from disposal of property, equipment and leaseholds improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-285">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-286">198.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-287">114.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-288">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-289">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options and issuance of ESPP shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="f-290">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="f-291">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-292">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-293">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-294">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-295">156.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-296">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-297">317.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-298">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-299">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="6" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-301">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-302" continuedAt="f-302-1" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-302-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its subsidiaries (&#8220;Arvinas&#8221; or the "Company&#8221;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-303" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2024 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2024, forming part of Arvinas&#8217; 2024 Annual Report on Form 10-K filed with the SEC on February&#160;11, 2025.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-304" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-305" continuedAt="f-305-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-305-1">The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities" scale="6" id="f-306">861.2</ix:nonFraction> million as of June&#160;30, 2025.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-307" continuedAt="f-307-1" escape="true">Summary of Accounting Pronouncements and Significant Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-308" continuedAt="f-308-1" escape="true"><ix:continuation id="f-307-1" continuedAt="f-307-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recently adopted accounting pronouncements that have had a material impact on the Company's</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, "Disaggregation of Income Statement Expenses," which requires </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-307-2"><ix:continuation id="f-308-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures of certain disaggregated income statement expense captions into specified categories within the footnotes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU No. 2024-03 will have on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the six months ended June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-309" continuedAt="f-309-1" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-311" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-310" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-312">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-313">154.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-315">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-316">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-317">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:continuation id="f-309-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div></ix:continuation></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-318" continuedAt="f-318-1" escape="true">Research Collaboration and License Agreements </ix:nonNumeric></span><ix:continuation id="f-318-1" continuedAt="f-318-2"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-318-2" continuedAt="f-318-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;Vepdegestrant (ARV-471) Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound vepdegestrant (the &#8220;Licensed Products&#8221;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-319">650.0</ix:nonFraction> million. In addition, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" scale="9" id="f-320">1.4</ix:nonFraction> billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-321">400.0</ix:nonFraction> million in regulatory milestones are related to marketing approvals and $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" scale="9" id="f-322">1.0</ix:nonFraction> billion are related to sales-based milestones. There were <ix:nonFraction unitRef="usd" contextRef="c-55" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-323"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-324">no</ix:nonFraction></ix:nonFraction> regulatory or sales-based milestone payments received through June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-318-3" continuedAt="f-318-4"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="arvn:DirectAndIncrementalCostsIncurredToObtainTheContract" scale="6" id="f-325">12.9</ix:nonFraction> million. In accordance with Accounting Standards Codification ("ASC") 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-326">12.9</ix:nonFraction> million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-327">28.0</ix:nonFraction> million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of June&#160;30, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-328">3.8</ix:nonFraction>&#160;million in non-refundable option payments if Pfizer exercises its option for such target protein. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-329">225.0</ix:nonFraction>&#160;million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-330">550.0</ix:nonFraction>&#160;million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were <ix:nonFraction unitRef="usd" contextRef="c-63" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-331">no</ix:nonFraction> sales-based milestone payments or royalties received through June&#160;30, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis License and Asset Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and has all research, development, manufacturing, and commercialization rights with respect to the Company&#8217;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the &#8220;HSR Termination&#8221;). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-332">150.0</ix:nonFraction>&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-7" name="arvn:RevenueRemainingPerformanceObligationContingentPayments" format="ixt:num-dot-decimal" scale="9" id="f-333">1.01</ix:nonFraction>&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> being met, as well as tiered royalties based on worldwide net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, subject to reduction under certain circumstances as provided in the Novartis License Agreement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were <ix:nonFraction unitRef="usd" contextRef="c-65" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-334">no</ix:nonFraction> development, regulatory or commercial milestone payments, or sales-based royalties received through June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company determined the fair value of the assets sold under </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-318-4" continuedAt="f-318-5"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Novartis Asset Agreement to be $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-335">20.0</ix:nonFraction>&#160;million, which was recognized at the time of sale as revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and the fair value of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novartis License Agreement to be $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-336">130.0</ix:nonFraction>&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis also reimbursed the Company for development costs incurred during the technology transfer period, which was recognized as revenue as costs were incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to Novartis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="6" id="f-337">3.0</ix:nonFraction>&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="6" id="f-338">3.0</ix:nonFraction>&#160;million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-339">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license. The Company also received an additional $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-340">12.0</ix:nonFraction> million from Bayer AG from inception through 2023. These payments were recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-341">197.5</ix:nonFraction>&#160;million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-342">490.0</ix:nonFraction>&#160;million in sales-based milestone payments for all designated target</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-73" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-343"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-344">no</ix:nonFraction></ix:nonFraction> development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restated Genentech Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Restated Genentech Agreement&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-345">34.5</ix:nonFraction> million (in addition to $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-346">11.0</ix:nonFraction> million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period, which concluded during the first quarter of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-347">44.0</ix:nonFraction>&#160;million per target protein in development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-348">52.5</ix:nonFraction>&#160;million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-349">60.0</ix:nonFraction>&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were <ix:nonFraction unitRef="usd" contextRef="c-80" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="f-350">no</ix:nonFraction> development, regulatory or commercial milestone payments or royalties received through June&#160;30, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-318-5" continuedAt="f-318-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-351" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the six months ended June&#160;30, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-352">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="f-354">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="f-355">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="f-356">5.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" format="ixt:fixed-zero" scale="6" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-358">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-359">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-360">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-361">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="f-362">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="f-363">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" scale="6" id="f-364">24.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" scale="6" id="f-365">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-366">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-367">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-368">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-369">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="f-371">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="f-372">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="f-373">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-374">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-375">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-376">448.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-377">549.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="f-379">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-380">211.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-381">56.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from new collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" format="ixt:fixed-zero" scale="6" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" scale="6" id="f-383">23.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-384">237.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-385">599.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-386">150.2</ix:nonFraction>&#160;million, an increase in operating expenses of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-387">2.6</ix:nonFraction>&#160;million, an increase in net income of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-388">147.6</ix:nonFraction>&#160;million, and an increase in basic and diluted earnings per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-389">2.04</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-390">2.03</ix:nonFraction>, respectively, for the six months ended June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease in revenue and net income of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-391"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-392">2.5</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and a decrease in basic and diluted earnings per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-393"><ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-394">0.03</ix:nonFraction></ix:nonFraction> for the six months ended June&#160;30, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024 and the six months ended June&#160;30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="f-395" escape="true"><ix:continuation id="f-318-6"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June&#160;30, 2025 totaled $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-396">237.0</ix:nonFraction> million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-397">69.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-398">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-399">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-400">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-401">237.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ib1a91da8aebb40c396ab14e42856cfb2_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-406" continuedAt="f-406-1" escape="true">Marketable Securities and Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="f-406-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-407" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-408">685.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-409">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-410">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-411">686.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-412">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-415">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-416">745.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-417">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-418">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-419">746.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-420">934.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-421">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-422">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-423">935.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-424">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-427">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-428">937.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-429">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-430">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-431">938.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-432" continuedAt="f-432-1" escape="true">Property, Equipment and Leasehold Improvements </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-433" escape="true"><ix:continuation id="f-432-1" continuedAt="f-432-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-434">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-435">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-436">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-437">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-438">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-439">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-440">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-441">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-442">26.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-443">25.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-444">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-445">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-432-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-446">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-447">1.2</ix:nonFraction> million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-448">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-449">2.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-450" continuedAt="f-450-1" escape="true">Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-450-1" continuedAt="f-450-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at June&#160;30, 2025 totaled <ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="f-451">6.9</ix:nonFraction>%. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than December 2029. The leases have a weighted average remaining term of approximately <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-452">4.4</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-453" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-454">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-455">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-456">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-457">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" id="f-458" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-459">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-460">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-461">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment, and in February 2025, the Company entered into a Ninth Amendment to its lease (collectively the &#8220;Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#8220;Building 5 Premises&#8221;). The Building 5 Lease Amendments extended the term of the original lease to December 31, 2029, and expanded the Building 5 Premises to include approximately <ix:nonFraction unitRef="sqft" contextRef="c-12" decimals="-2" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-463">10,900</ix:nonFraction> square feet of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-450-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional laboratory and office space in the first quarter of 2025, resulting in an increase in the Company's ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-464">1.5</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-465" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of June&#160;30, 2025, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="f-466">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-467">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-468">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-469">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-470">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-471">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-472">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-473">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-474" continuedAt="f-474-1" escape="true">Accounts Payable and Accrued Liabilities </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-475" escape="true"><ix:continuation id="f-474-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-476">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-477">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-478">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-479">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-480">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-481">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-482">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-483">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="f-484">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="f-485">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent" scale="6" id="f-486">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent" scale="6" id="f-487">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-488">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-489">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ib1a91da8aebb40c396ab14e42856cfb2_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-490" continuedAt="f-490-1" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="f-490-1" continuedAt="f-490-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-491" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-492">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-493">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-494">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-495">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-496">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-497">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-498">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-499">2.0</ix:nonFraction> million under the 2018 Assistance Agreement in September 2018, of which $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" scale="6" id="f-500">1.0</ix:nonFraction> million was forgiven upon meeting certain employment conditions. Borrowings under the 2018 Assistance Agreement bear an interest rate of <ix:nonFraction unitRef="number" contextRef="c-101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-501">3.25</ix:nonFraction>% per annum, with interest-only payments required for the first <ix:nonNumeric contextRef="c-102" name="arvn:DebtInstrumentInterestPaymentsTerm" format="ixt-sec:durmonth" id="f-502">60</ix:nonNumeric> months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-503">2.0</ix:nonFraction> million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="f-504">7.5</ix:nonFraction>% of the total amount of funding received.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-490-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-505" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of June&#160;30, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="6" id="f-506">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="f-507">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="f-508">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="f-509">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-510">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2025 and 2024, interest expense was <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="f-511"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="f-512"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="f-513"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="f-514">immaterial</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-515" continuedAt="f-515-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended and restated the Equity Distribution Agreement with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStock" scale="6" id="f-516">262.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the six mo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nths </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-517">no</ix:nonFraction> shares were issued under this agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-518">311,850</ix:nonFraction> shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to <ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="f-519">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-520">3,601,429</ix:nonFraction> shares remained available for purchase. During the six months ended June&#160;30, 2025 and 2024, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-521">86,008</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-522">34,515</ix:nonFraction> shares of common stock, respectively, under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-523">4,067,007</ix:nonFraction> shares of common stock; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-524">1,277,181</ix:nonFraction> shares) issued in respect of incentive units granted under the Fourth Amendment to the Company&#8217;s Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-525">4,989,593</ix:nonFraction> shares of the Company&#8217;s common stock, <ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-526">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-527">1,855,723</ix:nonFraction> shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic restructuring plan initiated by the Company in the second quarter of 2025, as further discussed below in Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company modified the vesting terms of certain Restricted Stock Units previously granted to employees. The incremental impact of the modification was fully recognized during the three and six months ended June&#160;30, 2025 as a decrease to compensation expense </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-515-2" continuedAt="f-515-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-528"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-529">1.7</ix:nonFraction></ix:nonFraction>&#160;million. There were no remaining unrecognized compensation expenses related to the modified awards at June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-530">10.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-531">21.6</ix:nonFraction> million, respectively, related to the issuance of incentive awards, including $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-532"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-533">0.2</ix:nonFraction></ix:nonFraction> million related to the 2018 ESPP in each period presented.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-534">25.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-535">40.2</ix:nonFraction> million, respectively, relating to the issuance of incentive awards, including $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-536">0.4</ix:nonFraction> million related to the 2018 ESPP in each period presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-537">60.5</ix:nonFraction> million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately <ix:nonNumeric contextRef="c-118" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-538">1.6</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-539" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the six months ended June&#160;30, 2025 and 2024 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-540">72.1</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-541">80.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-542">72.9</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-543">75.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-121" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-544">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-122" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-545">5.7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-546">5.4</ix:nonNumeric> - <ix:nonNumeric contextRef="c-124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-547">5.5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-548">3.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-549">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-550">3.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-551">4.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-552">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-553">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-554">6.61</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-555">17.70</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-556">24.94</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-557">47.00</ix:nonFraction></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-558" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" format="ixt:num-dot-decimal" scale="0" id="f-559">255,611</ix:nonFraction> shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-560">7,892,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-561">44.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-562">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-563">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-564">2,165,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-565">12.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled/ Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-566">503,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-567">44.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-568">9,553,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-569">37.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-131" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-570">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-571">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and exercisable </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-572">6,195,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-573">45.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-131" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-574">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="6" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and expected to vest </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-576">9,212,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-577">37.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-131" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-578">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-579">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-515-3"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during the six months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-580">12.54</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-581">28.08</ix:nonFraction>, respectively. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-582">no</ix:nonFraction> options exercised during the six months ended June&#160;30, 2025. The total intrinsic value of options exercised during the six months ended June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-583">3.5</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units ("RSUs")</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-584" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" format="ixt:num-dot-decimal" scale="0" id="f-585">170,365</ix:nonFraction> shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-586">2,311,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-587">42.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-588">3,382,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-589">13.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-590">911,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-591">43.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-592">628,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-593">26.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-594">4,153,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-595">21.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSUs granted during the six months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-596">13.98</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-597">44.98</ix:nonFraction>, respectively. The total intrinsic value of RSUs released during the six months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" scale="6" id="f-598">14.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" scale="6" id="f-599">11.4</ix:nonFraction> million, respectively. The total fair value of RSUs vested during the six months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-600">42.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-601">10.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-602" continuedAt="f-602-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-602-1" continuedAt="f-602-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025, the Company recognized income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-603">0.3</ix:nonFraction> million, resulting in an effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-604">0.6</ix:nonFraction>%, as compared to income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-605">0.2</ix:nonFraction> million, resulting in an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-606">0.6</ix:nonFraction>)%, in the same period for 2024. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-607">21.0</ix:nonFraction>% for the three months ended June&#160;30, 2025 and the Company&#8217;s overall effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-608">0.6</ix:nonFraction>% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-609">21.0</ix:nonFraction>% for the three months ended June&#160;30, 2024 and the Company&#8217;s overall effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-610">0.6</ix:nonFraction>)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2025, the Company recognized income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-611">0.2</ix:nonFraction> million, resulting in an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-612">0.9</ix:nonFraction>)%, as compared to income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-613">0.3</ix:nonFraction> million resulting in an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-614">0.3</ix:nonFraction>)% in the same period for 2024. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-615">21.0</ix:nonFraction>% for the six months ended June&#160;30, 2025 and the Company&#8217;s overall effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-616">0.9</ix:nonFraction>)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-617">21.0</ix:nonFraction>% for the six months ended June&#160;30, 2024 and the Company&#8217;s overall effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-618">0.3</ix:nonFraction>)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-602-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; (the &#8220;OBBB Act&#8221;) was enacted into law. The OBBB Act includes changes to U.S. tax with multiple effective dates starting in 2025. These changes include provisions allowing accelerated tax deductions for qualified property and research expenditures. Although the Company does not expect the OBBB Act to have a material impact on its estimated annual effective tax rate in 2025, it continues to assess the impact of the OBBB Act on subsequent periods.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-619" continuedAt="f-619-1" escape="true">(Loss) Earnings Per Common Share </ix:nonNumeric></span></div><ix:continuation id="f-619-1" continuedAt="f-619-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-620" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted (loss) earnings per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-621">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-622">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-623">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-624">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-625">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-626">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-627">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-628">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Number of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-631">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-635">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-637">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-638">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-639">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-640">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Loss) earnings per common share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-641">0.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-642">0.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-643">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-644">1.46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-645">0.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-646">0.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-647">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-648">1.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and six months ended June&#160;30, 2024 gives effect to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants issued in November 2023 which allowed holders to acquire up </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-649">3,422,380</ix:nonFraction> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a nominal exercise price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-650">0.001</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share. As of June&#160;30, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration and the Company issued <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-651">3,422,186</ix:nonFraction> shares of common stock to the holders.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-652" continuedAt="f-652-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three months ended June&#160;30, 2025 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-653">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-654">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-655">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-652-1"><ix:continuation id="f-619-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three and six months ended June&#160;30, 2024 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three and Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-656"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-657">8.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-658"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-659">2.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-660"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-661">10.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-662" continuedAt="f-662-1" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="f-662-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of <ix:nonFraction unitRef="number" contextRef="c-145" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-663">50</ix:nonFraction>%. A <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" scale="-2" id="f-664">15</ix:nonFraction>% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-665">43.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-148" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-666">44.5</ix:nonFraction>% as of June&#160;30, 2025 and 2024, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss of Oerth Bio for the three months ended June&#160;30, 2025 and 2024 totaled $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-667">0.7</ix:nonFraction> million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-668">0.8</ix:nonFraction> million, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net lo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ss of Oerth Bio for the six months ended June&#160;30, 2025 and 2024 totaled $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-669">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-670">1.5</ix:nonFraction> million, res</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment was <ix:nonFraction unitRef="usd" contextRef="c-153" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-671"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-672">zero</ix:nonFraction></ix:nonFraction>. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and six months ended June&#160;30, 2025 and 2024 were immaterial.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-673" continuedAt="f-673-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-673-1" continuedAt="f-673-2"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company entered into an Amended and Restated License Agreement (the &#8220;Amended License Agreement&#8221;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-4" name="arvn:PaymentsForCollaboration" format="ixt:num-dot-decimal" scale="6" id="f-674">14.95</ix:nonFraction>&#160;million to Yale in June 2024, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Collaboration and License Agreements,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the agreements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company made another $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-675">5.0</ix:nonFraction>&#160;million payment to Yale in June 2025 on the first anniversary of signing, which was included in the company's accounts payable and accrued liabilities as of June 30, 2024. Thereafter, the Company will also pay to Yale (1) up to $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-676">15.0</ix:nonFraction>&#160;million if it secures approval of the first and second royalty products (as defined in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-673-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#8220;collaboration products,&#8221; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#8220;meaningfully involved products.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement to pay to Yale a minimum license maintenance royalty totaling $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="arvn:AnnualLicenseFeePayment" format="ixt:num-dot-decimal" scale="6" id="f-677">0.1</ix:nonFraction>&#160;million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first <ix:nonFraction unitRef="product" contextRef="c-159" decimals="INF" name="arvn:NumberOfLicensedProducts" format="ixt-sec:numwordsen" scale="0" id="f-678">two</ix:nonFraction> licensed products for the development of the protein degradation technologies totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="arvn:RequiredMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-679">3.0</ix:nonFraction>&#160;million for the first licensed product and approximately $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="arvn:RequiredMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-680">1.5</ix:nonFraction>&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-681">0.2</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-682">0.5</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_567"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-683" continuedAt="f-683-1" escape="true">Restructuring Activity</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="f-683-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#8217;s workforce by approximately <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-684">33</ix:nonFraction>% across all areas of the Company, as part of the Company&#8217;s decision to streamline operations across the organization and enable the efficient progression of the Company&#8217;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, the restructuring activities were substantially completed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Restructuring Charges</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company recognized restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-685">1.0</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-686">7.4</ix:nonFraction>&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, offset by a reversal of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-687">6.4</ix:nonFraction>&#160;million of non-cash stock compensation and bonus expenses, of which $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-688">0.6</ix:nonFraction>&#160;million is reflected in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-689">0.4</ix:nonFraction>&#160;million is reflected in general and administrative expenses in the accompanying unaudited condensed consolidated financial statements. The Company's restructuring accrual totaled $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-690">2.2</ix:nonFraction>&#160;million as of June 30, 2025.</span></div></ix:continuation><div id="ib1a91da8aebb40c396ab14e42856cfb2_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-691" continuedAt="f-691-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-691-1" continuedAt="f-691-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are organized into <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-692"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-693">one</ix:nonFraction></ix:nonFraction> operating and reportable segment focused on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-806, targeting Kirsten rat sarcoma, or KRAS, G12D for mutated cancers, including pancreatic and colorectal cancers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also generated revenue through the sale of assets based on fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have intra-entity sales or transfers.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><ix:continuation id="f-691-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the operating segment are the same as those described in the Company's </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the year ended December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 2,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Accounting Pronouncements and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as net income (loss). The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-694" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-695">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-696">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-697">211.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-698">101.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-699">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-700">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-701">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-702">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-703">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-704">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-705">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-706">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-707">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-708">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-709">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-710">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806 </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-711">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-712">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-713">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-714">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-715">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-716">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-717">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-718">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-720">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-722">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-723">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-725">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-727">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-728">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-729">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-730">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense<br/>(including stock-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-731">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-732">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-733">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-734">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-735">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-736">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-737">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-738">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-739">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-740">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-741">159.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-742">178.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-743">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-744">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-745">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-746">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-747">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-748">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-749">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-750">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-751">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-752">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-753">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-754">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-755">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-756">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-757">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-758">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-759">61.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-760">35.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-761">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-762">104.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(**)&#160;&#160;&#160;&#160;Includes primarily realized foreign exchange gains/ losses.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-763">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-764">1.2</ix:nonFraction> million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-765">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-766">2.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amount and certainty of cash flows from operations and from outside sources, so as to allow investors to better view our company from management&#8217;s perspective. You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and the related notes and discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed on February&#160;11, 2025. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed on February&#160;11, 2025 and elsewhere in this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. </span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_121"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, degrader platform, we are pioneering the development of protein degradation therapies designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We are currently progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor, or ER, for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer; ARV-393, targeting the B-cell lymphoma 6, or BCL6 protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma, or NHL; ARV-102, targeting the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leucine-rich repeat kinase 2, or LRRK2, protein for the treatment of neurodegenerative disorder</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s; and ARV-806, targeting Kirsten rat sarcoma, or KRAS, G12D for mutated cancers, including pancreatic and colorectal cancers. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our pipeline, which includes an overview of our pivotal trial for vepdegestrant, as well as our clinical and preclinical programs, is summarized below. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><img src="arvn-20250630_g1.jpg" alt="Pipeline Slide.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-1"/></div><div style="text-indent:36pt"><img src="arvn-20250630_g2.jpg" alt="Pivotal trial.jpg" style="height:29px;margin-bottom:5pt;vertical-align:text-bottom;width:95px" id="i-2"/></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">The agents noted in the graph above are currently under investigation; their safety and effectiveness for these investigational uses have not been established.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">Defined terms in graph above, not defined elsewhere: 2L, second-line; AR, androgen receptor; KAT6, lysine acetyltransferase 6.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">Footnotes in graph: a. The trial (NCT04606446) is currently evaluating Pfizer, Inc.&#8217;s KAT6 inhibitor (PF-07248144) in combination with endocrine therapies following cyclin-dependent kinase, or CDK, 4/6 inhibitor treatments; the trial is being operationalized and funded by Pfizer, Inc. and will include a vepdegestrant/KAT6 cohort;  b. Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, or relapsed/refractory mature B cell NHL. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the programs above and our early-stage collaborations, including with Pfizer, Inc., or Pfizer, and Genentech, Inc. and F. Hoffman-La Roche Ltd., or Genentech, we are conducting exploratory research and development work on multiple other undisclosed targets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology Programs: Vepdegestrant and ARV-393</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estrogen Receptor Program: Vepdegestrant</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to harness the body&#8217;s natural protein disposal system to specifically target and degrade the ER for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. We are co-developing vepdegestrant with Pfizer, pursuant to a collaboration agreement that we and Pfizer entered into in July 2021. We granted Pfizer worldwide co-exclusive rights to develop and commercialize vepdegestrant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, vepdegestrant demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a cyclin-dependent kinase, or CDK, 4/6 inhibitor.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Pfizer, have several ongoing clinical trials of vepdegestrant, and Pfizer has a clinical trial which it plans to add a vepdegestrant combination cohort to,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are summarized below. </span></div><div style="margin-top:12pt;text-indent:36pt"><img src="arvn-20250630_g3.jpg" alt="Vep Pipeline.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-3"/></div><div style="margin-top:12pt;text-indent:36pt"><img src="arvn-20250630_g2.jpg" alt="Pivotal trial.jpg" style="height:29px;margin-bottom:5pt;vertical-align:text-bottom;width:95px" id="i-4"/></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">Vepdegestrant is currently under investigation; its safety and effectiveness for these investigational uses have not been established. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">Defined terms in graph above, not defined elsewhere: CDK4i, cyclin-dependent 4 inhibitor.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">Footnotes in graph: a. The trial (NCT04606446) is currently evaluating Pfizer&#8217;s KAT6 inhibitor (PF-07248144) in combination with endocrine therapies following CDK4/6 inhibitor treatments; the trial is being operationalized and funded by Pfizer and will now include a vepdegestrant/KAT6 cohort; b. Studies fully enrolled except for ribociclib combination trial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">VERITAC-2 Clinical Trial and New Drug Application</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we, along with Pfizer, announced positive topline results from the Phase 3 VERITAC-2 clinical trial in the estrogen receptor 1-mutant, or ESR1m, population, and in the second quarter of 2025, we, along with Pfizer announced detailed results from this clinical trial. These detailed results, which are included below, were presented in a late-breaking oral presentation at the American Society of Clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology, or ASCO, 2025 Annual Meeting and were highlighted in the ASCO press briefing and selected for Best of ASCO, and were also simultaneously published in the New England Journal of Medicine. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results from VERITAC-2, in the second quarter of 2025, we and Pfizer submitted a new drug application to the U.S. Food and Drug Administration, or FDA, for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This represents the first NDA submitted for a PROTAC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Design</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 VERITAC-2 clinical trial is a global randomized study evaluating the efficacy and safety of vepdegestrant as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 26 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. The primary endpoint was progression-free survival, or PFS, in the intent-to-treat, or ITT and ESR1 mutation populations as determined by blinded independent central review, or BICR. Overall survival, or OS, was the key secondary endpoint.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Results</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 VERITAC-2 trial met its primary endpoint in the ESR1m population, demonstrating a statistically significant and clinically meaningful improvement in PFS compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population. The trial did not reach statistical significance in improvement in PFS in the ITT population.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Overall survival was not mature at the time of the analysis of data, with less than a quarter of the required number of events having occurred. The trial will continue to assess overall survival as a key secondary endpoint. In the trial, vepdegestrant was generally well tolerated and its safety profile was consistent with what has been observed in previous studies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Detailed results from the Phase 3 VERITAC-2 clinical trial included the following:</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">PFS</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in PFS among ESR1m patients, reducing the risk of disease progression or death by 43% compared to fulvestrant [Hazard Ratio, or HR=0.57 (95% CI 0.42&#8211;0.77); 2-sided P&lt;0.001].</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The median PFS, as assessed by BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investigator-assessed PFS was consistent with the BICR-assessed PFS.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In ESR1m patients, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The trial did not reach statistical significance in improvement in PFS in the ITT population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant [HR=0.83 (95% CI 0.68&#8211;1.02); 2-sided P=0.07].</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Tolerability and Safety Profile</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Vepdegestrant was generally well tolerated in the clinical trial, with a safety profile consistent with what has been observed in previous studies, and mostly low-grade treatment-emergent adverse events, or TEAEs, were reported.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Rates and severity of gastrointestinal adverse events were low with vepdegestrant (nausea, 13.5%; vomiting, 6.4%; diarrhea, 6.4%). Grade 4 TEAEs were reported in five patients (1.6%) in the vepdegestrant arm versus nine&#8239;patients (2.9%) in the fulvestrant arm.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">The three most common TEAEs observed with vepdegestrant were fatigue (26.6%), increased alanine transaminase (ALT) (14.4%) and increased aspartate aminotransferase (AST) (14.4%); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">TEAEs leading to treatment discontinuation occurred in 2.9% of patients taking vepdegestrant versus 0.7% of patients taking fulvestrant.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Other Data Points</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Additional secondary endpoints include clinical benefit rate (&#8220;CBR&#8221;) and objective response rate, or ORR, and duration of response by BICR. In patients with an ESR1 mutation, CBR was 42.1% with vepdegestrant versus 20.2% with fulvestrant [odds ratio 2.88 (95% CI: 1.57&#8211;5.39); nominal P&lt;0.001] and ORR was 18.6% with vepdegestrant versus 4.0% with fulvestrant [odds ratio 5.45 (95% CI: 1.69&#8211;22.73); nominal P=0.001]. The median duration of response was not reached.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that, based on these strong data from VERITAC-2, vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1m setting. Currently, as part of our global collaboration with Pfizer, we and Pfizer plan to present patient reported outcomes data from the VERITAC-2 clinical trial evaluating vepdegestrant versus fulvestrant for previously treated patients with ESR1 mutated- ER+/HER2- advanced breast cancer in the fourth quarter of 2025 at the European Society for Medical Oncology 2025 Congress. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Other Clinical Trials</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second quarter of 2025, we announced that we and Pfizer removed two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan: a first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and a second-line Phase 3 combination trial with a CDK4/6 inhibitor.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in the second quarter of 2025, Pfizer added a vepdegestrant combination cohort to its ongoing Phase 1 clinical trial evaluating Pfizer&#8217;s investigational KAT6 inhibitor in combination with endocrine therapies following CDK4/6 inhibitor treatment. This clinical trial is being operationalized and funded solely by Pfizer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, as part of our global collaboration with Pfizer, we and Pfizer plan to present results of the TACTIVE-N clinical trial in the fourth quarter of 2025 at the European Society for Medical Oncology 2025 Congress. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Pfizer, continue market preparations for vepdegestrant in advance of the prescription drug user fee action date. While we continue to believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1m setting, given our and Pfizer&#8217;s decision to remove the two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan as noted above, we have determined that it is no longer viable for us to build out our commercial infrastructure as we had previously planned and we are in active discussions with Pfizer to revise our collaboration to determine the most efficient path to make vepdegestrant, if approved, available to patients.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hematology Program: ARV-393</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. Deregulation of BCL6 function (e.g., via chromosomal translocation, mutations) may lead to malignant transformation and development of NHL. During B-cell development, tightly controlled BCL6 protein expression regulates more than 600 genes to facilitate rapid B-cell proliferation and tolerance of somatic hypermutation and gene recombination for antibody generation. Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. Prior to the advent of PROTAC technology, the BCL6 protein was considered "undruggable." We believe that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with NHL</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and that current preclinical data suggest that ARV-393 has the potential to be an attractive combination partner for development of novel therapies for lymphoma, including chemo-free combination regimens and/or &#8220;all oral&#8221; treatment options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently enrolling a Phase 1 first-in-human clinical trial of ARV-393 in patients with relapsed/refractory NHL. This is an open-label, multicenter, Phase 1 dose escalation study to evaluate the safety, tolerability and preliminary anti-tumor activity of ARV-393 as a single agent in adult patients with relapsed/refractory NHL. We plan to share preliminary clinical data from this ongoing Phase 1 clinical trial in patients with NHL in the second half of 2025.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second quarter of 2025, we presented preclinical data of ARV-393 in combination with standard of care, or SOC, chemotherapy and biologic agents, as well as oral, investigational small molecule inhibitors in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">high grade and aggressive diffuse large B-cell lymphoma, or DLBCL, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> models at the American Association for Cancer Research Annual Meeting. Based on these preclinical data, in aggressive DLBCL models, ARV-393 showed strong synergistic antitumor activity, including complete regressions, in combination with SOC chemotherapy and biologics, as well as investigational oral small molecule inhibitors. In particular:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, or R-CHOP), induced significantly greater tumor growth inhibition, or TGI, compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin), resulted in tumor regressions and demonstrated significantly stronger TGI compared with either agent alone; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">in preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the second quarter of 2025, we presented new data from preclinical studies of ARV-393 at the European Hematology Association 2025 Congress in Milan, Italy. In these preclinical studies, ARV-393 demonstrated significant single-agent activity in a patient derived xenograft, or PDX, model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type, or nTFHL-AI (which is also known and referred to as AITL), and PDX models of transformed follicular lymphoma, or tFL. In addition, in these preclinical studies, in combination with oral small molecule inhibitors, or SMIs, ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft, or CDX, models of high-grade B-cell lymphoma, or HGBCL, and DLBCL. We believe these preclinical data potentially suggest the broad utility of ARV-393 across NHL subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies including chemotherapy-free approaches. Key findings from these preclinical studies included:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">ARV-393 monotherapy treatment resulted in robust (&#8805;95%) tumor growth inhibition, or TGI, in two PDX models of tFL.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">ARV-393 in combination with five classes of SMIs targeting potentially cooperative oncogenic drivers (tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax) demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to share preclinical data for ARV-393 in combination with glofitamab, an emerging SOC option, in models of aggressive high grade DLBCL in the second half of 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neuroscience Program: ARV-102 </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-102 is our first oral PROTAC protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade LRRK2, which is a large, multidomain scaffolding kinase that plays a critical role in effective endolysosomal trafficking.  Unlike traditional SMIs that only block LRRK2&#8217;s kinase activity, LRRK2 degraders eliminate pathologic scaffolding function, GTPase activity and the kinase activity of LRRK2 implicated in disease.  We believe our LRRK2 degraders are particularly well positioned to be evaluated in two diseases where there are no disease modifying therapies available:  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Parkinson&#8217;s Disease, or PD, where increased LRRK2 expression and activity contributes to neurodegeneration and pathogenesis of PD, and; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Progressive Supranuclear Palsy, or PSP, where genetic variations in LRRK2 are associated with PSP progression. Additionally, we have published data associating the tau pathology of PSP with LRRK2 &#8211;mediated endolysosomal dysfunction. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting two ongoing clinical trials with ARV-102, a Phase 1 clinical trial in healthy volunteers and a Phase 1 clinical trial in patients with PD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed enrollment for the single ascending dose, or SAD, and multiple ascending dose, or MAD cohorts of the ARV-102 Phase 1 clinical trial in healthy volunteers in the first quarter of 2025 and we expect to share final data from the SAD and MAD cohorts of this clinical trial in the second half of 2025. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed enrollment in the SAD cohort of the ARV-102 Phase 1 clinical trial in patients with PD in t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he second q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uarter of 2025. We expect to share initial data from this SAD cohort of the Phase 1 clinical trial in the second half of 2025. Further, in the second quarter of 2025, we received Clinical Trial Application approval in the Netherlands to initiate a multiple dose cohort of the Phase 1 clinical trial in patients with PD, and we expect to initiate enrollment in this cohort in the second half </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2025. We expect to present initial data from the multiple dose cohort in 2026. We also plan to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we presented data from the first-in-human clinical trial of ARV-102 at the 2025 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases, or AD/PD&#8482; 2025, including results from the randomized, double-blind, placebo-controlled SAD cohort, and initial results from the MAD cohort, of the Phase 1 healthy volunteer clinical trial. The ARV-102 Phase 1 clinical trial is designed to assess the safety, pharmacokinetics, and pharmacodynamics of orally administered ARV-102 in healthy male volunteers. This clinical trial is a single-center, randomized, double-blind, placebo-controlled trial evaluating outcomes in both SAD and MAD cohorts. In the SAD cohort, volunteers were randomized three to one, to either placebo or a single dose of ARV-102 (10 mg, 30 mg, 60 mg, 90 mg, 150 mg, or 200 mg) on day 1 with follow-up until day 10. In the MAD cohort, volunteers were randomized to either placebo or a once daily dose of ARV-102 (10 mg, 20 mg, 40 mg, or 80 mg) for 14 days with follow-up until day 28.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the clinical trial, ARV-102 demonstrated substantial reduction of LRRK2 in cerebral spinal fluid, or CSF, with a promising safety/tolerability profile and favorable pharmacodynamic outcomes. Key findings from the clinical trial indicated brain penetration, substantial central and peripheral LRRK2 protein degradation, and signified downstream LRRK2 pathway engagement. The specific data presented at AD/PD&#8482; 2025 are outlined below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Safety Profile</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">At the time of data cutoff (March 13, 2025), the SAD cohort of the Phase 1 clinical trial was completed and the MAD cohort was ongoing. Based on evaluation of the available data from single and multiple oral doses, ARV-102 was well tolerated in healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Of the 47 volunteers across all SAD dose levels, the primary treatment related adverse events were headache and fatigue. Headaches occurred in 17.1% (6/35) of treated individuals compared to 0% (0/12) in placebo controls. Fatigue occurred in 8.6% (3/35) of the treated individuals compared to 25% (3/12) in placebo controls.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Procedural pain associated with the lumbar puncture occurred in 28.6% (10/35) of treated individuals compared to 41.7% (5/12) in placebo controls. Post lumbar puncture syndrome was only observed in the treated cohort, at a rate of 17.1% (6/35).</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">No serious adverse events were reported in either the SAD or MAD cohorts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">ARV-102 Exposure in Plasma and CSF</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-102 exhibited median maximum concentration six hours after oral administration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The area under the concentration-time curve in the first 24 hours post dosing and the maximum plasma concentration increased in a dose-dependent manner and the median terminal plasma half-life was 73 hours.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-102 levels in CSF increased in a dose dependent manner in both the SAD and MAD cohorts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Pharmacodynamic Evaluation</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">At single doses of greater than or equal to 60 mg and repeated doses of greater than or equal to 20 mg, LRRK2 reduction of greater than 90% in peripheral blood mononuclear cells was observed.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-102 at single doses of greater than or equal to 30 mg induced greater than 50% decreases in peripheral phospho-Rab10T73, a LRRK2 substrate and biomarker for downstream LRRK2 activity; data for this endpoint in the MAD cohort is pending.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ARV-102 at single doses of greater than or equal to 30 mg resulted in greater than 90% decrease of bis(monoacylglycerol)phosphate in urine, a biomarker of lysosomal function; data for this endpoint in the MAD cohort is pending.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In CSF, ARV-102 induced dose-dependent LRRK2 reduction, with greater than 50% LRRK2 reduction at single doses of greater than or equal to 60 mg and repeated doses of greater than or equal to 20 mg.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-806</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KRAS, is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. KRAS G12D is a well-characterized oncogenic driver associated with poor prognosis and resistance to standard treatments across several major tumor types, including pancreatic, colorectal, and lung cancers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-806, our PROTAC KRAS G12D degrader, is a potent small molecule degrader of KRAS G12D and is designed to eliminate, rather than inhibit, KRAS G12D. In the preclinical setting, ARV-806 demonstrated high potency and selectivity, with robust antitumor activity through dose-responsive degradation of KRAS G12D in KRAS G12D mutated cancers, including pancreatic and colorectal cancers. ARV-806 bound to both the active and inactive forms of KRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S G12D, achieving potent and durable elimination rather than inhibition of the target in all models tested. In addition, in preclinical studies, ARV-806 achieved </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potency approximately 25 times greater than KRAS inhibitors and 40 times greater than the leading clinical-stage degrader.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed an investigational new drug application with the FDA for ARV-806 in the first quarter of 2025 and received a safe-to-proceed letter from the FDA in the second quarter of 2025. We initiated enrollment in a first-in-human Phase 1 clinical trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations in the second quarter of 2025. We anticipate sharing preclinical data from ARV-806 in the second half of 2025. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Program: Bavdegalutamide (ARV-110)</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavdegalutamide is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the androgen receptor, or AR, for the treatment of men with metastatic castration resistant prostate cancer. Clinical trials for bavdegalutamide (ARV-110-101 and ARV-110-103) were completed in the second quarter of 2025.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing collaborations with third parties and for the manufacture of initial quantities of our product candidates and preparing for commercialization, including by beginning to build a commercial infrastructure. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of assets and equity interests, proceeds from our collaborations and a licensing arrangement, grant funding and debt financing. Since inception through June&#160;30, 2025, we raised approximately $1.7&#160;billion in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross proceeds from the sale of assets and equity interests and the exercise of stock options and had received an aggregate of $913.0&#160;million in payments primarily from collaboration partners and a licensing arrangement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage company, with product candidates in clinical development and other drug discovery activities in the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and our ability to manage our expenses. In April 2025, we committed to and approved a reduction of our workforce by approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33%</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> across all areas of our company, as part of our decision to streamline operations across our organization and enable the efficient progression of our portfolio. The workforce reduction was aimed at reducing internal costs while minimally impacting our targeted clinical stage programs to drive value over the next several years by aligning our operations with long-term program development objective. The workforce reduction was substantially completed by the end of the second quarter of 2025. We incurred net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">restructuring charges of $1.0&#160;million, including $7.4&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, offset by a reversal of $6.4&#160;million of non-cash stock compensation and bonus expenses, in the second quarter of 2025. We expect to achieve annual operating cost savings of $80.0&#160;million, on a run-rate basis. Refer to Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in this Quarterly Report on F</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">orm 10-Q for further details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses and, even in light of our workforce reduction, we expect to continue to incur increasing operating losses for at least the next several years. In addition to any additional costs not currently contemplated due to the events associated with or resulting from our workforce reduction, our ability to achieve profitability and our financial position will depend, in part, on the rate of our future expenditures, potential collaboration revenue, our ability to successfully implement cost avoidance measures and reduce overhead costs and our ability to obtain additional funding. We expect to continue to incur significant expenses associated with: our ongoing and anticipated preclinical and clinical activities, development activities, researc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h activities in oncology, neuroscience and other disease areas, managing our employees and retaining key talent in research, clinical trials, quality and other functional areas, including general and administrative, sales and commercial as we move towards potential commercialization, increased expenses incurred with CMOs to supply us with product for our preclinical and clinical studies, and expenses incurred with contract research organizations, or CROs, for the synthesis of compounds in our preclinical development activities, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as other associated costs including those related to partnering with us on our clinical trial portfolio and the m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anagement of our intellectual property portfolio. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenue from product sales in the near future, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_124"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. Our revenues to date have been generated through research collaborations, a licensing arrangement and an asset sale. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue recognized in the near term will be derived from our current collaboration agreements and licensing arrangement and any additional arrangements that we may enter into in the future. To date, we have not received any development, regulatory and commercial milestone payments or royalties under any of the collaboration agreements or licensing arrangement.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a Collaboration Agreement with Pfizer, or the Vepdegestrant (ARV-471) Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant (ARV-471), or the Licensed Products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Vepdegestrant (ARV-471) Collaboration Agreement, we received an upfront, non-refundable payment of $650.0 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs for the Licensed Products, subject to certain exceptions. Except for certain regions described below, we will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Vepdegestrant (ARV-471) Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products are no longer commercialized or developed for commercialization in such country. Pfizer may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the Vepdegestrant (ARV-471) Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the Vepdegestrant (ARV-471) Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the Vepdegestrant (ARV-471) Collaboration Agreement anywhere in the world during the term of the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">llaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of target proteins, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial target proteins. For each identified target protein, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial target proteins candidates, subject to the stage of research for such target protein. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of our technology license and to fund Pfizer-related research, as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $3.8 million in non-refundable option payments if Pfizer exercises its option for the single target protein remaining under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Transaction </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a transaction, or the Novartis Transaction, including both a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement, with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novart</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is Pharma AG, or Novartis. The Novartis Transaction closed in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024 upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, at which time the Novartis License Agreement and the Novartis Asset Agreement became effective. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and commercialization of luxdegalutamide (ARV-766), our second generation PROTAC AR degrader for patients with prostate cancer. Pursuant to the Novartis Asset Agreement, we sold to Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of and as consideration for entering into the Novartis Transaction, we received a one-time, upfront payment in the aggregate amount of $150.0&#160;million from Novartis. Under the Novartis License Agreement, we are also eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory, and commercial milestones for luxdegalutamide (ARV-766) being met, as well as tiered royalties based upon worldwide net sales of luxdegalutamide (ARV-766), subject to reduction under certain circumstances as provided in the Novartis License Agreement. Novartis announced the recent initiation of two Phase 2 combination clinical trials - one in metastatic castration resistant prostate cancer, and the other is metastatic hormone sensitive prostate cancer - which will both identify recommended Phase 3 doses and, we believe, further validate our ability to develop potentially best-in-class protein degraders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of target proteins, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayer Collaboration Agreement, we and Bayer conducted a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each target protein selected by Bayer. During the term of the Bayer Collaboration Agreement, we were not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any target protein selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront non-refundable payment of $17.5 million and an additional $12.0 million in aggregate from inception through 2023. We were also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated target proteins. In addition, we were eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated, effective August 12, 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech focused on PROTAC targeted protein degrader discovery and research for target proteins based on our proprietary platform technology, other than excluded target proteins as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech had the right to designate up to ten target proteins for further discovery and research utilizing our PROTAC platform technology and also had the right to remove a target protein from the collaboration and substitute a different target protein that was not an excluded target protein at any time prior to us commencing research on such target protein or in certain circumstances following commencement of research by us. The research phase of the collaboration with Genentech has ended. Genentech is no longer able to nominate new target proteins into the collaboration, and there are no active targets in the collaboration for which Arvinas was conducting research activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time we entered into the original agreement with Genentech, we received an upfront payment of $11.0 million, and at the time we entered into the Restated Genentech Agreement, we received an additional $34.5 million in upfront and expansion target payments. We are eligible to receive payments aggregating up to $44.0 million per target protein upon the achievement of specified development milestones; payments aggregating up to $52.5 million per target protein (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60.0 million per PROTAC targeted protein degrader directed against the applicable target protein, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">employee related expenses, including salaries, benefits, stock-based compensation expense and travel, for personnel engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expenses incurred under agreements with third parties, including CROs and other third parties that conduct research, preclinical and clinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs of laboratory supplies and developing preclinical studies and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs incurred in the development of intellectual property; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">third-party licensing fees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee and infrastruc</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ture resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for the three and six mo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nths </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;30, 2025 and 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Program-specific external expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806 </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total program-specific external expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unallocated internal expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense<br/>(including stock-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total unallocated internal expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of vepdegestrant, ARV-102, ARV-393 and ARV-806, and continue to discover and develop additional product candidates. Research and development expenses related to vepdegestrant are shared equally with Pfizer since July 22, 2021, the effective date of the Vepdegestrant (ARV-471) Collaboration Agreement. We may receive reimbursement from, or make payments to, Pfizer to satisfy the cost sharing requirements. These payments are accounted for pursuant to ASC 808, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are recorded as an offset or an increase to research and development expenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot determine with certainty the duration and costs of ongoing and future clinical trials and launch and commercialization preparations of vepdegestrant, ARV-102, ARV-393, ARV-806, or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successfully completing preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receiving marketing approvals, and any related terms, from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">making or maintaining arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales, marketing, market access and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we manage our personnel, including retaining or hiring of key employees, and, as a result of any future need to increase our headcount to support research and development activities relating to our product candidates, develop our infrastructure and build out commercial operations for any potential launch of commercial sales of our products. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with the Nasdaq Stock Market and U.S. Securities and Exchange Commission requirements; director and officer insurance costs; and investor and public relations costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists primarily of interest income from marketable securities and money market accounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2013, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal or state earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $111.0&#160;million of federal net operating loss carryforwards, all of which may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of our taxable income in the year in which carryforwards are used, $129.0 million of state and local net operating loss carryforwards which expire at various dates beginning in 2035, $37.7 million of federal tax credit carryforwards and $22.4 million of state tax credit carryforwards as of December 31, 2024 which expire at various dates beginning in 2040. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to generate federal and state net operating losses and credit carryforwards in 2025 and future periods. The revenue recognition and capitalization of research expenses are timing differences for tax purposes and deferred tax assets were established. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, Arvinas, Inc. had four wholly owned subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_127"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting estimates from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the Securities and Exchange Commission on February&#160;11, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three and Six Months Ended June&#160;30, 2025 and 2024</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of GAAP and Non-GAAP Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Six Months Ended<br/>June 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development reconciliation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: restructuring expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: stock-based compensation expense (*)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">138.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative reconciliation</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: restructuring expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: stock-based compensation expense (*)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">17.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Excludes restructuring related stock-based compensation. See Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the unaudited condensed consolidated financial statements for further details. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended June&#160;30, 2025 totaled $22.4&#160;million, compared to $76.5&#160;million for the three months ended June&#160;30, 2024. The decrease of $54.1&#160;million was primarily due to $45.6&#160;million of decreased revenue from the Novartis License Agreement and the Novartis Asset Agreement, both of which were entered into during the three months ended June 30, 2024 and were completed by </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024 as the technology transfer of our ongoing and planned clinical trials of luxdegalutamide (ARV-766) were transitioned to Novartis. R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer decreased by $6.8&#160;million related to the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan and revenue from the Bayer Collaboration Agreement decreased by $1.6&#160;million as a result of the termination of the Bayer Collaboration Agreement in August 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the six months ended June&#160;30, 2025 totaled $211.2&#160;million, compared to $101.8&#160;million for the six months ended June&#160;30, 2024. The increase of $109.4&#160;million was primarily due to an increase in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer of $161.0&#160;million related primarily to changes in total program cost estimates resulting from the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan, offset by a decrease of $45.6&#160;million of revenue from the Novartis License Agreement and the Novartis Asset Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we completed the technology transfer of our ongoing and planned clinical trials of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Novartis in 2024, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a decrease of $2.8&#160;million of revenue from the Pfizer Research Collaboration Agreement due to changes in estimates of the performance period duration under the agreement resulting from updated research timelines and a decrease of $3.2&#160;million in revenue from the Bayer Collaboration Agreement as a result of the termination of the Bayer Collaboration Agreement in August 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended June&#160;30, 2025 totaled $68.6&#160;million, compared to $93.7&#160;million for the three months ended June&#160;30, 2024. The decrease of $25.1&#160;million was primarily due to a decrease in external expenses of $18.3&#160;million and a decrease in compensation and related personnel expenses of $7.9&#160;million, which are not allocated by program. External expenses include (i) program-specific expenses, which decreased by $15.9&#160;million, primarily driven by decreases in our vepdegestrant (ARV-471) and luxdegalutamide (ARV-766) programs of $10.0&#160;million and $9.5&#160;million, respectively, partially offset by increases in our ARV-102 and ARV-806 programs of $2.1&#160;million and $1.5&#160;million, respectively, and (ii) our non-program specific expenses, which decreased by $2.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP research and development expenses for the three months ended June&#160;30, 2025 totaled $59.5&#160;million, compared to $83.0&#160;million for the three months ended June&#160;30, 2024, excluding $0.6&#160;million of restructuring expense for the three months ended June&#160;30, 2025, and  $8.5&#160;million and $10.7&#160;million of non-cash stock-based compensation expense for the three months ended June&#160;30, 2025 and 2024, respectively. We define non-GAAP research and development expenses as GAAP research and development expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the six months ended June&#160;30, 2025 totaled $159.4&#160;million, compared to $178.0&#160;million for the six months ended June&#160;30, 2024. The decrease of $18.6&#160;million was primarily due to a decrease in external expenses of $10.5&#160;million and a decrease in compensation and related personnel expenses of $9.3&#160;million, which are not allocated by program. External expenses include (i) program-specific expenses, which decreased by $5.9&#160;million, primarily driven by decreases in our luxdegalutamide (ARV-766), vepdegestrant (ARV-471) and bavdegalutamide (ARV-110) programs of $13.2&#160;million, $4.9&#160;million and $2.1&#160;million, respectively, partially offset by increases in our ARV-102, ARV-806, ARV-393 and other programs of $7.3&#160;million, $2.3&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2&#160;million and $2.5&#160;million, respectively, and (ii) our non-program specific expenses, which decreased by $4.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP research and development expenses for the six months ended June&#160;30, 2025 totaled $138.8&#160;million, compared to $155.0&#160;million for the six months ended June&#160;30, 2024, excluding $0.6&#160;million of restructuring expense for the six months ended June&#160;30, 2025, and $20.0&#160;million and $23.0&#160;million of non-cash stock-based compensation expense for the six months ended June&#160;30, 2025 and 2024, respectively. We define non-GAAP research and development expenses as GAAP research and development expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses totaled $25.3&#160;million for the three months ended June&#160;30, 2025, compared to $31.3&#160;million for the three months ended June&#160;30, 2024. The decrease of $6.0&#160;million was primarily due to a decrease in personnel and infrastructure related costs of $4.8&#160;million and professional fees of $2.2&#160;million, partially offset by an increase in costs related to developing our commercial operations of $1.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP general and administrative expenses for the three months ended June&#160;30, 2025 totaled $18.1&#160;million, compared to $20.4&#160;million for the three months ended June&#160;30, 2024, excluding $0.4&#160;million of restructuring expense for the three months ended June&#160;30, 2025, and $6.8&#160;million and $10.9&#160;million of non-cash stock-based compensation expense for the three months ended June&#160;30, 2025 and 2024, respectively. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">define non-GAAP general and administrative expenses as GAAP general and administrative expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses totaled $51.9&#160;million for the six months ended June&#160;30, 2025, compared to $55.6&#160;million for the six months ended June&#160;30, 2024. The decrease of $3.7&#160;million was primarily due to a decrease in personnel and infrastructure related costs of $7.2&#160;million, partially offset by an increase in costs related to developing our commercial operations of $3.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP general and administrative expenses for the six months ended June&#160;30, 2025 totaled $41.3&#160;million, compared to $38.4&#160;million for the six months ended June&#160;30, 2024, excluding  $0.4&#160;million of restructuring expense for the six months ended June&#160;30, 2025, and $10.2&#160;million and $17.2&#160;million of non-cash stock-based compensation expense for the six months ended June&#160;30, 2025 and 2024, respectively. We define non-GAAP general and administrative expenses as GAAP general and administrative expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income totaled $10.0&#160;million for the three months ended June&#160;30, 2025, compared to $13.5&#160;million for the three months ended June&#160;30, 2024. The decrease of $3.5&#160;million was primarily due to a decrease in interest income of $3.3&#160;million on our marketable securities and an increase in realized foreign exchange losses of $0.2&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income totaled $21.6&#160;million for the six months ended June&#160;30, 2025, compared to $27.5&#160;million for the six months ended June&#160;30, 2024. The decrease of $5.9&#160;million was primarily due to a decrease in interest income of $5.7&#160;million on our marketable securities and an increase in realized foreign exchange losses of $0.2&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit totaled $0.3&#160;million for the three months ended June&#160;30, 2025, compared to an income tax expense of $0.2&#160;million for the three months ended June&#160;30, 2024. The current and prior income tax totals were driven by the effect of equity compensation and the valuation allowance recorded against the full amount of our net deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit totaled $0.2&#160;million for the six months ended June&#160;30, 2025, compared to an income tax expense of $0.3&#160;million for the six months ended June&#160;30, 2024. The current and prior year income tax totals were driven by the effect of equity compensation and the valuation allowance recorded against the full amount of our net deferred tax assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Information </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the non-GAAP financial measures non-GAAP research and development expense and non-GAAP general and administrative expense, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.  </span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_136"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sales of assets and equity interests, proceeds from our collaborations and a license arrangement, grant funding and debt financing. Since inception </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through June&#160;30, 2025, we had received an aggregate of $913.0&#160;million in payments from collaboration partners and a licensing arrangement, grant funding and forgivable and partially forgivable loans from the State of Connecticut, and raised approximately $1.7&#160;billion in gross proceeds from the sale of assets and equity interests, and the exercise of stock options, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">October 2018: completion of our initial public offering in which we issued and sold an aggregate of 7,700,482 shares of common stock, for aggregate gross proceeds of $123.2 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">July 2019: sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">November 2019: completion of a follow-on offering in which we issued and sold 5,227,273 shares of common stock for aggregate gross proceeds of $115.0 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September &#8211; December 2020: sale of 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $65.6 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">December 2020: completion of a follow-on offering in which we issued and sold 6,571,428 shares of common stock for aggregate gross proceeds of $460.0 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September 2021: issuance of 3,457,815 shares of common stock to Pfizer for aggregate gross proceeds of $350.0 million;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">July - September 2023: sale of 1,449,275 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $37.2 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">November 2023: sale of 12,963,542 shares of common stock and pre-funded warrants to purchase 3,422,380 shares of common stock in a private placement for aggregate gross proceeds of $350.0 million before fees and expenses; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">April 2024: sale of AR-V7 to Novartis under the Novartis Asset Agreement for $20.0 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we amended and restated the Equity Distribution Agreement with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Piper Sandler &amp; Company and Cantor Fitzgerald &amp; Co.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to which we may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$262.8 million of the common stock registered under our universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the six months ended June&#160;30, 2025, no shares were issued under the amended and restated agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, restricted cash and marketable securities totaled $861.2 million and $1.0 billion as of June&#160;30, 2025 and December&#160;31, 2024, respectively. We had an outstanding loan balance of $0.7 million and $0.8 million as of June&#160;30, 2025 and December&#160;31, 2024, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(184.3)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(47.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137.1)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">198.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(114.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">313.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(156.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">171.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June&#160;30, 2025 increased by $137.1 million, compared with the six months ended June&#160;30, 2024, primarily due to a decrease in deferred revenue of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$261.3 million, driven by changes in total Vepdegestrant (ARV-471) Collaboration Agreement program cost estimates resulting from the removal of two Phase 3 combination trials from the development plan, a decrease in non-cash charges of $9.7 million, as well as a decrease in accounts payable and accrued liabilities of $3.7 million, partially offset by an increase in our net income of $126.3 million and a decrease in accounts receivable of $5.2 million. The change in non-cash charges was primarily due to a decrease in stock-based compensation of $14.9 million and depreciation and amortization expense of $0.9 million, partially offset by net accretion of bond discounts/premiums of $3.9 million and the amortization of costs to obtain a contract of $2.0 million, related to the changes in total Vepdegestrant (ARV-471) Collaboration Agreement noted above.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash from investing activities for the six months ended June&#160;30, 2025 increased by $313.0 million, compared with the six months ended June&#160;30, 2024, primarily due to a net increase in maturities over a net decrease in purchases of marketable securities of $313.9 million, partially offset by an increase in purchases of equipment and leasehold improvements of $0.8 million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash from financing activities for the six months ended June&#160;30, 2025 decreased by $4.6 million, compared with the six months ended June&#160;30, 2024, primarily due to decreased proceeds from the exercise of stock options and issuance of ESPP shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. Even following our workforce reduction, where we expect to recognize cost savings, we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue our ongoing and planned clinical trials of our product candidates, including vepdegestrant, for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer, ARV-102, our PROTAC protein degrader designed to target the LRRK2 protein, ARV-393, our </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROTAC protein degrader designed to target the BCL6 protein, and ARV-806, our PROTAC protein degrader designed to target KRAS G12D for mutated cancers; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">progress additional PROTAC protein degrader programs into IND- or CTA-enabling studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make decisions with respect to our personnel, including retention or future hiring of key employees, and establishment of a sales, marketing, market access, and distribution infrastructure to launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make decisions with respect to our infrastructure and capabilities, including to support our operations as a public company and our research, product development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make or maintain arrangements with third-party manufacturers, or establish manufacturing capabilities, for both clinical and commercial supplies of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">expand, maintain and protect our intellectual property portfolio.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and marketable securities totaling approximately $861.2 million as of June&#160;30, 2025. We believe that our cash, cash equivalents and marketable securities as of June&#160;30, 2025 will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of 2028. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs and results of our ongoing and planned clinical trials of vepdegestrant ARV-102, ARV-393, and ARV-806;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our collaborations, including with Pfizer and Genentech;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, or enter into license, marketing and royalty arrangements, and similar transactions for the development or commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations, including with Pfizer and Genentech and our out-license to Novartis, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an additional assistance agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space. We borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">damages of 7.5% of the total amount of funding received. As of June&#160;30, 2025, $0.7 million remains outstanding under the 2018 Assistance Agreement.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and marketable securities. Interest income earned on these assets totaled $22.0&#160;million and $27.6&#160;million for the six months ended June&#160;30, 2025 and 2024, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of June&#160;30, 2025, our cash equivalents consisted of bank deposits and money market funds, and our marketable securities included interest-earning securities. Our outstanding debt totaled $0.7 million and $0.8&#160;million as of June&#160;30, 2025 and December&#160;31, 2024, respectively, and carries a fixed interest rate of 3.25% per annum.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_142"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended June&#160;30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business and regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material litigation or legal proceedings.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties discussed in &#8220;Part I, Item 1A, Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed with the U.S. Securities and Exchange Commission, or SEC, on February&#160;11, 2025, together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. New or revised risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. The risk factor disclosures in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 are qualified by the information that is described in this Quarterly Report on Form 10-Q. If any of the risks in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 actually occur, our business, prospects, operating results and financial condition could suffer materially. In such an event, the trading price of our common stock could decline and you might lose all or part of your investment. The new and revised risks described below and the risks described in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">New Risk Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risks included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, the following risks may also affect our business:</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cost savings plan and the associated workforce reduction implemented in April 2025 may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, we committed to and approved a reduction in our workforce by approximately 33% across all areas of our company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company&#8217;s portfolio. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our cost savings plan and associated workforce reduction due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from our cost savings plan and associated workforce reduction, our operating results and financial condition would be adversely affected. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our cost savings plan may be disruptive to our operations, including conducting clinical trials and potentially commercializing our product candidates, including vepdegestrant, which could affect our ability to generate product revenue. In addition, our reductions in workforce could yield unanticipated consequences, such as attrition beyond planned staff reductions, or disruptions in our day-to-day operations. Our workforce reduction could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing, if approved, our product candidates, including vepdegestrant, ARV-393, ARV-102, and ARV-806, in the future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the U.S. Food and Drug Administration, or FDA, and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">development program and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory agencies in foreign jurisdictions, such as the European Medicines Agency, or EMA, play an important role in the development of our product candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including investigational new drug applications, or INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted, then correspondingly our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the loss of FDA leadership and personnel could lead to disruptions and delays in FDA guidance, review and approval of our product candidates. Pursuant to President Trump's Executive Order, or E.O., 14210, &#8220;Implementing the President&#8217;s &#8216;Department of Government Efficiency&#8217; Workforce Optimization Initiative,&#8221; the Secretary of Health and Human Services, or HHS, announced on March 27, 2025, a reorganization and reduction in force, or RIF, across the Department of HHS of approximately 20,000 employees (82,000 to 62,000), with FDA&#8217;s workforce of approximately 20,000 to decrease by 3,500 full-time employees. Shortly thereafter, thousands of employees at the FDA were fired on April 1, 2025. Subsequently, the FDA indicated that roughly a quarter of those employees who received RIF notices had been reinstated. On July 14, 2025, following litigation reaching the U.S. Supreme Court, the administration began to carry out these layoffs across HHS, including the FDA. There are also ongoing deliberations within the administration and Congress over potentially substantial proposed cuts to the overall budget for HHS and funding of the FDA for the 2026 federal fiscal year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the FDA&#8217;s review of marketing applications and other activities for new drugs and biologics is largely funded through the user fee program established under the Prescription Drug User Fee Act, or PDUFA, it remains unclear how the administration&#8217;s RIF and budget cuts will impact this program and the ability of the FDA to provide guidance and review our product candidates in a timely manner. For example, while the FDA RIF did not reportedly specifically target FDA reviewers, many operations, administrative and policy staff that help support such reviews were affected and those losses could lead to delays in PDUFA reviews and related activities. As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources. In addition, while currently unclear, there is a risk that the RIF and budget cutbacks could threaten the integrity of the PDUFA program itself. That is because, for the FDA to obligate user fees collected under PDUFA in the first place, a certain amount of non-user fee appropriations must be spent on the process for the review of applications plus certain other costs during the same fiscal year. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also substantial uncertainty as to how regulatory reform measures being implemented by the Trump Administration across the government will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office, the President has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. These include E.O. 14192, &#8220;Unleashing Prosperity Through Deregulation,&#8221; January 31, 2025; E.O. 14212, &#8220;Establishing the President&#8217;s Make America Healthy Again Commission,&#8221; February 13, 2025; and E.O. 14219, Ensuring Lawful Governance and Implementing the President&#8217;s &#8216;Department of Government Efficiency&#8221; Deregulatory Initiative,&#8221; February 21, 2025. If these or other orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, actions by the U.S. government have significantly disrupted the operations of U.S. government agencies such as the National Institutes of Health, National Science Foundation, Centers for Disease Control and Prevention, and FDA, which have traditionally provided funding for basic research, research and development, and clinical testing. These U.S. government actions have included, among other things, suspending, terminating and withholding of disbursements of funds owed under ongoing contracts, grants, and other financial assistance agreements; declining to continue multi-year research projects for additional annual budget periods; canceling or delaying solicitations for new contract, grant and other financial assistance awards; canceling or delaying proposal evaluation processes and issuance of such new awards; substantially reducing federal agency staff responsible for managing contract and financial assistance programs; eliminating agency information and resources for facilitating research activity; delaying or terminating federal agency procedures for authorizing international transactions; initiating aggressive enforcement actions that may disrupt the operations of major research universities that are significant contributors to life sciences research in the U.S., and threatening access to federal agency contracts and other funding awards based on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies&#8217; otherwise lawful corporate policies and choice of counsel. These U.S. government actions could, directly or indirectly, significantly disrupt, delay, prevent, or increase the costs of our research and product commercialization programs, including our ability to develop new product candidates, conduct clinical trials, implement research collaborations with other companies or institutions, and obtain approvals to market and sell new products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, disruptions at the FDA and other government agencies may result from public health events similar to the COVID-19 pandemic. For example, during the pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development programs or delay the agency&#8217;s review and processing of our regulatory submissions, including INDs and new drug applications or biologic license applications, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Amended Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks listed below, which were included in our Annual Report on Form 10-K for the year ended December 31, 2024, are replaced in their entirety by the following. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses totaled $198.9 million, $367.3 million and $282.5 million for the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, we had an accumulated deficit of $1,531.6 million. Although we had income of $21.7&#160;million for the six months ended June 30, 2025, we have historically incurred losses, and expect to continue to incur losses in the future.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and have financed our operations primarily </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through sales of our assets and equity interests, proceeds from our collaborations, grant funding and debt financing. We are still in the early stages of development of our product candidates, and we have not completed development of any product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve profitability also depends on our ability to manage our expenses. For example, in April 2025, we committed to and approved a reduction in our workforce by approximately 33% across all areas of our company, as part of our decision to streamline operations across the organization and enable the efficient progression of our portfolio, which workforce reduction was substantially completed by the end of the second quarter of 2025. Additionally, the workforce reduction could impact our operations, which could affect our ability to generate future revenue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. In addition to any additional costs not currently contemplated due to events associated with or resulting from the workforce reduction noted above, our ability to achieve profitability and our financial position will depend, in part, on the rate of our future expenditures, on product revenue, if any, collaboration revenue, if any, and our ability to obtain additional funding. We expect to continue to incur significant expenses and anticipate that our expenses will increase substantially if and as we:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue our ongoing and planned clinical trials of our product candidates, including vepdegestrant, for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer, ARV-102, our PROTAC protein degrader designed to target the LRRK2 protein, ARV-393, our PROTAC protein degrader designed to target the BCL6 protein, and ARV-806, our PROTAC protein degrader designed to target KRAS G12D for mutated cancers; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">progress additional PROTAC protein degrader programs into IND- or CTA-enabling studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make decisions with respect to our personnel, including retention or future hiring of key employees, and establishment of a sales, marketing, market access, and distribution infrastructure to launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make decisions with respect to our infrastructure and capabilities, including to support our operations as a public company and our research, product development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make or maintain arrangements with third-party manufacturers, or establish manufacturin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g capabilities, for both clinical and commercial supplies of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand, maintain and protect our intellectual property portfolio.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our expenses could increase beyond our expectations if we are required by the FDA, EMA, or other regulatory authorities to perform trials in addition to those that we currently expect or anticipate, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our current or future product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to continue to increase substantially in connection with our ongoing activities, particularly as we continue our ongoing and initiate our planned clinical trials of vepdegestrant, ARV-393, ARV-102 and ARV-806, advance our other oncology programs and neurodegenerative programs, and continue research and development and initiate additional clinical trials of and potentially seek marketing approval for our lead programs and our other product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We continue to incur significant costs associated with operating as a public company. In addition, we will incur certain costs in connection with our reduction in workforce, and may incur additional costs not currently contemplated due to events associated with or resulting from the reduction in workforce and the charge that we expect to incur in connection with the workforce reduction is an estimate and subject to a number of assumptions, and actual results may differ materially. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms or not at all, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had cash, cash equivalents and marketable securities totaling approximately $861.2 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June&#160;30, 2025. Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of June&#160;30, 2025 will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of 2028. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs and results of our ongoing and planned clinical trials of vepdegestrant, ARV-102, ARV-393, and ARV-806;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our collaborations, including with Pfizer and Genentech;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, or enter into license, marketing and royalty arrangements, and similar transactions for the development or commercialization of our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. For example, though we have since out-licensed JSC462 (previously luxdegalutamide (ARV-766) to Novartis and completed our clinical trials for bavdegalutamide, in 2023, we announced that we planned to prioritize the initiation of a Phase 3 clinical trial with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">metastatic castration resistant prostate cancer</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> instead of the previously planned Phase 3 clinical trial for bavdegalutamide. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our April 2025 workforce reduction may cause us to reprioritize our portfolio and evaluate future strategic decisions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, marketing or other royalty arrangements or similar transactions in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and our ability to manage the search for and appointment of a new chief executive officer, as well as our ability to attract, train, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. Although we have offer letters or employment agreements with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, sales, marketing and market access personnel has been and will continue to be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. For example, in July 2025, we announced that our chairperson, president and chief executive officer notified us of his plans to retire from his role as our president and chief executive officer following the search for, and the appointment of, a new chief executive officer. In addition, in June 2025, we announced that our president of research and development notified us of his retirement. Any significant leadership change or executive management transition, such as our transition to a new chief executive officer, once identified, involves inherent risk and can be difficult to manage. Initially, such changes could be disruptive to our daily operations or relationships with employees and collaborators, make it more difficult to hire and retain key employees or impact our public or market perception, any of which could have a negative impact on our business or share price. In addition, management transitions inherently cause some loss of institutional knowledge, which could negatively affect strategy and operation execution during the transitional phase. Management transitions may also create uncertainty and involve a diversion of resources and management attention, which could negatively impact our ability to operate effectively or execute our strategies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to grow the size of our organization in the future based on how our organization evolves and managing future growth will involve implementation and improvement of our managerial, operational and financial systems and procedures and recruitment and training of additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, attracting or replacing executive officers and key employees, consultants and advisors may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. For example, we may have difficulty identifying and attracting a qualified candidate to serve as our new chief executive officer which may materially impact our corporate strategy and business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our April 2025 workforce reduction could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. In addition, we may not be able to retain our existing employees or hire new employees quickly enough to meet our needs. At the same time, we may face high turnover, requiring us to expend time and resources to source, train and integrate new employees. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we offer remote and hybrid work arrangements, allowing us to seek talent from outside our New Haven headquarters area, we still may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Any or all of these competing factors may limit our ability to continue to attract and retain high </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quality personnel, which could negatively affect our ability to successfully develop and commercialize our investigational products and to grow our business and operations as currently contemplated.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. These consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract, train, retain and motivate high quality personnel, our ability to pursue our corporate growth strategy will be limited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income, sales, use or other tax laws, statutes, rules, or regulations could be enacted or amended at any</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">time, which could affect our business or financial condition, including causing potentially adverse impacts to our effective tax rate, tax liabilities, and cash tax obligations. For example, the Inflation Reduction Act, or IRA, was signed into law in August 2022, and the One Big Beautiful Bill Act, or OBBB Act, was signed into law in July 2025. The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded corporations. The 1% excise tax generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. The OBBB Act contains numerous tax provisions that we are currently in the process of evaluating. While at this time, the OBBB Act is not expected to have a material impact on our business or financial condition, this could change in the future and we will continue to assess the impact of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> OBBB Act on subsequent periods.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The recent changes under the OBBB Act include tax rate extensions and changes to the business interest deduction limitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and amortization of foreign research and development expenditures), the bonus depreciation deduction rules, and the international tax framework. Regulatory guidance under the IRA, the OBBB Act, and other tax-related legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the IRA, the OBBB Act and additional tax legislation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deleted Risk Factor</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factor included in our Annual Report on Form 10-K for the year ended December 31, 2024 "</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." is hereby deleted in its entirety. </span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Unregistered Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act during the three months ended June&#160;30, 2025.</span></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director and Officer Trading Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-767"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-768">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-769"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-770">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575923000073/exhibit31-secondamendeda.htm">Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on June 21, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101-iansconsultin.htm">Consulting Agreement, dated June 6, 2025, by and between Arvinas Operations, Inc. and Ian Taylor, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20250630x10qex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20250630x10qex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20250630x10qex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20250630x10qex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101). </span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><div id="ib1a91da8aebb40c396ab14e42856cfb2_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib1a91da8aebb40c396ab14e42856cfb2_10">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Houston, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">John Houston, Ph.D.</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">President and Chief Executive Officer</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Andrew Saik</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Andrew Saik</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer  <br/>(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vice President and Chief Accounting Officer <br/>(Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-iansconsultin.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit101-iansconsultin</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit101-iansconsultin001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-iansconsultin009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-iansconsultin009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>arvn-20250630x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i32cdcec90a5045cc8eec9c9491b42a56_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Houston, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;6, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>arvn-20250630x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieab3b14657cc460f9cbd1a700e6d2c55_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew Saik, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;6, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Saik</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>arvn-20250630x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib87ccbe66ebc4218a29d47f2f2ffb282_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;6, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>arvn-20250630x10qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iad3f64ac739a4e098a983cc306807d78_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;6, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Saik</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arvn-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arvinas.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPronouncementsandSignificantAccountingPolicies" roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreements" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements">
        <link:definition>9952158 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>9952159 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovements" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements">
        <link:definition>9952160 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilities" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities">
        <link:definition>9952161 - Disclosure - Right-of-Use Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>9952162 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.arvinas.com/role/LongTermDebt">
        <link:definition>9952163 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.arvinas.com/role/Equity">
        <link:definition>9952164 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arvinas.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerCommonShare" roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShare">
        <link:definition>9952166 - Disclosure - (Loss) Earnings Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://www.arvinas.com/role/EquityMethodInvestments">
        <link:definition>9952167 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arvinas.com/role/CommitmentsandContingencies">
        <link:definition>9952168 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivity" roleURI="http://www.arvinas.com/role/RestructuringActivity">
        <link:definition>9952169 - Disclosure - Restructuring Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.arvinas.com/role/SegmentInformation">
        <link:definition>9952170 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies" roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables" roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTables" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables">
        <link:definition>9955513 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsTables" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables">
        <link:definition>9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesTables" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables">
        <link:definition>9955516 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.arvinas.com/role/LongTermDebtTables">
        <link:definition>9955518 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.arvinas.com/role/EquityTables">
        <link:definition>9955519 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerCommonShareTables" roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareTables">
        <link:definition>9955520 - Disclosure - (Loss) Earnings Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.arvinas.com/role/SegmentInformationTables">
        <link:definition>9955521 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>9955522 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails">
        <link:definition>9955523 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>9955524 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails">
        <link:definition>9955525 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
        <link:definition>9955526 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
        <link:definition>9955526 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsDetails" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails">
        <link:definition>9955527 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
        <link:definition>9955528 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>9955529 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
        <link:definition>9955530 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails">
        <link:definition>9955531 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>9955532 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>9955533 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955533 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9955534 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>9955535 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>9955536 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails">
        <link:definition>9955537 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails">
        <link:definition>9955538 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
        <link:definition>9955539 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofStockOptionActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails">
        <link:definition>9955540 - Disclosure - Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofRestrictedStockDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails">
        <link:definition>9955541 - Disclosure - Equity - Summary of Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesDetails">
        <link:definition>9955542 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails" roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails">
        <link:definition>9955543 - Disclosure - (Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerCommonShareAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails">
        <link:definition>9955544 - Disclosure - (Loss) Earnings Per Common Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails">
        <link:definition>9955545 - Disclosure - (Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails">
        <link:definition>9955546 - Disclosure - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955547 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivityDetails" roleURI="http://www.arvinas.com/role/RestructuringActivityDetails">
        <link:definition>9955548 - Disclosure - Restructuring Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9955549 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationFinancialInformationDetails" roleURI="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails">
        <link:definition>9955550 - Disclosure - Segment Information - Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssets" abstract="false" name="CollaborationContractAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" abstract="false" name="ProceedsFromMaturitiesOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" abstract="true" name="ResearchCollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" abstract="true" name="ResearchCollaborationAndLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PfizerIncorporationMember" abstract="true" name="PfizerIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_NovartisPharmaAGMember" abstract="true" name="NovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" abstract="true" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryAndSalesBasedMilestonesMember" abstract="true" name="RegulatoryAndSalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OptionPaymentsToLicenseAgreementMember" abstract="true" name="OptionPaymentsToLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonePaymentsMember" abstract="true" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchFundingPaymentsMember" abstract="true" name="ResearchFundingPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RemovalOfCombinationTrialsMember" abstract="true" name="RemovalOfCombinationTrialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_UpdatedResearchTimelinesMember" abstract="true" name="UpdatedResearchTimelinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" abstract="true" name="ResearchCollaborationAndLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" abstract="false" name="DirectAndIncrementalCostsIncurredToObtainTheContract" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_RevenueRemainingPerformanceObligationContingentPayments" abstract="false" name="RevenueRemainingPerformanceObligationContingentPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrent" abstract="false" name="AccountsPayableContractBalancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentAdditions" abstract="false" name="AccountsPayableContractBalancesCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentPayments" abstract="false" name="AccountsPayableContractBalancesCurrentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" abstract="true" name="ChangeInCollaborationContractAssetAndOtherAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CapitalizedContractCostAmortizationDuringPeriod" abstract="false" name="CapitalizedContractCostAmortizationDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PercentageOfIncrementalBorrowingForLeasePayments" abstract="false" name="PercentageOfIncrementalBorrowingForLeasePayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" abstract="true" name="SupplementalNonCashInformationRelatedToLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" abstract="false" name="AccruedGeneralAndAdministrativeAndCommercialCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndEighteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DebtInstrumentLoanForgiveness" abstract="false" name="DebtInstrumentLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DebtInstrumentInterestPaymentsTerm" abstract="false" name="DebtInstrumentInterestPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_PercentageOfLiquidatedDamages" abstract="false" name="PercentageOfLiquidatedDamages" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_PiperSandlerAndCantorMember" abstract="true" name="PiperSandlerAndCantorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MaximumAggregateOfferingPriceOfCommonStock" abstract="false" name="MaximumAggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" abstract="false" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_EarningsLossPerCommonShareEPSAbstract" abstract="true" name="EarningsLossPerCommonShareEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_BayerCropScienceLPMember" abstract="true" name="BayerCropScienceLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OerthBioLimitedLiabilityCorporationMember" abstract="true" name="OerthBioLimitedLiabilityCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" abstract="false" name="FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_YaleUniversityMember" abstract="true" name="YaleUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" abstract="true" name="UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" abstract="true" name="MilestonePaymentOnFirstAnniversaryOfSigningMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" abstract="true" name="MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SuccessBasedMilestonePaymentsMember" abstract="true" name="SuccessBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LicenseFirstLicensedProductMember" abstract="true" name="LicenseFirstLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LicenseSecondLicensedProductMember" abstract="true" name="LicenseSecondLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PaymentsForCollaboration" abstract="false" name="PaymentsForCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AnnualLicenseFeePayment" abstract="false" name="AnnualLicenseFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_NumberOfLicensedProducts" abstract="false" name="NumberOfLicensedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_RequiredMilestonePayments" abstract="false" name="RequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_StockCompensationAndBonusExpenseMember" abstract="true" name="StockCompensationAndBonusExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV471Member" abstract="true" name="ARV471Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV102Member" abstract="true" name="ARV102Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV393Member" abstract="true" name="ARV393Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV806Member" abstract="true" name="ARV806Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV110Member" abstract="true" name="ARV110Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV766Member" abstract="true" name="ARV766Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OtherProgramsMember" abstract="true" name="OtherProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchAndDevelopmentExpenseProgramSpecific" abstract="false" name="ResearchAndDevelopmentExpenseProgramSpecific" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" abstract="false" name="ResearchAndDevelopmentExpenseNonProgramSpecific" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arvn-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b6d58edb-7cf0-443d-9718-17a551844e98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5b0e198d-3523-4cbb-859d-2c092381274d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6d58edb-7cf0-443d-9718-17a551844e98" xlink:to="loc_us-gaap_LiabilitiesCurrent_5b0e198d-3523-4cbb-859d-2c092381274d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a48a7807-cb35-40e4-97d9-a4dd6aa3d943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6d58edb-7cf0-443d-9718-17a551844e98" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a48a7807-cb35-40e4-97d9-a4dd6aa3d943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a9c3df02-37e1-46c0-8aaa-e52bc3d1847f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6d58edb-7cf0-443d-9718-17a551844e98" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a9c3df02-37e1-46c0-8aaa-e52bc3d1847f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad836c4a-58fa-4bd5-9ed8-553065dd7402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6d58edb-7cf0-443d-9718-17a551844e98" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad836c4a-58fa-4bd5-9ed8-553065dd7402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0401e6e4-5c74-4140-b76b-f1d7cf13583f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac16e997-cf2e-4e1d-a38c-6876e1ddf88c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0401e6e4-5c74-4140-b76b-f1d7cf13583f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac16e997-cf2e-4e1d-a38c-6876e1ddf88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a21cff80-563c-4d40-9789-1390720d2e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0401e6e4-5c74-4140-b76b-f1d7cf13583f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a21cff80-563c-4d40-9789-1390720d2e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c5ad97a-d3a4-4e55-85cb-9cfcabc6da55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0401e6e4-5c74-4140-b76b-f1d7cf13583f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c5ad97a-d3a4-4e55-85cb-9cfcabc6da55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52a290ff-b57f-4689-9673-691bcb6e8760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_739dd2ca-57e4-4f84-9980-f330e9005a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52a290ff-b57f-4689-9673-691bcb6e8760" xlink:to="loc_us-gaap_Liabilities_739dd2ca-57e4-4f84-9980-f330e9005a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9050c82a-3c39-4c58-9aca-99063f49c905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52a290ff-b57f-4689-9673-691bcb6e8760" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9050c82a-3c39-4c58-9aca-99063f49c905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c5a0039e-2aaf-4654-b437-b239c90ad971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52a290ff-b57f-4689-9673-691bcb6e8760" xlink:to="loc_us-gaap_StockholdersEquity_c5a0039e-2aaf-4654-b437-b239c90ad971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3fe2614c-0f1b-4446-b9c1-627afb0dd988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3fe2614c-0f1b-4446-b9c1-627afb0dd988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b6b01aa1-c8bd-48cd-b6d0-fcf6e5b2cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b6b01aa1-c8bd-48cd-b6d0-fcf6e5b2cc4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_12e087f9-cd27-4341-9a84-c7f4bba79692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_12e087f9-cd27-4341-9a84-c7f4bba79692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c6f16a9-de2f-4ff4-80cc-c02f66eecd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c6f16a9-de2f-4ff4-80cc-c02f66eecd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3685753b-d73a-45de-b188-a5762f5f5fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_998b12bc-a0a0-40d9-82d6-672fa78745f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3685753b-d73a-45de-b188-a5762f5f5fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9ba5c7c0-8262-487d-855c-c2ad3cfa29bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e4d9e7a-55a8-4599-9cc4-caa06a80c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9ba5c7c0-8262-487d-855c-c2ad3cfa29bd" xlink:to="loc_us-gaap_AssetsCurrent_7e4d9e7a-55a8-4599-9cc4-caa06a80c2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a4e7d2e-4d30-4a35-be6a-1cf2e9e45dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9ba5c7c0-8262-487d-855c-c2ad3cfa29bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4a4e7d2e-4d30-4a35-be6a-1cf2e9e45dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba6f3ef7-5f46-4040-8b5e-651a216a6443" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9ba5c7c0-8262-487d-855c-c2ad3cfa29bd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba6f3ef7-5f46-4040-8b5e-651a216a6443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_524edcdc-2013-4e74-ab5d-d8fd08f92ec1" xlink:href="arvn-20250630.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9ba5c7c0-8262-487d-855c-c2ad3cfa29bd" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_524edcdc-2013-4e74-ab5d-d8fd08f92ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4538b3bb-3608-4cc0-87a6-9cd1773e6e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:to="loc_us-gaap_CommonStockValue_4538b3bb-3608-4cc0-87a6-9cd1773e6e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab58c4d6-f8d9-4631-b3b6-8d6f6c071a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab58c4d6-f8d9-4631-b3b6-8d6f6c071a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_094de6ef-1129-432f-9b4e-793778361864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:to="loc_us-gaap_AdditionalPaidInCapital_094de6ef-1129-432f-9b4e-793778361864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_671e7382-c0dd-4466-af0c-6c4cebbad937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_671e7382-c0dd-4466-af0c-6c4cebbad937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2131825b-8bfe-48ec-b218-565fa7969614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a17a5788-52dc-49bd-b3b2-78fb8e0b7778" xlink:to="loc_us-gaap_PreferredStockValue_2131825b-8bfe-48ec-b218-565fa7969614" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2d16cb2a-4f78-41f0-86f2-1d0305ec940d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_38855f7e-2003-4892-b285-b382a913f1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2d16cb2a-4f78-41f0-86f2-1d0305ec940d" xlink:to="loc_us-gaap_Revenues_38855f7e-2003-4892-b285-b382a913f1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f0f6d30f-953f-4296-bbf0-bacbaabd1cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2d16cb2a-4f78-41f0-86f2-1d0305ec940d" xlink:to="loc_us-gaap_OperatingExpenses_f0f6d30f-953f-4296-bbf0-bacbaabd1cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b46f6977-d8b2-417e-9549-312fe1820f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fbd636ce-038f-47ee-ac9e-c5ec8ee4e7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b46f6977-d8b2-417e-9549-312fe1820f2b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fbd636ce-038f-47ee-ac9e-c5ec8ee4e7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c4859cb9-565c-432f-8a72-c6caca635adc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b46f6977-d8b2-417e-9549-312fe1820f2b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c4859cb9-565c-432f-8a72-c6caca635adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dc9829e-a04f-4b56-8f24-78aef9043a14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47368ac7-9cab-4ace-aee2-11693bbc6413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dc9829e-a04f-4b56-8f24-78aef9043a14" xlink:to="loc_us-gaap_NetIncomeLoss_47368ac7-9cab-4ace-aee2-11693bbc6413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4d757d44-b53b-4b02-9322-e3204c349547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dc9829e-a04f-4b56-8f24-78aef9043a14" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4d757d44-b53b-4b02-9322-e3204c349547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_58abaaed-61a8-460d-aa48-a46f65c8335c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bdf3ecb5-c7a1-468d-b927-b9d86c3a329a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_58abaaed-61a8-460d-aa48-a46f65c8335c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bdf3ecb5-c7a1-468d-b927-b9d86c3a329a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_137a5582-8306-41b9-a7db-3eeb01c24860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_58abaaed-61a8-460d-aa48-a46f65c8335c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_137a5582-8306-41b9-a7db-3eeb01c24860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c6ff05c-0226-4f22-8cbd-75c3c3cc9753" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8c11a799-a809-4149-b6d5-455504de858d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c6ff05c-0226-4f22-8cbd-75c3c3cc9753" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8c11a799-a809-4149-b6d5-455504de858d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a975a408-04cd-4a91-b71b-e97c1a499624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c6ff05c-0226-4f22-8cbd-75c3c3cc9753" xlink:to="loc_us-gaap_OperatingIncomeLoss_a975a408-04cd-4a91-b71b-e97c1a499624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_355d2f93-2b49-4c6f-b48f-865dce630ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a943f87-3eb3-44c3-8a93-13597676e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_355d2f93-2b49-4c6f-b48f-865dce630ca5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a943f87-3eb3-44c3-8a93-13597676e89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dbf46197-7c4b-4243-ba00-52d3de59e288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_355d2f93-2b49-4c6f-b48f-865dce630ca5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dbf46197-7c4b-4243-ba00-52d3de59e288" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c06994d8-edb1-47c1-8ac2-db14168f3824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_dfe0fae2-0ec2-45ff-a485-cbd95e5193ce" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c06994d8-edb1-47c1-8ac2-db14168f3824" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_dfe0fae2-0ec2-45ff-a485-cbd95e5193ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_531703e9-ab2a-472e-93db-53156a6ff11a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c06994d8-edb1-47c1-8ac2-db14168f3824" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_531703e9-ab2a-472e-93db-53156a6ff11a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721996a1-85c3-497c-a073-7cc152c6537f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f70760f1-3a8c-40d3-a7cf-0234c4037226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721996a1-85c3-497c-a073-7cc152c6537f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f70760f1-3a8c-40d3-a7cf-0234c4037226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_23b228d5-7073-4234-bb5a-ec076ee1e312" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721996a1-85c3-497c-a073-7cc152c6537f" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_23b228d5-7073-4234-bb5a-ec076ee1e312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ece0888-312f-41d3-8841-442a62cc2f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721996a1-85c3-497c-a073-7cc152c6537f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ece0888-312f-41d3-8841-442a62cc2f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0d9efe70-67f1-4698-ac8b-c5b8dcecc7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721996a1-85c3-497c-a073-7cc152c6537f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0d9efe70-67f1-4698-ac8b-c5b8dcecc7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7138862d-1af8-45b0-a09f-0cc114f7b6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_NetIncomeLoss_7138862d-1af8-45b0-a09f-0cc114f7b6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c3ea48ef-260a-4c6f-a43d-3c544c6dbea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_DepreciationAndAmortization_c3ea48ef-260a-4c6f-a43d-3c544c6dbea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a281889b-db3e-4e3a-a8ac-aed62f1415ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a281889b-db3e-4e3a-a8ac-aed62f1415ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_eebb93ad-8155-45d4-9268-b283dd7dbc34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_eebb93ad-8155-45d4-9268-b283dd7dbc34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_54b06053-680c-488d-bbd9-803e25509b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_54b06053-680c-488d-bbd9-803e25509b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_00f23231-1018-4040-a4d2-f54df8d143fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_ShareBasedCompensation_00f23231-1018-4040-a4d2-f54df8d143fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_44490de8-0150-4d81-bb70-eadf75043d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_44490de8-0150-4d81-bb70-eadf75043d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f6de6e98-e182-47f0-a8e4-1c0a6bc21b08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f6de6e98-e182-47f0-a8e4-1c0a6bc21b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4dff2b5f-c066-4c36-8649-a4614bdf72c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4dff2b5f-c066-4c36-8649-a4614bdf72c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4f5043fe-45cc-484a-b091-61fafbcb3921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4f5043fe-45cc-484a-b091-61fafbcb3921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_950d62ca-6ed4-41a5-a213-b2e4141f0b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_950d62ca-6ed4-41a5-a213-b2e4141f0b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab7d1feb-8557-4f0c-8d30-0895c3c0e06a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab7d1feb-8557-4f0c-8d30-0895c3c0e06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_493dfc27-c347-4a19-b9ea-8a311f72d194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_543efab1-004f-4634-bdc2-af543d07ebce" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_493dfc27-c347-4a19-b9ea-8a311f72d194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ccd5634-8313-4800-a56a-079aa5dd02d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f9d4544-117a-454e-973e-198c37d8a939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ccd5634-8313-4800-a56a-079aa5dd02d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f9d4544-117a-454e-973e-198c37d8a939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df3c6ee4-b2f3-4697-969c-b8161bf6ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ccd5634-8313-4800-a56a-079aa5dd02d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df3c6ee4-b2f3-4697-969c-b8161bf6ef40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d5ae24ea-0a09-43a4-b4aa-78e3db4ebabf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ccd5634-8313-4800-a56a-079aa5dd02d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d5ae24ea-0a09-43a4-b4aa-78e3db4ebabf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae29a1cc-28f5-49b4-ab4c-618c1e663670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1dfa251c-3a83-4dd5-ac7e-a6806cd462a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae29a1cc-28f5-49b4-ab4c-618c1e663670" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1dfa251c-3a83-4dd5-ac7e-a6806cd462a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_98c6cdc1-72b8-45b3-802f-8176c1e57dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae29a1cc-28f5-49b4-ab4c-618c1e663670" xlink:to="loc_us-gaap_RestrictedCashCurrent_98c6cdc1-72b8-45b3-802f-8176c1e57dd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd2958f2-c633-4d5c-b03c-d0afb64ccfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e3953ef-fa5b-45f0-b3e6-f2c58adb774e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd2958f2-c633-4d5c-b03c-d0afb64ccfc4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e3953ef-fa5b-45f0-b3e6-f2c58adb774e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26bbfe68-d101-483e-afe8-c516213a40e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd2958f2-c633-4d5c-b03c-d0afb64ccfc4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26bbfe68-d101-483e-afe8-c516213a40e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b31333e8-8f1f-40c3-805b-c3fa40c732da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd2958f2-c633-4d5c-b03c-d0afb64ccfc4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b31333e8-8f1f-40c3-805b-c3fa40c732da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c291e8a4-f5f5-4c44-b50e-17d94baf1f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6ed4809f-9ae4-4058-b01a-4f535e20ef09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c291e8a4-f5f5-4c44-b50e-17d94baf1f7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6ed4809f-9ae4-4058-b01a-4f535e20ef09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cbd2eb36-bccd-4f09-aa1a-095b7a2c1d53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c291e8a4-f5f5-4c44-b50e-17d94baf1f7d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cbd2eb36-bccd-4f09-aa1a-095b7a2c1d53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33e4d882-3ad6-44e3-840b-f6bfc6ab69e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e2cfba64-c6c1-4e51-bd9e-dac416506b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33e4d882-3ad6-44e3-840b-f6bfc6ab69e1" xlink:to="loc_us-gaap_OperatingLeaseLiability_e2cfba64-c6c1-4e51-bd9e-dac416506b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f1fcf2c1-e7ff-48c0-a1c9-0419be55a9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33e4d882-3ad6-44e3-840b-f6bfc6ab69e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f1fcf2c1-e7ff-48c0-a1c9-0419be55a9aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f07b3153-2ba7-4133-a70a-979b4e1a8e20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f07b3153-2ba7-4133-a70a-979b4e1a8e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fa2cc23-b122-421a-ad32-c6b8551ab494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fa2cc23-b122-421a-ad32-c6b8551ab494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2d698fc2-d3fe-4832-8859-9137de224c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2d698fc2-d3fe-4832-8859-9137de224c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ca88b46-3219-4e26-894f-b2fd76fae64d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ca88b46-3219-4e26-894f-b2fd76fae64d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8bccfe5-6344-4d17-9351-f40024471b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb3a6c4f-75b2-4a91-9ba1-01b22189a84d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8bccfe5-6344-4d17-9351-f40024471b90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_178abaf4-f8a4-46a2-afaf-4f4da36fa06f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_us-gaap_AccountsPayableCurrent_178abaf4-f8a4-46a2-afaf-4f4da36fa06f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_10eb3589-a4a8-4ae5-a554-31c4cda9dccf" xlink:href="arvn-20250630.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_10eb3589-a4a8-4ae5-a554-31c4cda9dccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_86eb3973-e409-4612-8182-ba0e38b6eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_86eb3973-e409-4612-8182-ba0e38b6eb1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65803040-894f-444a-8010-b6e934de068e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65803040-894f-444a-8010-b6e934de068e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a79b6a15-7bee-4755-bd9f-309c858401ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a79b6a15-7bee-4755-bd9f-309c858401ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_4e9db0a4-35b5-493e-b882-0f6ce73c7363" xlink:href="arvn-20250630.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e1c3f18-03b1-46bb-801e-e59ae69041d6" xlink:to="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_4e9db0a4-35b5-493e-b882-0f6ce73c7363" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_af87e54d-cb10-4c5a-b78f-b6bc0b1bf3de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bebb1705-44bd-44d7-ad65-1c1b32d15fed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af87e54d-cb10-4c5a-b78f-b6bc0b1bf3de" xlink:to="loc_us-gaap_LongTermDebtCurrent_bebb1705-44bd-44d7-ad65-1c1b32d15fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_50c189bf-0cf3-4de0-94a6-7bed223e4fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af87e54d-cb10-4c5a-b78f-b6bc0b1bf3de" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_50c189bf-0cf3-4de0-94a6-7bed223e4fb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1ead87bd-3fbc-4366-a83b-aa9044e2b333" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_09c53b77-4d89-4e50-8f01-f2a1dc3a7cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ead87bd-3fbc-4366-a83b-aa9044e2b333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_09c53b77-4d89-4e50-8f01-f2a1dc3a7cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4183bc43-6752-47af-9e3b-bb530004e9df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ead87bd-3fbc-4366-a83b-aa9044e2b333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4183bc43-6752-47af-9e3b-bb530004e9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9bcb0241-1c3a-4960-9675-b34e8baa9380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ead87bd-3fbc-4366-a83b-aa9044e2b333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9bcb0241-1c3a-4960-9675-b34e8baa9380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a85bd329-d2bb-4101-a117-a8cc85808732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ead87bd-3fbc-4366-a83b-aa9044e2b333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a85bd329-d2bb-4101-a117-a8cc85808732" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee6745ec-f84c-476f-af4e-a2f3d246edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6c3ddf78-b305-4da4-9410-8cc4feadc5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee6745ec-f84c-476f-af4e-a2f3d246edb1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6c3ddf78-b305-4da4-9410-8cc4feadc5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f98d3528-2aae-4342-aa0d-b32a3d1ffd33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee6745ec-f84c-476f-af4e-a2f3d246edb1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f98d3528-2aae-4342-aa0d-b32a3d1ffd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d918ff1f-bc33-4ffa-a2fb-dac373a05fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b42ae886-203c-4a4a-b220-2e540d6404a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d918ff1f-bc33-4ffa-a2fb-dac373a05fac" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b42ae886-203c-4a4a-b220-2e540d6404a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformationFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6f95ed6f-8d85-43e0-949b-035c4dbd6e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_ed700d47-d3ee-4dd0-ad5e-e548751c29fe" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6f95ed6f-8d85-43e0-949b-035c4dbd6e10" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_ed700d47-d3ee-4dd0-ad5e-e548751c29fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_9ce9b116-868f-48c3-92b0-a462d8724852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6f95ed6f-8d85-43e0-949b-035c4dbd6e10" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_9ce9b116-868f-48c3-92b0-a462d8724852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_f78a1d2e-d9ad-419b-ad1f-e2a7f0b6521b" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6f95ed6f-8d85-43e0-949b-035c4dbd6e10" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_f78a1d2e-d9ad-419b-ad1f-e2a7f0b6521b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_fec75bf8-1e3a-4b16-8fa6-1e844f6baa19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6f95ed6f-8d85-43e0-949b-035c4dbd6e10" xlink:to="loc_us-gaap_LaborAndRelatedExpense_fec75bf8-1e3a-4b16-8fa6-1e844f6baa19" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arvn-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:to="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_010dd20e-c88e-4f55-a7b4-df92258fab3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:to="loc_us-gaap_EquityComponentDomain_010dd20e-c88e-4f55-a7b4-df92258fab3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:to="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba43c865-7a58-489c-822f-e3513598c438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_CommonStockMember_ba43c865-7a58-489c-822f-e3513598c438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6451a8ac-60ff-4f72-928e-cc573958cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_RetainedEarningsMember_6451a8ac-60ff-4f72-928e-cc573958cb1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6d94db66-f76a-40ad-b73a-2b76b0e8ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6d94db66-f76a-40ad-b73a-2b76b0e8ec7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d9caf10-bafb-4e33-9c19-692327bf76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d9caf10-bafb-4e33-9c19-692327bf76a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dfe6d153-abda-4e3b-83ee-6bba05559047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dfe6d153-abda-4e3b-83ee-6bba05559047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e734838-3192-4a19-8e01-456613478949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockholdersEquity_7e734838-3192-4a19-8e01-456613478949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ef221e-ded7-4981-b507-b0d70342a142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ef221e-ded7-4981-b507-b0d70342a142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47858da2-b382-4171-9097-dab309565e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_NetIncomeLoss_47858da2-b382-4171-9097-dab309565e9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e4d337f-76d7-497b-955c-3c576d0ed202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e4d337f-76d7-497b-955c-3c576d0ed202" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f4805311-6ac9-4ee3-81b3-e00124f79331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f4805311-6ac9-4ee3-81b3-e00124f79331" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_4d5af611-aaf0-4408-a2bf-3f126127f6e4" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_4d5af611-aaf0-4408-a2bf-3f126127f6e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed93ca34-94e9-4012-816e-a818763ea2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed93ca34-94e9-4012-816e-a818763ea2c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_72385ca0-e87e-46cc-8081-5179c72f5578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_915faa47-84ad-4a82-8cf1-db40ef2352f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6089ed05-5b67-4947-b756-d40640497e50_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6089ed05-5b67-4947-b756-d40640497e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_79e933ec-e62e-4f02-8e3d-79dadb5dd658" xlink:href="arvn-20250630.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_PfizerIncorporationMember_79e933ec-e62e-4f02-8e3d-79dadb5dd658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember_d5b559b8-493a-4597-92b4-c3081756a0a2" xlink:href="arvn-20250630.xsd#arvn_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_NovartisPharmaAGMember_d5b559b8-493a-4597-92b4-c3081756a0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_51e6b09a-23fd-4c40-bf93-9950684583b6" xlink:href="arvn-20250630.xsd#arvn_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_BayerAGMember_51e6b09a-23fd-4c40-bf93-9950684583b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_46c494ea-27af-442f-8854-2888c6a2bd7f" xlink:href="arvn-20250630.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_46c494ea-27af-442f-8854-2888c6a2bd7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0eb36c14-ffbe-4a74-a804-c5ddc65dd918_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:to="loc_srt_ProductsAndServicesDomain_0eb36c14-ffbe-4a74-a804-c5ddc65dd918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:to="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5b37c82-c4a3-4ac7-af01-b16c5bcdd87c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:to="loc_us-gaap_LicenseMember_b5b37c82-c4a3-4ac7-af01-b16c5bcdd87c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92d1a223-b307-414f-a3fc-26857f83bc13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92d1a223-b307-414f-a3fc-26857f83bc13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_91e7324a-b27d-4478-a579-40d481d784c7" xlink:href="arvn-20250630.xsd#arvn_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_CollaborationAgreementMember_91e7324a-b27d-4478-a579-40d481d784c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_58623a0c-9239-4733-84fe-1e94d1a7c05f" xlink:href="arvn-20250630.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_58623a0c-9239-4733-84fe-1e94d1a7c05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_e2ebae02-e209-420f-94b0-f8d8cd700f32" xlink:href="arvn-20250630.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_e2ebae02-e209-420f-94b0-f8d8cd700f32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_669c44fb-cca2-4dd0-99b3-18023d4d9921" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_SalesBasedMilestonesMember_669c44fb-cca2-4dd0-99b3-18023d4d9921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_7f176741-afe5-43ee-9d68-3e86a4ff78b4" xlink:href="arvn-20250630.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_7f176741-afe5-43ee-9d68-3e86a4ff78b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_3c74ab62-99a4-4d88-8ea4-c171da5a7997" xlink:href="arvn-20250630.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_3c74ab62-99a4-4d88-8ea4-c171da5a7997" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_d6a1e9df-6c4d-4c9d-8e32-c00fcfcca9a9" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_d6a1e9df-6c4d-4c9d-8e32-c00fcfcca9a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_04f4fc05-2dae-48ab-acc5-0921b15463f6" xlink:href="arvn-20250630.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_ResearchFundingPaymentsMember_04f4fc05-2dae-48ab-acc5-0921b15463f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_9d9a60fe-4b00-452b-af89-5298ad88be0e" xlink:href="arvn-20250630.xsd#arvn_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_CommercialMilestonesMember_9d9a60fe-4b00-452b-af89-5298ad88be0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b7cae6d-a56a-47f2-a639-2a322990187d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:to="loc_srt_RangeMember_7b7cae6d-a56a-47f2-a639-2a322990187d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:to="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a543d0a-73f9-4ee5-833f-4325f854a969" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:to="loc_srt_MaximumMember_8a543d0a-73f9-4ee5-833f-4325f854a969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember_982d3eaf-e976-4eb4-b434-0b912ebdebee" xlink:href="arvn-20250630.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:to="loc_arvn_RemovalOfCombinationTrialsMember_982d3eaf-e976-4eb4-b434-0b912ebdebee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember_a84b15e9-5263-4ca7-afcb-444408e214d3" xlink:href="arvn-20250630.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:to="loc_arvn_UpdatedResearchTimelinesMember_a84b15e9-5263-4ca7-afcb-444408e214d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_c0395857-08da-4112-aff7-5f1596e41c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_c0395857-08da-4112-aff7-5f1596e41c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_89eadc2f-350a-4ff8-8c30-6bdfa0991e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ProceedsFromCollaborators_89eadc2f-350a-4ff8-8c30-6bdfa0991e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_0130bd71-0994-4e80-83aa-c0769ca25bae" xlink:href="arvn-20250630.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_0130bd71-0994-4e80-83aa-c0769ca25bae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_86424d09-c7f0-4034-ab3e-561081f762cc" xlink:href="arvn-20250630.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_86424d09-c7f0-4034-ab3e-561081f762cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d7e4c804-4775-4704-8602-7caa12228e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d7e4c804-4775-4704-8602-7caa12228e5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_47c70dd3-b933-47ec-8fdb-557ff2d5977a" xlink:href="arvn-20250630.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_47c70dd3-b933-47ec-8fdb-557ff2d5977a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee8d34e1-550c-42a2-adac-7de6d7fd42dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee8d34e1-550c-42a2-adac-7de6d7fd42dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6ed48118-ff5d-443a-bf20-2944fb820c12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6ed48118-ff5d-443a-bf20-2944fb820c12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_b7606a72-dfc5-44a1-a3fc-7ae6197b3573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_CapitalizedContractCostGross_b7606a72-dfc5-44a1-a3fc-7ae6197b3573" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4229e55d-c263-4dee-9a6f-30f0790be4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_Revenues_4229e55d-c263-4dee-9a6f-30f0790be4be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3923587d-47c6-4d5f-b41c-933ebfa5db61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_OperatingExpenses_3923587d-47c6-4d5f-b41c-933ebfa5db61" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_266be44e-2af6-421b-b9cd-e791d6573965" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_NetIncomeLoss_266be44e-2af6-421b-b9cd-e791d6573965" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f309e5b6-ec81-4b77-b34a-67abafbcc142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_EarningsPerShareBasic_f309e5b6-ec81-4b77-b34a-67abafbcc142" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_596ecff2-ee26-40ee-b2d3-2f60551faf36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_596ecff2-ee26-40ee-b2d3-2f60551faf36" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d07ec056-b58a-414e-8390-4cd6aaa18209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d07ec056-b58a-414e-8390-4cd6aaa18209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be0327e8-0bdc-48ed-b333-9db5ccb8048e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be0327e8-0bdc-48ed-b333-9db5ccb8048e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_667f286d-24c3-46c2-9506-14ab94f1ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_667f286d-24c3-46c2-9506-14ab94f1ac8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7930364d-b01f-4f6d-b366-cf07ee2c882a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7930364d-b01f-4f6d-b366-cf07ee2c882a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a82e5195-c99c-4559-8ee9-ca2e363ae35a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a82e5195-c99c-4559-8ee9-ca2e363ae35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7e1f69cc-40ba-43e6-b5bc-0f47c36ce36e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7e1f69cc-40ba-43e6-b5bc-0f47c36ce36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_46d38edd-746c-41b7-a25e-b1388e0672f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_46d38edd-746c-41b7-a25e-b1388e0672f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5348b9ec-fef8-43ff-b1c3-d90628eb2f19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5348b9ec-fef8-43ff-b1c3-d90628eb2f19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df99cd08-0742-432d-a764-3215c3ac8da3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df99cd08-0742-432d-a764-3215c3ac8da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a47db257-3648-483f-8f56-8dc3c2636f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a47db257-3648-483f-8f56-8dc3c2636f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c50a4d2-f4f8-446a-9ab0-f00b8e449ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c50a4d2-f4f8-446a-9ab0-f00b8e449ab7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_55335c7c-ec3d-422d-80d5-8b724fce35ff" xlink:href="arvn-20250630.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_arvn_LaboratoryEquipmentMember_55335c7c-ec3d-422d-80d5-8b724fce35ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a41ab387-7145-449c-b95a-650a96afea34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a41ab387-7145-449c-b95a-650a96afea34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_808cf92f-3b07-4750-90de-9766c1265aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_us-gaap_OfficeEquipmentMember_808cf92f-3b07-4750-90de-9766c1265aa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d40cff42-86e3-464f-88e2-f0cc35fe2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d40cff42-86e3-464f-88e2-f0cc35fe2a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4321307-d5ac-464c-9a70-0e6dab7b0b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4321307-d5ac-464c-9a70-0e6dab7b0b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba1df304-bdf1-4a2c-b562-71a988627492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba1df304-bdf1-4a2c-b562-71a988627492" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:to="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ef0eb61-9e5d-419d-81a1-8d4e611b956b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:to="loc_srt_RangeMember_4ef0eb61-9e5d-419d-81a1-8d4e611b956b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:to="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a5efd44-1f96-4121-b982-7dee01959760" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:to="loc_srt_MinimumMember_7a5efd44-1f96-4121-b982-7dee01959760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1d79c44f-6e20-4970-9ab7-22f4bd98f460" xlink:href="arvn-20250630.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1d79c44f-6e20-4970-9ab7-22f4bd98f460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d87d2ba9-5c24-4d1f-bfe2-2e9af8d88abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d87d2ba9-5c24-4d1f-bfe2-2e9af8d88abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_5749e940-4c64-4300-89a8-368108fa1202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_5749e940-4c64-4300-89a8-368108fa1202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5715ff64-88cd-4dfe-b981-05efeacba06c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5715ff64-88cd-4dfe-b981-05efeacba06c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:to="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2703885d-8b4d-4191-ad93-7d2f4d226a63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2703885d-8b4d-4191-ad93-7d2f4d226a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_c05a56a3-68fd-4787-9881-ab9944981b4f" xlink:href="arvn-20250630.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_c05a56a3-68fd-4787-9881-ab9944981b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:to="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fef2a60d-ec91-4613-94c8-eba1468a8d1e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:to="loc_srt_SegmentGeographicalDomain_fef2a60d-ec91-4613-94c8-eba1468a8d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:to="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_93b675b8-9853-4081-acb3-18ef6a7b0c61" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:to="loc_stpr_CT_93b675b8-9853-4081-acb3-18ef6a7b0c61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4b4d23fe-6077-47c4-adcd-0ebcf324b903" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4b4d23fe-6077-47c4-adcd-0ebcf324b903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_7151faf3-9181-46b2-af8f-2e4d8cc55bd8" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_7151faf3-9181-46b2-af8f-2e4d8cc55bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bf6b0e9-e04f-4fdc-b668-81fadf8e3c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bf6b0e9-e04f-4fdc-b668-81fadf8e3c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_7b46e040-65d9-4852-b9f3-0bd190335133" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_7b46e040-65d9-4852-b9f3-0bd190335133" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_ee0de77e-caa2-4ea4-96af-41ada49b4a17" xlink:href="arvn-20250630.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_ee0de77e-caa2-4ea4-96af-41ada49b4a17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d2f5be4d-033c-404d-a035-c240eaaf9298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_InterestExpense_d2f5be4d-033c-404d-a035-c240eaaf9298" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf01a8d0-3874-4044-9d31-a2241401cbfb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf01a8d0-3874-4044-9d31-a2241401cbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_ae334e92-f343-4a66-b9f0-3253f1724763" xlink:href="arvn-20250630.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:to="loc_arvn_PiperSandlerAndCantorMember_ae334e92-f343-4a66-b9f0-3253f1724763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b25d92e-f7b6-4026-a160-ec5cef6433de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b25d92e-f7b6-4026-a160-ec5cef6433de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_b2f36b68-5711-4644-bf39-fe38dacb92d5" xlink:href="arvn-20250630.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:to="loc_arvn_AtTheMarketOfferingMember_b2f36b68-5711-4644-bf39-fe38dacb92d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4671ace5-21dc-4d58-8f78-84f630cfd687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:to="loc_us-gaap_EmployeeStockMember_4671ace5-21dc-4d58-8f78-84f630cfd687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6843dbcf-2014-4631-b418-c4634461fe81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6843dbcf-2014-4631-b418-c4634461fe81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_66c7f659-8187-4e50-9f28-dd4c9a5b4aa3" xlink:href="arvn-20250630.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:to="loc_arvn_EquityDistributionAgreementMember_66c7f659-8187-4e50-9f28-dd4c9a5b4aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b168bae-a354-4c96-b480-34b6f43c2503_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:to="loc_us-gaap_PlanNameDomain_9b168bae-a354-4c96-b480-34b6f43c2503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:to="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_832c9488-a2d5-4c97-8130-298963a4569c" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_832c9488-a2d5-4c97-8130-298963a4569c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_690fe995-0aef-422f-8da0-8ec0064e3396_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:to="loc_srt_RangeMember_690fe995-0aef-422f-8da0-8ec0064e3396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:to="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49a1326-491a-449d-ae54-488d30aecd03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_MaximumMember_f49a1326-491a-449d-ae54-488d30aecd03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c80a8301-85e9-4a11-9eb7-90beba9edd8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_MinimumMember_c80a8301-85e9-4a11-9eb7-90beba9edd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a5e0ca3f-efce-41d3-af6d-3a2b81e0e4fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_WeightedAverageMember_a5e0ca3f-efce-41d3-af6d-3a2b81e0e4fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca9777c1-a346-4ff4-9172-b1d91de58bfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca9777c1-a346-4ff4-9172-b1d91de58bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fe2010b2-b804-4737-ae28-0013c63be738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:to="loc_us-gaap_EmployeeStockMember_fe2010b2-b804-4737-ae28-0013c63be738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9821f9ee-77bd-4d30-9a95-038a5962fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9821f9ee-77bd-4d30-9a95-038a5962fecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_4c81ba0d-5a77-4500-af46-3eda4aaaa831" xlink:href="arvn-20250630.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_4c81ba0d-5a77-4500-af46-3eda4aaaa831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f64850fd-d4af-4a9a-836f-db6f8c732fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f64850fd-d4af-4a9a-836f-db6f8c732fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c370948-40a3-40af-bc51-7eb6e90a20e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c370948-40a3-40af-bc51-7eb6e90a20e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_e7326d55-bd27-47fa-bbcf-c602e0dfdef3" xlink:href="arvn-20250630.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_e7326d55-bd27-47fa-bbcf-c602e0dfdef3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c8a5290c-9bfc-43e6-abd1-b0935e4ae024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c8a5290c-9bfc-43e6-abd1-b0935e4ae024" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb503a6c-2ac4-46f3-a59d-9c3195c282ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb503a6c-2ac4-46f3-a59d-9c3195c282ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_0ae5d47c-e27a-48c6-8729-39ebffa366e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_0ae5d47c-e27a-48c6-8729-39ebffa366e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a380d8b3-ac4b-4fca-aa82-11e7105e4e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a380d8b3-ac4b-4fca-aa82-11e7105e4e92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f5ccf0a7-59f7-49fc-9319-a59b862c695b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f5ccf0a7-59f7-49fc-9319-a59b862c695b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2c887fee-7df3-40a0-ae68-dc5a1725cb50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2c887fee-7df3-40a0-ae68-dc5a1725cb50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf088008-a74f-4e59-a21e-b734a191f729" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf088008-a74f-4e59-a21e-b734a191f729" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37da608f-0071-460d-8c34-26c11d74a041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37da608f-0071-460d-8c34-26c11d74a041" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_23cda6db-4109-4bfb-8636-b74b188d8282" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_23cda6db-4109-4bfb-8636-b74b188d8282" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4090ea20-9c8c-4955-8d16-c641c177eb32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4090ea20-9c8c-4955-8d16-c641c177eb32" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab98152b-e2fd-40cc-9d3a-6969852a5ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab98152b-e2fd-40cc-9d3a-6969852a5ab3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_7aae79d7-515a-4b42-a7aa-396d37dc4043" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_7aae79d7-515a-4b42-a7aa-396d37dc4043" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ffe97f1-fc82-43bf-817a-12f8817499c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ffe97f1-fc82-43bf-817a-12f8817499c1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_2e18f971-04be-41c7-97c2-ac0770d9858d" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_2e18f971-04be-41c7-97c2-ac0770d9858d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e447bd0d-d34d-422f-b80e-078763d5c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e447bd0d-d34d-422f-b80e-078763d5c03c" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:to="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779b158b-ff70-4507-b1ca-5526a9cdc638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779b158b-ff70-4507-b1ca-5526a9cdc638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d347b573-831e-4df7-9f33-ad774bc62fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d347b573-831e-4df7-9f33-ad774bc62fcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:to="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7b47433-fcde-44c1-9237-3d4b8d88dd6b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:to="loc_srt_RangeMember_d7b47433-fcde-44c1-9237-3d4b8d88dd6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:to="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6749ede0-3e24-46b8-ae7e-de9a560ea525" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:to="loc_srt_MinimumMember_6749ede0-3e24-46b8-ae7e-de9a560ea525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31875e97-5910-44c8-8996-11f33643fb0b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:to="loc_srt_MaximumMember_31875e97-5910-44c8-8996-11f33643fb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ff018851-7dbb-4c66-9df8-bb291dd7060d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ff018851-7dbb-4c66-9df8-bb291dd7060d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dfef65fb-9bdc-4db2-aa8b-3cd4abf59e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dfef65fb-9bdc-4db2-aa8b-3cd4abf59e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd9bc3d6-5399-4f0d-9a41-3c6458b93d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd9bc3d6-5399-4f0d-9a41-3c6458b93d5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3d42bcb0-4b5d-430f-97ef-ebf8d20b90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3d42bcb0-4b5d-430f-97ef-ebf8d20b90c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b8c9e3a3-080d-4127-a3b0-51ff4aa830a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b8c9e3a3-080d-4127-a3b0-51ff4aa830a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5dc0276c-ccbb-48f0-aff7-f1b5fba0aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5dc0276c-ccbb-48f0-aff7-f1b5fba0aba8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5629d040-8a67-484e-85a9-8754c10ae904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5629d040-8a67-484e-85a9-8754c10ae904" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:to="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_70ae5457-8620-43f9-aa21-6ac27de194e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:to="loc_us-gaap_PlanNameDomain_70ae5457-8620-43f9-aa21-6ac27de194e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:to="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_0116b52e-e974-44a1-905d-4f369422edfa" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_0116b52e-e974-44a1-905d-4f369422edfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1424276-6fdb-4054-a393-4c8da29b421c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1424276-6fdb-4054-a393-4c8da29b421c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f10dab01-d6f8-4caa-a586-4e4f231bd52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f10dab01-d6f8-4caa-a586-4e4f231bd52f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9936ab2a-a57b-4460-9436-939f43f00e54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9936ab2a-a57b-4460-9436-939f43f00e54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09222003-464b-4db3-84cc-3b4bdcd5900a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c5a336e-cff2-4512-8947-e8b42d6bb076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c5a336e-cff2-4512-8947-e8b42d6bb076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_85c5d3bc-5910-4cc7-8662-c34ac3dcbdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_85c5d3bc-5910-4cc7-8662-c34ac3dcbdb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3d7c6ed-e9e9-48b1-b3f0-bba848873f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3d7c6ed-e9e9-48b1-b3f0-bba848873f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41aff9cc-181d-41ca-935f-e328501df810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41aff9cc-181d-41ca-935f-e328501df810" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_507c6a06-b663-441e-a590-109031063811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_507c6a06-b663-441e-a590-109031063811" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31c08ba5-d29e-41dd-ad90-b7e67d37672d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_088d434a-ff58-4d36-93e8-f627df31879f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_088d434a-ff58-4d36-93e8-f627df31879f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f62ea883-7631-4e7f-abc3-e48f1db78bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f62ea883-7631-4e7f-abc3-e48f1db78bd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd66263b-836f-49c0-b363-1672a84c7063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd66263b-836f-49c0-b363-1672a84c7063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cd4ee51-bb5e-4cdb-8a6f-ac9368686334" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cd4ee51-bb5e-4cdb-8a6f-ac9368686334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9e7cb350-36ad-4c4a-98d8-a5ef190f1a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9e7cb350-36ad-4c4a-98d8-a5ef190f1a5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:href="arvn-20250630.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_edca342d-e5cc-4748-9879-750ea7375bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_edca342d-e5cc-4748-9879-750ea7375bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af631406-432c-478f-9e63-b2d3bea0c91b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af631406-432c-478f-9e63-b2d3bea0c91b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bb81862e-b45b-44d0-8614-6748cf895b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bb81862e-b45b-44d0-8614-6748cf895b18" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquitySummaryofRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:to="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7743a0ad-529a-432f-9cf0-91d2bd9bffe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:to="loc_us-gaap_PlanNameDomain_7743a0ad-529a-432f-9cf0-91d2bd9bffe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:to="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_171ae5dc-921d-4627-9f85-26908ba9b7b5" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_171ae5dc-921d-4627-9f85-26908ba9b7b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:to="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1b19522-02a6-442f-bbe1-f57be334133b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1b19522-02a6-442f-bbe1-f57be334133b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03ee5f06-7824-4a6b-a2d4-f68ca37fd463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03ee5f06-7824-4a6b-a2d4-f68ca37fd463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4de80b7a-6e7c-4ff1-a5e0-40035e14f6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4de80b7a-6e7c-4ff1-a5e0-40035e14f6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_969233a0-9432-4895-884c-12a823f98d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_969233a0-9432-4895-884c-12a823f98d68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_085f77fd-39ee-4e25-9c25-cb683f120957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_085f77fd-39ee-4e25-9c25-cb683f120957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d7252e71-b11d-431e-a2b9-fca9200370a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d7252e71-b11d-431e-a2b9-fca9200370a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae21a4a5-0b81-45fd-a63e-ae04749fa72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_351e6d87-0fdf-4f03-8172-f69d3aae620d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_351e6d87-0fdf-4f03-8172-f69d3aae620d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc3d2cec-4400-4fa6-a8d8-390a646f5cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc3d2cec-4400-4fa6-a8d8-390a646f5cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3771860a-5976-469b-83d8-2735e7f74219" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3771860a-5976-469b-83d8-2735e7f74219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_28633395-0132-4e39-8ed3-7e893aa710e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_28633395-0132-4e39-8ed3-7e893aa710e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72e0bd07-0efe-44dc-bfb9-4f9a05d3d338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_65532f7d-df97-4ce7-aba6-0c876022260b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_65532f7d-df97-4ce7-aba6-0c876022260b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_32d1b3cd-23c3-4bc4-80f9-9a782b29da9c" xlink:href="arvn-20250630.xsd#arvn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:to="loc_arvn_PreFundedWarrantMember_32d1b3cd-23c3-4bc4-80f9-9a782b29da9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_169d2e3f-8721-46c7-acdb-538057036df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_169d2e3f-8721-46c7-acdb-538057036df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8dea2b53-86ec-447c-b98b-b058ff2b5e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8dea2b53-86ec-447c-b98b-b058ff2b5e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_3bf6c9fc-732c-4968-aece-8389a28dfceb" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_3bf6c9fc-732c-4968-aece-8389a28dfceb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8503e31c-3bcd-43d3-8e13-cb0d88c7860b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8503e31c-3bcd-43d3-8e13-cb0d88c7860b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78ed098b-714a-4142-8de0-6f43f0e4bd63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78ed098b-714a-4142-8de0-6f43f0e4bd63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c538bd4-24f8-494d-960c-9acf369c9bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c538bd4-24f8-494d-960c-9acf369c9bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d6588a3-9d02-43b1-ad90-422ea2d7c256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d6588a3-9d02-43b1-ad90-422ea2d7c256" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3014b65-2ed8-4d78-bddf-11094b5dbc00_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3014b65-2ed8-4d78-bddf-11094b5dbc00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_a7e7f607-6dbc-498f-84a3-94bf7042b004" xlink:href="arvn-20250630.xsd#arvn_BayerCropScienceLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:to="loc_arvn_BayerCropScienceLPMember_a7e7f607-6dbc-498f-84a3-94bf7042b004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_94e5c2f9-4386-4f40-a24d-4a4c66821903_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:to="loc_dei_EntityDomain_94e5c2f9-4386-4f40-a24d-4a4c66821903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:to="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_043a0621-e3a3-4674-a6fd-64ebd775e96d" xlink:href="arvn-20250630.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_043a0621-e3a3-4674-a6fd-64ebd775e96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ace8b83-df14-4266-8cfc-e802ac5aec30_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ace8b83-df14-4266-8cfc-e802ac5aec30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_cbd55055-906d-4dce-b4f6-dcf31808dd24" xlink:href="arvn-20250630.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_cbd55055-906d-4dce-b4f6-dcf31808dd24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_202af56e-29fc-43ed-8f97-26e37c189b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_202af56e-29fc-43ed-8f97-26e37c189b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_513717c6-d0de-4201-babc-046d4eb4b284" xlink:href="arvn-20250630.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_513717c6-d0de-4201-babc-046d4eb4b284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ed24982-111f-4e1a-b7ac-074c9adca2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_NetIncomeLoss_8ed24982-111f-4e1a-b7ac-074c9adca2ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fa441f08-9c96-41f3-b075-2de52cb6bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_EquityMethodInvestments_fa441f08-9c96-41f3-b075-2de52cb6bf7d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_43882fcb-5908-4efc-b127-2735c24ccb91" xlink:href="arvn-20250630.xsd#arvn_YaleUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:to="loc_arvn_YaleUniversityMember_43882fcb-5908-4efc-b127-2735c24ccb91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_617a736a-ab20-4448-8b3c-ac4514023264_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_617a736a-ab20-4448-8b3c-ac4514023264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_37f7d245-625f-4d8a-aa58-5974f06b6e18" xlink:href="arvn-20250630.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_37f7d245-625f-4d8a-aa58-5974f06b6e18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_1bcb57b8-04bd-4404-b43f-4ad3a67b4d06" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_1bcb57b8-04bd-4404-b43f-4ad3a67b4d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_68543bd7-25cd-452a-b57a-e91188c05554" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_68543bd7-25cd-452a-b57a-e91188c05554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_4b98554f-0946-410b-8d81-53a0ce432b1e" xlink:href="arvn-20250630.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_4b98554f-0946-410b-8d81-53a0ce432b1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d092248e-a94b-4f63-8597-e1dba7c98d45_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:to="loc_srt_RangeMember_d092248e-a94b-4f63-8597-e1dba7c98d45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:to="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a7154d5-cbff-4594-94dc-873f308f8c2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:to="loc_srt_MaximumMember_1a7154d5-cbff-4594-94dc-873f308f8c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f8cefb37-735e-4ffa-b1c3-3b098a61ac74" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:to="loc_srt_MinimumMember_f8cefb37-735e-4ffa-b1c3-3b098a61ac74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ba53dc0b-0a34-4c15-9f0f-70d02337b357_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:to="loc_srt_ProductsAndServicesDomain_ba53dc0b-0a34-4c15-9f0f-70d02337b357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:to="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_9b2bbaa8-7c63-45fb-bd7b-79b5053afa79" xlink:href="arvn-20250630.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_9b2bbaa8-7c63-45fb-bd7b-79b5053afa79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_04caba62-4549-48d3-9d2f-c6872511fe04" xlink:href="arvn-20250630.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_04caba62-4549-48d3-9d2f-c6872511fe04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration_423a5d19-3e7e-4da2-8794-23eca6717210" xlink:href="arvn-20250630.xsd#arvn_PaymentsForCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_PaymentsForCollaboration_423a5d19-3e7e-4da2-8794-23eca6717210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_0a656420-9e4c-43a1-98be-c1bae537d267" xlink:href="arvn-20250630.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_0a656420-9e4c-43a1-98be-c1bae537d267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_87d39589-5f58-433e-8a64-889738c1d088" xlink:href="arvn-20250630.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_AnnualLicenseFeePayment_87d39589-5f58-433e-8a64-889738c1d088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts_ff2ec161-29c3-4e76-9ccf-65ae7e442fcc" xlink:href="arvn-20250630.xsd#arvn_NumberOfLicensedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_NumberOfLicensedProducts_ff2ec161-29c3-4e76-9ccf-65ae7e442fcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_83a99b51-e6b0-4e47-8758-7819f67a778f" xlink:href="arvn-20250630.xsd#arvn_RequiredMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_RequiredMilestonePayments_83a99b51-e6b0-4e47-8758-7819f67a778f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ad3f9851-8911-44f3-9e5f-e3658851987e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_us-gaap_PaymentsForRoyalties_ad3f9851-8911-44f3-9e5f-e3658851987e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RestructuringActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_24a903d5-d9f0-4280-8964-cee348a66d3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_24a903d5-d9f0-4280-8964-cee348a66d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_55b5d8db-de21-40b4-b9cf-8ab04d3db69c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:to="loc_us-gaap_EmployeeSeveranceMember_55b5d8db-de21-40b4-b9cf-8ab04d3db69c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember_9a5f1a49-892c-4e83-9e96-5b5d04d20397" xlink:href="arvn-20250630.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:to="loc_arvn_StockCompensationAndBonusExpenseMember_9a5f1a49-892c-4e83-9e96-5b5d04d20397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e46877e8-e04b-4cc5-a7a1-5d399db6674f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e46877e8-e04b-4cc5-a7a1-5d399db6674f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00fb2ace-01ce-4539-bce1-6836b85f4e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00fb2ace-01ce-4539-bce1-6836b85f4e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbef40e2-c8f4-4859-8508-cd6f9a4dbd03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbef40e2-c8f4-4859-8508-cd6f9a4dbd03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_48445c4a-ab42-46b4-95ea-ace283ea1f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_48445c4a-ab42-46b4-95ea-ace283ea1f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ab821128-e3a9-4d54-9578-68f0a35cccba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringCharges_ab821128-e3a9-4d54-9578-68f0a35cccba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4201a4f-e807-48c5-beb6-2c92e874be89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringReserve_b4201a4f-e807-48c5-beb6-2c92e874be89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformationFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06de6f6f-b910-4737-8ca0-e1953d47fccb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:to="loc_us-gaap_SegmentDomain_06de6f6f-b910-4737-8ca0-e1953d47fccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:to="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember_6249f45d-f6d3-4ad3-88ce-78edc0a35945" xlink:href="arvn-20250630.xsd#arvn_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:to="loc_arvn_ReportableSegmentMember_6249f45d-f6d3-4ad3-88ce-78edc0a35945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:to="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18a6be72-1dcf-44d3-b65d-b1d52a038e4e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:to="loc_srt_ProductsAndServicesDomain_18a6be72-1dcf-44d3-b65d-b1d52a038e4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:to="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member_60faebfd-416d-4b98-965b-bfb61d480aec" xlink:href="arvn-20250630.xsd#arvn_ARV471Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV471Member_60faebfd-416d-4b98-965b-bfb61d480aec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member_12771f5d-5c60-4184-81a6-e425751fbb86" xlink:href="arvn-20250630.xsd#arvn_ARV102Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV102Member_12771f5d-5c60-4184-81a6-e425751fbb86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member_8e39a7f5-599c-4e6d-b5e7-5faa3f09a746" xlink:href="arvn-20250630.xsd#arvn_ARV393Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV393Member_8e39a7f5-599c-4e6d-b5e7-5faa3f09a746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member_a2640faf-83bc-4959-827c-73c4e4f83f89" xlink:href="arvn-20250630.xsd#arvn_ARV806Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV806Member_a2640faf-83bc-4959-827c-73c4e4f83f89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member_3c69d8dc-cf50-4ce1-9f20-a5e674887592" xlink:href="arvn-20250630.xsd#arvn_ARV110Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV110Member_3c69d8dc-cf50-4ce1-9f20-a5e674887592" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member_5f3191f4-4a10-43a1-a373-78f49e332f3e" xlink:href="arvn-20250630.xsd#arvn_ARV766Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV766Member_5f3191f4-4a10-43a1-a373-78f49e332f3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember_d979a88a-0977-41a4-acb8-4e6762e68c61" xlink:href="arvn-20250630.xsd#arvn_OtherProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_OtherProgramsMember_d979a88a-0977-41a4-acb8-4e6762e68c61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd03264e-9e1e-4483-8f54-751f0e2d32fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_Revenues_cd03264e-9e1e-4483-8f54-751f0e2d32fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_8d6c982b-5954-41e3-bf15-de8681aeb85b" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_8d6c982b-5954-41e3-bf15-de8681aeb85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_cb2c9b85-a54f-43ef-bca9-ed6257c94b04" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_cb2c9b85-a54f-43ef-bca9-ed6257c94b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_aee54c4c-b80f-4535-a938-60593c83671c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_LaborAndRelatedExpense_aee54c4c-b80f-4535-a938-60593c83671c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_565a37be-e3f1-4baa-b752-0402e7f8059e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_565a37be-e3f1-4baa-b752-0402e7f8059e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e18b2a59-a76c-4ea5-88c2-3459c64477cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e18b2a59-a76c-4ea5-88c2-3459c64477cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_710c580b-c855-43a9-bb9c-310cb32f9b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_710c580b-c855-43a9-bb9c-310cb32f9b4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_f72804cc-994d-45b6-817e-6efbb9f33ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_f72804cc-994d-45b6-817e-6efbb9f33ccc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dcbfb598-1e31-40a4-98f7-2f33d0e135db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dcbfb598-1e31-40a4-98f7-2f33d0e135db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4632d6d4-4ad4-45dc-9d09-276ca2868bed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4632d6d4-4ad4-45dc-9d09-276ca2868bed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f1c1446-d746-49c0-9df5-84d448e50f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_NetIncomeLoss_5f1c1446-d746-49c0-9df5-84d448e50f2e" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arvn-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_dde97e95-a152-4dac-8116-d727575e098c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accounting Pronouncements and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_37063c26-1845-4f6d-b335-87fc7962dcda_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_5f506276-7da1-4cb9-a8c4-d71e92f66e5f_terseLabel_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arvn-20250630.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5d9950eb-b198-4f0d-ab0e-e4ba7ac7d574_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_b840d5c7-d5dd-4f9a-9ff1-9ec4084d097d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6a56d415-2688-430b-ba3b-26f9b83bb5e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e91b1440-e2ee-46db-b756-d22fd91abe1a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bcb1f6c0-0e70-4422-ab83-1596c720eefe_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2e4ab597-8634-485d-b8b7-5af259ec722e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_ab750796-15f8-4e62-bbbf-771500312734_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_f724a260-50a9-4c65-9355-22fb361052c1_terseLabel_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Updated Research Timelines</link:label>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_label_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Updated Research Timelines [Member]</link:label>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_documentation_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Updated Research Timelines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember" xlink:href="arvn-20250630.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_UpdatedResearchTimelinesMember" xlink:to="lab_arvn_UpdatedResearchTimelinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a03b8055-da98-4287-a950-8f46cc403c84_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_0f641ad4-1ce6-4cc8-9655-205c01ffd75d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_b1ff016e-1497-4348-a2f8-0452e16ea03f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_c56383f3-00ba-436e-aeed-5bbd8e3bc951_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_67881a41-5fa7-47dd-a455-a152ba54af5a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_084c23ae-0039-456f-b988-5b0274ec591b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4b8b77b6-6c20-4017-8ef5-d7c888459d26_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d57aee9-7236-4e03-9c49-829c4287f887_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="arvn-20250630.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4ef61a66-02f0-47bb-b327-1770dbda8094_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of reportable segment financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_87c0d4a7-a475-4a50-b47a-a6828a2edef8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_23853061-f571-4129-b392-98ceabb8e3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_87306ae6-08b6-4554-b765-2836897b65a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e55ffafe-3c6c-4910-ae14-6b7da9fad1b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_35f8bb18-b2ae-4953-ab7f-158a04e9d3c5_terseLabel_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payment for license</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_label_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual License Fee Payment</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_documentation_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual License Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment" xlink:href="arvn-20250630.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AnnualLicenseFeePayment" xlink:to="lab_arvn_AnnualLicenseFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5cde5215-2ab0-4cd1-8a96-7714cc8b0a68_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8872f1e3-ce38-454a-888e-81784b034730_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_50674d8e-aa04-44d7-972d-9f3755d31bc5_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesTable" xlink:to="lab_arvn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ac263275-a0d2-42d9-ac76-7a6db03a9dc5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9110ee53-21c5-4d43-bd47-b41347ef20df_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fe69c50d-6fd5-48d2-a33c-2cb74bb72d1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0580b0cb-5192-46e9-a3b1-50bc03e2f2b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9c56e7f5-5f79-4a53-ac4e-d4b7421b8def_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fc4ab874-9c0e-4072-a3c8-8c0bca4f1859_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_727098e8-5652-490d-87f4-94ed3acdeba9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_63071e6f-b9dd-4dec-8de9-db8c0a55b5b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6ff37320-ef6c-484f-9937-79e6e75d896c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_de4ab58e-cbf8-41be-8fca-4dc63c9380a8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled/ Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fcaf50f3-3737-4ded-b5af-a6e7be9451da_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60c23ee8-3294-488d-8b41-0b0bc0f9b7e0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6d4ebf64-5e04-435c-b701-211ecdab661d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0a8e5e3f-1501-46fe-ac4c-08c2e2536569_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1b862967-0c8b-4f74-af89-c35fae623a74_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_321bc158-97d5-464e-a348-0dffd9b28104_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:to="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4274c4d1-f5f5-46af-a246-a278a1d6fcff_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e1dda28a-2aaf-4b66-b27d-1f74b7f26796_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9298ab78-9dfe-4c4f-b580-3813c0a8c087_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_39b80615-b753-414e-8e2a-7744ea6942de_terseLabel_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future grant of incentive units to service providers percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_label_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Grant Of Incentive Units To Service Providers Percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_documentation_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future grant of incentive units to service providers, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:href="arvn-20250630.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:to="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_882e9370-84cf-49c3-bf2e-376e255ee8cd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_e0b07da5-8edf-4a28-9287-1c262aaf6319_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_619be754-39d0-4625-8a82-4cce736feb4c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_74d1867c-681e-4c7c-bee7-35972d2065d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_54c84055-d110-48a5-a84e-df9adde5207b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b6aafc13-f359-4817-92af-8140b40e7f0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_a8bf28a0-010a-4126-b6dc-2c22ada36bac_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and issuance of ESPP shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_label_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_documentation_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:to="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0d83f1c3-246e-4b82-a210-d88bde17a240_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9079cb55-3567-4619-8ca6-735e2b07a7b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7917d308-80cd-4195-9731-aa780afdc8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6f8ce19e-2c6a-41a9-9041-b9f2ee946cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_ae08b724-c395-4cf6-8fe5-06344287a90c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_41f371ee-0a5f-4aaf-9cc7-7b048a7548b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_36dd952e-6aba-48ab-a8e0-7756352fd392_terseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:href="arvn-20250630.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_2c3c06fb-8200-443c-adbf-619e3ee025ad_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_cc7399c8-0976-4f83-9a75-c52bc58a6ffa_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6be7c76d-7ecb-48ae-a057-9e41b900228f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5fcca881-1bd5-41b2-91e3-d08589ccdf08_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ee9da94e-8530-47ae-b2ae-5f824edf835c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_c91317ca-0b34-435e-8da4-5df2c905c4ab_periodStartLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_50d2511a-9673-45b1-bc02-a8fd75720444_periodEndLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_324b7bed-7457-4106-afa6-d0c031761f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property, equipment and leaseholds improvements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6bd766f4-963c-457b-a14f-0abeb40bfa47_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_a9130547-785e-4c56-8d5b-9f9c8550da76_terseLabel_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oerth</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_label_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_documentation_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oerth Bio LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:href="arvn-20250630.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_425f502d-f03d-4b69-baf3-887c381cf0c9_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current installments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2ff2ddb7-1b70-4c03-bf2d-ba842f4a6aaa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ab1bd6d2-44dd-4cf1-a9b4-53d426e89ecb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_66aad1a1-2790-45c1-ae7f-3c0002dfe490_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_73c5c5e4-1d9e-4394-8d73-f672f1585e79_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring accrual</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0c4da11d-2d92-4888-bf67-3b2203827301_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_70af5504-fd43-40ed-8ea8-2617e068c173_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument interest payments term (in months)</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_label_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Payments Term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument interest payments term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e0a38ef3-8988-4344-8c58-7024ada59392_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d0d26c10-d468-4a74-b833-01448d1e99c1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1e483fe-683f-46eb-b70b-dfb5c097697a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_01f4b8c8-8268-40e5-b94c-ef16389d90b1_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_6df16f5a-30f6-49a4-aa98-f78f15d4d761_terseLabel_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:href="arvn-20250630.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:to="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_901d143b-9af4-4f94-9ae6-f06a4e65e375_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_81d855a4-fe82-46e0-9e3a-dbfd39fac17a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_a2272159-a7a0-4d3a-b407-b27b99c6e794_terseLabel_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity distribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember" xlink:href="arvn-20250630.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityDistributionAgreementMember" xlink:to="lab_arvn_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a2b9adc2-8988-4550-a4d5-c83cc9de43e0_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_50e69b8c-8ed9-4bc3-bb03-a509aa519728_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab3cbc8d-3f12-4b05-b0f7-e3b9f2fd1ac9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RequiredMilestonePayments_b5259bc5-7000-457a-ba75-4b8e409707ad_terseLabel_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required milestone payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_label_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_documentation_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments" xlink:href="arvn-20250630.xsd#arvn_RequiredMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RequiredMilestonePayments" xlink:to="lab_arvn_RequiredMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1484d4aa-602e-4506-8bed-e95084fcdeb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_739d338b-7a6f-43f4-9d40-7de72c83b47c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_a4fe2604-2d75-4839-96ed-3d07192131d9_terseLabel_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities: Deferred revenue</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="arvn-20250630.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a66fddd7-a6bb-4c9e-9052-b8f35bca472c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_a72ed1c6-7a01-42ba-849a-cce77c292512_negatedLabel_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_label_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_documentation_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:href="arvn-20250630.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:to="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c7905075-73d9-437d-8bf7-adfae23d62d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4f64699c-4ef1-4d5c-b163-6c248b674dee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f714eb9b-830c-40ce-ad66-91c826e752b5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_117da418-ba10-4236-849c-706c895f90ea_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expense, net</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_23ebf214-5f74-49a4-ae03-11068250e570_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e3ac7b4c-1c42-40bf-a97d-b5ee34ed5b36_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1530dadf-726a-4041-a0dc-d8f24909b92c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_675190dd-1f47-4612-8f61-df585a9b44af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6ba9254a-f2b4-46e2-8d84-fafb02129984_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_82aeb39c-a0ff-46f8-a65c-172564562028_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30f2eba7-8df8-422f-b652-aef6cac5d2d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7af6c8e-0d9a-4271-8509-259a8f8ee3ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_64646081-94e4-4fda-aaa5-1832946b5296_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_b3b014f9-8ffc-4bab-8136-17bb9fd0ad88_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fab7809d-3382-4444-93c4-0deb8ec7866b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_71109388-81e5-46cc-ae2e-770855be5244_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_020cdf7b-673f-416c-8f63-0e27eacf6cbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_e0646a93-8aa1-45d6-bcb1-091829f52789_terseLabel_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Piper Sandler and Cantor</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_label_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piper Sandler And Cantor [Member]</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_documentation_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Piper sandler and cantor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember" xlink:href="arvn-20250630.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PiperSandlerAndCantorMember" xlink:to="lab_arvn_PiperSandlerAndCantorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7d47dde1-02d5-4760-83cb-4ab3c004e943_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_0530f190-cec7-4574-baab-1e3a613dcc15_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_4e1de471-75cb-459f-8a45-78a614252b60_terseLabel_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Second Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Second Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Second Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember" xlink:href="arvn-20250630.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseSecondLicensedProductMember" xlink:to="lab_arvn_LicenseSecondLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OtherProgramsMember_684c8e51-9dcd-4d3c-a078-2c981b3e2f07_terseLabel_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other programs</link:label>
    <link:label id="lab_arvn_OtherProgramsMember_label_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Programs [Member]</link:label>
    <link:label id="lab_arvn_OtherProgramsMember_documentation_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember" xlink:href="arvn-20250630.xsd#arvn_OtherProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OtherProgramsMember" xlink:to="lab_arvn_OtherProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_5a69b84e-e9cb-4a00-a396-3141c825da4c_terseLabel_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payments</link:label>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_label_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Contingent Payments</link:label>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_documentation_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Contingent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:href="arvn-20250630.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:to="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_d5503d5b-ec8a-4823-b3e9-1200d99388a6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_994f1522-0a5e-472a-8ea9-e46b1300ce5d_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_5d111ddf-36c7-4580-9919-789cf9504e65_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f62fc45e-f152-4526-8334-d969b31f58a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NovartisPharmaAGMember_8c088231-cf38-4148-a356-a08b492d38cb_terseLabel_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:label id="lab_arvn_NovartisPharmaAGMember_label_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_arvn_NovartisPharmaAGMember_documentation_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember" xlink:href="arvn-20250630.xsd#arvn_NovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NovartisPharmaAGMember" xlink:to="lab_arvn_NovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2a59fa9d-de40-4e40-8a38-45bd000f5393_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8fd4034c-7204-4a42-9286-37292a786724_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7f6f7f47-a0b3-414f-a2b8-f9af87b7effa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9b76b330-2d3e-4ca7-be87-156f1adc0c1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cebf5b17-9d23-421c-9d97-7cd5c8979e66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b341ef85-5c07-4a97-9157-1fb932fa3467_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d8fc35b-6541-468e-94f7-0283e72c949d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b020c3b-a821-4708-91cc-7c5bf47e6860_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80aa9b72-7630-4e5b-8cef-bb0ed40773cf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6c64c335-7c91-4a45-a5c3-234f3e671f50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_59841c6e-01e7-4f9b-8457-18074f6bd967_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5e8e69f9-2609-4745-a8a6-db3af8d17ca2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_f31ccb6b-e162-4901-bbaf-046e30c57265_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of inducement grants (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3a66de0a-ca36-4b59-a7ed-e19b027063af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_070fef58-d236-4d47-8ba1-a50b3c2d9032_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_59a1a669-d716-498f-a992-4ba6bb1c08c6_terseLabel_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement direct and incremental costs incurred</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_label_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_documentation_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct and incremental costs incurred to obtain the contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:href="arvn-20250630.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:to="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_67068cb0-bc7e-4371-8a23-4e4dbc1bd357_terseLabel_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract" xlink:href="arvn-20250630.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract" xlink:to="lab_arvn_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_dbdc11f7-2207-43f7-af62-c1b7f1ee3ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in reserved shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_81ef7001-b91f-49ec-9a4e-f9aa73ad295b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PaymentsForCollaboration_b8266577-dca9-4efc-876b-e5971d2d6765_terseLabel_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for collaboration</link:label>
    <link:label id="lab_arvn_PaymentsForCollaboration_label_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Collaboration</link:label>
    <link:label id="lab_arvn_PaymentsForCollaboration_documentation_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration" xlink:href="arvn-20250630.xsd#arvn_PaymentsForCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PaymentsForCollaboration" xlink:to="lab_arvn_PaymentsForCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b3149614-b80f-4c63-83ea-3c8d288fe213_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8614375-4fe9-4b61-8277-c04c32e5885a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_ee73ae0e-843b-49c6-8577-77e135a0930c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e5888d4a-700f-4a54-870a-b5246fdab3a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_20d39fa6-9894-43fa-b5fb-65c002de5228_terseLabel_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_label_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="arvn-20250630.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:to="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PreFundedWarrantMember_b2ce6838-539e-4158-8cde-5be3420e4f94_terseLabel_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_arvn_PreFundedWarrantMember_label_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_arvn_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember" xlink:href="arvn-20250630.xsd#arvn_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PreFundedWarrantMember" xlink:to="lab_arvn_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87889edb-b15f-4b04-9ed2-6587c6cc5b77_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b5cd2105-7e4d-47ef-916f-f6b3093b3c84_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Activity</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1439f006-ba2e-438c-a9fa-dcc129909491_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b74dea78-616e-41f4-a311-2e9aafc015e3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_7ed7a6fe-4046-49ca-aacc-93f21bf19398_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_53a144c5-30ac-4174-9284-0fba1c7cace3_terseLabel_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program-specific external expense</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_label_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Program Specific</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_documentation_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Program Specific</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:to="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65cc493d-eac5-4f41-8502-6e3b70898db1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7ecbe218-de0b-4a26-96ca-dd79b937cd0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a80f6a9b-95cb-47c7-a01a-791f8a6fb3d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f94a2f6-e147-45c5-810d-64a2a91a3e7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0abc3644-6a82-4f75-90b6-604be4e10601_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0ab97624-268c-4fc0-8db7-021b73243bc5_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e3f4256-c165-4cd5-95f6-fbf09a8474f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d4a9617b-b559-4322-b4ba-a13057391a8b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV102Member_8ba48b1a-cb83-49ee-95d5-3cc21f154eb7_terseLabel_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-102</link:label>
    <link:label id="lab_arvn_ARV102Member_label_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-102 [Member]</link:label>
    <link:label id="lab_arvn_ARV102Member_documentation_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-102</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member" xlink:href="arvn-20250630.xsd#arvn_ARV102Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV102Member" xlink:to="lab_arvn_ARV102Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5dede000-57d3-44f5-ac7b-061ebd15d3db_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fb389544-60ad-4f51-ab41-d0b75598d768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d8b5d334-1d00-4e89-beb8-fa54f5e7164f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_fccf4e48-cf1c-4fcb-8820-51b6a0b46e4c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2d7fc76b-eb83-4ebd-8735-2f6cc38d5f6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d7fbb0cd-46d8-4ae2-b6b1-b4ea83df887c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_c646f230-e8e9-4785-9fa4-2100a937d8e2_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and eighteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:href="arvn-20250630.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_02bf5d87-78ef-44c9-91a5-50761ab154a8_terseLabel_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License First Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License First Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License First Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember" xlink:href="arvn-20250630.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseFirstLicensedProductMember" xlink:to="lab_arvn_LicenseFirstLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bf1401fe-a176-465a-b311-a88289f7e1ab_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_be04acc2-f86b-4853-b26a-0fc23843d47a_terseLabel_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Removal of Combination Trials</link:label>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_label_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Removal Of Combination Trials [Member]</link:label>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_documentation_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Removal Of Combination Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember" xlink:href="arvn-20250630.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RemovalOfCombinationTrialsMember" xlink:to="lab_arvn_RemovalOfCombinationTrialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3a225725-cfb4-4ae8-b67b-587885acb310_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_730acca7-1d5f-45b5-8987-3c53e8aba4cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_554748c2-d5bf-4087-a170-408bf43b0913_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a29e37e1-5a0c-48d5-ae70-2e0428f5e524_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_28bd7a8c-84f5-4372-83b3-4749651110a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_96a67710-b981-45c7-9b44-99f1ab81f2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6221adba-c6ea-4205-9cb5-92ddc6ed28cb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1a144b91-52da-42e2-b6a0-8902df23dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in workforce (as a percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommercialMilestonesMember_0a2e5ac0-472f-4d9e-b3e5-24ffb6542ed8_terseLabel_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_label_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember" xlink:href="arvn-20250630.xsd#arvn_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommercialMilestonesMember" xlink:to="lab_arvn_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_39be7bf6-90ce-4ed1-8495-c55b9c2d51ce_terseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration contract asset and other assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration contract asset and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:href="arvn-20250630.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_04ea026a-c96c-4d85-8571-cc070e71128a_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20250630.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ReportableSegmentMember_ef2f36a1-60cb-4465-89ec-faefef0362a8_terseLabel_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_arvn_ReportableSegmentMember_label_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_arvn_ReportableSegmentMember_documentation_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember" xlink:href="arvn-20250630.xsd#arvn_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ReportableSegmentMember" xlink:to="lab_arvn_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_10c3d2eb-bf9f-4d38-8f3a-20520f78a55e_terseLabel_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:href="arvn-20250630.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:to="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_59356a03-14bf-4df8-b51a-b8da1a5a2803_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_aaa06622-5701-4372-af48-5367f51fb75f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_8dddf453-b489-4d8b-a6d0-7d9108b6911a_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Change in Accounting Estimate, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_24d79c97-e0ff-4556-9ca2-8ce2bc6f458b_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_aca9c159-6aa4-477b-85b5-cecf2ac3721c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8ab4ba62-a081-43c1-9fa8-a4be524dbccb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7b9c4eee-53d2-4177-a5d1-7317b92e8ff7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_11ff952f-f59d-4ed7-8702-0d675705622a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_736db711-19a0-4f2c-8dea-55cd36b7ca10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_03739244-260d-4265-b793-69b5a0591351_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_a4ca03c2-929d-4c50-90b9-ff99c45d06b8_verboseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c09bf45b-2ca8-4d61-867a-344daebd78ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_42784232-e592-4894-930c-34a844a9da17_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4dec5670-aa83-4cb3-9bd8-37d354eeb0ab_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e3118fb3-6ab1-4c8e-b09c-812c39be1162_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_ec998932-5e2a-4453-9fad-8b86e1113530_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from new collaborations</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized From New Collaboration</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized From New Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:to="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_65014520-4605-49ea-8494-14ea22b109eb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_2b025f04-160a-4536-8966-fb44a8cb0981_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to collaboration agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_86097a13-c600-4f1b-9307-f622d2273ca2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ae007cd1-ef58-443d-a5bc-da8231bbbf07_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_4015313d-7e3f-48ee-9da3-64e827bd57df_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_189597d9-2aec-475a-91f1-2f399af50c1f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV471Member_c03bb1f9-d9dd-4e81-8bc1-17cb30944238_terseLabel_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vepdegestrant ARV-471</link:label>
    <link:label id="lab_arvn_ARV471Member_label_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-471 [Member]</link:label>
    <link:label id="lab_arvn_ARV471Member_documentation_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-471</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member" xlink:href="arvn-20250630.xsd#arvn_ARV471Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV471Member" xlink:to="lab_arvn_ARV471Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d22c9359-1d41-46d3-bd67-e2e1678caee3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2f2805f-f218-48e6-ade4-ed1b4b6fbc8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6fad145e-84b6-4c14-8d28-43ba610de73e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_0732b656-1c7f-4c53-9957-70d01a4f030c_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_38e1d678-dcc3-476f-a4ed-3dd0d09676db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7d3e18fa-58c9-416f-a487-5b7eec95b198_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_849acf82-9798-40fc-9338-e99bd9e7438b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Minimum Future Payments on Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5958d778-87b2-4716-be7e-fbc940482c1b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_31102bb5-a0c4-4ea6-bb64-3de03842de96_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b567d596-0bbc-4675-a9ed-57d076568bba_terseLabel_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental non-cash information:</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_label_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_documentation_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental non-cash information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:href="arvn-20250630.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_657e9d87-03da-4556-8efe-3464b3ecf2e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_e305600e-a9a7-49d5-a023-adb9f07e2a8b_terseLabel_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Payments</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_label_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Payments [Member]</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_documentation_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research funding payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember" xlink:href="arvn-20250630.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchFundingPaymentsMember" xlink:to="lab_arvn_ResearchFundingPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV806Member_e3196c47-9fb0-4267-b4ce-7a30aa32265b_terseLabel_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-806</link:label>
    <link:label id="lab_arvn_ARV806Member_label_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-806 [Member]</link:label>
    <link:label id="lab_arvn_ARV806Member_documentation_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-806</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member" xlink:href="arvn-20250630.xsd#arvn_ARV806Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV806Member" xlink:to="lab_arvn_ARV806Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_73c36fa0-8854-49f0-ae7a-b309779646db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7b22dcb9-1c28-41a2-86b2-38748ed7dc73_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_851abc4c-d2a9-4cfb-be55-7f92823b43ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0c2d0301-c272-4731-a378-beb2609d6886_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_35255041-b645-4347-b2ce-b8303c5a58ba_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d5be6742-8566-4c5d-a5dd-026fc554d8a9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_624e1c69-f9f2-4962-acec-7b03b6fddd00_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c79c6fb4-ef67-4f1b-b588-8b53bf076a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_312f298e-df46-4e62-8404-d34a3208aeb6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f14be884-70bd-4b3a-89ac-1129db9caecf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_93a7e352-e372-47a0-8f0e-c12149fbf5d8_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bea4407c-d65c-4c6f-874e-ee768fc7d695_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7f389ece-ed45-4646-9e6c-dbf4e4505e46_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_14aa3d62-f9bd-4ea8-b68f-f89ea2cdbbd0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_303d4241-1d78-4957-9e73-751b967e1a68_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_75227143-98cd-4ea4-8046-a971226461d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_53046d7e-8876-4fae-9953-6afaf7ea93fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/ Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f554f940-6f4f-4cde-b070-649cbf4c869e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_779e3ef3-4ad2-4f6b-802f-1051995b3960_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_49234c2c-6478-4759-ac79-89ae1db11f13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0b039366-441d-4a74-bd4d-663bff60edb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_18c3b435-a818-4c32-8176-048c253b6f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7016f3b7-f4db-4f37-b289-d10cfa60a3a2_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8488db9c-5d17-4ae4-8c7a-028cc9f89258_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_01baa6ec-5969-4e16-95c1-c3f84b14e6e5_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc26b2db-c367-4ec8-b5d8-b92637fd9a85_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_08cfac3b-351e-4041-8a25-8e96ac425f04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument bearing interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_94677e42-c2db-4a91-88af-376a96d93da8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_a9b04221-f19c-402d-8dde-220b685536e3_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_label_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument loan forgiveness.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentLoanForgiveness" xlink:to="lab_arvn_DebtInstrumentLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_320a3c14-8022-486a-8156-67365884eae9_terseLabel_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative and commercial expenses</link:label>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_label_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative And Commercial, Current</link:label>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative And Commercial, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:href="arvn-20250630.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:to="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_21d95914-0381-4ea8-a6b2-bf25e4d3c205_terseLabel_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_label_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_documentation_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:href="arvn-20250630.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_63861d3a-1655-4cc5-805e-6b0f70852daa_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5dca6ab6-6c53-4f7e-83ee-d49e39af6f3c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_02aad896-9d5d-4343-9709-02f141caea59_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_4561e0fa-c455-4ad2-ba58-b6de2d70abc7_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of liquidated damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_label_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Liquidated Damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_documentation_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of liquidated damages.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages" xlink:href="arvn-20250630.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfLiquidatedDamages" xlink:to="lab_arvn_PercentageOfLiquidatedDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_19f916db-97a8-427d-83c3-4e78fbc0ee94_verboseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related personnel expense (including stock-based compensation)</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_14d2404e-f5dc-4c13-8a85-93777ffdf766_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_a46f7b43-5446-4263-a09d-3ae14c4c949e_terseLabel_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval of First and Second Royalty Products</link:label>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_label_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval Of First And Second Royalty Products [Member]</link:label>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_documentation_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval Of First And Second Royalty Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:to="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ab1eaeb0-fa2b-4850-b9bd-e1851cd9bfe1_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of stock options and RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1172280e-704f-4434-93bb-d5881e81af48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8cc472b3-0fc4-4d44-9816-b4d3e981a9e9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled/ Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5dd9bf8f-0281-4aca-81ed-26cbbf63597d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_44acd1fc-882b-43e7-bfb2-ed17a7ebb94f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c0130f84-7594-440a-8e2c-9dbf0dd430c6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2f92f803-491a-415b-a730-95e7c6d78905_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_af473b04-e087-4d4f-97cd-0a09a6bdfb57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fadcb982-7e76-4c32-a64a-6ecda3e381f9_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net accretion of bond discounts/premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cd3e080b-d741-45bf-af0a-80c765e0af1f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6a5fe8c4-b778-4330-98e9-d50efa0a1a53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2482d15e-afea-48bd-81d4-fb0638277294_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7b6d9a9d-08f0-47ce-b3bd-79cebc74ce94_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7da27882-9c8e-4846-bb4d-dde301f8e5ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationAgreementMember_054d0bf8-d277-488c-a776-c6ba340c546e_terseLabel_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_label_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember" xlink:href="arvn-20250630.xsd#arvn_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationAgreementMember" xlink:to="lab_arvn_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e7dc5ec2-16ca-417e-b0e1-a5b32db8b5e7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_e2a80a46-064b-4c97-8b23-833929862e84_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:to="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0874149f-cfe1-4736-90f2-1d0fa1810db5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8df7875c-2ab0-4478-a01a-5a12a62be731_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_92b027c0-2729-4266-ac96-de9936dc5a22_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cd37ad56-1a12-465d-984b-bb3e59de51f5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_a362bc82-6f8b-42c7-ad32-715db56b7e77_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_4d5ca9f2-280a-417a-94cb-6cab548afb2c_terseLabel_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum aggregate offering price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:href="arvn-20250630.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:to="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d6c4875f-f3ee-4d3e-aa59-59c169a14305_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b48e9650-3e41-4a84-b99a-9289f3dd173d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d2809ba-c61b-4a87-bb1f-e2bec3be22ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5b11759f-a6e3-4717-90c4-d52d0763b4f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Consolidated Statements of Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c0a6c1e0-7bfc-4aec-86e6-9ae0ab91428b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from balances held at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_faedbd17-7d01-4891-b868-224f898aaf26_verboseLabel_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for pre-funded warrants (in shares)</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_51c8be35-99c7-46e8-9cce-1eedb6905367_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_607b0468-f5cc-4ad7-994a-27f387471132_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_b46f17c5-2fe9-4ca6-8afa-e0d5c99bc01a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_adcf1df7-4126-424d-bf8d-71d657cdde80_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_d1247582-959e-470d-9731-d6850a2d62a9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_17a4351c-1890-42bd-af62-5c9e55c19ea3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe7d753a-d24c-47c6-88bd-405fd3a60ff9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d7dd12d-2042-4682-91d2-19b6b4ec35e8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_cdb5d56e-d615-4c72-9f16-6ad7d3ffc3f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04b73d24-ddbe-493a-9a3a-6900d1480a8c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7839efd9-667a-4949-baa4-0d938ee50a38_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_50729c96-f964-41f3-bf73-40d73713f952_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_YaleUniversityMember_ceed6f20-aba9-4b61-ab44-6a8275e2e63c_terseLabel_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yale University</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_label_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yale University [Member]</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_documentation_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Yale University</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember" xlink:href="arvn-20250630.xsd#arvn_YaleUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_YaleUniversityMember" xlink:to="lab_arvn_YaleUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_de0d7750-c6be-4c54-9146-b73f39512086_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Transaction Price Allocated to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8b0e77b-2d27-44c6-9c13-a4471743e28e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_297f49c0-0b08-45b2-8a1d-02a60251b40b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to be purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f593ed9f-ee69-4aff-bf8f-42cfed689b1d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aff3e39f-ea03-4d57-95b4-bfc4e6c86cb6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_3d5a0b63-ff4d-44cf-bcde-e4f2c32ede79_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_c74da893-705a-412a-a891-17df364d79ef_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:href="arvn-20250630.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1476c81c-1477-462d-b4d0-8df1a3013331_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0993d04f-5a2e-4ab1-b7af-82faeff8cc97_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, zero shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c22a2c14-42b7-4369-86fc-e9741fd64d69_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0719d314-5bc7-47bb-bd72-e53ba7ea4d94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b963b3af-d819-455a-9514-423eeec2f385_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 73.2 and 68.8 shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_913a3496-6d60-4f60-9085-03e172366613_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9294be2f-3c7c-4b4c-888a-567786433b9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d21aab4-09a0-483a-bad2-6128fc2e5c53_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07d02697-c054-48e6-9bd0-29d9a8d08e83_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_20f79787-28d7-4968-9a88-17ad7521fd93_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_2412bbfc-9e14-47e1-b986-7a0b95587871_terseLabel_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets: Collaboration contract asset</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_label_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:href="arvn-20250630.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:to="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d4fe70a4-b2a7-4281-8e28-576c28210225_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ab2d6c15-f2ff-492c-8395-3f124d2e2f73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_96284eb0-ce3b-492d-99fd-a4c877cb1fe9_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement grants (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6e11130a-58fb-4b2d-8d82-705df18d4772_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d69a64a1-c8e4-4a73-b760-5dcd58a2b75f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_c0b04e42-cf72-4852-973d-f27683a10273_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest, percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_985e8642-4374-4d6d-b369-e85da122bc9b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5a0ae3f4-6502-4205-8fbc-088af665660f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerCropScienceLPMember_27fb2fc6-5a23-4311-936e-504e62e1f32e_terseLabel_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer LP</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_label_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer Crop Science L P [Member]</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_documentation_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer CropScience LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember" xlink:href="arvn-20250630.xsd#arvn_BayerCropScienceLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerCropScienceLPMember" xlink:to="lab_arvn_BayerCropScienceLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c29317a2-4030-4fe4-aa8a-613672fd193b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_a197d78b-b8e8-4d3e-87df-ed46e8b7094b_terseLabel_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arvn-20250630.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_10171fb5-0db8-4b67-9f8e-f016bba82927_terseLabel_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Payments To License Agreement</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_label_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Payments To License Agreement [Member]</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_documentation_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option payments to license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:href="arvn-20250630.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_26788cad-b607-46ba-a94d-20635b341f8d_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20250630.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_6488ad82-49a6-41a5-bbb4-71d3e3d061d2_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory and Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory And Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:href="arvn-20250630.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:to="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_b9ff695d-d0e0-49d3-9f6d-5050fbb967fe_terseLabel_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:href="arvn-20250630.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_e5cec11a-5132-482a-b2c8-3e3d0f787ccb_terseLabel_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Compensation And Bonus Expense</link:label>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_label_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation And Bonus Expense [Member]</link:label>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_documentation_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Compensation And Bonus Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember" xlink:href="arvn-20250630.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockCompensationAndBonusExpenseMember" xlink:to="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24fbf05d-d99b-44d9-ad7d-e281c182c6f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5efb66e6-eb72-451e-a6b4-5d81596e77c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerAGMember_6944e92a-2008-4cfe-965b-9c96f2e0a831_terseLabel_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer Collaboration Agreement</link:label>
    <link:label id="lab_arvn_BayerAGMember_label_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer A G [Member]</link:label>
    <link:label id="lab_arvn_BayerAGMember_documentation_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember" xlink:href="arvn-20250630.xsd#arvn_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerAGMember" xlink:to="lab_arvn_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_150e1d44-2dc5-4a8b-81f9-4fe950dae12e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0c72243d-8e86-464d-8933-0a754e769ce7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d5cf61b2-3107-45a9-b684-1d5a8065da46_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_0c9e7f3b-c9e3-455c-ab10-77ceab3fe2b7_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7fea3478-ff84-4847-a355-c4809f58ff96_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06e4833a-dddb-49d5-90ad-b1d1b237d113_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_3a76cb83-1ca4-4b39-97ad-285984d0ad6a_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d5546e06-460e-4077-b28b-913c6873c6a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05a91846-9ee2-4d94-8e35-04eb8fe0aca9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f552bfc6-d6a5-436e-a78a-9ee0f557cb19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_583cbcfd-c77e-43cd-b51b-0ae6004e6888_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_28232dc8-e686-4254-ac67-d391fc87f87f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_606819f3-d052-47fa-bd25-65e09f897f3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_897764e5-4781-4a0a-80ae-470a54e1a544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in reserved shares as percentage of outstanding common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2c05cba2-cc1f-4460-9345-000861b8900e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_fe3907b8-15f2-400a-ab82-b0c62cc47b0e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_7bb521cc-7223-434f-8a94-29b5699a6578_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_435e532a-5165-4b46-9409-e852971e7318_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease for laboratory and office space (in sq feet)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c5ab6a2f-ad9c-4c0b-bb53-eb788847145e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_20e52f1d-524a-45ba-a074-baf396ffb40b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bfb56a62-d0fb-4e96-a81e-930e18ad2da5_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fc74a96d-f4a0-441e-bae0-ecf7475be63e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7191dc46-0bd5-4f41-a5bf-aa3652c1b8fb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_9699e73b-71e9-4b44-ad41-700d24158adb_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_bd604efa-ac83-4332-9b73-ae5819f8a463_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State of Connecticut</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_39d9c215-d646-4039-949a-994220dbefe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9df71097-1a3b-4f1e-bb59-3d43588b4fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_937e702f-1782-4cc7-abc5-2ec2d66653ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4a764d1d-5431-48a1-8e9e-d42d6eb1a133_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b80af720-4ffd-4633-80af-8c64938a83af_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b2f14792-21e9-4ba9-abf9-a06ca2b0c392_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2fd0f6a0-e901-4ea7-86f1-e652a917106f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_83a4ae77-8f09-4ee0-9740-131646e22f93_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d2818b58-06f3-49e6-91f3-64a454045d67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_9fda816c-d8ca-4353-a105-437c601c80b6_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonesMember" xlink:to="lab_arvn_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0004de75-c196-46f8-801d-52eefe74a8d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) earnings per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f9f92181-a38a-462f-9e6d-7bbd02f97ee4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_31ed1e08-dc93-46a6-83ef-083ffe6837d5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_f6a9e144-8a4c-4a6e-b7eb-290a1a215728_terseLabel_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance represented as percentage on outstanding common stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_label_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_documentation_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:href="arvn-20250630.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_97061744-930b-4d89-b6ea-8b117e6e0fe4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_7205da02-9b8f-4a8d-8b1f-528fc5de9f9e_terseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_45a131cc-9a76-451f-8b27-cacc88aac40f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b2b2e5ef-7947-4d44-91a9-2041ca90edc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8bdfb5fd-7652-426a-a19a-720527ec7b46_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_ae62d90e-a5ca-4d24-a3ad-2e62d9f40890_terseLabel_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment the Company will make</link:label>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payment</link:label>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="arvn-20250630.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_994a491f-fcb1-4b36-b8d7-1dc16edd1587_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6eb6d3b1-4d8a-4ecc-bf53-74f1224d3ea3_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0ac2954a-0a13-479a-9869-4a86510de640_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator adjustments for diluted EPS:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_517e2df3-8706-44de-bd63-7d65020c0532_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_cde4618e-5fb2-40ca-a025-78cfde224a5f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d6b9c093-ba7b-44a4-9dda-aca22bc7ebb4_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Grant Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a97e1f1e-a100-4223-8e4e-f2d626ee2516_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d610eb70-5ff4-4658-a97b-b8920f692985_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_57a894fa-ec44-49af-b366-49e6da67c2d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV110Member_86bd380e-e851-4fe8-9fa2-1aca1227f0da_terseLabel_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bavdegalutamide (ARV-110)</link:label>
    <link:label id="lab_arvn_ARV110Member_label_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-110 [Member]</link:label>
    <link:label id="lab_arvn_ARV110Member_documentation_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-110</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member" xlink:href="arvn-20250630.xsd#arvn_ARV110Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV110Member" xlink:to="lab_arvn_ARV110Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_984a6296-3ad5-4497-ab1c-ce2cd31f49bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_772d8323-b4a2-4c58-8ee3-278a5c337bad_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_65d030d1-1aae-419f-801e-fcf1b2ebf42f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expense</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_31ba5497-dc06-4510-97dc-59ae292eff64_terseLabel_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non program-specific external expense</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_label_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Non-Program Specific</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_documentation_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Non-Program Specific</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:to="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a827a7b8-2af0-4663-ad8b-34ede4b21168_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3f2c8d46-6f9f-46a5-b029-9ec63dc85108_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_969451c1-8269-4b12-9210-8aba2c6572bf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e873f3d0-36ff-4f84-b05f-c4eab22c34c5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PfizerIncorporationMember_f4e65268-6fed-41e4-93ae-d29b477528de_terseLabel_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer, Inc.</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_label_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Incorporation [Member]</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_documentation_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember" xlink:href="arvn-20250630.xsd#arvn_PfizerIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PfizerIncorporationMember" xlink:to="lab_arvn_PfizerIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_d57fbf64-f878-471b-9eba-dbf584283cd7_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a8f0cbfd-e4e1-4111-85b9-161cd2dc72ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d3660f73-1064-46f6-935c-c30e436e0df0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f5aab289-bea5-419a-a65e-da8c798d27ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af51de4e-a8db-46b2-b943-9cb1bdd7f0f7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_3a0f6704-c470-47f2-8259-81cb5f250fae_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_06a37fb2-3aa6-40ba-9ca9-9dbddeb097e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3a764113-5dd0-472b-b6d3-7311e6f4d0c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1f55598e-1334-4ab0-8cfc-857681b58310_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_a5f596a7-8963-42a0-857f-bc2c215e3ce7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract revenue receivable if milestones achieved</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_77559f5b-288b-49ec-a1b8-44675c36decb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b9d1f056-b662-419f-a6b2-6fdb7c78848c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_178cd72a-511c-47fc-8207-63a7590bdacb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2f92a7a1-437a-479e-84e7-5b7a829e6e07_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_35811550-76c7-481c-ab5f-15348edc0b5b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c26e141b-0a3c-4fb8-bde1-ef3f41ba5922_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfLicensedProducts_781387f3-ff63-4d3e-91f9-82e97acc8690_terseLabel_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of licensed products</link:label>
    <link:label id="lab_arvn_NumberOfLicensedProducts_label_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Licensed Products</link:label>
    <link:label id="lab_arvn_NumberOfLicensedProducts_documentation_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Licensed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts" xlink:href="arvn-20250630.xsd#arvn_NumberOfLicensedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfLicensedProducts" xlink:to="lab_arvn_NumberOfLicensedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_a0b2f71e-32de-4500-a505-92f07e1693bc_terseLabel_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements</link:label>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_label_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member]</link:label>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_documentation_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:href="arvn-20250630.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:to="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_58c9169c-8b2e-4841-bf3e-49f139b25020_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ae747c7b-d119-4ec3-bc5b-3e4e8bb728ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_7c5c9580-f056-4770-9892-d4fd8f867248_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8b45b966-de4a-4ac0-84f0-63a60d5c3544_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6593c837-4a46-41ef-9286-34a0ffa8be27_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_297b1b15-2dbb-4228-901e-0fedc2f0e2be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_81497217-0dc2-45ff-b686-e373e626603d_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6b4028e9-dde8-4036-9da6-7aed2c6ccf75_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_23f79c28-1ddd-4d6c-84b9-8e0758a1315b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares remained available for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c0921c63-9a9c-44a7-a675-2d956a5bd4ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5aab25a5-9950-44b9-92ab-3ac48f805b74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_34bcb1f2-3511-48fb-ba45-bcb46ce1f43f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d38afc0e-ca29-469f-bdd8-2499ab3af98d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8c3ca61b-53a8-46d8-ab31-798f6cd198b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_872e6421-3758-43f6-b008-2dd54c59a92b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value of options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV766Member_f88ab31a-9528-494c-a996-30825db6d679_terseLabel_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Luxdegalutamide (ARV-766)</link:label>
    <link:label id="lab_arvn_ARV766Member_label_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-766 [Member]</link:label>
    <link:label id="lab_arvn_ARV766Member_documentation_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-766</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member" xlink:href="arvn-20250630.xsd#arvn_ARV766Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV766Member" xlink:to="lab_arvn_ARV766Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_805addea-126f-473e-9a62-a9e803a854de_terseLabel_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment on First Anniversary of Signing</link:label>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_label_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment On First Anniversary Of Signing [Member]</link:label>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_documentation_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment On First Anniversary Of Signing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:to="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0769eb5f-0931-47b5-b13d-2a96b3a90950_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ef5d94af-7b6e-4a82-b7a4-fd4b9596930e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1a10e469-7c3e-4d9a-aaba-77cfa14d84bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_86334f5e-dc95-48f6-b6f4-6e6c4463f8d2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV393Member_0bc8d29e-59eb-40cf-8b6c-8d8f08a0fbc4_terseLabel_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-393</link:label>
    <link:label id="lab_arvn_ARV393Member_label_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-393 [Member]</link:label>
    <link:label id="lab_arvn_ARV393Member_documentation_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-393</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member" xlink:href="arvn-20250630.xsd#arvn_ARV393Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV393Member" xlink:to="lab_arvn_ARV393Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_81b7ac88-5bd8-4ba4-a0dd-ac9173d7c7f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_62c7f770-0b9f-4139-8b42-e60b793b86ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_df349395-e8ef-4f43-9cc0-e82c70503b64_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_85591dfb-2db4-495d-b482-73f6bfdfe43e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_afcda200-2d0b-4aba-b5fc-3dcccf2022e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_4eac2777-8444-4418-8e92-8ea39566a282_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Related to Marketing Approvals</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:href="arvn-20250630.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:to="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b3adb04a-93b1-448d-9554-fdf58abe7ce7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d13e04da-b80a-4d16-bf39-4969720ba37e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1be18072-1046-4984-a6cf-c9b33dbbc44a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_a0641569-f2ac-455b-bf44-4f5b9bac6bc5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_07dcd526-f8ce-42ff-a90a-d7f0b298c71b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a912d823-5bad-4754-be41-0fdeccec18b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33487f4e-be01-4d83-a4e1-9c7102c2a320_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32ca30ee-da22-42f1-bf14-d0d78f58cfe4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6308aeb8-6d1b-4e08-a9e9-3b57385efb18_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3c5758b5-3b8a-4b30-a4a3-a18aa604ad2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted (Loss) Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_ec8bc74d-deb7-4c72-a852-568d61b0dad0_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of incremental borrowing for lease payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_label_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Incremental Borrowing For Lease Payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_documentation_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of incremental borrowing for lease payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:href="arvn-20250630.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:to="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2fe0dfbf-9cc3-410c-8ea7-6cabc313fe0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_f19c2ffe-f118-43a2-bd4c-04bb24b9c071_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_db401387-eeec-4cfa-8cbd-62cfdaeced5b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_e3741489-6742-4264-93fa-f2557cc78503_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18495f87-a327-42be-8f48-2919922590a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33f68265-eb25-4e19-bf9e-6a7e464c6c78_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6c59ba9-7c12-4115-9eda-a9b02e2fd173_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_fca00af6-bd1f-441d-aab6-07da69a77141_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_13c394e3-060d-43cc-ad43-a925352797db_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_03c5e53f-0fd7-43b2-ae25-1f6aec96ba00_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of RSUs released</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c567fab-0069-419f-b776-cb76fb073ac3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4a26daaf-d02d-47b4-b66d-362399f3deab_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_7759475f-7852-4969-b578-9b7d9c64a09c_terseLabel_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember" xlink:href="arvn-20250630.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LaboratoryEquipmentMember" xlink:to="lab_arvn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_16b16436-2005-4d71-b563-ca5a4927289e_terseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember" xlink:href="arvn-20250630.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AtTheMarketOfferingMember" xlink:to="lab_arvn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8b52756c-7234-4a34-88e3-4b00a6dd9983_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b95921f3-4fe3-4ed9-bab6-90f3f22b0a1f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d7aef7e2-6ff7-45a9-a20c-2851a5361050_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/ Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_626ef03c-3189-4863-a0dc-7aa34a7b93d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7573097f-b95a-42ed-8ca0-8997ec8199cd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b7d7aeb2-54d1-4127-8a4c-98a60bcbc7a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EarningsLossPerCommonShareEPSAbstract_5693dfd6-c20c-489a-afbf-c61960d7bc17_verboseLabel_en-US" xlink:label="lab_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) earnings per common share</link:label>
    <link:label id="lab_arvn_EarningsLossPerCommonShareEPSAbstract_label_en-US" xlink:label="lab_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings (Loss) Per Common Share, EPS [Abstract]</link:label>
    <link:label id="lab_arvn_EarningsLossPerCommonShareEPSAbstract_documentation_en-US" xlink:label="lab_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings (Loss) Per Common Share, EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:href="arvn-20250630.xsd#arvn_EarningsLossPerCommonShareEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:to="lab_arvn_EarningsLossPerCommonShareEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_8c79f811-b584-4d78-b189-6151e5027dc0_terseLabel_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_arvn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8c7698b6-ee1c-4e83-95ff-b65f34afd3ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_778d7a47-5bb9-4300-91f8-1bd386a9abf6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_a17793d2-7a8a-4cca-9438-c0aa2f132fc2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cb3cc0dc-0fa0-43c9-9702-238402b362c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f08397c0-0a96-43dc-85fc-035e7d8d6ac0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c143132a-fe9a-4671-a45e-f3403e7374d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7e763ad8-37b8-43ec-9c84-275e875d90c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_eaea29ad-97bb-415b-881e-bba001bdefc9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2f295c0-a3b6-413d-b17d-683f58368821_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6631f5d4-6d08-4b86-8424-371d65da9d60_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3554e7d8-a1e8-4ded-8acb-b01ff376f603_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_935df9db-7fec-4037-aa8b-68214bcc21c8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Denominator adjustments for diluted EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_47e70863-21d7-4764-ba6a-bebda4eec7df_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arvn-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cf2f8fce-f596-448a-9bd0-7a89c854fb1a,g:f97ac110-e11b-4fcc-b3c0-93d7d7d91370-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CoverPage" xlink:type="simple" xlink:href="arvn-20250630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7bd8e8b8-85f4-488b-a76b-c056937f0d4e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentType_7bd8e8b8-85f4-488b-a76b-c056937f0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_903858e4-11f0-4708-a3c1-a250c3d5bf47" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentQuarterlyReport_903858e4-11f0-4708-a3c1-a250c3d5bf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cb280281-146a-4f3d-871a-bc9e5d36522d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentPeriodEndDate_cb280281-146a-4f3d-871a-bc9e5d36522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_75daba64-7f62-489d-bc8a-b5ce89304d17" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentTransitionReport_75daba64-7f62-489d-bc8a-b5ce89304d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e31fa75d-9ba8-476a-aeea-624439fa60f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityFileNumber_e31fa75d-9ba8-476a-aeea-624439fa60f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_50f4a441-7835-4c0d-a2f5-edf0fdd4325b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityRegistrantName_50f4a441-7835-4c0d-a2f5-edf0fdd4325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_64ab6593-fdf6-4ff4-a9e2-a4a2655c917b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityIncorporationStateCountryCode_64ab6593-fdf6-4ff4-a9e2-a4a2655c917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0cdb3ca2-46bc-46e3-8d36-640c9803588d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityTaxIdentificationNumber_0cdb3ca2-46bc-46e3-8d36-640c9803588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_64cab3ea-b92b-42f8-b5ab-81d3ef8b1b9e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityAddressAddressLine1_64cab3ea-b92b-42f8-b5ab-81d3ef8b1b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_028ab544-1697-4333-add4-dcda8fde3af7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityAddressAddressLine2_028ab544-1697-4333-add4-dcda8fde3af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_46200167-c19f-401e-be95-1f6dd7cc7f32" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityAddressCityOrTown_46200167-c19f-401e-be95-1f6dd7cc7f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0641a41c-df81-4cd5-aedf-2a0748e237d9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityAddressStateOrProvince_0641a41c-df81-4cd5-aedf-2a0748e237d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_aa9ebb01-7620-4d42-b535-d49fe1f93663" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityAddressPostalZipCode_aa9ebb01-7620-4d42-b535-d49fe1f93663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8a3f924-392e-4bb7-8a3f-75eb50caca8f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_CityAreaCode_c8a3f924-392e-4bb7-8a3f-75eb50caca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_71cf6f19-b345-4bfa-bd48-0cb576d74692" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_LocalPhoneNumber_71cf6f19-b345-4bfa-bd48-0cb576d74692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4317ad8e-ce7c-41dd-8b57-4f05400aeec2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_Security12bTitle_4317ad8e-ce7c-41dd-8b57-4f05400aeec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8ad2d39c-0d64-42a7-8bc1-3d1c6918b646" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_TradingSymbol_8ad2d39c-0d64-42a7-8bc1-3d1c6918b646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ca5090ff-3d44-44f0-98d2-84631aa5de53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_SecurityExchangeName_ca5090ff-3d44-44f0-98d2-84631aa5de53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_59b0de2b-8ce8-4078-9e28-4f514edf1fe2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityCurrentReportingStatus_59b0de2b-8ce8-4078-9e28-4f514edf1fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2ef14680-5b91-4af3-b9c6-d69e557b9b61" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityInteractiveDataCurrent_2ef14680-5b91-4af3-b9c6-d69e557b9b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b01c7499-7061-40de-b731-9d5877b8e57b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityFilerCategory_b01c7499-7061-40de-b731-9d5877b8e57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_61ef539e-1c9c-4417-9f28-a7fddbdd7b10" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntitySmallBusiness_61ef539e-1c9c-4417-9f28-a7fddbdd7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b121ca3-f992-4354-a83e-539d13d73999" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b121ca3-f992-4354-a83e-539d13d73999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38299363-464e-4c28-b9ef-18f487a2f2f5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityShellCompany_38299363-464e-4c28-b9ef-18f487a2f2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a9b126ae-4913-42a1-bc12-1ec911573197" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a9b126ae-4913-42a1-bc12-1ec911573197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae8b5017-b8da-4fbc-9c6c-cfa112da8ae1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_AmendmentFlag_ae8b5017-b8da-4fbc-9c6c-cfa112da8ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2c1cd7e6-67cb-4520-b469-037e695c53f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentFiscalYearFocus_2c1cd7e6-67cb-4520-b469-037e695c53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6c409cb1-3d36-45e0-9ca3-8a197793ea43" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6c409cb1-3d36-45e0-9ca3-8a197793ea43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6102d9aa-6cbf-4a96-9da6-4c4c2fac610f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_EntityCentralIndexKey_6102d9aa-6cbf-4a96-9da6-4c4c2fac610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9db65a96-9e11-4e95-9829-2adfc6bb1af7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab118e01-37ae-492c-9c61-a668ee2de865" xlink:to="loc_dei_CurrentFiscalYearEndDate_9db65a96-9e11-4e95-9829-2adfc6bb1af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4e99f6de-4e61-449b-93f7-2672d6e6c350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4e99f6de-4e61-449b-93f7-2672d6e6c350" xlink:to="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8ad8353-1bf8-425f-b0c3-d3535a27f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8ad8353-1bf8-425f-b0c3-d3535a27f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b0de38f6-94c0-4b26-8412-1dd417f254dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b0de38f6-94c0-4b26-8412-1dd417f254dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c577d67b-e82a-4938-baa2-f23fa9140c90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c577d67b-e82a-4938-baa2-f23fa9140c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ce869558-17bf-4ab7-979f-9617bb150d22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ce869558-17bf-4ab7-979f-9617bb150d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6495c02-fb92-4822-9bd6-d1bdb26d067c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6495c02-fb92-4822-9bd6-d1bdb26d067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8b0f8fa2-fa1a-4f24-a1d3-87f5222e7dde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4a109a-95cd-4d3c-952f-c4c85280f81f" xlink:to="loc_us-gaap_AssetsCurrent_8b0f8fa2-fa1a-4f24-a1d3-87f5222e7dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a8cc529a-de04-4122-bc6d-e69c8d504337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a8cc529a-de04-4122-bc6d-e69c8d504337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0715698-eeb6-45eb-9e7f-0f0556bd0fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0715698-eeb6-45eb-9e7f-0f0556bd0fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_1c302d87-d8d0-479e-93c7-74a12289dbe5" xlink:href="arvn-20250630.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_1c302d87-d8d0-479e-93c7-74a12289dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4c2e6403-13a1-45b5-80d7-325a97e9c992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b6f1f16a-53c3-4530-afe3-ff6ac18dcbd6" xlink:to="loc_us-gaap_Assets_4c2e6403-13a1-45b5-80d7-325a97e9c992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4e99f6de-4e61-449b-93f7-2672d6e6c350" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d1ed2c82-7958-4675-9249-0bcd745a1d38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d1ed2c82-7958-4675-9249-0bcd745a1d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5deb8d14-4532-4671-96fa-585897404b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5deb8d14-4532-4671-96fa-585897404b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c53d5c46-7e02-435f-9ba3-36e1ec69887d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c53d5c46-7e02-435f-9ba3-36e1ec69887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_385df8b6-455b-48d9-8762-11fe1d197ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2838a25a-5108-48b3-b93d-7ef9e03ad636" xlink:to="loc_us-gaap_LiabilitiesCurrent_385df8b6-455b-48d9-8762-11fe1d197ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31e8678d-b7a0-448d-85c8-019b991594b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31e8678d-b7a0-448d-85c8-019b991594b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d0acde90-3f99-4c8a-b727-b99ea999b625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d0acde90-3f99-4c8a-b727-b99ea999b625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_154f76f5-4da1-4347-bbbd-2b4f36f5db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_154f76f5-4da1-4347-bbbd-2b4f36f5db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_836a02b0-cc44-46cb-b86a-95871c019301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_Liabilities_836a02b0-cc44-46cb-b86a-95871c019301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2eb71a5c-1f60-4998-b71a-91ed07054723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2eb71a5c-1f60-4998-b71a-91ed07054723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9edd4986-4b67-4fb4-8109-35fae91dbdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_PreferredStockValue_9edd4986-4b67-4fb4-8109-35fae91dbdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73c3b13b-8b88-4490-9671-8f40940a60f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_CommonStockValue_73c3b13b-8b88-4490-9671-8f40940a60f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a090430-86b1-4b7e-a489-56a0a467f688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a090430-86b1-4b7e-a489-56a0a467f688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d119eea2-7902-4701-a2c5-8be027a9528c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d119eea2-7902-4701-a2c5-8be027a9528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9fbda351-af25-462f-8112-c5b5307f4385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9fbda351-af25-462f-8112-c5b5307f4385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b45a310-b7de-457b-b761-8884e3ff61d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64ce3861-e2bb-420c-80e3-197bfc50948e" xlink:to="loc_us-gaap_StockholdersEquity_1b45a310-b7de-457b-b761-8884e3ff61d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1938a4e6-4c2b-40af-9a8f-c00f2c04347a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7613a5c-aae7-459c-a110-f165d57a8683" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1938a4e6-4c2b-40af-9a8f-c00f2c04347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_64591fa2-6fb9-4eec-bfe7-3a4db44a01c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_64591fa2-6fb9-4eec-bfe7-3a4db44a01c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_99b1c8b6-63e1-4e2e-86c8-5680d66446ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_99b1c8b6-63e1-4e2e-86c8-5680d66446ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3e383cde-614f-4a69-ba06-2644ff072a97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3e383cde-614f-4a69-ba06-2644ff072a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07f6269b-bf23-48b0-83de-274bdbcea41d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07f6269b-bf23-48b0-83de-274bdbcea41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7e50acbf-eedb-4ab5-83cf-d395803d9c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_CommonStockSharesIssued_7e50acbf-eedb-4ab5-83cf-d395803d9c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21933b7f-cff7-4f2c-b3f9-767f79c00b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fa3abf4-52f3-4340-bed8-ecb85275778b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21933b7f-cff7-4f2c-b3f9-767f79c00b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_8b9924da-3874-44ae-86ed-09e071ece45b" xlink:href="arvn-20250630.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_8b9924da-3874-44ae-86ed-09e071ece45b" xlink:to="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f018409a-2633-4d68-bbeb-561fee3db569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_Revenues_f018409a-2633-4d68-bbeb-561fee3db569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d7a8b17d-2e40-47bb-b57b-ed27cd82f5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d7a8b17d-2e40-47bb-b57b-ed27cd82f5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bb20a9b6-bc73-45ad-9527-21b96a469495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d7a8b17d-2e40-47bb-b57b-ed27cd82f5c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bb20a9b6-bc73-45ad-9527-21b96a469495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_67e01c3d-3f7b-4673-acc6-ed425e2449af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d7a8b17d-2e40-47bb-b57b-ed27cd82f5c0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_67e01c3d-3f7b-4673-acc6-ed425e2449af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_663a2916-ad91-430d-960e-dca688a0c714" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d7a8b17d-2e40-47bb-b57b-ed27cd82f5c0" xlink:to="loc_us-gaap_OperatingExpenses_663a2916-ad91-430d-960e-dca688a0c714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5b8c0612-e695-4869-99bc-8e24437212b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_OperatingIncomeLoss_5b8c0612-e695-4869-99bc-8e24437212b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17a375a2-4523-4594-a782-d5a9dad1486b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17a375a2-4523-4594-a782-d5a9dad1486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_249044cf-7ebf-475c-bd3a-b75e4419ab8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17a375a2-4523-4594-a782-d5a9dad1486b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_249044cf-7ebf-475c-bd3a-b75e4419ab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_58401dbf-3c6b-4bad-8578-c620b491d36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17a375a2-4523-4594-a782-d5a9dad1486b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_58401dbf-3c6b-4bad-8578-c620b491d36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_63c69bd4-a32d-4648-95a8-996f02c6d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17a375a2-4523-4594-a782-d5a9dad1486b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_63c69bd4-a32d-4648-95a8-996f02c6d7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b4a91a3-7c50-4c08-ba2f-ef80859eae86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b4a91a3-7c50-4c08-ba2f-ef80859eae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_86d5fb3e-b1c5-4054-b6bd-6d7bd6251b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_86d5fb3e-b1c5-4054-b6bd-6d7bd6251b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_861e1554-c73b-4640-a09b-a6fe798cef14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_NetIncomeLoss_861e1554-c73b-4640-a09b-a6fe798cef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_07d2c378-0043-4658-9008-0439ea9227f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_EarningsPerShareAbstract_07d2c378-0043-4658-9008-0439ea9227f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1212ae08-dab2-49b8-a0e6-b1b6a8d34777" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07d2c378-0043-4658-9008-0439ea9227f3" xlink:to="loc_us-gaap_EarningsPerShareBasic_1212ae08-dab2-49b8-a0e6-b1b6a8d34777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5cc21338-20e0-4bf6-9f9c-3fcc2ef9d4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07d2c378-0043-4658-9008-0439ea9227f3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5cc21338-20e0-4bf6-9f9c-3fcc2ef9d4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ff01ec37-0cb3-4ea3-8b91-bce2264505ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8722d0c3-9966-4b78-840f-c3990af93442" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ff01ec37-0cb3-4ea3-8b91-bce2264505ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_471d1941-0c76-4ae9-a876-ca7cd47a26d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ff01ec37-0cb3-4ea3-8b91-bce2264505ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_471d1941-0c76-4ae9-a876-ca7cd47a26d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f38dec4a-61d8-4482-9609-744d5b842c90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ff01ec37-0cb3-4ea3-8b91-bce2264505ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f38dec4a-61d8-4482-9609-744d5b842c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27c4b5f4-08f1-4e13-929a-90fd871e34b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_8b9924da-3874-44ae-86ed-09e071ece45b" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27c4b5f4-08f1-4e13-929a-90fd871e34b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37b03112-d7c7-4cde-a656-cca0446ecac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27c4b5f4-08f1-4e13-929a-90fd871e34b8" xlink:to="loc_us-gaap_NetIncomeLoss_37b03112-d7c7-4cde-a656-cca0446ecac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_771d3d62-6bc1-428f-928f-24d6699142af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27c4b5f4-08f1-4e13-929a-90fd871e34b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_771d3d62-6bc1-428f-928f-24d6699142af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f22a46c-aad5-40e7-8d7c-ce229856b3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_771d3d62-6bc1-428f-928f-24d6699142af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f22a46c-aad5-40e7-8d7c-ce229856b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8249dc3f-afb7-4318-9e58-d25aa3f74e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27c4b5f4-08f1-4e13-929a-90fd871e34b8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8249dc3f-afb7-4318-9e58-d25aa3f74e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dac29391-dfaa-49cd-8ee1-0a50777d943d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dac29391-dfaa-49cd-8ee1-0a50777d943d" xlink:to="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_010dd20e-c88e-4f55-a7b4-df92258fab3f" xlink:to="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba43c865-7a58-489c-822f-e3513598c438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_CommonStockMember_ba43c865-7a58-489c-822f-e3513598c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6451a8ac-60ff-4f72-928e-cc573958cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_RetainedEarningsMember_6451a8ac-60ff-4f72-928e-cc573958cb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6d94db66-f76a-40ad-b73a-2b76b0e8ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6d94db66-f76a-40ad-b73a-2b76b0e8ec7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d9caf10-bafb-4e33-9c19-692327bf76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55619c27-0d2e-46e0-8222-c4fe0a441960" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d9caf10-bafb-4e33-9c19-692327bf76a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0348992c-af9f-4ec3-a5a5-e24495c8a258" xlink:to="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ad95995-de8e-4171-89c9-36e4cca4e12c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dfe6d153-abda-4e3b-83ee-6bba05559047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dfe6d153-abda-4e3b-83ee-6bba05559047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e734838-3192-4a19-8e01-456613478949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockholdersEquity_7e734838-3192-4a19-8e01-456613478949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ef221e-ded7-4981-b507-b0d70342a142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ef221e-ded7-4981-b507-b0d70342a142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47858da2-b382-4171-9097-dab309565e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_NetIncomeLoss_47858da2-b382-4171-9097-dab309565e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e4d337f-76d7-497b-955c-3c576d0ed202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0e4d337f-76d7-497b-955c-3c576d0ed202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f4805311-6ac9-4ee3-81b3-e00124f79331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f4805311-6ac9-4ee3-81b3-e00124f79331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_4d5af611-aaf0-4408-a2bf-3f126127f6e4" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesWarrantsExercised_4d5af611-aaf0-4408-a2bf-3f126127f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed93ca34-94e9-4012-816e-a818763ea2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed93ca34-94e9-4012-816e-a818763ea2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_72385ca0-e87e-46cc-8081-5179c72f5578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_72385ca0-e87e-46cc-8081-5179c72f5578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_915faa47-84ad-4a82-8cf1-db40ef2352f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57188687-9650-4bca-be42-6f2928f0f857" xlink:to="loc_us-gaap_StockholdersEquity_915faa47-84ad-4a82-8cf1-db40ef2352f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20250630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d1d311a-d9e7-48bc-9469-92f36144f524" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d1d311a-d9e7-48bc-9469-92f36144f524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b07c3641-776d-4309-84d4-e136a240cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d1d311a-d9e7-48bc-9469-92f36144f524" xlink:to="loc_us-gaap_NetIncomeLoss_b07c3641-776d-4309-84d4-e136a240cdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d1d311a-d9e7-48bc-9469-92f36144f524" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d2ab7393-7c7c-4da7-8620-2f7369179138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_DepreciationAndAmortization_d2ab7393-7c7c-4da7-8620-2f7369179138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c778c205-3ded-4f62-b0f9-745398d01db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c778c205-3ded-4f62-b0f9-745398d01db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_cd8cd792-2910-424b-be5c-9910cb7ebf65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_cd8cd792-2910-424b-be5c-9910cb7ebf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_0c8b0c6c-7d88-494b-805c-a4589e7d3822" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_0c8b0c6c-7d88-494b-805c-a4589e7d3822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eff9ede3-a5f7-4031-8d95-be432f86a9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_ShareBasedCompensation_eff9ede3-a5f7-4031-8d95-be432f86a9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2472d406-6590-40ec-8fd0-f354f69cfe2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff78b38f-f94a-413f-91dd-5624e0b41094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff78b38f-f94a-413f-91dd-5624e0b41094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_97f37fb7-bd14-4cd8-ac62-ded0cd21af85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_97f37fb7-bd14-4cd8-ac62-ded0cd21af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1a2dc20-6a4d-4aee-8596-7976898b3e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1a2dc20-6a4d-4aee-8596-7976898b3e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6f002573-a835-4812-99de-7ba942d5ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6f002573-a835-4812-99de-7ba942d5ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cdd35ccb-ed20-49f9-85f7-bf9efeb27bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cdd35ccb-ed20-49f9-85f7-bf9efeb27bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8e0cc24b-713e-4a17-b1de-6eee62ec8915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8e0cc24b-713e-4a17-b1de-6eee62ec8915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e4b232d-cc6a-4384-92a7-2bc404a8c582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70085325-da91-4f28-892a-b99dd8f4c434" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e4b232d-cc6a-4384-92a7-2bc404a8c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60fe11d6-f2d0-4f6e-a4e7-ef66ca53b7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d1d311a-d9e7-48bc-9469-92f36144f524" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60fe11d6-f2d0-4f6e-a4e7-ef66ca53b7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd4127c2-fa3f-4ad6-91ed-78f4fae1c930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd4127c2-fa3f-4ad6-91ed-78f4fae1c930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_b1a03279-c338-4e57-b7a0-f0fe8ded1134" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_b1a03279-c338-4e57-b7a0-f0fe8ded1134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_00477e44-b9fd-45c4-b523-91c27abeb008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_00477e44-b9fd-45c4-b523-91c27abeb008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da1685a0-66a1-4a69-a74b-677d0b293766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da1685a0-66a1-4a69-a74b-677d0b293766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b30ccbe6-a528-4d24-8d5c-d81642ac9c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ccf656b-244c-47ce-8633-0912f27efcd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b30ccbe6-a528-4d24-8d5c-d81642ac9c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0579ec66-daf6-4e28-95d0-70180fd9a760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0579ec66-daf6-4e28-95d0-70180fd9a760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_73cf9fa0-08b1-42cb-ac99-e8673424df68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0579ec66-daf6-4e28-95d0-70180fd9a760" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_73cf9fa0-08b1-42cb-ac99-e8673424df68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_cb190d81-9156-4a0d-82b4-2d5115749425" xlink:href="arvn-20250630.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0579ec66-daf6-4e28-95d0-70180fd9a760" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_cb190d81-9156-4a0d-82b4-2d5115749425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb5b5c07-8da7-40e1-8ee6-37dac74a7c38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0579ec66-daf6-4e28-95d0-70180fd9a760" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb5b5c07-8da7-40e1-8ee6-37dac74a7c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a34f8bc-8a20-42aa-a31c-754a76286ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a34f8bc-8a20-42aa-a31c-754a76286ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aed30fc1-6a79-4764-a6fd-f8294b8f3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aed30fc1-6a79-4764-a6fd-f8294b8f3b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa13e36e-5752-4b8c-922f-ae0ceca0ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa13e36e-5752-4b8c-922f-ae0ceca0ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f6f921d9-a388-4ae8-85d7-b0cab3704316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b10b87-78ec-43b7-bcd5-1b0a98265742" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f6f921d9-a388-4ae8-85d7-b0cab3704316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_d689b518-09d7-4cad-9968-54d529181f42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f6f921d9-a388-4ae8-85d7-b0cab3704316" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_d689b518-09d7-4cad-9968-54d529181f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="arvn-20250630.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f39df47-6834-4c0f-991c-3f95796de749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_fdc7ea5e-1299-4b5f-9f62-bbdbbfbbefb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f39df47-6834-4c0f-991c-3f95796de749" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_fdc7ea5e-1299-4b5f-9f62-bbdbbfbbefb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arvn-20250630.xsd#SummaryofAccountingPronouncementsandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_51e6be20-391c-4623-8eb0-2b2eaece9fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e877dcbc-a307-4f28-aace-25f19617f45f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51e6be20-391c-4623-8eb0-2b2eaece9fd0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e877dcbc-a307-4f28-aace-25f19617f45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_1bddf11d-f27e-45d6-8c89-5d88021e216c" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_34e2a871-5625-42a6-939e-2ccd199747ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_1bddf11d-f27e-45d6-8c89-5d88021e216c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_34e2a871-5625-42a6-939e-2ccd199747ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="arvn-20250630.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_46f0730c-13eb-4657-93aa-b7285dee7d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ea5ebb9a-e27f-4c72-a3a0-209e4eccd400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46f0730c-13eb-4657-93aa-b7285dee7d1e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ea5ebb9a-e27f-4c72-a3a0-209e4eccd400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aef4991b-3466-4ad8-8306-e390665ae679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8ea2e2ce-2312-4db6-8b94-41ef322182b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aef4991b-3466-4ad8-8306-e390665ae679" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8ea2e2ce-2312-4db6-8b94-41ef322182b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e2589015-b604-4a86-ac1e-9369c25eec83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_03480b92-d653-48b1-aa79-78f4ce648f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e2589015-b604-4a86-ac1e-9369c25eec83" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_03480b92-d653-48b1-aa79-78f4ce648f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="arvn-20250630.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_de6a359a-713f-44c8-8848-063efce24664" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4b62cdf7-b664-4127-97ef-bc0d80a07c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_de6a359a-713f-44c8-8848-063efce24664" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4b62cdf7-b664-4127-97ef-bc0d80a07c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebt" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_233c8abf-684d-41d5-b5be-98d32a1e812e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_66b26040-9494-4607-9e16-eb2afcc33eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_233c8abf-684d-41d5-b5be-98d32a1e812e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_66b26040-9494-4607-9e16-eb2afcc33eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/Equity" xlink:type="simple" xlink:href="arvn-20250630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14845369-00d9-493b-9727-ece3bf2a12ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f077f82e-c257-45de-8c37-26b33c0cc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14845369-00d9-493b-9727-ece3bf2a12ca" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f077f82e-c257-45de-8c37-26b33c0cc5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arvn-20250630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a841d504-7921-465b-a17f-0423c4ce3478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb575fda-93e1-43a4-9d99-86d3212e558d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a841d504-7921-465b-a17f-0423c4ce3478" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb575fda-93e1-43a4-9d99-86d3212e558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShare" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5fc3544f-a14e-4fae-93ae-762c207dfb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3a359df9-e3da-481d-8492-d0c118df419e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5fc3544f-a14e-4fae-93ae-762c207dfb33" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3a359df9-e3da-481d-8492-d0c118df419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e6db3c56-6ff3-48a9-9bd5-626f15731adf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_67334191-38f7-4ad3-818c-dfacac937893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e6db3c56-6ff3-48a9-9bd5-626f15731adf" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_67334191-38f7-4ad3-818c-dfacac937893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arvn-20250630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce2ac660-0fe4-4f85-a97d-cabf73ecaaba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e80c45a5-27c1-481c-8ea5-266e9526ef12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce2ac660-0fe4-4f85-a97d-cabf73ecaaba" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e80c45a5-27c1-481c-8ea5-266e9526ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivity" xlink:type="simple" xlink:href="arvn-20250630.xsd#RestructuringActivity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RestructuringActivity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c76c2f4a-523d-4a29-893a-bffdac15cc74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_80f4d870-98a7-43b2-9386-41f80f8794e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c76c2f4a-523d-4a29-893a-bffdac15cc74" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_80f4d870-98a7-43b2-9386-41f80f8794e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformation" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_83e85842-7495-4b4c-ba63-05cc0f789314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_fdd25e16-d083-4d33-acb2-cb90de979683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_83e85842-7495-4b4c-ba63-05cc0f789314" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_fdd25e16-d083-4d33-acb2-cb90de979683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arvn-20250630.xsd#SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_25e88bd7-19a4-4059-a1cc-39dd4aa92a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_25e88bd7-19a4-4059-a1cc-39dd4aa92a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_18727d12-3ee3-4358-bba6-6122a8f5ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:to="loc_us-gaap_UseOfEstimates_18727d12-3ee3-4358-bba6-6122a8f5ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_bf34996f-b6ec-4704-8ef2-39ff5c79616e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_bf34996f-b6ec-4704-8ef2-39ff5c79616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_990d9e29-c67c-49c8-b965-4fdb39c780c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_990d9e29-c67c-49c8-b965-4fdb39c780c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1a873b38-e6a1-41db-964e-efc9cf9af4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f37eec4-0f37-4cb8-9e14-44000e2e4264" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1a873b38-e6a1-41db-964e-efc9cf9af4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf39f3e7-8d44-4952-bebc-0476af9c9d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0b89b8ca-06fe-459a-b7c7-5330c3716acc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf39f3e7-8d44-4952-bebc-0476af9c9d2f" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0b89b8ca-06fe-459a-b7c7-5330c3716acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bd940a8c-1973-4abe-983f-72ea153f8164" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf39f3e7-8d44-4952-bebc-0476af9c9d2f" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bd940a8c-1973-4abe-983f-72ea153f8164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_6de5c5b8-d21f-4e30-8d0d-17587f2a1707" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c469ff7d-35a9-4168-8d77-184bdbaab4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_6de5c5b8-d21f-4e30-8d0d-17587f2a1707" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c469ff7d-35a9-4168-8d77-184bdbaab4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_5d663d2d-1e2f-4e16-91ad-ec128de0c927" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_6de5c5b8-d21f-4e30-8d0d-17587f2a1707" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_5d663d2d-1e2f-4e16-91ad-ec128de0c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_630cc6cf-864f-4c0f-a26a-a121452e9c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_df13105a-f63c-4fda-badf-19f9e9f29f70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_630cc6cf-864f-4c0f-a26a-a121452e9c8b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_df13105a-f63c-4fda-badf-19f9e9f29f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dda0786e-9954-474f-a260-fd37223410a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e6495da-e106-4910-9ca2-4154e6b756c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dda0786e-9954-474f-a260-fd37223410a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e6495da-e106-4910-9ca2-4154e6b756c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1c734f61-a493-4968-885c-a7e494f6cfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a3bde1ea-25e7-4227-b0fe-c267e9c1283e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c734f61-a493-4968-885c-a7e494f6cfd5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a3bde1ea-25e7-4227-b0fe-c267e9c1283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_d18b46aa-d99f-49a4-ab23-6705aebe108c" xlink:href="arvn-20250630.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c734f61-a493-4968-885c-a7e494f6cfd5" xlink:to="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_d18b46aa-d99f-49a4-ab23-6705aebe108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a86a3983-b6f3-43df-8a4b-1a805af2d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c734f61-a493-4968-885c-a7e494f6cfd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a86a3983-b6f3-43df-8a4b-1a805af2d6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3388eb20-0ade-4189-b364-355bed893c99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_11fac37c-1f8d-4c26-a928-3187089f0660" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3388eb20-0ade-4189-b364-355bed893c99" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_11fac37c-1f8d-4c26-a928-3187089f0660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3dca4541-19fa-414b-9018-d0aa10e47d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_dd256d34-f40e-4b5e-8d9f-50c00e7cfc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3dca4541-19fa-414b-9018-d0aa10e47d20" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_dd256d34-f40e-4b5e-8d9f-50c00e7cfc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b51a3f5a-10cc-47f7-bc6c-767af2520df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3dca4541-19fa-414b-9018-d0aa10e47d20" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b51a3f5a-10cc-47f7-bc6c-767af2520df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5379c4-2e67-4ee7-a394-179454d116b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b11c6e19-148b-435b-80f2-8e8e846c93b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5379c4-2e67-4ee7-a394-179454d116b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b11c6e19-148b-435b-80f2-8e8e846c93b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_152f843d-de1c-468a-be41-0fbbca1ababb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5379c4-2e67-4ee7-a394-179454d116b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_152f843d-de1c-468a-be41-0fbbca1ababb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_c6369436-ff48-4855-af27-0e9571c50352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5379c4-2e67-4ee7-a394-179454d116b7" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_c6369436-ff48-4855-af27-0e9571c50352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_339b6899-0a9c-46f0-b49d-ba578c353f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12b6d457-9a76-4516-890d-bb716b07b7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_339b6899-0a9c-46f0-b49d-ba578c353f27" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12b6d457-9a76-4516-890d-bb716b07b7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_84405804-e1c0-4dc8-a34e-9d06dadb918c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_339b6899-0a9c-46f0-b49d-ba578c353f27" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_84405804-e1c0-4dc8-a34e-9d06dadb918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_95b60c9b-4377-458b-ad7e-6121e605bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_db2d54ea-1ace-42d0-b056-4ae5616ed84d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95b60c9b-4377-458b-ad7e-6121e605bcd8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_db2d54ea-1ace-42d0-b056-4ae5616ed84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_caf214b8-e323-4832-8887-dee10c7dd3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_900904ac-f6b7-41e0-9a97-cacdefd82a61" xlink:href="arvn-20250630.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_caf214b8-e323-4832-8887-dee10c7dd3bc" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_900904ac-f6b7-41e0-9a97-cacdefd82a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8913ac8-c0e0-4759-851e-03c32d088f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c96cf3c-d02c-449a-9610-31ab40b70d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8913ac8-c0e0-4759-851e-03c32d088f6e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c96cf3c-d02c-449a-9610-31ab40b70d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_86514b1e-14e6-4898-8985-1fc7ea3a6457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8913ac8-c0e0-4759-851e-03c32d088f6e" xlink:to="loc_us-gaap_RestrictedCashCurrent_86514b1e-14e6-4898-8985-1fc7ea3a6457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fefced9f-d90d-44a7-967f-f21cbc13eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8913ac8-c0e0-4759-851e-03c32d088f6e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fefced9f-d90d-44a7-967f-f21cbc13eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_4b5177f4-d13a-4f80-8dc3-fbc6dc283fd5" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_4b5177f4-d13a-4f80-8dc3-fbc6dc283fd5" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6089ed05-5b67-4947-b756-d40640497e50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_79e933ec-e62e-4f02-8e3d-79dadb5dd658" xlink:href="arvn-20250630.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_PfizerIncorporationMember_79e933ec-e62e-4f02-8e3d-79dadb5dd658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember_d5b559b8-493a-4597-92b4-c3081756a0a2" xlink:href="arvn-20250630.xsd#arvn_NovartisPharmaAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_NovartisPharmaAGMember_d5b559b8-493a-4597-92b4-c3081756a0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_51e6b09a-23fd-4c40-bf93-9950684583b6" xlink:href="arvn-20250630.xsd#arvn_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_BayerAGMember_51e6b09a-23fd-4c40-bf93-9950684583b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_46c494ea-27af-442f-8854-2888c6a2bd7f" xlink:href="arvn-20250630.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65c9d02c-ab6f-408a-8475-710b07b94c90" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_46c494ea-27af-442f-8854-2888c6a2bd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0eb36c14-ffbe-4a74-a804-c5ddc65dd918" xlink:to="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5b37c82-c4a3-4ac7-af01-b16c5bcdd87c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36d94156-df25-4de2-a321-70c471602ab2" xlink:to="loc_us-gaap_LicenseMember_b5b37c82-c4a3-4ac7-af01-b16c5bcdd87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92d1a223-b307-414f-a3fc-26857f83bc13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_91e7324a-b27d-4478-a579-40d481d784c7" xlink:href="arvn-20250630.xsd#arvn_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_CollaborationAgreementMember_91e7324a-b27d-4478-a579-40d481d784c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_58623a0c-9239-4733-84fe-1e94d1a7c05f" xlink:href="arvn-20250630.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_58623a0c-9239-4733-84fe-1e94d1a7c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_e2ebae02-e209-420f-94b0-f8d8cd700f32" xlink:href="arvn-20250630.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_e2ebae02-e209-420f-94b0-f8d8cd700f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_669c44fb-cca2-4dd0-99b3-18023d4d9921" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_SalesBasedMilestonesMember_669c44fb-cca2-4dd0-99b3-18023d4d9921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_7f176741-afe5-43ee-9d68-3e86a4ff78b4" xlink:href="arvn-20250630.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_7f176741-afe5-43ee-9d68-3e86a4ff78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_3c74ab62-99a4-4d88-8ea4-c171da5a7997" xlink:href="arvn-20250630.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_3c74ab62-99a4-4d88-8ea4-c171da5a7997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_d6a1e9df-6c4d-4c9d-8e32-c00fcfcca9a9" xlink:href="arvn-20250630.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_d6a1e9df-6c4d-4c9d-8e32-c00fcfcca9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_04f4fc05-2dae-48ab-acc5-0921b15463f6" xlink:href="arvn-20250630.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_ResearchFundingPaymentsMember_04f4fc05-2dae-48ab-acc5-0921b15463f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_9d9a60fe-4b00-452b-af89-5298ad88be0e" xlink:href="arvn-20250630.xsd#arvn_CommercialMilestonesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04b0dfe5-bcab-4f5f-b604-5eb854cb91e6" xlink:to="loc_arvn_CommercialMilestonesMember_9d9a60fe-4b00-452b-af89-5298ad88be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b7cae6d-a56a-47f2-a639-2a322990187d" xlink:to="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a543d0a-73f9-4ee5-833f-4325f854a969" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_959c3d6e-d604-489c-8f7b-da98bfd234c7" xlink:to="loc_srt_MaximumMember_8a543d0a-73f9-4ee5-833f-4325f854a969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5abf6bf3-e5c5-4b9a-83a9-8ab46a9cc4a2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember_982d3eaf-e976-4eb4-b434-0b912ebdebee" xlink:href="arvn-20250630.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:to="loc_arvn_RemovalOfCombinationTrialsMember_982d3eaf-e976-4eb4-b434-0b912ebdebee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember_a84b15e9-5263-4ca7-afcb-444408e214d3" xlink:href="arvn-20250630.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_69c13b1f-5fc1-4d02-b989-b615bc665a5a" xlink:to="loc_arvn_UpdatedResearchTimelinesMember_a84b15e9-5263-4ca7-afcb-444408e214d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_602d0319-e875-408d-8cfe-af13a244c93a" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_c0395857-08da-4112-aff7-5f1596e41c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_c0395857-08da-4112-aff7-5f1596e41c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_89eadc2f-350a-4ff8-8c30-6bdfa0991e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ProceedsFromCollaborators_89eadc2f-350a-4ff8-8c30-6bdfa0991e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_0130bd71-0994-4e80-83aa-c0769ca25bae" xlink:href="arvn-20250630.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_0130bd71-0994-4e80-83aa-c0769ca25bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_86424d09-c7f0-4034-ab3e-561081f762cc" xlink:href="arvn-20250630.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_86424d09-c7f0-4034-ab3e-561081f762cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d7e4c804-4775-4704-8602-7caa12228e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d7e4c804-4775-4704-8602-7caa12228e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_47c70dd3-b933-47ec-8fdb-557ff2d5977a" xlink:href="arvn-20250630.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_47c70dd3-b933-47ec-8fdb-557ff2d5977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee8d34e1-550c-42a2-adac-7de6d7fd42dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee8d34e1-550c-42a2-adac-7de6d7fd42dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6ed48118-ff5d-443a-bf20-2944fb820c12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6ed48118-ff5d-443a-bf20-2944fb820c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_b7606a72-dfc5-44a1-a3fc-7ae6197b3573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_CapitalizedContractCostGross_b7606a72-dfc5-44a1-a3fc-7ae6197b3573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4229e55d-c263-4dee-9a6f-30f0790be4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_Revenues_4229e55d-c263-4dee-9a6f-30f0790be4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3923587d-47c6-4d5f-b41c-933ebfa5db61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_OperatingExpenses_3923587d-47c6-4d5f-b41c-933ebfa5db61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_266be44e-2af6-421b-b9cd-e791d6573965" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_NetIncomeLoss_266be44e-2af6-421b-b9cd-e791d6573965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f309e5b6-ec81-4b77-b34a-67abafbcc142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_EarningsPerShareBasic_f309e5b6-ec81-4b77-b34a-67abafbcc142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_596ecff2-ee26-40ee-b2d3-2f60551faf36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_3b604111-a7ca-4be9-b69d-51eadcbae08d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_596ecff2-ee26-40ee-b2d3-2f60551faf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_0e2e66a8-a4f9-4d53-8da7-0fdfbfd96509" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:href="arvn-20250630.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_0e2e66a8-a4f9-4d53-8da7-0fdfbfd96509" xlink:to="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_267a4f5b-40d5-4e67-9ee4-335b3a8d1fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_267a4f5b-40d5-4e67-9ee4-335b3a8d1fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_4bf79a0e-7c2c-4e52-8c8b-e8ccdd140e02" xlink:href="arvn-20250630.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_4bf79a0e-7c2c-4e52-8c8b-e8ccdd140e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_e5f42cb3-eef8-44c9-9b5e-09009e675646" xlink:href="arvn-20250630.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_e5f42cb3-eef8-44c9-9b5e-09009e675646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bad799df-8b3b-4f39-b319-299770763f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_086e53a4-0df6-4ab8-bc80-e2d994f7c0b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bad799df-8b3b-4f39-b319-299770763f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:href="arvn-20250630.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_0e2e66a8-a4f9-4d53-8da7-0fdfbfd96509" xlink:to="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_dbf616bf-9b85-43e9-ae43-c3bd6d95b347" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_dbf616bf-9b85-43e9-ae43-c3bd6d95b347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_788494a5-149c-4a07-9bf0-25c5bd5a2217" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_788494a5-149c-4a07-9bf0-25c5bd5a2217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments_42d51302-cae3-4afa-8e49-b418f66e3bac" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentPayments_42d51302-cae3-4afa-8e49-b418f66e3bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_72c4926a-6dff-4a8b-bb20-e5f4a134d655" xlink:href="arvn-20250630.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_cd2264b2-23d0-46b5-90ed-48b1d616cb63" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_72c4926a-6dff-4a8b-bb20-e5f4a134d655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:href="arvn-20250630.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_0e2e66a8-a4f9-4d53-8da7-0fdfbfd96509" xlink:to="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_8b3158ae-dd9e-472a-ba49-6b0e4099540e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_8b3158ae-dd9e-472a-ba49-6b0e4099540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_f7555f12-7fbd-4edf-969b-6159c4d5b00e" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:to="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_f7555f12-7fbd-4edf-969b-6159c4d5b00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_85384b46-ab2a-4b1c-afe4-0cf648b15e41" xlink:href="arvn-20250630.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:to="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_85384b46-ab2a-4b1c-afe4-0cf648b15e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_986834a9-01e0-4bd3-a15e-ded299e476a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_b1960124-b1dc-4ba0-8787-023f6e2548a5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_986834a9-01e0-4bd3-a15e-ded299e476a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:href="arvn-20250630.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_0e2e66a8-a4f9-4d53-8da7-0fdfbfd96509" xlink:to="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4358b7e0-6d6c-4e25-a94b-b497f4815706" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4358b7e0-6d6c-4e25-a94b-b497f4815706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_fa9605c3-31e7-4ba3-ad9b-1a0b5da94641" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:to="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_fa9605c3-31e7-4ba3-ad9b-1a0b5da94641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dbba17e4-9559-4b39-a93d-c170033f682e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dbba17e4-9559-4b39-a93d-c170033f682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_874736ea-a295-4e11-8a38-487588475ec3" xlink:href="arvn-20250630.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:to="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_874736ea-a295-4e11-8a38-487588475ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c7a685b9-51ca-4dd7-83a6-43d9c145fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_9056f74c-238b-4269-81cf-4d47dec6604b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c7a685b9-51ca-4dd7-83a6-43d9c145fa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_148684c9-f4f1-48c4-a541-7cba07c8ced2" xlink:href="arvn-20250630.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_148684c9-f4f1-48c4-a541-7cba07c8ced2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d07ec056-b58a-414e-8390-4cd6aaa18209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d07ec056-b58a-414e-8390-4cd6aaa18209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5f7a718a-58f1-4e4a-a862-3094bdbb6b99" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_de2ede6a-f4c8-4e73-acda-3a1793bd6c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f4a52e28-3367-4521-93f0-ed900c25e1cd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_eb76e518-a3da-4b1f-b82e-213ad9548500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1abeb42d-eb90-4710-b7a7-fba0d2439fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1abeb42d-eb90-4710-b7a7-fba0d2439fa5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be0327e8-0bdc-48ed-b333-9db5ccb8048e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_667f286d-24c3-46c2-9506-14ab94f1ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d00300-82d1-4420-b46e-c3d14a7582f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_667f286d-24c3-46c2-9506-14ab94f1ac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7930364d-b01f-4f6d-b366-cf07ee2c882a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a82e5195-c99c-4559-8ee9-ca2e363ae35a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd595101-abc9-4b64-adad-1594a12481c7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a82e5195-c99c-4559-8ee9-ca2e363ae35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e784eaa-7e2d-49e5-8a45-8af431f1ed4a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7e1f69cc-40ba-43e6-b5bc-0f47c36ce36e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7e1f69cc-40ba-43e6-b5bc-0f47c36ce36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_46d38edd-746c-41b7-a25e-b1388e0672f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9259798-0659-4f30-a01c-d7146c7287b0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_46d38edd-746c-41b7-a25e-b1388e0672f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56e7603b-b4a6-4169-8107-837e52e2c6b1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5348b9ec-fef8-43ff-b1c3-d90628eb2f19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5348b9ec-fef8-43ff-b1c3-d90628eb2f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df99cd08-0742-432d-a764-3215c3ac8da3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df99cd08-0742-432d-a764-3215c3ac8da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a47db257-3648-483f-8f56-8dc3c2636f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a47db257-3648-483f-8f56-8dc3c2636f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c50a4d2-f4f8-446a-9ab0-f00b8e449ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c097be36-a1f8-4aeb-ab2b-d46e94ca79c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c50a4d2-f4f8-446a-9ab0-f00b8e449ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_18137d8c-250a-48ba-a2e1-b8e2a5fa2075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_18137d8c-250a-48ba-a2e1-b8e2a5fa2075" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37eb9424-e0af-4d48-80ff-88ffb5e0a1b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_55335c7c-ec3d-422d-80d5-8b724fce35ff" xlink:href="arvn-20250630.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_arvn_LaboratoryEquipmentMember_55335c7c-ec3d-422d-80d5-8b724fce35ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a41ab387-7145-449c-b95a-650a96afea34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a41ab387-7145-449c-b95a-650a96afea34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_808cf92f-3b07-4750-90de-9766c1265aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2e400e-6220-48e6-aa0f-48bcab53e182" xlink:to="loc_us-gaap_OfficeEquipmentMember_808cf92f-3b07-4750-90de-9766c1265aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fdde1755-aa7e-4b2c-9851-213d79dd63db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d40cff42-86e3-464f-88e2-f0cc35fe2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d40cff42-86e3-464f-88e2-f0cc35fe2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4321307-d5ac-464c-9a70-0e6dab7b0b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4321307-d5ac-464c-9a70-0e6dab7b0b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba1df304-bdf1-4a2c-b562-71a988627492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_865470cf-a013-462b-84f9-f839f674fa54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba1df304-bdf1-4a2c-b562-71a988627492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86b938a1-14cd-497e-9934-dfd4616dcb80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a0155574-ba53-46b7-8c3f-9f9fcd78e69c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86b938a1-14cd-497e-9934-dfd4616dcb80" xlink:to="loc_us-gaap_DepreciationAndAmortization_a0155574-ba53-46b7-8c3f-9f9fcd78e69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5f7044b2-a499-496e-90d8-2a5d05e2b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5f7044b2-a499-496e-90d8-2a5d05e2b6da" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:to="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ef0eb61-9e5d-419d-81a1-8d4e611b956b" xlink:to="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a5efd44-1f96-4121-b982-7dee01959760" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4de94f73-f37f-4622-9536-8fa8162ef1ab" xlink:to="loc_srt_MinimumMember_7a5efd44-1f96-4121-b982-7dee01959760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ad037017-7061-492e-89e2-ada1d5a3a06b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1d79c44f-6e20-4970-9ab7-22f4bd98f460" xlink:href="arvn-20250630.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_1d79c44f-6e20-4970-9ab7-22f4bd98f460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d87d2ba9-5c24-4d1f-bfe2-2e9af8d88abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d87d2ba9-5c24-4d1f-bfe2-2e9af8d88abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_5749e940-4c64-4300-89a8-368108fa1202" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_5749e940-4c64-4300-89a8-368108fa1202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5715ff64-88cd-4dfe-b981-05efeacba06c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_931d6765-27ae-48b4-a373-92ebabf73fb5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5715ff64-88cd-4dfe-b981-05efeacba06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9d9e257d-0b1f-40e1-9b98-38b1f403456d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e607770b-50be-4659-a1e6-cc5278c6889b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d9e257d-0b1f-40e1-9b98-38b1f403456d" xlink:to="loc_us-gaap_OperatingLeaseCost_e607770b-50be-4659-a1e6-cc5278c6889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_369e256d-83fc-4017-8f4b-dea219ce6b91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_3434d6ba-cdb3-4bdf-a9ab-f890b030c5fb" xlink:href="arvn-20250630.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_369e256d-83fc-4017-8f4b-dea219ce6b91" xlink:to="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_3434d6ba-cdb3-4bdf-a9ab-f890b030c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_09710512-c405-4658-ad3f-001d1c454bef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_3434d6ba-cdb3-4bdf-a9ab-f890b030c5fb" xlink:to="loc_us-gaap_OperatingLeasePayments_09710512-c405-4658-ad3f-001d1c454bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b0bf6ca3-4a98-4b64-bf0f-f860b27ee049" xlink:href="arvn-20250630.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_369e256d-83fc-4017-8f4b-dea219ce6b91" xlink:to="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b0bf6ca3-4a98-4b64-bf0f-f860b27ee049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_962e50b2-4f99-4e05-a90c-30992e6ff372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b0bf6ca3-4a98-4b64-bf0f-f860b27ee049" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_962e50b2-4f99-4e05-a90c-30992e6ff372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_200fab49-4a49-4670-aadc-ad6957065f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_200fab49-4a49-4670-aadc-ad6957065f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a50c3c93-8502-463f-9d81-edef1070eaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a50c3c93-8502-463f-9d81-edef1070eaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_30c4b77b-5a55-4ae9-96c3-070f1d58a572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_30c4b77b-5a55-4ae9-96c3-070f1d58a572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90555ce5-263c-4ba8-aaee-705ebe1402d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90555ce5-263c-4ba8-aaee-705ebe1402d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2d1da500-3bf0-4355-a90d-6662b7d33ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2d1da500-3bf0-4355-a90d-6662b7d33ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8f47a4b5-8a2c-44e2-be3f-02356d6c3b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8f47a4b5-8a2c-44e2-be3f-02356d6c3b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_71a30172-a58c-48a4-8096-ebca825debf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_71a30172-a58c-48a4-8096-ebca825debf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d8ca6992-4ae0-4339-a6d9-e8002d0fee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_056ffa52-02d8-4e54-a8f4-c99cfacbc50d" xlink:to="loc_us-gaap_OperatingLeaseLiability_d8ca6992-4ae0-4339-a6d9-e8002d0fee0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_67713781-51b1-428b-867d-785deacc25b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f3f3c793-28a5-4127-be52-b85ae16ae797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_67713781-51b1-428b-867d-785deacc25b1" xlink:to="loc_us-gaap_AccountsPayableCurrent_f3f3c793-28a5-4127-be52-b85ae16ae797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_67713781-51b1-428b-867d-785deacc25b1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_cbc58871-2ec2-457a-a8e1-896cf3d502fb" xlink:href="arvn-20250630.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_cbc58871-2ec2-457a-a8e1-896cf3d502fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_670d4577-e147-408a-87a2-5c21fd175096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_670d4577-e147-408a-87a2-5c21fd175096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_ecdf1a78-ac79-459b-bccf-3caecb90e0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_ecdf1a78-ac79-459b-bccf-3caecb90e0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_07da4f23-62e0-4590-afd5-579003fe391f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_07da4f23-62e0-4590-afd5-579003fe391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_962a993a-0575-4980-b487-206c3d01ad5c" xlink:href="arvn-20250630.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e8d8866e-484c-476e-9be3-c339384cc5fe" xlink:to="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_962a993a-0575-4980-b487-206c3d01ad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_532cdec1-8cbd-445c-879c-51304b7cd9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_67713781-51b1-428b-867d-785deacc25b1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_532cdec1-8cbd-445c-879c-51304b7cd9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9b790ea1-81e8-4dd1-b3eb-52a636d6f747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcf65f0a-7859-4cd3-b489-664504f61033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b790ea1-81e8-4dd1-b3eb-52a636d6f747" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcf65f0a-7859-4cd3-b489-664504f61033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a8f2c98-cad9-4461-9844-fc0595126665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b790ea1-81e8-4dd1-b3eb-52a636d6f747" xlink:to="loc_us-gaap_LongTermDebt_6a8f2c98-cad9-4461-9844-fc0595126665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3053f52c-323d-4001-ae21-ec6b6316576d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b790ea1-81e8-4dd1-b3eb-52a636d6f747" xlink:to="loc_us-gaap_LongTermDebtCurrent_3053f52c-323d-4001-ae21-ec6b6316576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8165f3bf-0833-4b2b-b04a-38b201e237bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b790ea1-81e8-4dd1-b3eb-52a636d6f747" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8165f3bf-0833-4b2b-b04a-38b201e237bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_543ae1df-1f0b-44b9-bd6e-08f5b8042b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_543ae1df-1f0b-44b9-bd6e-08f5b8042b38" xlink:to="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:to="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2703885d-8b4d-4191-ad93-7d2f4d226a63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_c05a56a3-68fd-4787-9881-ab9944981b4f" xlink:href="arvn-20250630.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d91287ba-f6a7-422e-9a63-007b1bb6228d" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_c05a56a3-68fd-4787-9881-ab9944981b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:to="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fef2a60d-ec91-4613-94c8-eba1468a8d1e" xlink:to="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_93b675b8-9853-4081-acb3-18ef6a7b0c61" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fe424a82-0f44-4c9a-816f-5e15db5be73f" xlink:to="loc_stpr_CT_93b675b8-9853-4081-acb3-18ef6a7b0c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8f363fab-6650-41a7-8814-ef1ea0d2819f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4b4d23fe-6077-47c4-adcd-0ebcf324b903" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4b4d23fe-6077-47c4-adcd-0ebcf324b903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_7151faf3-9181-46b2-af8f-2e4d8cc55bd8" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_7151faf3-9181-46b2-af8f-2e4d8cc55bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bf6b0e9-e04f-4fdc-b668-81fadf8e3c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bf6b0e9-e04f-4fdc-b668-81fadf8e3c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_7b46e040-65d9-4852-b9f3-0bd190335133" xlink:href="arvn-20250630.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_7b46e040-65d9-4852-b9f3-0bd190335133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_ee0de77e-caa2-4ea4-96af-41ada49b4a17" xlink:href="arvn-20250630.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_ee0de77e-caa2-4ea4-96af-41ada49b4a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d2f5be4d-033c-404d-a035-c240eaaf9298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d62c992c-eada-4be4-a02b-7ab0faca8b4d" xlink:to="loc_us-gaap_InterestExpense_d2f5be4d-033c-404d-a035-c240eaaf9298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_603d2b03-90a1-42ff-8467-668ab43c7f46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_603d2b03-90a1-42ff-8467-668ab43c7f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638dd89b-06f2-4fa4-bb67-e5ef9a726c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638dd89b-06f2-4fa4-bb67-e5ef9a726c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e73d0336-e6f4-4f82-bf3f-6593adf46722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e73d0336-e6f4-4f82-bf3f-6593adf46722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c46962dd-c076-453a-b5a1-6651ff6a64db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c46962dd-c076-453a-b5a1-6651ff6a64db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_287add02-1bbd-476e-9347-8380c3dcfb92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14f224b8-6c7b-41f2-9543-d40f4700ce7e" xlink:to="loc_us-gaap_LongTermDebt_287add02-1bbd-476e-9347-8380c3dcfb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afb4aa6f-0ac4-449b-b23e-c55a5bf53507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afb4aa6f-0ac4-449b-b23e-c55a5bf53507" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bf01a8d0-3874-4044-9d31-a2241401cbfb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_ae334e92-f343-4a66-b9f0-3253f1724763" xlink:href="arvn-20250630.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed848449-69e8-4835-8816-b7ae182d0cbf" xlink:to="loc_arvn_PiperSandlerAndCantorMember_ae334e92-f343-4a66-b9f0-3253f1724763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b25d92e-f7b6-4026-a160-ec5cef6433de" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_b2f36b68-5711-4644-bf39-fe38dacb92d5" xlink:href="arvn-20250630.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:to="loc_arvn_AtTheMarketOfferingMember_b2f36b68-5711-4644-bf39-fe38dacb92d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4671ace5-21dc-4d58-8f78-84f630cfd687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2ae1dd1-0e64-42f3-828d-a7ef947a5745" xlink:to="loc_us-gaap_EmployeeStockMember_4671ace5-21dc-4d58-8f78-84f630cfd687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6843dbcf-2014-4631-b418-c4634461fe81" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_66c7f659-8187-4e50-9f28-dd4c9a5b4aa3" xlink:href="arvn-20250630.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e2cb243-815d-4096-be0f-811a807165e6" xlink:to="loc_arvn_EquityDistributionAgreementMember_66c7f659-8187-4e50-9f28-dd4c9a5b4aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b168bae-a354-4c96-b480-34b6f43c2503" xlink:to="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_832c9488-a2d5-4c97-8130-298963a4569c" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_76fdce44-1638-436e-a6e0-252305ff86c0" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_832c9488-a2d5-4c97-8130-298963a4569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_690fe995-0aef-422f-8da0-8ec0064e3396" xlink:to="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49a1326-491a-449d-ae54-488d30aecd03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_MaximumMember_f49a1326-491a-449d-ae54-488d30aecd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c80a8301-85e9-4a11-9eb7-90beba9edd8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_MinimumMember_c80a8301-85e9-4a11-9eb7-90beba9edd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a5e0ca3f-efce-41d3-af6d-3a2b81e0e4fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2923f53e-151a-4ee4-bb02-d29b591c2cb2" xlink:to="loc_srt_WeightedAverageMember_a5e0ca3f-efce-41d3-af6d-3a2b81e0e4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ca9777c1-a346-4ff4-9172-b1d91de58bfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fe2010b2-b804-4737-ae28-0013c63be738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:to="loc_us-gaap_EmployeeStockMember_fe2010b2-b804-4737-ae28-0013c63be738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9821f9ee-77bd-4d30-9a95-038a5962fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e770eca-fc51-494a-a069-64353db40ebe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9821f9ee-77bd-4d30-9a95-038a5962fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21dca4ab-ae1b-4e84-b415-eeff271634f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_4c81ba0d-5a77-4500-af46-3eda4aaaa831" xlink:href="arvn-20250630.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_4c81ba0d-5a77-4500-af46-3eda4aaaa831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f64850fd-d4af-4a9a-836f-db6f8c732fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f64850fd-d4af-4a9a-836f-db6f8c732fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c370948-40a3-40af-bc51-7eb6e90a20e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c370948-40a3-40af-bc51-7eb6e90a20e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_e7326d55-bd27-47fa-bbcf-c602e0dfdef3" xlink:href="arvn-20250630.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_e7326d55-bd27-47fa-bbcf-c602e0dfdef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c8a5290c-9bfc-43e6-abd1-b0935e4ae024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c8a5290c-9bfc-43e6-abd1-b0935e4ae024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb503a6c-2ac4-46f3-a59d-9c3195c282ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb503a6c-2ac4-46f3-a59d-9c3195c282ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_0ae5d47c-e27a-48c6-8729-39ebffa366e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_0ae5d47c-e27a-48c6-8729-39ebffa366e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a380d8b3-ac4b-4fca-aa82-11e7105e4e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a380d8b3-ac4b-4fca-aa82-11e7105e4e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f5ccf0a7-59f7-49fc-9319-a59b862c695b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f5ccf0a7-59f7-49fc-9319-a59b862c695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2c887fee-7df3-40a0-ae68-dc5a1725cb50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2c887fee-7df3-40a0-ae68-dc5a1725cb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf088008-a74f-4e59-a21e-b734a191f729" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf088008-a74f-4e59-a21e-b734a191f729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37da608f-0071-460d-8c34-26c11d74a041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37da608f-0071-460d-8c34-26c11d74a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_23cda6db-4109-4bfb-8636-b74b188d8282" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_23cda6db-4109-4bfb-8636-b74b188d8282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4090ea20-9c8c-4955-8d16-c641c177eb32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4090ea20-9c8c-4955-8d16-c641c177eb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab98152b-e2fd-40cc-9d3a-6969852a5ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab98152b-e2fd-40cc-9d3a-6969852a5ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_7aae79d7-515a-4b42-a7aa-396d37dc4043" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_7aae79d7-515a-4b42-a7aa-396d37dc4043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ffe97f1-fc82-43bf-817a-12f8817499c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ffe97f1-fc82-43bf-817a-12f8817499c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_2e18f971-04be-41c7-97c2-ac0770d9858d" xlink:href="arvn-20250630.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_2e18f971-04be-41c7-97c2-ac0770d9858d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e447bd0d-d34d-422f-b80e-078763d5c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f475915-2e68-410e-a0b7-22a87d0f5f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e447bd0d-d34d-422f-b80e-078763d5c03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_840d1605-6fea-4f50-95a7-da9327257d30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_840d1605-6fea-4f50-95a7-da9327257d30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:to="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_779b158b-ff70-4507-b1ca-5526a9cdc638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d347b573-831e-4df7-9f33-ad774bc62fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf60863-5f93-4e04-b168-fec65c9a5475" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d347b573-831e-4df7-9f33-ad774bc62fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:to="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d7b47433-fcde-44c1-9237-3d4b8d88dd6b" xlink:to="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6749ede0-3e24-46b8-ae7e-de9a560ea525" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:to="loc_srt_MinimumMember_6749ede0-3e24-46b8-ae7e-de9a560ea525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31875e97-5910-44c8-8996-11f33643fb0b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_593afc78-c9d1-428b-a1dd-ae87b55767b1" xlink:to="loc_srt_MaximumMember_31875e97-5910-44c8-8996-11f33643fb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f88cf52a-2745-4c81-a9ff-bd0c63bf8d79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ff018851-7dbb-4c66-9df8-bb291dd7060d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ff018851-7dbb-4c66-9df8-bb291dd7060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dfef65fb-9bdc-4db2-aa8b-3cd4abf59e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dfef65fb-9bdc-4db2-aa8b-3cd4abf59e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd9bc3d6-5399-4f0d-9a41-3c6458b93d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd9bc3d6-5399-4f0d-9a41-3c6458b93d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3d42bcb0-4b5d-430f-97ef-ebf8d20b90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3d42bcb0-4b5d-430f-97ef-ebf8d20b90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b8c9e3a3-080d-4127-a3b0-51ff4aa830a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b8c9e3a3-080d-4127-a3b0-51ff4aa830a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5dc0276c-ccbb-48f0-aff7-f1b5fba0aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5dc0276c-ccbb-48f0-aff7-f1b5fba0aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5629d040-8a67-484e-85a9-8754c10ae904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31a3f826-fb89-48b9-aa29-d82b16071c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5629d040-8a67-484e-85a9-8754c10ae904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a32f822e-13d5-4eaa-8d27-3365b62c0735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a32f822e-13d5-4eaa-8d27-3365b62c0735" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:to="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_70ae5457-8620-43f9-aa21-6ac27de194e9" xlink:to="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_0116b52e-e974-44a1-905d-4f369422edfa" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6c6b55f4-0498-4d76-b258-b2da473a3eaa" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_0116b52e-e974-44a1-905d-4f369422edfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4564908f-c883-407e-a25d-2e49c299d47f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1424276-6fdb-4054-a393-4c8da29b421c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1424276-6fdb-4054-a393-4c8da29b421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f10dab01-d6f8-4caa-a586-4e4f231bd52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f10dab01-d6f8-4caa-a586-4e4f231bd52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9936ab2a-a57b-4460-9436-939f43f00e54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9936ab2a-a57b-4460-9436-939f43f00e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09222003-464b-4db3-84cc-3b4bdcd5900a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_475d22cc-8e11-45ca-8aec-68326527effd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09222003-464b-4db3-84cc-3b4bdcd5900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c5a336e-cff2-4512-8947-e8b42d6bb076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c5a336e-cff2-4512-8947-e8b42d6bb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_85c5d3bc-5910-4cc7-8662-c34ac3dcbdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_85c5d3bc-5910-4cc7-8662-c34ac3dcbdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3d7c6ed-e9e9-48b1-b3f0-bba848873f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3d7c6ed-e9e9-48b1-b3f0-bba848873f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41aff9cc-181d-41ca-935f-e328501df810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41aff9cc-181d-41ca-935f-e328501df810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_507c6a06-b663-441e-a590-109031063811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_507c6a06-b663-441e-a590-109031063811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31c08ba5-d29e-41dd-ad90-b7e67d37672d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_f313c4ad-782f-485f-bab3-c2de6d3c31fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31c08ba5-d29e-41dd-ad90-b7e67d37672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_088d434a-ff58-4d36-93e8-f627df31879f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_088d434a-ff58-4d36-93e8-f627df31879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f62ea883-7631-4e7f-abc3-e48f1db78bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f62ea883-7631-4e7f-abc3-e48f1db78bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd66263b-836f-49c0-b363-1672a84c7063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd66263b-836f-49c0-b363-1672a84c7063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cd4ee51-bb5e-4cdb-8a6f-ac9368686334" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cd4ee51-bb5e-4cdb-8a6f-ac9368686334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9e7cb350-36ad-4c4a-98d8-a5ef190f1a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e21fd86-75e1-417d-89b1-2893d4abdb98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9e7cb350-36ad-4c4a-98d8-a5ef190f1a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:href="arvn-20250630.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36477039-0213-4538-991b-849079f2175c" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_edca342d-e5cc-4748-9879-750ea7375bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_edca342d-e5cc-4748-9879-750ea7375bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af631406-432c-478f-9e63-b2d3bea0c91b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af631406-432c-478f-9e63-b2d3bea0c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bb81862e-b45b-44d0-8614-6748cf895b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_23805945-2b80-4ed8-9114-f55e82e67f98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bb81862e-b45b-44d0-8614-6748cf895b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquitySummaryofRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_765bf7c0-6b17-4af2-b366-57e1974fadc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_765bf7c0-6b17-4af2-b366-57e1974fadc1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:to="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7743a0ad-529a-432f-9cf0-91d2bd9bffe5" xlink:to="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_171ae5dc-921d-4627-9f85-26908ba9b7b5" xlink:href="arvn-20250630.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_da6f3255-450e-4b41-86da-27929fd973f3" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_171ae5dc-921d-4627-9f85-26908ba9b7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:to="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d1b19522-02a6-442f-bbe1-f57be334133b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03ee5f06-7824-4a6b-a2d4-f68ca37fd463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31a05a93-8910-4551-b887-50aa0d783fa2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03ee5f06-7824-4a6b-a2d4-f68ca37fd463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf75e87-b9d2-47ac-b412-0cc673dc4fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4de80b7a-6e7c-4ff1-a5e0-40035e14f6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4de80b7a-6e7c-4ff1-a5e0-40035e14f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_969233a0-9432-4895-884c-12a823f98d68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_969233a0-9432-4895-884c-12a823f98d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_085f77fd-39ee-4e25-9c25-cb683f120957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_085f77fd-39ee-4e25-9c25-cb683f120957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d7252e71-b11d-431e-a2b9-fca9200370a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d7252e71-b11d-431e-a2b9-fca9200370a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae21a4a5-0b81-45fd-a63e-ae04749fa72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_974597a7-850c-43ad-8645-233a21a30ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae21a4a5-0b81-45fd-a63e-ae04749fa72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38f8818c-96d3-4b3c-bcea-58362bfac50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_351e6d87-0fdf-4f03-8172-f69d3aae620d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_351e6d87-0fdf-4f03-8172-f69d3aae620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc3d2cec-4400-4fa6-a8d8-390a646f5cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc3d2cec-4400-4fa6-a8d8-390a646f5cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3771860a-5976-469b-83d8-2735e7f74219" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3771860a-5976-469b-83d8-2735e7f74219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_28633395-0132-4e39-8ed3-7e893aa710e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_28633395-0132-4e39-8ed3-7e893aa710e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72e0bd07-0efe-44dc-bfb9-4f9a05d3d338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7fea76fe-6a7d-4f21-b390-bf437347528a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72e0bd07-0efe-44dc-bfb9-4f9a05d3d338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b7bb1e4-4902-4251-8fc0-33e7973d8441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f0b71e57-eec8-4676-9f7d-1153a880329f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b7bb1e4-4902-4251-8fc0-33e7973d8441" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f0b71e57-eec8-4676-9f7d-1153a880329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f0687616-2dad-43dd-b542-17396b58ac81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b7bb1e4-4902-4251-8fc0-33e7973d8441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f0687616-2dad-43dd-b542-17396b58ac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_25cf47b8-31d5-436b-a53a-dfafd8a704f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b7bb1e4-4902-4251-8fc0-33e7973d8441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_25cf47b8-31d5-436b-a53a-dfafd8a704f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29e473e6-c2c1-45bf-a97f-b168eb8f5e84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:to="loc_us-gaap_NetIncomeLoss_29e473e6-c2c1-45bf-a97f-b168eb8f5e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56ad5e95-9088-4f9a-8631-9c639f7f0cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56ad5e95-9088-4f9a-8631-9c639f7f0cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5b066fb2-e666-4b31-8b0c-fa6a05edc6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5b066fb2-e666-4b31-8b0c-fa6a05edc6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e6329cd2-e2ea-402f-8f4f-aa0f7b318ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5b066fb2-e666-4b31-8b0c-fa6a05edc6c9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e6329cd2-e2ea-402f-8f4f-aa0f7b318ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_cf0f72c4-43fb-4142-adb9-1d98e94f3b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5b066fb2-e666-4b31-8b0c-fa6a05edc6c9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_cf0f72c4-43fb-4142-adb9-1d98e94f3b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a199c74c-21da-42f5-bbcc-29052a15ee08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a199c74c-21da-42f5-bbcc-29052a15ee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EarningsLossPerCommonShareEPSAbstract_b3910cfc-0032-43eb-ba82-14448298282f" xlink:href="arvn-20250630.xsd#arvn_EarningsLossPerCommonShareEPSAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79d15094-e86b-4371-a448-db9dac9c44bf" xlink:to="loc_arvn_EarningsLossPerCommonShareEPSAbstract_b3910cfc-0032-43eb-ba82-14448298282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_36f1c549-1b34-4119-a245-5a9c08044f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_EarningsLossPerCommonShareEPSAbstract_b3910cfc-0032-43eb-ba82-14448298282f" xlink:to="loc_us-gaap_EarningsPerShareBasic_36f1c549-1b34-4119-a245-5a9c08044f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0deea6a9-39af-4568-933d-95ddf56febb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_EarningsLossPerCommonShareEPSAbstract_b3910cfc-0032-43eb-ba82-14448298282f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0deea6a9-39af-4568-933d-95ddf56febb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b62704dc-3d14-44ad-8a93-9b5be114331b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b62704dc-3d14-44ad-8a93-9b5be114331b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65532f7d-df97-4ce7-aba6-0c876022260b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_32d1b3cd-23c3-4bc4-80f9-9a782b29da9c" xlink:href="arvn-20250630.xsd#arvn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0ae62b4d-8172-4d2a-8130-dd95b36b6062" xlink:to="loc_arvn_PreFundedWarrantMember_32d1b3cd-23c3-4bc4-80f9-9a782b29da9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4bd8b36e-eb09-485f-9872-3ad5e499c178" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_169d2e3f-8721-46c7-acdb-538057036df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_169d2e3f-8721-46c7-acdb-538057036df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8dea2b53-86ec-447c-b98b-b058ff2b5e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8dea2b53-86ec-447c-b98b-b058ff2b5e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_3bf6c9fc-732c-4968-aece-8389a28dfceb" xlink:href="arvn-20250630.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16a56d6f-48ed-43c7-8a5b-aaa9b41fdba9" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_3bf6c9fc-732c-4968-aece-8389a28dfceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_93c31948-ac11-4ce1-840e-9bf8bff20b08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93c31948-ac11-4ce1-840e-9bf8bff20b08" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8503e31c-3bcd-43d3-8e13-cb0d88c7860b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78ed098b-714a-4142-8de0-6f43f0e4bd63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78ed098b-714a-4142-8de0-6f43f0e4bd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c538bd4-24f8-494d-960c-9acf369c9bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_018e1288-2dd5-4c9b-93b2-6200f67e0704" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c538bd4-24f8-494d-960c-9acf369c9bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_217cdc0f-ad99-4d67-a485-6be967974edc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d6588a3-9d02-43b1-ad90-422ea2d7c256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_00d34d16-700c-44e2-bee0-1bab77a88c67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d6588a3-9d02-43b1-ad90-422ea2d7c256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#EquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b5a7faab-6903-4f03-a35d-98c8a2a45019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b5a7faab-6903-4f03-a35d-98c8a2a45019" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3014b65-2ed8-4d78-bddf-11094b5dbc00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_a7e7f607-6dbc-498f-84a3-94bf7042b004" xlink:href="arvn-20250630.xsd#arvn_BayerCropScienceLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d841d6-f6e2-40c8-a545-d2bdbdaa9b66" xlink:to="loc_arvn_BayerCropScienceLPMember_a7e7f607-6dbc-498f-84a3-94bf7042b004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_94e5c2f9-4386-4f40-a24d-4a4c66821903" xlink:to="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_043a0621-e3a3-4674-a6fd-64ebd775e96d" xlink:href="arvn-20250630.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8f5b6a34-7f6b-43e1-bbd4-dffc55739fc1" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_043a0621-e3a3-4674-a6fd-64ebd775e96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7ace8b83-df14-4266-8cfc-e802ac5aec30" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_cbd55055-906d-4dce-b4f6-dcf31808dd24" xlink:href="arvn-20250630.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_38b03a36-8e95-4721-8751-f6b7bbf31122" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_cbd55055-906d-4dce-b4f6-dcf31808dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dad13f26-7d5b-47a5-8e51-fcb5b6205deb" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_202af56e-29fc-43ed-8f97-26e37c189b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_202af56e-29fc-43ed-8f97-26e37c189b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_513717c6-d0de-4201-babc-046d4eb4b284" xlink:href="arvn-20250630.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_513717c6-d0de-4201-babc-046d4eb4b284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ed24982-111f-4e1a-b7ac-074c9adca2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_NetIncomeLoss_8ed24982-111f-4e1a-b7ac-074c9adca2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fa441f08-9c96-41f3-b075-2de52cb6bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fdb75349-4b21-4817-86eb-dc6ba608793d" xlink:to="loc_us-gaap_EquityMethodInvestments_fa441f08-9c96-41f3-b075-2de52cb6bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cc7f8cfd-cd4b-46c5-89e8-77dcd86e476e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cc7f8cfd-cd4b-46c5-89e8-77dcd86e476e" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ad944ccb-cc2a-4d17-ae6e-8bbf45810ea1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_43882fcb-5908-4efc-b127-2735c24ccb91" xlink:href="arvn-20250630.xsd#arvn_YaleUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcc27046-16c7-404c-bdaa-0fd76b0e808d" xlink:to="loc_arvn_YaleUniversityMember_43882fcb-5908-4efc-b127-2735c24ccb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_617a736a-ab20-4448-8b3c-ac4514023264" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_37f7d245-625f-4d8a-aa58-5974f06b6e18" xlink:href="arvn-20250630.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_37f7d245-625f-4d8a-aa58-5974f06b6e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_1bcb57b8-04bd-4404-b43f-4ad3a67b4d06" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_1bcb57b8-04bd-4404-b43f-4ad3a67b4d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_68543bd7-25cd-452a-b57a-e91188c05554" xlink:href="arvn-20250630.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_68543bd7-25cd-452a-b57a-e91188c05554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_4b98554f-0946-410b-8d81-53a0ce432b1e" xlink:href="arvn-20250630.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71967995-2f91-4ceb-b25f-fd487f238765" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_4b98554f-0946-410b-8d81-53a0ce432b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d092248e-a94b-4f63-8597-e1dba7c98d45" xlink:to="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a7154d5-cbff-4594-94dc-873f308f8c2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:to="loc_srt_MaximumMember_1a7154d5-cbff-4594-94dc-873f308f8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f8cefb37-735e-4ffa-b1c3-3b098a61ac74" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ecf922c5-7f6e-4208-bae8-25d5e4f6e158" xlink:to="loc_srt_MinimumMember_f8cefb37-735e-4ffa-b1c3-3b098a61ac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ba53dc0b-0a34-4c15-9f0f-70d02337b357" xlink:to="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_9b2bbaa8-7c63-45fb-bd7b-79b5053afa79" xlink:href="arvn-20250630.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_9b2bbaa8-7c63-45fb-bd7b-79b5053afa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_04caba62-4549-48d3-9d2f-c6872511fe04" xlink:href="arvn-20250630.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70361d01-4fd1-4856-8aaf-6850b2e40bc6" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_04caba62-4549-48d3-9d2f-c6872511fe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:href="arvn-20250630.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_b8cbdbac-8eb7-429f-bf6d-0b736d9dd369" xlink:to="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration_423a5d19-3e7e-4da2-8794-23eca6717210" xlink:href="arvn-20250630.xsd#arvn_PaymentsForCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_PaymentsForCollaboration_423a5d19-3e7e-4da2-8794-23eca6717210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_0a656420-9e4c-43a1-98be-c1bae537d267" xlink:href="arvn-20250630.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_0a656420-9e4c-43a1-98be-c1bae537d267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_87d39589-5f58-433e-8a64-889738c1d088" xlink:href="arvn-20250630.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_AnnualLicenseFeePayment_87d39589-5f58-433e-8a64-889738c1d088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts_ff2ec161-29c3-4e76-9ccf-65ae7e442fcc" xlink:href="arvn-20250630.xsd#arvn_NumberOfLicensedProducts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_NumberOfLicensedProducts_ff2ec161-29c3-4e76-9ccf-65ae7e442fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_83a99b51-e6b0-4e47-8758-7819f67a778f" xlink:href="arvn-20250630.xsd#arvn_RequiredMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_arvn_RequiredMilestonePayments_83a99b51-e6b0-4e47-8758-7819f67a778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ad3f9851-8911-44f3-9e5f-e3658851987e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_e3a5517c-55e1-4bf4-bbcb-d506e84e0f67" xlink:to="loc_us-gaap_PaymentsForRoyalties_ad3f9851-8911-44f3-9e5f-e3658851987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#RestructuringActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e45593ba-93f3-4aac-9127-3c3c4e12c545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e45593ba-93f3-4aac-9127-3c3c4e12c545" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_24a903d5-d9f0-4280-8964-cee348a66d3b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_55b5d8db-de21-40b4-b9cf-8ab04d3db69c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:to="loc_us-gaap_EmployeeSeveranceMember_55b5d8db-de21-40b4-b9cf-8ab04d3db69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember_9a5f1a49-892c-4e83-9e96-5b5d04d20397" xlink:href="arvn-20250630.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c47757d-63f5-4714-b3a6-7dce2a64c6fa" xlink:to="loc_arvn_StockCompensationAndBonusExpenseMember_9a5f1a49-892c-4e83-9e96-5b5d04d20397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e46877e8-e04b-4cc5-a7a1-5d399db6674f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00fb2ace-01ce-4539-bce1-6836b85f4e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00fb2ace-01ce-4539-bce1-6836b85f4e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbef40e2-c8f4-4859-8508-cd6f9a4dbd03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_54a3e079-a20e-40a7-bcea-01808334ca7b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbef40e2-c8f4-4859-8508-cd6f9a4dbd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_675b877f-ec5e-4797-9c44-4189e767b4e3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_48445c4a-ab42-46b4-95ea-ace283ea1f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_48445c4a-ab42-46b4-95ea-ace283ea1f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ab821128-e3a9-4d54-9578-68f0a35cccba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringCharges_ab821128-e3a9-4d54-9578-68f0a35cccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4201a4f-e807-48c5-beb6-2c92e874be89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_402306d4-d8d9-49ed-991a-0c80822d409f" xlink:to="loc_us-gaap_RestructuringReserve_b4201a4f-e807-48c5-beb6-2c92e874be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ac9e86be-2204-4d3b-a01c-c335b0b29a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_15185b8e-5524-4041-af96-52cf7ade8e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ac9e86be-2204-4d3b-a01c-c335b0b29a2c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_15185b8e-5524-4041-af96-52cf7ade8e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_80e491be-8bc7-404e-b668-4fb546958b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ac9e86be-2204-4d3b-a01c-c335b0b29a2c" xlink:to="loc_us-gaap_NumberOfReportableSegments_80e491be-8bc7-404e-b668-4fb546958b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5de8cb94-3b11-4742-b7a7-d8384cf63675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ac9e86be-2204-4d3b-a01c-c335b0b29a2c" xlink:to="loc_us-gaap_DepreciationAndAmortization_5de8cb94-3b11-4742-b7a7-d8384cf63675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20250630.xsd#SegmentInformationFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5e7f5e8c-db7b-428b-99dd-07c35c4b71ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5e7f5e8c-db7b-428b-99dd-07c35c4b71ed" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06de6f6f-b910-4737-8ca0-e1953d47fccb" xlink:to="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember_6249f45d-f6d3-4ad3-88ce-78edc0a35945" xlink:href="arvn-20250630.xsd#arvn_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b8992d98-03a1-47bd-86dd-61110c7e6f3e" xlink:to="loc_arvn_ReportableSegmentMember_6249f45d-f6d3-4ad3-88ce-78edc0a35945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:to="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_18a6be72-1dcf-44d3-b65d-b1d52a038e4e" xlink:to="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member_60faebfd-416d-4b98-965b-bfb61d480aec" xlink:href="arvn-20250630.xsd#arvn_ARV471Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV471Member_60faebfd-416d-4b98-965b-bfb61d480aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member_12771f5d-5c60-4184-81a6-e425751fbb86" xlink:href="arvn-20250630.xsd#arvn_ARV102Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV102Member_12771f5d-5c60-4184-81a6-e425751fbb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member_8e39a7f5-599c-4e6d-b5e7-5faa3f09a746" xlink:href="arvn-20250630.xsd#arvn_ARV393Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV393Member_8e39a7f5-599c-4e6d-b5e7-5faa3f09a746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member_a2640faf-83bc-4959-827c-73c4e4f83f89" xlink:href="arvn-20250630.xsd#arvn_ARV806Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV806Member_a2640faf-83bc-4959-827c-73c4e4f83f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member_3c69d8dc-cf50-4ce1-9f20-a5e674887592" xlink:href="arvn-20250630.xsd#arvn_ARV110Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV110Member_3c69d8dc-cf50-4ce1-9f20-a5e674887592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member_5f3191f4-4a10-43a1-a373-78f49e332f3e" xlink:href="arvn-20250630.xsd#arvn_ARV766Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_ARV766Member_5f3191f4-4a10-43a1-a373-78f49e332f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember_d979a88a-0977-41a4-acb8-4e6762e68c61" xlink:href="arvn-20250630.xsd#arvn_OtherProgramsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b13ea456-3591-4b64-b273-7d78701aa972" xlink:to="loc_arvn_OtherProgramsMember_d979a88a-0977-41a4-acb8-4e6762e68c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0f1ec069-4b2d-4258-ae6c-0198a75e5007" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd03264e-9e1e-4483-8f54-751f0e2d32fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_Revenues_cd03264e-9e1e-4483-8f54-751f0e2d32fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_8d6c982b-5954-41e3-bf15-de8681aeb85b" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_8d6c982b-5954-41e3-bf15-de8681aeb85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_cb2c9b85-a54f-43ef-bca9-ed6257c94b04" xlink:href="arvn-20250630.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_cb2c9b85-a54f-43ef-bca9-ed6257c94b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_aee54c4c-b80f-4535-a938-60593c83671c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_LaborAndRelatedExpense_aee54c4c-b80f-4535-a938-60593c83671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_565a37be-e3f1-4baa-b752-0402e7f8059e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_565a37be-e3f1-4baa-b752-0402e7f8059e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e18b2a59-a76c-4ea5-88c2-3459c64477cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e18b2a59-a76c-4ea5-88c2-3459c64477cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_710c580b-c855-43a9-bb9c-310cb32f9b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_710c580b-c855-43a9-bb9c-310cb32f9b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_f72804cc-994d-45b6-817e-6efbb9f33ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_f72804cc-994d-45b6-817e-6efbb9f33ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dcbfb598-1e31-40a4-98f7-2f33d0e135db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_8f99e7a3-6b9c-48d9-a110-15aa124cd4a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dcbfb598-1e31-40a4-98f7-2f33d0e135db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4632d6d4-4ad4-45dc-9d09-276ca2868bed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4632d6d4-4ad4-45dc-9d09-276ca2868bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f1c1446-d746-49c0-9df5-84d448e50f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_35f5c743-e3ef-4015-8799-579b5dd8e7c7" xlink:to="loc_us-gaap_NetIncomeLoss_5f1c1446-d746-49c0-9df5-84d448e50f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>arvn-20250630_g1.jpg
<TEXT>
begin 644 arvn-20250630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'U!%4# 2(  A$! Q$!_\0
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M_P FZ?$S_L7;[_T0]?AM7TV4TJ=2G)SBGKU1\[F=2=.<5"36A[Y_PW=\=O\
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M ,%]I_\ &:/^&[OCM_T/]Q_X+[3_ .,UX'11]6H?R+[D'UBM_._O9]'^&?\
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MM0_D7W(/K%;^=_>SWS_AN[X[?]#_ ''_ (+[3_XS1_PW=\=O^A_N/_!?:?\
MQFO Z*/JU#^1?<@^L5OYW][/?/\ AN[X[?\ 0_W'_@OM/_C-'_#=WQV_Z'^X
M_P#!?:?_ !FO Z*/JU#^1?<@^L5OYW][/?/^&[OCM_T/]Q_X+[3_ .,T?\-W
M?';_ *'^X_\ !?:?_&:\#HH^K4/Y%]R#ZQ6_G?WL]\_X;N^.W_0_W'_@OM/_
M (S1_P -W?';_H?[C_P7VG_QFO Z*/JU#^1?<@^L5OYW][/?/^&[OCM_T/\
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M!T4?5J'\B^Y!]8K?SO[V?J?^Q5^V]%\7H[?P7XYNHK?QJ@Q:7Q"QQZHH[8&
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MW@,K'YFR3FLI1_=N"_O->K<E^33]8EQE[ZF_)/T2C^J:]),]"^$'_))?!/\
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MI4RB[-)WT@O7EO?\;/\  J,ES*3TM*4O2[5OO5UY7OV/0?!O_(GZ%_UX0?\
MHM:V:KZ?8Q:;86UG "(;>)8D#')VJ !S]!5BMZDE.<I+JS"G%QA&+Z(****S
M- HHHH \R_:<_P"3=/B9_P!B[??^B'K\-J_<G]IS_DW3XF?]B[??^B'K\-J^
MKR?^'/U/F<V_B1]#]E;%O'<.H?"QK=]-B^$J^%E/B4ZI]G$6[R%\O&[]YGI_
ML8W9YQ7F/P2EOI/V?_&0^$?B71/!OVCQY=1Z1J&K;!:&W::,+$H9'!+IA47&
M3D $&OAG]H;]H0_'J+P6G]@?V&/#FDKIG_'Y]H^T8"_O/]6FW[OW>?K3]-_:
M*DTS]FF]^$T6AD27&K+JJZVM[M,95D8((O+ZY3[V_OTH^I5&I2:U<MO+VG-=
MZZ^[LNWNG-#%*,*5/^6._9^S<;+M[V[[ZGV_+J.D77_!1CPE96VG^3KMAX?F
MBUF^6T:V2\N# [!T4CYAM(^?)SG&3MKS'XK1^-OBA\9/"'@;QO\ %;PAXW\&
M:IXNV#0?#MS;R7=G&COA9_+A1T.PM&<N>2>I&:\X/[=OVGXM>!/B)>>!8Y_$
M'A_2)=*U"1-4V?VIN3:LG^I/E;6:1MOSYWXSQFN%^('Q\\%:OJUIXC\#?"\^
M ?&D&KKJYUT>([B_WN&9V7R9$" ,Y!X],8P:JGA:L*M%RCI%-/9Z\[=[/I;5
M6U2T+J8B,X5E"5G+;?\ Y]I6TO=W5G?1O5Z'M'[2G[7OC#X7_%?Q+\.O#6EZ
M#8^ ](B_LF/P_-I:&"5&B7+MC# Y8[0I"XQD&L/]K]1_PS'^S6<<_P!B/S_V
MQMJRO%W[9G@KQY?/XB\0? C0-4\<O9_9WUBXU%VMG?8%$CVACVOC QN8L
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M&YOI;+PQ;Z/:+/)I$I=DC6XE6-1&\;E,[LD%2-S%@M?*VF_MSW3?\*HO]?\
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MQS[50/[*^A?V#>78^+/A<ZG%="&'3OM]E^^AQS-YGVO:O/&T\UX_11];Q/\
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MRWTSIJ<?VRS/]F1B0*KY^U_OLH2^%Y&,=37C%%'UO$_S_@O\@_U=P?9_>_\
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M;SR6TK^T++B#9GS_ #?M>W[WR[.O>M2X_9)\)1ZYK=K%\;/"TVG6EFTUA?\
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M1-,C^V68_M.,R%6?/VO]SA 'PW)SCJ*MVO[)/A*77=$M9OC9X6@TV[LUGO\
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M1117GG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CO[5'_)-]._
M[&#2O_2N.OFK]HK_ )(OXG_ZXQ_^CDKZ5_:H_P"2;Z=_V,&E?^E<=?-7[17_
M "1?Q/\ ]<8__1R5_/\ QU_R564?XH?^G$?H?#__ "+ZWJ__ $D\1^(GPA\,
M:E^RW\/OB+X.TA[34VN6TG7D2>68S7'*K)M9V"99,@* /WR\=*]DT/\ 9H^&
M-I\=OAY\-=2\/?;;]/#$FH>(I!?W*BXNBB[/NRC9M*N<+@$.N<UYW^QO\</
MO@WPQXF\'_$N_P#L7AZXO;/5[)C:S3C[3#(K$$1(Q&3%">1CY2.]/^$_[1WA
MX?MEZ]\2/%6IG3=!O!=Q07/V>67;%M$< V(K-G8BYXZYZ5_24K^T<5L[R_\
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MK$2ZEHV(/4C!P*S? G[(?C7QZOBTP7NAZ2?"VH'3M4_M6]:%8F4G>^\(R[%
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M=[U[_AY>?;C?V)_ >A^)/&WB;Q)XGTRUU?0/"NB7&I2V=["LT,DFTA0R,"K
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M[N)VNY)3O0Q8=R0,-NX!W8[5P/A/XB:;^S1XYTAOAI\6/^$DT/5KB >()O\
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M7/&.@:-<30K<10ZAJD$#R1MD*ZAW!*G!P1QP:^-/">EWNI_M&?&=+;X,Z/\
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M_#9'PY_Z-O\ !?\ WS;_ /R+1S2_E#VE3_GW^*/E&BOJ[_ALCX<_]&W^"_\
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M=<C?_K#[_P#UJ^F/^&R/AS_T;?X+_P"^;?\ ^1:/^&R/AS_T;?X+_P"^;?\
M^1:?LX?\^U^ ?7,5VE_X%_P3YL7QMKRWEM=#5;GS[>+R8GW_ '4]/?\ 'VJ#
M_A*-7^P_8_[1N/LWG>?Y?F'_ %F<[L]>O/UYKZ:_X;(^'/\ T;?X+_[YM_\
MY%H_X;(^'/\ T;?X+_[YM_\ Y%H]G#_GVOP']<Q?:7_@7_!/FQO&VO->7-T=
M5N?M%Q%Y,K[\;D]/;\/4UFWFIW5_%;1W,[S);IY<0<YV+DG ]LFOJ7_ALCX<
M_P#1M_@O_OFW_P#D6C_ALCX<_P#1M_@O_OFW_P#D6G&$8N\86^XF6*Q,U:46
MUZ_\$^4:*^KO^&R/AS_T;?X+_P"^;?\ ^1:/^&R/AS_T;?X+_P"^;?\ ^1:U
MYI?RF/M*G_/O\4?*-%?5W_#9'PY_Z-O\%_\ ?-O_ /(M'_#9'PY_Z-O\%_\
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M?_Y%H_X;(^'/_1M_@O\ [YM__D6CFE_*'M*G_/O\4?*-%?5W_#9'PY_Z-O\
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M_B*/;KL']I0_E9^*%%?M?_PSU\+?^B;^$O\ P26W_P 11_PSU\+?^B;^$O\
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MAR0P+,2'X<V>2$U+4XHX3NL8DN %L&)R6B^7GD=)-X RH 4E3Y[^T!XP\1>
M_"/@[PCX+U1X/&7B'4;;2+#4+M5NI(XT :>X<2!M^$7YBP)^?/6LSX1_&G7?
M&G[,?B#Q!J-P$\;^'K74+/4)/*0;+VW1R&* ;>1L8C&,DC&*AT::A.:6D?Q\
M_P 5\[';&OBI*#YK<WX7O;IILTK=$UL[/O="^!?AOPW?ZK=Z?)J,,FM7'VO6
ME-T675)@2=\H(^3DDE8?+4YP05XK87X>Q+B1-<UA;V+"6UX9T:2VB&1Y2AD*
MNN"<F178\$L2JD?&'@;]H[XE0V/PUUK_ (6EI/C_ %+Q)J<=E?>!8M+M([NT
MC9V#.7@PX("@Y8*/F!PP!KZ ^$/Q6U^/XN?%GP3XVU5;HZ#,NJ:9<2010[=-
MD7<!\BKN" H"QR<DY-:SP\8M\W2__DMOR3O\F$JV)@G:5]GMW;6UN^COOHMC
MT_\ X5KIN/)^V:E_9^-WV'[6WE^=C'G;_P#6;^_W]N[Y]N_YJBN_AG::A:SQ
M7>K:K=2W2-!?3R2QYO(&&TPNH0(J8XRBJPRQ# LQ/%?LK^./%'Q.^'^H>+_$
M=XTUKJ^JW4NC6K6\<7V6Q5RD:?*H+'*M\S$DC'-</^U=\=O%GAU]1\._#>]C
ML=7T'36US7M4:".=;.W Q% %=67S)6(.",A1GO6,J$(OE<?^!I=_<M_FD.G7
MQ4ZCIQJ:IVO\[?B[>KMV1T^@_L3_  G\+^)IM>TK0Y[34A(D]F_VMY$L)5.X
M20HY*YW '#AQQC&.*]+'PYL\@/J6IRQS'=?1/< K?L#D-+\O')Z1[ 1A2"H"
MC@9M,^(GQ(^&'@37-!^)J^![J31X;O5)FT*VOA=R20QOO/F%1&%.\X48^;V%
M<3^R[XZ^*WQ'^'OC?7)O$ECXI?\ M!K'PU>ZQIZ6,$J1L0\[I;J&VMN!VY)R
MA7<.M;SH\SE&6KCZ][?C^1G'$5^15%4WLOPTZ=+7]==SW1?A[$N)$US6%O8L
M);7AG1I+:(9'E*&0JZX)R9%=CP2Q*J0?\*UTW'D_;-2_L_&[[#]K;R_.QCSM
M_P#K-_?[^W=\^W?\U>6?LF_$7QAXY'Q&M/&6M1ZW=Z#XBFTR&>&TCMD$:#&%
M5 .,@D;BQYZFO2?A#\6M'^-'A-O$.AVU_:V2W4MF8]2A$4N^,X8X#,,?C]<$
M$5D\/#M?1/Y/_APEBL5!N\]G;YZ_Y-KMKW9:;X>Q-F1]<UAKV7*7-X)T62YB
M.!Y3!4"HN ,&-48<D,"S$A^'-GDA-2U.*.$[K&)+@!;!B<EHOEYY'23> ,J
M%)4_,GB_XL>,]4_:,^('A3_A=^D_"O0=%6T:Q75--L)EF,D*,ZJTY1B023]Y
MOO=JU/CM\3/&WA/XK?#GP7;?%BQ\%Z?J&B//J7B6^TVS>&:>,-^]*RX5-Y7
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MHFI?%[2?B0+F_L_$%A8OIS1VTB+;W4+;OEF4H6;:6R,,.0,YQ7GGA']CC1O
MFHQ3Z%\0_B'IMFE]]O;2K;6TBLI7W!F#Q+" RM@ ]R.,U] 441DXVMT_SO\
MF'M)V:OO^FB.)^%OPDT?X36>MPZ7<7M]-K.IS:M>W6HR))-)-+C=RJJ-HQP,
M=SS7 V_[('A33?#<FCZ7X@\5:+&NK3ZO:76EZFMM/822J%DCA9(P!&0H&U@Q
M]^37NE%*[_)?)6M^2#VLTV[[N_SU_P W]YY]\)?@AX>^#L6J/I4VHZIJVJR+
M+J&M:U=&YO;MER%\R0@9QD] .M6/A'\']&^"^AZCI6B7%]<VU]J,VIRM?R([
MB23;N"E44;1M& 03[FNYHI\S;O\ +Y?TD0Y2=[O=W^?],X3XO?!7PQ\;M @T
MOQ'!.#:S"XL[ZRE\FYM)?[\;X.#[$$<#C(&. N/V.?#.J>'-4TC6/%OC7Q =
M2,"W%]J^L"YN##%)YBP M'M$9<!B N>!R*]KCU[3Y[C4;>"]M[FZT[:+NWAE
M5Y8"R;U#J#E25((!QD$&L_P#XTL?B+X,T?Q-IL5Q!8:I;K<PQW2JLJJW0,%9
M@#]":(MQUCY/_+\C3VE2,4D]/Z_X?\3"^+?P9T'XR>"HO#&L/=V-E!<0W5O/
MIKI'/;R1_=*%E8#@D=.A-3Z+\*-*T/XE:SXXCNKZ?6-6L(-/N$G=##LB^ZP4
M("&/?DCT KM:*5W_ %YJS_ SYGR\O3_@W_-'D_PS_9G\&_"C7O%>IZ.M[-'X
MC7RKG3[Z1)+6&+<[&*) @(3YR,,6XP*YK1_V+_!OA_41_9WB'QA9^'A="[_X
M16+6W72BX8, 8MNXC(!Y<GCK7OM%-2E%II[%NK.7-=[[_=;\CP;6/V0=&U#Q
MIXA\3:;X^\?>%KW7KG[5>P^']92TA=^<<"+) R<;B<9-=S!\%M%A^*UA\06O
MM3GUVST8:(JS3(T+Q!BWF.-FXR$DY.['M7H%-9A&I9B%51DD]!2YG%)7T7^5
MOR"52<_B?]:?Y(X3X6?!G1/@_-XE_L&YOC::YJ+ZG)8W,B-!;2O]X0A44JIX
M&"6^Z.:[VO+O#W[06C>(-3\/Q#1=:L-*\13RV^BZY=I;BTU!T#,-BI,TR!U1
MF4R1ID#L2!7J--WTOZ?=T)GS<S<MWK_7SN<YXX_Y!MK_ -?2_P#H+5^&5?N;
MXX_Y!MK_ -?2_P#H+5^&5=-#J>QENT_E^I]M?LC^ 3KW[-?B75]"^'?A;QUX
MRB\0K!;1>)+*"5?(V6_F#?(5V@*SL &Z]CT/J'AWP?X,T7]J;QEI/A>+2M!^
MT?#R<:Q!I[#['97;31A^!@* FPD #UP"37Q1H?QR.C?L\^(OA;_8OG#5]4CU
M+^U?M6WRMOE?)Y6P[L^5UW#[W3BH?@/\:?\ A2.M>(K_ /L;^VO[7T6XT?R_
MM7D>5YK(?,SL;=C9]WC.>HK>K'F<VMN5I>=Z=K>E_P =;G2J-2\I7W?_ +<G
M?Y)'H7B3]D?2;"/P#JFA_$BTU_PIXKU%M,&LKI<L1MY5W<"'>S/DHZ@?*<@=
MCFM3XB?L.S>%?#&F:WHOB^35+>ZUBWT>5-9T"YT9H6F<1K(!,2SH&9<L!C&2
M"<5S_P ._P!KBX^'?@OX=:%;>%X;R7PCJ]QJ?VF:\(6[699T:/8(_P!V0)SA
MMS<J#CM75_$;]N>U\>>%/[ 'P_9;,ZM;:K(FK>()M327RYA(\++-'_JWQMV
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M53^)_P"S)X?^#FFW8OOB=H]_XYTJ*UN[GPF]@RAA(Z#8DQDQ(0&W% H8J,D
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M .@?+!I6MW#_ .H[+!,Q_@[*Y^[T/RX*\M2G]J)XV+P>]2FO5'W=X9_YBO\
MU_R_TK:K%\,_\Q7_ *_Y?Z5M5R'AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^0-?_ /7O)_Z": #1?^0-8?\
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MY_\ !LUY!\-?!MA9_'#XT7JW&JFXM;JS>-)=7NWB82V"EB\32E)!DL%WJ=@
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M!8$\D'K6WI6DV.@Z;;Z?IME;Z=86R"."UM8EBBB4=%5% "CV JY34NG]=O\
M@]>NNK*DN=I]>K[[?=Z>;[V6/XX_Y!MK_P!?2_\ H+5^&5?N;XX_Y!MK_P!?
M2_\ H+5^&5;4.IZV6[3^7ZA73^%_AGXD\:>'?$6NZ-IOVS2O#T*W&IW'GQI]
MGC;=M.UF#-G8W"@GBOIC]D_X%^#_ !E\,SK_ (R\*:1J$=UK?V"#4M<\3SZ4
MA3:@\N%(E/F2;M^%;;NS@'BO4/!?P\\+?"+6OVF_#L6CWNL>%+&PTZ<Z1%.P
MFEB:&65H1)]X#+$;OO =R>:VJR]G"=MU&Z[=-^O4[?K*DVH*[35__ N5VU[G
MYX45]X6?[)_PW^(7CCX1:EI>D7GA+0/$VDW6I7_AZ6]DE<^2L3*J22$N-QE&
M2.JKD!2<UG_$GX$_!7[;X-CT*;PU9:S)XJM-,O\ 0-#\62:J;JSDF",6WE9(
MW'?: %R>2<$5S>]&#W;M^/+^?8(XNG)75[6O^?\ EZ'P_17W_??![X KJ'Q:
MT[_A7NIQ'X>11WT]S'K4Y:]5E>0PJK.0J_)LR<L0<Y!YKGY/V<_A_P"*OB!\
M'=2\,^";A?#_ (LT2[U*_P##\VM2K%!Y4:%7:X8M(%#3*#MZX! Z@YPJQJ6:
MV>ORLW^C_4'BX*]TU;T\O/S1\05<T?1=0\1:G;Z;I5A<ZGJ-PVR&TLX6EEE;
M&<*B@DG /0=J^Z?B%^R3\.-=C^%T_AVVL- 77O$!TN_;P_KTVKVDD(BED;RY
MYE!\S$!484 %SD-@5A6?A/X:K\?-!\->%_AUXF\'WFC^+5TFXUR+5+L1747E
M2Y!E$@:"1B RA#DIDY[5<9J326][?EK^*)EC(JG*<4_=3?W7_P#D6?%^I:;=
MZ/J%Q8W]K-8WMM(T4]M<QF.2)U.&5E(!4@\$&NFM_A)XNO/!>G>*[;1)KK0]
M1U :5:36[I))/='.(EA5C(2<''RX/2OJK6/A-\._!?AWQ]\0O%OA+5_B'))X
MVNM%MM/CU2Y1K>,3,OF22AC([DYY<MN)0<$EJUK'2=-?X'^ M-L+#5=$TEOB
MVD$%C>226U]:PF60"-V5M\<BCC(;<",YSS3IR]IRKOR_BX_I(NIB.67NK2\E
M_P" QF]/G&VO_!/D5O@SXUA\-^(M=N/#UU9:=X=FB@U4WA6WFM9)-NQ6A<B3
M)W+T4]:XNOT:N;/P]X6\*_M+1:UHFI^+= L=:LGETQM2G>XN%6.(@/<LS2[0
M<$L22%4^E?/O[3G[/VFZ3K'@*Z^&GA76(/\ A*=&_M%O#,:37EU:LH1F)!W/
MC$@!ST*'Z5A"MSJ,K:24?QCS:_B*AB%43Y]'>2\M&E]^OIV/F>M7P_X2USQ9
M)<QZ'HNH:R]K$9YUT^UDG,48ZNX0':H]3Q7=?LT^"](\??'?PEX<\0V1O=)O
M;EXKFU,CQ%P(G;&Y"&'*CH1TKZ4^'6B_#G4OC%\1O#'@WPYK/A2V\.>'=6AN
MKB#Q#>(^H3PS1(DC>7*,*#YG[LDJP8$C(XUG+EBVNBD__ 5<UJ5N6?LTM=/Q
M=CY#\5?#/Q)X)T'PYK6M:;]BTWQ%;M=:9/Y\<GVB-=N6VJQ*_?7A@#S7,5^B
M T?P-XF^'/[->@>,O NH>+FUK3Q86MW:WDUO'I^Y(B[L(B-Y.%."<!4<]L'A
M-<_9]^&?P-\'^-/%7B'PQJ'Q(AM?$[:+8Z?!J$MJEI#@$-))%SN^;:2<@G8,
M#)-+VEI.+\_PDE^J,*>+4HQYE[S_ !W\_P"Z]SXJK5T;PGKGB.UU"ZTG1M0U
M2VTZ+S[V:SM7F2UCP3OD900B_*>6P.#Z5]OW7[)/PWTWXG:WJSZ-JMSX5T_P
MA%XE'A);B07#3.91Y/F!O,P!$>-V=S#G Q7,^!-#\&>)/!/Q=UGPOX5\2^ K
M%?!"WR:;-J]XD,LW^D@R(PD'VF$A5'[P%<AQM'.1U$DVO/Y6O_D]C3ZQ%J\5
MI[O_ )-R_I)'QC7=ZW\"?'_A_5K32[CPKJ%QJ%UIJZQ';Z>@O7^QL<"9A"7V
MKG@[L8XSC-?0WQ7^$OPP^#_AG3/"LWP_\0>)O%&H>%Y-7_X2S3[J8K#<;"=W
MD!O+,2$98G[J%<[B<U[/J7AZV\2?'+28+J?4($A^$JSJVG:C<63EEE& S0NC
M,O/*DE3QD' HJ5%",I?RW_!2?YQ,UB>9Q:6C3?XP2^5I>I^?WB3X:>)/"'AG
MP]X@U?3?LFD>((WETRY\^-_/5" QVJQ9<;A]X#K7,5^@^GZ;X(U[X-_LX:)X
MR\#:CXQ76%DT^VFL[N:!+ NR[I&\H@N> =I( 5'/;%?)GQT^#%W\/_B5XYL-
M T[4=1\+Z!>K$^I);O)#:K(%9$EE VJPWA?F(R15.5IN#[R_!I?JC3#8CVU.
M#DK2:3];MK3[NNIY717TU^R!\,OAUXZTOQ'/XUTV/4M26XM[32H=4U"XTW3Y
M9')S']IB4_OCQMC/+<8'4CTOP!^S3X*MO$'Q)/B+P+9II.E:]'864GBKQ7)I
MD-NCHCB(20!R[XD0KN^\'49SFG*7++E\K_E_FA2Q4(WT>CMT_P SX:HK[TN_
MV8OA3X5^,WQ/LM3T&[U'PQH?AB'7[:QBOYED@;YBZ(X<%@1&<;R?O5%!\/?V
M?FL/A'J\WPSU",?$2<6,-@NNW+16+B14,A?>'<[G08R!MR< C!B%15$N57OI
M\[M6^^+$L7%MI1;M^D5)]>B9\(45]<>-_P!G'PEX:^#_ ,:[ZQTN:^U[PUXJ
MCT_2[OSYFDBM6>W.PH&VMA96&YE)[UWFG_LQ_#./XV6&@ZAX9F71_P#A7@UV
MZM4O;A9/M@E"M("9,AL9&TG;G^&E&M"4/:=+7^7+S?E^);Q$%)QL^OX-+\Y(
M^"Z*^Z?@Y\)OA+\5/#\_BL?"_3-#\/W6KIIUH?$/C2[M1@(@80[0QDD+[B$8
MC/0'@U6U/]FCX;_#GQ%\:M?U3P]J'BOP_P"$#:#3_#L-[+"W[^))&+RH=^U"
M_P![)PJL3N(JG44;\VEE?\O\T3'%0E+DBG?:VF][=[:/<^---\):YK6DZAJF
MGZ+J%_IFG@->7MM:R20VP/0R.H*I_P "(K*52S #J>*^O_#7AOPWJGPW_:!O
M- T7Q)X/TJVTW2[FRT2^U*ZA\II8W+^9&)0LZ,1E#*&RI! &:?\ 'KX5_"[X
M10WW@BR^'GB+4_$EKH4>HIXPMKN:5!+N&7DASY:P\$,X'&<8[U?-RU5":WMZ
MZJ[\M%_3+5;7EM_PUH[_ /@2/GCQ5\"?'_@S5K_3M3\*Z@+K3[-+^\%F@NTM
MK=PQ621X2ZHI"MRQ'W365XR^&OB3X?V>@W>O:=]@M]=LDU'3G\^.3S[=@"KX
M1B5R".&P?:OT ^-7A^VUCQE\<+J:?4(9;#X?VL\(LM1N+5&81W/^M2)U65>/
MNR!EY/')J*X\*> ?'\/P \*>,/ ^H^(KK6/"5O%;:M;WLT$6GJELKG*QD!B3
MUW'CY>#DUSTZLIT^;KS6^7O_ (^ZOQ.:.,]U2DNEW_X#%]_-GYO45VWQ ^%^
MJ>%/$'BT6&GZA?\ AK0M7GTMM:6V=K<,DA15>4#8'(V\9'6O<_V2_@UX3\;^
M ?$'B'Q=X7TG4[6WU*&RAU'7O$TVCVJ%E7,:F)6+299<;A@[@ 0<UT1DI1YU
MY?C:WYG96JJBKO76VA\K45]Z7?[,7PI\*_&;XGV6IZ#=ZCX8T/PQ#K]M8Q7\
MRR0-\Q=$<."P(C.-Y/WJQ;']G?X7_%F\^"&N^'=#N_".B^+;F]AU+2?[0EN2
M?LR2.5660EADPLN1C(8$ $5G"HIQ4DM/RU:U_P# 7M<P6+@[NSLO_D5+\F?)
MNC_#?Q-KG@;7/%MAI[3>&]&EBCU"[^T1J(G<@(-A8,V2PY53C-<^VH732RRF
MYF,DJ[)',ARZ^A.>17W9XNB\&VG[*_QPL?!O@N^\&6FGZQ;V$\=W=RW"W3Q7
M,:B53(25..J@D#BO(_V+_@;X3^+'_";ZSXNBM[VQ\/6D+Q65[J+V%J[R>8=\
MTZ LB*(NH_O9P<8J8RC44IV]U)/Y-)_Y?A<UABIPH.I*ZM)QLO)I+KOKK^!\
MVB\N%6$">0"$YB&\_NSG.5].?2@WEPRS*9Y")CF4;S\YSG+>O/K7W7'\!_@+
MX@^*6D^&-'DT>]E\2Z%=K##H?B2348M*U&$*R,D@<,X=&<@2K@F'A1DBJ?@G
M]D7P2VH?"GP1XGL6@\9:A:76O:_)'>2+(ULA(BM0FXJN2XRRJ&Q"^#SD-.&C
M:M?_ #=_NY6_NZDO,$DVV]/RM_4?738^(EU"Z66.47,PDC78CB0Y1?0'/ J/
M[3-Y'D^:_D[M_E[CMW=,X]?>OMSXD_ GX*_;?!L>A3>&K+69/%5IIE_H&A^+
M)-5-U9R3!&+;RLD;COM "Y/)."+EO\#_ (,>*OVA-<\ :;X(U*PMO"-I<ZE?
MR1:K/*^J[1%LMT1F)109>"I#':,GDU"E3M=+O]T4FWZ)2]?F:/&.VM_Z=N_6
MWY'Q3H=GK'BCQ!::9ISS76JZI,EE$GG;3,[L$5"S$#!) Y.*WO$GPP\=>#Y]
M6@U/0M4AC\.3K!?7$*-/;6$K;2%::,M&I.Y?XN<BOJCPK\./AWXL\,^ _B=X
M0\&7_P /KVP\<V&F26%U?S7D=XAN(QN5I3G()'0#!5U.<9K4^-WAZVU#PQ^T
MSJ<L^H+/9Z_IZQPPZC<16S!OLX;S(%<12''0NI(P,8P*?NN<81CKK_[CM^$R
M5C9RK1A=^\TO.]W?KWB?"IO+AEF4SR$3',HWGYSG.6]>?6G+J%TLL<HN9A)&
MNQ'$ARB^@.>!7Z'3?L\_ >3XP:C\-O\ A ]0AO4\/_VX=6BUBXQ$ 57RXT:0
M@GDME\\G&,8QY[%\'/A'\0/#_P '_%_A_P (W7AW3-?\5'0]0TJXU2><7$7[
MW#%R^Y6/E#[A7[Y'. :(.G4:C%;Z?>^7\U;_ (!']I<L>=\RTO\ AS=_GZGQ
M?]IF\CR?-?R=V_R]QV[NF<>OO1-=37,CR32R2R/PS.Q)..F2:^O-2_9Y\'67
M_#2DI\.2QV_A)8_[ D>XN MLQ5V8 [_WAQL/S[N"/6M3XD?L_P#PUA_9]U35
M/!WAN2Z\1Z1I5K=WUY-JD\>IVDI93*;FPEVJD902$,O)Q\JX&ZI]K3^*W2+^
M4M?TU_4V^M7FJ3;U=O+I_P#)?F?%=%%%=1J%%%% !1110 5ZC^S[^S[XA_:"
M\8II.DH;73+<J^HZK(A,5K&3_P"/.<':O?V )!^S[^S[XA_:"\8II.DH;73+
M<J^HZK(A,5K&3_X\YP=J]_8 D?KC\+?A;X>^#W@ZS\-^&[,6MC;C+R-@RW$A
M'S22-_$QQ^' &  *QJ5.71;GGXK%*BN6/Q?D0_"7PK;>!O":^'[*>ZN;339F
MM8IKR8RRNJA0"S'J?T'0   5VE8OAG_F*_\ 7_+_ $K:K@/FV[N["BBB@044
M44 %%%% !1110 4444 %%%% !1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^
M0-?_ /7O)_Z": #1?^0-8?\ 7O'_ .@BKM4M%_Y UA_U[Q_^@BKM !1110 5
MP/QE^!G@SX^>%3H/C/1TU*U5B]O.K&.XM9"/OQ2#E3TR.AQ@@CBN^HK:C6J8
M>I&K1DXR6S6C0'Y>_%#_ ()+>*-#OWO_ (:>+[74[>-O,BL]8+6MW'@\!94!
M1V]R(ZH_#OX9_ML>!?%VB:,^I^)K/1IKZ"WFO)M3MM3M[:%G"M)AWDPJJ2V,
M=NE?JA17W:XVS&I1]CBX4ZR[SC=_A9?@:>T?4YGXD?#O1/BQX)U3PGXC@EN=
M$U)42YA@G>%G575P-Z$,!E1G!Y&1T-<]\0]=TO\ 9Y^ .M:AID*6>F>%-"9-
M/MV.0/*BV6\>3URP1>>N>:]'KF/B1\-O#OQ<\'WWA7Q98-JF@WQC-Q:+<RP>
M9L=77+1,K8#*IQGM7QN&KJ,Z=/$-NBI)M+Y7:5TKM*Q'J?,_[*_[,?A[QE^Q
M9X:\-^-[.YO;?Q).?$M_''<R0-/)*VZ%F9"&/[H0GD\D9KU*^_8_^']YX\U#
MQG%)XDTSQ+?+Y4VH:5XBO;.3RL*!$OE2+MC 5 $'R@*..*]CTK2[70]+L].L
M85MK*SA2W@A3.(XT4*JCV  %6J]#$YUC:V(JUJ=645.4G9-I>\]5^"^Y=A\S
MN>*:Y^R#\.]<\:ZEXG:+6]/O]5CCCU2+2]<N[.'4=@ 5K@12*7;CDD\G).22
M3VOP]^#OA;X7:MXIU/P_926^H>)K]M2U2XFN'F>><ECG+$[0"[848 R:[:BN
M"IF&+K4_95*LG&R5FW:RM9?*R^Y=A784445YX@HHHH *I:M_QZI_U\0?^C4J
M[5+5O^/5/^OB#_T:E %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y"S\62V/B'Q<-<UGPY;Z)IK6OV;R;HK<VJR1@M]MWG
M:A9S^[QC*X[UJ:#XX\.>*;Z_LM%\0:7J][I[;+RWL+V.>2V;)&V158E#E6&#
MCD'TKY[^+'@W7-5M?VA$M]#U"\&JPZ.MDL5H[_;-D:B01 #]YMY!VYQWKT>Z
M\,SZ;^T!X+N--TJ2UT6U\+WUC)-:VQ2VBQ-:F&$E1M7 #E5]FP.M6DFXI]5_
M[;?]+?,WE"*AS7U__9_S_ ]$\2>*M%\'::=0U_6+#0[#>(_M6I7*6\6X]%WN
M0,G!XS5+5/B)X5T3P_9Z[J/B;1[#1+PJ+;4KJ_BCMI]REEV2LP5L@$C!Y )K
M@OBE#<Z+\7O /BN[TG4=7\.Z?;:A:RG3;&6^DL;J58_*G,$2M(0426/<BG;O
MYP&K$NKA-%^+'ASQQ)X3UJ'PI-HMW9VT=KHLLUQ87<ESYKS/:0JTL?GH,EMF
MX' DVLV*45=+SO\ *U]/G;3U0<BM??3[]>GIU_X:_L2^+]!?2;'5%UO3FTR^
M94M+T7<?DW#-G:(WSM<G!Q@G.*QO^%Q^ ?[$_MG_ (3CPW_8_P!H^R?VA_:U
MO]G\[;N\KS-^W?MYVYSCFO!KSX<ZGJWA-#+X7N3HNM?$NVUF'1KBQ+-#I[,@
M>2>#!\M697D97 *^9\P!R!WEKX%6X^-_Q7U6Y\/"2&^\.V%G;WTMEE;C*7 F
MB1ROSYVPAE!/1,C@4I6C!S?W?]NIV_%KY?(M4X7M?^N;E_X/]7.D\:_%J+P7
M\2/"^E7][I>G^&M1TR^OKO4KZ41"(PM;K'B0N$53YQSD'/RX([ZNN>-OMVC^
M'=4\*Z]X9N--U#5(+>2]OKS=!<P,S*Z6SQMAYR1A1D@D$&O!O#>EZCX:D_9_
MUC7_  EKFHPZ'X7N(;YXM(ENYM-N&6T1&>,*9 XPPPBEP-QV[58BS_PB.N:A
M8G5[70-2M--U;XGV>M6FGR64D<\-JOEI+<RQ$;H@[QO(=X! 8%L$UMR)2C&_
M6U_^XEOR=_1?='*N3F\O_;6_S7X^E_?M6^)W@[0;Q;34_%FAZ==M<&T6"[U*
M&*0S!48Q!68'>!)&=O7#J>XJQXJ\>^&? L=N_B3Q%I/A]+DL(&U6^BMA*5QN
M"[V&[&1G'J*\/U'P'>3:!^TK-_PCL[ZCK/VB.QD^PDRWT8TR(1K$=N9%$N\
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M[S>?\%*_A]<:KIUTOAOQ,$MO,W Q6^3N7 Q^^J__ ,///AU_T+/BC_OS;?\
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MNH\,>*?CIX+OM=U#2_$GBB.?4K@W6KM)X8:X:>?8%#6ZRQD,. N1Y>%5>,
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M5GJ7V:;1]#\4OJYGMSD;V67#HZD#("X'(R>")]M%)-]?\[?F5#$0J34(_P#
M_K3T/F#PUX1UWQG?-9>']%U'7;Q4\QK?3;22XD"CJQ5 3CWK,N+>6UGDAFC>
M&:-BCQR*596!P00>A!KZO_X)W^/]>LOC!9>$+>^\GP_>+<WUS:K$@,TJP84L
M^-Q QPN<9YQFOFSQTOF>/?$"YQNU.X'_ )%:M/>=:%)+XE?\;%TZCG.I%KX;
M?BF8%%?9GQF^#/PN^'=\WPXL? 'B"]\2'2(+I/&D%U-+''*[A3)+#N$8A'.Y
MP.,XQWKM(?V=?@[<?&"[^#0\ :U'J5OHPNO^$T;4Y\M)L!\SR<^5MR<;L8W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYPL0# J2-K CGI6M_P ,._&__H19?_!C9_\ QZC_ (8=^-__ $(LO_@QL_\
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M2Q$F,[]FYPI)PKDCIQP*ZW_AAWXW_P#0BR_^#&S_ /CU'_##OQO_ .A%E_\
M!C9__'J%*"22>WZ;%RJ4)?%)/[CD;[]HGXAZE\3+'X@W/B)I?%UE%Y%OJ!M+
M?$<>UEVB/R_+QAW_ (?XB>M.\+?M'?$;P7I>OZ;HWB1[.QUZ>6YU&'[+!(LT
MDHVR,-T9V%AQ\F.@]*ZS_AAWXW_]"++_ .#&S_\ CU'_  P[\;_^A%E_\&-G
M_P#'JE^S:L[6V^3U:^;U%[2AW73MTV^[H<9'^T!X]AUSPEK":]C4?"EH+#1I
MOL=O_HL(0H$V^7A_E)&7#'WKFK/QUKVG^-!XNM=2EMO$?VQK\7\(5&$[,69L
M ;>23E<8P2,8XKU*7]BGXTPW$$#^")5EFW>6O]H6GS8&3_RUJ;_AAWXW_P#0
MBR_^#&S_ /CU5S1OS)Z_YZO[V'M*%K77;IMV,+Q[^U5\4_B=X:O/#_B;Q4VI
MZ/>>7Y]K]AMH@WEN'0Y2)2,, >",XYR*X_PO\3O$W@OPWXCT'1M2^QZ3XBA2
M#4[?R(G^T(N[:-S*67&]N5(/->F_\,._&_\ Z$67_P &-G_\>H_X8=^-_P#T
M(LO_ (,;/_X]2O#E<=+/?S]052A%637X&#H_[5'Q1T'3])LK+Q1LBTFSDT^Q
M>33[666"W<*&C65XB^"$3OD;1CI7*?#WXK>*OA7>ZC=^%]6;39M1M6L[O=!%
M.DT+$$JR2*R]NN,CGGDUZ3_PP[\;_P#H19?_  8V?_QZC_AAWXW_ /0BR_\
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ME568$31)&T9(+*0-\K2 $$A1Q4__  P[\;_^A%E_\&-G_P#'J/\ AAWXW_\
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M;)Y9CCFJL7PQ\JW\.0_\)9XH?^Q9GF\QM2RU_ND#[+H[?WJC&T#C"DBNUHH
MXJ7X8^;;^(X?^$L\4)_;4R3>8NI8:PVR%]EJ=O[I3G:1SE0!5JU\ _9=>T34
M_P#A(_$$O]EV2V?V.6^W6]WA67S9TV_/*=^2V1RJG'%=710!Y_\ \*A_XI7^
MQ/\ A-?&'_'[]L_M'^U?],^YL\KS-G^J_BVX^]SFM6Z\ _:M>UO4_P#A(_$$
M7]J636?V.*^VV]IE57S8$V_)*-F0V3RS''-=710!Q47PQ\JW\.0_\)9XH?\
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M^&/FV_B.'_A+/%"?VU,DWF+J6&L-LA?9:G;^Z4YVD<Y4 5:M? /V77M$U/\
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M_P"'HUY_T3F#_P '#?\ QBC^QL=_)^*_S#^UL'_/^#_R/M&Z\ ?:M>UO4_\
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MX5#_ ,4K_8G_  FOC#_C]^V_VE_:O^F?ZO9Y7F;/]5_%MQ][G->@44 <I=>
M/M6O:WJ?_"1^((O[4LFLOL<5]MM[3*JOFP)M_=RC9D-D\LQQS52+X8^5;^&X
M?^$L\4/_ &+,\WF-J66O]T@?9=';^]48V@<84D5VU% '$R_#'S;?Q)#_ ,)9
MXH3^VIDF\Q=2PUAMD+[+4[?W2G.TCG*@"K=KX ^RZ]HFI_\ "1^()?[+LELO
ML<M]NM[O"LOFSIM_>2G?DMD<JIQQ75T4 >?_ /"H?^*5_L3_ (37QA_Q^_;?
M[2_M7_3/]7L\KS-G^J_BVX^]SFM6Z\ ?:M>UO4_^$C\01?VI9-9?8XK[;;VF
M55?-@3;^[E&S(;)Y9CCFNKHH XF+X8^5;^&X?^$L\4/_ &+,\WF-J66O]T@?
M9=';^]48V@<84D42_#'S;?Q)#_PEGBA/[:F2;S%U+#6&V0OLM3M_=*<[2.<J
M *[:B@#E+7P!]EU[1-3_ .$C\02_V79+9?8Y;[=;W>%9?-G3;^\E._);(Y53
MCBL2\^%?V'P5/IG_  F'BNX\FY;4?MD^I[KA\1[?(9]O,)QDICKSFO1JI:U_
MR!K_ /Z]Y/\ T$T <-9_"O[=X)ATS_A+_%=OYURNH?;(-3VW"9C"^0K[>(1U
M"8Z\YK<N/ /VC7]8U3_A(_$$7]I6;6?V*.^Q;6N55?-A3;\D@VY#9/+,<<UN
MZ+_R!K#_ *]X_P#T$5=H XB/X7^78Z!;?\);XI;^R)VG\YM2S)>[G#[+D[?W
MB#&T#CY213YOAGYR^(A_PE?B9/[9=7RFHX-CARV+;Y?W8.=I'/  KM** .2M
M_A[]GU70K[_A)?$4G]DVPMOLTE_F&\P&'F7"[?WC_-G=QR!Z5GGX2Y\.W6D_
M\)GXN'GW8N_MW]J?Z5'@8\I'V<1]]N.M=[10!RLG@'S-?NM4_P"$C\0+Y]F;
M/[$M]BVCRH7S43;Q)QG=GJ2<507X5[=)TFQ_X2_Q6?[/N6N/M)U/]]<Y(/ES
M-M^=!C 7C@FNYHH XZ;X;^=<>()?^$H\21_VPNW8FH86RYSFV&W]V>W?BE@^
M'/D7F@3_ /"4>))/[(C\ORI-0RE[R3NN1M_>'GKQ7844 <*WPIW:-J>G_P#"
M8>+!]NN1<_:AJ?[^WP2?+B?;\J'/W<'I6@O@';K\>J?\)'X@.RS^Q_8C??Z,
MWR[?-*;>9.^[/7G%=510!P:_"?;H-EI?_"9>+3]ENC=?;3JG^DRY&/+D?9\T
M?^SBKUQ\._M&I:]>?\)-XBC_ +6@,'D1W^(K/('SVZ[?W;<=>>IKKJ* .,A^
M&ODMX=/_  E7B9_[&)/SZCG[=EMV+GY?WGIVXXJ*3X6^9I^N6G_"7>*E_M6X
M6?SUU+$MGARVRW;;^[0YP1SP *[BB@#E8? /DZ]INJ?\)'X@D^PV8L_L3WV;
M:XPK+YLJ;?FD.[.[(Y ..*RO^%1_\4S'HW_":>+_ )+S[9_:']J_Z6WR;?*,
MFSF/OMQUYS7?T4 <I<_#_P"T:YKFI?\ "2>((O[4LVL_L<=]BWL\JJ^;;IM_
M=R#;D-D\LQQS6?-\._[/LO#2_P#"3>([G^QKK=FXO]YOO,F0XN?E_>!>B],"
MN[JEJW_'JG_7Q!_Z-2@"[1110 5S'Q-\;6WPW^'WB#Q/=8,6EV<EP%8XWN!\
MB?5FVK^-=/7B?[4GP[\2_%WP[X;\':/;R#0]0U>%]?OX;B*-[:SC.X[0YRS%
ML$8#8*#(K2E"-2I&$G9-ZOLNI$YNG!S2NTKV[^7S.4_9=^*WCS4_&6L^#/B9
MJ*W^NOI-EK^G2"UBMR+>9!YD96-5!*.RKSDY#5X_KW[0WQ"ANOBGJO\ PN32
M= ?POK5S;:;X3OM+LGEU&))"%1&P)3Q\N0&Z<L.2/3[W]FGQ+\,_C)X \:^$
MM<\3^.C!<-8:U_PDVKPSR06+C&8V<1DJNYVV#)R%('6N;3]DG6->\-_&.XU#
M0K?3O%U]XAGU?PMJRS0_:<*YDCVRHQ:-7/&&(P3D@8S7T*GA/:.MI9I:66C4
MDM(O^[KMWL>#R8KD5%WNGO=ZIQ;UDO[WW>Z=Q)\9O&VB_%/X-SZ^W]F>&?&^
MD"WO-(:W11::F4#@[ROF#<710A;UXR*ZOPI\0_$/C3]ISQ=H5CJ&SP5X5TR"
MWNK98(SYVH2G>#YA7?\ *FX%0P&5Z5SWQ=^''CGXM?LX^'C/I8M/BEHTEIJ4
M-L;F'/VR%MKD2!_+&Y=S#YL<@'I4WP?_ &=H]6^$.M:9\5-'6YUGQ5K$VM:S
M8K=D;)3+F)!+"_10JM@-CYB*Y9>PY)3=DTY1LK/=W4EWM%R2?=1U1O#V]XQ5
M[2497=U:RU3[7:C=><M&=I\=M0\0:;I.G2:5\0]!^&6G-(ZWFMZS!%-)OP#%
M%"DK+&2V),Y.< 8!YKP?P[^U!X^T?]F#Q9XQU86NMZG8:O\ V7H^NO:_9X+^
M-G5!<F,!054EL;0 < 'D-7J/C;X7M\._!.C>&_ ?PHT'Q[X2@FFFG\.ZO?@2
M1S,04FBDNO,3 S)D'GYAMXS7G_PG^ /BWP7\)_B1%K7@O3-77Q+?+=V?P\_M
M0+;6T?F$L@GY1'VD893_ ,LDY!X"H^P5%\UFKJU[)OWE=;W5U?6_*EYFE;VS
MK1Y;IV=[7:7NNSVL[.VF]_(WO ?Q ^(G@7X]Z'\/_&GBZP\<V?B31Y-0L[V'
M3XK-[69 S%,1_>0A&^8\G((Q@@\KJ7Q:^)OA7XO^"])@^)/AWX@7>L:J;/5_
M!^@Z?$5TN,,!*?.4M* @+',A4C;R" <7_P!GW]FG4/#?Q2'CB;P)I_PRM-.L
M9;73]"CUA]4FFN)!AIYI]Q&W:2H4'//3N<#QM\#_ (B_%3QAX;Q\+?#?PWU/
M3M56_P!0\<:-J4):[(.79(XU67+'YAYF3G&6&2:[(_5_K"3<;<OO:12O>72[
M6BM?E=_Q.&7UA8>5N:]_=^*_PQ\D]7>W,K+TL?:=%%%?,GT@4444 %%%% !1
M110 4444 %%</I/Q>T;6/BUK?P\AM[Y=;TFQCU">:2-!;M&^S 5@Y8M\XSE0
M.O-8EG^T9X9OM+^)%_'9ZH(? <TT&IAH8]TK1ABWD_O/F'R'&[;VK;V-2U[=
M+_)NU_O9E[6%[7UO;YVO;[M3U.BO'OA=^TI9_%?5M/M=/\!>.M+L;Z%IX=:U
M;1EAT\H$+ ^<LC#YL87&<DBCX-_M3>#_ (W^*M8\/:';ZI9:EIL;2LFI01QB
M9%D\MFC*2-D!L9S@_,/?&LL+6BY)QV5WY(RCBJ,DFI:-V7J>PT5Y#-^U!X0B
M^.$/PL2WU2?7Y)/)-W%#&;-)/*,I1G\S=N"@9PIP2!ZXG^,O[2OA/X&ZQHNF
M^((=2N)M3!DWZ?"DB6L0=$\V8LZE4W.!D ]#QTS*PU:4H147>>J\RI8BE%3D
MY:1W\CU>BO%?B]^U-H_P7U*YAUOP;XSN].@$9.N:?I:/IS%P"JK.\J@GG&/7
MBI6_:F\-:7X&NO%'B/0?%'@ZVCNEL[:QU_2C!>7TK+N46\09MX/3.0!@Y(IK
M"UI0511T8GB*49<CEKO\NY[+17C/@G]JGPQXL\967A74-"\4>"M;OU+6%MXJ
MTLV?VS&<B,[F!/!ZXST&3Q77>%/B]HWC#XB^+O!EG;WT6J^&/(^V2SQH(9/-
M7<OED.2<#KN"_C4RP]6#:E'I?Y7M?[]!QQ%*2NI=;?-ZH[BBO'_'O[3_ (9\
M$^+KCPM9:-XD\:>(+2,2WMAX5TPWKV:D @R_,H&<CH3C(SC-=!\-?CGX1^*G
MA&^\1:3?M;6>G%TU&+44^SRV+*NYA,I.%P,G()'!YX-)T*JI^U<?=[_UT*]M
M3=3V2E[W;]/7R/0**^?O^&TO"=TLU[IGA3QQK7AR%V5_$FGZ"\FG *<,WF%@
MV!W^7/M7>:#\=O#FO?$;5?!?EWVGZI8Z?'JJ37T:1P7=JZ@^;"P<D@;AG<%(
MY]#BI8:M!7E%K2_W$1Q-&3M&5^AZ+17$_"/XM:5\9_"\OB'0[+4+;2A=RVL$
MVH1)']J\LX,L85VRA.0"<'*G@8KMJQG"5.3C-6:-HSC47-%W04445!9Y#^UA
M_P D"\8?]@ZY_P#1$E?CO7[$?M8?\D"\8?\ 8.N?_1$E?CO7W7#W\&?K^A\;
MGG\6'H%%?77@3X?_  O\,_LK^%_B!XE^'<WC76=2UE],DCM]6NK61@9954JL
M;;6($8 4*,D]:]D\+_LO_#_P;^TK!I]EHEOJ&C:OX4N-070M;B6[^Q3+/"@(
M\T,1D,0"Q)!#\XZ>G4S.E3<HN+TYNVKBKM;WV[HX*>6U:D8RYEK9]=G+E3VM
MOYGYPT5[?\1_V1?&?PU\"7'BVXU'P_K>EV=PMK?+HM^;B2RD)"E9044 ABJD
M D@D=N:W;?\ 85\=W=O/%!KOA&?Q!!9_;9?#<6K[M11,9 ,83:">F2VW/>NO
MZ[AN7GYU;^G^J^\Y/J>(YN7D=_Z1\YT5[C\/OV0?&/Q \&Z=XE_M;PYX<LM3
MG:VTZ'7]0:VFO9%)&V)0C9)*L "03M)QCFJGP]_93\7^/M&U36)+_0?"VBZ?
M>-I[ZEXBO_LT$EPK;6C1E5LD-@9X!)P"35O%4(N2<U>.Y"PU9I-1>NW]?(\9
MHKM/BW\(_$/P5\7R>'?$D4*W8B6>*>UD\R&XB;.)$; )&01R <@\5]#?LA?"
MOX/?%C3=2TO5]#U?6_$]KIDE_=SW=TUO:0,)-J) L+AFX()+_@*FMBZ=*@\0
MO>CY#IX:<ZZP[]V3TU\]OON?(M%>C?!_X%Z_\;/^$A.AWFF6G]AV?VZY_M*=
MX]Z<\)M1LGY3UP/>N9^'_@F^^(_C31_#&F2V\%_JEPMM#)=,RQ*QZ%BJL0/H
M#6_M8.4H7U6_S_X8YW&48*;6CO\ AO\ F<_17T?K/[!WQ#T?2]<N!JGAF_O]
M'A:YN='LM1:2]\H;MKB/RP &"DKN() Z9XK!^'G[(/C#X@>#=/\ %$FK>'?"
MNE:E,(-/;Q'?M:O>,20/+41MG)! !P3U (YKG6.PTHN2FK*WX[?>=+P=>+47
M!ZW_  W^X\.HKW32?V-?B'JWQ'U_P.$TVUUS2+'^T2+BX817<)8*IA<(<[B<
M#=M (()&#53XH?LG^+OA;X&'BZYU/P_K^B)<_8[B;0;YKC[-+NVE9,HHR'&T
MX)PW!I_7,/>*YUK:WSV#ZK7M)\C]W?RLK_EJ>+45ZC^S'X+T;XA_';PGX=\0
M6?V_1[Z:5+BV\UX]X$,C ;D(8<J#P1TKV7P;^RJ]Y^UM<Z%JOP_UQ?ADNI7T
M:2RV]W':^0L<IA_TG@D;@F&W\\#)S14Q5.E-TY[J+E\ET]>PZ6%J5J?M(;<R
MC]]]?334^2:*]ZL_V6];^(7CSXC#PX^E>'/"/AO6+RT;4M=O&AM($29PL?F$
M.Q(0+DGID9//-#Q9^R'\0/"OBSPMH4<>G:[_ ,),=NF:EI%UYMG,0NYOWC*I
M "?-DC!7)&<&B.,H2:CS6;5[?*_Y:B>%K).2C=*^OH[?F>*45]W?"/\ 9-7X
M:^"?B[-XP7PAXMN(-%E6VDLF6]DTVYCAE=@WF1JT,F&C(QSP/:O%O ?[$/CC
MQYH.@ZDFM^%]$EUVW-WIVFZMJ#QWEQ  #YBQI$^5VE6X/ 89Q6$<QP\G+WM%
M;7O=-_H=$LNKQA"5M9-JW:UO\[>I\]45]A^&?@7::5^S5\6])?3M"\4^,=-U
M^VTZSU;2HENGWN;4>5!,R!Q\TC*0,?-N!H^"/[..K_#'XV2^'M?T?P/X\U67
MP]-?2Z+J-[(8K%?,APTA-K(!+R0 %/!8[AQE?VC1:FU]F]O.T5+3Y/J-9?5M
M!]W9^7O<NOS/CRBO=O O[(_BSXF> [/QS9:OX9T7P[?7$L?F:M?O;BUVR,G[
MPF,@ L-HP23D<"N&^,WP5\1? GQ8GA_Q']EDN);=;J"YL9#)!-&Q(W*2JGJI
M&" >/3!KJCBJ,Y^R4O>['++#58P=3E]WO^IP5%?7>G_!.Q^(W[*/PDM-&LM"
MTKQ9KOB.XM#K5Y"(GE"B\98Y)D1I"#Y:@#D9"UY1X?\ V5?&.O>-/&_AMKG2
M=,N/!\+3ZG>7T\B6P0<@HRQL3N4%AE1P.<=*CZY24IQF[<K?W)VN6\)5M!Q5
M^:WWN]E^!XW17TGI/[!/C[5K71+C^WO"=E%K5K%<V'VS49(VG+H7\I5\K<TB
MJ-Q !&#P3SBKJ'["OQ&TW0=9OI;KP^^H:3;M=W.A0ZB9;\0C=M<1JA7#!25R
MP)QCKQ2ECL+%M.HM!1P>(FDXP;OM\SYVHKWOP=^QIXQ\9>"-!\6QZYX8TK0=
M81C'=:KJ#VXA;S/+2.3,9^=VSM"[LXYP<9]<_9H_9HN/!_QC\<^#/'?A[2-;
MOHO#IN;$SPI=6[EY J2Q&1>#G<N2%((-16Q]&C&;3O**>G73=>H4\)5J<DK6
MC)QUZ>\]'Z'Q117M?Q*_9+\8_#3P7'XIDU#0?$>DF[%C-)X?O6NC;S%MFQ\H
MHSO^0A2<-P:Z>S_8)^(-U':V\NL^%+'Q!<VAO(_#EUJA742@Z_NQ&5X/!.[
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M_I6U6+X9_P"8K_U_R_TK:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^-/'WP]U[X?R27<UUH'B-DCU+3G\QRBVX+'S%)^8,0"-WR]JE^&GQ.^'^N?
M^\\&:#J/@&WN=&UV\EL+#XF1%K&:T>XF>&1"S [_ "Y ,_,PPP(^8&O@&BB>
M61FY-S>K3Z;KJ^_:^_S-/[3G=-177[GT\N_;R/>_VQO'TOC?X@:/'+K_ (:\
M1'3=*CMS<^%;5XK.)B[L8E9Y9/,V@K\P('S8V@@UZO\ L+Z7H/P]75O%6O\
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M]OIOU%]4@DDF]-M=M+?J?(M]^R9\0H]&\2_#W3/$OA^#X7:_K!U.>6:"8ZK
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M_@JG_P#B*_;JBC_6*I_S[7WA_84/^?C^X_$7_A4GCG_H3/$/_@JG_P#B*/\
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M0_\ @JG_ /B*_;JBC_6*I_S[7WA_84/^?C^X_$7_ (5)XY_Z$SQ#_P""J?\
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MZQ5/^?:^\/["A_S\?W'XB_\ "I/'/_0F>(?_  53_P#Q%'_"I/'/_0F>(?\
MP53_ /Q%?MU11_K%4_Y]K[P_L*'_ #\?W'XB_P#"I/'/_0F>(?\ P53_ /Q%
M'_"I/'/_ $)GB'_P53__ !%?MU11_K%4_P"?:^\/["A_S\?W'XB_\*D\<_\
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M]M\]?[(W?:?+\G>=WVCOOV8QLXSGM5V#_A-_[?TOSO\ A'_[$^QK_:'E^?\
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M#R_.\^';NQU<#.<\XVYKXBUKXWZ'J'[*.@_#&*TU!=>L-6:_EN6CC%J8R\Q
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M96_-_C^ECCK1M2<59O7;?9?AV\[GV_<?!L/^W$/&/_"<>#!_IZR_\(^VK?\
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MO5W>'S/'YTF[>U8;E_TJYB<H2",]<$@_2LW_ (:L^#NE_$74?BEI?A#Q.WQ
MNK3RQ:W4L TY)C&$+A@Y?)  )V].0H))K@[S]J2QN/@WX4T0V5]+XNTKQ6?$
MMS,R(EI*3/-,55@Y<$F0?P^O-3%Q4H\_ES=OC3T^5SNC.C#G<;;2Y;7O9PLK
MWZW.BT;]D[PEJ/[66N?#"34M:70+'3OMD=RLT/VHOY<389O*VXS(>BCH*R_
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M=77<KVU/KH*2BE)W84444RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(93D$>M6E:7,MUI^OX[OOU,O8TI)0^>[OM:^]]E9=N@ZBBBF=04444 %%%%
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MZD]^*U?A?\8M!_9G\1?%7P_X^34-)U*^\076K:8JV,LBZA#)]P1,JD9.!RQ
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M_P >HM'N')1_G?W?\$^6/*?^XWY4>4_]QORKZG_X>/\ Q3_Z!_AG_P  IO\
MX]1_P\?^*?\ T#_#/_@%-_\ 'J+1[AR4?YW]W_!/ECRG_N-^5;'B'Q9XB\7?
M93KNLZIK1M4\JW_M"ZDG\E./E3>3M' X'I7T?_P\?^*?_0/\,_\ @%-_\>H_
MX>/_ !3_ .@?X9_\ IO_ (]1:/<?+1_G?W?\$^6/+?\ N-^5'E/_ '&_*OIZ
M?_@HA\3KB\M;EK#PWYEONV8LYL?,,'/[ZK/_  \?^*?_ $#_  S_ . 4W_QZ
MBT>XN2C_ #O[O^"?+'E/_<;\J/*?^XWY5]3_ /#Q_P"*?_0/\,_^ 4W_ ,>H
M_P"'C_Q3_P"@?X9_\ IO_CU%H]PY*/\ ._N_X)\L>4_]QORH\I_[C?E7U/\
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MPO3=WU,72_\ D8]<_P"V'_H!K:K%TO\ Y&/7/^V'_H!K:K4] **** "BBB@
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MA^.W[3%W=Z=I;Z9H.C^%+BUL;:Z(:5U\Z$LTF"0,X4;03@+U.::C%RY?)_\
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M>4B_=@ MP >S,#3=-)MWT[_<N_GZZ;:H?U-Z+FUUOY6O_EZ:WN?G97M_PO\
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M:X4444RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7PS_S%?\
MK_E_I6U6+X9_YBO_ %_R_P!*VJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *I:U_R!K__ *]Y/_035VJ6M?\ (&O_ /KWD_\ 030 :+_R!K#_
M *]X_P#T$5=JEHO_ "!K#_KWC_\ 015V@ HHHH **** "BBB@ HHHH ****
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MSMQY\2+M5=OE[5('&5 /O7!^&?$NI>#?$&GZYH]S]CU2PF6>VGV*^QU.0=K
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M3<$JQ?<$RG*+PA XZ53M?BYXNL? <?@RWUAX/#D=X-02TCAC5EN 01()0OF
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M^IYE\-_BUXM^$.K3ZEX1UJ;1KN>/RI2B)(DBYR R.K*V.Q(R,G%=)XF_:?\
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MS][C% 'H%%<I=>/_ ++KVMZ9_P (WX@E_LNR:]^V16.ZWN\*K>5 ^[]Y*=^
MN!RK#/%5(OB=YMOX;F_X1/Q0G]M3/#Y;:;AK#;($WW0W?NE.=P/.5!- ';45
MQ,OQ.\JW\23?\(GXH?\ L69(?+73<M?[I"F^U&[]ZHQN)XPI!JW:^/\ [5KV
MB:9_PC?B"+^U+);W[9+8[;>TRK-Y4[[OW<HV8*X/+*,\T =717G_ /PM[_BE
M?[;_ .$*\8?\?OV+^S?[*_TS_5[_ #?+W_ZK^'=G[W&*U;KQ_P#9=>UO3/\
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MHHKT3S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC-Q2:=U[S23WVNUM?T/TH_X:M\-?] K5O^^(O_BZ/^&K?#7_ $"M6_[XB_\
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MQ1A1R;(*U:='5-.RO)Z^ZI7^YO[F?>?_  U;X:_Z!6K?]\1?_%T?\-6^&O\
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M_0*U;_OB+_XNOSE@_:_\-7FI:5:6WA3QE<IJTIBTZZ32E$5Y@X+Q$R NHZG
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M>U]OZ[_)_B";Q1\=(?AYX7@\ :[X6&B7]M>ZIJ&L6GV>VA6%=I6!B?WF<G&
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M10 52UK_ ) U_P#]>\G_ *":NU2UK_D#7_\ U[R?^@F@ T7_ ) UA_U[Q_\
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MHHHKP3W HHHH **** "BBB@ HHHH ***=##)<2I%$C22NP5409+$\  =S1N
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M/5/^OB#_ -&I0!=HHHH *R_$WAG3/&6A7>C:S:+?:;=J%F@9F7< 01RI!!!
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MM'J%O_;$)_L^,. )-V,2Y4EMJ\C&*DF\4>+T_P"$BV>"/,^PL!IG_$VA']I
MN03T_<X7#?-GKBC_ %-RG^67_@3#_6_-?YE_X"CPO_AE/Q1_T$](_P"_DO\
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MR_\  F'^M^:_S+_P%'@?_#*?BC_H)Z1_W\E_^-T?\,I^*/\ H)Z1_P!_)?\
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M  %'C'_#*?BC_H)Z1_W\E_\ C=>E?!_X#P^ [@ZIK$EOJ&L@D0^3EHH%]5W
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MF7%FL]WJ/]I1'[).58F#R\;GPP5=XX^;/:@#JJ*X#_A,O'7_  BZ7W_"N_\
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ME^+_ /H:M;_\&,W_ ,51_P ++\7_ /0U:W_X,9O_ (J@#],J*_,W_A9?B_\
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M44 8NE_\C'KG_;#_ - -;58NE_\ (QZY_P!L/_0#6U0 4444 %%%% !1110
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M^&1I?WE+M;\/^'?WGRIXJL9/ /PQL=3MUVZ-XN\,6]G>*/NQWL<"M$__  -
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M#?\ ))]<_P"O>7_T4]?GE2 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KT3X,_&;5/A%KWG0[KO1[A@+S3RW#C^^OHX['OT/MYW4D$$MU-'##&
MTTTC!$CC4LS,3@  =230!^D.C^+-+\;2^&M8T>Z6[L;A9RK+U4[!E6'9AT(-
M=C7S]^SU\']3^%_]FW.KW4BZAJGF2/IROF*V 3C/K(<\D>@';-?0- !1110
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M_!_\9H ^*Z*^U/\ ABCP3_T%M?\ ^_\ !_\ &:/^&*/!/_06U_\ [_P?_&:
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MD)8%<-CD$5+%XLT.:_L;&/6=/DO;Z$7-I;+=1F2XB()$D:YRRD*QW#(P#Z4
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M^7=D8SUSQ6[+XLT.&_OK&36=/CO;&$W-W;-=1B2WB !,DBYRJ@,IW' P1ZT
M:U%8B^./#DD>FR+K^EM'J3F.Q87L9%TX8*5B.[YR&(7"YY(%#>./#D<>I2-K
M^EK'IKB.^8WL8%JY8J%E.[Y"6!7#8Y!% &W163%XLT.:_L;&/6=/DO;Z$7-I
M;+=1F2XB()$D:YRRD*QW#(P#Z55_X6%X5_LK^T_^$FT?^S?.^S?;/M\7D^;M
MW>7OW8W;>=N<XYH Z"BLF7Q9H<-_?6,FLZ?'>V,)N;NV:ZC$EO$ "9)%SE5
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M6<@O8MMRX8*5C.[YR"0,#/)Q0!N45BMXU\/1_P!HEM>TQ1II"WN;R,?923M
ME^;Y.1CYL<T^/Q?H4UU86R:UISW.H1^=9PK=QE[E#D[HQG+C@\C(X- &O16!
M_P )_P"%QI\M_P#\))I'V&&7R)+K[=%Y228SL+;L!L=CS5IO%FB+J$EB=9T\
M7T</VE[8W2>8L6,^85SD+@@[NF* -6BL)?'GAEK.TNQXBTDVMW(8;><7T6R:
M0'!1&W89L]AS4LGC+0(Y-0C?7--233ANO4:[C!MAG&9!GY.?[V* -BBL>/QE
MH$DNGQ)KFFO)J"[K-%NXR;D=,QC/SC_=S41\>>&5L[J[/B+21:VLHAN)_MT6
MR&0\!';=A6]CS0!NT5E#Q9HC:@EB-9T\WSP_:5MOM2>8T6,^8%SDKCG=TQ5;
M_A/_  P=/AOQXCTG[#-+Y$5S]NB\MY.NQ6W8+>PYH WJ*R)/&&@PW5_;/K>G
M)<:?'YMY"UW&'MDX^:09R@Y')QU%,3QIX>D_L[;KVF-_:1(LMMY&?M1!VD1?
M-\_/'RYYH VJ*PV\=>&UM[^=O$&E+!82"*\D-[%MMG)*A9#N^0D@C!QR*GC\
M6:)+J%K8IK.GO>W4(N;>V6Z0R31$$B1%SEEP"=PXP#0!JT5S_P#PL+PM_98U
M/_A)='_LYIOLXO/M\7DF7&[R]^[&['.W.<5:D\6:'#?7UE)K.GI>6,)N;NW:
MZC$EO$ "9)%SE% 93N.!@CUH C\,_P#,5_Z_Y?Z5M5QGA3QIX>N/[8\K7M,D
MV2S7[;+R,[;88S,?FXC_ -OI[UL+XX\.21Z;(NOZ6T>I.8[%A>QD73A@I6([
MOG(8A<+GD@4 ;=%8C>./#D<>I2-K^EK'IKB.^8WL8%JY8J%E.[Y"6!7#8Y!%
M2Q>+-#FO[&QCUG3Y+V^A%S:6RW49DN(B"1)&N<LI"L=PR, ^E &M17/_ /"P
MO"O]E?VG_P )-H_]F^=]F^V?;XO)\W;N\O?NQNV\[<YQS5J7Q9H<-_?6,FLZ
M?'>V,)N;NV:ZC$EO$ "9)%SE5 93N.!@CUH UJ*Q%\<>')(]-D77]+:/4G,=
MBPO8R+IPP4K$=WSD,0N%SR0*&\<>'(X]2D;7]+6/37$=\QO8P+5RQ4+*=WR$
ML"N&QR"* -NBLF+Q9H<U_8V,>LZ?)>WT(N;2V6ZC,EQ$02)(USEE(5CN&1@'
MTJK_ ,+"\*_V5_:?_"3:/_9OG?9OMGV^+R?-V[O+W[L;MO.W.<<T =!163+X
MLT.&_OK&36=/CO;&$W-W;-=1B2WB !,DBYRJ@,IW' P1ZU$OCCPY)'ILBZ_I
M;1ZDYCL6%[&1=.&"E8CN^<AB%PN>2!0!MT5B-XX\.1QZE(VOZ6L>FN([YC>Q
M@6KEBH64[OD)8%<-CD$5+%XLT.:_L;&/6=/DO;Z$7-I;+=1F2XB()$D:YRRD
M*QW#(P#Z4 :U%<__ ,+"\*_V5_:?_"3:/_9OG?9OMGV^+R?-V[O+W[L;MO.W
M.<<U:E\6:'#?WUC)K.GQWMC";F[MFNHQ);Q  F21<Y50&4[C@8(]: -:BL1?
M''AR2/39%U_2VCU)S'8L+V,BZ<,%*Q'=\Y#$+A<\D"AO''AR./4I&U_2UCTU
MQ'?,;V,"U<L5"RG=\A+ KAL<@B@#;JEK7_(&O_\ KWD_]!-5HO%FAS7]C8QZ
MSI\E[?0BYM+9;J,R7$1!(DC7.64A6.X9& ?2LO4_'GAJZ\,7=[#XBTF:SD+V
M:7$=[$T;3E"1$&#8+D<[>N.U &[HO_(&L/\ KWC_ /015VN6TOQWX:M?#%I>
MS>(=*BLXREF]Q)>Q+&LX0$Q%BV X'.WKBM23Q9HD.H7EC)K.GI?6<)N;FV:Z
M0201  F1USE5PRG<>,$>M &K16&OCCPX\.GS+X@TMH=0D,5G(+V/;<N&"E8S
MN^<AB!A<\G%.;QMX>C&HEM>TQ1IK!;TF\C'V4EMH$OS?(<@CYL<\4 ;5%9$?
MB[0IKJPM4UK3GN;^,36<*W49>YC()#QKG+K@'D9'!JO_ ,+ \+_V=+J'_"2:
M1]@BE^SR77VZ+RDDQG86W8#8[=: -^BLIO%FB+J$MBVLZ>+V*'[3);&Z3S$B
MQGS"N<A<$'=TP:KKX\\--:6ET/$6DFUO)##;3"]BV32 X*(V[#-D]!S0!NT5
MC/XR\/QR:A&^N::CZ<,WJM=Q@VPSC,@S\G/][%+'XRT"6;3XDUS37EU!=]FB
MW<9:Y7UC&?G'^[F@#8HK"/CSPRMG<WA\1:2+2UE$,\_VZ+RXI#T1VW85O8\U
M8'BS1#J"V(UG3S>M#]I6V^U)YABQGS N<[<<[NF* -6BL'_A/O#!L(+X>(])
M-E/+Y$5S]NB\N23^XK;L%O8<U/)XPT&&YO[=];TY+C3T\V\B:[C#VR<?-(,Y
M0<CDXZT :]%8R>-/#TG]G!-=TQCJ1(LMMY&?M6#@^5\WS\\?+GFF-XZ\-K;W
MUPWB#2A!82"*[E-[%MMW)VA9#NPA)!&#CD4 ;E%94?BS1)-0MK%-9T][VZA%
MS!;+=(9)8B"1(BYRRX!.X<8!JI_PL'PM_9:ZE_PDNC_V<TWV=;S[?%Y)EQN\
ML/NQNQSC.<4 =!5+5O\ CU3_ *^(/_1J56D\6Z'#?7UE)K.GI>6,)N+NW:ZC
M$EO$ "9)%SE% 8')P,$>M4;[QAH-Y9Z68-;TZ<:E<QBR,=W&WVHI,@<18/S[
M3UVYQWH Z2BBB@ K/U+P]I6LW5E=:AIEG?7-B_F6LUS;I(]N^0=T9()4Y53D
M8^Z/2M"N5^*6N7OAOX?ZUJ6G3?9[VWA#12[%;:=P&<,"#U[BJC'F:BNH&@W@
MGPZZZDK:!I;+J3![Y39QXNF#%@9?E^<AB3EL\G-21^$="BN["Z31=/2ZL(A#
M9S+:QA[:, @)&V,HN">!@<FO(_%'Q,UVVC\#6;:Y%X<@U;3H[FZUR:S68&4H
M#MVD;0,XSTQN'0"M#Q]XL\2^%_ 7AN5?$EE]NO-16WEUFUAC>%X6WE9,,-H^
M7:3CC@X.*ZOJL_=5UJ[=>]NW_!\CF^L1LW;97_"_]=#T3_A ?#']GS6'_".:
M3]AFE\^2U^PQ>4\F,;V7;@M[GFK)\*:(=0:_.CZ>;YH?L[77V5/-,6,>66QG
M;CC'3%>>?##QGK-]XL\0:5J&NVOB?1[&W29=;MX$BC5C@E"4^7H6/4_=ZUBV
M'Q2\1Z]\2] >VN/LOA+5;F:"UMVA3=.D2\REBNX!F/&"/N_FOJLW+E36U_PO
M]X.O%1YFO(]4_P"$"\,BQM[(>'-)%G;RF>&W^PQ>7%(>KJNW ;W'-3R>#]!D
MN+^X?1-.>?4$\N\E:TC+7*<?+(<9<<#@YZ5X]XP^+]S+XVU;2X_%UOX.T_37
M$"2'33>RW4G\61@A5!XSQ^/;LO%TGBJX\,Q:IH_BO3["QM=-^TR7BVBRF[E"
MDD_-E40@ @C)Y-2\/**C*3LGZ_Y?D6JJE)QCJUZ?U^AUJ^"_#T?]G;=!TQ?[
M-)-EBSC'V4DY)B^7Y.>?EQS36\#^'&@U"%O#^EF'4'$MY&;*/;<N&W!I!M^<
MAB3EL\G-8GP=\5ZEXT\ V&J:JBB\D9T,BKM$H5B ^.V<=N,@UVU95*;IS<);
MHNG-5(J:ZF5'X3T2'4+*^CT;3TOK&$6UK<K:H)+>( @1QMC*J S#:,#!/K53
M_A7WA;^RVTS_ (1K1_[.:;[0;/[!%Y)EQM\S9MQNQQG&<5T%%9EF4_A71)-0
MN+]M'T]KZXA-O-=-:H99(B #&S8R5P ,'C %5QX%\-+:V=J/#VE"VLY#-;0_
M8HMD#DY+(NW"MGG(YK=HH QW\&Z!))J$CZ'IK2:B-MZS6D9-R,YQ(<?/S_>S
M0G@W0(Y-/D30]-633AMLF6TC!MAG.(SCY.?[N*V** ,(^!?#36MY:GP]I1MK
MR037,/V*+9.X.0SKMPS9YR>:L)X5T2/4+>_71]/6^MX1;PW2VJ"6.( @1JV,
MA<$C XP36K10!S__  K[PM_9:Z9_PC6C_P!G+-]H%G]@B\D2XV^9LVXW8XSC
M.*-4^'OA77+^6^U+PSH^H7LN/,N;JPBED?  &6923@ #Z 5T%% &3+X3T.:_
MOKZ31M/DO;Z$VUW<M:QF2XB( ,<C8RRD*HVG(P!Z5$O@?PY''IL:Z!I:QZ:Y
MDL5%E&!:N6#%HAM^0E@&RN.0#6W10!B-X'\.21ZE&V@:6T>I.)+Y391D73AB
MP:4;?G(8ELMGDDU+%X3T.&_L;Z/1M/CO;&$6UI<K:QB2WB ($<;8RJ@,PVC
MP3ZUK44 <_\ \*]\*_V5_9G_  C.C_V;YWVG[']@B\GS=NWS-FW&[;QNQG'%
M6I?">AS7]]?2:-I\E[?0FVN[EK6,R7$1 !CD;&64A5&TY& /2M:B@#$7P/X<
MCCTV-= TM8]-<R6*BRC M7+!BT0V_(2P#97'(!H;P/X<DCU*-M TMH]2<27R
MFRC(NG#%@THV_.0Q+9;/))K;HH R8O">APW]C?1Z-I\=[8PBVM+E;6,26\0!
M CC;&54!F&T8&"?6JO\ PKWPK_97]F?\(SH_]F^=]I^Q_8(O)\W;M\S9MQNV
M\;L9QQ7044 9,OA/0YK^^OI-&T^2]OH3;7=RUK&9+B(@ QR-C+*0JC:<C 'I
M42^!_#D<>FQKH&EK'IKF2Q4648%JY8,6B&WY"6 ;*XY -;=% &(W@?PY)'J4
M;:!I;1ZDXDOE-E&1=.&+!I1M^<AB6RV>234L7A/0X;^QOH]&T^.]L81;6ERM
MK&)+>( @1QMC*J S#:,#!/K6M10!S_\ PKWPK_97]F?\(SH_]F^=]I^Q_8(O
M)\W;M\S9MQNV\;L9QQ5J7PGH<U_?7TFC:?)>WT)MKNY:UC,EQ$0 8Y&QEE(5
M1M.1@#TK6HH Q%\#^'(X]-C70-+6/37,EBHLHP+5RP8M$-OR$L V5QR :&\#
M^')(]2C;0-+:/4G$E\ILHR+IPQ8-*-OSD,2V6SR2:VZ* .,\5^"_#UQ_8_FZ
M#IDFR6&P7?9QG;;#.(1\O$?^QT]JW8_">APWUC>QZ-IZ7EC"+:TN%M8Q);Q
M$".-L910&8;1@8)]:C\3?\PK_K_B_K6U0!S_ /PKWPM_99TS_A&M'_LYIOM!
ML_L$7DF7&WS-FW&['&[&<5;D\)Z)+J%U?/HVGO>W4)MKBY:U0R31$ &-VQEE
MP -IXP!7"_M!?M$>%/V;_!L.O>)C=W<UY<K8Z9H^EP^=>ZC<M]V&&/(R?<D
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MG)X!S4GA#XC>$_B%H\VK>%O$^C>)=*@=HY;[1]0BNX(W !*L\;%00""03T-
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M^T_8_L$7D^;MV^9LVXW;>-V,XXJU+X3T.:_OKZ31M/DO;Z$VUW<M:QF2XB(
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M7>NWW_!/O5M8L?"%CX"T[Q#XOM=*\0>)?"6@R6D&I:#"I"ZG]A&W:C,0&"A
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M** "BBB@ HHHH **** "BBB@#%U3_D8]#_[;_P#H K:K%U3_ )&/0_\ MO\
M^@"MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%TO\
MY&/7/^V'_H!K:K%TO_D8]<_[8?\ H!K:H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Q?#/\ S%?^O^7^E;58OAG_ )BO_7_+_2MJ@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6M?\@:_P#^O>3_ -!-
M7:I:U_R!K_\ Z]Y/_030 :+_ ,@:P_Z]X_\ T$5=JEHO_(&L/^O>/_T$5=H
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MG.?XO:BBCJ#^%OT_-&E_9OC?_H8?#_\ X(9__DVC^S?&_P#T,/A__P $,_\
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MH /[-\;_ /0P^'__  0S_P#R;1_9OC?_ *&'P_\ ^"&?_P"3:** #^S?&_\
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MS_\ R;110 ?V;XW_ .AA\/\ _@AG_P#DVC^S?&__ $,/A_\ \$,__P FT44
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MS_\ R;110 ?V;XW_ .AA\/\ _@AG_P#DVC^S?&__ $,/A_\ \$,__P FT44
M']F^-_\ H8?#_P#X(9__ )-H_LWQO_T,/A__ ,$,_P#\FT44 ']F^-_^AA\/
M_P#@AG_^3:/[-\;_ /0P^'__  0S_P#R;110 ?V;XW_Z&'P__P""&?\ ^3:/
M[-\;_P#0P^'_ /P0S_\ R;110 ?V;XW_ .AA\/\ _@AG_P#DVC^S?&__ $,/
MA_\ \$,__P FT44 ']F^-_\ H8?#_P#X(9__ )-I\.D^+)KB 7^N:-/:+*DD
:D=OHTT4C!6#8#FZ8+TZE3110!U%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>arvn-20250630_g2.jpg
<TEXT>
begin 644 arvn-20250630_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  = %\# 2(  A$! Q$!_\0
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JM'V&TBM?.V[=^Q N[&3C.,XR:TJ*%[JY5MI^%[?FP?O/F>^OX[_D?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arvn-20250630_g3.jpg
<TEXT>
begin 644 arvn-20250630_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &_!*P# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ HHHH **YOQA\2O"7P]-H/%'B?1_#AN]_V?\
MM:_BMO.VXW;-[#=C<N<=-P]:YW_AI#X3?]%-\'_^#VU_^+K14YR5TF0ZD(NS
M9Z-17G/_  TA\)O^BF^#_P#P>VO_ ,71_P -(?";_HIO@_\ \'MK_P#%T_95
M/Y7]PO:0_F1Z-17G/_#2'PF_Z*;X/_\ ![:__%T?\-(?";_HIO@__P 'MK_\
M71[*I_*_N#VD/YD>C45YS_PTA\)O^BF^#_\ P>VO_P 71_PTA\)O^BF^#_\
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M_BZ/^&D/A-_T4WP?_P"#VU_^+H]E4_E?W![2'\R/1J*\Y_X:0^$W_13?!_\
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M/"ME?6LK03VUQK-NDD4BDJR,I?*L"""#R"*K_P##2'PF_P"BF^#_ /P>VO\
M\76GLJG\K^XCVD/YD>C45YS_ ,-(?";_ **;X/\ _![:_P#Q='_#2'PF_P"B
MF^#_ /P>VO\ \71[*I_*_N#VD/YD>C45YS_PTA\)O^BF^#__  >VO_Q='_#2
M'PF_Z*;X/_\ ![:__%T>RJ?RO[@]I#^9'HU%><_\-(?";_HIO@__ ,'MK_\
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MU'39K>%R1D!7=0"2/0T<T;)WW'RRNU;8YBBBBK("BBB@ HHHH **** /K_\
M8I_;6N/@W>6W@WQE<R77@:XDVV]TV7?2G8]1W,))RRC[N2R]PWV1^WO>V^I?
ML>^,+NTGCNK6X73Y89X7#I(C7MN596'!!!!!'K7X\5Z[HO[2/B*R^ ?B;X3Z
MBS:GX?U'R)-/:5SOT^2.YCF8*>\;!&^7LQR,98'QZ^!4JT:]/=-7^_<]6CC7
M&C*C4VL['D5%*,G@<FNSUKX*?$/PWI<VIZOX"\3:7IL*[I;R]T>XAA1?5G9
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M[4'Q-UC1]0TN[\3&2RU#28=#N8UL;9"]E%OV0[EC# #S'R003GDGBL[X?_M
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M0,G ST%8G@W]KCXN> ;K6[G1/&4\%QK5W]NU":XM+>Y>>;:%W$RQL1P ,#
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M ?AEK*YLSX=TDVES*)Y[?[#%Y<L@Z.R[<,WN>:W:* ,K_A$]$_M 7W]C:?\
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MD?=G_#K#X4_]##XR_P# VT_^1J/^'6'PI_Z&'QE_X&VG_P C5\)_\+[^)O\
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MC_AUA\*?^AA\9?\ @;:?_(U?"?\ POOXF_\ 11?%G_@\NO\ XY1_POOXF_\
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MXR_\#;3_ .1J^$_^%]_$W_HHOBS_ ,'EU_\ '*/^%]_$W_HHOBS_ ,'EU_\
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M_P 'EU_\<H_X7W\3?^BB^+/_  >77_QRCV^*_P"?@?V#2[(^[/\ AUA\*?\
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M_$W_ **+XL_\'EU_\<H_X7W\3?\ HHOBS_P>77_QRCV^*_Y^"_L&EV1]V?\
M#K#X4_\ 0P^,O_ VT_\ D:C_ (=8?"G_ *&'QE_X&VG_ ,C5\)_\+[^)O_11
M?%G_ (/+K_XY1_POOXF_]%%\6?\ @\NO_CE'M\5_S\#^P:79'W9_PZP^%/\
MT,/C+_P-M/\ Y&H_X=8?"G_H8?&7_@;:?_(U?"?_  OOXF_]%%\6?^#RZ_\
MCE'_  OOXF_]%%\6?^#RZ_\ CE'M\5_S\#^P:79'W9_PZP^%/_0P^,O_  -M
M/_D:C_AUA\*?^AA\9?\ @;:?_(U?"?\ POOXF_\ 11?%G_@\NO\ XY1_POOX
MF_\ 11?%G_@\NO\ XY1[?%?\_ _L&EV1]V?\.L/A3_T,/C+_ ,#;3_Y&H_X=
M8?"G_H8?&7_@;:?_ "-7PG_POOXF_P#11?%G_@\NO_CE'_"^_B;_ -%%\6?^
M#RZ_^.4>WQ7_ #\#^P:79'W9_P .L/A3_P!##XR_\#;3_P"1J/\ AUA\*?\
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ME'M\5_S\#^P:79'W9_PZP^%/_0P^,O\ P-M/_D:C_AUA\*?^AA\9?^!MI_\
M(U?"?_"^_B;_ -%%\6?^#RZ_^.5I^&?VFOBEX6U^QU:'QWK]]):2B06VI:E/
M<V\H[K)&[D,I&1Z]P0<&CV^*_P"?@?V#2[(^V?\ AUA\*?\ H8?&7_@;:?\
MR-1_PZP^%/\ T,/C+_P-M/\ Y&KV_P#9T_:+T#]H;P@-0T\K9:U:A5U+2'?,
MELY_B']Z-L':WX'!!%>M5SO&XE.SFSRI8"C!N,H:GQ-H_P#P2_\ A;J'VWS/
M$'B\>3=/"NV\M1E5QC/^C=>:T/\ AUA\*?\ H8?&7_@;:?\ R-7U?X9_YBO_
M %_R_P!*VJ7U[$_SLGZGA_Y$?&W_  ZP^%/_ $,/C+_P-M/_ )&H_P"'6'PI
M_P"AA\9?^!MI_P#(U?9-%'U[$_SL/J>'_D1\;?\ #K#X4_\ 0P^,O_ VT_\
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M0!BZI_R,>A_]M_\ T 5M5BZI_P C'H?_ &W_ /0!6U0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9^O_P#()G_X#_Z$*T*S]?\ ^03/_P !_P#0
MA6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EOQU_P"//2/^
MNDG\EK\^/VUO^0EX3_ZY7/\ Z%'7Z#_'7_CSTC_KI)_):_/C]M;_ )"7A/\
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M 4444 %%%% !1110 445/I]A<ZK?6]E96\EW=W$BQ0P0H7>1V. J@<DDGI0
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M*^&O_1/?"O\ X)+;_P"(H_X45\-?^B>^%?\ P26W_P 17<T4<S[ASR[G#?\
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M_P""2V_^(H_X45\-?^B>^%?_  26W_Q%=S11S/N'/+N<-_PHKX:_]$]\*_\
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M ,$EM_\ $4?\**^&O_1/?"O_ ()+;_XBNYHHYGW#GEW.&_X45\-?^B>^%?\
MP26W_P 163XK^"'PYM] NI(O 'A>.0;<,FC6P(^<=]E>GUB^,/\ D7+O_@'_
M *&M',^X<\NY@?\ "BOAK_T3WPK_ ."2V_\ B*/^%%?#7_HGOA7_ ,$EM_\
M$5W-4M8UJP\/:;<:CJE[;Z=I]NNZ:ZNI!'%&,XRS$X R1UHNPYY]SD_^%%?#
M7_HGOA7_ ,$EM_\ $4?\**^&O_1/?"O_ ()+;_XBH_\ A?WPSZ?\+!\,?^#>
M#_XNMGPO\2/"?C>XE@\/>)=)UR>)-\D>GWL<S(N<9(4D@9(_.G[Q;]HM7<RO
M^%%?#7_HGOA7_P $EM_\11_PHKX:_P#1/?"O_@DMO_B*[FBES/N1SR[G#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/+?^"NR_^,UX-11R1[!["E_(ON1[M-^W'\;KB&2*3QNS1R*59?[,LN01@_\
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M  5V7_QFC_ANGXX_]#RW_@KLO_C->#44<D>P>PI?R+[D>\_\-T_''_H>6_\
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MH Q=4_Y&/0_^V_\ Z *VJQ=4_P"1CT/_ +;_ /H K:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,_7_P#D$S_\!_\ 0A6A6?K_ /R"9_\ @/\
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M@ACE@P/H >1V+F<G?37\.;3_ ,E_JYQ0^L>SU^+E7:W-:5[V[/EV[O?IHI\
M_#_B&QUZ;PEXWEUJ7P_J%M::C'>:0+16AFG$ N+9A/)YJARORL(S@Y]JO^./
MV9]+\-M\0['1_&<NN:]X)2.>_M)=(^S030M($)BE\YB73<FY611DD*S8R<YO
MCSH&@VNN1>$/!4VA'7M1M[S4C>:N+L"&&<3K;6X$$?E(7 Y;S#@ 9INK?M&'
M5/$_Q6U@>'_)/CJU-MY/VW=]A_>(^[/E_O/N8QA>M9?O-+]G?;>T;)>3=_\
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M+?B=H>MZO::-K4>GV>ES7]C<PZ1-/%J4L<BI]GB<8!8DO]W<?D(V]<=%X?\
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MR7>W_P"Q;D_]*HZ[VN"D_P"2[V__ &+<G_I5'31<>IWM%%%(@**** "BBB@
MHHHH **** "BBB@ HHHH Q?#/_,5_P"O^7^E;58OAG_F*_\ 7_+_ $K:H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%U3_D8]#_[;_P#H K:K
M%U3_ )&/0_\ MO\ ^@"MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !ZC_AB'X&?]"3#_ .#.\_\ CU'MXA_:-+L_Z^9^1-%?KM_PQ#\#/^A)A_\
M!G>?_'J/^&(?@9_T),/_ (,[S_X]1[>(?VC2[/\ KYGY$T5^NW_#$/P,_P"A
M)A_\&=Y_\>H_X8A^!G_0DP_^#.\_^/4>WB']HTNS_KYGY$T5^NW_  Q#\#/^
MA)A_\&=Y_P#'J/\ AB'X&?\ 0DP_^#.\_P#CU'MXA_:-+L_Z^9^1-%?KM_PQ
M#\#/^A)A_P#!G>?_ !ZC_AB'X&?]"3#_ .#.\_\ CU'MXA_:-+L_Z^9^1-%?
MKM_PQ#\#/^A)A_\ !G>?_'J/^&(?@9_T),/_ (,[S_X]1[>(?VC2[/\ KYGY
M$T5^NW_#$/P,_P"A)A_\&=Y_\>H_X8A^!G_0DP_^#.\_^/4>WB']HTNS_KYG
MY$T5^MNJ?L3_  .M]-NY8_!<*R)"[*?[3N^"%)'_ "VHTO\ 8G^!UQIMI+)X
M+A:1X49C_:=WR2H)_P"6U'MXA_:-+L_Z^9^25%?KM_PQ#\#/^A)A_P#!G>?_
M !ZC_AB'X&?]"3#_ .#.\_\ CU'MXA_:-+L_Z^9^1-%?KM_PQ#\#/^A)A_\
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M#.\_^/4?\,0_ S_H28?_  9WG_QZCV\0_M&EV?\ 7S/R)HK]=O\ AB'X&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% &+X9_YBO_ %_R_P!*VJQ?#/\ S%?^O^7^E;5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8NJ?\C'H?_;?_ - %;58NJ?\ (QZ'_P!M
M_P#T 5M4 %%%% !115+6KR;3]'OKJVMWO+B""26*WC&6E95)" >I(Q^-5&+D
MU%=29244Y/H7:*_,34]!^)?@VZFU&ZL/$NB2-(TKW2QSPKN)R3O&!U/K75^#
M_P!KKXC>%7B2?5(]>M$X,&J1!R1_UT7#Y^K&OU&KP#B94_:8+$0J?A]S5U^1
M^6TN/\-&I[/&X>=/\?O3Y7]US]$**\.^$?[67A7XE7%OIE^K>'=<EPJ07+AH
M9F](Y..3Z, >PS7N-?GF.R_%9;5]CBZ;A+S_ $>S^1^B8',,+F5+VV$J*<?+
MIZK=/U"BBBO//0"BBB@ HHHH **** "BBB@ HHHH **** "BJNI:G9Z+I]S?
MZA=P6%C;1F6>ZN9%CBB0#)9F8@* .YJL/%&C'P]_;XU:Q.A>1]J_M3[2GV;R
M<9\SS<[=F.=V<4>8[,TZ*KZ?J%KJUC;WME<PWEG<1K+#<6[AXY4895E8<$$$
M$$=:L4;""BBN>\,^/]!\8:KKVFZ1?_;+W0KK[%J,7DR)Y$V,[<LH#<=U)'O0
M/6USH:***!!1110 4444 %%%% !1110!GZ__ ,@F?_@/_H0K0K/U_P#Y!,__
M  '_ -"%:% !1110 45PGQ.^.7@7X-Q6S^,?$=MHS7/^IA9'FF<=V$<:L^W/
M&[&/>HO#OQ\^'_BWP3JOB[2/$UK?:!I,337UQ&DF^V55+$O$5\P< X&W)QQF
MGT<NB-/9ST=GKL>@45Y[;_'[P#=?#&?XAP^(8Y?!\#;)=16VF)1O,$>TQ;/,
M!W,HQM[@].:E^(_QV\!_".RL;KQ;XDM](2^7=;1M')+-*O\ >$4:L^WWQ@9H
M<6M&A*$I.R7?\-_NZG>T5YS>?M$?#>P^']KXVN/%MC'X9NF*07AW[I7!P46+
M;YA<=U"Y&.14WPR^/G@#XQO=1^#_ !+;:O/;+OEM_+D@F5<XW>7*JL5R0-P&
M.13Y7KIMN')+EYK:'H%%<WX!^(GA[XG>&TU_PSJ(U/2'DDB6Y\F2(%D8JPVR
M*IX(ZXQ7GUU^V)\&K/Q&VAR^/+ 7RR>466*9K<-_U\!#%CWWX'K1RN_+;4%3
MF[V6V_D>RT5ROCOXJ>$OAGX?37/$^O6>DZ7)@132.6,Q(R!&J@M(<<X4'CFN
M'TS]KWX1ZSX?U;6[+Q>EQIVE"-KUUL+KS(5=PBN8S%O*[F4;@I )&2,TDF]A
MJG.24DG9GL5%<IJ7Q2\+:5XB\-:%/JJG5?$B/)I5O!#)-]H15#,^Y%(5=I!W
M,0.O/!KJZ+-;F?;S"BBBD!\;?\%/O^21^%?^PX/_ $GEK\V*_2?_ (*??\DC
M\*_]AP?^D\M?G3X:T63Q)XBTK2(FV2W]W%:JWH7<*#^M>AAUS)(^CP<E##\S
MV5S.HKZ,^*7A"V^*7[0WC72+>36(K+PXJ:7IVD^'M$DU6\:"VV6X$4*LB+&I
M4LS/(OW^ Q.!I:7^S?X3\&>)OB7H7C'4=3O9='\+_P!M:?<0:88WCC<P$3M$
M;E")D,C)Y#_*?F)88 *56/)SOLW\DK_?;_A[*YV.JHODE\6EUVV7X-_UL?,-
M%?3F@_ &T^*'AGX86,.LZ9H=C?:9KM^FJKH7EW<D=M<G!NV6=O-)'3'^K'RC
M?UKB=&^"_@[6/ 7B/QLOCC5;?PYHU];V!\SP\GVNX>5204B%V4&"!]Z0?+DY
M! 4ZRDHR<6]O_DG'\6K$QQ%.3Y;ZWMUWM?\ +4\9HKZ!\4?LMZ5HNL>*M!TW
MQU_;'B/1-$;Q"MNNDF&VGM L<FTS&8E9C%('VA&3H/,SG%/2/V:].O/$6A^#
M;[QD;#X@:SIRWUOI?]F>98Q221F6&WFNO.#+(R;2=L+*I<#)J>>/]?/_ "97
MMJ?+S7TW^6FOIJM=M4>%45ZOJWP;T'PCX;T&?Q5XR?1O$&N:9)JMGIT.E-<V
M\4.&\C[1.L@9#*R,!LBDV\%L"O0/B=\#+>\\5ZOJ.KZII/AKPYX?\-:9?WUS
MH&A^67>= L,:6WG8>9WX9VD0$Y8XZ42FHV_KO_E_6@G6BIJ#OJNS[Q7;O)'S
M173K\2-=6,J+E%9!MMI!& ]FN I6 _\ +,%0 0O85]%?#GP_HZ_ G7=.T+6(
M?$.F77C301'<:AIK1C,F-T<]N7P=I)5E61E8#A^>+_B[PSH=E\&OBMIGB#5H
M= L-/^)+*#H.C;E=U@D416]J9E6->20&E 55(W,< XU'"4G&2O;]5#_Y+Y_,
MO#XJ3^'36WW<UO\ TGY;]#YH;XE:RS;7^RR6[Y:>U:W4PW,AP3)*G1WR =QY
MR!70^+?V@O%GC"#0EN9+2TNM(T^/38KZSB*W$L*.S@2.6).2W(&%.!QUSZOX
M3^&*^"-4^)OP\NM2BUO0-<\%GQ'I>I1PF,7'D(+FVF"9.PX\U2,GN,D'GY>H
M5*DWR\OG^:U\[II_*_9=$,5.I[Z>VB>G5)_K\OF=2OQ*UE&PGV6.W3!@M5MU
M$-LXR1)$G1'R2=PYR32#XE:[M7-Q&[-Q<NT8+7B@%0LY_P"6@"DC#=C7+T57
ML*?;^OZ_'4U^L5>_]?UIZ:;'LGAW]J+Q!HNAZ7I5]X>\-^([?2+F2YTM]3M9
MEDL-^W=%$8)H\1G:/E;/''3BN:\5_'#Q1XU\17VL:O+:7,M\YDNK;[,HMYWP
M &>/HQ 5 ">@05P%%-T*;:;6QE"<J;;CU_7?[^O?J=3_ ,+-\1?ZS[>?MF?^
M/[:/M&S=N\KS.OE[N=O2A?B5K*-A/LL=NF#!:K;J(;9QDB2).B/DD[ASDFN6
MHI?5Z7\IK]8J_P W]?U^G9'4#XE:[M7-Q&[-Q<NT8+7B@%0LY_Y: *2,-V-#
M?$K7=K8N(T9>+9UC :S4@*5@/_+(%0!A>PKEZ*/84OY?Z_K\--@^L5?YOZ_K
M7UUWU.I;XE:RS;7^RR6[Y:>U:W4PW,AP3)*G1WR =QYR!7.7U]/J5Y/=7,C3
M7$SF221NK,3DFH:*N-.$/A1G.K.HK2?]?U_6H4445H9!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
M?O[!=O\ $6/X:Z[)J+;?ATV#IT=X&\TW'FKN-OZ1==V>"WW>=U>5?L=_L=W7
MQDOH/%7BJ"6T\$6\F8XCE'U-U/**>HC!X9AU^Z.<E?TG\0:?:Z3X->RLK>*T
ML[>..*&"% B1HK* J@<  =JY:U1?"CQL=B(V]E'5G0T445R'AA7!2?\ )=[?
M_L6Y/_2J.N]K@I/^2[V__8MR?^E4=-%QZG>T444B HHKYW\%?$3XR_%B/7-9
M\+/X%L/#<&L7FGV']JV=[)/-%#(4$C-',%.<'H!T--+F=OG^7^9I&%US7LMO
MS_R9]$45DZ+KEO>32:7-J>GW>OV,,+:C:V4HW0LZY#&,L616(8KNZ@=37(_%
M;XI67AGX/^-_$^AZI9WEQHUI<QK+;2I,L-XB[5C?&0&60J"IY[$5,O=3?84(
M.I)16[LOO/1**\'OO'WBS2O$GP2\-7.M*E]JEE/J7B6Z>"%?-B@M59\C;B,-
M*XY3;C;U%>Q?\)9H8\.?\)"=9T\:!Y/VC^U?M4?V7RO[_FYV[??.*TE%PO?S
M_#3\T_N9-G:+757_ *\^OHT:U%1V]Q%=V\4\$J302J'CDC8,KJ1D$$=01WJ2
MHV$%%%% !1110!B^&?\ F*_]?\O]*VJQ?#/_ #%?^O\ E_I6U0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &+JG_(QZ'_VW_\ 0!6U6+JG_(QZ
M'_VW_P#0!6U0 4444 %?*7[0'[7E]X5\37?AOP8MH\UBYAO-3F7S=LRG#QHO
M3*D;23GD$8&,GZMK\5_A/^U#XA_9O^,7BR'Q_P"#=/\ $[W6K3RZO9ZE;K]L
MM+EI6,KV\K*<9))VD;6X(*YS7Z'P?E5+,*E>O4I*JZ234&TN9M^>FENNFJ/%
MS;!X['8;V. K>RE=7?6VNB[/8^D%_:X^*JR!CXG5ESG8=.M<?3_59_6OLF?X
M-^&_B9X+T>3QCH-G/KTUA"UW?6\0@G$YC4N0Z8/WLG!X]J\\\#_M0? ;XK>$
M[Z^T!M'N]3@LY+@^&[ZQCAU"5E0MY*0LO[UCC'[K>"2,9K\Q=3\9?M/6]Y)-
M+J7Q5TS[9,\R013:G!&69BQ"(" !D]!7UOU*6=SY<'16 J4GK=<KE?M91=E;
M7?='C9/PYB</[6&9XAXB,DK*=VEO?23?D?:WQX_9/OOA=IEQXAT2_.J^'H,&
M=;C:EQ; D $XP'&2.1@\],<U].?!_P <76F_LWZ;XK\4SO(VGZ7<7MU/(?F:
M"$R%6)/4^4BG)Z]:_,SX._LO_'G]ICQQI*?$%O%\'A*WN8Y;_4/%MS<@^4""
MRPK.=SNRY4%1@$\D5]R_\%#/&-K\)_V1-8TG3%6Q_M8V_A^RACX"1M\SJ!Z>
M3%(OXUS9YSXQX/)*]>->LYJ\HJW+%Z6;N]=;O;1*ZZG3EW#.'RC,)XG!R:A.
M-G#HG=.Z_'TOIN<#X=_;X^*'B'X.W_Q4M?@U8W/@K3;DP7DT?B#;.%4H'=4,
M.2H+@9&<$$XP":C_ &F/VOKOXB?"/X6Z/\*;RZTK7/BI=?9([K.RYL(EF6"5
M,J?E<RMLW@_=1R",@C(\$?LW_'OQ3^S)X=^$T4O@WP/X)N[19;_4%EN+G5)T
MED-PR%-@122^&7(X&W=C.?/_  O\ ]!^('[:^F?"K3KW4XO!WPO\.BW:^L+D
MVUP\X_>R2B1/N2-=7A)QS\A X%%'"9''$5*\(Q7L'.=HN4E[.*M'FNVG)S::
M2>UTS[&T;GO=K^Q)K?@']ICP%XO^'>KP:!X-TNPBBUP3WMQ)?:I,K2>:95.5
MD,JL@))4#!('RKG[&K\U?V63:>*_$O[07B#Q#X]\56GPJT".33;.[N/$%RTB
M0FX+^:DA8GS-EN@^4;OW^T9S7*_"V;Q9_P (W\1/V@H]7\70?#GPTDI\*Z%K
M&N7-S_:%T&$44MQE_GBC=E=U^ZS93)"-GR\PR;$8^HX8K$7E24(IN/Q2GK&%
M[ZR][7HEO9"<;[L_52BOS$\"^&?C]XT^'GA#XA^$=#\7ZI\0+[48]6N?%-[X
MOM%TZ^L\N/LWV$W 58L;/E* _*W0$*.K\)V?C#]K+]L+XS0Z?X^\1>%_ V@P
MR:1NT:\90LH7[.GEJ257>T,TA8#)&0"-V1XU3AB-)U)2Q4.6FFY-:V:DHVM%
MM^\W[M[-V=TB>7S/T0HKSO\ 9_\ ACJ?P<^%&B^$]8\377B_4+'S3)JUV&#R
M;Y&<* SL=JA@HRQX7MT'HE?&5X0IU90IRYHIM)VM==[/57,PHHHK  HHHH *
M*** *6M:1:^(-'OM+OHEGLKV"2VGB8</&ZE6!^H)KX'T_7M2F^$:?LXRW+_\
M)+_PF'_".NRG]Y_90D^T-./]G:"/]TU]_P!W,]O:S2QP/=21HS+!&5#2$#(4
M%B%R>G) YY(KR*/X4Q0_$R3QVG@?35\=21?-KO\ :$OV8Q^4$\KR]V?-P F_
MRL;?FSG]W1&I&G/WE=.W2^J=U^J?DV>AATY0=FDUJKM*SLU?5^=].J7R^;_&
M'[1'Q6_X3_Q9HWP_L?$$>E>$+S^R;'1=%\(IJ=K<+#\G^E7.\20[MIP(U/RX
M[\UZ/KWQ"^*/C?XR:CX2T+QE9?#V!/"EGKKQZAI4-S+;3$9EC DQ@9;#E]VT
M)P!S74?$#]G+PG\4?$4_B3Q#\*X+W4+P>4,:J]K<AP %EN?)F$90\@E"[@*O
M#9*IRWB?]F"[\??&'5]=\7>$-*UOPQ%HUKI]O:+J$D<TSQ/]ZW965D.S_GHX
M!/RDD'>%[:,HQ33OU=G_ "O7SUL[/TT.WV-/>+BDEWC_ #1\^UU=VTUU6W+>
M'_VDOB/\4?"?P<T+2]9L_"?B+Q=<7\-[XD>PCN$Q:$@&.%_D+2=QQ\W VYKE
M=(^+7BGX)>$_CCJT%W:Z[XJD\7V^EG5+:T!B,C(P:<0AL;L(<)G&\@<CBOH_
MQ-\#]%\:>#=)\(ZK\-],?0K,AM*A6[,0TL9.X3-'(LA8C#'RBP9B0QP!(4TK
MX)Z!HOAG6]$MOA;90^'=5,2:KH\=ZKM=R(H598-T@157:I!)C<DLQ 8?/3KT
M_>M%Z^3U7-%_+16LB51CI\-K[<T?[W6^NZ6O;L[GCGA7]H/XO>'?!GQ%O?$%
MEKEU;:7HO]H:7KGB[PNNB$7/F*AAV1NT<G#AE&[<2N,<UK>%_B1\7='F\4^+
MM2U;Q%J?@OP_X:DU!K3Q+X9M]+>\O_*8^4FU$D\M" Q=<C@C)X)U-<_9(M;#
MX>^*_#'@7PII_A35_$%JD5QJSZE/=V;0JXD\@K,[N'W#;N5 ,?.&!^2N>_9_
M_9F\;_##Q8WB/4/#6AZ78W>GS:;-X9T'4+B6&X9SA9;S[5-(I0#.1&6/(PA.
M:KVL)*36FEMNMG_FM5K=7V5V2HP6J<7=[7CM[OGIM+[^C:*7P%^/WQC\4>-?
M#5SJUIXAUKPSK<4CWDVH>$ET_3=/S&7C>"\C9C+'N&-T@'R^YX/!_P 3/BMX
MLF\3>&/%WC3^P-<U31+R\L;.7P] ULJH0PDL+F-V2ZC,6]6+D$;@5W8)KU+P
MG^S+X4\ ^+H?$>A_#.SL]:T\RL]U%JLYBN5D4HRVT+S%5)C=\K*JJ#A02#O7
M0\ ? /0/AGK5YJ?AGX:Z;I.I:JC1K=27KSK9Q,?G297D;!*XX@!4DE"0H#G.
M=:G)22B]4UMZ_P# UW_,?LXQES1<>CWCT?KIIVWVWNGX1X#\6>/OA+^Q/H?B
M71_%\-W-=WMG#I=G-IL(33XFNG26%FY,H<\EB R] 1UKK?C%X\^)WPSN-!\*
MK\3=8UOQ=-:S:E<Q>%_ EO?W#PE\*6C:152)2&7<,L<9(Z5W^E_L[^%]%\.Z
MCI-K\+X[?0[N\@N[_38-8D,US<Q$E)8&,X41*Q&%9HR06R@VA6U/B9\%-/\
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M6WBV#";8V4JNT<# X'2G>)/!/AWQE9Q6GB#0-+UVTA;='!J5G'<1H<8R%=2
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M  T-\+/^BD>$_P#P=VW_ ,71_P -#?"S_HI'A/\ \'=M_P#%T2YYMN3=WO\
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MZ?\ S[_K[C\8/L<__/"3_O@T?8Y_^>$G_?!K]JO^&AOA9_T4CPG_ .#NV_\
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MBJ"6T\$6\F8XCE'U-U/**>HC!&&8=?NCG)7]!_\ AH;X6?\ 12/"?_@[MO\
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MIRJ)64# 293Q*H]\,,8# 9KW^BNW!XS$8"LL1A9N$UU7];>0TVM4?C)\5_\
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M_9-+TZW>ZNI_[3LW\N-%+,VU9BQP > ":Y#Q]\#?'/POT#1M;\3Z!)I6F:P
M;*=IXI/,RH< JCDH=I!PX!Z^AK3FCW.Z-2$FE&2=_P!-SA**];\*_LG?%GQK
MX4A\2:/X,NKG1YHS-%,\\$+RIC.Y(W=78$="%.>V:WX_V$_CC(BNO@C*L,C_
M (FUC_\ 'Z;DHNS9/MJ7\R^\\%HKUF']E/XI7-Y86D7A??<W]G<7]K&-0M<R
MP0,BRL/WO\)D3Y>ISP#@UQWA/X8^)O'.C^(=4T33#>:?X?MQ=:G.T\<0MXSN
MP?G8%B=K?*N3QTHC)3^'4OVD;7N<O17LOBK]COXO>"?#6H>(-:\(_8M(L(3<
M7-Q_:5F_EQCJ=JS%C] ":X[X8?!GQC\9K^^LO!VC'6;FQA$]Q&+F&'8A. <R
M.H//89-)2BVTGL+VM/EY^96[WT.+HKIX/AGXFN/"6N>)ETMQHNAW266HW$DL
M:-;S.VU4,98.3GCA3COBN8IW3V+33V"BBBF,***Z?QY\/=1^'DFA)J,UK.=8
MTFVUFW^RNS;89@2BON48<8.0,CW-/I?^OZT%=7L<Q1112&%%%7+?1=1O-+O-
M2@L+J?3K-HTN;R.%FA@9R0@=P,*6*G&3S@XZ4>8%.BBB@ HJ6TM)]0NH;6UA
MDN;F9UCBAA0L\CDX"J!R220 !3]0T^[TB_N+&^M9K*]MY&BFMKB,QR1.IPRL
MI&00>"#0!7HK<\:>"=:^'OB"71/$%E_9^IQ1QRO!YJ2861%D0[D8KRK*>O&>
M>:PZ Z)]PHHHH **** "BK&FV,FJ:A:V<159;B584+DA06( S[<UW'C?X&^*
M_ C>*)+RWM[O3_#>H)I=_J%I<*8EG==R*JOMD8$=]F/6E*2C:_7_ ("_-K[R
M.>*ERMZ_\/\ Y,\_HHHIEA1110 45=UG0]2\.Z@]CJVGW6F7R*K-;7D+0R*&
M4,I*L 0"I!'J"#5*@ HHK9'@OQ"VN+HPT'4SK#1>>NG_ &.3[08_+\W>(]N[
M;Y?SYQC;STYH\POT,:BMMO!.M)X*C\7-98\/27[:6MYYJ<W(C$ACV;M_W"#G
M&.V<UB4^M@33V"BBBD 4444 %%%% !1110 4444 %>X?LO\ [4&L_L\^)MK>
M;J7A.]D']H:7NZ=O.BSP) /P8#![$>'T4FE)69$X1J1<9+0_=7P9XST;XA>&
M;#Q!X?OX]2TJ]C\R&>(_F".H8'((/(((-+XP_P"1<N_^ ?\ H:U^3/[+_P"U
M#K/[//B;:WFZEX3O9!_:&E[NG;SHL\"0#\& P>Q'ZF+XST;X@_#9/$'A^_BU
M+2;V-)(;B(]?G7((ZJP.05/(((-<%2FX,^9Q&'E0EY':4445D<85P4G_ "7>
MW_[%N3_TJCKO:X*3_DN]O_V+<G_I5'31<>IWM%%%(@**K:EJ5KH^GW5_>SI:
MV=K$TTT\APL:*"68GL  37A-Y^U%J=GH-EXRD^']W#\.+N[AMXM:N-1CCO'C
ME<1I<+9["3&S,N,R!BI#;<4XIR?*O+\=OOZ%J$FN9'O]%>.^-_V@+WP_\5I/
MA]X?\'7?BS7O[*CU*-;>[2"-2TC*1,[KMB0*H)<DDEU4(<YIGAW]HR/5/A!X
MT\9:GX?DT;4?"4U[9ZEH[7:R@7-N,F-)PN&#$J-P7J3P<<GV7/IO]SM^9?L9
MW2MO9?>KK[SV6BO$=%_:0NW\%W7CCQ)X,NO#'@A=/CNK34)KU);J]E<HJQ1V
MH4, [,=C,1N&TE5W<10?M#>)M%\0>&8/&OPTNO"6A>([Y--L-3;5H;J1+B0$
MPI/ J@Q%@#T9L'@U?LY<W+U_7MZ^6Y/)*W-_7?\ #J>RW&NZ;9ZM9Z7/J%K!
MJ=XKO;64DZK-.J %RB$Y8*",D#C(S2:7KVF:XUXNFZC::@UG<-:70M9UE,$R
MXW1/M)VN,C*GD9%>+"[BUK]KK6K^9LV/@WPDD3D](Y[F4R,?KY40KE?@C\2(
M/AK\!M#UNYTRZUCQ3X\UJ\O[#1;+;Y][//.[+\S$!$6-59G;A1^ *C&\;_U=
MR:2^:39<J5M%OI]SCS-_+3[SZBI&8(I9B%4#))X KRCP;\;KZ\\;:OX2\9^&
MH_"&L:?I2ZV'AU-;ZV>SW%&<R!$*,K Y4KT!(->9_$3]J'Q+=?"7Q'XKTKX<
M:E'X(N;&XAT[Q))?Q+.6=3'#<-9D;UB,A7#;LXPVW%1)22;2O_5OS5OO'3HR
MG-1>FJ7W_GIKH?2^CZUI_B+38-1TJ_M=3T^X&Z&[LYEFBD )!*NI(/((X/:K
MM<9\&?"H\$?"7P?H6S8]CI5O%(O_ $T\L%S_ -]%J[.M*D5";BNC.6+YDFC%
M\,_\Q7_K_E_I6U6+X9_YBO\ U_R_TK:K,H**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#%U3_D8]#_[;_P#H K:K%U3_ )&/0_\ MO\ ^@"MJ@#E
M?%'Q7\$>!]6M]+\1^,?#^@:G<(LD-GJFJ06TTJEBH94=P2"P(! Z@BM6'Q/I
MD_B>Z\/)<[M8M;2*_FMO+;Y8)7D2-]V-IRT,@P#D;>0,C/RO=?$*W^%/A/XE
MV>HZ[X3\,?$2;5]4U&]LO&=CYA\1VC--]B6W7[1 94:$10J5,@4JR%-V16S\
M1-<UW1=>\::EH\<VDZHO@30#+_9]N?,L86O[M;EXH]K8:*(RL 5.-@XXI1U2
M?I^,6_PM9O[TBI*S:\[?=)1_%.Z_-GTAXG\3:;X-\/:AKFL7/V/2]/A:XN;C
MRV?RXU&2=J@L?H 36FK!E!'0\U\<>--9TV\\$_&2Q\#>+-2\8^!5\'>;)>MK
M$VN16^I%I 8X;J625BYBV,T(8A?D.T;_ )M3_A8NF>';SQY>^$?%OB+Q?X1M
MO"T=SJ<\.L27C66I&X*@+/,7%FYC:1I455$*QA]B8%/_ "?X7W];:=[KOI/_
M  /QY=O_  +7T?;7Z?\ $GB?3/"&EC4=7N?LEGY\%KYGEL_[R:5(8EPH)YDD
M1<XP,Y. ":U:^(]!\:77B+PG\1-,75;;5=#T_P 2>%);!K+Q/<^([=#+?V_F
MB*_N4621=T8RO*HV\ ]17OG[1&OQZ*O@N'5];N?#7@N]U@PZ]J]K?R:>88A;
MRM"CW495H$>=8E+ATR=J[L.06U97\[?>HO\ 4(^\F_7\#V"BOEWQ%XJ\)_\
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M&:7*WI_6OY[K[Q<DOZ_K\3T+2='L- TV#3],LK?3K"W79#:VD2Q11KG.%50
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MRH)&/8TM20?&W_!3[_DD?A7_ +#@_P#2>6OS8K])_P#@I]_R2/PK_P!AP?\
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MZC'>^(=5O(]26%;U;B]E<70BQY(E!;YPF!MW9VXXQ5#4];U'6OLG]H7]U?\
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M;0M4C\0>.?$XN-5M3:2":UBN+_S)'F7&8U$4:Y+8 S7V!13C+EMY<J^ZS?\
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M^M8C_GW^#/S1_P"&=/BI_P!$X\5?^">X_P#B*/\ AG3XJ?\ 1./%7_@GN/\
MXBOTN_X;R^!W_0Z-_P""F]_^,T?\-Y? [_H=&_\ !3>__&:/:3_E#ZUB/^??
MX,_-'_AG3XJ?]$X\5?\ @GN/_B*/^&=/BI_T3CQ5_P"">X_^(K]+O^&\O@=_
MT.C?^"F]_P#C-'_#>7P._P"AT;_P4WO_ ,9H]I/^4/K6(_Y]_@S\T?\ AG3X
MJ?\ 1./%7_@GN/\ XBC_ (9T^*G_ $3CQ5_X)[C_ .(K]+O^&\O@=_T.C?\
M@IO?_C-'_#>7P._Z'1O_  4WO_QFCVD_Y0^M8C_GW^#/S1_X9T^*G_1./%7_
M ()[C_XBC_AG3XJ?]$X\5?\ @GN/_B*_2[_AO+X'?]#HW_@IO?\ XS1_PWE\
M#O\ H=&_\%-[_P#&:/:3_E#ZUB/^??X,_-'_ (9T^*G_ $3CQ5_X)[C_ .(H
M_P"&=/BI_P!$X\5?^">X_P#B*_2[_AO+X'?]#HW_ (*;W_XS1_PWE\#O^AT;
M_P %-[_\9H]I/^4/K6(_Y]_@S\T?^&=/BI_T3CQ5_P"">X_^(H_X9T^*G_1.
M/%7_ ()[C_XBOTN_X;R^!W_0Z-_X*;W_ .,T?\-Y? [_ *'1O_!3>_\ QFCV
MD_Y0^M8C_GW^#/S1_P"&=/BI_P!$X\5?^">X_P#B*/\ AG3XJ?\ 1./%7_@G
MN/\ XBOTN_X;R^!W_0Z-_P""F]_^,T?\-Y? [_H=&_\ !3>__&:/:3_E#ZUB
M/^??X,_-"3]G?XI11L[_  Z\4HBC+,VCW   [_<HC_9W^*4L:NGPZ\4NC#*L
MNCW!!![_ '*_275/V[/@C<:;=Q1^,F:22%U4?V5>C)*D#_EC1I?[=GP1M]-M
M(I/&3+)'"BL/[*O3@A0#_P L:/:3_E#ZUB/^??X,_-O_ (9T^*G_ $3CQ5_X
M)[C_ .(H_P"&=/BI_P!$X\5?^">X_P#B*_2[_AO+X'?]#HW_ (*;W_XS1_PW
ME\#O^AT;_P %-[_\9H]I/^4/K6(_Y]_@S\T?^&=/BI_T3CQ5_P"">X_^(H_X
M9T^*G_1./%7_ ()[C_XBOTN_X;R^!W_0Z-_X*;W_ .,T?\-Y? [_ *'1O_!3
M>_\ QFCVD_Y0^M8C_GW^#/S1_P"&=/BI_P!$X\5?^">X_P#B*/\ AG3XJ?\
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MO_QFCVD_Y0^M8C_GW^#/S1_X9T^*G_1./%7_ ()[C_XBC_AG3XJ?]$X\5?\
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M:?-_?W%%%%0<P4444 8OAG_F*_\ 7_+_ $K:K%\,_P#,5_Z_Y?Z5M4 %%%%
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M^S*T1B(R6._Y"1\^[UZ\UU%%/R_K^M7]X!1112 **** "BBB@ HHHH ****
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M=\5Z_P#'WXD>!(?@OX(^%G@+6+KQ38Z+=3:A=ZW<6CVHDE??\B1N P&9'Z]
M%Y/-;WP)\6VNC_"ZQNM65O\ A*/"=S=WWA*'9YIE-W;O'M<*#Y4:3HDV^7:O
M/#5JZB@I3ELG]ZMLO.^J\KZ&D?;N"<8W;;^5V^6]MELGVN>/:5^SOX_UIS';
M:+#YS7-S9P03ZE:PRWDMN2)EMD>4-<A"""80XR,9S2^'?V=O'_BC0='UFQT:
MW73-8G-KI]Q>:I:6HNIP[1^2@EE4F0LC )C<<$@$<U[MH_B6[U#P7\/Y-/\
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MIIPN"(E.XD*Y!QCOD"(M\EWO[OXI7^YZ6^?1E3G/GDHK2_;S2^>FNA\_^-?
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M!!K@J4W!GS.(P\J$O([2BBBLCC"N"D_Y+O;_ /8MR?\ I5'7>UP4G_)=[?\
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M+JG_ ",>A_\ ;?\ ] %;5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M/PW\,Z7J7C'Q5JFF7GB:'PWX4T.6VTO4=3NY(Y;B[ C#R2>9YOEQ\L(T=1T
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MJ0Z5!_;6K:N\#$J\AC1+8R3M<%-I,I(A '$>37:>.?A#X ^%^B_%O5'\,?\
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MHHH Q?#/_,5_Z_Y?Z5M5B^&?^8K_ -?\O]*VJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q=4_P"1CT/_ +;_ /H K:K%U3_D8]#_ .V__H K
M:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_7_ /D$S_\  ?\
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MTZ%I;/S _E&XC=;C!( ,8D\L\Y3DBD_X>H2?]$R7_P 'I_\ D:C_ (>H2?\
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M:INFMAB DAP5VC^[C/?-=[_P]0D_Z)DO_@]/_P C4?\ #U"3_HF2_P#@]/\
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M9IH^U)N5L8#X3E1]P+TJUJ?[/O[4NL:)_9EYHMK.GV(::;QIM*%^UJ/^6!O
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M!7QP_P"A/C_\&MG_ /':_6^BCV\@_M"KV7]?,_)#_A@KXX?]"?'_ .#6S_\
MCM'_  P5\</^A/C_ /!K9_\ QVOUOHH]O(/[0J]E_7S/R.D_8-^.*8QX+63_
M '=6LN/SFK[2_9!_8^M/@AI\?B/Q+%#>^.;F/'!#QZ<A',<9Z%R.&<?0<9+?
M3]%3*K*2L8U<95JQY7HO(*Q?&'_(N7?_  #_ -#6MJL7QA_R+EW_ , _]#6L
M3A-JBBB@ K@I/^2[V_\ V+<G_I5'7>UP4G_)=[?_ +%N3_TJCIHN/4[VBBBD
M0%%%% !1110 4444 %%%% !1110 4444 8OAG_F*_P#7_+_2MJL7PS_S%?\
MK_E_I6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+JG_ ",>
MA_\ ;?\ ] %;58NJ?\C'H?\ VW_] %;5 !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=4_Y&/0_P#MO_Z
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MA5A GD A.8AO/[LYSE?3GTJ9*K*/*[6LUUV<5%_A%+\?(4:.%C:U]+=NEO\
M*_X=;GU1X?\ B3%8^'_"^A7NB:K'8KX,U+POJ]U"UL6M&N'\Y90K3 #;\GR3
M-$3D@<CFCJ&N:-:Z)\/M%T0>/-'C\)0ZI&-:L3:PZDT]PT;">"W2?,L.[>K*
ML@&QA^];!KYE-Y<,LRF>0B8YE&\_.<YRWKSZTY=0NEECE%S,)(UV(XD.47T!
MSP*2C64N:ZOKWZMO\Y/\_)2L/A4E%<UOEVM\]/\ +NWZA^TIXHM/%WCJROK7
M3EMI1IT45YJ!AM8)=4N@SF:ZEBMF:*-V<D%0S'"@D\\>3T;B>"<BONG]BO\
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M** "BBB@ HHHH **** "L7QA_P BY=_\ _\ 0UK:K%\8?\BY=_\  /\ T-:
M-JJ>L1ZA-IMPFEW-M9Z@RXAGO+=KB)&SU:-70L/8.OUJY10!P?\ 8_Q.Q_R-
MWA+/_8K77_RQJ3PWX,\0V_C1_$?B'7=,U.8:>VGQ0Z9I4EFJJ9%D+,7N)MQR
MN.,=:[BBG<OG84444B HHHH **** "BBB@ HHHH **** "BBB@#%\,_\Q7_K
M_E_I6U6+X9_YBO\ U_R_TK:H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#%U3_ )&/0_\ MO\ ^@"MJL75/^1CT/\ [;_^@"MJ@ HHHH ****
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M?\^%QTS]Z/TSC[_X?_6YH MUBZ7_ ,C'KG_;#_T U>-[-_T#[@]?XH_3_?\
M\XK'TV\E7Q#KA%C<,?W/ ://"_[_ '_I0!TE%5&O)ANQ87!QTPT?/./[_P"-
M'VR;=C[!<8]=T?KC^_\ C]/?B@"W151;V8[<V%P,]<M'QS_O_C^-(+Z8X_XE
M]P,D?Q1\?^/]OZT 7**J?;9O^?"X'3^*/TS_ '_P_&C[;-_SX7'3/WH_3./O
M_A]?;F@"W15/[=-Q_P 2^X[_ ,4?IG^_^%!O9AG_ (E]P>O\4?\ \7W_ *4
M7**J->S+NQ87#8SC#1\\_P"__G%'VR;)'V"X/ONCYYQ_?_'_ .OQ0!;HJH+R
M;('V"X'ONCXYQ_?_ !_^OQ2+?3-MSI]PN2,Y:/CG_?\ \YH N453%[-_T#[@
M=/XH_P#XOM_6C[;-S_Q+[CI_>C],_P!_\/\ .: +E%5/MLW_ #X7'3/WH_3.
M/O\ X?7VYI#>S?\ 0/N#U_BC]/\ ?_#\* +E8OC#_D7+O_@'_H:U>-],,_\
M$ON#@G^*/GI_M]_Z5D>+[N5O#]X#93J/E^8M'C_6+_M4 ='153[9-NQ]@N/K
MNC]<?W_Q^GOQ0MY,=O\ H%P,]<M'QSC^_P#C0!;HJF+Z8X_XE]P,D?Q1\=?]
MOM_6C[=-_P! ^X'3^*/T_P!_\/QH N454^VS?\^%QTS]Z/TSC[_X?_6YI/ML
MW_0/N.G]Z/TS_?\ P_SF@"Y150WLW/\ H%P>O\4?_P 7W_I2-?3+NQI]PV"<
M8:/GG_?_ ,XH N454-Y-DC[!<'WW1\\X_O\ X_YQ0+R;('V"X'ONCXYQ_?\
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MM'QSW^?_ #F@"W15,7LQQ_Q+[@=/XH__ (OM_6C[;-_T#[CM_%'Z9_O_ (4
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M7P._Z'1O_!3>_P#QFCDEV#V%7^1_<>_T5X!_PWE\#O\ H=&_\%-[_P#&:/\
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M %_R_P!*VJQ?#/\ S%?^O^7^E;5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8NJ?\C'H?_;?_ - %;58NJ?\ (QZ'_P!M_P#T 5M4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &?K_\ R"9_^ _^A"M"L_7_ /D$
MS_\  ?\ T(5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\;?
M\%/O^21^%?\ L.#_ -)Y:_-BOTG_ ."GW_)(_"O_ &'!_P"D\M?FP.3CI7?1
M^$^EP'\$^VM7^">@_&;Q7^S_ .*_#N@Z=I>A^(H5AURTTVTCBMEFM<RSAD0
M9<+*F3_<%3:Q^QK9_&[Q#?>,=.U>V\&:-KVH30:#I>B^')+JU^SP_NTEE> K
M';B3RR^6&/FZDG%<9\'OVFK7X0?![6_!4=W%J<VZY:UU3)233Y)H=F;:(J?/
M&\L<L\74G'-;'PU_:JTCPC\--&\$:WYVN-I9D.F7NE>(K[0U^SELJER]OSO
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MG>893L\K8-N/-Z[CTZ<UVOA7]JC1;7X9^'/"GC#X9Z;XWN/#?G#1[^\O6B6
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M110 4444 %%%% !1110 4444 8NJ?\C'H?\ VW_] %;58NJ?\C'H?_;?_P!
M%;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GZ_P#\@F?_ (#_
M .A"M"L_7_\ D$S_ / ?_0A6A0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'QM_P %/O\ DD?A7_L.#_TGEK\V*_2?_@I]_P DC\*_]AP?^D\M
M?FQ7?1^ ^EP'\$]PTG]C[QSK>J>"[*SGTF7_ (2G23K<-QY\HBLK4*K%KEC'
M\A^=1\N[DU2^$7[+7BCXV:UXFL/#6J:&\.A2B&74+BXE2VN69F5?)81$MNV$
MC(7C'K7VM;ZKIOB7X/> ?A5/?'0M8\:> H(M-U:/@F6*-";=S_=<,>!U 8=2
M*\\\*:AX:_8_^#G@S2?'R^)+#Q)JNMR:[/!X<%N[DVT@1(IS*P_=$;3A>2=W
M([MR]^4;Z7:7G[[7_DJ7S:OLT8K$U90M'XWT\K7O\WIY'@/PU_8_\0_%#2I+
MG3_&7@K3]0MUGDO-%U'572_L5AE,;M/"L3&-00#DG&&7UJ+0_P!D7Q)XDUG7
M8-.\5^#;K0]%ACEO?%*:N3I,;.,B/S]F2X'7Y<#C)Y&?J72_ L'A']JGXJZE
MIX4Z/XE\!W>MVCQCY2)7A\S'U=6;Z,*XG]CV2Z\0?LR^+?#_ (<\/>'/&7BB
M'Q EXV@>(PCP20-'"HE9&8 [2CD$GJI[X%3S2EKM[J=O-S<6OE:__ -)UY).
M<7HVK>C2:_R/DSQ-\-I_"OQ&'@^YUW0KF4SP0_VQ:WOF:<!*J,LAFVC" ."Q
MQQ@UE>,_#/\ PAOB>_T7^UM+US[(X3^T-%N?M%I-E0<QR8&X<XZ=0:^BOC1H
M_A#0?VV/#%EX.M[&SLHM5TH7EKIH MH;OST\Q$"_* !MR!P#N'!S7T7\2/B#
MJWPM\+_M$>)]!-O'K-EXFT\6TUQ"LHB9[:SC+A6XW!7;&:F-6\8OO?\ .*_6
MYK*O*,HQ2W2\M[GP]\(_@I_PM3PE\0];_MG^S/\ A$=).J>1]E\[[7A7/E[M
MZ[/N=<-UZ5S'P_\  O\ PL#5KJP_X2'0O#?D6LEU]I\07OV6&3:1^[1MIS(<
M\+WP:_2;Q%KC^#O&_P 6O%>FVMFFJ_\ "N['5WWP@QS7*F[P[K_%]Q!SV44S
MP1K$WC+Q)\+/%VJ+!+X@UGX>:F]_>1PK&TY5[,C(4 8!=R!T&XXI3JRBF[='
M]ZYO_D3FAC'*[MH[6^Z+M^)\!_%7X*?\*R\!_#GQ)_;/]I?\)A827WV7[+Y7
MV3;Y?R[M[;\^9UPO3IS6/IGPGO\ 7/#OAS4-+UG0M2U+7M3&E6OAZ#4%&I)*
MS%4:6)@ D;$ !RV/F7IFOT;^$<GCG_A7OP$'AEM+_P"$8720?$_VLQ>:+4QC
M9C=\VW(?[O\ $%SQFN,MO&UOX+\%_#J_\(7]OI^AW?Q6NK)9HEC,)L9;BY5U
M7<" A0\$8P,8(K>$N:K[-][?^3)?KOKZ$QQ=3V::5W_P)/MTY=O-:GYY>)/#
MNH>$?$&HZ)JUO]DU33[A[6Z@WJ_ER(Q5EW*2IP0>02*SJ_42\@^(:^,?B\]I
M-I4_Q6\F,^#A=?9?-31S<2[1'P%S]_/F<YV;^,58L=42Q^+D5SJ:Z3<?$:S^
M&UW+XD6U57C-PLMLR+(%X/(DX]".V*R5:R3EV;^Z+E^EGV>FIUO$^\XQCUMO
MZ:[;._NOJM;(_,+P_H=UXFU[3='L4$E[J%S':P*> 9'8*H_,BO?KK]C#4;SQ
MYXW\/:+XUT$V?@Z*V;5=7U\OI\"-*A8A2HE&U=I!9BO/:L/X1_$:_P#B5^UE
MX+\4>,+B*\U"\UFS$TPA2-2Z[8XCM4  @JG;J,U]'>"[FU\.^(/VN[GQ/H[:
M]80SK-<Z8UTUO]IA,ERRIYJ?,@*E<$=*TJ2<*3F]&HR?W<OX:O\  *M2<9-1
M_N?^32:=O2WXG@T?[#?CYO'"^&Y-4\-PK)I#ZW!K+WTAT^>V1T5RL@B+9'F(
M>5 P<YKRGXG?#?\ X5EK5MIW_"4>&_%GGVXN/M?AC4/MD$>69=C/M7#_ "YQ
MCH1ZU]D_L]_M K\9OBEKC/X9M]$\*^'/ 5Y9V6@V]RS 0B2WWJ9MH.65%7(
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M5SY:A68G;G Z9XK8\=?LX^+/ GQ<TOX<S/8ZMXAU(0&W.F2220D2DA269%(
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M_P!#6MJL7QA_R+EW_P  _P#0UH VJ*** "BBB@ HHHH **** "BBB@ HHHH
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M_D>C_AV-\3/^AA\)_P#@3<__ "/7Z944_;3*^OUNY^9O_#L;XF?]##X3_P#
MFY_^1Z/^'8WQ,_Z&'PG_ .!-S_\ (]?IE11[:8?7ZW<_,W_AV-\3/^AA\)_^
M!-S_ /(]'_#L;XF?]##X3_\  FY_^1Z_3*BCVTP^OUNY^9;?\$Q_B=CY?$'A
M,GWNKH?^V]?;7[.?[.>@?L\^$!I^GA;W6[H*VI:NZ8DN''\*_P!V-<G:OXG)
M)->M45$JDI*S,:N*JUERR>@5BZ7_ ,C'KG_;#_T UM5BZ7_R,>N?]L/_ $ U
MF<AM4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XP_Y%R[_P"
M?^AK6U6+XP_Y%R[_ . ?^AK0!M4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!B^&?\ F*_]?\O]*VJQ?#/_ #%?^O\ E_I6U0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &+JG_(QZ'_VW_\ 0!6U6+JG_(QZ
M'_VW_P#0!6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%<_JGB;4=/OI;>#PGK&IQ)C;=6LMFL;Y / DN$;@G'*CD'J,&JG_"
M9:O_ -")X@_[_P"G?_)= '5T5RG_  F6K_\ 0B>(/^_^G?\ R71_PF6K_P#0
MB>(/^_\ IW_R70!U=%<I_P )EJ__ $(GB#_O_IW_ ,ET?\)EJ_\ T(GB#_O_
M *=_\ET =717*?\ "9:O_P!")X@_[_Z=_P#)='_"9:O_ -")X@_[_P"G?_)=
M '5T5RG_  F6K_\ 0B>(/^_^G?\ R71_PF6K_P#0B>(/^_\ IW_R70!U=%<I
M_P )EJ__ $(GB#_O_IW_ ,ET?\)EJ_\ T(GB#_O_ *=_\ET =717*?\ "9:O
M_P!")X@_[_Z=_P#)='_"9:O_ -")X@_[_P"G?_)= '5T5RG_  F6K_\ 0B>(
M/^_^G?\ R71_PF6K_P#0B>(/^_\ IW_R70!U=%<I_P )EJ__ $(GB#_O_IW_
M ,ET?\)EJ_\ T(GB#_O_ *=_\ET ;>O_ /()G_X#_P"A"M"N/N_$>KZI;O;?
M\(7K=MYF/WLT]AM&#GG;<D]NPJ7_ (3+5_\ H1/$'_?_ $[_ .2Z .KHKE/^
M$RU?_H1/$'_?_3O_ )+H_P"$RU?_ *$3Q!_W_P!._P#DN@#JZ*Y3_A,M7_Z$
M3Q!_W_T[_P"2Z/\ A,M7_P"A$\0?]_\ 3O\ Y+H ZNBN4_X3+5_^A$\0?]_]
M._\ DNC_ (3+5_\ H1/$'_?_ $[_ .2Z .KHKE/^$RU?_H1/$'_?_3O_ )+H
M_P"$RU?_ *$3Q!_W_P!._P#DN@#JZ*Y3_A,M7_Z$3Q!_W_T[_P"2Z/\ A,M7
M_P"A$\0?]_\ 3O\ Y+H ZNBN4_X3+5_^A$\0?]_]._\ DNC_ (3+5_\ H1/$
M'_?_ $[_ .2Z .KHKE/^$RU?_H1/$'_?_3O_ )+H_P"$RU?_ *$3Q!_W_P!.
M_P#DN@#JZ*Y3_A,M7_Z$3Q!_W_T[_P"2Z/\ A,M7_P"A$\0?]_\ 3O\ Y+H
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MB>(/^_\ IW_R71_PF6K_ /0B>(/^_P#IW_R70!U=%<I_PF6K_P#0B>(/^_\
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MRU?_ *$3Q!_W_P!._P#DNJ>L:]K.M:=+9IX+UNV:3&))I[#8,$'G;<D]NPH
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M_P#DN@#JZ*Y3_A,M7_Z$3Q!_W_T[_P"2Z/\ A,M7_P"A$\0?]_\ 3O\ Y+H
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M*Y3_ (3+5_\ H1/$'_?_ $[_ .2Z/^$RU?\ Z$3Q!_W_ -._^2Z .KHKE/\
MA,M7_P"A$\0?]_\ 3O\ Y+H_X3+5_P#H1/$'_?\ T[_Y+H ZNBN4_P"$RU?_
M *$3Q!_W_P!._P#DNC_A,M7_ .A$\0?]_P#3O_DN@#JZ*Y3_ (3+5_\ H1/$
M'_?_ $[_ .2Z/^$RU?\ Z$3Q!_W_ -._^2Z .KHKE/\ A,M7_P"A$\0?]_\
M3O\ Y+H_X3+5_P#H1/$'_?\ T[_Y+H ZNBN4_P"$RU?_ *$3Q!_W_P!._P#D
MNC_A,M7_ .A$\0?]_P#3O_DN@#JZ*Y3_ (3+5_\ H1/$'_?_ $[_ .2Z/^$R
MU?\ Z$3Q!_W_ -._^2Z .KHKE/\ A,M7_P"A$\0?]_\ 3O\ Y+H_X3+5_P#H
M1/$'_?\ T[_Y+H ZNBN4_P"$RU?_ *$3Q!_W_P!._P#DNNEM)GN+6&62"2UD
;D16:"8J7C)&2K%25R.AP2..": )J*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit101-iansconsultin001.jpg
<TEXT>
begin 644 exhibit101-iansconsultin001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BFCWO"<D;'W<?[I']:EJ
M*7?OBV]-_P WS8XVG\^<?Y% $M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5FTA.GW&GBT $XWJP*')&.GR_K3?BMX3UGQ?::1:Z5! PM+Q;F1YIM@P 1M
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M^%M8\&:'/I&K6\8=I#,)HI R'/&WUSQ0!M_$3Q'=>%_!E]J-I9RW$HC*AXV
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M%% !1110 4444 %%%% !1110 4444 %%%% !5*__ ./BP_Z^#_Z+>KM4K_\
MX^+#_KX/_HMZ +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45QOB'Q+K_A[1)M3GL+ K]LC@BB\QMQ1Y @9CC&><X%1>+_
M !%XBT&WB=+:S$,EU:Q+<*2W$DNQUP>^""#TY- ';T51BU.TU*WNO[+U"TN)
M8=T;-'*L@BD Z-@\8/:LGPYJ9LO!%C?Z_KVGW+"(&?44F00.2V,A^%ZD+]:
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M?%A_U\'_ -%O5VJ=Z 9[')QB<XXZ_NWH N4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '"?%NXAA\%JDDJ([WUJ55F +!9D+
M8^@&32_%*6,^&=- =29=7LO+ /W_ -ZIX]> 379W-C:7FW[5:P3[00OFQAL9
MZXSZTZ2UMY5C62")Q$0T89 =A'0CT- '!1Q6Z?%+Q- %B2VDT.%IT&%1FW2
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M** "BBB@ HHHH **** "BBB@ HHHH **** "J5__ ,?%A_U\'_T6]7:I7_\
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MJ.XQC&2,$]*Q%\.ZJVM>%WET^86UOHT]E=.KQDPO($ &-W.,'IFHO!NG^+]
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M4D$HYWL3A6!.,'D\D59T/0=2T;QYI$D]M-+:1>'4TUKM2'3SU?>0><@84X)
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M2W.Z[5W:5U^[&JJP('!);G''%,_X2G4-1N=+TO2HK5-2N],74IGN0S10QG
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M^;Y2 /?M46G^-II/$T.AZC8P6UQ=69O(5CN-[1H.=LRE1L;!'3<.O/'(!V
M4    < "F3PK<6\L#E@LB%"5;! (QP1T->62_%G4X_"-QKPT6TEWZE]@L8([
MH[I"#M;.5&<GD;<]><8R=[Q!X[O]+\2'0[#28+F[&G?;D2>Z,33')!BC 0[F
M^7IQ0!V-C96VFV4-G9PK#;0KLCC7HH]*EFFBMXFEFE2.->KNP 'XFN1U3QP+
M'X@V7AJ*&%H?LLEY?W+R8^S1JK$9'09.SDGOT[CC_$?CUO%'PP)CLX[=];U
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M":C P_L<:9)YL18QX7&8N1M!."P.<X%0+\/KQ8/!,)U"!E\.N&D;RR#, H4
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MS*0X.\YY?YSSWJV/ =U-K=E?WE_!/-971FBO_( NWC.<0LW]T;B![8XKN:*
M,W7+.]OK!8K&2W5_,!=+F/?'*F""C#T.<_A7(?\ "N)H-'"Z9J2Z9J4-^]_9
MFVC_ '%LS(4,:H?X"#S^/2O0:* .+O\ PAJVJ:+(;S5X6UMYK>83I 1"GDMN
M5 A)XR6R>OS'T '61+=I8*LDD4MV(^7VE$9\>G) S5BB@#BHO!-W)X=FT^YU
M"..[74FU*TN[>,CR93(7'RDX(Y(P<C!JT_AO4;Z]FU349K-]16Q>SM1$K"--
M_P!YCGG)X'L,]<UU=% '#2>!KUOAUI'AP7T O--D@D2<H=C-$VX9'7!Q6@OA
MS43XN37);FU<C3?LKH$8;I.I;V7/;K74T4 8OA32+G0O#=KIEV]N\D&X;K=2
MJ8+$\ \CK6)?^#M1O-1\5W2W=K&-:M(K:(;"3'Y88!F]<AC7:T4 <DGAC45\
M3:!JS7-KLTZQ>TFC"MEBVW+*3_NCK5SQ?X>G\16%@EK=1V]S8ZA!?1-(A96:
M-L[2!S@Y-=#10!R4OA:_D\4:GJS7ENT=WI8LE7800_\ >/MR>*Q;'X?:YI.D
M:$VFZ[#!K&E0/:F1HF:"XA8@A73(Z8R/>O1Z* *6E6=Q8V9CN[V2\N'=I))6
M&!DGHJ\[5'0#-<I/X*U"_P!7M+R\O+99K.\,\-_;HR77E%B3"QZ%2#M.>W:N
MXHH \M\5:%J&E^'_ !E=W5S:!=;EA1&BM]QA4_NR9"V<J 0>G'S&JVC65^&G
MT6SU30-5&H63VLUS9EV>&-4*H7.YA@;CA<C.>.E>MT4 <18>#=5LM/\ !UH-
M0MF30B?/ 0@3C8T8QZ$!B?K5-OAYJ.RWQJML\MMK*:FD\EN?,GV[@%E?.20&
M(!] *]#HH Y*#PG>1:WXEF-^AT_6DY0H3+&WE[.#TQU(_"J.D>"-4L[CPT]Y
MJ-K*FAPO;QK%$P+IY81223UXR:[NB@#@M"^'DMMX(U?PWJ]W#/'?W,EP)85(
M,98A@>>ZL 1]*U] T?Q);722Z_KT=ZMNK) EM$8A)G W2\G<P XQ@#)-=-10
M!P'C:VGN/'?@_P"R3PQW$<LT@$W*L HXQ^7(YHO/A_?7%LLQU.&YOY-274+I
M;N(M!(0,! H.<*,!<YZ#-=S+9VT\\<\MM#)+%_JY'0%DYSP>W0?E4U 'F'BC
MP]-I.A>)(Y;^+9XAU.$I*T)V6Q8H"9#G 4!/O9'..Y%&BZ7<7]Q?:-J%QI&J
MVVK6K+=7FFJQ>/8 %\QW9LC# *N?<<9KT^B@#E/#^@>)=/N(DU;Q+]LLK4;(
M(HK<1M*.QE;DD@=A@'OFIO$?AB75=9T;7+&Y2#4M*D9HO,7*2(XVNK>GRDX(
MKI:* ./U#PE>WNDZX/.LO[4UA%BFF\ME2.-5VJHP<MC).3CJ:Z328;NVTFV@
MOGA>YCC".T((4XX!&>>F*N44 >?2^!=5?1_%^D)?VHM-;N9KB%FC;?&TNTMN
MP>@P0*M6'@W4K3Q/H>JO=6C1Z9I/]G>6%;,AP/F]AD"NWHH X2S\':Q:^';;
M2Y)M+N8UO9I[B">$M#<1/N.QACJ&;.>?NBMWPAH#^&M!&G-(C*)I9$CBW>7"
MK,2$7<<X -;U% '-:)X>NH-5U34M9:TNKB\D7844D11J,*@W#H.3GN37/IX;
MU'PMHWC!S<68TR^26XMX(4(:W=EP1EN"#U/H:]%HH \H\/+?Z%=:(//T?5Y7
MC6T46LKRSQ1;1D@EB H(R<8%=#H/@:YT[X=R^&+K40L[,[)>VFY'5B^]7ZYW
M!O?M786]I;6@86UO%"&)+>6@7))).<>Y)^I-34 <DGAW7=6T>[T_Q+J\$RSV
MK6_^@PF/EL?O#DGYACC'3)JI;^&/%TMD+?5?$T=RL%O)%"(HFB\]V4J'F(/.
MT$<#@GDYXKN** //X_ VJK+X,D:\LRWAY3&_RM^^78$R/0XR?K4\_@2YU&'Q
M+;W][$D>J72W=K+;J?,MY$QL)SP<;5)_$5W-% '!77A+Q1KGAK4;#7=<MY;J
M:U>T@-O&T<1#  R2*#\S<<#H,G YJQ9^#]1M=:\+WINK5H]'LI+65<-F0N%!
M*^F-HZ^IKM:* ,#PSI>I:3_:-M=R6S69O9YK01*0VR61I3N]P7*X'IFL&RL/
M^$>^+.JWUPOEVFO00K!+@D&:,$%6/1201C/7H.>*[VFLBN,.H8 @X(SR#D'\
MZ '5PB^!M2T;Q?J>O^'-2MHO[4^:ZMKR$LN_KN5E.>O;WKNZ* .,\1^#M1\1
M^'H+:YU.)K^*^AO=_EL(LH?N!<G P3SWI5\&WK7FM:S<:A'+K5_:&UMF:,F&
MS3'W5'4@G!)X)Q7944 >9'X97<%EX)L+>XM_LNB3-->J0P6>0@8<#KG.[_OJ
MK<OP_P!3U/7=&U+5-3@,^E7;SQW<"L)Y8RQ80L>FW!(/MQ7H5% 'E5U\/?$-
MQ/X\G-U:&36T\NU)R&9 A 4D8VCG'?/>KG_"N+PGP/&ES;PVWA_=)-"FXK))
ME<$9)ST;K[^M>DT4 >:7/P_U:YT;QY;FY@%SKUR9+5^XC'*JQ_,8[?C5ZU\$
M7R?$'3->FDLA9V.D+9Q6R1?)#+T)B7H@QQQVXKO:* /*KKX8ZB_@>WT=)K*2
M^N-86_U&4J561=S$XP<G&5Q[#%=''X4U!OBK)XGN;BWEL([!;6SA*X>$GEL8
M]P>O9\=J[*B@ KB(--;6?B;<>($8M!IEDUA!N7"F8MER#W ''U)]*[>D5508
M50HR3@#')Y- &;X>35X]#MEUV6*34@#YS0C"DY.,?ABM.BB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG?#,]C
MSTG/_HMZN56NVVS6@RPS,1PV,_(W7UH LT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !56\C9YK,KT28L?IY;C^M6JJW>WSK/<2#YQVX/4['
M_IF@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <3J.J7VE_%'2=.FU*;^R]5LIUBA/E@)<(5.<XSC:< 9ZFLKP;XRE.D^+
M!JNJOJ-UHMS+AU55\R$9V,FU<')!'?I[UM?$G29[_P ,B_T]0-5TN5;NS<#D
M,.&7CD@@\CV'I6/)X/OHO%6@K:$Q6,FFK#J)&"1Y+JZC).3N+;3P>!0!H:C-
MJUKI'AEY=<FM;FZG@2[=VA .4+.N"F.2,<>M/\6:Q=6_B+PO:Z=JICBO[\PW
M"121$E C'@$$]0.1T]LBI/'82YDT>VDTJ^U"W2]2:X2WM3* @!&3V(R1D<DC
M.!6/XHTC3XM<\+WFC^'IXGM;]+F>2STPKMA*-D,0H.<[?EZ]<B@!XUZ\M?BW
M?:+?Z\\&DQZ6MP@F:)!YA=!]XJ.Q/%/\1:GJ^G^ ?$6MV.NR2I!.TUC,(TSY
M:[49#\N"N\.0V.A'-9<T0N?BU>:S?>&M1O-'ETQ;96ETUG'F;T.=C#/ !YQ5
MKQ)+>:E\/_$&EZ?X9OK>V?$%A;"V97E).]VVC[B9.T?0\\X !JW.K7MMXU\/
M6=EK7VN*[\Q;ZR8(YC C+!\J,I\P YX/2JUSKUU!\7IM'N]<:TTH:3]I6-VC
M0>;YBK]YEST)XS5:;2[GP[XEM/%^@Z9<S6^HJMMJMA';E) !G$H0@'(;).>H
M^M5KH&7XL3:Y<>'=3O-*;2/LREM.=OWHD5@-K#/13S[T =WX=FDN8[^X&JC4
M;22Z;[+( /D15567( !PZOSWS7*:-XHU"X^)]U%.S#1+Z)X-/+-\K20-AV4X
MQ\V6Q@G./:B[U76!H&HVVC>';S2[,NEM:!+1O.!?YI90@X55!X]2#]*J>)_"
M!TOPUI=[HLFM7E[I,T,]C:,SN&VX!0C'R@KD$GZ4 ;/B[Q-)H/BS0H+V\EL-
M$NED6:[5!L$O 17<@A%YZ^N,\9K:\.#4@=2:]O1>VKW.^PF!0Y@*+CE>OS;N
MM9]]J,^HPP?;O#EU<Z)>6P^TP2PAI8)-^ &BY+>ORYQMS[USNAMJG@G2/$FI
MQ:1=2Z']I673M, V31)G$AP?NIC# 'G@\#- 'I4\RV]O+,RNRQH7(12S$ 9X
M ZGVKS.;QE/XC\-^'M2L7O[8S:_;I*/(>%6@:X*A=S !_E"@[2>^>XKTBPO(
M]1T^WO80PCGC610PP0",\UY/;66LP?#_ ,*Z;)I.H+<Z7KT#72QQ%\QQ3,S,
M-N=R@8^O;- 'H&F>,=*U.UU*Y NK9-.D*7 NH&C88[A>I![>M3:%XHL-?EN(
M8(KRVG@PWDWMNT$CQG[LBJV"4)! ..H-<3K>B:OK6O\ BTV=G,OFVU@]H\Z,
ML<[PL7:,$D!<\#/;.>U;OA>6?4]:-_-X4N-(FAMO(GN+P@O(<YV1X8Y0')R?
M; H F\2ZQJ9\2Z1X;TF1;::\5[BXN6 )2!" P0'C<2P'/2M*YL-5BU'2I+34
MIY+9)R+R*4)\\?EO@YV@YW[.E97B73-3A\6:1XFTVU^V"SAEM[FV# .8GP2R
M9(RP*CCOSWK4@UB[U4I'::5>6T;'$TU['Y6Q=N?E4G<QS@<<=3GH" 1R^,]'
MAU5+&22X578QB\-L_P!F\S./+\[&S<>>,]B.O%0ZIX\T+1[C4X+J6X+Z:L+7
M0BMWDV"3)!^4= !DGH,CG/%<E8:1JEO\.9?!ESIUQ-J2R-"MPT3>3("^X3&3
MD#@Y()SGUI;_ $Z^:?QY$FGWK&]L+:&W9;5MLSQQLK!3CGDCGOVX&: .OL_'
M.@7_ (B31+:\,ES+#Y\,@C;RIEQD[)/NMP0>"1^M5KOXD>&;.!YY+UVBBNC:
MSM'"S>2P&2[@#(3IAL8.1C(YKF-,MM1M[OX=+)HMT%L-.$-W/]F??"_E"/:W
M'"[A_7IS3+661[GXB6$.DS:C+>:AY,<(7,;LT*##MT0<Y)...F3Q0!V6J>.]
M TF_BLIKJ269XEG;[-"TJQ0DX\V1E!54SCDGN#TI^J>--'TJYMK=Y)KF6YMG
MNH5LXC.9$7'0+DG)88QU^G->=:IX?U.TM]2LI]-NW6TT$06TUI$-ERWEDN)'
MZ_*0 JYQ]:TM LK^WU+P'/+IUZL6G^'Y(;IOL[8C<I& O3D_(W ]O44 =A#X
M\\/31:5(MW-MU1Q':'[)*0S[MNPD+A6!ZAB/7IS6K%K-G-KD^CH9C=P0K-)^
MY?8%8X'SXVY]LY_(X\ZM-&NA\'=12[@DLKVRGFO[8W"^6T<D;F6-N<8SC&?<
MUV'@VSD.FOK=T"+[6-EW*I.1&"HVH/8#^9H N:SXDTS1I4MKJ6X-Q*A<1VMM
M)/(J#JY5%8A1ZD8KF? _BBWM?AUI5_K%_<W$MU<7$<;F*2::8^?)@!%4L> .
MW QTJ>:*^T+XE7>JRV][>Z?JEK%!$T*;_L\B'&PCLIR6STR37*Z9I6N:;X)\
M,7%SX=O;V2PN+O[99K+Y<^R68D.H!RQYSC//ZT >B_\ "7Z&=,^WI>-)#YPM
MRD4$CRK*3@(8@I<-QT*YK*UWQ)I&I>%WN[?5[VRCCOHH?,CMY(YO-$B_N]CA
M3ST.1C!-8%UHL=_I=TTOAB]TRTN]1CFAELP3>1R*K$7+J,XPP VXS@Y.>E5M
M2M]=N?A[)975IJ>H7 U2$P/-:%9IH8Y(R7=5SC@-@G!.!QVH [N\\9:)8WS6
M<MS(TZ74-I($A<A))?N9.,8/3(S@\'O21^--!FU2&PCO'9YY###.()/L\D@!
M)19MOEEN#P&Z\=>*S+"T>^\4^+%:SN8(KN*W6*>:UV*[(C LI_B*DK@G!XXX
M -<GX.T;4=/T:Q\.7_A*X;5-/N?-COYVWV:[9-ZR@AQE@&.% SD<XY( .[3Q
MSH$FI)8K<W#2277V..1;.9H9)AU190NPD8.>>,'TJ+QWXI?PGHL%W';S2R3W
M44 :.$R*FYADL!STR!ZD@5QMOI%W%XITVYTG2-3B@EU1I;[3;^'=;0\DFXC<
MX <=1@G.[IZ]-\4H9Y?!GF0023FWO;6=TB7<VQ)5)P._% &M<^,-(M84D?[>
MQ=/,,2:=<-+&F<%GC";D'!Y8#/;-:NGZA::KI\%_8SI/:SH'BE0\,#_GIVKD
MX&NM#\6ZOJ<^EWL]MJ<$4L3V\1F>-D7!B8+G;GKZ>]:/@;2)]&\.F&=#%YUS
M-<1VY&/(1W+*F,G& 1QVSB@!U]XXT+3]6;3I[B8/%(L=Q.MNY@MF89422XV+
MG(ZGZXIE[XZT6PO;ZVF:X)L7@6XD2(M'&)@65BPX"@<ECP,UR=_87=OJOB'3
M;OP7)J<>HS&XM+B)_P!Q,6 &V?YAMVD#G'0?G4GTC563X@Q_V7<AKVRM(K81
M0/LE:.+8X3/4!NG/(YH ]"U?Q3IND6\4C&>\EGC\V"WL83/)*F1EE5>H^8'/
MI5=_''A\:;]OAO6N8C(L4:V\+N\TA (6-0,N<'D#.,'.,&N$_P")GI$W@ZZA
MTG4)=0M_#XM+I8K82^42J##1[E(PZY)!Y P.M.5O(T+P]8:/:7]W!8:F8M19
MX0+RV9@6 "_P!MW4=!CUH [Z/QCH$NB7&L+J %E;2&*<M$ZO&X.-C1D;PW(X
MQDY&.M)9^-/#U\\R1:B$D@#&>.XB>%X0%#;G5U!08((+8![9KR+4K&>R\(>*
M[2\T_4%E?Q+#+;JV&=RWE[<<D/TZ \Y'(K4U;39?$-OXBL5@N[?7=<LXEMXK
MJR-M%(("IP&RV6( &2?3H.@!Z5HGB[2M?O);2S^U1S)&)D6ZM9(#+$>DB;P-
MRYXS_P#6JEXNU?4H;[2-!T65(-2U21R+B1-RPPQ@&1L=V^90![^U4?"+"[U:
M&X?PC>:3=061AFGNQP"64^7$=QRF0Q[=%JUXNTW5%UO1/$>D67V^XTTS12V?
MF+&9(I5 8J3QN!4<=\F@"YJFF:XB:>VEZO.[17,9NEF$?[V'/SC[HP?I3[WQ
MIH5A>"VGNI,>:L#SQV\CP12,0 CRJI16R1P2,=\4Z'Q#<7LEO'9:+J :0@S-
M=PF!85[Y+?>/H%S]17#6>D:CI7@WQ!X5GT2:>\U"[G,$T:,\#"9OEE+X(4IP
M<$#!4?6@#M]3\9Z+I5S?6UQ/(UQ911RRPQ1,[8<D+M 'S=.<=!R<5-J7B?3=
M+2U:3[5<?:5\R-;.UDN&\L8RY" D*-RY/N*Y^TAO;+7-3CG@OKCR-#@MQ>?9
MV(N9$W[BO)R?G!Q[GK@FN:;2+L>!?#J.NN:7JUGI\BQW5K Y:*0,H\N10#\K
M=>1CY<YH ]!L_&6@W]W:6MK?-+-=VAO(%6"3]Y$#@D';C((QM^][5S_B/Q3;
MZEH_AS4-#U&<VUWKUI:LT:F/S%\WYE8, P'RD=L].036+I5IJ^G:[X)UC5-+
MEB)TZ6QN([:+B*9V!7*#[N0"2<8!ZU0TW3[\^ ?#JR6.JR3V_B5;QPUL7D\M
M)V+M( 3@X)/&22, 'J #M;;QS;OXWU?1IUN8K:RA@Q(UE,%5V,A=G?;A4P%P
MS8!P<$UJZ7XPT'669;/4%)6(3@31O#OB)($B[P-Z9!&Y<CWKC+N2]@\=>,!;
MZ5+<RZEH]M-:))$?+DV*ZE6]#E@,'FLWP\^/'OAF^^S7_DOH\ZB1K7RP7#$L
MHC"G:%^Z!\O08R.H!Z#I_C;P]J<]C!;:BK27T7FVX*,%D'.5#XV[Q@Y3.X8/
M%5/"WC6W\2ZIJ=HD5S%]GF981+9RQ[D4+DEF4 -EONDY]JY/1M(U*T\+^ 8)
M-*NC/9:D6N4: YA5B_S'*\ ;QS^O&:TO#U]=>&V\7&?1]1N)(KYKA8[>+<95
M<#;M).#W)],'.* /1:PK'QCH.I:@MC:WQ>9W=(F,,BQRLA(81R%0CXP?ND]*
MO:=JB:MH5OJEG&6%Q )8XW.TY(SM/''/%>0Z9#-/?^"M3^R:DABU*5+FW6$K
M;VKE'!5(QSC<?OXP<DYZ@ 'J=OXKT>ZU9-,BN)C<R-(L>;658Y"AP^V0KL;!
M!!P35G6-=TW0;>*;4KGREED$42*C2/*YZ*B*"S'V ->;^$H;RU\6Z:MC9:C;
MV<JRRW>EWUN=FEELD&&3:!AFR,#/!]JWOB-/Y5QX>26UE^S2WA5KZW@,LUJ^
MWY#& #@M\PW8.,>M &])XR\/1:7!J3ZI"+6>=;9&PV[S2<;"N-RL">00".^*
MLZ7XCTK6KR]M-/NO.GL7"3J8W7:3G!!8 ,#@X*Y'O7AT=C>Q^%;B/[%> Q>,
MUE8/"Q;9F/!/'/2O4M&CF7XH>(I7MWCBDM+=8Y"F%DVYW<]R-PH N^*;R.UU
M?PT)-;.G"34-HA$;/]L)1E$9QP!\V<G@<'J!4\OC3P]%,T1U*-F2\%D^T$A)
M2 <,<8 Y'S=,G&<\5@?$2UN+OQ!X'2W@EE*:TDKE$)"HHRQ)[<9_*LJ^TZ[;
MP]XYCDTZ]=YM6,UL$B+>8,)AEP.0"ISUZ4 =WK.NV%D382W[6UW-$S(Z0M)Y
M0Q]]\ A5'JV!QUK$\*^*H(_A]H>IZU>RR75Y"&.(6>65R3G;&BECSZ#&/:J=
MM>2:#X]OI;^WN)(]8M;9-/:*%G.Z-#OC./N<MNRV!SUX-<5:VUWHVB^ ?%5W
MIUW<Z;I]@]K>1PJ1-%O.%;9P2N<=.?Z@'JP\:>'3::?=?VI$(M0G-O;%E8%I
M!G*E2,KC'.X#'&<9%3Z?XHT34[2[NK748?)M',=PTN8O)/\ M!P"!Z$\'M7G
M^M2K'9^%;ZWTC[)8S>)(KF"!8F,SJT,A9V3D[B<G YZ5'J6CZGKVKZ_XIT/S
MGLG6W5+)D,9OW@8%^I!'W2@)'7...H!WT7C+0);&]O#?^5#91B6X-Q#)"R(1
MD-M=0Q![$ Y[9J:S\4:-J&K?V7;7H>], N5C\MUW1G&&5B,,.1T/&:\^OM=L
M=7\*:YK5GHES:02Z9-92RW22>>TS+A(T09W %N3P!^=:!M\>*/!\,)GAD_L2
M:$-Y+*H)C7:K$?=^ZQP>ZCOB@"/XF>,UM--M;31]3FBNGU"&*1X8VV.N\!T$
MNW:6&1D*VX?G79WWBS0M-OA9W>HQQS!PCG:S)"Q *B1P"L9((QO(SGC->3:Y
M-?77@;1_"SZ=?OK6F7]LMTHMV*N Y_>*_1@V"1W]0*V;QH-,UG7="U?PE>:J
MVK7CWMEY1+1708*-KDMB,J5 )/;G'J =[>>,-!L+F_M[C4%$U@D<ERB1NYC5
MS\I^4'/KQT')P.:K:EXSTZPU[2]-\Q76^@DNO/7+)Y2C@J1G<22, =L^U<3!
M#-%XN^(32PE -$A0E0Q7<(FR%)ZXJ'1I)-*?X?:M-:74EJ-/FLCY,+.RS/C:
MI Z9P1D\<4 >N3W$%M;M<3S1Q0H-S22,%51ZDGBL_3?$FDZL;A;6Y8/;J&EC
MGA>!T4C(;;(%.W_:QCWK/\=Z=J&J>$IXM,#-=1R17 A!P9@CAS'GMD#%<IJ5
MW-\2O"^MIX?T:>SN9[+[,U[>#R'9@P;R1W(QGGIS[F@#M]/\5:)JEX;2UO@;
MCDHDL;Q&4#JT>\#S%_VER/>JL?CSPQ,MLT>K1,MS=&TB(1^90<;3Q\O(X)P#
MV-8,^J1>+M3\,75EI]RE[87+7%XSH5^Q)L99(V)QEF; P <A<\"N%M9XT^%=
M\\8F223Q(LF/*96Q]H#@_P#? S0!ZS:^+]/N->US3FFCB324C,KR$J2Q5F?
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M\-K;R7%Q*D4,:EGD=@JJ!U))Z"N*U'QCK5AH<&LOIEFEE++:CS'G;B*4*"_
MXVL3QZ8J?6O$@2W\5QWVF07>E:7:;I%W9,Q*%FC8$8Z8_.@#L(Y$FB26-@T;
MJ&5AT(/0TZN0D\2SK)HVBZ+96[ZC=6 O#%*[+%!  !R0">2<#Z&H#XYN8X-+
MLKNQBT_7+Y)F,%Y+LBC$3;6);K@\%>.0: .VHKSU/B'>G1]/EGL+6UO+G4I=
M/DDGE(MD*9PP?&2K<;3CDFNVTJXN;O3(9[N.*.=P=PB8LG4X()Z@C!_&@!]]
MJ%GIEJUU?W4-K;KUDF<(H_$T^TO+:_M4NK.XBN+>3.R6)PZM@X."..H(K@?'
M%QKG_"8^&[2V2Q>UDN'>**9F&]UC_CXXP2<8JP=8D\/Z?J\F@Z/:-I.D32M>
MJMP06?:LLHB'(&-Q!!(Y!&!B@#O*KWEE;:A;-;7<2RPL061NAP<C/XBN0F\<
M7M]=Z7;Z!IL-TVI:<U]"UQ*4 VL@*M@''WB/KCMS79P/));Q/+'Y<C("Z9SM
M..10 RYN;;3[.2XN9HK>VB7+R2,%5![GM4P((!!R#TKPJ_U;7->^&_Q#GUCR
M)8(;V2*(B4MY3)Y0"(OW0H!SD<DDY]:]$F\92Z+K%U8ZQ:(EK%ILNHV\UNQ=
MGBB WA@<8;GCUH [*BN.T;QE=7NM6%C=VMJ8M1B>6WDLYO-,)4;MLW925(P1
MQD$5K^+M:/AWPEJFKJA=K6W9U _O=!^I% &D]_9QW8M'NX%N6 (A,@#D'.#M
MSGG!_(U8KF=%\':5;:)!#?01ZG<R+ON+N\C5Y)V;DEB1SUP/0 "J-KJ%QX?D
MT?P3IY2]U.+3A*9[I]J+''A.=HSG) ''3J30!VE%<1+XZN[>PM]^EK-J*ZI'
MIMY!!-Q"['(92V-P*D$?7ZTRY\;ZK:0Z_')I$+7FB&.6X5)CL>%QN!4XR6V@
M^V10!W58>A^&(=!U+5KV&_O+AM3N/M$T<Y0JCXQ\NU0<8 &"3T%9<_C6>67P
MT--TY9DUVV,\?FS!&C'E;UR/3D FJMOX[OI+'7+5M)#^(=*ECB:RA<E)/,8*
MCAB!\O.2>VTT =U17 M\1C%HGB><V]K<WV@(KRBUGWPRAP2NUNN>"",<$5>;
MQ5JW]MQ:5_9]JD]]9?:M/9IF*L5"F19,#Y?O<$9S0!I:UX1TW7M6L]0O7NMU
MNC1- DQ6*=#SMD7N,X/;ISD<5N@   # '0"N*T_QQ=:CX2AU&.QBCU6>_%@M
MC(Y^63S-K!B!P53<Q_W:[5FV(S8)P,X R30 M%<-I?CZ6]UK3+6XLHH8=3\Q
M88_,/VB$KT\U#T!&2,>U4[_XEW=MI6HZI#HVZSTS5SI]VQF&Y4#A&< =?F)P
M/I[T >BD@ DG '4FH;6\MKZ'SK2XAN(LE=\3AUR.",BN=OO$*ZCJ.IZ'86J7
M?V.'_3G,BA5WHV$ YRW R#C K(^#2>7\.+1?.$G[^;CO'\Y^0\8R.G''I0!W
M]%<5J8;6?B?:Z+=$MIMGIOV]K<CY996D**3Z[<$X/'.?2M&Y\,6=IXALM?LX
MX+<VD<J7$:Q#]XC+P1CHP('7L6% '245Q(\<W*:;IVO3:8$T"_:-%D,F)X2[
M!49U/&TDXX.1D5%JWC^YT^S\3W46FQR1Z%<1QN&EP9$(!9AQUYX% '=T5QOB
M+QE=Z;?RV.F6EM<74=@;U8)YBLEQUPD2@$NW'0>H]:EMO%6H7-[K-N-/CB-I
MI\5[;K,65B75CLD!'!!7!QF@#J99XH IED5 S!%+'&6)P!]2:DKRF]\0OXN\
M._#[6VM1!)<>((=T:G<%PLN>?3@&MV'5];TK4?%^JZA"UW8V<J1V]M;.68*L
M8<;4/&XB5<D>GM0!N:IX6MM1U ZC!>W^G:@R+$]S9R@,\:DD*58,N,GKC/O6
MI96%MI\;I;H1O<N[,Y9F8]26))-<OHGB[4+W5M4T>^LK/^T;&T2YVVEQO0EL
MC86(X8,I'2JFD>/[G4)O#MQ-IT4>F:[&5MY$D)D28#)#+C&WAN0<]* .LU;1
MK/6K>**[$G[F431/%(T;1N.C J1R,U%9>'[6TN(+J6:YO;R&,QI<W4I=@#UP
M.%!/? &<5S7P]U36]6N]>NM2DCD@_M":.,"1CY(0(JHJD 8^^21W(]\='X@U
MU="M;=Q:RW=Q<W"6\$$7WF9CU^@&23V H TA=6YNC:B>(W 3>8MXWA>F<=<>
M]2UYA#J+Z-\0]=U75K2*&:VT)9IDM6W"8!V.5)QT  YQUK>L/&LSZJUG>VD&
MU[1[N*2TF$H0( 3'(>@?D]..#0!U\DD<,3RRNJ1HI9G8X"@=23V%-@FBN8(Y
MX)%DAE4.CH<AE(R"#W!%<A'XE;4O#-]/J6GPW-E)I\UP7L;CS(I(@/FC+\;7
M*MT^OI4=MXGGM-#\,0:5HH8:EI+2VL*.=L3) KI&3V7D+N/MZT =O17!:A\0
M;JS1]NG0F:QACEU&W>?$@9E#&.$8^=AS^E:,OC"9]?DTZSL%F$%M%/+&TH6=
MQ)]W8G?;@[O3B@#K**0Y ) R>PKA=&\97D/A[6=7UNV7%KJ#VX2VE$HW!DC5
M%QZL1]">>E '=T5S%MXFO8/$]MH>LZ<EM+?+))92PR^8CJ@RRMT(8#GTP1S6
M]J%T;'3KF[6%IC!$TGEKU; S@>] %FJU_8V^IV4EG=*SP2C#JKE=P]"00<'N
M.XXKC]+\>7MR?#UQJ&D"UT_6XHU@E$NYUF92V&7LI X.<^H%._X6"B:C9-)%
M:?V7=W)LUDBNEDE20N55F4<!"0><\9'K0!V<$,5M!'!#&L<4:A411@*!T J,
M7]FU\UBMW ;M5W- )!Y@'J5SG%<W9^++_4=0D@L]&>2*UU*;3[MS)@QE45D<
M>JG<![5QGAO4[*Q\.#7]>T\W6HQZU+%;2I)F0S._EA021QCCGC':@#U^BN6;
MQ9=6;7EGJ.FJFIVUB;U8HKA=EPHX;86P1@]<CN*H-\0I(](AU.70[R.WN#:"
M$R?*7,Y*D 'J5*\CKM(- '<45Q$OC/6(M3UK2#H<?]I6,/VRW7[1^[FMLX#;
ML<-D,,8ZCK72Z!K=KXCT&RUBR)-O=1AU##!4]"I]P01^% &E17-:MXK^P^(4
MT6WLS/="U:\9&<(9(QD8CS]YL@<>F:EB\2RRW\UN-+F$<6G)?^<9% ^?.(R.
MH;Y7]OEH Z"HYKB&W56GFCB5G"*78*"Q. !GN3P!7.Z;XQCU:ST>:TLFD?4X
MY)$59598E3J&8<!L\8['([5RWBK5)-;T+PY<SV$EM>VOB>SMYXV4X6190&V$
M]4)QANXQ0!VGB'PU#XBDTR2:^N[4Z==+>1?9_+^:100"V]&X +<#'7Z8VZP]
M#\0-JNHZGI\]FUK<V$BJZE@P8,N00?SI_B77X_#NF)<N@=YIDMX@QVH';A2S
M=ESU- &S17+S>,X;-5BOK;[+=O=/;1I+* CA(Q*TF_H$"<Y-9H^),'V">1+%
M[JYL[VVL[M+.195'G%0'0CEURP &,Y(% '=5#=7EK86[7%Y<PV\*_>DF<(H^
MI/%<]'XMF35M,T^\T:YMFO[BXMUE<@(IBR0<]]X&5]<'TK%\<>(=-N/ .M7F
MIZ*][IMO<-!&AGVK<E3C>"IR%W9'KP?:@#T$$$9'(HKE[KQ3<1MJD.GZ1-<_
MV7#'+,Q8*KY&XHG<MLZ=LD4^X\9V4!B7;&KO9K>,D]PD3*&!*KANK?*<CM0!
MTM%<K9^.;+4;'2I[.'S)=3MI;B"!YE1F,>W=&,_>;Y^WH:Z'3[O[?IMM>>2\
M/GQ+)Y<@PR9&<'W% $EQ<P6D#SW,T<,*#+22,%51[D\"I%8,H92"I&01T-<#
MXCMYM4^)6AV=Q9M/9Q6=S-Y!G C<_*FYE(YP'./?'I4NE^)K'1/"LCZ=9WMW
MHVDS&U>Z>0%]BG#OR 6"G(]>* .ZHKD=1\;M#J,MAI>ESZC*+."]B>$Y66.2
M4)QWR!D_2NKE=D@=T7<ZJ2%)QD^F: '.ZQH7=@J@9))P!2UXWJ^L:CJ_PNT/
M5+^-C-/J\$@V2K)P97&U2.P' Y.?6NYN?'-MIH\1'5+26W&B+'(Y!#"9) 2F
MSID_*01ZT =717*Z5XYL]3\00:/Y'ES7%K]IB99DD4@ %E.T_*PR.#ZU;\;>
M(&\+>#M2UF- \MO&!&IZ%V8(N?;+#- &G=Z79WUY9W=S#YDUFS/ 2QPC$8)Q
MG!./7I5RN3T_P9IESH$2ZDAO;Z:+?)?2G]\&;))5^JXW'&#P*=9ZN-$N-+\)
MX^VZN++SG ;:OEJ=NXD]R1T]C0!U5%<BGCR"6WL&BTN^>>XO_P"S[BW507M)
M><[QG[N 3D9&.:@G\>W"1ZVL?A^[,^D<W&741LN,_*_1CC^'@T ;FC>'QI&I
M:MJ#7T]U/J4RR2>8J*J;1M4*%4?PX!)SG&>.:V:Y>[\91Q:OH5A:V,MT=8@D
MGA>-AM4(H)W'M]X<_6H;+Q];7FGRR_V;>QWT&H)IT]C@-)%(Q&&.#]S!SNZ<
M'TH ZZBN&N/B5;6^B^(+Y]-N%ET6Z6UFAWJVYG8*A4@XP2R^XS6I_P )8XUB
MYTAM*G6_CL/[0BB,B_O(]VW!/\+9[<_6@#I:*Y2T\=V=[X;T?6(;9R-3N!;Q
MV^\>8'W%6&.Y7:<X]#75T (&5L[6!P<'!Z&EK@M.\4Z1HGA6]U:TTZXCL5U:
M2"X0R;F$K3"-F&3R-S9QGI70:7XD6^\1:CH4]G):WMG''-@L'62-\X8$=.1C
M!H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "JEXN9[+YL8F)^O[MZM
MU2O_ /CXL/\ KX/_ *+>@"[1110 4444 %%%% !1110 4444 %%%% !1110!
MR'B+PMJ-QXHL?$^AW5O%J-M"UL\-PI\N6-R,DD<@K]X>N,<9S5;5?"OB)H](
MU*PUF*?7-.EE=S.ICAN5DV[XR%SM7Y5QUQBNXHH XZ\\,:QJ%MI[WE_;S7<6
MHK?3 H1&H"A?+0>@QU/?)[UJ7>FZ@?&%GJEM]G-J+5[><2,P=<L&!4#@],<U
MNT4 >=Z%X+US2CX9\V6RD.EWEU)<.&;=.LH8"0\??^;)'ZU4U/X=:OJ.G>([
M?[7:HVK:K#>J.2(U1\D< 9)"KV[XR>M>GT4 <I:^']1MOB%_;8-NUB^DQV+C
M>?,#J[-D#&".0.M=%J,-S<:;=0V<RP7,D3+%*R[@C$<$CO@]JRM)\5VFL>)-
M8T2"WN4FTHHLTDBA58L,C;SD].N*WJ /-1\.KB^L]91[;3]$-ZD6RWL&,L?G
M1-O24Y"X.>, 8(%:QT#Q+KNC7T&O7MG;SSV4EG'':;GC^8C,K9QEN!QVY]:[
M2B@#%?P_%<>#1X?NRDR&R%J[E."0FW< <XY&1Z5BV/A'4I?AE=>']3O8SJU_
M;R1W5V,R*9&&W=VS\H'ITKM** .*N_!5\NJZ)K>FZC%%JFFV8LI!+$6BN(O3
M&<J<Y.0:K:CX'UF2XT_7+764D\1V<KLTLL96&6-\;HMO.U< 8ZG.?6N^K.U+
M53IUSI\(LYY_MEP(-\0R(OE)W-[<8_&@#%E\.:M/9W'VZ[L]1>Y:1I[6>)A
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MTMEJ]FEQ')<D;C<1 ))TZ[AM8GN2:3Q3K^M+<^+A:ZG<6EYI0MVTVVBV8F#
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MDGO6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 54O5W3V1SC$Y/3_IF]6ZJ7I GLLC.9SCV_=O0!;HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME;7<<IG6WFVABH!!Y! Z4 =[17!SQR6N@>*!::_?7:6<+>6\KGS8)EC).'
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MH **** "JEX 9[+(S^^..<8_=O\ G5NJMVN9K/Y@,3$\XY^1_7^E %JBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?LJWOB
M75([FTD>SGL(8&,D9V/AY=RY[\.M<MH_@:YTKQ-JFFO)<2Z!<Z7)!9.6W&V5
MW!>,D]\ME<YX'M7H]% '*^'[N_T30[32=1TJ[,]E$+>.6W'G)<*@VJ^X ;2P
M&<'&,T_PAHEY8#5]0U.-8KS5[QKF2W5@RQ+M"*N1U.U1D^IKIZ* /);/X;W-
MG8>*K.1I+BWACFCT12N#&)0)9-N,9)?8H/8H?6NL\#66H:7X*2\U.VDDUJZ0
MW5XF LDDFW"KC@ A55?PKKJ:Z+)&T;J&1@0RD<$'M0!C^%=?'B;0(=3-JUJ[
M/)%)"SA]CHY4@,.&&1U%9_C2.\G;1%L[.XN/L^IP74PB3.(UW9YR.>G'/T[C
MH[.SMM/M([6SMXK>WC&$BB4*JCV Z5/0!R'Q"L+K5M"L;>SM)+AQJ%M.Z!,X
MC20,Q/X56\:Z&+[3]%ETO2AYL6K6EU)Y< 5UB1\MGC/ [5W%% '$:C;RW/Q&
MTW56TJZFL(=.F@D<PY"NS*R_*1GHIY%4/$=KJ&J^&O%&BZ5H$]M:R6[>2SC:
M;J>0@G:N/E48Y.?XNG%>C44 >8-X<U72X?#OBG1M.D_M6TM4L]0L"51IX0,$
M9.1N4C@]Q6MKMM<7_C;P]J(TNYELK:*4S,T.=I;@#;USQZ5W-% '#ZE#=RVG
MB*VTW1I8+.:R;:!%M:YN'!7@$\  #/3K6EX6T&V@\/Z,UWIZQ7]I:>0Q9-K+
ME0''N#M'Y5TU% '#^#-*N? UE=Z%-9W-Q8I<O-9W<*^9O1R/E<#D,#GM@BJ\
M6BZI?/XE\1:AI[6UY?V?V*TLU8.XA .UGQG#DMR <#'?&:] HH \DT?PAJ^A
M>&_#&NV%BPU_2X#:WMF2%^U0%B63.#\PX(/U'I6OXFLKS6/&_A'4QI%S+8V/
MGO=!X3F-F50O&>>A]:]$HH XTS7VG:S?76E:*T6FK:M<SH(=DEY<8VJJ_P!W
M 49.._M6_P"'=;M_$GAZQUBU5EANXA(JMU7U!^AR*OS0Q7$+0S1K)&XPR,,@
MT0P16T"0P1)%$@VJB* %'H * //;&WU.#POJ^ER:-?/(VH2,#Y:[61I@P(R0
M6&"3QGH?85HZ_H\VL:X\=O;7$4=[HT]J]SRB1LV-@8=^_':NUHH \M\*Z1//
M-I$<O@R32]0TUE\^]N9"\0"K@^1\Q)+=.0  3R>*U?B;.;9_"$ZP2SE/$,!\
MN( LW[N7@9(YKO:R]8T&TUN33WNFE#6%RMW!Y; 8D4$ G@YX8\>] 'G7B72=
M7OY];\0:7HD\0G:TA\KR_P#29A&VYIU1@ & (50<YV9.*OS:;J$C>-[>#3+X
M1ZEHR&"6==S3R^2ZX)SPW(7;CMG->E44 >;ZWI-\WPR\-Q06%R;JSDT^2XAA
M@#3J(RN_"GC(YZ\5)JVC:CK?CN\FCMKBUM[SPT;-;B1/E24S%@I(Z<?SKT2B
M@#R7P[HVH"/3K4>#VLM6TMD9[^YD+P.%7YO)^;[S<KR,*"3[5>\,Z9J.G^)=
M&73M)O++2/*E-Y97JATLI-IP8)#R2S'!P<$'H.WIE% '&^,X-0D\0^&)K:VN
MGM(9YFN9K2/=+'F/"J#_  JQ)!/ZBN6:*[TSP9]@BTW4-.U*/79&L8F599'S
M(9-R L!(-I.?F'0^V?6ZR==\.V/B&*W6[:YCDMI/-@FMIVADC?!&0RD=B10!
MYC)!=:WX2\96#:7JB^(=6"W!2[LUM_-4%$0(HD;Y5 ');/?FM[Q=H>H7FE^%
M]7M=/FO#INUKO2S\DDR/&%;[I4;TYP.G)[<'L-'\/6FC-))%->75Q( K3WMR
M\\FWKM!8G ]A6M0!Y'?^%KC5=,_M/2O"KZ=%%>V]W)87$A2ZOQ'Y@*NP8A
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MF0Q_?'&#C'R-U]: +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTU" ,(;J%)XPPP=K*&&?P->)ZA'XKT&UU'Q5X5GCU;PGK#OJ-W83KM=%DR9
M.XXR"0>W0XJ^_CK5)]<\.Z)X:MKB#39-$%Q%!;F(R2MY9"HKS<$(0 <9/RDG
MC- 'L]%>1ZGXF\9V>G>"[J>X%I<7.H?8-3M\0R+(V3@Y4':2%;A2,5+X^O\
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M*LNT '.!DD]>.<B/Q!XA=DTS^T46[M->%A+<RPI_I4)7<,+@#=@C.WIC/0T
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M.=J@H#V;ISSW/>M[1=0\3-XF>UOK"=M(>V5TNK@11O',,AEVHQW*>"#VZ<T
M=;1110 4444 %%%% !1110 4444 %%%% !1110 54O5W3V1R!B<GD]?W;]*M
MU3O699[$*Q :<@X/4>6YH N4444 %%%% !1110 4444 %%%% !1110 4444
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MZ7KHDTQXP\,]S;I:NN[)5"P&\$9Y5C@GFO4/^$J\;?\ 1.+C_P '%M_C3_\
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M/V&*X C4-DD*<;E'/0&NN61&D:-74NF-R@\KGID5BZAK%\GB*PTC3;2*??\
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M1:GK<*M]KU%(DFSC \L$#'ID$9^@K6HH YRY\&:=?7NM7-XTDPU>W6WGC.
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M*** "JEZ6$]EM'!G.>,\>6]6ZIWI GL<J#F<X]OW;T 7**** "BBB@ HHHH
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ML'DMQ:H(W8="5Q@G@<UA:UX+%[>VTEI!I#6<$!ACL;VQ62*+G.Y ,;3TS]*
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M&.E;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*_\ ^/BP_P"O
M@_\ HMZNU2O_ /CXL/\ KX/_ *+>@"[1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU<G ]!WJ>D(# @@$'J#0!X7XU\6>%O&.HZ-=#7;JS33+E;E8SHL\C.00<$Y
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MLOF(C ?+M(P21DDG@=*Z^LK5O$6G:)=:?;7LDBRW]PMM;A8V8,[' !(&!^-
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MNT?SK*;SH)$<JRG&",CL0<$=ZIW/@_1[NUU:VEAE,6K2"6[43,-YP!Z\# '
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M7!L8Q)<+%@\QJ003NV9X/R[C5K0?#4.BM)<RW4^H:E,H2:^N2/,D4$E5X
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MJQQ&..F1G/(X-4=-M[>7X<^(=.U&,#Q.;JX#I.W^D-,SDQ%"3DY&S!'''L:
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M)0BL3T[  ^V*]BM]:TZ76[C0X)/],M(4EDC5#M1&X7GIVZ4 :5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5.]_U]CP#^_/X?NWJY5.^
M&9['GI.?_1;T 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D"*&+!0&;J<<FEHH **** "BBB@ HHHH **** "BBB@ HHHH YW4
M_#]]/XFBUNPU!(94LS:>5-%YB*"X;<O(P3C!]0!5G0= 71Y+Z[EF-QJ&H2++
M=S8VJ[*NU=J]@% %;-% !1110 4444 %%%% ",BL5+*"5.1D=#426EM'=R7:
M6\2W,JA))@@#NHZ MU(&3^=344 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH7FTO4+:\B1MK-;RAPIQG!QT-7J "BBB@ HHHH **** "BBB@ HI 0>AS2T
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M14M !1110 445!=7MK8Q"6\N8;>,L$#S2! 6/09/<T 3T444 %%%% !1110
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MFU&"%)KEI$@MTD)"^8[;06QS@=3]*X#X=^-_#_A3PI::)<:I>7VQV:W=-.=
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M30/#=AI4MV]W):Q"-IWZN?\ /'X4 <?\0]3\167BWPC::/=VT,-Y=.I24/\
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MA)ZL%VGG)X;GI6JNC?:?B/K>CMJ>J+I\NF17(A2_<&.5F9=R'.Y>%!QG&>M
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MS0]8M?$&B6FK69)M[J,2)GJ![^]6+^]ATW3KJ_N6*P6T+S2$#.%4$G]!7#>
M)GT;Q%X@\(RVQM+>VE%[IL#@#%O+RP7!(*A\\Y/)([8K?\>6:7G@37$>66/;
M83N&C<KT0G!]0<8(/8T /T+Q,=:G6-]+N[5);6.[MYG 9)8W&1\PX##C(///
M>MW8G/RKSUXK@+=I+;Q+X5\-QWDHTTZ5).[(^!<NH15 8'C );"G'X5@:Y>:
MWI CTO\ MB]D5/$4<2W2L 6ADCW^43R?ESWP.G).10!Z]Y:<_(O/7BN>?Q%:
M2:I?:?I^E3WSV4>9Y(47RPV.(PQ/+XXQ5[3--N])\/\ V%;Z6]NHQ+Y=Q<G+
M,2S,@8]\9 _"N3^#)D'@%8[DG[<MW/\ :ED_U@DWG._/.[Z\T =+X?URP\1P
M7,MO930-;3&"6.YA".KKU&/K6QY$0.?*3/\ NCZ5Q?BK4TLM5T?3-)GM;8ZG
MJBQ:A)'(J/C;N*Y[.PP/[Q[<FL'Q7J6JZ-?^)]'L=1N%B_LVWU&VE+%FMF,W
ME,F3R0V >O'- 'J8AB7&(T&.!A1Q2>1%MV^4F,@XVCJ.E<'+9ZS9>)M>BL=6
MF'V[16GM?M4^Y(+G<5# $8502O'/2N:BU'4+=;^RU6_U'3M7L]!FDDM'G,B3
MLNTBYCE!VC!'*GU^M 'L1AC)),:$GD_*.?\ .*Q-+UW2]2L[F\\E;6."\>T;
MST"DR*VW]6/%<^^H7G]O^ '^UR>1>VLPNE\W E?R59"1WP=WY_2N7GQ/80)O
M?RY/&,^0DA&X>8>X/- 'L M+9<XMXAD8.$'2G^3%N#>6FX'(.T=:\;\:ZOJE
MA;^);W1=<NIFTVZMH@%.V.R'R@Q_,<RL203P1R<G(Q6C?-J%]X^\::9)K>HQ
M6MOIL-U!'!+LV-M8X! X&3ST)H ].D%I'+%'(L2O*2D8(&6."Q _ $_A6-I>
MMZ5K>N:MIJV#)<Z?($D:>#:)?]I21R..M</H,L_B#5_AYJ6H/)-<SZ1=O-()
M"G(\O!P#UYYQU[]*[?7M/_L_1=8O=+N8K/5KF/"7EPP(WYPBY8X R=H'3)SR
M>H!NBW@"[1#'MZ8VC%(;2V.,V\1QP,H*XKP5J$UQKU[:7KW]IJ%O9PK<Z;=,
M9%5LM^^CDR0RM[="*CU^*]N_B?I^F)J]_;6EWI=PSQP2!0I#( 5XX/N<GKC&
M: .X^PVF<_98<_\ 7,4&SM2,&VAP.,;!7DD.KZ^@TG07U-KIXM7N;8W$UR+<
MW:1?=C+@$Y.[L,G;4\'_  E?VS1M'OO$""Z75I8Y3!)YN(#"S"-R%7YPH.#Z
MD,>U ';ZSJ^F:3JECI::6+J_O$DDCBCB4 (B[F+,>!Z#U-:6B3VFI:7:ZG;V
M7V;SXPX1XPKKGL?>O.I=!GTOXC>%;6ZUF\NWM],N1)(\Q1KE5!PI^8$GD$XR
M3L!(P"1&-4U.Y^%LOC*/7)WOX)WNBJ@K&$1RIM]G<<8W8SGG.* /6Z*X+1XM
M3USQ+KPDUJ[@@LM0MY(8XB!A&MD9HSD8VY<?E[UQ_AK4M<O/#/@[7)/$-X)I
M]7%C<1NRF.:-F?J#_%@8!]Q0![;17FHO+C1XO&VD/KU_FT$5S#=R1^=+")E^
MZH_B.5.%QW_*O<WFN6&E>,U>\O[%(K.WN[%IYHGD@W*P8$EL LR'@DX['ID
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M6NI645Y93QSVTRAHY(SD,#7#ZK\06FT+QE<:0T"3:&&CB>3YC(ZIECLXX!.
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M0-Q]<T 4]+\$:'H^J27]G;RK([EUC:9FBB8YR40G"DY/05I:SHEAK]A]BU&
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M1PR;IL%]S>7EA@DGMTZ]JO\ A6PO8]>1K*/7+32+6*2&5-7F+_:"2"C1J22
MN&R3C[V/IVSW5O$6$EQ$A1"[!G VJ.I/M[T&[ME@2<W$0A?&V0N-K9Z8/0T
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M^&MGJ5Q';36R7>X7DJQO#&T++&)%.,$_*!G'((YKU^B@#A/C##YWPSU12&V
M(794W;%W#)Q[5DVNJ6C?&&W9KV+[#%X963,CA40;V9F(/W?E"DY[8KU!E5U*
ML RD8((R"*4  8' H \%TO5],'PO^'\#:C:>?;^(+=IHS.NZ,"9R2PSD  J>
M>Q%;]MJZ#QO8PV=S!>K=:Q+Y^E7,2_:K"3:Y:52/F"<=2.C8KUNB@#DO'_C"
MV\*:*@-Q#'>WDBP0!Y0I0,<&7'7:N<D_2N-\36B?#J/PIK5SJ$%U;Z7(+/RT
M@6.62!EP[#YOG((#''4UZ_10!Y'XHU[3;7Q;K=M-J]G%%K.DP1PR761&H);Y
ME8 @C:Q;DCG '6I-.DT7_A-_"EI!J-G?6+:)+:)+O4I.0P!7'<\'CK7</H%_
M!J=[>:=K#P+>NKRQRPB4*P &5)Y' /'3-7]$T>#0].^QP/)(#(\KO(>6=V+,
M?;))XH \HO;O2DE\3^'O$MQJL=U<ZA)+;:="BYOH68>3Y;;"<80+U& ,=N*L
MALHF\4Z#XJO=4BO[[4Y)[2SC09ODW@P^6VQCR54 ;N, <<U[E10!XSK,\3Z=
M\5/->%9A;P[T5L[9#"1@?CD#UJS?ZO977BGP8=*U:P^U/HUY'%*LZ$"5HT5,
MGG^-6'U4CL:]=HH \0\*OI\^B:-I$DVH#Q/HMTJ'3%,<;1NK_O)-X3/EE2VX
M[OF''<9@N-0TZ3X0>*G2^LSO\12&)O-'S9ND<;<=<H"PQV&>F:]UP,DXY-+0
M!YSH.K:;;?%#QE++=1!+BULKF!Q\PDB2)][J1U R.17<:/JUIKND6NJ6+E[6
MYC$D99<''N*MM#$SEVB0N5V%BHR5]/I[4J(L:*B*%11@*HP * . \8:E81_$
MWP+;O>VRSQW-SOC:50R[X&5,C.1N;@>IX%2ZU+;_ /"XM AFDBRVF7.4<CD?
M3Z _D:[RB@#P;0]4CL_#7A34+FZF&CV-_?17<MN/,^RN9'\LN #M 4\9'1AZ
MUZ-X!M]*C.KW6ARW5UI][<FY%W-]R:5F;S-GRKP".HR/RKLF574JP#*1@@C(
M(H50JA5   P .U 'EWA:[@\$^,?%-KXAE73H-3OC=65W=OLBG7'S .3C(R."
M0>16AXU\0V^M>%+TZ+)+>6EM+!)<W=HVZ(H)E+H&!^;"@D@9X^N*] =%D7:Z
MAAD'!&>1R*<    , =J /*?$-W8:YKUYJ6@W=M=6*^'+R&_GMGWH,C,2N5Z'
M[YQUZUCV$&F1ZO\ "2.U6%K<VLK$K+E3(822-V>HDS\OKQ[5[6L4:A@L:@-]
MX =>,<_@ */)BP@\M,(,)\H^4>WIT'Y4 >,QQV,_A/XJ1>7%-8PWDSQQQX*J
M1&&RO8'<"<^M-UK4;%K[2M7\,QG4H+?0[B+5H]/D$A"%!Y:2LG ;<9#SSP3C
MBO4_$6D7&K:!=Z98SP6C72&-Y'A+@*002 ".>G6KNGV?V2RCBE$+3; )I(X]
M@D8#!.* /,_#L^B#Q--<W&H:9/8W'AXHT5O#BUC@B<Y0$\-M5B&].X%8^G26
MVG_#WX82BXACO/[6A190X#^4S.)5!Z[<%0W;IFO:H[:WB*&.")"@(7:@&T'D
M@4DL >W\N-44J/W9* A&'0X]J /,KG0[C2/&.J>'+"*:+3/%$?VH26R!1;,A
M"S].1N5UYZ9( Y)KO[_0K.^\-3:$5\NTDMC;J%'W!MP"/IQ6=X>\-7]A>#4M
M;UAM5U-8&MDF$0A1(V?>0$!/)(7)_P!D5TM 'AT&IW>D>&])UZ6T=W\'R'1[
MQ4 Q/MS$VP^@_=G) SFM_P 0Z:=.7P'#>W#SZ@VO),\LI/.X,S#UR,J!]*]/
M>&*6,QR1HZ'JK*"#WZ4XHK$$J"1T)'2@#S&;5=.'B'XFQ"\A1UT^$LK3C!(@
M=68#M@E%/OCU KJ_ H_XMOX=!_Z!5OG/_7):Z$PQ%64QH5;[P*C!^M*8T*%"
MBE#D%<<'/6@#PRSTX'X+:7JFBGSIH6$.HO!(TC_9!,S21JI)Q_"2N!\N?7GI
M%O?#.J7NLZCIU\VH6<^CR+J-S(R+; J1Y0D&U09,%L9Y"CWKTZ.&*%"D42(I
M))55 !)ZTU;6W2 P+!$(3UC"#;^72@#S;PZME=>)_!TUS>VT^I#P](2R;2TR
MED Z8X_UA'&.&QWKD(+?3[+P+X9N+6X@('BT,3YV[RP+@C'TVJI[\$'O7O7D
MQ>8)/*3>!M#;1D#TS48LK01A!:P[ VX+Y8P#Z_6@#S*2/16\2>/[76_LX2:"
M)VCF8*SQA<!AWQN( ([D4WPU>/I7B[1Y?$DBVMU<>&(H0UQM!ED68DQJ1]YP
M"ORKSR..E>I/!"\J2O$C2)]UBH)7Z'M2O#%(Z.\:,R'*EE!*GV]* /%="33;
MS1OAS%,(7EENKR-HY2N]XB90RD'DIG *].E:FLQ66@:E=&QN+>\TW[=86EUI
M2NRW<#H8Q#Y!4[B0 #CJ<'G@UZD;&T+1L;6 F/[A\L?+SGCTI3:6S3B<V\1F
M'20H-WY]: /(8'TB675]$UJ_NXM;_MAKJ"S'R23G>&B9"4)P0,<'IGUKK?BQ
MH5]XC^'&H65A \MW\DJPIRS[6!*CU-=F8(6G6<Q(95&%D*C<!Z U)0!REKX_
M\-MI$4J:G;R78A!_LZ*16NRX'^K$.=Q?/&,5D:7J%I%XR\2KXA*VC75M#<6W
MVL[%^R+'\PY. 58ONQTSUKO1;0+.9U@C$S#!D"#<?QZT36T%P5,T$<I0Y7>@
M;'TS0!Y)H-O/;^(_AY!<(RHL>JB%7!_U.$\OKVVXQ3-*BM#X:M8;35+329UU
M^Z.GFY4>2S!B!&02.H. .OI7K[6\#SK.T,9E4860J-P'L:C^P69B\K[)!Y>[
M=L\L8SZX]: /)K'Q!9R>(O"^L7PM],M0]_#).\P%L\I<DM%(Q =&))![_A4/
M@_4+.W^''BV::\@CB&J7 +O* H+2<<D]\C'KFO86M+9X5A>WB:)?NH4!4?04
MC6-H\9C:U@9"V_:8P1N]<>M ' ^(-4T6Q\1>))+E!/-/X?@:*.V :>:+=<;S
M'ZC!4D]@ >U<[H4EK_PEWAJW^UZ9)97NASVK0VAW1R*BJ%B9S_K2!NX(R,GC
MFO8C;0&59##'YBJ4#;1D*>V?3VIJV-H@ 6U@&%*C$8X!ZCZ&@#Q/2)Y+7PC\
M)KB$A)SJ/DE\ G8Y=77GL0:]1\+WME)-JMC#-$]U!?3M-$A!:(-(=N['W<]0
M#UQQ6R-.L5VXLK<;>5Q$O'TXJ9(8HV=DC16<Y8JH!8^I]: .1@CA'Q=O74QF
M4Z-'N49W#]ZV">WKC\:XR\F,GP>C9]O_  E$6I0>8I*^=]O^TKG[N/F(SC'\
M/3@5ZZUG:M/Y[6T)FZ^88QN_/K2_8[87'V@6\/G_ //38-WIUZT <#H6B:7J
M?C_Q%+=VHEFL=0BNK=LD>7(8P"PP>IQSG@X'I5GX@V\,NN>#Q)$C^=JAMI=R
M@[X7B?<A]5.!D=#@5VT5M! [O%!'&SG+LB %OKZT26MO+,LTD$3RK]UV0%A]
M#0!Y#J%MX9T[6_$^@ZU?1Z/:2VUO;:<CPJ%, B'W"RG=MD+'KG/X5A^*+_3I
M(/$MHMPD6H)H-LADO&7S+E5C+8B3@AN[$9Z#BO>I+:":1))8(W=#E&9 2OT/
M:FR6=K+(TDEM"[LA1F9 25/4$^GM0!Y!+<[+!]2TZZTZ_7^P[1;[3+I@#+"J
M?ZR)\]BY'^\,=<5I:0OAV^G\=6OB66"*=[A3<>=(4=+,0Q>2<]OPZGKVKTHZ
M;8D(#96Q"*%3,2_*!T XX%2R6MO,Z/+!$[1\HS("5^GI0!XAX'TLW_C0VOB6
M&&X,OAV SI*,HR[B4+@\%@H3)/0BM32=2TJTM/!=A:7L7DQS7RV\LUV!:E0S
M)AO[[[7&T9'WB>]>M-9VKS><UM"TI&-Y0%L8QU^E,.G616-39VY6,ED'E+A2
M>XXXH \!,]K?^"/"4<MS#/ GBB:*3;("H7=)A>O *LN!Z$=C76:UH]KI%]XV
M30H([?2V\.3?;(8#B%+G8VW"CY5<I@D>A![\^J?8K4PS0_9H?*F8M*GEC#D]
M2P[D^]-73[)+<6ZV=NL .1$(E"Y]<8Q0!Y!:WT,-]:6VNZM9Z;8SZ!9Q6;ZA
M;*\4BF,><JL2 ,G;N!//'I7>>#I38^ T>>?4)H+5)?+GNH]LSQ+G:P!)XP/E
MSU&*Z2;3[*XCCCFM+>2.,Y17C!"GKP"..@JP    , 4 >$:3=Z.^O> M1C>*
MVLKEKZ.)9F7<ZEO^6C\ N68?+CJQJCX5T^TC\$>"-82VC74AXDAMOM(7YS$S
ML&0GN/KTKWQ-.L8O]79VZ?.9/EB4?,>K=.O)Y]Z/[/LC&(S9V^P'<%\I< ^N
M,4 >/:VVD:GX&^(,NK"%=8BG?S5FE^>,KD6P7." 1T'0DD<Y-=Y?7-]-\*7G
M\/N9[XZ6OV5K<[BS; /E([]>G>NDETVPGN#<365M).4,9D>)2Q4]5R1G'M5D
M *    . !VH \UT*Y\):F^@&Q=;W4?[.-C<012!RD6SYA<J>>",#=W8^M<Y8
M_9C\._A@RA7GCUFU&\#<R F0L,XXR0..^.^*]GAL[6WEDD@MH8I)#EV1 I8^
MY'6F+IM@CETLK96,OGDB)0?,P1OZ?>Y//7F@#S*",0ZSX>AO+B#5].N]5N)+
M.[0[)T<H^Y)5;.Y>6!QC[JYK#T2XL['P%X9B<QQ6<FM/%J.P[<0?:+CRQ)CG
M87! SQU]Z]IBTVPAN3<Q65M'.<DRI$H8YZ\XS2KI]DB3(MG;JDYS*HB4"0^K
M<<_C0!XU\3[:SM;?Q4-(,+1S6MM-J,:29\F<31B,A0.&9"<\],'O6QI_A[1Y
M?B78V;Z;;?9+GPS]IN(!&!'/+YR#=(HX<\D_,#S@]0#7I<>EZ?#;_9XK"U2'
M(/EK"H7\L8J3[%:><LWV6'S578K^6,A<8P#Z8H \=TAH[KP/X2LIT,\C:[/'
M;QS2;8?DDFVJ^>J@ 84<Y QTJA%/!<:"426VD2V\=QK:+"P9(HB\9(B]$RQZ
M<<^]>UMH^F/ ('TZT:(2>:(S I4/_>QCK[TXZ7I[>9FPM3YC^8^85^9O[QXY
M/O0!YWXBTBS^'%_IOB?1[#-HL[V^HI]YMD[C#@GD8?:.N,$#'>NS\*:1_96C
M[I;=8+V\D:ZNU!!/FOR03WP,#\*K:SH&IZYJT<-U>Q)H,;PSFVC3]Y))&P8!
MF_N[@IXYXKI: /(UM[37O"7BVXUJT@M/$D=V\D@(!N(&48MBN!N&5P%(ZY)!
M.35H1P1^(/$$VH011W,WA:.2\$FU5<X<,9!G.<*!GT'7BO1Y],T^ZN8[FXL;
M:6XCY262%69/H2,BG3:=97-PEQ/9V\LZ*561XE9E!Z@$C(!H \:\*V^B%?!#
M:S%II3^P[DQ?;'C9#()D*X8DC=]X\'(YZ<UZ;HUUXLEU*1-:TS3+>R .R2VN
MFD<G/&05';WK6_LO3B;8_8+7-K_Q[_N5_=?[O'R_A5N@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *K71Q+:_O&7,IX'\7R-P?Y_A5FJMX$,UGN.")C
MM]SY;^WIF@"U1110 4444 %%%% !1110 4444 %%%% !1110!D:QK\&E7%K9
MI#)=ZC=D_9[2(J&<+C<<L0  #G)-<GXP\<SQ_#O6M0TF">'4K,FVN(G*B2T<
M_P 1YP<9!!&>H]ZT_%.AWH\2:3XKTRW-Y=:;'+%)9[PIFB<<["> P/J<'I7/
M:OX'U35?#?BN[AMC'J_B 1 6DDR[843H"1QNY8GGT% &_P"!=#BMX%UM(+ZQ
MFO+9%GM))E:*5Q\WGX&?G;)YST[4E_\ $6VM+C7K>'2-1NYM%9?M*0JN2A3>
M7&2. /Q]*8GP^TO67TO4];M+B/4K&WB@54NSL'EG*G ..O/XUS.G7FK6OQ5\
M=#2-)74)W-N 'G6-%/DI][/./I0!VTWC6S>=H-+M+G4Y8K>.ZF6W 'EQ2#*-
M\Q&21DX'/%2/XPLY8--;3+>;4)]1C>:"WCPC[$QN9MY 7!(&#SDXKF;+P]K'
M@GQ%]MTRP?6(+^SM[.94=8VA>%0JN2Q V')Z9(Q59_"^O^%6T;6]$LQ?7,*7
M$=[IYF +>?()"4;@85AW]!0 _6-<MM9\2> M5\V:TM)+BYWQS-LQ(J$%6'(.
M"&YZ<=:Z4^-[:WT=-3O["ZLXKBX6WLUEVEKEF^X5 / /^UCWKF?%/A#5_%LO
MADZOIL,L*RS-?QQ3 ?9ED7"A#QN*]<\\BH;[PYXSU?P]#%J"12ZCH.H?:M.N
M&91]N2(D('4?=9@ <].: -'7_B%-_P (UJATJQF35K.6&&:!I$)A64X60$$J
MP.. #UZXYKM])N[B]TV*>[LYK.<Y#0S;=PP<9.TD<]>O>N(U2+Q5X@\&ZE)/
MH<5C<DPO;V*2*TLFQ]S!FS@$] .V,]Z[K3I;J?3X)KVW6VN74,\(;=L)[9[D
M4 <#=ZG+I'Q7URZCLKN_V:+;OY$!!('F/G&2 .!^-;5O\0])OM6T"RL8YKF/
M6XI)+:X7 5=BLQ# G(/RGMWJEJMMK6D?$&?7+'1I-3M[ZPBLL12HAA978[GW
M$?+\W;TK!3P+K'AK5?!U]96T>I'3Y[@7<=OMA5/.5AE0> @+=/0"@#J!\0;;
M^RQ='3+Q9VU+^S4M69 S2_[V[:!@$Y)I-1U;3[]_#4NK6%_:7<NIE+6 L/DE
M7>OSE25*X!(_"N>A\-:TWA?5;76/#UOJ GU::=K47'SO"0=KQNS?*X.,9/3/
M2C3O"OB"+1_"@:WE9-.U@W"VUQ*AEMK4JRJK,.&89SQZX[4 =+??$&PL8M2E
M:QO7CTNX2&^(0 P*P5A(03DKANW/'2I-3\>:=8H9K>&6^MXXEFFE@90(T8!@
M<,06)!S@9.*YO5_"VNWEA\0O+L5\S6I(4LH_.7YU5%0L3V'&:JZ1HGBWP<T2
MZ5H\.HVVIV]N;A)YE5K2Y$01B?5/E'3^M '27/Q+T@1S3:?#<:E;VT,=Q=26
M^/W,<@!5MK$%N#G"@X_&KK>,X7U)[>TTV\NK:&YCM;BZ3:%AD?! *DAB!N7D
M CFN,U_PMXEOKV+?8!]7@2..PUZQE6'9\H+B://*!MV!@\<>N="]\.ZI<^,X
M=4@TA[+5(KR+?J4$P\JZM% 5Q(N>6('IG&WGB@#THD 9/ KCS\1-*75+2V,4
MJVEW=&TBO6= AE )QMSNQE2-V,5UTB>9$Z9QN!&:\[T2P\6:?,?##6426%NY
M>#6@$/[K=N"[#U?DK^M &A+\1[> :A!+I%ZFHV5S';FP+1^;+O&5=!NP5]ZL
M7WC^SMK_ %JQMM.OKVZT>%)KF.!!G#+NPN2,D#!_'BN;U&T\9:CJ*^)K+2%M
M=8M;\VEM;2%0DMCM!9I&R>2V<8QC XZYK:??ZKI7CSQ-?V>@W5[<WUI:SR6B
MNJ/;R% NPEB P&WEE)':@#K9OB%I3:?:W6G1R7YN+;[6(XF5"L0SDDN0,Y!&
M,Y)J6U\=Z;?R:;'8P7-R^H6#WT2HH^ZN/E//WB3C\.:Y>+0?$W@EM,N-)T^+
M6TDM?LU];KLB*/N9PZD]5!=Q],5L0:-K*>/=(U2[A$D46G3I-)$%"QNSY$8&
M><#C/?% %FS^(FFZGI.F7FG6T]S<:@S)'9[D2167[X)8A>#[\]J?)\0-/$%F
ML5K<R:A=0-.+%ML<B*C;7W%B%&&!'7GMFN#T3P;>IX&T_2?$/A66]@%Y-)(L
M4P6XMRQ^5U(89&,Y&?2M0Z%XKTB70_%"6']J:K!9-I]Y9R2@R,A<LK[\X+ !
M=Q[Y- '21?$73+RQTZ?3;:YO)KZ%YTMUVHZHAPY.X@9!(&!R>W0UU&GWT6I:
M=;WT <13QB1 Z[6 (SR#TKSSQ-HFIZWI5LNL>&VN;M!)+;RZ=,BR6,Q)V@,2
M RX"Y[9QD'MWNAPWMOH5A#J4_GWR0(L\N -[XY.!QUH YG4;K2T^*FG0R/J7
M]H)ILLJI&X^SE >=R]2_IBI+'XC:7?VVC7<-K=_8]6O&LX+AD 57YV;AG(W;
M3CT[XJGJFE:K)\7;'5H[&:338-*FA><,-H=CD #.<\>E<OHGAG7K'P!X.LI]
M(N1=:=KT5W<Q J2D2A\MUP?O"@#OKKQM96NH>4;.\>R6<6LE^B9B28G 3KD\
MX&0,#/6J\_Q$TFUM?$,\\-R@T*Y2"[7:"<,P"NN#R.2<=>.E96G6OBO0;ZX\
M/6>E0R:=<7$D\&J!UV0*[%B&0\E@2>._%<UXA\)>)O/\=Z9::2]Y%KJP7$%X
MLJ*@:/!92"<Y)R!^% '>W'C_ $V"]DLQ:WDMQ':07CI%%N(CD<+D ==H.XX[
M XI8?'^ES3WH\FY6VL;B:WNKID_=PM&H;D]>0>/I6!H.D:O:?$N/4KG2KB.T
M?1;>U,H*E5E5264\_AGUJOX>\+ZO?^'O&UA=VLVF2:M?RS6S3;3E&50"<$_W
M>1UH ZFU\?:/-<W<%T9+)[>W:['GX D@'&\8)[Y^4_-[<BLB77/[7\<>%G2T
MU"W21;IT64XCDBV#;)@-CG/ .6&>GIG3V'BSQGX9U+2=0T&WT9Q9- LKLKF=
MSC 0@_*N5&<^HJ>$^*M5\0>%9[GPQ)9Q:6TBW,CS1$,6C"%D&20.I'? QWH
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MQ 2N26*C Z&J,/B_4)]*58_#FHC6"!&;:5-L:R="3)TV#KD=NE4;"2^T2_\
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M H*2B-'+;@<\Y;^$#@5T/BG7O^$>TE+E8UDFFN(K:)6SC<[ 9./09/;.,9H
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MUGNZF8XXSSY;U;JK=J3-9D+G$Q/T^1Z +5%%% !1110 4444 %%%% !1110
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M([O3+F:\DGGM3+]JGE!#NPWJ1G<>YQP,\5O7'B%(/%]GX>^SN9+FU>Z$V1M
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MPW%NQ+89<#D-@C_ZPKU&B@#AM7\'ZWJ&AVMB^I0W=R=0BO[JYN"R#<C*0D:
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MM//4YZY]^M8D7@+1(=/M;"/[<MM:W'VF)!>R_+)G.?O<\\_B?6@#D=1UF_\
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M)9M,M625UV-++*TKE<Y"[F).,]J .9U.Q,&H>/)8[J[,CZ8LNUGR@)BE  Z
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M-W.;*:SAMUADDWAW7JX'&S&!ZYW'ICD ZBBBB@ HHHH **** "BBB@ HHHH
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M6FV^HQZU8BTN"5BEDF6,.1U #8.1Z=:O-JVGIJ<&FM>P"]N(FFB@WC<Z#&6
M].?T/H:\DTCPXGBFV^(6D>88G_M?S[1FZ)(OS!@/0L"#]378^ KV?Q(UQXDO
M(S%.(UTU8RP8 Q,?,8$?WG)_!%H ZC5=9TW0[,W>J7L-I!D+OE;&2>P]:L6E
MW;7]LES9W$5Q;R<I+$X=6[<$<&N)\6RP+X[\/I)-'9S-#,L5W=$&'DJ#&%.
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MM+E@=Q[G(  'Y9J+X<!$7Q3'$5\E=?N?*5?NA"J'Y?;.>G'6J/EZ6/BSK_\
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M>*<Z=<?VFUW]A?3E(\Q)^I4D\8VX;/H0: +GA;PPV@6[RWM_+JFJS +/?S*
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MR%E!\C?RLC$'&PKR"*8_Q$V7&IVG_"/:JUY:@206ZHNZZBSCS%YP!QGGG&*
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M\:^+3J%\396:6VP/PL0*G('U/X\UNZ3XEL-7NY;.(7$%Y$@E-O=1&.0QG@.
M>JD\9]0: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"X_UEO\N?WA
M_#Y6J>HIEW/"=S#:^>._RD<\>] $M%%% !1110 4444 %%%% !1110 4444
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MYQ@CG%:M '&^']&U"Q^%4.A7-LZ7T>GM:E%<<L5(R&!Z<]<BL/1_"&M6>@>
M+2:U43:/=-)> 2*0BE7&1SS]X=*].IB2QRE_+=6V-M;:<X/H?>@#SG1=&\1Z
M==II<GAS2C!%>>8-6RF[R"Q;[N-QD&<9Z<UZ21D8IDLL<$3RS2+'&@W,['
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MA;5+6TCN/*DD6(JS9=6 4DE@.>P/T2^T76KS7?$U]%I4BPZCX>%K LLR!O.
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MWULT N=1DFARRG>AQ@\$X_&MG1-=L?$-@U[I[R- LKQ9DC*'<IP>#R/QK2H
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MU_7+F[CNH-+U"XLA;B)5\YC*D<3!L\!<\@]<]:ZFP^'&E:;>*]KJ&KI8I/\
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M6[RI<3,,B,.'0)C@9/K5?6_'^N:)<R27EM:6XM%C62Q*%WNMV-TBNK$1 8(
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MUV;RIX.>H!]* /4XM>@6_LM,N@(]1N+0W4D:L"D0&T-EL\_,P QG/6M/S8R
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M96%O9>%OB5);6PWPW;P+N\Q\1D*6) )Y'7<1QW.,T >Z6=TEY:0SH5_>1J^
M0<9&:F#*20""1U&>E>;FVET#5+G4-)CD+WGAY[@QAW;?.A0!@#\O ?H!W.>U
M9_A*")K_ ,/:Q;>);9I+Q=MS! LDCW1V'(DS(P4@C[VT8QCO0!Z3K>LVV@Z8
M]]<I-(H9(TB@0O)([,%554=220*R9O$6MV, N+_PRZ0LP0?9[Q960E@ 7&T
M+SDD%L?3D8OQ(C>UU;PGKMQ)MTG3=0+7G#$)N ".0!C (QD]-P]:[6]O+&WL
M_-O)81;O@ N00^>@'K0!;I"RJ"6( 'J:\U-NNNKXSO=0GNH+_2[N5+5EN'00
M1QQAXV"J0""=S'(.1Q4&AI=^*-4N(]:GF:*Z\.6,\\"NT>)FW,Q &-O/8>E
M'J)('4XI:\:BNM2U?PYX7>62?55CTTW-UI(F^SW,@W%1<*P/S;>@7CJ#U-7_
M  >=.O/%.D?9;O4IK2YT"5U%[.P=B)E3Y@&(WA=P..>_7F@#NO$.O2Z)-I2)
M9^>E[=K;.^['E9'!Z<_I5Y-4@N'OHK,_:)[,[9$0C[Y7(7).,].O3->2:%*\
M_@WP\TL\D[+XDD17ED,C!1(X W9.>,=?PK<T?2(8-0\>7=J)EO?MDJP%96SN
M:%6. 652<DGD\>HH ]!TRYNKK3+>>_L_L-VZ;I;8RK)Y9[C<O!_"K@((R#D'
MO7E%K81ZA?\ @&SNM0OFAN=*O-ZQSN!*=D0^8@>C,<G'('/8T[?5+U/!5E9F
M2\GMD\0&P:.!SYSVX8X0$?,<>W.!0!['7/:QXD:PUFUT/3+ 7^J31&Y: S"%
M8X =ID+D$'YL#:,GG/05D^ ]-U*RU/Q \_\ :$>DO=YTV*\<E@N,/PWS ;AQ
MGM3/%WAVS\2^);>*RO[G2_$MA;"YM[V(94Q%F78PS\PW<D?3F@#I=%UM-9^V
MI]DN;2XLI_L\\5PH!#[%;(()!7##![UJUXSJ'BC5SX:N=/UA8+2_M=8AL-3O
MX6,<4Z$ ARP 9<C:O'3CL>$\1VVI:#X4\9(NN !K6&YAM+6>1S:GY%)\QN0&
MP2!F@#V>L[7+Z\TW2)[NPL'O[B/;MMXSAGR0#CZ D_A7GWBS13X3?2O%$%UJ
M%S:6VIB?4(I+F1E6&3 +8!Z(WS =.>>*-6M;BT^'>N:P-0NE.J7J7<3>:P\F
M%I$"JO.0"O/']Z@#U%22H+#:2.1Z4M>;RI%XDU/Q7:WNM2V%SI31):8FVK:Q
M>4CB?Y6&[>Q).XG 4#CG-6\:?Q/K&M6+7J17-K91MIURU[)!\C1[OM/EJ,.
M^<\X^7'% 'J5%>.:E?/J-N^K7-W<WNG-;6T2ZA8S.C6$@'SRO#\I*,WS=_E]
MJ].TVQM8=6U&^BOGN)[L0F2,RY6-53"X7HN>3GO^ H U:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "H9T9I+<J.%D);ITVL._P!1TJ:HIFP\(QU?'3_9
M/O0!+1110 4444 %%%% !1110 4444 %%%% !1110!7O;"TU&W-O>VT-S"2&
M\N5 PR.AP:;/IEA<V0LY[*WDM1TA>(%!]!T'4UC^(M8,>IZ9X=M)S%?ZJT@\
MQ>6AA12SOC.0>BJ>F3[8J&T>S3Q[<PQ:Y?2S1:>HDTMF+Q1 $8DYY+$?4GG/
M:@#:.C:8;);,Z?;&U5@PA\H;,COCIFITLK6.ZDNDMXUN)%"O*%&YE'0$^E<
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M8$>2YX ;CCJ.OJ*P-2UZ71O'\C7NHN-(&CR7K6Y3_5;& 9@ ,MQUSTH Z/\
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M0%13@XYY/J!CZY>MB\ATKPK;ZK<0W]S#XE@A%RDGS #?M9L #?C 88QR?8@
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MVCOI9K6#P_/>B%PH5I0Q 8[0,_='Z^M2_:=?TG3(O$,7B:'4+.XTR6>6.Y4
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MXODU9O#-A9:Y<03WMAXCM8U:-MSF)MK(9<<!^3VZ 'OFK/B7Q?KT#_$6*WU
MPC2H8!9E44&+>J%L'').XX)Z9H ]>HKS>X\0:GI'BB0"\EN8)?#3:CY,Q!5)
M8RH&WCC.XYZYJ;1KGQ %TG44U0SVNIVSM,+R6,@SL@,7DA?NC.01TQCB@#T*
MBN#\%:[?7>J_8-3EO[>\%J99K+447?YFX9:-E4!DZ\#ID<"G37VI^(]3\26.
MG:O]@O-)=4M84D7:S^7N#R_+N*$L 1DC H [JBN%T[4]5\5:OK%K!K M8]/B
MMUA>Q5&CEE9=S/N8,67(P ,#&<Y[9&@^(O$GB>T\..]^EL9KF]LK\0Q;?-$8
M.)$)SAAM^F2?04 >HT5X]<:_X@TSPEXAODUZXG;P[J@MHMZ1DW,8D52)3MR3
MAR,C'3IFM^_O=3O_ (@Z_H*:S<V]JNC)/$+?"O!)O^\"5ZG\>* /0JQ;;Q-9
M7&IZS9/%<VXT@*UQ<3Q[(F5DWY5L\@#KG'XUPNF:]KD>G>!];N-4>XDUBX2Q
MN;8J!#L97.\#KO!0?-GG)XQ@#)\>:EJUSI7Q*LY]0G-OIYLA;HFU0B. Q4XZ
MYW<GJ<"@#V,7MLSVZ">,M<(7A&?OJ,$D>HY'YU/7FXMYXOB;I]R^H74Q70VF
M _=F/[XRHP@ !QU !-2:1K7B34-)TCQ#%,WV6X<2W45RT/E>2P;"Q[0&W@[0
M,]>^>E 'HE%>>^']:\3:MIN@:PMQFVNILWBS+$$\MBP"H%&_<I"CD^N:?X=\
M1ZF_B2#3->DO+*_<SJ8)X4\BZVD[6@<*.  3@\XZYQD@'?T5S.HZE?R^.+'0
M[:[2UMFL9+J5E"M*Y#!0%# C SDG'I7&ZUXG\26"V5BVI?Z0GB0:?).D**9H
M#'YBY&, \C., XH ]/GTZSN;RWNY[6*2YML^3*R@M'D8.#VJS7):U_;>A_#3
M4))-7DGU:TM99?MB6ZY8C<0-O3@8&?;/M6)<:QX@T'Q+H$.H:F;N+7H)4E6*
M)52VF2/>K1 @G;V.[/J<8Q0!Z117CD7BOQ)I_@_3/$-WJ8DDU*Y73883&K(-
MTK$3D[@-VQ6&,$9V]N*Z+5+_ ,9V;:LD,<LT3V\<MFI\DW"[7"S!53ALJP()
MZ'C'>@#T&BO-U\<3.]C8VM[,\]_K(L\W4"Q36L8C5F5EP/F)!()!R&^E3>)M
M8\1>'=&U27^U[62:"^M6MBR(7^SR2*A60  #DM@@=!0!V&I:U;Z7>Z=:RQ7$
MDE_/Y,?E1[@A )+,>PX_6ETC6K76EO&M!+MM+I[20R)MRZ8W8'7 )QSCH>V#
M7,:G=:YHFNZ%9RZO]I@U'59 <PJKK#L++&2!S@CJ .PY[\M#-K6E>'O&NMZ/
MJ<<$ECK]W/\ 9S"&6;!4,LA//(QC;C'OG@ ]1CUBWEU^;1E2;[1#;K<.Y3$>
MUB0 &[G@\5&WAS26UP:T;,'4@NT7&]LA?3KC'M7*6GB#4]4\4ZK;PWLUI:MH
M=O?6R36ZEK=Y"Q.Y<9)X&03GKR*S]%\2Z\P\#ZC>WQD36E>"YL]B>6IVY616
M W9^7)!)ZG&* /3Z*\GN/&6O2H?L>IH^J'6OLDFEQVZ,UO;[MI)&"QX&_<3C
MG%=MXJU*[TK3;"&TNDBN;R\AM/M,P'RAC\S#C;NP#@$8R1Q0!I:MH>F:Y%#%
MJEE%=)!*)HUD&=KCH?UK0KS[6]8U[1]3UK38M4,Q&C-J%G--"FZ*1&VD-M4
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MF&Q#'(6%6PH4GJN,8KK)="TJ;3%TV33K9[)5"K 8QM '8"KZ(J*%10JCH ,
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MG&X]^0?RKUF/2["(702SA47;%KC"#]Z2,$MZ\5!:Z!I%D(Q;:;;1".$P)LC
MVQDY*CV)[4 >56FGV:0?"Z1-PDNXEAN'$IS)&(2X0\\@,!@=NE,U)SI/AOQ;
M96<HBL+36[=9%@)/E6[%"^%YP.3GJ,9Z5ZXFC:9$EFJ6%NJV0 M@(Q^Y &!M
M].#4J:?9HDZ):PJL^?- 0?/GKGUZF@#D_#ECH-IXM>?1]2:>2YT_=+#;^6(
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MR>E6M(T/3M"AEBTVW\B.:0RNH=F!<]6Y)Y/>@#1HHHH **** "BBB@ HHHH
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M2:Y^R"UV*)UFW[-C*2-ISSR1P<UF>(O'[6WAN2\TS3]0^TI?+8S*;<.UK)N
MRZ!N0<X!!P<CGD9P+#PSX@TSP_<V<VE3-#+XB>\D$+Q-.T#,-C)EBH.0-V2"
M!DBKC:/J:Z9XM1-%OH6EU2VO(=DBF29$:)CL.[[P"-W_ !H [N[UJ/3]!N=7
MO[2ZMHK>-I)(657D"K[(Q!_.N;LOBAHUY)#&UEJL3W%F+RU!M&;[4-H8K%MS
MO8;@"!WSZ5M:Y#?ZMX*U"!;'9?7-I(BVIE4X8@@ MP/UQ7$:5X0UZVU#X>R2
MV&U-'L9(;UO.C/EL0H'\7S?=/3- &UJGC#1=8^&^H:M<QZK;V:[X+B*&-EN8
M9%.&4XSL((QDXQ[5=_X372=-L+2&%-1O=FFI?/L3S)(K?  >0DC+'/098X)Q
M7-OX:UYOA_XPTC^RI/MFIZA=W%LOG189)7RN3OXX'.:SX=&UJ+76BLK&^W)H
M%MIM_P#9'@.)-O.2\BC<HQC&>&.>M &OXB\36MWK/@_7-.GO[C3I6N'$<$,N
M9U"\8BP"QR..._'!J]?_ !&BD\/Z9J&EZ?>R2WNII8- \026%P_SJRL1@X![
M\9!.,5G:5I_V^7P@=%TZ[BL=#FFMKJ.[9%EMRHVX8;N2>ORYX-1S:)XBM[&>
M0:1-(5\5'4DA26)GDMV;@CYL Y/0D8ZT ==XQN)_^%>:[<Q_:+*==.GD7# 2
M1D(3U4G!XZ@_2J?ACQ?IUREAI$BW<%P+%'CGNHF2*YVHN_RI&QYF <G';FM7
MQ)9W6M>"]5LK>$QW=Y82Q1Q2, 5=XR I()'4XR"17-+H6H>(8_#T5Q:7=@FF
M6<J2RSE29)6B\K: &R1R6)(P0!Z\ &Y9^---O-0M+41744=\7%G=2HJPW.TG
M[ASGG!*@@;@,C(K3U;6(-'@A>6*>:2XF6""&!-SR.W0#H , DDD  ')K@]!T
M+Q!#;:/I<^@VUI<Z9*@;5&D26)X4! ,2Y+*[9(P0, DYYQ6SX[DN8[_PVUA:
MM<7RWY>-8W3?M$;;AM9E!!& <L,<=Z +=OX_T.XLK^XS>1/8,4N(9;5U99,X
M$8.-KN3C"JQ)R,=:JS?$S1+33[ZZO+;4K5[&>*"XMIK;;*AD^XQ&<!3S@Y[&
MN-U'2KO7;2ZMK32[R/Q#!JD.M2VVH+'$+M5W1[4*N0  ,9)[#US6AXGT#7/$
M?AO4UL_"_P!@GN)K)ECEN8C-+Y;EG9FW8V@$!03G@\#- '9:7XTTK5+F_@*W
M=@UD@ED.HP-;;HB2!(-^#LX/)Q59?B!I(G:&YM[ZUD-BVH0K-",SP@9)0*2<
MX_A.&]NM8^O^%=5U?7M=,5J$M[W04LHKAI%QYRNS;2,Y Y'.*K6]GK6K69BF
M\'+87MO8202W,T\;;W*$!(,$_*20<G '2@#<L?B1I&H:4VHV]GJIAQ!Y0:T(
M,YE8JBQ\X8Y4@\X'K5?5_B'!!X2?6;#3]1D=+X64EN;<^;$XD"L&49YQT]21
M63;>'M:T_P"&WA+2IK"4SV5Y$;Z. QO)'&-Y)0YX.2HRIS@GWIK:+K-IX;\2
M6MMHTZ8UM+Z&-91(;B'=&[!,L?G^4Y' R>#UH Z?4?'5EI9(GTO5V\J'S[HP
MVN\6JYQ^\(.!T)X)X!/2K6J^+M.TYK:.)+G49;F$W"1Z=&)V$(&?,(!^Z>Q_
MB) &37*SZ;J6E^+M4G_X1FYU6PU\+(VR9%-O(L>PI("P780!SD]<<]*72]$U
MGP_XWM=9FTL7$-[I<=C+'IP 2TE0[@,.V=F!C=GKCUH WOAU<&[\%6EP9KB8
MR23-YEQ+O<_O&_$#_9/(Z8%8>C>,M-\.+?Q:O>WLRRZY=Q-=-$[PVG[S"+(Y
M&$7&,8XZ^AK?\ 65Y8>$H8+^S-I/Y\[&(XS@RL03CN00:YSQ!HVM:YX3UWPJ
MFER"ZNKR66*[E*B 1-<%U;=DG.W@@#/MW(!U.F^,+#4_$.J:)%;7<=UIJAYV
ME150J?NE3NY!QG^>*NV.NP7V@'6%AEAM_+:11*5RRC/(*L1@XX.>:XCQ3X9:
MVUG16TN]:"?4(QH]X(N&>$+N:08_C55(R>F[I7?3Z7:S:*^E"%%M&@^SK&5R
MJIMP!@^@H YGPFE]XFT>T\1ZAJ=VC79-Q;6UNX2.",\*I&/G..26SR>*LV&K
MWOA_0+2W\0&ZU#6))YHXX[:$/+.HF8(V$PJC84))P .O-4?"<NL^%]#M/#NH
M:#=3R6:&&WN;)D>*=%'!)8KL;MAL<]#Z%_:ZW;^(-&\376G+<-!!<6US;6?S
M21)(X,;+D_,0 H8#N20<"@"W+\2/#T/AZ367DNO+BN$MIK;[.PGAE8X"NAY7
MZGCTR<5;M?&NCW+ZJLAN[1M, >X6[M9(F,9SB15899200.,\=.F?.M?\$Z_/
M;^);Q+&5FU?5[::.UC=3((8OF9F()49V\#)YQW.*ZB_TF]E\=>(KI]$:_LI]
M)@@2)RJI<,'8L@8G&<'OB@#2N?B!IUE97%U=Z=JUNEO)"D@EM@"%E'R2=<;.
M""<\$$'!%:DFMP7%_J6DQI<Q7-M:B<RE %*N#@H><D$'M7G=]X6U;4?#/B+3
MX4U"YTT+%-81Z@O^D+(IW-$H8?.@!X)/). 3R:ZVU&IW'B:[NI-+NXK*XTE$
MB:1E^5P6)5ESE2<C@9]\4 <?:^.+CPWX2\%1QI?W<^JS^9<R""6Y9X\MN5<_
MQDD8 Z =*[D^.](%XD#1W:Q&=;66Y>';%!.PR(I&)&UN5[8RP&<G%<*FA:S!
MH_P[F31[SSM(O#%=0KD-&C8RW!&5P/IV/I4NO:%J^H6^J@:->O=?V]!.AB54
MA,2R)\ZKNRQ*@EF(SGTP* .PU+XBZ!I;WRS?V@_]GW"P7C16$K+;Y&=[G;@)
M@YSW[9R*IW'CEHOBA!X>6.5[!].^T>9#:O-OD9UVD% <)@G)/ XYK&UK1-6G
MM/B:L6GSR-J"PBS"KS-B!5.WUP<BFZ%H^L:;\0-!OI=)NGMO^$=BLY)%"@12
M9CR&R1C&T\=>. : /4Z*SM%U"ZU.P:XO-.ET^4321B&5LDJK$!N@X8#/XUHT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5!<'$MMR1F0CO_<;T_K4]0SQEY+<A0=DA/)QCY6'X]: )J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K)N?#>FW5_+>LD\5Q,H65X+F2+S .FX*P!Z]ZUJ* *NGZ?:Z58Q6
M5E$(K>(81 2<<YZGDU:HHH **** "L[4M"L-6GMY[J.3S[?/E2Q3/$Z9ZX92
M#6C10!3L=+M=/,C0+(9),;Y996D=L=,LQ)-7*** "BBB@ HHHH **** "BBB
M@#&T[PKHVE:M=ZI9VA2\NW:261I7?D\G 8D+GVQ6S110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4%PH:2W.]5VR$X(^]\K<#^?X5/44Q >'..7X
MRN?X3^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45E^(-=M?#FBW&IW>2D2_+&I :1NRKGN:T+>7S[:*;:5\Q VT]1D
M9Q0!)1110 4444 %%%% !17+ZMXXLK#61HUC9W>K:H"/.M;)5)@4@$,Y8A5'
M([_RJ;0_%T.MZU<Z4NFW]K<VMNDUQ]IB"B-FZ)G/)QSD<>] '14444 %%<[X
MD\7VGAR>VM3;7%[>W*NZ6MMMW[$!+.=Q  &/7J:C\(^.-,\9M?\ ]F1W"I:.
MBEYDV^8&7<"!UQCUQ0!TU%<S/XWL+?QW:^$7M[G[=<HTB2;1Y>T(7SG.>Q'3
MJ*Z:@ HHJO=W]K8"$W4Z0B:98(]YQOD8X51[F@"Q16#8^++&^\8ZEX9CAN%O
M+"%)G=H_W;*V.C>HR.N,]LX-;U !16!X9\5VWB=]3C@M;BWETZZ:TG28+Q(O
MW@"I(.#D?A5;QCXZL/!"6L^JVMW]CN'\L7,2AE1L$X(SGH/3^1H ZBBJ>E7Y
MU33(+XVTML)E#K'+C=M/0G!(Y'-/O[^TTNQFOKZ=(+6%=TDKG 4>] %FBN8\
M,^.-/\47MQ:6]M=V\L427""X3;YL+YV2+@G@XS@X/M73T %%%% !1110 45A
M:SXMTS1] U75]YNH=+<QW,<&"RN-N5Y(&?F'YUM12+-"DJ<JZAA]#0 ^BBB@
M HHI"0JEF(  R2>U "T5S4GC6P:Y$=A:7^I0JQ6:YLX#)%%P>=W\70CY<UK:
M-K-EK^FIJ&GR-);N[H&9"ARK%6&#SU!H OT444 %%%% !17/Z#XOL->M=4N8
MTEMHM-NI+69K@!>4."W!Z?6N@H ***BN+J"T1&N)DB5W6-2[8W,QP /<F@"6
MBBB@ HI&;8C-@G S@#)-9'ASQ#;^);">[MH)X4ANI;5EG4*VZ-MI.,\?CS0!
ML4444 %%%% !16)=^)K:S\5Z=X>>VNOM%^DKQR[,1@1J&/)Z_>'3/O6W0 45
MA^+/%%KX1T==1N[>XG1YT@5( "VYNG4@ <5N4 %%%% !116/K/B2PT72[R_E
M9IDM'6.5(1N96., ^G4&@#8HIL;B2-'' 8 C-.H **CBGBGW^5(K['*-@]&'
M45)0 45FZ-K":REZR6MQ;_9+R6T(G7;O*'&]?53V-:5 !1110 45F3:Y:0>(
M[30F#F[N;>2Y7 ^4(A4')^K?I6G0 451U#5;;3M-OKV0M(EDA:98QEAA0V,>
MN"/SJ>RNEOK&WNU1T6:-9 CC#*",X/O0!/1110 44A(&,D#)P,TM !1165KO
MB+3?#VBWNJWLX\BS'[P1_,V['"X]3D?G0!JT5'!,MQ;Q3*"%D0. >H!&:JZ7
MJMOJ\,\ML)0(+B2V?S$*_.C;3C/4>A% %ZBBH[B>.UMI;B9ML42%W;T &2:
M)**KV%[!J6G6U_:N7M[F)9HF(QE6 (.#[&K% !1110 4444 %%%% !112 @D
M@$$C@^U "T444 %%%% !1110 4444 %%%% !1110 4444 %0S,H>#<N27PO
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M+DOJ$)WR$DEOO<=3[5!XH7Q9XPMX[;6/A[>RVT;B185U*)5#@$;N&SG!/YT
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M$DDJI4["2225QD\U.WA73UM+""V:XM38N9(98),/N;.XL3G<6R<[LY))Z\T
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M)=5MTMKIF=/F5 0I&%X/S&F0> M(M3HSV\EW%<:1!]FMKA)!O\O^ZW&&'X4
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M:Q<K<RQJ5_=N  =I*GKM'Y#&* ,RPO-7TSQ!JMI_:@O$_L<7MO;W*K&ENX+
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M;5,D[@[EW' X#!>F.%QWK9M]%CMO$5[K"7$IDNX8XI(CC9A,[2.,Y^9OS]J
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MFXL2<T >LKJ%D]V;1+N!KE>L0D!<?AUK.LM4GCN]4.JW%A!;170BM2LPSMV
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M6NV\/VMMIGBE!::]!/;7UEOCTZVB;RQMQ^^R9&P2"!T&?J* .VHHHH ****
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MAI<4=Q+ );-E$J!9"H"D-]X8Y[<]3743:_!I_P!GLH;:]U&Y%J)VC@"-(L?
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MA;B2VA>9/NR,@+#Z&D;3[)KLW;6D!N"NTRF,;B,8QGKC%9MAXIT^_P!;U#2
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MS\::/?ZA:6EN\SB]61K2<1'RKGR_O;&[XY^N* -F&PL[>XDN(;2".:3EY$C
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M2KY+A&=!EE5RNTD ] :I7?Q'\(62NUQKD"JER;5B%=@L@ )!(!X 89;H,]:
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M[2T>W>T>:2!MDD38R0F>&^5>^.M=)XF\.Q>)]#?39[JXMB721)[=MKQNI!#
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M*Z'(R.X]: (U\07\/B5M!OK:UBN+F!IM/F1V9)M@7>&&,J06_$5B?"RTENO
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M7+1\V$MI:FUB9/F9-HDDYY(X/'O0 [2/',MWKO\ 9=Y;0)*=(_M1A#(2T/S
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M%Q \<$;&&5F<$Y8$-G;T/X8K$T#QAK&MR^$])FO#;SZCI3WMS>)$@:1UP J
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MP+%>PQ%=LVU2JDY!(P#CC%=/)+'"NZ6144G&6.*0SQ!48RH%<@*2PPQ/8>M
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MIVI^'/!EKHDD;:W8WUL);=?EG@51MF\Q,DC&,'=GGO6!=2VI^'?Q'F$D)?\
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MVMU)=6]A;13R1K$\B1 %D7HO'8>E,LM"T?39$DL=*L;5T4HK06Z(54G) ('
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M!DD#:PX)/7TKV*\TG3]1N+6XO+*">:T?S+>21 6C;U![?_6'I40T'1Q&L?\
M9=F46<W*JT"D+*3G>,CAO?K0!Y-XE-QI6A_$6QT.)H8K>XLU\NV7'E0M#&9"
M,'.",Y]B:W;&X\/?\+>T7^Q;NQ>-]#EB46\JMNVNFT<'D[5/O@&O0;?2--M+
MBYN+;3K2&>Y),\D<*JTI/)W$#+=3UJ"P\.Z+I<D<EAI5G:O&&5&AA52H8Y8
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MP_?W365W=V2WBM!#?W:&XCMBOS?-SDAL[4/)R!U.:]$H AN[N&PLY[NY?9!
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M%6!/((P0>.>,'K0!E^&/%6G>&?"/A#29;?4+BYO]/$D(BC\S<1&9"N6(Y/(
M'L.!6W=?$#3+*V^TS6E]]FC2![J=8UVVOFXVB0%@P/S#("DBN;M?"6O"?X>R
MR66T:+&R7NZ9,I\A08P>1TZ=NO-0>./#?B#6SXG06,]PTD<(T_RI L1C5E=@
MRD_-)E6 ]B/>@#MI/%UO'X@O]$;3M0^UV=F;T?+&%GC! _=DOSR<<XQWQQ4&
MD^.M.UG1].U.UM+X1:A<M;0HZ('W*2"2 QX&T_ETJGXF\/7VJZOX?UVP26VO
MH9#:WB;T.+24$2>H+*=I';KP>,+X9\*2Z)K^H1A FC6\WGZ8@V_*\J_ONV<
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M'3?#^CR-=?:;K3DFAGEW/'.0/G59& +,.">.A%:LWC/1((8[AYY3:/.8!=K
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M?4$4-YK1L@0$E0FU0<#)QR>O<\UNUP=_XMN]#TZW@A@MTCM](2\:XNBP20@
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M=@#&'#@_)+\P(]>O0'UH [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;V%$^SI'@)(,[I <]6& >!T[TZY\76<=]H<%K&UU'J[L(9D("JH&2QSS70T
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MX@\8_P"FVWF^('@"_*P6)$159CZG[Q"^PYY..]J%[NWCNXK5YE6>4,T<9/+
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M;2I;=;JRO([E8[DE4E"]BP!*]<\#M563P]K;^-=5UKRM.:VN=(%C$AN9 S2
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MMII(M+")9F,$J* 6F5<[3EB0&&>%JKXS,U_X@TO1;;4]0A>>VN)#;Z?,87!
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M[E:<F251T4MV49/ ]:DNO"M@]S;Z@3?2W5E9/:0>7/ABC#D#) W' Y)'0=*
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M*MT+95\M+,H 5DP>""5 0\_,W'%<UX>T^U3X*>(+N:WBCGAEO8XI73:50O\
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MT.!FNY\/0J/B3XSG!^9UL4(W+_#$QZ9S_$>HQZ9P< '84444 %%%% !1110
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M7-Q+;->"*WCR5A7&7;.,#G [D]* */@SPI-X8BU1+BXAN3=ZC+?1LD94Q[P
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MDMI!)$6QC*8S@Y'.,5M+J]HVK2Z8&?[3';BY8%#C820"#T/(Z4 2G3[(Z>;
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M3I5GGN;Z&Q4/&X6%W9<^:."F%.>><XXH T7\$^&9))7;1;0F6[6]D&SAIE!
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MS^5->R>5;J58[WQG&0,#C/7TJ[0!Y_X>\-7VE?$V_O3;N--&EV]G!,QSO,8
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M],TZ*[O-)YDTZX.T2JT>QAG! (ZUWU8TGBS0X=/U._DOU2VTR4PWCM&P\IP
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M[N,-AP054]2![\XXH KV?C*[NO%YT629;6^%Z4-A<( &M@K'S(Y!P['"G&>
M3QQ7>3,Z02-& SA25!. 3CBN0M_!-Z+RP:[UM;BTL=0DOH8Q:;9<L7*QF3>?
ME&\\;>:ZR\MUO+*>V8D+-&T9([ C']: /-]/\>:JOB?P_IEZ\<SW\LUM>11P
MXC@E5=P"2CY7P" 0"?K69!\1/$/_  CMKK$L]N1_PDC:7+$+<$-#G@CD<C'K
MS726?PXFMSX8,VORS'0)7:(_9E7?&5VJG!XP!U.XG)Y]*8^%,@\,IH_]N)E=
M8_M;SOL?5_[FWS.G/7- %F]UW4_$,'C*'3)X8;;2XFM8@Z ^;+Y>YRQY.WD
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MW@E($D84L5!!)/ R IK1\,6-NGQ5\:E?.W1K8,,S.1DQN3GGGZ'@=J .^!R
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M1&Q/7:06SU.1F@#T"BFN@D1D;.",'!(/YBO'-2O=8CLO%?A2QU:\E\16U_\
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ME\Z4$I;Q(/F<@?>/8+QSU(%$[>)=*ET>(75OJ=M)<""]E>T*3!2#B3*L%'(
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MH#7M):*VE&HVWEW)80MY@P^W.2/8;3ST_.EU#7=*TNW6>]O[>&-@&5F?J"0
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MS+<N-8G2XE(8*T4B !60@<$;15OPYX4@\/233G4+_4;N5%B-Q?2B1U122%7
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M!6BU6Q%K]CO8D@A;"PDB,K$SDG=)T)!]!QR,^R6-NUK8V\#L'DCB5&<#&X@
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M=*F    & .U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5C7VW_ (2O1\J"WD7.#GI_J^V?Z5LUE7AC
M_P"$DTL,LQD,-QM93\@'R9W>_3'XT :M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 6BL?7M>CT9].@$?F7.H7(MH%)PN[!8DGL  35O2[J[NK%9+^R^QW.YE:'S
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M)DU"X%XTA@"M%/@_,N,<<C@YZ5;LI%C\4V/BB^TWQ/<ZU;6YMVECLTBCF&&
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M?P[X=O(A?7'B:+2[W4+F?S/.@B) 3  3#@D 8]3U-;6KZO::)I[7MXSB(,J
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M[NJNY5U*QC:<+\_&3V]\UV=8^J>)++2=9TK2KA93<ZH[I;[5^7Y "V3VX(H
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M70YC9&3386^P@+;=?W0 P-O/'%27?AS1[ZXDN+G3X9)94"2,1@NHZ!L=?QH
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M2%F;D!7E9P<'HV]/RZ<<@'"^'!JOB2;P9_;%[? W&FWC7!5M@N$W[4W?5"K
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M99B<=\9XS6WXA\.6-OXW\(QB2[*7%_>RR9NI!@M;NQ"D$;1GT(].176+X/\
M#T>EIIB:1;+9(XD6!5PNX8P?KP*N:EHNG:N]L]]:I,]M)YD+'(*-WP1ZC@^H
MH \ZF-[H6OZSX7_XFES#KR+)I=T9GF\L$!9$!+?*$!+Y].N>*]*TVPBTK3+:
MP@+M%;QB-3(Q9B .Y-<_I%AK][KR:EKL%E9V]BDL5E:VLC.6+$#S'/ &%7
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MGD+LQ^3+Y]_0' [ 5TY\(:.=6U+4F@D>?4X/L]V&F8I+'MVX*YQTS^9J'3O
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M+E[5)C&8I#. 2,=#@=>O-==+X,T26YN9OL\J"Z<27,*3.L4S#NZ X/OZU/\
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M#K,B2S1E@!&R !2A !'W0>2>14WA?PC9>%X9/+N+J]NY0%DO+Q]\K*,[5S@
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M(/"UKX=CC@N_^)A+;QHW\;1 MCG@D;L=@2* /499XH(C+-*D<:]7=@ /Q-2
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MR_S8)0' SR.!V/X5M5DW#%O%-BF&.RVE;/0#)4>O/3T./;N :U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (<[3MQG'&:QO#.ARZ!I\UI)
M<K<"2XDN-P3:078L1U/<\5M44 %%%% '.:YX6DUS6[.[EU6ZCL(4V3Z>A'E7
M'.1N_3/L*Z( *    . !2T4 %%%% !1110 5FZ_I"Z]H=UIC75Q:^>H FMVV
MNA!!!!_"M*B@#F;7PYJDD]JVLZZ]_#;.)8XEMUBRX'!8CDXZ_6NFHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Z;9S0P "&.2!66, 8PH(P.!VI'T;2Y+R.\?3;-KJ/'ES&!2Z8Z8;&1BKU%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ER*&\3P,6DREJV
M.%Y8=?4\>_X=]2L]P[Z_%F%?+BMRPE."06;! [C@"@#0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BD!SG@CZTM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9QP/$:DS%2;7 CVC#8;KGV
M]/>M&LORF/BGS?,CVBRQL*C=G>>0>H% &I1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %90!_P"$M9L+C["!G//^L/;TK5K.'F?\)(W)\O[&
M.,G&=Y[=/ZT :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5D!O^*P=<#'V!3G'/^L/>M>LT$?\)*PVMG[&/FV#'WSQNZ_ATH TJ*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,$<G_"3M+C]U]C"YV_Q;
MSWQ_6M.LL*?^$J9MK8^Q ;MG'WSQG^E &I1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9H)_P"$F9=O'V,'=\W]\^^/TS6E68(I?^$G>;R3
MY7V,)YN/XMY.,_2@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit101-iansconsultin002.jpg
<TEXT>
begin 644 exhibit101-iansconsultin002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D @'OP*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD7<5^< -Z Y
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***CBE\W?\ NW3:Q7YQC/N/:@"2BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***BN+B.VB$DA(4NJ<#/+,%'ZD4 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1C/6BB@ HHHH **** "BBB@ HHHH ****
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M=9M4=8;K5XI$$@PR@XX/Y5T'Q8AC?P)<RL@,B21!6[@&10<?6@#N*0D*I9B
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M.V,R>X96VGZ&K<WB_4_^$XFT>VDTB6..XBA-B\C)=[&VEY5S\K*%); YPIH
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M&/:@#DM-\,7LOB3QA)J-DJV&K0QPQ2M(KM(JH5.Y1TZY_'M4.AZ/XOMK?3M
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M/DO8WUO!'%)YF9"T:*N6&.,X)X-6_%6DZGJNN>'7L[>)K:QO1=3RR2@8 !7
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MXB63RF8,5!&0"1Q0!SW_  B-W;-XDAT^]@CLM:8R>3)"6\B5TVRN#GG=UP>
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MRWOVQ;;*QR>6$PN>!@?CS[UNT44 %%%% !1110 4444 %%%% !1110 4444
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M$/ [GUQ63XDO=4M-$\?Z(^LW\T>F017<,[LGFLLRL3$QV_=!'&,'G&<5V?\
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M?G0!YZ9;C0-&UG3K2YN%CNO%!MWO);AE,2,D1 :3EAGA P!//XT_Q(FM>&?
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M9!8PR2R)$#^\F;<[DDDLQ[L222?4UQNI_$+??^$O[#A-Y9ZT\I9D"E]J(24
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M<-W & 3A1D"K/@OQ-:VOA;P=I]U'=*^H6$:07#I\CR+'DKR=V<*2"5P1WYH
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M34;>+S7(VJ(U!"!5[<$L?4L>G06=3T#0/'']GZA+-)<1V4KF)K>X948@X96
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MK23[-% S-=W/E23[VP?*7'S[5R21WX[UTGB#4I]'\/W^I6]LMS):P/-Y32;
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M4>*VN1 3$Z/M#!E))^ZHZ&I-?\ :GJVE:9:0:Q")[:\6_GN+F%I&EG!!X 8
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M%0BXX.PG/ [$BNZ\6:"OB?PO?Z,T@C-S& DA!(1U(96P",X8 U@#P=K+>*-
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M(D#+QG/WLY)R3G@8  /1**\6BU/Q1>:5XQNH?$]U%-X<NY&A:1(R+A%7<5E
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M-?Z^L]R;&[<1V,4C,$\I!CS IX^<Y(..F/6@#2U/7K73+NTLBDEQ>W38BMH
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M!P"<#I[5OOJ-E$[I)=P(R8WAI -N>F?R-*M]:/<BV2YA:<J7$8<%L#'./Q%
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M;_:95+;=L>=N_'89XK&\7>,8-(\%'6],NK:43F-;:8_.A#L%WXR,@9SU XH
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M\H#&S!;:?^!=P#U&:Y7P'X)6WTM)==TV[AOH;V>=(9[LR1?-(61Q&KLF0#Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2:L/&VI:9;RRZ?=:7 D)CB)%S-DMO08^;Y2HR*];VK@C:,'J,=:  JA5  '
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M,2#\H[9QC/OQ47B35-<O?C)X>TZTO[:*/[(]U K0EA'N3#;OF^;.#@X&,]Z
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ML>29"C9[\=1G@CWI]AXIU;Q/K$>E6D\>GLNCPW[2*H9GDE3*@ ]%4\G@Y]J
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MUU)9BW"%1A?+7&,\DGCO7I%5[Z^@TVRDN[EBL,8!8@9ZG'\S0!,BE8U4L6(
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MB!GO+@C7(EBG4D$(H0IA/3Y2?Q.:SYOA];-!I1MM4O;.^T^$6PO;?:LDT(&
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M$@/&<C(."/J/2O,M(U?S+KP-J<\H?1QIYM97:#RUAO/+7YFR!@$ J#TR:W/
M4#'7?%5];9_LNZO]ULP/R.P4;V49/!/?C- &GK^KZA/K</AG0YHK;49K8W<M
MY*@D%M"&VA@F1O8MP!G'!)IUK#XCL/$%E;W6J)J&FRI*SNUJL<J, NT%E^4C
M.[& #S@YK*\0W*>&?B%9>([M+A].NM/.G2R11%Q;LLGF*S!<G!RPZ<8'K6W>
M:S#JC76D:9YD\TEF[FXB_P!7$2"$!;^\3V'(QSB@"Y%XBTB?4DTZ/4(6NW+J
MD6>6*_> ]<=\54N?&GANSC:2XUFS1$NOL;,9!@38!*9]0",^E<!>13:Q\.?#
M6D:8CPZ_:WEO$R;B);9XR?-<D\@85CN'!S@9S3!;6)\-?$K[1;PL6U.=HPT8
M)(,: %1CGYLCCOF@#TW4/$6D:4X6_P!0AMSM#Y<\!2< D] "0>M+)X@TF'[?
MYE_ O]GJ'N\M_J5(R"WH,<UYOXOOG@MI=0TNZ)NDTJW\[3[F'S;?4;8LWRA<
M</N+#UP>E'BB]BM-6\;:?-'*EUJNA8LHT@=O/80R A2%ZCC\Q0!O>-?$-_9:
MOX*;2K]5L=2U)(IPJ!A-&VTC#'H,9Z=<^U:VF>.=(U"YU>-IX[>/3;EX&DD8
M@-L169CQA0"Q'7M7!ZU<QWNG_"]X/,(@OK;S0T;(4"JH)((!QD=>E17=XMAX
M<^(EC+:&:Y;6GNO)DBD*^2_E!9,KC(RK< Y^4T >H6WBC1+NSNKN+481#:1^
M;<%SM,2XSE@>1Q4%CXT\/:E<?9[34X99_L_VD1K]XQ^H'?Z>]>=75_97TGC4
M6D]Y=&Z\.,R//;,GF$))POR*,#*@>ON:G\.QQVUW\,6,*HYM+M)6V@$$Q #<
M<=R"!TYX]J .^\,>+=-\5VTT^GLV(Y73:RD$A6VYY QG'2L'7/%;^'?B'''J
MFJQV^AMIK3>7(% $@;!P>I[<?Y#/A9>Q)I5[I#I,E[!?74LL;PLNQ6F8KR1C
MD'(Q4WB4V-I\0]&O=3A'V,6-RGFR0[T#94XR%.#@'KU[4 =%_P )3H7EZ=)_
M:MKLU)@EFV_B=B< +ZG/%6XM5L9]5N-,BN$>]MD22:(=45L[2?KBO.;;P?+K
M7P]U-;6-]-GFU2;5-(W*4>V^?,?!P4S@\#[N[VKJ? T?VS2G\0SV[PWVL;9I
ME<<J%&U5^G!(^N: +&J>,M+TKQ'8:)-(?M5UO)^5L(JKG.<8/)48]\]JY[PQ
MXSBMI]:M_$.J$O#K$MG!/+L5=@QL!V\+]2!DGZXG\53+9_$[P;>3)*+<17L)
MD2)G =UC"@[0<9P?R->=:PH?1/BJL:22)-J,#6X*LV]M_P Q7UZ'IQ0![7J?
MB/2]'D:.\N0CI&)755+%$SMW-CH,\9K2CFCF@2>-U:)U#JX/!4C(->1^)KK3
M[/QQ/<ZW8ZM<:?JFF0)!/ILEPHE8;LQMY;*"#G(R/6O3-$M3%X>M+66R^R!8
M0AMO-,GEC'W=W?B@#F]%U75/'#7>HZ=JDFEZ/#.]O;^5 CR7)4@&0EP0JYW
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M)%&ZX9AL)! /0>U,BAD/AWQ[';V.M,EYI8:V>^6226;="5 RV6W9(^7MGH*
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M:^@AE2UQ"7)!R\@]/[S>@':@#T+4?%>EZ7/<13M.QMHEFN'BA9UAC.3N<@8
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M(F !4@D=N.G?O72T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;6_A3XJ,-M+97NGR&SO$,N-C!U!*,!\RD'OCC/X@'I%AJVFZJKMIVH6EXL9
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MCJ!WZ$FN>\5^"O$&NS^)(4739[;4(56SFN9&$EMA1E54*1R5'.1U[XQ7I=%
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M ,X/K0!JZ5K?B77?%NN:?;7MG;VFGR6<BEK?<Q22/>T9YZXR,]B*)_$/B%/
M,?BN*ZLG;<+E[0!3'Y!?!0.2#O"XS_M @ \5T&D^%8=(\2:KK45]=22:D(Q+
M!)M\M=@VIMP >!QR3UK-3X>VB6YTP:C>?V$;@7 TSY?+#;]^W=C=LW_-MSU]
MN* .9N?%'B"6X^(9CU$0IH.V>T58@<A$+E&S_"V #WQFNAL]<US^VO":3SPS
M6VLVLLMQ&D&!$RQ*Z[6],G')^E2GX>69'B?_ (F=]GQ$-MT<1_("""$^7CY3
MCG/YU;'@Y!>Z%=?VK>;M&B,5NNR+# IL;=\F>5 Z8H X.W\7>*G\)>)?$JZC
M&QTG59(_LIMP5DA18P5SU'!)SZDFNITS[1+\0O$SFX<1BTMB$8 C!5N!Z#-<
MSX%\/)K\/BJQO+JZ339-:DDDLUC58KA#M*D$J&P2O., X%>@CPO&GB:YUJ._
MNT-S D,ELK+Y9VY /3/<\9Q0!YGX1O\ 7-'^%ZZMI$D1@M-4N)+Z%XPQ: 2G
M>RG/4#)QSG''->E:)K,FOZK=W5E,&T6%(XX7"?Z^0@L[ GG: T8^NZN=:R3X
M?Z%'X=T[3M4UXZK)/Y2%8]J.PRPD;Y0%.2>_0UU7A71E\/\ AC3],5 A@A =
M1T#'D@?CF@#"\.O]N^)/BV>8!I+'[-:0$C[J&,2''IDM7&V-_J^@>%]1U^TU
M%E@M?$$T;V31 K,LERJ-N)YR,Y&.E=]]AN-%\;S7]I92SV6L*BW;1X_<RH-J
MN1G)4K@' XP#ZT@\!V 6>W:[NFTV:]^W-8G9Y9EW!^NW<1N&<9Q0!DS>)=5@
MUGQ_"L^8])M;>XM%8(-C-&Y89)Q@E!U]ZJ">]U+QGX(OI+VX66\TR>1D4#R4
M;RU)(7'WCNZYZ"NCO? UA>:UJ>I"[NX?[4MA;WMO&R^7, I56(()R Q[TH\$
M6*C0RE[?)+H\30PRK*-[HP *L<=.!TQTH L>)+K4;:\T!-/G2,7&I+#.KKD/
M%Y;LWT.$X]ZY6;Q3JNE)J>FO?K+<)K4%A;W<T0/E), Q:0 @8'S 'UVBNPUW
MP^VMS:?*-3O+)K&X%Q']GV?,X!'S;E.1AB,>]97_  K[3IKK6IKV\N[M=6>.
M2:-RBB-HSE"A5001QW/2@!D=[J6A^.M-T6>_EO[758+B;=.HW0O'MX7 'RD-
MT]:A\3?\E+\'_2Z_] %;UAX=2UU,:C=7UU?W4<9BA>X*_N4.-P7:!UVKDG)X
MHU+PY!J7B#2M8DN9XY=-\SRXTV['WC!W9&?R(H \Z;QCKMKXFTHM?_:TN]:.
MG3^2@^R+&3PJ$X9I .K#*]1G-9VB^([WPOX=\;:NDQN;@:[]G0W!! 9A&JLQ
M]%STKN3\-+!H;.(ZMJA2QU#[?: R+^Y;).P?+]W)[\^]6U^'NBAM:203RV>K
ML9)[-W'E*Y !=1C(;Y1SGCMC- &8\_B;P_;:A<3:A;W-I_9LUQ%Y\X>59T3=
ME0% :,@=.WKS6OX..JWFCZ;JU[J1GBO=+M9/):, I*8P7;/^UGI46F> ;'3]
M,GL9]1U'4%DA>V22\F#O#"P 9$( P"!UZ^];NBZ5'H>BVFEPS2RPVL8BB:4@
ML$'W02 .@P/PH \EO(KI?"OQ1,EU)=-%>,,R@$X$<;>W &<#^==?9ZAJ5CXQ
ML+9KJ5K'4-&:X59@/)@DCV#@ 9 P>=Q .1@YXK2N/ NF7+ZX'GO!#K0_TJ!9
M<(20H+ 8X)"@9^M22^#K>?4-.NY;^[8V5HUF(R$VR1L,-N^7J0%Y&/NCWH Y
M#P]XDUN7Q+HXGNYKN"^::&YG!3[)(ZC<#;#ARH'&_P"Z2#@GK39_$>MV_A.\
M\17&HW!ETG73;R6Z(J)<0_:$BVMP<?*<@CN:Z6R^'EA82Z2T.I:ELTJ5GM8V
MF!54(QY73E1^?OBK,O@31Y?#UWH;&Y^QW=Y]MF E.YI/,$AY]"R@T 1_$I"W
MP\UMOM3VZI:N691G(QC!QS^54XHM7TC3O#:IJ\DJ3W<2W*W&UF9#& $0@#@$
M9Z=S72ZWHEMK^ASZ1>/-]EG4)+L;#.N1D9]\<U5G\,P3P:9 U_J CT^02(%G
MP9"/NASC)Q_2@#B=0U76M#\0^)]%?4KRXNKZQ$F@^8Z@"1_D"+D %E<@Y)P%
MZ]S5AI]?OO%%QX:CUB<3:7IT,AECF6)KF5P<N<JV0"!P.F[FNWO]!L-1UC3=
M4N(\W.G,[0, ."PP<GKTS^=9VM^"M-UO6+?5S/>6>H0KY?VBSF,;/&>J-Z@_
MGZ4 9'B;7=6TOX1W^I/) ^JPVI1Y;5_,0/G:6!&.G/T-:+>$[/5OA]9^'3<R
MPVGD1 R6I"E@N#P>>I&:U3X<TMO#;: ]L&TYHC"T3$G<ON>I/?-8=EH5[JGA
M1= U.2^TV?3Y$CBN[2;!E5#\D@/3D#E3^(Z4 2>&;W5K?Q%JOA[5+L7J6D<<
MUM<&,AVC?( <C@L,'I53P,L6G^)?%VB0>2+>VO4N(UB)P@F3<5/&,[@3U[]!
MQGH?L5OH-M?7]K:7%W=R_,X!WRS$<*H)/ _(#K5+P;H5YI%G>W6IO&VIZG<M
M=W0B^XC$ !!ZX4 9[D4 8%W>WOBV^\66D&I7FFQ:.IMXHX0%:1BA)=\YRI(P
MN,<9]:QM+N+]/#7@32[74[N/[3I9<Q6"_,Q"*0SNV=B+GGWX '2N\O?!VG7F
MMSZL);NWN+J'R+L6\Q1;A-I4;QZ@'@CFF6W@O3[*#38+*YOK6'3X6@C2*<C>
MA.<.>IP: .)77M=F\(^$/&C:G/\ 9/,B75X5*I&8BQ0R8//#;<X/?/ SC8U*
M?Q'<:/KVIZ3=37"RWD8L88I%SY"8$GED_P 3'?CDY^7%)>Z+=Z3HW_"#:/HE
MU=:5>6\B"_FN%,=MO;E64\[0I)&.3@#N2.OET&R?2+;3(Q);VUL8S"+=S&5V
M'(Y'T_&@#'\ ZJFK:/=SI?7UP!=LHBU!0MQ;851Y;@>X8CV85R%SK^LPZG;:
MG;ZQ/=VD_B*.P 3Y;8P2,4"H"N691R6!QN]:].T_3(=-%QY3RNUQ,9I7E<NS
M-M"]3V 51^%<U)\-M&D0(+B_2./4%U"WC2<A+>0.&PB] N0>.V3C% &3H^@F
MY\:^)8#K>L*(U@4NLX5FRAZG;V[8K"T:6]T[P'H-G8:C.?[6U"2SD,TK(R@&
M7(C<)E&8K]X@^N3UKTVT\.V5EKUYK,+W(NKS:)@TS%#M! ^7H,9K,'P^T,^'
MWT2073V9NGNX_P!^0T+LQ;Y&&"H!)_,T <MX@N_$6C>$[B*?5D^U6VK6OD-'
M*9I1"\H(2;:H9OH!D@8YKLI-#DM/">IZ?+JU_<>:L[BX>7$J!LG:K#H!T'M5
M2;X<^'Y]"?1Y4NVM995FE9KES)*RXP68G)Q@5U+Q+) T+Y9&7:<GJ,8H \=B
MM2GA'X:[+RYD,^JP.'EP2A,,F0HP,#Z^M$GBO5M#C\7Z=_:LTD5KJ]M:P7=R
MP+VZ3C+L6/ "\D$C ^G%>@)X&TB.STVU#WIATRX^T6BFY8^4P& ![ $X'O2G
MP+H+S:S)-;/,-8(-Y'+(61R.A [$>U %+PY;:]IWB&:/4-4CGT^ZA\R"&>Y$
MLX=3@LI"KE2"IZ<$UA7.H>(?$OB7Q1IMEJ L7THJED8[@1X)CSOD4@EUR?85
MV/A_PCI7AK>;%;AY&4)YES.TK*H_A!8G ]A537/A_H'B#5QJMW#<1WOE^4\M
MM</$9$X^5MIY''2@#C=?UG4M0@18=6NI+NST5;N1=+8Q+'*2P,LA8?,I"C:@
M!/4X (-:[7>I:UK^CZ>VIW%O!J?A^5YO)X*R'8-ZGLPW''Z5OW/@70[F]N+K
MRIHFN;5;.=(I2J2QJ"%##N0#C/L*ELO!VE6&HV-_#]I^TV4#6\3/.S?(< @Y
MZ_=7\J ,#P_$]M\3_$\3SO-)'I=@IF?&YR%D^8XXR>M<QH>OZHWAOPO8OK$J
MMJM_=B>[DN/+D^1B5B5G!QDX' (XP.HKTR/PS8Q:W>ZO&]RMW>QK%,PF."J@
MA<#MC<:S'^&_AJ3PXFA26DCV<<[7$1:4^9'(Q)+*W4'DT <WK<VMZ!X>6VDU
M?SFCUBUB0"8O,D,C@;9'&"3SD''(QUKH[\77@7X=:G-;75UJ<]A;RS127C>8
M_<C<>I _D*E_X0#0_P"RH]/(NS$EPER7:Y8R22*059V)RV-HQGL*Z6:&*X@>
M&:-9(I%*NCC(8'@@CN* /- M_H\'A[Q%9ZMJ%[+K5Q!#>6DUQOB82H23&IX0
MJ<D8XQG.<5-X'TIH?''BYO[2OY/(O(@0\H(ES$.7XY_2NLT[PGIFES6CV_V@
MK9[OLT4DS,D.X$':IX'!(^E2:9X;L=)U.^U"V>Y\^^D$D^^8LK,!@<>PH X1
M=/<?'^8?VA?,O]EK<!3+D#+L-@&.%X'%96FWL^FZ%HFMP7%['+!KCZ:UC"6,
M!B>5]R^7&I4D9X*Y' P3TKT^?POIEQXFA\0LDHU&*+R0Z2$*R<X!'0]36=#\
M/=#M])M]-A-['!!>_;T9;I]YG_O%NIYYY[T <Q=7&HZS_:NL6NM&SN=,O'$:
M2W3)%;*F 1+#M!8,!GYO4$4_XP_Z=\.;&9;J11)>6N6@<H'#'!]\<Y'X5TE]
M\.O#.HZV^K7-BS7,I!G42L$GQC'F*.&Z9YK8UK0--\0:2^F:C;B2U;!"@[2I
M'0J1T([4 <+?17FI^)3X5_M.]6"UT^.XC9;TP33.S-EBX7Y@N ,#L>:?&-1U
M*XT/3+O7YI9;W3;RRN;BQG5%\Q#&?-3."7[?+DCGMNKI]6\$Z-K0L3>)<&2R
MSY,R3LDF">06!R0>XJQ'X6TV&]TZY@$T']G1^7;112E8T4C!&T<$'C.>X![4
M >7:I-J0T3X@RG6]1\W1KJ)[1H[AUQLC&%/3(/4@<$^M=7:27FG?$S2XO[0N
MYX]7TV6>YBFD+1JZ>6%,:]$ZG..M=!_PAFBF'6H6MW:/6FWWJM(2'.,9'I5H
M^'+ ZI8ZD1,;JRA,$+^8>$.,@^N<#/TH \I_MG69? _C&X&KW@N;;7Q;0R^;
M@K&;A8MN3P!M;MCGFNI)E\.>,?$$!URY33Y=(_M!I+VX$GV:4R.N4#'A<#H!
MC@<CC/0IX(T./3KVP6"3[/>W7VN<>:<O+OWYS_O8/X"K-]X7TO4IYYKR*28S
MVOV296D.V2+DX([\DGZF@#@?#S%-32UO/[=2#4-!DEDCNIII&8JP'F<*1&Q&
MXX!SRH(!P#7DM3HWP8T&YL+_ %"&68V+LWVER3N(RHR?E7#8P,< 5WUCX*T;
M3]0LK^*.=KNT@^SQS23NS&/LK9/S =L^IID'@70[?1CI*Q3O:>:LH22=FVE3
ME<9/ '8"@#)N(F\2:SXGL[F_NK9M/6-+7[+<-$T8*;]^ >23QR",#%<W9:AJ
M7BG4?!3WEWJEDM];7]O.D,K1K+Y:C;,,8P6Z@\^W3GT>^\-Z??ZC_:#B6*Y:
M/R9'AD*>:G]U\?>'/>E'AO2UO=,NDM_+DTR-HK0(<+$K !@![@ 'Z4 8GPYN
MKF32=6T^YN9KD:5JUS8133N7D>-""I=CU/S8S["NQK/TK1K+1A="S1E^U3M<
MS%F)WR-C<WU.!6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117 Q22>)O&?B/2K_4[NU2PCC6T@
MM97@9%8',VY2-_/&#D#;TYH Z?Q#KBZ%9P2>5YTUQ<);PQEMH+,<9)] ,FG:
M-J=Y?M?1WNG26;VMP8E8G*3* "'0]P:\XG:?5O#WA:XU*YGDN(]8-L+@7#1>
M:B.ZJ_!VY( .>^>*[_Q)I=O-X)U/3F:Y$'V*104DD>3A#W!WN?;)STYS0!#J
MGBI;'4= @@MOM%OK$H2.Y60!5!7<#CJ>.:UM6N[FQTB[NK.S>\N(HB\=NAP9
M6'10:\WNK6-;#X91 R;9)(RV96)YMQG!SD?ATK,AU;4H/#?Q/MEU&\8:5<2?
M8I'N':2$;2<!R<X&* /9+>1Y;:*22,QNZ!F0_P )(Y%25YCXAN=5@EMKW?<7
MVEIHZF[@L[TQ7-F2#FXVAAYF1GKTV''>N_TFZMYM L;N&X>:V>UCD2>0$,Z%
M00Q!YR1SS0!F:OXOLM'\6Z'H$Q7SM4$I#%\;-H&WCON.0/I715X[J,.L^)-%
MU?7H=,DD$TD=[IEWYRIY20$%-JMADR#(3]>G-=!XH\2R7W@W0M9TO48TL[B[
M@>[,<A622(@EDC ^8OG'RCYL \4 >A45YC']MET?QUJD5QJ,>F?97?2?.N)4
MECVPL9&VL=ZYD!(W8..G&*SKEM5L/#G@^Z&K7'D:T;5=0N;N\=4C_<95<A@R
M[VZE2,E1D_-R >OT5Y%JEUJFA:==6W_"2I-#)J]J6<&4K9Q2$Y0S,Q)4D#^+
M(SVR*?XAN-0TO0O%HBUUY6:TBNH_LDDLGV-LA?ED+'&X<[,]B1QF@#UJBN N
M['?\0=,LUU+4$MK[3IIKNV6\D42,I0*R_/E,9/"8]ZYY?$.IOH&E02ZA]EM1
MXCN;"6[EF<#RH_,\N.1@=_S$*-V1T&3S0![!3)98[>%YII$CBC4N[NP"JHY)
M)/05X]KZ7]CI%W9GQ&UTIUJP*"VF=C:B23#1EV9MW0-M;.,@G@BGZP\T?B3X
MB:-]HN)-/_X1]KOR996<"78?F!))';@8' XH ]6TO48-7TNVU&V$@@N8Q)'Y
MB[6VGH<5;KFO =O;0^#-':WD=V>PMS)NG:3!\L< $G;]!BN1FO'O/ 7B36I=
M8O+75;:><>8DL@\@QR'RU\H-MQC';YL\YH ]3K/UK6+70=+DO[L2M&C*@2%-
M[NS,%554<DDD<"N!72IO%?BD6^HZE?6HDT2SNY;:&X,9,HE?YMN<X^7!&W'/
MKUVOB1;6UQI>B)="4I_;=DH:.1T*YE )+*1CC//;ZT :\7B!Y?&UQX?^SJ$A
MLUN?.W<DEL8QBMVO-GTVSU'XF:K92S2?8Y=#5&*SMRI?KOSGCZU1:])L?!NE
M3ZL(-.GM)P;N68A)Y44*B.P8<8)."?F_"@#U>L!O$;W/B.71=,M#<26Z;KJY
M9ML4#'HA(R=Q!!QCI5/P*C6UA>V3:PVJB&Y++.-S1HK*#Y2N2=P4Y[D@$ UA
M_#ITTSQ/XPTB]4V^I3ZM->QQR+@RP.QV.IZ,,>AX]J .PTK5[B^U+4;"ZL)+
M:2R*#S"<I,&!(9#W'&/KFM>N-\;:U#:Z)>2:?=!+F.6VANYX%W-%$TN#EATP
M"YQG*YSQD9P_$5G'X;O8SX<NY8(+S3[MY[6.<M& L3,LRC=E6W$#<.O'?% '
MIU%>+:!I]H^E?#.Y::ZCO[N)[9YHYBI>'RW<H>V.G/!]\U8U6)-/\#_$G3+4
M.MK:/_H\$<I/E*8T)QCD#.21]<\4 >PT5Y1;VUGH%[X?U"RU&[BO;_3G;4$$
MK3*\$<)8RD$D!D)0#ZX ZU1\+3,OBGPO<VMRAMK^.X)E-SFXO$"[EDG .-V2
M<+R5Z=N #V6BO&DCCAT+2M2BEG\^/QAY:RO(X:.-[@JZD=LJ<'/KUK9\0S2>
M"/%]Q>V]K<W-KX@MC D:!Y-MX"2JCK@.&/' R"?6@#K=<\07&CZYHEF+$36N
MHS- \_FA3$^,K\I^]G!Z>E;]8VD>&]/TW3=+MS;I))8)B*23YF1B/F(/J<FO
M,]9U&Q'C6ZU.Z47^DOJUO:+>03.LUC<1,H,)C;&Y&=,G'!R3R10![+17"_&
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M3]GZ=HT@5YM-G-T5P"Q^< M[XH ];KGO%&O76B3:.EM%"XO;Y+>4R9^52#R
M".?J?SK+\+WFL#X065W(DK:JNF%E61=C%@IV\8] .W-<>RZ,^F>"-6LI;<ZK
M<7T7VJX5QYLDA7]X),<ELYR".#Z4 >RT5XU,FD:G<:^U[XDEL-=L]6GD5FA
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M,5WD#IA5C7! ZOQTH ]+I&940N[!549))P *XGQJZ'Q+X:@U&65=%FFD6X0
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M^,9YSGWKE?#=MIG_  J?PG?2A([W^U[>$7+2A90CS[9$5PVY5*%LKD<$\=Z
M/<+6_L[[S?L=W!<>2YCE\F0/L<=5.#P?8U'#JVG7-T+6#4+66X*>8(DF5G*_
MWL YQ[UY]:Z;I*>*/'6D6]K;1V1L()&M8HU6,,4?)P.^0/TK$T&ULY/#O@&]
MTM89-?\ ,@^TR1/F<PE3O\S!R4  ^]P,"@#UN+6-,GU!]/AU&TDO8\[[9)U,
MBXZY4'(H?6-,CN/L\FHVBS^:(?+:=0WF$9"8SG<<C Z\UX_HTEA_;O@[4+&6
M-;1M3U!9'D(,X!$O-PYY)8@<'T'7%3>(+'2O["\?L+>%C9WT3VP\L!8'*QY,
M1'0ENNW!)]: /6HM8TR?4'L(=1M)+V/.^W2=3(N.N5!R*DLM0LM2B>6QO+>Z
MC1RC/!*KA6'4$@]>1Q[UYYKLZ^&=<TGQI;6WFQ:C9"QNPB[G+L 86&[!Y;Y6
M)QQCBNGT4:3X/T_1_#<ER$N9PPA4H<RODN_(&,Y)ZT =%--%;023SRI%#&I=
MY'8*JJ!DDD] !6)J_C#1-)\.2ZXVH6L]FIV1O%,K"63LBD'&:POBG<VL.BZ2
MEU;-+YFK6PCD:0QPQ/NP&E;^[R>.,^M>::O'#-X<\?QF:*?RM:LYD8QJNS+(
M#(%[#&X9Z$9YZT >]6^IV=QI::BMU;_92F\S"52@'?YLXXK@]8^([W7A/3M6
M\.26LCW.JQV,D1Q*Z*TK*#@'AF"Y&>QKM]+@T]]#@AM$M9+)XL8A53$X(YX7
MY2#S7AY\F+X)^'/LOEI>P:U'YWE8$D>VXE(W8Y& <C/3- 'O%KJ-C?&86EY;
MW!@<I+Y4JOY;#J&P>#[&F6.KZ;JC2KI^HVEVT) E%O,LA3.<;L$XZ'KZ&O*M
M3L9=-U?XA67AF 6LK:9;20P62;27P^\HJC[V,=.<D5I^#YO#^J:]H]YH4_FW
M5M9O!=1VUI]G6&(CI-D#G>HVKUY+#(!- '7>)/$;://I^G6<*7&JZE*8[6&1
MMJX499V(YV@?T%5KN_\ %.E7>EK<1:??VUU<)!<RV\3Q&VW?Q8+-N';.1@D5
MB^.+&XL?'/AGQ6RR2:98>;!=[,L8@^ '"@'CU/; KKCXATV2ZMK2VN5NY[D_
M(MM^]"#&=[E>%7W.,\ 9- %HZKIPU(::;^U%^1N%KYR^:1C.=F<].>E1W6N:
M38BX-WJ5I!]FV>?YDRKY6_[N[)XSCC/6O*IULW^'.MV6H1@>*5NY74$$W#W1
M?$,B #=MP5 Z@+P3C-3_ -FVUSK'Q%BU>VM;F9=.LY098U8&9;9PSKD=0QZC
MUH ]235+"6_-C'>V[W8C$A@60%PIZ-CKBJ\WB/1+9B+C5[&$B4P'S+A5_> 9
M*\GJ,CBO,M!M=/T\?#2XLX;:&^NH?]-E10)9"UN2?,;&3\X/7N*S;[3]"N/#
M?Q!-S;6DNIC4IQ9@1[IUE.W9LP-PR^#QQUSQF@#V.]US2=-NH[:^U2RM9Y1N
M2.>=49AG' )YYXIUUJ^FV,LD5U?6\$D</VAUDD"E8\XWG/09XSZUX9XJF$D7
MC:WN62WU$:79"3[2-TUTX3.(U.,*,-DC/4$XQ746-KI6M_%*R:YM+:[M&\,Q
MAOM$(9&=96&<-PW X.#Q@CCF@#T6;Q'H=O%!+/K.GQ1W"[H6>Z11*/523R/I
M4.K:S"EIJ-O8:GI\>IVUN9=L[[EA]&D4'.,UYMH6D7FJ?!K2+G2O+;7M'FEG
MM%D8 KB=\QG/0-'D8..W05V_@ZVBU.SN/$EU:*MSK(60J[*^(0/D7CC')./>
M@#1B\16UGX?L]1U^>#2WG"JRSOL <]AN^F<>E:MM=6][;)<VL\4\$@RDL3AE
M8>Q'!KBO'<,+ZUI$T&HV]CK$,-P]JU[$'MI$PHD1LD;6((P?8_2MGP*ZR>"=
M+9--_LT&(_Z("2(SN.<$\X)Y&>QH T1KVD-K']D#4[0ZEC/V7SE\SIG[N<].
M?IS3+CQ%HEHSK<:O8Q&.40N'N%&V0]%//#<'BO+=VG7'PMM[-+*Y7Q)#?(JQ
MX)NUO/.!:4D#.T\L6/&WC.<5+;V7A:Y\3^/;;4K2PD=7$D:3Q[3N*')C+_Q$
MXR5]O:@#T"X\8:3!XJM_#_VVT^UO&9)5>=5,8XV#!ZLV[@#G'-)H.I2N-;N+
M_7-/O+:"[D,;0,H6UA R$=NF0.23[\UQ/APW&C^-])G\0))#/+X7@M]TJ[FD
MG$YR@(SN<!E) R0#D\5AV.^'3/$T]JJ/81^+EN;F.(;]UFLH+$(O++T[8(S0
M![!9>(]%U+3Y]0L]4M)[. $S3)*"L>!D[CVXYYI\&N:5<ZA_9\&H6\EYY0F\
MA9 7V$9#8],$&O.O%8M[O4O$=]I<@^P'PY-'>SPIOCDE/^JQ_"[!=_0\9 /6
MBV>T@\3?#!;9X6C73[J-C$PP"8H@ >?4$8]0: /5:*R?#WB/3?$]A)>:7*\D
M44S02"2-D97 !(((]"#^-:U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8^I^%]*U>_6^NH&^UK U
MOYT;E&:(YRA(ZJ<GBMBLN_\ $>C:7<FWO=1@AF"AF1FY4$X!/H,GO0!7N_">
MDWD%C;M"\=O8%3;0Q.52,KT( [C-;,L,<\#PS1K)%(I1T<9# C!!!Z@US&JZ
MU>VWQ \,Z;;W -AJ-O=O,FU2&,:H4(;&1]X]_2F^#]7U34M8\3VU_-YMO8:A
M]GM6,84[=H)!( !ZB@"_!X1TBWATR)(I=FFR&6UW2LVQL8[]L<8IA\&:*8=8
MA^SMLUA]]Z Y_>GG_&M;4GDBTRYEBE,3QQ,ZN #@@9Z$&N/^&OC*]\2Z?/::
MVD<6LVVV214 59(G^9'49)Q@C/N: -N?P9HEPD2R6\GR6RVA83,#)"N<(YS\
MPY/7U-:MYI]O?:;+I\JE;:6/RF2,[?DZ8&.@QQ7':'XKU+7/B/J>E;DBTBWM
M%GM&C4;YOG,;%B<\%E?&,< 5TMMXFT6\F$-OJ$,CL&*8SA]O7:<8;'MF@"S!
MI=I:Z2NF0(8[18S$J*<;5/8&N)\1_#^V73;*QT;1;2YTJ.\^UW>G/+L,IVX&
MQCP#Z@D Y.370:!XTTS7M)N]31_(MK>9XV:3(X5BH;D#J0>*NCQ+HQM+VZ-_
M&L-BNZY9P5\H<X)!&<<'\J ./\/^ ;>.YE9=#_L33)X6@N]/^U>8;K( 4ML.
MT 8/<DY/0=>R?P[I,OA_^P9;-)=,V"/[/)EEV@Y Y[ XQZ8%8OB#Q%9WND2C
M2O$5O92V]W;+-.03L#,K!<8_B7IV.>M;-YXDT?3[B6"ZOXHI(0ID!S\@8X7<
M1P,GUH K6G@SP]9>'GT&+2H#ICG+P.NX,?4Y[^]1VG@7PW8Z'-HMMI<4>GSR
M>9-",XE/^UZC@<>U95WKE[#\8++2OMI&EOHTERT1P%W;\;L_1>_3)]:Z&T\3
MZ+?7T%E;:A%)<3HTD2 ']XJG#%3C! H >/#VE#4;;4/LB_:[:'R(92[%DCQC
M:.>E5)/!GAZ71+C1GTR)M/N)/.DA.2"^<[N3G.><UO5EMXCT=+Z.R:_B%Q),
M8$7G#2?W >F?:@"E!X'\-VVB0Z/'I4(L891,L0R/W@Z.2#DM[GT'I5N3PQHT
MM]=WKV$;7%Y ;:YD).98L;=IYZ8J&[\9>'K%[E+G5(8VM91#/D']VY&0&XXR
M*L:CKVE6#""YU*.WE>(RC'+!/[^,' ]SQ0 F@>&])\,:?]BT>RCM82Q9@HY8
M^I/>F3>%=$N-6?4Y=/B:[DV^8W.)"OW2R]&([9'<UF?#75;S6_A]I6I:A.T]
MU<"5Y)#W/FO^F,"NBO\ 4+32[-[N^N$@MT(#2.> 2<#]2* (5T33DUM]96U4
M:B\8B:?<=Q0?P]<8]J-9T73]?TR73M3MDN+63[R-Z]C]:H:AKEM=^'=;FTN]
M_P!(L890[*N&BD";@"&'I@_C7.Z+K6J2V?@#S+J5UU"Q62Z9L$ROY(;).,YR
M2>OX4 =-#X2T&WF$L&F0Q.(/LP\O*CRL$;< XQR:B_X0CPU_83:'_8]M_9C2
M>;]FP2H;U'/'X5OUSUKXMLKGQ3JNC[PJZ?! [R%6'SOYA8'C& J(<_[1]* -
M?3M,LM(L8K+3K6*VMHAA(HEV@56U+P_I.KW-O<W]C'-<6V?)FY5X\\'##!%%
MCXATK4_^/.\2;]R+@;5/,9Z,..1]*H6GCKPW?/8K;:DCB^=H[=PC;78,1MW8
MP"<' /)% &E;Z'I=KI,FE0V,*V$@8/!MRK;N6SGKG)JI8^$-!TZVGM[;3HUC
MGB\B0$DDQ9.(P2<A1D\#BI;KQ/HME-<17%_'&]NZI-D'",V, G&!G(JA<:A;
MS^+-'6+7)HOM5K,T5BL7RSC /F$D<;??U_, GC\&>'H4LTCTU%6R8M; ._[D
MG@[>>*Q_%W@VWD\,>)#H&EH=9U6W,3LCA6F+'^(LP&!D_A^5)H7C?3+:&UT_
M5-0G>\GN[F)9IH\@$3R*JNZ@(K8 P..V!1!K\MO\3]=LKZ^9=.L]+AN$5V"I
M'EFWL?7MR: -+PIX7L-)T>W9]*C@OY;1(+KS,.Q '*DY(V^P.*GL/!7AK2Y8
M9;'1;.WDAE::-XX\%7(VDY^A(J;3O$^DZK?O8VMR3<JN\1NA0NG]]<CYE]QZ
M5L4 <\? OA@Z:=..CP&S:;[0826*F3^]UZU1TO3_ !'>:\YUN.TATG3KEFT^
M.,[WG&W:C.<G 4$]>2<'L,Z3^,="2W6Y:]'V8W+6AFV-L25>H8X^7GCGOQ5B
MR\1Z9?:C>V$4[+=68W2QRH4.WIO7/WESQD<4 :M9"^%M"34GU%=*M1=O)YS2
M>6.9./GQTW<=>M0Z;XOT;5KU;6TN69I 6A=HV5)@.NQB,-^%<CXV\:*UUX:A
MT/4I0D^M003/"I"2IYFUEW8P1D$$ T =YJ^BZ;KUE]BU6TCNK;>'\N3.-PZ&
MDO\ 0M*U735T[4+""ZLU 58IDW!<# QGH<=ZQK/4;.V\5>(9)_$4TR6UO')-
M9RIMCLE ;+ XYS@G\.IK1TCQ/I>M7+VUI,_GK$)A'+&R,T1Z2+GJI]: )KWP
M_I&HZ2NE7FFVTU@JA5MVC&Q0.F!V_"L;1/#4]IKOB*>]MK+^SM0$44%O$=P\
MI$V%64J ,CL,C%=76#<>,M$M+^2UGN701L(WG,3>2'R!M,F-N[)QCUH L:?X
M7T+2I;>6PTJTMY+:,Q0LD8!C4DD@'MG)S]:+/POH.GZA<:A::19PW=Q_K9DA
M 9NN?IG)SCK7-:]J#:GXV&@C4M0LH8M/:8-9[D+3%]HR1U &"!D#.:[#3+:Y
ML]+M;:\O#>7,42I+<E-GFL!RVW)QGZT 5M.\.:-I%[<7FG:9:VEQ<@"5X8PF
MX#ITK+U#PE"=,31M&M[73M,N+CS;\1K@R)N!:,*./G&03G@=CGBYJGBW2-'G
MECO)90L(!GE2%FC@SR-[ 87CFHIO&NBV^KSZ9+-*MQ#:->Y,3;'A4 ED;HW7
MM0!OHB1QJB*%10 JJ,  =A6;'X;T2&]>\CTFR2Y>3S6E$"ABV ,YQUX%4Y?&
M>CV\=@UP]Q"U^CO;QR6[AV"C)XQD'T'4U'%XZT&72$U,7$HMVO18$-"P=)RP
M7:RXR.2.OK0!K2:-ILVK1:K)8V[:A$A2.Y,8+JI[ _YZFHG\/:-)J\6K-I=I
M_:$18I<B(!P2,$D]^/6JK>+M*V1F)KB:22:2!(8K=S(6C)#G;C.T8Z].10?%
MVDFTLKB"2:Y%[O,,<$+.Y"#YR5 R-O .>Y [T 6&\,Z$]U=W4FCV,D]V0;AW
M@5C)C&,Y'L/RJV=-L6T_[ ;*W-EC;]G,2^7C.<;<8ZUD2>--'2PMKM6N)5N(
M&N$CC@9I!$IPS%<9 !P/QJO<ZGI=WXD\-W":E?![R"62TBA;$$Z%0V9 1V&,
M<B@"35=&U+3-"@M?!$6EZ?-',A:.:+;&\8!!!V@G/3GKQ6EH&E?V-I$=HSB2
M4L\LKJ,!G=BS$>V35!_&VAQR1[IY?L\DWV<7?DMY DR1M+XP.1C/3.!1>>-]
M%L9=2BD>Y=]-:,70BMW<IO4LIX'(PIR>U &]<6\%W \%S#'-"XP\<BAE8>X/
M!JK_ &+I1TV/3CIMH;&/[ENT*F-?HN,=S^=6;:YAO+:*YMY%DAE4.CJ<A@>A
MK*USQ3IOAVZT^WU SJ]_,L%N4A9PTA( 4D=#DCK0!K6]O!:0)!;0QPPH,)'&
MH55'L!P*JR:+I<MW<W4NG6KSW,8BGD>)294'16R.1_@/05G/XQTJ(:P9?M,7
M]D+ONM\## YP5X^;IVKFO^$D&E^/M?N[JXO)M/33K:9+=%9_+W9R50=!QD_6
M@#N+K2=-OGB>[T^UN&A_U32PJY3Z9''0=*2;2-,N+U+V;3K22[0@I.\"LZD=
M,,1D8KG=6US1=1?PQ.FJWXCOKL/9BQ)"W)P3B3C[@Y)''2KM]XTTJPO/*D,S
M0+.+>:[2,F&&0\!6;IG) ]B>: -BUTVPL99I;2RMK>28YE>&)4,AYY8@<]3U
M]:L)&D2E8T5 26(48Y)R3]2237"Q^(;70/%/BHWDU[<+"UM(5WO((8W0GA<8
M500YR#G\AGN()X;JWCN+>1989%#(Z'(8'H0: *HT;2@]RPTVSW761<'R%S-D
MY._CYN?6IK.PLM.B,5C:06L9.2D$809]< 52US7[/0(('NA*\ES*(+>&%"SR
MR$$A0/P[UG2^.]%@TBUU*62:.*XNQ9[6B(:.7=M(?TP: -U]/LI-0CU![2!K
MR-#&EP8QO53U ;KC_$T)IUE'?/?)9VZW<@P\ZQ*)&&,<MC)Z"L3_ (32Q:&#
MR;6^FN[A9'CLXX#YNU&VEB#]T9/!/6MG2]3M-9TR#4+&42VTZ[D<=^<'\001
M^% %B:&*XA>&:-)(I%*NCJ&5@>H(/454ET329YHYI=,LI)8U"H[VZEE Z ''
M K*\=W=C9>#[V74KN^M+7Y T]CQ,IWC&TX.,G Z=Z+WQ=I^FW-[8F*[GN+"S
M6ZF1(RS;#Q^)[F@#5BT328+26TATRRCMIO\ 60I;J$?ZJ!@_C5FVM;>SMTM[
M6"*"!/NQQ(%5>_ ' J+3=0M]6TRUU"U8M;W,2RQDC&589%8OC7Q#/X>T6%K-
M4:^O;J*RMC(#L221@H9L=AG- &Y>V%EJ,(AOK2"ZB#;@D\8=0?7!'7D_G4D%
MO#:P)!;PQPPH,)'&H55'H .E<GJ7A+48]'D;2M?U7^UE7*R373-'(?X@4)VJ
M""0,?=.#VYTM5\5VFF331+;7EV;;:;DVL1=8 03ECZX&<=<$4 :5OI.FVD<\
M=MI]I"EQQ,L<*J).OW@!SU/7UJ(^']%-NEN=(L##&Q=(_LR;58]2!C / YK.
MN?&NDPW6G6T#R7<FHP2S6HMEW^8(P,CCH><<TD?C/39M&34(4F=FNS9?9MN)
M!."08R#QD8/>@#2N])MC!>O:6=LEY<Q.AE"!68L,?,P&>P_(5G>#O#,7AOP_
M86LT%J=0M[9;>6ZBC&Z4+P,MC..!P:;'XTT^4Z<!;7BF^O&L0'A*F*91DJX/
M3@'GIP:H>*?$"7?A3Q=;VAN;:\TN%D=L[""4#JRD=B"* .LCLK2'/E6L*9E,
MQVQ@9D/5_P#>.3SUYIC:;8O++*]E;-)+M,CF)27VG*Y..<'D>E>=:5XWU&T;
MP/I/V&YNEO=&BNKJ=4\QY#Y:=/H3DFNH_P"$ZTH:A';,EP();W^SX[KRSY3W
M&<; >O7(STR#0!#;>&M6?Q,9]0U"UDT.UE$VG6,-N$,3!<#<1V7)P.YP>,5L
M:CHW]I:QIUW-,OV>Q9I4A\L9,N,*V[J  6X[YK(O_B#I5A:W]R;>]E@T^[-I
M=R1PG$+ *26]OG'/UI(_&3S?$(>'(]/N3 +(7)G\O@[F 5@<_=X8=.N* .HN
M+:"\@:"Y@CGA;!:.5 RG!R,@^X!ILEE:2^?YEK"_VA=LVZ,'S%QC#>HQZUS&
MES-X5T/5=0U:^O9+$7+20B] ,R[FVA<CJ&<@*,#&1ZULZ3KB:K/<VYL[NUGM
MPA>.XCV\,,C!Z'IVH TT18T5$4*BC"JHP /05';6=M9HZ6MO# KN781(%#,>
MI..I]Z9J%[%ING7-],&,5O&TCA!DX R<"L"T\>:1=ZA8VNVYA2^5?LUQ-"4B
ME<@'8&/\6#0!U%116T$#RO#!'&TK;Y&1 "[8QDXZGCK7.S^.-.MD>YEMKQ=-
MCF:"2_\ *_=(P;:2>^-W&<8ZU9O/%5K;7-U##;SW7V01&X:$ ^6)/NG&<D8Y
MX[4 ;U1P6\-M$L4$,<4:@ )&H4  8' ]@!^%8=]XMM;*ZNHOLMS+':3PV\\J
M*-J/)C:.3DCYER1QS45[XWTRQ-U+(D[6-G<K:W5XJYCAD) (/?@D D#C- '0
M?9H#="Z,$?V@)Y8EV#>%SG;GKC/.*EKG)O&5E%?RVPM[ATAOH["695&U)7 Q
MD9SCD#..]+#XPM+C4Q:16ETT?VMK,W(0;%E7&0><CKQD<T =%7->%]!NM'GU
M:2\2W8WM\]XAC<L4+#&.0.@[CUJMHVO:3:Z?K=Y!+?2A=7F@DCG.YS<?*/+C
M']W.,#ZU>C\6V7]IWFF7$%S;W]M ;CR'3)EC'>,CAOPH W3#$S.QC0LZA')4
M991G /J.3Q[FG*JHH50%4#  & !7)Z5\0=+U6XTN-;:]@BU52;.>:+"2D#)4
M'UP#76T <_XBT;5=8NK.*TU9K+3OG6^CC7]Y,A' 5OX3VSUYXK<MX(K6VBMX
M4"11($11T50, 5S.L^/]'T6YU"&;SY!I@B-\\:9$'F$!<^O4'C/6DN_'EC!J
M6H:?;65Y>75E9I>-' @^>-B "N2,]<_0&@#J)8HYXS'+&LB'JKC(/X4^N?\
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M>2!U_F* /*SK&FOXV^&_^GVZL-,N,J\@5EWQ1!,@\C<0<9ZX.*T?AMJ-A?\
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MJ-P<$8!SPO' KUZB@ KPZYO/,O[>X,-Q;P:9XM!GL[>#]U "6 E=MI9G<L.
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M5IHK6[%O/X:DMEN&MI!&)&E#A2Q7 .WG!^G7BNVN]2L;!XDO+RWMVE8)&)9
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MZWLF2/4M* .URW$<D8."K<$\8'/(K3&CZQ+K'@:XGT]4-G:2+>>0 L<#F(#
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MM7TN6UFR]M<Q[6VM@E3[T[3[&'3-.M[&WW^1;H(X][;B%'09/6@#@&TO6XO
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MNQ%7).!C)ZFO,[7PQXG@^Q27-G:75[!K/VFXNWN"7N(<L%(_NA58#:?3@<T
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MYM8+==\K-(#&,9.1WR3R2<YYYP #'U#XBW]CH^OWCZ+:K/HMUY$UO)?E=Z$
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M9-#+!<2/#<2N@8@*"6VJ<X!^7W)SBNAT'3M0M(IKG5[N*YU&Y*F4P*RPH%&
MJ*Q) ZG/4DGVJCK?AZ^O/$^E:YIUU;Q364,\+)/&64B0#!&,'(('&<$>G6@#
M*O/&^K1:)?>(+31H+C2+.8H5,[+<3(C%7D5=F!@@84GD9.1QGL[.[BOK*"[@
M),4T8D0D8.",BN.7P9JMOI6IZ#:ZI%'I-_(SK(H99[8.<R*IY# DG&2-N3][
MH.RL[6*QLH+2 $10H(T!.2 !@4 >8I-JNHWOQ&M]0-G<Z? 614GF==@$(9%'
M!"CG);J#T]MC3O%-QHLOAW3;ZUA.GWND&:WGA<M*&AA1W#J0 !@G!!)R!P*N
M6OA?5;+Q!XANH[JS>PUAQ(T3*XD!$83&X' '!.<'\*=-X.DN+WPO/+/$R:/:
MS6LT1!Q,LD:QD@]N%S^- &-#\3VDDT6:.Q6YM=3E"NEN)#+:HY_=LWR[6X^\
M,C:3U/6NXUN^?3-!U'4(H_,DM;6694_O%5+ ?CBN2TCP3KED8=,N_$7G>'K:
M4/;VT47ES;5.4C:0'E!QQU.,9QQ7=LJNC(P!5A@@]Q0!QWP_T.P7P9:7LJQW
MMUJT NKVXE4,TS2 ,RD^@SC'3BD%]!X4U;2O!^D6R&;4'GN(]XVQ6T()8\#E
MB"<!>,\\CC-C0O#>J^&;2YTW3;^WDTO)-C'/&=]IDD[<C[Z@G@'!]S5:]\%7
M\LFBZG'K/G:_IDC,UY/$0MQ&^=\913A%/&,9QCCK0!4O/'>K:?;:FEUI=DMY
MI-S MZ!<ML>"4J%DB)49/)!#%0,=>U6G\3^(4\3ZEH3Z=IXDC@:ZM)TD=U\H
M;@!(,#YR0O ..3R<<LUGP/=ZUINL1SW5LEWK$T7VF2-6'EV\9!2-.3\W!^<C
MJQXX JY/X9U";QA/KWG62[]/-I'&4=F1CSNW9 (SVQT'6@#-M_']]>Z?X0NX
M--ME77V*,C7!+1,%)R!@97Y>3U&1P>[HO'.JPSZKHU]I-M_PD%E&DZQV]P3;
M20L0HD+L 5"D_,,9QR,\XY_4=)N_"Z?#?P^U[;RS6VI,$<*4$BJC>YQ][!X/
M4=._0ZIX"NM6;4=0DN[2+6+JYADCE\EI(TABVE82"1N4D$L>,D].!0!(?&UZ
M;/Q4]M;:?=R:%&L@=+DJDH\LNP. Q!!4@#OP<C-20>*]4_M;0+2YM[-4UVQ:
M6U:,L?+G6(2,K<\J03@CT[YXJQ>"M>_XJ3[3J^GR)K=F('2*T>,0MY9C&WYS
MA0"3CG)]*L7/AR73AX5U.XNHS%X8M91,%5F,RF'RR0 ,YP,XYR>/>@"&#QU?
MOX<O9IK"%=<MK_[ +&(LX:3(QCH2"IW9QT!]*WXO#D2^*SX@;R4G:W\EEBBV
MLY.W)=L_-@* !CBN8\,+IWBKQW=>+]*R^E?9$A5V4J);D,P,@![JAVYQ_$:]
M#H Y#PIXJOO$9MI633Q$\<GVF&*5O.M9%8 (RL 3D9R<#GU&"6_%*,2?#G5@
M4+E45E C#\AP1UZ#/\7;KVIVD>$+BV\06.M7TMFU[;VCV\TUM"4:[)(PS\XX
M Z<\DGCI6SXFT./Q)X=O=)E<)]HCPKE<A''*MC(S@@'&: .:TOQ/K>G:WI>D
M>(;+3[>#5("-.FM)FEVNB@E)=P7D@C&T=OQ%2+XC7LOACPIJ_P!AMPVLZFMC
M-'N;" RM'N4^O&>:Z&S\-7,NKZ9J>L744\NFVIAMX84*QB1N'EY.<E< *<@8
M)!R:YR'X::@FC:-I1UF 6^CZH+ZU(MB6*AVDVO\ -R=QZC;QZT :VG^,;C4]
M<N]/@%FD]I?"WELYB4E,7_/5"2 _'. . #R3@&A-XM_LT>/;NWTRT2YT<*^Y
M8F7[1^[R"[<$GJ.. .YS5J;P/>7VIV-QJ%]#/]@U3[?;7(BQ<+'R?)+=UR1S
MZ*!S27G@O4;RT\7VTEY9A=>P(V6(AH/DV?,?X^ ".G.?6@"/_A.KZPUG3K75
M;*W$%[I4FHG[.Q+P&- SKR?GSV/R_C3-%\<Z[J=SH\C^'IS9:D TA2WE3[&&
M&4)D<!9 > <!>O&>\TG@6[N_$&C:E>WEM)'9::^GW,*HP$P==K%>?EX^M1>&
M_ FOZ1):6VH>,;F^TJQQ]FM5@$9) ^4.V265>RY[#TQ0!:T+QC>:P\K(MFYA
M-P+BS!*7%LR?<4@L=^[^\, <8SUIW@GQ==^*A'.WV P& M/'"666UF!4>6ZL
M<G().[ Z=*IVO@'4SJ6GZC>ZS#]NL+6>V2\M[8K+.9!@-(2QSM&"!ZY.14<O
MA35-,BFUJYUM8[^VTI[07=I9DO*Q;/FN@/SD  !<'DDYS0!Z%7"P7=\?BOK"
M-=JUO9Z7"XA:(X 9V)VG?C)V\DCTKH/"7]K_ /"+V(UU@^H*I61PN"ZAB$8C
M)PQ7:2/4FJ;^&;I?'<FOP7L2VEU9BUO+5XB6DV[BI5L_+C=Z>OL0 8ND>.=;
MU!]+N)-"G6RNP[W!%K*HMHP"5;S#\KY '  ^M:VDZ_K.JV6D:K!:6LFG:@Y+
MH"R/!$0=KEB<$\#*X'+<'CG/\.>!=5T>5;*]\1R7N@6Y+6M@( A4[LJ'?EF5
M<],\X'88IFF^ =4L;U;.7Q+-+X9AD\R#3!$ P&<JC2=2@/;V'2@#F--\4ZCX
M2\/>*=6CL[>:TA\472,CL=\V^7!P1]S''4-G/:NNN?%&N/XI\0:+9V]BHTVR
MCNX99%=]^[/RL 1@G'!SQCOVS[[X;7M[X6UO16U2W1=1U1M2C80G]T6DWE#S
M\PX&#@=ZV8_"=^OBG6=:;482=1T]+3REB(5&7/S'YN>I_.@!EGXNO=6U'1M.
MLK:WBFO=..HW,LK%EA3(4!5!!8ECZC '>N6\6^)+K6_A?XVL-2MH8-2TIA;S
MBW9FBD!*,KJ6 (R">.<8]ZZ+_A"=1M;+0YM-U6"+6M*A^S?:I8"T=Q#W1D##
M&3@\<@C@T[5/ 3:CX5U72EOH8K[69A+J%Z+<G?TX5-_& % &3P">22: -!=:
MU"]U;4=,TN.V#:?;1L7GRPDE=257 8%0 !D\]?:L:/XASWDWARUM[!8)M4FG
MM[B6<,T=M+$/F08P')(.#D<#-:=_X<UL:HVHZ-K-M:3W-LEO=+-:F525SAT
M8889/!S7%?$/2DT]/#%C=:RVG:?8I---J,UE]HBDF("@NG0,2S$$_P!XXYZ@
M&S!XX\07/@2Z\1Q6VG,UE=O%/%&K2*\2/M=T8/R<<@<],9[UU-KK5UJ7B)(+
M#[++I4=HLT\^27WORBK@XQM!)STX]:XO0?%$>CZ<\&MZBFL:)J$D=OIUS!I?
MD>>[JQ>/RUX*X"X;')8\GMUO@/PXGACPK;V7DB*>1FFF7=N(9CPI/?:NU?\
M@- %WQ)K1T338I8EC>ZN;F*TMHY&P'DD8*!^ R3[ USVO^,=6\.ZG>6%Q903
M#^S7O;.[1&5&9#AXV4D\C(.0?XAQ71>)M!B\2:%/ILDI@9RKQ3JN3%(I#*P'
M'0@=Q]:YZY\!W>KB\N]8U=)=4FLFL(98;<K##$3G=Y98DN><G<!R!CB@#8\+
M7VN:I;&_U2.PCM;FW@EM4M7+D%DS(&)X/S$ 8)&!705F>'M*;0O#NGZ2]S]I
M-G L'G;-N\*, XR<''O6G0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117%:GJ^NS?$1_#5C>PVL,
MNCF]CF-N)#&XEV="><@_I0!VM%>8)XR\07=EX?ACN+:"\N-6GTN[E$.]7*(^
M'49X&5!Q^'UTM.U3Q#JNK2^'3JT-O?Z7:1M?7D-L&$MPXSM56 &P#!R.N>V#
M0!WM9&D>)=-US4=4LM/E:63395AN&VX7>1G /?&"#7*Z=XMU;7SI.DP/;Z?J
M4_VAKN?&\HD$@0^6I&"68]SP,GGBN#M-:U;PO%\0+^TO$:^BUZWC>5H5PX9B
MI^7H.#VH ]GM?#6E66N76M6\$J:A=?Z^4W$A\SL 5+;< =!CCMBM:N&N?$FJ
MZ+KVIRWTGVC2HM%&H0Q[%4^:&PR @9Q]WDY^][5+9OXG\BQNYM9MYK2_LV9R
M8DB-O*R[D,?7?Z;3Z9SV(!V:LKKE2"/44M>4^&M8UK3_ (3:-JSWUS<_:G4W
M$RP+(]K$2Y=U4#+\@9ZX!)QQ78^"=3NM6T66ZN-4MM30W#B"YMU"[H^P90!M
M8="/6@#I:**J:IJ$&DZ7<W]RZI#;QEV9NG% #H-0M+J[NK2&=7N+1E6>,=4+
M*&&?J#4K3PI.D#2H)G!*(6&Y@.I [UY!I5M-X3\:Z+KDQU"1-<5[?5))(#&H
MGD;?$6!P#C)3/8+[UN7,&I3?'6.)-2*PQZ*)U5HT)13,0R*"IZ[1DY!QWXQ0
M!Z+)(D,3RR.J1H"S,QP% ZDFN<-SX;@\=VRI;QOKVH61=;E$SF!.GS= #GMU
MQSVJG\55G;X9ZZ;>YDMV6W)8H 2Z]"G/8YP<5RFEV.I+XA\$Q_VG<>9)X?D6
M-WA39"2BXP 1EAD#D= .3V /7**\QTWQ5K:^#]!A,\M[J-Y?363W<,:[F$;2
M#<!+M7<0@X..]=-X.O=<F_M&SUN&8-;2K]GGG$:R2Q,N1N6,E0001D'GT'2@
M#<U+5+'2+7[3?W,<$6=H+'EF[*H'+,>P&2>U4K;Q5H]U?V]BES(EY<EA#!/;
MR1.^U=Q(5U!QCG/2N=OG>7XVZ1%,A\F+2+B2 MC&\N@)7GKC(Z#CUKI]8@LT
M\G5KB/?<::LLUO\ /MR3&P8?B,T :E%>9W>O^(=.\.6'C87AO(+I8O.THHJ1
M11R-U5L!MRY R<Y]*H7NM>)+D^/KJSU][2/0IA/;QM C@A(MYCY_A)!'KS^%
M 'K=%<+!K&KV7C708KN^%U9^(+:4K;"(1BT:.,294\EL@D$'V/M7.2Z[XJM/
M"R^*%U;SA8ZG/!+9-& D\1G*?,W!RHQC'IWS0!Z[17E_BW6]>L[S5M0M=7:)
M=->W-O9PQ&2)P^T,+@A"5R6. #G SW%:&MW>L7GB[7-+L];FLK>WTF*Y00PJ
M723>W(+<<A<'^8H ] K,U_7K#PUI$NJ:D\B6L3*'9$+D9(&<#MS7GD'BK79]
M*\'^,)[WRM)NE%OJMNB@*C,V$E&1P,C#<\9&!R<='I:2^,],U^:6^NH]-U"X
M-M;(A&%AC^1F0XS^\(8GV(QZT ==;W$-W;17-M*DT$R"2.2-@RNI&001U!%2
MUYUXOU#4]!U73[*VEGT[PS%8LKW-G!YAMY!\L>_ )5!Q[<<UVGA^62;PYIDD
MUY%>S&UC\RYA;<DK[1N93QD$Y- &C17FL>IZ_967B#6[C5)+J/1;N[5+4( M
MPFQ=H;&,;6SC!Z9_ T_5/$FGW-IK%VU_/I<EC)<7J3O;89@A<&!4D9N>FW/0
M#WH ]*HKS%]5UA8?!FLG5YR-:O(FN;=<>4J2+N6-1U 7.,YYQDU1U/7M8M?"
M_CF8:Q=K-INL+%:2J%+(A\L[.<#;\Y'KCUH ]<HKR_5->\0:UXCUC0-,2^BE
MT^PC>"6REB0O-(BL'?S&'R@Y'&>I]JA\0:UK4=IIUS>ZM=V%O+IP22[T]1+%
M!?*0'$A56^7<&&>@ - 'J9FB$RPF11*P+*F>2!U./Q%/K@-(T6ZN_&MIJ]QK
MMQ,YTJ"9T@=3!(Q)W;#C(0D9P,9KOZ ,K6O$%EH<<8G6>>YF.(+2VC,DTI[[
M5'IW)P!ZU%IOB:TU+4WTPVM]:7\<?FO!<VY&U<X!WC*'/LQ[^AK#TLI)\7-?
M-[E;J*QMTL QX:W.2[ ?]=,C/7CTK6\43V>CZ?>>(?LT<NI6-C,8"2 VW )'
M7[N0I- '045YKJ.I:QX5;PKJC:Q<:C;:G<16E[;RA<,TJEA)& /EQCIGTK&N
MM7\00:1K^KKK]T7T;Q'+;I"43RYHCY.$88Z#<V,?WC0!['17F^NZ_=Z7XIN&
MU74KG3].9[8V5RH)MEP094EQG!(SRQ'!'UIVJZEJMMI'Q#==2NE?3U\ZR?"@
MPXA#X7KE=P[^_% '8:AK\&G:]I.D/!-)-J?F^6Z ;4$:AFW$GT/Z&M**>&??
MY4J2>6Y1]K [6'4'T/M7#76^_P!;^'T\SDSR03LTN/FRUL"2".A)Y_#VKF_#
MK7&F>"=4GM]7D@EEUR6 M/*S$KYPW>6 I)E89 XYS0![#17BEWXB\0PZ;\0;
M6TU2]C?2I(IK22Y :5$.UF7@'@@D\\C(SCG'6107L7BZ,3:S?26>I:&]Q);*
MP7RI(C"-T;=LB1N/UH [JWN8+N+S;::.:/<5W1L&&0<$9'<$8J6N4^'5LL/@
MRPF6>YD6:/<$FDW[!N;@?UY-8/CK4KZRUV475]J6FZ4+1/L^HV*B1+:<L<F9
M!SM(V@$\=>G4 '86GB."[\4WV@?9;F*XM(4G,CJ-DBL2 5()].^*V:\LUFQG
MU7Q7JDEOJ\]O,NA0S":V&UIB/,QV)"[B&P.N *=<:EJ&JV/AUI=1O9FFTIYY
M[+3R$FD?*!96;("H/FR21S@ '/ !W&O>([?0)M-CN+:XD^WW2VJ/$H*HQZ;C
MG@4^UUZ*Z\2ZAH@MY$FLHHY6D=EPZOG!4 YQP1D@<BO.+36[S7_AQX.U"^W2
M7+ZS%')(2,G9*Z GGJ=HZ \UTVF_\EFU[_L$6O\ Z')0!V]%<1\0[C4[:?PP
MNFZI/8_;-62RF\M58,DB,<D$'D;./J:Y?6K[5_#>G>--*BU>]N$T^SAOK2XF
M8%XBQ.Y"<?,"1GGWH ]?HKSJ\DU.RU_3=(>]O'LM?F:=[@/M-OB,?N$.._+>
MH _&JE[!K,Y\7>$].U&]>2SLXKO3I?-_>B1@Q\HN>H++W/>@#U"L_1=3;5]+
MCO7LKFR9WD7R+E-LB[7*Y(]\9'L17&^$]2U#Q1>Z3+YD\5IIFG>7>-N(,MVX
MV,A&.J!"3GD%QQ6!I7B/4M2\(^%=+NK^[CEUF_NH[C4N 0L<TF$#=F8* ..@
M- 'I.F>(8]2US5-*%G<P2Z>RAGE7Y9 V<%2,C''0G/L*V*\EO3<>&$\?2Z?J
M)CG5;589[J0L;?S,+N)Y.U=Q/0G^5;?AF#Q!IGBFWBO=1L3IUU9D+:C4&N97
MD0+F528EP".HSC+"@#O)9HH=GFR(F]@B[FQN8] />LC2/$<6KZUK6F):S0R:
M5*D4C2$?.77<",$\8P?Q[5SWC[38]2\1^#XI9;B-3>RKN@F:,C,1/;O\O7MS
MZFL%[.5]=^)L\=]=0?95@EC$+[3O2T#*Q/4].G0T >LT5Y/#KNO>(]1T2Q_=
M9N?#T-Z5DOC:">:11N="L;$E/3H-U=IX&FU!_#<=MJU_;7VH6DCP33V[EU8@
M\98JN3C&<"@"75O%$>GZQ%I%II]UJ.HO%Y[0VVP"*/=M#.688!.<=<X-.T;Q
M*NK:E<Z=)IM]87EM$DLL=TJ=&SC:58@C@\UR_P /-T/C3QY#=[EO'U,2*LN=
MS0D-Y9&>JXSBM?XA:P=#\):MJ%@Z+JL-J!&1@NB,ZJ6QZ#.?PH ZZBN!UIKG
MPWKFB_8;N[N8-1ADM)X]^\Y6,N+@$G@@CGM@],XKE_#XU;5/!/@[6VUJ\%[/
M>BVN9#-C?%([ @+C!;.WG@@#\" >S45Y/=W5WI.F?$72K34+UHM,C@FMGDD+
M2QO)%O;#G)(SS[9(I=*^VZ=/X$U0ZY=RG5K/;=P3R,X<FVWAU4# VD#/(X.:
M /3[BPL[MT>YM()G3[C21ABOTSTJQ7CVG:SJR>(O!T\&I7=[9ZC<7$5S?/&(
MH[P;<KMBR=H&#@\9Q4EY]K_LR?4#K%]YUKXG$$/[U@#&944H0 <C /7CD\B@
M#UVBO.M:U-_!OQ"%]?33G1=4M65-SLRP7"\X"^K] !WZ=:ZWPO:7=GX=M%U"
M21[V5?.G\PY*.YW%/HN=OX4 :R1I$@2-%11T"C IU>8ZO<7.D^--;TFYDU!K
M76K!9M,*3'*W",0Z1^_S*Q] .AS5KP;/J&M6VEV=S>3+-I=M+!J923YQ<AM@
M5CZX#/\ EZB@#J;'Q+!)HECJ.IP2Z2]Y.MO';78*R>8TA1%QC.6X/T.>G-)I
M'B2/5]=UG2EM989-+D2-W<\2;EW CVKR2.-]9\'?#Z>>6>YN&\0@*7<EC&)V
M+;N<@@#WP.]7M5LBC_%&:*\FC>U2&YA:WE9&1TA)7) !/;(Y!H ]IHK-T21[
M_P -:?+<JX>:UC:0.1NR5&<E3_(UY-+=^)?['U'0+.Y=M;\/Z@]V9)IG5KNT
M7+@D '.X84=!QZYH ]KK*US5Y](2R:#2[K4#<W:6[BV4GR58$F1N.%&,'ZBO
M/-<U*^U;P-XJ\3V]W/#8W2Q#3"CLC"-",OC^$LQ/U'I3O%^GWGAVPT.6VUC4
M91?^([=Y1)+]U61B4&/X=R@XSWQ0!Z;_ &A:?:[BU\]1-;1)-,IXV(V[:2>G
M\#?E3K*\M]1L+>^M)!+;7$2RQ2 $;D89!YYY!%>:SZ=;/K7Q/=H6RMK$P?S3
MR3:L3QGU]>.>*S[!@NG_  ^TE]1>QLKS28YI0SD)<2"%0(R0P(X)/!'2@#V&
MBO,=2MKFRTC3M,C\12W./$%O&LD!*M%&Y)\LL6.\ 'N?3TK?\)B2U\5>*M,^
MTS2VUM-;M"DKEBF^(,V"?>@#KZ*Y+Q'=13>+M&T:]E,=C<V]Q*X#M'YCKMPN
MX$8QDGK7+27LMOK&A>&(]9-SH[7%TCWDKG#,JG9;,P(8E0<[MV20* /5J@>]
MMH[V*S>>,7,JL\<6[YF4=3CT&1S[UYC>"XTQ]"T^VUY[V$>)HX"$W*8XFB=S
M"S%B7&0#DGT':I+?P[;Z9\6]*M'GFN431YG$LTC&3_7E@"W< -@<GW]2 =G:
M^(+@)KUQJFFRV%CIDC^7<2<B>)4W,X'7 P?Z5GV_C'4;G4-'AB\,7LMIJ<4<
MPO(G#1P(X)_>'  ( SC/<#N,\5;O->6/Q;@N;B>>.#SC"KRL1'^Y<X'/ ]JN
M:AY^F:+\,(;:2>!)KZT6=5D;#9AY5N>1[=* /5Z*\HT^5-<TK7;O4?$L^GW]
MKJ[#SFD"B%$*[8PF[E2/4 Y8]>#69XLOK]1XQO\ 3;JXE:TDA'VVYN_LZ6<@
M"$)$B[M^=W)8*.O)H ]@&H6SZA-81RAKR*)97BP1A6R <XQR0:@T:\O-1T[S
MM1TUK"?S'0PNX?(!P&!'8]:Y#2K"V/QBUNYD!\XZ=:NI\X\L1(I^7/I_C5*>
M]N+6T\*:<C-_9FHZC/'?3-,V[<&8HF[.1N(/_?..] 'IFT<<#CI2UX[XSGNM
M%B\;:=IU_,+*#2;>[C03,6M9FD92 Q)/S!=W7N.*V[.2;3OC#9Z=;W$XM+O1
MWN9XGE9P\H<?-R3@\GIB@#T>FR2)#$\LKJD:*69F. H'4DURGQ#O9K31+!%9
MXK2ZU.VM[V='*&&!G^9MP^[G 7/^U6%JT#VGC'4M(T^6XELKK0)9KBU,A98Y
M-Q"."6)!;IC ''?)P =%I7BZ;6)=+GM-'N)-*U)7:.\0@B+;G'F =-V..:ZB
MN(^$EI#!\-M%F12)9;8"0ER1PS=B<#J>E=O0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G>IVM_<
M_&5'L)Y;1_[ ,2W9M_,B#^?G8P. 3CG[PZ5Z)6)K/B)-.O;?2[.W-[J]TC20
MVJN%PB]7=OX%[9/4\#F@#,'@.W0:*([Z5/[,NI+W.P'SYWSN9L]!\S\#U'/'
M-S4O#,\NMOK6D:D=.U&6!;>9G@$T<B*21E"1A@3U!^N:K:5XFUI]<M-'US0%
ML)[B*259XKH2Q-MZJ#@'/(ZC\ZZK()QD9H X^3X?V\-II/\ 9>HSV=_I4DLD
M%VRB0N9/]8)%X#!O;'MBJMO\,[?[)XEAO]1>Z;7+A;EG$"IY#KR&49.2#SS[
M<5W6X9QD4%@.I ^M '-0>#X_[434+V_ENY6T[^S[J-HU6.=,DY*_P]3T/IG-
M4= ^'L6B_98;C6;[4;*PE:2PMKC:!;[E*\D#+X!;&>!GIGFNSW#GD<5RWBGQ
M/?:#K/AZTM[".>VU.^2UEF:3!3=Z* <\<YZ<?C0!#I_@1].T.RTN'7+H1:?=
M_:+(K$@$2X<"-A@EUPYSDY..HH@\!)96R)8ZM=6TK:J-4N710%G?^)-HP%0\
M8 Z8'6N@T[6K'5;B]ALY?,-E+Y,K8^7?@$@'OC/YU?# C((Q0 M9NM:0-:MH
MK=[N6"))HYG6-482;&#A6W*>,J.F*T=P]1ZUB7GB RZ#J-_H<"ZE/:,R)$)
MJRLN,@-TQSU]10 _Q+X=B\3:5'8S7EQ;".>.=98-N[<AW#[P(Z@=JIW'A$S^
M)[37DU>[BNXK46DY5(_W\0<N ?E^4[CR5QD<5JZ3J\&JZ+9ZD 8$N45@LORD
M$]OSK0!!&10!G:_HT'B'0+W2+EWCANXC$SQ_>7/<5CZ=X,-G/HEU<:S=W%WI
M5H;5'V(JR*0 25P<' '?/UKIRZA@I8;CT&>32[@#C(SZ4 <2?AGIYT)M).J:
MGL6]-];3>8HDM9"23Y9V]"23@YZFM_0- 70X)C)>W%_>W#!I[NY(WR8^Z..
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M)D!C(  YSDX P,UT=% '/W'@CP[=>(1KLVF1/J ()<D[68=&*YP2,=2*CN?
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M+M&&/OZTZ.-(D"1HJ(.BJ, 4 ><R:M;:9\5M?AO;A;0W&DQM!/-P/EWDX/\
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3N8J3G@@<=16Y9_$V'5(M'ATZQ634-2NY[81RS;8T,./,;> <C!4C R<]N:
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MLK(I<#H#CF@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'6
M-!?6/$>BW4S V&G&2X,>X@M/\HC/!Z %SSGM6]10!EW2:R?$5@UM) -($4GV
MM&&7+\;-OMUS6I110 4444 %%%% $%[=PZ?8SWEQ(L<,$;2.['   R:\<\(/
MI.@^/]?\3OXGT":TU9G98EOT62(LP< @]>N#Z5[1+%'-$\4J+)&ZE61QD,#U
M!'<5GIX>T1)HYDT?3UEB"K&XMD#(%^Z <<8[>E 'SK9:%9P^"3HR^+O#;*=0
M346D-VRD!48A=I')//0>GK7>W&M:(OQ0T_Q9#XIT+[-+9FTN(6NF+H5R21AL
M?3( /H3@UZ</#^C @C2+ $1F($6R?<(P5Z=,<8J=-,L(YO.2RMEEVA=XB4'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-XET2W=DFU:SC*W(LSNF Q.1D1_[V#TJE)XUT"+Q.= DU6R2\6,%E>X52'+
M+'R>6.>@Y_,5YC>6RC1/B5((HQ)+JF(2R %@0OW3U.<'ICIU].UTT"W^)ANI
M-BQW>AP1POOR9&5V)&,]@<^_X4 =RS!5+,0% R2>U<,_Q LM8A\00:%JEB;C
M3DW02*?/,P";G*QJ=Q )QD9%=#X:\3Z=XKTQK_33,$20Q/'/&4=&'8J?;!_&
MO/HYX+33_B>DZ2>:]Y)((_*+%T,2JI53@-SD<?X4 >BZ7KMA?2I8"^@DU..W
MCFGMU<;T#*#DCL.1^8IL/BKP_<:O_9,.M:?+J.YD^S)<*TFY<[EP#U&#D=1@
MUQ$U['=>(O ,VGEHXFM91Y@C"E 448*M@CD'CVZ5S_AR2"_ATW1+O3=9;Q!I
M>H(P@"F. %'YF,A3 4J"2"<L3C!S0!Z7XP\8Z9X/TLW-Y<P"X8J(;=Y K298
M D#K@9R3TJ>\\9>&=/6W:[\0:9"+E!)"6NDPZ'.&'/W>#STXK/\ B2$/@FX,
MD<\D:W-JSK!]_:+B,DC\!FN,U34+&S\;ZY<ZO)K2Z;K5E;M9M9P.PD559&C(
M"DJ2<D9P.<]Q0!Z;>Z_I.G;OMFH6\(6'SV+OPL>0-Y/89(&:@N_%OAVPN&M[
MS6K&"995A9))E4AR 0#GV(/XBO-M&TVVB\?^%('TN:UM&\/R1&UO 9#&"^5C
M<L.3C/!'&*C\01-)I'Q7$<3,TLD CVH<OB)!QZ\@B@#U2S\0:/J&IW&FV>IV
MEQ>VXW3012JSH,XY ]#P?3-9'B;Q#J&DZYHEC;V4YL[Z4I->I;M,L)&-JD+T
MW=,]JXW2$,7Q0\(2%&6+_A&(XMQ4@;\M\N?7VKUN@#C] \4RZM;^(A=NVFW6
MF3NDOVJ(".W0 E6R2-P*C<22!SQQR</P#X^O-5\,S>(_%.IZ99:=Y[P0,8_)
M$A'0Y9SSP?EZ_E6G\5]5DL_ FI6%E%-<:A?PFWBA@3>VUN'8CKMVY&?4BN1U
MO19-1\ >!_!6F1R?Z;)'+<3 #$"1C=)NSC!W,>/]DB@#U2#Q%H]Q>S6<6I6S
M7$, N9(]XRD1 (<^@P0<^]5V\8^&TL([XZW8_9)9C!%,)@5DD'\*G^+\,UYG
MI'VC1/%7C_Q%%93>;86RV5I"D#9E"@8?.T*<E5. 2>N<<9RQX>EMM \ >&;V
MTNY5N[LZC>S0P%Q$3\VSC..2 3Z GB@#VS4M;TS2 #J%]#;DHTFUVYVJ,LV.
MNT#J>@H_MO2S>VED-0MC=7D?FV\(D!>5,9W*.I& >:\DO%OWU7Q^@M+N?6=3
ME&F:=$,C;"R8\P$_=0<L3TSW&:L^)?"5YH;_  XM=&MY+R[TNX*$KD*4.TL7
M(Z+D?D: /3#XET4:1_:IU*W%AYAB$Y?"EPVW:/?<",55N/&_AFUM[V>;6[-4
MLB%N09.8F.0%8=0V01MZ\'BN,ETC^R/%_AW2Y()+FUL[6[U$1QQG9+=DECST
M'5MH)[UP-F;J\\#"&ZTO44G\2Z[YFJW4=LW*!]Q55 )ZGC@<GC.#@ ]-F\>-
MJMGX4ETS4M-LKK5+M&DLKF3,DD!+#"@9P3@=<<\9S783^(M'MIWAFU&W1XY$
MBD^;B-V^ZK'HK'L#@FO/=2MFNOBA?SVUC<"30]!:/3CY#[3(V02K8P2 2!R<
M[CCIQA:!X?U35?"WA;PU%;W$.;@:MK%ZXP05<E8V)&3(3M/7("^E 'KL_B71
M;:\O+2;4K=+BRB$UTA;F%",@OZ9!'7KFDC\3Z+-8V-Y%J,,D%^";4H26FP"3
MM4<G !SQQCFO([X:Q>Z1\0/%3Z==++?[-,L;0P,7,2D+N9<'&0<YSC.?:I/$
M>DM%X'T&UTJUO%UKP_#:75A,L1 N&=@'7;]X?WB",@=>] '=R>)+F^\2Z;)H
MUY#=Z%=6<WG2QQ%EMV4,1*7Z8) 4+WY/:M#PCJ.I3^%4O-?DC65&D)G:,PAX
ME8[9"K?=!49^G-;5A"T-C$LD,$,Q4-,EN,)YAY;'J,YY/-6&8(I9B H&23V%
M '/Q^._"TTEG&FN6>Z]9EMLO@2D-M.">.O ]3P,U:TGQ3H.O?:?[*U:TN_LW
M,WE2 [!ZGVX//3BO,D66X\(WH%G(K7'C W,*R0,I:(W"N)&!' VYR2.@JYJ>
ME7NI^./'5M!#)C4-"6"WE9#Y;OL88W#_ 'AV)Y_, ]"M/$VB7]S';VVI6\DL
MD)N(U#8\R('&]2?O+P>1D<4EOXHT.Y"&/4[?:\3SHSML5XT^^ZDX!4=R.!7F
M/@^"TF:PDMO#6OP:II=C+Y[:@\@A0F+840%CN+,J_* ."3VQ2>&YIV\8>$+A
M;;54C^QS021RV$D<-L2J_NUR,8^4_-EOK0!Z-;>.?"]Y)9I;ZY9NUY(8K?#\
M.X.-N>Q)Z \GMFK9\2:0MZ]H;Y/.CG2V<8.%E;[J%L8#'(XSFO*;RSN'^'?A
MV,6-P;BW\2"5XPA#;!.[%R/3!7DUJ7$<UGXDO+W1K:\DN)]5BCN]'G@+07"Y
M'[Y&9 $("[MW08YY(H ]0O+RWT^TDNKJ01PQC+-@GO@<#DG/85@Z[XBA?PGX
MCN=)O"M]IEG-(RE"KPR+&77<CC(S@'D<CI47Q"FGA\+,T%A]K'GQ>8!"9FB7
M>#YBH/O%>O\ G%<7:"4P_$E);752=2LO-MFN+9D:=/LVP8., EC@*>1T(R"*
M -J37M8.J_#F-;]Q%JUN[WJ")3YS+ KY/!(Y)Z8%=5XJNOL?A^>4:N-*;<BK
M=>5YFTE@  O.2>GXUPLT4O\ :WPLS:SNMK PG*QG$1,"(-Q[?,.GM76_$.X\
MCP)JP$$EQ)+"8XH(T9C(QZ+A>>?7M0!<N_%6B:3,MGJ.JQ178MA<&-P0[)G&
M[;C/)[=:Q_%GBZ.+P_I<VBWF\:Q>P6<-[;Q^:L:R-AG7@@L,$!3W[<5EV5PL
M?Q0%[-:2^0_AN)4*Q,RJX=G9-W0';C@GGBN5LVEL_A=X$MYK.]$]EK<,]Q$M
MK(S1HDKLQ( ST8?7M0!Z1:ZY:Z+<W=MJNNO=R-FYBB:V/G00<#+JBY"@_P 1
M ZBM"?Q9H-NEF\FJ6^R\B>:V9&W"5$&6*D9S@5@)>/H_CS6KB[M+B73]3M(9
M+:XB@+QEHU8-&S#HQZ@'KSZ\\99:'?Z+K7P[6ZLYHQ%+?2S*%+"V$KJR*Q'"
M]<?A0!Z4WCCPVL4TO]IJR0VL=Y(4B=ML+_=<X7H<_P"-36/C#P_J=U;V]CJ<
M,[W.X0-&"4E*C<RJ^-I8#DJ#D>E<#JMC.OCOQTR6<OES^'A#;NL1VL_EGY0<
M8SR.*FT)Y+;1?AI!+9W@DA=O.Q"W[G]Q)%\XQD9=U&>G6@#O9?$NDP7\=E+=
M,DLLXMHV:%_+>7!.P2;=I;@\9SQ6?8>*X=3UOQ#I06:W_LL1CSF@<'YH]Q;D
M8X[>N,C(->=:E+J<EM>O+I6J6]Y9:S'.]O:VH:V5/-XEV@_ORP/3/!YP  :Z
M_2;AK;Q_XP6:TOE2\2WGBE,+B/8EN QW>N>, 9S]. #8T36K"S\-:/\ :=9-
M^]R@C@GV,TMT1U(0#<Q &2<< 9/K5J;Q;H5OIMSJ$^HI%:VLHAN&D5E,#G&%
M=2,J3D=0.H]17!Z+%>Z;X?\ !NM-9W4MMIL<T%Y;QV[-/'OXW[,9(&,G'.#D
M9JAXB\/W]]HWBW7K2WNY(M5N+'[-9_9G$K+',A+[",\@GC&<+0!ZK::YIU]?
MR6,%R#=1QB4Q.C(S1DX#KN W)GC<N1[US?C_ ,3W6@3^'[2U:6/^T=06&:6*
M$R,L8!)"@*<L?3!/H*58+@_&)+_[-.+27P^(5F,3!1)YY?:3C@[1G!JA\2HK
MJ75_"4MO87UTEGJ8N9VMK5Y1'&%().T'UZ=: -+1I#I6L:BE_P")[S4V@MTD
M%H]L=T$3$E68*N6;J.F<+S6S#XHT:Y.EB"]60ZJK-9;$8^:%&6/3C /?%88N
M[BU\=Z]>IIU_-%%ID>TK;,%D=-S;%./F)R.F>:Y?1H]0\*^)ENUT74I;#Q%$
M;B\B@LW9M,E8],A3D>HZY&?2@#OT\8^'I)88TU2%A/.;:*4 F-Y0,E!)C:3[
M9K ^(/BB%/ _B+^Q=6,5_8IY;SP*Q$+Y *%PI"OC(Z@@D=*XSP_H<NG3VWAG
M5O!ES<WT-V)H;]996L]A<LLK8.%;C'3KUQ2:MIVI:=X(\<>%AIFJ7=[=:@]W
M;2Q6KND\3M&V=^,9&,'WZ9H ]HO'6.QN'>5HE6-B9%&2@QU ]JYO0O$.EV'A
MC1#<:O=WHOAY=M<W$+M)<M@GHH/) )'K[UN:G*_]@W<H@E\PVSGR53>^=I^7
M"YR>V!FO,K*VU!O#OPWMWTO45GL+U6O%:RD7R0L;*2WR\#+C!Z'G'0T >F:1
MK5CKEM+/82LZPS/!*KHR-'(IY5E8 @]#@CN*T*XCP''<#7?%US+8W=M%=:BL
MT+W-N\7F)L R P'<&NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK%U?Q3IFBW:6EPTLETT1G\
MB",NZQ X,A Z*#QF@#:HK!F\8Z+"--(N7E74D+VC1Q,1* I; .,9(' ZU1OO
MB+H&G:!_;5P]T+19VMY=L#%X95X*./X30!UE%4&U>U774T<^9]K>W-R,+\H0
M-MY/KGM5XG )/04 +17&Z+X^M;R+7+G4XY+"VT^\EA$DL+*%C14Y8^I+$@>F
M/QU;?Q;ILZWX=;BWFL(?M$\$T1601X)# =P<'\J -VBN:L?'6BW^J6.GHUQ%
M+?PF:U>:$JDP !(5NA8 CBFOX^T&.9@TTQMENOL9NUB+0^=_<W#OGC.,9XS0
M!T]%<7?MIC^+]0GANM5&III#;HT8I D?)#<C&_)Z\XQVK'^%WBFPMO!/AG2[
MQKF.>XA*132Q,(I)-S$('Z;L9X[XH ],HKA?#&J1V%[XSN;^YE,<.K[%,D@=
MC^YC"JH '7H%'TKH]-\16>I:C-IPCN+:^AB69K>YCV.8V. XZY&>/K0!KT45
MR<_Q#T2WCN)I%N_L]O>&REF$!*I("HY]!E@ >] '65BVF@_8;^]\J2*33+YV
MGGM)HMV)6^\RMG&T]2I!YY!YQ3;/Q9IEYK%WI8,T%Q;0?:7^T1&-3%G&\$_P
MY!YJ.S\9:5>W5G"GVA$OMWV.>2+;'<8Y^0_09&<9% %\:/:VMO$NFVUI:RP1
M^5;O]G#")?0 $<=>XHT71XM%LFA21I999&FGG?[TLC<LQ_H.P %>>?$3Q78Z
MGX>LTLC>-:MJ]O&;M(_]'DV2C<"QR&7/J""1WQ6R=5T'2O'_ (EOF:^-[;:?
M!)>9(\H1Y.-H..0 "3GG- '=T5@P>+M/N3I!ABNWCU6+S;:1825VXS\Q['%9
M\_Q$T6!8YG\X6?VV2QN+DH0EM(A(P^1D9X_,9H ZZBL31_$UMJ^J:AIH@GMK
MJS(/ESKM,D9Z2*/[I((__76W0!#<VEM>1>5=6\4\><[)4##/K@TGV&T^R?9/
MLL'V8?\ +'RQLZY^[TZ\U@ZMXPBTJ^DB&G7ES:6Q OKR%04M<J&^89R>""<
MX!S7/>--734O%>@^&Y;.XN]*NXGO)T@;_CY"CY%X8':#ACVX% '=_P!EZ>8)
M(38VWE2MOD3R5VNWJ1CD^]6E4*H50 H& !T%9OA_2+;0M$M].LS<?9X@3&MP
M^YT!.=N?;.*JZUXGBTJZ6RM[.XU&_*"9[6V WI#G!D.2!CKQU/:@#6-G:EG8
MVT)9W#N2@RS#H3ZD8&#1)9VLMS'<R6T+SQ_<E9 67Z'J*Y^#QYH]PVE,HN1:
MZJJFUNVBQ$6(/R,W\+9&,'OP*8?'5E%HEOJMS9W4-O<Z@+*W^7<90S8650.2
MI +# R10!TK6MNUTMRT$1N%7:LI0;P/0'KBE>"&25)7B1I(\['*@E<]<'M7*
M)\0K!8]:6ZLKNUNM*@-R]M(HWRP]G7'8\?3(S4=I\0X+JW>4:1?AGB@DLU"@
M_;#)'O C/0XZ$GIU- '9!%"! H"@8"@<8]*@6PLTA\E+2!8O[@C 7ICI]*YM
M/'=L^E7,QL+D:E;W2V3Z:2OF&=N50-]WE?FSG&*A/Q B_L^=UTFY.H1ZA_9R
MV'F('>;;NP&)V_=!/7G'J: .O2.*$N41$,C;F( &YL8R?4\#\J1X(9)(Y)(D
M>2(DQLR@E"1@X/;BN0U;6-(U";PU->6UZD[ZJ8K9!A?+G0.K!_4##?6K&I>.
M(K2[O(['3+G4[?3V U"XMF7;;]V&"<L5 )('(Z=>* .J"J%VA0!Z8H "@
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M*^)OA5XMANH(+6]TR8P2H95<*ZLC!@1G&0V!WSD4 >ITR*:*=2T4B2*"02C
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MJ)LXM&TZ1=E[#,?/N8DSL0KC !PH;IQD"O0:8TL:RI$TB"1\E5)Y;'7 [XH
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M\31R/&[.I(CCV\@D@_,W ]ZW]8\)1ZOXOT;7))!LL$=9(2/];R&3/^ZZAOJ
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M(@R3PDY*.OUYX]3ZU<;P1>Q6VESVNK+_ &O:7,MU-=3P[EGDD!#$J".@P!Z
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MP3@'OCH0>:X&X\%:TFA3R65W=:?KVI:DU_--IS*B(6.0DIX+HH[<Y.?6O3:
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MD4 8(;?SCD?I6M_A]!;Q:A"FK7RP7%X+VW1-J_8Y=Q8F,XZ'(R#Z>YK6\/\
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MGV^DZQIRW%XT.JR/).S2+N4N.=A"\?CFH+KP-:W^FZA97^JZI<_;XE@FF>5
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M,M:QIAHU3>TI/ 0+W)/&.G/.!7&Z7J-YXEU^/1$UZ1+&UTB&Y\ZVD*SW;RY
MDSCA5P#CU;G(Z<]K\U[K/@R;3[[4KQ;C2-?BT_[="W,ZAUQ(1T,@# GT(]Z
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M69[J2U5+60F>)-[1_*>0.,G\:X3P[+>Q^*HXI=D%K=:)YD<*W1D>0#A9)%P
MKD'. 2.3R: /4JQ?%VMS>'/"FHZQ!!'/):0F01R/M!_&O)?"2N?"OP^U?[3.
M+Z76!:R2F5F\R)DE)5@3@_='/4=JNS7*>)OAYXVU/6 R7XGF@\IGV&!%"B-
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MYZDDDGTTZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *XWQ3Y$'CSP7>3NL:I-=Q!V. "\/ ^I(%
M=E4<L$,X431)(%.1O4'!]>: /([&VMM1\-7D=I?1VCGQ//)9M)#NA>16!59
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MV-QOMUA!4)@@9R#QNQZ<]^Q]*:WA9U=H8RR_=)49'TI3%&9!(8U+CHQ'/YT
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M7Z8(..G->LZ/J=MJ^EP7EFS/ ZC:Y0J&X'3/45<6*-$*+&JJ>H P#3@ H
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M)H%_JLD#S+9V[SM&A&6"J21D_2N3/@G4=$CTD^'+F#SH;N2:^:YR!,91AY,
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M8R/]E)CF@4 +\N[Y6&.N?PH Q?!_B.#1='UF0P;;VYU^6UCLI&\I(Y2,A2V
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M^DW*RJK$P,&&,@_*:\J\$>)K_1OAYX3L[*S6=;F"=Y+NY8K#"$)(0D9^8D@
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M03A0>.3G(Z9S2^&_&6/#]M;V&F:=:ZA>:Q-816MO&8X(64;F9B!\Q"C/&,Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L37M%O=4DAFL=4^Q21PRPL&@65'60IG(/<;./J:VZR=?UO^Q;>T*0K
M/<7EW':6\3.45G;)Y;!P  QZ=L=Z .8U#X:(ZZ/<Z1K-SI>J:9;K:"\B13YL
M(S\K(?EZDD<=_I5[6/ QN[.P;3-8N]/U6QWB+4.))&5R2ZN#PP).?J!5S3-4
M\43ZN]KJ'AZ"VM(T<?:TO%=97S\NU<;@I'J,Y/MS1TOQ;J^N> [?Q#IFAQSW
M<\I$=E]IQE!*4)+D#!P#V]_:@":3P1&[Z%)_:5P9-,N3=222*&:YD( )8]N,
M]/Z4GB'P9/JNM0ZMI6MW.C79C\FZ:V13]IC_ (=P/&Y?F /4;JZRB@#E+OP4
MIU#0+K3;^2P&DJ\>U(U<S1MMW*2V<$E1D]>33;7P9+!=:9-=ZO/>1Z2'^Q1&
M%%9-RE!E^K84D<]>":ZVB@#G_!FGZOIF@+::U=RW5PDK[)9F!D,>[Y=Q7C./
M2H?%?A%O$=SIU[:ZK<Z7J-@S^3<VZACM< ,I!X(.%_*NFK!U+Q!+9>,M#T-8
M$:/48KF1Y23E/*"D #WW?I0!3?P-:Q:/:VNGWDUG?6TYNAJ  >1YF&)'8-P2
M_.?TQBJ^L> AK6A7]A<:K*+K4)8Y+F\$(W,L9#*@7.% *@_GZUV.]=^S<-V,
M[<\X]:1G1"H9E!<[5!/4X)P/P!/X4 <M)X/N6\6/XA37)TN6T_[ $$*$*O!W
M#WW#=^E5;?X>)%X*A\.3:O<S?9KL7=M=F-0\;A_,&1T8!B?SQVKM:0L%QD@9
M.!F@#E)? T-S;ZS)=WTD^IZM:&SFO3& 4BVE=J)T'!/XU7T_P)=6$V@NNORL
MFBQO% GV91O5U"D-SSP!^5=>MU;O$DB3Q-'(VU&#@ACZ ]SP:?)(D2[I'5%R
M!EC@9/ H X5OAY?MI[1'Q7>F\6_-_;W7D1@PR,"' 7H0=QX[&IU^'B)!K$2:
MQ=?\3"[6^B9XT;[-< J3*N1RQ*=^ .,5V,D\41 DE1"02-S <#DG\*IW^MV&
MG06DTTVY+R>.W@,8W;W<\8QV[YH R)O",LVM:)JCZO,]QID31.9(E;[0'QO+
M>F?;I50_#ZW,DMH=2N#H$LWGOI!53&6R6(W?>VEB#MSV Z5V!EC$HB+J)&!(
M3/) ZG%.H Y5_"-XVIZU=KKTPCU.W%L+<VZ&.! "%VCV!;KQ\QJL/ <UMHEE
M8:=K]W92V]D+%[E(D+2Q#IG(X(Z CH":[&22.&,R2NJ(.K,< ?C6!X3\0S^(
M8M7:XMXH&L=3GL0L;%@1'@9R<=<GL* *=MH&I67C>SN;.YGBT.VT_P"RM;R2
M[D<C 3:N<@C'+'Z<YS71ZC:RWNFW%K#<&WDFC*"4*&*9XS@\&I4N()+?[0DT
M;0XSY@8%<>N>E.$L;1>:)%,>-V\'C'KGTH Y"'X<Z9%X0A\/&XN&CM9GGL;G
M($MJQ8L"I'7!)Z]<U:D\%Q7>D7MIJ&HW-U=7\0M[J]*JKM#NR8U &%!!*^O.
M>M=&EU;R0+/'/$T+<"17!4\XZ].O%96IW]^9M,?2)]->W:\$5X9Y>=F#D(1U
M?V]<>] %27P?%/:>'[>;4+EUT6Y6XBR%_>E595#<=@<9%/G\&:9<MKS2R73-
MK@1;MO,&=J A0O'  .*WGGACV[Y47>^Q=S ;F]![^U9;>)M,'B=?#PG#:AY/
MG,@(P@XP#SG)SD  \"@#+F\!61CT$VEY<VMSH@$5M<)M9S ./*;(P05P,]>]
M(?A_IDGA_4-&FN+MK:_OGOI]CA269]^T<' !P>/05N:9<W36]Y)J$UI^ZN9E
M5H7R$B#';O/9MN,^E6DO;66V:YCN87@7.Z59 5&.N3TH Y;4/A_;7]UJKG5+
MY;?4[98I[9GW(9% 59>>^T8(Z'OT%37O@.QNYM/N4O\ 4+:\M(%MVN;:<H\\
M:CA7QP>>>E=(EW;2SF".XB>4*',:N"P4]\>G(_.FQW]G+<M;1W<#SKD-$L@+
M#'7(ZT <RWAF6W\9:3=Z<EQ;:=90,CJ+K]RP*L-@B[L20Q<^G?-=5/"EQ!)!
M*,QR*48>H(P:DJN]_9Q ^9=P)A_+.Z0##]=OU]J .<M/ EE:WFE7#:AJ-Q_9
MCNULMQ-OVA@1MSC) R.I/2F6?PXT"QU5[R%+D0&X%TECY[?9XYA_&J=,YY]!
M72W6HV5D&-U=P0;5#-YD@7 )P#SVSQ2R7UI#,D,MU DLF-B-( 6STP.] %*X
MT&UN?$MEKKY^TVD$L"# P0Y4Y_#!_,U0UKP/I&N:LFJ3->6]X(3!)):W#1>=
M$?X'QU'^/TK=N+ZTM"HN;J"$M]T22!<_3--NM0L[&)9;N[@@C;[K2R!0?IF@
M#+'A/38]9TW4X/.@?3K<VUM#$P$:QGJ-N/8=^PJM#X%TBW=HHO.736F%PVF[
MP;<R9W9VD=-V#M!QD#BMZ:^M+>))9[J"*-_NN\@4-]">M-EU*Q@$9FO;:,2#
M<A>51N'J,GD4 <5;Z4VL^._$Z3G6K.UECAB#*CQ0W"A"K88C!],K@X/7TVXO
M!&DV^MV&J6YN(9=/MS;6D22 1Q1D8( QS^)-;-UJNGV)C%W?6T!E*K&))0I8
ML<#&>N2<47>JZ?83117E];V\DV?+664*6P,G&: .:A^&^C6VC6FE07%_':VE
MX+Z$"8968'(;)7L><5-J?P]T#5?$0UR6*XAO"H6;[-,8UN%X^60#[P. ".X%
M=4#D9'2H)[VUM9(H[BXBB>8D1J[@%R%+''K@ G\* ,!_ VE'6;_58Y;N">^M
M?LDRQ2 )Y07: %QQ@#BFV7@'1;#3=(L8?M(BTF<SVA\W#(QSD$@#(.3U]:U?
M^$BT7[/;7']JV?DW,WD02><NV23GY5.>3P>/:IM1U?3=(2-]1O[:T61@B&>4
M)N). !GZB@#,;P;I;ZC%=NUTZQ79O4MWF)B6<DMY@4]#EB<9QWQFH/!F@7&@
MV^I+-OCCNKV2XBMVE\SR58\_-[G+8[9Q5J^\6Z58:WI^E274'G7L;2HQF4!4
M X;D\@]JH>&?$C7$,AUO4;1+JXU":VM(0/+#!#C:@;#,>YSZ^F* -76/#EAK
M=U8W5R9X[FQD+P302F-USC<N1U4X&1WQ5!O >C?9+BWB:]@$]\;\O%=.K+,>
MI!SWY_,UK:GKNDZ,81J>I6MF9G"1B>4)O8]AFI-0U;3]*MUGO[V"VB=@JO*X
M4,3T ]: *U_X=L-1U:UU.83)=6\;Q!XI2FY&P2K$<D9 /U%3-H]HVOIK90_;
M4M6M V>/++!\8^JC]:Y/P1XOEU"QU^[UO4;80VFK3VT,W")Y:GY0/7@9[UV-
MAJ=CJL!GL+N&YB#%"\+A@&'4''>@#.T[PII&F^'9=!BMR^GS&0RI(V2_F,6;
M)&#W_+%)IGA33M+3;&]W/MC,41N+AI#$A&-J9Z# '/7CK6O<W,%E:RW-U,D,
M$2EY))&VJH'4DFJ<.O:1<7QLH=2M'NA")S"LH+",C(;'ICG- %"V\&:-:>$W
M\,PPRKICKM*>:V[!QGYNO:I)?"^EB=[_ .QM/?BT-KYAF9&EC&2$8@@'ZD5:
MM_$.C7=TEK;ZI9RSNC2)&DRDLJG#$#N 012Z;K^D:Q+)%IVI6MU)$ SK#(&*
M@]#QVXZT 9G@C0)O#F@O92K'"KW#S16L4C2):HV/W:LW+#(+9/=C5O7O"^E>
M)%@.H0OYUNVZ"XAD:.6(]RK*014\?B#1Y=6;28]3M6U!,AK82@N" ">/8$?G
M2'Q%HRZPND'5+0:BQVBV,H\PG;NQCUQS0!!-X3T6;2H=.6T\J""3SH6B<K)'
M)S\X?.=W)R2<G)SFN?\ '?A*2Z\!:IIV@Z?]IOKN2.1UDF^:9@5Y9W8=EQUX
M P*M>/O%D.B>&M7%CJEM!J]M;^:D;8=U![[<CD@'&:V;?Q#I@7R)M1@%W#;)
M//&S .B,!AB.P)- %/\ L:/1[.YU?2]):ZUHVJHD<UQEV Z1[V8@#.>_XT_P
MSIMW +[4M2MHK6^U)UEFMXB"(L*% +#[QP.34TGB[P]%:6MVVL6?V>Z#M#()
M05<(&+D'T 5LGMBDD\8>'8HH))=9LXUGA^T1[Y0"T?\ >^GO0!+IWAO2M)LK
MFSL8)((+EV>1%N)/O,<D@ELKDDGC%<OXC\(D_P!AV%AH$>H:)8.TC0&^>.:-
MOX3&S-VY.-P[#BNJU'Q)HFDQQOJ&JVELDB>8C2RA05_O?3GK6FK!E#*001D$
M=Z .(TSP9;W45[9ZAID]KHDD4<,6G37\DV=C;@QPY"8P!M4D<5T;>&])?53J
M;VI>\-L;0R/*[9A/5""<8X].M5-;\8Z5H.L:;I=W.JW%](5 .0(U",VXG&.J
M@8]ZM-XHT-;Q+0ZG;>>]P+58]XR92NX)]<$?F* (8O!^AP):K':2+]D9FMV^
MTR[HMP"D*V[(4@#Y<XXZ5E7O@>R%UX?BTO3K.VM-+F,HD+/OC]E&<$MW+9K=
ML?$FCZE?-9V>H0S7"@G8K<L!U(]0,\XKEO&OC6*PNM,LM)UB!;TZM;6ES;@*
MQ9'<!UYZ$#KCD9YH [MT$D;(V=K#!P2#^8K+LO#&C:?HLVCV]BO]GS;S)!([
M2!MW+9W$GDG-.U#Q'H^E7<=M?:A!!*Y  =L8STR>V>@SU--N_$^B6/VK[3J=
MNGV1T2X!<9C9ONAO3(!/TH P-3\ Z=8>"]:TOPMIMM:W-] 4&YB=Y]"S$GUQ
M67I'@DV>J6$^E^&QX?:*1)9KA=2:;< </$(\D-N4 ;CC&<CD5VL/B/1[C6!I
M,-_"]\8A,L2MDLF <@]#P0>.Q%1_\)5H?]L_V1_:4'V[?Y9CW='QG;GINQVZ
MT 0OX+\.R0SPR:8CQ3W NGC=W*B8'.]03A3DG.W&<G-/E\(:%-?WM]+8^9<W
MT'V:Y=YG/F1<?+@M@#CM4DGB71OMAL!J<"W9N/L@0,"PF*[MN/7'-8/@CQ.]
MQX/TZYUR]$EY=7D]LC[1^\99751A>/NK^E &Q8>#= TR]M[VTT\)<V]O]FBD
M,KL5B_N<L<CT!Z4EOX*\.VNFMI\&F1QVK2"4*'?*.#D,C9RA&3C:1C/%3CQ1
MHAU9M,_M* 7BOY1C+8^?^YGIN]NM:] &5+X;TF?2Y]-FM3+:W&/.5Y78R8P!
MN8G<> !R>U4=7M]<MK6TTKP[#"EN\+PO=SREVM?EPC ,27/L?QJ/_A.=+_X3
MF3PON FBM?/>9FPH;<!Y8&.3@DY]JM)XS\.- D_]KVRPO UR)&?"^6K;"V3V
MW<4 :FG62:;IEI8QG,=M"D*GV50!_*H=5T;3];A@BU"#SD@F6XBP[(4D7.U@
M5(((R:;8Z]IFH?:1;W:%K4 SH_RM&"-P+ \@$<YKEQXM34_B'HECIFHF2PFM
M+B66(1$!RH&QPQ'(.3C''% &^OA'04L;^R73HUM=0E\ZZA#,$D?C)(SCG SC
MKBK7]B:;_:/V\VJM<_9_LN]B3^ZSG;@G&*AM_$VCW5Y#:Q7T;2SLZPYX$K(<
M.$/1B.X%6=5U>QT2Q:]U&X6"W5@I=O4G % &5#X%\-036$L>EH&T^0RVF9'(
MA8G)V@G YYQTKHJS+#Q#I>IWU[96EVDEQ9$"XCP04SG&<]N#^516'BG1M2N/
M(M;U'D,#7*C!&Z(-M+J3U7/&10!)%X=TJ#4)+Z*T"3R2>:^UV"%^[[,[=W^U
MC/O39_#&BW-]=WL]A&]Q=PF"=R3^\C/!4C..:I1>//#,SVBKJ\ ^U[A S9"O
MM+ \GCJK?E5NP\4Z)J5A>7MMJ$1M[+/VEW^3R0!N);/08YH EB\/:5!+9R16
M@1[-"EN0[?NE/4#GH<#/KBJ]MX0\.V>KG5;;1K.&^)SYR1@'/KCIGGK2VWBW
M0KN6:*+4H?,A@^TLC':?*X_> 'JO(YZ<U-IOB+2]6F2&TN=TKP"X1'0H7B)Q
MO4$<C/&?>@"?3=(L-(29-/MEMUFD,LBH3AG/5OJ:QO'VA7?B7PC<Z59I!(\L
MD3/%,Y19$616*[@"5SMZX-=-6/;^*-'NM5&FPW>ZZ+2*J[" QC.' .,'!ZT
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MOX[>ST>[DL[>7[39:1;VUYI.J1^9]O@.3& X"L)5#<X'7:,<9/JFC^+M-O\
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M%48!/7\*P\7</AB'5+32'OETGQ/<7MS:S0/O:)O,&] >N X88!YP>Q!]FHH
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MHDMNN<RAN0%P,X;!Q@XJ;3_&MA?:C]BEL]0L)'A,\#7L C%P@SDIR22 ,D$
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MB4-&3=3$ E(QOY(!&=VW'X''!'P/K5_HVN::RSPMHUTTOATY*J?F$B@9(!'
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M]T <DG!SP 1S3?#_ (&U.3P)K>BZM;PV=U=W<MU;2+*)/+=FWHQP.JMCUZ4
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MN>-?WD[CESG)/ZUQ>H>%O$+ZSXK2T>S%AK%F##,RCS(Y\;=I'ICG.<<=,G@
MT[KQ;??\)#INDV&G02R7VFM>H9K@H P(PI(4\8)YQ^55[7XBV]UH.@WJ6+"^
MUFX-M!9F3HRLRNQ8*?E&TG..1BI4\,:I'XQT35@]FUM8:6UG*/,97:0]U&TC
M;P.2<\GCCG#M/AYK5OX>T "?3X]9T&[EGMSYDDD-PCLQ*N2H*'YR. V,#UP
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M\P X&WS#@@<=Q0!UVG>(K34_$&L:/ LGG:5Y(G9A@%I%+ #Z #GWK7KS[P+
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M$7DB8.68@Y"J$YSN)R*ZJL33_$]IJ/BC5-!BBF%QIT<<DLC ;&WYP!SGMZ4
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M7=R+R;RC+ H*P<9W/SP* ,J#PO>23:/)JFJ1WG]EJ3$$M?+WR[=H=OF/(!/
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MB2W))(V,,$8S^..:M3>!=,ET;[#YUV)_/6Z%[YI,PG"A?,#'O@ 8Z8[5T]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !117,6%U<Z]XJU!C)Y>F:1-]F2, JTMQ
ML5F9CG[JAP ,<DD^E '3T5YEX6\9VOA[1X;36IKR5&U&XMFOBCR0V[^<RI$\
MIY)XZXZ8SBNB:_N="\=Q6-U<F33=:5FM%;):"X0 LN?[K+R/<&@#JZ*** "B
MBB@ HJ&[NHK*SGNYV*PP1M)(0"2%49/ Y/ KD_!UM?:_HL/B'79Y#/J,8F@M
MHI"L=O"V3& %/+;2,L>>G'% '945S%G+)X2TJ.TOKFZU.YGNWCLT:16GF#'*
MKEBH^4=2> !R:KW'Q#TVSTO6;N[L=0@GT;:;RS>-?-16.%8'=M8'&<AC0!U]
M%<O:^/-)N-4%@\=U;R267]H0-+'Q-!MR6 !)7'HP4^U+:^-8;RW2>+2M0,<M
MDU] Q\K;-&NW@-OP&^<'#$'UH Z>FAU9F4,"R_> /(^M8MAXG@U&/1YH;.Z%
MOJJ%H97" (0I;:PW;LX4] 1[UY;)XEO/"MW\4=7LT26ZBO;9(_-;(7(*YP3S
MCL/Z4 >W45R=[XW@TF)X;S3[YKRVL&OKJ%1%NBC7.22'VY."<*35@>-+"230
MH[>VNIVUN&6:SVJHSL3>0=S#!(Z=O>@#I**\_P!>\=O+X7@OM+MKF&X.K0Z?
M<PR[!+ WF@,C#<1D@C&">&%=S(S26#,Z-$S1$E&(RAQT)!(R/8T 3 AAD$$>
MU+7GO@?Q$NG^#O",-U&\EOJ*&#^T&D 7SR6*J03N)<AN<=<>O&Q>>/=-M%U*
M7[/<26NFR^3<W"M&JJPQNP&<,0N1D@8],T =517*/XW1]8N].L](OKMK.ZM[
M>YDCV[8TE3>)>OW ",]#U].8[7XC:->/I;1QW(M-4G-O:W1"[&?)4 J&WKN(
M(&5% '7*RL3M8'!P<'H:6O'O WB>70=*\07D^FWU[:1ZU<_:KJ-E/D(&(W$,
MP9@.,XS@9/;![^P\9:??Z_J&CK%-%-90)<^9*4"31,,AXR&)(QUR!C- '145
ME>&]9/B#P_9ZJ;*:S^TIO$,Q!8#UXZ@]0>,@C@5DR>.;>'4(89;"=+26_&G)
M<LZ#,Q( PF=VW.1GV'&.@!U=%<EJOCVVTQ]:(TR]N+?1MGVR:,* -PW?*"<M
MM')Z=L9SQ#>_$ PZHNFV>@:A>WC:?'J AC:,-Y;-C ^;!( 8XSV &<Y !V=%
M<7J7Q&L[!;RY2PN+G3K&Z-I=W$3KNCD!"D"/.Y@"<$\>V:?JGC^#3FN9TT^:
M?3[*817=R)%4KD*=T:<M(!NYZ=.,T =C17'2>/4DU"^@TW2YKZ&Q\H7$J2JC
M R!2,(?F( ;GOD8 -;GB/4[C1_#6H:G:VHN9;:W>81,^P$*,G)]@"?TH U:*
MXW1/%%TWAOP[$]C<W>K7]@DJAG0!\1*S2NP)VJ6(&<9RPXK5\.^)H=?EU"U-
MK+:7^G2B&[MY"&V,1D%6'# CH: -VBN=U;Q/)IWB.UT.#2Y;FYN[62XMV\U4
M1F0@%"3R.#G..XQGG&(WQ.A_LFPNDTBX^U7&JKI,]J\R*8)]P5N?X@">"!SW
MQ0!WM%<I9^*M6O@EK'X=\K5E3S;FTN+P(L"995)<*=Q8J<87&.<CC-!?B;:S
MV^CRVVE7<AO]0;3Y8V95:WE4$D$?Q=.,<8[CI0!W5%<*WC^_CM=>+^&I/M>A
MN#>0+>(5$1C$F\,0,G;D[<=NM7KOQI(-5TBRTO29+X:I9O=P3&81+M"!ER""
M1G*Y)QC/<\4 =94?GQ>?Y'FIYVW?Y>X;MN<9QUQGO7GNJ>,M7U'3;!=.TY;6
M[.L+I][#-=;3&ZD':K*IRK>N,X/3GB16O(_C#>2QVL+WQ\,Q,8/M!"%_M#C
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M'SCD_>  XZ]>.<K7?B'J&B:5J2M86\FJZ;?06TZ*6\MHYL%)%^HR,$\$'VH
M]$HKB/\ A)/$<OB+6-$B@TI9X+5+RSE;S"NPY^60<$DD?PYQU]C2E^(FH-HG
M@Z_M=-MVDUZY%O)')*P"$@_=./49YZ#C'< 'HE%>?)XWU^&WUVSNM'M9=8TJ
M>VC9;69C"R3#(?+ ' &2135^(UQ-HWC&YM;>UFET$@Q2!F$<X*[AD=1C!'7G
MVH ]#HKDH/$>J/XECTIUL_\ 3-,-[:$1N"K @%7R<$?,OH>M5;+QS)J.AVXA
M2VCUZ2^_L][63<4CF7)<$CG 0%@>_'KB@#MZ*!TYZUQ/C+Q?J?AZ_:.WALHK
M2.R>X-S=[F$D@^[$JJ0<G!Y ./2@#MJ*\]A^(-WJFI^$;?2H;1HM>M)IF>8/
M^Z=$)('3(# CISCJ.M)I7Q$N]0\/6CO:P)J]UJCZ4@4-Y/F*3E^N=NT$XS[9
MH [FWU*RNKVZL[>ZAEN;3;]HB1P6B+ E0WH2 3BK5<-X2CO(_B+XU^V11*["
MQ*R11E!*OEN-V"3W!'7^&NYH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I9B  ,DGM0 M%4
M8]9TN:01Q:E9NY. JSJ3GTQFKU !1110 4455U#4K+2K1KO4+N&UMUX,DSA5
MSV&3W]J +5%%% !1110 453O-6L+"ZM+6ZNHXKB\<I;Q$_/(1UP.N!D9/09&
M:N4 %%%% !7$^"S'IGB;Q;HDS$7+ZFVI1YX\R*9%.5]=K*5)]:ZK4=5L=)BC
MEO[J.W26588RY^\['"J/4DTEWI%A?7MK>7%N&N;5MT,JL59?;((R/8\4 >6O
MX?UJ]\-ZWX1?2+B.6]UXW0NVQY(MVG64N&SR0%QMZY-=;X@LS?>._"=I;8_X
ME_GWDPW?<B"B-?S9L#Z'TKLJJVNFV=E<7%Q;VZI/<MOFDZLY]R>WH.@H M44
M44 %%4=4UG3]%CMY-1N5MTN)UMXBP)W2-G"\#O@U>H 9-#'<0203('BD4HZM
MT8$8(->=:"?$/P_M(_#C:+?Z]8Q,?L5Y:F,;(R>$D#%<$>O/7VKTBB@#@=7T
M[Q!=?V!XGFL2=5TJYE:33[>56S;2C:R@XPS@*IZ@?>'I6+XH\+ZCX@TWQ5K-
MO8WD=YJMM#I]K92 !MJ2 F1AVSC(YX'7K7K%% 'FT^EZU>?$K3?$$6D2+;_V
M&T3I.5'ERN,B-^?7@XH\,>'YH=:NK:WT&]T+3WTYX[FW-P'MFN'*X,6">@##
M(P,$<5Z310!YWX;L]<L=-\*Z>VBRI'I=T\%P\LJ@E1$ZB50."AW'K@YQQSFN
M;UWP/XAU"Q^(BQZ>0VHWD,]D/,7]\L?)QSQD'C/TZUZWI^K66JM="RF\T6LQ
M@D8 [=X ) /?&<<=ZNT >9ZSIOB77M?AEU#0Q<:3<Z>P6RDG4+;S\_ZTC[P(
M(Z;L<\4S0]"U_?\ #VXGTB2!='AGBO%>:/<F^((IQGGUQUKT^L6^\6:%IMP;
M>YU!!*IPZQJTGE_[VT';U'7% '#:SH?B*;PQJ@71F\^/7DU2"%9E9IXQ('VC
M#$!N/8<CODGTM9)Y--$CP;;AH=QAW='Q]W/UXS2V=[:ZA:I=65Q%<6[YVRQ,
M&5L''!'!Y%3T >8/H'B27PAX3LY-' O=.U>*]NHTN4*JB.S':2Q)SNXR2>.:
ME31O$VAZYJ6F6.E6-YI.JW#SV]X<#["7R7#J?O#C(QU)Z^GI5% '%Z'H>I1^
M*?%LFH6ACL=36!(+A7CRX2+RV) )()Y(R.F![5C^$M%\6Z5Y'AV]L+-K33YD
M:/6MREGA#*PC5",Y(#(3Q@'/89],HH \ML/"?B"QTSQ'X8%G$\.KW$TPU$R#
MRHHY=V1M/S%QZ8QR.<5:\2Z/IMUK/A2RM=24:E S6,I@(,DEN(_WJ,.0O8\\
MC/&,UZ16;8>'](TS4+R_L]/@AO+V0R7$ZK\\C'KR>W'0<=?6@#01%CC5$4*J
MC  ["O*[KPSXGQ+-+ID%W=+K\%RERUS\\ELLNY1@ [54''KC)KU:J]]>0Z=8
M7%[<L5@MXVED(4DA5&3P.M 'DU_IFJ7OBCQ9/;^'K?5M/NI8(;I?[3^S)F./
M)!7O@GDDX/&!UK>\,#4-5\;6_B>'2_L^DW6BQVF3*N8Y$D9B O4KS@$<'KTJ
MY%J'@O5DTG4FTJ&27Q$V(6DM 7DVC.7/M@=3_7':QQI#$L42*D:#:JJ, #T%
M 'G8T#QIIFK:O9Z:=,FT[4KF2ZM[ZYP7L"[;F&S;\YR21VZ9[BG#P_XNTG7[
M^/3VL+[2]3.X3W) DL9-H#/C&7!/(7/&!R*]$KGX?&.ES:U%IB^?F=Y(H+D)
MNAED3&]%8$\C)Z@=#Z4 <=JWA'Q%?:G\UNLMW#=0?8];AF2&2*%57<)%'+\[
M^.^>P KT'6-/?4_#VH::) KW5K) )".A9"N?UINJ:]INCM$EY<8GFSY5O&AD
MEDQUVHH+'ZXQS2:=X@TS5+J2TM;AOM<2!Y+>6)XY$4XP2K $ YX/?M0!QUEX
M?\1:=8>&-5@L+<:II5FNGW5F)U+7%OM4$!R-JD,H<<\XQGM70>'-%O+36=:U
MO4%ACN=5>+]S'SY4<:E5#'."W))QQ7244 <!XIENH?BGX8DL[=;B==/OBL1?
M9O\ ]7QD\#\:I3^ ]:FM;68R6S7DNO#6;L-(WR*CADA4]"0ORYP!_.O09M+L
M+C48-0FLX)+V!2L4[1@N@/4 ]15N@#E=4TS6;#Q2_B#1XHKQ9K-;6XL9)?+9
MF5\HZL01P&8$<=<\G%<^W@76S<:3<F2Q%U_;CZO?/$S*$)0J%3(.>,#/M^-=
M??>*+*P\5Z7X=DCF-YJ*2/$P7Y%"*6.3_P !-;$<T4I<1R(Y1MKA6!VMZ'T-
M '&S>$M0DN?'3K+;@>((4CMB6.$Q 8CNX_'C-8%W9W^C^-OAWIZ_99;JTT^X
M@8%\+)L@Q\I(R"< ]/7MFO5*J3Z7875_;7\]E!+>6V?(G>,%XLC!VGJ,T <.
MWA#6(; 7T,-M)JDVMIJTMOYI5%X"[=W.<*!SCMQ6L=*O++QS-XKOY[&"R&DI
M9RCS6RA60N6R5 QEL5JZWXGTG0-+_M*^NE%IYRPF1/F"L6V\GM@]?2M&>WMM
M0LW@N(HKBVF7#(X#(ZGU'0B@#AO"^BV;_$+7-9TV:*;2Y%21%3)07+C]XZ]C
ME<9([D^]=)XP\/?\)1X8N]*6<P22;'BD[+(C!TSQTW*,^V:U;*RM=.M([2RM
MHK:VB&$BB0*JCV Z54U[6H?#^CS:E/!//'$57R[=-[DLP48'U/Y4 8VFV'B2
MZUO2]4U865LMI:36\D$+[VD9RF6+%>G[L$ 8([DYQ5/3_"VM:=HD>GI+831_
MVC-/+!,2R20.2=F2GW@6SD"NTBD$L*2 $!U#8/49JAJ6M0:7?:9:2Q2N^H3F
M"-D7*JP4MECV&!0!PL?PZUC3((+G1;^QM=0L]0DN+2.0.\*P. &A<GYB, =,
M8R?8C5UWPMX@U[PY-:W=_9-?37EO.57>L$21.K;4!W')V\GN3^%=E<W5O9VS
MW%U/%!!&,O+*X55'J2>!4@((!!!!Z$4 <RF@ZE8>+[[7-/:T,>HVL4=W;RNP
MS-'D*X;:>-IVXXZ9Y-9-KX%NK'PY;Z/*MAJT+I*UX+PLF^9WW[U(5B.>.WKU
MKN9)X82@EE1#(VQ S ;F]!ZFL^WUN.X\07FCBUNDDM8DE:=XR(G#$\*W<\4
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MDEB,LQY_O>PKI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC3EELH[6WCNE42/AG+2,H)P<%5'?&>Q& #>\4ZA<:7X9NKJWN[>UF0(HN+@
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MQG'.W)8#MD<8KH;E;_2_%^DZ=!K%W-;ZI;W"RK.V]XVC52LJ';M YP0>"67
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MQ;N929(9"2Q96ZCDG\ZOZ=XIT/5M2FTZPU."XO(-_F0H<LNPJ&S]"ZC\:UZ
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M$!B=2P=<]> >/ITJ;7?B)!IM]#8V%I'>W,EHMZ?-NX[=!$QP,,_5C@X ].U
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M@!50&R2<9[<<FO7Z* /*(]<L=&UCP[XGOV9/#LVABSBE6-FCMY]X8D@#C<H
MSCG;]*NW)TS3/^$,>#2Y+'34U&9;>.12[*'5RKX(9AN)) X(SCCI7I5)N&[;
MD9';- 'BVM:3J6H7?Q.@TV&9YYI+.2-5!3S%0(SJI[DJI&!ZXK2U9[+QYX5U
M./PWI]TFJOI(MWN)(WC5 C_\>^3@%L[LX].3TKUBB@#S7PIJ^CZOJUMJ%O#J
M\NH:=8O!=B>(H+4+UC*A0&<D9 Y.*[W2=4M]9TR'4+595BESA9D*.I!*D,IY
M!!!&/:K4T;2P21K(T;.I4.O521U'N*@TVPBTNPBLX6=D3)+R-N9V))9F/<DD
MD^YH R/'-E<W_@O4X+3S6F$6\1Q9W2[2&,?!'W@-OX]#TKGO[6TGQ)I]]J6E
M:-=?:/[(EM9IWMW0Q##8@"X^=@^> #CUYQ7H5% 'CM[H]]%\/_ FHV^F7,C:
M8UM)J%M%&RS%5CV\KPS%3VI=2AL9-%U#4M,TO4KFVEEM/,OM0$[OE67]X(N&
M8*O.[N<YS7L-% 'BVIV]Q-:_$ 1Q7TWG&UNHWFMV4R1J.6'RC.,'C&>.E6]0
M C\;6OB*\M=9NM&O-(CM[>735G22%T.XAU3:V&SQGU]J]>HH \<U'1[*P@LG
MTZVO]!O;*Q<:=.86GCEC=SB&8%3\SD],\;@!SQ7:^'/$DD=MX?TC5]*DTS4+
MRR!2*.(B!'0']T".%.Q"P7/ 'M775G2Z/:2ZS'JUPTDDT"D0*[_NX200S*.S
M$$@GTH T:\^L/M&@_$+Q7<:G;W=Q%J$<$EE/%;M("B(08OE!"D'L<9Z]Z] 5
M@RAE((/0BEH \,TG3[S18O"^KZIINMR::ND"S>&R,RSVLH8DY$95RK>_ Z5U
M%I9V5J_AS&AW-I9R:Q+>)#(LURRJ;>4"23<&\MB[+QGJ<^M>ET4 <<(DM/BQ
M;B.RDC@_L,Q++' ?+W>=D)N"X! !.">_ &><?PUX4NM-\77>EW$;RZ-973ZG
M8NZ_)NFS\@]T.['USP:](5E;.U@<'!P>AI: /&HK."*;5]#UKPGK-[<2ZC+/
M;_9YIQ:W :3<CMAPBD9&<XZ5H:I!J-MJXFT2UNH;DW\27VFS6Q>UO%'!G1MI
M"MQDG=D[1GG&?5:* ,G2=>BU;4-3LEMKB"73YO+<31E?,!SAUSU4[3@^U:%T
MC2V<\:?>:-E'U(J"PTR#3S,\;2RS3-F2::0N[#)(7)Z*,G ' ^I)-V@#PZYC
MU.?P'X5T1M#U!-0TC6+<W2"W8J47>/,#=""2#U..^*OZAI<=CX@\2:=K'A_6
M=575+IKJREMY9O(D#*H\MPCA5VD=6Z@^U>Q44 >8^*/#VO\ ]I:1<:>5CNM5
MM?[)U>XMHR5C0J2)%!.1M.<'/?![54\2:!)X>\:Z5JBZ9J5YX?CT[^SF73I9
M%E@Y7!(C(9@<<]NYZ5ZS3?,02",NN\C(7//Y4 >:W^A&VTCPA#I>C3VEM;^(
M4O&M_FD:*+$F7<DDYRPSSWI(X;W2=#\7>'KK3;RZGNYKF:TF2(NESYPRO/0,
M"><^G6O2W=(P"[*H)QDG'-.H \PTL-X3\3^&],OUDE:V\-F&5X5,N&1E' "E
MB/ITX'/%16>A"WTG28[VQU/3Y3=WE[;75M^\DL"S957 4@A@WW<=L5VS>&S)
MXSB\1R7TA>&V>UCMQ& H1B&//4G*UO4 87@]=77PS;+K;(]\&<,ZQB/>NX[6
M*CH2N"1ZU2^(FDZEK'A&6'28HYKV&:*XCADQME\MPVTYZ@XZ<?6NJHH XN\#
MZWX@L=3CLK^WALM.G9Y"I0N\@4"%EQE@.6P.-P'I5KX;V<]A\/=$M;N!X+J"
MV$<D<BX92"<BNGAFCN(4FAD62)QN5U.0P]0:AO\ 4;+2[;[1?W4-M#N">9,X
M5=Q. ,GN30!8=@B,[9PHR<#/Z5XA;Z7K*^";.W;2KM+E/%8O546WS+ )-^]O
M7KWYXQVKW"B@#S:]M]57Q1XXN;'37F,^F0):K-#F.>50X88. ?O+UZU7T73[
ML>*&U'^SM7>*;0);=YKT#+2B0'8%R0@ZX4*![')KU&B@#QSP1::WX3BT*[_L
MZ]FM;J VE_;.C/+:NKL59,_=0YY XR<\5/8:/JNE+J'AJZ\+6^I37%S)-9ZK
M+$)(6WMOW2AB6RA[$DDCKWKULD*I9B  ,DGM4%E?6NI6<=Y8W$5Q;2 E)8F#
M*W.."/<4 ><-HVK6VL07.G6UY;W_ /:G^F0ER]I>18YN"I.U&X!XY!&,=Z]/
MHHH XJ\L[VT^+%GJHL[B>RN=.^R>9&,K$X?=\W/ QWQVKD-0\,:Y/\/+O38]
M,G:\_P"$C>[6/*Y:(S%]P.<?=KV2B@#QCQIHVLZ]I?C&!M)OWN3)&]BL1"0R
M0_+@D+C>X.XX?=CMCG/1Z-IFJ67Q:N]1ETZ;[%?:5#&D_&U&7JK<\'BO1**
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M\4K0VIGQ';QH3DL^TGDE1PIY:L[QGK[S>#GN=8\*;GMM3B@$%U*?*)+ +*A
M!=>1Q@=_2G6'@77],\)^'K>RU*W@UC0GD$1P6AN8W/S*XX(R/R('?D6-?\&>
M(/$'AR:WN-4MCJ%U=6\\BL'$$"Q'(6,<GD@9/?)- &E=>*=5_P"$IO\ 0=*T
M2&ZEL[2.XW2W?E*Q;^'.TD=,#@@YY*U5LOB&=1TFTOX-(D@25)O/>\F\J."6
M,[3%O"MN8G.,#D#UXK/5]47XM:U_9:6;SG2K?S5N790&W'!7 .0!V./K3K/P
M#J6DW^ER6MQ9W4,:3?:EN 0%ED<N98QSR"<#/. .>] %"3XA7^OMX'ETRU6V
M@U>ZD,\4DQW9B7.S<%^[D@YQDXZ#OLZE\1ULY-66WTT7/]FS>2\8E<2S, I?
MRU$9!QNP,L,D'IU.+I7PUUK3-#\+(EY9G4-"O99!N#>7)$XP??(P#^=;C^%?
M$5CK.J+H^K6\>E:N[3S^?&6EMI6&&,>, @@#@]#^H!/J/B676=/UVUTK3XKB
M*SM&6Z-S,T3"1HBPC"[&!.",Y(P3CGG$WPS!7X:Z%B)8S]E'R@\=3WR>O7\>
M@Z"JWA/6++6]7ETN]M/L&L1+]I2X1B\4JQ^7N7!P=P )SSGO6SX1T>\\/>$K
M#2;N>"XN;6,Q^9#'L0C)QQCTQD]^M '+V_Q"UAM.EUF?1[4:5%++9E8KAFE^
MTK-Y:?P_<;(Z D<_0W[CQU>V9UN*;0)II],M3<J;=F,<N#@IN9%PPR#P"".>
M.@C3P+=W7@6[T&^O((;F2[>[AGM(P!&_F>8F00-V#P2>2*;<>%O%NIV5Q/J&
MOVL>K) 8;,V2/'"A)4EW!)WDX(P1@ ^] "Q?$"X?0[O5DL+*]M(;5)(IK&^\
MQ9IF<((B"@*?,1R<\5-%XVU*.\OK.Z\/7#316;7=NUN',<FTA3&695(;<>N,
M8R<#%4?^%<SWD^N3W$]IISZG:10!=-0@)*C;Q.?NY;=C\!UIE]X$\2ZWX=EM
M=5\2!;];1;6$VV\0L ZL6D!.69M@4D=B>#F@"SIGQ!N[^YU^U&G6DDVEVBWD
M;Q73>5,I!)3=LZKM(W $$@\"F)X[UN+3K'4+G0[4P:I]E6P1+HAV>107W_*=
MH7)Y]NG/"VO@K6[>]U&Z:]TYA>:.FGB". QK&R[NA'4?,3DC/;@5+=> ;B_^
M'FC^'Y-1^R:CI:1>1>6X+!7CX!P<=0!GTH P?B-=:O??#CQ!;:WI,44MC+;M
M#=0N?*GS(GS(#R"-Q7!)]<]J[73-=U&7Q9?:)J-K;Q[+9+N!X')^1CMVOG^(
M$=1QS^)P-?\ !'B#Q%X:O+>_UBV?4[P1(_E^9';1(C[_ )4R26)QDG^@KH(=
M'U)?&PUN22T-L^GK:R1KN#A@V[(/0C)([<4 /U;7+J/7+?0M+AA:_G@:X,MQ
MN\J)%(&2%Y8DG&,CZ]CSE]\0=1TZUDMY])B;5+;5+;3YXTE.QUE(VRQY'\0#
M84M\IZDUTFLZ'=7.LV6M:9<Q0WUK&\+),F8YXVP2K$<@@C(//?CFN?U3P%?W
M]E)<K>VQUFXU.VU":1E<0CR<;8U&2<#GGC.2>* .HT>YU;^S[J77K>W@FBGE
MV?9R2K0@_*W4\D<XKSKQ)XAN_%'@C3]:6&WBTNXU>U\C:S>=&HF"[CD88L>W
MR[1W:O69(UEB>-QE7!4CU!KS^/X=7L7AQ/#D>K0+I5M>Q7-I_HY,JHL@DV,=
MV#@\ ^G7F@"Q=^-=7N$U*XT/1WNH]-OGLY+<PLTER48*Y1E.U,9.,YSC^&K$
MWBN^T[Q9J^E:E]CCMX=/:^LI4C?<RKG>'&[G;QTQG-02^!=1@U75AI6M_8]'
MUEFEOK<QF21)&^^T+$X7?DYR#CC'08OZQX%L-3N/#\D<DT"Z0?+ 23)E@V8,
M3DY+*<*"">1NSUH S(_%OB![G2]'EL[:VUFXL#J%R&MY)5A3<$"!%;.[)ZEN
M,=.>*>IWUYK=IX2O=5TB6POXM;1&BD!'0,-R]]I'/-;_ (D\+W]_KEAX@T/4
MH['5;2,P'SHR\4\+')1P""<'D<]0/K3'\&SLNE9U4R2VNH'4+B66')FD.>%
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M\6FWMQ;K$PEE(0AU  *JWS9QGG'-4K2SO[/XZZ>FH:H^H2G0Y#YCPI'@[QG
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M6/K6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M M';00O/*0,\[(U9@.#SC'!K,\%:[K.LVU\FLZ7/8S6TV(C<((WFC(RK,H)
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MX #AA&[#&3P?<54M/$>H:_-XH.GW!LDTB1K:))H0Q:5 =SL.3M) QCG'/4X
M!VU175U!96LMU<R+%!$A>1VZ*!U->>KKVN>*6T!--OAICZGHL]RQ\O<$E!C
M8 ]0"3^!/?FMWQO!=2?#G4XY;LI<+9-YLD2@;R%YP#T!- &AI?B>RU;438Q0
MW44QMQ=1F:,!9(B<!E()[]C@^U;5<3J.I7^C7_A"**=)%U&X%M.7A7=Y?E%L
M CD<J*RO$_B?7+#P]XMEBNT5],OK6"VD55#%':+<&P<_QGG _&@#TNLR_P!=
MM--U;3=-G2?SM09T@98\IE1DAF[<?G^!KD;GQ'J'AW6_%27,\U]#:Z8-1B5@
M,1MALHO^R<# )[&J4T.J'7O E[?ZFMVUW/)-(AB"[':#.(\=$ SD$GDB@#OM
M-UFVU6XU""".X1[&X-O+YT+("P .5)&&&".1_49T*\NUSQ3K4?P^\<:C%>-#
M=Z;JDMM;2*@!2,&, =^S$YK0DU[6-/\ B9JFC13->6[Z4]_#!)@%)%*J$4]E
M.>_>@#T&JEII>GV%Q=7%G8VUO-=/YEQ)%$JM*WJQ Y/)Z^IKS/P]XAU_5)/#
M%['J4\L^I/(NIVOE QVX3/W1CY>F,Y-=CXEU.Z36-%T2VEDM1J4DGF72@?*J
M+NV*3T=NW'0&@#IJ*\F\4^(_$'A;2/$^F)J?VB2RLX+FTO7"F95EE$95\=2.
M2&P.WI7?Z):ZC_9TS7NIM<"Y DA8(%>%609&>_.2#0!M5G:_JZZ#H-[JKVT]
MRMK&9#% NYV^@_F>PR:\JN-<\2Q^'-9TM-5N9-9T+5"VY3^]N;4+YAW<<Y7<
M!@#[H^M;MSK.OZII'B_6=+O?(L[:SC7393@HQ2/?,P'7=DE0>G Z\T >@0W]
MO,MOM?#W$1FB0\,5&,\>VY?SJKH>M1Z[:37,4$L*QW$D&),9)1L$\'VKAO*N
M]3^)^A*^J7L0;P[]H(BDP"WFQ[LC&/F[_A7)RZ[JND>&-<U;3M0DMY-+\0M$
M(%C41S+(R$B3NWWCCIC.* /9;FQT73KFY\03V-G%=11,\U]]G7S=BKSE@-Q&
MT=/:HY/$-I'XDL]$V2FXN[9[F-\#9L4@'WS\PKGOBIYEQ\*-8E2>2%A;"0^6
M<;AD94^QS6=/I[#QUH.F?;KDR2Z'=JMVQ!F0%T/#= 0#@''84 >DT5Y#8^+=
M>FM=$T1KS>]WJ][I\M](Q25E@/R?,JD!FZ9V_E7>^%QJ%JVH:;J>H17DUO*'
MC_?^;*D3C($AV+SD/CCICTH Z&BO(-7UG6;+PG\0)(=8O?.TB^5;28N"Z+M0
M[<XY'S&KOC75M2T_69;F>[U"+3HX$CAN]-8%+*1B,FZ3J5.5((R<9P,T >I4
M5YI/>>(/$=WK\NFZE#9W&F7*QV:M=F.$P[=PED4(Q8-DCL"!QC'.[XJ\276G
M_#YM:TZZLQ.ZQ;;G/F0+N8 OGC*C)- '75S#>,D_M-8HM.N9K#[8MB]ZG1)F
M(4 J>=N2 6[&L>>"^\/>*=*M4U?4;VRUQ9;>599=S0RB/<)D;'R\+C&,9(/U
MF^'FD"TBU&8:A?RA-1N4\J6;<C?-]XC'6@#N:*\5\=:MK-K=^)-7LM8OI%TF
M2$VX@8QVL#9 >)_^>CD,I(Q@ ]<G%:%TU[KGQ \4:?/JM_!:IHD,T:6TYCV-
M][C'3GJ>IZ4 >M45Y2=?U>Q\#^$O&]Q>W<]O;P(-5MH\?OXW4KYF.FY6(/;/
MJ*[#PI)+J=WJNO-]JCM[Z58[:"=SA8XP5WJO0;SELCJ,4 =-6+K>OOI=Y96%
MI8O>W]X6,<(D$8"J,LQ8^F1QR>:X739+WQ79>)];NM7O;*[TJ^N(+1()RD,*
MQHI!9/XLG.<Y[XQ59[-_%FO^!]2U"[OK6XO=.FDD2&9H=C>6N[8",C.3_0]R
M >CVVOVS:387M^KZ<]Y(D*6]R-K^:QVA .I.<_@,]*CTWQ"FH^)];T5;=HVT
MI;<M*6!$GFJS# [8VUR?Q7TX7]QX.5I+B-6UV&$O#(4*[P>0<_>^7@XXYZ=X
MKW3)O[5\=QF>YMTBTVREMYX)]LK>7'-@LPY^\I!SU'M0!Z717E]OJMQXH/AF
MQOKJ2W^V:*EX5COC;_:)650<%06^7)/;J.N#72^'Q?#PGJ&GMJ,5]=V336D<
MOS,5VK\BNQ +,,C+ <T 6T\3F^O#'H^G3:C;PSM!<W*2*B1L,9V[OOXSSCC(
MQFKVB:U;:]8O=6T<\:),\++,FTAD.#W((R.H-<Q\()(#\--+AB0I+;AHIT/5
M9 QW9':I/$]U:O<Z1I]G?1V=I?:KY-X]KD/(X4MY9*?=+$#+9_G0!VM%>+^,
M;C6=$TKQII5IJ-V;&UCM;JTG\YO,MVEF :+?G)'4CO@@5L2Z#>IX_31I]<U8
MVVJZ4\]T5NV^66-T'[H_P#GMC(H ]0HKP_6-8U23X6Z:PU*[CGMM>^P^?',R
MR21I,R#>W<D=?4U:UZ:X\)3^+-%C\1Z@FGMI*7JW%Q(9Y;>9I"A1#G/*KP,C
MDYR!S0![-1D'I7C^GG44O?&&GO=WUK"NB6]U%%]K:22%RC$Y8YPQV_,!QZ&I
M]&@DL/$G@:6/4KZ9-;TR:*ZC>Z9HP$@1E*KT!!SS]: /6:R&UPQ^*X]#DLIE
M66U-Q%=]8W(;#)[$#!YZY]J\\L+B\TV76/A[//?MJ-S="6PNY)9&=[20\OO&
M<;-C#L.@ZYKTV'2;*&^2^6$&[6 6XF8EF\L'..?>@"[FBO)M"9K#QCX?&J27
M[W%WY[PZC979DL=1W*Y'F*QRA48VJ 0#CG%:7C6;4;_QWINA1WT-G9R:=+/'
MY[R(D\^]4"Y1E)(#9 R>N<'B@#T>C(]:\B1[^UG\)^#[O6I+RUN[B[6[NH9'
M#N8F#)%O)W8P<'DY JIKADL_"GQ"BM+F]SI^HPM;3"YD9X\B,E0V[.U=S<=O
M>@#V61F6-RB[W"DA<XR>PJEHMY?7VD07.I6'V"[<'S+8R+)L.>FX<&N&O);E
M?C)J,"WDZPR>'))/+28X5A(@#!<\'D\X'4^M<[X<CFU#P3\/IY]4OHI)[R2W
ME*7++YJNLA.[U.4&#U'.* /:L@C((Q1N'/(XZ\]*\3UE+O1Y?%/ARSU:[M--
ML&LKV"\EG9FMY994#;F)Y3!+;3[UMWFGI-\7[O13<72Z9<Z2]_/:I.P62;>$
MR><XPQX!QP* /4<@#)(QZT;EP#D8/0YKQ9=>U*Y\*^";.ZOXXK:\N9XKFYNL
MF-Q$&\M'VLK') [_ ,//O#XH@NM&\%75HNO"\:WUJVEC-J)$6 2-GR]Q8A@.
MH /&>>U 'MKRQQQO(S@*@)8YZ5'97D.H6%O>V[%H+B)98R1C*L 1Q]#7DNK:
M3;VMQX_L$\TV3Z M[Y3S,P$VR3YADYZJ#Z9KN_!K6&F^#_#UMYJ1275E$R))
M(29&\M2V,G]!0!TI8*,L0![T;UX^8<].>M<MXOAGNKS2HK4V5Q+%))<-IUU*
M8S<HJX)0@'+ L.",<\]J\_@O+:XO_AE=:<UY':27$\6VY?Y^-X*MC@X8$#Z"
M@#VG<I&=PQ]: P.<$<=:\ E^TW'A;Q!(NH7$ M?%P5BDCC$1GV;>. .0>>./
M7%=?J>FPZ?XMUK1K&:\2QOM#:XN$CFE)@F5FV.'YVE@&!R1G;]!0!Z@&4MM#
M#.,XS7':1XOU36_#FMWUEI,37^GZA+9Q6K3;!+L*Y)8@;3@G\JXVU\^RNOAW
MJ]I-.VKZL/)O7N)"1-%Y><.N3]W^' P,\\FJ)7/P=^(+><(&36KIE<$@9#Q\
M?+GKTZD<\G'- 'N)95ZL!GU-#.JXW,!GIDUY1XCDN;_QIXBTJZUW3K"-[&,6
MZW<;,R1[&+/$0R[6!.21GH*JZO'=7&EIJ,ERFLQ0:)'%>V9;R+J)27Q<Q[F(
M4MWSR0G7M0![%165HVL:?J$$4%K>K-.EO'(\;?+*JLH(++P1G/<5JT %%%%
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M[T>TN=0MUM+J6,-+ 'W"-C_#GOB@"EX?\.)H;7=Q+>W%_?WCA[BZN,!GP,*
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MMO)5LF3?NY(R-JY],CCFM.Q\4:'J33K::I;2-!&)I1OVE(R,ASG'RXP<].:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6:3BR*M;*Y.(F'1@/7WJM>^#M!U"_O+V[T^.6:]B$5QNR1( -H)'3<!P#U%
M'#_9+<?&:ZO'B25I=&BGA/=Y5.05)X)X7H?KUJIX;E-[IGA_6Y]7L8KLWI^U
MI$)7N9GEW))"R[\C&<@8^39D <UZ0_A70Y+K2[EM.A,NE1B.R;'^I4   ?0
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M&ZD_+CKQ72^");Y]5UR/4/L<\T1MU%_9X"72;#@LH)"N.ASSC;VVUV05020
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M4@OI[\.CI(R@;(U8X93@Y(&.G<FO1ZA6[MWNI+59XS<1J'>(,-R@]"1^%34
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MQ,=1U.46EG-"%21 1 IB#$_(N57.>6]#723ZWIUOY?F72DRQ&= @+DQC'S8
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M?]OPWRO#:N\3Q&9&R) -I..HSQ@YQ@UUMP'?XOVTRZ?=&--->%[DV3B-')#
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M0O) /&<Y'%>H5YI'X7U[PW\5=2\2:78)J.FZNB).AN0DL#<9(W]1\N<9[X
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MTH L:/JECI-S;>$](AN+R2TLQ.Y>1?W*,?D#'C).> !TJG/\2K1-+M+Q-/N
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M.MQ#YRH"#N!0C+?WLX!XZ5-JOB?6I?%^NZ/I]U:6:Z9I:WD9EA,AF<Y)W'(
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M90KN<]1@  8XY]L=310!P%QX&U.Z^&VE^&9;BS%S8M#B9=VQEC(P>5SDX_\
MKUM#P_>+XGU75$:T$=Y8):H/GW[EW8+=L?-V'YUTM% 'GMGX#U.UTSPE"]Q8
MSOH)?=%(&\J;<N V,<,IY'%6-)\'ZQHNDQZ?!<V,J1ZJ;X-(7!*%RY'?GD#
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M\1Z5K$U_%')96<MLZP;E$A<8+8.< 8! ZY YXKK*9+*D$+RR-M1%+,?0#DT
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MOFZ?8SE-L)V,OS$#+8W' X JYIO@VXM=7T^_OM8:].GK,L'^C+&Y$AZ,X.2
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MYD$C1(K E5!XZN!ST%4XO%.L+'JVERRVYU/2M3M+5[D1 I-#,4*MMW##X8Y
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M&*\>&;RL>>J*3D=3@C'/T[UR*_"K2(= LM*M]0U*/[#>F]MKGS$\R-V^\.%
M(//4<9_"NTN;;[192VPFEB\R,IYJ$;UR,9!((S]0: /*/AZ=3T_X5^'I[;5I
M46XO((O+:WCPB/*490<$G.X')YX[<U>\0^(_$%CJ_C*R@U:-8;'2TNK4&)/,
MC=V[<<@ 8R?45T=E\/M-LO"/_"-+?:@]BC*\+,\8D@96W!E94'.[GYLT^[\
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M3YVHJJW#?:9.57. O/RCD],54_X0G1DM=,AM4N+1M,C,5I-;SLLD:'JI;/S
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M\F\&Z!<:Z=9DT]#>D@LVX[6(Q@LN=I/ Y(S3+_P/X=U+66U:ZTU'O'QYCAF
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M=*FTVV>Q7!$)0;01T/U]^M(?#6D-!>0O9)(M[M%RTA+-,%Z!B>2/8T <);6
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M#2K0"P_X],1#]QSGY?3GTH \\B9]3^&>N:\]_.FN6TMU*LR3$,LD4C;(]O0
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MEU>V%G]MN(4+) '"[L=>3P*R=-\7MJ&L:7;#39X[/5+ 7=O<%E)5QDNCC/&
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M$6]S<?VUI_DVK!;B3[2FV(GH&.>#]:FFUK3;=[59KR-#=1/-"6X#(@#,V>@
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M\M--6Y2XNQ$2 7V89R!@9(- &K%XDTVX\40ZE!?ZQ+)-HJW@TE(V9?+.2K;
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MB<GKECA<]<=!BM"W\9F$:A::OISV6K65J;S[(LHD$\0!^>-NAY!&#@C&<8H
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M6EE%=[#'_:,<X9<]/,\LKUQSC.,U#'H.I:)XMO=8TR&&]BU&W47:S2".3SD
M56#8/!  (X QF@!J^/%O8=!FTK39KE=6:= KL$:*2-&;:W;JN,] ,FLN/XH2
M)X=U*ZO=(6WU.PU%=-DMA<!HQ*Q&UC)CA.>3C\ZL6'A76-,F\,;5M[@V=W<W
M-])YFP S!P=BXYQO_2J=GX/U^RO_ !),L&G3PZGJL=X(+CYUDAYWHP((!Z8-
M &G>>,M7T[3!=7NC01.NJQ:>ZFY;#I)LQ+&=GS#+GCCIZ\5?_MV2^\5:UX9N
MK*'R(+%+A91(6\Q7W+M92!C[I[FL&W\$ZM9>&M9LK>1"LE]'=:;I\LN^.V".
MK[0Y!(#$'@=.W4UKVNB:H/&FI:]+# D=WID5L(1+EA(K,>N.GS=: .-@\1ZY
MI&F?#C2-'@MS%J,9,OF/L+[ /ES@X'S9/&3@#CG/2:G\0+W3=1_>Z*$TQ=1B
MTUYYIC'(\C]6C0K\Z D#.>>3VJ@O@;7(K3P/,);66\\/F1)T+%5D#[1D''8+
MT[YJM>^!/$]W!J\<TUC=3R:K%?VMY.[;VC1]PA/78HP, <<GB@#?U3QGJEKJ
MVLZ;9:&D]QIUHEVJR703S8RS MD @<+P.O/05CW?B_6M6\7^#CHBP#3-1MI+
MKRI;@H7_ '9R),!LA>P7/S<G@5NR^'-2F\6:OJS"$1WND+8JH?E7&XYZ=,MC
M\*P[/P1KNES>#+BS^QM)HT+VURDLSX964@N#WZYVG^@H [[5]5M]%TN:_N2=
MD8X12-SL>%5<]23@"N>3Q7J]CJNF6FNZ-#:QZGE+=[>Y,I6;!81N"HP2 >02
M.*U_%&@Q^)?#UUI;S20M*N8IHW*F.0<JW!!X(!K'BT?Q!J2Z-%K1M0NFR">:
M2)MWVJ15PO!'RC))/.>* &>%/%^K^)?LLYT2.*R>6XAN)DN XB>-L+C@;@W/
M(_\ KUL>(M9O=*%E'8V"W,MU,4:2:0QP0(%+,\C@':,+QQR:J>!M%U'0=$GL
M]2%MYSW<UP#;<)^\<M@#M@G&*9XLT75=3U+1+S3S;30V4TC7%G=LPBE#+M5B
M!P2AR1D=>F* ,R/XA3/I?AN[_LQ6.K:BUA((9O,$14N"RD#YA\GMQ2W'C76[
M73/$\DFAP&]T-Q(8?M!"36Y4N&#8/S  Y&,<517P?XD%CI4<ITUI=-UEK]3%
MF,2(QD) &,*?GP!STK2M[8>&/%?B+7];N+&VTS5I(%CEEDP4*QA K$C&#@F@
M"U9>+KG4E\,"TM;5I-7A-S.AF;]Q$%!8@[?F(+!<''/YAOQ*O=7L?!\\FCRK
M!*[QQO/YA1XPSJN4PIYYZ]NO/2JGPYTO[,NJWT#[])N+IO[*!4#RX"22%'9"
MY8@=,=.M;'CG0;KQ+X1O=*LIA#<R[#&Y8J%*L&ZCGM0!SL@U:+XCV+-;61U1
MM#E12TSM%E91CY]H/0Y/R]_QI)/%@UOP?X1UF?1H+DWVK6T;*S';;2>:4\Q>
MY((.*W(=$U5O%NFZQ=/ 4M],:VD1&))E9@203R1\HZUBV'@_5[/P7H6B>7:F
M73=2CNW99#M9%F,N%R"0><4 6KSQEKB^)M2TBRT6WD3398'N)GN,?Z-("2X&
M/O JW'H*Y/Q]K&H>(/#FBZG]ELX])FU> VS>8QF=?- 5\;< ,,\9XXY/2N^L
M_#EPGC+Q#JESL-GJ=K!;JJM\PV!@<_7=^E<K/\/?$<WAR#PZ=3LFL;"]BGL9
MFC8.L2,"(V X.W&,]Z /1-7OCI>BW^H",2&UMY)PA.-VU2V,]NE<;;>.=9%A
MX<UG4-*MK;1M4$*32>:3+$\B95@!QL+8'7.#DUUGB%4;PQJJSC=&;*8. VW(
MV'//;ZUPOA#2=1\0>"?"5O>&S_LFUBM[HF-&5Y#&OR1LC#&,X);^+''#4 :F
MH^-;_2O$NF6%W!8I%J.H&UAMR["Y,? $V.FW=G\,8SS@/BWQ#)::M(FEVD)T
MR^FMYWD+N@B2$.L@X4G)(R/0C&:I7'@379$B2/4[;?:ZL-0AN)HV>24;R<.<
M]%#$ <@\=,5T6C:#?6=SKT.H/:36.I7+W ,"F)_G54*G'?:@.X'))- '*V'B
M_P 16'PY\/\ B*[>RNX[N6+[=)(K*T2228W@@XXSTP . *[2SU>YO?%6H:?'
M%&;&RB0/-SN,S<[1ST"X/3O7')]C\)>"8_!_B;4+6>>>UDMK*W@A<M.!N QU
M^8Y7'3FNN\'Z+<:#X9L[.]N9+J_V![N>1R[22D?-ECR<= ?04 9_C/4&LM5\
M*QMI]G=17.K)#YD^2\#E&(= .,X##)/&>ASQS.J_$G7[$>+IX=/TU[?P]=QQ
MLKO('EB?@8(XW9Q[?7OV/B?P_=:Y?Z#-!/#%'INH+>R!U)+[5*A1CI]X_D*Y
MC4?AM?WUKXT@&HVR_P#"1312(3&W[D(V<'GG(H E_MV]N/B:CSSQV^DV^C"]
MCWH1A7.7+'=C("CGH/2K=SXSU2T\)V_BIK*WFTR692T$0;S4MF;:LF2<%N5)
M7  &>>*5O!6H+XETW4HKRU-N-.73]0@EC9Q*@'.SG"YS4:>!-1;1%\-3:K'_
M &!%<*\:QH1/Y"D,(2Q.#R!EO3C% '9WES+%I<]U:0&XF2%I(H0<>8P7(7/;
M)P*X[1/&M_J.K'3)182W T\W$OD!@L$X )A+9(;;N )&.G09Q74Z[IAUCP_?
MZ8DS0&YMWB61&*E"1@'CG%<?HG@KQ#I^JV%Y=ZMI\@MK*2S:."T\L.N $YSG
M.1DF@!;7QMK/]E>%-7O;2Q2RUF>*UECA+F1))0=C#)QM! R.3CIZ59M/&6HI
M/XFL=2M(4U'2@)+>&!&(GB;_ %;Y)YR>"!TQUYJ!O!.K?\(KX9TEKZS,FB7L
M-TTHC?$HB)VJ!V)R<TTC2/''C73[[3!,T&E>8+Z<V\D23L" D+%@-Y5P7P<A
M?QH [FR-T;& WOEBZ,8,OE A=V.<9R<9KA4\;ZO-X2/C"&&R.CI<MFV,;^<]
ML)"A</NP'XW;2N.V>]>@UPT'@2\L["?P]::DD7AF:4MY.TF>.,Y9XE<G!4MW
M(S@D<]: *T(N=1^*UVK7%K+;/HR *]N3F-GSC[W?_(J[\0&D\/\ PXN(=%,=
MDL0B@C5$^5(RP4J!VX.*MQ>'=3A\=S:_'/9"VDMUM?(V-NV!L[L],]L8Q6CX
MJT%?$OAN\THS>2TR@QR[<['!!!QWY% '*:DM^/BOX=2"2V-P='N@TCHVU1N3
M!"@Y/..-PSSR*EM?'>HW%O86IMK8:K=:I<66!&Y4QP;B\@3.<X"_+N[]:T[7
MPMJ9\0Z-K=_JL4MU8V<MM.([?:LV]@W'/R@8 '4\5GO\/KN30GMQK'DZG'J+
M:E:7L<63!*Q)*_,3N3!Q@]NW% '0>']2U:]FU"#5; V_V>8""<1E%N(R,@A2
M3@@Y!&3V/>N?BNGU/XT7=A=?/;:9ID<UM&?NK*[$,^/7!Q^%=!X>T&?26N;R
M_P!0DU#4[P(+B=EV+A 0JJ@X4#)]SGFHM=\,'4-0AUC3+O\ L_6K>,QI<B,.
MLB'G9(O\2YZ=QDXZT 3ZU:Z?:3KXFNW>)M+MIF9UQ@QD98'C/&W/&*PI?%FL
M:?H^@:UJ-O9K8ZA/'%=)&K!K99?]6^[<01G:#QU8>E;-MH5]-.TFMZI]O3:R
M);QP^3%AN"67)WG''/ YXK)TOP+<6J6%C?:N]YI.FS+<65OY>QPZL2@=\G>J
M@\#'7![4 8&H>.-?M[/Q=?+<V<4>BZFL,$;P<3)M7]WN+#;DG)/)YXQQ76:?
M=:V/$MW%=WEM-975DMU9QK#@VS#"LI(/S@Y!R3USC K+D^'4\EAXAM?[<Q_;
M=T+F9OL:'9V*C)Y!PO7I@^M;"Z/>V>IQZK=:U&;:VLC \1ME12NT%F+;N.5S
M[#B@#B['QWXL7X?Z5XQO(=.:SDG"WD 1@_E/)L5T8'C!(7:0>.234WB#XBZ[
MH9O':UTUO)U6*S6%=TA$3_Q.X?"L2&P,=JS_ (;^'9/$OP]T.&]UQY=,M9_.
METV.$(=RL2L3L#DJ"0V"/3G@5OZC\+(M0L[^T.LS107.H)J$:K;1YCD!R=S8
MR^>@R>,4 6-8\0:[#JOBN"RN+..+2]/BNX!)%N).UV8'GG.W&>PQ@ \D7QM>
MPW'A*[OEL[?2-<M$9WV,7CN7165 V[&T[B,E>WO5Z\\%RW>I:]>#5W0ZO8K9
M,GD B(!=NX<\DY;\_:N<U^P$_AZQ^'4-G=:E>VL=H1>?9UCBBA251OW$\,$4
MCCD\^N* .Q\+:G/K=G=:H;@36-Q<,;'"!?W(P <]3D@GFL/5"K_&GP^F65H]
M*N6^4CY@648(W9QP3TZ_CCMH((K:"."")(H8U"I'&H55 Z  =!7-WOA2[N?'
M%OXEAUCR##!]F%O]F5PT>=Q&XG@D]P >W- ',ZMXI\1V&D>)]:2^A-OHFKM&
M+=K<?O8-D?R$]>-^00<D]\<5L7&MZQ>^*?$.CVU['9PV>F0W$$J0!W5W+$D[
MB0>%QTQS27/P_GO?#OB'2+G7'==:NOM,DJVRJ8R0H( SR,(OY>]:?_"*LOB3
M4]8BORAO[%+1XC""%V9VL#G_ &CQ0!SFC>-=3UV+PQHZRK:ZGJFF->W=T(@3
M$H&%**1M+%@>O  Z<BJVN>(?$\/A/Q(+*^E_M7P]=*AGBMX\W411&RR,K '#
M$_* . >G%;]EX @T_3=,BMM0E2_TI9([&^\M=R1-_P LW7HXQZ\]QBMO1M!A
MTJ"[\V4W=U?2^=>3R*!YS[0OW>@7:H 6@#D_^$DUF[OM3N](O$GL+'0TN(UN
M?+6*6X=2ZEF"@@;0"<,!SVZUDZ-XNUFZU!M'?5Y+U+G09+_[:;>-'BE7"_NR
MH"LF2<;E)Z<XKL-.\":98>"[GPONE>RN1*LC [6VN2< \XP" /I5?3O ,5EK
M=GJDNJ7-S)!IATUT=% E0XY/IT'U/>@#E+#4M9T3X,Z%J4&J-)<7%Q:-ND@C
MRB2.BL@P #U)R03SUZ5U,-WK'B?4-;.EZU_9UOIMT;*$10QR>;*JJSF3>I.T
M%MH"D="<]*FA\!68\*P>'KF_O)K2"=9HB"JE-C!D0<'Y00/_ -7%79O"R?VS
M/J5CJ-Y9270 NXX6&R;"X#8(PK\#YASQB@#D-+\9:UXF?PF8+I=/75["X:X$
M4*OME3*AEW9P PR <^^:SK7QGXMN_!XN8V:466K26NH7UM AG6V1CF14(*;L
M#GY2/:N^L_!FDV%QH\MHLT0TF%H+:-7RNUNN[(R3WZU5LO 5AI:?\2Z^O[>4
M7,UT'WJP+R## @K@K[?K0!9\$:E+J_AB*\DU1=3#S3".[5%3S(Q(P3(4  [0
M >.M9G]HZKXD\3^(-*L-5DTN+1Q$BO!#&[22NI?+[U.5 QPNT]>?3?\ #_AZ
MR\-V$EK9!OWTS7$SL<F25L;FQT&<#@<4V7PY:-K$^JVTUQ9WEQ"(9W@9<2@?
M=)# C(R<'KZYH XNP\1^)_$1T+[-*+1M0M[VWNO*B#1V\D6-MPN[)(W;5P21
M\U=\7N[/0FDN)H'O(;8L\K#;&7"\D^BYK.C\(:=#?Z/=P2W,)TJ-H[>.-E"L
M&&&W\9;/4Y/7GKS6Q>V<.H6%Q97"[H9XVC<>JD8- 'G'A7Q-J\_B/0(+C4KB
M]BU?3I9Y_/A18TDCV_Z@JJG9ECR<Y&#[U+'?^);+1M"U6\UMYI_[6%A<VS6T
M:I,CW!A);;R''4%3MX'!YST=OX+M[;4=%O$U*^>328I((C,RL7C<*-C';SC:
M.>OO2S>";&XT2+2)KV^:VBNA=+AHU.\/YG9 ,;N< ?I0!@7OBK4O"NNZ]::U
M>M<P/:_;-)^6-7;G:T0PHRP)7&<\9/8UV6@VU_::':0ZG>/=WP3,TSA02QYQ
M\H XSCIVKE9+2[\7^-=+N[G1);&RT&XG;S[KK<L5VJ(P#]W^(DCL .]=Y0!Y
MI-J.NZIX7U3Q?IFOSPRV<UPT>F20QB!8H)&!212IDWLB$GY@07XP*CEM[S4O
MBSHMTNKWMJ;G0I)PL<<)\H;X\QC=&?E).3G)]".E=7<^!])N8=1MF:Y6RU&X
M^TW5HDF(Y),@D]-PW$ G!&<5<D\.6DGB2VUT2SI=6\#6R(I41^62"5QCU /7
MM0!F?$I;X_#W69-.N;J"YBMV=3; ;GQU7H3@CKC!]ZYW4K&>'6_!%DFI7 E,
M4P%V8XO,7*@\#9LXZ#Y>GOS7H]W:PWUG-:7"[H9D,;KZ@C!K&@\(6,$FD2M<
MWL\FE*RV[SS;V;=UWDC+<<4 <$?%OB&W\.V5@EZ9+VX\0S:6+V;8)&B24CY<
M@+O8#:"1C)_+L/"C>(H]9UFVUHC['N2;3TDF62:.-L@ABO;*\$D]_2GS_#_0
M[K1[G2[E;F:WFO'OP3.5>*=B271EQC!)('(K2T+P[:>'X9%@GO;J:7'F7-]<
MM/*X'0%F/09/ P* .<O)$D^-FG07W,4>BO)IX=3M\\RD2E3W;8%SZ#'K75:H
MEBBPWEVJM):LTD&7VDOM/ R0"2,\5!KWAG2_$:6XU"*7S+9S);S03/%)$Q&"
M592".*?#H4"7L=Y<7-U>31(4C-PX*IGN% "[L<;L9QWH X2[U;6XOAM:>-(-
M6N#>)MO)K5]IAEC9P#%C;P N0",'/))[1ZIJ>LW6H^.(XM;U"TCTRUM+VT6,
M1@QEHI2T9RA^4D#/?Y1S77IX(TE+1;#=<MI:3B=-/:3]PK!BV-N,E,G.PDKT
MXJS+X5TV:ZUBX=93)J\*0W9W_>100H'I@,?SH X+1_$.N-XD\"W$^JSS0^(+
M"2:YM651%&RQH1L &1]X]2:JS7WB)_!OBG6AXIU!+G0=3O([<;8@DJQ, !(-
MGS<9X&!D]*]"@\&:/;3Z)-''+NT6%H;+,GW$( (/KP!U]*YKPQX734XO%$6K
MP7T-MJ.KSRM:L71)X=PV-D_,,XR0"/0C'% &5KGBK59M)U74].U"X-Q#!8S"
M&W7]U:!E#2 D@AF.3\IS@8Z9S727::AJ?CV[TQ=:O[2TET>.X2&)D1HG,A7(
M^7/\//.><>F+5_\ #G0=1N]0N)3J$8U#!N(8+Z6.)G  #[%8 M@ <Y''2M.W
M\-6=KJ2ZA#<7HNEM!9B1YS(?+!W#)?.XY).3D\^G% ')7NJZEI_ACPMXGGU.
MZ%K$L*ZJK8"RHX"^:PQQAB#QC(-=%HHFUQ-7NKF:0V-U.8K3R;A@#"HQN4@\
M;CNY!Y&*R=7TF[MM)7P7I6D3S:9>0NC7\TRNML&;+95N20"2N.^.@%=CIUA;
MZ5IMKI]HFRWMHEAB7.<*HP/Y4 <CXJO9M N-+BM+>YDT:VMI?ML5A+B>!<IY
M4H4?,RC;(".AR<YQBNE\/W45[X?L+J"\:\BEA5TN'&#("/O$>M1ZEX=LM3U"
M&_D::*ZCA>#S(9-N^-^JN.C#N <X))&#5W3["VTO3[>PLHA%;6Z".*,=%4=!
M0!Y7;S:_K.H^/S!XEO;1M)N";)/,41*1&6PVX'"\>H SGM4^AZCJ_BGQE-8S
MZQ>VD3Z'97R_97V[)6*LQ ((P>00>QJSX>\$2W?B3QG+KEE=Q:?J5ZIB07&Q
M+B-<CD(V<9YYQD=>.*[6U\,Z99^(YM>@C=+V6V6U;#D)Y:D$ +TXQ0!P=YJN
MK2_"_5_%:ZK=PZE#/--&B,1'$(Y2GE!#P1@').3DD@],.OM;N]>7QY#=3LD6
MDZ8%M[>-BH<O;&1G<9^;DXP>,8XZY[*Y\%Z)=373/;R+#=RI-<6\<S)%+(O1
MBH(YZ9Q@-@9S2:GX*T35M2DU"XAG2>:#[//]GN9(5GBP1MD", PP3U]O04 <
MGI6IW,4WPNAM;J9+:]L9(KB+)"R!+7<,J?1AU_I69H_BK5I-1GTNYNYWM[GQ
M3+8>>SG=%$(PXC5@<@L>!Z#/3BN]F\#Z%+IVE6(@GCBTI]]F\=S(LD7J ^=V
M#Z9Z<4J^!O#PL-3LC8[H-2G-Q<JTC',A_B7GY3P.5P>!0!Q?CJ'['H5WI+:U
M=7KC5;*X".[;[:*68*(R^[+#*,1GD?E6AXTO=6T>[N&"WK:$+)(Y+RTNG\^P
M;+#SBF?G X))/\)]ZZ=?!>@IH%QHJVC?8[A@\NZ9VD9AC#;V);(VC'/&.*9>
M>"-#OS&;B*[<+"ENR_;I@LL2YPL@WX<<G.[)/?- &W?2O!I]S-&,R1Q,RC'<
M D5Y]+J4Z^ =)\0V&LW$UX\]N96,K,DK.X5XS'R!C)&,#!':O2" 001D'M6!
M:>#-"L;YKJWM)$!D,PM_M$AMUD))+B$ML#9/7'&,C% '-^%[:XU3QCXEDEU.
M^1-/UG>D*2_NY 80-K ]NA&,=*]#K.T[0M.TF\O[NR@:.?4)?.N6,KOO?UPQ
M('7MCMZ"M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBL'QEJ%SI?A>ZN[2]BLI4*#[1* 1&I8
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M&Z20Z#<VXD;[%8>)XXK#9*?EBRHVYYX!9ACBK<WAG3I-5\?VLD0>U@BANK:
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MR<FO2+34[._GNX+6X262TE\F=5_Y9O@'!]\$4 6Z*** "BBB@ HHHH ****
M"BBB@ I"0 22 !U)I:@O+.WU"TEM+N)98)1M=&Z,/2@"<'(R.E%-CC2&)(HU
M"HBA54=@.@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9'B708_$NB2:;)=36NZ2.59H<;D
M9'#J1D$=5%:]% '%W/P]%U-J\TNO:@TFJVD5M='9$ Y1=H? 7&<%N!QD_2KU
MWX=>.ZTS5YKJ>]N=(MG"(D2A[D[<'., ,<#I@9KIJ* .&\*PR:]XINO%\FD/
MIT,MJEM;K<1;)Y,$EF<'IV ]JZ[4]-MM7TRYT^\C$EO<1F-P0#P1U&>]6Z*
M.8TSP;':SZ=+J.I7.JMID>RR^U*@\H\C>2H&Y]I"Y/8=,DDVO#OAE/#TVHRI
M?W-TVH7!NIC/MR)#UVX POH.<8ZUNT4 <_JGA6/4?%&G:_%J%W9W5G$T+" K
MB>,L&V/D'(R,UDQ?#33H/"\VAQZE?A)+T7ZSDQETF#!A@;,;=PS@@_6NVHH
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MQ-)MEU(];@)SGGG'3=R><9]ZV:* ,.\\&^'K^YN[BZTJ"22[79<'D"49!^8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:G<-<[+P.'MI& !*[1\V2!U(I)?#_C+3-:U1M"U&P>PU)A(S7I<R6TFP*SH
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MW# ;D/&UAV/:NT\/^#-8TK5='U";4;+=9Z6VG2Q16Y"NN5*D'/7*@D_X\*?
MM]+X-\0Z%<:C;NVJR22I+% 4$;.<D$;CD9 H =/XKU*/6+71+>&%KA+-+JZF
M\J6; 9@% 5%)R<'DXQUYQ527QIXAG.@VD.DQV5_JRWL8CO$<>7)#&61MIP2I
MP.N.#5NZ\%ZN]_INL67B!;76+:W^S3N+;=!<)G."F[MV.:LS>$;^77?#NJ-J
MRRR:5)-+,9H<F=I4V-C# * .@P?QH OWLVKMX&EGD6"VU7["7E4@LB/LRPP#
M]>]<7;17UCJ/@""3RTF6VD0!"P!'ECAL\]:],O;87EA<VI;:)HFCW8Z9!&?U
MKE--\(:C:MX8DGU*!Y-'A>*8+;[?.!&!C! 7  [&@"A)X_OK'1;;[?8HFJ3:
MS_9 0*P5CNVB4+][:05;'4@C&:WO#6J:W=WNH66L6006VPP7D<+QQW(8'.%?
MD$$8(Y[>M8,GPTDN="O-/GU8).VKOJUI=00;6@E9BP!R3D _2NET'1M1L)I[
MO5M8;4;V=$C8K"(HT"EB-J#.,[CG)- &#=ZCJ=K\3;]I98GT^RT,7*1[#\BM
M*V_GNQ\D>W';G)8>*/$,UWI-TVG&YTW4F4-';VDJO9JPR'9VP&'K@<5MW/AV
M67Q@-<BO$6*2Q%E<VSP!_,179EP2>.78$8.1BL30?A_>:3);V=WK\U]HEE,+
MBRLVBV/$XY4-(#EE!SA<8Z>E %%/&OB27P_J&O1V6G-9::=0CNHR[!RT&?+*
M^Q(P1[YK3'B'7O[3\/P 6)BUJS=T/EN##(L:ODG."#D\<'COS3++P-?V_@SQ
M!H$VJP2-JTEPZS+;%1#YV=W&X[L9..15N+PGJ(O?#%Q)JL)_L2!HF5;;'GE@
MJ$_>^4; 0/<Y]J +?A#6KS6+74H[\V[76G:A+9226X(20H%.X YQ][!'J*BG
MU36=2\0:AIFD/;6T=A&F^:XB,F^1AD* && !WJ7PMX=NO#\NM-/>0W":CJ$E
M\JQQ%/+9P PR6.1P/3O1<>&[B/Q))K.E7R6LETBQWD<D7F"0+T*\C:V#CN/:
M@#@M?U[5?$NF^$;V*2WLP?$,5I/#L+[;A&D&0<C<GR],#/'2NZU:"]TGP9JM
MS:RVUMJWV=[B6YM[;AY57[VWG)PH'.>E4[SP,9[?1[6WOU@M],O!J (@!>6Y
MW,=S'.-OSMD8STYXKJ-0LUU#3;JR=BB7$+Q,R]0&!&1^= 'F4 U5M%^')^UV
M\L\I#1R"$[%S:G;GGG!SSD9JSJ'C#4T\ >*[B_33;FZTNZ:S/F0L(902J\ID
MDG+8QG!XZ5T5IX,:&V\-1SZF\C:%CRRL**)<1^7SZ#&>E1W_ (!M]0T37],F
MOYMFLW7VF1_+7,9RI 7Z;1R?2@#$\0>,]<TV^>S6:QT\O90OIT]] WDWLY!+
MIY@8!,<#!]?I7HMJTKVD+3J%F**9%'0-CD?G7)ZCX$;4=/U/3Y=:NFLM0ABB
MD@D17"%%"EDS]TG&?3/-=(=.V:+_ &=;W$D.(/)28 %EXQGZT >5>+-2U:6_
MO_%]I;SD>'KSR;.-(I&2:%3MN68A=N,Y&<\;#Z5V?BGQ9+I^F>'[C3&B$>LW
MT%NMS,,I%'(I;=C(YP..W/Y[>FZ*FF^&;?15F,D<-L+<2,@RPVXR1T)]?6O/
M/$'A1]#\,>&?#0U74?[-BU'>]]' ':!4C=D5E"D%2Y4Y;@8_( BU;Q_XET[P
MSXKNO]",FD:HEC!<>65#J60'()(R QY]QQ6WK?B+Q!I,]EIXG@FN-6NI'MWA
MB4M% $!"*K.H9\Y.<_A5)?#UUXJL+_PP^M74VBQ11[KW[&(',XDW80A0KKA<
ML1_>'J<=1XC\%VWB2QTZ.:]N+>\TZ19;:\@P'1P,9QT/TZ4 <P/&/BNVL[#2
M]1TF2WU:]NY8()%C1GEA12_F"/?MW;0,@L!DYYZ5'J'B?QGI?A"^NKZW6TGM
MK^"&WGGA7=<0R2*N2BN0K#=Z]JWK_P"'%AJ>DI!=ZA>R:G'.ERFJ%AYRRJ %
M8#&W P.,8I;GX?QWFB3V-WK-[<7-S-#+<7L@4R2")@RK@# &1V'<T 8UWK/B
ME-:\4:0FKVR_V;9I?PW M!NP58F/&[&/EZ]?Z.G\>:G=1>%K2UMW6YUG3EOI
M7MT1W7 4E45V4<[NN3@=C732^$8)=:UK4VNY?,U6S2SD3:,(B@C(]SDUG7WP
MZM+S0]%LEU&YMKS1MHL[^W55D0+P%(Q@C  P>#B@#"C\6^+TO/#^G7UK%;3W
M.IR6URY0,1$%S&7"L1&[+DXSSM..!537-8U:]\*>(["XU4DV6KPV(NEMT'FJ
MQCW1E<D<%O7.#C []</ 5L'TESJ5X[6%X;UFDVNT\I/5F(S@#(P,#!]A2W?@
M*TOH/$4<]_=-_;3H['C%NR9VF,= 1QSU.T>E '3VD#VUJD+S-,RY&]E )&>.
M!QP./PJ:N/DT+6!X[TF^BN[IK&UM'2Y>2<".4G. (Q_%R#N/  &,G-=A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !116?K>HRZ3HUU?064U[+"A9+>'[TA[ 4 7I)$BC:21U1%&6
M9C@ >YJG)K6F0V]O</?0"&YF6"!]^1([-M"KZY/%<:GC/^W=/\2:-=6\$5[;
M:6UP?LTXFC*LC KNP/F5@0>WO7-V0S\*/AO\BL?[7L.&./\ EHW- 'LE%9'B
M/6)]$TU+FWM!<N\R1'?)Y<<0/61V_A10,DUR5M\5K5M,U6>XL@;BPOTL%6WF
MWQSNYPA5B!QWY% 'HE%<)X@\4^([#0_$/_$H2TNK&V$T%WYF^&0,!G;QG>IS
MP1CBH4\7W.@:7H.G74=C%-<6*O'-<W3K$P"J%7S"A^<YR<_7- 'H-4[W5;#3
MKBT@N[J.&:\E\FW1CS(^,X JJFLM;^%SK&JVQLWCMS-/!G<8R!RN>]><^*;K
M5[SQA\/[C4K2UMXYM0\R)(I2[IE!\K9 &?I0!ZY17 IX_OKOR;ZQTLS:<;M[
M=HE20SLHD\K>/EV !@3C)./2DN_&VK->37FG6<4^E65VUM<0"&5KB;:VQF0@
M;1M.3@YR%/3- '?T5Q>J^*-;M;;Q%/;6-H$T>>,YDD)\Z'RUD8 =GP1C/'/?
M%4-/^(-_?>)_#D1L88](U^Q::W&XF>-UP27/3!##@?7/:@#T.JVH:A::5837
MU].D%K N^25S@*/6N%LO'VIZL(]7TW35ET4W#0>3Y<AN9%#A#*IQL 'S';DD
M@=0>*J^/-<O]7\'>)S86]L^E64<UK=>:[++(P R8S@@!<GKG/M0!Z7%(DT22
MQL&1U#*P[@]#574]+M-7M1;WD6]%<2(02K1N.C*1R".QK-GO;C3? 3WUHL;7
M%MIOG1B7.TE8\\X^E<UH_C'7)+OPO<:BMBVEZ_;H(1!&RRI.8MYW9)&WAN!G
MMS0!Z"B[(U0%B% &6.2?J:I0:-8V^L7&K)#F^N(Q$\S,2=@.0HST&>PKC+#Q
MOK6H366J6VG"XT>\N/)2VB@?[0D9) G+G"8XR5Z@'KVJY;Z]XHU"[&I:?:64
M^C_;/LWV7!6XVAF1I-Y.T88 XQTSS0!VU%>;7?CO7Y_M.H:1I7GV%M?&V6U,
M#M-=HIP\BN#M0!L@ @YVGI4USXPUV7QF=)MOL-HL=[!"+.[A?SKJ E3++&^X
M*<*3P <;3GTH ]#HKSRZ\9ZN?&7]E07&FV_EW\4$EC<QLLTD#%098W+!6/)^
M4 ].]0V'CK6AXCLH-06Q^RWNJ3:>MM A,MOM4M&S2!BI) )*X! (]Z /2:*X
M9-2\;ZEJ&H0V4>DVZV%X]N^_=('!@1TP<J<[G&>G!]JJZ/XPU36O#NE)#>6:
MZ[=7_P!FNHS:LHM2@+3*4+DDC:1G(SN'2@#T.BN;\3^(7TR^TC1[-D34M7E:
M."22/>D:H 78C(S@$8&>2:Y36O'.NZ!I?B339#:W>NZ1!'=Q3K"RQ30,P&2@
M)(8<Y&<>AH ]/K.UK7-.\/6 O=3N/(MS(L>_:3\S' '%1Z>^I6ZZE/JTT#6X
ME:2V,8P4AV@X;W!S7F'BS4/$/BWX9S:Y;S6ZZ7>W-N(M/%N7E,8N%"L'!^^6
M"DKM(QGF@#V2BO.-1\4^*+[5M930+??#I5R($A6U#FY<*"ZM(7&P'<,84GO5
M;Q'XW\0Z?JUU;@6FD$P0-IJZA&?+NY& ,JO(" I7)&,C[N><T =[;^(--NM>
MNM%BG)O[5%DEC*$85NAST-:=>;WWB_5K?7_',,)M@NC:4+NVW19RX5V.[D$@
M[<=:B'B3Q/'X/L]<N+ZRCAU".S1':,9MV8GS7P2 V1C H [_ %;6++0[(7=_
M(8X3(L0(4MEF. ./<U;DE2*!IG.$52Q..@ S7C>MZ_J>N^"_$^E7+PW=[INI
M0P02M;>6LR,5*;XR3WSGC!&*Z_3[_7]/\4MHNL75O>6UW8/<PM!;^68"IPR=
M3D?,,$\\4 =9I6J6FM:7;ZE82>;:W"[XWVD;AG&<&KE>4>'_ !#=6OA+P5I&
MEF?_ $RW>1Y4B62411GH%+8RV>N3C'0UVG@R_P!=O=,N5\06OD7<%T\4;8"F
M6+@HY4$[3@\CVH T-%\0:=X@CNI--E:5+6X:VE+(5Q( "1R.VX5IUXQ83^)[
M"Q\<ZSH-W:)!9:]=7$EO/$29U159QNSA?EQVR?7@5U<GBVXTSQ0KZI<O'H^H
M::;RP1H=I1D3?*K\9R%&<?6@#O*YC58?"NC:H/%-[:0?;GE2T^V)'O=7)V 9
M'0\[3_\ 6JUHIU27PO\ :-1O0MY<1M,KA% @##*CT)48R3UKS2=9F^#]A<7%
M[)=RSZQ;N\C;<,WVH98;1W//4T >T45YCJ'C'6/#$7C%;NZ349-+M89[9WB"
M .ZA<%5ZKN^;KG!QGO6]I<OBBS\606VH2&?2;BV8-+-Y2LMPN#A-N/E(W'!R
M1CKQ0!9U[1_",%T=4UBPLS<W++$6:/<\[9&U=H^\>E:4&MZ<-4BT9=\%V8O,
MC@>(IE!QD<8P,?RKEQ,+CXW&#4" +;2-VFQR8P2SCS77D_-QC/!QGJ.:ZG66
MLK.'^V+F/?+IT,TT0#8) 0[@/7@4 :E%>83^*]9T?P7H/C2]U#[3!=F%KZR2
M-!&L<N3^[(&X,N0,$G.#TI=<U;Q9I?AC7]576(3-I^I8M=T*K')""H*2#!..
M3R"#[T >G45PVG:IJ]OX[L-,N]3:[MM1TEKHIY:!8958<QD#)7!Z,3ZYKF(?
M%/BF#X>:7XO;57NG2_>&>Q%JF+B+SVB &!G?QP1@=!CN0#V"BO*M>\4:W9ZC
MJ5U:ZO(UO9ZG#"8X88GMHX6*HRR.1N#[F['C !'-;+7NL7GB/QG:#6+JWMM-
MCMI;3R8XLH6B=G7+(<@G;[\=1W .NM]&TZTU.XU*"SBCO;@;9IP/F<9S@FKU
M>7KXKUJ'3?!?BB]O]FEZ@D<.I0A8TBC=Q\LF2"P&>",XZ=*Z_P *WNHZM;W^
MIWC%;6YN6^P1?*=MNORJX(&3OP7YSC(H W([F&:::&.16DA(611_"2,@'\#4
MM>1PZA?>'-/^(6J6]U+)/'JJQ1F380"RQ+O( [9^F!TKJKC4=5T3QIHMG)>3
M:E8:K"\3(R(#!*F&\P%5&5(R"#TZT =E17&^)KW5H?&OAZQL]1GMK*]6:.=4
M@1@2%R"&8'##J!R..16"/$&N:6TN@'4FN9K?7+:Q6]EV>;)!(AD"GC:'^79N
M.<YSC)H ]0HKR[6]6\2:+8ZM&^I>5''<6+6YEE22>-99MDBN5'W3CY>,]>:F
MUJ\U[2OB1H&BQZ]</8:K-=SLAB3=&NU=J!B"2%8L1GUP00!0!Z765-K8B\3V
MVB"QNG::V:X-RJ_ND"G&TGU.>E>?:Q<:YI'A#Q3?'7[QYM$U FR+$ E2(W"R
MG_EH,2;<<?R W-6U#45^+>F:;'?S)8OI-Q.UNI 4N"%!XY)Z=<X[4 =I;7<%
MXCO;RK(J.T;%>S*<$?@:FKC/AC;O%X/A=[F>7?+*2LI!P?,;)'&?S-<CJ_B'
M5K:X%_;:E<R2?\)!'8&=)L6QB,@4QI$<@D#@MC(/0T >PTA.%)P3@=!7D^K7
M>NW-Y\0PVK:A;KIL ET](Y?)"XBW @C'R[L\]\8)XKH;#4KOQ#K]AI]W+<P0
M)I$-^6MY6B,LK\9)4Y*C^[TSUSQ@ U?"^H:=XJL%\0)I4,,QGEB5Y$5I?W;M
M&"6QD$A>G;I71UP_PE&/ ,())Q>7?)[_ .D25R(\1ZHNOZ%<1ZS>W(O=8EMF
MN(P5M+B'G")&Q(&T ?, 3G(W'K0![-17DT=WJ]CXQM(=6U34;=KG7'-M=I,T
MMI<6Y#A;;8#L1L@#)&003G-6=(O;^/Q)86VJWVJ07TMY+Y=P)FFL[^([L*H!
MV(P&,# .5/UH [S0=3O=5LYI[[29],=+AXTBF<,SH#\K\=,^G;WJU?ZC::;%
M%)=S")99HX$)_B=V"J/Q)KR\7VNOI,XL[R6>=O$-Y'/:M<^7/<Q(Q CB?(VD
M!1PI' ^M9>JP66KZ/HEV][J%S-'XK@A1+FYF$UHCR#,1RV=PV\-UZ8- 'LFI
MZE::1IMQJ%]*(K6W0R2N1G:HK'_X2V%_&UIX<BMF?[1IW]H?:=^ %W%5 7')
M.">V..O;-^)UE!+\/+N*4S&.%H67$SY.)% W$'+?CGG!ZBLS4] TV?XE:;9"
M2ZVW&AW$,I-V[2F/S 1\S$N.7?G/MVQ0!Z/17CUKXBN;S0O"NGVVK2M'=:E>
M6DDEQ>&*1UC=_*C>5!G)78..N1SS79^#!?65WJVDWUZDQMGC>&!97F-M&R_<
M,C %N0<9Y H T;GQ,G]I3Z=IEC<:G=VVW[0L!55BR"0"[D+GC[H.>13M#\21
MZU>WUD;*ZM+NQ$?VB*X !4N"0 02#P <CCGZUS_PW9(+KQ38R(8KV/6)9I8V
M7#%7 V-[@@<'VJ7QUK<.FVA%C>16UW)>6EKJ$\>/,A@=CU;^ X+$$]-V?>@#
MMJ*\PU&RD\(ZU<Z;H<]R-,OM)O+J:!YFD$,JKQ*K,2PW$X(SR>>U9.C68?4/
MATPN+I&U/2[NUNBEPXW1K$& '/RG=SD8.: /9:*\F=)K/X:>/=/@:X:&PO[B
M"T1I"&CCV1MM#$DD99CDDGFKL<"Z%XHL;VUU*Y7^U-*EEO$,IF)D1%*S[2=N
M .,  =  !0!Z917C/AZ2XTSQCX+6!IHUU6QN#>SNV6O]L1=9'!).<\@GG''3
MBL.TLVF\$:%K-O=EM1MO$S1HTUPPVH\[955#8+'"DYR< \X% 'T%17E/B">'
MP#XXO[V.R,D'B6V\J)N"5O 2-O/17W D<\@GVKN_#>EV'AG1[#P_#<1M/# "
M06Q),1C?)M))Y8_09Q0!MU5N]0M;%[=+B4(]Q*(HEZEF/H*X?QQ%;:EXLTO2
M[EC>K]BN)_[,8[(^R^<SYZJ"0!@D<FN#L-,76=.^%\]U:K=6@N)[:1G'F97.
M44G@$85N2.U 'NU[?6^GVXGNI1'&9$C!/=G8*H_$D5@CQ3,?B3_PBWV11 --
M-[]H+\DAU7;CTYK,^)6E6-QX=TJ*2WM?*AU2S1$D7C:954JH]QQCIBN?U30-
M,U#XOOHT]JHT[_A'&'V>(F,869" "N" " >".E 'K&1MW9&,9S2@@@$'(->%
M2ZI?W'AWP+87NI6MO8737:S-J:-)!*8\"%9/F!(ZD9.,@'G%>B_#JP_LO1K^
MQ&IVU_'%?R%&M4*Q1*P5]B9)X&XG@G!)':@"X?$\]_K%QIV@V$=^;-BEW<37
M!ABBD'1 0C%FZYP.,<FI_#NO76LRZE!>:8VGSV,XA9#,) Y*!L@@#CGC^G2N
M5^$\C62>(] OI2VK6>JS37 ))WK(05<$DDAASSSSS4OQ%UE#8V5G'O\ [.DU
MB"SU:1 1B)@6*[AV)VJ3GOCO0!Z DB2)O1U9?[P.13?/BRX\U,H,N-P^4>_I
M7F6LZ);Z;XDU31]+L1#HM[H<L]_;P@K$LBDB-QC&QC@C ZX)QQFJ.KZ=86OB
MCP2ED0]OK"&WOW#[OMT8C##S&_CY4<GZ=": /7%EC>+S5D1H\9WA@1CZT)-%
M(6"2(Q0X;# X^M> M"D?PL\6V\>^.+3/$8^QB-ROD_Z2J<$'/W6(YKI/$VFV
M'ACQ7=+I[RV.G76B3S:O]FF;S=JL DJY)RY9L9.<@M]: /68KB&?=Y,T<FWK
ML8''Y4"XA+JHFC+.-RC<,D>HKRK1H(T\>7UC=VEE;69\*Q&2VAE/E[1(V"Y
M&&V^@X&,4_3--T^+3OAE?+#']M81QB=I"9&0V[L5R>67)Z9P.U 'J*75O)&T
MB3Q,B_>97! ^IK"NO$%Y;>.-/T;["CZ?>VK2+=K*-RR#<2"O]W:HY]37!R:3
M'X;UW6O!MA +>+Q*5ET\+ED1=N)P?[H"@D#WXKU:&RMH)!+'"@E$2P^9CYBB
MYV@GT&X_F: 'BY@,WDB>,R_W-XW?E4M>3Z%,D/BO0K>[$&HV4TMU+HVJPS?O
MF!)+K,#RQY.2,<BO6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *P/&NC7GB#PE?Z983)%<SH OF$
MA'P02C8_A8#!]C6_10!YSIW@C6QX@U&_O/[,@BO=#&G;+3?MA89&%4CE<8.<
M_A2?\(-KJ?#SPUHT5Q8#4-&N8KL[]YCE:)BR+D<@'@$XKT>B@#F/&^AZEKFG
M6*:8ULTEM>Q7$EM>$^1<(IY5P <X.&';(_+EW^&%[=W?B5;F^@2WU.YAOX)8
MU/F17*<].FS)(]<5Z?10!QB^&_$&L^&;ZR\2:I;M=W%L]NBV:LL2Y PS G+'
M(_ $U2NO"/B#4-"LK+4'T2]6.Q$$UG=0,\(E'"NAZ@@9&[K]*] HH PK7PTB
M^"HO#E[<RW*"T^S23%B&;C&>/3M]!7.2^#/$.I:GX>N-3U.P:/1+H2QM%"X>
M9-N/FR< UZ!10!PVE^"];T.:6PTSQ"(M!DG:=83 #-#N<NR1MT"G..1GDTB^
M"=8M-7U--,U[['HFI3FXF@1#Y\3MDN8GS\NXX.>W.*Z;Q!K#:#H\E^MA=7[*
MZ((+5=SMN8+P/QK4H XBZ\+^(KJV\26[7VF>7JX 3]U)F+"+'R<\_*OYU0M?
MA[JMG=>#9H]1LS_PC]NUO(&B;]\&P"1SQPH_&O1J* .#TOP'J>B7%YI^G:^]
MOX=N7:5;9(\3P,QR5CDS\J_F:74/ E]-;^(-.LM2AATS6O,DD1XBTD<KJ =I
MSC;QGUKH+;Q-:W/BZ]\.+!.ES:6Z7#2. $=7)QMYR>ASG%:LUW;P7%O!+*JR
MW#%8D)Y<A2QQ] #0!EW^DW<_@^71X)X?M$EF;4RR*=O*;2<"N;M?!&KPP>#K
M:2^L3#X?*EBL;[IB$9..<#Y2#]<UWU9MGJLMWK6HZ>=-NX8K,H!=R!1%,64,
M0G.3C.#QC.: .7T?P)J6CW+Z?!K\R^&O-\^*SCRDT1W[_+64'(CSU'4CC/)J
MQ9^#-2L)[BSMO$-S'HLTQN?*5<7"2%]Q19!TC/IC/)YKLJS]*U*74DN6ETV[
ML3#.T*BY !E Z.N"?E- ',P^!;S3]2U./2M8:TT;5)&GNK;RPTBRMPQC;HH(
M !X)XXI^N^![CQ!+%#>:JSV<=V+N)A&%N+8C&%BD'*\CKUKLZ* ..NO!,U_J
M5G)?:E]JMK.[-];R2Q W,,F\,$1^@3 QC'8>E4K?X?W\2:=&=5@\O3M8DO[?
M;;!3Y;9^5L=6^9N?<5WU% &#';Q^%[?6M5NKJ6>">4WDJB+)0A%0XYR1A!Q6
M7X7M;/5/$NI>*;.*ZCM;F-(H1-&T:R-@%Y55N><*N<<[/:NRK%O?$26?BC3M
M#-I*TE[&\BS[E"*%'(QG)/X >] "Z]X=M]<ETZY:0P7FG7(N+:X1 64XPRG/
M\+#J.,X'I6/K'P^M=;@UHW5ZXN]6ACMY;A(@"D2'(51]>I[\5V-% $<<96!8
MY&WD+@G&,_A7&3?#J-M /A^#5[F'1Q<+/';>6KE KAQ'N;.4! ('7CK7975S
M%9VDUU.VV*&-I';T4#)_05A>'O$UQKYM9AH\T%A>6OVJWN3(&&-P 1P!\KD'
M. 6& >: ,S4?AX+O5KZ\L_$&I:=#J/\ Q_6EL5\N<[0I.&!VD@<D<T_4?A];
MZCIE]I#:E<KI%S'!&EGM#"W$2@#RB?NYV@GWSZUV5% '(W7@2.ZU'7[IM3N,
M:QI_]GR(RAO*3:5!4GDGYCUHNO D5QX8T31TU.XADT>:*>VND1=V] 0,J>#P
MQKH-6N[RRL3-86'V^<2(OD"41DJ6 )!((X!SSCIU%7J .(?X;6UQ::]:WFKW
MUS#K$R3R"3;^[=1C*C&.0 #QT ]*V[;PYY>I/J%S>R7%S]E%K%E0J1)W(4=R
M>3]!6Y10!QA^'ELOA[2M.@U6]M[S2D,=KJ,) F52,%3V(/H?05OZ'HW]C6LJ
M/>W-]<3/YDUQ<$;G;:%[  #"CBJ&I>,+*VTCQ#>6 6]FT.-FN8=Y0;E7>5W8
M/.!Z&MG3+S^T=*L[[R_+^TP)-LSG;N4'&>_6@#FSX"@"ZK;1:I>Q6&JW375W
M;H1EV8 ,H?J%8  CN.,U2\1V]IXOUZT\//H,LR:;=Q3SWUS$%CB0 /B,]7WX
MV$#@#.>@KNZR_$>NV_AK0+K5KE&>. +\BG!9F8*H]LLPH U*XX?#^ Z&^D2:
MK>26IO5O(PX4F(J^\*O'3=ZUNZ;>ZK/?7=OJ.E1VJ0A##/#<^:DV<Y'**01C
MGCO5/QAXAG\-:/%>P6T<YDNX;<AW*[1(X7/ YQGIQ0!'=^"["^O=:GN99736
M+86UQ&,#"A< J>Q[TSP]X)M= GAE;4;_ %!K9#%:?;)=_P!F0X!5, =0 .>P
M%6H/$$DWC>[\/-;QJL%E'=K*)"6<,Q7!&W QM/<U6O?$\]M\0]+\,K;1F&[M
M);EYRQW#;P !V[^OX4 7M<\.6NN-;7#33VM]:%C:WENV)(=V-P&<@@@ $$'-
M1P>&HS??:]1O;G47$1A6*XV^4JE=K$(!C+#.2>N36Y10!S5IX,M+.*RM$N[A
MM.L;C[1;6;8*QD?<7.,E5/*CKG')Q5>Y\#+>:+JNF3ZS?M'J-P+AI 5#Q-D$
MA,#@<"NMHH PAX;A3Q#9:[)=W$EQ9V1M K?,'4G)8]RQP/RKCO '@YKSP;8V
M^N'4!##=3O+I5Y %B)\UV3*L@)7#!NI!)]L5L'Q1XEU'3AJ>A:+9W-K(\D,:
M37)1U*,P\QB0!L^7[HR><Y/2NJBU&%K]-/9A]K-OY[(IR%7('\SQ]* .7NOA
MKILZZK'#J&HVT&HW*W;PPS85)@X<N..<D=#D=\9QC77PK9I=ZS=+<72SZO!%
M#<R!QG$:LH*\8!(8YK=HH \]U#26M=%A^'5II>I7=C+9JG]I2 &*)"Y#*S8
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M>GKSC H TX+'Q!J/B)VU4VT&DV-QYEDL)+/<<$*9,]-OMU)IUSX8:[\>VOB
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MQ&8(%L@VR*(G)Y;DDG&?]T5U->=:MXWN-1T7Q@MBES82Z/A8IVB*MD*K'.[
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MR2;#@D# !&5X]>>]&AO:S^*_A_?:F(98Y]$EC$\_S^9*#@+SU8#IWYKVH6\
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M)F0LDCLPR!@'!%<IH2BU^%?@N&6SN8Y[75K=YX_LK[HRLC%F(VY^Z>M>RT4
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M?@".6WF86%A.LC& D1N410&))V]&]>0/K5WX66=W8Z5KB7EN\#RZS<3HK1[
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MYZ5J AE#*001D$=Z\;^(5R&\0^)K2&)K6Y?2(P)DB:66\&2?+7(*HHY)QR:
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MK@D#@X8^G-6M:\(ZUXJO_$GVJUAT^UU'2HK:W9I@[B56+?.%R ,DCC/ '?-
M&_I'C6'4==BT>YTZ>QNYX&N(!)+%('13@\HQP>0<'U^M=37 :)IOB5&@NM1T
M71M,?3XI&W6LBDW<FPJ-QVCRTYR><YQZ8KJ/#&JW&M^'K74+NWB@GE#;TAE$
MB AB/E8=1Q0!QOQ9E:&;PC(BRN1K"?NXSR_R,<8R 3D#K^E:DOQ#%K9ZR;W0
M[VTO])A%U-92O&6> _\ +1&4E6 P>_8]^*D\?>'-2UY=#GTU89)--U!;MXI)
M-A=0I!"G&,\]\52UOP;?>)6\1WEPL5M+?:8-/LX'.=N/G#R,IZ[SC R,#/?%
M '1WGB$6OB6'0_LK&:XM)+F&7=\AV$ J>,@\]>:R/AIKFI>(?"QO]199'>ZG
M4.#R )" N,= !C.>:IV>A^([SQ7X>UC4;.V@2ST^6UN%^TAV#LHPXVJ <D=.
M@S5KX:Z%K/AK0KC2=5M[=$BN9)()89]YE#NS$E=HVXR!U.>>G< Z/7-731-+
M>]:"2<AT1(HQ\SLS!0/UK$U#QS%IVD>(;R73Y7DT3;YT4<JD29 (VM[9.<@'
M@\&KGC33=4U7PY)::1*J7+2QLRM(8Q)&&!9-PY7(R,BN0?PGXCNM)\86C:7I
MEF=8@C^SK#<F11)MVD,2@^N<=?7K0!M7'Q%@LX+.6]TV2R%_*!9?:KB-!+%Y
M8<RD@D*J[@".6R> :UO"GBRP\66,\]G\LMM*89XMP<*W4$,.&!&""/7L<BL?
M5_#VMR)X;UC38[-M8TF%H9;6<[89ED15< K]W&W(X_PK;\.6&IVPN[O56@2>
M\=7^R6W,5N%4+@-U8G&2<#Z<4 2>)==_X1S2A?FQGO 9XX?*@*A_G8*"-Q /
M)'%4SXPM;76-4T[4X39O86OVWS"X=7@R1NXY!&.1@]1S3_&>G7^IZ)'!IMK;
MW-REW!.%GDV*!'('X.#@_+CIWK(U3PO?Z[XBUD74"PZ3J>DBR:02CS4<$D$+
MR,?,?7D4 : \72V]SI*ZEI3VD&KOY-I*)@^V0J659 !\NX XQNZ<XJ+P)K>J
M:[9ZC<:@D0":A/$NR0G8%( 4#:./?-5?[ U_48O#%IJ*V<*:1=+<7,T,A(F\
MM"L812,\YRV<8QQFK7@W1-8T";4K2Y2T.GR7DUQ#*LC&5][ C*XPHQGN30!T
MM]%'/83QS1I)&4.5=00?P->7>')K*#P5\-HK[2/MEQ+<*+8I)M\A]KGS,=P!
MDUZAJ!G&G7'V6$37!C81QL^P,V. 3V'OS]#7!+X*UA]$\#6<C6XFT*[CFNCY
MG#*@V_+@<G!SSCH>] $[?$QAI&KZHFAS26VE:A]BGV7"EV^[\R#&#]X9!(^I
MK<TOQ3)?>)I=#N=,>TG%BE^A,RN?+9R@#8X#9'(!8>YKC/\ A /$*^$O$NDH
MNG^=J>J"]B9IR5"'9D$[.HV>G?KQ73P:#K4/Q&;7ME@U@^FQV!'VAQ* K%R^
MWR\'EB,;N@SGM0!PUSXH>T\"6D_A>Q32X+GQ%]CN5,Q9R3)EBIQP&P0?05UF
MK_$^PTK4-2L?(AFN-/C4RH+H R2$$F-/EY( Y+;>2!S6"WPV\0IX&324FTTW
MT.M_VJG[U_+9<EMF=F<Y('2MR3POXGTSQ+<ZOX?N-*C75(4_M&VN-^U9QP98
MRHR>.Q(S^6 #97Q.NK3W>GZ;IC7DL-E'<3Q7)\D8E#;(\,I^8A3G( &1SUQ4
M^%;(_P ,M#,891Y+ AF!P0[ CCMG./:H;;PKK6A>)Y-5TJ\M[Q-0MX8-0-\6
M$A>(%5E&T88X."#CIP>>-GP=HD_AWPGI^DW,D,DUO'AC"I"Y)R>I)/)//'T%
M &7X]U75],E\.)ISPI#=ZQ;VUQN8J[ MN"@] #M(/7KBK$OB?4+J;5!H^F1W
M46E2+%<.\V/-D"[I(XQC.Y05Y; ).!T-3>,M!O-=L=..GO"MWI^I07T2SDB-
MRA.0Q ) PQZ=P*SY_#6MV=[JTFD36)M]94&Y@N'=%MI=NUY8\*V\MG)!V_='
M// !T>A:Q;>(-#L]6M%D6"ZC$BK(N&7U!'J#D5H5P5C!J?A36_"OAG39TN-(
MBM7BNE\L^86 )$C'&%7(/ /4UWM !1110 4444 %%%% !1110 4444 %%%%
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MU1?XB65K9ZO)?Z?=6]UID23RVH9'=XFX$B$-AE!R#@G!H Z]8HT=G6-0[=6
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MPP6DD71KL"!W.<0R9*+G_9VL/IBB777C^*TVD#3;/>-)%PMV(\S,-S80D#.
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MDX&>1@-[Y/2O3Z* /)/#]IJVGV4WA>]\&7-Q*EV[07LI#6;H9-RR/\W!&<X
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M2.H[9SSBH]'T+7#XOL]2;0QHBP--]N>VN(_*U$8(C/EJ>&S\V3TZ<YX]'HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
M@YP<=>V:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit101-iansconsultin003.jpg
<TEXT>
begin 644 exhibit101-iansconsultin003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW/E^;;;U)/FG80>AV-S
M^6?SJQ44Q(>'&>7P<+G^$_E0!+1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %0S#]Y!\P7Y^A/7Y6XZ_YQ4U5[G;YMKEL'S3CW.QJ +%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!<%A);[>AD.[KTVM_
M]:IZ@N& DM@2.9"!G/\ =:@">BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *JW;8FM!LW9F(SD_+\C\_T_&K55;M=TUH<$XF)X7./D?\J +5
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]H)>2(E=K)@8W$/D@X ]ZV[;Q1=+XMN]$OK%8R-.&HVYB8LWEAMC*X.,/G&
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MWD$ES9RP17,EL[KM$T0!9/<9!&?PH HZMXBT[19-/2\>7-_=+:0-'$SKYC'
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MHO$VI3Z/X8U/4K:+S9[:V>5$QG<0,B@#5J.."*)Y'CB1'E;?(RJ 7; &3ZG
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M<;BHZ9P ,_A5;Q-X9L?%6E?8;TRQE'$L%Q"VV2"0='4]C_0FMC(!P2*"0.I
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M13\-M(<2_O4\5. 0^"";EN/R->^A%6,1A0$ VA1T K-'AS15A6$:5:"-9OM
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M&U/5=4%Y86\OFZ=8B (ML^W;N)_B(&0/3)/7H :N@:1'H6A6FFQG=Y$8#/\
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MQG&/>H?%MA?:KX CL+;2II+EI+0M;%HR56.:-V!);:?E4]^:Y;Q+HWB36_\
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M:A/+(V[RE3<CQ] >HSQUX'3-6++Q3K>W^U;_ $VU&@SVKW,,MM(S30JB%\2
M@ E@#C'3ISUH [*BN$T/QEK6I:IILTVF0_V+JJ%[=X5<RVRE0R&8GY?F']WH
M2!D]:V_%FM7NC6MI]B6U1IYQ')=7F?(MTQDLV""2>%49&2PH Z"BO-M3^)&H
M6O@VSU:WT^W-VVIKIUR)"WE@AMKN@X)&>F<8SSTP;$'C'Q+/J7BC1X],T^;5
M=':.:&.*1]D\3H'V9//F8.,XQD]..0#T&BN-L_%6HZO:^%FTQ;%I]1037ZR!
ML0QI@2A<'(8,2HSGD<]#5[7O$%]IGB30M)M+.*9=3^T R/)@H8XRP&/<XY]
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M$2[M8+A$8.JS1APK#H1GH1ZT <=\.]"GTCPL\BI*;B1W6S:^R)%M0Q\E&[J
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M7,L;9& K#:.O?VKTB42"!Q $\T*=@?.W..,X[41V\$4LLL<,:23$-*ZJ 7(
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M5WAG<6_D2^2"JE=NW'7/3O7.0^"M5;P[9^&;O4H&TBUD7#QH1-+"C;HXV[#
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MCC<,\#A) /X6*AL?DP/XT 2T444 %%%% !1110 4444 %%%% !1110 4444
M%5[DXEM>6&93]T]?D;K[?_6JQ5:Z"F6TR%SYIQG/]QNF/ZT 6:*** "BBB@
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M$O"L7]D^']1U.:^N+NTT^..W@N]JK:%H@KA555.2./G+$#CBIM,^'NF:5?\
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M^EVEX4"&XA27:#D+N4'&>,]:Q+CP58W6G>(+&XOK^2'7)#)<9= 8\@+B,A>
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MVB)NY7_=M_"=S'(&.* /,O#NKZM+X-\#:W+JMX]W=:PEA<;I3MEBD=]VX>O
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MV/C'Q%+HO@?4M<THV]T]O"70E\IP<9R.N#VK8TZZ\ZRMA-<0R7+1*S["!DD
MD@=A7B^L6K6&B_$ZVT\[/#T44:6T8.(TF*JTBQCH!DG./45U6N6]KH=SI'Q#
MLK59%BMEAU$Q@%GMW"@.,?>92% Z\'\@#T:.>*5G6.5'9#M<*P)4^A]*)9X8
M #-*D8)P"[ 9/XUB^%-&.EZ8]Q<V\46I7TC7-WLP<.QSMW=PHP/P/K6'J4=G
MJ'Q1^P:W#;S6,>D"6TBN &C+F4J[888#XVCJ3CF@#1\#^(+G6_#;ZCJ<RK(;
MN>+F!H54(Y50"V-W SN'<D=0:Z+[9:BT^U_:8?LVW=YWF#9CUW=,5XA]I@MO
M _A][J^MX=%&JW@>1[<7"P/YL@0,F""O4Y8D@L.W396PLWMKRPTW6[:8-K D
MMH;NU_T S"-V>W4 _<YY(S@X(R<T >C:W=:@+""31I[$.;F,2/</\OE9^?'^
MUCI6G)<0PL%EFC1FZ!F S7B=V^FW?PZO9#8VUI/;^((?W,<X:!)1,BL8B. -
MI;/'&370:]'8W?C#Q-I][';W[7EA;+;&66)?L;8EX^=P1R%DRH_D* /2OM5N
M-N;B+Y@2OSCD#J1]*5;FW>V%RL\30,-PE#@J1ZYZ5YZ-&TJV\:^%[ 0VDML-
M*N$R -LGS(3P/E())./6N2T*:S/@>VTNYN0T(\5R06T<DJK"R(Q95D^\#'G^
M$=21@]Z /8=4UZPTG2&U.>>-K?*JK*P(=F.  ?QJ\;JW$8D,\01N Q<8/XUX
M9J L4\/>*M*G6U>*V\00/;P(F(XUW0[F1>=HS(<_[Q]ZT_$=KI#>.-0T:^O[
M32],GTZ,V*2VB-;D$2>8T>?E5N<Y')H ]@EN8("HFGCC+= [@9_.I%8,H92"
M",@CO7C%QIUO<Z=IVH6M[9ZPUKI!C:SUF/;+/!N;$R,<[6(&>1GIG!XKTKP3
M<P7?@?1);:.:.'[%$B)-]]0JA<'@9/'7 S0!L/>6L=P('N85F;&(V<!CG...
MO8_D:9-J-E;&03WEO%Y0!DWRJNP'H3D\9KQCQ+-9WDFK:A;F$R6_B&U'G7/-
MRF'C#!>GEQ 8QUSDDXJ>_AT[4/%GQ4$ZPSQKI\3H'P0'6WX(SW#"@#V2:Y@M
MXQ)-/'&C$ ,[@ D\ 9-<IX#\2:AXBE\1+?& BPU22U@,*X'E@*1D]SSUKDM*
MOK2]USP99:\(9;"3P]%);BY(>*2XV#<2",;@!W]ZU?A*D$+^+H;9$CMX]<F6
M-$7"@;5X'MG- 'HDL\,"AII4C!. 78#)].:'GACV;Y47S.$RP&[C/'KQS7$>
M+9=-NO&.GZ?>QVDIAL)KF0:@,P1QEE7<%_BDX(&#P"WJ*YK3(([C1OAN=2-M
M,IEG5Y#<%@$:&0HN2>I4KD=NE 'K/VRU-N;@7,/D@D&3S!M&/?I3H[F"9W2*
M:-W0X=5<$J??TKP3Q%96EEH'CRVT[(TFWU&Q>)/NQP.94W^7V[^W4^E=+KEA
M%I7B-)_!JQ)<W&C7,FI?96!8J IADQG[Q<MR,DX/I0!ZI%>6L\\D$5S#)-']
M^-) 67ZCM6;9WE['JVLG4+JQ&G0M']G*R#?&-OS>9Z<]/:N$OET^*#P9>^%X
MX%U"YO(5=XU422P$9E\P]3P"><\CUJKXJ6U?3/B:H\MLFU=AD'Y@JX/UR!^5
M 'JO]HV1,P^V6^85WRCS5_=KURW/ ]S5#2/$VE:SI3:G;748LUD9!+(P52 Q
M4-SV..#WKB9;/2;?Q-;F"* 37WAJX:YC7;^_(,6TD=SRPY'YUSWAW3+"\^&7
MAQ+>>ULKZ6ZR?.MUDAGD4.1'<C XQG&>A(Q0![;')'*F^-U=3W4Y%8TOBC3T
M\5IX;253J#VK7/WAM0!E4 \YR=V<>E9_P^N8KK0+@QZ;;Z>T=]/%+#:MF'S%
M;#-&<?=/MQUKFI;*P'[0B23VUL"VD-*C/&O,HD3# G^(#OUH Z3P/XEGUG0%
MN-7N+9+R2]N+=%4A _ER%0%!.3P!7237]G;W$=O-=P13R_ZN-Y K/] >37B@
M%NOPKAO@(A=6OB5C!/QOCW7G.T]1D=:GU^?29==\3V/BS5OL6H--YEB8[1'=
MK?:IB\IRI;<#G(4CDD]R: /;*Y@:OK.NRWB:$ME!:VTQA6]G;S1,RD;@JJ>
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MOSQ^;9.A\+$>7:9V;%!VJ3GYL#C/'T&<4 >L1:G83NB0WUM([IYB*DJDLO\
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MPSPW$8D@E25#T9&##\Q7EX\/:5?>%-7L8Y-/TF]?5Y8S,D22;<7!*(X(!*'
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M34DL/#:Z9)86DWDH\*S)*RR@AU(&X#&>^#VH ]6N+^TMK=)Y;NWBCDP(Y))
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M\88KO4QL0'"G.0>V>#UK8T;Q]8:I)K+3P7-C;Z9*\<CW,+(!MZDMT&<C ZT
M=+_9UG_:"7_V6+[6D1A6;:-P0D$KGTR!^5%II]I8M.UK;10F>0S2E%QO<]6/
MJ:P[+QQIEW8:E=RVNHV7]G()+B&[M624*02&"\D@X//L:;;>/-(N[R&V@BOW
M-Q9&]MG%JVRX0*&*QG^)\$<#Z4 ;-MHVF6=]<7MM86T-U<$&69(P&? P,GZ5
M:%O"MPUP(D$S*$:0#YB!T&?Q-><Z3XVO?&WA?7UAM]6TJ>*25+>Y@L6+; ^U
M57/!EZ@@?=SGC&:WD\17?ASP_ID'B&.;4-<> M/%ID!E9M@RTFT8P.@SQEB
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M&PF"2/O##\=^!@YH [:H+FSMKSR_M-O'-Y;!TWJ#M8<@BN;/C[3UODMFT_5
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M<GGY<MGH36YXK\-:AXE\26\5L;BTMI] N+-[OR21&TC)A2#Z@,"/Y'%>DT4
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M>V16MHJ?O,(@0,XSA<D,?IC//%>H44 97AI'C\,:;!-%)')%;1Q2)(A4AE4
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MDN5CN8]\,A7LPZ\9R"#P<&@#"M/'<]UI>H+%%;R:C#J_]E6^W=Y4C,PVN>^
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M.(@#$K2!2,_[2C_@-;&H^"(]:U?59]4DCEM-1L([*2) 5<!&+!@WKDYQTX%
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M?%:E+31FU-I)B?WAW,JH,' 'R\GWK7\)ZQ<^(/#-EJUU!' ]U&)!'&6PH/\
MO '^GI7GGBB*RN/%DL.HZUI.E366GQ6J?VBS1?: P8N4Q(N^(Y52#D95ACKG
M=L-3\3WL_A^6.[BDC\]TNEALG6*Y@(!$P+<HH&<9/S$<9!H ] KD/$7BR^TG
MQMH&@6MG!*FJ)*QE=R"A0>@[<C]:Z^O,/'!F_P"%O^!O(:-9/+NO]9TZ+Z4
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M0O,)U0&)0I VLV>&.>!CL:\WUS6-;M;:UOY=2NV\/RZ2@BU:R_Y9W)S^\DC
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MW<Q/)*A11\P.>Y) (S].*LWEQJT%SX=T/^VENIYGNEFE\]K?SGCV[8RZJQ!
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M.10!TFE^,K76+C3Q::;J9M;^-Y(+UH (2JDCD[LKG&1D#((KHZ\B\.7EQ8^
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M)R._ XR0#NI[^""<6Y8M<&)I5B7EF5>N/SQ57P]K4?B'0K;58K>:W2X#$13
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M33A>6S)"PN(BLW^J.\8?C/'K0!@W'@+PY=W>I7$]BS'4L&Z03R*DA!!W;0P
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ML4_GM_K4P043'\><?D:YWQ#X^^S^'O%MSI2QFYT)UB#N=RR.54GCCH6(^HH
MZ?4/#]EJ>K:?J5R9S/8.7@59F5 Q!!)4'!.#BJ%QX&T*YTN_TZ2WF-K?W N;
ME//<[Y P;.2<CD#ICI6EI.IP7]M&@O()[M(D:=8F&5++G. 3@&J_B7Q#%X<L
M()VA\^:YNHK6"#S AD=V X)X&!D\^E %.[\!Z#?7KW5Q!(S2VBVDR>80DZ*"
M%\Q>CD9X)ST'I3HO!.DVZ1BW>]B9;;[([K=N3+%S\KY)!QN.#C([$8%48O%T
MD'CK7]/U*YL[?2-/LK>X29G QOSDNV>.1T..Q[UUOG1>6LGFIL895MPP1[4
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M(2</*5Y*#DD=P*[1+:"*9YHX(TE?[SJ@!;ZGO1/;0741BN(8YHSU210P_(T
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MM:P,D?W%,8(7Z#M3DM+:*8S1V\22GJZH Q_&@":BBB@ HHHH **** "BBB@
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MP 3CZBN>\5^(?MEGX7ETA[BZT[4]0C#O9NJ^?%Y<C>7DL",E1D<=""1TJ/\
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M[BW,TCWEP]M!;A )&D0D..3CY<')SCZY%8GB3XAK::):W.D0.\]QJ:::XF0
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M&/S;*1 =IR<J$(SNYX..:OV^CZO:^,?#-S)HT?V:VM;J.5[+RDAMC*P*H%W
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M *JW9Q-9_O"F9B, 9W?(_'MZ_A5JJMV^V:S&XC=,1CGGY'../IW]* +5%%%
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M9Q\K?E4]5KH1F6U\Q=Q$IV';G!V-S[<9Y]\=Z +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!RLGB&]US6-3T;PZ]M#)IVU
M+F]N!Y@1V!(5(P1N(XR21CI@]K>GZAK4>O3Z=JL5J;:.T6>.]A1D5VW$,I#$
M@$8!ZGJ#WKD?#<L?@;Q;XGM]<?[-:ZA<B\M+QXR(W! #*7Z @XX/OBM/QAK#
M:WX3U2#1$FN8DACDFDB1L3PD_.D3=W*9QCCF@#J[+6M+U)YDLM0MKAH0#((I
M0VP'."?;@\U%%XET.>\AM(=7L9+F=F6*)9U+.5SN &><8/Y5Q,S:;J7B;PK?
M^']ODPV\L-Z$R!';",A4D'3(8 8/3FN2\+M8V?@'P/);0VSSW'B"&%9Y(0LW
MEAF)(Y)!P #@D88CO0![-=:_I%E>K976IVL-T[*BQ/* Q9N@QZFEDUW28H+N
M>34;58K23RKAS*,1/Q\K>AY'!]:\VU4-:^(KYK"Y2\M[K68OMFE7D!$H<*H,
ML$F0< !3C! '?L:'B&5;;3OBA82L\5W-+'<11A3O:,I& Z^HR".O48H [_4M
M;N]/\;V$,UW;Q:+)I]Q<2[@ 5,>T[F8G[H!/8#WJ;1/&NCZWIUY?QWMHEO;2
MLC.+A6&P'"N2/N[NP-9EZT$_C_0H'W2*NFSQS*<LHW[,!EQCG!Y)[$8KD8;Z
MRM/!0MK>&*-X?$IBE>1,1PGSVQ)(J*N1P,#U*]1Q0!Z>WB;0DTO^U&UBQ%AN
MV_:#.NS/IG.,TI\1Z*(KZ0:I:.M@GF76R4,85QNRP'3CFO%_$,=J/!GC^RBB
M6X:/6(YXD=/WA,D: ?*%& =I (Y//3OM:I81I\0=5@M[!_*F\(,DD-LOEF1S
MYGR@X(WD="0?H: /2?#?B?3/%6EQWVFSJZL 6C+ O'GH& /!QVK2O;VUTZSE
MN[VXBM[:(;I)96"JH]23TKE/A=<6TG@'3((1B:WA"3J4*E7[@Y R>,?A4?Q2
MN8HO"<=O/%&8;J\AC:>;=Y-OAMV^3:02HVXQW) /% '3V.MZ7JEK-=6.H6US
M! Q662*4,J$#)!(Z<$&H;'Q/H.I;_L6LV%QL&6\NX4X&,YZ^G/TKRN]\M8/B
M<GVR2.*6*RDCG$& ^8E!8*,#!8%3^/6MGPWJ'AS6?&;S,ND0W9TY+,62Q[I"
MXR7Y( ("\ 8!QGC% '>VWB+1[QV6VU.UEVP^>Q24$"/)&[/ID&G:;K^D:PD[
MZ;J=I=K 0)3#*K>7GD;L=.E>3:1I@;X#:;>V5I.;Y$C2X:V3]\T*W&9$Y&2-
MN3CV_"K.N)9ZYI>M7_A!;ZZO9-/2.X<0"*,HLV3%M"KF7&_L<#@T >HZ?KVD
MZJDKZ?J5K<K" 9#%*&" C()QT%)IVOZ1JTSPZ?J5K=2QH'=(90Q53T) [&O/
MHKSPYK-A=WVG?;[NTFTEK>\EM8UC,<8QMC"A!N<$GCMS5KP/=3CQE>V4@BU*
M.&Q2*'5[>,Q@1HV!#*O3S 23D?D* /0KN[@L+.:[NI!'!"ADD<]%4#)-<]X:
M\<Z1XC\/MK"W$%M"DC*X>=3L&XA2Q[%@,XZ\XK?OUWZ==+MW;H7&,9SP:\4\
M)G9\//"\WEA].LM;G;4E$>0@#N5+#V)0Y[?A0![1I^J6&JPO+I]Y!=1HYC=H
M7#!6'4''0\U9DD2*-I)'5$499F. ![FN&T82W?Q-O-2T=U.B36"&Y<(0DLQ)
M*LAQ@G:1D]QBNUNTCEM)DEC22-D(9'&0PQT.: *$?B;1)=0MK"/5;1[JZC,L
M$2R@F10<9'KW_(^E2QZ[I,L\<$>HVKRR2M B)*"6D4;F48[@$$UY!8#3=2\%
M^&;?2[91KL>I1RJ!%^\2-9FWMD ?N]N0#TZ5M^'=$%UJWCQK2W6*Z^TLVF2-
M"R>2[1,H="1@9)ZKSQSVH ]#AU[2+C4/[/AU*UDO.1Y*R@MQR>/:JLWC#PW;
MOLFUW3HV\YK?#7"@^8,93K]X9''N*X:S>SO_  ?X2L;:*XAURRO+19$CCVR0
M2*P%P7.,8*"0G/WLCKFL:XTN >&/B%%)IXGD.KM):[[=@<L(_FC^4G.0>G4C
MJ* /7++7M)U*XO8+/4;:>6R;;<JD@/E'&>?\]CZ5##XJ\/W$UI%#K5A))>9^
MS(MPI,V"0=HSS@@CCTKEM+BM(_B3'#;V@CM)= 590MILC>0R@X9L?,=N>#T_
M$XX72[73M5^&OAZRL[4/X@75O,B%O&%9-MT[,2Q'"!<]#UQ0!Z9#XZL=5U#7
MM*TV> 7>G(R([MG?*%8L-G!(4CD@\TSPCXPM+GPIX>?6M5M8]5U&V618Y) C
M2L?[J]_PKF_"30V7B'XA6=PK+=R7;SQJ8CDIY1Y!Y]?7FJB:-(?A%X5UR.-X
M]4\.1I=1I*NW@8$B$$=U''3D#F@#U6'5+"XU&XT^&\ADO+8*9X%<%XP0"-P[
M9!!_&I;N[MK"TENKN>."WB7=)+*P55'J2>E8WA2SF2RN-5O"#?:K+]IEPH 1
M<!8T'&<*BKG.?F+'/-,\?1I+\//$BNBN!IEPP##/(C8@_4$ _A0!I6VNZ3>7
MCV=MJ5I-<QQ"9XDE4LJ'HQ&>!R.:AM_$^AW=S!;V^K6<LLZR/$J3 [PAPY'T
M.<_0^E>=M81WM_X&;0X1'>6Z))J<T<3)_H_EKO61B/FW=,'.:AT_03=_"^^;
M3-/VZE;W5UY)DA\N186G8LJYZ!DSQGG- 'IMGXCT74$F>SU6TG6&/S9#'*&V
M)_>..W!YID/B?0KC3?[1AU>RDLO,$7VA)E*;R<!<YQG)QBN,O9(M5\5^#;OP
M_!.AB)%YLB:(1VWEY".",#DCY>O/;K46FZ,T?BW4/"9MF724OH]84Q8$:I]X
M1MSP3*H; &,*: .JL+JXD\>:M;-K5M/;QVT3)IR?ZR GJS?7'ZBJ<_BJ*Z\?
MZ-I6FZG;30/%<&[@C=6;*J"AZYQ][MC/>N1U*RU*;QU\0SI44T=U/HT26LJ*
MR;I O.UNF<X]ZO:#J&GW6I^!FMXAYT5K-;3OY3!HW6( QL2O&#NX)Z]J .]B
M\1:-/J1TZ+5+1[T.T9@68%]R_>7'J.XK3KQCPE:6?DZ+I%VNK_\ "0:5J >6
MU+;$WAV\R??M^=,%N_S<#O7L] ')3:YJ'B'6-2T;P[<169TR6-+N^FC\W+'D
MQHG0G'5B>#V/6K>CS:_:ZC/::W-:W%M%;B1+V&%HMYSSO!RH('H?? K \/QR
M>%/''B=-3BD6WU:X%[;72(6C*A<%6(^ZPYZT_P =WE]XE\':]IGAZ"Y,T<*D
MS%"BS+G+(A/).T'^5 '6V6OZ1J,LL5EJ=I/)$@=UCE!*KZGV]ZC3Q+HKW5I;
M+J=J9KR-I;=/,&9%4X)'KS_(^E<M,]GK'B7PS>:1$RV\5O.+X+'M46QCVK&X
M(YQ)MPHZ;3QQ7/R:;9#PUX("61)AUD>:?LQW+&&EW;N.%R0?2@#TNW\1:+=Z
M;<:C;:K9RV5LQ6>X292D9 !(9LX& 1^=.L=>TC4KR6TL=3M+FYA4-)%#,K,@
M(R"0#QFO-M9MXK:'XFP0VXBLVLH'A18-D>1$0Q'8G.,GKT]*?##:/J/@^]T2
MU5I+.PEEU$6Z>6[QFW^4,<#)+XQ[\T >CPZ]I-QJ3Z=#J5K)>H&+0+*"XV]>
M/;O5=?%?AYQ 5UNP(N)6AAQ<+^\<=5'/)'I7C>@W$<^K?#N\B18U-Y=PO;*K
MG[/N4X1W;YFD^]DD\X/ Y%0V>GNOPN8K8R?:XO$V5*P$NB^<-V.,@8'/TH ]
MPMO$&CWFJS:7;:G:37\&?-MDE!D3'7*]15C3]2LM6LUN]/NX;JV8D++"X921
MP>17!>+-,U#1O&-MX@T&*(2:M;MIEP,<^:P+12'H< CDYS@#TKM]#T>TT#1;
M32[&,)!;1A%X&6/=CC').2?<T %YKNE:=?6]C>ZC;6]U<_ZF&60*TG./E!ZU
M$GB70WM;RY75K,P61 NI/.7;"3_>/;\:Q?B-8O+X:&J6R(;W29DO86;@@*P+
M@'W7([<XKC[ZWEOO$+Z*8I;:+QI;_:9CL&Z'RF'&W=P3%M!/.6YXZ4 =I/KR
MVOB>YNIM>TX:)!I@N'M@X,J'<3YIQ_ 1@"LG4_'?]HZ?X:U#P_>P-:7NLP6E
MT N7$;$^N-N0O<9Y%006<"_&J\M1;J;0Z!%$R&/*-B1L ]CQCK7-:9<P)\-/
M %N'0R1ZY:I<!4)VD.^5/'!&1_*@#V.PU*RU2!I["[@NHE=HV>%PX##@C([B
MK5><> D%O\1_'D$:>5;^=;&)%7";MK[\#IGE,_4>U=KXAAN;CPWJD-F[K=/:
M2K$4.&W[3C!^M #[/6]+U"ZEM;/4;6XGB&7CBE5F4=,D"F6WB'1KS5)-,MM4
MLYK^,$O;),ID4#KE<YXS7#Z9J/A_6F@F\)V7V?7(=+DM8U,!1+'(#".88ZA@
M.!D]:RKYM/U+PGX<CT>U,7B2WO+8>7'$4GB<']Z9,#.TKO))X)([T >ES^)-
M$M79)]6LHV658&#SJ,2,,A>O4^E5KV>[_P"$PTR"#5;.*V\B5I[%SF:8\;64
M>@YY]Z\LT@>'GN?B)::Q%"\CZK,+>-H]S%\-M\OC[V1QCFMS18[JPUSP+#KD
MB?VY)I5S'(S#$C<*55CW8#@^X)H ]'CU?39;\V$=_;/=KG,*R@OQUXIJ:WI<
MNIMIJ:A;-?*"3;B4;P!P>.O<5Y/X0;1;K3=%TR>#4U\1Z7>"9[-%42";)5YF
M<H,QG))R>>G/%3:7((O&6D6UI+%JNGF_ED6&:-DOM/<[]Q9@?FBRV?F'<#T-
M 'L-9]WKNDV%W':7>HVL%Q(RJD<DH5B6.%&#ZG@5H5Y:DUM_9?C/2=<7_B:7
M-U=26T3*3)-&%)A,?<D8XQT/I0!M>-?&L6BZYI.@IJ-KI\E]O>XO9I$_T6)%
M+9VGNV, GC\>G2^'_P"TO[$MO[6GMY[S!W36_P!R1<G:W3J5P3VSFO,)+/RO
M%'PW_P"$FBA;41:7"7[SJI4GR3L#D\9R#U[@U["JA5"J  !@ =J ,^^U[2-,
MN8[:^U.TMIY<;(Y90K-DX'!]3Q6;=:IJ,7CVQTI3$+&>PGG'R<[U9 ,G/3YC
MV'6N#\=W=C/>^,K27;#)'I\6Z'[.))KHA2R.I)(5$)YPN>"<C KH;:^@?Q_X
M7B,BF9]$EY+ L2?+8 \9SA6/)['B@#4\"ZSJ.LV>J/J<L4DUMJ,ULIB38NU<
M8P,G^==57#_#-UDLM?9""IUJYY'U%7OB1!JUSX U:+1/,^W-%\HB)#D9&0N.
M^* *-[XNDE\=>&;+2M4L+G3-0DN8YTAP[YCB9N6S_>'8=C73PZ_I%QJ$EA#J
M=I)=QAF>%9074+C<2/;(S]:\TGN-"N?$O@*^T*U#Q+;WJ.((2LGEK;L-A..H
M;CGN?>LKPU-;IXC\"7$-P%T]Y;^%+<Q$&W+I\L<LA)+R,V<Y[\8XR0#T_0_&
MVB:\FH26M[ ([*:2-F:0?,J!=SX[*"X&3_6M73=8TW6(I)=-OK>[2-S&[02!
MPK>AQT->7WLFCP^#/&UM!:1-=QZC-%=(L?EF-'E!4LR@-Y>W!X]#CI6KX65;
M;XJ:C'#=F>&YT6WN'9(Q&CR;V!8  9XQR<GGK0!Z1698^(M%U.XE@L=5L[F:
M%2TB13*Q4 X).#T!XJUJ,QM]-NIA#),8XF811_>? Z#W->->%_LL.O?#\PW4
M,L$EM?Q2QVT3>5'E581EB"SG.<[B>5) % 'KB>(-'DN;>V35+-IKEG6"-9E)
MD*'#!1GG!X-8_COQ1%X?\,ZH]KJ5I;ZM%:-/;QS$,3C_ &>^<$#WKA-/CMW^
M%]I?&UBCO$UTE7CAVL@-X2=N!P-OIQBI-=NHH_#WQ%L-713J\QN);<M'S+:A
M08=IP<A>_H<\@\T >HZ%<2WGA[3+F=MTLUI%([>K% 2?S-3W.H65G-%#<W<$
M,DQ(C21PI<@$G /7@&J?AC_D5-(!# K90J0P(((0 @@UR_C\:>?$?@U9S"+K
M^U!]X L8O+<,#S]TDKGMTH ZN7Q#HT%M;W,NJV:07./)D:90LF3CY3GGD@4^
M[UO2K%[=+O4;6!KC'DB255\S) &.>>2/S%>8:E#H>B>-]8TG7(38:1J%G%#I
M\D,"F((01)&"5;:[.2?EQG@]:K:[!8:-I8GTR>!);?34MGTS7HPRW-J&R@#<
M%7Z'&?3(&* /5FU[25GNX#J5J)K.,27*>:-T2'HS#L/>L7Q'KD_D>'KC1;V-
M[>_U&*,O"%?S8F!)VDG&..N>G3FN<M1%9_$?4)+M1$NL:%#]DM\MO;:,,F<?
M>'MV(-4K:_M[3X?_  ]=$^[?P1JKN5VD!U;)VY.!GL.E '::1X[T76?$&KZ3
M;W4(?32%9S*O[W RY4>B]"?7-;6FZQINL1R2:;?6]VD3;':&0,%;&<''0X(-
M>.6=CHRW_P 2[+48IX(WO(1FQAS,D3;>4P#\O*DCN,UU'PWDNW\0:Z+LVEXR
MQP*NJ6198KI0"!E"2HD QN(]0.U 'H[,%4LQ  &23VK.L/$.C:HL[6&J6=RL
M !E,4RL(P1D9P>,BJWC"2.+P?JSS03SQK;.6B@8J[#'0$<BN%\._V:/&VV::
M.[ANO#T:RO';;()0)#@*@7LO&2S9&.G< ]#M_$&CW=Y#:6^J6<MS/%YT423*
M6=/[P /(]ZP_'OBG^P?#]X=/O;9-6C5'2)\,VTL 3M^F:\VLD6+PA\,+V.U2
M*]_M:*,S6Z!<0F8H0V!T(8 \]6.>M3ZI>6R^ ?%FFWGF?VS_ &D\TB2QMYCQ
MB9=CCKE0N "#@8Q0![9 Q>WB9N24!/Y57U'5=/TBW%QJ-[!:0DXWS.%'3/4^
MPJ>U_P"/2'_KFO\ *O./&\\)\=V5H\3J9=+N%,CEBLH((\J)<%1(?[Q!XSQW
MH Z#QEK>HZ5+X;?3YX!;7VKV]I/E-S,CY/RG. ,#TI="U?4;SQ_XJTN[FC:U
ML([,VR(FW:)%D8Y]3P.?:O.=+OXIOAI\,8GN ]PVNV^%9LL0CR _EN7\Q7;>
M&9X7^+7CA$EC9O)T_P"4,"?E20'\B1GZT =W1110 4444 %%%% !1110 444
M4 %%%% !1110 5!<1[Y;8[2=DA.1V^1AD_G^M3U7N=OFVVXX/FG'S8R=C?G]
M/Q[4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BN<UOQG8:+J8TW[-
M=WEX+:2\DAME4E(4ZL=S*#U' )/M26?C*UO]4_LZWT[4&N&T]=1BRL8$L38
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MGG/.1P".:T[/Q4+O5#:G2[R.!KJ6UBN\QM&TD98," Q9>5;&1SB@#H%4*,*
M!Z 4!0HPH '7@4$[5).>!G@9KCM.^(^F:A9S7_V2[AT^W-P+BZE3"0F(@;6/
M9FR"!_6@#L$147:BA1Z 8I555SM4#)R<#J:YG3?%MEK>I2:)<6TUI<S0M+$C
M3(WFP]"P:-CM//3((K \%>(X]+^&OA.-+>XOK[4(S'!!'*I>1AN9V+.P   )
MY/<"@#T:FB-%4JJ*%/4 <&N'O_B"6TC1;[3-*NYQ?ZJNGRINC#0L&(=3EL$D
MJ0#G'J1P#<U?Q_9Z/--'/IM[BUCCDO')B MPW.#\_P [ $$A-W!% '6@!5"J
M  . !VILH<PN(PI<@XW$@9]\5S%[XQM)Y$L=+LKO59+BR6\_T1D4+ _1B69<
M$C) ')K)^"\TL_PRTZ2:1Y'+/EG8DGGU- '3^&=&ET/18;&>2.5X2X61 ?NE
MBP'))XS6S7(>-/$6I:+?:%;V.GW$T5Y?QPRRQ-'R#D^6 S#D@=3@>_-2W?C9
M$FN(-.TB^U*XL@AU"&V,9>UW#(4C=AWZ\(3TZT =2% )( !/4^M+533-3L]9
MTRVU+3YUGM+E!)%(O1@?U!]CR*Y_7?$.IV7C+1-*M=,N9;:<333/&8OWH5,;
M5W.,8+JQSCH,9R: .J?=L;9C=CC/3-8'@WP])X7\-6VD2RQSFW:0K*HP2'=G
M/ZMC\*X?0/%%OX0@\6W=Y:WLMC'XCDCFF#;_ +.ACC )W'+8QT&2!^%=AK?C
M>UTFX>*&TEO?(A$]T8I8T,,9&0<.P+,0"0JY/'O0!TX4!BP R>IQUKF?$/AC
M4-=U>V<:[/;Z/Y8CO-/1%*S@$G[QY&<@''85OV%];:GI]O?V<HEMKB-9(G (
MW*1D'GI67JVOQVVH+H]M876HWTL7FO!;,JF.(G&YF9E"YYQSDD4 ;:JJ(%4!
M548 '0"L[Q#ILFL^'-2TN.18VO;:2WWL,A0ZE2?P!KSCX=^(8=%\'7+R6]Y/
M/<ZS<Q06[SHTF0 <.S-B/ '.XYZ'D$5H^+O$=EXB^'>LR0M-:W>GRQ)-$9,-
M%(77 RC88$-QR0<T =YI-F^GZ/9V<C*[V\"1,ZC ;:H&?TJY7+7%W81_$*.!
M+.[DU6/29'CVR*L31>8ORJ"<;BV.3C&.M/M_&"7F@+JUMI=TX>\^R+;$H)=P
M?82><#!!XST% '38 I-H#%L#)ZFN.U#XCZ787<X:"1["TN?LMY>B2,+!(, @
MINWD D D# _"KLWB\175W"-(U!OL=Y%;3L(\[4==WG<9_=@=30!TM(%4=% Y
MSP.]<EIGQ L-4?2)([6=++5WECLYVQEF3^\O50PS@\].<5S/A/Q?#X=\/7\^
MHVVHS6::S=1SW@0NEN"^%+$G)7G&1G'?% 'J>!G.!GIFEK@(+R#2_BKXDNKB
MX>.SBT:"YE+NS*F&?<P!Z<+VK3LO'NGSZFEG=6\MF)[=[FUD=T?SD0;GX0DJ
MP&#M//Y4 =9UHKF]$\7KK-Y;P'2KRVCNX7N+6X<QM'-&I49RK$J?F'RD9KHG
M=8XV=V"JH))/0"@!0 !@#%+7'P^/XI+K1XVT741%K1/]GR#RR95"[BS+N!0;
M?FY[4V7XDZ1!>HL\4\-@]P;5;Z0IL:7H %!+[201N*@9H W_ !'I3:YX<U#2
MEE$1NX&BWD9VY[U8TRS^P:7:6C$,\$"1,P'WMJ@9KF[_ ,?V]@E],^EWS6MA
M?FRNY\*%A 5&,IY^[^\'\ZL:YXUM='N)88[.>\-O"+BY,;QIY41R01O8%S@$
M[5R>/<4 =*(T&,(HP=W3OZTH '08KEI/'NG23)#IEO<ZF\NFC4X/LJ;O-B\P
M1D#ONRV<8['O4-[\0[&QO9$?3[UK&&\2QFO5V;(YV .PJ6W<;E!.,9R.U %J
MW\-:@_BB?4]2UN>ZL%E\ZRT_8H2!]N-Q.,G S@9QR:Z:N.M?&DK>*/$EG=Z=
M<1:?HRQB6X#1E4&QI&D8;MV"I7  8\<XSBI=+^(&F:AJ<%A/;W-A-=1-+:K<
M[,RJJEGR$9MA !.&P<4 =60&!! (/4&DV+N#;1N' ..E>6^,_$_]M67AR>QM
M+^&SGUB$0WCLB1SKANP?=@\XW+@X^E>J4 )M&<X&?6D$: 8"+C.[&._K7G7Q
M%\2K=^"/$]MI]E?S):(T$U[ R+'%*-I(SO#'!(#8!QR#WK:T7Q19V]S9>&9!
M+-?0:1'=F:':T,J*J@E&W9.21C(&: .L"J"2% )ZD"EKE#X\L6L]'N8;&^D&
MJF58$$8+!D4G!P2,G&!^/I5/3]<TC4O'=HQ@U2'5I=(2X\F8D11Q,2<%,_?S
MD' [#F@#ME15)*J 6.3@=:0(H<N% 8\$XY-<IIOQ T_4H-%NEM+J&RU=C';W
M,P 42;F"QMS]YMAQC/8=34U]XYTZQFU(?9;V>WTME2^NH40QP$@'G+!C@$$[
M0<4 'A?PHWA_4]>O))TG_M2^:\4!?]63GBNE*(S!BJEEZ$CD4RUN$N[2*YBW
M>7*@==PP<'D5R^K>);ZU\?Z/H,.GW#V]S!-+)(K1_-MVC(RP.%W9/?T!H ZO
M8H<OM&XC&<<T"- Y<(H<]6 Y->0>!?%-OX5TV\AU W-Q;S>(9[+[5N+K!\Q"
M%V8\@X[?X9[76/B!I>CWUY;M%-.M@4^W31M&JVX89'#,"Q P3M!QGUXH ZRF
ME$+ARJEEZ$CD41R++&DB-N1P&4CN#7*ZMX[M],\2'08M+U"]OOLK7*I;Q?>
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MF0DG&T;L8Z^U:.K>+[;2[J2".QO+YH;/[=/]E"9CAY ;#,N[.UN%R>/I0!T
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MP5&PN#E#N]L 9Q7:>%--N]*\.V]K?):1W +.T5H@6./+$A1@#. 0,XYK:HH
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MK*2  #N.QA@\''7/;I^!L5#.R+) '7),A"\=#M;^F: )J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5>Y)$MMA]N93QDC=\C<?U_"K%0SDB2# 8YD(.!G'RMUYXH
M FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5>Y_P!;:_=_UIZD_P!QNE6*KW*AI;8E<[921P>/
MD8=OKWH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,Z;
MY(#AOE?/&/[K#G/U[<_AFIJK7$Z)<VL)#,\C,0!G@!3DG\P/QH LT444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !112.ZQHSNP55&2Q. !ZT +17":7K]@VBW_CW49YIK0/*+-=G,,"ML
M 1>[.5W9[YQG%7+7Q)9>)[R\\+:A:7>G7[VWG^6LO)B)^5UD3HP/;L1WH Z^
MBN4\#ZX^H0:CI%S++->Z-<&TEGD !F&,J_U(Z^]=70 4444 %%%97B768_#_
M (:U'5I3\MK TG3/.../KB@#5HKF-'\+L-"1-5U2_O;^==\]TMS)%\QY&Q5;
M:H&>!CMSFJUEK=WHEAIWAR8'5O$R6?F-"LH3S(T8(9&D88'4>I)_.@#L**Y:
M;QQ:1VNG3+8WF^]U(::89%"/#*2<AQGT4D$9!XYYID/C=/LFM?;=.DM=0TF2
M-)K,RJ^1)CRFWCY<-GZK@YH ZRBN5O?&\6G:1+>7NF74,T$]O!- 2I ,I4;D
M;.'4;CR.I4CCM-?Z]I]_J6K^%RER+N&P,\C#Y5*,"!AE.0?RH Z2BO,?"/B"
M]MK7P+HT5FWV:[T^2=Y8G1@^Q<%<<8 +JV>YXQ74+XSM_P"W;73Y+*XCBO+F
M6TM;@E2))8BXD&W.54;#@GKZ="0#IJ*XVZ^($=M!J5W_ &1=R66FWXL[J=&4
MA!P#)C/S %APN2.<XQBK&F>);Z]\>:UHDNGO'!8PP,CK(K;@Y?YSR,9 ' ST
MH ZJBLG5]<73+NRLX[9[FZO&(CC#J@PO+$LW' Z#O7-7&KVVK>(O"VK6]E=.
MS_;XHX9%^970;3QG:IRC ,3WZ\T =W17)VOCB.\\/PW\.EW;WDMXVG_84PS)
M<+NW*S#C:-IR_0 9K(\5ZU;^)/ ]]);_ &VUEL=1A@F0#)#K(FY<H2&0@\G)
M'KTH ]#HKC#"1\9%D#.RG122K.2JGS<94'H3QG'H*V?$'B6VT%K*W:&6XO;]
MVBM((Q@.X7/S,>%'3D^O0T ;5%<C:_$/2KZTMVM+>\GO)[M[);1(LL)ESN!;
M[H48)+9QCFLK6/'5VVB+)'97-A=0ZI'8WJJR.T!++]T' <-N !&!@DYXH ]#
MHID3M)&&:)XF/5'(R/R)'ZUY[HWB[3=(T:V:QT6\2._UZ6P97F0LL[R'<S'/
MKNP!D?+U'< ]%HK!\/\ BB'7;W4M/>UEL]1TUT6YMY"&VAP2A#+D'(!^F/H3
M1O=?N_\ A8EKX=%L?LCV;7#2),FYSRN"N=RJ.QXR<XS@T =917F?@KQ,VB^%
M?#MG?6]W-%=WLUC)?R[@1<-,^T%7 =MQ_BQ@'K@@XZ6[\<Z99JUQ)'*;!;D6
MK7:,C*)"P084-N(W'!('![8Y !T]%4]4U.UT;3+C4+UV2W@7>Y52QQ[ <DUC
MQ>,($N+N'4;"ZL'@M6O8_, ;SH5&25VDY8=U&<<>M '245S%OXXL)KB2"2TO
M8)%T\:BJ2HNYX3UX#'##(R#ZU%8^/+2ZFTTW&GWEG::I'NL[N<+Y<CX),9P<
MJV , @%N<=* .LHKD-/^(NE:A?:="MO=Q0:F[Q65Q(@Q*Z,RL"H)91\O!(&>
M>G=\?CVQDFTZ3['=+IVHW#VMM>D K)('V#"J2P5B#AB!ZG YH ZRBO+=4\1Q
MZ'HWC2]T2SNHKU-5CAGEDD1@)7\I-Z@]!AA@<\CG%=S:>(8+CQ!+H4EO<P7T
M5LMR?."!70G;E2&.>>OI0!LT51TG5(=8LC>6X/D&62.-]P(D".5WJ0>5.,BL
MR]\9:=9:?J.H^7//8:?(8[FY@V.J," _&[<=N><#L>I% '0T5YGKVJP^*?'F
MC^');.6YT2YTU[[:K!?/W<(Q!(X4#(!YR>F0*ZF:[M/ /@M)+V>]O+>PC5#(
M1YDTG.!WY/- '1T5RFH^/+*PT?7+[[#>,^CJIG@*J"2R[EP02".<$C..>.*M
MV/BZTO/$[Z ]I=VUW]F^UQ>>@ EBR 3C.5.6'# 'VH Z"BL#Q<UHNF6RWL=Z
MT37L 4V9(=7WC:>.<9QG';-5;_QO!9?VP5TN_N!H\Z1WGDJI*1M&'\P#/S#!
MY Y'4XH ZFBL>[U^V6[ET^UCEO+M;7[2\=NR91#D*268#D@X^E<9\-M;@TWP
M3HMD4DNKV\CGNUBC=-YB$N#(Y=E'5E'7))/7!P >ET5R:_$31)+?3YK=;RX^
MVW3V2I##N>*=1DHZYR#[\C'.<<T^'Q[I6R_CO4ELKZQN$MY;*4J9"TAQ$%(.
MTE@0>&P.<D8S0!U-%<C=_$;1;%-6-S#?1R:7Y1N8_(RVV0[4=<$AE+''!/Y<
MU='BZRBU>_TZ]AFM'M;/[>C2C_76_1G '*D-D;6PW3CT .AHKR_Q%JIU+XA?
M#R9+:\MX9Y)Y46==N0821E03@\]#@UU4WC;3[>XM_-BE6RN;K[%%=AD96GWE
M NT,6 + @,1CUP.: .FHKD)OB%I\,$ET;&^6TM;[[#?S21A/LKG 4E<[G!9D
M'R@\'/;EEGXDOKOXG:GHWE2?9+&UB B1X3EG^8RME@X &%  /7)ZB@#LJ*S-
M3URUTN[LK-TFFO+UV6W@A4%FVC+')(4 #G)(]!D\51M_&.G75O \4-T9Y[V2
MQ2U* 2^:F=_&<;0%)W9QB@#H:*YB\\>:3I^G:M=W<5Y$^E.JW=L8<S(K8VN%
M!.4.<A@<<'T-32>*X_[2FTR'3[IM0-HUW:12&-%O%'&$?=C.2,@X(!R1TH Z
M&BN'T_QJVE>%O#UUK\5W)>:S,J1"*-"=TK;HQ@-C #* >O'(!K2F\<:;!83W
M;6UWMMK9;JZC*HKVZ,2/G5F&#\I..3Q0!TU%85UXLT^">2"&.XNY8K$:A(L"
M [(3G:26(&3AL '/!]JRH_&$][XOTJTL;2XFTR]TT7@DV(N0S !CO8$!0<D<
MGGH: .RHKGAXOLOL]G>?9;S^S[NX%O%>A5:+);:K'#%@C-P&(QR.Q%0MXYTT
M7\UDEI?RS07R6$XCA#>4[C*LP!R$/3=TSQ0!T]%9&O\ B&V\.P6T]W;W#P3W
M"6_F0A2$9V"KN!8'&3V!J-?%-C]LU>VE22 Z4GF3O,\:J5()# [NF!U.!0!M
MT5Y])K>CS>.8M1MX=0?63H33P6S,J1M#G?@DMC<<KP.F/K6/:^([SQ!I7@?7
M+Z*ZMI[K5!'MCDVQS*4D8#:&P1E5Y8 \>AH ]9HK-T;6H=92[,=O<VTMI<-;
M30W*!75P >Q(((8$$'!!K+UCQSI6BZW)I%Q%>27:637NV&(,&C4\@<]>^/;U
MP* .FHKEKCQ[I5I'<3SP7L=G;W"6TMTT:A [$#@;MS ,P4D*<$^QQ9C\7V$]
MRL4$%U-&;XV!GC52BRCU^;..,9Q0!T%%<A<_$;1[.QDOKBWOTLH+U[&XN/(#
M+!*C;#NP22,]"H-6-1\=:7IBW<L\-V;6SN$MKBY5%V([$ 8!8,P!9<E0>OL<
M '3T5SM_XTTRQ6^D6.ZNH-/E2&[FM8PZPNV#@\Y. RDX!QGGOC.TGQ?>ZE\0
M]:T(:?+]CL$A"R*4X+IO+ME@<$,  ,GU YP =G17*>*_$=]I6N>'M+L+2::3
M4;E]YC6,[HXT+N@WNH#$ <D\#/4\5)-XZTR&VU*Y^S7\D&EN([V2.$$0O@$K
MU^8KD9VY'N: .GHJ&.Y2:S6Y@!F1TWH$QEP1D8S@<^]>5:CKNL:WX$M]6U%)
M+)_[>B\E58!1$L^W82C$M@KR2![ ]: /6Z*YL^-M-B35S=PW=J^DE/M$<B*S
M$-]TKL9@<_7ZXJU8>*+"_P!<DT;9/!J"6ZW7E3*/FB)QN!4D<'@C.?:@#:HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *K7*(;BU=@-XD(4YQC*-GZ]/\
MXJS3)-VZ/&<;N<8]#UH ?1110 4444 %%%% !1110 4444 %%%% !1110 45
M#=75O96[3W4\<,*]7D8*!Z<FJMEKFEZB(?LE_;RM,NZ- X#L.>=IY['MVH T
M**** "BBB@ HHHH **** "BBB@ HHK.N=<T^TUJSTB6<"^O%9XH0,DJO5CZ#
MM0!HU'<0K<VTL#DA94*$CJ 1BI** /+M.TO5K?X47_A30KJ)]=TUI+<KO (!
MD8IR0 -R8(S4^@^&]4T[XA6^MSZ5%8Z:-%$$K_:UD*2[V=M_<GGDC(]_3T'[
M!:?;_M_V:+[7L\OSMOS;?3-27-M!>6[V]S$DL+C#(XR&'N* .,\!V$TFL^)_
M$4BJ(M4O1]F(!&Z*-0@;!['&0>]=Q3(HDAB2*)%2-%"JJC 4#@ 4^@ HHHH
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MG^(?M*VSQ0/YD@BE4[T/3H!NR1_#7I59T&A:9;:W=:S%9QKJ-TB)-/R68*,
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M/S(-N,^:GS)C/'W@!^-<=J?A/6I]<T>2Y$4_]JJ]OK[6\9\HQ@%U49.0H("
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M'^>GK<<BRQK(AW(X#*1W!IU 'F.M>&M2U[7/&J1VLL*7%O9"UDF4K',\1+$
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M7C4:AJIU#S'M0VQ24.S&[K\@^;]*U9/"5Y!KNH7^EZL+6+4PGVR)[<2$LJ;
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MYT34)+.] +*)$3:2\8Y.<..#Z&NFMM:GOO$45I:11OI_V%;J2XYSN<X11VY
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M'$XQM&/G^7Y?KS^5 $<GQ$OK+4M-M]1TA;<7VI_8!#YF98U9@L<C=@#R<'G
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M98WA+3JF[<4#[L8SWQFMZPTK4;+Q%?W"W4']EW)1U@\LF0.(U0_-GIA!V[T
M;E%%% !1110 4444 %%%% !1110 4444 %%%% !44V=\.-WW^<$_W3UQ_6I:
MBE0,\1)'ROG_ ,=(_K0!+1110 4444 %%%% !1110 4444 %%%% !1110!A7
MOB-[/QAI>@FP=EOXI9!=>8 J[!G&WJ3^7XUNUQ?BFR6^\=>&+:=B;::"^B=%
MRK$&( _,#D<'M@^]<G$%_P"$)TO0%NI)XFUN2SCMF)/VJ.-VQ&SYRJC R>O&
M.^" >P45X]"NHS^!?$3I<W!F\/ZY,;6.*9P/)CV,8LYR5PS#!Z<=@*9XN\37
MT^@>(/%^C^=';+:Q65A>1RN%=7(,D@7. 5)V@X!!% 'LE%<7X<TI-'\11K;:
MP/LEY9M,FG_:I)PYW F=2Y)&=W..#GVJC\0(UO\ Q!I&F-ONO,MKF1K(NT<8
M "_OV8$<KT4=<MQ0!Z%17B\5W=:C+\+C=W5P[3/.DI\Y@7Q&1DD'.<=^M1:9
MI>HW/@SQ';:3?WB2>'];NQ:0).Y\V!&YMSSR& [YY^IH ]MHKCO"M[#XIUNX
M\4Q6CI;&SCM;.9F(WJ3OEXSC[VT9Q_#P>:RO'\"ZOXCL=*\PR&"RFO-AD,26
MC [5N78'+;?F 4=\DT >C56OK^VTVV-Q=RB*+<JY/<DX  [G)KRS2)KZ\UCX
M;ZG>2R27=S93Q7$X.!.NS(+#OG ;.?PYJAJ^CV"G2(H"_P!G@\9K;0>3<NOE
M(R[G1=I&W##C'(QCB@#T*R\7R77Q$O?"<FEM"+:S^UK=-,#Y@W*N H' ^;J3
MVZ5U->-:YI5G/\1_$UC*UR43PLQ7_2'+':RGYGW;CR!U)SWIOA69_&5MX5T;
M7KZ::QET5[B2V\UD-S(LFP%F4ACA1G&<>U 'L]9EQJ%]%XAM+&/3G>PD@DDF
MO=P"Q,,;5QUYY_2O+[V34]'C@T)+N]^PZ;XHL+2VG,K RP2;7,3'^()D*,]L
M5K:KI$-AX\\/Z49[Z:PELK_S/M$[%%1AN(SCD@]S\V,9)H ]%LKZVU&W,]I,
MLL6]DWJ<@E25.#WY!JQ7AEMX3@E^$-CK&EV<U_>6S>9]F-S,\=S#'*Q\O9NP
M1R2 !U_&N\\)BW\1>)KSQ=!O^R_9(K&S(RJD+EI/E/4ASMS_ +)';- '63ZE
M:6VHVEA+*%N;L.84Q]X( 6_($5;KS;Q?I-K>_%+0/.2=_-L+L,BW$BA@%&%P
MK# /<#KWS6-<32VWP[D\=VEQ,_B1)2\T@9OG_>!6MV3.-H  "XX(R.<Y /8J
M*YOQ?J5]9> [_4;+?%>+;JX*J6,>2-QQCL">W:N(U"PAT30-5U;2=9\H7^C7
M-P!;W4SO<S)'O6?=GY6!')X!R<^E 'K=4M.U6SU47)LI?-6VG:WD8 @!UQD
M]^O45YQ!:K%XD\ ,DDX&L:1+;7R"5MLJ);*R\9^4@GJN#7,:0D.C>#-)2":>
MVM[_ %R>QNI#>2K&L"RR$*?FPH) !.,G<?4T >]T5Y#XCTFY\/\ @_7].TG5
M"#;FVNK#3[>9Y&MI#(HQELDJS?-M.1GFO2-!T"V\/6]U#;3W,JW5U)=N;B0.
M0[G+8.!Q]<T 2:??WUUJ6I6]SICVMO;2*EO.T@87((R6 Q\N#QWK1)"J68@
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M-B*T.UO.8,<?WB#EO?.<]ZY?1K5Q<?#FUB::.&32'E>8RM(Q+0("J[L[0."
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MLR;C\H&,';QRO'2N3MM6UB/1?A[J2:UJ/VC4KG['=;IMZR)ESDJV1NZ?-C/
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MCI1:>,O#]Y%=21ZE$JVL/GS>9\FV/GY^?X>#S4UKXHT:]NHK:WOHWEEM?MB
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M2O.%[JEK"8 AE#2#*!R I([ YITGB318M133WU.U6[=U18O,&2S#*K]2.@H
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MSP,8P5SCCD5[0"#G!!QQ2T >4^--"NKKQ8EMH'F636VDR2!(8"L,[><CF%F
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MC)OE9@ H'  (Y)SGMWJSJNGZ@WB_1M4M+>.>W@AG@GS*%9-Y0AL'J/E/OR*
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MI%IVH:%J.F7-S$\UHMP8F\]4P6 V.=K $<-BLS3/B9:ZE9:7?C1M1CT_4)3
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M5076;)]>?10[?;DMQ<LA7 \LMM!SWY]*Y70Y]2G^*7BJWEU#?;VT%EY<9B&
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M5NG7 ]:K: +V/XUZY'?/%+)_9,)62*+:-N\X!ST//3/./:@#T>BBB@ HHHH
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MK<36BV_]FWQM 1)N\P!0=W08Z]*Z6@#DK?P7)!9^'(/[4?=HTSRAQ$O[T$,
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M'7-62\C+:K!%"T;1'$8C#!2"#S]XY_I5/3_ XL;'PU:&]\Q-$E>53Y>#(2&
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M.*,=%4=!5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "HY!EXO][^\1V/YU)4<F[='M( W<\XXP?S[4 2
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'8!D!/5L=<=C
M3Z@N%W26YVDXD)X[?*W6@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB;.UQDY'1LC)Z=:TK/7M4?Q%]CNK&'['/IWVZU:!LR,5*AT8$XS\ZD=N>O%
M'345P6B>/;W7-+GO+>TLMRPSN\'GL9;.1 =J3)CD''W@5ZXQWJ+1_B-=:G%X
M,F?3X43Q#Y\<@\QLPO'GD<<@[3P?4<\9H [NVOK2\>=+6YAF:WD,4PC<,8W
M!*MCH<$<'UJ>O*M1EOK#PYXZETORH)QK +N!MPA6+<3S_=SR#GOUXK>\0^*M
M6T58[:"UL8F2Q-R9[F1WBE8$@11XPQ<X!YZ9'7K0!V]%<9'XPU/47\/IINE1
M?\3C36O!)--Q VU2H8#EAEAG'-<_JWB?5?$'A3176**UGE\0QZ=>I%.ZJY24
M@A& R%)4'/!P,<YH ]3JO>WUIIMI)=WUU#;6T8R\TSA$7MR3P*SM?UN7P]X6
MN]8GLFN9+6'S'@MV^\>^"1T_"N#\5:[<^)/A%KEPZ64B".(PW=G+YD4I,@R
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MQXB7@C=CKSQN'7-/MO&SS:KH4$VEM!8:S;>9!>/,,+-@GR2N/O8&0<\^G!H
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MJUU_3S>VBS+&)7B*S)L8,IVL".W(H T:*** "BBB@ HHHH **** "D95="C
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M8ZKIB:UIMM]A</ YMYX!PNX [BP 4Y&!G/:N]NKNWLHA+<S)#&65 SM@%B<
M?4DU-0!Q%]X,O[K6-$N)+J"[M[4W1O1,S*9O/78P5<, H'(4GL.>]9J^!_$S
M>&5T.YO["YC@U)+FVN)G=GC@5]P3E>", 9Z8)'&.?2:S='U6354NFDTZ[LO(
MN'@5;J,H9 O\:^JGL: .<U#P9<ZW?^)(]1%FNG:O!'&ACD=Y8WC!"/@@ =<X
M![=\FIX_#.HZKK.BZGXA>S$NC[VACLBQ261EVEF#KE0!C !//.>U==10!QK^
M +277==NV9%L]3M?*6W4?+'(P(DDVXZL-O(/.#52?P'>K\,H_#$%Y#+>@QM)
M<S959"K DG )Z "N]HH XFZ\+^)K3Q%>ZAX?URTMK?4E0745W;M+Y+J@3S8@
M& +85>&XX[TYO!VIV.HWCZ3J4!M-0LUM[I+Z)I&WI'L60%2 S-_%G'08]*[2
MB@#QV\T:]\,:=X+\.-?Z4EW9K<3"XU%'^R.P7 7.X'=\^1R.G3M6A8Z;KVOV
MC6MNVCV=UI%RMS9ZGIBL;29V'SQ%2=QX/S,"?O8ZBO4&1'&'56^HS2JJH,*H
M ] * .-/A[Q)(B7E[>Z9?WLLJFYM9(GCM1$%("1\L0<DDLP.>.F,'7\):')X
M=T"/3Y#"&$DDGEP%C'&&8G:F[G S6Y6/XA\16WANUM;BZAGDCN+J.V!B480N
M<!G)("KGC)/4@=Z .&O/AKK+^&]6T>WOK K=:NFH0R.K*VT,&(<@'+9  //'
MX5?UWP5KVL:CK$T.H6UDE[ID=C#)'(Y>-D??N(VCAONG!X'//2O0J* .#L_!
M&I"]:6ZFTV&!]&.F^39QLHC.[((+9W#&>N#_ #KHO"^EW^D>';73M2N+:XD@
MB6,&"-E  &,$DG=WYP/IWK:HH XK3?"VM>$EN+3PQ<6$NF3SO<+;ZB9-UNS8
MRJ,N<ID$X(!!)Y.:EU+P?J-Y-I^IIK;-K%C=O=QO-%F$[DV&%4!^1"O&?F89
M)Y-=A6-8>(H=0\3:IHL-M,'TU8S-.<;"SC<%&#G..>: ,36?"NK:QI>O-)/9
M)J.J6J6D:+N\J&,$]6QEC\S'.T=A5A]%U]]6L;A9+"&&'3)+&1DE<R*S["77
MY0#@QK@<=^E=910!YWI7@#4AJ5I>:I<627$-C):W%W:,YFOF88W2Y '3G^(Y
M[BJNA?#O6],'@V&YOK%HM FN7=HD8EUD!P.>^6/88QWKTZJNHZA;:5I\]]>2
M>7;P+N=L9P/I0!RC>&=:DMO$]O))8E-4G-Q;.K-E" @5&7: ?N<MGOT[U)=>
M'M<OM:AU*1M'29]/^S2R/"\K6[Y<DQ9(!!W@'.,[1]*L:5XRDU'6DTN7PWK=
MG*Q;,T]M^Y1=I8%I%) )&/EZY-=.DB2J61@P!*DCU!P1^8H XS0_"^LZ8_AA
MYFL)#I=@UE/M8J6'R@,IVDGA1D9 R:RXO NO0>'4M5GL/MEOKO\ ;$(61S&_
MSES&WR@_Q?H#Q7I-8VO>([?0)=,CFAFD;4+Z*RCV*<*SD\D].,'CK0 _5+35
M[K0#!:7=M'J>%/F-$?*8@C*E22=I&1WKAK[X;ZI<V>N_9I-/LWU9(HS9PNWV
M:(HRL9 -G+-MQC'3N:]/HH X+Q%X1U[7]5FO8[BTT^0Z4]E%+!<R&1)&97SG
M8!MW+M/&2O3'2ET;PCK.GZ]#J,O]E1QQZ2]CY%F9(QN,@8'=VSU+8)!Z>M=Y
M10!YMJ7@?7]0\+:'I(;3$DTR\2X+^?(1(J,"HY3.3SD_CSG ZCQOH=YXE\(7
MNCV3V\<UT%7?<9VJ P8G@')X_K70T4 <3J7@^_U?Q)>WMR]M'9ZAI/\ 9\ZQ
MRL9(R<DLOR@,,X'4>OM3U\-Z[J5SH*ZY<:<;?1YA<B2V\PR7$JJ50D-P@PQ)
M&6R<5V=% '*> ] U;PSHS:5J$ME);Q2R/ \&[<V^1G.[. ,;L<>E9I\&ZOL\
M<@26/_%1*5@S(_[H&,QY;Y?0[N._'O7>T4 >=1^"/$$;Q@W6E3Q'2HK#9=1O
M*+9D4JS1CC.[@GIT[XJQ<>!M0U'P!I&BW-\EMJ.GR1LMS;,S8"DJ=K-R&*$\
MX.#7>T4 <5XD\$7-Q-H>H^&KJ"PU+1@8[<3(3"\1 #(P'8@=1S]*W/#]AJEM
M%/=:S=QS7]TP:2.#<((0!@+&&R>G)R>34^OZPF@:#>:M);7%REK'YC16Z;G(
M^GH.I/8 GM5ZWG2YMHKB/.R5 ZYZX(S0!Y]/X(UM_#7BG0HIK Q:M<RRPS.[
M@J),$[@%/3'3OGMCF?6/ ]_XBU2S;418I90Z7-82*DK2.3(J_. 4 ^5ER/7@
M\=*[ZB@#BM \-^)HK?3K'7]6MIK/3&5H6LPZ2W!3A/-/3:!C('WB.3ZZ'BG1
MKS6!Y*V&F:A9O$8S#>DH8G)^^K!&['D<?=&*Z6B@#A+#P=J^D:YI%]:WT4S1
MZ0-+O)I<[E"MO61 <[CDD8;T%5])\+>(;%M!9[;1S+87!%U,VYGN$*[3-GC$
MA'8Y[]CQZ'10!P4GA?76\-3V48L(KJUU+^T+!@[E96$YE E QP0=O4^O85;3
M0?$#ZAJ^I--IT5U?6<$2( 70/&6)5MP.4.[!X!]*[*B@#EO"WAJ;1=4U.^:&
MUL8[T1YL;.0O#YB[@91E5VE@5&!QQDY)XC.@ZOI?B'6+_1_L<T6K!7E6ZD9/
M*E5=@885MP( XXZ>]=;65JGB+3]'U'3;"[:07&HS>3;JJ$@M@DY;H.GKGD<4
M <Q:^"M2TJ^\)BQGM9K/0HYT<RNR/.95VEL!6 QR>ISGM6[XNTN^U;2(XK#R
MGDBN(YGMYFVQW"*>8V."0#_GCBM^B@#S#4OA_K>HP>+K93IL$6N)9B+:S*(?
M*11MP%/ VX]_:NBB\-:B?B1%XHE>U6#^R_L3PJ[%@Y96)!V@$9&.W]*ZVB@#
MDM9T+6XO%2>(/#LNG^=+;BUNX+U6VNH;*NK+R&&2.XQ[U#%X:UR/Q1H^K27-
MI<K:6]PD_F.RLTDS[FV_*<(,* .#BNSHH \WF\#Z_/X731I)K(A=7.H&3[5(
M"R&8RE 1&-IR<94 =\=JS=);6?\ A;'C&/3+>U>26&V25Y9V3R<A_G7"G=CG
MCCM7K548-%TNUU.?4[?3K2*_G&V:Y2%5DD''#,!D]!^5 '*0^"+VTU+PV([J
M*XLM+LI[2=Y7999O- !;: 1QMSR><^V:@C\):XWAF3P7+]E_L4+Y*ZAYI\]H
M,YVB/:0' ^7=G'?':O0** /.-1L-)\4>.M#&E:A)Y-G#*+_[(V4E2-U"02=L
M%PV01R 0.N1K:CH/B*S\7W&N>';NQ,=]#'%=VU^&*ADX5TV\C /()Y_+'2V&
ME:=I2R+I]C;6BRN7D$$2H'8]2<#DU<H X)_"WB;1-5CU;0]2MK^ZGMX[;4%U
M,,/-V,Q5U*]" Q'.> .IR:Z,Z!Y_A*YT*\O9Y_M=O-#-<D_.?-W;B,YQC<<
MYP .M;5% '#V6B>*Y[72]*U>YM)+/3[F.:6]C<^=>"([XQL*X3YE3=R2<'FM
M'PCH6H:)<Z_)>_9RFHZD]]%Y,A8J'505;*CIM'/?)].>GHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "F2'#1^[8Z>QI]0SR>7) , [W*_>QCY6/X]
M.G^% $U%%% !1110 4444 %%%% !1110 4444 %%%% '"^)-,\_XH>$[O[9<
MIF*Z41H^%&U <CZYP?:N7:>ZLM)\0ZMI^I36LMGXE+"-8"H?<8T*NI'((9NG
M'(/45Z5JWANQUC5-+U&X:9;C3I&DB,4A4,",%6QU'0_AZ$U2N/ FBW-IJ%K*
M+LPZA<BZN%%RXW2#OUX[=/0>E ')W5]XB\27GB"2PO(;*XT74C! LMV8HD1
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M"V$26PNV'GJ/X<<C/)/3K0!R7AS6M5\0:3I.@7=W>0>(+2_+:DS\.(XFW$G
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M>PP>376^*O"&F^+K*&"_\Z.6W?S;:X@<I)"^,;E/]#QP*I:A\/=%O] BTO\
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MOG06\6TK(W<N6!)R.O/>@#G&\5:W!K.F7"WK7<%UK8TV4PQC[((F+8VDX9I
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M)0F0#]SY20<<8K9T_0!I^O7NI)>W+QW$$,$=JS?NX1&",@>ISU_QH V****
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MQNC(K*\J@J6^Z#D]3V]:\1UZ>UD@US5K:ZMH9!XCM756/^E(RN$8DG!C& <
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M-%K:?"'PUJEL(8[ZUUC9!.F R(UXZL![;6/'3F@#V'3=:@U34-3M;="5L)A
M\H(*L^W+*/=<@'ZU>GNK>V\O[1/%%YKB./S'"[W/11GJ3Z5S'AD:7#XD\20Q
MK:)??VAN"*%$FPP0$GUQG/XUS5[?>'QXQ\4:=XREM8'NXXULGN3M5K?9@A&/
M ;<S<#!_*@#TRXNK>TB$MS/%#&6"[I'"C). ,GN32R3PPM&LDJ(TC;4#, 6/
MH/4UYKI4D-UX]^SZU!C2I-'ABT>/44&)0.93M.5W_=SWVA>U8EI%'N\*6$R.
MVGKXCO$L7D=E+6P1RI!X)4\CGJ..E 'J.N>)M.T/PS<:]+.DUI%'O0Q.#YQ/
M"JI'!).!6BMW$+>.69UAW1^85D8*5'&<Y],C\Z\$UV.U/@WXD6P@B1+36T:
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M^T&/ES&^N1<NBPJD4;!550B#@8"CGDY[T^[\5Z;976H03^>OV!5,TGEG868
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M!\PY^OI0!NP016UO'!!&L<,:A$11@*H&  *K/I&GR6U[;O:1F*]):Y7'$I(
M.?P %5]0\1:;IK1I)*TLKA6\JW0R.J$XWE5Y"^]96I^-+.*Y\/0:;-#<#6)C
MY<VUFC\E5+N01_%@8'7GK0!T5U86=]%'%=6L,\<;AT61 P5AT(ST-,DTNPEN
M7N7LX#/(I1Y=@#LI&,%NI&.*M*0RAAT(R*Y+QC?W=EK?A-+:\FACN=4$,T28
MVRJ8W.&[XXH Z>UL[6QA\FTMH8(LYV1(%&?7 JL^A:3);FW?3;1H3(9=AB7
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M@FE55N%BC574$-\I)!Y..E>M44 <%I]K<WFH7NJP^&IK(R6!@DDO&$EU-(>
MJL7.$7GK][((K+F\.ZTWP9T;0UTR8ZE;O:"6#>F5$<JLQSNQC />O4:* .&D
M@OQXG\803Z7->0:AI\36BDXBE58F5HF?C:2['CG@YSZ.\)Z9J&C^()[6$Z@^
MC&V4JFHOO>T;/RQQODETQGC/RX'7-=O10 5YAJ7AK5I[+QS&-,DD.HWD,EF
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MA@&(!^HK=JC;Z19V^JW.J+&6O;A1&\SG<P0<A%]%R2<#N<T 7J*** "BBB@
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M\2B[N!]DUJ)8SY1Q)$5& 1D8]_PH PK;XB:T^HM";**:!M/N)UD-C-;B.>-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !52];;/9#'6<C_ ,AO5NJEX%\^
MRW=?...<<^6_YT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *BN+:"ZB,5Q#'-&>J2(&'Y&I:* &QQI%&L<:*B*,*JC  ] *=110 R:&
M*XB,4T22QGJKJ&!_ TX *    . !2T4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKMH8(;:(101)%&O1$4*!^ HF@AN%"S11R '(#J#C\Z /)M=TZ/0/'L-L]_\
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M2#8^YF.XEA\O(K:N--U*6X^';_V/.XLL_:PX3_1OW(7+<GG/3'IZT :7P_\
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M')7.78IUSNX!Z8]ZJZOI>IS_ !@T#5(K*9]-M+&:.6X#+L1WR ,9SV&<#N*
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MUO1A;S7ED-\T)54CF ),>WUP,\9QFE\?-J<>H^'I;/1I+^UBNB]Q+;6Z2W$
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M\3:=>H;E9;<AHD2-E+D<D DC'0_A0!VD'C?0)]'N]4%X4M[2;R)A)&RR(Y(
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MZ]#GVS6HB[$5=Q;: ,L<D_6N TWXAW&L7?A>*UM;>-=6:YM[K>Q9K:>&,L5
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ME"A1-V<8Z="<$G&<"@#J:*XJP\5ZO-8:O;7-O8)J^F7:0RL'9;?RV*_O<GG
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MX/EH.>A7!/(].AKU*>W@NH6AN(8YHF&&210P(Z<@T\ *H50  , #M0!QNO\
MA367\4Q>(?#.I6UC>20&WO$ND>2.=1]P[01RO./K]:K7O@C6;26PU'P]K8BU
MF-&BO+B_#3+<QLV\J1V <DC&, XS7>44 <0GA+6H'A,FHP:K%/'+_:5OJ)8Q
M3ROLP57!"JH7 7' -;'@[PVWA;PE::+)=M=-"K;I".,L22%!Z 9K?J(7,)NS
M:B1?/""0IW"DXS^8H \U3X=:['X1U'P\-1L&@FU);RV)B92BB7S2&(ZDD <
M <UMZQX2U35M?U&]%]#:P7ND+IV8&*S1N&9PX?' RY!'<>_3M** //=&\&:_
M9Z_H&J7%QI4*V%I+:SVUI;E(]CD$",9X.0,D\>U;/@+PYJ/A3PXFC7U[!=16
MS,MLT410B/)/S9)R>:ZFB@#A9?!NK1>-M?UNQOK1+;5K$0&-T8R+(J[5.[^$
M9)/'H/J%L_"6N06WA*VDN[,IH>WS75GW3X1DZ8[@@\]\_6NYHH X'0O!&O:/
MJ,=F_B$2>&;6;S;2S6,K*H#;DC9^Z@_G@5U'B30+7Q-H<^EW;R1I)AEEB;:\
M;J<JP/J" :UJHZMJ#Z;:1S1V<UVSSQ0^7$1N^=PN[GC SG\* .<M=&\:FWCL
M+SQ!8&V7*M=0V[BX=.,=6P&X;+#U![<I)X4U33?%&HZWH%Y:+_:4"1W,%VC$
M>8B[5D!!YXQD=_7FNRHH X6W\ R:;J/A:33YK?R-'EGFN&==KW,DR%7;"C /
M.1GT ]ZR;SX9ZM=^%]<T@ZE:[M1U5;^-B'*QJ""5QZY7]37=>)M?A\,>'KK6
M+B&2:.#8/+CQEBSA!U[989]JU2<*2 3@=!WH \X*:HGQ2U.#19K%+L:);K+]
MJ+%=X=L. O) &!CCK3Y/AYJME<Z0^BZG91BUADCN6N[;S"TDK;I)4 (PQR>I
M]!TK?\(:II/B>&Y\166E16MQ+,]L\S(GGR+&=OSLO/\ "."3T'M734 >6Z3\
M--8TJ#PO&E_9RC0KJ>5=RLOFH^ H.,X( S^-:YN8?!.I:WK?BW4;"&TUFXC6
M+RXY6QMCVA&&"#\JYS@<Y]L=W45Q:V]VBI<013*K!U61 P##H1GN/6@#EOA_
MH%OHNDW4UN9##>74LELD@8&&VWMY48#<A<$M@XY<T_Q/X7O-<\3^&M3@G@CA
MTBX:>1'SNDW  @8X' KJZ* . O?!VOW6D^*=.%UIRIK<[RI(H93"&55P0%^8
MX7.>I)I=4\&Z]?ZBDD&H:=;Q3:8ME<2R6QFDBQN!\DY7 8/SGT^E=1XAUQ/#
M^GQWDEM).KW$4!$?5=[!0?7OV!J9=3+>()=*^QW 5+5+D76W]T=S,NS/]X;<
MX]#0!YWJEG"WA'2O 5SJ'F>*K:. VLMHDBF#:Q5)]PZ!5')SU],BO3;*SAT^
MRAM+==L4*!%!.3QW)[GU-)]AM!?&^%K!]L*>6;CRQYA3.=N[KC/:IR<*2 3@
M=!WH Y#1?"%Q8>*?%.HWDMO/9:X(QY2[@R! XP?J'/3IBL[0?!/B+3C;Z3>:
M^)/#MC+YEK'"&6X=0V4C=\\HO' Z].@KK/#VNQ>(M+-_!"\4?G21!78%OD8J
M<XX!XZ4EEK-OJFLZOI(@;.G^4DS/@J_F+NP!Z8QU]>G<@'FF@^']2\4V'BC1
MWN+:+1)_$UVURR@^?M24,57MR0O/;!X-=E+X7U*RU769M%N;6*TU>,&:.8-F
M&;;L,B$=<KCCCD#&*Z/3M(TS2(WCTS3K2R1SN=;:!8PQ]2% S5R@#D;?PG=V
M&M^&Y;2XA:PTBRDM&$V3++O"C.<8&-@^N32VGAO5[/XA7VN0WEF--O8D6:%H
MF,N4!  .0 ,G/0]*ZVB@#DO$7A[6K[Q1INJZ9>VHBA@D@DM[R,ND;'YEF0 _
M?! 'TXSSQD_\(/K@\':;H?V^Q>6VO_M<L[QG$@6;S%&P@CG//H<5Z'10!SUI
MHM_!XXO]:>2U-I=6L4 1=PD79DY/&#DL?P K$\<?;_\ A-/!?]FRVZ77VBY(
M%QNV.OE?,O'.2,X]#S@XKO*HW.BZ5>WL-[=Z993W<)!BGE@5GC(.058C(P>>
M* .*U'P1J][I\][#<6\.L7.HQ7MQ Q+V\J(-HA;IE>=W(Y(%7+/9X+;6[OQ/
M?Z?%INIW4;Q;(2JAVC",A'.1A%P?J3UKMZIRC3=2FDLIEMKJ2V:.5X9 KF-N
MJ,0>AX)!]J .8\#:"NE>';Z2R21$O9I9;*&Y+9AA)/EH0>0.2<=MWK6?I?@'
M4[#1_"5C)>6;MH=X\\KHK*)58DX48X/S'VX%>AT4 <5>^#]0UP>(K+6KBT?3
MM2D2:V^SJRRP.@4(23PWW%/U'OQ6B\-^+[WP_J=GKFIV-Q.;2:ULA AC1MZ%
M2\G7)P> *[ZB@#B5\(ZE'=>!Y$FMBOA^ QSABV9"81$=O'IDC-4]/\(^*-+T
MS4K&SU*P1&U1KVV,D1(DC=BTD<@[@YQ[8S7H51W%Q#:P//<2I%$@RSNV /QH
M YGP7X7F\.?VK-,R1"_N?.2RMY";>V&.B @8))8DC@_+Z5@^)O >M:ZWBB#[
M=;-;ZK&AMI9@7D@"*,0J. JEAG(]>A-=Q/JJP:[::4;6X9KF&259U3,:["H(
M8]C\PZ\5H4 <W%H^I'QC/JLHLUMI-/6W8 $R&0'.0<#"\D<YSQTQ7'Z+\/=>
M\/:9HEWIT]HNKZ?<7 FCW%8[FVE?<8RV,\$*1QP<GK7JE% ',>$M$U32K[7;
MO4GMB=1NQ<(L!8[/E (.?H.>]-ET?5X/'%UJ]K]EDLKJRC@=')$BLC,>.,'.
M['/3KS6GI7B*SU?5=6TZW659],E6*?>  2PR"N"3CCN!6M0!Y]+X-UM_AI:Z
M!!/;6]]:SB0 ,3%*@<ML; '!!QTQQTJG=^ =:N;;Q>B-IMN-=LX(HXH0VV%H
MU*[>@XP>OZ5Z;10!R5OHNK07OA<*D/V?3;1HKAC)SN,87Y1CG!'KWK.T?PAJ
MT7B73-9OTL8[ZS@DBN[NV.UM0+# +J  .?F]<^U=]6?%K$$VO7.CK%.)[>!)
MVD9,1LK$@ '/)X.: .-M_!&J#P#=:%]HCM=06[:\M+R)B0LAF,H]QC[I^IJ'
M4/"OC#Q!X0U.UUS4K>34+BW-K!!:DQP!203(X).YN,#I@?6O2** .9U33=4O
MK328)+6TN;01,NI64N&20E !M+#LV?3BK?A+1I] \-VVG7$OF/'N(7>6$:DY
M" GDA1@9]J=IOB6RU/Q#JVB0Q3I=:68Q.74!#O4,-I!.>#W K9H \]'@S6K7
MP[JGAFTFL6TV\N7DAFG7>8H7<LZ,I'S-G.#_ +7M6I)HFI#Q_8:O%;6YL;6Q
M:S)9AYARP.X<9 &/7G^>EXG\4V/A2TM;F_BN9([FY2V3R$#;6;H3DC ]ZGL=
M>MK_ %[5-(BAN5GTTQB61X\1MO0,-K9YX//2@"_=VL5]9SVDZ[H9XVC<9QE2
M,'^=<9;^![^Q\!ZAH]GJC)JEPFQ+UAA@B\1H2N. @"Y&.I-=S10!P/A_POK.
ME^+H-9DL]-M[8Z5]@:UM6(\HK(7!'&&W$G/3'O42^$=:E\&6%A-':K?Z;JRZ
MC JS'9+B8R[6../O$?@#7H=8VJ^*--TB.PDE:29+Z^2PB:!-X$K/LPQZ !@0
M?H>M '(W'@G6]5'BA[N2UM)]3^S36S12,X26+##/ .-RK^M;/AC3?%QU-M0\
M4ZA9-Y<)AAMK!&1"202[Y8[C@8'ID]*ZZB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *H7JDZGIQPNT-)R5YSM['/'?C!S[8YOUG7T(;5--EV)N1I!
MYA(! *'('/? /_ : -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C?$D
M=W+X[\-6T>I74-E=1W2W%O&VU7VQ_*<CD'+=?:N4N+F_TOP0VI/JES>3:5KJ
M06VZ0A/+$ZQA&QR_RL1ELFO1=0\,Z9J>LV>K7*W/VVSSY#QW4L83/7Y58 YZ
M'(Y'6LX_#WPZ=&;2#!>&Q:Y-TT?V^?YI20=Q._)Y /UYZT <IX]O[T7WB&33
M[J[GN=+LH+B)()?+2Q<[SN;L[..@P<!3G&173B^?4_'!TJ2>6..UTR.Z"QR%
M=[N[+N./0*1^-2:A\/M U.[N+JYCNFEN+7[+,?M+D2*!A68$G<RC."?4YSQ5
MN3P;HDK:>[VTIDL$$<+BXD#%0<X<AOG!(Y#9SSF@#S?PEJ-U8^&?">E1S_N;
M_4+R&9I)3%YA7?M4N%."6QTZGBN[\&VVH:;<:OIE_JL-ZL$ZM;Q+(SO;1,N5
M1V(&>G'M4TO@+PW/X=BT*;3]]C%)YT8,K!T?.XLK@AE.?0CKCI6MI&B:=H5D
MMIIMLL$0 SR69L=V8Y+'W)- '-ZS//'\5O"\"3RB"6SO&>(,=K%0F"1Z\FO-
M[3Q!K-KX/M-635+MKR/Q5)8AI)"P:%V)92#P>1^%>QW_ (9TS4=:M]7N%N?M
MUM$\,,D=U+&$5AAL*K 9/KC/ ]!65_PK7PO_ &8FG?8[G[*EV;T)]MF_UW]_
M._)- &_K-U+8Z)?W<"AI8;=Y$!SR0I(Z5Q6GWD-I9Z%XD@UV>[6^MS');O)O
M-],4+(BCHK AA@8[YKT)E5U*L RD8(/0BN?TCP/X<T/49K_3M-2&>5BWWV94
M).3L4DJG7^$"@#C[RXO+?P#IWC&WU*8ZI)]F><^8=DB/*-T13)&1O(.,<@XQ
MT"^();];+Q_>1ZE=QM8*DULJ.0(W2,.,'TR!Q_C776G@?0+&Z>>WM9E5YVN3
M ;F5H/,))+"(ML!R<CCCM2R^"=#G35TEBNG75\"]!O9OW@SG ^;Y1VPN...G
M% '/W5U>77C/PA%)?W M-5TNX-Q:JV$9EC0[AW!_>'OV%<U8>(]4M+BS\+">
M4V=OKUSIOVR:;89HT162-WP2&/F8&!R$KT7_ (0G1?MMC>;;T7%C"8+:07\^
M8T(P1]_OQU]!Z5&/ /AS^RKW37LI)K>]G^TS^=<R2.TN -X=F+*W Y!!XH Y
M"_U?5/#NI1Z/-J\45E)J=I& DY=[2!E.4:1U'WV7@YR!4?CRW;3O"'B#3GUF
M6Z;[=9W44))#6\4DZ+L)S\P+!S7=1^#/#Z>')= .G))ITH(>.5F=F).<ER2V
M1V.<CC&,5#'X$\/1>';G0DLF^Q7)S+NE9W)!!!WL2V00".>.U %'5)9;;XD^
M%;-+B<PO;7K.K2Y#$!,9'?&>#VKF#K.HR_"^?QO_ &A<1ZK;332^49/W>Q)R
MODLO VD*/0\\&N\7PAHZ:CIM^([G[3IL1BMG-Y*=JG[V1NPV>Y;).!GH*3_A
M#=$%X]RMO,HDF\][=;F06[2<?,8=VPG@'[O7GK0!RU[:7.M>(_%^E76J7RVJ
M6-M<6XBE*&!\,WRX'3<H."3GH>*[;0+B6[\.:9<SN7FEM(I'8_Q,4!)_.J#^
M#-'>_P!0O<7R7&H($N7COYTWJ""  'XQC'&."1T)K5TS3;;1]-@T^S61;:!0
MD:R2M(5 Z#+$F@#SG5]1U?2O$6M^&I-1U&2;58EN=$F@;=)$?NM&<C  ;DGG
MY2.<UL^$M7OO$PMYYOM5M]CM&M[Z,/A1=[MKH<\Y7&>O\0ZUUTNFVD^HV^H2
M0H;JW5DCEVC<JM]X9ZX.!^51P:/96MI>6UO%Y*7DDLLS0GRW9Y"2S;EP0W/7
MKP.>* /&;M)KK1/AA->7<\]R=9V/,7(+GS3ENO7C\*ZC5-*_M#4/'H^VWENU
MNEK/$\$A0J\<&X'/?) R#QP*Z*3X=^'9-'L=*%O<+:V-RMU;#[5(S1N#G 9B
M2%/.0/7UYJRW@K1FDU&3%\K:BH6Z*ZA.-X' '#\ #CC'''2@#0T"_EU7P]IV
MH30^1+<VT<KQ;MVPLH)&>,_6O)M-1CX&^*LCS3.RW>I1C>Y.0 P'XX KU_3-
M-MM(TV#3[,2"V@79&LDK2$#TW,23CZ\#BL>3P+H$KZPS6TH&L#%XB7$B*^?O
M8 (V[L<XQGO0!S%G+=Z?XM\"1P7LXM=4TJ5+BW+$J?*A5E(].7/2JFG7NOW_
M (-OT@NFN;O^VIX?*GN0LUQ C8,:N!@-M!_*NT'@G1!=:7<^7=F;2T,=FYOI
MB8U/4?>YXP.<\ #M44?@'0(K=X4BO55KG[5D:A/N67G+J=^5)R<XZ]Z (O V
MJ_VK:ZFYN+QS'>LOV>]CVS6ORK^Z;D@X.<8]>IIWC62ZN8M/T:TLWN_MLX>Z
MC1@K?9HR&DP2R@$DHO)Z,:V]+TBRT:W>&RB*"1S)([NSO(YZLSL2S'W)-0?\
M([I__"0C7<7/V\(8]WVJ79M/;R]VW'?IU /44 <;\/KM](\4:]X4N[66T8R?
MVE8QR[/]2^ R_(2ORMZ'G<>!BJ\VK:I?336MCJ.HMJR:\\<D2H1$MHLQ4@$#
M;@1@'.<AB>]=G<^$=(N_$D?B&6.Y_M.)!&DJ7<J@(/X=H8+CU&,'/-<'#X2N
M7.H076@:L-3N)YYFO+;5GAMF>1BVY0'PN-W0J>G.>X!<M1?:E\3]>L!JEZEO
MIUO92Q1K+NW;9"Q4_P"\%P?KFHK/5]?U?08==M-6L[)H=0WW:7MZVV)0Q4V[
MH(_E(RO?.>]=CHGA*STJ^&K2///K,MM'!=W1GDVSE5 SL+;1R">G&3ZU7@^'
MOARW\03:U':2>?-)YSQ&9C"9>?WGEYV[N1VXP",'F@#D(_$6O7_@T^)HM3T^
MV-O?.]P\EXXC6-)2IB,8C;&4 '<Y.>]2ZE+J%W'X\N$U6\@;2!'=6#12_P"K
M86HD(Y^\I)(P1W_+J_\ A7_AT^()M9^R/YLQ5Y+?S"(&D7I(8_NEL8Y/IGKD
MT]_ NAR+J:LM]C4R/MF-0G'F@#;@_/TVG&!QC Z4 <M8:M?VOB+P]=?:YY?[
M:T5[J[B=]R>:D:L&1?X>I&!QS5?0M4\0ZKX=T'Q%%KEND3W?^FBYN"0ZLVWR
M0BQX5@< <^O-=O;^#]&M=1T^^CAN//T^#[-:[[J5ECCV[=NTMM/'J.P]*KV'
M@'P]IFLS:E:VC*TC>9]G9RT"29R9$0\*_;(_QR >:MJ6LIX?\1:Y!K=\EQ9>
M)C#"CDG=&!$I1@,CD8'3C!]:[?1X,_%CQ"_FS?\ 'E:2;?,.W)WCIZ<?_6K1
M/P]\.MIUY8&"[^S7ES]JN$^WS_O)?[Q._/I^0]!5T>$])&N6VL>7,;RWA6!7
M,S?.JYP7Y_>$9X+9QUZ\T 4/'FH3V&F6 MM4^PRSWT<>%3=)<+@DQ)Z,<#GM
M^-<W8ZKXEU"R\76L#RI>VM]$MK!)<J'0$*6C$F",D _B3@UW.O\ AW3O$NG"
MRU&)F1)%EBDC<I)$XZ,C#E36>O@30E_M("&<)J+0M,BSLF&B&%*E2"#W)SDG
MO0!'X.U9M3GUE)&OXI8+E5:SODQ);Y0<9#$,IP6!'J?PP=:-[J?Q=AT:#5;J
MVM_[&EE=8VP%;>@!7'?[N<]LCO79Z)H%EH,,JVS7$TTQ5I[FZF:664@  LS<
M]!T& .P%,;PSI;^)X_$30R_VG'$85E$[A=AZKLSMQWZ=0#UH X:\NO$>NWGB
M9=+U2R@N-+OML,DUU)&+15CSEHQ&P<-E\DGI]*LSWM[JL7B:]77V#Z7IT?V>
M*SD "NUN)3-T&0Q.!GLI_#I;[P-X>U'71K-Q8_Z65"R;)&1)L'(\Q00'Q_M9
MZ_2LWQ7X*TNZMM1U:TTZ9]5:Q:W2.VE9%F^0J@9,A6QN[^@]!0!E>$==U&_D
M\'-=7DTGV[1WDG!<XDD7;\Y]^OIUJ!M4U)O -I?R7]VTT.NK$Q$AW31_:?+V
M$A2<8(Z#/'UK5\/>"H+SP3X8M]9AO;:^TVV",L5P8G!*E60LAY4^Q[#W%:Q\
M":&^BII+I=FT6Y:ZVK=R1DR,^_)*$=&Y [8% &3?Z1JVK>.=3@37+NTL(+>T
MN8XXQD^9YCGC@?*0C@C)^\/3 Q]-US7=3\*6GB5M7L+.&._:2\GENWV)")BI
MB\K80#LV@9/7GOFN\L_#>G6.M3:O#]K-[-&(I'DNY9 5'0;68CCGMW/K5)?
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MHRD@^ZW!P2#R,YP14/B+PCI?B:6SEO?M$4]H^Y)K64Q2%3]Y"PYVGN!@^XH
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M!<O?ZAOUV(0W6'0!5"A1L^3CY1CG/Y\T 9VD7FJKXFT1Y=5EN8-2T9KB2T8
M*LBK%AEXR =QZ^M8D'B'5-832XK37I8-7EU>6WO;9(PQMX1G<FTAE^7,?SG
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M!DE2]O\ 4+MT$7VF_G,KI&.0B]E7/.!U/7H, '1T444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNGV2,C)9VZLBE5(B *@]0..G)H33[)$D1+.W5)<"11$H#XZ9XYJS10!5&F6
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?>AO[4T[A"N9,Y'S
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M(P=F G95.<#L!5BTL8+'4O'=[#JM];269+^;)>23(A,!;<R#' SD+R1CKR,
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M '9:UXN32[NZMK;3KG49K* 7-VEN0&BC)X(W8W' )P.P^E=#%()8DD 8!U#
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M3.(X@[ ;V/11ZG@UR/@'59-5EU4IJ<UQ90M'%%:7@/VJT<!O,$I(R<G&TY/
MI/&MC]I\1^%'-[=0C[:R!(I0BY\MSNP5;+<>WU% &UHWB>RUS5]9TZT24/I4
MRP3.ZX#.02=O? QC/]*VZ\*NKW4; _$O5=-OS97%CJ5K(FS"ARN%(;/4$9X[
MDUT/B/Q!J\\]^MMJ,PEMM,BNX(;$@>5(5+,\^< J< !2><GC/( /4&GB2:.%
MY4623.Q"W+8ZX'>I*\VD:XO/BQX:N'NYE,VB22%%V[5)*DX!!Z]^_ ]*]"O8
MIY[&>*UN?LUPZ$13[ _EMCAMIX.#V[T 3T5Y+_PL:^%GX9O4N9946<6^O1F*
M,"(EQ"6+!3MQ(<X'4$#CK6DFM:K:WFFVDM_<*_B+5;CRWP&%M;HIPL>00I.%
MZYZL1CL >D45YQJ>MZWH1\3Z2M^\HT_38K^QNY%5I@&+*R2<8;YD.#@'!YSP
M:V9=8U&/XB:/I(N2;*YTN6XEC*+S(K* <XR/O'B@#<T37;+Q!:375@9&BBG>
MW8R(4.]#AN#SUXY]*;8Z_9ZAKVJ:/ LPNM-6)IRZ;5_>!BNT]^%/MR.M>9^'
M/$4FF6-KHELTD5SK/B.^B6Y0*?)1)LN<$')(.!QQG/;!Z;PK%)!\3?&<4ES+
M<%8-.P\H&[&V7C@ &@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "L^
M[>3^V-/C5V$9$K.H(P2 ,9'7N?;U[5H51N1%_:UB6,WF;90BH?DZ#)8?R^IH
M O4444 %%%% !1110 4444 %%%% !1110 4444 4=5T;3];MDM]1MEFC1Q(G
MS%61AT96!!!]P:BA\/Z;%?17IBEFN801#)<W$DQBR,'9O8[21P2,9[U:N=1L
MK-]EU=P0L4:3$D@4[5&6//8 $DU'-K&F6Q03ZA;1EPK*'E4;@W0CGO0!43PM
MHT1<)9E4>X^U-$)7$9EZ[MF=N<C/3KS4<GA#0Y)]6F>S<R:NGEWQ^T2#SEV[
M<'YN!CCC'%:5UJ5C8E1=WD$!<$KYD@7('<9H34K&0P!+N!C<#,($@/F#_9]:
M *,GAC29#&6AGS';?9 1=2@F+.=I(;GZGFDD\*Z-)/8S_9"DEC"8+<Q3/'LC
M.,H0K#<O X.:AU_4Q-X9U*;2=:L;2>%2/M<LBF.!O]OL/QJRFM:?8V5JNHZM
M9+.;99F=I54.ORJ7'/W2S#GW% $'_"':#_9%OI*V)2QMIOM$4*3R*%DW;]V0
MV3\Q)YJ>3PUI$L^H3/9@G48_*O%$C!)UQM^90=I..-V,X[U8?6M+CNTM'U&U
M6YD.$B,JAF.,\#/H15FYNK>RMWN+J:.&!!EI)&"JOU)H Q8/!7A^WOH[V.Q;
M[5';_9A*UQ(S&+CY6);Y@,#&<XP,8P*;!X'\/6UII]K#8ND&GW!NK5%N9<1R
MDDEOO<GD]<]3ZUI1ZUI4JW)CU&U<6K;+@K,I\IO1N>#]:6/6=,FM%NXM0M7M
MF<(LJRJ5+'H,YZ^U %:Q\,:/INIW.HV=GY5U<RM-*PD<AG;[S;2< GO@5/J&
MAZ?JEY97=W"[7%DSM;R),\;1EAM;E2,Y''-266K:=J1G%C?VUR;=S',(90WE
ML.H;'0TEGJ^FZA))'9W]M</& 76*4,5!Z$XH S8O!7AZ""SABT_9'9W1O(0L
MT@(F.?G)W98\G[V>M27/A'1+QM0-Q:/(=1=)+G-Q)\[( %(^;Y2  !MQTHOO
M%VAV-E/<'4[25HH99A%',K.XC^]@ \X(P?2LZ'Q')XA\*:1J^EWMKI[74\#.
MMPX;Y206B_WR#Q0!=M_!NC6NI7E_#%<)<7EL+:X?[5(3*HX!+;MVX#C.<U/%
MX6TB"WTZ"*"98M-</:(+F7$1"E?[W/#,.<\&K%SKFDV;RI<ZG:0M$Z)(LDRJ
M49ON@Y/!/;UJU/=VUM&'GGBB0Y(9V !P,G] 30!))&)8V1BP##!VL5/YCD5A
MP^#-!M[/3[.*R9;?3YS<6L?VB3$<A8L6^]SR2><]:VHIX9UW0RI(OJC U7;5
M=.2"2=KZV$4;^6[F485O0GL: *4OA71YKB_F:VD#:@0;M4N)%2; Q\RA@#P,
M'CD<'-2OX>TU]9@U;R72Z@@%NGERLJ% =R@J#M."3C([_3%BYU73K-RES?6T
M+A=Y624*0N0,\]LD#\:?/J-E:V8O+B[@BMCC$SR *<].>G- $6KZ18Z[I<VF
MZE"9[.<8DCWLFX=<94@TS^P[#^T;;4#'*;JVB,,3F>0[4/48W8/0<D$\5SG@
MCQ-<Z[J'BHW=U%):V&IM!;,N JQ #'/?ZUTZZOIK02S+?VQBAP)'$JX3/3)S
MQ0!COX!\.-8QV@LI42*Z-[$RW4N^.<\EU;=D')SUQGFE'@/PZ+?5+;[$_P!G
MU3:;R+[1(!*RY^8_-G)SR<\X%;T%W;7+R)!/'*T1 D","5)&0#Z<'-<OJ?BZ
M"]@\0V.AZA;+?Z;;;Q,2) )<.S)MSR5"C/;YL=0: -B'PUI-OK!U:*V9+UH%
MMWD$TG[Q%Z!EW8;ZD$U2T;P'X9\/WPO-,TM()U!"DRNX3/7:K,0OX 5=T+68
M-2T^SW2>7>R6L<\EK*P\Z,, ?F7J.M6TU.PDO#:)>V[7(.#$) 6'&>G6@!FL
M:/8Z]IDNG:C )K:7&Y<D$$'(((Y!!P0:R4\":"E[<7?DW)FN;3['<,UW(3-'
MQC<=V20!C.>A^E,^(&IZEHWA&YU'2KE(+F!E(+Q"0,"<8(/U!_"J<.NZQHFL
MZ/8:Q-!?VVKMY<%Q''Y4D4GE[MK+T*\-SUY'6@#7_P"$7TFVCTZ2"TF+:3%L
ML8UNI0$ 7 7&[!XX^;/%97AVWU?5_$*^)-8TE-+DCLVLX[=RKR\N&+%AVX
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M3L<^8.-Q/+#!)'S'BNF\Q-F_>NS&=V>*BAO;6YSY%S#)A0QV.#@'.#].#^5
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M*"*>28J PB4@'"@#)R2?TQSG<HH **** "BBB@ HHHH **** "BBB@ HHHH
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M^M @A5PZQ(' P&"C.* /$+V.PEN?$&A7=_KL.JRZG+/%9VZ!8KAF<>28V(8
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MC#,$4 H#DG!)&?7ZUW.E6]I;^//#<L$4,,ESHCO,8T53*QV'+="3U/3UKO\
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M#A0!Z=30!YC-I]E<>'_BF[6L+O#>S/;-L&4D\I2"A['<!T[UHA9(/B3X4:Q
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MMH987L+F &)@Y0[E('RM\F,D$8/0<DRZ%X?;3-1U'49GA6:\**+>UC$<44:
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MF"4AV!G57VN .QQSFMV7Q]>R^)O#-I8VD<MEKMD]PBMQ)&PC9@"<XQD#)^M
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MK%N((?=CJ.YQC(KH?AYXRN_%\4T\DEG+;K#&VZ#Y6CE.=\;(22-O !Z'K[4
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MQ\2C.(D .<X!/?MQ0!UM%<.OC:ZU5M"LM+MHHM0U2R:^S<Y,:(N 5!'5B3^
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M1110 53GA9M4M)1C:B2 _-@\[>V.>GJ/Q[7*Q;^;9XLT:''WX+DYX[>7[>]
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M73;E54L/F=ALY)_3FN7F3P3/X=TK2W\7R;M/U"2^60:7<?.6.[!&SUKZ)HH
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M;PW8>)9]/CVHBNMA<X*+_"0$&01UJKHOB?POI7B^;79?&4MR+FQBM9X6TNX
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M?V!YJ1E(6S(KKM!//7'7L:(OAY?P>%)-'BU*V$LFK?V@TWE,/E\WS-HP<YR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6+?[?^$MT;.W/D7.,D9_Y9^V?U%;59EWC_A(=-_<R,?*G_>#.U/N<'MSV
MSZ'% &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX)X- '5T5R?@W6[F[N]:T*]#O<:-<B$3L<F6-AN0DXQN"D ^N,UUE !1110
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MVT^Z:'2;Q+:]<;?W:L%/F 9RP&X9'IGTKJHI8YX4FB=9(W4,CJ<A@>00>XH
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M)$N2N,_Q*<ALXSQFHO!_B;3QX TZ^M["[M].BLVD)EN%?R8T9E.YW89^Z3Z
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MH/,RDS;4( .3S_GI4%S\1-$L[2*]G2\6R>_?3FN!#E8YE)&& .[!*G! (^E
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M5; ZA/8?:XOM5O$L\T>[F-#G#'TZ&IK.[M[^R@O+659;>=!)%(O1E(R"/PH
MX"X35?%*>&(9M!N-+ETN_CO+UVC CB$2L-D?.7#G &W.!C-6OAX;J*[\2?;-
M,O[,W^L37D N+=E!B*( 2>@.5/&<UW=% !1110 4444 %%%% !1110 4444
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M/+*$EB1DMQU INI>*O%.CV6NF6RBG2STU[RVU VLD,1=1S&RL<D]Q@]JNO\
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MK-M&U"T-U<M'E38IY?F*2Q/SCL>.*Z'1]&ELO#46D:A=+>[8?(9Q$(P5V[<
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M+"QQG=@=,<\"LSPI->Z+XTDTWR[FTBF\/->74+RY:6X4J#*2<E6.YOS&>@H
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M1=>(9M5OY+K3]>:W55F"))']J6/:R@8/R<=,#KC->O4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !69,LI\26K H8A;R @OR#D<@8_,Y].*TZH30L^N
M6LHB5ECAD!D.,KDC@<9YQSR.@X- %^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"EJ&D6.J- ]W!NEMV+0S(S))$2,':ZD,N1P<'D<&JT_A?0[G3%TZ;2
M[9[19O/$93I+DGS >N_)/S=>3S4NI:YIVDR117ERJ32JS1PCYG=5&6(4<D <
MFJT?BS19FTP17R.-3!-FZ@E9<=0#TS[4 6_[%T\V%Q9/;^9;W/\ KUE=G,O
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M/.#FM"UN8;RV2XMWWQ.,JP'45F:CXKT/2;[['>ZC#%.-I="<^6&Z%_[H/J:
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M>>0XE P&7+?*< #Y<< #L*R?B+KM_HGAB4Z,2=7GR+5 H8_*"[M@\8"J3_\
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M"S2L/X@H&=O&[&,U5O+;Q;IATUH-8_M-)+RWCO%:R166(MB1E*]!ZYS@=_4
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M5D4ABI*$,0 /4\#!'!'I=(&4G 89],T 5=/U&#4[7[3;B41;BH,D;1DX[X8
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M"[BU1KF3Y8V*AMRY6/&!UZD>O&FO@W65^'_ARSA-K%KVA-'+"9)"8F9 5()
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M<8W@%1P,=,YR>G>K6F^"M>T_P'=:)]FMI+J;5/M09I?E$9DWD@@CY@!WXR:
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MD.JW=FM_:BWN(80N'PK*.2,XPW0=<"I;3P+:V>NZ-JR7]TTFEV L(XV";)$
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MT4 >=ZQ8:;J5K#X"TS3KV)]-DM9([D1[4MT!SY@?/7 9>.26],D>AJH50JC
M P .U+@9SWHH Y2Z\&N;[4GT[59K&SU4EKZV2-6WN5VLR$_<)&,GU&:NV'AL
MZ;XB;4;>\=;/[%'9I8[1LC5/NE3U'4UO44 4=:TU=9T6\TUI6B6YB,9D0 E0
M>XS7/VO@2*V\2:+K+:I=S2:58&RC60*3*#G+.<=<'MCI7744 <IIO@R31[&U
MAL-8ND>"[FNFW*NR;S"<JZC&0/;'-11>!!:+H#66J2V\VD/,P98DVRK,<R+M
MQ@#TQTKL** .?T3PK%H\FMJUW)=V^K7#7,L4R*-KN-K@$ ?*0%&.V#ZUFZ;X
M!2RA\/Q3:I/<#0YWDMBR@'84*K&<=E!Z]:[*B@#E;CP?+<:/:V+:Q<"2WU3^
MTA.(T!9O-:3:1C&-S9J>?PE!=ZSK=Y<S"2#5;-+1X3&/D501D'WW'CZ>E='1
M0!Q.A^ ;K24E6Z\3:EJ*K;O;VB7!4K K+MS@#YCCUJ*S^&T5GIOA>S&I2,N@
M3/-&3&/WK,Q)SZ<$CBN[HH X"[^%]M<6NHP1:E-&+C51JMO\@(@FR=Q_V@=S
M<'IGVJS)\/WFT_Q-:SZO+,VO(@ED:)08R%VD@# YXX[8KMJ* .:NO"K7.L^'
MM2-VH?2(W388LB3<H4D<_*>/UK-:"V\"QWLU_=WE[9:I>R[+9+4.L;REG(.T
M9.3\N3GJ/<UV]&* .7^'^A-H'A6&"2Q6QFFD>=[8$,8MS$A"PZX&!^%6O$OA
ML^('TJ5+V2TFTZ\%U&Z(&R0K+@@\=&-;U% '*W/@^9I]5^PZS=6-OJC+)<+"
M!N60##-&3]W<  >#^%=):6L5E9P6D"[88(UCC7T51@#\A4U% &!'X2T^+7-5
MU91F;48A&R$#;'\NUF4?WF&W<>^T>E9=SX C?P'8^%;:[6*WMF1F=X0_F;6W
M$%>F"3S79T4 <PGA6XC\2:KK"ZBH>_LDM/+\GB/:#M8<\\L3BLA_AM(NAZ/;
M6>O7=GJFEQM!%J,"@.\+')1AT(Z?E7?44 <7)\/HS<Z#<KJ,CW.F73W<LTR!
MFNI64*6?&.P[>WI6AX9\+-X<U#6K@7GGIJEX]XR&/;Y;L>0#GD5TE% '/:_X
M7&K:E8ZM9WLMAJMCN6*X0!@T;?>1U/#*>OL:<OAV>\N;J76=2DO(YK=K9;9%
M\N)$;[QVCJQ]3T[5OT4 <EI_@R6RTW3-)?4O/TK3GW10R1 L^TYC#-GD+QT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9PV_P#"1M\IW_9!\W/3>>/2M&LP0C_A*&F^
M?/V()]SY?OD_>SU]J -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *SQC_A(6^<[OLH^7;VWGG.?TQ6A60JC_A+W;S!N^P*-FWMYAYS0!KT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !60%/\ PF#OQC[
MHZC/^L/;K6O6./\ D<W_ .P>O_HPT ;%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5E Q_\):PV-YOV$'=N^7'F'C&.OOG\*U:R C?\)@[[
M3M^P*-V.,^8>* ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *R H_X3!VW#/V!1MYS_K#S6O66@(\4RG=@&S7Y<CGYSSUS[=,4 :E%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D*/^*PD."?] 49[#]X
M>*UZSUCF_P"$@DE,0\C[,JB3:,[MQ^7/7ISZ4 :%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit101-iansconsultin004.jpg
<TEXT>
begin 644 exhibit101-iansconsultin004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M202VJX8JSL?E8'"@XQ@GO56U\;>(#!I.H7-OIHL+C49-/GC7>)2WFLBLF>,
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M38'VY)!!^4C/49Z5IC7=<C\87N@W;V$8GLWN]-EAB=RJJP4B4%AD\@\8Z^U
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MTC^]F@#N:*XKP-K7B3Q)8:9K5XVGC3KFS;S8XE8.LXD8'&<_+@ 8)R.:[6@
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M+W/N< =20*H2^*Y;.[M(=2T#4;-+NX2WAF9X'3>QP VV0[?ZX]>* ,2:XL_
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M>,;@#%YF"/4$D#KCCK5VSN]7\0,VC0ZM/8M:Z3:7)N(U0S7$LH?DLV0$!09
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M%F"V0C6Z!2)6"J0@58AW+9)Z9YY[!O NEOKFL:I+/>2-J]L;6[MVD'E-&1C
M 4$<$\Y[FF1> -+B&D;;S4]^EQM#'(;HEY(VP"CG&=N .%QB@#EM-\2:WJMK
MX&\W4'CDOWG6Y>)0#)M#*#C&,]^F,]JS=<M=9;PIKNEWWB"]E_LC5X(XY0P+
M7$$TD95)21\V!(.V,C&","N[L? &DZ>NCK!/?8TF:2:WW3!L[\Y5N/N\]!BE
M3P'I_E:U%/?ZE<IJ\@FG$TX)212"K(0H(VX7 Y "@8Q0!T<$,D-JL3W,D\BC
M!FD"[F/J0H _("O'8-<\4ZAX.N;B._U"8IKMQ#>-:%!<_9ER/W((X(.. /6O
M8;6V^RV<=L)II=B!?-E?<[>Y)ZFN>M? .CV5L([62\AF6XDNHKE)\21RR##L
M.,'/<$$<GB@";P1JQUGPU'=_VBNH+YLBI<$;9"H8X$B[5VN!@$8[9[UQ6IZS
MJ<7BN"]@UBY=HO$%OI\L$<I^Q^3(0GEA2!ND )8D$X/T KT;1]$L="M9(+*-
MAYTK3S2.Q9Y9&QN=B>I.!^59'_" Z+F?_C[V2ZBFI+&)SMBG5PY9!VW$'/?D
MX(H F\>75U8^ ]<O+*ZEMKFWLY)8Y8L;@57/<'T^OIBN134M?\/ZUH4\FLF_
MM]<LG,L-V,);21Q;U=,'('/S9SG&2<D8['QM9W5_X&UJQL;=[BZN+.2&*,$9
M9F4@?>./SJKHWA"Q%E87&I1W-Q=167V=([N8O]G5D"R(N#WQR22>!S@"@#EO
M NMZC<:[I32ZAJ-Y#J^GRW,QNS^[\U67)A7 *)EB ".0!CU.-=0>(-5^%\NM
M7_B:?RIU\M[>- PD(NL!MQQC(RI &,$>F*]#TKP'I6D7&F7$5QJ$LNFPM!;&
M6Y)VQG'R$# *C P.GKFIX?!FD0^&KK02DTEG=.TDAD?<_F,02X..&W#<#V/(
MH PM8_M#POXG\.7MSKNH76C2SR6<\<QC14DD7]VS;$4%05(YZ$C'7%;W@];]
M]*N;V_GFD:^O)KF%)7W>3"S?NT'H-H!QV)-86IZ5JNH(_@]].N[C2"(B^KWM
MRLID4$,X(ZENPX KNXXTAB2*-0J(H55'8#H* ."A75O%>H>()4UV?3?[,O&M
M;**S;A60 [YE/^L#$_=/&!CCK6-I^K>(/&6KZ?;)K-QI!O/#[7>V$*PBF$Z)
MN P"P(4\$\;R >:[J;PCILFLRZI$]U:SW Q=+;3F-;GC WXYR.,$$'BK%OX;
MTRUUI=6CB<726XM8OG(6*$8^15'&,@'G/- '/?%&VG?X6:N#?7$<L%KO>2 A
M/-(ZAN#\I[@?G573DN+C6;3PJU_J<5C;Z<M[Y_VDB6X9W/R>8 &VI['IMSTY
M[75=,M-:TJYTV^C\RUN8S'*F2,@^XK+N?!]A<VEC']IOXKJRC,<%]'<$7"J<
M;AN.00<#C&/0# H I>!-2U*Y@U73=4F%S+I-ZUG'=?Q31@ JSGN^",GCFN:U
M>6?0=8\0Z1?ZWJ[)J=NEWI+PW+F6)@Q5HD//.YD./[O7I7HVFZ59:1!)#8VZ
MPI)(TSX))=V^\Q)Y)/<FDN-)LKK5;+4YH0UW9"18)/[H< ,/QP/R^M 'F&C7
MVH^*_"MM:M>WJWVGZ7=Q:@K3.&>X ,:B09 .<%QG)P!TS5C29+O29/AM.VK7
M"PWUBEI/;%@("!;[DXQ]_=M&<\]ASBO1;?1K&T_M'[/$8O[0F,]QY;%"SE%0
ML"N""0HY'.<FJK^%='D72@UM)_Q*O^/(BYD!AXQU#<\<<YXXZ4 </=^(K_3(
M/&#/JEPJP:K;P+<O$&-M'(8U.U> <;B!WYS5CQ?8W&B^#O%L#:M->6DU@);:
M"YE::6/ VN=S9.TG:0.><XQ77MX2T.2'4X9+$21:H_F7B22NRRMQS@G / Z8
MZ"H;?P5HD.GSV;PSSK<1"&:6>YD:61!T4ONSM'H,"@#F=.NM0TWXIZ?8-J-S
M<VVI:09Y(96_=1.FT#RE'W1USDD\FG^.@X^(?@)[@$Z?]ME!!R%$Q3]V21WS
MC'O77#PYI0U>UU7[,WVZU@^SPS&9\K'_ '<9P?QS5K4]+L=9T^6PU&UCN;67
M&^*09!P01^1 /X4 .OXK*:W"WZPM#YB$";&W>&!7KWSC'O7 7::KKFF>*]7&
MMWMC<Z==S0V*VLQ$4:0 'YHP<,S'=G=G@C' KM(/#NF6ZVB+#*Z6F/(2:XDE
M5".A 9B,CL>H[4V7PSI,TE[(;=T-\0;H0SR1B8XQE@K '(X/J.M '!VD^I>+
M-=L([G4M2L;;5_#D=RZ6LVT12%E)\OY>#S@DY)![5%'?ZSJ?@+PU?^?J%] %
MG-]!:3^1=W*@E$D&3G"G!9=W<=<8KT%?#.D)JHU..T,=X+<6HDCE=,1#HH .
M !GTJ"+P?H<$MK-%:2)-:K(L,HN9=ZASEQNW9()YY)YYH X[1K]YM8\%2VNL
MZC=V=ZMV)&GG<%PB[D61#QO!)!/7Y:S=6-Y??!;QC#+<W-U+%>W$2O=3;F")
M*N!DGC '3_&O19/".B26MG;_ &1T6R=I+=HKB2-XV;.XAU8-SGGGFEA\*:3!
MI-YI:PR_9+R626>,3NNXNQ+#Y2,#G&!VZYH Y6"R$_QCU=WO+U5M]+MIT5;E
MP@.]\@J#@K\H^7IU]:QO".I:C_PD/A6<ZO?7D6KI>B>2XE)CN0@#HT<9_P!6
MJG@< \]Q7IG]A:<-474Q PO!"(#*)7!>,9PKC.'QD_>SUJA:^"M LI+![:SE
MC.GEC:8NI<0;OO!1NP%/=>A]* /(IM1U6/PCJNM_VSJ)N[#Q68(@;@A"A:,%
M6 QD8/3MVQDY[3P_I<<GQ<\33&YO<QQV\H474@4EMQP1G!7T4\"NH?P/X<?3
M;C3VT[-I<W7VR6/SI,--Q\^=V<\#VXJR?"^C'5EU0V>;P! 9#*Y#;,[2RYPS
M#)P2"?>@#"^(=Y<6,GA5X;F>&*77;>"=8V(62,AB58#DCY16-J5Y=Z1XTEN-
M4N=4BL;K4(DLKRWN6DMD  !@EB#?+EMW)'>N\U70=-UM[-]0MS*]G,)[=A*Z
M&.0=&&TCFHY_#.DW4A>>V:53.+DQ/-(8O,!R&\O=MSGGIUYZT 5?&D6IW'AN
M6#27C%U)(B[&N# TB[@617'W6(!&?3->=7&I/_9FGOI^H:U#+!XCLK>>RO9W
M+6RLP!C<[CO4X!Y..:]8U/2K/6+9+>]C=XTD65-DK1LKCH0RD$'\:IS^%=%N
M;*YM)K(/%<S+/,3*^]Y%(*MOSNR,#G/:@#@O&#2'3_B1%]JN&1;"-EC>8NJ9
M0D[0<A0?:K%K87_AK7O"UY!KNHWJ:L1;W=I<MN3'EE@Z*H 3;C'3'(Y]>R3P
M?H"-?M_9R,VH1"&\+NS?:%'3?DG<?<\^]02:):Z%-:WND:-]IN4"VVYIF9XH
M.I"ER>!Z#'6@#@+?6M02P@T26^GFCN/$%_8O<W=RUNQ2(ML4S(">>.<#)&WI
M5N>?5-#N(O#MWJ$?V"_U*&!C'>R22V<;(6,?FLJGYRO!SD D#'!'4Z7X)LI_
M#=WI^OV4%U]NO[B_FA)RJ/)(S *0 <A2!GKG-:,?@WP]%X;D\/+I</\ 94G+
MVY+')SG.XG=G(!SG(P* /-/B+I::7X9?27U6:\!UJVGBC:1P]M$YP$+;OFY5
MR,^N<#@UZ_:10V<,=DDSR-&F1YTIDD(SU)8DGZFLB/P/X:AT"30X])A33I'$
MCPJS LX((8MG=D8'.<\5=LO#^E:=>QWEI:+%/':K9JP9N(58L%P3CJ2<]: .
M8\12"T^*WA2XO<?8I+>Y@@9R-L=P0#GGH2@90>^<5U6KO8QVL;WR1/MF0P+(
MN<S _)CWS4FI:3I^LVOV;4K*"[A#!PDR!@K#HPST(SU'(J*WT*PMKQ+L)-+<
M)N\N2XN9)C'NQNV[V.W.!TQTH \X:6>Z^'EYXT.IWL&K1-)."MS(T2;)"/*\
MO.-G\)'7WR*?=6=WJ%WXY%YJFI106]M'=6D4=VV48PLV],'(4-N&PY''TKO'
M\*:))--(]@I$TPGEB\QO*>4$'>8\[2V0/FQG@4X^%]%:\U.[.GQFXU2+R;V0
MELS)MV[3SP,#'&* .)U+4-8GTC1M;N+6?4+)])62\^PW!BG@=L-YJ(I&[IVY
M !QZ%MI?SR:[K"QW\\]N/#,4T3EB-S;3\^,\,<5WG_"/Z:MM%;QQ2Q1Q0+;I
MY5Q)&1&O1=RL"0/<TV7PUI$UY#=M9A9H;8VB&-V0>2>L9"D!EXZ$&@#S_P ,
M2WFH>"_ %Y<2/._VP&663YF.5<#YB"1^8JFUA#H&E_$*XL+VZMKF"=(8IS-+
M(Z[HXL<[B2Q)P#C(R.HKT)?!7AQ=.L=/72XA:6$OG6L09@(GW;MPYZYJ:Y\*
M:'>+JBW%@LB:IM^VJ9&VRE0 #C. 1@<C!X% 'G)EU!;_ ,9:67U"PMUTJ&Z@
M0:@S26[ -R/[I;@D9/3OGB;07NM.\4^"]U_J%Q'K.ESB\6[G,F]D5"IVDD*>
M>H//\^XA\"^&;>\:\BTF%;E[<VKR!FW/&0!AN>> !D\X[U=/AW26N;"Y:S5I
MK!2MJ[.Q,(/4+D^P_(>E '(?#[PQILWA,O(+AEDN[I'B-RYC94NI< KG'U]>
M])XP34-.U:XODM)[_1(M-,4EI8W.R6U.?]8D8(SQW'( XKKM)\,Z+H5S=7.F
M:?#;SW;EYY%R6<DDGDGIDDX'%&H>&M'U6ZDN;RR62>2'[.[AF4O%G)0X(RI/
M4'@T /LXXM2\-6\:7D[1SVJ 7,;E)""H^8$=&[UY-=2W>E^ O#WB>QUW4;K4
M8[V*U;?,2DJ>:R-$R="1R,XR2.M>RNHL[ K:V^X0QXBA3 Z#A1Z5RG@WPI:V
M>@Z:VHZ0L&H6SM*8VE,B+*2<R*,[=Q'\6,\F@#E)KG5M6L=;U*#7+"PNK/59
M"]S+>2!K6.&0HL9AV8PRC)&3N+?A5SPQI5QK_B7Q!.^LZ@EK9:XDL=N7)#+Y
M0)1L\[3N'R]MO'>NTE\%^&9M:&L2:)9-J&\2>>8ADN.0Q[%L]^M7[71K"QGN
MYK6 Q27CF2X97;]XW3<>>N !GVH \@PVC?#>2^T^>YM+F?5Y+6>=;EC]GC>Y
MVG /0X4 ' (W$]SGHO%,-UHFJWD.EWLL=KJ.C73RH]P0()(DRDJ'/R]?FQUZ
MXSG/9VOA70K/3KO3X-,@6SO&+W$!&Y)&/4D'/)XY]A4PT#2_+N$:U$@N(?L\
MIE=G+1<_)DDG;R>.G- 'GFK6ES%\/=*UR/5+Q;J[@TF.7_22!]^,%@/XB0YR
M#P>O:D?1XI?&GBS1)M2U*.P6RCU"*W6XE7,C;MSA\YV@@?+G;STXX[^Y\,:-
M>Z5!I=S8I-8V[*T,$C,50J,+CGC Z>E2?\(_IGVNYNOL[>?=1B*>3S7S(@!
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M#2-/@LXY&W.L2XW'&.:TJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW<0Q&W9-PFP,!RH'/3!/?/ [M\ 1:/>2^'9)]8G;Q!8ETGL$BB617VLKF4A
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M6)Y#L!]0HKE_#B_8-,\':GY4G]C6UW>07$(0_NYY)6"2E<D;0=WS9_B!  /
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M5T-U>6UC$)+J>.%"P4,[ 9/I7DVC7ITKXE:%<W<5T8+CPW%:0E(';][OBRO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI8VT"W!+3".,+YA/=L=:9::'I-@839Z;:0&!66(Q0JNP,06 P.,D GZ5?HH
MI7&CZ9=VLUK<:?:RV\Q!EB>)2KD'(R,<\T/H^F27/VE]/M6G\GR/,,2EO+_N
M9Q]WVJ[10!!%8VD(016T*"--B;4 VKZ#T'M53_A']&^PM9?V59_9'<2-!Y"[
M"P  ;&,9P!S[5I44 (JJJA5 "@8  X JM'IMC#=&ZBL[=+@KM,JQ@-CGC/XG
M\ZM44 17%M!=P/!<PQS0N,,DBA@1[@TV.SM8K;[-';Q+!C'EA %Q]*GHH @M
MK*ULXS';6T,*'/RQH%'))/3W)_.@V-HT2Q-:P&-3E5,8P#Z@5/10!QEIX3U'
M3]7UJ[5].OUU*Y,Z27J,7MQM"J@'(91@8'R_X;.C>&;'2]-L;>2&"YN+6(QB
MX:!5/S'+!0/N+GHHX P.U;5% %(:/I@6T4:?:@6>?LP\E?W/&/EXXXXXJ=;2
MV02!+>)1)]\! -WU]:FHH B%K;A&001!7X9=@P?K2?9+;]W_ */%^Z_U?R#Y
M/IZ5-10!!%9VL#!HK:&-@, H@! IUQ;0748CN((YD!!"R*&&1T/-2T4 0M:6
MS@A[>)@6W$% <GU^M+]EMQ*\OD1>8XPS;!EAZ$]ZEHH @CL;2)P\=K C#D%8
MP"*<EK;QS-,D$2RM]YU0!C]34M% $<-O#;J5ABCC4G)"* "?PH>"*21)'B1G
M3[K,H)7Z'M4E% %<V%F8O+-I 8R<[?+&,^N*?]FMR[/Y$6]EVLVP9(]#[5+1
M0!%#;06^?(ACBW==B!<_E2^1#YWG>4GFD8W[1NQ]:DHH AFM()G\QHD\T#"R
M[ 67Z$BN T_X=ZK9Z*/#\VK:=<:25DCDE;3R+ID<DMA]Y ;YCAL''7M7HM%
M%>UL;>RB1(8P"J+'O/+, ,#+=3^-/6V@25I4AC61OO.$ )^IJ6B@"-;>%)6E
M6&-9&^\X4 GZFFK:6R1B-;>)4!R%" #/KBIJ* (U@A69IEB02L,,X4;B/<TT
M6ELH<+;Q 2?? 0?-]?6IJ* (_L\.%'DQX0Y4;1P<YX_&E2&*.1Y$B17?EF"@
M%OJ>]/HH 0JK8W*#@Y&1T-((T5V<(H9L;F Y..F:=10!%]FM]NWR(]N<XV#%
M/\M/,\S8N_INQS^=.HH 8T4;.':-2PZ,1R*000A&011[6ZC:,&I** (TMX8X
M?)2&-8NFP* OY4Y$2- D:*JCH%& *=10!%]F@*[?)CQG.-HZTI@A+,QB0EA@
MDJ.:DHH B^S0%0I@CP.@V#BG&*,N',:EAP&QR*?10!']GAV;/)CVYSC:,9KE
M/^$3U2TU"];2]5M(K2\D::3[58">5'/7:VY01Z @X]ZZ^B@"AIND6FFZ9!81
MQJ\<(X+*.2>2?Q-7Z** &"*-266- Q.XD#J?6N?T'PR^D:WKM_--#/'J=RMR
MB>5AHFVA2-V>1PO8=ZZ.B@!DD,4N/,C1\=-R@XH:*-V5GC5BO0D9Q3Z* &)%
M'&24C12>I48S0\4<C!GC5B.A(SBGT4 ,,49D$AC4N/XL<_G3Z** &[$*E=B[
M3U&.#2"&,1F,1H$/50HQ^5/HH 88HS'Y9C4I_=QQ^5"Q1KC;&HP,# Z"GT4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.F:OOLY#.^8BC +CGD <8/%=QIMI$WQGU:3,@9M'M9&VRL,MYCCG!Y' XZ4
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MB.3@=NGKFK&MZ:9[B;2KE;F?3+#Q#IL=D')*PQN4#H'.6(Y]01D $#@@'?\
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MSBYE@/Q*\.R13B<ZCHLXDF67RVE "LLG&W=D XPHQDGC'',Z8A@T+P#JJ27
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MV6IV.I&86=U%.8)&BE"-DHXX(-.?4;.._%B]S$+HQ&80EOF* @%L>G(H S-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(N5RJ!2I[9VD#'7%>TQ:?9PES%:PH7?S&*H!E_[Q]_>I?L\.&'DQX;DC:.:
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M2K-&'4. 21AT*G@^AYI]% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<5&\7>-8[CPYIVI1P6%]>:E+:3@HC%DV!HV^5F"G!&1_2@#URLS4]>LM)O\
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M'H\FG,\S@WQU&*;(#PW&[=O4CW[=*OR>%+.Y@U=+RXN;A]5A\BX=GQA " $
MX7&X].YK:2>&7'ERH^2P&U@<D'!_(\&D^U6YF6'SXO-8L F\;B1C/'MD9^M
M%?2=.72=,ALEN)[@1+@23MN<_4UAWO@+2[V?66::ZCAU="+JWCDVQLY7;Y@
M_BQ^![]:Z:.:*4N(Y$<QML<*P.UL9P?0X(_.D6>%BH66,EBP ##DJ<,/P/7T
MH YJ?P)I\UO<V:W-S'8W-O#;36X8$-'$-JC)&02."14=_P##S1KW67U*-KJU
M>=%CNHK>8HERJC #@=>,C\:ZE[B"*:*&2:-)9<^6C, SX&3@=\"FM=6ZRM$U
MQ$)%*@J7&06.%X]\<>M $9TZT_LLZ:L")9F'R/*48 3&,#\*YNP^'FEV,NA2
MBZO99-%+"T:27.$*[=A]@*V]#UNVU^TFN[-6-LEQ) DAZ2[#M+#VW CGTK0,
MT2S+"9$$K LJ%AN('4@4 <J_P_TQ]$;2OM%T(#J!U!2&&Y9"Q;CVR3506]UX
MK\::?=W6CW%A;:%+.=]U&I,\AVK&8V!/RXW$]L[1SU';22QQ &1U0%@H+'&2
M3@#ZDUBWNH:D=;T==-?3GTF<RK=S229?< -BQX;DG#YX/3M0!N5R]CX#TC3M
M5-[ ]V(O-\^.S,[>1')DG<J=!R<@= >E="+RU:[:T%S";E5W-"'&\#U*]<5@
MZ3XBFDU7Q!!JTEG;6UA>)#;R;@FY&0,-Q+$;LDCM]* (9/A_I,DLZ"2Z73KF
M0S7&G"7]Q*Y.22.HR0#@$"KW_"*V2ZM?ZA'-<QO>VPM98UDP@0+M7 [$#./J
M:L_V]9'Q.GA]) ][]D>[D52#Y:*R*-WH3OX_W3[5>AO+6YEFB@N899(3ME1'
M#&,^C =#]: ,*'P7IMO::/!%)<I_9!9K-_,Y3((Y]>#CGM4TGA#2)M:U#59H
MI)+B_M?LEP'<E&C]-O2K'B37[/PQH-SJUZ3Y4*_*HZNYX51[DX%9LMSXF2#P
M])/-I=K-/> :A$Q('EE'(C0DY9P<<CJ1G&,B@"+3? &G:;<:;,M]J4W]FNS6
MB27)*QAA@KCN.O7U-267@'1=/U1[RW^U+$T@E%G]H?R$DW;MP3.!SSCIGFM_
M^T++?L^V6^_S?)V^:N?,QG9U^]CG'6GW%Y:VAB%S<PPF5PD8D<+O8] ,]3[4
M <TWP\T)M)U'3"+K[+J%T+RY43G+R;M^<]ANP<>U73X3L3KTFKB:Y6>6W6"9
M5D($VT,%9O4@,:AGUJ^@\>Q:4_DKIAT][II"N&#!@.6)QC&>WUK:&IV!%L1?
M6V+G_4?O5_>_[O/S?A0!SD'P[T6S@TB&S>[@72I)7MRLYW8E.74GK@GFGV?P
M_P!%L--MK"V:]CM[:^^W0JMRPV29R /]D9/'3DYZTOC_ ,03Z!X.U>\TVYMT
MU*UMO/1' <A=P7=MSTZ\],U:2[U1O%MM#]KL?[,>P+O 2//,NX?,!G[N/;%
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M (1Y;N)6O9)660;QO#,3M)P. >WM7:7G@KP]?WEY=7.G(\MX )OF(#-M*[\
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M:Q!6VD#L6B4]5!)SMY/R].3QS0!Y/>&?1_@5I<UC>W,4L^H1H[)=.1L\]QM
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MC:^OK6-KJ'7K5HK*W)9@MX@+;2/X5<>G<<^M=XWA[27M;JU-C'Y%U.;B>,9
MDD)R7.#UR <^H%8D>F>(=6\4I-KB6,>DZ9=-<6 MV;S)G*%5+@\ *';ZGVH
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ML-'M+>6[!69XXP"P(P1GL#Z#%3)X:T6/16T9--MUTUF#&V"_)G<&SCZ@'ZT
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M):36DFD6LEO/,)Y8Y$W*\@_C(/?WJZFCZ?%J+:A';(MVT8A,JD@E!T7Z#TH
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MQ<C:6P%!Z8.#U[&[XNU-)IO%=JMO<1NUQ;,EK96Q_P!)4&,FX>0(=P QP".
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M]OJ$T >V,:OQ-G^_@'@'.>?:@#K8?B9X5FO?L@U K*'G1P\3*(S"I:3<<<8
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M;:[J6)VG@ X[XXR =)2$@8R0,]*Y:S\<VUYJ6MV,>F7WG:5;QW#H A:573>
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MCB"HNXCGZD  5NW'CVRTV;5+;5[.YLKJPL_MQBX?SX<<F-@<$@_*0<<]\<T
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M/W>PA@3V'?/M7/W/CS4;'P_;>+9[6V?P[<LA$,:L+J.-SA6)+;"<D9''7J:
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M9S0QAAPT?S@@^H;=@YQ77T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQVVJR"=X%==D4HV_.HQWVC()/X4 9D^M^(;_ ,;>*],M-4CM(=-LHI[;=$"
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M^73;;1UMY%>W \R9G#$[BV1M&.@'I6SI7A.#2?%&K:[#>W+RZF0TT+A-@(
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M"3"KN*EMN!QDKG\33KOPW#9:F?$5M)?R7EO9>4UM!(%^UB,$HK<<G.0.0.:
M.2T#Q#K-SIL7A+4;N\'B9-1-O<7$>W(A0B1I<XP%*?*,]2V.<&O4@,*!DG Z
MFN5\+6<USJ^I^)+G2Y-,EU!8XEMY@!+MCSAG ) )+'@=JW;'35L;N_N!=7,Q
MO)A,4FDW+%A0NU!V'RYQZF@"]1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$ XR <
M=*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKF=.U>_U7Q!J<XFBMM!TUVMLL 'F
MF3_6,Q(XC7..,'*DY(H Z:BN&U#Q8MYXV\'V>DZAYEC?279G"+\L@2!BO)'(
MW<\>@K6TC79SXGU'PYJ"L;JWC%U;SD ">W8D X'0J?E/KQ0!T=%%% !1110
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MMY=/3?<VDD)\Y5[$*/O*<]1QU]* .EHKEQXZT]M0%B+6]-Q):?:K=!"3]H7
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M$MC?Z7\+;F&^L9K>5O$OVA$?;\Z/.64C!/8U[I67K_A^P\2Z>ECJ*.\"3),
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M0/HEPLEVPN4("JK1\>IP0WZ4 ;MYX^6%5OK32;B\T6.\:SNKV)LM&X;;N2,
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M9/O-&,8(4?F5/2J5AKGB%/%7B\W%G:SVFG1JT,-O<,TCX1G10I7 9AUY&#C
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M"3Q=(/%3ZE9PW4NB:S8F'39'9@DMT!D!5_AW;@N3CE3TQ0!Z'_;R_P#"8?\
M"/?9I-_V$WOG@_+C>$V_7.3^%:]>8Q:"L7Q2T_1Y;RXFAA\+-%-(SGS)AYX'
M+9R#DAL@YXQ5+2-7N-3\&^&K6:\N[G4)+VXC2TB?:UW%$\D?[Q^JHHVEGY/
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MJ;(4'R+N+8'U->>>/[Z:._U1+82WLD&DM(\'V@VT5HOS'S3(#DL2H 7';J*
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M<M_A[HMI::+;6YNHX]&E::UQ,3AV8DDYZ]2,>AJ6\\"Z7?G7/M,MVXUG9]I
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M9)(L_,JMG:?QVFN0U[Q3-HOQ'TVRNM2BM=&?3I[BX60(HW*5"DL>>_08S[T
M;T_A?3KC7FUMFNUOVMS:^8ERZXC)R5 !P.>?K5.+P#X?AL;"S2WG$5A<M=6Y
M%R^Y78EF^;.2"225/!K7AUO2[C3H-0CU"V-G<8\J8R!5?/0 GO[=:GLKZTU&
MW%Q97$5Q"21OC8$9'!'UH Y]_A[X:?2+C2_L!6TGN_MCJDK*1+G(8$'(Q[58
M_P"$+T7^T'O/)G#2>5OB^T/Y3^5C9E,X.,#MVIXU!D\77,#ZW:?9H[,2-I^T
M>9&<\R,W88QP:=9>+M U&XLX+35()9+U'>V R/-"G#8)'7(/'7OTH 9J'@[1
M]3U*:_FCG2>>(0S>3</&LJ YPRJ0#]3]*37/!F@>(S9G4K!9/L9S#L=DP/[I
MVD97V/%;DLT<$32S2)'&HRSNP  ]R:ST\1:/);74\>HV[I:Y,VQ]S)C/51SS
M@XXY[9S0 Z]T+3-0T1M&N;2-M/9%3R!\H 4@KC'3! (^E)KN@:9XETM]-U:U
M6XM7.=I)!!'0@CD$>M><GQUJ<7@>W\6#6X)3>#R18F!0L,KRA%*X&_"C<3N/
MS8&,9%=79ZJ?#HN9=?\ %<.HVD[K]D8PH)$ &&!$2X(R1SCC/)H EG^'WAV?
MP[%H)M94TZ-Q)Y4=PZEWR#N9@<L<@<DUTL48BB2-2Q"*%!8Y/'J>]4+_ ,0:
M1IEBM[>:C;QV[H9$8/N\Q1C)4#);J.F:RM6\:Z=INJ:#9QS0S+J\AV2[\(L>
MPMO#8P>@'7O0!I:SX<TO7GM9+^W+36C[[>:-V22)L@Y5E((S@54N?!>A76C)
MI$EHPL%E\UH4E=1(V<Y?!RW//-;-Q=PV]F]T\L:Q*N[>6 4^G/O7GWAGQ9<W
MUIH>OZCXDACM-2=H)-.DMU"K*V3&J.HW @+SN)')Z<4 >A6MLEG;1V\1<QQC
M"[V+''U-9]]X:TC4M5BU*[LUENHHS$K$G!4G.".A_'UJ*3Q?H$>EQ:D=2C:U
ME+"-HU9V<J2&PJ@L<8.>.*L/XCT:.*RE_M.U:.^F$%J\<@<2N>RD9]* *-AX
M(T#3!IOV2S:-]-R+63S7+H&SN&2<D'/(-4Y=$O\ PTT:^#]*L7%[<%[^2\N7
M!!(.'[[CD\\YP ,=Q;?QUX9CLY[M]6B$,$ODRG:V4;W&,X]\8]ZZ!'61%=&#
M(PRK*<@CU% %;2[+^SM+MK/<K-%&%9E0*&;NV!TR<G\:S?&>CWFO^$-2TJPE
MBBN+J+RU:897&1N!X.,KD9[9S6+<^,].UWPUXA:TU;^S1;>= EX4;=&%"J9"
M,9'SL0,<X&1STU+?Q;HEK9VD%WK<=Q<G3DO3+Y15IHL#][M4<;B0=HYYX% '
M-Z)X)"ZI9WD?AR+0GM9TF:87IF>0!2I10IP >^?7@9Y'2KX&\.KK3:L-.4W)
M?S,%V,8?.=X3.T-GOBGV_C?PU=OIZ0:O!(VH,4M@H/S-C.#Q\I] V,]JL:IX
MGT?19_)O[ORY GF,$B>3RTSC<^T'8/=L#KZ4 6[G2[2[U"ROIHRUQ9%S VXC
M:6&UN._%4]?\+:+XG@BBUBPCN1"X>,G(93[$<UH2WMO#I[W[2 VR1&8R("WR
M 9R,=>/2N:\._$#2==TBYU"27[*D#G=YB.HV%RJ')49+8Z#/)Q0!M/X=TB2\
ML;MM/A^T6"[+5P,&%?1?2F-X8T1[K4+EM-A,VHQ^7=O@YF7&,-ZC %2:3K^F
M:Y]H&GW!D:V?RYHWC>-XVQD95P".#Z5A>*_'4'AKQ#H>DM!+(U_*?-=89'V1
MA6Y7:#N;(Z#G'- &Q;>%M$M)K2:WTZ*.2TB:&W89_=HV<J.>G-0?\(5X;_LL
MZ;_9%O\ 8C/]H,/.TR?WNO6J5MJ]E8:WXDO;OQ*T]K;1QR2VS1_N[%0IR P'
M+'!)'7IQTJR?'?AKS7B&J1LZ6PN\*C'=&<<K@?,>1P.>>E $VL>#M!UZ[L;K
M4M.CGFL3F%R2"/8X^\.!P<BI9?"VAS:G)J4FG0F\DB,+3<ABA&"O7@8]*6/Q
M/HDVBQ:O'J4#6,W$<@/WC_="]2W^SC/M4NCZ[INO033:;<><D$K02@QLC(XQ
ME2K $$9]* *7_"%^'/[,MM.&D6ZVEK-Y\$2C C?.<CTIMQX'\-7:WRSZ1;N+
MZ59KC(/SNIR#[<^E;LTT=O"\TSJD4:EG=C@*!U)K&T[QCH.JWCVMI?@S+!]I
M*R1/$#%G&\%U *Y[B@"S!X>TFVU=]5ALHTOG78TX)W%?3KTK3K$TKQ?H6MW4
M=M87WF2RQF6)7B>/S4'5D+* P^F:VZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQ['97FL>%].
MNK=+J2>\DDCM[@ VY"1G<\@/!VAN!W)KMZK7>G6=^83>6L,_DN7C\Q VUB"N
M1GV)H \;L6M7\.Z'-(D$HL/$LMO"_!$,>\_*A.=JXV\<=![50\3V5I>P_%=;
M6WMYF1[:X01H&*D(C.XP/]\DY]:]L70M*6SELQIUM]FFE,TD7EC:SDY+$>N:
M?;Z/IMJ;CR+"VC^T@";;&/G&T+@^VT 8Z<4 ><ZEH>CW.N_#_3%L[9;">"]\
MV"'$:.&MP&X7&22><>]<UINI3P^';G3'NYH=%LO%:V4H1VQ%9D$["V<A-Q ^
MG'2O;H=,L+=8%ALK>,6XQ#MC \L?[/I2KIUBB2HMG;JLQW2 1* Y]3QS0!YG
MKNEV6CW>KV>@1+'I5YHMU/?P03[(K=P@\IU0$;2^"#CJ![51UG0]*7X)RZXW
MG"YO]+L99R)R%DE"QA6*Y )Z9^G0X%>M#3[)8I(A9VXCD&'01+AOJ,<TKV-F
M]JMJ]K UNN,0F,%!CIQTH \_A\/:+?\ Q,\5#6-(L)(KBVLOL\D\"DR%A(K,
MA(ZY &1Z"LC1O#<MC<W'PX-E'+IL-VFH?:9H%99+1B6VG/\ &'&S/IGCBO2]
M2TB.=3=V<%JFJP0/'9W$L0;RBV#T],@5G^%]&U>U>;5/$5S;7&L7$:PN;4$1
M1QJ6*JN0#_$23CJ: -33M8TO4;B[L]/O()Y;!_)N(XFSY+?W3Z="/PKB_%%S
MH4?CH1>,&L%TQM.VV'VQ=T?F%CYA.X;0^ N.<XKJM+\/)I^M:AJLDL<ES=DJ
M/*A$2K'N+ $ G<W/+'KZ"M.YLK6]55NK:&=5.5$L88 ^HS0!Y99M;2ZUX7TR
M[=[_ ,(&TD2WGU.(,ES<[F" [NOR [0>W/THZGIUG::'XCL[>-9-+T_7+9K'
MSE+I;Y6,R*A(.%!)Z>I]:]CFM;>XC6.>"*5%(*JZ!@".AP:1;2V6U-JMO$+<
M@@Q!!LP>O'2@#R#Q!'IL_CKQDJL$:7PN3)+%C!.QN3R,G 7J>0 .!56_T'2C
M\,O#.J26L4D]U)I\<[2 ,I5-P&0>.C,/QKV4:98*"%L;8 IY9 B7E/[O3I[4
MYK&S:S^QM:P&U  \DQC9P<_=Z=: /&?'VC:1!<Z[?6]M9ZK96T%O!>:;M$4N
MGIMRC6SXPH())5>I8]QBO6=,US2KNZ;2[6\B:]MH8WEM=W[R-64%<CZ$?G5O
M^S+#=N^PVV>.?*7L,#MZ ?E5"#P[;Q>*KC7S(6N)8!;H@0*J(,$].6)(ZGL
M.U '*^+=.TE_B;X;NM2L;)K<VUT9IKB%"I*J"NXD<XZC/3M5?P3H>FWOB;Q+
M>3Q[[C3]?F>W)<DINB0,>>>?_91Z5Z+/:V]UL^T012[&W)YB!MI]1GH:2*RM
M89))(K:&.27_ %C+& 7^I[T >&WHDM_A5X42&22)D\0.K-"[(R@W,N?FX8<'
MVX-2^+M%M[>/X@6GART9=/&FP2W$4 Q$LZR!VP.@(C&3BO:UT^R2!H%L[=86
M.6C$2A2<8R1C'0 5(EM!%$8HX8TC;.450 <]>* .&MKW2KSQ?X;@$]K))/H5
MQ&0/OLI\@A2?3 <X]B:X32K#3K'PCX<OHHK:WN;;Q%+!%=%0'2/SY $W8)QR
M>/?\:]QAL+.W"B&T@C"Y("1@8SUZ#O2#3K%8Q&+.W"*_F!1$N W][&.OO0!X
MIXLO]+N3XCOWFL8KBSUV%8GO1FX#Q^6#L*C*1\,0>>YQ74ZVR-\4]0AFF>*U
MD\-2>:ZY; W]=HY8@$] ?UKT.33[*4RF2TMW,P E+1@[P.@/'/XU)]GAWE_)
MCWE=I;:,X]/I0!Y=X6U&#PKXBN+'5([""U@TA)5U2R*I#<0HRA3(@R0X\P@'
MOSP>WI]I=V]_9PW=I,DUO,@DCD0Y5U(R"*K7.DV\EG<6]M'#;?:.)'CA7+#Z
M8P3CN<U+IFGP:3IEKI]L"(+:-8D!.3@# H \CUQBOA?Q1,C(8$\4I)>?N]_[
M@/&22O1A['C@T:HNE7V@>-+W3M?DNX;_ $]7N;Q8]MHD@( 7Y 2788#8!.,5
M[#':V\2,D<$2(_WE5  ?K67K?A^+5/#D^D6IALDD*$;8 R#:X8@H",@XP1D<
M&@#S7P3%H?B?QC%J]Q#I<?D:3'9Q:?)+#-(SC!:4*I8( /E]>N<=YO#4"CP9
MX6@M-7CL;R'4;S[''+ 3#<;9905<*<#Y,D'/XFNQTSPYJUQ>07/B%M'9;5RT
M,%A:LH+#(5V=CG."?E Q[FNE^Q6IC$?V:'8#D+Y8QGUQ0!Y-+/%>>#O#4JV2
M6;GQ9 9HHGS&)!,=Q0G^#/3VK!\9ZCIQL/%:01I:.-=MOM"SX::1P5.\?W4P
MIQ@$\-V)Q[RUK;LBHT$11/NJ4&%^E->RM)&=GM86,@PY:,'<.O/K0!P&DG3H
MOBWXG2[E0G5+.U:&.X3 N(_+VMLSPZ_+STYR,<9K T;P^VK? [2)[9S%>Z1<
M3:A;*!U:*XD8)CW Q^5>PM;PO)YC0QE]NS<5&=OIGTHC@BA4K%$D:GJ%4 4
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MBG>6@8-L7(& <=/\Y- 'BFB:Q81"TL1)_:FE0Z)<M%,D:)?6480[HG ;'*X
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MB"/>O;RBL5+*"5.02.E+0!X7XNOK>[F\:V]I%%;-<64=PG[AI?[10*I$JG!
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M^7<NT9YYJY/HFMIKOA>_3PY#%#;ZC<W5Q;6)B5;=)(_+4L<KO?/S$@'TSP*
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MD/-7)S$(]YST )W>ORG SB@#I;3QG87.M)ISQ36XFL_MMK<2[0EQ'@$[><Y
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M07-E#'8QM'LLA_Q^,1C>_ Q@?P\\\UVU !1110 4444 %%%% !1110 4444
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MI7=NCPVXB41QA&V_,PQEI/EZDXY.!WIGBFV>S\0:+XF"2/!I_FPW2QH781R
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MNOM>IDF>\W@3#Y-B[2  NT#@8X/-3I=Z@?$$MH]BBZ<MN)$N_.&YI-V"FSJ
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M0R RHDH(<1_PEAV8CG';.*P[/QL]UHUU=_V:3=IJDFFV]FLH+/(K8 =AE4.
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M))'O]*Z33?AIHUAX;NM ENM1OK">7SU6YF7=#)G=NC**NT[N?\FIE^'FD_\
M")W?AZ2YOYHKO!ENYI5:X)#!E.XKC@@8XH T?$<\VC^#=5N;:60S06LKQR2,
M68-M.#GVK-^&L$9^&^A.R!WGMEGE9ADO(WS%CZG)K?@T>TAT4Z21)+:M$8G\
MV0L\@8?,6;J2<GFN;TCPO-:>'YO"$TMW!9P<V6H6<FQUCW @%CG#@D]B",4
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MU<6MQI?B"66'[).$4\Q94DEE8')Y8G\JZ?57E\'^,)M165FL]6T]H[:&29F
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MYL00;9-WWLCOG)S0!R#3))\9WBCN-T$OAMI'593M)\]0&]!\IZ^AKEO#68=
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M/\.WEQ%&-)N<R\.V<P$ D8SG&.,'GM6O\4;"3Q1X%UO2M*NP;^S"2S01GYB
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MR5**C"2$-_>).[ Y.[V% 'HFHZSI6D11RZGJ5G91R'"/<SK&&/7 +$9JUO\
M/MM]O*AWIF.0?,O(X/N*\EL[X:+XJTR74H;W1],NM&CM+1KM1*L6UVRDI.=K
M,NTY.,Y /(KL_A_!'IW@FVC6*YMK*,N;<7DA,@AW':S J-N1SMYP#UH RO\
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M7EX2N"'91A.><(,*,^GO7*.MU;WGCW2_['O]]ZCWD$\5NS12CRT3:#U+DYX
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MDT;MG:,#Y0>N,U2^($5O?> 673O#]XUY>A&BABTYO-CPZDAP%^0@9Z]<'&:
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M4NFNEMH5N&7:TH0!R/0GKCBN.\+ZOI.D>#FO+5-5>TDU&>.&*?,TTDAF92$
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M"P2(<G,1W9R?E!W9Z'UH [9+RUD5BES"P098JX.T>IIG]HV/_/Y;_P#?U?\
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M+/Q]<OX=U^YNK*%=6TF=K?[#$S'>Y.(NHS\Y(QC/6NKU"^N=/T&>^-HT]S#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MAN+2VNU"W-O%,JG($B!@/SJ:B@!D44<$2Q0QI'&O147 'X"GT44 %%%% !11
M10 4444 -DC2:-HY45T8896&01[BDBBC@C6.*-(XUZ*@P!^%/HH **** "BB
MB@ I" RE6 ((P0>]+10!%!;06L9CMX(X4)R5C0*,^N!4M%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3@X63\/K7I\DT,<D4<DD:R2DK&K, 7.,D =^ 3^%!FABEC@,D:22 ^7&6 +
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MJ@Q2KN&P+TR<?*/:O4Z* ,RTMKC3_#%O:I;VZW-O9K&(+<$Q!E0#:FX@[<C
MR1Q7F6B6-_9ZWX,NI=*U=A:_;!<M+;A?(\Q% 5(U/$8)QG'8=:]@HH \2ET+
M6'^'VA6:Z5?&XM_$#7$L?V=@RQ^>TF_!'3:1_+K72>+=)*>.K&&P,4:>(X7M
M-20MM+QQC=N&/XMNY?Q'I7H%_J-GI=M]HOKF*WAW!-\C8&XG 'XFL?0?!FE>
M']3O]2M&NIKF]<N[W,[2E,G)"D]!D_6@#;DC"6;10Q*0L95(STZ<#Z5X=;>&
M_$%Y<>%YGT34+9[>2\@NP$5([9I0NWRE!XC&#\W\S7N]% 'G?AI=66STKP_J
M?A-_MFC!(TU&<HUML4!?,1L[BY7L!P3SC%9T%MJMGX.\<Z5)H6IM-=WE_);/
M%&")?.)\O;@Y/4$G& .OI7JM% 'GFB+J>B:RNL7>FWUQ;:EI=K%*Z0EYX9XE
M(*NH^8@Y)W8P#]:H2:#J=L_A;=97+,=?DU&:-$++:Q,'P&(X!^89'J3Z5ZE1
M0!QW@NSN[76_%DES:SPI<:F9(6DC*B1<8RN>HXJ'4DNH_BYIE^MA>2V<>E36
M[SQP,R*[.K $_13^.*[>JTU_:6]Y:V<UQ&EQ=;A!&QYDVC+8]<#F@#S;4Y-8
MF\%Z')9Z!J!O+75U=[:: A@@=B7(!SMP:].FABNK:2":,20RH4=''#*1@@CZ
M5)10!P7P]\-:EIAGGU6:=A:-)8Z?#-_RSMUD;#C/=AM'T45CZ7I&O64=O?6V
MF70FTS7KJ>2R=@JW%O-N!D3) 9@K9'(ZD<UZK10!YY=Z5J.JZEXGUM+":UBO
M-)CL+6(QXFG;+DNR]5P6"\]AGH*JG3]9FN/#GG:5>?9XM+:W<0$1NMQC&V1L
MY"<9!!P3@Y/%>FT4 >1:3I>NVR?#W4&T#4#_ &5'<07-OF,.I>(JIP7  SW.
M.WM5B\\(ZU>R^)3';S17":W#J]DA91'>!8POEELX'(/7H=IKU6B@#SS5-)U3
MQ7XDTO6/[,N+!-+MKN*2&Z*AI)9$4!4()# $?>R!Z$\XQ=*\%^(;;1?AY:RZ
M=MET:]DEO1YT9\M&9L$?-\W7MFO7:* .=\<:'=>(?"MQ8V+1"Z$D<T0E&5=H
MW#A3Z9VXSVS6-+8ZGXC\9Z#K3Z9<Z?%H\=RL\5PRAI'D5,+&5)##Y3DY _45
MW=% '+^![#4=.TW4(]2LWMI9M2N;E TB/E))"PY4GG!YK.U2RU6X^(-PSV=W
M)IATHB%K;:J/*"<B1B02>1M&<<DFNOL=2L]2%P;.X2;[-.]O-M_@D7[RGW%6
MJ /*_#OA37K2Y^'+W&G-&FBVMW'>L98SY;2(%7 #9/3M6GHOAAO^$.US2/$-
MLEJEU=W$T<DCHX4-DJZX)P5QGM7H-<_XC\&:-XJN+&;5H9939L6C5)F16!QD
M, <$<#_)- %/P'I\QT>/7M0<OJFJV\+S-T4(J80*.V1\Q]V/3H*OB;3=3N?&
M%G.EA+<:>^GS6X>V9%99VR1YI)!\O:#@9QNQQG%=HB+&BHBA548 '0"G4 >-
MV-OJ&BZ[\,K>^LIVO[6ROH9+8.I<X106!+;<8 /7/(XSQ4WB7P[J5E%JNOR0
M(]Q?Z]875M8^8L;8B(159N5W,?RZDYR!Z-J/ANRU/7]+UJ9YUN]-WB#RY-JX
M< ,&'<$ 5-KFBQ:[8BSFNKJWC$BR$VTFQB5.1SC/! /X4 <U)IFH:IXGO==.
MGSVZ1Z7)9P0R,@::0DYX#=!M&"Q'7(XYK''AK747X?.-+E+:-N2]C\V+Y R!
M=P._G&.@SGVP,^G*-JA2Q8@8R>IJG9ZM8:A=7=M:74<T]HX2X13S&QYP?>@#
MA/#6D>*O#ELOAA]%L[[38KMYH-5:X0*B,YDYA(+%@2P_+GC-9O\ PC/B66 M
M>://+>1^)8]2#QW,"QO L@;Y5W#G']X ].>U>M44 >?S:!K$4GC:"*P\]=;8
M&VE+1^6,PB,[P6S@$9/'3IFL[5_ VK7OB^W*0;M/7PX-+:Z$B ++E^=I.['(
MY KT=M2LUU5-+:X07SPF=8?XC&" 6^F2!5J@#S3P+X=UG2$TVQO?">E6#6*A
M)M5BDCD>YVKM&T ;E)P,DGUXYKTNBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNZQHSNP5%!+,
MQP /4TZN?\7V>L:CI L=)BMW$\@2Z\VX:$^3_$J,JG#$<9[9H Y7PUXMU!OB
M)=6FI+Y>F:Y +O23G<A*90@-C&615<KGC(_O<]3?^*A:ZU<Z-;:5?7FH16?V
MN-(U"I*,X #D[1SZD?0US_B#P+<1Z7I;^&+:&/4[&YCFB-W>RF.(#[R@8.1@
ME>@X-:5K8>(SXPN=:N;&Q2)M,%M'$E\S9E#;N<Q@ $G&>O&<'I0!6N/&RZCJ
MG@T:,TSV.M//*TBHH+)'&24(;I\V,_[O!-:&C3Z:WCSQ0ENERM\D5G]K:5QY
M9RLFS8.W R3WR/2N5TOP3XFT?1_!9@CTZ34- >X25'G;RY(Y05+ [<Y /2MA
M?!MWJ'BWQ/<:K&B:5JJVHC-M=LLN8,@!@%& V[/7MCG- $GQ UJZM9M#T&SF
MDMY-:N_(>XB8K)%&!N8H1T)Z9[9JSKW@Y9K>PFT:2:VO+*:!@HN75+B-74LL
MW/[S@$Y;))[\TW4? -G/9V8L[NX2\L+HW=K<74C7&UR,$'<<E<=L^]7;)_%U
MU]G34(-,L K;IY;:9I_,&?NJK*NW/J2: &W7C*RMK.XOQ:W4FG6LQBN;M579
M&%R&;&=Q"G /'J><4^[\6V]OJ;V$-C>74JVL=V# @(>-W" @Y]<]<'CH:YU/
M"OB"PLM:\.V<=C+HVI2RR174LAWVXE.9 T>T[SEF(Y'OBM32/#^JZ5XQ2=4M
MGT>+2HK!)&G8SDH2VXJ5QU8CKV!]J %M/'UM>WEW%#I>H-#9W%Q;W$XC!6)H
M4#'...3N Y[>]3P^.M,N)?#PCBG,6O)(UI( IP57=M8 G!(S],8/?%/PEX<U
M>PT[Q)::NMI&-3O[B[B:VE+X$W4'*CIQ7->'/ _BVP3P?%??V7''X?GF#&*9
MV,D,B$$\J/F^8C'% '2V_P 1K*>P743IFH1Z;]L:UENV5=D1#%-Q&<D;@ 2!
M@9Z\5)8^))-1\2^*M.N[>3[#IL<*#8RD%6C9R^>#E@0,#/W1TR:XKP3I6K^(
M? M]H8:U31[G4;E)9_-+2K%YK;D"8ZG^]NXST-=8?"VKZ?XFUNXTO[(^FZM9
MQ))Y\C"1)8HFC55 &-I&TDGGKQ0!'X'U_2K7P/H$>G6E[LOGG2TMGD$DORNY
M8LQP,<'GW J]=^/;2PT2]OKRPNH;JQFC@N;-L;D:0@*0>C(2P^8?T-87ASP3
MXAT'PSH6R2T_MC2))4$0G8P7$$LFYU)V_*V#P=I^Z/6I?$7@K6-;T?5[C%D-
M8U*2U!C\UEBBBAD#A=VW+'@\X'7VH ZRT\113^*+SP_/:RV]Y#"+F(L0RS0$
M[=X(Z?-D8//&:Y[5((Q\9-#P#MGTVX>1"Q*,R,FUMO3<,GG&?R%7XM&U8_$X
M^()(;5; Z2MCQ.3)O\SS"=NW&,DKU[9]JS]?TCQ;-X_L]=TFSTJ2ULK26WC6
MYNG1I#)@DD!#@ J!C)R,^O !U'B#7K/PWH\NIWHE,,95=L2%F9F. ,#W-<\O
MQ$@&GZQ)+IDWV[2%22ZLX9%D(C?HRD=> <C (Q5?6=/\?:WX>UBV\S3-/N9O
M+6S6VN'(V;\N'?8""5XR!^51^#_!&HZ%XFUN[O4TX:=J=I#&;>U!&UU!!&,<
MCYF^8G)ZT =#!XLM;C5=)L4AD_XF=J;J&4_=P!DJ??D?Y%4?^$V:7RH[/3#/
M<7,LXM%^THJ7$4;;?,5^GS'[H[CG.*PY/AQ?'PM9PPWD4.M:;.#I]P@'[F%7
M;;'NVYQL8YXZ\=LU>\5>"IM0T_3K/3[&PG@T^W\NV$\SPRP2  (Z2J"1MP.,
M<^HH W]3\1)!X-NM=LXR62W9X8IQY9:09 0@]#NX_E6<+N7PCH.G@Z?+>ZKJ
M$RB?#;=TS#+L[G(51@@=N !VJ;5?#-S?_#^30[BZ:^OE@&RXD^4O,AW(Q_X$
M!^59-\=0\;^&],6S^S&>WND&K6%X616*@AT8 9(W?,!T; YP: )D^)5DVA1W
MILI!=R:BVFK;>8"AF4\_O0-NW'.[\!6]X>UV;6=/NKF\TV;39+:YD@>*8YSL
MQ\X.!E3G@]Q7(P?#_4K/2M2TU%T:YL+C59+T6DUKA)8W5?DR/]60<@%0>![X
M&]X2\,WVE>$Y=(UF^-YYQ?Y S,((V'^J5FY8+R 3U]!0!SNM^)$\20>%KZVT
M^8:=-K]J;2Z8XWX\P%BO!4<8&<YSV-:UY\2M.M7GN$A2;2;:?[//>+<IN#@D
M,4C^\Z@XY'7G .*H0>!M<M](TO18;VR2QT;4H+JRE>,O)+$N\LKC@ Y88(ZX
MYZU<LO"6OZ)J;66CZK!%X;N))9I(VC/GP,QW$1MT())ZXQ[T 9DT$FO?%O5=
M-U'3(;BQ_LB-%9I03$C,X\Q?ER&/ X((QG-3:'XJTK0M$MXM-T*>"WG\02:2
M(1/O?S,MF1F8G))4]_QKH[;P[=P>/+WQ";N!H+FSCM!!Y1W*$)8'=G!Y8]JY
M^+X>:DEC;0G5;0RP>(#K>X6[8))8^7C=TRQYH TS\0+.VBU==2M)+*[TV6*)
M[=G#[S-_JL,.!N]^G>HQ\1;&RCU!]:BBLELX!/N@NDN1("=I V\AMV!@C] :
M9>> [B^UOQ!J$FHQH-2:VE@$<1W02VX_=DDG##GD8%%WX-UCQ+H%[I7BK6HK
MB.90L?V*W\K:0V0YR3D\#CH.>M &?=WU[??$KPE)?:$; %+DQ3M,'9\Q9V$
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M?/;796Z)DC"R["5&WD#J2<5V_A>?4;C3IY-0:X<&Y?[.]S!Y,C1X'5.J_-N
MSS@ ]ZX?P9H5SKOAO5+";4&BTRXU6]^TVZQ@/(AE) #=@PSGCD'B@#4U'X@7
MEA=7,QL;4:='=6\$(>8K/<K+M'F(N,;!N&#R#@^E7[/QC,GC34] U>.VM!:P
M"YAD&\F>+&2PR,#;@@_2J%S\.+B3^V8X=86*&^G@FA)M5:2'R]OR%\Y*#8N%
MXQSZTW4S#XL\065A:PW@N=,N7AO[Q[1HT:+;AT#D88/QP#TYH ZWPWJ%YJWA
MO3]1O[46MS=0K,\ S^[W<@<\YP15+6-=O(/$FGZ%IL=L;FZ@EN7DN2RJB(5
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MJ[IKHR0 PNC-SF0XPP_A5<GOC'- %?Q1XHU;2O$VD:+I.GVUW/?PSR 3S^4
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MJ : .Y1PZ*XSA@",C%.KC?B0=1L] AUG39[Y7TRX2XF@M9"HGA!^=6 Z\?\
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M9_9<=JDD=LKXGC.3N=_1?Q[5-<ZU:ZIH>H2:)K=@LT*.HN=ZR) XSRXST!%
M&M=6T-[:36MP@>":-HY$)QN4C!''L:R[SPMI%]X9B\/SVV=/AB2.%0Q#1;
MC*W4,,#FIKC6K#2=*@N]7U*TMT,:EII) J,<<D$]JG?5M.BAM9I+ZW2*ZQ]G
M=I !+D9&T]^.: *%MX4TNVO;F\5)WN;JV6UN)))W)E1<@9YZ\GD8J-O!NB_8
MM-M(8)K>+36W6AAN'5HL\$ YS@C@@]JT]/U73]6BDDTZ]M[I(W,;M#('"L.H
M..]&I:MIVC6WVC4KV"TAS@/-(%!/XT 8LGP_\,S:3>:9+IJR6MY<M=2JSL3Y
MK?Q Y^4@8''8#K5'7/ =I/X=&F:9'*MR]Q%+]NENG,L3Q@[9BQ)+$=-O3GM4
MOCOQE%X;\,QW=G<6[75[(D%H[.I4%SCS,9Y4=:TO#4^H3PW,EUJ=GJ=GYF+:
MZ@P&('#JX4;<A@1Q^- &NULDUF;:Y G1H]DF\##C&#D>]86G^!?#^F2VLEO9
MONLY6EM T[D6Y8894&>%/IS_ "J_8^(]%U.YEMK'5;2XGB#-(D<H8J%."3]#
MQ21>)=#GN[:UBU:S>XNE+01K,I:4 D$J.XR#^5 $$_@_0;C3]0L); -:ZC<&
MYNXO-<"60G)8X/&2!P..*EUKPQH_B"U@@U.S$XMV#0R;V62)AW5P=P/3OSBE
MLO$^A:C9W=Y9:M9W%M9@M<RQRAEB !)+'MP"?PK0M+NWOK2*ZM)DFMY5W1R1
MME6'J#0!@W_@3P[J&@QZ-+8;+6&0RPM'(PDBD)R75\[MV3G)-.F\$:%-IEG8
M?9Y8XK2;SXGBF=)?,[L7!W$G)R<Y-7E\2:(UR]L-6L_.C)#*9E&"#@CKV)%.
ME\0:/!J"V$NI6J7;[=L+2C<=V=O'O@X]: ,[5].?2I+K7]"T7^T-;E1861KH
MQ^9&#G&6.T8R34_AG3)K*VNKR]MHK?4-0G-Q<QQ/N"G "KGN0H S5NWU[2;O
M5+C2[?4;:6_MQF:W20%XQ_M#MU%1R^)M#@L(K^75K1;25S'',91M=AG(![D8
M/Y4 6M2TRRU>R>SU"VCN+=^J..XZ$>A'8CD51D\*:--;W<$EJ[)>1K%.3<2;
MG0=%W;LA?8'')]34LGB3188H))-5M%2>%[B(F4?O(U&68>H [U5F\:^&8+:2
MXDURQ$48B+MYP^42@&,GV8$$>W- &Q:6D-C9PVENK+#"@1%9BQ '09))/XU2
MN/#^FW6JG4YH'-X8&M_,$SK^[/5< XYP#T[4MQXATBT=DGU&VC9;4WA#2#B$
M8S)_N\CFH$\6:!))IT:ZO9F345#6:>:,S ]U'?GB@"&'P5X?M[73[:&PV0Z=
M.;BU03R8BD))+#YN>IZ^IIEQX%\-74TTDNF F:87$BK-(JM*&W;]H;&[/?&:
MT-0\0:1I4\<%]J$$$LA ".X!Y. 3Z#)')J&]\5Z#IUS<6]YJEM#+;HLDJNX&
MQ6!(S]0"?H* 'R^&]*FU6YU-[9A>7,(@FD69U\Q " " V.,GG&>:C7PIH:^'
M5\/G3HY-*4;5MI2T@49SP6)(QVYX[5F:G\0-'T[Q)HNC^:DAU-&E\\/A(XPA
M96SCYMV  /?/UZB6>*"W>XED5(47>SL< #U)H QK#P;X>TS1;C1[32H$T^Y!
M$T!RP?/J22?\*CL_ WAG3]'O-)M=(ACL;Q=MQ&&8^8/0L3G]:MVOB?1;V.Y>
MWU&!UM@#*=V-H/1OH?7I7F(^(6IW'AV\\9VNKPBT@:X']E2Q ';@K!R,G=N
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M]>0*TJY^U\::+>7UI912W'VF[A$\$;VTBF2,_P 0R.@[^E=!0 4444 %%%%
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MD2WZZ9+I,.LZ9I^I_8KK6+*9I;M99I9VC+;WVMDJJC SQG:>HQ7M6!Z4  #
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MW-SV&1D]!D4 >5Z+#<Z;\0_#M_-97+6]]X?@M8V2)CMD7)8/Q\G##KBM/3-
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MV\3)E#=,I5L'/0'YL= <4 ;=UX]T>UN+@$7,EG:W*VMU?QH#!!*W 5FSDX)
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MD]0#M]!URVU_3OM=NDL3*[12PS+AXI%.&5A_G/6LW5O&,6G7-S%9Z9?:K]B
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M//3BLVP^'4@\/>'K>\)^V6MUYU^1,3YZ%"A5F[C:L:XZ87'- ":O>7NM>)?
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M7*S1S$_<*GMBH_$.NW-EJ&G:1IJP'4-0+['GR4C55R6('7L,9% '0T5Y_?\
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M, XP"JL,'G.#[5N)K^LV_B#3+2[:V:#5-+DN(@  T-Q&$+ Y(W)A^W/'IDT
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MKB+Q'+K(U6,N^C'2Q&UL2!RIWYWY/W>G7WKM*BN;F&TMWN+B18X8QEG8X %
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M5E+RQN?E12#\B^V6<_5C6;HWP^&CLEO_ &S=76DV[^;9V$Z@I ^<K\PY(!/
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MRTTPQ/%=0ZS?>9]H#*1A8P[]" =Q*]>,\XZ/3/">F:4+18?/>.S&+6.64LL
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M::..;)>,NQ)< CC=G@X.16M?6]RGBGQ'I<.IZJ;.#2DO8;=+^7>LY+C(?<7
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M%Z]TMN-'BF^SS737'E.=P)+,3ACCD#BMWX8LR?"?0F09<665&,Y.36I;>"]
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M)P.G ]!Z"K+Z582?;=UI#F^79=,%P9AMV@,>I^7B@#R[6+1'M='\007%R/\
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M::[IDEC>)E&^9' &Z)Q]UU/9@>0: ..\5")?BWX%DD5 2+U=[#K^Y.!GIU/
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MV7!XR0N.F<'-=1HWBK2=2N8]+BU2"ZU!(=SF,$+(5.URO8X/4#ID5@VDC?\
M"X-9D^RW1AETJ*%)3;N(V='<LN_&.A'>N-TFTN[FX\$ VEW;-Y>I6KK);F*.
MVDDB(2,*.@&#SC) R2: /5(/%FC77B Z)!=A[P1L_"G8<'!4-T+#T%<!XM\0
MW.F>"O%]UI7B:\N+NWU,1C,80V9+C,2G!++U&?;ZYL^%KR==+T3P]/X5N'U;
M29PK2SP.EO$%)4S)(0<DJ<@#).:P->_M*^\">/+*'2KYC-K7FVW^C2[IE9UY
M52,D )UZ<]!Q0!Z1/JT-EKOVJ[UF11%I+3RZ6L>[ # F7.,Y_AQBN;O_ !C9
M>(?A_8:N==ETB1KR'=);0LYW%SMC*Y[CKSQ5IU>?XHQ7$=K<>3<>'FB65H'"
MARX8(6(P#@'AN>.W2N,U.UOIO@QX>TE-,U WNGZA;Q3Q?9'R"I8DCCE0/XNE
M 'J^L>,=%T+4K>POKAUN)RH 2,L(]QP"Y'"@^IINI^--#TC44L;NY82MY8)2
M,LJ%V"J&8<#)8'GMS7&3(=&UKQ'IFJZ%JNIV^LW;7-H]JCF&57C1?+DVD!<$
M8RWK4&O1:E::JLNDQ:C97GF65O<:>+8W-I>P_(#ABI"[,LI;(/';K0!VMCJ=
MQ8^,9_#]Y</.EQ;F]LI) ,A0V'C)XR02".IQWXJ3QK-%;^&Y)9=6N=,"RQD3
MVR;W8[AA O?=TQ6!KMG/>_&GPO)!&[1V%G<3W#C.$5U9%R?4L>GL?2M3XCRR
M1^#KA8(YI)FDCV)#;/.S$,#]U"#T'?B@"35O'^@:'=W=G>SW'VBS@2>=([=G
M*JQP.@Z_RKHK2Z@OK2&[M95E@F021R*<AE(R"*\_U#?)\0=<N?LMXZMX9$(<
M6K[&<,[E <<MAEX&>N.M;OPW:<_#W1DN8;N&>*#RGCNTVR*5)&",#CCCCICK
MUH LWWC31M/U7^SYII3(K(DDJ1%HHF<D*'<<*>._M6#JWB5_#WQ$OY]0NKEM
M%CT6&7R8TWA96F=<A5&2<*>:H-%<V>B>)?#<^G7;7M[=326LB0,\4PE)VG>!
MA<8YSC''K2Z?87_AGQKI]WJT5W?1CP]#I[7<4+2[YUE9B#C)'!ZGB@#4UCXA
M6UMJ'AJ/3HYKNVU4F4R00-+F+;P!CHVXKU]ZV4\8Z-)KD>DI/(9Y)&B23RSY
M32*,L@?IN'I7(>'K'5?"RZ UYI\\B7%U=EX;>+>UOYIW(7(. ,#!XZGK65/I
M^IS-;.VF7D;6GB^*<VT4!$:0[F^=<??SD,6.<;L9'2@#J(?$NB:+KOB^_N-;
MO;E;+R&NX&B)CM!@A53 Y).[/T'ID[&F^.-#U76KC2;:>47<$7G,LD3*"N!G
M:3UQGG'H:X'5_#NLW?\ PLTP:3-_Q-(K9+/:/]>R;PV,GW'MZ5M66D:DOC3P
M;>_8)Q;6FCR07$NT 1NRKA3W[&@#2T?Q-HNC:/9AM3U&\COM3>SMYKM2[O(7
M(P#@?)D<&M32?&FC:SI%]J<$LL<%B6^T":(HR8&<X/.".1ZUQ\>EZG=Z!H7G
M6=],8?$IU!LQ"-EBWR.K;3E@I+*<,6;D@MW$NN:;>?;?B+/<V,WV&]TZW2W<
M #S66-U8*<YZE>M '5Z;XTT;4[V*R26:"\FC66*"YA:-W1LX8 CIP>?:M/5]
M6M-#TR74+YV6"+&=JEF))P  .2?85Q'AR=[;Q1:7FMPWMI=3V4>FVD;V^R+Y
M07;<V3EB1QT  [GFM;QOI-_=W6@:K8P?:O[*OA-+:]3(C#:2HSR5SD#VH MG
MQSH\>CZGJ5P;FW33!_I4,\)25,@8^7J<Y'/2KNB>)+#7Y[V*R,I-FR+(73:#
MO0,,>O!KB?$NCW^O?\)-JMA8W12[T-K""*1=KRREFZ*<8 ]37>:%$T6AV*R0
M-#,MO&DBL &W*H'/Y4 8^H>/]&TW7GT:9;MKM+B"W81P%E#2KN4Y],=33D\>
M:1)JGV%4O,M+)!%.8"(I94!+(C=">./7M5;3M/O9/&?BV62WFA@O(;=+:XD7
M"Y1&4[2I#8!(/4'T([<CX:\,/9_V?HUSX-4:GI]Q%NU:7+6[+&P;S5PP.X@'
M''WB,\4 =+H?Q"BN?#U]J^K6EU:1Q7;0PIY))D!?:BK_ 'GXY Z59U+Q3I&J
M^"-;O6N;^Q@L]\%V8TV7%NX ) !S\WS#\ZYI(=?MO#*:;_95T)(=>+7,T%NI
M8P&1G\R ,2 <[>N< GOR&7>C:E<^#_B!IEKHUY'-?W33VJN"?.#1Q#JS$ELJ
M2><?3I0!UA\:Z7IUU::,L6HW-Z=.%VL0B+RF, #YL\[^>?QS5>_\3Z)K.B^'
M-32_OK>"]U2!;80KM:63>5\N0$<)G.?I6='I>IS_ !0TG5_[.N8[)-%>%Y'4
M#9(<84\]>*Q[/P]K47@SPW;/I=R+BU\3)>S18&Y(1*S%CSZ$4 =G?>/](L5U
M0F*]E.ESB&\$4!)B!&=Y_P!CKS[5>U7Q7IVDR1Q.)YYGMVNA%;QEW$2XR^/3
MG\>U<K=Z9?7.B^/;3^RKT/?7#-;Y5/WX,:J"I Z94]03@]369JMYJT?BK2;G
M2]*U&#4WT,0W?E11S/ K/A2Z%P#M(<C!()[&@#T3P[XBT_Q3H\>JZ8TK6DC,
MJ-)&4)P<'@]LUG7WCS1-/OYK6:60K;W,5I<3JF8X99!E0Q_F>V14W@J.RM/#
M%MIUC;W%NEB/(DBN$"R!\!F+ $C)+;N/6O-/$/A[Q%?#Q,K:+<R33ZQ:SVWV
M=56)H4*Y?@C<^!@ELF@#O+SXC:19W>L6QM=1EDTAD%UY5N2%#9.[_=&T\_2M
M6#Q/87/B"'1XA*TTUF+V.7;^[:,G'!]?\:XJ71M8N=1^(L[:=,B:G:VR61*@
M^:41P0!D\_,*7Q/:WVF>%_"NL6#)9Z[:26UJD<ZG,PDVJT!QGJ?Y9!SB@#O-
M)UJ#66O/L\,Z):SM 9)$PLC#J5/< \5PR>)X] ^(OC+[7]ONH8[>RE2"%3*8
MDV2&1P.RC(S]17=:#I,>A:%9:7'*\RVT0C\QQRY[D_4YKETMM3T?QWXHU-=)
MFO(-1M+;[,8L$,\2L"C9/&2X_(T :EEXYTC4=4TJPM/.DDU2S-[;/LPI0#/.
M3D'VJ"Q^(>CZC8Z9<V\=V6U.X>WMH3%AV=!E@><# !ZFN3T?P=JOAO6_"6JM
M927 M[>YBO8X&#&%IFWC P,J"S#/H!2:1X8N?^$?@TW5_#5Q!LU.ZFMY;&;]
M[I^6!C>-L_,.>">N!E30!T5_XGT;5[?P_/.NJ6PEUA8846,H1<)N 27_ &>2
M<=]OM4VI_$C1]+&HM+;:A+'IMP;>[>&W++$< [B<_=^;@]\'TKGY=(\13>'_
M  LEY!>7EQ:>(4NY&D5/-6V4N 9-N 6PPSWI^J>&M7N]/^(MO%9/OU5D%GD@
M"7]V 2/QH Z?4?'>DZ?-=1E+N<VELEW<F"$L(HGZ$GZ<X'.*DO?&>G6MI<7<
M$-Q?6UO;1W4DMJH8>6_0CD9XYX[5YY'X6U32M<DN[WPE'KMGJ-A:H4)7S+:6
M.%8RK;CC:<<UJ:OX;U./2/\ B7Z9<6&O06J):7>G./*&6+?9W4$ QKPN2.1S
MZB@#J;GQ]I4$NHHD5U/_ &:+<W9B0'R_.^YU//OCI707]W]@L9KLPR3+"A=D
MCQN( R<9(S7F^MZ%K5S>3W^F:9+I_B3,$<>H0.&M[M=HWK.AX" @]L\#!ZBO
M3HPYA43;#)M&_:/E)QSC/:@#"@\76%Q)H*)%<8UN(RVS;1@ )OPW/!Q7)^.]
M;676/"LUO/-%%;>(1:S*K$>;A23P/O =.?6LU_ 6NRZ-K6F1A8%TB\:Y\-2@
M9=,MYNW))R.=F3SZY%:VJ^$]1,7@@6T#3/8ZDM]J#\ AF&7/_?3''L* -=/B
M3HQT74M2E@O8!IUTMI<6\L.)5D8@*-N>Y8?K46L^.T'AOQ3-ID$ZZCHL161)
M%4>6[)E6Y)# =<>U8&JZ3XK@B\776EVCI+>ZE;R1!,-)) H"N4W$@-@?AVQQ
MBO%X4UF2?X@VT>G74,&L6JR6;SR*P=PF"&[[R<]?7G- '=+XIC@M+<2VUS/.
M;+[9)L" ^6!]_&[N>PR:%\::?/<VEM9P75W-<V7V[9"@/E1$9!<DC!/0#N:Y
MF[TN^U'3K.:Z\/W=M?6VF^3975M+BX@F(V<E6 V\@X.1UR.U6=&T[7- \1'5
M;NR:^_M/3;:*Z-O@&">%2.5/56W=1T(Z8H V$\>:1<VND3V0FNO[5\P6ZQJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNE'R 1SR3C!J6+QNZV6O27FDO%<Z/;_:9(H;A95DCVE@0_ !^4Y! (]Z .M
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MG#$C' R..3GT'?'\0^+[S3=<FTNQLH&:VT\W\L]W*8XRH) 1< DM\I^G'KP
M=?6?K6C6>OZ7)I]\)/)<ALQ2-&ZL#D,&!R"" :YR'QO<WEQX;BM-,CSK>GF\
M427&/+;8&"DA3QSC=C/M6=8?$\76C6326")JUWJC:6EN)"8_,#8+;L?= YQW
MZ4 =-8Z/I_\ :4;2:I<:E=Z<,(D]PK&#<,9*J!R0#@L">N.];U>?^"HY8OB1
MX[$\-O%*38LXMR=C$Q.=W(')ZGW/4]:Z7Q!K=QI$FG06]DTSWMQY/GL0(H."
M2S\@] <#N: -NBO.3\3IDT&RU(Z?"XEUPZ1+Y<I*G!;]XG'0[>].UCQ3K_\
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MI&W@\@@'GD\].*WK;Q1J<7C)M"U.SMT633#J,;0L28]K*K1MR=QRWW@%Z=*
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MGAW1]2O+A[I;F1U=G3^(L6+-RQ)SZ\UZS:74%]9PW=M()()D#QN.C*>0:FH
M\YN].U;7/B4FJ7>ER?V;I6FF73EE! -TX!.0&Y(QC_\ 5FN('A/Q(WPDFL_^
M$=NHM4U+61/J$*,-TD6XG(!;@#"KC(_K7N>HZE9Z39/>7]PEO;H55I'Z L0
M/Q) _&K5 'FNHZ/JEW\3_"Z'1Y#H.F6#,LZ'9Y4S*5^;#=@JX _O'KVV+?X9
M>'K#3[ZWLH[I);RSDM))9KN67*N,$X+8!^@%=E68WB+1Q!J4XU&W>+3 QO6C
M;>(-H)8-C.",'(ZB@#@_!E[XI\+:);^%;GPI=74UD6AAOH'5;9USD,S,<CKS
MQ^%7-5TS6[?QMH6MWEM/JJ6FFRPJEJ%VK=L1EFR!A6& ".A7G%=_;SQ75M%<
M0.'AE0.C#^)2,@_E4E 'C>H^ =2LO UOH:VUQ>7NMZM'<ZM+%@I"A?<P[< >
MG4@]L5T?C?0;W4[[POH%A8/_ ,(\+E6U%(D C\J,#8A[XX[>WI7H-% '"?$+
M2]6OG\-6NCZ8L\$6II/<-N 2,(IV[AD$C)SQ_=QWKB_$%KK&@67Q"UJ\MF^V
M:E)'8V=S)M^>)EV[8QSQT'/MW%>WUS/C'2?#5[:07GB4LL-M*IA<SR*J2$_*
MP53@MD\$@T <UI/A*6YU'P\L%G<V>A^';8FUCF"H]S<LN"[#&1C).< $G-8!
M\(^)G^%MWIEQITHU+4M:\^\C#HS/$9 Q)*X'89P!],&O:4QL7!R,<&EH \LG
MT'Q3I/Q NM=@TZVU+&D"TTI(SLBMY 5RK9.5'WCG/.<9]([OP%='3_"OAF6S
M>]M1>MJ&KW3MF,MRQ7J#RQP!CH.<\Y]7HH X#P3HNJVOCKQAJNIVC1I=W$:6
MLK@?/&HP,>W2G?%6P\1:_P"&9M T#2_/:["F6Y>=$1%#9*X)R2<#\">>*[VB
M@#B+6'Q-+_9&D6VER:+I=JJ&>Z^U1/(P0?ZM5!;ANY/_ ->N)O?!WBB\\(6V
MF2:8)Y?^$@>75D$OEG4DW%C)NXVJ1P.1VXKVVJ]_?VNEZ?<7][,L-K;QF261
MNBJ!DF@#B?$GA.XUOQQ_:#P2&QM=&D@501MGE9B54CN!@-VY"UEZ;X0\2Z3X
M'TZ6+R;C7[>&"VCBVHJP6N5\V,;\@LPW98^P&,5W,WBG2K>#199YFC76'2.T
M#*<LSKN4''3L/J16S0!POPW\-7/AW^W<VDMCIUU?&6SLII%=H1C#_=R,%NG.
M< 9KNJ*RK7Q%IU[XAO=#@D=KVRC22<%"%4-TY/7\* ,[QIIMWJEI8P1Z9%JE
MC]HS>6A*H[)L;:R.S#:5;:>.3QR #GF;7PSXEA/A3[3&]U]BU*:ZF,MPCM;P
MLI5(RQQO8;NH'8UW.HZ_I^F:IINFW$C?;-1=DMXD7).T99CZ <<^]:= 'F=[
MX?\ $JZ3XBCM+/#76N"[$2SJ#<VN5WKG/R[@OL>:;/X:UYM,\;Z3!HUM%#?V
MRQV+0SC:Y,>S;R!@#&<FO3JC>XAC+*\J!E0R%<\A1WQZ4 </'I>M+J_@VY;1
MGVZ;:R1W3+=1$1ET"8P>6QMSD'&.Q/3I?%-O=7GA75+.RMC<7-S:R01QAU7E
MU*Y)8@8&:M:1JMKKFDVVIV+,UK<IOC9A@D>N*NT <#I6F:_;3^"H9-(*1:59
M&WO)3/&0"8E3Y0&R>4!Z'@^O3#7P#X@N=/UY0([.].O?VKISR.KJV!@ X)QD
M9ZCO7IFK:O8Z'I\E_J,QAM8_OR"-G"CU.T' ]^E1PZ_I\^C#5XI)GL2-PD6V
MD)(]0NW<1SU QCF@#B=8T7QCK_AFYDELK*PN7$0_LJ&=2)520L^Z8 8W# QS
M@=\DU)<>%]9FD\2LFF6,":GH0M(5CF)990C@(3P,?,.?;K7<Z9J=IK&G0W]A
M*9;68;HY-C+N&<9P0#BHM<UFV\/Z-<:I>+,UO;@%Q"FYL%@,X_'GVH Y72]#
MUFTUOPA,]DH@L=(:SO',JGRWVIC !YY3MGK6]XNT_4-4\,W5IIA3[2^WY'.T
M2*&!9,]LC(SVS6T98Q*(BZB1@2$SR0.IQ3J ."L=!UNRU;Q%*MC$+34=,B%M
M$MP,0RI&4\G'0@DEM_\ M53F\):]<_\ " O);VZ/H$NRZ FR"@78&7CG(0-C
M_:QV-=CXC\2V'A:PBO-1\[RI9TMU\I-QW,<#/H*U9)HX8'GE=4B12[.QP% &
M230!G^(K.[U'PUJ=E82B&[GMI(X9"<;7*D _G7G=EX3UFSUO2-1ETBWM+.RT
M6:UE$=RK,DA!R6X);/MT[D]*[2#QSH4US!!)-<6S7,X@M3<6TD:W+'H8R1A@
M>.?<>HK?8PSB6!BD@QMDCR#P1T(]Q0!Y5X$T_5M:\"^$K:.&UM],M95O)9EE
M+F8I*Q" 9R&W#<V>,\#'03:78W^JP^,-$M+-1:ZAJ$T$MQ+* 8%9 &8KCDG/
MR@ ^^.M>E6&G66E6:6>GVL-K;)G;%"@15R<G 'O3+"RT^V66;3X+>-;E_-D>
M!0!*Q_B)'4^] &!:>%KFR\<VFKQ2PG3[;1O[,5&8^:<.K!CQC^'%8D?@C7M-
MTE)M/O;<:I::K<:A#&&/ESI)G,3$C@D$C/3.*]&HH X+5]&\5ZOHR7-ZEK-.
M]S!++HJ2D0^2I.Z,R9&Y\D$GA3L P1UJ+X,UV:'Q;;[-/MUU.[CNK1S(S*'5
M4X*@9"Y7KU]JZ2R\=Z'J$<A@:^:6' GA&GSL\#8SL<!#M8>E;EC>PZC86][;
MMF&>-9$)ZX(SS[T <W#HVKZCXET_7]3CM8)=/M9X(K='+!I'(!?=CA2%'')Y
MKFI/A]XAL_"VB?V;=V":WHLT\L:D,\-PDC,Q0[NF<X_D1V]1HH R- MM5BMY
MIM7:U2XF?<+>T!\N%>RY/+'U/ )Z 5CZOH&JW?BR6\B%M<V-QIKVX%RY!M9,
M_P  4<A@Q)R"?EZ@<'=NM86UURPTMK.\D-XKLMQ'%NBCVC)#G^'_ !('>M*@
M#SC1? FJP+X*GNWMXI=!MY(9HTDW;\X"XRA[#)Y'L>]02?#W6!H[(KV#WD7B
M,ZW"/-?:5+[S&3MZ\ 9Q7IU% ')WGA:XU#QR-9NTLY=/DTAM.GMV9BS;I Y/
M3!'&*75O >ES^$]8T;1[6VTU]1@\II(X^"1G;GZ9/YU8N_&5E!<W4-K9:CJ(
MM/\ CXDL;?S%C;NN<C+#N%R1Q6EH>MV/B+2TU+3I&DM7=T5F4J258J>#SU!H
M Y^;PG>ZIJ5I?ZF;57LM/DMH(H)&(,C@ L6*YQ@<8'?O6?;^!-3B^#DG@QKB
MS^VF%X5F#-Y>&D+9/RYZ$]J]!HH X2/P9JEGX@T'7+::SEN;#2ETV:"1F5"!
MGYU8*3U/0@5!>_#R\:TAU*PN[6V\41:A+J'VH(3"[R$!D(.3LV!5XQRH/6O0
MJ* .!U3PMXJUC3K"6^O].EU*WU6WOS$AD2V1822$3(9LMGDG\N*/BA<:;J&@
MOH/GRMK,LL,EE!;$><)-XVN,C[HY)_V0:[J>>*VMY+BXE2*&)2\DDC!510,D
MDG@ #O4!M+%KD:HMK#+="+"SJ@+E>N WISZ]Z #2[%-,TNVLX^D,84G^\>Y_
M$Y-<KJ'A#4KGQO>ZTES:36EUIQLUBN Q:W;G#(!P02>>E.@^)FC26<=]/::E
M:Z>T[6YO9X (HW4E2'(8[1D8R1C-=D"&4,I!!Y!'>@#AM&\%:AIL_A*26>T(
MT:R>VG"%_G)7 9<CVR<XZ\5CP?"_4X-.C*7]HNHVFN/JMJ^&9"K$G8W''4<@
M'I[UZE10!RV@>']4T[Q;KFM7UQ9NFJI!F&!&S&T:E0-Q/(P3S@9/.!TI/%GA
MJ^UO5="O[*>#_B6W)EDMKDMY<JE<=@?F'45TDEU$AF16$DT,8D:%#EPISCCK
MSM8#UP?2J>@:O_;VA6FJ?9+BT%RF_P BX7:Z<D<C\,CV(H X2'X<:RMC':2Z
MCI[1P:\=8C*12*6R6)4_,<?>Z#.,=36YJ?@^]U%_%B"\ABAUN")8G )>%T39
MD]B#@'V]Z[&B@#C[CPSK.H7?AF[N[NQ672)WE=8D<AP4*  D\G:3D\<]A6G<
M>#M F2]V:9;0S7D4\<L\<8#D3#]X<^_4UNUF:_KMIX<TE]2O3B%9(XS@@'+N
M$'7TW9/L#0!SOAOPKXCL%M;'6?$$=UI5C$88(+:'RVN%VE1YQ/4 'A5[X)/%
M%AX/U.TTFR\/O>PG1[.X66.52PF9%?<L17&W X&<]!T[UVM% '/:+X?N=)NO
M$%PTT,AU*Z:XC49 3Y< 'CV&:RK?P+,/A=/X/GNH59X98XYH$*JNYBZ\'/ )
M_*NPM;NWOK9+FUF2:!\[9$.5;!QP>XXZTEY>6^GV<UW=RK#;PH7DD;HH'4T
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MZ8)S706GB9)(]9GO["[TZUTN1@T]S&0LJ!<F1..5^E;<<BRQK(ARC ,I]0:
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MGW%M"5,P,94H5' 8,?7G(K,\?>%ET3P[I<=JUQ<W5UK\5[>7*H69I"1N?'.
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M'@DD@#W- &]17C$^L:YIVM^)M(^UWMM GAYKV*.6\>>6&4%%W"1B2"022 <
M]*L>%(;VTB^'^HQ:QJ)CO[;RKFTDG=H7_=9#!3\H/R_4DDT >@>,_$3^%/#%
MSK"6GVKR612F_:!N8*"3Z9(Z5N32QP0O-*X2-%+,QZ #J:\1UB4^(_@[JWBN
M[N;AM0N;A8VB$S>5"BW:J(PGW<8 .<9SWKU'QS;17?@;689@QC-JY(5RN<#/
M4$<<=.] $<OBV"27P\VGQBYL]8D*I<9VA5VE@<=3G%=)7DFD6V_1?AS(9[MY
MII?,>XDG,S9,+# 9BV!P/E''%1R:U<Z-H.H6J:I<)8P^*/[/:ZN;HY@@V(64
MR9RHW%AD$$ ]J /7ZY[4_$<^G^--"T(60:#5(YV-R9,;#&N[ 7OU'YU7\,Z=
M>Z;K%^EWJ_VE9XHY([3SY9A#C(+!I"3@^F>U9GC"26'XC^"Y(8_,E2'4F1/[
MS"!<#\30!WE%>/7$T\/PXL?&MOKMRFNN4:1IKLR([.X$EL$)VJ-PQ@#(V^U6
MH[>'Q7=>)+O4?$$^G:MHVHR?8Y/M.U+&)%!5]F=N&&[<3G(X/ Q0!ZO7/7/B
M&>#Q[9>'A;*8+BQ>Y,Y;G<K8V@?YZ^U<3XIA?5;S7+V&>:Z_LRQANK5YGDB2
MUG"%E:-5QEFR"<\=!]-EI)IOBMX=EN$V3/HDK2+C&&+#(_.@#:\9>)I_#%KI
MDT%FMP+S4(;-RS[1&)&QN]S725P7Q7_Y NA?]AZR_P#0ZY3QW*LJ>(_$&FW;
MW%UI=Q#%%>^8R-8N'5'AB QD'<VXGKG'.!@ ]HHKS'Q?"=#\7MMM99].\46C
MV<\:LP'VM1^ZPP^Z64D>^TGM65X5LGBM(_"VH*8O^$;GN;B\NB&VIG+PR\GD
M,&9O^ '@4 >QT5XYX-MK'3?'FBQWVZ75;C39)(-4@?S(M3C8[O,D+?-OQW.>
M"!75^-;2VUOQ+X=T=XEO'1Y;N6RFQY)C"[/,DSR=I;Y0.I/8 F@#N**\2LI9
MKWPMX$$UQ,-GB.2S'ES.H,2M, .O) 1<$\CL1DU!_:]SX;M/&FF6E[<VFDV.
ML6L",DA+6D$K'SF1CE@3R>YR<CF@#T^?Q+<1?$6T\,_9$%O-8/=_:"_)*L%V
M@=NO>NE)P,FO+=/T32M#^,FC0:-$L5H^A2LJ1OE#\ZC</<@ D]^M;7Q!!34O
M",B22*9=:2U<!SM:.2*56&W.,D$C.,C/!H [C.1D45XK-HEE)XIUGP9J4]NF
MEV.EI_90U+K'&R9DF1CC)5@1GL%(XYK2NI;+4[CPI;:I;OJ]E)I,PC2:%7DD
M=55?M!7GA@ 58'C>#QG@ ]8K,\1:G+HOAS4-3AA$TEM TBQDX#$#UKSRU\-O
MI>E?#][^_GM[ZVOUCDDN;UWQNC?]T/F*C<$5,#@YQ@YQ4ES'I-K;_$BUTN&R
M0A%DF\A@7W-%R&'8;@Q SU+<#N >B:-?/J6B65](JH]Q DC*O0$C/%)>:S8V
M&I:?I\\N+K4'=+>,#)8JI9C[  5YA>Q6FI+H6GW$2W)B\/27*P70#6ZG: '"
M]Y.H!["N9\+V=GJ>H?"V74;:"[::&]CF>X0.76-9?+#$]0N!@'I@8H ]PM+O
M49/$6HVL]O$FGPQPM;2J^7D9MV\$9X P,5IAE8D @E3@X/0]:\D\07%[9:Y\
M0?[,#M+]FL'E;[S)$VX2E3UX3<0!P.PYYM&QT;1/%'A1?##0PZ5J]I/'=QVY
M(6Y@1 RRL1W7<?G)#?-^0!Z>)8RP42*6.< 'DXX/Y4H="Y0,I<#)7/(%>!>%
MK#3H?#WP_P!6C5!J3ZNUMY_VAB_E^9*=@'3'S<CWSSFNCU'3["V\4Q:Q-8VF
MI6]QK\"B_@!CNK:<,%"'*_-&"!D#KG\0 >N4U)(Y03&ZN 2"5.<'TKC_ (FS
M>5X403AO[-EO(8M19'*LMLS8<@_D#G'!)[5F1:#H5AX_@T[2K&U.F:CI;/J%
ME&JM;[48>5(R=,MEAN.<X^M &SH?B+5M<.G:E:6EO+HE])-M=25DBC7(1VR>
M=Q!X XR/>NI>:*-T1Y$5W^ZI8 M]/6N#^#VEV%I\/-*NX;&TBO)HW6>>*-=T
MNV1P,N/O=/6N$^(8L9M0\;ZC%!$;RP2TQ<W17S(9!]P0C&0#W)X;@<X- 'NT
MD\,6?,E1,+N.Y@,#U^E*)HC)Y8D0O@';N&<'OBO)IM+T_4_B!<27UI#<F^\(
M+<7'FKN#R"10&P> 0%'3'2JL-M+8?#KPOXWL;(76HZ-;;)$6/YIK890J2.<(
M.1]#[T >R"2,R&,.ID49*YY ^E,FN8+<J)IXXR_W0[@9^F:PO"]M+.;S7KR&
M-+G47S%A,.MLN?*5C]/FQV+5PT[:+<>+O&%AXYN+>U:Y\I-.>\<(WV8 D&%F
MX^^,X7G<.>10!ZO-<06RAIYHXE)P"[!03^-#3PK(D;2H)'Y12PRWT'>O.=/_
M +.U;X@7]CKL;$2:1"FFV]X<,;=@1,=O9RPP2.< <U@:7'<6>H^ ;O4W_<IJ
ME_!9W5P3O-LR.( S-_>R-HS@@KB@#V075NR.PGB*H=KD.,*?0^AIEQ?VMK:7
M%U-/&L-N"96W#"8&3GWKQGQ)_9\_@?QGY(A:.U\1Q-&58%8G,L08KS\I^9P<
M8ZGU-;-Q86EEXF\:6>F6\,-O+HD<S0PHNQW^?YBO0G'<\\T >@Z'KUGKNA6>
MK6[A(;J,.JNPRN1G!]\5!+?ZF_BBP@M/L#Z/+;R/-(9?WI<$!=@!Y'//'X^O
ME>E6ND3Z-\,'M([,S&Y6*[>%4+%S:Y97('4@)D'G&/:MY=%TOPM\2M&T_2A'
M YT.[C@0D&21MX<#)^\?O$#T!H ],6ZMWG,"SQ-*O6,."P_"D%W;&?R!<1>=
M_P \]XW?EUKQKP_<V]]:>' ^LJ_B*PO=TNG0VZQW?FMD3"3G)3!+,<8.T>E:
M&G31V_B;PV%6+6=+N+VY.G:JA/VB%F+%XY<\L,[\G Z#/(R0#T?7+K4;2*Q.
MG1VSM)>PQ3_:'V@0LV'*\C+8Z#^=79;VT@\SSKJ&/R\;]\@&W/3.>F:XWXF!
M/(\+.P7*^(['#'M^\YK(FTC3+[QWX[2\L+.XB^P6LVR:-''F".7Y\'OSUH ]
M/+*%W%@% SG/&*A^W6GEK)]J@V,=JMY@P3Z U@?#RXDN_AWX?FE<O(]C'N)8
MDGCU/->>7&C2WW]N> +2)A/I=W_:NGSNBL@C;$B1X_ZZ%E/'2@#T#QYXEN?#
MGA*_U/2VM);NT:+='-E@ SJO(!!S\U=)%<PRR20QSQ22Q8$JHP)0GID=J\5\
M22-J_P *O$'B^_2."364M$MHB0&2)9$^7/<EM[?3%=AIMGIMK\47M;2&UBM[
MCP^K- L:CS )<9..&X.#UZB@#I= U*\FT,76MRV$=QYTJ,UM*#$%#L%YR><
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MK.WNXKZ.2WN;D6L,B LKRDD;00/4'GI7+:YKUW9>"_%^HZ9KB7UQ9W$@B(B
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MSG<IVL"",#VP*Z.R\5:1J%_!9V]RS2W$;2P9C8+*H)!*MC!Z&J'C'Q%>:/\
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M6A7-IIUS;7HG34=XM1&I+2; 6?CM@ YS0!H#1]/%S=W'V2,RW:!+AB,^8HZ
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MI')<R1K& JC[JJ.@SD]SD]:WJ* "BBB@!OEH9!(47> 5#8Y /49_ ?E3J**
M(V@B>9)FB1I8P0CE064'&<'MG _*I*** "BBB@ HHHH **** "BBB@ HHHH
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MW$"2*H"D'RCU+-@?UKI/ NEK)\-;32=1LGB)AE@N()4*'YF;/Y@YR/6NQHH
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MD8GL!T'J3T [DU9AB6"".)<[44*,]< 8KD/BI'$_PZU,S!,(86#.F[:?-3G
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ME;BP;<%)V<C))]>>O2I8? =O'?V\TVK:A<VMOJ+ZE%9S>68TG;=@@A ^ 7)
MW>E=8&!S@@XX-)YL>W=O7'3.: .,E^&MA,;I&U34_L\]ZEXD'GX2!@VX[,8Q
MN/<Y([=ZT(_!EL/$FH:S-J%[<_;[46DUI,4:'R@,!1\N[N3UYR<YKHGECC&7
MD50/4XK/O;N]^V:>MA]E>V>X9+MWEPRJ%/"#NVX $=L&@#!M/AW8VEGI,/\
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MJR3PQ,BR2QHSG:@9@"QP3@>IP"?P--FN[:V*">XBB+G""1PNXXS@9Z\ G\*
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MEU&V-K=D3.!*FTKR <9P<9ZUIR7]G%]G\R[@3[0VV#=(!YIQG"\\G'/%4O\
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M7;J0.Q.36I10!FOX>TB2ZDN7TZW,TK!Y&V??(.03ZU*^D:?)J@U-[2,WPA,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/<<U-=^$] U#3K33[S2K:XM+0@V\4J;A'],UKA1'$$B10%7"J. /0>PH \
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M_P S *O)]1UXQR/3O$N]O &KG0BID-A,;4VN,;MAQMQQUK5&E:</M&-/M?\
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M%!X1BN+8^2?$EPUJDPRR6NUQCGD*6]@.1[9O:I!9V_A;X@;88&4:@HM_*0
MML'R[._4''H<]Z]GHH \XOY]('QHMYKZ2R^SR^')-KSE=KG[0O<\$[0?PS7+
MZ/'%I5QHJ01QP6<VL7DNF7.H#;'!;G . >"[-N*=,@Y'K7IEQX8>X\<KXA>Y
M@>#^SFT][1X-VY3('W;MV.HQC%= \4<NWS$5]K!EW#.".A'O0!Y7HQTH^%=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%([K&C.[!549+$X 'K2UR/BFY-_XCT3PTCE4NF>ZN@3Q)!&,%#QSDLN0>V:
M.M5E=%=&#*PR"#D$4T31-,T*RH95 +(&&X#W%<KJ/B>;3+K4--T?1X;I-(LA
M/.IN?)VKM)5$ 5LG"GK@#CFLSQ9J,5IX6@\>6MLUI>6ZQ3?-@F6%B,I(%/S#
M:QQSP<4 >@44R&59X(Y5SM=0PSZ$9I] !1110 4R6:.")I9I$CC7JSL !^)I
M]>>V]W'XF^+6KZ7>>9+8:19Q;;251Y32NV2Y4_>(  !^M '>0W=M<8\FXBDW
M D;'!R <$\>]35R6K:=I7A:^?Q:D:01VFGRVS6L,842%Y(V4C' .4(Z<[NV.
M2'Q3JMKJNFV^M:5;6UMJK[+:6WNC*8VV;MD@*#GAOF''(';) .MHKS[_ (3;
M78;:RU6\L+&'2SJ#V%TBNS2AO.:-'C;A60<9.,G!( Z5H)XMU*Y\576G6EC9
MRVUI<QVLT3W#)<_-M)F52N&0*W0<\'GM0!V-5DU&RDU&73TNX6O8D$DD <%T
M4]"1U -<*_Q U-/#4NI&RM/.BUI=.=0S;3&90FX=]V"/;/Y4DPN8OBQXA?31
M;)>-X?A*/.2J!_,<!F(!)P /RQQ0!Z)17F/AWQ/K\7@CPP&2S>[U4D#4)I'D
MBB&"Y:1?EY."H4-C..>U7(O'VJR:!I=T-/M);R?6O[*G2&4^6V"P9XR<8SMX
M!SC/>@#T*BO'_$WC+Q,W@_QI8S/96FKZ/+&IFM X4P2*""I))W]>>!R*]!TF
M[U.T\&B[U)+:2ZAMFD46SN5D4+E,EANW8P#UYY[X !L7M[;:=937EY/'!;0J
M7DED8*J@=R33[>>*ZMHKB%P\4J!T8="I&0:\PO=;U7Q#\,O$,NJ-I%U!+H;W
M"FR5E,$IC8F.16=CN! P>.G05L^'=>U2SN?#.EWUK:+8:EIX%HT4A:57CB5B
M9,X&"O0+G!')YH [JLP^(M'"Z@S:C;JFG$+=N7 6$D9PQZ"N-T[QSK2^(-,M
MM8MK"&#5+N:VAM(58W%MMR4,K;BIR 3@ 'E3W.,N_ABAL_BRL<",IC#E -H!
M-MDGC/.?FSZ_G0!ZM#-'<01SQ.'CD4.C#H01D&GUA6]W-9^!(+RWB5YH=-65
M(Y')!(C! ) R?K7(Z7XV\3W4OA.66VTLVFNVAX&\2+,$+EO14R5&/F/&<\\
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M1K6".SCDYVF10[2*,8!Y"YZ\"MOQ"FG:']K\72H?M5G9/'@' D&<JIXSG=@
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M_$1Z8LW?@#1;W2(;&=KUIX91<1Z@;EC=+,% \T2'^+"CVXZ=*Z?S$R!O7)X
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MJV,]DNEPB">1)9 ,Y9UQM;/7/'6B?P5X>N4ODETY"M\R/<J&8!RH !Z^P^M
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M^'_[6U"SN#<0[H48,RPQL0P.S!;&3VY&!7K,?AW1H;RWNX],M4N+>+R895B
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M/4\&@#U_Q1K#Z#X7U35(422:SM9)TC=L!BJDX_2I]&OWO]!L+^X"1R7$"2,
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MVED<G@*!FO*GTF;2/$NL^!+'3T32]?*W,,J(,PQGBXR3UQT4=MXQTQ79>/\
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M\C@U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44Q)8Y'D1'#-&VUP#]TX!P?P(/XT^@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1139)$BC9Y'5$49+,< "@
M!U%4[?5M/N[D6]O=PRS&,3;$;)V'HWT-3M<P+<K;-*@G==RQD\L/4#O0!+11
M10 4444 %%%0W5W;V4/FW,R11E@H9SC)/0?6@":BJ5OK&G75S]F@O8'GP3Y0
M<;L#&>.O<5=H **** "BBJC:G9IJD>FM.HO)(S*D7<J#@G]: +=%%% !112
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M% !16 GBVSEUW6=(CMKIKG2;=+B7"KB0,"0$YR3QW K5TV^&I:;;WJP30"9
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MR>(@RQ/.5W;SDAE)!P,=\YKJ?#WP_709EA_MN]N](@F\^STZ8*4MVYQ\WWF
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M(?(*]]^6'UQR*C'P^L[S2);'7]0O-99@J)/<,%>)5<LH4J,YSC).=VU<] *
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M&J[9)$C0@@XSU8\9QTJGX9UCQAXATK2/$-NLQ6XNW>XBDEB$'V<N5V*H^;*
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M^N"IDF9BQR 5! )PIP2,@#(ZT7V@:9J6J6.IW5KOO+'=]GE$C*5#8R" 0&'
MX.10!Y9>WMU'\+-*\>6<UQ-XE6.(>:79Q(6D*O$8\X(R2,8R.V#7L@Y )K#A
M\&^'[?46OH=.5)6D\[RQ(_DB3&-XBSY8;C[P7.>>M;M !1110 4444 %%%%
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MXMY)TLXB[+%MWD<9 R1[?E7F<_B75[2;5=*35[G[/'XDL]/CN6QYD$$H#/\
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M5?'G@8,P!-U<8!/7]V*H>.98?%>MZ'H&D3+<7=KJ$5W=,F3'!&AW?.PX!.,
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MD;<\C'J['NQ/)JU<7,<,)8RQ*Q4E-[8!X_E6#X)\1R^(?!NG:S?^3!->!FV
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MU/L.30!6;PWHCZ=)ISZ7:M9RN7DA:,%78]2P/4^YK0A@BMX5AAC6.-1A448
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M3E#@SQJ1D=B"1CWK9;Q5IT.JZAI]X);.:RM_M3-<!566'NZ$$[@#P?0D9ZT
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M;@V\1D*JT; 9 YQDBL1DGTS0?%_AZ\TF\O6NI9Y;;RUV_;%N.BJ><%2V"3T
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MQG'?WKT?4-+L-6@6'4+2&YC5MRK*N<'U%1V6D:9I D>SLX+;</G9% R.O)H
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M"SDM]D,\3R74C!1D%=H1,Y/WLG X]0#=LO'5O?:O#IT>F7RO<6)O+9Y%"K.
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M>O,X(_=*JL"H W9<@C(_/&C\0ZUXC^(_A2>SO8K2PO=)>^AMY(3)L) #!L.
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M,V4+*,E0.F>_/%0?VWXFU^77&T28J-+9+:%8_+VS7"INDWAADH=Z@;2IXZT
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MAC/G;-Y9F*Y/(W'HP'/4^TQ21RPI)$P:-U#*5Z$'IB@!]%%% !1110 4444
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M>4YPQX^\,D^GM725P^I^,?$NFQ?:9/"=NMH]S'!"\VJ[)'WOM4E!$2.Q(R2
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MR-K$9'//%.O-)TW4+BWN+W3[6YFMB3!)-"KM$3C)4D97.!T]!0!X1I,ND?\
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MJ@  8 ':EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJ*Z$QM)A;$+.8V\LGH&QQ^M %5=:TM]
M7.DKJ%LVH*F\VPD'F!?7;UKD==^(2G1/%;^'_+EO-"7:[2897;&6*@,,A>Y/
M<$8/?G@+2[\#:08UB'B:#4(8KAX\1SF<2#S2>,D$;CZ$'J*SKF"PA@^+<,J6
MD$ZJ3"F%1@GDY&T<<'Y>G4^M 'K>D:S9Z@BVJ7L$M_#!&]Q"C@O'N7()';/-
M2PZYI5QJDNF0ZA;27\2>9);K("ZKQR1Z<C\Z\T::W@\?:5%IT]O%<W?A66.
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MAI8\+/&W!9#GD!N#G'/3(YKFO"OBC3K#PS;160UW56DOI[>&.<(UPVQB6/+
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MC:)+)?-$DJ.KAW8@'&5QM]&/M0!M2^,I-/EU6+5=(GMGL;6.[7RY5E$R.2H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@9JW9>/K+4-%TN^M[67S]1NFLX[9W4,LJE@X)SC VDY':@#K, D' R.AH
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M&!T"Q,< @M%NKB=P&.&8JJJN?]DY/TK@?"WB#4='L)],@A^T:IJ7B74(R\*
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MY0!:'S%;> #TQG\N_?>LM(NW^)6NWEY:*^FW>GQ6\;.NX/@G<IRH&.>F3U_
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MG<D"L>\\)>*X-5\3:I901M]LU*VNHK6&Z$7VF&,LK(S\%6(VMZ'..>17JU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
M,Y.<8[4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-1B
M\:L49"0"5;&1['%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit101-iansconsultin005.jpg
<TEXT>
begin 644 exhibit101-iansconsultin005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZI9/J.G2VJ7$ENTF,2Q
MLRLN"#P5(/;'6KE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%07EM]LM'M_/F@WX_>0/M<8.>#^% $]%%%
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M"8FETK45NKDK,0KH _ XYY<'!]*]&H X;5=2M8OBK86@T=)M072YIHKMI<'
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M96(R2%)./]X#&!5/2="\4^$3<:=HO]G7^BF4O9QW<C126JGEDRJD,N2<>GY
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M#$;5*D':"5X/..]6_"^H>++K6=%N[T.FD7UB#-]HFB/F3E-X:(*=P!&?EP,
M4 =EJ^NV>B_9%N1,\MW,(((H(FD9W()Z <# )). /6F:3XAL=9NKVUM?M"W%
MB46YBG@:-HV8$@?,!G@9R,CD8-8OCC0+K6VTY]'U..PUVS=I[-I1E'&,,K#'
M3D=*YS_A+M1ATOQ''_9UOIWC6VB@64%PT,^6")*I.,+EC][IQR: /4J*\UU;
M4/$^CV&L>9)+;JND33V\TMW%*_G0C)*J%R58$9],C&">(M3F\3Z)HB>*;G7)
M+G30]K<SVD<>UD@*_O0&ZGE@>F<+[T >DWEREE93W<BLR01M(P098A1DX'KQ
M46F:A%JVE6FHP)(D-U"DR+*NU@K $ CL>:Y-M>FURQ\3ZII5[/%96-L]O;2*
M!M>9%+O(N1T&53/LWMC/\/ZO>>(9="TF74[N-#X?AOIYA^[DN)'P 0P/;!)'
M^T.: /1Z*\XCU;7Y-2TWPY-=B\OX;"2>[FL9EB$[^:L:X9AP$!+''?CZPRZW
MXEM-.TY]5AN[B*TEN8-4;2'666,KM,+. ?[A+,!Z].@H ]-JEJ&K66EO9I>3
MK$;RX%M"6. 9""0,^^TCZD#O53PK?C4O"VG78OHKXO" UU$?EE(X+=!@Y!R.
MQR*\]\7V/_":RZMJ%@UX9=*7R--*P.\9N8W#NXV\'.-F>HY_$ ]:HK@KGQA<
M:G\-;'7[9Q8-<R0QW3E23;J7"R$#KD<]^/PK+OM6U9+#QI<Z;KEQ)IEA AL9
MUVR RE3YJ^8022K < \;J /4:*\PM-:UU-$\* W\MY<>(HH926D6)HMMOYCJ
MAVG[Y [9'//<)-KWBG27L]'NUC$M]JL<-NTMTKS+;E"Y5F7HV5V!B.>>N :
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M  Z"GT4 %%%% !1110 57N;"SO9()+JUAG>!]\1D0-Y;>HST/O5BB@ HHHH
M**** "BBB@"I=Z787\]O/=VD,\ML^^%Y$!,;>H]#5NBB@ J"\L[;4+.6TO(4
MGMY5VR1N,JP]"*GHH BM[>&TMH[>VB2&")0B1QJ%50.@ '05+110 4444 %%
M%% !1110!3@TG3[74;C4(+2*.\N %FF5<-(!TR>]7*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9,S0RVKJ"-W!!#*P((XP15'_ (0;2IDU?^T7N-1EU9%CNIKEE#%%  1=BJ%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5#=7'V6V>;RI9=N/DB7<QYQP
M*FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=UK=Q'$R0XC7YHV+-(<*"/<[CP!GMW&@V-W%\1_$\TEK<1P2VUND4SQ,J2$
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M=-EOM1B2%((CB;+%EB)/4%0<L".A[9!W;[QGH]A=RV\DDT@MVV7,T,+/%;'
M.)&' ."/IWQ7 :9#J5IX$\%V%SHFI17&EZI%]J5K)I2$CW;G38&.,L!GC(SC
M(Z[7V.\TS3O%.C26%]<G5YIYK&>.!Y(V$L:@*YR?+(8G.[:.,^M '4W'B_1H
M+Y;(7+37+V9O8HX(S)YL7JI'!SD?G6AI>IVNLZ9;ZC9.7MYTW(2,'W!'8@Y!
M'J*\N\,^&M5T;QSX;AGL[IH['PZ;>>Y\LF)93@E _0X.0/8"NK^&=E>Z?X+6
M&\M)K:X^TW#^5.I1L&1B,_6@#3MO&6C7>J)813OF25H(IRA$4DJYW1JW=AM;
MCV-0MX\T)(Y97GE6"&_.GS3-$52*4!2=Q/1?F R>]</+I.I7FH>'=1;1-5%W
M;:\9+E2H6&&/#@^6@(&PG:=^,GG)[56USPYK-[X#\;V%OIER]U>^(Y9;:/RR
M#*C",!QG^'@_-TX- 'H7B#Q/9VL&HZ?;7+_VC%9R3%H4WBW^4[&?KC)Z=?RI
M? EQ+<> ]&N;F5I)7M5>221LEB>2237,FWU:SU;Q5 VC7LT.N6RFSGB12JL+
M?:4DYRASW/7H,FN@\)V%TGPTT_3YX9+:Z^P>4T<J[61B".1VH R/%/BRUO+?
M3TL+V[A635(H$=$Q%=8;YU#8R0 ">, X[]*WG\<:$FJM8&Y?<ETMDTPC)C6X
M8X$1;^]^GO7%0#68?!&A>'SX=U-KO3KNUBNI-@V!4;/F*<X=3MYQTSS6?J]A
MXENY[F\D\/W8O;+Q%!.5LALAFME8,'"YQ*YXRQ!(VC.,&@#KM-^(,<_B37[2
M^@DM;#39?*6=X2 NU-S,[9P ?X1W_&NATCQ+8:S>36< GBNH8TE:&>/8QC;[
MKCV-<3)9ZY:WWC^&TT)[F:^ECGM#<1*UO,/*5<?,<,<J1CZ9QFK'@^RN;;QB
MEPUAK(AGT=%>ZU#<2T@D)8'<?D//" #CG&* .LU;Q7I6BZC;Z?=R3?:[B-I(
M8HX6<N%ZXP.3[>]4[;Q[H-U8V-TLLZK>WO\ 9Z)) RLD^<;'&/E/U]:P_%UX
MMA\4_!\[V\\ZK:WP*P1-(PXCY"J"3^ K)N]$U%[B/5UTR]1+SQ+!J;6XAWM!
M;Q*%+L@Y#-G=M +<],@T =4^OV&H:_H-Q#>WJ>9!>/%9&!E%QMV@DAL89<'
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M%ZD#.1G%=^K;E# $9&<&@!:*S?$&I7&D:#>7]K927MQ#&6CMTZNW09]!W)[
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M='?4Y/C7<'5K2TM[@>'DQ]EF,BL///.2JD'.1C';K0!Z-1110 4444 %%%%
M!1110 4444 %%%% !1110 5!>6<&H6CVMRA>%\;E#%<X.1R"#U%3T4 %%%%
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MTP -Y%LNZ1AD X'L#G\*KR>(K:/Q8GAWR9S=-9/>[POR;%=4QGN<M0!S/_"
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M9_,@F021O@C*D9!P>14U ''2^$M4E\0Z1JL^K17IM'D>6.YA^4,VT;HESA"
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M^C%PMN5M '8,7VGJ0.#UYXH YW1_!>LZ#G2=/UU(_#HF,R1&$_:4#-O9!("
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAK1H-+M9[J>&%=JO<R[VQV'8  <8 %5KOPAIEUK4FK*US;75Q&(KHV\Q07*
M$!7'MGJN#[T <!J,MWKR?#O4KN\OH;FZNS#.(Y#"&(CDRX53QG&01V(KUT#
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MIO@TTG[TJ %_B^7  ^[CI573_ FC6.DS:>S7MU]HB2&>YGNW\Z5$SM4NI&
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M;.]U<6OV.5S,^'AY^0KNQCD]L\T>'- @\,Z-#I=M=WES#"H2-KN7>RJ!@*,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#YI HP,GVH [&6ZMX7"2SQ1N5+A7< [1U/T%-%Y:M#',+F$Q2D+&X<8<GH
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MX&3$L@+ ?3K7E%O:V=EXB^&=W9K%#=7>FS1S/&0IFQ:J5#?WOFZ9[@>E87A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-#B7;C(90"<J?7..#G&#0!T+6\#NCM#&SQ_<8J"5^GI3?LEMY_G_ &>+SO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#BO&DUU;^*/"+V6F0W=R;JX5';@H3;N,;NR\DGUV\5D2?
M$76[70M5%UI=HNNZ3<PQW5LLC&-HY#A60]R?? X-=CK^C7&HW.E7UC);QWNG
M7/FQM/'N4HRE'7CD95CT/4#.<5SVH?#^>\L]7ECNXHM4U:YAEN)1N\L1Q/N5
M%'7ID'/7)H BO?'>HV%ZFCWD%K:ZO,\DL:&.25%M1PCL$!.68,,?[)-3Z;XU
MU+4+'2VEL%LI);B6WO9[E&2*,H.&3=@L&)7&<=3Z5=\0^%;^^U:Q\0:->V]E
MKUM#]G>2:,R0RQ')*E<YX))!!!YYS4$WA+6)-5TC5)-4AO+JTDEDF2Y5O*W.
M ,QJ#\A51@?4]R: *^G>.K_6M#TC[!90+J^IR3QH'9C!&(3\[L0,[<8Q[L!6
M/X@UO5KW2='N-3T86VH6?B2&! /N38+#>A8@A3[^E7K;X>:KI^CZ0+'5;6/5
MM*NKB:"X>$M&R2YW*RY]"*O7/A'7[I;.>YUN*ZNX]1AOI5D1EA3RUQLB4$[0
M<DD]: +WA+Q/>:SJFNZ3J-M%%>Z1<)&[P$^7(K@E2,\YX.?PIVI:WK4GB2XT
M;1;.U8VUF+F2>Z+;2S;@B#'J0,G/ [&GZ)X<N]+\8>(=9EN8GAU4PE8EW;HS
M&NWDGUS^%27.C:G%XGEUC3;V,)/;+!-;7&XIE22K@#OSCZ4 <AXDUV]\4^!=
M/O+.VLHXGU&""\@NYF7;*LZJ4W+_  [AR<]*ZR[CO]'\'ZQ>PP:?;:L89KF1
M[93Y;2!>'.1DG"CJ.U4I?"%_!H-AIVGW\"R1Z@M_=37",_F,'\S"C/ +8_ 8
MKIM2LSJ.CW=BSA#<V[PE@.FY2,_K0!Y?;3:M=CX<75Z+4W4BN]N8W;!S:9'F
M%AGKR<9_2N@'CR:RTB_&IBT&JVFI)IP2%9#&[N%8$  MPI9B,?PFK-EX7UJW
MM?"ENVI0)'HORS)"&5;E!'Y:Y'3ISZ9Z56N/A_/=#796OHXKR\U./4K"=$.;
M62-0JD@\-P"/3YJ +_A+Q3=ZUJ&H:??VP66V"O%<Q02QQ3HW7'F*"&4X!'N,
M=ZYOQ'_:;_&31U=+#[(-.N"HE:0[XLCS,C&-V.@'KR:Z[0M#U."^_M77]0CO
M-3$+6R?9E:.%(RP8X0D_,2JY/L!VJ"_\*3:AX]M-?EFA^RV]E):>1M.YP_4D
M]/6@##M/&,]MX1C\2:;IUK%X7@FV+ JE9EMU<HT@ ^4889V^@]:N1^--2NM>
MU*TLK.UN+.SCM+M9ED8%[:4,6;! ^8!<CZTVW\!75MX9F\)+>Q/X?D9L%E/V
MA8VDWLF?NGJPSC/-:&D^$#IOB35;W?"+"\LH+**WC#;HTB#*O)Z\-^E &5HW
MQ%EUF]T9[>QEDLM2=T8+;2A[<<^6S,1L(('.#P2.M-F\>:M)IZ:A8V5I+%-K
M1TJ*.1F4A=VT2,WU!) '3O4_AOP3K6@)!I?_  D&[0;6;S+>&.,I,5R3L9P?
MNY/;K7 VUU)#-<:Q::WX>N=0>\FO5T6=7>X,N<*BPJ^!,0H&X)NR<Y/6@#T5
M?$^M:G)KL6D06)DTA8XV,Q?9--MW2*#Q@ < ^O7%,7Q(-3U_P;/'I]I):ZG#
M/)'.YS-;N(B6"]L$<9^OM3[#PO?V=SJ>H:9*EE_;D:S75M<C>UM.4P2I4\]>
M1TR.*LP>#VLKOPH;6Z_T?0TF1UDR6FWQ[,YSC.<GGUH Y23XH:U%X?CUF32K
M18(-7.F7BF1MQ^;AH^,$8(Z]P:U->\?:G:2^)SIEA;2Q>'XXGE6=R&FW .V,
M= %/7GD'BH[CX:7=WX1N=#GU?=YNKG48V*DK$N01&H)X&<D^[$UR>MI'J'CG
MQ%)>^(= L3'-#:QVNL.R^9&BJX!0.H="Y)&X-F@#V31[B\NM+@N+^.".:50^
MV!BR@$9') .:Y?XD:R=%L-'G_LRSOEDU*&(BZ&?*W' =?]H5%X?UWQ/JNL:7
M/<6\:6$T4J7$21D!0,F.<,>S_+A3SAB>U:WC+PLWBNSL+87(@6VO([EB5R6V
M'.!0!SFK^-_$EI-XK:TLM+>'0)8]RR.X:6-D#\$<!L'Z?6MZ]UW6KN:<:!:6
MTL<-@+D&X)W2R.I,<8 /&<<D^M5KWP1-=+XM O(U/B Q_P )_=!$"?CP,_6F
M7'A/Q!;:G;7NAZ]':_Z'%:7,$\)DC?9_&HR,-Z'\Z ,+Q9/<7GCGX;W,MJ;2
M[E-T7AE',;[8N#CJ :M6'Q%U*X\'VVMS6EJ'.LC39D3=@J9 @9>>#R#S6S<>
M!O.UGPW?G4II3H\DTC-.=[SM+MR2>WW>*R(OAM?6^CKI$6J0FR35AJ(WQ'>W
M[Q7VDYXQ@]/44 2>*]:O-;\(^+Q8V=O-::>);1EFY,C*O[QP<X&S((R.2IZ5
M;DU=H/$O@RS6VMKBWO;.4V]]/'MFWK#N("@ )N4 G\1BG77@S4UM_$5AINIP
M06.M-+.V^++Q2R+A\8P"K=R>>36G<>&[BYU?PWJ$ES&SZ/'(#N#$R,\>PG))
M/YDGD_6@#F[+Q[K<EAI.I7=C8)9W6I-ITZH[EPWF,@9<C&/E[]?:DUSXD7UA
M_P );/96-O+;^'9((V61F#3F3&>1]W!SZY]JO0?#^6+PYIVE&^0FTU4ZCYFP
M_-F1GV_FV*XW5+739O%GB&_N_$GAZVFGO CV.J;F+)$H0;HMZA^A*Y5NQ% '
MK*7]XOALZC):B:[%LTXM[<GYSM+!5W8Y/ Y[FN4T?QU?76L:=IUY!:B:]TM[
MTQQ$[K>13_JVSGM]"".E;44=WXM^'TMO>J;*ZU*RDA<JI&W<I7< ><$8./0U
ME:=X'U"TU31KN:_M6CT[3Y+'RXX2NX%0 V<]>,F@"KIGCO5[F'PK?7%I9"SU
MJ8VKI&6\R.7]X<C/&W"#WR:LV?C6^@C\30ZU':VU]I<HCMHT#?OP_$) )R=Q
M*CCH>*?:^ Y;72?#-D+U&.B7ANMQ0_O<[QCVX?\ 2J:0:!XX\>:9KFG9OH--
MCD$TV#Y0E!'E@JPY93N8'MP?2@#IM:U34-'\#7NK2QP?VA9V#7,D8R8_,5-S
M*.<XR",UG/XHU#^U?"=M';P&/6[2:60D-^[=(E< 'T);'3M71:MIT.KZ/>Z;
M<9\F[@>!\?W64@_SKF+7PEJHN_"]S=7]H9-"66+]U"?WT;(J#J<J<*<]LXH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BN?M-;N]4\3W=G90HNF::3%=W,A^:2<JK!$&>  P)8]S@>M9;Z]
MKFD^$[76=1>PO/LTLHU06G(6(.PW(<CYD &1Z@T =I12*RNBNI!5AD$=Q2T
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MH R_ ]U_PD]ZWBF16BECM%TUH'3#12HV91]-V/R[=*ZCQ 0/#>J%NGV27/\
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M^O\ W0_>_P"]Z_C26FCZ982"2ST^UMW"[ T42J0N<XX'3/- %VBBB@ HHHH
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M-L"*L>UFRF<DL1@@ #K4GAFPUE4L] O/"5M:-IJK'+JS[&61=A >$@;MY_\
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M#/!&01_^L9N^%[K5KF>+^T/!T>CRZ=&1=7/D*_G$#&V#;ECG&<C/ISD4 5_
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MMS7>6GBQKCQ+:://HU]:?:[+[5#-/MP2,;XR 2-R@KG!/6@#I**** "BBB@
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M$T46=Q#2;493[#J._M0!Z=17#:UXTU"P7Q#<6UK:/%HQ1#%)+AYBVTY]L G
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M62)0Q1^,$X/(!R*KP>-]6;0]*UB6QM#;W.JM82K!*7RIF,2R*<< $<YZX]Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVL@4(8PHY\LJ-O7..]=+<ZW%;:OI>GBVN91J"R,EQ$F8X]@!^<]L@\?0UJ4
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M,\O%TQ::#YL^5(2>67.*\B\;WVH7OACQ_:WFHW5Q%9:O D D?[JX/RX&!CV
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M0V4R)!<K=0H+N7;#(#D%%W87J>@_D* .+O[R[/A_QWJ<EW<27.B:RUQ9%I"
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ML4MM*542%6?]WNR53(5MOTSFH]'D_M_6? &LWTSI?:CI=P+AHKB6/S?+$;*
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MF(OA;"2X>4+\C[<G.T 8!]J\\T+4M4O-1\-F?4K^6UUJ&?[2SSLBSE3N62(
MAHLY(&TJ" ..:]!T'3[F'PQ;6&JEY9?)*2B24RM@Y^5G_B..">]4=/\  FBZ
M9_91@^ULVEEOLQDN6;:#GY<'C !P..PH \_GN]:70H[6#5-2?6M OY7U(?;F
M#2V:.7RPY!+1E=O'K6OJ6IWCV=[K,6LWMMI^I:E!:V<4!:22:, JPAW<(SG)
M##H%S7<IX;TR.^U6\%N//U5%2Z; RRA=H&<9Z55N_!NE7>@Z=HY^T16VG21R
MVSQ28D1TSM.[UY/YT <4^I>(5^'_ (H=+^\MK[3-2,5IO=9) F(F6.1L$M]\
M@D<X[UHS6VK0^*;?P]_;%W/;W<4VH[I+IHI5/R+Y0=?FV*22!QU&<XYW$\!:
M/'!J\"R7_EZJZR7"_:WX=?XU]&.!D]]H]*M>(?!^C^)X;==1AD\^V(-O=PR&
M.>$@@Y5QSVH ?X9ENET+R;V^BO[FTD>!YT8L6VG@,<#Y@, G'7FN%L-4UK4?
M =QXS&KW1U&VGFE6UA8- \2.5\@QX R0/O?>SSGM7IMC8VVFV:6EI'Y<*9PN
MXL<DY)).2222<FL6W\%:-:74TL"7$<$SF62T6=A TA8,7*@\DD=.G/2@#F(-
M/.H?%YY'O=2M]VBPW9B6Y*[2TIRA']WY>F!WK9\<2:O"UE/8Q7=W80%GO+.P
MN##<.. K*1AB!DY4$?I6ZF@6":_+K@63^T)8UA:7S&QY8Z(%Z8SD],Y)YHU/
M0K35)%G=[B"Z2-HX[BWE*.BD@D#MS@=0: .+T?4FG\0>%/LNL:A>VM[:7R3B
M61ADQE-N],_*Z[BI/7.*AAUC6+&WT[0Y;RX5KK7)[%[YR69H1O8*CN20W103
MG[IKK6\&:/Y&GQPQ26\EA(TL,\+[)-S_ .L);OO_ (O6F2^!M FTF;39+1S;
MR7+7:_O6W0RDYWQG/R$9/3'?U- ',>)HVTS2QI<FMRWHCUJQ>%)9-TT2/,IV
M2/\ Q#.[:#@X Y.*VM#OKR'XB>(-%DNYKFT2"&]B\]MS1-(6!13QA!M&!UZ\
MU<_X0;2!IHLU:\#&:*>2Z-PS3S21XV-([9+8P" >!CI6A#H-I!XEN=>C>87=
MS;I;RKN&PJI)4XQU&3W[T 8'B+4KZU^)W@NPANY4L[U;XW$"D!9"D0*D]S@M
MZXX%<E?:EK5AX2TO7_[=O9)XM<:V,<D@$<D37+(5<#K@#@GH.@]?2[WP]9:A
MX@TW6K@RFZTT2"V ?"KO7:^1WR,?]\CWSFW'@32;G1$TEY;P6J7OVU0LV&$F
M\OUQTW$G% &!9VSK\8M?N$O;E2-+MIRH92I^9QMY!PO'08ZD]:@DU'5K/P1I
MGC.VUJZNKF=[=[BUX>"5)9%4QJF!L*[Q\RX)V\YS7;0^&["#Q!<:VAG-[<1+
M#(QE)4HHX7;TQU/U)JM:^#-(LVVQBX:T$WGI9O,3 DF<[@O?GG!R >0 : .5
MTB?5M0O/%E_/K=]C1M1N8H(D8*K((%PK#&TX."#C(.3WK-T[7]9AG^'\O]JW
M4G]NVBPW:RL' _=[MZ@C&_/<YSG'3 '=V/@^QTZVUF""ZO2-7D:6Y9Y%)#L,
M,5^7C(P/P%1+X%TA&\/E7NE_L%0MF!(.PV_-QSQ0!RD6KZMI?AKQ#87FOXFM
M=4%I:W<V3+Y;D,$4[<M)M)4$CKST%<[?ZAJ]QX+\96%[?77EV5U 8(YIEEEB
M1RI,<CX.2#UYX/&<<5Z3<_#_ $B]LK^VNIKZ8WMVEZ\K3#?'*F-I0X^7@8^E
M/C\!:$@U16CGE74XT2Z628D.5_C_ -\\'/MVH S]3U&ZTOQ5X2MOMUU+;R6M
M[)/"J@M/LC5E^50,D9P !W]:R&U+6?\ A!++QK#KD\UW(8I6MF*_9A')*%,6
MQ5'*[@-Q^;(//:NM3PA9I?Z3>&]U%Y-+5Q )+C<&+YW%LC)SG&,X  P!3+?P
M1I5J_EQ/=BP\_P \:<9<VROG/"8Z;OFVYVYYQ0!R.IZOK(F\?-;ZS.K:0T5S
M;1Q[3M C#E#D'@E3QQG)SD5Z3I\[W6FVMQ(I5Y84=E(P02 2*PIO ^GW$6N1
MR7E^PUK'VO\ >CH.,+\O Q\OTJ[:^&[:TU.SOUNKUY;2S^QQH\W[LIG.2H &
M[@<_[(]* -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .2\=ZUJGAJP@UFSF@^Q1RQP7<,T><+
M)(J"0-G@KGIT.:BU+Q%JNF^/M TF22Q?2=6,S)* 1("D9(3K@@ED((Y/3Z])
MK.F0:UHM[IERBO%=0M$P8 CD=>?0\UXG:Z?KUOX)N?$VI>7<:AX8EBAL8FW#
M:ELY\UB<YPZL1C'15]L 'I-Y=Z]+J_B5H=4MK/2[*V2.!YHU 2X,8=BS9R%4
M,AZ?Q^Q%)#XVTS1X/#^G:KJ]I<7M[:)(]TD@$;_*/W@)ZAFZ8]:K7.G;OA1J
MCRQR/<:C;27DR,WG'S)!NV@@#('RJ/8"N>T5[.#_ (5K/>[53^R B,T9;+B-
M" ,=^">_2@#JO!WBLW^FR-K5];)=R:I<V=NI(C\SRW*A5&>3BNBU'7=)TB1(
M]1U*UM'D4NJS2A25! )Y[9(Y]Z\CN+23_A5NJD6<WVV/Q$\D!$#>8H-VK;EX
MR 5!.1VKIM/D,'B[Q6OBA0T-ZJ"P<PEA):[6RBX'4=2/7F@#NO[6T\:C#IYO
M8/MDT?FQ0>8-[I_> [CWK!UCXA^&])TN"_&I6]S%<7(M8O(D#!I,C<">@V@Y
M.?ZUQ^E/+H!\"W>N>8JHEY$)BC,41QF)6XR#M"CZBL)H[>/18[F6T*6L/CYI
M2SPG$<)E(SC'W>,?AB@#V34-0W^&KO4-,N(7_P!%>6"8?.A(4D'@\BN8LM8U
M2?3/!,TFM6-O->JC7<5SA9+O*9*QCUR>U='JKV__  B=ZULH$+6<@C5$(X*G
M "X_2O,9;>>:W^$\GV>9WMY$$S>4^8\( =V1D<^M 'IS>*O#ZO&K:U8!I+@V
MJ#[0OS3 @%!SRP)''O4T.MZ7>B[2TU.TE>U'[\I,K>5QGYL'BO&!IJMX UUU
MTR1;A?$[2PC[.=ZQ&5""OR@@8!Z =*]$AMM*M_&=]!;6444-YI*;D2W*QR$,
M^<\8SM(ZT 5+'QNFB^&-)EU?5+/5+J^OVM$GM9 (R-YRV2.=J]?>MY-8A/B"
MZN#KEC_9<6FQS-;Y&Y"78F4MGA2N!_GGRO1HWTWP!X+FNX9;>*T\3M)-OC8&
M-"TV"1C./F'YUU6O-;3>)/$_EV]S)!>>&0S!$(2:0&0#C8<R;2@!SP.Q[ '<
M6?B/1M0OQ8V>IVMQ=&%9Q%%*&;RV *MQV((/T--/B;0EO6LFU>R6Y5S&T1G4
M,& R5Z]< G%</###;ZK\-Y-.LS&C0O'<2+;,C!!;;55R<D#< ,,3R!R:QH;K
M3M2MUT[4GBMK2T\0RWDD\]N?GC5GXR !DL0-QR-N: /2/%WBJR\(>&[C6+O]
MXJ+^ZB5L&5NR@_UKG3X\ \>^1)?6Z: NB#4'DXP'\QE)W>VW&/6I?BY#Y_PM
MU98(6E B5E$/8 ]>AX JA%);7_Q%TRZD07&FOH&T,UME"=^2"<<_=Z$<8XZT
M =S)K^CQ:7#JDFIVBV$Q"Q7!E&QR3@ 'H2:M6=[;:A:1W5G<1W%O(,I+$P96
M'L17C@>.T;1)Y+?45T6TNM2MIOL]LV;9GD<PNJA<]"-K '%=_P" [*UL]+O?
ML$=^MG+=O)$]Z^6DR!E@I V+G.!^/>@#$U/Q->>(_$E_H_AK7K:RETY(P@D
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MJA86&H6URRG#+%*&(. >@]B/SKRJYDB?1_B'I=HXMH+'4HIT6/\ U>6VYC*
M?<)3Y@#SD].^UX.U/0_$/Q%U'6K._L#<M81VJVL)W2$*V6D)QQR0N.> .>U
M&WXQ\6QZ1?Z3H=M>QVNH:G.%$[["MO&N&=F#'J1P/<Y[8-O2M<;3M.M8/%&K
M:6-0F8B)XI0JSJ6^1@#C!(*\#C)XKE_B#:6<GQ!\%336T#1K/.;N22,%0A50
MN\^F<@9XS4/^@VMMXQL-;C6._NI7^RQO\QECV*(A"<#(!V\*.#^= 'HUYJ^G
M:=N^VWUO;[$\QO-D"X7(7)SVR0,^]12:_I$,ZP2:G:+*TZVX0S+DRGHF,_>/
MI7F'AK2X+KQ#X?LO%D2RZG_PCX1XK@DF0[R0KCHQ"ACSW!-5=52VN-/^*$L$
M<<DD%[&+9D3+1S;$!V8Y#;QVYS0!ZY:ZSIE]?W-A:ZA;3WEKCSX(Y0SQY_O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %-**5*E1@]1CK65KFO)H\EE;1VTEW?WTC);6T;*I?:I9
MR2Q  "@G\@.M<9XRUN'Q+\,QJEFEW;-%J$"E&)5XW6=4=6VG!'+#T[T >E
M# &!3?+3Y?D7Y?N\=/I7"698?'74D,DAC.A12!&8E0WFD9 / X';_&NAUKQ&
MVEWT=C:Z5>ZC=O ]QY=L% 5%XR68@9)( '4T ;E(0"02!QTKF)O'6G))I:06
MU[<'5;22YLO+A_UQ1=QC&>C8YYP/>LW_ (6GHZ:.U[-:7T4\-^FGW-FT?[V"
M5CQD="..HZ].M '<E0W4 XYYH**5VE1C.<8KB-1\5V^M:+XGTIK*_P!/O[/3
MI9_+N5\MGC*N%D0@],K^!X]:H:/J-BME\-+>^@O9+R>P1[:X5\1AOLN7#\Y8
MX[8]Z /1Z*YA/&D,EU;%-+OVTRYN1:1:B%4QM*6VCY=VX(2"-Y&,X]155OB/
MI(OX8EM[I[.:^&FI>!1L-S@DKM)W8&#EL8STSUH [&BO(?"GBF;0[CQK/-9:
MGJ,-MKDRNT0,GD0AB,Y)R0H'09P!V%7]:OK:7XM^"=1L[II+2]MKARRRL8V0
M0NP8+G&?PH ].*AAA@".O(I:XNU^)&G3:A917%G<V=I?R>3:74S(1+)V!126
M0'D@L #BKGC>]TZRLM+_ +2MKN:*74[=(S;MMV2E_D+'(^7/YT =.R[D9<D9
M&,CJ*XV#P?K*:=_8USXD:YTG?\_FVX-Q)&22T;29QSG&[&>O-+J'Q"@T]M;+
M:/?/%HLR)>NKQ?(C+NW@;N1@@@#GGD"L_P 1ZU-J/BKPI:VVFW%YI-[%/<@H
M\:BXS#\O#,"-H?/S8Y(P"10!W\<4<4*PH@$:J%"]@!QBG    # '85Q-KX@L
MO"NE>3%I^H/H%A(8)-2EE60)\QR<9+LBGC=CC\,U;?QW ?%4V@VNF7EU+"D$
MCRPA2NR4@;P,YVC()/UH ZRBN)N?B58VEF=0FTV]_LV/49-.GNEV$12*^P$K
MG<03Z#I^5:-EXSMKC5-6TZ\L+RQN--A6Y=95#[X6SAQL+>G3K^N #I:*Y:S\
M;6]W>16?V.2.YNM/.H6B-(H\Y!_"<_=;IUXYZ\&N>LO% USPCX<U/7M,OH7N
M]7@^SM#*@3S&F;R_NMDH!@$,!GWZT >E5!>VJWUA<VCL52>)HF9>H# C(_.L
M#4/&,=I=7L=KI=[?1:<1]NGAV*L V[CC<P+D#G"@TK^-+)]2M;&QM+F^DN]/
M-_;-"%594!P%!8C![\X[4 10>&=7GBL[75=>\ZSM&1E6VMQ"\Y0_+YC9(QP"
M0H7)]N*ZG SG STS6/X5\2VGBWP_!J]FDD<<I96CDQN1E)!!Q]/RKF(/$>E>
M&;7Q;JPL-3VVNHA;H2RAR\C;0"@+?*GS+@>AZ=J /0**Y^7Q=9VFN7^EZA#+
M:26MH;Y'<JRS0 [688)QAB!AL$YX%0VGBA-1U.#2;W2;ZR.H6[S6[R$ .@R"
M"5.4;&#CKAAT- %&R\%ZK8Z.=!B\2.='R54-:J9Q$3S%O! P1D;MN[DFN@L-
M L-.O?M<*.9A"+:-G<D1PCI&HZ!1CZ^]<+\/O$,NE?#KPDLUG<7:7\LEN9T<
M$QN97P6W=1QUSGBN@F^(.G65SX@AOH9(3HH1I0I#&57.$V]!DG  )SG\Z .N
MHKS&&[N+CXXPRW%A/;2+H#.D#RABY,G\/. <<$<<@\]ZU/#_ (ITC3_#FBM8
MZ=J2V&HWLT$3,/-,3F5\^8021E@<=<>O% '=45RR>.;*+1M9U#4;2XL7TF3R
M[FW<JSY(!0 J=I+;@!@]3S4MAXM^T^)8_#]SI5W;7SV8O<DJT:Q<#DY!R&(7
M !Y]N: .DI-JY)VC)&"<=J21BD3NL;2,JDA%QEO89(&?J17G?AOX@7)\,C5-
M:L;PR7VH20V$:>63*3*R+$H#9&W;R6 Z$Y/% 'HU)M7^Z.N>G>L31_$B:GJM
M]I-Q9S6.H6>&:&4@B1#G:Z,.JG'U'>LR?7;R[^(D_AO[#*^G1Z<))98I%4[I
M' #$[@P "L/ER<GITH ZX  D@ 9Y/O2UY5\/O%46A>"O#5K?6MR;>_N[BW2^
MWJRB5KF4*K MNR<=<8Y'X=)=_$73;2Y+F(OI:7 M9;])D*I)G;]S.\KN(7.,
M4 =B    , = **R]>U^Q\/6<=Q>O\T\H@@B&-TLK9VH,\#..I( [D5AKX^@-
MCJLRZ9=37.DLOVRUMF65U1ERKH0<," >X(P>/4 ["F[$/\"]<]._K7,WOC2*
M+2M4U.PL9+^RL;#[8+B*51'*<%BBMZA1N/7@]SQ65HOC]G\,:+)?6YEUG4(M
MZ6YFAB\Q1DM)DMA4&,<\YP,4 =[4=P)C;2"V9%G*GRVD!*ANQ('45R=O\1M)
MN;>S=+>\$US?_P!G&$HNZ*XVE@C'..0."#@^HJOKGB_49/".J3Z5IES;ZM;7
M0LV@G,8:%V90KG+88$.I&"0<]<<T ;WA/1)/#GAFQTB25)3:1B(2*#\P]>>E
M;59\NJI9:'-JNHPRV<5O"\TR28=D5022=A8'@9P":P++QXMR;Z*;1-0@NK2U
M2]^SX1FEA;NI!QD=US0!U^.<TF!G..?6N=MO&%O?:+HVIV=E=3IJLJQQ1*%W
MID$DL,X&T*2>>,55L/'UG?ZI9VRV%VEKJ$\L%C>L4,=PT6X/P&W*/E;&1R.:
M .MI-J@@X&1P#BO.-9FTR\\.?$-=/>]M[F$M]IFDD9<3+$""F#D*,+]>>QK7
MD\5_V!IEC;-I>H7SP:;%=7<ENJE88L;<DDC<Q*MA1DD GM0!V 4 D@#)ZGUH
M95;&Y0<'(R.AKSF\UM[+XL2S6\%_>QR^&TGBM( S;G,YYQ]U"0 ,G'2J7B;Q
M1I_B"+P9J5G)<"%M<B@FART;)+D HXR,E6(SU'U!H ]3*J6W%1GIG%+7):I\
M0--TJ\G26VN&M+6807=V"@6)C@#"%M[@%ADJI _ UUBL&4,I!4C(([T !52P
M8@9'?%#*K8W*#@Y&1T-<A-)+XB\?2:?'=XTS1$C>[@4LK27+_/&"1C*JH!ZD
M'< >E/M?B%I=YJ-C!#:WS6E]</:V]_Y8\IY5!RN,[QTP"5&3[<T =8%4 @*
M#U&*3RTV!-B[1T&.!7'Z5JO]C_$"\\)R>8T-S;_VC9O(Y<C+$2)DDX&02/3D
M>E.U^\TB+XA>&K:Z2].I2K,;8QR;80H W;Q_$>F* .O*JQ!*@D="1THP,YP,
M]*Y/_A/;4O&PTK4A;?V@VGS7+1 )!('"9<YZ;B!D<>I'2N5URYF\0?%MO#FH
MVVH?V7'ICR+'',D81RZ?O\AQD ?4C/W>M 'JNQ>/E'!R..E!C1G#%%++T)'(
MKD].\6VEI9V226VH_P!EL5MH=6NC'LE;.T%OFW ,<88KSFISXXL5O+BW:RU
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(JRLF'7.T_*1GKTZ4 <UJ&BZQJ>K^(]1.G) D^CG3K-#(AEF8[B68@X503@
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M+/"P:(W"R\@R 'Y5QC/7VYHG\/ZK<_%.?63921Z;-I#6/G>9'N5V93G;NS@
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M@BLYXK'[3>F<;PKD[51,'ID$DGM6I'X,N;+5-3U+3M8:&\U.*);F62W5\R(
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MH=<M@9W<C'..M9]YX*U47.G:CI'B%;'5;:Q%C/</9B5;B,'(RA88P<D8/<T
M4_MFJWWBSPW<2:=!9:I-H]WYB3J=T3YCQDC.4W ?+G.#71>#M?F\1:$;NXB2
M.XAN);679]UGC<J67T!Q5>Q\)RV&MZ9?IJ3RK:PS).)PSM,\I5F<'=A?F4<
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M^T(!%N'*AA\@(Z9[5UG@:\6Z_M826-QIUZMR/M-C+)O6)MB\QG.-AZC&!UH
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M%OQ'H,,R2)F(7#2$AYE QCH,< C)K2^%:-#\/;" D,D+S1QOG)=1*V&/N>:
M.G;5+1-9BTDR_P"FR6[W*Q@?\LU95)/IRXQZ\^E7*\VUI8[/XNW%[#;QFYC\
M+3SJ0@),BS+M/N>*K3O':>#?"FNZ;>37%])>6_F7&]M]QYS8E#Y))').T\#
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M@)/>2>'7:4LQ;=(!&1D'/.6/OS0!ZG6'XL\0GPQHHU$6HN5\^*$IYFP_O'"
M]#T+"O/M$?5-2LM!\0#5[*VNUNU:^3,C3R.[%7MVCR0!V (^3&1CDUEW%PGB
M#X;7FMZC/(NH_P!OKD>:Y\K$ZHL6,\+MQ\IXR<XH ]QJO:7UM?+*UM*LBQ2M
M$Q7H'7@C\#Q4[*KH48!E88(/((KPKPAJ%Q8_#KPW D0CL]4U9K;4KU6*NB&7
MA21R-Y^7=V!/3.: /=J*XG3XI-*^*=U86DT[:==Z8+N2!IBT<$HDVC8I^[N!
M)P,#CZ5I>,Y-0CTVV.F1VUS<_:4;[%/*(_M2CDHI)ZXYQ@YQ0!TE%>,6NI12
MWG@A]*GU2 R:Q/%/;WCONB&TEH6+'#!3P,Y/XU)?ZS=6UMJ,375Q!93>*K>U
MFE25E,<#89^>J@D8Z_Q>^* /1/&?B1O"7A6\UI;/[6;8 ^3YFS=DXZX./RK8
ML[C[78V]SMV^=&LFW.<9&<5Y-\1+6VL?#/C!+;67N4NK6&==/ )CM &(RI!P
M-Y)., \5I^%5DT[XG/903W)M+K08+R2&2X9T64NP+*K'CIT'3VH ]-K TKQ9
M9ZMXIUG0(HW6YTL1EV8C#AP3QSGC'/U%6_$6LQ:!H5SJ$D;RL@"Q0QC+RR,<
M*BCN22!7EUI8ZGX.\2>&]5N=/DLXYF.GZG<O<)*DQE8LK,>JX<?>)]!WP0#T
M#6?%<VE>([+1(M(FO+F^B>6V,4J*I" ;PQ8C!&1TSUJYI.M75_J=Y8WFDW%@
M\")(C2.KK(K9'5<C(*],]Q7-^)A._P 6?!ZP2)&?LE^0[)N_ACSQD>U;^@QW
M5A?ZG::C>BYN+BZ>Z@QGB';&N,$G;ALC&?>@#>HKE/%UN]WJ6C0H+FX*/)-]
MAAE\I)\!5S(^1A5WYQSDX&*Y#3FO-4\->#_M.J7EE,-7FM#);7A;S8P)<*VY
ML,3L498%AS@<F@#UJL3_ (2)?^$R_P"$>^RMN^R_:?/+#!&<8 ZUPD^H_P#"
M/IXOT:UNKN*TMK^RC25KB5Y+:.>./>XE9B5 .XY/ )-:6G:;::=\8F%H'VR:
M2I):5G!P0 1DG' YQU//4T =Y?7MOIMC->74BQP0J6=F. !5?39&U*Q@O;S3
MUMIW&5C<J[*N?EY'J,'';-<Y\1Y0=.T2PFC5['4-9MK:\W$C$62_W@1CYD49
M]\=Z765CUCQ_::!>_:H["/37O%\FX>%9Y/,";3M(SM'./]H'Z@#K;QC%?6>H
MW5]I#PV^GZJVGS>80YC 53YI & N6YP3@<YKL!@CCI7FO@NVBB\-^/+0%GB7
M6+Z,&:1I"5\I!\S,26X[DFMKX67]UJ7PTT.YO)#)-Y+1ER ,JKLJ]/\ 9 'X
M4 ;OB'5CH6@7FJ"U>Y^S1F0Q(P4L![FKUM-]HM89]NWS$5\9SC(S7E6O0P^(
M_#7CK4+J6;[3:RRVD ^T2((4C"$?)NP"3R3CG<1T.*T;^WFUW7UTLW2I'#I$
M'DV\E\]ON:3?NE0)RQ 51D]"#QSD@'H3WEM'>16;SQBYE5G2(M\S*,9('H,B
MIZ\HT?1A<^,O"]QJ-])?W5MIDT;7D-W(@G:&8!25W98'&23\KGKGBJ^GZFP\
M3^&=6@NK^>RU&_N8Q?-(^RX5PVR,PC@!2  S8(QG!QP =AJ7C6YTFR\2WMWH
M-TEKHVPQ2EP!=@]2OICCUZBNDTR]_M'2K2]V>7]HB679G.W(SC->.:WO30OB
MO ]W?7 B\H(+F=I%C4@D*F[..2?PVUH:G#J9M--NO+N;_18M$C2:&QO/*FL9
M",F?:"-WRCC/]TXZF@#UN2*.9=LL:NN<X89%. "@   #@ 54TV[6\T:SO(KA
M;I)K=)5F1"@E!4$,%/(!SG';->7V%S=>(? VL^+;F_NK;6K2:=HO)N'1(!"S
M!8S'NV[2/O C+9^F #T/5=>^PZE!IEK;_:K^:&2=8M^WY$'/.#R20!5C0]4?
M6-#MM1FLI[%YE)>WN!AXR"00?RS],5YQ%I5KK'Q+T6[NFOEDO='-U*JWTZ8<
ML#@#?E5R?NC ]J[GQO$LW@/7E9I%VZ?,X*2,A!5"PY!!Z@?7H>* &7GBR*#7
MO#FGV]N;BWUP2-%=K( BJL1DR!U.0!Z#GKVKHJ\ALM.@BN?A3$KW++<6T[/O
MN9&(+67.TEB4'H%P!VQ47]KZAIFC7WA^"YE:T3Q)_90NY[EP\4#H)#OEY(Y.
MP'C ([T >QT5R7A'3KK1M1U"PDU."6U94E@L5N9+A[;(PQWR?-M8\@$]<X[U
M5\=M>C4=(>V$MU:Q+.]YI]M=^3/)&4VB1 &!;83GU!P1SB@#MZ*\@TS47;Q]
MX$%EK5_>V=U9W2N]Q(P>555V42J3RRG')[@4^QDUBX\*PC3O-O'MM?G\VT:\
M*O<PJS$Q@LWN/EZ8'UH ]9$,0E,HC02'J^T9/XT^O'GN8=5OO!]IHVNZY:VD
MU[?V=S%Y[))&0COY;!L_,F0H)R0 ,$'D17NLZCH>H:CX5@O9?[-&KVL*7EU<
MR[T28,[1&4'<HRH 8'(#'OS0![-4%Y>6VGV<UY>3QP6T*EY)9&PJ@=R:\KU&
M[U#PE87=D=?BM[2YN[5@T3/</90REE8[Y!RK;#CN,DYZ4GQ$T.WL/"'BXQZQ
M/-#=6T5U#I_F';!M*(6!#<ACDD="3WQ0!ZS%*D\*31,'C=0RL.A!Y!IS$JC$
M*6(&0H[^U>0QB>[\7S^$+2Y,5E9:<KVJ75[,'D>56W2!@27*@Y&>%/(P1QO6
M.G7.HZMI>D:WK[W,FGZ=YA%M.T:WDI<KYAPP+[ @!!SRQS[@'3^%?$*>*-$&
MI);/;#SI83$[ D%'*'D<=JUIYXK6WEN)Y%CAB0O([' 50,DD^F*XGX1Q^3X$
M$6]GV7UVNYSDG$[\DGJ:M^,Y9K^\TOP];AW2[E\Z_CCQN:U3[R\]F;:IP<X)
MH W- UJ'Q!X?LM7MXV6.ZB$BH2"1[9''6L/3/%__  D4E]##X7U%WT^X-O.D
MY@4JX /&9/0CFLKP+=S:/XMU[PK=B2*+S/MVF1/$$'DM]\+M&,!CTSW^M5-&
MLM7OKWX@0Z3?PVLKZDZ+OAW$L84QAMPV_D?6@#T'2-175=,BNUMIK;<64PS
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MRXT[^T(;V%[3=M\U6XW9QCZYXQUS0!FWVB7&I7]I:F."VT2Q=)5BCX>5U&5
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M& .O:NFL;.'3["VLK<%8;>)8HP3G"J !^@J)M6T];J2U:[B$\47G/'NY6/\
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MT]J27P3H<P3-O*K+:+8LR3NI> =$;!Y')_,U,_B;1].M<:EK5BLT$"R7#&0
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M ^5;:Z;<%#ZG!%:GABZU*[TMWU*2VG=9W6&ZMB-ES%GY7V\[#R5*Y/*YSS0
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M[2]5^..F.+BVN+.;P^Q.Y@58;W89!]N>>W-=%\*;JWNOASIOV>6)Q$98F$;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH7M[1[[01'+<8!VSV[C/FKS\K *YV\U-<>/A;>,DL&D632[K37NK:=(_NRA
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M!6HEQ')<2P*V9(@I8>F<X_E0!+1110 453LM4M-0N+V"VDWO93>1,1T#[5;
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M F-M^XJWS?.?N\GC@\<UVNOZS<Z3)ID=M9?:#>WB6S.S[5B#9.X]^V![ULT
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M>!]3CUJ2]\->(#H\5W$L5[$;<2[RJA5=,D!6"C&?85V]% ' 3?#19KO6-U[
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M ]AC''M5V#6!/XAN](^S2JUM"DQF)&U@Y( '.?X36E0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Q'C;]UXJ\&75Y_R"(;^3[2S\QK*T9$!8>OF$8;L>XKK-1-@;39J(A>W=
MT39*H8,Q8!1CN=V,>]37-M!>6TEO<PI-#(-KQNN0P]Q61IW@[0=*NX[JTT\+
M-&NV-I)7DV#K\H8D ^X]_6@#BW>YUO0?$VN/=WD6K:1J%REIY=PZK;B-1A?+
M!VG*DYR"3N//HRRM&\9>(([7Q"+E'NO#5O+=V:NT021G)/R]5.X=/89SBN[O
M/"^C7^H/?7-EYD\FWS#YCA9-OW=R@[6Q[@T2>%]'EU:XU1K5OMUQ%Y$LRSR*
M2F,;>&P!].AYZT ><V^H:W>?#GPQJCPW.H""VE-Y9P73VT[A'55D4J1EDV\@
MGOGDXK5T?5I;SQ9X2%OJ5]-87NAS2LLTS?O"&7:S#."PR1NZUU'_  @_AP6=
MG:KIHCALE=;<1S2(8P_W@"&!P?3-6KKPMHE[:V%O<:?&\=@P:UY(,1QC@@YQ
MZC//>@#SU=0FE^%=C)<WL]Z[:\L(G>=B647I"Y+<L  !CZ>E:MYI%KI>L>,M
M2AOK^T?[&+II%N92J2&-P7V9VM@ 8!SC QCBNED\%>'9=*BTQM,0644YN$B2
M1U D)W;N""3DY]JM7'AS2KK4KF_GMA)-<VOV28,Q*O%SP1T[GF@#SO2!?:5X
MDELO.O+..[\-27D\,ERTLPF1U42%G)"M@G[IQ^0K,L8I]/\ ^%;ZG!=WLDNJ
M1BQNYI)F^:%TW!,K@#!R0>N><D\UZ2G@7PZC696QQ]DMI+6'$K B-R"1D')]
MCGC)IX\$>'0FGI_9^5T^0R6F9Y#Y+''(^;V% '*_"+3[:*SUV>.2Y+)K=W&@
M:ZD92H*X)4MM)_VB,^]7O$-L]Q\5?#LGG2JEM8W4P'F$(AV[-Y7!!^_CMVYX
MP>GTSPWI&CWU[>6%DD,]Y(99V!)W.222,],YYQ3;SPOHU_K<&L75D)=0@4I%
M,9&R@((( SCD$]N] ' ^"S=Z7XLL=-U5KN&]N()IA-%=R36FJ9"DRC<QVNHQ
MT'\1]!6QX\/]H:]H>AK=32&Z+M)I\,K1>8@Q^\D=2"$7T[G'I71Z5X2T/1;M
M+JPL?+G2(PH[2N^Q"02J[B<#('2I]5\.Z1K<UK-J5A%<2VK[X7;(9#]1V]NE
M 'E6DZWK,GPLTKQ9/J5Y--I%X?M,:SLOVFW$FPA@#AB%.<L">.35A]4U&77M
M1TN%KNXT[Q-%NTJ6>XDE4$.!($R2%786D' X'T%>D6'A;1=,T2YT:TL4CTZY
MWB6W#$JP<88=<C(JVFD:?$FGHEJBKI__ !Z8_P"67R%./^ L10!XMXS:?3/^
M$BU#3KG49#H;VZ6D\US*([5U10T: M\Y(*EB1C\ZZ2VMQKWQ>OK6ZO+PPP:=
M97JQI*559D?(P.F,$Y_WC76ZIX!\.:O<:G<7>G@SZG"L-S(K$%@O0CL&Z<CG
MBKUEX7T?3]5_M2VM-E\85MS-YCDF-0 %P3C' [4 >::3=SZOH-OXKN?$$%CK
M-E=;;UY993Y ,NUK=H,D*&& !@'.#G-=OX]U&>PTRPB26:VM;R^BMKN\AD,;
MVT39^8,.A)"KG_:K07P?X>7Q ->72+5=4'2X"X.?7'3/OC-:EY96VH6DMI>0
M1SV\J[7CD7*L/I0!Q*:>-%\<6&@6,U\-(O\ 3YY9H?M<IV2*X.]7+;E+%SG:
M1FH/A)'8Z?\ #?2+N2ZDB:X+Q#S[M]A<S.%559MH)/' !-==I_AK2-+21;2T
MV&2/RB[2.[A/[H9B2![ BL'5_AOH]UX;.B:=;K9P/*KAC)(_D8)):,%L!N3C
MMDYYH W_ !-<_8_"^J7/VM[3RK61_M"+EHL*?F ]1UKSW1FU*SU2^A:[NH+>
M[\.F\W/>O,[2JVT2EV+;6*;?N\ 8]!7J%U96][82V5W&)[>:,QR(_.]2,$'Z
MUD6_@S0+66"2'3XU:&U:S4@GF(XX/KTX)Y&30!YKH<]WIFH_#.:.\G9M2L?(
MN \S,C1^5N "] 00.<?G27UI;^(/AY+XIEO[QM4EOHEN%%TX"*MRJ"$QJV%
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MH]L)3,)P<$A9 <AE7.%.3V ITW@WPY/KZ:[+I%LVIH0PGVG.X9P2.A//4C-
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MDG@;O<]>W'2N;\/>"(+J^OK[6](NK:9M1DNTC:Z!AF4D%-Z)(P8@C.#QG\J
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M6.V\+;U7>?+C<@@LJ?=!.3SCO3)O .ASZ*VDR+<-:M>?;6'G')EW;LY],]J
M.$\;>(=7@_X2#4M)UN5VTN2V $$A2.SW;5='0C;*S%B><[1Z&M'Q!J5[;>*'
MN[Z^U!M#>:)8-1TV\VP6AR (YHU/S98C).>&%=-J?PX\-ZK/J4UQ;3!M16-;
MD1SLJL4((;:#@-\H&>OYFI+GP!H=U=Q7$@O,(8V>$73^7,4^Z9%SACZYZXYH
M Y*RF\2>(WU^_@\01Z?=Z?J31)&\C[+>!,$J\6-IW#<=Q!/(P1C [/QEK5UH
M?@35-7L@)+F"U,D9"[ADX^;'H,Y_"F77@/P]>>)AX@FLB;[@OB0^7*0, NG1
MB*Z*6&*>%X9HTDB=2K(Z@JP]"#U% '"7UQ=>'=6T*.TU6\O$U@31RB>X$GS"
M,N)D#<*JXY"_+M/ ) S>\!Q:A>:+I>M7NLSW;SV BEAW!H7D#D^:IQG)Y'N"
M/08T--\':5I:;83=2%(FAA::=I# C=0F?N__ %@*T-$T>VT#28-,LVF:W@&(
M_.?>P'IF@#A?'-_K>G>('N_/U$:*D"HL^F.#]AF&2SSQX^=2&4@'( '3N:/C
MG7M3L)=5OK"_O)'TU;=@\,ABMK8$KN64<B1F#YQC@8/'?M=5\$Z3K&HW5[<-
M=H]Y EO=)#.429%)(##\<9]*AU+X>^'=6NM0GN[:9CJ$2QW"+<.J-M  ;:#C
M<  ,^PH Q_$.K3:5JWBZ]LI?]*M-'@<;CN$9S*0<9./7D ?7K5_1K;5[75=-
MNY==6>ROXW:6WFFWF20H&5HLCC 4Y4';CD#KG4'A#3?[:?5#)>/));?9'A>X
M9HFBQC:5/7USUS5;PUX T#PG=RW.EP3"20;5\Z9I!$.>$!^[0!T]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$I%(ZL0$7<!D@#)Q5B"^LX?CCID2SVP,OAV.,89>7WNP ]R,'UP: /4J***
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MX2'B9IR-,, G#D8)4]!CU[4 3>&]%;P]H<&EF\ENU@+;)90 VTL2%X[#.![
M5JUR]CXNG:]\C5])?3XY+(WT,ZR^:GEC[RN=HV.!@X&X8/6H-)\</J%UIGVG
M1I[2QU=-^G7)E5_,^4L%D4?ZMBHW#EACOGB@#KZ*\YB^*P%E8:A=^'[JWL+G
M4I--EE\Y6:"0$A,IU;.TYQPO8L>*W+/Q=>.VOI?Z#/:3:5&MPD0G5S<0L'VN
M"<*O^K;(R<8- '545PUA\1OM-QH:W&B7,$.M6:SV<J2*^^;;N,6.,<=&. ?8
M<U$OQ-'_  A=_K\FBRQSZ;>_8KZR-PI,3"0(2KX^;!([#O\ 6@#OJ*Y?4/%T
MNG>*KO1I-,\V.'29-42:*<;W".JE"A4 ')/.X]/>JFF^/7O;SP\)]'>VL=<M
M5EM[HW"MB4J7\HJ!G[O\7&>>.* .P26.4N(Y%8HVUPISM/7!]^13ZX+3_$NE
MZ0GB>\M]+GCE76?LK1^<"]U<-M0$ \*"2._3GKQ5T^._L4.LQZMI,\%_I81F
MM[5C.LZN0$,;E5R2Q P0,?3F@#L*:SHA4,P!8X4$]3[5YYK'Q U2W\*^)I$T
M9+?6M&CC,T'VK>B)*NY9 ^T9P,_+@'(JX;^&23P4NLZ;=2:G-*_V>:21/W;"
M)LR/L.,LO.!Q\W;% '<T5QUWXYDMC/?II8F\/VMQ]GN=06Y >,@[6<1%?F16
M(!.[.,D XY;>>/9/M&L0:3HDVHR:;;070Q<(BSQR[CN4\\!5SZDG&!UH [.B
MLZSUNRO?#T6N)*!8O;_:=Y[)MR3^ KG[3QQ.+^T35]'_ +.L-1?9IMV;M9//
M)QL#K@>6S C R>>* .O:1%8*SJ&/0$\FG5X]X0BF\:>+O$3:[IDKFQU-7M[E
MIU#V1BP8XUVGODDXXXZG-=QJ7BZ>Q\03V$&D->6UI'&]W+#<IYT6_.TB$X++
MP,G(ZG .* .IHKB)_'E[!8>)ICH#-<:!<!9X5N<^;"5#^8AV9SM.=I &/XO2
M]KGB^XL);FVTC1+C5KRTB2XN8EE$2QQ,"003DLWRG"J#^% '4;EW;<C=C.,\
MXI:\UGOP?B?;ZSINGS7=Q<^&FFCMBPC>3,R8^]PO&,_H#78^%M?3Q-X>M]46
MW-L\FY9("X?RW4E67/&<$$=!0!L ANA!P<<4M<%I'BG3=,M7EAT:_MTU'Q!)
M9L)&#,MP[ .S\_*-VX +N' Z9.+4OC&\FT77V_L:XM-0TZ,L+=I8RX5D++(Q
MR%'N 2>.] '8B1&<H'4L.J@\BG5X]X*N-/M?#OA[Q%=:/>2^([F-H;>431JV
MH/(6+9^?E1C)+@8XP#777'Q$M=.T>^NM4TVZM;W3O*^W68*N85<@>8&!PZ<G
MD<G'2@#LZ*Y.3QE<P:LFG3^'[R.::\FM[8F1<7"1QEPZD\?-P #@#/)XQ5,_
M$&>#2K2_O?#MW;1BZ-MJ.9 19'=MW9P/,&>X P/PR =Q17(>)?'2Z)<S6]EI
MKZD]I;K>7A681K#;DXW D'>W?:.H[U#_ ,)-JEW\0+:PL].FFT?[ MR9HIHQ
MO\P@!L$\J/8YZ\$8R =HK*V=I!P<'![U2U;3$UBP>SDN;FWC?[[6TFQF7NN<
M=#[<UP?AGQ-HNCZ3J+:;I-["]SK,]K;VLLI>2ZN>K>H09!ZG ZDUJO\ $2*R
MTK59]6T:]M-0TJ-)+NR5DD.QNCHV0'0=SP1CITR =G'&D421QJ%1 %4#L!3J
MY^Q\4+<^(5TFYL9+0SVWVFREDD5A<J,;\ =,97@\D'H*SKWQ1?1?$.+1(]-N
M7M8K0S2/&\7[S) W?,XPJ\^_7B@#L:*X]?B%9M;_ -I_V=>?V"9!"NJ H8RQ
M8KNV[MVS.,-CG/0#D['B#Q%:^'[2WEF1YI;J98+:"+[TTAR0H)X' )R>.* -
MBL33_#JZ?XFU36DNG<ZBL8>$H,+L& 0>M8C_ !$2#0+Z^N=)GAOK"]2QN+,R
MJVV1MN"'7(*X;KCJ",=ZG;QU]GN_$<%UHMXK:-$EQY<+I))<0L#\ZKD =&.,
MYP/7B@#KZ*YR/Q?!=Z/H>HV-C<SIK$J1PQY0,BD%BS<D<*K'@GI^(LZUXD@T
MF\M=.CMY;S5+Q7:UM(BJF3:,DEF("@<9)_(]* -JDWKOV;ANQG&>:X76/&%_
M>^';F/1["X@U>.\BL+N-FCWV+R,JAP"P$F=RE<$ @Y)7FN?N]0N;+XT7&I0Z
M1<S7?_"/L19&1 Y/FQCE@Q4#N2">/4\4 >MT5R<OC_34T72KU8I/M.JQL]K:
M22)&Q*C+!F9@J@9&3GOQGI4#?$G2S::3/#:W4O\ :%VUF5503!*H.Y6P2"<X
M QP<YSCF@#LZ*YG4/%S:7X!;Q-=Z3<I+';B22P)PZ/T*DD< 'J<=!TSQ26WC
M>SDUC^S[NQO;#S;=[FUGND"I<(@!?;@DY4'.".G- '3T5REC\0-(O]0L;14F
MC^WAOLLC21,LA W8PKEE)'0,!5#2OB;::II2:LND7\>G,LI\]@NU660(B$YP
M&?(QS@'@G'- '=45S4GC.VLK*6;5=/O=/FCGCMEMY CM/*XRJQ%6(;OZ=#G&
M*<?&%M&^I6]S87EI>V-H;TVT_EEY8AD;DV,P(R,'TR* .CHKE[#QQ8WNHZ59
MRV=Y9G5+5;BT>Y0*)"4#F,8)^8 \Y].,U?U;Q"ND:GIUG+IU[*M_+Y,=Q%Y?
ME(^"<,6<$< XX.>@R>* -FDR"2 1D=1Z5RA\?6,=AK=S/INHP/H[JEQ;N(C(
MY.,;,2$'.1W&:YC3-=C\/>+O'FIRV-\\"M822QC#/ K0LS%ANX R3@9]A0!Z
MG17,:IXULK*WAEL8'U#S88[G,4L<:"%L$-N=@,E<E5')(QQU$*^/["Z-DNFV
M-]?/>6<MW"L46,A"%*Y.!G)(Z\8]Q0!UM8FJ:$^H:S9ZI:Z@UM<V:21 >6)$
M(?&<J>_ YJ7PYKT'B318=1@C>(L6CEA<Y,4BG#H2.N"",UYYJ?B'^R+#Q9-X
M9TN^BOY-8CMYYRPD;>Z)F1(F8<_-M"\9X.1V /0=*T"/3M1O=4GN&NM0O BR
MS,@4!$!VJH'0<D]3R:UP0P!4@@]Q67=W:MX9O+G4;.[@B6VD::$E/-VA3G&Q
MB,D9QS7.:3XKTW3M!T>TTG2+^>-[!KN.VB9#)';J<9.]AN.2!@$]?ID [BBL
MK4]<BTWPQ/KC6\KQQ6WVCR>CGC(4^A]>M9'_  G4$222W6G7,,,CQK8ON4?:
MPR!BPWE0H4Y!R<< YYQ0!UE85[X?N)_$*ZS::K-;SK;&V$3QB6,*65B5!QM)
M*KG!YP,]!BE;>/\ 2;NU9X(;M[E+[^SVLPJ^:)\$[2=VSHI.=V/>FCXA:2NF
M/=SVU];S+??V=]CFC43&<Y(088KR!D'=C'<4 ;6EZ2;">ZNI[E[J\NBOF3,H
M7"J/E0 =%!+'ZL:TJYQ?&5KY,HETZ_@O$O/L26,@C\Z638K_ "8<J1M8')8<
M U6N_B!IEAIVJW-Y9ZA!-I8#7-HT2F4*>CC#%2I_O;L4 =917+6WCS3)M9N=
M.FANK;R[/[?#/*@V7$'&73!SP2.#@_K4>D^.-(\2S6VGB"]MCJ=HT]IYX5?M
M$7(8J48E2/0X/(H ZP,&&5((]11D$D<9%>9_#WQ18:3X4T/39K2Z2&XEEB2]
M"EH#,9I/D+,=V\G.>-N<@'&*DTWQ OAV^^(&K7<%Y>6]GJ,9=(,.Z)Y*9(#,
M!M&23SP,T >DTA( ))  [FL9/$<4EUH]NMA>&35(GG3'ED0H@4EI"'X'SJ,K
MNY('>N9\>:FS^(=#T"XT>^N["\>1Y?L\J+YY5>(\;U..<G) XZ'/ !WX(8 @
M@@\@BEKA].U_2?"FA7%E866JWFF:1+)'<7$<:NMJ-Y8J26!98PV#M#8"U:G^
M(.GB_O+&QL+^_N+:TAO +>-2LL<K*%*G.3C=N/'0'K0!UU%<G-\0=(MW222&
M[%@]U]C6_P!J&$RY(QC=OQN!7.W&1U[U.WC*!-2@M6TK4Q!/>O8I>[(_),JD
M@_Q[@,JPSMY(H Z6BN6@\>Z3->:?$\-Y!;:E)Y5E>RQJ(9W[*"&)!)X&X#)Z
M4[_A-[-=2LK673M1B@OKMK.VO'1/)DD )P,/NP=I )7M0!TKQI(A1T5E/9AD
M4H(.<$''!KE(/B%I-Q>V$26][]DU"Y>TM;\HHADE3.X?>W#E6&2N"0?K7'^#
MO$]KX8E\7OJ$=\]G%X@FC>Z"F1(%R%4N2<XX XSV[4 >N<=**Y%9UTGQMXBU
M&\E=;---MYB2Q8*%,FXA<<=.Q.?;I5VP\76MYJ]OID]C?V%Q=PF>T^UQJ%N%
M'+;"K'D#!(." PXH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .?\4Z;<:G'9P"PBO[+S";F
M!RJL./D=&)^5E;GCG\N>4G\+^)[73-%N;6*WU"\T^:=&L]0G$GF6TA4[#(5^
M^-B_,/UKTLD#J<5EZ?XBTW4]8U'2K29GN].V"Y0QLH7=G&"1S]T]* .0OO#O
MB4II6OVEIIR:U83S.FG(P2$0RJJM%O &6^4'?CKGC&*EU#1?%.I:=:7]RD U
M"'5;>]&GPW'R1PIG<@?C+G<V3T/%=]1D#O0!Y/KG@?Q%J+>.YX[> MK<%M%9
MQ^: 1L^]N/08R?KBMSQ;X:UC4_!GA_3;")6N[.ZM))OWH4*L8^8@]^F/QKO*
M* /.8_"^O6^M>.76T@DMM=A MY?/ ((A90"#[L/;BJK^#]>TJ+PSJ5AIVGZE
M>6>DPZ;?6%VX53M0?,DAR 0PQT.17J%4]5U.UT72KG4KUG6VMD+R%(RY ^@!
M- '$W?AC5[ZTBM]5TVPO(GAF?_1-L#V<Q=3&L;C!QMSD]20.G2M>STGQ!;_#
M=]+GOS<ZV;-XUG<C(8@[06[X! W=\9KJ(95G@CF4,%D4, ZE2 1GD'H?:GT
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MI,;8HD<;2NK*B* #A0N,]^M=K69!X@TVZUZZT2"9GO[6-9)XPC80-TR<8YH
MRO FDW^C:+=6VH6XAD>_N)T'FB3*.Y8<CZUS5[H'B1+/Q)/#I<<LLVL1:G:0
M><H:58PF5+9."?+X&.,]\\>FU2T_5;35'O4M79C9W+6LVY"N) %) SU&&'-
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MJWTUT8%;>Q*"- /[H!.>Y]NM=9X1UBZU;2[A-051J%A=265TZ+A))$Q\Z#/
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M7AY?#MO?1"Y,YO+Z:]<E-NUI&W$#D\#M0!S<OB?4U\:?V5)?16DAOU6*QN(
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M8 25R,.F3\IQD8P0<^U ''6FOZQXI\2^ +XWRV<5_93S/;J@*B5  6&>N0W
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M44 %%%% !1110 @ 4    = *6BB@ HHHH 145<[5 SUP*6BB@ HHHH ****
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M'[V,RQ@/DL@Y+ #G;[]*YKQ9XDO;'4O"1TF]@-EJFH+#*P57$D94M\K>^.U
M':445Q_CKQNGA$6"K;R3O-*KS[ "(;<,H=VST^\ /K[4 =A152ZU2PL889;N
M]@@CF8+$TD@7>QZ!<]2?052E\5:'%IVHW_\ :=N]OIV1=.CAO+([''?MB@#8
MHKCH/%(UK1?#U_:ZI::9)?743-!*P?SX^=T2''+'*\CH>*[&@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HJK>:E8Z> ;R[@MP>AED"Y_.DMM3L+R=X+:]MYIHQEXXY S*/<
M#I0!;HHK/77M(:.WD74[-DN)O(A83*1))G&Q>>6SVH T**** "BBB@ HHHH
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MI<ZQ:6^J^)(KW3KJ3^U[9)+&[&G2$3H8L"(X4D%2,_-C[W05T/PV+_\ "M]
M62&:&2.S2-DFC*,"ORG@\]N/48-=%#?V=Q>3VD-U#)<VX4S0HX+1ALXW#J,X
M/7THEO[.WNX+2:ZACN;C/DQ,X#28Y.T=3B@#S3QW<,_BO4+ 6=U;27&@RQ0W
M]I92323,V[]T-HP,8SZ\X!&:SO"9;_A(O 3R0[(H=%G1WDBVE')V[22,@\'
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MM!6/#XC*Y#'KA>1STYZ5:\6W<,/_  F5J--EOH?L=LXMH=P1SOVG[@#?+P6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M659C$B@$#=NP3TX]Z71_"'BG3_+TRZUV&XT2S<262QAHK@[3E(Y''5.F<<G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 0S6EM<2PRSV\4LD#;XG=
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M1"S902#C#8Z8/45SM_XBU*ST70(XGTZYU;57CA\U)/W&XKN=TQDL  2!W]:
M.NHK-T9M5^QNNL_9#<I(P5[8G:Z=F(/W2>>,GZU=MKJWO+=;BUGBG@?[LD3A
ME;MP1Q0!+14<<\,I(CEC<A0V%8'@YP?IP?RJ&TU.PU!(WLKZVN4E4O&T,JN'
M4'!(P>1GC/K0!:HKF/&GB&YT71Y)=+FLGO898!+#*=S+')*J9"@Y[\9XX-6O
M&&L7.@^&+K4;,0&>+;M$V=O+ =NIYH W:*K6M[!<EHDGB>XC1&FB1P6CW#(R
M.HSSC/I4PEC9V174NN,J#R,T /HKG_#NMWFJ:KXAM;N)(TT^^\B JI&Y-BMD
MGN<DU2/BFZ;XG6_AR-;9K"33#>^:I)9CO*@9SC'RG\Z .MHK'O/$5K:^)=/T
M$#S+R\CDEPI_U2(/O-[$G%9O@WQ/-K-E<G5);2*Z&IW5G!&AV^8(F/W03EC@
M$G'IF@#JJ*8TL:,JNZJSG"@G!)QGC\ :HZ[KEAX<T:XU74I?*M8%W,0,D^@
M[DT :-%<TVJ>(QX=DU0Z=9QS"!IULV=R^ I*H2!C<3@'%:^E:B+_ $?3KV79
M%)=P1R[-W=DW$#UQS^5 %ZBHWN(8I(HY)HTDE)$:LP!<@9( [\ FHUO[-X;>
M9+N!HKD@0.) 5E)&1M.?FR 3Q0!8HJ&>[MK:.62XN(HDB3S)&D<*$7U)/0<'
MFGR2QPQ-+)(J1J"S,QP !U)- #Z*C$\)CC<2H4DQL8,,-GICUJ.TOK34+2.[
MLKJ"YMI,[)H9 Z-@XX8<'D&@"Q14;3PK<);M+&)G5G2,L-S*I 8@=2!N7)[9
M'K3R0.I H 6BHI[JWM49[B>*%%4N6D<* H&2>>P')J0L NXD >N: %HKD/"_
MB>^UGQEXJTJ<6YM-+>W%JT2D%A(KD[B3@_='2M*75;K3]<U%]1N--@T.WM$F
M$K3;98V)()<'@*<'!]5(YH W:*IZ5J,6K:/8ZE$-L=W;QSHI.2 ZA@/UJYVS
M0 44UY$CC:1F 51ECZ"O/CXSUX>'W\6Q6UC-H3023?9B2D\07('S<ALD=,#&
M: /0Z*Y#3]0\6G6].2_33%TVZS([@LDHS&S")5)^9P0"3Z \56TCQ3K?B#3?
M$QLH+&*\T[47L[?SF(C*J$)9S^)H [BBF1MF-"S+N*@D@\?A67-XBLX?%5KX
M=P[7EQ;/<Y&-JHI Y]R3^E &O129&<9&:,@]Q0 M%%% !1110 4444 %%%%
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M?#DPVVP&S:.B,<_,5'4GOG@5D:#);PZ#\*[H20QW1O+B)IB 7*_O JD]<<X
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M!"H90!@ '' QQ2IIMC'=F[2RMUN3DF98E#G/7YL9H \DU.]8Z9XZ6 L\8UZ
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M;(?X<[6P#[5S>B:/KMA:VVK#P]<3C3_$-Q=2VLUN1*87R!)&K ;B,Y&.<]*
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M,UW6F^+-/GUFQT:W@N?*N;%;FSNV7]U.H^\H/]Y05)_WNW< Z6BBB@ HHHH
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M(=I.4.>.1WSZ>]2?#S4_$6K:SXEEU.>RDM(-2GM55"_F(T;;0%!X"8&?4DT
M=J=4LAJZZ4;E/MS0&X\G/S>6&"EOIE@*;IFKV&LV[W&G74=S$DC1,\9R RG!
M%<S<1*OQBM9DCS*_A^=22<!L3Q8'ZUSNA^-M3C\+V=]:Z/ID8N==>SN(X-R"
M,-(06 )^9B>^1UZ=J .ZO?"NG7NMKK)-S!J B\DSV\[1EDR2%('!&2:6-M%\
M,W$%GYJPW&J7+&,2.6>>4C)Y//3\!6#)X@\7Q0Z[;-8:2=1TT)<QN)'\B6!@
MQ"_WO,^1AG &:IW'BY=9A\":E%I-M+!JMT"))MS-:R>6V0O YR"-QZ@'CT /
M1**\QT/7_%,(\:WUQ:6%U)97DBJD,K\LD*!552/N]"26'?CO3H_&^NW6D:]9
MA])?5[73!?P3VOF"$H5(<<DY964@$'!R.F#0!Z!>ZI9:=):QW=PD3W4HAA5N
MKN>PJY7FECJ]W%X5\!+J=C8W$MY+:K&[,TAC7R01)D@?O.OJ![]:V+[Q3K-P
MVHW6@VMA/8Z5*\5TMPS^;,RX++'M&%P">3G)[#K0!V=%<4GB[4]<FL!X9M[)
M[?4-,DO+>>]9@%D5T4JZKS@!NV22>V.=3P5XCD\4>&XM0GABAN5ED@GCA?<@
M=&*_*>X( /XT 3Z]X5TOQ)-92ZBLY>R9FA,,[1XW8R#M(R#@<5L1QK%&L:*%
M1 %4#L!7.>/O$5WX4\(7.LV<,,TL$D*E9L[=KR*A. 02?F]?\*I7WB#Q&ME:
MPVEKID6I7C330FX:1H4MT9<%M@W%R)%XX')].0#LJ*X&X\9:XWANSN8["TTZ
M^:[^S74FIADMTPN2ZX(9E;("]SZ5#?>/M1@\):9>K'I]M?W=T]I+<7>\6D;Q
M[@S$CY@&*';G\: /1**X6/Q=X@U*"VTZRTW3[/Q!<"69([N=I(!;QNJ^;E0"
MP?<-N,=SVP<[4_B/JVEZ'>M<Z9;1ZOINH06EY'N9HF21AB2/H<,,XSC'O0!Z
M745Q<0VEM)<7$JQ0Q*6=W. H'<UQL7C+5+&;7[35K"T>]T^U^WV\5E(Q$D+9
M"ABP'S KR<8]JIKXBOM4TKQ!H^L+I\T\6EBZ2:Q5O)='0@CYB<X8'!'!&#[4
M =UI^H6FJZ?#?V,Z3VLZ[XY4.0PI;._M-021[.YBG6*1HG,;!@KKU4^XKS?P
M3XNU.WTWPQ#J%C =%U2!;:RNH1L=)E'W95R5^8!L;?[O/7AGA?6IM!T#6(;>
M%);RX\175M:B562,,<'+8+,5'/3)[>] 'J=%<[X3UC5M3@O(-:LHH+RTF\LR
MVZN()U(R&CW_ #8YP<]Q7/\ BGX@ZAX?UF\3^SH%TW3DCGG>9B9KF(G:QA4<
M#:2.6X.<<&@#T*BO'KOQ'X@/Q0U:[L8[-X8/#9N+>.6=U CW*X8@*07R>G Q
MQFM7PKXN\03^#M$>:WL9M3UG?]DD:9]K/\SLTH"?*!Z*3GIQ0!Z!)I=G-JD.
MI20[[J%#'$Y)P@/7 Z9]^M7*\XO_ (BZAHFBZ[!JEG9GQ#I$*3M'$[+;S1NP
M4.I;GC)^7N1C//%[_A,-:MO[*GOM.MDM=7U*.WL]CY;R9('="YSPP=1G (QG
M )H [FBN M?B'+%'>:;J,%J?$%K?+9&*)F6"1I S(58@MC8ISQG(/'2F3^,_
M%%AH^I/<:!;75[IZK*\EL\BP2Q,3EDW+N)3^)?8D=: /0JBN;F&SMI+FYE6*
M&)2SR.<!0.YKF[[Q3.M^9-,C@O=.M]-:^N2A)E;*YB"<X^8 GD=*S_#VO:IX
MMTZ_M[FTT:[MY+;=%<6L[R6[LQ/[F0%<AE&"?7(P!0!VMO/%=6\=Q!(LD,BA
MD=3D,#T(JE?:_I.FWD-I>ZA;V]Q,5$<<C@%B3@?F3BFZ'I1T+P]:Z;$_FM;Q
M[5+' SR<#T49P/0 5YI'?75MXF\<W/B'3=-FL88(9+J%;AW.U8RR*@* ,2P'
M7;C/>@#UZBN&L_&>KVJS7>NZ=;#3S:27B36!D;R%10VR4NJC<<G!'!QBHM.\
M:ZZU]$=0T:-[&^MGN+0V(D=X2J[MDQ(QE@>"O&01S0!V.EZ39:-9_9;"'RHM
MY<C<6+,3DL2>22:NUQG@;Q=J'BE&GGBTUK62/SHY+&9F,.2 (958##CG)Z''
M04GC#Q9JVASS1Z?:6(6WMOM)DOI&'VC&2T<2J,E@HR6Z#C(YS0!VE%<;+XJU
MNYO]"MM+TBU8:MITMWYEQ.P$#($X;:IRN9%&>^[MBJ\?CC4+W1=+BL+*V;7[
M^::W$,K$0QM"2LKDC+% 1QWY'2@#K;75]/OK^[L;6[BEN;,A;B-&R8R1D ^]
M7:\Y^',EW)XN\<&]MXH)_P"T(]Z1990?+ X8A<@]?NCK6AJWBO7GO]13PYI=
MM>0:/(J7JS2-YLQ*[BD(7C<%(Y;N<8H UH?!VE6TEV;7[3;QWDC2W$,,[*DK
M,,$D>X %;5G:06%E!9VL8BMX(UBB0=%51@#\A7,:EK^N7]Z]AX6@TUKNUABG
MO5U)W'E^8"4C 3^,@$DDX''7/%33_'SZMJ/A@6=J@L]72Y$IER)(Y(B00,<8
MW*P_*@#N*J6NFVEE=75S!$1-=,&F<L26QG YZ 9/ ]:\[D^*6H1:<T[Z3;&2
M/Q"=&?$S;<!C\X&,YVJ1]>?:K4NK>+7^(.BV,T&GQC['<S/;?:65'Q(%#Y"M
MD[""%[9;F@#T6BN>\3:_>Z9/8:=I5BEWJ>H.R0B5BL4049+N0"<#C@<GVK(7
MQEK$=C:6%UHJ0^([JZ>SABD<K;2L@+-*K<MY>T;L8SV]Z .XHKAKGQIJFCZ#
MK)U6PM3K.E1)+(L#L+>5'.%=21N &#D=MIKGO$OC/Q*_@Y+BV&DEOMMO!)>6
M<[O#.LA'^K.,J0W# YP/7/ !ZU4%M>6]XKM;3)*(W,;[3G:P."#[UQNL>+M9
MTWQ!::8L>B+.;=)I;6:Z=7G+.RA8&*@,1MY!&22 *36;N30/B=X?>!E2WUX2
MVUXC$G+1INC8=@<G'N#]* .OCTRRBU2?4TMU%[/&L3S'EBB]%]ADYP*MU@^*
M]7O](T^%M.CM/M$\OE":]D*00_*3N<CDC("@#J6 K'/CB]B\/:1JL^E($N;X
MV=YMFR(2)6BRN0"V6 ], T =:^H6D>HQZ>]S&MY+&TJ0EOF9 0"P'H"1^=62
M<#)KC++6-2;Q7HVGZSI-E%J$MG=3/-"^[RPLBA54^A4J3[CH*@\,>-M3U^\(
MDTZS^QR1R2?N;@F:T*XVQW",/E9N>1QQCWH [.TO+:_MQ<6DZ30DD!T.02#@
M_K4]>?Z3XP%OI7AS[+I$$$&JW\MJ8X9.(2-[9'9L[3SQ5P>-KC3_  [K=UJU
MK =2TBX$$MO:R$JQ<*T1!/(!$B@GU5L#M0!VE%<II'B35KCQ5=>']1TRVCF@
MA2Y,]M<%D,;E@.& .01CWZ\=*MZOKMW%K46A:1:PSZG);-=EKIVCACB!V@EE
M5B6+$87'0'D8H Z"J]]8V^HVQMKJ/S(2RLR'HV"",^HR!Q7GUY\49(-.14TY
M/[2AU:/2KU&<^7'(6 9D/5EZXZ'UKM=)N]5ETN675K&*WO(Y) (H9-ZLH.5P
MQQU&!VYSTZ4 :E%>;6WQ)U,>&=/UZ]TB%;;4E$-I'%(69KIG<*AP#A=J_>QU
M!XY J^/'M['H^O75SI*12Z8(C'('D^SS"0<-O9%("D'=\O'XT =U37=8T9W8
M*JC))Z 5PD?CG6#93WO]DZ=<6<$ULGVFUOV>.596VDH?+&64D J<?6KEWXKN
MAXYG\*7&G0B"73Y+J.Y6<L648&&0J,=3W- '36&HV6KV*7FGW4=S;2 [)8FR
MI^AJMI"Z39/=:5ICQ"6U</<Q*^YT:3+ OGG+<GFO%O"FIZO;:1\-['3TMFM[
MB6XDVSS-'OE1'&&(#?+A\CC)/I@&N\O/%::1<^.KN#1;>._TJ&V>:;S<_:6:
M(E2W3A>G7)'I0!Z#17'VGB^^_P"$U70]0TU88+FQ%Y:3QODG:!Y@8=!RPQC/
M3GK5#2OB+=:A'HM[)H\:Z=K4\D%F\5SNE!5B 70J H(4GACB@#OZ:[K&A=V"
MJ!DLQP!3JX#Q3XFDU2T\5Z-I]E'-;:99NFHW$LNTIOC+?NEP=[!<G!*C(QGO
M0!V?]K:>!9$WL %]C[+EQ^^^7=\OKQS5RO/M,NHXM/\ AO:OID%R+BU79<2_
M>@*VA8%!ZG&,]A^C+/XBW[6MWJFH:5':Z39W-S;32;]S&16"Q!<?>W'(/N0/
MJ >B45QEOXYGMY+K^VM,%M!%:&ZCEMG>4$#[R-N1=K<C'4'!YXYL1>(=>:62
M.?1((%DL)+JVG^T,R*XZ),=@V'D=">AH Z6YN[>S1'N)DB6218D+MC<['"J/
M<D@5-7E$%WJ=_P"!?"5UJ\5J\DVL6,L4RSEW9FFR6(* *>2, ]">>,'I[3QC
M>'7/$&EZCI]M;2Z5;BXB\NY:0W*$'# ;!@< 'K@D4 =A6)HWAQ-'UC6=16\F
MG?59Q-(DBJ A"[0%P!P  .?2EL-<E'A--;URVCTQA 9YH3+N\I>H!)"\XQQC
MKQ6+_P )GJ=I>:,^JZ$+73M7F6"WE6XW2Q._,:RH5 4D<'#-@\<]: .TJM-J
M-G;WUM8S7,4=U<AC!$S8:0+C=@=\9'YUSGA_Q1J>N:C/$-,B2TM[Z:VEF$F2
MH490X[Y/4]N..>(?$FIVUM\0?"=C+I5O<37/V@Q7DA^:#:%R$'J<KG/I^0!V
M5-DD2&)I975(T!9F8X  [FN%@^(-U-I=OJ+:/'';/JITUV:Z&1^]\M648^8Y
MZCCCN:K>-O$5UJ7AKQ9:V.G0W&FV-M)!>3/=&*0MLRXC&Q@< ]3CF@#NCJ=B
M);.(W<(DO03;+N&9@%W';ZX'-6ZX6/4+2VU;P'9S:0MQ=7-G+]GO2<?9ML +
M >[  =N/I3[?X@N='.L7FDO;:?&\\4LAF4MYB2;$51QNW8Z]CQS0!T^FZ1%I
M4EP+:646\K;TMR?DA))+;!V!)SCIZ5H5PD_Q$?1DGE\0:9]F@6 312VKO,K$
MLJ[&)10K98<<YY/:I=4\2^(H-+UV)]$6UO;2T^T6\XG+02*>HW[00Z\\8QP.
M>] '77-]:V;P)<7$<3SN(XE=L%V/8>IJQ7D;W.I7FE?#N?5((DF.L1>7(DQD
M,B&%SN)*C!)SQSTZUTEAX[O9AXIBO=)A@OM"4D6L5PTC3DIN3'R#AL@#&3D]
M* .XJ.>>&VB,L\J1HHR6<X%,L9IKBPMIKF'R)Y(E>2+=GRV(!*Y[X/%<%X_O
M]0C\9>#[""QBG@ENGF7?.%WNL; JPVGC#@@Y_#H: /0(9XKF%9H)$DB<95T.
M0?QJ2O.[/7XO"\NH6&F>&I8=)L=2=+R83';"K0K,9 ,$=6(V@\97UP->W\7W
M:?V;=:GIL=KINJ2QQ6<RW&Z0-)DQB1"HVD@#H6P3B@"<>#S%J-Q-:ZUJ-M9W
M,AEELHV4H68?,0Q!89Z\&M:VT/3[6]BO(H )X;<6T;$GY(\YP!T&3U/4X%<K
M)\0IAH[ZS%HSMIUO?O971,P\U-L@C#*H!#?,23R, 9S6QIOB:6Y\67GAV^T]
MK6[BMQ>0L) ZR0%MH)/9MV<CD>YH Z*BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ!I$>O>'
M[_2Y0F+F%D5G4,$;'RM@]U;# ]B :P9/ D4\>@F>Y\R>QD+WDC+_ ,?FX N'
MQC(,BHV#_=KL** ..U3P7/J?CQ]=>ZB6TDTEM-:(*=_)<[@>G\?Z50@\!ZK;
M^'_#^BC4K1[;1]2AN4=H#N>*-L@'DC<<GGMQBO0** .!NOA[<WNO>);Z34E@
M35?LS6TD"D2VLD)RC]<$YYK53PU?W^K6-_K=[#+)I]M-!#]G4KYC2A5:1^V=
MJX"@8^8UU-% 'GJ?#[4Q;^'K9]8B,6B7YGA81-O:+:0%//7G'IBMWPQX:N?#
MVH:VYO4EL]0OY;V.+R\,C2'+ G/KFN@N;J"S@,UQ*L<895+-TRQ  _$D#\:E
MH YV;0KU_'<7B!);80QZ?)9>60V\[G5PV>G!7&/0US=K\/-5MO#>G:6-3MB]
MKK']HNX60*Z;V?9C/7+=\CCIGFO1J* .8ET#56U?Q'=)=VI@U.VB@@1E;=%M
M4J2><'[S' QV]S6+9?#_ %&ST?P=IO\ :,+1:#<_:)L*<3D%L8!Z8#'GZUZ#
M10!Q%SX'O)5\1P1:E&EKJUR+M4,63OVJ&1SW0[1QW!(IW_"%WTVLW.HS7UM$
M;C0SI1BMH2BQDLS!EYZ L:[6LNZU>6VUVSTU=+O9HKA&9KR- 8H2.@8YX)H
MYE/!FL-I?A2TFO[-GT.XC9F6-@)(D4( .?O$ \^M66\):G9W.K0Z1J,$&G:J
MYEE66,M+#(W#E"#@@@< ]">M=C45S*T%M+,D+S,BEA''C<^.PS@9H YG2_"M
MQHNMZ:=.-I#H]A8O9QP88R$,48L2>,Y0?G6+9:1K7@[3](TVSU"&2:YUAY9X
MDMV830N<LN3G9M&3N)'3'>NWT?4)-5TFWO9;&YL9)5RUM<KMDC.>A%7J .:\
M>>'+KQ9X2N=%M+B&W>XDB9I)5) ".'X [Y4"H=8\,ZI-_9=_HNHV]CK%C!]G
M:22'S(IXSMW(XX. 5R.>#]:ZNB@#BI?"&L/=:=>RZQ'>W,-P\]Q'>1%X0S*%
M_=+U3:%^49_B8]ZAM_!FKV]@]G-=Z;J=O+?7%S<0WMHNR=9#N&X*,%@W.<'T
MZ8QU6N:Y8>'=+DU#4IO*@4A1W+L>%51W)-5=!\0OK,MU;W.D7^F75KM\R.Z5
M2K!LX*.C%6''K0!S6F?#R\T :;=Z3JJ?;[(2Q8N$9XGMY'#F$9)*A2/E(Y]>
M.*;K_P /=0UG2[]/[3A:^U"^ANKB22/"(L6-D:@=0,8RWUK?3QE:79WZ5I^H
MZK:JY26ZLXE,<;!MI'S,K,1WV!JVM/OX-3T^&]MM_DS+N3>I5L>X/(^AH XO
MQ!X#U#7+[7YUU&*V&HZ;%80E%8M'M?<2?8Y(P.U6H_!M\VM7=Y->VJ07FD)I
M\L4$!78R[L%.?N_,>/85V=% '#:'X%NK+2=#TO4;RWGM=#F\^U$49#22 ,$9
MR3Q@.>!G/K5:'P#JJ:7>Q_VG!!J!U5]4M;B%68+(QY5PQR1@8X/>O0J1F"J6
M.< 9X&3^5 &1H>GZI;*USK6H)=WSJ$(MU:.!%!.-J%CSZMU[5RFN_#W4=6'B
MB./4;-$UI5"220%I(@-OR;L_<X)QZFNFT3Q9INM>&[+70YM+2\?RX1<D*Q8N
M44'DC)(Z9[UNT <)%X N4\3MJ3W\36\^B?V5<1B,AN@&Y3G'8=:ATWP#JFG>
M'M'M8]4M_M^B2DV,@C;RF0@AA(,Y)()Z="!UKT&H)KVVM[BW@FG1)KABL*,>
M7(&3C\* .%USX?WVMP:Y=2WELNJZK#%;;]I\NWB0[L+W))]?Z5HZWX8U?5(O
M#")>6H.D745U,T@8F9T4KP1TSN)KL** /-9OAKJ-UJ>NZFVJ06M_>7<-[93P
M1EC;2QJRC(;@@ACFM&6^;PK92WOCW7XYEO!]D2*VMW6 #!S\@R=QZ$_3%=S7
M/:WJ^E_:AI[:9)K-] R2_8X(4D>+)^60ER%7IU)!]* ,KP]X7FL_!5S#IT\U
MC?W:-]GGE7+PQ@GR4;<"=JK@8/S#)Y!YJ_X>\+R:5KE_K$WV2&>]BCCF@LE*
MQ.RY/FD'^(YQTZ#J<U>T;Q/IVNW5U:6OVA+JS"?:H9X6C:%F&=ISP3[J2/<U
MLT %<*/!%[?WGB9M5FM/L^N0K&WV<OOA*KM4C/!YYKNJ* .+TSPIKTNFW&E>
M)-;@O]/^RM:Q+!!Y3.K#;NEY(8A>@ QR3SQ2:/X6\3Z?:+97'B<2VUFA2P:.
M$K(WRE5\YB2' RIQCG'-=K6+IWB:SU"]UJW"O"ND2B.>67 4_+N)'L!WH S-
M"\)36/B>;Q!=/:Q74UJMO-'9!ECG88_>.#W&,#'YFH-9\&W^H^(=3U""]M5C
MOM/^QJ)H2[P<$'8<\!LC/T%=F"&4,#D$9!I: .-TOPOK6G3>')#?6LO]E6,U
MI-N,N9O,*$8)).!Y2]<]^F!5.R\#:O9Z?920ZG:PZK97UQ=1ND;&*59B2R.,
MY_B//L*[J6:. *97"AF"#/=B< ?G63'XGLI/%TWAORKE;R*!9_,:/]TX/8-G
MJ/<"@"AX4\-ZCHNJ:YJ&HW\%S)JDZ3E8HB@0A I'7IQQ[54N/"6N6GB6^U+0
M=<AM+74W5KRWFMMY5@H7?&01\Q [^U=I61?^(;?3_$FD:))%*UQJ8F:-U'R(
M(U#')]\]J ,U?#-_IFL/J>D7\9EN;:.WO%O$W><R9V2EASN .,="/PJ@? EU
M90:%)I>HH;[2FF<R72,RSM,2TC'G(.YB?QKN** /+KGX7:G)IT]O'J=H7D\0
MMK(9HV Q\V$X[_-UKJ-5\.ZI=^+-*UZRO;6![:VDMITEB+Y5V4DIR.?E/6NI
MHH YGQ=X7GU]M.O=.O5LM4TV?SK:61"Z$D8*LN1D&J=YX0U6^CL;^;7 =>LY
M_M$4P@_<*2FQHU0DX1AD$YSR3UQC;NO$-O:>*-.T!HI3<7T,LZ2 ?(JQXR"?
M7GM6O0!S,NAZO.;^^>[M%U&X2*)%V%H4B1MVPYY(;<^?]ZN?NOAG)/HVIVUM
M/::?)=WEO>1V]LC?9HGBQR%R,%B.< =!Z5Z-6+KGB./1KBTLXK&YU"_NPY@M
M;8H&94&68EV4 #COGD<4 <YXB\$ZMXEMY+>^O+!UF\J19C$?-LI5VAV@;J 0
MN1D]6-.U.T'B7XD:*+:0-!X;:26[8C_EI)'A$&>">C'T'UKKM)U$:MI<-Z+6
MYM3(#F"Z39)&02"&&3SD5;2-(@1&BH"22%&.3U- '.^)?#MYK.K:'?6MW#&N
MG322/;W$9>.7<N V,_>7JI[9-94_A?Q'-HXL#>Z>S)J;WJRE9(R5\XR 84Y&
M2S=^F.O-=S10!S6HZ#J=YXQLM6AOTAM(+*6V,:YWAW(/F+D%<C QD&L;1? V
MIV7B&VUJ\N+ WJ64EO=3VR,C7KMC:TH&!QCKU]Z[J:>*W0/-(L:EE0%C@;F(
M51]22!^-24 >>6/@/5K2Q\/V[7=BS:5J4E\S;6_>!@W XZ_.W)R>!SUJAXVL
MK_1?#WBFXO+BS,6NW,"0ADW) Q\N/+[A@#:N2W8],8S7J5,EBCGB:*:-)(VZ
MJZY!_ T <%HS7^C^-(+.ZETR\N=0C8SM;RRO-&B#Y"V]FPG;L,GU)KH-6T*[
MD\16>OZ5+;QWT4#VDRW 8I+ S!\#!X8,O!QT8^U:]GI]EI\?EV5G;VR8QMAB
M5!^0%6: /-=3^&E_>VQE75(WU"?5DU.X:8,8P4^[&G<*,8Y[5Z-.)&MI%BV^
M:4(7=]W..,^U244 <!;_  [G;X<6'AF[O(1>:;(LUE>0AL)*I)5BIZ_>8$<C
M!]<5I0Z-XIEM;J74-5L)KYT6**-(7%L$SE]T98[F;IGJ ..ISUM% 'G\?P_O
M(-*UVWL;ZWTU]0DBFM[>V0FWM98V5MZHW&6*C(  X'6I8_"FN7?BJ#Q)>W%G
M'=C2'M&@0$J)GYSG^Z",>]=W0>!F@#R^R^&NL:9IWA*.VO[%[G09IF)>-ML@
MD &<#!R "?RJ]J_@75]1F\7;+RQ$?B".&/+JV8A&FS..ASUK>_X3736\/WFM
M0P7EQ:VMV;1EBB_>%A($)"L1P"><XX!K<^WVG]I'3OM,7VT0^?Y&X;_+SMW8
M],\9H X^X\-ZA:^*[/Q3<3P&*PTN2WF@B1W9N,DH,<_=''?-<?H4%_H7AO2O
M$ ?2KZ,7)GM[=)I#(QFD(*Q)NV"3:Q&T+P01ZUZUH^I#6-,CO?LES:;V=3!=
M(%D7:Y7D9.,[<_0T0:)I-K>M>V^F645VWWIX[=5D/U8#- &-X5U#5[W4=;2^
MFBN;**YQ:SHFS;UW1$8YV8'S<Y)/I63J'@?4DU7Q!+I-["MIXB@>.\2X7)A?
MRRBLF.HY/%=[10!Q<7A;6((?!XCNK,G0H=LRN&'FL8?*XQTP"3SU]JAM? <T
M_A/6- U::V,-[<O=0M:AAY3L^\'GKA@#Z'O797U[!IMA<7MT^R"",R2-Z #-
M9^C:^=6NKFVETG4M.GMU1REZB#>K9P5*.P/0YYXH PX/#'B'4],GT_Q'K$#6
M_P!F:WC6QB*>9D$;Y,DYXVD 8YS3M%T3Q5Y,VG:[JEM-916S6T,L*$27&Y0/
M,D!. 1SP.IYK:UCQ'9Z/:P3LDUR)[E;9!;KN <MM^9NB@>Y^F3Q6C>7265C<
M7<BNR01M(RQKN8A1D@#N>.E '%VOA;Q OA'1M)DETU)=.NH9?E#A2L+AEZ=V
MVY.>F:S]3?2_&OB[2&T#4%:\MGDAU62'<O\ HR,I:%P0/O2;-O'9L=#7H.FW
MRZGI=I?I&\:W,*2A'&&4, <'WYI;;3[*RDFDM+.W@>=M\K11*ID;U8@<GZT
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MMVB-,?7';FI;^'_$&I6UAHNMV]BFF:=.D@N(I"7NEB/[OY<?)G )Y/I7>44
M>9P^$/$(^'FK:2\%JM[=ZFUW%&MP<!&G$A#,!UQGCH>];\6CZL?BF^O/;P+I
MITE;$-YN7W"0R9VX]3C\*ZVB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***9*9%C)B17?LK-M!_'!_E0 ^BBB@ HHHH **** "BBB@ HHHH ****
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M!\&PI>-';WUG.\L)SY9<*A#$#&?O'@G%=.?"&BM!J<!MYO+U1R]XOVJ7]ZQ
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MM2NKZY:2[TZ1IVBG:/,GE*20%Q@YSDBO2V\-Z6\M_*T4S/?PK!<DW,A\Q "
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MW"K,09)"!GGL"5!P.,^W% #=*.HV?C[5+&:_EN-/FM$NX8Y7W&)R[!E'HO3
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M#Q$=0OGO(K(611F0QR1@YRPV9SNYR".?;BK6KZ!;ZM-;W/VBYM+VVSY%U:N
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M::A!*D5Q&F?NY50I'0?=[>O- &?+J6OPZ[X1TV[U-3/<R7D%YY*J-X1&,;D
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M **** "BBB@ HHHH **** "BBB@ HHHH *HZP\T>ES/ (S*-NT22O&OWAU9
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M+4['2+-KS4;J.VMU(!DD. "3@4 <]I5UJ.C_  TL&M](N+G4K.Q@A-BY*.9
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MO@K=>'K.T8W%UJ\BQ2"1-HC68.TC9(V@<C'4D<5Z#_PIGPA_SSU+_P &$O\
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M9VDI@'ON!Z9(](HH \?T32]37QIX>UFX\/ZCQI;6MS))$@"2X^ZJ9&Q1DC.
M#GCN:@71M5_X0'1K8^%KNZGT:[E\ZQE B%RDOFJQC8-V#]<=Z]BN;JWLK=I[
MJ>.&%/O/(P51^)J16#J&4@J1D$=Q0!R7@31+;2H-0N;/1GTBVO)5>.VFSYW"
MX+/EFY))X]![TZ]BN8O'<LGV.[FANM+,,<\:DQ1,K,Q#G.,G*XX)],<UUE%
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M"9H6C$D;(@#+N'(RIKM** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJEJTL\.F326Z2/*-NU8R@8_,.A=E'3U(J[69XAGEMM#N98;4W4B[<0AD4M\P
M'5P5]^1VH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** .,^(.HZKIX\.
M#3KA(([K6[6VG;YMQ5G' P1E3@@@]17+I?:SI_COQ]=:-!:7-U!;6DC"8LJD
M*LA( SG<?KBN\\7:#<^(--M(K*[6UN;2^@O(G=2R$QONPP'4>WKBL^U\'7%I
MK7B+45O(G;6;>.)P4(V,JL,]>^X_I0!A7'Q/N9)+&VL[)//FTE=0ED,4DJ!G
M!V1J$!/)!R3T]^:[7POK$VO^&K#5+BSDLI[B/,EO(I!C8$@C! .,@X]L5R<'
MP[U+3'TJ]TC7!:ZE9:>NG2LT6Z&:)22IV<8.23QQG]>UT^RET[2UMOM#7$XW
MLTTO\;L2Q) Z#)/ Z#B@#SCPK?#2O OB2^AT@WMS;:AJ$L:^3N#E9&(7/6KF
MOQ7+?\*^CMXK>UL'OHY6#*SF*;RF9$ .20<OZ8VCD9KH?#WA[4_#NG75I!<V
MDOGW4UUO=6^5I&+8QZ#-0CPIJ42Z.(M1B)LKM[VX9E?,\SA@V"&X7#MQSV]*
M .4L$AB^(7CJWU(VS:7:V4+3PBWPAC9#*^%#<$LS$]<DUIZ5X_D1M(0V+&PN
M+5WD6&UF4V85"ZAF8;6&T;<C^+IQ6Q#X-D'BG7]5GGBDM]:A2WG@ (*HJ;.#
MZD57TGP=K=O!%IVJ>));W2K>-HX8UC\N212A0"5A]X!3T]0">E $J:]XEF72
M+B+2XI+'4;:2662/AK,[08RV3A@<\_0US?A/4=4G^%:W]W';ZG)+J,GG)<#
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M0\%Q)!+"MQ&[$2?*X&&48XSSFMR'Q-K4-_HPU.*RMK34[B6)"H9FV[=\1SG
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M;'3]#EUFYFV6,4/GM)@GY,9SBN9O/".J7>A>*=.:ZLU.M.YC<*W[L,NWGU/
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M:D]E$\MP/*V(@!)_>IGJK=L]C0!U%%%% !1110 4444 %%%% !1110 4444
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M9YRV>2?6M-KRV4H&N(@74LN7'S =2/:FV5]::E:1W=E<Q7%O(,I+$P96^A%
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M/,:+F0??4$LOU !)'M6-+K4DWB+1GLM7TIM&N[::5HVDS+-M (>(C@J,\^E
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M^)[O087+75I DLY[*6/"_7'/T(_"]!J-E=74]K!=PRSP$"6-'!9,C(R.W'-
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MD5<[2R@#)Y^GM6_10 4444 %%%% !1110 4444 %%%% !1110 4444 %</\
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M;1PR@"[CW;#L/7 B9=N0/QS7NE1F")E=3$A5SEP5&&/OZ]!0!X]XHTRTT)_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7,.KO/Y*<MY;0Q[,?7:0/I7$:/)!!_PK^:*=4,^J7),$0)\A7$A,;N1N+!B
M<GKT& #0!ZCHVJWAU6[T35$7[7;(LL=PO"W,;$_,%P,$8P0,C/UQ6]7&W=M+
M+\7]-N(ES'!I$RSMC.W=(NT9SP25/;L:[*@ HHHH *"0 23@#O14=Q%Y]M+$
M&VET*[L9QD8S0!QNG:YK?C/.H>';RVL-&BG,:27%L99+O;PQQD;%SP._!Z5I
M:'K.HQ:=JEQXJ$%@;6\D19#^[B,( VN&)Y!Y/7CIVK ^&EXGA[1'\(ZQ-%;Z
MEI<K\,=JR1NQ=65CPWW\<=.E.\0:Y'JJ:%J;6KGP_%JVRX:>+B53&RI* ?\
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MCO=-TZWU35+-M:O(VG%LC!6*Y;[J\$J IY(SQS6W/K6EVU_%83ZC:Q7DIQ'
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M[I_-ASC*E7()[D=ORJ:+QII\M_H=J;6^C_MJV^TVLKPCR\;-Y5B#\K!>WZT
M="(T"[0BA?0#BC8F0=JY'0XZ5R<'C[3[S4;*W6RO1IVH326MMJ14"&293C:,
M'<,X."0,X...:Y[PSXBB\+VVJ17,%]<6C^)KBS%QO,@@R4"!BQW8)/;(]2*
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M[7;"Y15\^+)&Y<$XQ_=;!P0<5G_"FXFNOASITUQ-)-*TMUNDD8LS?Z1)U)H
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MC) S[GTK8\*R7>H7%E-+X5N-*DM$>*XEO7!(;:HVP88EE)YW$ 87')Z=M10
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M?LQQ_0GGF@#V^BO&]>UG7/"T_BZPLM<N&CA:QEM[B^D\PV_GS;74,P/R@?7
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M 4N,'@$G /-8<=[<V>LZ'X4?Q!?7EJ]S.)]09MDK,B[DMBXY)P1E@<G& 0:
M/2:*\3\7ZOK.B-XXTNTUF]:VM;2WNK5_M#F6U=C\R^9][!ZX)/ ^M7KJ\O(-
M>UK3_P"TKZ2UNO"GVXQ2W,CA)B'RR$GY.@X&!0!ZO97MOJ-I'=6DJRP29*2+
MT8 XR/;BIZ\L\)B2V\$?#UH+VYA6XF6.9?.)C=3!*=I!/JHP!QGG%6=#@N;C
MQAJOA/4-6U/[-IEE$;)A=/%+*)-V^0NI!?;\H&<X^M '4^+O$[>%[.PG6R-V
M;N^BM-OF! F\XW9P<X]*Z&O$SK&IZCX;M;/4+N>4V/BJ*SCNG8))+&I# EN
M3DXSWQZU[0D\,LDD<<J.\9PZJP)4^X[4 9NIZO+:WT6GV4$-Q?2P2W"QR3>6
M-J%1V5CR7&..QJIX5\0ZCX@BNY+_ ,/WFCB)U6);HC=*".3@=,'CO6;?6<5W
M\5+2.3[2H&DO('CNY4R?.3@!6 QP,XZYYS7GWB'Q%K5GIWCUX-6OD:TUJVAM
MR)VS$C$!E7G@'/:@#W2BO.I-2GTOQUJEN=6N;>Q;PV-0=II&G6&;S&7S%5R0
M, #Y1@''2LW0=2UF'Q=I-C--?+:7.BS3,]Q>-*;IU*XFVDGRB=Q(4'@''84
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MQ^)]9TJ[:W9-AM!L\I,'F0$#:3C.,G%;=GK6F:@TZVE]!*T'^M"OR@]3[>]
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MV@BP8/;RI.R2(P&W.X$'H2*A_P"$*T1;"]L(;=[>UNY8YGAMY#&J.C*RL@7
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MJ=KJ,/VHW=M;&U622Y=B\>XL V3\V"3C/3/TJ\^NZ3'9?;'U"W6V\SRO,,@
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MO]9&D@++]13DOK2218TN86=F*JJN"20,D#Z=Z +%%%% !1110 4444 %%%%
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M_$=;C6##!876DB*VNKB3;&DBR.TD?/&65D/OLQS78I&D:[4157T48%))%'*
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MK#;Z].U=[H^D6>A:9%IUA%Y=O&68+GNS%F/XLQ.!QSQ@58N;.VO(Q'=6\,Z
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M=E+%>N)XB SJJX'S9/W/_'A[X ._\.Z_!XCTPWL%M<VI29X)8+I LD;H<,"
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MU2VDS:3Q"5'88^7'?TK$M/'6E7MYIT4,5U]GU)F6TO"B^5*R]N&W#(!(RHR
M:T(]*N9O"[:9>SQBXE@:.22W4(JEL_=&. ,\?2N-\&Z7XDT>VTWP[=:';"'3
M9 &U8NA62,$D;%QNR1@9[4 ;;?$/2TTZ+4'LM1%I)?MIYD$2L4E#;!E0Q8AB
M,#:"?4"M&S\56EY>ZA8BUO(KNRA6X:"9%5GB;.UE^; S@\-M8=P*XB3P]K,/
M@J2W_LB>6YC\1_;T@21-S1>>)=P)X^Z<8X.?2M];&^B^(FO:@UG*+&XTJ.)+
MD@!=Z%B5ZY/#>F.#0!9L/B#I=_+HH2TU"*WUD-]BNI8E$;L!G8<,64^F1@XX
M-5M U"VTB7QE>WVH>9;P:N?G9B=H\B$B, D\@DK@=37+^$M-O==\%?#N&WM9
M$@T^X6]N+A\!55%<*!SEBQ;MTQS6AJWA/4/$.F^*K*.Q>Q:35X]1M"^TK<E(
MXQC.?EW-&<D]-P]Z .LC\6Q'4!I]QI6H6M[);/<V\$OE$W"J!N"E9"H/(&&*
M]:;;^,[&Z\,0Z[#9WC133I;QVVU!,SM((P-N[&<G)&<X!K.AL=0UWQ1H.JW6
MF2Z?'I=O(TOGLI+22+MV+CJ!@DGIR/PS_#>A'_A.M50QB71["Z-[8L<X2YF0
MB0#G! !)''5_88 ->Z^(FCV<FZ:&\%E]K^Q_;0BF+S=VW &[>1GC<%(Z\UG^
M./%(E\*>*;?38+]I-/A:*6]@*JD4NU6P&W!B0&&=H..]9.CZ3XJT:.Z\-1:#
M;M;->226NL.\;A(WD+EG0YRP).!@<8^M-U'2?$EMI'C+P]%H3W<>J3SW5I?0
M/&J$2J"5<$AMP(QW[=@* /0[0NWAJ NYWFS4EP^3G9USGGZYKB_!GCNRC\/:
M#:7O]I3/<L;4ZA+"3$9PQ^5G).2?497_ &C7;:?;3)X=M;66,).+1(W1CG:V
MP @D>_I7!KX?U:_\":3X1DTV2U>*>/[3<[@8HDBE#AERV7#8P!U]<4 =9:>+
M["ZL-7O&@N;=-)E:&Z68*&5U 8@88YX(YZ'/&:UXKV-].6^E5[>,Q>:XFP#&
M,9.[D@8[UP>L:!)=?$>"73;J$V6L6ROJD0&X[8&&R0'.!N^5.G1?R[77=/?5
MO#VIZ;'(L;W=I+;J[#(4NA4$CVS0!D6?CS1[V32P!=11:KO^PS2PX2<KV'=2
M>P8#-+HWCK2=>N(8K".[<274UIYC0X5)(E#,&.>,@\>N#6)'IFJZIX9\,:+?
M:*]O=6,]O)<3><"MN(,?,C+RS.!M&.FXY/'-KX9:/?:+HVI6VHVKP32:G/<(
M&'WD=OE(/T% ';T444 %%%% !1110 4444 %%%% !1110 4444 %5[EMLMJ-
MY7=*1@#[WR-P?Y_A5BJ]RH:6V)[2D]?]AO:@"Q1110 4444 %%%% !1110 4
M444 %%%% !1110 45S/C36K_ $6#1C8-"K7NK6UE(9$+861L$CWQ6%!XC\33
MZC/X5WVYUVUMA<7%[#"&C&Y_E 1F7JO7D]?:@#T.BN$?Q)XH%_X>TN6QL[.]
MU$7*3B5_,*&(?ZP;,K@Y!VDYYQZXY[6OB3KFB:#XAM9UM7UG1;F&)[A(R$FC
MD ;<%SP<'IDT >N45Q%UK?B :R_ANWEM9-1\A[HW42*?*3S (U,;,.V<G/O5
M37/%NN:1HFE3:K"ND>;,\%[>A%NE@9?N$HA. _S'/.W&#U% 'H5%<-'XGU35
M?L&F6,UNNI2V7VV::W59D\LMM0KN95(;D\$XQ[BHU\4^)([_ ,/:=J.GP6-U
MJ,UQ:RYD67!2+>LHVD@ X^Z3GF@#O:*\@U;Q%K'B+X?ZY:RWD5M=Z9J2V=U<
MI'\MPF1_#GY<[AGGL?6O4=(@N[;2X8;Z[CNIU',T<?EJ1GC R>V.] %ZBO,=
M.\;ZNWC+2-/GO8;F"_GGAFBBM"([=E3>J+."4D('!P?K@\58OO%NOV?A_5-;
M,NGO'I>J-;26\0R)H]Z( ')^5AN)[\\4 >C45PEWXHU/0_B#<6&L31KHKZ?)
M>6CK#@NR'YDW$\L!SCZ>M=#X2O-2U'PO8WNKILO+A3(R>68RJEB5!4]"%VY]
MZ +FG:Q8:L]TMC<+.+67R9'3E=^ 2 W0XSSCH>#5H01+,TPC02L,,X')'UK@
M]3O]?TF'Q7JFEBR%OI]V;EXY02TZK;1LZYXV=.O.:9IOCO4-3\2/9QPQ1VTO
MAY=5B#*=R294%3ZCYOT]Z /0ZI7FJV6GW=E:W4PCEO9#%;J1]]P"V/R!K@+3
MXD7!\)^%M7U PV<6INPN;IHF>.,C. <?=!QU/3!-:U]XDU..^\(9BL=FIW;P
MS-&WFC:$<AHV'&&"@_CB@#MJ*\KU+XA:Y!I?B2^A%D!HFKPVYC\MB987=%V^
MQ^;.1FMF7Q9J^K>)]5TO0;8?\2F*&1Q(BDSO(&.P[F78!MQD9.: .[HKSO6?
M'6IZ9J^D6=_':Z.;JQ^T$W)\R-[C)!@,B_*@'!WYQS3]=\;:MIOB6XTM(+.V
ME\E&T]+U]D>H,Q4';+G"D$D!#R?Q% 'H-4]5TNSUK3+C3=0A\ZTN%V2Q[BNX
M?52"/P-&K7XTO2+R_*>9]GB:39G&[ SC/:L*WO/$UAJ$MQJ:VMQI3VK7!>(J
MAM749\O)/S@C^+';WH Z&RL;73K2.TLH(X+>,82.,8 JQ7"2^)?$%A;Z1K=S
M#;7&EZB\,4EM;?,UJ9#A7\Q20XR0">G/%8]UX_UU/#WB36(Q:J-%ULVAA,9/
MFPK(L97.>"2<Y[4 >IT5RBZUJUGXUN])O3;36DNG27]J\:E3'Y;JC(W)W9W@
MYKFM*\<>);W0=+\2RPV9TR:_>UN+:*-C(%:8QHX;L%XSQSUH ]0HKSZ?Q9XD
MO9=7OM#TX75II-Y)9M:@+NN3&0'(8L"I&3@!3G'?-1Z+<7DWQ@\3&2X65+2Q
M@2,%&_=HQ8E5 Z\@'- '=:;JEEJ]I]KL+A9X-[1[USC<K%6'/H015NO,]-\9
M:G+X1\/75G!8I-J.L-9,AC,2(F^3HN <_*,]^34H^(U[I^G^,Y;^RBN9?#UP
MJ+Y)*"99&.T<YQM! SWQ0!Z/17&Z7XAUJ3Q;!HUS_9\T$UG]M-Q"Q) +$;!@
MXXXPW.:O^-M>U#PSX=?5K&SCNA!(GGQONR(RP!88],Y/L* .CK&UF+0=6N[?
M0]62&>XE1KB"%P=P"X!=2/ND9'((([5AW'CZWL/$6IV%Y) EK:V'VN.;:R[V
M #-&"V [!60_*?XP/6GV^L7K:_H=I=06GVRYTF2XDN&BVNK#;\H!.0,G)'M0
M!H-:^&?!=HM].8K--XB6XN)7E<ESPH9B6.3V]JWKBWANK>2WN(DEAD4JZ.,A
M@>Q%>+:V;^Z^$2/.5G-UK495K<J3< W'WOEXYP,#GH.3Q7H^CZW?R>,]8T"_
M:&3[/%'=6\D2%<1N6&QLGDC:.>^30!:L/!^A:9=BYM;)A(O*>9/)(J?[JLQ"
M_@!6A::K87]U=VUI=1S36;B.X5#GRV(R ??%<GXV%Z?%?@X07D,4!OVS%)&Q
MWN(V(Y'MGT'O7/2ZIJ.AZK\0M5TYX UGJ%I++'*F1*GDH"@.?ESGKVH ]9I"
M0 23@#J37%ZAXEUG4-6O-*\/VZ?:K"W@N9=VQUD\P,1'DL !\OWAFNET.]N]
M1T2TN]0L6L;N2,&:V8Y,;=Q0 _3=6LM7CN)+&831P3M [@?*77&<'N!G&1Z&
MKM>0PZOKGAG1O$>O:?';3:?9>(;R2\M&C822Q[P"5?H"..Q&!UXKI'\4Z@)_
M%]K#=6\S:?8I>V,ZIE0LD;,N<<,,KG.><T =U5&;5K6#6+72I&87-U%)+$,<
M%4QNY_X$*XG4?'%W;Z-X>O#>6=G!J-MO.H21F2 SX&(F925C!R3N)_A/3!K2
M_M;47\:^&8+B+3E2\TZ>64QX=U<!"0DAZKR.G7'- '945YW9^,-<DT+PUK,_
MV$QZCJ?V&XMXF5@ \KHK)("0VW:.F=PYJ]>ZWXENY;J^T"WBN[2TN&A^S Q@
M7&TX<^:SC:?P[4 =M17 :AXRU.'Q4^F#[/8R+#$UK;WJ$)?,Z@L$F^[E2<8&
M<G\<2:5XSN[SQM?Z+=R6MK-;S^6EE*I5I(MN[S4<\.3D?*.@YH [NBO/-(\7
M>*-<B@UG3](2;3'NWMW@+HF(0<><)&8%CQT (.>#Q3M,\::A>^-9M(D>.*=9
M2ITVXMVB9800/.25N'."#M'][CI0!Z#16%XH\0GP]:63I;M/->7D5I&-K%5+
MG&YB < #/I6))XAUG0]7O=)U*:WO)FTZ:^LYUB\L?N^J,H)]5YXH [BD9@JE
MF("@9)/05S'@G5-<UO1K35=42&."[LXI4C5"KK)SOR#V/##ZUE2/J4GQN%NM
MVBVJ:&)5C*9PIG <=>I*CGT H [#2=6LM<TV/4-.G$]I(SJD@'#;6*G'XJ:N
MUY?INLZEX?\ #VAW4$HDTZXUJ:RE@GA99F\VZD4,2Q)4@\D'K6U>:WXEO)K^
MYT*T\^*PNC +5XUC^T[=N_+R,I3J<'&#@'D&@#MJ*S[F\O$T![V"R+W@M_-6
MU#ALOMSLW#@\\9'6N"T;XCN?#VKZU=7"WUM8VWFRQ^1]GG@FX'E-&3DKS]\<
M<$<D&@#TVBN%@USQ7IEK=W^L6L4E@NGR7GG*L8,+HN[RPJR$R C//'3WJH?$
MGBZ+X>7'B/R;*5OL,-S&NTJR\'S25[X&& []* /1:S]&U#3M8TY-4TQDDM[H
MEO,5<%BIVG/N"N/PK"T[7[K7/$B0Z9>(UG;:?'->(\''FRC=$%;.3QDL!TPO
M.3QC>$_&%]J^AZ#9006MO?7\-U)N2,"&".*1D7:H(R>%X^M 'HU%<=_PD&OV
M0L--O=/B.J7-W+ CJZE988USYV-WREN/E)XR?2LR]\5>+-$\.WDFIZ0QFM;J
M.)[Z-%9?L[ DS^4C,3MX!4>N>QP >B45A^%M7FUO3);N2>PN(O/9+>XLI=Z2
MQ@##'^ZV=P*]L5DSZ[K.L:_K&FZ#):P-HIC\WST+?:'=2P3/&P8 ^89ZT =E
M17G]AXUU?Q*]@="M;94N;*Y6;SV(-M=Q; 0>/F0,P&0>=V>U=C'/?0Z#Y]Y'
M$M]';EI$1BR;PO.#@<9H OUEZMX=TC79[.;5+)+I[-F> 2$[5+#!RN<'CU!K
MB+3QSXCCT/PYKE_86HL=1GCM)T 99%9WVI*,XX)[8Z'.3Q6C:>+]3D7Q%>2Q
MVOV+1+RX$X^8,8(XBPQUYW 9]C0!W54]4U6PT6PDOM3NX;6UC^]+*V /;W/M
M7.VGB/76L-!U*YTZT:RU(QB?R93OMO-QY9^;[PRP!QR,^F:QO$.NWOB/P+XA
MGLHEC@MKAK=%",\K!&7+ *1SG. #^- 'HR.LB*ZG*L,@^HI:YRVUN\/B*[TE
MH8?*@TZ.ZBD).XL<@AAVZ5D^&?'%UXGTS1/*@@MK_4;2>ZD5@[)$J/L&/7)]
M3V- '<T5YSX@U#Q%L\)1WT<-G<2:U'!.@;>)MJN0WRDX5MJMMZCI5V7QGJ">
M++C06M[:"[BEA$4-P2GVN%MN^6)R0"1EALY/RGKS@ [FBLOQ'K47A[0+K5)E
MW"$*JKG 9V8(@)[ LRC/;K6?<:_>Z=XIT?1;R*W<:I%,8I8MPVR1*&((/8@_
MI0!>N_%&AV.I1Z=<ZI;)=R.$$6_)5CT#8^[G/&[&>U:U>>^!;1M1N?%T>H16
MUS"OB.8E9$+894B*D9Z 8&/2M75KS5!\1M%LK?8+-[&XE9G0X,@*  D>Q/%
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M1T^HK>L_$-V?'5UX:O+:+Y;$7\-Q$QY0N4VL#WR.M '1T444 %%%% !1110
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MW23W$J["S-T"[?X0/3GM7944 <)!\.VAT37[+^U T^K7AO!-Y'RQ.""ORYY
MVKWYYZ9X[!+.1]+-G>74D[O$8Y)E C8Y&"1M^[[8JW10!Q5AX#GMH_#ZW&L-
M+_85PSVNRW5 T10H%?DY;!Y;OZ9JQ<>!X[KP_K.CR7\JPZG?&[+HBAHP71RH
M['[N,^]=;10!P.N26GC'7;'0X4N/M>DZ@D]U,]LR($53NVL1@AB0N,G\A7?
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M@7]W(7PI.W.=IJ:Y\%7EY?69N=9\RQM+TWD2FWQ<(=[,(UE#<)R 1C) QG'
M[*D9E1&=B%51DDG@"@#BM.\ 2:7>WL-MKERNA7DK3R:<8U)#LP)"R=1&>05
MSSUJ4>#+VZU73Y]5U2WO+;3KHW5IBTVSJ<\*92QRHR>,#/'I5^_\4K;ZIX:M
M+2V%RFN.^R8R;5C18_,W=#DD#@<?6NBH R/$F@1>(M+%J\K0312K<6TRC)BE
M0Y5L=QGJ.XXK-/A6[O/M=WJFI1SZG-92644L,!CBB1Q@D(6))SR?F_*NIHH
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M6,.K6A:")'EE6*7@&<.V2I;<H/(R<8YQ6=IC-%X?U_PVI;0+R"*)/LES<O)
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M96F%K L0D?JV!C)H \ZT^]U%?!FN>)5U#4)[[2Y=1@B6>4,%7S.&=>F4 S[
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MS@CUH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=\Q$]B 2,
MSD''?]V]7*IWP!GL<G'[\X]_W;T 7**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K+_LF7_A)1J_VP[1;FW$'EC&-P;.[.>HK4HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAEMI72(D @,ZJ5!Y'4T =#12*P90P.01D&EH **,@5FVNNV-YKE_H\+R&\L
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M' VIG_:(K4T[4;/5K"*^L+A+BUE!*2H<AN<4 6J*** "BBD9E12S,%51DDG
M H 6BJ.DZQ8:YID6I:=<":TF+".3! ;:Q4\'GJ#5Z@ HHI"0,9/6@!:**RM;
M\1Z7X?2$ZC.R/.6$44<322/M&YB%4$X &2>@H U:*AM;J"^M(KJUF2:WF4/'
M(ARK*>A!J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=ZN9
M[$Y Q.3SW_=O5RJ5_P#\?%A_U\'_ -%O0!=HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_!Q7
M4?%'B[4Y6E>>'4CI\>]R5CBCCC.%';+,2?7BN-TB[UWP[X8?Q':ZA;?V/:ZG
M<&^L3'\[H9]I(8D ./3@8QR.:[?3K6X\->,]1C9)9].UV<7,3QQ<6]P%VNKD
M<X954@],@CW*VO@2*WM182:E/-IHOVOOLSHOS,3NV,W= V6Q@'U)H BUN8V7
MQ-\*/"SK_:45U;3*IP&"1^8I([D$''IFNSKDEMCX@\<VVIB.XAMM#$L*>=%M
M6:61=K%,]E'?OFNMH **** "BBD;.T[2 V."1F@#Q^Q75/#&H:UXLTR&:]L/
M[6O5U6R23G8LAQ*BG W*!SSR*T[/Q1'8VGB;5M-:.X%]JL$5I*2 F98HPKG.
M.!G)''X5V^BZ(=)@O899TN8[NYEN7!BVX,C%F'4Y'-8MO\.=+MO#>J:"DTRV
M5[>/>1! %:U<D,-A'92!C/;@YH S[_6=<\/>)8="OM2%S;:M:W#V5YY*K+!-
M& 2"!P5PW''I[US/A#5=:T7X366MQWXDMTU&1KP2Q*2L)N'61LYR3SGO[5Z/
M%X7\Z^M[_5KTZA>VUL]O!-Y0CV!_OMM!QN(VC..@]SG,T'X?1Z+X5U'P_+JU
MQ>6EVLB(LD:JL 9G;Y0.IR_))YVCI0!F7?CMM,\3^(=,O+_=LMO,TY5MBH\S
M !CW?Q-N=.>GS =0:VE36XO$&EZ;<:FC@Z3,SW"6^&:=6C4MSQMP_P!WU )I
M\/@6PCC\-"2>:670@?+D< F<E-I+YR>IW<'K6A<Z+<3^*;+64U$QQVT#P&U$
M*D2*Y!.6/(Y53QZ>YH \NTQ=3?X>VEU/?M<R/X@"E9HP"6%WC<6').!766^N
M^)K/Q)XET>3[+J5S!8IJ%A&JF(?,67RR>2>5X]?49XLIX DATIM.BUR<6PU%
M;^)'@1O+(<R%<]2"QZD]!@8J?6/ YU?5=2OVU::UEOK*.SS;IM:())YBL"2>
M<]?:@#BKWQ5J=_X'\3^5XAC>6UTP&2)H3!>6L^3YBLI &/X00?7&>*VK'4-7
MT_0_#-@FIQQ)<Z9YZS&)6D)6%=L21C)8#)8MC@#J.^M??#RUU2ZUB\O[UWN]
M3T\6#O'&$5% /S[<G+9.>N..E(? ,ROH\T.OW,%UI]B=/:9((R9H>.,$$*>!
MR* ,>P\8Z[J>E>$#%+;QW.K+-'/(T>1O52 P7TR,X_#-4M-\?:Y!H>IVUU)!
M=:I%K_\ 8UM.8RJ$M+L#L >@Y/Y5TFE?#\:7;>'HAJC2MHKRLC-"!YH<DX(S
MQ@''>J\GPNLI['5K:;49P;_4CJD<T2!9+>;>6&TY((&<8(H ?:V.JV?CNZ>\
MOYKU8M( @EVJBKESGS5!&XY'RD X&[.,\\KH_C'Q->^'?"4R75K')>ZQ/83[
M;?:& W;,#L!M.1U/'O7>6'A2_MM9FU2[\27M]/+9_93'+%&D0YR&VH!T^O<\
MUF6'PUCT^RT6UCU61ETO49-00M"/WCMGY3SP!N;]* ,]O%GB'0- \4IJ+1:C
M>Z5=)#%<Q1A%198E=7<'^%=XSC_Z]:^EWGB";QU+8?VQ97&DVUO'/*@@)F8N
MK  L, ?, PQGCBLGQMHM]I7ASQ%<Q3W-X=;NX3<-;V_SVL?RH655SO"H@&,9
M/K3?!\6K6?B6"ST_6)]5TN-&^WS7=@L! V?NMC@ N01C'( _"@#TRO+[TZ_X
M2N=<OX;2#7_"^H7,LUS%:D"YMB5(?@\.!@ \D@#L.GJ%<POA.Y@MM4M+76IH
M[349GE:)H$;R Y.]8SQ@'/?/J,4 <[>^)=3U6Y72O"QU"X@ATR.X2\MQ S,[
M@^7O\UTRN,$[>N>U6K/7-?U?4=.T*[F@TK55TV2ZOHD8.[29V)M(!7:#\QY/
MW@/6KFL_#Z.\FLI]$U>\T&>UMEM ]GCYX5^ZA!].U,U7X;V]X=,N-/UB_P!,
MU&QC>/[= 5,LRN<MO)'.3D_4F@#%UE_$37?@>TU'4HH[_P"WRI<O:J&CD94.
MUL'T&>#ZGVK2O?$6HZ7>^-9$,-Q+8QV<=G"$V-OD3 9F("E2[>O&TYQQF_=^
M HY]-TFVBUF_BNM.N&G6^.UYG+!@V<C;DY'..,4LW@.VNKOQ ]W?SSV^MVT,
M$\+*H*F--JN&]>I],F@!GVS6M#\1:)9W]Z+Z+58WAD(C"^5<*A<LH[(0",<X
MXYK"LO$/B./1_#VIW5[YS3:R=.NXHX,HR-(Z[O4$;5 QZ].:ZS3_  Q-:W&F
MRW>KW%Z-.@:&W$B*,D\!W(^\X4;<\=3QDUG_ /""/_8NGZ?_ &L0UEJ0U%)Q
M;*6+[F;&"2!RQY';B@#LJY3X@@'0['(!QJUD1_W_ $KJZQ/$^@R^(M.BM(K\
MV7EW$=P)%B#MN1@R]3C&0.U $^IC2].>37+\*&MX"OF,-Q5>20H]3STY-<#J
MNCSV?@O1=&+S6":KK:B6.$;&CCD=Y/+...F 1TZUTWB_P7-XMFT]FUV[L$LG
M\U$MHTYEP0'RP/3/3Z^N:RK[X=Z@?#[Q0>([R[U=+Z*_BO+S!.Z,8"<?=&,\
M^] &KXGOKBTU32--@U1=.MKD.I,2>9.[ #:J(%.1U)/M61;:A)XO^#!U;443
M[;';37$<B @I- S[)!U(.8P>/4BM2723XKO],UZWO;[2KBR6:VEA, #,&(#J
M=W3[G##L<BLX>'YM!\('P+ITDU\]Y',J3W$6(X8)'_>;F'5@'?'4DD<8% ':
M:5?C5-'L=06,QK=6\<X0G)7<H;&?QJY7+6.CZC:>.GN+:XFCT*'3EM5M'_U8
M<%=OECV .2?7 ]1U- 'E$WBCQ#;Z;J>I-J:N-,\2FQ:+R5Q-!F,8SV.&/XFN
ME>^U7Q#K6OV&F:B+$Z6B0PD(&#3.@<,^?X1P,#U-$GP_AET?5-/?4)/^)CJI
MU.1Q$/E8E3L ST^7K[U=N_"<AUNXU/2]6GTU[R,)>)'$CB; (5AN!VL >H]!
MG- ''6.H:AXJ\3>%;U]0FMIHA?13PHBF(3P[8W90>H.YL$\@'MDU3NM4UC0=
M&\<Z]8WB0?8->D?[.\(Q/^[A&&[XQC!'7K7<OX)@CDT)[#4+FS.DB1<HJL;A
M9 N_?D=25!R/4U5N_ 'VS0/$6E2:M*$UR[:ZE<0C]T2%!503TPBCDT 4WU_4
MK_Q[#86-Q;PI=: UU )8,O#*3\K-SR.1\H/8]*H:3XHUS^R?!FNZE>AX]4NO
ML%W:11+@R.7".&SP 5YZUT[^$9?^$F;78=8GCN?[,_L] 8E8*<DB7!XSDYQC
M!Q5,> Y?[(\/Z<VMS.FCW@O-S0*3<.&++OYR.K=#SF@#G?$'C'7TA\52:==6
M\=]I=[#;65@8P7=6QEV&?F#Y^7IC::]/M!,MG"+A]\P0>8VT#+8YX'2O%-0L
MI9/%^JS-K7B2RU![V3RH+72_. '.TI)MQ]T#OQFO9-'^W?V+9?VGM^W>0GVC
M;TWX^;]: .6\7D?\)[X%!')NKH YZ'[.W-<\WC;7])TO4=/D;^TM437DTBWF
M5%0D2)Y@."P7(7(&2!G':N\U?P\-5U[1-4-UY1TJ625(Q'GS"Z%""<\<'\ZQ
MKSX<V.HVFN6][=R-_:EZM\DD2['MIE4*K(<GH .OOZT <YK?B'QOH7A?Q%<R
MPRVZ6D,<]G=7R0-(P+;9$*Q2,,\@@]N_:K_BC7?%&D>(+'3+29;A-9G)MUAB
M3SH(TBRX4R.JLQ;D9/ SUJX_PV:X\-ZEI5_XAOK^>_B6![RZ4,T<:MN"H!@#
MGKG.:U?%/@R+Q1:6!:_GL=1L'\RVO;7AD;&&P#G@CM0!S.KZSXNL?AY+>:I#
M%:7EG?P(_F+%(]Q TBJ"55V5'RP/4_=/K6GKE]XJ&I^*(+&]L[>UL]/ANK1C
M S2*QW[@<X!!\M^F<?+[BK-SX#,_AC^R%UJZ\V6XCN+N]F02R7#(0P!SPHRJ
M]/3'<YTY?#US+?ZQ=?VB!_:5JEL5\C_5!5< J=WK(QYSVH E\):R?$/A'2M6
M8QF2ZM4DD$?W5?'S#\&R/PJ+Q=?7VGZ*)K$3#,\:3SPP^<]O"3\\@3^+ ],X
MSG!QBK/AO2)- \/66DR7C7@M(Q$DSH$8H.%! XX&!GOBI]3LKB\2V-K>FTE@
MG67=Y8<. ""A![$'Z^E 'F^JZI-JVG^$;IM3L]3SXI1(;BW0HNT)*%#+QAAW
M%:T'B'6+*W\96-S?037VD/'+#=2*$C2.6,,-PS_"0V?48Q6G-X),RV&[40'M
M-5.JY6V50\A##;@$87#'W]ZBU#P$+^Y\07!U)HY=8-N^5AR(7A&$."WSCU4\
M&@!?#.MWM]=:G8W%RU_;16D%Q;WGV?R@ZR*>#G&3E<@@8P:P+L@V'PM*KM!D
M@P,YQ^XKJ=+\*7NGZK=:C/X@N;N:ZM5@F22%%C9EW;7VKTP&Q@8]\DU$/!;_
M &#PW;OJC2/H4@:*1H /-"KM4, 1C XX]* .LK@=9U#Q3?>/;[PWI6HV=E%_
M94=Y#,\!=D)D*MGGD_*?0 &N^KSVZM[RX^-5U]BOA:G_ (1U(RYA$@W&9R.I
MZC(;'YC% %"T\7^)-3D\+V7FVUK<Z@^H65VWDGY9X(WVN 3P-R@X^HK2L-:U
M_5GU?38+^*"_T*)(IIF@#1W,Y0L3CJ$^[Z'K6A;^!(;.Z\/S6U\P&C/-*OF1
M[VGDE4K(SG=U.XGCH?;BKESX68:IJ5_INHO8OJ4'E7*B(2!G PLHR>& X]#W
M!Q0!R$FK7/B?7? NI6CI:7TUKJ"@.-Z+((T!..XR/4=:HWOC_5;CX>VM\8[5
M[ZWUM=+NGDA#+(0>70$_*2"/H<UW%MX*M[+4?#UQ:W3QPZ+#+%'$5W>:9% 9
MF.>ORYZ=S6,WPLMV\.RZ1_:LNR35_P"U3)Y(R'X^7&>G'UH QK2'7)_'GC@>
M&;VTLYTGMVF:Z@,F]A%]T8;@'CG]*E'Q!O-6C\$7T$0M5U&^EL;N-D5F64#;
ME6YPN=WUXKK7\(/'J&M7MCJ<EK/K$2)<,(\F-U4KOCY^4X/0Y'%07O@"PN)/
M#@M9?LD&A7 N(8DCSYC=]QSWZ],YH S_ (8?VDW_  DQU'4/M4D6MW$#$1!=
M[*$&[\L#'H!6YX_U"[TKP#KE]8R&*ZAM':.0#)4XZCZ4[P]X8?P_J>LW":E+
M/;:E>/>"V:)0(I'QN.[J>@]L=N];ES;PW=M+;7$:R0RH4D1APRD8(- &-X1L
M;2#P7I4,4,?E26<;.-H(<LH+$^N236,AFT?7].\$^'I(K6!+.2^GEE4N\<?F
M!55!]WEBW7H!6AI?A6[T71I](L-;F2R.5MB\0>6U4_PH^><=1N!IA\%);:EI
M6HZ9J,UO=Z? ]L6G!F%PCG)$F2"3NYX(Z_3 !A7WC76+&RAMVDL9-1L]:M]-
MORL;[9$E(VNN<;25;D<\@XXP:U8=1\2Z?8^)%NWM=2O[1#<6B6\3+G<I*Q[,
MDG!&,YR:DG\#FYTM;:34V,YU4:I+/Y &^0,"%V@\+@ =S@=:GU+PE-J&HZM=
MKJTMNU_;10*(TP8-C;@RG=R>3D=/UR <3<^--=A\&>(=;L-=M+Z*P2!K=S;!
M760EA+%*AP01E"#@<>O-=38^)-0F^(EKHLLD9LY]#CO]HCPWFERIY],#--OO
MAQ:ZE%XE^TWSB?7H8HYFBCVHAC!VL%SR<G)R?RJSI_@RYM?%5CK\^K^=/;:4
M--:-+;8LN'9@Y^8XZCCVZ]J .)M(+^\\.>#K2RO(+2VEUN[:1980XRD\SIC9
M\F05XY SC&1Q6IXE\9:_H-S=,U[IY_L^6U5[-8M\EQ$[*C2,0?W66<8!'\)Z
MYKH%\$RII>G6RZG&;G3[][Z*YDLU8DN[O(I7=CG>0",8P.XJA>?#BYO+?7[=
M_$+^7JYBE+-9H7BF0J=VX$94[>4P.O!% &CK5WXFDU+5[+2;G3[<6]G!<P2S
M1,Y4LTH92N><^7UR,<<'-<IJ$OB+Q9J'@>\L]0M;.6:T>]:-X2\:2A/O 9R?
MO8P:]"&D3F\N[A[U6:YLX[5R(<$%-YWCG')D8XQZ5B1>"+NUL]!BLM>D@GTF
M)H!/]E1S+&>,8/ . .>>G2@#L!G SR>]>=:GI>LW7QBLF6_LS:KILLBK+:!G
MCCWHK*I/&22!G^Z2.]>C#IUS6)/H,\OC"WUY-1,:PVK6IM?)!5U8[B2V<YR%
M/'I]: ..L_$^N:7H$^L7,&GQZ7H]Q>6]W9VJ&,D*56$1[@  #G.<<&MU=3\1
MZ5K>D0ZBUK>Z?J?[II(H]CV\^PMCK@H0I]\BK%GX*M(?#6JZ%=7#W-KJ,TLK
MG!#+YF"1DDYP>03[4^U\-WYO=-FU/6!>Q:<I\B-;;RRS[=HD<[CN;&>@ Y/%
M '.:?XE\5W&E:;J[R:<T)U%K&[MO*="Q:?R496ZC!*Y!&2,_2MWPWK&KOXCU
M;0-9$5Q/:)'<I=VT>R/RY,A8V!.=P*MSR"!V[LL?!UW9^&+?26U>.:>/4%OI
M+IK3 D83>=C8'XRP'?IGCTT;7P^]MXRU#7_M4;B\MHK?R?)(9 A8YW;L');^
M[V'/7(!N4444 %%%% !1110 4444 %%%% !1110 4444 %4K[_CXL.1_Q\'J
M?^F;U=JI>JS3V17&!.2<@=/+?U_IS^&: +=%%% !1110 4444 %%%% !1110
M 4444 %%%% &#XEU^XT*32!#9+<)?ZA%9N[3!/*#G&[!^\<9X]JWNM<CX^MH
M;R'P_;3W,]O'+K4"[X"P8G:Y"Y'(!QC/;.>!7G^HRWWAR\\<:%I.H7<&E0VL
M$T4K3,WV1Y" X60DE>.>O&,^M 'M-S))%:32PQ&:5$9DC!QO8#A<]L]*IZ%?
M7FHZ'9WFH61L;N:,/);%MQC/IFO.DTZXTNYO[JW\10S07.C2!;2QN'8!D0D7
M.=_!.U06 Y/?FL_2#)=:!\+EEN+G_2GFCG*SNI<&&3.2"#G/.>H]: /9J,YK
MQN[N+O2/!OCK2K"ZF2WTJ_C6W+W#>:(G\MW0.3DDAF"C.>0.36]X3M(K[QY/
MJ^F#4K/1X].2,V5SYL*&Y. 66)L;MJ#!8@Y9L@DB@#T:C(/0UE>)KB*T\,:G
M/-=RVD:6SEIXER\8QU4>OI[UPWA#S;3X@PV@A^RPOH$3>3YI<MM; =O]H@\]
M_4F@#TZC(]:I:O$)M&O8V9U#0.,HY0CY3T8$$?4&O%M+T[[+X*\'^(;/4;HZ
MM'J"6PS=28FB:4AH]KG& #G@8X[CF@#W;(SBC(SC/->,B>Y7[!K%E<%_.\2,
MOVV[NE2653(8W0#.T1@*0%;GIM )%;U\D^G>+XKBYL8[VRO-7C6#4[23,UF_
M \J4=XR<C&< OTSB@#T?(SUJAIMW?7,E^M]8BU6&Z:*W;S WGQ!5(D]LDL,>
MU>6Z9"-/O-(-\YO8+O76D@UJVE)=GRVV&96^8+U7J0-HXSBK-IHIU3PKX[MK
M"24W4&NW$D'F,TC;TCBPNYCDY QU[X[4 >LYHS7E-QK]]K.@ZOXQTB(I;VNC
MM'9LB_O#.1^\)&,GRR!C(QP2..:?X*L9/M_AC6$URW?[19>3/;Q7#R-<MY9?
M=)EL;U.<GGKCB@#U.C(K&\6ZG>:+X2U34M/M_M%W;6[211[2V2/8<G'7\*XE
M@;#1?!FN:;<%[Z[NX(;F02;A=),292V3@X.2#VQ@8'% 'IV1ZBER*\?O_#<L
M5]XI\+^9(&U61+[2B+HJT> =Y49SM4@Y48!# <9R+-KJ \2>$;W5O)N+:WT[
M1VL=\>]9_M  \S:P!)"[0H89Y9_>@#U?-&>:\N\/6LEG=>"-4CN+B6>_L?L]
MUOF(5U$0(;RW.%P1_" >3P<UE^&I9]1@TKQ)-JMG!JLFJJEZ@EE,S%I3&8&B
M+[5^4C QP%#8H ]ES17F?A7P^-2\0:M/<ZGJ+/I6MO+ RW9(8,BDHV.JYP,'
ML,5W7B"\N-/\.ZC>6D32W$%N[QHI&20#CKQQU_"@#2S7*:CXLNTNM3AT;2QJ
M9TQHTN4278^YN2J@CDA2#U[USE]IUMX=O_"NJ:)J,IFO+E;:Y62Z:8WL;JS,
MQ!)!(/.0./I4_@70].@\;>+Y([?#VFI+Y+&1B5WPJ6Y)YZGKG':@#T>C-97B
M:'S_  MJT?FRQ%K27#Q.5=?E/((Z&O.M*E>&7X=:\9IWO]6B6VO"TS;)%-OD
M'9G:""O8#J: /6LU375;%M7?2EN8S?I")V@'+*A. 3Z<UY;M?4OAJ?%T=[-'
MX@ANC>,9;IH]CK+AK;&>%P-H0]21W-6=+TFQ/Q]UR64 2+9PW$86=QF0DC)&
M<$XSP>.>!0!ZK1D>M9/BA2WA/5PKNC"RF(9&VL"$)X->4^'+,W.F_#F\-W>I
M<WT4MM<R1W+ R1A';'7KGN/FYZ\ @ ]LHS7D4UU=:!X-\<:?93W=O;6.HQP6
M]QO>22**4Q!RK$Y^4.V.<CU[ULW]J?#GC30;72I[G[+J=G<QWBM*7W^5%N24
MD\AR6Y88SQF@#T3-&<UXB@N;3X3Z9KD5]<QW<ZKIT]R;AU\N%[G)D+9^4J,_
M-Z$Y-=SX:L&TWQ+,8]7L'@N[9#]@MG9^4&!*"2<9&,]B>>N: .PN;F&SM9;F
MYE2*")"\DCG 50,DDU@77BL1>*/#VE06HEM=9AFFCN_,Q@(F_&W&>05Z^OM5
M?XF64%]\.]92XM&NEC@,JHLFS:R\A\Y&0OWL=\=#7,WVBV,7BKX?:=&LPM9K
M:_+_ .DR%SNAC)P^[</P- 'J6:,UX?HFI75WX7LM&EO;J3[/XG>RMH0Y+7,2
M 2B.1V/W?F.<Y^4 8-/U2=H/AAXIT]#>V\NEZQ#Y7^E.X1))HMJJX;YEVL>#
MTR.XH ]MHKA= M?[*^)^MV-K+.;.:RAN'CFN7EQ(68;EWL3R.N/0>U;?C;5+
MW1?!6K:CIR%[RWMRT0"[N>F<=\=?PH W\T9'K7F]WI\.@ZAX1O\ 1-2F9KJY
M6UNE>Y:4WL;AF9VR2"0W.X#(X' XKD[6U6T\.1:S#<7B:A!XI:U2<W<K'ROM
M&TJ06PV5X.<YH ]THKQJ_:ZUWQ+XT@DUR/3KFPFB-N]Q))NM8E4,)(E! Y(.
M<9S@ ]>?6=)F>YT>SGDD,KR0HS2%-F\D#G;VSZ4 7,@=Z,XKS2\\,V.L>//$
MECJ%[J#6CV4%SY?VLJ(GRV&4YR ",@?=SSCICEM!U'5/$]WIFDZW<*L*:3)]
MG>\G:-;L^88S*-A'SA< 9]R.N: /=*,CUKR/2T:YU7POH\NNW%X434+*9AY@
MCN$5<;@22'*A@N\'J3Z$!+.QLM3USQ3X6U?4IK1--L[2TL'>XPZ1+'N,PR<;
MB<$D<XX- 'KN<49%>5WTTGB'Q)>V']L6QB;1('MWO$:+"R [IT (P^<9X!7C
MD4T:-%J7B^P@O[Z[NHY?#<OGR?:)$6<K+&N1M;*YP"<?>P,YYH ])U'5['25
MMS>W"1&YF6"$'K([= !5VOG^R*:MX1^'EQJ3)<-%KDEJLC,2?*4R85O^^5Z]
M0!GJ:]]A1(H8XXN(U4*O.>!TH RI-;E?Q,FC6EF9@D0EN[@N L .=JXZECCI
MZ<TRT\0&Z\67VA-8S0_9;=)Q-(1B4,Q7*@=N#S6'X$:1_$/C5I0=XUC:,G.%
M$28&?2K\7_)4[O\ [ L/_H^6@!O_  E\P\20:=+I;16<]W)9Q73R@&21%W$A
M<<KU&?536O!JS76O7.GPP,8;6,&:X.0OF-R$7U(')],BN0\1Z4-/URV>SU.6
M34;RZDETZRD&Z."9TP\I."0@ +8X&YCW-0V>H77AR>ZTJSN(S::5<VD4[7;;
MY;M[F10SL_5<;^#@] #Q0!U^DZ\+_4K_ $RZA6UO[20X@,@8R0\;95_V3G'L
M:V:X+6TBA^,_A>:WDW75Q8W4-U&&SMA4;D8CL"Y89/!QCM79ZE-/;:7>3VT1
MEN(H'>*, DNP4D# ZY- %K/-<IJWBO4(;K4H-&T@:DVFF$3JLP5F+\LJC^\J
MX8@^M<DI>W\,>!=:L[BXEU&]U.U%W*9"SRB8'S5?U"\_*>%V]L5L^#;&VE\:
M^,9WA7S;;5$,3C@KF!01QV^8\=,G/6@#O(W+Q([*4+*"5/4>U<_?>*XXTT*:
MQA%Q;:K<"(2L2NQ2I.[&"3T_KTJYXKMHKOPCJ\$ZEHVLY<@,5Z*2.1SVKS;2
M]*MT\#?#RVM2\9N9X)Y,REB6,.6QNSMX'08QVP>: /8,YHSFO"GU:YT+3/&F
MD6FI2V>GVVL0P+.QD=K6&3:)"&Y;'ODD=NQKT#PO:?V=XIN434+.2&\LHY$M
M+(NZ1B,A1(26(!8/]6VD\[30!VM&1ZURWQ$U?4-"\$WU_IJCSDVJ\G>*,L S
M@=R <UA:U%%X<\4^%8M&&VWU/?97<&3(LL2QEE8@Y^8'JW?/)- 'HV1ZU6AO
M[:XOKFSBE#3VNSSE'\&X$@'WP,_C7AEIJ]U%X'T&Y>8^;;^,/(4@8/E@O\IQ
M@D=.OH/05U>FZ;:2^)/'\_V@VETDX6*X:Y:-59X,9(S@]^2#C)QB@#TNZNH+
M*SGN[B01P01M)(YYVJHR3Q["DL[RWO[&WO;6026]Q&LL4@! 9&&0>?4&O'];
MMXQX2\2Z3>VES8WEII4+O!'>.]O-CI*AR"3GALYR0,Y[S6:6R:1X(TZ"YGN)
M'TDW4E@\\A5LP(#(SDG:%R2JXP#C&* /8:*\3T&]N]2T7X:7%YJEY)=3W<D<
MF+ASYJ!'.7.2"PX&20W)Q[7/MD^G:+K6C07-U#8OXF_LT2/(S/! Z1E@KL21
MDLV"2?O4 >AV_B"2?QA?Z$;/:MK:QW*3>:#Y@8D8V]N0>M6?#VHWVJZ1'=ZC
MIS:=<,[J;=GW$ ,0#GW S7*Z'I-IHWQ&U2TL3.L"Z/#M5Y7<+\[#*EB>O4X/
M7GJ:YG3#/_87@$+>W;E]8G2=VN'8R?/(/G.>3@=^G:@#V2F"./>7"+O[MCFN
M$^QW>@^&O&-II%XPD@E9[1KR=F$)>%&(WL<XRQ.2>IK*\*6-O?>--.O])BUJ
MUL(M-!O([EYXHGG&%7Y6.'8#))Y!R#DDF@#U.FR2)%$\CL%1 69CT '6J^I!
MSI5X([A;9S ^V=C@1G:<,?8=:\DM[.."UUC1=3M]0M]3AT5W>-+R8P7X4@^>
MDA<#=G:&!Y^;'3.0#U^UNH;VTBNK=]\,JAT8J1D'H<'FIJ\J6VCAC\#>&A<S
MQ:9JD,DU[LO)?G9(8RL8<MN53G.U2.G3DU3UV^OO"%U=:#I]]=?V+<7]DDEY
M-=;C81S,5DB#,VY1M4,&_A!]<&@#TCQ5KP\,^&;W6/LYN1;(&\H,%SR!U_'-
M:EM-]HM89B-ID17QZ9&:\F\6:3:>'O!_BVQL=3EGM;JW2X@LV>246P!"M\Y)
MQN/(!.3@XS@UTG@R[DU#Q!?'4S-!J=E;1PQ6?FYB6V<*RR+CABQ7D]1C''&0
M#NJ*IZM=266C7UW"%,L%O)(@8$@E5)&<<]J\ZM;'[+H_AKQ9IFNW,NH7\MJM
MV;B<E;\3,N] A)5",D@*/E"D=C0!U.J^*[FVU74+#3-+;4)=.MX[BY590K?.
M3M51CD[58_@!WKIHW\V)) K+N4-AA@C/K7G.@:'9'XO>*G+79:WBL9H_]-FQ
MN99"<C=\P]%.0!P !7=:U=)9:'?W,EXEDL4#M]I<96(X.&([X/;O0!>HS7DG
MA&:[T_Q7X>ACN+_R-5TF:>X6[N6D\]UVD3;"3Y9?<6P/4# P15'0H;AO!_P^
M\2#4;O\ M)[^*VG>2X9A/%)(ZNI4G!)SG/7J>PH ]IHKS.XEU'PUXD\1:5%-
M<7CZQ;)/H\5U=.1OR4DC1G.!C<'P.0/8#'?:+IYTK1+*P:5YFMX5C,CL6+$#
MJ2>30!>K!U/Q&VF^+-#T1K,NNJ^=MN-XPAC0N1MZ]A^=<M?.OBSQCXDT/4KJ
M6QCTR&+[!)%</"5=TW>=PP#%6/&<CY:2_G5O%OPUD>]%T$CO0]V1M$I6VPS\
M]B03F@#TBBO*/#K72^*/#NH1W]Y);7S72233WQ<7R>6[HZQ;B$12,#H>??FG
MI1N+3QAH8U2[OK>\NKIY%U&WO7GL]7&&PNU6VH0", @#Y3CB@#V.BO,O!Z7-
MAXQBLM7?5(M1:VF=9&OGN+2_4N&#IN.%9 0,8'!/UKM/%FJ7.B>$]4U.SA\Z
MYMK=I(X\$Y('M0!LURNI>+KBVUB:UL-)EU"WLY8HK^6)OGA:3&,)CY\*0QQT
M!KGKJ"3PX_AG6=&O;JX.H31V]\)[QIQ<HZY! 9C@J>1L' )[5/X(T.WL_'/C
M&19KV0PWL0C\V]D?AH58A@6^;&< L"0 !GB@#T2BL?Q7<FT\*:I.+\V#+;/M
MN0FXQG'! [G/0>M</X/GU*S^(PTUYKU+*YT&*[:VO;QYW$F\KN^<G:QYRH./
MRH ]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7KJL]D&VY:<A<G'/
MEN>.>> ?6K=5KK/FVN"O^M/4X_@;ISS^M %FBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"K?Z;9ZI;K!?6Z3QJXD4-_"PZ,#U!'8CFHX='TZ"RFLTM(C;
MSY\Y'&[S,C!W9SNXXYJ]10!BZ;X1\/:/'<IIVCVELMRI6;RX\%U/4$^GM5B/
MP_I,4=C''80JE@Q>U4# A)S]WTZFM*B@#D/%WAD7&B7*Z5I5O=R7%W%<WMH[
M!/MJH1E"[<*>%Y_V<=ZS/"/AJ6#78]1_X0RR\,B!65C%>+-)<!@?E^3Y0N3G
MGG*K@>GH5% $5Q;PW=M);W$22PR*5>-QD,#V(JC:>'M(L+V.]MK&*.ZB@^SI
M-R7$?'RY/..!6G10!3U43'2+P6\#SS&%Q'$C*I=B#@ L0!^)KE_ OAB.R\.:
M7_:V@QV>J62E,/(LV&SS(I4D MG)Z'FNTHH PI/!?AJ5F:31;-BT_P!HR8^D
MF0=P]#P,XZXYJ\VB::]XMVUI&9TE\Y6.>),8W8Z;L<9ZU?HH RH/#6BVT\<T
M.FVZ/'(9DPO"R'JX'3=[]:MV>G6>G^?]DMTA\^0RR[1]]SU8^IX'/M5JB@"G
MINE6&D6"V.GVL5O:J6(B0<<DD_F2:I:9X2\/Z+?27NFZ/9VMS)G=+%$ >>N/
M3IVK9HH *R[7PYH]C.LUM811LC%D SM0GJ57HIY/( ZGUK4HH KM8VKWZ7S0
M1F[2,Q+,5^8(2"1GTR!4#:)I;Z9/IIL8?L5P6:6 +A7+'+$CW/-7Z* ,U?#^
MDQSV,\=C$DEA&8K5D!7RD.,J,=N!Q[5#%X4T"#6WUJ+2+1-2<EFN1&-Y)SDY
M]3D\^];%% %*PTFQTQ[A[. 1-</YDIW$[V]3DU<90RE6 ((P0>]+10!DV?AC
M1-/EADM=-MXV@+&'"Y$18Y;:#]W.3T]:M6>DV.GS3S6MLL4MP_F3."<R-ZGU
MJY10!%=6T-[:RVUPF^&52CKDC<IZCBJ"^'=(0::%L8@-,&+(#.(.-ORC/IQ6
MI10!E?\ ",Z+]J>X&G0B6287#D9 :7.=Y'0MGG-/D\/Z3-K2:S)I\#ZC&H5;
M@KE@!G'\S^=:5% $5S;0WEK+;7""2&5"CH>C*>"*SK?PSHUJFG)!I\2)II8V
M8&<0E@0=O/H36M10!GKH>F+;WL'V.-H;YV>YC?++*QZD@TEKH6F63A[>T1&$
M)MU.2=L9.=HR>!P.!Z"M&B@#/M]"TNUT?^R(K&$:=M93;%=R$$DD8/N34.B>
M%]#\."4:/I=M9>;_ *PQ)@M]3UK6HH BNK:"]M)K6YB66"9#')&XR&4C!!_"
MJ$7AS2(9["9+)1+IZLEHQ9B8588(&3W'%:E% &(GA#0(X/)CTR%$^TF[&W((
MF(P7!!R"0,4H\(>'EM;RU32+5+>]='N(D3:LC(05) XX('Y5M44 5$TRRCU.
M344MT%Y*@C>;^(J.@^E6F4,I5@"I&"#WI:* ,K3O#>CZ1*)+"PB@90P7;G"!
MCE@HSA03SQ0/#6C"Q%D-/A^S"X^U>7@X\W.[?]<\UJT4 9%]X6T'4M4AU.]T
MFTGO82"D[Q L".G/?'O6O110!PT>A7&J^/\ 6+C5_#[#2Y;:."&X:Y1EF"$Y
M#(K;L'<>""..>M='JOAC0]<M;>VU/2[6ZAM_]2DB B/IP/3H/RK6HH SET+2
MD:S9+&%#9J4MBB[?*4]0N.@.!4.J>%M!UJ]@O-3TFTN[F#_5R2Q!B!Z>X]C6
MO10!BZIX1\/:W/!-J6CV=U)  (FDC!V@=!]/:KS:38->Q7AM(OM$,)@C?;RD
M9QE1[<"KE% &')X.\.RZ='I[Z/:FSCF,Z0[,*)#G+?4Y-;4<:11K'&H1$ 55
M48  Z 4ZB@#!&DWFG^)Y=1T]87M+[:+V)W*LK+D"1."#P1D''"\9K5%A:C4&
MOQ"OVID$9E[E1T'TY/YU9HH K'3[-M174#;1&\6/REG*C>$SG /85%/HVG7-
M^E[-:1O<H5(?U*G*DCH<'D9S@]*O44 <_IV@-_PD][XBU!8S>2Q"UMT4[A!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !56[+":SQC'G'.5SQY;_E5JJMX 9K/*Y_?''.,?NW_.
M@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;O_76?WO]
M<>@S_ _6K54;_?\ :M/PP"^>VX8Z_NWH O4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5*__P"/BP_Z^#_Z+>KM4K__ (^+#_KX/_HMZ +M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51O]WVK3L ;?/;
M)SS_ *MZO52O_P#CXL/^O@_^BWH NT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5*__ ./BP_Z^#_Z+>KM4[W;Y]CN!)\\XP<8/EO0!<HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J-^3]JT\8X\]N?0^
M6_\ G\*O53O$D>[L=BDJLK.Y Z?(P'/3O_GF@"Y1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit101-iansconsultin006.jpg
<TEXT>
begin 644 exhibit101-iansconsultin006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JM=K<K#/+:ONF\HB*)P-F_L3T/MUQ5FB@"
MMIS7KZ=;-J*11WIC!F6%B4#XYP3VJS110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (1DCDC'ZTM%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !12$@=2!VYI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKG+
MOQ6T*:E-:Z1>WD&GR^5*T"Y=V&-P1>K8SV[@B@#HZ*PO^$CEGNKN"PTJZN&M
M84DE+8C^9UW",;NKXP2.VY<]:SH/'<%];Z#/I^GW$Z:P)/*)(78R*Q*MZ'*X
MSTH ZZBN+_X3B^DU6]TVW\/7,UY9V,%Y+$KJ#F3):,$_Q #@=R#5W3_&]AJO
M]E1V44DESJ,<LBP%@#%Y1 </Z$,P&/8^E '3T5Q5[\1;6UL+N5;"9[NRU".P
MN;0.N]&=@%8<_,#GCZ5<B\77227,5]H5W:-!]H=II2%@\J-N',I^4;E(.#Z'
MTH ZFF++&TCQK(ID0 LH/*YZ9';H:\YO?']WJ%_X&;283'8:Z\LDJR<28CVX
M7.< 9)SZ\>]:[:UI.F^-?$$T]DT,]IID,]Q=B0MYD8W';MS@8XQZY- '945S
M4OBTVDVE/>Z?+;V>ILL<4[./W<C#*JX[9X ]^*R+GXBRPZ+?:O\ V.XL]/U/
M[#=LTRYV[Q'N3'WCN9>..,T =Y12.6"$JNY@.!G&:XV?XA0VWAZYU>XTRXB6
MTO#9W4#R*'A<$<GMC#!N#T(H ["6:.")I9I$CC499W8  >Y-*CK(BNC!D8 J
MRG((]17GOQ%URWU#PIXITA+61Q:6$<\LQQL#,054?[7&?RK3\,>)O-U"S\.O
M921L-'AOK:8N&$D6%0YY.#N/J?K0!UT4L<\8DBD21#T9#D'\:5W6-=SL%&0,
MDXY)P*X?PQXCTNT\.Z3%ING&!-0O;B&WM5GWE2))"S$L2>H)/H3BJOBC5GU#
M1-,;4M-GM+J#Q':6VQ@=KN)%.]#D;D(/!]NE 'HE1S3Q6\?F32I$F0-SL%&2
M<#DUC:5X@>]\1:KHES;+#<V(20%'W"2)\[3['Y3D54\?W]KIOAC[1>:='J$(
MN[=?)D;"[C*H5CZX.#CVH ZBBN5O_%\]MK][IEMI;7+V:([Q"4+-,'QAXD/W
MT&2"?4$=JZ=V986=4W,%R%SC)]* 'T5YWI_Q(OY]-T;5[SP]-#I6HR?9WF1]
MSPRF0JNY?[AQC)[\8JRWQ"F72/$]X=.7S=$U VGEB3.]?EPQP,C[Q[=J .W$
M\1G, E0S!=YCW#<%Z9QZ42SQ0;/-E2/>P1-[ ;F/0#U/M7 227L7Q;U.?3K2
M*>Y?P_"42278I;SGZGDCMVK/UWQ%:^*]"\&:K!$8Y5\36D,T3<M#("P=,_7'
MZ4 =WK%BVLR645MJ"Q&ROHKFXC0@EU7)"'TR=I]]N.^:V*X<:U8:'XC\77AT
MD1O!]D$LT+EI+IF4[05/"XR!QZG-:-CJ^IWFHSZ/KN@-%&\!F$\),L#)TV,<
M#Y^N1]* .CAGBN85E@E26)ONNC!@?H14E>7^&/$-[X?\#^"E6SMSI=W$D$]W
M)(5%NQ/RY '0] ?4C/'-=M8ZQ=7WB;4;!+1?L%FB#[4&/S2GEDQC' QGZB@#
M:HKC]<UO5+7XC>&](AC3[!=Q7,KD.0[LB8P>VT;P>^2.V.8[3QS=7WB35=,M
MM%FDBTJY:*ZE1PQ"^7N4JO<LP(Q]* .TJO=WUK81++=W$<$;.L8:1L LQP!^
M)-<7I7Q#,WB-M*U2WM;3.GMJ!V7&Y[9!R4G!QL<*02/K7.>,]:N?$'AC2M6N
MM/CM]*FU2V>SF$F9O++=64X"DX' :@#U^FNZQQL[L%102S'H!7&:CXZO+:2[
MELM O;RTL;I[:;RXG,LI7&6B 4AE!)!R1RIIGBC6[_4++7;#3=-M[FWLK,F\
M-Q(4;<R;PB#!!8+@\D#)% '96MU!>VD-U;2K+!,@DCD4Y#*1D$5-6%X+*MX&
MT$JP8?V?!R"#_ /2K'B36?[ T"ZU/RA(( "0S;54$@98]@,Y- &K17#P^.;V
M/36N+G3[>Y:>]CM-/?3KCSHKHN/O!L<!3N#>FTUK:;XAN6\0OH.KVL5O?^1]
MIA:%R\<T><':2 05)&<CN,4 ;MQ<P6D#37,R11+C+NV ,\"I:X?XM(K> Y"0
M"5O;0J3V/GH/ZFM"\\1:G<ZQ?:?H%A;7;:<%^UO<3% 79=P1, Y..N<8R/>@
M#J**\\B^)CZH^@#1]/C?^UUF5?M,VPQ2QAOD.,]QU]#FKB^.+NV\'C4+VPB.
MJ+?#36BCDQ$9RVT-D\A,D'U'O0!V]%<UH?B:ZU#Q#J6@WMDD=[IR1/-+"Y:(
MK("5VD@'.!SFI_%&N76AVMM);6T+B:;9)<7,OEP6ZXR7D;L.P]R* -ZBN";X
MBD>&/[2>VM[>:+5&TNY:XD98(77.YRP&=O  R!R1G%=1X=U.XU?2$N[F.V5V
M=E#6LWFQ.H. R-W!H TI9HX(FEFD2.-1EG=@ ![DTV"YM[J-9+>>.:-@2K1N
M&!P<'!'O7$JLGB;XHZI97ZQR:5H5M#Y=LQ)$D\PW"0CH=JAE&<XSD=36S?Z=
M8Z%>R^)4/V:&UM)/M44$ /G*/F!/?(P>GJ<T =%17%7/C34-(?2;G6=-@BTS
M59T@AEMYB[PL^2GF @#H.=N>:P)?BEJEM9:CJ4VDVS:?IVKFPN-LI$A0[ A4
M="?FYR>WO0!ZI17#ZQXXN;/Q4ND6R6"[8(9Q#=2E)KL.6!$/\)(QW/)X]ZL7
M7BO5+6U\6.^GVWF:)$+B$&1P)HRA?GY>&PI'&1GO0!TL^J6-KJ-II\]U&EW=
M[_L\)/S2;1EL#V'-6Z\RO;_^VO&WPUUF%8,WEM=R#:VX!C;$E<@= 3C\^*C\
M'>+_ !%=^%-9UV[LX;V7[?(B10R%0FTA.0>%C4 '(YZD\T >HT5YO-\2KR'P
M]XKO?L=E-<:&(2CV\Y>&<2J&5@V 2.>W7M6O-XFUBW\3W>C26]D&FT\WNGMN
M; "8#K*?J>,=J .QJM]OM/[2_L[ST^V>3Y_DY^;R\[=WTSQ7,_#BZU._\*6U
M]J(MB+M3.KPR.Q9F8ELAN%'3 !(K'U*XO(?C1<1:<;0W\OAM%@6ZD*J6%Q(>
M@Y/3H* /1Z*X3_A.+^3P7I&M16EHKW4C1W<\TN+:V"%E=RPR=I9<+_O"JUQ\
M0KZ#P(FKRVMO;W@U Z=<2S*X@A8,5\YA]X)D#@\_,!0!Z)161X;U2XUC1UN[
MD6I<R.H>TE\R*10Q =3Z$<UAWWB37Y/&FH^'=*L[ O!IR7<,MR[@,S,5YQVR
M#P/S% '9T5PT'C6_UG2]!BT:TMDU;5[(W>+ER8K= ,%CM^9AN( '&?45L^'-
M=NM0N;_2M4CMXM6TXQ_:%MV+1LKC*.N1D X/';% '045QWC#Q/J.CW\-EI[Z
M?!));27"O>[F\YE(_=QHI#$XR2><<567QEJ^JZ?X=CTBRLX=2UBQ:\(O7;9"
MH53D!>6!+#'3C!XH [JJL&I6=SJ%W80W"/=6@0W$0/,>\$KGZ@&O,]5U?Q9J
M>O>"[>:VAT]Y[N<RVDC,@DEA1V#;AD^61@@8Y/7BMF36-5CUCQG'ING:9'J6
MGVUI-YI!8W)*.2'(P> NU?\ Z] '>T5Q-OXPOM3M/#NH:>MF=/N;>2ZU.:3=
MM@1%^8*>Q#Y'.>AJMIWC'7M2N=)U2VT^*;0=0<(8HX)3<0JV=LK-]PCID#H#
MU- '?T5B^+M9G\/>$M3U>VACFELX&E6.0D*V/7%<S8^,=?BOM"N=7M+%=&UA
M(X8G@W>9'<,N[+9.-APP'?I0!Z!17G6E>.]7N/%=EI]];644-_<SVZVJ;O/M
M#&I8>8V2K%@N<#ID=:DGU_Q5JFCZG/8IID<5K)?6\\B%Y"NR(^44QU._[PQ[
M#I0!V>JZQI^B6\<^HW26\4DJPJS]"[' %7J\AN]>UG2_A9X;O;^VTN^DFNK5
M%\]'D^1L8<Y(_>9[]*ZS4-=\5$7-_I&F6MU86UV8%M@2;BY5'*2$'(5"&5L9
MSD8Z4 =(NL:>^M2:.MTAU".(3/!W"$X!J]7"G7Y1\2]4TV/3K));?25N%N2I
M\UR<X5CV4$'CFLS2_'NOOH7A[Q+J5OIZZ'?%(;HQ*XEB=W**XY(";L#')_E0
M!Z;3)94@A>:5@L<:EF8] !R37FES\1M4LO$5C;W$5BL5SJ;64E@H+7$$>&\N
M1W#;06*L=N.F/>I-#U+Q/_PD?C;^TKO3[RVT]=J0"-EZQ>8B@] N&(.023WQ
M0!Z%87]MJ=A!?6<HEMIT#QN.C U8KS[1/%5W=Z5X8TK3+6QM[_4+(W3?NV$%
MO"F =J Y)R0 ,@>]5=1\?:YINBWT4UM8_P!N:9J%M;W:8;RGAF?"2(,Y&1V)
MXP?;(!Z7534M3L]'T^6_U"X2WM8L;Y7Z+D@#/XD5@Z1KVIOXWU;P]JB6O[N!
M+VS>W##]RSLNU\G[P*CIQ2?$;5+C1?!%[J%O;V<_E-%YB7:%TVF103M&,D$C
MN* .JHK@=6\2^*AXHUK1M,318Q:627=N]RSL[#/S90$%N,C(Z';G.:Z/P?KD
MGB7PCIFLS1+%+=P"1T7. >^,]J -6[NH+&TFN[J58K>%"\DCG 50,DFH].U"
MUU73K>_LI1+;7""2-P,;E/0UYG>3ZM<:[\4(I[J"2QMM.5%C\H[AFV9U .[
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M][9JK7$0SF,,,KGZ@@_C7&>(O%^L6'BJZTV&[TS3]GD"QCU*-E2^W8,A63(
M*YV@<\GGJ,/N?$&L6?B'Q@OV73U?3],6ZLW\M@9!L)_>,<;@&5NF!VSG. #O
MZ*\_T_Q;KBZQX4_M!;5K#7M.+K'#&?-2=(1*QSG&TC( '/2H8/&7B:<VM_%I
MWGV-Q=*!;1:?*)8[=BPRTA; =2N2,8P1WZ 'HU%>?1>+]7E\9'2Y+C3[.07I
MA_LV[C9)9;8 XFBDW8<L<\8Q\I'4<MT'Q?KNI^(ET^[GTRTF6]E6339[>2*X
M^S#.R1&9L/D@<@8ZT >AT5A^+==?PYX>EOX84EF\R.&)7;:N]W" L>PRU9*Z
MKX@T_P 50:#J5YI\HU*UDEL;F.V92DL9!D1DW\KM92#D'K0!KKXNT-]?_L1;
MY3?[S'Y>UL;P,E=V,;L<XS6W7GWPJ@NM1\%:;J&ISP7;&:XEC9X#YJR>=("Y
M<L<D\]AQ7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<,-'\6Z/XCU(:0]G/I.JR^>TEQ(P>RD(
MPQ5>0PX! XY_$UW-% '%C2_%&@ZW)=Z<8=7MKRWC2YBN)O(9;A%"^=G!!#*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$OB.:U$\+VLRVTBL0K!A*@(^4D$$-Z]ZL6CM_PLSPTFX[?^$<D.W/&=\7-
M'H5%%<Q=>-[.WU;5]+73=3GN]+A6XF2*)?GC(SN0E@&QZ=<@@ T =/16$/%=
MC*FE_9(KBZFU* 7,-O%L$@BP,NP9@ !N /.?3-<MXP^(OV;PU=OH\=Q%J,%_
M%8SI-&H:W9F'49P<KG!&1SS0!Z-14<+M)"KO&\;$<J^,C\B1^M4=:UVRT*WB
MEN_-9YY1#!#"A>260]%4#^N!0!I45YUH%P'^)WC1_LMV@6RM"T,A^8G$F=N3
MCGCH<5/X=\3:7HO@SPY!9:;J;QWL,HLX,"63<@+;7(QR>><8]<4 =]17(/\
M$&RCM)IY--OXVMK>.>[BD$<;V^_)",'<'?@$X';'J,W&\9V$N/[/MKJ_4V27
MY>%511"_*DF0KR1D@>W.* .CHK@AXYNK_P ;:!8Z?:3-I5]I\EZ6V*)'(X"\
MM@!<\]\UGZ=KMOX8UOQ_JMS:W,UO!>PM*+5 S*/*Y;!(XH ]-HK(A\1V5S/I
M44"2R?VG ;B%E"X6, '+<Y'W@. >:UZ "BN=N_%BQ7]]:V6EWE__ &=M^V20
M[%5,J6VJ68;F QD<8SU[&J?'VGS&T33[.\O9+W3GU"V6-1^\5>J8SD-G'48Y
MX)/% '645#:3_:K."X\J2+S8U?RY5*NF1G# ]".XKEOB%)I4>EZ9_:MA<W2'
M4X/(,!QY,N3AV/88W#H<YQQG- '7T5R]UXS"7&O6UII-W<W.B^4;B/>B;U<%
MMR$M@@*,\X/;BK,7BRROA9C2HI;^2ZMDO$2/:I6%C@.VXC&><#N0?K0!OT5X
MAX7_ +(;X37']LVET]J?$#;8[=U1TD\Y=F?F QNP#C/7/;(]%NO&T<&O:CI$
M.CZC=3Z>L#S&% WRRL1N'/0 9P>3SQP30!U5%<1_PL_1S<VK107$VFW,WV:*
M\B ;][N*_,F=RID8W$=>V.:MR>.H/.,MOIMW<:7'>"REOTQM$I8+\J_>903@
ML/0XS0!UE%<1!JM[J>H^,;*[@F-I;KY,2ML*(ODY)/.?F)]^W2J7@CQ);:/X
M/\%:;<V\X&H6BQQ77RB$,$SM))SD]ACGG'2@#T2BLG2M;_M35M8LTM72+3ID
M@%P6RLSE S >FW(!]ZUJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9--%;0O-/*D448+.[L%50
M.I)/04 /HJ&TN[>^MDN;69)H'&4D0Y5AZ@]Q4U !1110 4455FU*QMKZWL9K
MN&.[N<^3"S@/)@9.!U/0T 6J*** "BBB@ HHJI=:I8V5U;6MS=PQ7%TVR")W
M :0^P[T 6Z*** ,/QCHTGB'P=JVDPMB6ZMG2/IRV,@<^I %<IY%YK7PRT"]T
M^W\[4M*DAG-ENQODB.V2(G^$_>YP>G0UZ/5.TTVWLKN[N+<,ANF5Y4!^7<!C
M<!V)&,^N!0!C:#J\^IW5]J=UH5UI%LL* /?*J2R8W$D@$X [9/Y53^&MK+!X
M9GN)%*B\O[BZC7! V/(2I /3(P?QKH=9T:SU[3FT^_61[5V5G1)&3=@Y )4@
MXSCCOBKT<:11K'&H1$ 5548  Z 4 .HHHH **** .?\ '%K/?^"M5LK6"2>X
MN(&CCCC&26/3Z"LZXO=:/A.STS1])N!J<MLD#27(\N*U.T!F8]\<\+G.*[&B
M@#R\^%;OPEXB\%/96=UJEGIEG<6;R1*-RNX&&8= I)(SGC^>9HOAO6;3PEIU
MO/I=RMQ#XADNI4VYVQ[R=RXY(([\'V[GV.B@#D/%-C=W?C#PE=6]M-)!8W4L
MEPZH2$5HF0?J17*ZIHFK7.@>/X8-.NC-JUXDEDOED%UV(,^W*'K[5ZS10!XS
MJ=KJ,WCNZ-OI^HLK>'HK"]>R2.657D.>0[*%.%/KT''->C^#)M/;PU;VFFV]
MU;06&;,P70_>1LG!#<D$_0D<U2?PQX<\2WDVNVES<^;<J8)Y[&]DB$H7Y2K!
M6 .,8_"NATW3;32-/AL;*+R[>%0JKDD_4D\D^I/)H RO'-C=ZGX(U>SL83-=
M20'RXP<%R"#@?E6+&^HZEXJ\+ZO-HFHVB):3I<),%;R6<+C)!SU4]L],@=NZ
MHH \CO=!UF^\+QB+0)#)I&M2W<-E._EM>0N7.0RD[&_>$=3]WWKI_ FD7%K/
M?ZE+X?AT..Y"QI:^=YTS[,C>[XXXP N3T^E=%/XATBVCF>;4(%6&=;:0[L[9
M6QA#C^+D<>]6K:_M+N:XAM[B.26W8),BGYHR1D CMD<T 3R.(XV<AB%!.%&2
M?H.]>?>&O"$6I^"K_0]?T^5/,O[BX0NI5DWRLR.C=F P?YUWMY=V]A93WEW*
ML-O!&TDLC=$4#))^@IT$\5S;QSPN'BE4.CCHRD9!H \BLO 6NKX6O$NM\VJ6
M?B3^U(_N@7H7R^1G&W< >O<>]='K&GW6M:K)XAATJ\BN=.TJ:&UAE&QIYI5^
M[PQX'3/3)R,X!KOJJ6^J6-U?W5C!=1R75IM\^)3DQ[AD9^HH \_M[&_L+7P!
M'9Z'>[-.)6[0_+Y ,?EL2><\L3@=0.U=+>>!]-O=-O+&6XOGAN89(2DMR[JH
M<@D@$]B 1]*Z:B@#B-!OO$F@>'(]'O\ 0I]0U*QC6"":UE!AN@$&UFD<@J<\
M-D'U /2HYM&UJR\;:5XKN(X[IFM'L+ZVL]S>2&8,LD>[!905 ;H>X!Z#NZ*
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MM4%M-:Z[.7:)"Q(0IM*,2!GCT]: *X\4:[:3:+>ZA9V?]EZO<I;HL#LTD'F
M^6S'H<\9QP,]:JP^--7GT7Q7=""U2?1-0:W0')5XU"DY]\$U?M/#.N_8M#TR
M_P!4AGL]-G6::55(DN1&085(Z#! ).3G:.E8\OP_UY!XKM+/5+&&PUN=KJ/]
MTV^*0X^4CIM('/?Z4 :6J^,[]=1U*STVVA+:5IHO[EI\CS25W!$]L#EN>N*P
M;W5=2UK4OAMK$]C;0W=[---'$DI*K&]N2,L1G(!R1^%8VO2:IJGCF[TN37M+
MM?[,L(8IK>_\R%)U*;IC'M8$IP,YS76:=::SXFN?#>JS6]I NBW,IW1[TBNX
MVBV*\0*Y"X;OQQQD<T ;W@_Q#>ZY'J4&HVJ0W>G7;6LCQ',<N #N7\#3?%&O
M7VDW"Q6WV:"/[)-<?:+H_*\BXVQ*,Y+')/T'&:9X0\-WV@:CX@GNY;:2/4KW
M[5$(004^4+@\ =AT]Z@\2>&-8U3Q%]OL;G3Q;R:<]BZ7<3.T.XG<\>#U((!Z
M9 % %?\ X3;4)[WP?!;64.->LFN'WLW[EO*#@=.1DX/?VI(_&>IVVDS0WEM:
M2:Y_:G]F6\,3D1RN<$,3@E1L)8Y'&*ATSP9KEI<^$9;B?3)/["A>V?RU=2\9
M0(N"<\\9/0=O>G/X)UB\M]7>>_MX+V;54U/3Y(2[+;NH"@,#C.5R#CKN- $>
MN>,-2TL^(-#N3%'JD.FO?:?<QJ=DL8&"2,_*RMGZUSD5UJ=WX<^&-[=E;J]E
MU"-ED>5BSAH7.79N<YR?P%=A>^"[C6[K4]2U:6W74;C3VTZV^SEO+BC;)).>
M2Q8G\*SM-\#:_;:5X6L[N\T^8Z%>+,OEAT!B6+8%Y!RQ)9L\=<8[T 3W/CR[
MT>SUJ#4[>!]2L+J"U@\D.4N'F *   L,9.>#TXZBH;CQ]JMGI&O2MITDLNG6
M?VN&ZDLY[>&8#&Y/WB@AAV]1]#5C4/ VHZKJ'B*:>[MX5OI;>YTZ6/<9+6>%
M<(QR,$9YQ[D5$_@SQ1J?A_6(=<UR"[U&]LC90K$&CMHT)R79>[GUQTXH Z7P
M]?ZU?27;ZG9P0VI$3V<L4F3*K+EMP[$'^=<YJ'BWQ--X]U3PSHFG6,IM;-+A
M)IY2N,^HQSD\<?6NTTJ&YMM)M(+PPFXBB5)/(SLR!CC/.*\U)U*3XX>(DT>2
MTBN_[%B4&XR1NSPW'ID<=Z --?B+/<?V3;BT\BYN8IVO1'#)=&V>)BFS;&"3
MEQC)QQS3T\<ZO-;^'%_LK[/=:G<3VTL=PCQD-&I(90P!VL1GD=*==^!=6M;?
M2+W0M7ABUVQ26.6XN8MT4ZRL7DRHY'SG(JS_ ,(=JCW'ARZN=3BN+K3KN6ZN
MI&C*B4N,$(!]T#)QGT% %?4?%>LV4UMIT\NEV6KMIZ7/D7!(2XE)8-'&_"Y&
MT=\_,*N/XDU76=0UBR\.K:^;I*".7[4#B2X(W!!CHN.-WK2>+/"^K^)(]0L'
METN33+I4$0NH&=[9@/F9><$GG'3''7FG)X5U+1=?O]2\/7-HJ:GM:[AO%9@)
M%P/,7;CJN>#W[T 4D\<7VI7_ (8BTV"V2+6X;K_7$EH988\E3CMNX^E;'@GQ
M'<>)-(N9;R!(;RSO);.<1YV,R$?,N>Q!'XY':LZR\$7&E:KX9DLKF)K+2$G$
MJS9,DK3#YV!Y"X(! &.I&:T/!OAN\\-1:K%=74%PMY?R7D9BCV%-^,J?7&!S
M[^PH DN=9O+OQ//HFF-#&]K:">:69"PWL<(H'''!)-<Y8_$'4M5718[;3X8I
M[J[GT^\25_F@N(HV8[5X++D#GJ!6]J>@ZK%XE_MW0KFSBFF@6WNH;N-F1U4D
MJXVD'<,D>X^E9=EX%U#3KK0I(-3@=;2\FU#4&DC;==7$JE7( .%&&;&<XXZ\
MT =)IE[J,/A:*^UZ".&_CMS)=1PG*@@$G'X"N2T7Q_J&I3:+.+&:>UU)CYBQ
M6$ZBV1AE&,C+M8=B0<<Y%>@7$$=U;2V\HS'*A1QZ@C!K@O#W@/6M'EBTRX\0
M&X\.6LIEM;<*5F'S95&?/*+QQ^E %2X\;^([6POM2FATT6NGZP=/G12Q+KO1
M=RGMPW>M*PFU.?XP:W";Y3:VVFV^R$QX&&9SC/KD'GWJ*Y\!ZK>^&M4TZ?4[
M,7-]JO\ :/FI;MM0;E.T#=G^$<YK3_X1K5H?B'<>(+34+:.QNK:.&>!X2SML
M#[<'. ,L"?ICWH Y*'5M0U+P=X?DLVM=)%QK[6UQ%9Q;(W F<'H1U*Y/KGFN
MLB\0:C8>,[G2=:DMH;(VQN+*X"[?.50#+N.<)M)[]1S62G@#6+;P?9Z7::O:
M)J%IJ;:A%<&W8IDNS[2N[U8]^U+J9TKQ;XBTG2A)-?:AH]R1J$D<;1)&/+(8
M/D %7.. 2#SU% &YI6H^(;^U\/W;6D @N_,>^S\K11E28B >Y^7([9]J/B!K
MTWAKP3J.IVXS.@2.,_W6=U0'\-V?PK4OK74IM6TN>TO$BLX7D-Y"RY,RE"%
M/;#8-5?&&A?\)+X3U#204$D\?[IG&0L@(93^# 4 8>OQQ>'?"&CQ6.G6=Q#]
MNM4=;J,RX+.,R#.<ODYW'OWIWBF[C\.^,O#VK!F1-0G_ +-ND49\S?\ ZLD>
MH; SZ$U'>)>^-/"T6G:?>0:;JEE-";R*YB\UH70Y *JPZE01ZCZU/K%B/$WB
M[1K48EM]$G-S?$H0OG; 8E'N"0_&>@S0!K>-+M[#P3K5Y';VUR8+*60PW*[H
MY%"DLK#N",\5ACQ#J<6H>%--MDLXH]8TQWC B($4L<:OT!^YAL #TKH_$^E3
MZ[X7U+2;:>."2]MWM_-D0L%##!. 1S@G'O6!_P (CJ_]K>%[W^T+'&A6LD 7
M[._[TO&$)^]P/E!'XT 9UE\0-0O=!TE$MX1K%YJKZ7+D$11LA)9Q_>^0 XSU
M.,\51?5+_P /ZWX_U)5@GNK6&UE4^65#+MYR ?3/-78/AQJ4.@^0-7MH]4M]
M3?4[*ZAMMJH[?>5P22X.2,YSC [5H0^!KZ8>(6U76!<2:S9QV[O# (O+94()
M&#R,GH>W!S0!/+XMN+7Q5%83)$;1M#?5&8<$,K*-N3V.34.E:_XDOH=&UDVM
MN^CZA"T]S&%VR6:[=R<D_/GOP,?C4>D^"M8CU^SU36=8M[LQ:9)ITD<%MY8=
M&8$=STQ3O#_@;4M%N8K277WN= M23:V)B 9?16?/*CTP* *NB^,=?U^VTK6K
M+3]VF7MSY;VYB&88?,:/S/,W<G(!*[:ZOQ-KD?AW0+C4G0N4*1HH&<N[!%!]
MMS#-<QI'P]OM&U%;:#7Y3X:CN/M,6FF(;D<.) H?^Z&&<8KJ_$.B6_B+0KO2
M[GA)U^5QU1P<JP]PP!_"@#%N=8UG1/$>F66H26UU:ZHK0Q/%$8S!.J[@#R=R
ML,^A&.]5? NN>)?$4%MJ=[]@_LZ07$4B1*5=)8YG0$9/*E0/Q!]:GM/"^M3Z
MAIU[K^JVE]+ID+?9?*MVC#3,,>9)\QSQV&/6KW@GP]=>%_#BZ7=74-RRSRRK
M)%&4&'<O@@D]"Q_#% $7BC7;W2+ZRBB:&&TF23S)V0RN'QA%2)3N<Y.> > >
MG6N277M4\31^ [Q[F.V^U7DS2QQQ;@9$1P#UR!C/RGUYZ5V&M>&[S4/$>G:Q
M8ZH;*2WADMY5,0DWQO@\ \ Y YYXK%L_A_?V6BZ)9P:V$NM+OI9TNA!RT3AP
M5VYQNPPY/''2@#)TSQ-JNG7_ (^U.]O([T:9<)!!"4$><*=B ]AEO?OS6U/X
MA\2:4UW+>VJS6;Z=-=03^3Y:P21H6V/AFW C&#QT-+#\/6&I>)$N-1$NCZZ@
M,]OY>)?-VA2V_/3J<8[BH;3P-KW]F74.J>(8=0N5MVM]/DEM?EMPZ[&9ES\S
M;?PH AC\7^(7M/!UUMTT#7T$4J,Q"PN4WAPV><J"-F.I S4">-]>AT+QBTGV
M*:_\/7.Q9/+*1S)@'D9.#U[U;M_ WB""T\*6XURS4:!(&WK;/NF4+LVG+G&4
M)!^O:L;Q/X?NO#'A?QWJ=_J=J\&LJ9%2.)D=)#A5526(.1[=<4 =#_PD'B"S
M\1:58:A+8^1K%NY@D@A=C;S 9 //S@@]?EQ@^U/^$LMU<?#K3[B[N/.>62X;
M.W!SY\F>_K^56/#VAZC/<Z7K&KZE#<M:V?EVR6\1C!W@;G?).6P .,#K5GP1
MX9NO">A?V5/J(O(HY7,&(MFQ&8M@\\G+'F@#*ANM1'Q/U]I;N-K.QTV!XHC
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M]HZ+VR>.16-X8'B.W\1:G#K$BKI\T:2V-O+.LLT9  D^8#E<D=<]O>JT3/\
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M=8C*'3 XZ;<?J:R[35+JST.&SM+F2'^U/%TME)<0L Z(7=FVG&,G9MZ=">]
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M'=LSD^<J1(R@CIP3FNL\?2H;+3+)FED:\O5A%DC!1=_*QV,W50,;L@CIWZ4
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M0R8..N!QNZG&<U0^S6=WXEUKPM>WRH]C;)'IJZC<D>3$$R98SC);@DDGHHZ
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M:D8/\6U0!GN<ULVU[:WCW"6\Z2M;2^3,%.=CX!VGWPP/XU.S!5+,0% R2>U
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M_4YM-M;^&6]A&9(%/S*/<50_X3OPS_9B:B-6A-M(\D<;*&)D9/O!1C+?AUH
M+?P+X;M1:B#31']DN&N8"LTF8Y",$J=W /IT]J8O@#PTFCMI*V$@L6N/M31"
M[FYE_O9WY]\9QGGK6A<^)=%M-/MK^?4[9+6Z(6"7?D2$C( QUX&:N6&H6FJ6
M:7=C<)/;OD+(AR#@X/ZT <K'H6K:UXJCNM<M;6'3M'N7?3%CD,C3Y7:'?/3
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M(!!&,4WRH\J?+7*\*<=/I0!\_P"E[H](FO?L5QJ&GZ7XJGFO+6U9@\:_/MD
M7GY#SCO7JW@^YT74=2U35-$MKDP7D=N\E]*[E;A@'&%#'JHQDCJ6[XKJUC1
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MTKVBB@#R2]LK=[#1;O3M O;"&;Q/;791HY&E=03OED4YV#D_UJ37].OKJ_\
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M)<07OFW"!_-<<N.H\K'"J.GI0!V5K\0M)NK33;O[/>QVFH7#6\=RT.(XW#E
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MC4KB\C8RQN"LKE@ORL<$#KVH VO$&NKH=I$R6DMY=W$GE6UM$P4R/@GEF.%
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MBCN1:?9D*RL(YDQ,C ' VJ"V[H-O'6N_TW3[;2=,MM/LXQ';6T:Q1J.R@8%
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M7DYW8;/<<<5+)X1\3Z7XHEUOPY?Z6AO[>&*_M[])'3?&H0.A7!^Z!P<=_7@
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MA@"*XNM<$/D)!"&:$+"'FX9E#$\[>1_B =QJ^K6FAZ7-J-^[);0XWLJEB,D
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M7R8CC;'QUQ@\^]7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YG5?";W'B*/Q#I%^=/U41""5FB\
MV*>,'.UTR.G8@@]*Z:LW5=8739;2W2WENKN[DV1018R0/O.2> J@\D^H'4B@
M#/N_#=QK=I=VNNZ@+FWN(C%]GMXO*C4''/)9B>.YQ45EX8OU73(-1U<7EMID
M@D@Q!LE=E!53(VX[B >P&36C/J>H1?VOLT>:3[&JFU*R#%V2F2!_=PW!S_\
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MBBB@ HHHH **** "BBB@ HHHH *\^\/R/=_&;Q5)=,PDM;.VAMD9\@1MN+$
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M'2K'5D@6]MQ+Y$HFB.2IC<9PRD$$'D_G567PSI$]M<6\MH6CN9!+/F5]TK
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M8NV^U2@L3F1U7<>>F<9Q7G&I0V=WX#\<7-WQJ]K?W+)-(0LL;JP, 5NH!&P
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M]"?S-/ATC3;;49=0@TZTBOIAMEN4A59'''#,!D]!U]!0!Q?QA /@R$,#Y?\
M:-KO..%'FKR3V^M8OB#3;.SU_P 5IH<2I:OX=GEU.-#F+SBI,1 !PLF 2?48
M/<D^J75K;WUK):W<$<]O*NUXI5#*P]"#P:ATS2=.T:T^RZ98V]G;[MQC@C"
MG &3CJ< <^U 'F-QK&D'Q!\-;FVO+4QQPW$<CPR*0I^R85,],Y. IYR>E5M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9]]KFE:;Y@O=1MK<Q*&D$DH!0$@ GTR2/SK0KS2^M=+
MU+X[&RNH;2YBE\.D3PR!7#.+A2-RGJ0 ",]J .ZE\0:/!J,&GRZG:)>7 S%"
M9EW., \#Z$5BZ=K6HR_$C5]%NIXS:0645Q;QI%MP&8@DDYR>,<''MUK@;>YT
MNSO-;\.ZWY[Z[_:)N+&U\M<SJ2#"4DV$J!M'<8 _"KWBC48;?QAXNN#;F_\
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M*11-]GD;SV,#)A/EY^8J,#/K77^!Y_/\#Z+F&>%XK.*%XYXC&ZLBA3D'GJ*
M+E[XATVPOVL99RUTD!N7AC4LR1 X+D#H,U5;QEHGVFRMHKEKB:]M3=VR01ES
M+&.ZXZ_2N0\3B6?X@7EC+I]Z8KK2-L$MA!L>8Y)97N!\RJ-H^7(!SSGH:'A2
M-DU?P )[*_@>UT::!UEM'Q&Y*J S8PI.QB,]OJ* .[7QMH3VFFW0NSY.I3>1
M;-Y9^:3=MV>S9XP:U1J4#:NVF!9?M"PB9CY9V!2<#YNF20>/8^E>:^'-$BUO
MX7:CIUU%-:W=O=W%S!+- \;02"1GCD4L!Z \=LCO73?#N"ZN=!'B'4I6?4M8
M5)Y@?NQJ!A53T7'./5C0!O:WKMAX>T]K_4I'BM4^_*$+!/KCI3H]:LI=8_LI
M7?[7Y/GA2AP4Z;L].O%.UK2X-;T6\TRXQY5U$T3'&<9'!_ \UY3-8^,(M%T+
M75@\C7II(])*JCOY5LWRF1P#UW#?GC:"!GK0!Z(GC+1YK>UF@>><W4#7,,<4
M+,[1*VTOM'.,D?G3X_&&ARS:7''>J_\ :H+63 ';-C&<'VR*Y77+,Z9XGT72
MK:QO/[,&EO:1R64/[PMN4!&G W1K@9."N3Z]*Q[;23<_!K2KG[)<V6H^'7-W
M;K<1E'WQLV4YYPP.,_0\XH ]4MM2M[N^O;.+>9;)D2;*$*"RAP >AX(Z=,UD
M>-]2MM+\+SSW6J7.EQ-)&IN[:/>Z?,"0!VR 5R>F>_2K'A>T>'2?MD\1BN]1
MD^VW,>_=L=U'R@\<*H5>@^[GKFL'XMLTGP[U&RAAN)[FY\M8HX('D+%9$8_=
M!QP#UH V;_QEHVG:I=Z;-+,UY:6OVN6*.%G(BR!N&!SU'3UK,U3Q_:6^K>&[
M/3XVO(M9+2+/'&64Q*.=I!^]DKQ@\9]JP9K\'XH:W>K97S6O]@E%F&GN0S A
MMJL5W9P?NCKCGE17+Z/9WNF:5\--2ETO4FCL#<P7,26SM)&SE<97 ('RGD\>
M] 'K4GC'1HITC::38US]D,WE-Y:SYQY9;H&R<8]:=)XMT>*\>T:X8RQWL=@X
M$9(69UW*I/N._J0*\]@AN["?5_"TOA)]0OKB[FO+2^FA#VY61BZN[-D H3R.
MOR^^:Z7PO<Q?\)MXLMIK2\4O=)<1R36KB-PJ*I*,<@D'TQ["@#-M];;5)];O
MYM>U'28M-U/YV9/W20H@S&ZNN%W YZDYP?\ 9KKH/%^CSS74'G21SVUM]K>&
M6)D=H<9WJ#RP^G?BO/EM;CQ5X8\;66G65VMW=:C]JMH[VWD@6504*X+8!!*X
MQQ[CO6AI^J'5+2\U6/P?)IHM+"6"XGEM-L\K[>(HE W%<G.>G;UP =39^/=
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M49_LHN2!B*?<5V$<,W(P64%<Y&3BNB\4>(K;PKH%QJUU#/.D6U5B@7+NS'
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M([&U2X$\#M)%*SL56)25!W9VC.,<YX%5;OXA&R-\LNF)(UKIDFH,;>Y+H#&
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M5*N%,2G;RY!R#C'UH ]!HKA+_P >:C%?6]K;Z+Y$YM/M9M[^98GN.2/+B()
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M'Z5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ!& Q(Y'(Q6I)X=UJ*\\.ZFEM:R7-G=W,TUK&RK'$)8F0*KD [0=N<#G)..
M*[RB@#D;_P )27?C2WUD&,6UQ:?9]2@SE9-IW(1TSU*G/;'2LBS^'3CPCXAT
MJ9T^TW@FM;.5SD16P8M"G'1023Z\^PKT6L_4-:L],O;"TN6D$U]+Y, 6,D%L
M$\GH. >M '':1H?B/4;&33/$.CZ+9VS6DEM<7-JV9+HLA7("@>6.23SG.,8%
M2^&M'\1P36=MJ.EZ780:< /M=H5=[X*I4#!&8\\,3DGC'0FN[)"C+$ >IJC%
MK-E-K4VD)(YO88A-)&8V "$X!!(P<G/3/0T >;M\/]<D\ ^']%VP+=:?JQO)
M<R?*4\YY.#ZX8#ZBNU\:Z?JVI^''M]&*&Z\V-VC>4QB5%.63<.5STR.E=%10
M!YK_ ,(EKL>L^)Y;/3K&"QU;34MH5>Z.^-D1P 0%(Y+#// ]>E;)T+4(];\(
MW["%;?2;*>&[+,,@O'&H*^P*')]*Z"^UW3M.E,4\[-,J[C#!$\T@7.,E$!8#
MWQ3;'5M)\16]U#:7"74:9AN(\$%<CE6! (..U ''6FC6NJ?%*ZOK:[\_2DMX
MKUHH9 T+77S(K?+P2$YZGKGTKK_$=K=WNA7%O8P6]Q.[1_N;G'ER('4NIR#C
M*AAG'&:DT30M,\.:9'IVDVBVUI&25126Y)R<DDD_B?:M&@#S"X\ ZDV@:Y8Z
M?#'9VTMW;W6GV#S96/RF#,N1D(&([9Q3]9\#:MXB\1:]=7*006FJZ-%:#=+N
M,4JG=C Z@,!S[UZ910!Q>FV_C2_T66RUZ/3X'CM6A\R"0NUV^PKN/ 5%).<<
M\^E96E^"]8L=!\$6<B0M+H5RTMR%D&&4JX^7U^]WQTKTFB@#G_%^B7FM:7 =
M.F2*_LKF.[M_,SL=T_A;'(!R>16%K&@>*?&'A+5M/UEK"PDNK58X+>U=I0)
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MFJZL;V']X=@4SI)@G&>BGM6U;^'-;TGQ1J5]IL5BUCK<:R7L4TS!X+@*02A
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MY$RKM+QX5MP(YP<<CWKL:* /.[#P#JFB:IX9&FW5L^GZ49WN'N'/G3-,27
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M)'%TJ*X80EN!MZY.2V/KQZ'6?JNIOI@LMEC<77VF[CMCY*Y\H-G,C>BC')H
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M,@[RPS@\ 'KQ70Z->ZQ<>+M9AFN8KG2(E018@,;03=&CS_&, -G_ &NPKIJ
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M.Q\JORA5!Z =<]/K6W%X1M->TR*?4M3O+]9;(PP%MJ")'3#$*J@%O<@]/KD
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ME((/7:.1SUH \?@U?5/#MK\0-;TRZ6)[/7(_W31AEEWLL9#>P#DC'<"N\O\
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M]T;0G_L>>W"?VI<2B2.W <,05ZLV!QR.2/0D>@VUO%:6L-M"NV*%%C1?10,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCKJ* ,JV\/:?;^&ET%H_.LO),+K+R7!ZD^Y))J_:6D%C9PVEK$L4$*!(XU&
MJ@8 %344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444T
MR1B18RZB1@2%)Y(^E #J*C>>&.1(WE17?.U68 M@9.!]!3U8,H92"I&01T-
M"T444 %%%% !114+W=M',L+W$2RMC",X#'/3B@":BD5U==R,&7U!S2T %%%%
M !12,P52S$!0,DGM45M=V][#YUK/'/%N9=\;!AE2589'H00?<4 34444 %%%
M% !115634;&&_@L)+N!+R<,8H&D =PHR2%ZG H M445!>7MKI]LUQ>W,5O O
M!DE<*H_$T 3T57^WV8U :?\ :H?MIC,PM]XW[ 0"VWKC) S[U8H **K"_M&U
M%M/6YB-XD0F: ,-X0G 8CTR"/PJS0 450U#6]*TIXTU#4;6T>7[BSRJA;D#C
M)]2/SJ\"" 000>A% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$&/#?*"7.=Q;%<['\.]4BM[+3TUBT33;#4_M]O&+5C(<R,[*[%_]HXP!V_$
MN_\ "8:JUSK<L=I8'3M&O'2[>25U<0+'O9E 4[F'/' [>]1:'XUUG5KS2)3H
M5Q]@U $R$6DJ&U4C,;F1OED!&,X QGC-;&E>&7M+[Q&UX;:>RUB8R&%4(PI3
M8RMG(.1R?J:R/#?@;5]"N8K.?Q))=^'K1]]I8>0JLI#;D#R?>8*>V>2!VXH
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MF[,F0?D!7&!U#9]J8L6H:S\1-)NAK3V[_P!C[YHK1EEA619E$J*2.A92I/7
MH [31M>MM;DOTMX;F,V5P;>0S1[0S  Y7GD<]:U:\HTWQ=K(TKQ7)<:@6EAU
MM+"VF=4Q;I(44$ X!QNSR>:WXKC5= \5V/AZ;5IM035[6:2*XN%7?;2Q*N6X
M&&5BP.WC!'O0!W%%>;6^J:W;:IX!GFU:6>/5H/)NH"BA&80F3S/7=D#OCVIE
MGK6J'QN;74]7N]-G;4F6WL9H5-M=VP#!1'(!]XCYB"<Y&/H >F45S?B[4;JS
M72+2UNTM&U'4$M7G/54*LQ"\'YCMP/K6/JMWKWAZV.FMJL4KZCJ<=OI]U*"9
M((7&6WG;C<"'"DYSQ]* .\HKSK6]1USPS>ZK9Q:M+<PRZ1<7UF\Z(6MI(E&0
MS'[RL>>1QS531-5UU[[P1-/K$\T.N6$L5Q$RKA)%A\P2+QG<2.>U 'IJ2QR%
MPCJQ1MK '.T^A_.J.LW=EI%A<:W=6QD^Q0LY>.,-($ZD+^7K7F.APZ_I?@J6
M]3Q7.TMS?O:?Z6 5C_TAE9H_DW&0@' (QD]*T;?7M6&B^/[*+4;HR:/%YUG=
M7,6)E#6_F;6! Z$$ D9YH [_ $C4H->T.UU&.%T@NX1((YEP0".A%6[>WAM+
M=+>WACAAC&U(XU"JH] !T%>=VNK:S=:EX)LEU6:--2T:2:X?:K,TIB4A^1U!
M.0.E9MOXKU]O#NCZ8\MS+>W>JW&GO=1^6LY2%FP1O*IO8 <G'?% 'K59%OXB
ML[GQ1=^'T2<7=K;I<2,T95"K$@;2>O3J./?.:\^UCQ'XL\+:+-;W1=3=ZI#;
M6%S>-$]Q%#)]XNJ%E)4[@I)Y'7I6OHEK)9_&/5HGNYKD?V+;E7FP6 \U^,CK
MSD_C0!U^IZPFF7NG6S6T\QOIO)#Q@;8SC.6)(P/U],UI5Q/C2^U.R\3^$H[/
M5&M;6[OQ%<0X 64 ;L$[2>>F.![CK7&3:[XDF\/>)=17Q#>)+I.O/#'''#&-
MT1\L!7ST09;ISUZ]@#VFLB[\1V-IJ&C6F6F.KLRVTD6&0A8S)DG/0@<8S4?B
MHR-X)UATFDBD%A*ZR1-M8$(3P>W2N(2RN+.#X:V<=W,6DR3)*P;819L/E7IZ
MXY('O0!Z%K6JIHFDSZA);SW"Q 'RX$W.W..!5V*030I( 5#J&PPP1GUKRB36
MM:T[P3XILUU6XEN=&U%;>*^D ,LB-L8[N,?QD<#I4OC#5-:L=0N))=1U'3M,
M?3(EM+ZV7?##<Y)/G *2,C:,] ,<4 >I331V\$D\TBQQ1J7=V. J@9))]*YO
M3O'>F:A)9G[-?VUM?R&*RNKB#;'<MVVX)(R.1N"Y%:VIK9WGAR\6[G3[#-:.
M)90<KY90Y;/I@DUYY /$'P]M['3-<$.M^%A<0Q17JY6:RPR^69% P5#A<<^G
MT(!ZI17DL^L^+]8NM6O]+81Q6EZT>U[Y88;:.':3YBE"6\S+9] O;-:QO-8\
M6W'B"/3=?33;W2I4CMH8QF+[H??(3]Y7Y'3@#/.: .^-W;"\%F;B(7)3S!#O
M&\KG&['7&>]5-&U=-9M9ITMIX!%<20;9EVEBC8W#V/:N$\/VLEW\6=6N'OIG
MQIEK/&T5P7C.\N3MR/N>@^E5M*UG5)-&M-+FUNXBN-0\075BU^\0W!$WL%'\
M*LQ4*OU) XH ]5HKRGQ+?:OX=7Q-HL&L7;6ZZ-_:5K</M>6W(<QF/)QD'&<D
MY'.,UL://?VGB_1(Y=4N;B+5-*\Z2WDVE(VC2,94]>26)X[]: .TU+4(-*TZ
M>_NO,\B!=[^5$TC8_P!U03_AU/%9:>+M+?PC!XE_?+8SQ+)$A3]Z^XX50H/+
M$\ "M34_^05>?]<'_P#037*> XK&X^&7AF\OXH MK:I.CL,+$P!&X>G!/YT
M:WAOQ?8>)C=106][9W5LP$MK?P&&4 ]&VGMG(^H-;]<EH4+:IXOOO$TB26\+
MVZV%E'( IGB4^89<=>68@#T7.!FJOC.6^?Q!I%I;:E<Q0>5-++960_?W! &P
M@G 55;!)+ =N] ';T5X;;>*M>U30/ I?4KB&2;7&L;EE(W3*K;06/KC/3CFM
MF7Q%JNA:?XIM+>]FE%MJ]O:6\MPV]X5F*ACD]<9)&: /0X?$%M-XJN?#XAF6
MZ@M5NF=@-C(S%1CG/4'\JUJ\\T'3DTOXOZC;1W%Q.HT.!@UQ(7;F9^Y[5<\7
M37K>./"FF6VHW-K;Z@M[',(6 Y6 E6&1U!.?RH [>BO%M1U;6='MM?T-=7N9
MUTG5-/-O=%_WC1SO\T3G'.!_,5TX74(/%]OX1NKV^DL9X9[X7ADV/)ECB$$#
MHG!R#_$.G< ]"J.XE,%M+*(WD*(6"(,LV!G 'K7D>JR>(]0T'Q9HNF7=Y->>
M'[U&LIXVQ))$5#&)CGYB%8]LG:.]=!9ZE<^)(]8U^TNGBTJ/2C;VAAE/SR[2
M[O[%3A0>O!Z4 =EH^H-JVD6M^UI/:-.@<P3KMDC]F'8U1\/>)H?$%SJD"6L]
MM+IUS]GD2;&[. <\9'Y$^^*X'0M7N]<TSP-H=WJ-S";ZQ>]N;A'VR3E" (PW
MODDXYX%95I<2:(WC&SL[PQW$WB&&&6YN',(,;Y('F@-@G!7=MXSGOP >WT5Q
MWAA=9L_$U]::A<6*VDENDT%E%?/<R1$':6+-&IVMQ^(-<_XXU&6QUZ_EO[W4
M$TCR(HDN]/((TR;()\U <L&!5MQZ#C!Y- 'IB6T$=Q)<)!&LTF \@0!FQTR>
M]2UYE>W]V->\:1Q7\[0Q:%'<0%7.$?RS\R^F=H-&A:C<:_+H.E7M_<0'_A'H
M+M75]IGF>,!F)S\VWKCU- '6:UKMG;>(-(\.WFGM.NK&0))(%,0\M2Y!!Y)X
M';N.:WHHHX(EBBC6.-1A408 'L*\EU"&XF\2> ;&YUX:G<17-]!-?J@C+$1#
M.,9PV#@'UQ75?#N:Z%KKFG7-Y-=C3=6FM8IIWW.4 5AG_OHT =G17E&I7'B3
M7=;\6"PN[2V;3IHX+:2>_> 6H5%?>4$3!PQ)Y)Z<4V6]U+5U\:.=5F7R=,M[
MJW6VG*)%)Y)?Y68#Y2<'D?7N* /5I8HYXFBFC22-AAD<9!'N#206\-K"L-O#
M'%$OW4C4*H^@%>7Z/<7]MJ/@'4IM1OIEU:&2.\WRYC9_)S&-F..03D>G-5GM
M-2O])\<3'Q)J5K-I6HR_9':4;4"QHP!'&<YQSQTQGF@#T1O$4*>,(_#A@D\Z
M2T-VLV1M*AMI&.N?KBMFO++75KNY\4^'M;DBD>[D\*RW,UM$A9W?Y&"A>,G.
M0!D9JMJVHZE!\--,\7V.I7*ZJ;J*62,/N6422A3#M/& " .,_+[F@#URBO+;
MC5=5\(^*M8CFBN+\:U;)+HUH\K8$P)$D.<?*?G!^@ZBJ=Q=:_)X\_P"$6AGB
M:&STE2J7-\]OYLK9W2!@CEF&>G08H ]>HKRGR-:U&[\/:+J&O-]INM-N[:\N
MK&?AG5L;T) RP(';U[5W>MZ5<W?A*XL(+N?[:MJ5AN5.'\P)@-QW)_G0!MUG
M:IJ4^GS6*0Z;<WBW,XBD>'!$ /\ &W?%>9KXU6SN-!\0>:\FG0VXM-9 E)\B
M=E^48Y!<%2".#\Z^O%^^BU:PL?!TUS=W<-S=:F)+J"-OW:B3+>4V6)PG"C&<
MXYQ0!VFN>)K31=%U;40CW?\ 9B;YX8<;AQG&3@=.3[?E6G97(O;"WNU4JL\2
MR!3U&X X_6O&K&$_\*_^*$LHD\X7=^@+EONX..I] /PK<TNZO=,\?>$+!+V:
M2"_T1S<JY^5BJAE('0$=..U 'J%%<7XTGSKF@V27=PTLSRD:; "OVH;,9>0$
M;$4D$D GT!/%+\,]1OK_ ,/7R7\HDDL]4N;1#YGF81'X&\@%\9^\0"?2@#LZ
M*\RCNX=<TK6;^[U\:5J=AJ4B^>9.+:.-QA=F[!#(,9/]XUHVRGQ4WB7[1J,M
MG=VUT8K1T9D^RQB-6CDVY 8'=O)/!SCM0!WE%>+Z?J>J^(M;\!Q7]_>P?;M-
MNA<B"8IYQ3Y1)QW8#=[;N*NW%OK-CX=\0+:W5[.GAN_%Q9N\I8W<*JKR0NW\
M0 ROKTZT >MT5R7A2\3Q+?S>*(F86LUK#;V\8=BH(!>1NP)W/LSC_EG[U3^T
MRZW\4=0TC4!/#9:?9126L(E*+<LQ!:7C!(!^3&2,J?6@#I/$6OVOAO2&O[I6
M<&1(8HD(#2R.P55&2.YS[ $]J;H^L76HW=_;7>DW-B]HZIYD@)CFR,YC; W
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MIT[<''!(P:W%O[-[@6Z7<#3E0PC$@+$'G..N*<UY:I<"W:YA6<](RX#'\.M
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M<J.",J??IFO1UFB>$3+(C1$9#A@1CUS5:#5M-N;@6]OJ%I+.06$<<RLQ ZG
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M G/W\<'./:N]-C:&-HS:P;'.67RQACZFE^Q6GFB7[+#Y@3R]_EC.S^[GT]J
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M9V+-C'W1D]!P*UFMX7F65X8VE3[KE02/H: /']<DT[_A)_%>F^)->.FVUY!
M(%G@#^=;B(?<X/(DWG:.<]JFDL;'4?B)"-;T^-E;PL&N$O=KM&P920Q/5AZ^
MU>LRVT$[H\L$<C(<HSH"5/J/2@VMNSL[01%V&&8H,D>] 'AOA+3+*'2/AIJ$
M-A&ET]S(D]TL2AC\K85W!SVX!!Z'IT+8PUQINIZ9KVOWUMXA35)+J.Q2-3<2
M2 KY1C8@C!4(!CC'M7N7V.UPH^S0X7[HV#CZ4XVT#3B=H(S,!@2%!N ^O6@#
MR^^TO3;A/B8S6T<KB$2;954JLHMR0P&2-V<'=@'/ZPV][%9^)O FM:I=M!&?
M#^R6[GGP)W*I^[/4N^6W8/IGJ*]6-K;DN3!$3)]_*#YOKZTGV2V_=_Z/%^Z;
M='\@^0^H]#0!P&L7=K9_&FTNYPR):>'Y9;B;E@L?F\< 9X.?KD5W>GZC9ZMI
MT-_83I<6LZ;XY$Z,*S[?P^L4E_=O<;M2O5V278A7*H/NJJG(P/0YR>35[2].
MATG38K* EDC!^9L98DDDG''))/% 'BZZ7HES\/=;CM;6TAUVUUN>+3]@"S0W
M!G_=HA'W?H#CC/:NCT;P]8ZIX^\066NV%G<RK9:=-,53 >X4/ND!X.<YYX.#
M@]:Z7P1X=U#1+"[CUB'3C<27LMS$]HS.%5VW;<LBG@DC/.:Z@6\*RF588Q(>
MKA1D_C0!XM-##:^&O%H6T1M/@\7"6YA2/Y!;CRMYV@<KCL!S73ZZEI?>*KF;
M3VC>)_#LXN]@^1T8?N@W;^]C/J:]!2V@CW;((UW\-M0#=]:5+>".-HTAC5&Z
MJJ@ _A0!ROPYL+2/P7HU\EO&MW+I\,4LH&&95!P#ZXR?SKGM6O6M?B;X@@@N
M$AU"\T2**R#,09)=SX"X[_RKTR.*.%-D4:HOHHP*#%&91*8T,@& Y49 ^M '
MD-X;6\\!^#+;1-L.I6NJVT8B48D@E!S,' YS@L6YYR>N:ZSXL1O)\,]4"+N*
MM;NV.RK/&S'\ ":[%;>%)6E2&-9&ZL% )_&G.BR(4=0RGJ&&0: .&\ZRU+XM
M6%U!-%/;R^'I@"#N21#.G3C!'!SSW^M<3I=Q)IGA?PWJ%Q=SVVAV6L7J78A4
MD1@R.(6(&?E4\8P?O ]J]M^SP;P_DQ[@-H.T9 ]*1;:!(FB6",1MR4"#!_"@
M#EO [:7))K,^B-<S:?<W(N#<RGY)IF'[PID#CA<^^?2N=O-2T6WU+Q/HOB99
MGFN[N.:T@9&W7*JJF,1L..&7&.Q]J]/5510JJ%4#  & !2%$9U=E4LN=I(Y'
MTH \XL;Z&Q^(7BC_ (2>5;:.^TZV>VCN&R!"JR><BL..">0.O6LKPU#';ZCX
M BU.-%G1+\68G.76'/[H#C ^39U(;VZX];DABEV^9&C[3D;E!P:##$THD,:&
M0<!BHR/QH \#\2+&WPY\9HH5KA/%=P6"C+!3+D9]N#74Q?9W^,7C"1E60/H4
M>P@@%DVC< WI]W]*]2^SP@./)CPYRWRCYC[^M*(8@Q81H"1@G:.1_D#\J /&
MM,%A:^ _ANUN(XH$UB-G_> [&(EW9/<Y.#3[@Z5>-XG\,>(8M62_N-3GN[>S
MC!_TY2Q,1C(4X&U%!)X&,GOCV$6\ VXAC^7.WY1QGKBG%$+ARJEP,!L<B@#R
M^^N+.XUGQKYY0W/]AQ)/&Q5@N%?<I.>2">>,<]:@L-8L])O_  WK.MN1I<^@
M?8X[YHR0DVX%D. <%E7C_=/O7JPBC!)$:@D8)QUH>&.10KQHR@Y 901F@#R:
M=['PU<>&M02TO].\-P/>0"8*VZ)I'RDKAERJMA^HZ,*IW=EHUCJWA"2"VN)=
M*N/$$MS$TR$-,\D:%)1D+M42$''&0O .0*]F=%D0HZAE/4,,@T,B, &53CID
M=* /&]92UCTOXG2-%"KO=1@OM.YCA,<[<D;N@Z9S6GK=WIFD^,EO->O+FTT[
M4-#CM8;F*(LI.YBT9958@D$-7J=-9$< ,JD Y (Z4 >0V.G:?IWCOP+90P2Q
MVMM:7HM5O,^8 9/W;<@$%ER0" 0.#R*9;7UA)X:L[R2Z5K2R\7O<W$H&5A0R
MR%&;@X4EE^;_ &A7L=-=$D0HZJRGJ&&10!SWC"*YUGX?ZJFD9DGNK-C;X!RV
M1D8&.XKDXKW0_$L/A*/1(W34K*2-L6\2A[&(+B190/N _=QZD5Z?351$+%54
M%CEB!U/O0!P7@J_M)_B!XW6*XC<RW4#QA6^\%A56(]<-P?>CQ=J$>F?$KPA=
M7DA@LEBNT,K9VEF50%XYSG'48]Z[^C ...E 'A.I2:;+X'^* S"UW-JTC)M'
MSNO[L1].2-V_';.[WK5U&XM[WQ!KJV92&:Z\.AHWC1WEO4,9P%&-H4''(YKV
M&F[%+ARHW 8#8YQ0!Y'X9OK>S\1> ;BX<QQ3>%TLXW9&PTQ,0V=.O!K:^+-M
M>&ST#4HX9IM/TW5$NKY81N=(P"/, P<[<GUZ]/3T((BA0JJ HPN!T'H*=0!X
M5XN31SX/U74-%DN[FVO]1LIGO)P5$\JR,'VJ57[H );'.>I(-=BE_:6?Q<UJ
M6YN(XHQH< W.V!P[D\^P(/XUZ(  , 8%% 'AQN]+'@SX8R7,]LEI;7R"X+@[
M$98V)##;USZC&3R<<U=\0M;2Z)\1-8A99M,O?LPM6V92>1$P^PD<Y;C(XR*]
M%\0^'9]:U30[V#4%M3I=T;C8T'F>;E2NW.X8X)]>M;] 'G5GJ=EHWC,:OJ<R
M0:?J>DVT=G=LO[LE-S,FX=/O \X!SQTK.L?"<MSX$UEK"(6BC5GU?1EVJJ#8
MP>-@!T5L< XP".*]6KGO$/AJXU^\M3_;=[9V"H\=U9P8"W*L,8+=1_7VH \^
M\53?;?@[K6OWL1MK[7HXVC@<_,%XV(!CD[035VRNH%^+^D7#2J(8_"RAY"?E
M7#LQR?IS7J:(L:*B*%10 JJ, #T%.H \-T6]OK/X:^%=2LA<7%II-_=2:G;V
M?,RHSR[7 P?NAMW..#5CQ7>Z;>>%-?U.T%R;+4)[$174[.CWC).A<I&RCA5!
MYQV/85[510!Y=<W0G^*OB!()7>.X\-#8$;*2-G(X[G#<>Q/K6SX+UNRTOP9X
M4TZ1II7GC2R21('5#(L>X_?"G;P1G&,\=C7<44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!12#/.1BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M85]K2Q^8!CG.S*$D=3QS7H&N:C?Z3X?>[AM%N[M%4,J':BDX#.<G.P=3WP*
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MPPY.!R<X]*Y?P]K&J>&=)>ZABMGTMO$<]O<1%3YW[R8J"I!V@ L#C'.,9&:
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M_&SVZNOF"9%;=WY!(X(QGH3S0!Z#17.>,M0U#3/"YFM+RWM+MI88VG<#"[F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !169HFNVFO6]S-9K*%M[F2U?S%P=Z'!QSTK3H *
M*** "BBH+6\M;U'>UN(IUCD:)S$X8*ZG#*<="#U% $]%%% !1110 4444 %%
M%% !7G^B:99R6/B#P'J+7,:O-.\/;?;2G<#&Q&"06((QP0>*] II12P8J"R]
M"1R* .+\/:'XHTN:%O$/B"VGTO2PWV?RHMCRKM*AIF/]U2>!WY.<"G^#[0W_
M (AUWQ:=ZQ:DT=O;1M'M)BBR _//S$G\ #6[H6N0^(;:\ECMI85M[J2T9)@,
MDIP3@<8SG\*2WUVT?Q+-X>AB83VUJMPY!7:JEMJC .0>"<$#@#UH UZ**;(Q
M2-G"ERH)VKC)]AGB@!U%<O9^-[74-*\/:C::??30:U-Y2;(\F#AOF?'0 K^6
M3VQ744 0W=K#?6<]I<IO@GC:*1,D;E88(R.>AKD].\/^*-!B&E:7J]I/I"*B
M6TE^C/<6R \J"N%< ?=SC'?(%=E6'IGB,W-CJ=WJ>G7.DQ6%Q+&6NA@21ITD
M4XY4CTS]30!F7WA"]AO--U;2=5FDU>Q1X6DU!]RW,+MN9)-H'0@%<# QT]*>
MH^#]:NM!2%+NREU*?4X]2NWFW^5N7;A(P=Q"X10,].OM7=UCQ>([>[O+RVTZ
MVN;]K-_*N'MP@C23&=FYV4,PXR!G&1G% &!J/A/6[OQ3K.JVU_!:+>:?':V[
MPNPEC>-BZL>,;2QP0/X?K5,?#V]OWUZYU*XL;6YU;3?L#I8(WEYQS)AN^>WI
MW-=AHVNVVM_;1;Q7$3V5RUK,D\>TAU )QU!'/4?RQ6G0!PVA^#]:M=;T+5=4
MU*UDET^QELI(K:-EC925V%0>C<?,>^!@52F\":Y/H.HV9NM-2ZDUS^V+5U5M
MBMYF_;)@ MTQGKVR !7HU% 'FVL_#[7-8O\ 6I)=4T_R-5TT6\G^CGS$F"\;
M&.=L9;!(YXZ8/-;&D>&-9T_5M%NY+RR>.PT<Z?*J(P+OE2&&>WR+[]:[&L:V
M\117&O:KI;VTT']FQ1RR328VL'W'Y<9XPN>>>>GJ <C'\/-6M_#VDV%KJ=I'
M=:5JLE]!.T3,K(Y<G<O]X>8V!G' KI/%OAJ;Q-X7.F"^,5TC)*LNWY))$YPZ
MC^ GJ!70QR)-$DL;!D=0RL.X/2G4 >6>(=+UGPOI'B?6[BZCN?[2L8K8I:P8
M:*8CR]PZ8C4MGG<V.IJIH$UUHNN:9'HFJZ%K=M<K':3#3[1?-MTPQWN8R=J*
MV/O8SD]#7JNH7UKIFGSWU[*(K:!#)(Y!.%'7@<GZ"LO4_$^GZ+?Z/;W$4PCU
M5S%#<)'^[1\ J'/\.X$X^AH P-)^'LB_#^7PIK-W%*B7,DMK<VB%7B!<R*WS
M9PX9FY';'UJW;>$-3U#1]3L/%.MG43=1M;PO!"L)BC[-P/ODX)[9'3%=C10!
MQ6B>$_$,,;-KOB0WEQ;PO!8210*ODAACS6X^:3  ]!SZFK&A^$;BV\22Z]J]
MQ:S7ZQ_9H'LH6@#Q_P!^5=Q#/R?8=NO'1ZC>KIVF75ZR%UMXFE*A@"VT9QD\
M"JWAW6%\0^'-/UA(3"MY LPC+;BNX9QGO0!4N]%OG\7VNLVE['% ML;>YAD0
MN77<&&WG"GKD_P ^,8R?#Z1?#ATDZO\ >U7^TWE%OC+>9YA3;NZ;L=^U:VH>
M)Y=)T#7M5OM+FB72WD"1[Q_I**JLKJ<8 .['?!!ZD8J2T\0SWDNA^5I%TUMJ
MEJ;E[E2#';?(&"L>N3G Z?SP <WJGP^U._N/$JPZS';VNJRQ7$0$ >1)% !#
M%LC9\HX _$<@[-GX5NK/QD==35"4FLH[>ZA\H#S&3[K#LHY)(Z\<'!K=M-2M
M+^:ZAMI?,>UD\J8;2 K8!QDC!X(Z9JW0!SNO>&Y]4U[1M6L[[[)-8R,)#L#;
MXF'(&> V<<GU-9NI>!;C5=$\0:7<ZRODZO/YP*6@!@Z9 ^;YL@#KTY[<#J-3
MU2ST>T%U>RE(S(D2A49V=V(5555!9B2>@!JY0!Q)\!7-EJ<=_HFO3:;++;K!
M?JD(=+G:H59 I/RN ,9'^.=;58+7P]X!OX4$;6]II\B@7(W*^$/W_P"]D]?7
M-=!00",$9% 'F7A+PS)XA\(^%3?ZO:WNE6$$%U!#!"%;[0J\+(P)#! Q& %)
M/6NCT/P5%INE:QIU_<Q7\&JS/-,OV98P-XPPZG=TXSDC\JZD  8  'M2T <C
M;>"I7BTFWU?5Y-0M]*D$ML#%Y;LZY"F1MQW8!]!VS5V7PI;3>.(O$C%=Z6OD
M%,9W-NRK'Z G'U-=#10!S.H>$Y;[Q8^N+J;P;M-?3O+BC(949M^X.&X;<!VZ
M9'O4-OX-F%S>7EYJ4<][<:>; 31V@B^0G)9P&)=NG< 8X')KK*JZE>_V=I=U
M>^2TWV>)I?+4@%L#.,GB@#D]-^'W]F:/HUM#J2_;M&)%I>?91GRS]Y'7=R#[
M$=O2I[OP7<W$$K1ZND5_<W<-W=77V0-YAA=7B55W8505'J3ZU:T;Q->ZSH/A
M_5+?2':/4\-/B3_CU0J2&.0"PR ./7TKI: .6N/"=[/K>HZDFN20-?V4=LZ1
M0 ;&0DK(K9R.2W'HWT-6=*\,_8O$%UKMU<1S:A<6ZVSM!#Y*%%8MDKN;+9/7
M/0 8KH*YO4_%+:?XVT?P[]A+KJ,4LHN=_";!R-H!]N>!S0 ZZ\+L/$S^(-+O
MA9WTT MYUDB\V*50<J2H93N'KGIVK)U;X=)J'A6TT&#4_L\<5T+RXG-L&>XF
MW;RQ *@98DD#V'&*NZ_XMO?#_A76M:NM%D0Z?<&.*(S*?/CRH67(Z [NG48Q
M75T 5[FT%[ITUG<.2)H6BD9!MZC!(SG'7WKCO^$ NO[(\/Z<-=_=Z+(KPN;7
M#.%&%4D.,#'!]?TKN:* .$NOAU+<VWBBW_MK;'K\PEDS:!C#C' RW/  SVZC
M'&+NH>#;O4+6:VDU>/R;FS2TN4:TW A=PWQ@O\C8;'\72NGO9IK>PN)[>#SY
MHXV=(MX3>P&0,GIGUJMH6I_VSH5EJ6R-/M4*R[(Y/,"Y[;L#-  ^C6LF@?V,
M?,^R_9Q;@ELN !@')[CKGUK,G\+3:A<67]IZM+=VMC,EQ!&8(U=I%'!D8#!Y
MY^4)^-='7)>+?'$?@V]L6U*R']E73^6UXEP"\;8/_++&YATY7./Y@$2_#Z*'
M4;]K36M0M-*OYC<W6G0E0))BP9F\P@NJG'*J1UZXXJ6\\$&;6[N]L]:O+*SU
M#!U&RB566X(&W(9@2F1P=O6KOB;Q)+H$>F-!8K>?;[R.S0>?LP[_ '3G:1C@
M^G3WKH,XH Y^W\,M9>(;_5;/49(A>6\436QB5DW1J55B>I&#T!'3K698?#Z*
MR\,Z=I0U*07.ES--I][%$$>W)S\N"3N4Y(()^8''O733:I:P:K:Z:[-]IN4=
MXU"Y&%QG)[=:NT <EJ/@:+6M,U>WU/4)9;C542*:>*,($1#E51><#.3R3R34
MMKX.6W\66/B!M0>26UTP:=Y7E@!P&)WDYXZ]*Z"_FN(+&>6SMA=7*(6C@,@3
MS&[#<>!]:I6VL%+;35U.#[)J%[A?LJ'S2CX)(RN>!@_-T]Z )M;TW^V=%O-,
M-P\"7<9ADD106"-PP&>,E<C/;.:S;GPS+>^$X_#]QJUPL0C$$L\"*LDL07&T
MEMP!/&3CGG@9XD\/^(7UJ]UFWDMU@.G7K6HP^[> ,AN@QD=JW,C(&1D]J .>
MTGPJ^F:M'>R:WJ-Y%#:BWM[:;RTCB&>2%C1 3C &1QCOQB/5/!D&I^(+G4S?
M7$,=YIYL+NWC5<2H2><D':<$@GTQTQ6S!JUG<ZO=Z7%)NNK2..29<'"A]VWG
MU^0U<#*V<$'!P<'H: .:LO!<%JOATOJE]++H49C@;]VHD!380P"<C:,#O[D\
MU!?> K6XUN[U2RU74M,>_3R[Z*S=%2X7!&<%3M;I\PYQD#&<UU8="0 RDGI@
MU@>-?$K^$_#<NK1VJW31R1J8B^WAG"YZ=LB@#733X8-+73[8M!"D7E(4P2@Q
MCC<"#^(-<W<> K>71=&T^+5M01]&G2:SN"4++MX"L H#+MR.F?<UN6][?3ZG
M$ALD&GR68F%SYHR)2W*;>N,$'-: ="0 RDGH,T <:OPXL6M_$MK-J%VUMKTZ
MS2H@13$1C.TD'.<=^WYUM0^&;2'Q);ZXMQ<FZ@L/[/"$KL:+<&Y&W.<@'(-;
M)=58*6 )Z GK2T 9'B305\1:4+,W<MI(DT<\4\0!*.C!AP>#65-X#M+K_A)$
MGU"[,.O%#.B! 8RH ^4E3V '/;WYI_B#QG!I?A_4]3L(3>G3KI;6=!N&'.S.
M, DX#CI73JX;H02.H]* .<F\$Z?<Z[!J]S<W4\\-BUAL;RQ&\;==P"#GOQ@>
MU9EC\-HK$:3"->U22TTBZ\^R@8H!&NW&PX7YN2>3S@D#'6NV$B%R@=2PZ@'D
M54UC5;30]'N]4OG9+6UC,LA52QP/0"@"OKFA1:ZEHLMW<V_V6X6X0P;,EEZ9
MW*W'TQ6=XB\%6>O:G:ZQ#>WFFZQ:*4@O;1QD*?X65@59<GICGUJ31=;U;49H
M)[C2XH=+N+1+B.Z6X!*LP!V,O7//4<5T&] F_<NWUSQ0!S4W@J!KW1;N#5-0
MAN=+:8B;>LCSB48<.6!&20ISCMQCJ(](\"6VC6UM#::IJ"-;2SM&X,?^KE?>
MT9!0@C.#G&<]"!Q74ET52S, !U)-*74+N+ +USGB@#F+3P'IFGV6D6]C<WML
M^E&0V\Z.I<B0DN&RI4@DGC'';&!4E[X*L+_2+W3Y[FY/VV=9[FXQ$99"I!4'
M*$ # Q@ C'!KHPP90RD$'N*175\[6#8X.#F@# O?!VG:EK5SJEY+<327&GG3
MI(F*>7Y6[=TVYW9YSFJMGX%M[/6=+U,:QJDLVFVQM8O.>-@T9ZJWR>PY&&.!
MSQ6QI%YJ%S#<OJEI!:,EPR0JDP?=&/NLV. 3Z?3Z5I!U8D*P)'! /2@#D[7X
M>:1;Z?8::\][<:;87!N;>SFD7RU?<6&=JAF )) 8GWS4\O@;2[N^URYOIKN[
M&LQ)#<PRLJH$3.T+L4,,9/.372+(CDA'5B.N#G%.H YCP_X'LO#]TES_ &EJ
MNHO$FRW_ +1N1*+8'@^6,#&1@'V%2ZMX/L]6UHZHU]?VT[VC64JVTBJLL39R
M#E20>>"""*U+FYO8M6LH(K:-[*1)#<3M*%:(@#: O\6<G/IBN?M/%M[K%_?Q
MZ/8V]Q!8:DMC,&G"R,HQYLB@X&%SP/XL'% $>F?#;2])FT&6VU#4MVB+(EKN
M>,Y63.X-\G/4CL:2/X:Z3%I<U@+[4BK7QU"*8R)YD$Q.24(3&#Z,#79TWS$W
M[-Z[_P"[GF@#"TGPI;Z1KE[K":CJ%Q=WR1I<F=TVR;!A6VJH ./3'ZG._6?9
MZW87^I7UA;3;Y[%D2;L S+N 'KP0>..?7.-"@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2UO4I[
MSQQI7AB&XN+.-[:2_GFC;;YJJ=@C5NN<G<?8>_'6U@>)O"5GXG^PR37E]8W5
MC(SV]W8RB.5-PPP!((P1C/'84 <+I&IW6FZ-<6D5T\,M]XIFMGN>I5=P)]>2
M!C/O766$]]I'CG^Q'N;J]L;JR-U$\[[V@9&"E2V,D'<,9]#2VOP]T>UT2^TM
M;C49([N?[2TTMR7DCESD.A/"MGG.,GOGBM/2/#L.E7MQ?R7M[?W]PH1[F[=2
MP0=$"HJJH!R>%R23DF@#(\::AJ%KK?A2ULKQ[>.[U+9<;1GS(PI)4_6N2NO%
MFL>'+?Q;:O?O>>3J<%K93,VXVJS=V+#G;Z>O>O0M=\-0Z]>:9=27UY:RZ=,9
MX3;^7RQ&/FWHV1C/3'7Z5FVWP\TJ&]UR>>ZO;R+6FWW5M<M&T0<'Y63" J1D
M@<_G@8 ,^\N+WP_XIT+25U"^O;/6DEAE,DA9X75=PD1NJCJ".G3&*=\'XC_P
MK/1IVFF=Y(Y"P=R1GS7Y%;FD^$[?3+V*\FU#4-2N((1!;/?.C>0G<+M5>3QE
MCEC@<TOA?PG8^$[26UL;B[EB=RR+<2!A"I).Q   JY)XH R=0U2^B^*!T]+F
M1;/_ (1V:Y\D'Y?-$RJ'^N"17%Z/X@\07WA7P7</J]P);W79;6XDW9,L>Z7
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MQ@#\/>G>(K:-[WX@2/-+ /[/@!EBE*, (V/4 XZ^AKIHO 6A0R0LL=QB"_\
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M-\]Y-IL32R-ND&2$D;.=S)G:QR.I!(H X/P]>3>,9]?'B>2:WGM[. I;QR-
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MBS^SV<GFVT?E#;$^<[E'8YYIMWX2\/7UQ-<76C64TTY!E=X@2Y!!&?7H/RH
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M;Y&PRKN\S:&V8S][:0<=<'->3:<T=W\.?"\.G-#_ ,))%=6ZOE5\])%?]X9
M<-C&<^H/7FK,.G6VK:7X^-KY5UK-OJ-S-:>3N#H_V=54HHYW9+ ,.IYR>#0!
MZ?!J=A<WMQ907MM+=V^//@CE5GBSTW*#D9]Z;%JVFSZC+I\.H6DE]$NZ2V29
M3(@XY*@Y Y'YUYQX6NO#M_9^%XK991XBM+.6!HH]V^W?RCYAG';+#C=U+#%5
MO"<VDWMGX:L+R]F.N:;>'=91QA94E^8.\G\6PC))/7CJ<4 >HMJFGHT*O?6R
MM-*T,0,RCS)%SN1>>6&#D#D8/I2VFIV%_+<16=];7,EL_ESI#*KF)_[K 'Y3
MQT-?.US!;?\ "M-:D6&+>GB[<C!1E4*QG(]%Q^%>A7$$UOX]\26F@I';WC^&
M%6R2$*@\\&3;CMD$KUZ9&: /1X-3L+J[N+2WOK::YML>?#'*K/%GIN4'*Y]Z
M:NK::UU!:KJ%H;BX4O#$)EWRJ.I49R0/45Y/HUSH^L6?AV33_M#ZCIJM;SV.
M$MVLT9,2O/\ *<K\N>1\Q/')I%.DV_@?P;<6<L.^+4HU>>W;S&1\L7 (4G')
MR  ,'H!0!Z1IOBW2=4\2:EH4%U ;RP*AD$REG./FPN<_*>#Z$UL7%Q!:6\EQ
M<S1PP1*7DED8*J*.223P!7'^%_LD/CWQA&4@2YENX73YEWNOV>/)QU SGGH2
M3Z&I_&9\C5/#5[=8.E6]^3=97<J,T;+&[#!^4,>IP 2#VH U-3\4:78>&+G7
MHKZTN+.*-F26.X39(PZ*&SC)/'6LOPKJNLZQ-!?#5=&U+298/WQL_OP3X!V9
M#,",$=<&L0K8SW'CN[MG']EW5E"$F3;Y3S".0-L(ZG[@/O7:>&Y+:;P[8/:-
M$T?D(I,>,;E4*1QW&,?A0!G'QIIC^++GPY#>69O8K;S%!G7+29/[O;G.0!DC
MKBL_X>^,CX@\,Z7-K-Y9PZO?AWBM@PC>5 3RB$Y( !Y&>AJN)H;;XR:D+B6-
M&N=%B$"LPRY5Y"V![ UPGAJT:W^'O@.5K9H[B/Q%#YK>60ZQXDSDXR%Y'MS0
M!Z_;ZF8]:UM+S4]/^QVBPNL8?$ELI4EC*2< $C(Z<"K>FZWI.LB0Z7JEE?"(
M@2&UN$EV9Z9VDXS@UP3PQ7'BOXAP3O);P306*K+#&-PPC;F'&&(8C.<UH>#)
M[I_%FL0WIL[V>&WA0:K:+L$R@L-CKG =2#T['\  :WBOQ#/H]YHFGV[PP2:K
M=_9Q=7"%HXL#.",C+-]U1GJ:N:5=ZQ_:5_:ZK%"(($1H+J)2JR@YR3DX!&.1
M_C5#QBFDZC]CT'7+,36&HB4&4@_N70*5(8#Y2<G!R.1COBN#.DZTFB>,O#.@
M:A=WEC;QP2V4L[[CDG=+"LAZ_*N.O&Z@#U;3=<TG6/._LS4[.]\DXE^S3K)L
M/.,X)QT/Y5#%XFT.<7IM]8L9S8H9+D17".85&<EL'C&#U]*\PU:*'Q1I&H3Z
M%<WMQJ4FB21R.(/)6),Y\M_E!+DJ5"]< <8.:WM.OM&UZVLYM.L;I;V+1I;=
ME(:,6HV@>6P( +97 YZ#/0YH O-XWLM=\,V6IZ1X@TK3F>ZB$HNY4<JK,<1L
M WRNP&<=N?2NFU#Q%HNE7<5IJ&KV-I<RX,<,]PJ.P)P"%)R1G(S7G-K=VTGP
MO\&!948VNHZ>)@.3$5D&[/I@ Y],&M>TFM[+6O%MEXC02-?.9[:38")[4Q@+
M$C<992K?+VW \Y- ':W6JZ?8RB*[OK>"0Q/,$DD"DQH,LV/0=SVI]A?V>J6,
M5[87,5S:RC,<T+AE8=."/?BO+_#^FW=EXE\"V^IQLTL>C7,<GFQX*Y9"B-U^
M8+@>Y!-7?!NO6/AO0]0:_$D<,_B.ZAC*IQ&KR$JY](\?Q=!F@#TRLFS\4:!J
M.HMI]EK>GW%ZI(,$5RC/QUP <G'?'2K>J,5TF\80O.1 _P"Z1MK/\IX![$UX
MSX?"_P#"0_#YU9TMX([LO %(%F75-L3N?O.<'.>2>PH ]MGGAM;>6XN)8X8(
MD+R22,%5% R22>  .]4=-\0:/K$$\^FZG:7<,!VRR0RJRH<9Y(XZ5D?$"&\D
M\+F6TMVNEMKF&YN;55W&XA1PSQ@=\@=*X[5[JR\8VNK:MX9TW4!>OIZI=74T
M+1#8KJQMPC ;V90X)&0..>: /0=/\6^'=5N)X-/US3[J2"/S91#<*VU!U;(/
M0<9/09%+'XK\/S6EO=QZU8-;W,WV>&7[0NV23.-JG/)]JY?4;JU\2ZIX-N-$
M2026]V9Y%,6TV]OY;*ZNIQM).U1]*Y.9'A\'26#13"[3Q6L\D/EG<D?V@,&/
MHN!G)H ]6D\3Z##>?9)-8L5N//%MY1G7=YI&0F,_>]NO(]:J>%?&.D^+;1Y;
M"[MVE1W#0+,K2*H8J&*@Y .,C/K7*>%+"&X^*'C:2>T211<0O"TD8(#"-?F4
MD=01U'>M/X7W$47AH:45D6ZMIIC*A0X3,K8!;&,]\>G/2@"UJWB672OB!9V-
MS=PP:0VF374[2 *%9& W%CVP:W6\0:.FBKK+ZG:KIKJ'6Z:4",@],'^E<SJ@
M ^,.C22+^[&DSKN(X!+K@9]^:XWPH\MAX?\ !U_,'%CIU_>I>J%),#2RR"-V
M7KCYASV#9Z4 >E7?B.SO_"6HZIH.I6MSY,$C)+$PD"N%)&0#^AJ.P\46-EX/
MTO5M>U.VMA<Q)F:5@BN[#.!^1_*L"\@CNM:\4ZO:L'TN721!*\.#YDR[B<>X
M4@=.X]*S="D&G:KX,U"^21+%=&FM//882"?<A(8_PDA2/?% '0^$/%L5]I.I
MWVIZU8W$46JR6D,T)"QL/EV*O)W$YR,9)S74:9JVGZS:?:M-O(+N .4,D+A@
M&'4''>O)X(K6]M+Y66]LY6\4S36-VMN0+1M@*NZL%_=G!!Z]>OIVOP]N;VZT
MK46O[&&"==0F5IX(_+2[P0/."]MP /OU]: +3^-M';Q->^'8[^V74(+<.%:0
M F0[OD /5@ "0.QK$^'7CNVU;PYID6MZU9MKEU),JPLZI)(%E95^4>P'UK0^
M2W^(>M&1#&;G2H/+9F_UI5I<X^F17F-I:7,/P^\"QM;RI/#XAE9U*$,BEYN3
MZ#D?F* /;'\0:1'JHTMM1MQ?%Q'Y._Y@Y7<%/HQ49QUQSTK)TCQWHVK^*=1T
M&&]MA=6LGE1H9!OF8*2^T=]N#GZ'TKS_ %V>:>ZNQ]F>W$/B^W>2%(&):-"F
M;AV[*1TZ# KJ_#-RMC\1_%EG/%.);ZYAF@(A9D*+ H)+ ;5Y!')&3Q0!M>+O
M&.G>$;>S>]EC62[G$4:NX48R-S9/90<_E63I?C6W77?%,VI:O9C1+(V9M+@.
MNP++%N^\"<Y/]/6KOCJ0P1Z%<L&\B#5H'F8*3M7D9.!ZD5@K S^(/B@&A9EG
MMK<Q97(DQ:8X]<$B@#N;_7])TRUAN;S4+>&&92T3E\AP%+$C'4!023V'-6;&
M^M-2LHKRQN8KFVE&Z.6)@RL/8BO'DFGT6U\$ZO>Q:HNGIHJ6-S<62Y>VE 7.
M]0"V,J0>.HKT/P+ D&@2&&SNK:VENII81=L3*ZLV=[ \KDY./0]!0!=G\6^'
MK747T^XUJQANT=(VADG56#-]U>>Y]*F3Q%H\E]]C348#.9FMPH;@RJ,M&#T+
M@<E<Y%<CHMBTOQC\5W$]J7M9+2T$<CQY1F0<X)XR#^5<;I%C#+IT7A/5K#7[
MG7;*^:6.$LT=N[&5G$WF@8V@')).2>F<T >NKXGT1]4.FIJ4#7@E:'RE.3O5
M=Q7TR ,XK'T3XAZ+JVGW.H2SK96B7ILX9+@[/-?. !GN<'CK@9K @-Y9^+H)
M=*EFN;:YUF9;O3+J/:UNWSJUQ&Q'W,#/<'=@<FL"UD8_#/4]):SN)+V+6]TL
M)C=<*]T6#9QAAM!8CTZ\&@#T6X\0V.HWNE-IGB&U6'^T&MIHT ?[0ZH28@<<
M$9#'Z5J7'B'2+2[-K<7\,<PD2(@GA7?[BD] 6QP#R:YGQ7I\,?B'PA+9V\<<
M:ZJUQ-Y4> <Q,N]L#'4J,GVK!L;E],77/">K:)=:E>2:DUQ92RVSO#=[W#(\
MCA<#:<;NV%(&<8H [>+Q-:WUWK-E#.83IY\I[AHFV1OLW'<2 !CCOS47A[6[
M2/PMIMQ>Z_#J+7#>5%>!0ANGR<!4 &6X/ ':N?\ #4TEKXF\;Z?>031W=S+]
MKC/D.(WC\E$)5R,?>R ,YXKD_"]CJ.AZ5X UF]M;@V%D+BVNH/*8M;O(3ME9
M<?=&,$]N/6@#UC_A+?#PT>35CK-F+".3RGG,H"J^<;3Z-[=:EM?$FBWUS?V]
MMJEK+-I^?M:+(,PXSG=Z8P<_2O.?$]DUUHOCK5+6R::TOI+2*&%(B'N6B9?,
M8 KR#D@,,YVD]*L^(HY&^)LUZ;2XN=./AVX$@A4XEXR$! ^\1G% 'H.GZYIF
MJS/#97:32I&DK( 00C\JV".AP<'O4U[J-IIZQ&ZF$?G2"*,8)+N>B@#DG@UQ
MO@ZWOK#Q +*.<ZCHT>EQ^1?30B.:$[\+ >F<+D\C(XS6CXWLX+Q-)626>VN$
MO/,M;R.,N+>4(VUG&,%3R#G YZT 2W/C?2TN]$AM'>[35I9$BFAC9DQ&K%N0
M.2"N,#GKZ5I2^(](@O19RWT:3F5(-K @"1QE4)Q@,1T!Y->;/?7ZR^"M5U2Q
MN=EIJ=\9IH+-QYJLKJLWE %D#E@<'U]*J^*;VXE.LP7%A?6\[:O;M]GMK&22
M)HTEB/G2RH/G!5>%4Y!(&.M 'HNG^*X;[Q=K&A^3)&NFPPNTSQNH+/O)R2,
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M%.QECP3SDC<!\OU(KSVXLKZ+PUXD:2PU//\ PE%O=J)X"TKQ Q$MA1SPIZ4
M>LQ^)](FMUGANS,K221*L,3NY:,X<!0"QQ]*O6%_::I8Q7MC<1W%K*-T<L;9
M5A[&O,_&NG)IGC:Q\47&FZEJ6E3VAM7M].$BRP/DN'(4KD-NYR1R.]=AX)LC
M::+,ZZ6=,AN;E[B*UD+&55;',NXGYR021DXSUH O7'BC1K5M56>]"'2D22]!
MC?\ <JX)4GCD$ ],]*5/$^C2WEM:1WZ/<W5O]JAA56+O%S\P7&<<&O-/$,-W
M!XB^(-A]CO\ S-:L;<6,T5NQC8I&X8;^%&-W<CH>_%:6CP7)\2> )GM+B)8=
M(N$F$D9!B9A&%#>A.#Q[4 =HWB_0$T.WUJ35(4TVXE$,=R^54N6*X.1QR".<
M8QS3D\5Z)+%;O%?"3[3(\4"1QNSRLGW]J@;FQW(&,<UY?/#>P^&+]TL+JX5?
M&K7DD$4)=Y+<3;]P7NI"YSTK=\=6QTSQ;IVO2:)?ZII3VC6DL>FLZR0.7#B3
M"$9#=,$CG'/2@#M%\5:&\=FT6H1S&]+BW2%6D>0I]_"*"WRXYXX[XHC\4Z)+
M8V-[%?QR07SF.U**S&5QG*JH&<C:<C'&#7!E;K3Y_#UI_8EUINFW+7+*;*V:
M:YMMQ!5'<[BC/EBQ'';H,UBZ5IJKX!\.:?JNE:]:SV%W=R"^MH'\RRD$KLK%
M=OSJ0PZ9!/'/- 'JR^*-&>VLYTO-ZWKNELB1NTDK(2'"H!N.W!SQP!D\4G_"
M6:'_ &5<:G_:$?V2VD\J=MK;HGR!M=<;E/(X([UP.D76O68T#Q/K6D7C+$+F
MRN([6 ADC=@RW+0@9RQ4EN^#GGH:VM:9=ZOHGC'6[/2[Z)-5DM8K:U:W*R2B
M-AF79C(W%CR1G"YH ]*A\2Z3/=7-J+HQSVT'VF6.>%XB(LD>8-X&Y<@\C(XI
M(/$6DZC=+I]M?%;N:W\^)#&R.T9_C7<.1[\UQ6M0WJ^-]1EBTFYNUF\,+:Q!
MX&,,LJR.YC+8QG:1W]NM8WAV*]7XG:#J3V6L30W&D/;233VK1I#)D-C:0-J#
MH#CG(QGG !O?#CQQ:7'A#0(]<U@R:KJ32+&\V3YLF\_(&QM##(^7.1D#N*T-
M/UXV7C?QJ-4U IING0V4J-,_R0ATD+8'0<@=LGOGBN0\*Z;?S^ M+\%3:3J%
MOJ%M>I+=3&$Q1VZ1SJY82'AF(!"[,Y^E6_$>D7VOWOCB#3]/NEG=K*:":2%T
MCNO(^]$K8'<$<'G=QTH ])L->TW4KM[2VG;[2D2S-!+$\4GEMT;:X!*]LCC/
M'6M*O./!UH-3\0P:U;^&KS2%MX'AN'U-Y3,[GHL>YC\@P<DXY/ KT>@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*YG1_$=[=:\VEW]CL#6XFBN88Y/++=&0EE&".H]1734 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MRGBVUNFUOPSJ$&GS7L-G>MYR0@%D#H45\$C@$@D]NM=710!Y>=&UBZ\*ZS =
M&N3<2>)#=0Q%HP6C$J-YGS'&.&]SCCJ*N>(?#6K:WXF\2B*U:*VOO#XL;>Y:
M154S;G.#M.['S#/&.O7OZ)10!YY+9:SJOB+P7>/HEW:1Z='<Q7K;XP(F>$("
MGSDD9Z'TK(TOPMJ@*Z/?>$;"66RN=UGJ]PRNGE,Y=G(SN\W([  D\D=_6J*
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M^!D==B^E=GJ>EV6LZ=-I^HVR7-I-CS(GZ-@@C]0*L11)!"D42A(T4*JCH .
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M;&>V(4I=1KG DR.1C ( &<4 9VAZUXFOK/P[K<\\ T^_3S;U7>(1H'3,:Q8
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MTYKJ? 4HF^'OAYE4J/[.@7'T0#/Z54U+P#97VHW]Y;:A?6(U"U-M=P02 13
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MRWBZ;:V@MXW'[M'<E2^T=!D@D^@]J[RU\+6MGK5OJ,%Y?(MM;BUAM!(H@2,
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M6!W!B23D')YZT <EJ?B77;+0];A.I![S2-7M8$N]B#SXI7C^610,# ?!QC.
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M,PV @L Q&1VY-162ZU;W.I_#^2X:6ZN+O[3'=RR,0-/9LMANN\!=N/4YSWH
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M*2\L8T:7YQM#L6 3UR-F3]17DOE6FHMXIL?$6JR6.JQZFUQ"'MPUR8UD#0F
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M*. -K 87;WP0?;'?NZ* ,Y="TI-&.CC3[?\ LTJ4-ML&S:>HQ5;_ (1'P_\
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M1#;H=HXZ#)Z9/?WKC_AOX&C\.>&[)-7TJP&L6TDC"X1$=QN)P0^,]#BN\HH
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MXSUQR?SJ:B@"!K&T>W-N]K"T!.3&8QM)ZYQTIXMX!+YHAC$F,;PHSCTS4E%
M$26MO&P9((E89P50 \]:;]BM=C)]FAV,<LOEC!/J:GHH C2WACE,J0QK(5"%
MPH!*C.!GT&3Q[U)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(652 S 9.!
MD]32T %%%% !1110 4444 %%%% !115>*^M)[J:UBNH)+F#'FPI("\>>FX=1
MGWH L4444 %%%% !14<\\-K \]Q+'##&-SR2,%51ZDGI3U970.C!E89!!R"*
M %HHHH ***.E !13(9HKF".>&19(I%#HZG(92,@@^F*?0 4444 %%%% !14-
MO=V]UYOV>>.7RI#%)L8-L<=5..A'I3YIHK>"2:>1(HHU+.[L%55')))Z"@!]
M%1P3Q7,"3P2)+$XW(Z'(8>H/>I* "BJZ7UI+>RV4=S"UU$H>2$."ZJ>A(Z@5
M8H **** "BJUMJ%G>37,-M<Q326S^7.J-DQMC.#Z&K- !114<\\-K \]Q+'#
M"@R\DC!54>I)Z4 2455LM3L-23?8WUM=)DC=!*KCCKT/N/SJU0 4444 %%%5
MYKZU@NH+66XC6XGSY41;YGQU('H.YH L4444 %%%% !112$A022 !R2: %HJ
MA8ZUIFISRP6-]!/+$JLZ1ODJ#T./0^M7Z "BBB@ HHHH ***H'6M,%_'8F]A
M%U(66.(M@N5^\!ZD=\=* +]%%5K74+.]EN(K6YBFDMG\N94;)C;&<'T- %FB
MBB@ HHHH **** "BJ>HZK8:1%#)J%U';I-,L$;.>&D;[J_4U<H ***IZ=JMA
MJ\$D^GW4=Q''*T+M&<[77JI]Q0!<HHHH **** "BBB@ HHHH **** "BBB@
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M=Z['KEE=RV.II#Y#31C<LB9R%93P<<X],T 3:A::7I-RWB.98K<6=I*LKK&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAQCY@%<X' X'%:QO[WP_XVU:P2]O+Z"313J2BZFW^5*LA3"* ,*01D#@8]Z
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M,;?>2TMWR&(QD+@9R=O!&3FM#7[_ ,0>#]#\1:K!?J4-HCV<4UX]T5/FA/,
M<9'RMG&2,D<8&* /0+K5Y8/$=CI*:?-(MU%),UR'4)&J8!X)R3EE& /XL]JK
M>+O$]OX0\/R:O<V\DZ)(D?EQD DLP4=>W-85II,=MXO\-WK:GJLTDVGSDH]U
M))$[XB)8@Y"@Y)QPN0N!G%5?C9S\-KCG'^EV_P#Z,6@#T&)_-B20# 90V/K3
MZ\WU.XU'PSJFJ7EE?7EPDF@2WJVT[F2..9&4!E'88;[HXXJKH,FM/<:+J_\
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M:3,D\8D;8Y14*97[N1N;GKS7'Q23PZ!;1QW=VJP^.OL2?Z2Y/D^=MV')^88
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M^9(%V;0^!AB.>?QKF[;6X(-!\/G4+R2+1Y?$=S!>%9@B?\M#&K,,?(& )'3
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MIHM3L)Y)(XKVWD>*-99 L@.U#G#'T!P>?:I;>ZM[N,R6T\4R X+1N&&?3(H
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M-'O[M+6SU.TGN)(1.D4<H9FC/1@!V]ZMW%[:VC1+<7$432DK&'8#<0"QQZX
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MH8<HBQ29WR\@1Y&=I)&.1Q5R[\4:59>&9?$$URK:?%&9'>([^G! QU.>/K0
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MI]DTRU2UM]Q811YV@GK@=JKZAX8T35K];[4-,M[FY6%K</*N[]V>HQTJM?\
MC7P_IM_/976H*MQ#;K<NBJ6Q&S!0V0/5A^=6I?$FE07@MI;H(YG%MN*G9YI&
M0F[IN]LT +'X<TF*2TDCLU1[.#[/;LKL#%'C&U>>!C'Y#TK+U'2]6TV-+/PM
M:6$-M=NYNYIG;=$[#F4#^,YZCJ3W]-"7Q1H\5\]FUXOFQSI;N0I*K*PRJ%N@
M8^E-U#Q7HVERW$=U=X-LJM<%$9Q"&Z%R!A?QH OZ9I\&E:9;6%LH6*",(H'M
MW_'K4-[H.EZC>I>W5G&]TD9B6<$J^P]5W#!QR>/<UQ__  E[:=\0_$2ZAJ#M
MHUG86TR1I'O$9<@9 7+'.1_GFNZL[R"_LX;NUE66"9 \;KT8'H: *%WX7T*^
MBM(KG2;.6.S.;=#$-L?T'3'M3F\-Z(^GW5@VEVAM;N0RW$1B&)7)R6;U.><U
M!!XLT:YN+>**Z)6Z8I;S&-A%,PSD(Y&UCP> :A7QQX=;4?L"Z@IN?MHL-@1O
M]>5+!>GH#STSQ0!9D\*:#+I$.E-I5M]@@??';JN%5O7 [\DU/;Z%IEKJTVJP
M6:)?3*$EG!.YU   /J!@?E1<ZYI]IK5II$T^V^NU9X(MI)<+U(/MWK%\2>)=
M-_X1S6G769=,%A,+:>\2 LT+_*Q"@CYCM8=,]: .AU#3;'5;;[-J%I#<PYW!
M)4# 'U&>AYZCFJK^'-&DTV?3WTZ VMPV^>/;_K6XY8]6/ Y/I3;[Q'INFRM!
M-++),D(F=(86D94SC<0H.!_]>L+Q-X@D#^$+G2+W-IJ6JQ0NT>"LL3([8_-1
M^M '3WNE:?J6GFPOK.&XM" /)E0,O'3@^E5Y?#>BSZ5%I<FEVC6$+!H[;RAL
M4@YR!Z\G\ZJW7C'1+/4_L$]RZR"=;8R"%C$LI4,$+@;0V".,YY'K4&G^+[74
M]:UK35M[N(:8RQR2O PRQ4L3TX&,8)QGMQC(!IRZ!I$Z7R2Z=;.M_C[6#&/W
MV!@;O6HO^$6T'^QQI TFT&G!@_V98P$+#N0.I]S6+X7\165KX,T^ZO-?DUAY
MW>..Z^SE9+I@3PD8R3C';/2M1_&&BQ:3-J4UR\-O!.MM+YT3(T<C%0%92,@_
M,O4=Z +@T'2QK":M]C3[>D?E+/D[E3^Z.>![5HUG6FN6%YJUUI<4CB]MD$CQ
M21LA*$D!UR/F7((R,BM&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N1\8R-_;?ABWNU4Z//>2)=[
MC\K/Y3>4K>JEL\'C(%==45U:V][;26UU!'/!(I5XY%#*P/8@]: /)?$UD;.U
M\=P6S);>'S!;$%'"I#<Y!D$8Z E2I/N17I&E:'I=F+VYM(01J9$MQERZ2':%
MS@\<CKCK5P:7IXLHK(6-L+6(J8X?*&Q"O3 Z#':IX((;6WCM[>)(H8U")&BX
M55'   Z"@#RW2;(P>)+OX>Q6@73;>]35?-< @P;A((P.!_K %]ESWYJ?Q-)/
M;_$/5_[(MX7U(^%)I(V);<'$PXX('.0?7@8QSGTL01"X-P(D$S*$,FT;BH)(
M&?3D_G4,&FV-M-+-!9V\4LTAED=(P"[D8+$]SCC- 'FES<:6Z^!KW0RB:A<7
M"9$&%>1#'F02#!)]?F(P?>LBXOK&VT?QBMPUPZ3^)S %@E*AF)&5D)+?(<$'
M.1Z*. /8;?3+"SN9[FVLK>&>X(::2.(*TA'0L1UZFFKI&FK;W%NNGVHAN?\
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MY[, 3*SC!QD8XXSR=T:HNAZMK6DZMH%[?)KER+FV"6YD657"KY<AQA2,'@]
M*]0P/04M 'ET1,'C_P 5SRVEQ"#H42N0C/'O5<%4(49QD# )SU]AO_#^-Y_A
M9I5F!)#<)8BW<2(R%'VXY!&>#7944 >0WL5YK?@+2O!EI:SVVO6D\,4A,++'
M#Y+#,OF8P00,@@Y)-=!X*6WN/%?B\SV@$IU3S87DMBNY5C50P8CG#;AGZUWU
M% '&_$6VN(=+L_$&GVJW&H:/<K/&F2I=#\KID<X(/3GH.*RO&6D/IWP:U'36
MDENKRXC&^5869Y97D#%B%R2>OY5Z/UHH X&._P#[ \7:AJ%[#+-IVJV4,EK+
M'!)(VY%P8SUVYR"!@<DU@WUC-I%CX,MYX[GS/[?^WO!Y#'[+$PD^4[=P 4L!
MUKURB@#Q77I;Z]@UX7ND7D5Q9:I!=?8K2!A"4#QYGWJ!Y[D#.#TQT[UTVAZB
M-)\>^+S>V5]&EZ(;V"06S,K1)  W('WL@C;U]J]$HH \%\(Z=J6E^'_ WB"X
ML;N6VTF:ZBN[8PMYD*R9 D"XR0,YX'I6UXF?^T;'Q#KL=K=-IE[-8QQ0M:2&
M25X9#O?9P0,$#)'.T=AS[!10!YS!?P7/QHM[BW2\\B71EC$@MY5CW;BX5B<#
M.T@X(X^O3T:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LS6=;@T5;4207%S/=SB"WM[=07D8@G
M^(@   DDD 8K3KE_&5A'J@TRTN-/N;BW:X9FN;4L);1@A*.NWGD\'MS0!SOB
M'Q'_ &E=>$]5L5U"&*/59X9K0X627RTD#+L!^8Y7@9YS6]'\0]&?PY<:S)#?
MPBWN#:R6<MN1<"?M'L_O'(QSCGDCFN:M-.UT1^$(]1L;B[DL]7GD>=HR&$(5
MU223:  QW#KG/)/>J&I:9XCMH_%4EG8WS>?KT-Q'Y$8:40 #?) &&W?QP<G\
M* .D\0>)X==^'/BN2S2_L+RQM)DEBN(S#+$X0L.A(Y&#D'O1; C4OA_(+FX&
M^TE0PB1C&_\ HX;<W&"00,9/<X!YQB#2M4?3OB'IT>C7T2ZA#_H/FKN\[=#L
M'S9/.1D@],\GL-B"PO$U#P#--97PDL;:6.X"Q!DBW1*GSMU!W8Q@8QN)Z#(!
MU.O^([#PU:P7&H><(YYTMT,<18;V( R>BCGJ2*I:;XTTW4-1U2QDAO;";34\
MV;[=!Y0:+) D4D_=.T\G!]JA\>VTUWH$,<%I/<R)>V\VR&,N0$D5B< CL#Z_
M2LG7/#5[K7B7Q+$D3P0ZAH:6D5V2=IDW.<'V&1D=P30!LV?CG3+J[L;>2VOK
M3^T5W6$ES#L2ZX)PIR=IP.C[2<C JIX%\:3^+_[1>33+BWAANI8HI2%\LJA
MVYW9+<YZ8ZX/%5D&HZ[9>'M.GT6:UN;&Z@N+N6:,+%#Y/_/,]&+'@;<@ G.,
M<Q_"_3M2T*PU+2M2TZX@D%_/,)FQY;JS KM.><Y/;^$^V0"GXAUM-$^*\%Q+
M%?78727,=I:(TCL=XR43IG'))(X'>NCC\>:/<Z1IM_:"YN9-2D\FVLXD'GM(
M!EU*D@+L )8D@#'7D9SM7M[^P^)MGK8TZ>YT_P"P/;O)!%YC(^[(& "0#ZUQ
M]UX3\26$6D>*5T47=W#J%W>W6CQ3X94G!&%('+#//J<<=< 'H%KX]T>\T*WU
M2!;E_M%U]CCM?+'G&?)'ED9P#P>2<>]077C#2]2TO6[.:#5[62UAEBO%6T=F
M@^7G#IN3.TAAACP0:YG5K?4O^$;TN:/P^VG7,FMQ7%K8VP62:)5!+,V2H+$*
MQ(R,!L9XS5^PN(VB\2Z=-I^J0ZQK$,MWY=U B^:/+6(*@1SPN%ZG/S'GT -.
MU\7Z9HFA>%[1;;4K@ZAIP>S5(O,=Q'!OVL21ER!@ =2?QK:\->);3Q1ITEY:
MV]U;>5,T$D%V@26-UZAE!.*Y:VTC45/PY4V$H&EPE+QBI'DG[-Y?_H7^-:W@
M?3+S33KWVR!HOM&JS3Q;OXD.,&@"M:>-KF?XB:QH,VGRQ66FP1EY]R$ L-WF
M-SD+M(]<=3BK\'CC3Y;VQ@DLM0@@U!VCL[R6$>3.03C!#$KNP2NX#(YKE;_P
MGJ.H>//%T,T%U#8:]8Q0PWT&TB+:BJQ;)'<8QU/ZU9BL];U30?#&D3Z5-:W>
MG7T$MW(>(E2$M@JQ&&W #@9QNQGC- '7>)_$UEX3T@:EJ$=P\!F2'$"!B"QP
M"<D #WS56W\86L]_I]DVGZA#+?W%Q!%YL04 PC+,V3P".5QG(JA\4=)O=;\$
M36.G6TEQ=-<0.B(,G"R*Q/7T!]:F\00WQUSPIJD-E/<PVLTOVD*!OC$D17<5
M'H3SB@"I=?%#1K+3]0O+BRU&,6.H#3ID,:$B8^X8C;[Y_"M;1_%UMJ_B+4M#
M^PWMI=V(W_Z1%M6:,G:)$.>5)!Q[5Y?JOA'Q%>Z/XGC72I?-O/$B7L*@Y#Q
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M<8^;<QX#;OEV^N<XP361XJTK5;#Q:NO:9X=M_$,5[;I;3VMQ($,#*25=68,
MI!((P.1GO52Y\/:ZDNGQ7.F)>(UG<J$M76.*VGE9GVOSS&@;:" <A<[<G% '
M3GQI;3PZ0=-LKF]GU6W-S!$"J>7$-NYI"3P!N[ Y/ KD/%&OP:U>^ M5MX+R
M,G5VC:V=65P0IW*5Z'YE&#G'IQG$&G:5XNT73O#6M6WAY)[O3+%M/GL'NPDD
MB-@AP=I PR@^N*OZEH_BK5;[PIJFI6:M<6NJO=SV\$@86L) 54S@;B.I/UH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W5I;W
MUK+:W<$<]O*NV2*10RL/0@]:FHH KV5C::;9QV=C;16UM$,1Q1(%51G/ '2K
M%%% !1110 5 +*U%PUP+:'SG(9I-@W$@8!S]*GHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#DG(..V.XH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,/D9O,?"GTSZUZY7.S>"=$N/$:^()(9CJBL&6X\Y@0!C"@=-O'3W/K0!YIX
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M<UV= !1110 445Q,=S>>)_'VKZ7._DZ1H@B4QQ2LKW$LD8?+$?P@$C&>O/T
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MO<7=S 88HU&<LW'/(P/>N@HH YR_U;4=)T'39;?P_=ZB7C1)[>%D$D7R^C$
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M5SDCZ@9K4E\->*=/URUUS3+W3KJ^E@,&I)<J\:3#>60KC)&P,0,]AW)KO**
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MR1R ACP?O\Y[+[5Z/10!PO\ PB7B2WU+4+:QURV@T"]NOM)A\EO/A);=(D;
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M \#V/ANXBDL+R]V0V7V..*1U957>7+<KG.X^N.@Q573OAW8Z3!H4=E?W:-I
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M[20V!G!'H/0>IK9L9_$>HW]YX>;7C%>:5$CS7D=JG^DL^YA\K9"@# ]ZNO\
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MS%EMY%++\HVD8(&<$C[ON2(-7GN=(T^Y\2Z;XB>:>XTOBQED$BRR*I82(.Q
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MB_2[ENU5@4B64H'+=0@ QGI@4 ?1-8/C/7Y?#/A/4=7@BBGFM8O,6*1B PR
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M),??/WR.^: .M\4^)7T;^SULGM9))[^*WG1R69$8X)"KSGIU]:Z:O#Y&TI_
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MQ70$EU#(& 8<*,*>.<$].:V]0CLH?#]]##Y2QP>,XP(U4!8<RIP ,8X.?QH
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M!/JVCV.MV8M=0@$T*R)*HR5*NIR"".0?I5:+PQH\$M[+'9 27T2PW+&1B94
MP <GL"?SH_X2G0BEHZZI;NMW,MO"4;=ND;[J''0GT.*JZCX@M;W2]?@TG4-F
MHZ=;LTF(SNA8JQ4D,,'.T_E0 ZX\%>'+NSL+2;2XVAT\8M!O8&$?[+ Y'0=Z
MV+*RMM-LH;.S@2"VA4)'&@P%%<MHOC+3K7P;X?O=<U#RKF^L$GRX+,^$!=OE
M'09Y. *M7?CK1;37+'36G9S=VANTDCB=U,>5VD%0<YS0!NZAIUGJME)9W]O'
M<6\F-T;C(..152#PYI%O-;2I9JTEJ,0-(S2&/MQN)P?>JP\9>'VUC^REU*,W
MGG?9]H5MHEQG9NQC<1SC/8U'?>.?#>FW<]K<ZI&LT$T=O(BJSE9'#%5X!YPC
M<>U %G_A%M$^T3S_ -GQ![B4338)VR.#NW,N<$YYZ5+_ ,(]I7]H7E_]D'VJ
M\C$5Q+O;+H.@Z\#Z567Q?H4F@MKD=^KZ:L@B,ZHV-VX+C&,]3BM/4+^UTO3Y
M[^^G6"U@0O+(_15'>@#*7P7X>2!($TQ$B2 6P1'< Q@DA2 >0,GKGK4ESX2T
M&ZNK6ZETR'SK6+R('3*;(_[GRD?+UXJ&'QMX<N-5ETR+5(GO8H1.T*@EMA7=
MD8')P0<=:<OC/P\UI8W2ZDAM[Z0PV\NQ]KN'V;<XX.[CG% $L'A/0K:TL+6'
M3HT@T^4S6J!FQ$Y.21SZDTDGA+0I5U%7T]2FHY^UIO8++G&<C..PZ4UO&&@+
MJ,EA_:41N([@6SJN3ME*EMN1WP#4%IX\\,WVJ66G6^K0O=7L7FVR<CS%YQ@G
MN<'B@"[#X9TBWNH+F*U99H(/L\;><YVQ_P!WK[#\A7-:_P"![:5=+L[31;6^
MT6&>22XL)9BI#/UD5B3DCYOEXR3U%=#/XMT.VU8:9-?*MUYJPD;&VK(P!"EL
M;02".,]Z==>*='L]5&FSW3+<[UC($3LJNV-JE@, G<O!/<4 9OA'PZ^AW5\\
M>GP:98R;4@M(;EYNA/SOGA6(QPN0,=370W^GVFJ6;V=];I/;R8WQN,AL'/-9
M=[XQT'3M5&FW6H)'<[TC;*L51F^ZK-C"DYXR:5_%^B1ZTNDR7A2[>40H#&VU
MY/[@;&"W!XS0!:MO#^EV=]'>PV@%S%$88Y&=F*(<9 R3CH*@B\):!!KKZW%I
M5LFIN26N0OS$G.3]3D\ULUR$^OWVK^.)O#>E3?9K>Q@$M_>HJM(CM]R)0P(!
MQR20>,4 ;^E:'INB),FFVB6ZSR&60*2=S'J3D]:DL=)L-,ENY;*U2%[R8W%P
MR]9)" "Q_*LZWCUFPUV.*>]-[I+6TCM/.B+)'*&7 )154J06(X&,'.>*?8>+
M-'U*_BLK>Z/GS(SPJ\;*)E4D,4)&& QV]CWH ;'X.\.Q:1/I*:1;?8)VWR0%
M<J6QC=ST.._6I%\*: FAG15TFU&FD &W"?*<=">Y/OUJE!X_\-7/V5H=1#QW
M5PUM%((VV&0'&TMC /IGK5R7Q3I,-^UF]PWF+<I:,1&Q59G&50G'4C'YB@!+
M7PCH%EI2:9:Z5;PVB2>:L:+C:_9@>N[WSFK^G:;9Z5:_9K& 0Q;BY ))+'J2
M3R2?4UF_\)AHO]C#5OM+?8OM/V4R;#Q)OV8(_P![BN2O_%MUH7Q$\4M=7$TV
MFV&BQ74=KGY0^['&!QDGD\]?:@#T"_TZTU2U-K>PK- 2&*,3@D<CI4,VAZ9<
M3W4TUE$\EW%Y,[,,^8G]T^HK T'QY87WAW1[N_E$>H7]NKFWCA8%F\L.^Q3D
ME0#USBM#_A-= -AI]ZE^'M]0W_9F1&;?M4LPP!G( /'6@#8L[.WL+5+:UB$4
M,8PB#HH]JK:CHFG:K)')>VPDDC4JD@9E90<9 92",X%8-_X_TU/#\.JZ;YET
MLUZEDH\I@4D9L'<#@C'^%=/9W<5]:1W,(<1N,C>A4_B#R* *<_A[1[FXL)Y=
M.MVEL!BU;9S$,8P/;':HF\*:"]E%9G2K;[+%*9XX0F%60]6 ]:;8^+-'U&[M
MK:VNMSW:N]LQ4A9@A(;:>AQ@_AS5:3QUX>A:,27K*DMR]I')Y3E7F0X9 0.N
M?Y&@#4?1--?5DU1K2,WZ+L6<YW!?0'T]J8OA[2%MKRV&G6YAO6+W,93(E8G)
M+ ]3GG-4#XWT :F=/-[B=;@VS90@(X3>03V&WG)XJU9^)M*OKJ&VAN#YD]O]
MJA#*0)8N/G4]QR/SH 5?#&AII;Z:FE6B63D,\*Q@*Q!R"<=<'UI+WPMH6I?9
M_MNE6MR;==D1E3<57TR>U1VGBW1[Z2T6&X?%Y$\UL[1L%E1/O$$_G4VG^(M/
MU*[CMK=I?,EMS<Q[XF4/'N"[@3P>2/S% $QT736OWOC9Q&Z>+R&E(Y\O^[]/
M:JO_  B>@?9K:W.D6AAM9#+#&8\K&QP20/P%4_$OB>70]7T&QBM6E_M*[\EW
MV$A5",QQ@_>X'ZUSVF>*ET'Q#XM76M1O)[."^B6$NID%NC1J2#M&%7<X ]O7
M!- 'HU95[X8T+4KXWM[I-G<7)38998@Q*],<U#J'BS2-,FN8I[AF:T@6XN#&
MA<0Q'HS$=!P3]!5.#Q9]J\>+H$%NS6QTQ;X3[#\VY]JX.?NX![=<>E &G>>'
M-%U!+5+O2K.9;4 0*\((C Z #TXZ=*GN-(T^[OXKZXLXI+J%&CCE9<LJL""
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M>:W&FV8@F8-+&(%VR$'(+#&"<^M9NI^+;#2+R\ANXIUCM(HI))D3<"TC;40
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MO+90+/J,0= ]FI4.P()^<J,DA<]*Z6*^6\TF._L4,ZS0":!<[=X9<KUZ9R*
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MX9%):,[1GY@/2NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%06$8,F>4&YFW#)((&>I/LS+%<P.A(>-U*G:W4'@\BN1M_A\D3&UFUW4Y]%
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M=?:AK":!I=M:1ZL;+[=))<2&2W2/>% 4K@N3G/8 'OTJ%_'-[BS@ATJ.6_\
M[7.F7T2S';"0-V]25&X%=I&<=<<D5#I_@34-#OM/U;2[VV_M"&S:RN(98]L#
MQ%]ZJA497:>!G.0 *L2^%-8M,/I=U8O-<:G_ &G>M<JRAGP%"1A1PH"CDY/7
MUX &?\)CJPM?$]L-/M9=5T>2-(RLA6!_,"E2S-]T+NRW(X!/%86J^+QXE\&>
M-],N%MI9-/TPRK<VH;RI4DB8@J&Y!!4^HZ<UHZIX"U;4;[7;A+RQ@%]>6]Y%
M&0[J[P@*%E'&48 9 JXW@:\O;_Q)+?7UND&MZ;%9,EO$08BJLI(R>GS'']*
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M(38R,MW*R"3:FV3]V,$#DMR?2J:>,O$NJ:K>6%OIJ:2ZZ3]KB6]0F2.7."&
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MW=J+@QX"1PR..5('S%5 Z#N:Q_',^N1:;IL>L_99VMO%%K]E?Y0)H3N*EQG
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M(T0.\'.T?)]W(4^ORCGK7<T4 <P? ]A-K6JZC>7=Y>+J=H+.:UF=?*6,8QM
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MS9]J1;J0).%  #KG!R!@^M17O@+2;_4;VZEDNUBO;5+6:UCF*PE5X#;1_%M
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MAAR<[L=N*Q5@O-;TSPWHCZ/?6UYIEQ";NXDC9%MA$N"T4A 63=C;\N>&.<4
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M:YA>S\9?;I%D(0>0K'++O;+#T(SGL30!V>O?$&TLO#.IZAI\-Q)=V4H@>"2
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MBB[UBQO(])AFEAVP$;_+0(" P/))R<_4=JZ&3Q3::3,-&M["^N9[:PCN$CC
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MA0#MJ1F5%+,0% R23P*P_"NL7&NZ?=7TIMVM6O)DLI(%8"2!3M5CN/))#<C
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M=M=AC;W$4P7[WEN&Q^5>=3Z)I</BWP%9MI\<B"RNP#@-$%V*VW:RDGDY7G@
M\'.1-XNAM_"GB/PWJFCV8AEN[];2YM[5 BW",-N6Q_<SNZ'H>G6@#T&:XAMU
M5II4C#.J*78#+$X 'N34E>7_ !)O7UNYNM"L)UCN](M5U2,B4*S7(8^4JY[\
M$\=R.E=MX2UM?$7A73=5R#)/ IE &-LF,,,=N<\4 ;5%8/BC6;S2X+.WTR&&
M34=0G%O;&<'RD;:6+/MYP IZ5A7OBO7-&_MRQOTT^XU"TTYK^TF@C>&*1%4[
M@REG(((XYP>.1G@ [IE#HRMR&&#6)X:\(Z-X3@N8M(M?*^U2F:9V.YG8^I/8
M=AVR:9X:O==O_MEQJL-HEE*R2Z>T+98Q,N</R>1ZU0\7>(-7TFY,=@;*VABL
M9;IKB^@:5)G4@") LBMNQN).#QCWH ZZBN!MO&FJZOJ7ANWL(;6"/6=)DO=T
MP9C&XV8Z=0-V<=\8R.M9C^-O%D/A.+6'32 MEJCV&JR&"1@J+*(_.C4.">N2
M#^@H ]1HK%M;^]NO%EY;)+$=-MK:,D"$[FE<D\/NQ@*!QC^(<\<M\2:Q<:<E
ME:6(A&H:C/\ 9[=YU+1H<%BS $$X4'@$9.* -RJ$FM:=%K<6C/=(-0EC,J0?
MQ%!U->>>+->\1V?ASQ1HEU=V_P!OM=.-W'J$-JR+- ^590N_Y) <_,">,'&:
MH)%J:_$;PG$M[;R7C>'IQ!<?9V"+Q\A=3(Q8CC.&Y]J /8:*\OL?'VMWGAO2
M("D(UR_O+FU,T-LTR(L!(=Q&""W08&1USVQ5MO%GBBSTO2?[0LXH;J;5_L4K
M/;E/M$/\,B*6^3(/(.>0>E 'HM%4-%&J+I$"ZTUN^HC<)FM@1&WS'! //3%<
M6GBKQ%<>,O$=A ;+[!HLMM-(&C(=K=DD,B@YY?*K@\#@T >AT5Y]HOBCQ/J5
MUI-\MD\]AJ$F)K?["T0M8F&0_FESO((&1CG=QC%4QXM\4ZCI.F:QI$E@5U#5
MI;+[%<6Q+0Q"5D#<."S!4+MR!SP!B@#TVJ UK3SKG]BK<JVH>29S"H)*H"HR
M3T'++UZYKBKKQ5KL.@^.YEN+7[3H<[&TD^S'!0(LFUANY."5SGWQVJ>VO)KK
MX@Z7=,NZ=_"\D^,84LTL1X_&@#O:*\TT+QCKFH^(-/TF?4=,:YO+:Y-PEO;L
MZVDR$[=K[L. "H*Y/*GGGC*\&>(O$,7A?PU;_;K6XO-?O[D+-/ V8$1I&D/#
M?,QV_+T X!!'- 'I&M^%])\026\M_;N;BVW>3/%*T<D>[KAE(/(X_.K&D:+I
M^AVTD&G6_E))(99"79V=S@%F9B23P*XK6O%VNZ#9^)K>9[2>ZTU(+BVG$)4/
M#(^W:R[OO###/ Z'':GWOB'Q'H&H:3-KES:OIE_?- 'L[?:45T4Q;MQ./F#@
M]<Y&,4 >A45B:'?:A?ZEK3W 4:?%=^1983#,$4"0DYY_>;@.GW:I>*=7U/3M
M3TJ*VGM;73I6?[9<28>487Y%CCSELM@' .,YXQ0!U%%><Z7XXU34M+T)'A6"
MXO=4FL+BYV;541;LL%.=K-MX4YQSSQ4*^+?%<>C:S/YFGW4MIJHTNU,5DV9,
ME/WI_>X;AS\H Y7KVH ],HKRSQ)XQ\6Z3HGB&Y@MO(AM((I[2[O+7:[;F"/&
M4R!D$[@V,8XP>M7+GQAKOA[Q;J=EK,UE<V4.C3:HH@MV1HRC*-FXL=PY/.!G
M&<#I0!Z/17(6DWBF9=.F%Y:RV^H63.S^6L1MIB T> 22ZD':1U&"<\X&=I?B
MK7-7\-Z*L0BBUN:_:TO0R[D3RF/FGIQ\HR/3(!SUH ] HJKJ5_#I>EW>H7&[
MR;:%IGVJ6.U1DX Y/2N'OO$'B71] T#7[FZM;FWN[N);Z!+; 2&8@(4.[.Y<
MJ#G.2<\ <@'H5%<!X%UWQ)XDN]0N+NYLQ96.J7-HZ)#M:155-F.3C!))SG.[
MMCG?\<:W=>'/!FIZM90K+<V\8**P)&2P7)QZ Y_"@#H**\_O/%6IZ1K^O?Z0
MFH:5IVD"]0!%W-(>Q=<  A2<8_BZC JT^H>)=*G\/W%U=1WMIJ;I;WB+"J&V
MDD&4>/&?E!X(8L>1SSP =M17GEKXHUMK/4]"NYXD\3PWZ6T;Q1 H(Y/F24 \
M, @8D>HQQ2C7O%>K-K=QI"1D6&HFUMX 8U1U1E$AE9_FS@L05P!@=: /0J*X
MC3]3U_6/&>JVEMJEO#I^G741:(VP<S1,N2H?(V^N<'MTYSBZ=XOUV7P_X=UF
M6\$AO-8DL;F#R4"-'YLB*00,@@*O.>>>* /4:*\KUGQAXBL]"\7:E#?1"71=
M46*",VZ['B+H-C]^C=00?IVOWGB?7/#&OW,.K7T&HP#0Y]3V06PB6-XCRJ\D
MD$$=3V]^ #T6BN"T;5/%MTWAZ_E*/8W\+&]W^2J1LZ@QF( AB 2002Q(]ZH:
M9XJUZ2P\$W=U>)(^K7DMM=1K"H1E'F%6'&0V%4=<=>* /2P0<X(..#4-[=QV
M%C/>3!S%!&TCB-"[8 R< <D^U>>:?<ZS8>%?%NH6FKM/=0:G<;&O539&H9<G
MCG*ID 9QD#CM4NC>)[K6KSQ78-/<S6-KI\,UNUW;B&7]XC[L@*O'R@CCUH [
MZSNXK^R@NX=WE3QK(FY2IP1D9!Z57UC1-,\06#6.K645W;-R4D'0^H/4'Z4W
M0/\ D6]+_P"O2+_T 5Q7C/Q+K>EZAK0L]1B@2QTS[9;P0P"8LRM\WFEE 4$<
M !L\9&>E ';Z3HNF:%9BTTNQ@M(!CY8D S[D]2?<U;DFBB>)))%5I6V1@G!=
ML%L#U.%)^@-<?:>(KJ^\8QV,=\Z6USHPOEA,2_(Y(Y1B Q !Z,IY/;H>=TN^
MU'Q%>^ KZ^OYUG:>]W^7L"N41L,5V=<#''0$\\YH ]&TK6;76#?"U$H^QW+6
MLOFQE/G"JQP#SCYAS_3FM"O*Y+W5=(TCQAJEC?B![?Q V(UA1ED!$*D-NR>A
M'3!SGZ#I;?4=6UW6O$MA::C]A_L[RX+=EMU?]XT>_>V[[PY' Q]: .OJA;:O
M;7>L7^EQ"7[18I$TQ9"%_>!BH![\+SCID>^//+;Q-XCUW5O#NFK?0V,U_IEU
M+<K$@;RY4)C5U.>1NYP1C@\GM%XCUS6EL/B):R7Y232].L_)D@ 4JSQ,SD'&
M>3GZ4 >JHZR1JZ,&1AD,#D$4ZO.1JFK:#IW@N]_M$OH]PL5O?)+"A*EXP(V#
M@ CYL#G/6NL\/W6H7QU&YNV!M6O'2R& "(E^7)QURP8C/;% %G4M8@TNZT^W
MEAN9&OKC[/&T,194;:6RY_A''7_Z]:-<QXMU6\TR^\-):RLL=[JR6LZ #YD*
M.W7!(Y0=,<9KCM3\0Z[_ ,(WXNUB+598Y= UN188PB[9846/]VW'0[CS[YP:
M /6*1E#*58 J1@@C@BN(U'Q+=^'_ !3$^HWI;1[S3I;E$9$7R)(E#,H(&7R#
MD#/&#USQ#I^HZO>:MI'ARYU&:"XGTV;5+R5$4N49PB1(Q^Z5+Y)P?N@ \YH
MW]0O]&\!^'4<6K06$3K%'#:PEOF=L  >['J3WK6O;*UU73YK.]MUFM;B,I+%
M(.&4]C7D'B?6K_4_!_B/2-0F\]M)UJTM8[E$V22(98R"PZ;ASR.#QQZ]5J_B
M>_\ "_B+4K>^N9+NTFTUKO3(1$JN)$X:+< 2225()'\6,''(!UT^HPV&I:;I
M:VMPQNQ(L;PQYCA$:Y^<Y^4= /<@5H5PM]=ZOI_BGP%I\NI3.+M;A+T84"9T
MMRP)P/[W./85SC:WK=MX+;Q"^JW;WEAKLEN(F<>5-&UR(]LB@<@*>,$8- 'K
MM%>8>(O$6JIKGBZ W\MFVC6UM/I:0\>>71MY93GS/F&W&.,>O->AZ2+L:1:?
M;Y#)=^4IF8A1E\<_= '7TH CU;6;72--OKV;?*+*$SRQ0 -)M )X7/?!JS9W
M4=]8V]W$&$<\:RJ&&#AAD9_.O-98)X]:^([BXFF(LT(CW+SF%L+DJ<8[8_6B
M]UJ_\.7_ (5FMKN9[>\T2X:6UD.Z(-#!&R%5[').3GD4 >HT5YQX6NO$6IV^
M@>(FOG\G4%5]02:9/(VLG"PID[6#8'J><UZ/0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XIT6?
M7M%:UM;HVMU'+'/!-SA9$8,N1W&1TK:IKNL:,[L%11DL3@ 4 <7?^'-7\030
MW^IQV<%W:V%Q:PK%(S*SS*JLY]%PO Y/-;/@S1)_#GA#3-'NI(Y)K.+RF>/.
MUL$X(S[8JO+X]\/0PRW#W-R+2(D-=_8IC;\>DNS81Z$'GM72*P= RG((R* .
M8\1Z)JNH>)?#^HV<EL]I8/*9[:<$;BZ85P>>5(';/O7-6'@;Q%I^CVCVLVG0
MZOINIW%U:R-N99(968O$W'R[LKR.FT5Z;10!PFI^$M;U2TMKV[O()M6AU*.\
M2$L?(BC''EKD$C ).X8+'KD8J34?"FI3KXKMX/LWE:]8$-(S\QW'EF/& O*8
MP<G)KMZR/$OB.R\*Z))JVH)</;QLJL+>(NV6.!GL!SU) _$@4 <I<>#=96[C
M:+[#=?\ $H%C%-<NQ%FX0J6C3'1\\\Y^7T.*MP^&-:GU3PEJMT]E%/I%O-!<
M0QR.0P<(H*G R0$Y!XYKLGN88Y/+:11)L,FS/S%1U('7'(_.LSPUXCM?%&E-
MJ%G%-'$)I(=LR;6RK$9_'&: -9PQC8+C<0<9]:\YTKX>ZO8Z=X;BGO[*YN]*
MU"2\EG<.6EW@@@'U).3GK@5Z110!P\7@_5[:XUPPWEH8-1U5;XQ.I(DB*A7B
M?CH0HZ5SWB/PLWASPU<M;&TLX9]<M+J&VB4F" JR+^ )4,>F.E>EZOJ]GHE@
MUW>R%4SM1$&YY7/1$7JS'L!6-8Z_H7BRX&EW6FW"7B0B[-CJNGLC(F[:'PZ[
M3SQD$T 9FL^#M1\5MJ#ZM-:0)+8M:6J0 L5;?N$C$^ZH0 .*%\)^(=8T"33?
M$FIVDO\ HA@5K:,Y>7<I69R>-PVC  ZDGTKN@ !@# %% '%VGA[Q3>Z9)9:_
MK,$BBREM5:V4@SNX9?,E' X!&% Z\YJ&Q\'ZO%X?\*6$]Q:)+HD\;,T9;$D:
M)MXR/O')]J[:XG2VMI;B7(CB0NVU2QP!DX Y/T%4]#U9-=T2UU.."2!+A-XC
MEQN7G'./ITZ^H!XH Y9/!VK6MEXCTRVO+-].UB:21%E0AH/-!$F !\QR21DT
MVT\#7MCK^M7T%S;?9[W2XM/@C.[*;%V@M^%=W10!P5OX)U(:#IVCWYTK4+&U
MTY;9K:XB)0SJ?EE7C(XX[5U?A[2VT3P[IVEO.T[6END)D/\ %M&/RK2HH YB
M]T/5VU'67L[FT6VU.*-#YBMYD3!=C$=CQR >XKE/$UGI,FEZ;X%T:YE?7M+-
MNUN(P5>)!C<Y;@ %"<\]\5ZE52?^S[!IM2N!;6[;0LMRX53M!X#-Z9/ZT 2V
MEK#8V<-K;1)%#"@1(T7:J@= !VKG-8\+75[XVTKQ%:7,*FTMI;:2&9"0ROSD
M8[Y[5I0^(+>;Q7/X?6&47$-HMV9#C8R,Q48P<]0>N.E:] 'GUIX"U"S\+Z/I
ML4FG^?8:Q_:)X<1A=SMM7&.?F Y!&,]\$$O@?Q!;ZGJ4.F>($CT+59));NUG
MCWRQ-)C>8G'0GG&[(&>A/->@US&O>-K31;ZYL8K2XO[NTMA>745OM!BA+8W?
M,1D]3M'/';B@#H;6UAL;.&TMD$<$$:QQH.BJHP!^0K \/:%J>F:SK-[>W5M-
M#J4PF\J-3F(@!0,GJ,#TZUOVEU%?64%W 6,,\:R)O0J=K#(R#R#ST-34 <YJ
MNA7][XLTK6();98M.BF5(G!RYD !R0.  !TZYYZ"F?\ "-7E]XL@US5K]9(K
M)3]ALH5Q'$Y&&D8GEF(.!V _5EWXVBL=(;49],NTC&H+8!6 !)9P@<9ZKDUL
M)JC-X@ETHV=PJQVRSBZ*_NWRQ!4'U& 3]10!5\/:-/IMI<_VB\%Q>7%R]Q)*
MB<?-C YYP  ![ 55\*^'+SPY/JB/=Q365Y=R7442H5,)<Y*^A'?ZFKMYX@B@
M;2VM('OK>_N?(\^W.Y(^#\Q([9&*V* ,/Q/X?;7;:T:WN/LU_8W*W5K.5W!7
M&1AE[@@D'ZUEWGA;4M6CU.?4;FU^V7ED]A&(0WEP1N"&(SR6).>PXQ[UV%5=
M2O#I^EW=Z(7F-O"\HB3[S[5)VCW.,4 &FVG]GZ7:60.1;PI$#[* !V'IZ"N;
MU?PE>W_BF?5;>_BBAN=.-A*LD>]XQDG=&>@ZC(/7%=3;2_:+6*8HR>8@?:RD
M%<C."" 1^(!J6@#B-"\$7>DW?AJ>6^AF.C6$MB=J%?,5B,'Z@*OU.:S[F?2_
M!FD7V@:]<_:I-=N+N6W@BB9S(923Y0'J2V!ZDUZ/6;KU_!HVBWFLS6OVC^S[
M>2XVJ!NPJDG!/3@4 4O!F@CP[X6L;&3+78A0W,C<L\F!G)[XZ?A4OB/P^NO6
MMMLG:VN[.X6YMKA1DHX]O0@D'V-:&F7HU+2;._"&,7,"3!"<[=R@XS^-5=$U
M:?5DOC/IES8&VNY+95GQ^]5<8D7'!4Y[9Z&@##U;P4^N1:[+>7:)=ZG8BQ0Q
M(=L,8R>_))8D]NU16'@F[M/$&@:K-?12OI.FM8%50KYF1@-U..@_6M_7M;_L
M..Q<VK3K=7D-ID2H@0R.%!^8Y/7H 3QVZUK4 >=M\-KK_A'(+.WU<V>IV>H2
MWUI>PKG89&)92IX(^;'X#W%69O >H3V=C+<:PMWK$5W'=7-Y-$%$VS(5 JX
M !(X]2:[.YO;:S:!;B9(VN)1%$I/+N03@>O )^@-9WA[Q#'X@_M3R[9X/[/U
M"2Q8.P)9D"DMQT^]^E &S7+:9X2DL?%WB'5Y9XIK768XT> J<KL! Y]"&;/X
M5U-% '!:3\/KK2IO*N=<N=1T.U<36>E/&H",O*@MU(4]!G'K7FMC*\.IM?:)
MXI#^(VFE=M*ETI)+D2%B?)>38&_V6;( [8 %?0]&!0!Q%YX'N;ZV\1PQZ@;6
M#Q!"&G38&>*8JJG#=-FT8(QGDX(JVOA&X_MNTNWNX6@MM)?30/+(<AMN7SG
M/R@?G7644 <#I7P_U#3[SP]=-KBAM'C>!8XK5522)NH/?<<#)! X& .<K;?#
MJ6VT"TL8]4,-UIEX]SIEQ$F/(#.S%&R<L&#%3[?CGO:* .,U+P*^K:=K8N;]
M5U'5Q&DLRP@I'&C955'4X&>2>ISQ4/C'5=/DM/\ A!Y8Y;K5M0L08HHXSM(S
MMWD_P@%2?PKN:* ,_0M(AT'0K+2K<LT5K"L89CDMCJ3[DY-9&O\ A.36/%&A
M:Y!J#6LVE._R>6&$B.I5AST."0/K5O6O$/\ 8VL:)8FU\U=4N6MQ(),>60A;
M.,<_=]16Y0!X[XI\,Q^'/#UCIFHZQ+%I4FISWL^IRVB3K 6!VJZ;2IW,YY(
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MM*N!/&PQE^",,?3.#]16=X=UK7]2NH+ZZBLFT:^M_.1HG"O:-QA&R?GW<G(
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M;N-(YF\UBK*GW1MS@8R>@[TNNZ%8^(M,;3]121H"ZR#RY"C*RG<I!'(((!H
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M)W.J] YS\P]CFLZ:WU77_%,5G>Z,EGI&CW:7=O=%U<W3!&";1CY,%CGZ#UH
MV?#-G<6FA6XO2YNY099][$D,W..?3I^%><W^KWUH++6-,OY[J"Z\2>4MY+*%
M1H7F,9ACC!;>JX8;FV^H!S7KM<XW@/PT[3E]+C83W(NG5F)7S <Y S@#))P.
M,T <1<+?SR^,]0BO[U[C0;^2XLX4D.'/V<$(P[KN.<>U:WAA;QM3T&__ +<L
MYH;BU,;Q),[271:/>7*Y(5D92.."&/(.!7:6FB:?8W%]/!!MDOWWW.6)$C8Q
MD@^W'TJGH_@[P_H%V]UI>E6]M.Z[-Z+]U>I"^@Z<#T% &/XXOWAUGPUI\MW+
M:6%]>-'<.G E^0D1L<C:#USGM6+?PW.EZMI&AQ^(99].O]9DDG96 -O&$,B6
MY;)."5V]B1[UW^KZ+INO61L]4LXKJ#<&"R#.".A!['W%55\)Z FF+IRZ5;"U
M602A-@R) ,!\]=P_O=: ///$[W&D:?XTTK3KV[%O;VUK=199LP,[X9%<DDKA
M0?;)J_?7UYI'C'5OL,LKF7PN+TP[V;$RR%0X!X''IZ<UV\WAO2KG3[JRGMO-
MANV#3[W8M(1C&6)R>@J0Z!IQU5-3\@_:U@%MY@<\Q YV$9P1GG!H \RM4$B_
M#75WN'N;R_N US,\C,)',#$M@]#D8X J+3M3U!? /AM[N[GCN3XIAMYMTA!V
MB<@H>.@ Z''3\#Z';^!O#-K<PW$.D6Z202^="0.(W]5'0?05//X2T*Y:\,^F
MPR"\D26=6&5=T(*G'3J/QH X^6:'6;;Q!-J.M-I^H:9J+>7)&^##$A1E4+N&
MX,!W'<UD:A?2Z>OQ*UK2$>/487MGA<J2RAH$YVD\]6(X_P#K>BW'@[P]=ZI%
MJ,^DVTEU$@179.PZ9'0XSWJR/#VDKK$VK"QA%],@227'+@# R.A..,^G% '!
MW!ETC3+SQ%H6NI/(^C3R1V2AG$DBKO$IW.V"N3D8YZ4S3[2./6/ASJ'GO-+=
MQW$EQ/)*6WR/;$_0<Y&!CZ'MV^C^$= T!YGTO3(+=I@0^U>H/4<]![4VU\&>
M'+)[9K?2+5#:RF:W^3/DN<<K_=Z#IZ4 ;,4\4X8PRI(%8JQ1@<$=0<=Z\WTF
M4Z=\=_$":@H3^T+*$V,K%AN50 R#M]X,?6O0K+3;/3A.+.W2'[1,T\NP8WR-
MU8^_ J/4]&TW685BU&RAN57E?,7)4^H/4'Z4 <Y\0=8_LKP]J4NG)YFN1V,C
M0>6N9(HRRJSY . ,[N>NWVK(U!9M(USP5)HAFFCU!VM[V,2M(LL)0$R')_AY
M.>.O-=MIN@Z7I$#PV5E%&L@PYQN9QZ$GD_C4=EX8T736G:ST^&$S*58H,84]
M0O\ ='L* /'_ +7=VO@GPSJD%]=+>C7Y+8RB9CNB-RZE2"<$8XYKH);JXB\3
M6DMTYO-/O=6=K+5;&Z8F,\_Z/+$> !RN0>P..M=__P (KH/]G6VGG2+,VEM)
MYL,)B!5'SG<!ZY).:1/"NA1ZHNI)I5LEXLK3"54 /F-]Y_\ >.3SUYH \?CU
M.X@\ 0F>YG%R/%S6ZL;AU:,;S\ON-H(VM@=^H%;_ (G@B(^*$I0F0V]GG#$9
MVPY'3D=37H \)Z #<D:3:C[3,MQ-B,?/(K;@Q]\\Y[U8?0=)>XO+AM.MC->Q
M^5<R&,9F7&,,>XH X'6&@FNO[-L[DAHM&9YS)<F-+)7!'G ]9'RI&TD 8SD5
MD>&KAM6G^'7VN>=VN-,N5G0S,5D 0J"QSR<9[9'K7ID?A'P_%]D*:3:@VBLD
M)* E0QR1[Y//-.LO"F@:?);26FD6<+VV\0.L0S$'^\%/8'/2@#R988QHOAN&
MXD)AMO&;VL>YV CA7S0JC/0  #\*]<UGR8/#-Z%OOL,(MV478^;R01C?R><9
MSUJ)O"/AYM/FL#H]F+69Q))&(@ SCHWU]ZU)+2WELVLY((WMF3RVB905*XQC
M'IB@#Q'4I;C3=#U'1M;(^TC0&"3QS&YM;T(0!*=Q4QR9QCKDG/.,5UWV;3]$
MU?1=3C\Z.2[T*9+B2-RS2+%'$RG;GYF +8QSS]:ZN/P=X<AAN(4T6R$5PH25
M#$"&48(7'ID9QZU(GA?08YK:9=(LQ):J5@;RAF,$8(7T&": /-O#E].GB;P*
MR7CF&]M[Q)"]R9'N46-61Y!G:K$G.T=/4UJW<D4/@6!F>"**/Q&>% 18Q]N8
MX."0/7KTKLX_"F@0W-K<1:19QRVLK30,D04H[##$8]?Z5&_@WPU):/:OH=@U
MO))YKQ&!2K/S\Q'KR>: -2^YTZY_ZY-_(UXU\,[]18^&]/UE53S+!VT39*PC
ME;<WF;SQ^\S@ <\=#R:]H>V@DM&M7B1K=D,;1D?*5QC&/3%91\(>'&MK2W.B
M6!ALV+VR>0N(6)!)7T)P.GI0!YUI#6>LZ,FHWVLQ6NMVU^8YVB4FZ!6;_58W
M\J<]-N,'-5-'6QUNPN+Z\UTV/B#3]4D>?!+7!(<[8DW,,HR[1@*,D5ZJOAK0
MUU?^UETBR&HC_EZ\A?,Z8^]C/2IFT/2FU1=4;3;0WZC:+DPKY@'^]C- 'CEE
MI>FW=E\2KJ_GEA>TOI)(;A78M XCR&4;AELX &?;O7LFD23/H5A+=$B9K:-I
M2W'S;1G/XUQ_A?P/]CU[Q'=:UI]I<)=Z@+JSD;#\8'8]""*[J6&*>!X)8U>)
MU*LC#@@]J /+]6T;7?&%KXDNM-BTV>VU(I!97$UZZ/"L#$ JHB8$,X9L[AG(
MIE[XSB\3?"O2]=F3[/*NHVHN!"V1$Z3#+!BRA1@9!8X&<?[0])L='TW3;!K&
MQLH+>T?.Z&) JG(P>!5$>#?#2V?V-="T\6V=WDBW7;G&,XQCH: .1\5Z;;>!
M;O3/%6GI<-;6]VZ7ML7=U99R<R <X96/IT8CVJAXAL;NQ^'=C/J4*6^J7NMV
MUS<K&W5WG'!Z9(7 Z=J]2FLK6XLC9S6\<EL5"&)U!4KZ8J._TNPU5(4O[.&Y
M6&431B5 P1QT89Z$>M 'DGB*"%[KXJ%AE[=;*>'+',;B '<OI@DGVS5#5RVK
M^&[F64I>7*^$X)G:ZF#&)_*+;HHP,EV(R7R,;<8->TMI.G//<3/8V[2W&/.<
MQ@F3& -WK]U>OH*@C\.Z-#)#)'I=HKP0_9XF$0RD?]P>W/2@#RGQ#+%?6LE^
M@M-:2WT2W6^TZ]D9#M92PDMWP5+G'/'&WKSBO6-#DAN?#UA)"KK"]LFU7/S
M;1UI4T+28[.*T33;06T*A8XO)7:@!R !CIGFKZJJ*%4!5 P !@"@#PJS\B7X
M5^$6FD1W/BB/?(&P7S=/EB<Y)QCDX.,5JPK;Q>(OB3IK!?[/CM(YQ;DY17(<
MLP!!P<@'..M>K1:7I\%M';16-LD$1!2,1+M4CN!CK4OV.U+RO]FAW2C$AV#+
MCT/K0!Y+IUMIMO%X(MY[2VCT&]MV>Z<*OE2W*Q@1B4]/[V.>6'M2*D27_C'2
MTE$7A^&^L!:LLQ58F9HVD$9SP 6<G'0BO69-/LY;3[(]I UMC'E&,;/RZ4&P
MLS!Y!M8##U\LQC;^5 ' MH&EZ?\ $_3[:WB"V=YI][/+$924>1VCW'!]1GO7
M)".S'PLU.^*PM+IFKRKI\OF'?&HG& !_#P,8!.0,^P]N-M 95E,,9D4;5?8,
M@>@/I4?]GV7E&+[';^63N*>4N"?7&* /)M;DT[4/%_B>TUW5Q8L]O;O9BYMP
MZB$0 L;=B<[_ #"Q..?E7KT%EVTB[UO58/$*QS7"Z%&=-%SP\D&PEVPV0LF_
MKC)  KU&:QL[ED:>U@E9!A2\88K],]*)["SNI$DN+6"5T^ZSQAB/IF@#C_A&
MQ/PFT+R\,P@? SWWMQ7)6<4%W\/_ !%-JRA?$T5[<?/*V+A)"_[H(3\P&"H&
M.#S7K]K:6]C;1VUI!'!!&-J1QJ%51Z "D>SM993+);0O(<9=HP3QTY]J /+Y
M[6PD^+VA1:G:6#W$VD.;@20K\TO')!W<_4_B:]7J!K.U><3O;0M,.DA0%A^-
M3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 52U;5+71-)NM2O9!';6T;2.Q] ,\>]7:X;XP01S?"_
M63)$CF.(.FY0=K9QD>AP3S[T 7SXHG?Q5I%I']E73;[3Y+QV=SYJ%<'GL!AA
MS[-Z5TSSQ10M-)*BQ*NXNS *!ZYKSB&STIM?\#V0@MQ!/I5WNBCVJCDI#G<!
MUS@URMS?6=K:Z99MJPL=$AU>^M4$L$<D$&'8QJX8G@ _Q@'GT ) /=$=70.C
M!E(R"#D&FRRQP1M)+(L:+U9C@#\:Y+X?P6MK9ZC!8:E/?V:71*2&%4@4D998
MMO!7).>P-9OQJV#X<3LYPJW=L2<XP/-6@#OH[B&;?Y4T;[#M?:P.T^A]*2.Y
M@E7='-&Z[0^58$;3R#]#ZUY-XCL;"VUKSM#\N.6?0KR75!""P=#%^[9\' );
M=@GKS5>XM+&U\&_#W4"'C@N5T^UU*6+YO,B$>X1R G[FXG/L3UZ4 >PP7$%S
M")H)HY8FY#HP8'\12QW$$Q81S1N5.T[6!P?2O+=8M+;3]=\66NCRQV6E3: T
MU\UN!M@N<E8R .%)3=D#K@&F>$WTCQ3X@T2]C%A;'3-*$$T$5W$[R2DJ%7"$
M_*FPD$D'+#C@T >J+<P,^Q9XRVW?@,,[?7Z4D5W;W$)EAGBDC'5T<$#C/7Z5
MX9%IMI_PIC3]:2W"W,5W+!<7$8)>.U:]?S% Z$8QP>HK5CM= N[?6!8^)A)I
M>H621W=S!!$EM;OYB+&"B ?,VX@YQQU]@#UP7UH;3[6+J'[,!N\[S!LQZYZ5
M)#/%<Q++!*DL;#*NC @_B*\D6.'4K?5=#N;;3=(U*RU.UE#Q1A[*]D9#Y8*]
M@0GS#MP>376?#MQ]DUN)]*M-.NH=39+E+)RT$D@BC^>/(& 1MX]03WH [,D
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M[:W]NMQ9W,-Q"W22)PRG\17ESQZ;=-JD%MK!L)1XI5H)8HE=(I]F?F!ZAFW
M^YKI_A]-+-;ZS]HTV"VNDU!XY[FWR([UU509@.V>A ) (- '67%Q!:PM-<31
MPQ+U>1@H'XFJL>MZ5+8RWT>IV;VD61).LZE$YQRV<#FN?^),]I!X7B-[##)
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M""0.O3-=57 >#M"N=#\3_9IK:X:*TT6UTZ.\:';',T98L5.XD#YAU'8_CW]
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MM!42I*'C)P,%3C.>,=:EA\6E-6@TO4M,GL+R[21[)'D5Q.$ +#(/RMR.#ZT
M="1&9@2$\T+QTW8_PI51%9BJJ"QRQ Z_6O,O!-B/%5S+K6J6-U!J%KJL\L=V
MLZYPK;1"<$Y0#C'3C(ZY/<>(=<_L*R@F2SFO)KBYCM888N,NYZDGA0 "230!
MKTW8FXMM7+8R<=<=*Y.X\>06OAYM5FT^4-'?)8RP)*C%'9PF=P.".14H\=6%
MN^M1ZI!)82:2@FF1V5BT3?==<'N>,=N/6@#IFFB21(WD17DSL4L 6QUP.]/K
MS:2_O]1^)GAB6_TJ736^S3LL<DZR9RH_N\ BNYUS6+?0-#O-6NP[06L32N(U
MR2 .U %YW6-&=V"HH)9F. !ZFE!#*&4@@C(([UYSXHUV?7?AMK\MQIDUC$MC
M'/$ZW"N)5?/0KZ8Y!]:VK/Q:MGJ#:9J-C):1I9&YM)-V]KE(U_>$*HXQE< \
MG- '6X&<XYJLU[910>>]U;I"K[/,,BA0V<8STSGC%8&C>+AK&L+I-SI<UG+<
M6(OH?,<-NB)"_,!RC<C@_P!*\FU.(0_!G3HE#*J>)64+D]!<2  ^M 'T#@#.
M!UZT  # &!17!R?$:8PZI<6WAV\EM])O)8+YS*BE(X\YD /7@9QZ4 =Y17$:
MK\2+.T2XFT^U%_;6T4<TL@G6-MK@, B-\S':0>!WQ5J3QG/+KMUI>G:/->/#
M;V]PK+(J;EE)R>>@ P?4\T =;2$A5))  Y)/:N.N/',L*V%RNCS-I]QJ3Z?)
M<"13L82-&C #.06'7C%36/BF?45U^SO=$EM[K3H@YMO.#><C(6 ##@$X(H Z
MB&>*YA2:"5)8G&5=&#*P]01UJ2O*M+\3W\%SX#T_1-%2VT:_MY9(X1=98JD;
M?(2PZ+N5LYR2*]5H 1F"C+$ 9 Y/K2UYM\2K^[O&>QTEW6\T.)=<?Y-R2-&2
M4B/(/."<#TK8U7QY'IWPYM_%L=D;E9HX6\E),!6D(7&3V#''2@#L:CGN(;6!
MY[B:.&%!EI)&"JOU)KEX_%]Y'>Z;;7^C/;+J-X]M#,9U*E0@=6QU^8;ACL5/
MJ*R?%FN0:EX5\2'4- 34M*L[M;6.,7&PSNI 8GH5"R''!Y&: .A7PI$WB>76
MKC4K^Y#.LD5E+(#!"ZKM#*H&<X)ZD]:Z&N'UCQMJMG>Z[::=H*WDNE0QS[?M
M !EC()8@ $Y&,!>IJ?7/&D]C%8OI]C%(EQ827[RW<IAC1%52J!L$%V+?=] 3
M0!V-%<'=_$.5[;1CIEA!+<:E8?;ECN;CR@5P/D0X.YN>GM[UV.EWK:CI-G?/
M;RVS7,"2F"48>,LH.UAZC.#0!;HKS0^+=;T_XB:\-1MHTT:QLXW9!=9*1_O"
ML@7&"SL%7':MX^+-1L-8TRUUK1?L=OJD@AMYHYQ)Y<I#$1R#'4A>HR.M '5R
M2)%&TDCJB("S,QP !U)-,M[F"\@6>VFCFA?[LD;!E;MP16=XI5'\(ZTLDGEQ
MFPG#/C.T>6V3CO7 >#_%5[H/A#P>ESI 71+F*&U>^\X;HY7R%)3'W2<?-GO0
M!ZK17 'XCR/="Y@T^&;1EOFLY)5N,W"X(7S!$!RNX]CT&:[^@ HKS5OB9JL%
MG>ZK=>'432-.U*6QOIENPTD>V0(&5<?-R>>?IFM7_A,=2FUN^AM-,CFTZQGA
M\^X,H7$#Q;S( >XZX]![T =K17 Z7\0[B^O]'$FF+]CU7S3$T#/)+$BJ&1I%
MVX&X'UXIFG_$2Y?28]<U"SM%T86\L]Q-;7!DEMBK;51D(!R>GU% 'H-%<!9_
M$*\;49;*\TI58Z;]MBD@\UDW>7O,;DH-IQC_ /7Q5G2O%NL:C+X=F:PM8['6
M8)"K><=\4H1G (QRN%(R/;I0!VU-DDCAB>65UCC12S.QP% ZDGL*X_X=:QK6
MN:)->:J;9@;NX16C9MP*RLH&",!0!QSFH/BK<ZI!X0DCLDMVMKF6.WN3)*4;
M8[@$#'4$<$>A/% '6Z?JVG:JC/I][!<JN-WE2!MN>F<=*QV\&68N=0EMKV_M
M$U&3S+F*"<JKMP"1W7(&#C%9<4D\'B*^L=!TS2X-9\B.;4IB7$63Q&  /F)4
M-SQC ZUG2_$^YN8-#_LS21+<:A=36,\4DN/(N$& ,XY7.26]![T =[I6EVFB
MZ9!I]C&8[:%=J*6+'ZDGDGW-7*S]$FU*XT>VEU>VCMK\K^^BC?<JM[&N?;Q9
M?S>)[C2[&"PE^RWD5O/!)<%)Q&P5FF4$88 ,>!_=- '845YY?_$'4+7POJVJ
MI80-+8:HMD(]Y(=#(JYZ=?FJ]J?BK6WN-5DT#38;VWT>80W,3.?-G;:KL(\<
M @,.O4T =9'J-E-J$UA'=1/=P*&EA5P70'H2.V:S_$WAJT\4Z;'8WLUS%%',
M)@UO*8V) (P2.V&-><3ZI?V'Q&\8ZOIUM%]IAT.VN3#<DK@ ;F!QWP,5Z7X:
MUC_A(/#6FZOY/DF\MUE,>[.TD<C/>@">.;3M+>QTE)(8'D1EM;?."ZH!NVCO
M@$9J]7'Z_J8M?B-X4L#IUG/)=QWGDW4HS) 4C!8+QP&^4$CL#6%#\1]6&BZ!
MK4^GVAL]0U%M/GCCD;>C><\:LN1@CY1^= 'II ((/0URR> ].C$D"7NI+ITA
M<O8"Z;R3NR2,=<9/3-4K#QC>:AXJNM,4648MKUK9[21RMPT84D3+G *D@<#.
M!S[5DMX^\1MX<N=?BTJQ:QTZ]E@OE\\[_+C8AG3C'&/QH ])BBC@A2&) D:*
M%51T '04^O.-1^)DCMJKZ)9378TYUC$'V29S=-M#,%9%(3 *XSUYZ<5K?\)-
MK&IG6SHMA$[:45B$$S8:YFV*[(.?D #  G.3]* .Q)P"3T%16US#>6Z7%O(L
MD3YVLO0\XKA;"^U>3XE>(X;B>*2WMM-@DAMRA PV\X)SP<CD\YI-&\7,=+\(
MZ=965K:W>LK(XA4'R[>) S,0.">@ '&<GTH ] HKSR\\=ZIIEIK-G>6MD-9T
MRX@ 7S=D4]O*RA7!/1N6&WU%6Y_%&OZ;J7B&TN[*VN6M--;4;(6N[+CD"-@>
MIR.H]>!0!W%5K_4+/2[4W5]<1V\ 95+N<#). /Q) K#\(^()?$,4MTEU97=D
M8XVAGMLJ2Q!WJR$Y7!'&>M'C_49=(\%ZCJ,5K:7/V9!(8[L$H<,.<8Z@\T ;
M%]J]AIIC%Y=1Q-*"8T/+,!UP!R<9%36=Y;:A9Q7=G/'/;RKNCEC;*L/8UYQJ
M4EY/\:O#Z_:5!;2YWA^0E8\XW<9YS@<\5Z/96-KIMG':6-M#;6T8PD,*!$7G
M/ ' Y)H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N6^(Z12_#[6(I;=K@/ 56)9 A9B<+@GOG''>
MNIJAK6CVFO:7)I]Z',+E6S&Y1E92&4@CD$$ T >666G1ZC/#'X@L=7L=5N]*
M31K:XN+55@& Q_A=CN))Y.!@5K6NC7^J^!_"_AB\T^ZM;NQEM_M3E2%A2 XW
M)*.-S!1C:21N]JZ_3_"UM9S0S7-Y>ZA- 286O)B_E\ <#IGCKUYK=H X"7PQ
MJ<?Q/EN;=Y8]%U!(KRZ9.GGP, J=>-V02<<A,5SMYX4ETCQ9K\U[X+A\20ZK
M.UW9W*(A,#,"ICDW<@<YR,^O7I[#10!YWX*T#4-)\?:_<7%@+>SEL[.*!XTV
MQ$QQ*K*@[ $8KE;?PUXAA^'[6"Z=?)<2>)_M;Q)P6M]V[<P[KP#CKD#TKV>Z
MO+:QB66ZG2%&=8PSG +,< ?4FIZ /*VT/5%C^)).FW)_M*139[5.9QY>WY?Q
M[\=:VKVPO)_&O@^]2UNA:VMA<QSR>6<PM(D84'WRI^F.:[JLU/$.CR1)(FI6
MS(\QMU(D'S2 X*CWS0!YIX<T;4K=[?2+OP'I\&H6UQA==>TA=&C5MRR<?,9"
MH SGJ<GD8J;5-'UB^^&_B:R&GWCWMYK1FMXG0EGB^T1L&YZ#8A//3&/:O4KB
MXAM+>2XN)4BAC&YW<X"CW-%M<0WEK#<V\BRP3()(Y%.0RD9!'L10!P>JKKRW
MWC.RM='EECOK>.:QN2BM'(XA5'1@3U^48!'KFLO1;35X/&JZDFBZU$LFA-;"
M:\,;-YRON^;#E57D!5&#D'Y>]>I2RQP1/+*ZI&@+,S'  '<U%8W]IJ=E'>6-
MQ'<6THRDL9RK<XX- '+_  NL+[2OA[IUAJ5I+:W<#3"2.48/,K,"/;#"J7C.
M/7;CQ390P:5>7FC-92*S6<BQN9RPPCON#+&0JDXQD@=<8KO:* /(/#^FZ]I&
MA^#YI/#NHK)I<\\-Q:Q&,OM<'##Y\;.WS$?3'-3'0-;_ +)U21]%F$D7BL:N
ML096:XA#K_J\'EAC^+:/>O47O[2._BL7N(Q=2H72'/S,HZG'I5B@#BK:&];Q
M9XDNI-/NXH+O38!$73.7"MN3Y<C<-PZ$@]LUB>$M$U7P\WA?4Y=,N&SI/]F:
MA$J@M:;6WHP7[Q!)(;&>QQ7J!.!FLE_%&A1F4/JMJIA.),R ;#Z'TH \NU#P
MMJRQ#47T.YN9-0\1_P!I2V,8 :")25!9MV"3@-@'OC YKNM9L+RX^(/A^\CL
MI7M8(9A+.,;8V8# /.<\'M6U<>(='M3 )]2M8_/4/#ND \P'H1ZU9LM1LM1B
M\RRNX;A/6)PW\J /*+;1_$$'PUFT1O#]R+F'5T=3&Z#S$%R)#(.0=NU>O7)Z
M8YI]SX9U'2_%^LX\%6/B&TUB8W=O>SI%NM78897\P9P, X'7MSD#UBYN[>S1
M7N9HXE9PBEVQECT ]ZFH \O\1Z'K*ZDT^EZ7J*ZXL,,%MJ]G-''#-C[WVA-W
MW1S_  GMCD"O4*** /)M0\,>(+S3?%2II$RR7NO6U[;HTL69(D:/<>'P/N$X
M)':NF@L=6'Q=N-5;2I5TN328[1;HRQXWAVD/R[MW\6WIU'I79T4 <K\1]+O=
M;\!:GING6CW5W.J".)'5"2'5NK$#'%9WBVTUG4=/T;7;7P_#=W=H)%N=&O#&
MY>.5=KJK<KN&!WY7([X/=TA( )/04 ><:AH=Y?>';:._\'1-#->^<=/TZ6.*
M:PPF%D5]RJS@CL?XO:LA!KFDZEX"75K.\OM2B^V*T7GQM,4YV;F9@K,$VY^;
MKGDUZ2OB;1FTTZ@+^,6@G^S>:<@&3=LVCU^;BEN_#UC>Z[9:Q/YS7=D&$&)6
M"+N&#\O0Y!_E0!PMQX4UIK6?Q);Z:G]M-JO]H#3)Y$8.FP1;"V=H;;\V<XS5
MW4+3QE?>'['4+?2[&PU'2[J.YL]+CF!#H(VC:-F^ZI*NP !QP.:]"JG!JUC=
M:G=:=!<H]Y:JK3Q#K&&SMS]<&@#AO$>G^+/$/AA;J;3(X[J.[M;F'2DE0NOE
M2%F#2$[26&WIP,=Z[^TDFELX)+F$03O&K21!MVQB.5SWP>,U7O-8L;"_LK&Y
MG"7-ZQ6"/:27(&3TZ?C5Z@#R>Y\.>(K/5_'Z)H;WMIKMN3:S0W$8RQ38$*NP
M(^\23TP#C)P*LS:;KM^W@U)?#-Y$+&UFMKUS<6Y\D20^5E?G);INX[8[]/3Z
M* //_"UOXXL!#H6JVL L-- \O4K>12UXBCY8PI.5;G!) '''K65H'@G6Y/@M
M<>&;VU2RU/SC)$DTBNC%95E3<4)P"5P>XKU6B@#S^33?%7C3PW?6'B'3[;27
M"*;<1SB3?.C!E=L9 3<J\=2">E316WB;6]6T;4-5TP62:/'+++ )D9KNX*E5
M,>"0$QG[Q!^;&.,UUNJZK8Z'ID^HZC.(+2!=TDA!.!]!S5FWGCNK:*XA;=%*
M@=#C&01D4 <C\.=,U/1=%N+'4]-^R,US)<Q[7C*!9#NV?(>&7D$ ;>.":M^-
M]/U'4M-T^"PM3=QC4(FO;;SQ$)K?#!U8GJO()7N!CFNFWKOV;AOQG;GG'K2T
M >7ZAX.UF;3-?LK;3K:)9M8M[V!DD"^<B-&2 O1<!-HZ9]NIF\0^"-6\0ZMX
MI?;;P6FKZ;#;0.Q!D21,/\V!PI.5X)Y&<=*]*HH X6VT[Q)J/C#0]4U;2[6V
M2RMYXYFAN=Z[R0 0" <'!('/!YP>*ZG78M1GT>>/2OLQO& "+=9\MAGD-@'@
MC(Z5HT4 >2Q^ =7_ ++\4:?INEVVD6FHP+ EDUX7ADEW9:=2%)5=N%"X!..<
M8%=!JWAOQ!=ZWIFHV1L[=[/1[BU#^>Q99Y$ 4CY.55E'/Z5W5% 'G7ACPOJN
MEZ]I&I_V1;67^@36U^OVG>[ON5A(S8^=F8$Y.< G)S@5FWGP]\0W?@&WT/&G
M1W<6LF^)%PY0QF1GQG9G=\V,8]\]J]7HH 09P,C![UY'H4>IZP_CS2K#3[86
MM_JEQ9RSFX , 92COM"X;N<9SDC/<UZ[6?INAZ9I$UU+I]G';O=2&6<IG]XY
M.2Q]\F@#DK/POXE\-ZDT7A^YTZ72[B&&.7[:7$D31H$WJ%&&R ."1TK3M-'U
MBV\<WFKN+>:TET^*V1C.P?>F6)V[< $D]#[]ZZJB@#@[C0O%%SX<CLVM=+%V
MFK_;L"[?9Y?GF;&?+SG)QT]ZO?V/K<7B;Q#?I!9R6U_:QQ6^;EE8,JD?,-A
M'S'H3T]^.NHH \YL/!NOV-OX)E3^SA=: DT$\9E8HZ2(%W*0HY&.A Z]:]$D
M+B-C&H9P#M4G )],]J=10!QVC^$([J74;OQ5HNCWE]<W;2QR,BW&V,@!4!=
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MWJ-WH>O16%KJCK+=QM;;V20+M+1G. 2 .H/2NVILDB0Q/)(P5$!9F)X '4T
M<,_@"Z_M?7[Q-25TU/2%TU/.4LZD)MWLV?F)ZUT?A71Y?#_A;3=(FF2:2SA$
M1D12H;'?!K5AFCN(4FA</'(H9&4Y# ]"*J:SJL&AZ->:I<K(UO:1--((P"VT
M<D@$CM0!E:OX;GU+QKX=UU+F..+2%N0T)0EI/-0+P<\8Q7/?\*WNO^$3TC1?
M[2AW:?JIU#S?*.''FM(%QGU;&?:N]L[I+VQM[N,,$GC610W4!AD9_.IZ ./O
M?"FIZEJ-E-?:G T=EJ!O8+B.$K<(FXGR=^<;"#M/J.M<WX3TFZ\1^%]:TU;B
MVCTNZU>\6XPI,S*9B6 .<#(P.1G!-=%/\2-)@\+WVO26=_\ 9K.^-A+$8U$G
MF!@IX+=,GN<\=*ZNULK2Q1DM+6&W1CDK%&$!/KQ0!Q(\ ZAI>MWUQX9UB/2]
M.U$*;FU%ON*,%"[HVS\I('?/6I)?!FNVFNZC=Z'XE:SM-397NH98?,9'"!2\
M9S@,0 <D']!7<T4 <M#X2EM?%=UJMO>JMK=6$=G+;M'D_NPP4AL\?>Y^E9]M
MX DL;#PZ]K>1)J>@JZ6\IB_=RQN,,KC.<8]#Q^-=5<ZO;06>HSP[[M[!&::"
MW :3<%W; ./F(Q@>XJC?^*K73YM*M9+2[>_U-6:WLT0>9A5W-NR0HP#Z_3-
M&5=>"[J[_M*Y>_B&H:C/ TTHB^588B"L2C.<9!)/4Y^E6=4\-:G=Z[/JMCJX
MLII;%+4;80VTB3?N&>QY&/>MS2-336-,BOHX+B!9"P\NX38ZD,5.1^%7: ,#
M1O#K:=XAU?69I8C/J0B#1PJ50; 0&YZL<\GV%3>*=%D\0^'[C2DG2!;C:LC,
MF_Y002,>^*V:* .7;PK/+XUT_P 127$.ZTM&M1$L9Y##D@YXY_2NHK%U3Q);
M:7K^D:/)#*]QJ;2")EQM0(,DL<^XP!6U0 4444 %%%% !1110 4444 %%%%
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M_$ : +_8K6#QACD2&0/D'TR,4 8^K>)_[2\$Z!J]QI5I*EW?VT<T-PS$0N9
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M<B!))$B\O=N=5 W,"%&!QRV,UJ)X:U6;Q+X?UB[NK/.F6LT$D<2$;S)@9'8
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M9P?4UJW'A/5XM<.KZ9KD4-U=016VH-+:[A*J;L.@##:WS=.E '-QZ^_B;5?
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MQ<FYO LN"[$@L << XY H YWQMJVM:1J6I-/=7UEI<MO$-/O[=0T5M,"2PE
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M <!HOB+QAKWA0ZU;?V,KB65%MC!(&?RY"A 8OC+;3CCJ1]:[Q[F&,@2RQHQ
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MUUD2WTM];026Z237<C[HV;=M8$_-CMGV)R0"-'5+X6&FW<ZO$)8H'D17; )
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M@G.UF<-\G48'0'C%:^EZ'I]G$DZZ7;6UT\(CD$8#;1U*!O[H).!TK6) !).
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#S[POX:U+P]XNM UC+-96VB0:9]O$D861HSNW>7NW <D=^?;D^@T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5D>*-<'AOPU?ZP;66Y%I"9/*CQDX^O8=3[5KUB^+],N-:\':QI
MEIL^TW=G)#%O.!N92!D]J ..7Q'<:AKW@G5'>]C6ZL[J26P1&_>L(E;<%Q\V
M"V,D]^.YKJ(O&NDS:9'=Q><T\EPUHMCM N#.OWH]I/W@.3S@#G-8FCPZQ%:^
M"%GT2YBCM%>.Z)="T#>5Y:DJ#G:22<CH!R.:RI_#'B2&XN]1M=(AN);?Q!/?
M1V=Q,FV[MY$5/E;)V-\N<,!B@#O]%UZTUV.X^SK+%/:R^5<6\ZA9(FQG# $C
MD$$<]#6=J?C;3M/FO(H+>\U(V*%KPZ?&LHM\?PO\P^;'.T9/%.\+07C-=ZC<
M:5#I4=V$,5FL:"50!RTC*.2<]#TQ7(P:3KGA:7QC:-8_;;+5EN=0AO1+M6([
M,%),C(;[N,9SSZ' !UNE>-=.UF\-I:6]V9O[/CU% 47$D3_=VD-C.<C!QR*C
M_P"$ZTUM-TJ\AM+^5]4DDBMK9(U\TLF[<""P QM/>N0\(VMYIEWX2UJRTZXO
M++4=!M]/DV$9M=G[P.YQ@@[B.W([YI-,T;Q(FF>&++4M)N4LH;B9KB"RF56W
MEVD1F.X8B()!4X.0,CH* -GQ1XBL=7\.:'?V=_):PS:U;PL[2F$HP<AT<!@3
MC!RN>HSVS1J^MQ:!J/C/5-/M[VZOX+*V>2)Q^[5@)0I7)'RXY..O;-8%GX>\
M2Q^"(=+/AZ=+M-=-ZIBNX0J1B;?GYB,\$@ KVS@<5NZGHNM:GJ/C()I;0PZC
MIL=O:RRRQ_O'0.,<,2H._N.W.* -32O&GG3Z-I^H:3JEO>:A%E)I8%6)F";F
MY#G'T/-;MAJ\.HWM_;103K]BE$3R.H".V <*<\XR,UQ&N0S7/PUMA>QQ:/JV
MFK%<64,DRR.9(MNU2!C[Y^7:"?O#OQ79>'=)?1M(2WFE\ZZD9IKF4='F<Y<@
M=AG.!V&* *%]XUL+">\!L]0GMK)@EU=P0;HH3U.3G)QWP#BH;KQ[I<5Z]K:0
MW-^RV,=^KVJ;T>%WV;@>^.IQQC/H:QK+P]K&AZ1KWAZUTW[3:7\DKV=VDR83
MS<[A*K,"-I.?E#9!]13?"GA75/#?BVP1K62?3K308].^V!HP'E$A=FVE]X7!
M Z=0>,<T =;XB\26GAG1SJM[!<R6BLH=H%#%-Q"@D$CC) XJA=^.M*L-:U'2
M[N*Z@FL+)KZ1W1=C0@A<J=WJPZXIWC_1+OQ%X'U/2[ *UU*J/$K' =D=7VY/
M SMQD^M<U)I'B:]\:W?B"30(8TFT!K06TUVC@RF16V$CU //3WH WH/'MFMJ
M\VIZ;J&F,J*\:W$8(GW'"K&RDAV)(X[9&:S=2^(R+I?B"WATZ]M=:T^TDG2V
MF5"VS:2LO#8VC )&<CT-8@\$:ZS:G%I%F=/L,VUQ9V>K7"W"">-F) "L^V/!
MZ=<X-:TVG^)]3\/:N)_#>FZ?-/IDUI';6\J/-+*X*[M_"JG(.,DT 9/@/4K+
M[=X<O;NUU>'6M;AE$ER[+Y-ZRH79F^8GY0N%X&,X'%7O'OB&VU[X9>+U@%S:
MR:=(UI*)&V$NI4\%2<@AA]<U#I_A[Q#9:5X+NET:5KWP\9(YK-[B%?.66,H6
M1PY'RYS@X)I^K^&_$>J^$_&=DVF1I<ZK>![5!<H<J5C7<3T &T^YYXZ9 -VY
M\9#2[J'1K;2KO4;]=+CO5B@9 74MLP-Q'H35Z'QC87MCIDNG(]Q=:G#Y]M:D
M['V#[S-UV@'@GGD@5D6NEZPOCJ'4I=)E%I%H8LW=;B,AY0V[:OS@]\9('/M@
MU@6'A7Q#IVD^&=1308KK4-*MY+*XTZXGB'FQL=VY'RRCD#KSUH ZF/Q]%>:;
M87&F:3>7MU=/(CV:E4>#RB%EW$G!VLRCCKGBEN?'T2O;+8Z1>WK267VZ:)"B
M2PQ%BH)1FRQRK @=,>XSFZKX:U#5]'BBU?P_9W+-(\JP6-R(6LV^54*.0,G!
M8D^HX!X%0:YX2U>_T.RMKFT:ZU&VM8TM]0M+L1SQ3C?N+NVW='@ITR2=WRT
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MD!5Y" 2@'JN>?R]<<WXR\0"\T/Q+IME87ES':6,JW5U$YC6.382$4Y&XC@L
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M">(Q6)O)+23Y9$ 3>4.>C#!'UKFM,^(EW=C0KF]T)[/3]88PV]PTH;$Q&4!
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MO]2\"Z3>W[QN\]NLFY2<DDDG.:ZJN2T'PWK7A_0M'TJWU:!X;&X D)@P9+8
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M* "BBB@ HHHH **** *\&GV5M/)/!:6\4TF=\D<85FR<\D#GFK%%% !1110
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MOHIEE4K+&,C&.H.5(YH ZJBN?\&>*X/&?AU-8M[62VC>1X_+D8$@J<=1704
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKU8SN03Z6[[3[9?C^M63H/C\Z:=._M+PN+'R?(^SC39!'Y>-NS;OQMQQCTH
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MN2K7$J( TK!0H+'O@# JS0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8ZC<BVA:WN5EE4LVU'=1]U3Z$Y7OR"* .ZHKSR?XF2V^DWNJ'1F:VL=6.GW
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M+3QUJ]WHWA"Y6TBCN-7U*2SN8YE9=JHT@) Z@_N\X- 'HU4I=6L8=7M]*DN
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M<<5Z10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,_P/DC)YR% JAI7@F]TO3/#-JNIP,^BRR,SBV*B=&##& W#?-DGG)YQ7:44
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M720 ,"#T/'!'K62O@&YCM-*B77)99=,U.6_@EGB#,V_<2CXQGEVY]_:NWHH
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M[F[M&LGN;MP66 G)1<#CG!/J146F?#.PMK:6#5=2O]95K:2TB%ZX/DPOC(7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 (      .@%+110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit101-iansconsultin007.jpg
<TEXT>
begin 644 exhibit101-iansconsultin007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHOM,'
MVO[+YT?VC9YGE;ANVYQNQZ9XS0!+12(V]%8 C(S@C!'X4M !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4<T$5S$T4\22QMU1U# ]^AJ2B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JN+"T&HG4
M!;1?;&B$)GVC>8P<A<]<9).*L44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !14:3Q22R1)*C21$"10P)7(R,CM
MQ2/<P1SQP/-&LTF=D98!FQUP.] $M%%!( R3@"@ HJ*WN(+N$36\T<T39P\;
M!@<<'D5+0 44$@#)X%16UU;WD(FMIXYHB2 \;!AD'!Y'O0!+1110 4444 %%
M%5[J^M+%5:[N88%;H97"Y_.@"Q12 @@$$$'H14(O;4WALQ<1?:@F\P[QO"^N
M.N* )Z*** "BH9[NVMBHGN(HBW3S'"Y_.I597&58,,D9!STH 6BBB@ HHHH
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MX_M!7>(MPW%?7'7% $M%%% !1110 44A( ))P!U)JK_:NG?\_P#:_P#?Y?\
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M!=P74:RL55C&X;!(Z=*I6.B:XGCQ_$5XEH4DTB.S>."0_P"L5RYQD=,L1^%
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MINHI>*D[%4<!64@D D?>_2J\&B:UHNM:]>Z4MI,NJ^7.HG<J(;@*$;.!ED(
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M#'W@, <]\^U.UC7-2T+7]3T$W=Q+'>:9+?6%R%#/:M&IWJY/!4X!!Z@DCWH
M]"HKA=)O=:_X2S16N]2$UOJ>E&:>V0?NHY5"<QD@-@[CUYZ5A0>*]4ANY?M5
M_/;ZK:V%U<7%C.A,-S@$QR6YQ\R#ZYQCOU /5Z*\VT34?%L]OX>U&ZE5;>[^
M2]FDGBVOYBC8T:#(!#8 &23SD50TS4/$+Z1I6MRZY=L3K$EE-;2*NUT\^11G
M Z@8'&!@#CB@#U42QF8PB1?-"[BF>0/7%$LL<$+S32+'$BEG=S@*!U)/85YQ
MX.C=_BQXV9[FX<130A%:0D &,'&/0$G [5M_$ZU-YX!U"'S)$4[-Y1]N5W $
M$^F"<T =;'(DL:R1LKHX#*RG((/0BG5QL<\L?BFQ\*6]S<1VR:6;YYQ)N9L,
ML2(K= !RQX]/>I/ ^NWFH/J^C:C*+B]T:Y^SR78P//4Y9&VC[I"X!ZY(SF@#
MJ9;B"&2&.6:-'F8I$K, 7;!; ]3A2?H#69H7B2P\1/J*V(E_T"Z-K*9%VY<
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MFXAO-ZR2M*006?>I#9SSQV&,55G@M/ -E<7\=KJFLW6IWB+<RG;),Q((7.
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M&.U=9?ZA;:9I]Q?7<JQV]O&9)&)Z #-+8WBWVGVUV%,:SQ+(%8C*[@#@^_-
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MLUN) S?*6978+QR.$!_X$* &6G@VSL?&=YXEM[N]2:\C"SVPE_<R.  '(]<
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M2?8KBRFN#)L.=Z,@ W=/XCQ]* *MGX&L+6:S#WU_<V=E(\EM8W#HT$1/3 "
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M*QX_AOIEK::3!9W^HVSZ;=27*3I*!)*9#F0.0.C=,#%=D#D9%<EK7B+6=/\
M&.E:';6MB\>IQ3O#/*[Y4Q+N(8 >Z]/>@"'4/AMI=_'JT?V_4HDU.Z2[EC2<
M!(Y P)9% &"V!DG)XK2;P;IDFNZCJDQFF&HVHMKFUD?,+J.Y7N<<<U7;Q;)I
MWBVR\/:Q:+%+J$;-9W,+YCE90"RD'D$9_&MC29M0E^W?VC]E&R[=(!;N6Q#Q
MLWYZ.>I'N* ,3PW\/]-\,W_VN"_U2\*(8[>*]N?,2V4]1&,#''&3DXXSR<]#
MJ>F6>LZ;/I^H6Z3VLZE)(VZ$&JVNZ_9^'[!+N[W,LDZ0(J#)9W. *T&N(4?8
MTL:MQP6 /.0/SP<?2@#F=%^'^CZ/;S0R2WVIK+&8?^)E/YP6,_P*,  ?AGWJ
M?2?!EGI-Q9.M_J-S%8(4LK>XF#1VX((^4!020K%06+$#C-:=E-J#ZIJ:70M?
ML4<D8M&B<E\% 7$@['=T]B*GO]0MM,TZYO[J0);V\;22-UPH&30!REU\-M-N
MK;5+(ZCJ,5A?S)-]DBE"QP,L@D)C&/E+,,D^_P"-;%CX9CL/$EYK:ZEJ$LMU
M$L,D$CH8MJ_=X"@Y&3R23R:U[:<7-K#.%*B1 ^T]1D9P:YV_\4S'Q:/#&D6B
M3WR6PNKB6=RL<,9; Z<L3Z"@"&'P'#;BX6#7=9B634#?PB.=<6[%F9D0%2-I
M+MD$'(./KN:1HT&CQW(BDEFEN9C//-*%WR.0!D[0!T Z"JEKJ]]'XA72=3BM
MD,T#36\D#,=^UL,""., J?QK;!!Z$4 8VN^&X->N]+N)KV[MVTVY%U"L'EX:
M0 @%MRMD8)&!CK]*R&^'5B\&OQ-JVJ'^W6#7KYAR< C"_N\#@^E=AN7&<C'U
MHW#.,C\Z (K2V%G906JN\BPQK&'?&Y@!C)P ,\=A65:>'!:>)+O6AJM_)+=(
MJ202>5Y6U=VT#"!AC<>_/?-/\.^([/Q-9W-W8AQ#!=26VYQ@L4."0/3/2M?(
M!QD9H RO^$=T\>(+C61%BYNK7[+<K_!,H.5+#N0,C/H<=A6)H_PXTS1M52[A
MU'59K:&0R6^GSW :V@8]"B;>-O0<\5V&X<\CCK65)<:I%X@8R?9$T-+0NTC$
MB02AN?;;MH 4>'[$:O?:EY2_:+V!8)6\M0=HSW R>O<GI4FA:)9>'=&M]*T]
M"MM;KM7.,GODX &:Y4?$(WP\(W&G6B"SUZXDC)GD DC5#P0H/.<'/8<9ZUW0
M(/0@T +1110 4444 %%%% !1110 4444 %%%% !1110 5!>6B7UH]N\DT:OC
M+02M&XP<\,I!'2IZANDGDMG2VF6&8XVR-'O YYXR,\>] $U%%% !1110 444
M4 %%%% !1110 4444 %%%% 'G?CU4N?'_@:V&H-92&>\)EB=0Z?N#CKZ]/QJ
MKXBM&T;QAX--QKMS=NU\X*W;IPIC(R!@8[\UZ+/IUC<SK//9V\LJ?=DDB5F7
MZ$BBXTZQNYEFN;*WFE085Y(E9E[\$B@#QV>XMVU5=0M)8(HAXJ99_/4^?O(V
M\L#\J= %QVZ\FMK5;2X\*>-;ZVT.VC,OBF("'?$#%!.N S,,\KL);'J,<YKT
M5M(TUFE9K"V)FD660^4/G=>C'U(]:GDMX998I9(D:2(DQL1DJ3P<>E 'E>J6
M=OI_CQ=*UBZM[#0ET7[-I[SJAC;H)!\WR[N >><#TIFGQ6/_  DOP_L2[SVT
M%KJ-O$]YL#3QA8U1L?Q*PSCU%>IWFGV>H1K'>VD%RBL&59HPP!'?FAM/LGFB
MF>SMVEA $3F,%D Z '''X4 <G\-;BV_LW6M.M/+6WT[6;NWAC3HD>_<HZ]/F
M./ICM47B61M#^(NB^(KI?^)6UG+I\TPR?(9W5E=^.$^7&>V>>*[.VL;2S+FU
MM8(#(<N8HPNX^^.O6I9(TFB:*5%>-P596&0P/4$4 9-SXBTW]S#:W4-W<SLJ
MQ1P.LA^8X#D \*.I/8 UYA:?9KGX9ZLVI[!XJAOKB0$KBY%R)28M@ZG@K@ 8
MQ7KUKI]E8[_L=G;V^_&[R8E3=CIG YZFDDTRPENA=26-L]P"#YK1*7XZ<XS0
M!YB3';>-M=AU#[/%<7?AF)Y4("B:8>87./XB,?7BN6\*PVUQ?_"F&YCADC>S
MO%=)%!# I+P0>HKW:?3+"YNDNI[."6XC4HDKQ@LJGJ ?>E73+!6A9;&V#0C$
M1$2YC'HO''7M0!XA8S6<O@*R4H&L[3Q7M592"L*^8W?H!\WMUKKO$R+X9\36
M/C/1K.WN+6[MAILJ6T:Y+,V8I!@C(W$*3R<8ZUWYTC36M9+4Z?:_9Y&WO%Y*
M[6;U(Q@FL,>']5N=?9KV\M%T*UGCFL+.WAVL,)@A^V V6&,]N1C% &AX6T*'
MPWX<L]+B)8QKNED/621CN=C]6)^G KF]>ELX_BYX8#"%)C9W0DDD)&5*C:H_
MASG/O@GVKO*K2Z=97%PMQ-9V\DR\+(\2EA]"1F@#R;06T:V^'WAZ^DDBC>'6
MR@N$4&1-UPY*@XR <\]L<].:]@95D0JP#(PP0>00:J?V-I?V?[/_ &;9^3NW
M^7Y"[=V,9QC&<=ZN@   # '0"@#Q;Q!)HZ_!S6K6V-C%/%JWE2) 5#K_ *?D
M @8P=H.!Z"I_$,']E^*/%$/AM$2[N?#:21+:%2\DHD89VCDL5R<\^O>O5#HV
MED2@Z;:$2OYD@,"G>W]X\<GWJ2/3;"*X%Q'96R3J,"58E# 8QC.,].* /.?!
M1T6ZU;1;S3=82YO8K)H);-%1&B0JI/FA1NR&7^+'+5W/B?4K32= GN[^V6YL
M@\<<\;+N^1W5"=N#NQNSC'.,5?@L+*VF>:WM((I7^^\<85F^I YJ9T21=KJ&
M&0<$9Y!R#^8H \FCM3X$\0:5%X8U8:CI&IW2V\^DR2&=H5/65",D*HZCIR*Q
M;:XT[2?!'CI9[7?)%K[Q2) WEN$<QA2Q(RJ<'/'.#7M=OIEA:3--;6-M#*P(
M+QQ*K$'W I/[*T_-T?L-OF[Q]H_=#][CIN]?QH \AU&*-K+QO"DMC<BXTF"[
M1;.,"/ #+N R>0!UY_I5G5+RPA\0^$G>[BL]!?36V7)@1[=;DA?OEOE#%,C)
M/?WKU9--L8W+)9P*QB$!(C S&.B?[O)XH&F6 L4L196_V1  L!B&P8_V>E &
M'X$M[*T\.>3IMW]LL!<2F"<8VNI8GY< #:"2!C/ K#NO[.E^)>M6_B0 V<NF
MQ+9?:OE@V?-YH7)QOR0<CG ]J[^&&*WA6*")(HE&%1%"@?0"HKNPL[^-8[RU
M@N$4Y"S1AP#Z\T >1S_94\"V"7KVQMH?$,2:9-+(KM-9+<@(VX\D;<\]P >]
M>P0+"L"" ((L93R\;<>V*KS:3IMPL:SZ?:2K$NR,/"K!%]!D<"K2(D4:QQJJ
M(H"JJC  '0 4 <%X-O8/#^K:[H.JNMG<F]>[@>9U5+B*3G<A)YQC!],CUH\7
MZ]I6MZ/<VH$]QI=M=VRW]Q&=L3QLWS .#\P'!;L!D9S7;76GV5]L^V6=O<;,
M[?.B5]N>N,CCH*D2VMX[;[,D$2P;2OE! %QZ8Z8H \B\6I9V^O:[<:(Z?8YO
M"UT;G[-CR5D53Y1RIP&Y.._ JUHATJTT;X;:@J6QN]XMFE\U5;RVMI=P))Y
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MT&><4ZSL;33XFCL[:*W1W,C+$@4,QZDX[T <A.]N_P 2+Z#73;FS.G)]B2Y
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M]0.. :LVUK;V<7E6MO%!'G.R) HS]!0!Y_XDOM+M_BC;0>)# NE3Z0Z6[7)
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MQIMSZ9YQ^-=[%%'!$L44:QQJ,*J#  ]A5:XTC3;N8S7.GVDTIX+R0JS'\2*
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MAJ$]S872QRZ/:Q)=&$>674G>NX @'D< XX[\5S:Z4[S^/8M5\.ZE=V&HZK&
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M/U&.M=CX5?\ M'5)]4A\*KHEJ;=8@]S:+#=2ONR00.1&,#&>I.>U '74444
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M[T =-+J5E#?P6,EU$MW."8H2PWN ,D@>E&HZE9:39M=W]S';VZLJF20X&6(
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MLV\%K%;V;7]O.LA+30 G.5Q@%0,'GMG !XUO"UWK%_X=M+O7;:WMK^9=[PP
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MDT =A17$7/BW6 ^FZ9;6M@-;DL%OKR*=I!&BGY=JE03G=GJ.@-=!X:UF;7M
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M@^T>_M9/[!F+R,$8>:N, #T.">M=]5'6-7L]"TFYU._D*6UNA=RJEC] !U-
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M9)S"&N54";'\28)^7ZXH XB3X>:S_8.K:6FJ6TAO-734%FGC+?('$FTCGG<
M/3%:>IV[^'O%]SXVU:]MX]-338[%T2-V=,/OW<=?F8_A7;4C*KJ58 J1@@C@
MB@#D/!&GV?VK6M9LXYEM;Z\9[431LF(RJLY4. RJTFXXZ<#%:_BCP^GB31C8
MF<P2I+'/#,!G9(C!E..XXQCWINL^)K71M-FO$M[B_6"Y2UEBM-A9'8J #N91
M_$O?N*VZ .:MO#]_>:W9ZMKL]K+/8PRQ6R6J,@4R!0[EB<YPN,=.<]<8Q;[0
MY-,T.U'B35;9=!T:59PT<+%Y C?N]XYZ<9(SD^E=_56WNK+5[.1H7CN;9F>%
M^,JQ4E74@]>010!Y;;^$1XPU_P >QR220V=W<V_V:]C&1O1%.Y>S8(P?\:ZH
M^$=:U;1KJR\1^(/M#2VY@C-I"81&V01*?F^9^%] .<=37944 <GI'A_Q&@,6
MM^(5O+:*%X84AA*,^X;=\I+'<0,\=,G/4"L0^ =>_P"$/TW0AJE@3I][#<PN
M86 Q&Y< \\DD^V,5Z/69'K44GB2;1!;W"RQ6RW!F9<1L"V,*>Y'?MS0!ER^'
M=1L]7U*\T:_BBBU( SP3JS".7&WS4(.<D #;P.![U6LO!<FF^(M$OK6Y1K73
M=.DLRD@)>1G(.[/U'ZFNPHH YCP'X9N_">@2:;=W<=R3=2S(T8("JYW8P?<F
MDD\-7R^-+[7;:\@6&\L%M7A>,E@R[BI!STRW/TKJ** /-M.^'6J:=X7\,Z2M
M_9N^C:FM^TA5@) H8!0.WWSS["KJ^"-:TN^O+;P_KL=AH=]*9IH#!F:!V^^8
M7!^7/'7.*ZW^V]-_L^2_-Y$MI%(8GE8X56#;2#G_ &N*OT ><:NFB>*/$^GZ
M5I]U?'5-(N/)O)$$G_'O@%XY)#PP;Y01G)YKT<<#%,2&*)Y'CC1&E;?(54 N
MV ,GU. !] *?0!Q/_"'ZFNC^(+1+NS6?5M0:Z\S8Q"(=O!'<_+5YM U1O'7]
MO"YM8X&T\6+*BGS?O;]P)XX8G P>*ZBB@#@].\#:E8Q^&U?4+%ET6X=R$M-O
MG*RE22<_?.<D]SGUJIH,EGXL^(:^)M#:1M'6SVW3LC1B:Z!(3Y6'.U&;D<9(
M[].YUG5(M$T6]U6XBEDALX'GD2$ N549. 2!T![UGZ7XCAO[31);;3KE8=51
MY%=%4I!A=W[P@\$]L9R<T ;C[_+;R]N_!V[NF?>O-_\ A6VH_P#"&>']#_M"
MU\W2M0^V-+L;$@\TR;0.QYQ7I5% 'GA\ :M&VH-;ZE9AY]<75XW> EB ^X1N
M>I X QTQ6[KGA,:QXBTG55NC ;97ANU4?\?4)(81L/3<H/YUTU1-=0)=QVC2
MJ+B6-Y$C[LJE0Q_ NOYB@#F-?\,:I<>([;Q!H&IP65^MN;2=;B#S8YHMVX<
M@@@DD<]ZWM(L;C3]-CM[N_EO[D9:6YE !D8G.0HX4>@' J]67KFN0:%;VTT\
M%Q*L]S%;#R4SM,C!0S$X &2* ,!_ S7%SXE@N;F%],UP^:R"+][%* H5@22/
MEV@CC.<>E3Q>&-4U"ZTB;7]2AN%TJ3SHDMXMOG2@%5D<G)! )X'!R3Z5UE%
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ME7&>0RM@^F.*WM(\.R0:_=>(=2>"75)X%M@8$*I%$I)VC/WB3R2>>PXKH:*
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MRF1F.YF')VC:OIQG'85-!\2:Q>^*?#UC<7[LD%[?V-P=V!>+''F-\?Q%?XB
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+0L7QY8/);&.> ?2MV@ HHHH **JW>HVUC+:Q3R8DNI1#"@&2S8)Z>@ ))[
M5:H ***YW5O%D%EIL5[8)#?QO?16)(GV ,[JF0<'=@MV]* .BHHJ&ZNH;*TE
MNKF18X(4+N[' 4#DF@":BH[>=+JVBGC#!)4#KN&#@C/([5SGB7QG::'H6KW]
MLHNY=-:..6,' #R,%49]BP)% '3T444 %%%% !1110 44V5F2)V5-[*I(4=S
MZ50T*\O]0T2UN]3L/L%Y*I:2U+[O*Y.!GOQB@#1HK+O[W4H=<TJUM+ 365P9
M3=W);'D!5RH ]6)_3WK4H **** "BBB@ HKEKKQ7?/>ZM;Z/HHU+^S)(HIL7
M0C9G8;F"KM/*J0>2,YP*W[O4K.QFMH;B=$EN9/+A0GYG;V% %JBL?0=:EUB;
M5EDMXX5L;Y[12DN_?M522<#C[W3MT/(J0ZC?CQ,NF_V4_P!@-J9O[0\WY1(&
M \O;CK@DYSVH U**** "BL#PMXLL?%<.H268P;*\EM'&\-NVL0'&.S#D5OT
M%%%% !1110 4444 %%%5[>]MKN6YC@E61K:7RI@ISL?:&P??##\Z +%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'.#@X/:
MEHH \X\-%V^"VJ-*\CRF'43(9.I;?+FLZ#2(=,7P#J.E><VHS-%%<R"9F>>
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M6_EGTBSE?4%5+MGA!\X+]W=ZXP/R'H*ECT#1HK^"^CTFQ2\MXQ%#<+;H)(T
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MPVXR A&<$$'.>3DYR<G/6GWWA31-1NS<W-B&D:$02!9'19(QT1U4A77V8$4
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M]Q<12R!0T:N-PP00>"<^P/7I6G_PAV@'2+S2S8;K2]*FY#2N7FQC&YRVX@
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MO=/TV&WFV&-?+R%C4D$A%SM0$@$[0,]Z .7\!:=9P^*?&31VL2-#JP$9"@;
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M)%:Q2+#O,DHD<F(X7(R&'7 ]:Y#2=!U'PU_PKNPOX)Q/%/?>=Y<9D6 S1LJ
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MW7FL=YXX7:P.>>P]<=SH=S"WQ2\1F))%2XL[0!S;NJR/'Y@;YB,<!E^N1Z4
M=O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17/:GXDN--\5:9HITT/'J2R^1=&?"^8B%RA7:2
M,XZ_UXK,B\<W%SH^KS0Z;$FH:??K8?9FN"ZM(2H!W!<X._C H [%)8Y&D5)%
M9HVVN%.2IP#@^AP0?Q%'G1>?Y'F)YQ7?Y>X;MN<9QZ5YAX9U>XT&T\23V^G"
M6$>*)DNB) H@5A$,C/+'+#L.]=1J.HV%IX\MOM=@%:'2YYSJ;OA8(@R[E/.,
M'KD^E '54R*6.>,212)(C=&0Y!_&N6MO$]Q>:MI^G:CI/V>TUFWD:T82;V.T
M;F$@P-F4(('/.1FN8\$Z]_PC^BZ'81:?G2KK4+BP$R[4:*;S6$:A<_,N%;+=
M>A]: /4Z*RO$.O6WAW2C>W"O(6D2&*-.LDCL%5<]!R>IZ5S5S\2%M;'5I/[)
M:YN-.B2X:.SN!+&\18J7#X'W2K9&.,>G- '=57%]:-?-9"Z@-VJ;V@$@\P+Z
ME>N/>N;C\5WYU[4M&N-+2"ZCL3?6(,VX31@[6WD [2&(]>#[5Y]X3FLKO0M'
M\0Z]I<5QK$^J2)8WBS,;B:<2.%C8[.$"J1R3@*,"@#VVBN.?QV;!M3L]6TM[
M;5+&S>\6!)E=+J)1DM&QP>,'((!'OFEA\;R2#3(SI;_:=7*G34$R[)D,7FLS
M-U55&1RN3QA: .PHKCX_':BP4W>E36NHOJ)TQ+5W!5IL$@^8!C9M&=V..F,U
M!/\ $:&VAF673)3>6VIPZ=<0QRJRJTI^5U8XW+@^@YR/>@#MZ*X=_B!=K/J>
MGIX:NI-7TZ,3S6J3J5,1!(*N!RQQC;BI_P#A/K:ZT_2&L(HSJ&J6INXK:YF\
MH1Q@<L[8) SP..30!V-%<3#\0UNM.T*YM]*F\S5;B6V5))%"QR1[@4+=R2AQ
MQTYK*UCQSJMWHGD65I%;:I'K4.E7D:7(8Q[B#N1@#U!ZD<8.0<8H ]*) !).
M .I-,@GAN85F@E26)AE7C8,I^A%0J\K::S7MNBR>6WF0QR;QWX#$#.1["N(T
M/Q+'I_AWP[::7HMK:/J1F^SV;W.Q56/YC\P#<D>O>@#T&BJFEWDFH:5:WDML
M;:2:,.T+,&*$]LC@URFD>/'O+)]6O;*.'0VCGN$O(I&=H8H^TR!3M<X;H2.,
M=: .VHKDI?&<]D^DOJ.D-;VNK2B"TE6?>5D;F-95VC9N&>A;&*S?^%F@>&]0
MU=]'?=8:J-+D@2XR6<E!N4[>1EQQCM0!W]0F[MENUM#<1"Y9#(L)<;RH."P7
MKC)ZURVK>.&TVYU80Z9]IMM(BBEO9!<!77?SM5<?,0N#R1UKF-6N9I?BWX?U
M*UM!]MFT.9XK=W4[VW#"EP2 .<Y':@#U:BO-+_X@:I>#PH^G64%L-3OY+>XM
M[FX"R!XS@H" 05R.6 /8=Z]*4L44N &QR <@'ZT +1FBO*?&NNW]MXFM_$*Q
MJVC>&;Q%GV'+N)4:.8[<\E Z8^K4 >A:MH4&L76FSSSW$;:?<BYB6%PH9P"/
MFR#D8)XXZUJ5BZEKXA73HM.2*[O-1YM8I)?+#(%W,Y."0 ,=NI [UEVGC.::
M"WM9=."ZS)>RV+6_F%8O,B&68.5SL*X(.WN!0!UU%<E#XSF:QACETN1-7EOG
MT]+7<=C2H,E]Q&1'@;LXSCM5:Z\<7VDZ-JKZGHCC5=+A2>:"&4>5-$S8\R-S
MR5&&R" >,=Q0!VU5)=5TZ!;EI;^UC%J5%P7F4>46QM#<_+G(QGKFN83Q=JC3
M3V+Z0(]0GN#'IBR,1'-&(E?S&89( +$' ]NN<<=<7=G8^%_B!<7V@N8CJ$?G
MV+N5'G,(\OG.2ID.\$=00<#/ !['17+ZSXGU*SU*\TW3M#FN;J*T^T1-)(J1
MR<D'Y@3C'H0"><52M/B+;:M;:"=(L7GNM8>9$@G?R1"8ES+N;:>AP.!S0!V,
M]Q#:PF:XFCBB7&7D8*!G@<FI*\A\7^*;?Q;X-M+B*RGA:T\16MI/%+A@9%8%
M@N"=P^8<D#.>E=Q;>+<:SK>FW]FMF-+MUN3,T^Y9(B&.[[HVX"G/I^M '34R
M26.(*9)%0,P5=QQDGH![U3T6_FU31[:_FMEMS<()%C63?\I&5.<#MVQ6;XL>
M$PZ=;7&F?;8Y[Z(?/(JQQL&!5FR<]1Q@'D<XZT ;<UW;6\L,4]Q#%),Q6)'<
M*9"!G"@]3CTJ:O+9M#D\7^,]>L=?T6"XMA%# )1=!S:*RELQ;D!!) SC'XUU
MOB'Q<FBZI;:5!9/=7T\$ER TGEQK&@).7P>>P&._44 =+17'6GQ#L[_2_#NH
M6NG7DD6MSF!.!^Y8 D[N?]DX]@3QBHKWQ[=6.A76I3:!+$;/4/L5U'+.%$(.
MW$I;:1LPZG/H>] ';45D)K$[:Y:Z9]C0L]I]IGD2?*Q<X"CY1NR<X/'3H*IZ
MYXIDTC7--T>#29[NZU%9C 1*B(?+0,1DG(Z@=/SH Z.BN%B^),-Q:[(])G75
M%U)=,DLY9 H24KNR7&?DP#R0,X/%3'XAP#2(KW^S9C)_:XT>XB$BXAFWA"=W
M\2\@C Y]J .TJ.&XAN4+P31RJ&*ED8, 1P1QW%</9^*M?OO'%MIDFA_8HQ:3
MRF*XNP"ZB54$G"G/0X'N>>14/AO7+73M-O7T_09EN;W6IK>.!&),LG)+NY&
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MHZ+>B2YAAFEQ'>YB) 9&4X(!R-P_(T >M@@C(J,W$ N1;&:/[04,@BW#<5!
M+8ZXR0,^]<3XMF?X??#UQX?M,00RH@W2X\A9)0,KG.>6P!VR#SBJ,]U>VOQ2
M?47TY3>#PS([6B70;E;A?XB  ,=\>M 'H4MW;6\L,4UQ%').Q6)'< R$#)"@
M]3CGBIJ\YU7Q7X?UQ/!>I-ILUVE]?$6LF_9]FE4%6##O@@CCCC.:Z*S\437V
ML?9H=.62R^URVC74=TKM'(@8G>@'R@E2.O<9QF@#I**CN)X[6VEN)6VQQ(78
M^@ R:\Q\%ZYJ,/CZX@U%RUMXDM?[4M>/]4Z_)Y>>F1&J9Z]%]: /4JQ-(\/+
MI.NZWJ2732#594F:(H!Y;*@3@YY! %5=9\37UA>WEOIVAR:C]AMA<7#"=8R
M<X5!@EF(5CVZ>]03^-I#'IIL-!OKJ34K*2\MD+1J6"JK!3ACM)##D\9P.IH
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MX8(YK U+XD6^FW-T[Z>[:=::BFFSW)E <2MC)6/'S*-PR<CO@&@#MR0H))
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MY'AB.>Y^+'B*]N+5K26/3K2.2&1A(2SESE'_ +ORXXQSVXH ]"HHHH ****
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M (1C3M#U.RTR_MXA+YX>Y=2K%@T;1L(\\?,"..HY-=Y3$FBD9UCD1FC.UPK
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M$C'W<_B:]$JMJ-_;Z5IUQ?W3,MO;H9)"JEB /8<F@#,\:?\ (B>(?^P9<_\
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M6GQW5E=2@7KR7'E!(E(8C !+;L;<#UZBL?6O %LATFX\-V5I:WMA>K.LDDC
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M=*7@N(VBD&<9!&#7*:'\-['1Y(%DU34[^TMHWBMK.ZE!BB5A@C: ,\<<YZT
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MFN=6>WOKFU@U:,)=6T84QDA0N\ CAL#D]^] "> ITM?A;H-Q)G9%I<3M@9.
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M5XF"J#)MX ; ]..,4 ><:;J%[X6U3X@>));V6Y:POE22W54"W!8*JDMR0%W
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MHA=:K+:7UQ:IJB*ES&@4@E5V;E)&02O!/X]:6U\)P6&KM?6=W/#']@CL([4
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MW 5;TA-7/C/5Y7EO&TGRU4"Z554S#'^I4#.P+G<Q.&)&.A- '34444 %%%%
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MX]*42(9#&'7>!DKGD#Z5Y%H5C]@TSP?K5I%/+K$NF3Q&:25R)=L#LB,F<'+
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MY+X,;@C:H'?.3],5Y-\3CYU]XHNX&-Q<Z786SQS;RG]GOOW*$ /S,^=Q.,8
M'M73ZS!YGQ8T3-Q<[;G1KM719V4#&SE<'Y3\QY&#P/2@#T*LZPN]0GU'4H;N
MR6"V@E5;64/GSU* DX[8)Q7CVA^?9^&OAKKT-Y=?;[J_2QN)&F9A)#(SED92
M=IY&<D9SSG@8T=8:1X/B1FXNLQ7=LR%)FROR#CK]WVZ>U 'L-%>;PVUUI7BW
MQ"^GW;0&\T%;I9+B9V5;A=PWDR94* 5X'  Z 5B^$=+;6;CPAJEM-J"%[(OK
M$Z7$L/VE\?)O(93(V[)SSD=: /8J*X?XAVQN+[P?MGGB)UR-"8I&7Y3%(3D
MXS\HY/(YQU-<3KT6HZ+?>+=#T2>^%A!:0ZC;$S/(4O#(@"^8Q)(;KL8D''UH
M ]NHKR^\TQ$\>:9HM]]I;1M5$NH3QSS$QS7:[2$![*,$[,X/I@8K'U71[B^L
M/%_AVQ61K307BOM+96)*2;3(\ /4@\]3QN'I0![+*S)"[(NYPI*KZGTJIHUS
M>7NC6ESJ%K]DNY8@TT'_ #S;N*XK0?LOBZYN_&J.RJVFBSA2,LH5MI:4GIDA
MFV@^B_ERUO97%]X!\+.EBFNVT=E*;C3&N6BF8;_]:C;@2R_=_P"!<4 >O2W%
M^NMV]NEFC:>\+M)<^9RD@(VKMQT().?:KU>20:KGQ!H5YH]W=3Q'PK<20I+*
MT@,D>Q02A.-^1@X')'>JTBM8^ M"\8:1*\GB2>XA$LQ=G:\\UPLD;KG!'H,?
M+M&,8H ]DHKQ&ZLXY/!_CC4Y[B[6]T?7;B6SE-W*WDL$AQQNP^.@W CD^IK2
M\?R61OQJM];/?6-NMM#<W$%RRRZ8^[?O\L<,&#J3CJ !Z8 /7**Y;Q_JDFEZ
M! P>2&VN;ZWMKNYC<H8('<!WW#D<?+D<@L".E9*:7;Z-\0;72-*BB.CZIILK
M7UBK_+%Y114EQG^+?L./O8R<XX -;2O$NJ:S>)/9:7;3:(]U+;_:TNSY@$;%
M=Y0KC!92.&J;Q!XMAT?3-<GM8?M=UI-K]IEASM7&"<;L'!P"<5@_"'3K.'PA
M'?10(MRTUS 7':-;F4JH'0#+'IUXST%<WK>AZ3I\?Q.U*WA,=Z;1U+M*Y!\V
M/<_REL<GOCCMZ4 >LZ1>G4M%L;YE56N;>.4JIR 64$@?G3=)N+ZZLW?4;1+6
M<32((T?<"@8A6S@=1@_C7FWA^S?3?'_AHV\]RMOJOAT&Z0S2%9'14P0"=JX!
M&-N,9/3/+TM=0?P/:VUO.MU/'K4Y:SU&0YOU620^26<L<D 'DG.WGK0!ZI7-
M^-?&%MX+TNUO[J%IDGNX[<JIP0&SEOP _ES5#X8312^$&CAAFMA#?7,;6DQ#
M-:MYK$Q9R<@9X)YQ6/?6=QXO\1ZX5TO[19)$VCBY^UA#&IPTK*N#ELD8/M0!
MZ6"",@Y!HKRJ3Q+JE]\#]3E6Y-EKVG0-:W)$AB>*1"!U)R"5P0<\YJ/3="EG
MU*YO[*?4;70AH@+0?;)8E:\*G<XC##/RX))!!)SR>: /6:*\:AABLO"?A6>]
MFN5MM:AAMM1NI;V2*-(TB/EH2/NJW"G& >ISDDVM;>7POI1L;74HFTJXUV-+
MY44^58VTB$M&7ZJI;'/;=@8XH ];HKQCQE8)H?@S6ET[5E:!=0LKF"TMI69+
M0NZY4'/W6^\%Z#.<<UHS>%[5O$?B/1H6O39WFCQW\D9NY6+W):0!BV=YZ [=
MV#Z&@#U:BO(?[1CU^/P9INK7RR:7?:6&?S;F2-+JZ0J K.,%VR"=I/)'>K4]
MJI'A2P36;BZ%IK4MDSQLZJ$\J0[,MG>5 "A^3UY!S0!Z;>7D%A:M<W+[(E*@
MM]2 /U(J>O%-1TFP'AG7-*9Y6M=(\1PK8@74BF%7\HE0^XEN7?@G.23\IQ7I
M7B">7PYX#U6YTIII);.SFEA::9IV# $Y+.Q+8//)/ Q[4 =#17EE_I1\+2>&
MM6T+5[^[?4;B.SOI)[J287D;H3YIWL=I7;D%0.#CZO\ A'HZW>B6VNW%]=S7
M,-Q>0HAF)BVM*<DJ>^1UX/0'H* /4**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I7FCZ9J%Q#<
M7NGVMQ-""(Y)859D!!! )'3D\55C\+:#%9Q6B:39B"(N8D\H?NR_WMIZKGVQ
M4^HZWI^E2Q17=P$FE5W2-069E098@#G %<WXI\7Q+HFB2Z/<[UUJ^AMXKF($
M[8V/S,HQR<# 'OGM0!V"00QP"!(D6$+M$:J H'ICTK.'AK1%TQ].72K1;-V+
MF%8@%#$DY&.AR3@CIVQ7 W6NWB>,G\,'7[R&"2S-Y!<M;L9$>1MJ1M_LKM)R
M>N[!Z5V.D>*--D>STJ;5DN]1(,1F6$QI<2(!O*]O? )H VK2PM+",QV=M# C
M'+"- NX],G'4^]59_#^C75S]HGTJSDF\P2F1H%)9@, DXY(SQGI4,'BG1KF[
M@MH;U7DG>2.$A3MD>/[ZJ<8)'I7)#QJOB+PYX@E&K+HT5K>M:Q7<4+,\0! ^
M;(QO8G@#L10!UUSX7T.\N[N[GTRW>XO(?(N)-N#(GH<?SZTZ^\-:'J4]K->Z
M39W$EIQ TD*ML&,8'M[=*J2^+M$TUI;.\U(&YM+>.:?]VQ.UN V .]69?$^D
M16.GWGVQ9(-1*BT,2ES*2,C  S_A0!;;2=.>Z%TVGVK7 3RQ*85+A/[N<9Q[
M53O+&YTO23%X8L=/@F$JOY#)Y4;#/S?='!([XJ31?$>D^(HI)-*O4N5C(#[0
M1M//!R.O!K-UOQA:Z-XLT;0I ?,U .S-Y;-M4 A<8&,EOR'YT 1>&/"2Z=I^
MMQZI%;S-K&H3WD\(^9560Y"$G[V.><#K6M#X:T.W1TBTFR"O"('!A4[XP<[6
MS]X9YYKB/!OCNW@LM2/B/5F,[:U/:0&120JJ551\HP.3[=:[2_\ %&CZ;/<0
MW=XL;6RHTYVDK$'.U2Q P,F@"[+I>GSV:6<UC:R6L9!2%X5*+CIA2,#%03>'
M]'N+I;J73+1IUD$HD\H9+ 8!)[D #&>F!6D"" 0<@]#6/#XGTFXAU26.Y)72
MV9;S]VP,1 R01CL.>* '7OA?0M1N9[B\TFTFFN(O*F=XAF1?0GO['J.U6H])
MTV*YAN8]/M$G@C\J*585#1I_=4XR!["LZ]\8Z#I\[PW5^L<D<232@HQ\I'("
ML_'R@D]ZPKS6KX?&32-*BO6.F3Z3)<&%2-K-N(#>_ H Z:R\.:+IVJ7.IV>F
M6L%]<X\V>.,!FQ_+WQU[TL?AS18H9(5TJS,<DYN&1H58&0G.[![Y_*J&F:YI
MMGH,=U-K9OH9;N2&*X8?-(YD8", #D@C;P/X:Y:+Q!/=3_$);C7I[*SLFA2W
MNGCYL]T?.%P#PWYX'/>@#O9]%TJZ</<:99S,$\L-) K$)_=Y'3VIYTK3C=B[
M-A:FY">6)O)7>$_N[L9Q[5SW_"4&PU_2=$=GNDETQ[J6Y\IB[[=@##'&#DD_
MA6E!XKT>YT/^V8;HO8;P@E$;<DD+@#&>IQ0!2UGP;::G'864$5G9:=;7 NFC
M@M5#F0$$;3C"@]R!D^M=!=V-I?QK'>6L%Q&CAU6:,. PZ$ ]QZU.#D UC1>*
MM'FN8X$N\F6X:VC?8P1Y5ZJ&Q@G\>: + \/Z*%B4:18;8I#+&/LR81SU8<<'
MWI)_#VBW0N!/I%A+]IQYY>W0F7'3=QSCMFJ(\;^'3J$=@-3C^TR79LE3:W^N
M SL)QP>1^=:^H:A::582WU].L%M$,O(W04 4X?#6AV_G"'2;)$GB6&6-85".
MB] 5Q@X^E3)HFDQRV\J:79+);+L@<6Z Q+Z*<?*/I567Q7HL%K?W,]X(4T\*
MUT)$96C# %201G!R*9:>+M$OM4N-,MKSS+V"-I7A$;;BJG!(X^;!('% &K=6
M=K?1K'=VT-PBL'"RH' 8=#@]ZC&F:>+*2R%C;"TD)+P>2NQB3DY7&#DUP'A[
MQ))KMG'XDNM:N+&*"[F26'RR;>:'S-B#!Y#_ "C&#G).0:["3Q9HL,5_)->B
M+^ST62Z212K1JPRK%<9P?6@#0L=-L-+@,&GV5M:1%MQCMXEC4GUP .:9+H^E
MS73W4NFV<EPZ['E>!2[+Z$XR16?:>,="O[/[5:WPEBWQH-J-EFD * #&3D$'
MBK$/B32KBT>YBN@R)<&U*[3N\[=MV;>N<F@"9=#TA%MU32K%1;', %N@\H\\
MKQ\O4]/6B+1-)AU!M0BTNRCO7)+7*VZ"1B>N6QGFJG_"6:+]F$_VP;3=?8]F
MQM_G?W-N,YK$\8>(\>'[&]TJ^>(?VS;VDS*,$8FV2(V>G0@T =*NA:.J3HNE
M6(2X&)E%NF)1_M<<_C2MH>DM8&P;2[(V9()MS;IY9(Z?+C%8-UXOT'6M"UE+
M'7FM'M+=FGGC0B6W&/OA6&:S6U2\B\2> +>WU:XN;+4(+@S.Z[?M 2#<C,,9
MS\V<>PH [$Z-I3::-..F69L1TMC OE#G/W<8Z^U02^&-#GT==(DTFS.G*P=;
M81 (&!R#@=\]ZY#5/&B:#X5U_6-.U%M9G74F@@CDB;9;R$(!"<8.T=<^K5U.
MC^*]*UF]GT^VN";^V0-<0F)E*<X[CU!% &A#I>GV]VUW#86L=RRA3,D*AR!P
M!N SBIHK:&&6:6.,*\[!Y"/XB%"@_D /PIEE>P:A;"XMRQC+,N64KRI(/!]P
M15/4/$6EZ9<2P75T%EA@^T2HJEC'%G&]L#@9H EM]#TFSU"2_MM,LX;R48>>
M.!5=NYRP&>:H^&O#D6@1W3@6Z37<GF2I:Q>5"N.!L3MQC/J:P_%OC"*WN_#V
MGV%VXCU:<,\]NI9O("LQ*'!&3@#CG%=%H4=Q::+YMUJ<NHH^9HII8@C^61E0
M0.I ]A]* -!K*V>_COFA0W44;1)+CY@C%2P^A*K^5)]@M/L\MN;:(P3,S21L
M@*N6.6)!ZY)KRK4?B'J&L>%M&U>P:2P\WQ"EE(@7&^'+GG([A1G'O7>'Q3HV
MIZ+JT]GJHC2S1DGG5&S 2O#8(S[CZ4 7F\.:,UQ8S_V=;J]AD6NQ-HB![ #C
M%..@:,;5K4Z18&W:3S3%]F387_O8QC/O67;^*=)TWP[9W-WJINHUL8[E[KRB
M2\9 'FL /E!-=("& (((/(([T 9UWX?T>_E\V[TNSF?9Y9:2%3E>/E/'(XZ&
MI+G1M-NVM&N+&"0V;;K?*#]T>G'I_P#6K ^(>N:CH_AN1-#&_69PQM4 SP@W
M.W/'"@GGKT[UKZ5K=M>>%K36IIT2"2U6>25B %&W))].] "R^&=#FM5M9-)L
MS )S<"/R0%\P]6QW)[^HXZ5>NK*TOK5K6[M8;BW; :*6,.AQTR#Q659^+]"O
MKNUM(;Y?M%U +BWC9&4RQ$9#KD<C'>H+3QWX:O4D:WU2-EC@-PQVL/D#!2>1
MSR0,=>: -A=*TY)4E2PM5D2+R$<0J"L?]P''"^W2@:78+IDFF1V<$=C(CQM;
MQH$0JV=PP,8SD_G5*V\4:/=17DB7BH+/FX$JE"@QD$@@'I5:;QQX=M[>^FFU
M%8EL=OVE71@T8;&TD8S@YZT :5YHFF:A90V=Y90SV\#(T2.N=A7[I'<$8JM%
MX4T"$7:KH]F4O)1-.CQ!E=QT;:<C(JFOCWPTSW2#4EWVL?FR*8WSMSC(&/FY
M..,U?E\2:1#I-MJCWB?8[HJ(' )\PGH% Y)X- %MM,L'NXKMK&V-S$-L<QB7
M>@] V,@5GIX0\.QW27*:-9+,D_VA&6( +)C&X#H#_7GK44?C7P])%;R#4HQ]
MHN3:1JRD,9AU3!&0?K5/5/B#H6G^&M0UF.Y\Y+-O)*"-P?-(^52,9 )QSC'-
M &F?"N@-([G1[,L\XN23$/\ 6@YW#T/KCKSGK4R^'](6ZO;G^SK8RWP"W)9
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MK#JLEH]M%=-$#A6&-K#^(>QSBN.TKX<1))H[2>&M,TRZL# S:A:7;22,8\'
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MU6NO#>C7L]Y/<Z;;R37D!M[B1D^:2,\%2?2L;3O$>GZ3;R1ZEXA%Z&83Q3/
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M+<R2ER/]5NY" ]B1G/0C-8OARSU6R^&?A"S?3[I9HM8@:ZC:W8M%&CEBQ'4
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ML5'CUDVR ;HW8L/+Z< N%?MT_P!HUZ%'-!J%D9+6Y26&52JS0N&'<$@CT/\
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M^ =K>_!XKT2*[MI[B>WBN(I)H"!-&C@M&2,C<.HR.>:FH \ITVPU>#P3:O\
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MJ^,[&ZJWX$"O/HK37?\ A6&H:MK>CIJ&MRVD5J+22-W?;&X3<XY+-NS(=O7
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M_"@5>..,]2:KZIX=M?$VK17;ZQ<O80QM!/86\W[F5MV?GP>HX&*Z55"J% P
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MKRF[&3GC)SBLK1H=8TZ'4M6@TV\EL;/Q5/<O9)!EY8\,A9 !R5)[=QCM7N5
M '04 >9WEW::Q8W=RGAW4;6WO=5L7D-S;R;[D)+&78QX.U55?;.*T=,2Y3XS
M:Q*D-TEC-I4*[_)987D5S_%C!8!CCV)KMH;JWN'D2&>*1HFVR!'!*'T..AJ6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=O0EMIV;;[5-:O(LV7A:/=S(FWY02N!SU(J/6O#MS+KWA.?38(UL]'DDW+N
MVHT1C4*/;(_ 5G:=X5U-?$NEZM/9V=G=PS3MJ%U9N%%Y&581@H!R>03GI@D'
M)X $T/Q-I]AI]VNFZ%+'<3ZU-9QVR2K^^GY8N6. HP"3UP!WJQJOQ$&B0ZU'
MJ&D2QW^EVPNS"LP9)X6;:K(^,]>""HQ@]:S5\#ZZ-+>2"6UAU*WUY]4M5D8M
M&RG(VL0."58]NM2>*?"6O>)[/7I95LX9;NQ6RLK=3\R+O#L97[G*\ < 'USD
M W;#Q?)=>*;;19],:!;S3Q?6UPLX<.OR[E*X!4@L/7-:.M:VVF7%C96MI]LU
M"^=E@@,@C7"C+.S8.%'&< GD8!K%MO#NH0^,M"U)HT^S6.D-92L'&=YV'('I
M\N/QJQXQT/5[^33-6\/7%O#J^F2.8EN@3%+&ZX=& YYPN#D8Q^- #3XV6&TM
M8[O39K;5KJ\>QAL9&X>5>21)C!CQSO ]L9XK/U7XBS:)IFKR:AHAAU#2T6:6
MU^U K+"S;5DC?;R"V!@@$?ABH[WPEX@U:PT[5[^]@/B2PNA>0P1\6JG 5HAG
M+ %1UR?FYZ'%+KG@N_\ %5GXBEU(PVUQ?67V.QBB?/EHK;U,C8P27 SCHO'7
MF@#=O-<CD\4OX7NK%72XT][I9"P970,$964CU;U.:XGX<>(1I'@?1M.CMQ=7
M^H7]U%:VZ,$4(DC%F8@'"J,9X)Y'%=';Z+X@N?&.F:_J%O8Q-'I4MG<QPSLP
M#LRL&7*]"5Z=L]3CGFM*\">)=&TGP]>6:67]KZ1=W3M;22GRIHIS\PW=0P '
M;'6@#H/ 9)\1>,]]I]EE.IJ717W*?W8^8' Z\G\:@O+N?3_B?JDFE:)+?WK:
M1$S*CI"KGS&QEV;VQP#VSZC8\*:1J]AJFOW^K"V5M1N4FC2"1GV*$"[22!G&
M ,]_0=*9?:;K=EXRFUW3X8;Z&XL5M?L\LYB\EE+,&'!!#$@'H1C//2@#./Q0
MTZ:WL4M(%^WW22N;>[G$*P^6VQ@[@-@[N!Q@X/(KIO#6NIXDT&WU1+:6V\W<
MK0R]5925(SW&1P>]</)X"UW07TS6O#4UB^MPI/'>0W6\P3"9_,8K@@C#=!]/
M3GN]"MM1M].#:O/'+J$S>9.(2WE(Q_AC#$D* !^I[T 8#^/"FD7FJ?V1+]FL
M=4;3KK]Z-ZA75#(H .X;FQ@<U=L_&$3Z]>:-J5FVGW4%K]M4/*KAH<X))' 8
M'J 2.1R:YYO"FMKX6\1:>EI \VI:T]\@:90/*:57P<AANPF,$8Y[U;O_  A=
MZO\ $"XU2[B5=*NM$?3Y )?W@9V!/3T (R#0!=_X32>W@L-0U'1VL](OI%C2
MZ,X9HM_W&E3: BL< '<>6&<4Q?'@6UO[VZTJ:WL-/GN(;JX:0$1F(#'&,G=G
M'&0#WJ!O#6LZKX;L/#6L>0;6"5#<W<;8,L<3!H@BCHQ*IN)&  V,D@TRP\(7
MUWX1\1Z%JH6$ZC<SRQ3))OX?E2>^01R* +NB^.H=5UVWTJ2VB26Y@:>%K>Y$
MX4+C*R84;6Y'3<.O-:.N^)/[%U?1=/\ L;3'59I(4DWD+&ZH67. 3R1C/;D]
MJQ/#6D^-&U>VG\3W>F>1I\;10_88V#W)( W.2< <9P .3[5>\3Z+?:GXE\,W
MEO;"6WTVZ>>8F?9]Y"HP.Y!.?PQWH IZ?\0O[1TJ2>+1;@WT6H_V;);)*K(L
MN 2?,Z;,$<D#TQ0/B-:C1FOFL7:2+6%T>:.*3>HE+*"R,!EUPP/0$],5B+X*
M\00)>RP10?OO$!U)K3[1L2> H%\MF XY&>AZ"F#P1XACLKBT-KI^T^(X=75K
M5O+4HNS*A#]T_)_>/)H Z>/QC?&[^P3>'YHM0:VNIXK8W*$R>40% ]GW#!Q@
M4J^,KBYLKF^L-%FGM++*W9>3RW5U +K&I7#[<X)R!D'&:==Z1J$OQ%T[74MP
M;2#3Y+5_G7<&=U;.,]!M-9UMX>\0:#;^(K'3#;WEOJ,[W%F\[8%NTG$BNN>0
M.HQUR>E &M;>,;:\UO3["WA#0ZE9M>6-T9,+, !E0,9##()]B#[54TOQ[#K&
MB6M_9V6Z:XU#[!]F,PW(P/S$G'9<MQVQSS5;6_ 7GZ#X>L],GEAN=&D18I4E
M\MC$1MD&[!/*^F.0*MZ5X)M]*\77>IP%4L&59(+0+Q'.5VNX],JJC&.N30!F
M1ZS9^#+;6+BUTH26YUDQW!A(0QM)MP[9&",MR<\9KJAKBR>*?[$@@,NRU%S/
M.K<0[FPBGC&6PQ&#GY3QCFN5G@L;'3O$D7BB.WT]=:EDDC'VO>95"!1C@;6&
M!TSR:W/ ^G7EGX<MY]3F$^HW2(\LIC56VA0$4XZX7'/KD]Z .EHHHH ****
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M!LFS()!CCF-2/7+"L._\6^)$TCQ)JB:\R#2]=%I#'' A5T+1@*<CH,G\S[4
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MUY/XFOKOQ'\.]9UB2[FAC^V-!':*RLBI',%YXR2=I/MFO4[+_CPM_P#KDO\
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M26^NVEUK]WHR).+JUA2:0M&0A5R0,-WZ&O)O&MQK.L?#4:SJ-T$2XUB)H;5
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M(HKSY=7UG4],\6WUEJ9MSH]W);6R/$I!\A%9RY[[B2.V*Z[3]4?5O#%KJ]E
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MJ$B:!-=H1"(]\PF5%)/T[=.: /0:S;C6[2VURUT=EG-W<HTB;8CL"KU);I^
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MZ.5/Y@@T^H;H7)MG%HT2S\;3*I9>O.0"#TSWH FHHHH **** "BBB@ HHHH
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M0_X0T+K=]JD6K7<<EY9+9NBHF JK@,#C(.<G\:Z@D $DX ZFD!# $$$'D$4
M8_A;P^OA?0(-(CO9[N&WR(GF"A@O7'R@9YR<GGFL33OAY%97VD33ZS>7<&DR
MRRVMM+'&$0N",9"@X&>!GC KM*S/$-SJ5GH=S<:3%;R7J;2@N7VQ@;AN9CD<
M!=QZ]J .9;X:6S/=H-7OA:S:@E_'; C9 X8LP7_>+')]A4M[\.+&[\23ZHFI
M:A;6MVPDO-.@E*PW$G'SL/< 9'?'UKM*S;&?5'UK58;R&!;&,Q&Q>-LNZE/G
MWC/&'#8Z<4 <_-\/H95\21KJUW'#KRA)XXXXP(U"A $^7IL&WFK]S?0>!O"U
M@ERFH7\%N8[3S+>W$CJO0,RKC@8 ) STX-='10!P&G>$)=6\$FUFO+NSNWOY
MKZTO&3$\.Z1F5L'H=IP1[U8N_AO;WEEK%O)K.HEM6B@BN9"X8D1J%SA@1DXY
M/UKMZ* .;USPI)KUMI4=QK%TCZ=<QW:R)%'F25,[6(*X[G@<5F6_PVM8[BT%
MUJMY>65I?OJ$-I,J824EB,,!NV@L?ES@\5T/B;78/#/AN^UFX4O':Q[M@.-[
M$@*N>V20/QJ#3M3U;S[F35;6VBTX6ZW,5U"Y.!C)1@>20.<]_2@#E[WX2VUW
M;W-D/$&IQ:;/=F[%FA79&Y?>=O&>HX].?6NB?P?;3>(+_4[B[GGAO[5;6>RE
M"M$R+G';/<]^]-E\327+^&I],6)['5I"6D<,6">66&T#UQU/2M/6+B_&AWDV
MAI!<WZ*P@21OD9P<$'!]B.O44 <WHWPXM]-%PEYK.HZG"T#6UM'=N&%K&PP0
MGOCC/I^-1:?\,X['2-#T_P#M[4)$T>\^UPEPAW,,A5P0<* 2,#'4FNXA:1H8
MVE0)(5!90<A3W&>]/H Y&^\"K=3ZFD&L7MGIVJ/YEW90A=K,<;RK$97?SNQU
MS3U\#6T>JZG>P7TT,=_8"P^SQQQA(8P"%V_+G(W$\^M7K/Q)'>>,=1\/K P-
ME;QRM,<X9FY*CC' 9#U_BK=H X"S\$ZAH6K^%X]*U*_DL=+C:&=9I$$+Q$/G
M*CDR9*XXQ@=<UTGBCPY'XGTV&SDNYK40W,=RLD(4G<AW+]X$8SBMNB@#F[3P
MHUIXL?7AJUT6EMDBN+=0JQW$BC:)7 '+8_"IM;\/76JWRW5KKEY8,+=[<Q1J
MCQN&.<E6!Y]ZWJ* .-LOAY9Z;KFE:I8ZA=0MIM@MA'$%0JT8))SD9R22>*CT
M[X<Q:7!HT=KK-ZITJ[DGB<JF720EGB;  ()).>O/TKMJ* .'D^&MM-H,>D/J
MUZ8HM4;4T?"EMY8L%)8'(!)Y[U:O/"$RW?B'4H=5U![C5;3R#%%Y:%"H(0H<
M###)Y)[\]*ZZJ#ZS9)K\6B&1OMTELUTJ;3CRU8*3GZL* *NC:7<IX0M=*UB9
MKB?[((+F3>27RN#\WK[UA:/\/#I-SHMQ_;U].^DAXHMX4!H&!_=$#L/EYZ_*
M*[:B@#CM*\ 1:?J>CWESJ]Y?#1X'ALHYE11&&7:22H!;Y>.:O>+/",/BK^RW
M:]GL[C3KM;F&:'&<@8(Y]?7MBNCHH Y&[\#"2]OGLM7NK*RU':;^TC56$[ 8
M+!B,J6'#8ZUT&H:7%>Z%<Z5'(]I%-;M;J]O\K1*5V@IZ$=OI7*2^/YT\-7'B
M6/387T:"6X1I/M!$@$;E%.W;_$PQUX!S746%QJ<E[<Q7MI#' %5H9HI"P;/5
M2"!R/7WH YNR^'4,>H&]U'5[O491ISZ:AF1%(B8@Y)49+<8R?6H-(^&4.FR:
M"9M8NKM-%2:.!'C0!DDVC8V!R!M/US^%=Y6;>Z]I]AJ]AI4\Q^VWQ;R(E4L2
M%&68XZ >IH YW1?AW;Z/J[7)U>_NK".1I;33IF!AMF.<;1[9P/2HY?AM!+X=
MGTAM:OP)]2.IO<($63S2VX@87 &[GBNJTZ;4)GOOM]M' J7+);!&W%X0JX8^
MY.XX[# ]ZO4 <OXP\0C1K :>ME=WE[?VTRVPBB9E=U"C:Q4':3OXXQP?:L^P
M\#N=&\,.M]/I^HZ3;"$O" Q*,%WIANF2HYZ\'UKN*K7-]#:W%K X<R7,ACC"
MKGD L2?08!H Y6S^'\>GVMC!9ZQ=QBQO)KNV9HXW,?F;LH"RGY<,WUSFKNI^
M#UU'Q.^M_P!J74$CZ>^GF*)5 $;'=D'&0=P!SGMZ58\+Z[<:['JKW$$<)L]2
MFLU5&W9$>!DGW.3VQD#M6]0!Q]KX"A9[A]9U&;5G>S^P1/-&J,D.<D$K]XYP
M<GTJ*W\ 3+JVBW][XBO[YM)9S LR)\P((PQ R>,<]>.U=K10!P+?"NP;PQ+H
MW]IW:L-0.HVUT@59+>4G.5]1GU_F,U*_PWCF\+7>E7&MWMS>W4T4TNI7&'D)
MC<.J@'@*".GN?6NVE8I"[J 6520&.!^)[5SFG>(M0UCPC;ZKIME;W%Y)*$>W
M%P-@ DVOAQD<+D^^* (HO!0'B&+5;K4I;P?V6-,N8KB)6^TH&9MS'L<MV]*9
M8^"'MXK*RN]8GOM*L91+;6D\2$@K]P,_5@O8>PZXK<\0:J=#\/WVJ"$3&UA:
M7RRVW=CMG!Q5:UU?4[R7298=+1K"\M_-GG\_F!B 0NW'S YZ\4 8I^'^?"EW
MH7]ID+<ZC]O,P@Y5O-$NT#=TW #Z5=TRVU?_ (3S5;YI9_['EMTB$<_R@3I@
M9C4\[""V6SR>W&3N:9JMEK%I]KT^X6XM][()$^ZQ4X.#WY[U<H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "F2B0QD0LBR=BZE@/P!'\Z?3)9/*C+['
M?'\*#)- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** .%\96MM>>/O!$-
MY#%-;F2]WI, 5;_1SP0>#]*Y#4F@TJPN?)>2V\/0>*XMS1J3;Q1>7AAL "^4
M)-N1TS[U[%=V5I?P^3>6L-S%G=LFC#KGUP:!96HL_L8MH1:[=GD",;-OIMZ8
M]J .5\%-8'5-<_LJ^CO+)WAD+VL2+:K,5(<1E"<MA4+#/&1Z\\Q#;IIOC6*\
ME%O?:?>:],8KM1FZM;DAH_*?J?+RI QT&TG KU*UM+:R@6"TMXH(5R1'$@11
MGKP.*ACTC38;QKR+3[1+IB6:=85#DGJ2V,\T >3PQ+-\)[74[<QIXIAO"8IP
MQ,QNO/(V9/S,"#M*\Y':N@^*RN_@?31>A!.=2LQ($)P&+C=@^G7K7<?V1IOV
M[[=_9]I]KSN\_P E?,SZ[L9J2\L+/4(A%>VD%S&&W!)HPX!Z9P>_)H \BO!9
M^'O%GQ$"I+;V;Z;;S[;%TC;E=K$<\,3DDGGD^HRR)#9>(M8TVXET\1/X;93!
M:G]VV <;O[SXSSCI7K1T32C,\QTRR,KKM=_LZ[F'3!..13(M TB ((M,M5"0
M&V4"(8\H\E/H?2@#S6?1]/3X;Z+>0[;;4-1GTU9+B64JSE)% /7@A2PR.W6M
MBWT;3+'XAQZ)-I\*Z.NE236,$JAX3(\V9C\V?GY7@=%/;-=K)HVE30P0RZ;9
MO%!GR4:!2L>>NT8XZ#I4EWIEA?HB7EC;7*)]Q9HE<+],CB@#Q^TMK]O E_JT
M$8NUT#6Y9M,FEC!=K**3#*K,/N;=P&#QMP.@JS<NMQK%S80V[KI_C;_CVD6W
MVE I&]V! .3$&<'_ '21S7KGV6W^R?9!!&+;9Y?E!0%V8QMQTQCC%)):6\US
M#<20QO-!N\IV7)3<,'![9'% 'F1TRQU+XP:SH=Q;QR6\WAU8]Y&70!T&!V[@
M].JCISF/PA:WT^IV?@^ZME:W\*3%[BZ91B8D9M]HZ_=8DG_9Z\UZ#J6EM';W
MEWHMII\6M.A\JXFB W-_ML 6P:-"T=M,2[N+F1);^^F\^ZDC!"EMH4!02<*J
MJH'TSWH P?&$MO\ \)9X4M-1E9=.N)Y@T9($<DP3,8DSVSG [MBO/M5@MK?P
MEX^CMDC2%/$=MY83HOSP9Q^9KVR_TZRU2U-K?VL-S 3DQRH&&?7FH?[$TD6[
MV_\ 9EGY#L':+R%V,P& 2,8SB@#B/$<6CP>,])TQDMK>"&VN+R47K 6I25L.
M0IX>3.3C@ ,?6N8TN,0_#/PKXPE07$^AW4DD[XW2M;&61-JGJ0%92JY P!7L
MDNG64\]M/+:0/+:Y\AVC!,7&/E/:FV^EV-I:"TM[2&*W#^9Y:( N[=NSCUSS
M0!Y*?#MV/$&H^&FA%K;^)Y8]0W0KC[-!$RF2-L9&YL <$C+GM6-KMG8S7GQ6
M<P0,UI!;26[!1F&0"094]CVXKWLPQ-.LYB0RJI59"HW 'J ?3@52_L+2")@=
M*L<3G,H^SI^\.<_-QSSSS0!F^&M>M+FQTK3I[U'U673H[IHC]YD/&[TZ@_E6
M!XVBM?#OB72O%GV![D3;M,NX;>$/),)?N?+_ !G<H7D]#74KX=M4\0V^JH(T
M6VM?LT$$<*J$R22<@9QC@+T'/K6I-;PW 031)($<.H89PPZ'ZB@#R/0O#ERN
MJMX(N!&MK9:A'K$LB1_+)&?F$0)_Z:<=CM7ZBN7UM(3I'Q!9E4K%XFMV!Q]T
M;P"1Z<9KZ#6WA6Y>Y6)!,ZA&<#E@,X!^F3^=5ET;2TBN(DTVT6.Y_P!>JP*!
M+U^]QSU/7UH X>UL-)U'XFWMK+:6ESISZ!;L(GC5X6_?2'.#QWS7.^&]2;4+
M_P  1ZK,LNDR:,R1;US$]TN$VL6'+!0>/7ZYKUH:+I0.1IEF#Y?DY\A?N?W>
MG3VZ4HT?2Q9&R&FV8M2VXP"!=A/KMQC- 'E$D<-A<S&-H%T73O%-LUO,2NVW
M5QF7#GHN\@<'J<=*B\8PV-S#\3?(-L_F65A.NSGG#9;C/)XY]QZUZ])IEA+I
MQT][. V17;]G\L!,>FWI2MIMB\4\36D)2=!'*"@^=0, 'U '2@"@?[+;PQ>?
M8_LALS!)O\G&P_)SG;[5Y5X>M[6\\,_"J*XBAG#37"-%+@AE,4F[()Y' X__
M %5[-#8VEO8+816T2VBQ^4(0HV;,8VX],57CT+2(7B>+2K%'A.Z-EMT!0]<C
MCC\* /-WT&#4?!_B6UTKRXY=*U>6[LDCY5)(\.%P.QY&/>J&J7B>(/!&J>,]
M7BN+>VU&WM[.V@B=8Y8U#X<L[\*&<GGIM S7KUKIUE8M*UI9V]NTIS(88E0N
M>>3@<]3^=']G67V 6!M(#:8V^0R ICKT/'6@#Q6WFDBN/B3:&>T$+: TJPV7
MRVX;RY!E!T/  S6KI1VWGPG9=H?[%=@$_P#7N,9_&O3_ .Q-+R3_ &=:G,*V
MYS$IS&.B?0>E*^BZ5*D*2:99.L Q$K0*1&/]GCC\* /#_$=]IE]\&;ZZO9[5
MO$8NW:X=RJW(E64@9QAN%"X']W;3O$VI:;=/JMXJ^7-%JMC"SW'^N66,JN4Y
M^6+:K'/.=W3GCVR70])GGFGETVTDEG 65VA4F0 Y ;CG\:=+HNE323R2Z;:.
M\ZA96:%27 Z G'.,#\A0!PVD6VFP?$7Q6SKIZ37%O#+;^4 K,K(Y+#U8C.6'
M45Y]X=2(Z7X @8*T9U^\C96YRA)!!SU!'KUKWR72M.GN7N9K"VDG>,Q-(\2E
MF0\%22.F.U11^']%BD1X](L$>/E&6V0%?IQQ0!XM<21V/@[Q-I]JPBM+/Q:$
MBM0Y2.6/<G[@'. #@]<"N_\ !-M!-XCUK5K>.V@M[D1"&U22-I(L+AB0A*KN
M('0G..:T?$7@VWU*UMETVWT^W-O="Z>WDMAY5TRJP59-O(&3UYQZ'I4FA>&F
ML]135;JSTVRNA 83!IJ%8^6R2QXW]!C*C'- ',:E%;P>/O%C".S2XET5&A81
M@2EMLF[!/MU]L>E<MX=BAMM+^&E_:P(VI2"6(S$@L\8C;"$@YQG& 1@<\CO[
M3/H^FW5V;NXL+::X,9B\R2(,=AZKSVY-,_L'1P(1_9-CB$YB'V=/W?.?EXXY
MYXH \B\$'3;W2-"O+[64'B*#4CY]N#_IDCM*5*N2VYEV%6(QT6NI\=:?;:E\
M1? UM<,RH[WGF>6^TNHB!V,>ZGD$=P2.]=TFF6$>H2:@EG;K>2*%>X$8WL!V
M+=:2XTK3KNY2YN+"UFG3&V62%69<=,$C(H \BEMM(M/'&N^&M5N['3-.ATZ*
M+2Q>1AXT@(8RA&D(^;<RD]3\OH*FTVQTS4OB39Z;>1)>V,_A:!6%RG+@.^&(
MS@' !SV[5ZQ=Z;8W[Q/>6=O<-"VZ)I8PQ0\<C/3H/RILNDZ;/<O<RZ?:23R+
MM>5X5+,,8P3C)&.* /+/"]G9P^$OAUJOEP_VC]J6 W,AVN8FCE&PL>2  H /
M' Q5/4KVQ>>QUE+BVBBB\4QYDE&;N9@S(RN4'RH!D@'LHSR17K1\/Z*8EB.D
M6!C0EE3[,F%)ZD#%*=#TIIYYVTZU:6X97F<Q EV7!!)[X('Y4 >9ZBEI_:GQ
M4'E1O%]ALW55(7GR'.0<CG)SUJW;V-OI'Q"\'+;;3+<Z1-'=7!'[RY*I&%:1
MA]YN.I]Z]"ET/2)Y)9)=+LI'F_UK/;H2_.?F..>0.M.CT?2XIHIH]-LTEA7;
M$ZP*&0<\*<<#D]/6@#P31?)/A[PQ"PP&\:. 5.,+GD<?A^56=28Z=HWQ'@L+
MG[!##K-OY<4+&-2#C*#;P-W3T]:]N_L#1O*6+^R+#RT;>J?9DPK>H&.O K)\
M3^#[76]--M:P64#-<QW,ZO;@I<["2%DVD$C)ZYXH P_!]K8WWB^^U>WM+:UB
M-I#"EJTD+R>8F<R 1DA1A@N<Y)!Z4FI66GW_ ,6WM=1BAE@FT?#Q3 %' ?/*
MG@X.",]*OZ=X.EFU;3]5U&PTG3)["1V2+20V)05 &]]J'')^7!' YHO?"EWJ
M7Q$&K7VG:7<Z2+7[,!-*7E'?=L,>WKQ][ISGM0!YY9P11ZQX&LEN+FXLHM6U
M"VMI;HC<T"J%7GH5ZX/2NQTK2=)7QMK^B:E9VWV"ST^UBTZ*<9"VY5C(03_M
MGD]>!Z5W#Z%I$@A$FE6+"$;8MUNAV#.<+QP,^E/OM)TW4VB:_L+:Z:+/EF>)
M7VYZXR* /(H;4:5X7\*>-;AFN#HTTUM<2??+VAF=%8$$YP-I!R1@G'6M7Q9I
M<MK\*M:OKZTMK74+^]ANY%BV@IF>,*I;NP3@^I+8ZUZ7)86<EB+)K:+[*  (
M0H"  Y  'I@4Z[L;2_A$-Y:PW$0.X)-&'7/K@T ><>*8HX=;U#5&@L-0T[S[
M>.Y"OY=W;2*$VE'SRH)4[>.K=<UE>(KW4;";XJRZ0SBZ7[%M\L9* P*&8#UQ
MFO5'T329+F.X?3+-IX@ DA@7<H P,''8=*GBL+.&[DNXK2".YE&))EC =_J>
MIH X2>#2K77/"T^AVML5OH7@NO*0D/:^5NW.!U ;;RW]['>N0T&WMK+X??#?
M4K8".^EUB""2Z!Q*T3-+NCW==AXRN<>U>PVF@:/8+<+::79PK<Y$P2%1Y@/4
M'CD>W2G?V'I!BBB_LJQ\N)BT:?9TPA/4@8X/ H X* K9>+H))K6SO[*]U606
MMW%$5NK2;)+))D9V<,O;L.:U/%<D$_CGPY8:M$C:0ZRRYF'[I[@ !%8D[2<$
MD*<\C/:NI31-*CU)M233K5;UNMP(EWGKSG'7D\U-?:=9:G;FWOK2&YA/\$R!
MA^M 'AGBFQBM/"_Q#L8DCETRUN[>2RP"R6KL\>^./(PO4\+P 0*]:FT^SA\!
M74$-I D4FGNSQI& K$Q\D@=36J-'TM;(V0TVS%J6W& 0+L)]=N,9JU##';PK
M#$@2-!A5'0#TH \HT.TM#X<^&@C\B-SL:91@&3-NP.X#KGW_ !JMJ#P1Z)\3
M-%AM;6&PT^6*2VBBB"K&7B4M@#@<C/ ZD^M>GQ>&]$A$832;(>7(TJ9A4[7;
M!+#(ZG Y]AZ5,=%TIEN5.G6A%TV^X'DK^].<Y;CGGGF@#SGQS9K#=ZEJ$-MI
M^J6*VD"75H#BYMH020\ /R]/F' Z=3P*[W6-;73O#$VK(AW>2'ACD&"7;&U2
M/7)'%277AS1;Z6&6ZTJSFD@V^6[PJ2N.@SZ#TJW>6-KJ%OY%Y;QSP[@VR1<C
M(.0?SH \:O\ 1_$'@C2]"\17BVS0:+</)=M;2,998YV/F;MV,_,P.,]AZ5L^
M,M6@_P"$[T2626'4M+N-,G>&U29-I9MNV4[V",,' .<\\ UZ=<V=M>6YM[F"
M.:$XS'(H*G'J#P:XO7_!EU/K27UAI^BW]JMLMO'8Z@&B2WPVXLA56SDXXP,8
MH XJWT0:?+\.],U2Y@OYIKJZ%Q)#+YB3?N\<M_%C..?4UH/IGAZ#7M<\+:CJ
M$>G_ &>S@BTZ6]524MA&"6A=L88.6SCT'H:[GPYX/LM&@<RVMH9'G%S'%''F
M.U?:H(B)Y'*YSQGT%;5[I.GZE+!+>V4%Q);OOA>1 3&WJ#VZ#\J /*X%T;6I
M[[2=<OHXG;2;:*QN=4B4SRQ&+YIE+GY7WGG'=5//!J+2[6VO_&VHP:A;R75J
M/#D!C%\JOYFT$%SR1DX!S[UZOJ&BZ9JS1-J&GVUTT3!HS-&&*GKQFG2:5ITM
MS)<R6%L\\L9BDD:)2SH>JDXY''0T >2:/:VT/AOX;:M$-NH3WL,<ER\I:5HS
M'(#'N)R4Z?*./:DN9]#OH_$3ZGKDEGKUAJKRLXA5KI2K8A2#/+(5"@+TR6SP
M<UZLWA_1GMHK=M*LC#"Q:)/(7"$G)*\<'('3TI[Z)I<FJ)JCZ?;-?ITN#$-_
M3'7KT % 'EMQ86-Q'\4+B2V5I(HEGA#X)AE%KD.H!(60-W'.>]6M+@L;GXD^
M&+R_BMY9Y?#"3&:=0S/,)(@K;CR7R>#UKT;_ (1_1\W?_$KL_P#3"#<YA7]Z
M0<C=QSSS]>:<^B:6]Q:W#:=:F6T&+=_*7,0_V>.* .;UM[:Y^(FE:9K,$,FG
M2V$K6BSKN26YW+N4CH2$Y&1_$<9/3SNZ9;.^M;:QNIIM+M?&4-O:X8A(D8*)
M(D/]P%F7 X(^M>VWVFV6IPK%?6L5PBMN42*#M;U'H?<5%)HFE36\%O)IUJT-
MNV^&,Q+MC;.<@8X.: .>\16&G>&/ACJ%C#+=V]A!;NBM"P:5%9CP"W^]CGH*
MY[PC S>/M8TZ]M[!;6728&>TM_FB89P"XZ,VW@G%>EW=I;W]I+:W<*36\J[7
MC<9##T-4K7P[HUB +73;:$"!K<;$ _=L<E?H3S0!XZFEZ:W[/6I2BRM!.)YU
M23RU# _:F4 'MP2![&NJOQH<7CN?1M1.E6-E_9R/;0W,$8BD=W8R%0Q +?*,
MX'3K7=1Z#I$5C)8QZ;:+:2-O> 1 (S8 R5Z9P!^5)J&@:3JUO%!J&GV]U'#C
MRQ,FXKCT)YH \NTZ6Q'C'1]-U;4OMN@-H,T=I<WY&RXE\T9< _+OVA@#U*_6
MJXL/#W_";> DBF_M#3XH+R**>]7<S&-AL))&2 Q.TGCT]_7KW2-.U*TCM+VQ
MMY[>)@R121@JI P,#V!HN]'TV_:U:[L+>9K5MT!>,'RC_L^G0?D* /)]3M6O
M?"OB.(S7<4A\8;4E27RW3,D0!!/.,'C'MZ5LWRO8^+_&D.F7L&F%]%2X+'"1
MQSMYG[YAC&>!D\D]Z[>;PUHMQ:SVLVFP203R^?+&RY#R9SN(]>>M5O$?AJ+6
M=-U!;7R+;4;NW-O]L:$.=A(RI]00,?K0!PWAF"UU?Q)X7N[*"VTV/3;207<7
MF1;KZ1D 3"HQ+;2'?+ $%NF2<=/XGTS1KSQ?X>.IZ=8SM(94\RYME?.$)5=Q
M&.I)"YZY('6J&D^";C^T;>ZO-$\/Z6]O+'*LVFM))(VTYV_,JA0<8)YR"1[U
MVE_I=AJJ1)?VD-RL4@EC$J[MK#H1[T >%ZU:)9^"/%FKPW,GVZ'Q3+]GE5SF
MV_? 'RSP4)!P<=<"NHOET;5_$'BVPUW6([.X0JL#7(.^"#:"'A+G"_,"<KW
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M=WXSU(]S71Z?8Q:;IUO90#$4$:QK] * +-%%% !1110 4444 %%%% !1110
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M@2$H95EM75D1_NR$8^X3QNZ9K5\4R3Q^%]0>WTY=2;R2&M&./-0\..AR=I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+PPFYF\PHKL'?!QW*KG/]T5NT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 445!>6=OJ%H]K=1^9"^-R[B,X
M.1R.>HH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HK-.NV!US^QXI#/?*N^6.(;O(4C(,AZ
M+GC ZG/ Q5R[N/LEI+<>3+-Y:EO+A7<[>P'<T 3454TW4K/6-/AO["X6>UF&
M4D7O_@>V#TJW0 4444 %%%07EU%8V4]W,2(H(VD?'7 &3B@">BL,^+=)&I0:
M>SW2W4\+3QQFSERR @$_=[9%0:?XUTS5/$-MH]H)7DGLFO5D*X 57"%2.H8'
M@CVH Z.BJ&J:HNE_8MUM<3?:KI+8>2A81EL_,_HHQU]2/6K] !116;8:]I^I
M:IJ.FVTZM=Z>ZI<1Y&5R,@XSG% &E1110 4444 %%%% !1110 45$;F!;I;4
MSQBX92ZQ%QO*C@D#KCD<U+0 45G/K,">(HM%,4_GRVSW*R>6?+*JRJ1N[M\X
MX]ZT: "BL[5]9M]%2T:XBN)!=745JODQE@K.P4%C_"N2.34=IK]I>^(]0T2)
M9?M-A%%),67"XDSC'K]V@#5HK)O?$%K8^(]*T21)3<ZDLSQ,%^4"-06R?Q'%
M:U !1169I>N6VK7FI6UNDJMI\X@D,B%<L5#< ]N>M &G16;<ZW;VVOV.CM'.
MUS>1R2HRQDHJIC.YN@/(XK2H **SM=UFV\/Z-=:I>+*T%M&TCB*,L< $]NG3
MJ>*AA\06UQJUC8113,UY9->H^WY50%1@^YWB@#7HHHH **** "BBB@ HHHH
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M1965<9$432,<G'"J"3^ J:JFIZC;Z3I\M]=%Q#%C=L0N>2 .!R>2* +=%%%
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M(#$S9BPZXP%RI&1]:?XNTZ72/$&JV_@]%MTGT&:6_6V8?*0_RO@MC=C>/7%
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MBUQ< &Y7(;>7'9>$&#SP/:@#WI[NVC<H]Q$K!@F&< [CR!]3Z5#JEV]I83M
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MCUH ZY;*U2S%FMM"+4#:(1&-F/3;TQ4:Z5IRV)LEL+46A.3 (5\LG.?NXQU
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MI[XKE_!_C[3]*T'3+#6[NZENI[NZCENY(FV1M]HD"B5C]TD8P#[4 >G !0
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M4/<[E(]C0!N'2]//V?-C;'[,<P9B7]T?5>./PI]QI]E=NKW-I!,Z A6DC#$
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M[\;:79:Y_94D5X9//CMS.L!,(D<95=_3/\JWKJYBL[26YG8K%$A=R 3@ 9/
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M-(VFW5J"AVW#6X)=%;&#S@?C707:W.N>*M U4:=>VL.GV\DUP9X&!S(NT1J
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MDB+#<P'4@=\9%34 >2^+] U37Y_$.K6FG7"Q+%:+"DD966X\J42N43KT& "
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MC<&.<+C=GG' -=[10!7U"SCU'3KFRF_U=Q$T38]&!!_G7DMIX6\31^&]/NY
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MSVYZU%=>';Z/QC-XAT^6U,DUD+5H[A3\I4DJ00,]^: .?3XL6][I^D/8:?\
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MCGW?Z*S @LH'!SGKUIGA_P %:U8:UX>U2\O;8G3M*:QEA3=EB<$<\Y ('Y4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_6@!:*0LHZL!]31N7.-PSZ9H 6BDR,XR,^E&Y?[PZXZT +12!@20""1UHW
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MQR7%ON\J1E!9,]<'MG% 'D&G7;VD$D%R$'AR#Q=>6]VK#*01 XA0*.B>80,
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M%93V<>EVJV\YS+&(@ _.>?7D4 <'JVC02:3X9&G3Z;%J5RL=S]EU",M%J+)
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M7\(7%U:PNRZNJ&1T7(3RY"02?X<@$CVKK;?2;"TO9[VWM(HKF?\ ULJC#/\
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MWW(>>0<#\A7>?#VRM$U?Q<YMXDGB\03^60H#*ICCZ>W7]:ZP>'='6U@METZ
M06[^9%&%P$;^\!V-31:1I\.IRZE':1K>RJJ23 ?,P4$*#] 3^= %VBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,[4=:M=,N[2UE6:2XNQ(88XDW%@B[F_2N.U#7Q?^-O!-]ITU
MV;2\BOQ);AF7S-D8(5D)QN#>O.<>E3_$*![BZTX&RU,K'%/)#J.EI*\]I, -
MHVH#E7Z$'K],D8NEIK]UXI^'[:KI=TES;6UW+>7"6Q6)#)'M4.PX5SMR5/<C
MUH [2W\9Z1=:=;7D33$W-RUI' 4Q*9E)#)@G@C!/7I7'_$_Q.E_\+-6NM)NK
MB"2&Z^Q7 !,;QN#AXSCV/8D'-4K*UU:#1$B.E:KY<OB.X=_(MRLZ1')5DWX*
M*QX+ C@GFL36]&U8?#CQ?I,>AZJ;J3Q \\$8@DF,L;D$,K8)<84Y;Z9.30!Z
M0TEW%\78[<7=TUG-H[RM;M(QB1Q*J@A>@)&>N3Z8YIGQ$U8Z)%X?OS=W-M"-
M8ACG,+/AXR&RK*OW@<#C_'!9%)/>_%Z&X33K^.UAT5HVN9K5EC+M(C!0Y&,X
MZ@'L?2K7CVUO);71;RTM)[I-.U6&\N(K=-\AB4-DJO5CR.!R: )+#X@Z!J%A
MJ-U'+<QG3F5;FWFMG29"QPOR8R<GIBM33_$%GJ&IW&FA9H+ZWC65X)EPVQB0
M&R"1@D'OFO/[_0=;UNY\4:_IVFO ;L6@L[:<>5)>"%@6\Q7^X&QMP<' &0._
M0^#YSJ^HR:L/"+:$@A\@O<P^5/(V<X"X'R#U/4_2@#?U/7K33;VVL'CN)[NY
M1Y(X;=-S;$QN8\C &X<GZ#FN$^'GB[[/X5$VLWUU=7-[JL]O9QR2&25\,<(,
MGC !ZX_6MGQ#-?:#X\L==CT:\U*RN+%K"3[#$))87W[U)'7:>03D 8&>U<#H
M7A[7K/PY8:O-X;N;@V.L75Q+ITR[99(7R-RKGYB#V/7J,C&0#LO%_BZ+4?!$
MU[HE[<03P:C#;3A28I8G$JAD;'Y>AK<?5+.R\6:S(U_?RO:Z?%+/9*K/'&N7
MPZ*/XB <@#/ KD/$EE=7?@:XN[3PS)IZWEW:3)8VUH6N.)-SO(D8X..V,C'/
M/ U],G=OBWJDSZ=J0L]0TRW2&Y>QE6+<N]F5F*@*<-T..>.O% '11>+M+GTC
M2M4A,SVVJ3)#;$1\EFSC([#@TU_&.E17R6TGVA$>[-D+EHB(?.'\&X^_&>F>
M,YKFO"?@^_TW5+VTDN9XM.TR6==-QG#"=58N,\?)DJ",_>85D>'K.\L1%X1O
M/!QN;VSG+IK$]J&M77=O63?MY8!L8SU% '<6_CG0[K4!90W#O-]LFLF 0X22
M)2S[O084X)ZXXIVG^-=&U&[M+>.2:(WL3SVDDT11)T7J5)]N<'!QSBN0\-V=
MWK?AKQQH[V%[87=_=WC0SW%@]NDL<F5C()49XZ]^<]3FF>'[:YU+3$\/3^#9
M-/OK&T:TDU66W5$!\LINB<@%MQ R1V/- &IJ_C"WU*_\,MI4MZ+:ZU58EN$)
M2&X0!MP_VAD=\9QD9%;OCGQ%-X5\':CK%O;F>:WB)08^56/ +<C@$CI7"Z%<
M:M;>'?"WAZZ\+ZJ+S2M1@AN)OL_[I57?^\1^C+@<D<#/7D ]A\3-/NM4^'&N
M6=E!)/<R6_R11J69R&!P .2>* -*Y\36MI<VUF]O=/?7$;2QVL<8+E%QN;K@
M#GUJYI&KV>N:>M[8R%X2S(<C!5E.&4CL0>*Y%=2O+;Q'9>(IM(U0Z9?6/D.I
MM&DGLG5B5!B0%P'[\'!VYQ6OX-TF73K?5+N5)(O[4OY+U+=Q@PJP4!2.QXR1
MV)- &=?>)I-3E\7Z9';W5JVC6RLLZR;&,C1,X.5.<8VX'?G-+X'\16P\/^%]
M(N?/6]N-'@GCDD7Y)0(UW8;/)YZ&LFYAOK#Q-\0A+I6H/#J=E#+:W$%N94?;
M;^45&W)W;^-H&<<\#FJVCV5]'=?#E)-/OD^S:48K@M:R 0N(@N'.W"'(/7%
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M<SV6B:SIJ7'AVZL5FO[1H!'*S+CD_P".: -?6/%L&L:QX.FT>]U"**\U$A0
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M23M')#&$,;! 2-W4'IZXQ0 _Q-XI%S;^&1I,UPUGJU]%FXM6"F2+!8H#U!.
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M?BW2])>^6X:9A8QI+=-%&7$2N2%SCZ=/QK,\#V\#_;=3M=!O-(BN0B%;\O\
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M* "BBB@ HHHH **** "BBB@ HHHH ***9++'!&9)I$CC'5G8 #\30 ^BBB@
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M 'AZ4^P\;ZE=FUF_L?SK>[LWN8Q )"\;! RHQ*A3N&<$'MCG@D [FBO.-/\
MB5?7?A:XUL:;:W*PZ?)=R0VLY9X9%< 0R*5RIP2<]]C<"NA\,>)Y?$$S;8;>
M:S\A)$O[.;?$SDD-&<X*N.#CG@B@#IJ*XOQ-XQU#0[^^2*TM?L]E:&YQ<.RO
M=X!++%@'E0O.01R.G6JVI_$&ZM=6-C#IT$>_3TNK4W\_D"ZD;!\M&((R 1D=
M<G\P#O:*S=6O[JQ\-W>H0P1FY@MFF$4K$+D+D@D#/K7/V_B[4(-7LX]:M+2P
ML;O36O06E/F0,@!=7SQP#V_NF@#LJ;)(D4;22,%1 69CT '4UPG_  F^LV^B
MZ1X@O])MX-*OYHXI(Q(QFMTD;"2,<;<?=X']X<U5\.^(M7O[_P =OJ(MIXM,
MF>WBC VKL16(7&.0<G))SS0!W1U?3ETN/4S>0BQD0.D^[Y64\@@]\TVPUS2]
M4D\NPO[>Y?REFVQ.&.QNC?0UY=<ZC=7UQ\+6AMK*"&X59UM8]RQJWD'@#G"C
M/'6MA]:TSP?XG\3L-'T^TBM-/BO9)K=2))Y)'8;6/3EL <=30!Z14$E[;17<
M-I)/&MQ-DQQ%OF? R<"N0O/&]WH\\PU+3U>W2TDN?M%L) BLI $1WJ,DY&".
MO/ Q44D]_<^.O"L^H:;;1-+!</'/"[,8\Q#=&Q*CJ2",>A].0#M9KRVMYH89
MIXTEG;9$C-@N<$X [\ U-7!^._.3Q;X)FM4BENUOIA'%(Q4/F%@<M@X '/\
M*J5W\1M8TF/Q#;7^CVKZEHR)=,D,S".6W9L;E)!)*C.>!G'O0!Z317,6OB>7
M4O%>GZ=I\<,MC)IIOKF;#$Q[F C4'H"?FX/.!GC'-'7;B^;XF>&K-6@%MY5S
M,$\Q@S$*H)/&.-QX^G2@#K;.^M=0B>6TN(YXTD:-FC;(#*<,/J#5BO)/#^N7
M7A;0[Z[M;2%]+3Q5=6UXN#OCC>78C(<@##%<Y[>G6MR^^(%ZT^MG2--2ZBT>
M1H9(B',ERX"DB,H"!@-T/4^F,T =_165JVJW-CX9GU2TT^6[N4@$L=FO#NQ
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MEN-*33Y+U91,;Z0JD$B ;5X&6W9..YP:YO5]:EU^[\ ZU#:0)=OJ$\*QNS
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M?^$UDDT?0]3CM+>.UU*W:>6XN+CRX;8A5(5GQU8G ^E4K;Q'%XDTCPCK;Z3
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M1110 4444 <UXD\/7VKZA:W%M<P-;K!+!<6-X&>"8-@JVT<;E(Z^G'%9EIX
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MR[*6WXVXS\V[I@YSWK0T[5?.OI],N;86EY N]8@VY9(<X5T.!D=B/X3@=P2
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M0S&:/2K193%Y)<1#/EXQMSZ8[5%-X1\.W&FKITNBV+6:/O6$PC:K=,@=C[T
M9'AF;4+/PAJ<4-U!JEW823QVQC5RI(7<D>YCE\$[<@]L=0:XG1)I7T7PSXBL
M=>BBN9G0WD9N))Y;V5AF2(H>%.[<1V7'7'->O65C:Z;9Q6=E!'!;1+M2.-<*
MH]JHV'A?0=+U"6_L-(L[:[E)+RQ1!68GK^= 'E5[Y4WPHTSQ)_:,TVK7E[;/
M)=+<,I9VF 9 N< ;<C:/2M74YY(+_P"*B+<2I'#:6LD8\U@(V:%V)7GY<GGB
MMCQ=X M+O2I4T#2+.*]GO(+F23(0#9(K''H2-W3UYZUU%YX;T;4IYKF\TV"2
M>XA,$SD?,R$8()'MD9[=J .#EN)9_&O@&!IYOL]WI$WFQ>8VU_W:=1GKR>>3
M2:3&\%YJG@9A=2W)U)+HS&1@18EUD!+9[;?+ZY.<XKT'_A'M'\VRE.FVQEL4
M$=JYC!:%1CA3U'05:6PM4U"2_6!!=21K$\H'+*"2 ?H2: /(=7U&:>2_U73[
MR2XCBU^U@MKSS"FQ=RJ\*)D[P,').,[CC.*V_&>JWVC^(_$=W8J%FB\-1.DI
M5CL;SY1G@]@2>A/'U!Z^X\&^'+I[AYM'M&>YE6:5MF"SCHV1T/TJ_P#V1IWV
MY[[[%!]J>+R7FV#<R?W2?3VH \]L;18-5TN^T[6H$L=0M)8S;PW,L[7'R%Q(
M&.-A4CJ1T..N*HZ%%*/#GP]U<SW,FI7DZ6<TLDV=\+1RLZD,<'(0>^0IYQBO
M1+#PEX>TLS&QT:RMS,I63RX0-P/4?3VJ9?#FBI;6=NNEV@ALY/-MHQ$-L+_W
ME'8T 8?@O0M+L6U"XM$D\U-0N8_GN6D*_.1C!X7IG'OG/-5/AG>QQ^&GMII8
MH_\ B9W<5LA(&1YA8@#\2<5M7N@M8C4K_P -VUK!K6H$;YYRQC#8 WE<^@&<
M8S@9S6=-X#M7/AZ"*.".'291<>?@^>S@Y(! Z,Q)8]_QH ;KTDK?%#PE 6;R
M%BNY0HZ%_+VY/KPQ_.K4D87XH1$7-Q^^T64/#YI\M=LT>U@N.&^9N<^G3O;\
M4:!)K-I;SV,PMM6L)//LKDC[K=T;_8<?*P]#WQ5V/2;.:ZBU.ZT^U&J& 1R3
M!0S =2@;&2N<T <EX&A67X67!EW2-</?F9G))<^=*N3DGL!WK+GF^U?LWO+J
M(DG9M'ZMN+%@/D8\$\$*<^W/'-=?JOAZ4Z8ND:$MOIEI<2'[7)'&,^6<[PJX
M^\V3SVR36K)HVFS:0NDRV,#Z>L:Q"V9 4" 8 QTP,4 >?7Q_L'Q7X4NH;V>+
M^T=+N8KV1V+@I# KHP7H"#D\>I]:S_#-Q>0^*O!^)+DPZE;7OFW,DQ)OU5(W
M64QY/E\L<#.17IK>']'>:UE;3+5I+0%;=C$,Q C!"^G%5;7P;X>LC:FWTN%#
M:2O-!R3Y;N"&(R??IT'&.@H \<T6ZO$^'GAW61?WAOAXC6V\QKACF-Y,,I!/
M(QZUO:BS>(?"WQ&O]1DE^UV#WEK!&CN@BBC4[>,X^8<GUR>U>DCPIX?6PCL1
MHUB+2.;STA$*[%D_O >OO3+WPAH&H7UQ>76F12SW,)@G8D@2H?[R@X)]R,CU
MH P-<U2XT?X3V5U;.T;_ &6UC:12 8T;8K-STP"37+ZY+)HGQ N5T>:1A!X:
MDNH58EU#L6!D!)ZD(N?]T=:]8.FV1TW^SC:0FRV>7Y!0;-OICIBLS3?!OA[2
M;N&ZLM+ACN(8F@CE)9V6-CDKEB>/0=AP,"@#B_#%G/)?^&-=L_$L<EI<6_DW
M:"1Y#J$I0L7*M]Q@>2.W2L:XGGM?A-XLN+:XE@E3Q)-AXG*G!O$4C([88UZA
MIOA+P_H]Y<7>GZ3;6\]PQ:1T7J2,''IGT&*D/AC0C82V!TBR-I++Y\D'DC8\
MF<[B.YSWH XGQ%%?>&O'5SJ,,K2VNN:?):6\+R-M2]&"@P<@;@#Z=#^->/3K
MJV\1Z-X5U&198(=*\R%I;J2(W5P2?.(P3DKP0.V[OV])N-+L;HVAGM8I/L<H
MFM]R_P"K< @,/?!/YU7UCP[H_B!(EU;3X+OR6W1F1>4.1T/4=.?4<'B@#@-,
MTJ;53X>L+_Q#<Z@%M[ZUFN;9VB68+L7KW()^\.I4<T3QCX>^*C$OVZ]MM7L5
MMK',C.ZW*#!7DXR^0V>.5/%>@+X?T=;NUNETRU%Q:)Y=O((@&B7&,*>PK%MM
M.\0:IXECGUZ#3TTS3IY)[ 6[$R2.041G!X&$9^!W(/:@"P?"D<O@;_A'GN[E
M7,!471E8R+(<G?D$$X8YQGVKSB+Q.8K;P]XF$%R%T,_V=K:>8Q .?)!VG@D-
MAL\G#8SFO:ZS!X>T@6=_:?8(?L]_*TUU%CY9';&YB/4X!X[\]: .$UBTGTS2
M/#5TQNK:[O\ Q);2SQO.V0))&.QANQPN 5Y'7ZU#<:!IMEI?Q"N[<.TQN)3D
MRE@I:%"P X'5CZGWKTF^TJPU3R/M]G!<^1()8O-0-L<=&&>A]ZK/X<T>2]OK
MR33X7GOXEAN2X)$J#H"IX_3G ST% '%Z-;OI?COP]'#<S2+?Z-(USF1BC,GE
MA2%SA>O85=\1:>=5^(NG:;<3W(T^ZTFZ$\*2%4D^9!CKP><Y S[XR*ZQ-$TN
M.>UG33[=9;2/RK=Q&,Q)_=4]A[4^32=/EU*/49+.!KV-=B7!0%U7T!]* /)]
M.DNO$6E:C<3:O#8ZAI6JE)+F2>0/#''*/+38 !AD!'N3GV.L9H]:3Q3/=Z\^
MG7VEZOY<=P<XMH1LV *&Y#_-SQDD\<<]I<>$O#]UJRZK/I%I)?*<^<T?).00
M3V)! P3R.<=34EUX7T.]U9=4N=*M9;Y0%$SID\'(SZD8X)Y'..IH \^OFGU:
M+Q7=2:K%8:CI=X2ET\LB&TA0*R'RAD,&7)Z\[^@Z4L^H7ESXG\0SK>3[_P#A
M&HYD5&**KLI):.,@LOXD$<=>W?77A70K[6(]7NM+MY;^, +,R\\<C(Z'';/3
MM46M>';2ZMM2N[.PM?[8N+22!+ED&X[EP 6QTSB@#SC11/;^"? ?B..[NI=5
M:XBMC&\K/]ICD+!X^3@<?/D_W*Z7X6:=:V^G:M<Q9,O]JW<1?<V&42<<&KG@
M7P3;Z#X=T=-1L8/[6LH?+,BN64-D_,O;)!ZXSCBNBL-!TK2[VZO+&PA@N+IB
MTTB+@N3U^G(SQWR>I- 'EMSJ-\OB".^@N[B;;XO33VNVEV#RBQ#6ZQY.57IN
M.,GH*V#-;ZM9:WJMYJMSIFIZ5?DR;9C*;:-&RJ[ 0"'7MCG/J*ZN?P/X:N9+
MAY])BD-Q="\E#,Q#3#^+&<#..0.#W!J>;PEX?N-7&JS:1:O? 8\XIR>F,]B1
M@8)Y'..IH \UU74X8?%_BJ6=KR'2[J?34O+FV8+)%&T#;2P*Y"YP"<Y&>.AK
MH=5M(Q\1/#NF07%PEA-I5VK1QSL 0-F#UZ\GGK782^'M&FDOI)=,M'>_4)=L
MT0)G4= _J/K2P:!I%M/;3P:;:QRVL9B@=8P#&AZJI[#VH \O\%:W<:IINB:7
MJVI3_9WO[VS4F4JTXB4".-FQEN&8]025'/&#'JFBZMJ0\5Z-IU]/*VAW-O<Z
M<WGLI"NI>2 G=R,*!R>XZ5Z5)X/\.R:=]@.CVB6PE,ZI&FS9(?XU*X*M_M#!
MJ_8Z38:; \%G:10QR',@5?OG&,L>I/N: /+I_%;VGB"/Q3I:27%GJ]I_9UK$
MSL4>]4!E(7/W208S]WF-OK5R:TGT'QKX>MX"\]U:^'KP@R,7,DN4)R3R<M7<
MQ>%=$@TZRL(M/C2UL9OM%M&K,/+DR3N!SG.2<YZYYJY+I-A/JD&IRVD37L"-
M'%.5^95;J ?0T >7>%+FZU;P]X?\4#68H;]K@+>NURS_ &G>2/(,6 %).TC'
M0"L;5';7/AAI_B&]NY+C4IM:C65E=@J@7&T1[#P H [=>:]9MO!GARSUI]8M
M]'MH[]V#F8+T;!&X#HIP3D@ GO3)/!'AJ7[4'T>W9+I@\T9SL=@<[MN<!L@<
M@9- ',>(8+V_UCQ3 9+FXNH+*)](6R+@VSE6P&*X 8R*#S_"1VII>YF\0V7A
M36W>61-+CD222^>(7<Q!65E(7)*G&,^N14VJ>"1J.JZM-JF@6VIBXE0VLT=T
M;=HXE0!48KAN#N).3D$#L -'3_ &F7/AFTTWQ#86]V]NS-$!)(QMU+;@B2$[
M\   G///;B@#F=.O[B_\3Z-X0O-2>]L(X[J62>&1E$Q1BB0LV 6,8&2<\G!/
M3G=^&4(MU\6P!Y'$?B*X0-(Q9B!'$!DGJ:Z.\\*Z'?6=K:3Z;#Y-HV^W6/,9
MB/\ LE2",]_7H:MZ=I.GZ2DR:?9Q6RSRF:41KC>YZL?4]/RH \QFNY[SX=ZO
MXQ:ZN(]<L9[B6,!R!;F.1@L+)D@KMZ@]<_C5S38I_%OC+6H[B^U*P06FF7T4
M<%P0T#D.Y7D8P>A&.:[<>%M%&IRZ@+!!<2MOD^=MCMG.XIG:6R!\V,\=:FM=
M!TRSUF[U>"U"W]XJK/.78EPO08)P!],4 <YXFWR?$WP1"=QAQ?2$=MZQIM/U
MY;]:J27ET?CH+$W4WV3^Q1((=YVAB[@D#UX%=#XHT:ZU&*SO=,$']JZ?-YUJ
M;C.PY&UU;'."I/XXJ[#HMC_:PUN2S5=4>%8FFWEBJC/RCG&,D]/K0!X_JVJ:
MC/\ LZZ5J3ZA=?;9+A7>=96#N3,X.2.H]J[_ ,4W-U:>/O!DEI&96FDNK:6,
M/MS$R(S,?4*45L8YP.16G_PA'AS^P+70CIB'3+:4316YD<KO!)!/.6Y)X.13
MH='GNO$Z:Q?K'LLHG@L(OO,@?;OD+?WFV@?0>YR 96KE]4^(5KH5W+,FFG3F
MN1&I*B:3?M^\"#\HP?Q%<M?VVJVWAC6S!=7-W'X<U',#_:.9[0;'DMV.2<JI
M(+-DG'2O2M6T'3=;6(7]N9&A),<B2-&Z9ZX="&&<#//-6;;3[.SM6MK:VBB@
M<LS1HH );EB?<YYH \WUW6YY?#^L^+=),XAN&M[6VN?,/EBWWKOEVY&!RRY
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MNH'6)'GM%M8F:*92@Q 2O"LH&"<XP,Y%3Z.GV;5_B!/<VC10"PLHF'EEE+I
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MM4GA0=W..QZGBDL_B%<7.IZ;!)X?NK>TU6!7T^YED4++*8_,V'G*\9 ..2*
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M#RQE%E3[R$CJ*R/"?AD^&M-:*XU*YU._E(-Q>W))>3'"C!)PH' &?7U-;]%
M!1110 4444 ->-)%9716#+M8,,Y'I]*PK'PV]GXTU3Q"UXD@OK>* 0"'!C$>
M<'=N.<Y.>!VK?HH Q;S0I+KQ9IFMB[5$L8)H3!Y62_F;>=V[C&T=CWK:HHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JKJ,DL5A*\,B1R#&&D; '([X/\JM56O[E;2RDG>9(57&9'0N!D@=
M 030!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQG% 'JS.B8WL%R<#)QDT/(D?WW5?J<5Y#X^U2.V\>7MIJ5QY]I-H,J6EM'(
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M@+E2.>23VP>AZ5I>8F0-ZY)P.>_I7EWANYFUBU^&=_?2-+<-%<[FS@-B(X)
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M),>Z6-6QC&>#T/%:FJV]AXBG\?S:Y'&9=*06]JY<QF&/R=ZX((^\S,<]\XZ
M"@#T'P]JQUKPSI6K2HL+7UK%.8PV0I=0< ]^M:3.J_>8#OR:\.B?^U;KPWH^
MJ7VGV.D_\(U!-#]K1A&92 &*$2)A@,8.>,U<L].6]\<>'-&N]4FU.UDT&ZMY
M;A79!*H<H&&#P<8Y'IG- 'LVY2< C.,XSVJM9:E::A]I-K,LHMYF@E8= ZXW
M#/MG'US7FL%@GASQ2][J5M'=Z6]\D5KJEO*QEM67"".8$XV9&..^<]>,9M/T
M33/"/BJ5WFM&F\136JO:H'<CS5Q'@M@ XQG*]?S /;-RA2Q88'4YZ4!U8D!@
M2.H!Z5\_ZG))I^@?$ZTAQ#;P7-N(K=+AF\K<\><<\=>0.,Y'(Z]7-(WA_P 8
MWEQI8(N+CPM)?2ABS[YD=%1L$XP 3P/QH [;7O$,^D:YH-C';0RPZE=-;22-
M*0T9"%AA<<]#W&..N>+]A>7\^H:E#=V"V]K!*JVL_FAO/4J"3M_AP3CWKSB#
M3=,M+OX>ZO;*5O+V;][-O+><7@+,6Y SQUQ[5G^*+6:Q\(?$>19Y5VZI%)&\
M;,I!8QL1G<21\_3@>@[  ]G#*Q(# D<'!Z49!Z&O-I(CI/Q&\1QZ9(EI]HT7
M[4Q9OD$V]OG.>G7FN>\'V5YJNH>";J"64K;6TW]J2FX.R:3?O0<'YF)W/CTP
M>E 'M=5[N\BL]/GO7(,4,32L1Z*,G^5<;X_O)QJ_AG2IMR:-J%Z8[V0$KG S
M&A8= S #'?I6)J&FII^L^(O#MM:2S:#)I+WC1LV8K28*=H7C(W8SC/\ #0!U
M?A3Q%KNO&VN;[08[+3[RR%U#,MP79&) $;J5')!W9'&*L:OXH%MIT\^EPK>R
M6]]'939;:L;,5#-G^+;N&0.^1D4G@G3+.S\%:4EO L:W%E"\H!/S,8UR:\T&
M@VEMX6\9'3('ANK?76AB>.1RX7,1 4YX.3Z-SV/2@#VT$'(R"1UQ2YKS.Z6[
MT'Q#XNFTK[2]Q-HJW@BW%_\ 2/F&\!CCC X '3IS53P58):Z_H>H6FOZ?/;W
MEK(C06JRO)<-MWEI"TC8VD8W<<D+CD8 /5\T@=2F\,-O7.>*XGQCIL=WXO\
M"KRWUS;QRRW%M(L<Q0.&A8X'. 3C&0-W/!&*X^SABL=8U;P=--=3Z%#J]O'8
M0>8279HO-D@W$@E1G)RQZ=/FH ]FR,9R,>M5I]2M+>^M+*28"YNR_DQCDL%&
M6/T''/J0.]>2ZG9W$7P_O(%N(;>>S\01B);2X>2.(-+$I4%F!;;YF""",Y
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MV0F:YU&.*.&?[-)*RL(TEP#L+XV[N1QF@#4M;:"RM8K6UA2&"% D<:#"JHX
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MO[2]BL(HKBTC\JW>+*>6G7: I "^W2FQ>*-%GTZSOX+^.:VO7V6SQ*SF1N>
M ,YX/;BLG5_'FFV=OHDEA*EV-6O8[>%E#8V;L2-]0 1MZY(XH UU\,Z.MX;H
M6*>:;@W1RS%?.(P7VYQNQWQ4-QX-\-W?V[S]$LG^W.)+DF(9D<'.X^^><CO0
MWC#0434F?4%0:8%:]WQNI@#9V[@1WP?RJY_;>G!;1C<86[0R0,4;#*%W$YQQ
MQSSB@#/_ .$'\,?9[B :+:K%<QI'.J+M$JH<KNQUP0.3SP*NIX>TQ+Z&^6W;
M[5##]G27S7+"+.=A.>5R <'CBH['Q1HFI78M+/4899V@^T*@R"\6<;UR/F7W
M'%-MO%FA7C;8=1B)^S&[!8,H,(.TR D %<\9% $$?@;PO%<QW*:%9":.7SD?
MR\E7]1Z?3I4LGA'09H=0BDTV,QZA+YUVFYL3/G.6&>>>:=:^*]"OKRRM+;4H
M99[V#[1;*N?WD?J#C'8\=>#6C?WL&FZ?<WURY2WMXFED8*6VJHR3@<G@4 9>
MM>&[>_M=1EM56'4[FR:T6Z;YR%(X!!R",\\BN#T/P#>PW>G(WA;2M'^SNDC7
M]K>M)*"H'1< 9;!!/H:T;CQK)<ZKX&U**^:VTK4HKB2\B:/:OR6Y?DD9(#>G
M'%=?%XIT.?16UB/48CIZML,V",-G&,8SG/;% %S4]*L-9LFL]2M(;JW)#>7*
MNX9'0CT(]:A.@:8;.ZM#;$Q7>?M.9'+39&"&;.2,<8)Z5+IVK6.K),UC<++Y
M$IBE&"K(XZ@@@$&JFK>*M"T.Y2VU35+:UGD4NL<C8)&<9_,@4 7M.TZTTFQB
MLK&'R;:(8CC#$A1Z#)X'M69<^"_#=W+>RSZ/:N]\ZR7+;<&1AC!./H#QU(R>
M:FC\4:)-IUK?Q:A');7<P@@9 29).?D"@9+<'C'8TH\3Z(;*TO/[1A^SW<_V
M>!R2-\N2-@'7.01CVH D30-,CU)-1%MF\2+R5E>1F(3&-O)Z<?UZU!I'A+P_
MH%S+<Z3I%K9S2C#-"F.,YP/09["L>+X@6-[XPTW1=/4W%O=6TT[7*HQ */LV
M@8_O!LD],5;\/:O FD7=U=:['J,1U&6*.9$(V[I,)"!C)()"\=: (O%NA2:Y
MK'AT2:>+NPMKIYKG,NSR_P!V51@,\D%L\>A]>;\O@WP[-I)TM])M_L9F%P8U
M!7=)_?)!R6X R3R.*D/BK0Q9/=MJ,:PQS_9F+ @B7^YMQG=[8J]INI6>KV*7
MMC,)K=RRJX!&2K%6&#SP01^% &6_@KPU);W%N='MA#<3BYEC52JM(.C8'0_3
MOSUJUJ/AW2-6FLIM0L8[J2R)-NTN6*$XSWYZ#KGI37\2Z.FIW>FM>K]LLX?/
MGBV-E(\9W=.>/2B'Q-H]QI=IJ<5Z'L[R58;>54;$CL<  8SR1B@!(?"^B0?V
MAY>GQ8U'_C\#$L)^OW@3SU-5H/ WABVTS^SH-&MHK3SUN/+0$?O%Z-D'.1VK
M D\<6N@Z9J-Y/JRZN9=:-I;)#&?W!8H/))[E02<^^!FI)/&%KI?CJ_&IZL8M
M+.F07,"R *JEG8'Y<;R?ESF@#K[#2K#3!+]BM8X6F;?,ZCYY6_O.QY8^Y)IM
MIHUA8ZA=7]O 5N[L*)Y2[,T@7.T')/3)QZ9JU!/%<V\=Q!(LD,J!T=3D,I&0
M0?3%8Q\9^&Q,(?[8M3(;H6>T-G]\1G9]: &P>#M!TZ\N-1TK2;&SU.5'"W*0
MC*LPZ@=!SUQUKSS2?ASJ,>FV]C)X:TS3;W:JOK%K?.9(W&2950 8;=@@ @#/
MH,5Z7:>*=$O[Z*RM=2ADN)@[1(,_O APVTXPV",'%5Y?&_AF"?R9=9MHV\UH
M06)"F1?O*&Q@D9Z T 0MX \,S%I+G2H)KB1TEEFP59Y%YW?*0!DC) P#W%;-
MMI5C9W-Y<6]NJ2WC![ALD^80, G/MQ5=_$>D1W:VKWJ"5K@6HX.WSB,B/=C&
M[';.:;_PD^B_;&M/[0B-PMTMFT8R2)BNX(>.I - %6W\#>&+66.6'1+1&CG^
MT)\F0LG/S = >34T_A+0[JWO+>:Q#P7LHFN8C(^V5P<[B,XZ@?D/05S?B'QI
M VN>&[?1]50I/J+P7"*AQ,%!5@&. =K=<&NOUK6++0-'N=5U&7RK2V3=(^TM
MCG X )ZD4 96O^%DO;"^FTO;;ZQ+9-:0W4C,X52/NE22"N><8Z\]:XW2O 5Y
MY^B^7H%KH;V,J23WD-ZTKR;,951Z-SDFNUTSQGHFI:19WZWL2BZ=8DC!+-YI
M7=Y8&,EL>@K7T[4K+5K);RPN$GMV)4.GJ#@@^A!!&* (]5T;3];MEMM2MQ<0
M*P<1LS!=PY!(!YP:IOX2T&34;R_DTV)[J]M_LUR[DGS8\YVL"<'H.>M0ZK=O
M%XMT6!=9BMHV29I+$KE[D!>"/3;UJGHOQ%\/:SIUW?K=?9X+:;RCYPPS MM4
MX'/S$'"]?:@#H+/2[.PD:2WB(D9%C+N[.VQ<X7+$D 9/'3DU5O?#6DZA/<S7
M5JTCW48BG_?.!(@Z*P!P1UX]S5C2]9T[6H))M-NX[E(I#%(4/*.,$JPZ@\C@
M^M5M4\4Z'HMS]GU+4H;:41B5A)G"H20&8]%!((R?2@ N?"^BWFH/?3V*M</#
M]G=@[*'CVLN" <'AF )&1DXI)O"NB3FQ9K%4>P0QVLD3M&\2$8*AE(.".,9Q
MU]:D/B+21#J,IO%V:;_Q^81B8>-V2,9QCG/IS7+W'C:"R\=[;K58(_#[Z$+]
M)'&!N,P0'/4\=O>@!FH^'=1N+NST*PT:WLM"L=0BN(KB.;;F,*&;"#DMYA;.
M>H.>M=!<>"?#5UX@37IM(MVU-"&\\9&YAT9E!VL1@8)!(P/2J>N:]%(/#]SI
MGB&PMK>\N@07^?[7'@_*F.IR16I>^*-#T[58=+O-2@AO9BH2)SR2QPHST!)Z
M ]: *U[X(\-:CK:ZQ=Z1!-?#!,C%L.0, LF=K$=L@XJZGA_3(]=EUI+8C4)5
M57D\U\' V@[,[<@$C.,X)&:9<^)]$L]8BTFXU*"._E956 GG+?=![ GMGK5#
M2O'&CZQXIU'0;2=&GLUC.[=_K&._<JC'.T*,G_:]J .EHHHH **** "BBB@
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M(RJ1RS(NQB0."3D_A7I]% 'CB#[1\+;+P8D$R^(;2XAM3$(CF*1)@6F#="@
M)W ]ZZ+P2+.?QCXR\R%6F.J++$SQ<E5C5=RDCLVX<>]>@T4 <?\ $RTGNO!Y
MD@C:06EW;W<H7D^7'(K,0.YP#Q7&ZMJEOJVO^)=12SNC8WOA4+"\MLP!;=)@
M$8X.2, \YKUZ>6&"!Y9Y$CA127>1@%4=R2>U/5E9 R$%2,@CH10!Y3=:A:7D
MOARQTDR0:G<:#/;6\_D.JP.\2B,,V/EPR'Z8KF_$&I_;/AEIOA\:;J']J:3J
M%K%=*UNQ <,V65NC [3R/4>M>]TSS8C.8?,0S*H<ID;@#D X]#@\^QH \8-E
M;&:^\):UH>I7FKR7,UQ:7@WQPWF]BR22,K#:5/!YSA>#GBM'P+)#,?'OVVPW
MSK>SN$6$IYD0#(I1L<D@8SU.<GK7K-% 'B@M)Y](U2PT::YU?3#X<N5MC=0?
MO[)V0 0;\#(8=CDC;5X>*8[C3?#<(L=1%K/I4EK&]O PGFG41JT!&W*(=H;>
M.N!V!SZ[28'' XZ>U 'CWA6:*;7?AY(]M+&(M'N8"LL3?NY RKC)'!RC8/<#
M-95J)(X;?Q 89)M-TCQ/>7=W$$<N8Y7"Q2*G5L$[N*]W P,"F32QP0O--(D<
M4:EG=R J@<DDGH* /))[V&36?B#?):W$-M>:3:^4[V[*)&*.!CCDDL*S_"S_
M &?Q/\/7FAD5;?P_(LKM&P\HX/!]^",&O:5N;=I5A2>(R%!($#C)3INQZ>]1
M3ZE8VTKQ7%[;12)&)72255*H3M#$$\#/&>F: /GZPU)=&\(>"[_R+QK_ $_4
MKDB(P-Y80ERP8 %N0XPP!QGH<<]5:W/AR^\'W,DEYJCO/JT=Q=3PV[6\UK,Q
M)1UC.2%! '4]SS7H6N^&Y-6O(=1L=9O=+U"")HHYK<(Z%6(.'1U(89'M]:MZ
M3H<6ERSW#75S>WMQ@2W=UL\QE&=J_(JJ ,G  '6@#G/AW/J,QUK[7Y=S;K=!
M;?4Q%Y3WH"@%G7&,J J[AUQTXYJ79/A_XN3ZWJ@9=-O]-6VM[@*66-T;<5;'
MW<YR/6N_BFBGC$D,B21G.&1@0<<=12)<023R0)-&TT0!DC# L@.<9';.#CZ4
M >1Z4IM-;\+S7$;I!?ZM?7MK"Z'-O!.O[L,-N%))Z=MV,UZW'%':6PBMX%6.
M-<)%& H^@["I:* /"(=0BF7PW<+#?+]B\2 W-NEH8H;8OYORJ!]\Y/+\]3R
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M :[3X?7US?Z!<O<[9=E],D=ZL?EK?(#D3!/X<DD<9R5)[UU04!=H QTQ0 %
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MXJM+D^7=7MM8-%'@G=MBD+8/H.F:[_RTW[]B[_[V.:/+3S#)L7>1C=CG'UH
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MGP@X;)&1SU/-5;CP_KWA[_A*WMI;2XTC4DEO6:4GSHY3$%8 # (. 0<\8_,
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MTC!9!@D*Q'(!/(].<:UKXU2^\+Z?K%I8LTM[=+:I9R2;75RY4AL X( +$$<
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MLM;TV73]1A\^TF&)(BQ 8=<'%7** $50BA1T P*6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KD_B7#=3_#_5([))WN#Y6Q8(P[G]
MZF<*>#QFNLK#\7B ^%KP7,GEP_)N;$AQ\ZX_U9#=?0_I0!N4444 %%%% !11
M10 4444 %%%% !1110 4444 8VJZ+>:CJNGWD6K/;1V4IE6!858.Q5D.2>?N
MNP_&L)_AU'-#K,4NK3G^T;W[>CK$JO;7 QM=&]@H'Y^M=M10!Q,WP]-UITR7
M>N7%UJ4TD3/J,T$;2>7&V](P,850V3QR2:OZYX/;69+"]CU>ZL=8LXS&M_;J
MN64_>!0Y7!(!]L5T]% '*#P1%&^CS0:E=K<Z?<R7+SN=[7#2#;)NSP,C(&.G
M:FQ^!8;2XU'^SM2N;2RU.4S7ML%5Q(QX;:QY7(P./2NMHH R++1'LM>GOTOK
MAK9[6*WCLV;,<6PGYA[D$?E6O110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5@>-;JWL_"-]<72V;0IY>X7K8B.9% W':W<C'!YQ]:W
MZY'XGO''\.]5>:6UB0>3E[N$RQC]ZG50"3[<=<4 ==1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<I\2KNRL/A_JESJ-JEU:)Y6^%X]X;,J
M <;ESR0>HZ?A75UQGQ8-N/AGJYNV"P?N=Q,9?_ELF. 03SCO0!V=%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;MHW8QG'-(J(F=J*N>N!C-<4OQ.TXZ#'K)TK5&L66!C,D:;/WIVC&YE+ /\
M*2!^G-='_;UJ?$JZ"L<S7AM/MC$*-B1EBHR<]20>!GI0!J4444 %%%% !111
M0 4444 %%%% !1110 4444 %<?\ %&.UF^'FI1WL<CVS&+>J2B/_ ):H1\Q!
MQSCM785P7QH_Y)+K?_;#_P!'QT =[1110 4444 %%%% !1110 4444 %%%%
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MX^;&?XEKKX88K>%(88TCB085$& !Z 5#?:?9ZI9R6=_:PW5M)]^*9 RM]0:
M.,O/#&N:WK\6NS/;6%Q9:=-;6D4<K2JTTB<2;L+A03CE<G!X'%5M$\,Z]:G3
M9AI.EV.W3YK6XC-[)+(&=D.[?M.[)3IDXSG<<8/H<<:0QK'&@1%& JC  IU
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MVL7V7<MNZ0MNQABI Y[5#9^(["^\07NBP><;NSC62;=$RJ Q(&"1ST[<5K4
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MG2;;7=!TRSMI-.U)Y9K>ZDGVB R [U=2"QPW((R#GMBN]#J690P++U /(I:
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MN=3M//EL',EN?,90I.,Y (# X'!R*UU4*H50  , #M0 M%%% !1110 4444
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M]D%SM#K&B@ LJD@%CDGG.,9Z5I^(_#\'B33XK.XGEBCCN([C,>,ED8,HY[9
MH X/4-2\5+JWBOP_;^((4EM;,ZG;7CQHIB!SB$Y.U5!7[QS@'-6)O%.L:KIW
MA5_M)L8]5MG:4V>UKAY@ORA%.<(.69CP!P2*Z6[\%VUYJNM:BU]=)-JNGG3W
MV;1Y28(!7C.X$D\U3M?AY:6-UH]S::E=Q2Z99M9(RA/WD;')SQP?<4 8 \2Z
MW#H?ASQ+<ZB4T]9OLNK*$7:5#[5E']W)&&Y(P>V,UUVA3W6I:_J^HKJ;RZ7'
M+]DM[8(-@9 N]PV,_>++Z?+D=:YW6M/CT#PU;^"X=-O]<&K+.D3MMVP\J<RM
MQ@ OG/).VNXT?38=&T:STV ?NK:)8E]\#K0!P>J66L:C\1=>MM)U8Z7(-,MI
M!.J"1LAI/EVDXP?7%5=(\7:IXVM+&PM+B[L+M+)I[J:T126E#-%M'F8!7(W'
M'L.*[>7PVI\1SZU;WT\$]Q;K;S( K*R*21U'!RQYK)U#X<Z;<II9T^_U#2;C
M38O)BGLIMK.FX-M?.0PSD\]R: -C0-0O)/#27.K+&+N .EQY,BN"8R03QP"<
M<CL>*XSPWK'BGQ#:Z5XGM)I7M;NZ<36#B-88[<N4!#9W%UQGWZ8%=]H^D6VB
MZ5'I]MO:--Q9I&W-(S$EF8]R223]:YK3_AO8Z5>@V6J:E%IBW'VE-,64>0LF
M<^F<9P<9QP* .*A\1>+&T#4=8?7P3HNO-:RP^0BK<QF=8\$G[H&[C^=;]I)J
M\?CSQ[+'J_[NTMK9TCDB#!089&4*20% ))]\D\5LQ_#VTAT"\TE-1NO+O+\7
M\\C*C,S^8),=,8W*/RK0E\*12:IK-ZE]<Q#5H4BN(EVX!5"@8'&1P>G2@#@"
M-9\0^(/AW,VM>3/+I+WA8VZR RA$W,1G'(;'&,<XZU>?69= E\5?8U5;F^UV
M&QA90/W;S*J[\="1DM@]371KX"CCMM CBUF_ADT:%K>*:(HK21D!=K<8Z <C
MGBGW/@'3[VPUVSN;JZ>/5[E;IF4A6A=2"I0@<8*B@#-%UXNT/2=2ADE%W(9+
M>/3[R^V*Q>5U1@ZIQA2<CUSCM63I]E?6'QSM(-0U)M0E_L D3/&$/,K9&!QU
MSCVP.<9KHO\ A7=M<>';W2-3UG5-1^U)'']HN)1YD:HVY-N !D-SGJ:GM_!"
MQ^(5UR;6+V:^73SIZN0@PF20PP/O#- '5UQ'Q /G:EX4L)OFLKK55%Q"WW)0
MH+*&'<;@#@\9 KJM'TXZ3I-M8&[N+LP)M\^X;=(_NQ[FH=?T&R\2:1)IU\K>
M6S*Z2(</$ZG*NI[$'O0!-JNEV.LZ=+8ZC;I/:R8W(XXR#D'V((!!KA;F_P#$
MES8ZIXGT_6K:+2]+><6UBD8D6ZBAX8N^<@ED?&.@(ZUTDWA>>]LTL]0UV_N;
M965BHVQLY4Y&YE )''([U7F\#6S'74M]1O+:WUMBUW#&5VY*[6*Y'RY'7UH
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MBB@ HHHH **** "BBB@!"0 23@#J32UYK\0]0G'B[P]I%Y>6EGH=VDS2R7D
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MR7<UT6="#YJO*21\K $9 Z=>, ':T444 %%%% !1110 4444 %%%% !1110
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MO'86MHY:*Z+C9Y,1&,QA1]X9)QQ6EH7B'2_$EF]UI=SYT<;F.0%2C(PYPRD
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M?^&+"4Q3:HA<6ZW6(T9\Q,0 PP.GS"@#4F\/Z+<R2R3Z/I\KRJ%D9[9&+@=
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MFMS3-;TS65D;3[R*X\LX<*>5X!Y!Y[B@"_1110 4444 %%%% !1110 4444
M%%%% !1110 5S_C2VEN_#,\,,D\;ETPT$XA?[PZ.67'_ 'T.,CVKH*SM;NK2
MRT_[3?7C6EM&XWR@D8SP.1TY(H T:*** "BBB@ HHHH **** "BBB@ HHHH
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M_EQ+(X4R-_=7/4^PJ:@#ROPQI5\? /A+0YK"\M[VUNXYKA@A0VZHY))8^O3
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M_M>FR.Z2ER01(7)8R97.2>01P,<@%K3?'4]\=5FFTC[+9Z3>3VUY,]P&VB-
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M8EW=9'R<LW QC '/K63!X)\3W<_AFYU>]TYY](MKJ%O(1E5@Z(D8[Y/RDDX
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MI:V"S"3,P ;.\#&W:0<X[XZUGVOP^U:TU3PM<BZL95TR>>[OG(9&FGF_UA4
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ME]S*>,\>F.>NT2&Y@T6T2\N);BY,8:627&XL1DC@ <9Q0!!X?\1V/B6WNY[
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MR@A"?-9?E!5CQGWQQF/27UR_\>^'CKSFTU$:+<"Y@MY0RB02H,\94$C!(!-
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M:3RXF<1QEMH9B!@#/%;U>87?]H:'XA\7ZK+KT<UM;6<=U-9R1(WF@*^(^?N
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MX/-=)IU]'J%C#<*4#O&CO&K9,990V#^!%1:-/?2Z5 ^K"VCOB6618&RF0Q
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MG[5%\D>7?S/,&3MZ9)_.N]HH XX_#K3+BZ\0R:A<3WD6N,KS0R!5$97[I0J
M00 .<]J33?AU9VFF:A9W^J:AJIO;=K4S7D@+11-U5<  9."?7 ]*[*B@#D-'
M\#2:9>Z=>3^(-0O9M/AF@@,P0#RWQ@$ <E<#GO\ @*II\+[#_A'CI-QJ=[-L
MN3=VUR D<MO*2264J .2>AXKNZ* ..@\"36UG:)%XFU;[7;W37)NV9&>3*[=
MC C:5P3QBJ]SX*N;;5-+N]-OKP7*7S7=[+N1(K@MM#&51@G"KA0HQSS7<T4
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M_&EM:Q>"[H21V_E6RHR&Y&4CVLHR2>@ ZGTS6VVF6#WPOFL;9KL=)S$ID'_
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MDAB4LJ\_*#C(')X]Z /!-">QE\,_#M[T1-##K-S%(TX4*H^=@,G'RY(//?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS@5<IF1"@49V,>&/8'N: .]CECF3?&ZNN2,J<C(."/S!%/KBQ,-!^)MMI]N
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M!R>PYH -"TBXT[P;9:-=-#Y\%F+9VA)*$A=N1GGWKC3X!UYO#?AG2I)]+?\
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M%,TB[&FE.W.0,D*!C)[=N_HH X:_\'ZK/X;\/&WDL8]?T#8;5V+/#)A-C*W
M.& !XY! YI^I>'_$^M>$-5M;^ZT]M3U&-8A"I<6MNHSR."S,<Y/8X Z#GMJ*
M //_ !7X1UCQ'9QVSV>CR,MNBPW+3RQR6DVTAV0JN6'3 )'3D4LOAGQ7HWBF
MYU#P[?6,UMJ<:"]6^# QRH@42C;R<@#CUKO)IHK:!YIY4BBC4L[NP55 ZDD]
M!5*75H8M>M](:&?SIX'G679^[PI4$;O[WS#B@#.\0Z/JU]X,N-,T_5)$U(Q
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M<GI6]8:78Z9'LLK6* $ ,RK\SX& 6;JQ]R2:MT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4%PV)+<;6.9". 3CY6Z\U/56[&9K3Y6.)CT'3Y'ZT 6
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** .2\1ZQ,_BW1?"\$UQ:C4(Y9
MYKF' 8+& 0JL>A)Z\=*X_7?$^OZ+9>+M+34CYFD&TDM+N4@R,)F(VN>F.!R!
MGFO2M8T*TUGR))6EAN[4NUK=0-MD@9EVDJ>G3L00>X-4YO!NCW6D7>G7<4LZ
M7K*]U*TK"69EQ@EE(/8<# ]!0!:T"WO8;*26^OC=O<R>>IP,1!E7Y!CJH.['
ML1]:X/3M>U5=2\9ZA=ZC<3V_ANXFD2V&%$T?DEMAXXP5X/;)KTV"%+:WC@CW
M;(U"+N8DX P,D\FLZP\.:7IEWJ=U;6Y$FIR>;=[W9Q(V,="2!QQ@4 <EH\GB
M$7>B7LE[<K:7\$GVL74L;@R&(R)Y"#G((;Y3V%9<&J:X=&\,ZK%JMW]INM4:
MPD6Y7*.CN_SLFT<C:,#C'J>_7:/X"TC1;@26[WCQQ,[6D,MPS):;AAA$.V>>
M3DC)P0*M1>$-+CT^ULG^T20VEX;V#=,P:.3)(Y&"0-QZY]\T <1I_BG5]+@\
M?6TE_P#:6T>>/[)/>%?E\W(^8\#:" ?SK46\\3:#'J&I732/ID6F37#"ZN(Y
MG\].5*;<?(5Y(['\ZZ2/P=H<<VL2?8RYUC'VX22LRRXSC@G ZGIBJVC>!=(T
M:TFME>[NX722%%NYS((H7.3$OHOUR?4F@#AM?TJ[LOB!\/FO-6N;VYG:X\QF
M<,B/M0DQ\# Y_("KT.LZGI4^M>$M1U6[FUBXO4&F7(92Q@E^Z0<#!3:^>/IF
MNEA\!Z7:3Z5=F2^NGT99391RW!(3=MP/? 7 SV/.>,,T ZEKOB0Z[J>AR:4M
MK:O:VZ3E6DD+R LW!X $:8Z?>;K0!LZY#-'X4OHX;NYCGBM&*7$; 2;E7(.3
MQDD5PDNN:U%J'PRF74I3'JMNJ7D1P1,WD!BQ]\MG\*].FA2X@DAE7='(I1AZ
M@C!KE[#X>Z+82:2ZO>3?V0\C60EG+>5OZ#W"C( /KSDT <#INOZ]+X7CUR77
M+IYK;7_LGE;E"/&TX3:^1S@=/K72:Q->^)Y?&=JFHW%I!I,'V>"*#CS&:'>S
M2#!+#)V@ = >N:Z%/ ?AZ/2)-+2TD%I)=B]9/M$F?.#;MV<YZC..E+J'@K2K
M_5;C4E:YMKJZA^SW3V\Q47$>W: XZ' Q@]>!SB@#CM,UF\GB\'^&+:6XBC;0
M8;J9K.1$G8B- H&X@;>I/?I5JXO/%$%IH%A=7_E73Z[]DD>)U=WMS%(R^9@$
M!\*">V1Z5TMYX&TB[TO3K)#=6[:8NVRN8;AA- ,8P&.<C'&#D8I\_@VP<Z>;
M>XNK;[%=F\4QN&,LQ&"SEP2QVEA]&/M@ OZ7I]];>'X["_U.2ZNUC:-KT*%=
MLYPV.F0,?B*\?T..;_A / K/=RR-+K[D,^"5/G2C\>1GGN:]SKDK?X?:;:Z5
MIFG0WEZ(--OS?V^74D,6+%#E?NY8^_/6@#,T/5M5GU3QMH\FI2N=-E5K6=U4
MN@>,.1TP0#T]JHZMK5W9^&?#VHWU_K2:6]@KW5U8Q@S1RL%(>4'G9][&%X(Y
MSD5U*>#8H9]?GM]5OX9]:96FD3RR8MJA?D!0@948YR?QYILG@N(V-C!;ZOJ-
MM+:VHLS<Q^47FB'17#(5..V .IH U?#\SW'A[3YI+D73O K&<9Q)D?>Y Z_0
M5Y;X\:[\67&MK96>H?:=&=4TN6&VE=&N$(=V#*I"M_ /<=0*]8L]-AT_1XM-
MLV>&&&'RHF7!9!C (SQFH]%TE=%TB*P6ZN+K8SLT]P09)&=R[%B !G+'M0!S
M5WXNNK_X7#Q+HT:F9X%=Q(0/*&X"5N3U4;B/7 X[5!87E_!K.M6-EK-QJ&GV
M^EI=+<2LLC13N' 7( )!5 X Z<YZBJ>J>"#X=\&SZ9HB7]_'=W<4EPIE >,>
M9N>5=H4YZ?*..G'7,^E:!>)K@^Q:GXB;3KA)ENHM0"JD:E<+LW(&+;B,'G@'
M/N 8T>OZ_IWAOPW>W6K2W4_B"&VMA&D8!B8J6:123@.5V]>,Y/L-'4M4\2>%
MK*\1IY);>>:WCM)[^6-IXGD?:^=IV[ .A/<G-=&W@;2Y_!=OX8O)+B[M;:,)
M#/*P$T9&=K!E  *@X'';G-)'X$TA],N;/43<ZI)=1"*>ZO92\KJI)7D8"X)R
M-H% '/ZM<Z[H.F:W#'?7HW:<UU:27L\3SQR1E5<*JYRAWH<D\$X[C$LQUU?'
M>FV;:Y,+'6-,D9H@%#6\D87+1GWW#KGH?6M:+P%:)X?NM*EU75+A[F 6[WL\
MP>98P20JY7:!SV'/&<XK1_X1JW/B&PUE[NZ>6QM6M88F9?+ ;&YB ,[C@=\<
M=* .1MO$^HVNAZ3H]Y+?2:C<:E<Z8]\(T0S"$OF1"S8&[: ">X;VJKKFI^*-
M#T/Q#$VH-&MNL$UC)+(CW:H\H1@^W(V^A^O-==<>!M)OO#3:'?M<W<+3-<&:
M64^:)68L7!&-IW$G  '/2D7P+I4F@W6EWTEW?_:RAN+JYG)FE*L&4EAC&"HX
M&!QTZT <CXCU+5M,\0^*M*&JW4EO+H#:C$6^5K>17V8C([$'/X5U/PYTY['P
M1I#O=RSM/8P.5:161#Y8SL([$DG.3FKMQX1TR\U&6_O/.N+B:R-A*SR'#P'J
MN!@#+?-D<Y]N*R6\(RZ?+X9LM,NM3%MIDA+3&X0@1A-H1E8'<"    ,<G.>:
M -/QK=75IX:D:TN3;2//#$98S^]"M(H(B&#ND()51ZGK7!R^)-;B\,^.H8KR
M^ADTN)9;2:Z:-YT#+NPV.A[8(R/K7H_B'P_:>)--6SNI)HC',D\,\#;9(94.
M5=3R,@^H-8TGP\TV:'6HY;[4'_MB".*Z8S#)*@C>.."<\]O0"@"E%JNH:=XU
MT:*:_GN;75M-EFEMW3=Y31*AS&%&<G)R.<]JY/Q/%?W=CX%UO4-3EGFO]7LI
MS;[=L48=U90JXR" 0"2>3DUZ@?#EJ=:L-3,UQYMC;_9X(]PV*#]XXQR2, _0
M8Q6./AQI >S0W6HM9V5VMW:V;7!,<+KR /XL;OFP3UXZ<4 /^)FLWV@> -1U
M'39O)NHS$BOC. \J(2/?#'%8LGB/4=(\7WHFNYKFT'AI=2%NP&%E$FWC&.HZ
MUV'B;P]:>*M N-&O9)H[>=HV9H2 WR.KC!(/=13/^$6TPZV=5=)'F_L]=.",
MY*>2&+$$=R<C.<]![Y .-U#6=4T#1?#_ (E_M2>Y74+J"*[MYSNB"3'DQJHR
M"O;G\ZZ/QYK-UI6AVL-C)Y%UJ=]!IT=S_P \/-;!DQW(&<>^*GL_!FF6;VX\
MRYFM;219+*UFE+1VI5<#:.IZY^8G'; K3UK1K'7]+ET[4(O,MY"#P2"K @A@
M1R"" <T ><7,LGA3QCXIO4O+N\FM=!6=#<XD)*ECUX[XXK5\/S>*'UK2]2GE
M=M*O(#]H%S=1D,[*K(T2*/EYW#&3QBNBA\(:;'?SWL[7-U/<62V4S7$I82(,
MY)'J<\X_#%5]&\!:%H,\<MG'<_N=PMDDN7=;=6&"$!/'.3Z\^@  !YMX)NKM
M? 'AFTM=3^QK<ZM.DL5N2MQ<*-QVH2",YY)) P.N:V9I_$=SX,O-4M]4U&.X
MT?4) \9E3?/;(^75\ C=M)P0><"NIC^&_AZV32ULH[FU_LVY:XMVCN&+ L"&
M4EB3@Y_PQ4>H63>%K&YM-$T:^U'^U[B5Y L@9+=W'WCN/"DGMGO["@";2]3E
MU_QD]S97%S_9%K81G:.(Y9I,L/J53&?0FH=6U>YO_'UOX3BGGLH19?;9+B!L
M22?,5" X. -I)]<BM7P=X=7PIX4L-&$BRO;I^\D1=H9R<D@>F34VL>'K75Y8
M;KS9[2_@5E@O+9@LD8;&X#(((..A!% 'GD?BK6RKZ4-0E$NG>*+?36NM@9IX
M';@-Z''!/?TKH/"&IZE_PG7BS0KV\GNH+-H)K9YADJ) Q*Y QC@8'UK>E\(Z
M-+$D;6SC;>"^++*RL\X.0[$')(]ZL67A[3=.UJ_U>VA=+V_5%N7,K$/LR%X)
MP,9/3UH Y37H+B]^+VAVPU&[@@33IIQ'"^%+JX&2,=P2#[5RRZI?:!X<\2:S
M8W3Q/:^+KD-%N54F5I%4ABW X)P>QYKT_4_#=IJ>LZ?JQGN;>\LMRK);R;?,
MC;DQMZJ2 >,'CKR:S+OX?Z9=:3JFG+=7L,>HZ@=1D>-UW)*6#';D$ 9&>AH
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MWX31K?78O&6M2SW<T^ARJAMTN5 :*8$AECQUCQCD]21C."2 =/1110 4444
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MP#R>>HKO-)UG3]=M'NM-N!/"DKPLP4KAT)5A@@'@B@"Y)-%""9)40 %CN8#
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M:SO(KF^G>TU:W8+<%R')CG4\D 9 .?X<\<"ND^*LUF/"D%K>/<!;J^@C5(2
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MW09K5FMGQ<!3@["!ST_+FLSP[JGV'Q9XY^W:C))8VL\$B23L1Y6Y&+1J#V&
M!CK0!I:+H>NOK(U/Q-=:?<2VP>.S6SC90JMU9MW\6!CCIZUU58^D^)++5[ZY
ML8TG@O+=1(\%Q&4;8Q(5AZ@XJSJNL6FCPPO<F0M/*L,,42%WD<]  /Q/L!0
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MH!)$3,[[B2-O8 #OZ50\?^)5U'X57NK:-=7$$B7,4+%&*/&_GJCHV/J01TH
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M2W3+]HE:U60R*""<@\$\<%L@'L:MZ9IT&DZ9;:?:@B"WC$:9ZX'<U@:G\0M
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M)'IDD]*R/$OA.357TR&VMM-FTFSW[],N%,:2$J5!#*K8P">-O?K6O;Z_I_\
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MJY56\+":SQT,QSTZ>6_J?Y<_AF@"U1110 4444 %%%% !1110 4444 %%%%
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MOA^Y*W5NC.8Y("H=75O7:<D'T/3I700^*&O?$>CZ?IQ@N[6[LGO+B=58>6G
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M.D1C5@)&"L%/(!4 _C5;P[H5_I?B'Q+J-UY!CU.YCFA6)B2 L83!R!SP/SH
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MZ3HR3A](34HOM$QB/S.%(;@XP"?J13=+^(&HZB?#=T^B1P:?K$AMRYN=SI*
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M_/<K.+L[!M.?)'R\@L/O$#Z5$O@O58_",EBEO;K.-:&H+;I(H0Q^8&VYVX!
MST Y%7]1\*ZIJ?C6/6G$$43:++8R*'W;9'YXXY H P]#^(GB*/P=HVM7^@PS
MV5].$GOS?;!#OD*AC'L8A 2!USQ7=0:[/<>,+K1(K%6M;:TCN);SSNCN6"Q[
M-O7"DYSTKBM/MH/#/PQ'A7Q;+96K"UEC@'GAFG(+-E1C@@E<=3FNO\%Z9<Z;
MX:M3?R/+J-RBS7<CGDR%0,8[    =L4 =#1110 4444 %%%% !1110 4444
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M;W%S9MOMY9$!:(]<@]N@J_7 7^K:OX3\5:5IMSJ$VJ6VLQS(CR(BO;RQKNW
M* "I! (/3&?8M^'&H^(/$.EV6M7^JB6$&YMY[<Q*N]EE(1Q@<'&0?H/>@#T&
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM=-B6U'F%,RD8'\7R-P?Y_
MA5FH+@XDMOESF0]NGR-0!/1110 4444 %%%% !1110 4444 %%%% !1110!D
MZIX=L]5O[:^E>>&ZMHY(DE@?:=D@PP/J/Y'D<XJK;^"]$LY-'>V@DA.D>9]D
M"2M\OF8#[N[9 QSZFMR:XAMTWSS1Q+@G+L%& "3U] "?PJ,WUFL<$ANH DY
MA8R#$A(R-I[Y )XH Y^7P%HTMK) SWHW:@VHK*ERRR1S, "58<@''3W-+)X"
MT*6/7(GCN#'K;J]ZGGL Y&.GIG'/U-=%+<V\"EIIXHU +9=P. ,D\]L4GVNV
M\Z.'[1%YLJEHTWC<X'4@=Q0!F'PS8'5-*U$O<F;2X&@M@9B5"L I)'<D#&34
M^N:%8>(]+;3M2C=[=G5\)(R,&4AE(*D$8(!J[)=6\4T<,D\22RDB-&<!G(&2
M ._'-1:A=K:6DC"2)9MC&)9&QN8*3CWZ$_0&@#,L/".E6(NMZW%Z]U$(9WOY
MVN"Z#^'YR<#V'7 J'P]X(T?PS<-/8"Z9RAC3[1<O*(D)SM0,>!T]^*?X+UJY
MU[PEI^I7WE"ZN$+.(QA>"1P#]*W5FC>5XED0R)@N@897/3([4 9FO>&]-\1V
M\45_$V^%M\$\3E)86XY1QRIX'UJDG@;0A#JL4MO+<#5$CCNS/,SM((UVJ<DY
MSR3GKDUT18*,D@#WIHFB,K1"5/,50[)N&0IS@D>AP?R- '.Z?X$T*PTVXL&@
MEO89T,;F]E,S!/[H)Y X[5%9_#SP_9:?>V0CNIH[R%K>1KBY>1Q$W5%8G*CZ
M<UT":GI\EQ#;QWUL\\T?FQ1K*I:1/[RC.2/<5C>--?ET+POJ-Y8RVQO[:-)%
MCE.< N%R5!SCK^(H F7PEIZS:+,9;QGT=72U8W#9(8 '>?XN !S2'P?HSP:O
M#+;M*FKR&6[$CEMS8P",_=P,8QTP*UFO+>W@C>YN88]VT!G<*&8\#&3W/2BX
MO[.T)%S=P0D)O(DD"_+D#//;) S[B@# L? &@V=A>VCQ7%VM["8)Y+NX:60Q
MD$;0Q.5'/;'K18> ])T^YTZ>*?47?3BWV7S;QV\M6 &SK]P!1\O2NG!R,CI6
M WBJTEU;6-+LRDUUI=JL\IW_ "AFW80X[X7GZT 7M;T6UU_3&L+QI5B+JX:%
M]CJRG((/8@BJ+^$-/-VE[%->0WRVILWNXYSYLL?^VQSN(ZANH/0U!X$\1R^)
MO"&FZI>F%+N[C:0Q1G& &(X'7TK5L+B^DU'5$NA;_98ID%J\;Y;:8U+!QV(;
M/X$4 3:9IEKH^FPZ?91E+>$$(I8L>3DY)Y)R2<FL*X\!Z7=0ZY%-<7[1ZT0;
MM?/X./[HQ\O''':NG#*V<,#CT-+0!S,G@/1I;FWG8W8>&Q_L_P"2<H)(><!]
MN-V"2?K2S>!=&NO!UIX6NQ<W.FVP0)YLQ+D+T!88^G&..!BHH/&]G<_$&3PM
M"HD\NV:0W*Y*^<I&Z+.,9564GGC<!UKJ20.I ^M &3XA\,Z7XHTL:?J<!>%7
M62-HV*/$XZ,C#D&ET'PY8>'8)8[/SW>8AI9KF9I9'P,#+,<X'/ X&3ZFM-I8
MT0NTBJHZDG H66-T#K(C*>A!R* ,[6?#^G:\;)K^#S&LKA;F ]U<=/PJ6'1;
M"WU&]OXK=%N;U56=P,%PHP/YU>WK@'<,'H<TTRQJ4#2("YPN6'S'&>/7@'\J
M ./L_AAH-BFGI!/J@33IS-:*;^3$1/50,]/UZ\\FNATK18=(FO9()[B3[;<-
M<RB5@1YA !(X! PH&.G%6TO+62%9DN86B=MJN'!5CG& ?7/%3%E7JP'U- &7
MHWAO2M!L[NTT^U6*"ZGDN)8^H+/U&.P[ =,5FZ/X!T'0[\W=G!*0&+PP2REX
MK<G.3&AX3AB..QQ71/<V\<B1O/$KR E%9P"P'4@=\50NO$&FVVG6U\EU#/!=
M3QP6[0RJPE9V"@*<X;N>.P/I0!C_ /"NM W1A1?+#%<K=16ZWDGE1R Y^5,X
M'.>GJ>U;6O:%9^(M*?3KXRB%F5]T,A1U92""".AR*T@<C(H) &30!RC?#W17
M:^=Y+YY+ZT%G<R/<LS2IR,DGDL0Q&?0XJVWA/3XKO1[Z(W1DT6%X[*(2Y4*5
MVD'/4E<#)/85O;TX^9>>G/6H(]0LI9'CCO+=WCD\IU6525?&=I&>#CG'I0!S
M/AR*_P!;UU/$VIZ(NERK8FTCCE8/,<R%B21_#P,=#RWK75W%O%=VTMM<1K)#
M*ACD1AD,I&"#^%9$VHWH\:VFF*8EL7L);A\KEV=710 <\ !\]#6R'4G 8$^Q
MH YO0O FB^'I6DLQ=2.(S%$US<-+Y"'@K'N^Z.GUP*J#X::"NFVEBCWZ+:7C
M7L$J7)61)&SNPPY .>@KK([B"8L(IHY"C%6"L#@CJ#[U('5C@,"?8T <J_P[
MT%],OM.(NQ:WM[]NE1;AE_>\<@CD#@?D*TF\+Z6U[J=X8Y?M&IVXMKF03,"8
MP" %P?EZGD8/-:ES<0VEK+<W$BQPPH9)';HJ@9)/X5P(^(\E_!X-N[&UCAMM
M=NY(I!,V7C1"0<8XYQG- '11^"]'C.C-B[9M'&VS+74GR?4 X;CCGJ.*OZ[H
M=EXBTF33;\2>0[*V8WVLK*000>Q!%6K2^L[^ SV=U!<PABIDAD#KD=1D=Q3K
M:\MKV(RVEQ#/&&*EXG##(.",CN#0!@3> ]#N%U%9X[J5=1MX[>Z#W3GS53&"
M3G.[@9.<FKE_X6TO4M%M=(N4G:TM7C>)1.X8%/NY;.3CW]!6N[I&NYV55R!E
MC@<\"HX[RVF"&*XA<2 %-K@[@1D$>N1S]* ,.[\$:+>W]Q=31W!^U3)-<P^>
MWE3LHPN],[2/;'.!FGS>#=%GU'4+]X)/.U"T%G<;9F :(8 4 'Y>G;'4UL->
M6J1O(]S"J(Q5F,@ 5AU!/8U1UJZO$TR*XTNYLD8SQ9>X;Y&C+@, <]2#Q[XH
M IVO@W2K'^Q?LZSC^Q8VCLU,IP 5VG=ZG%>>V?@_45@D@&G^(+;5R\TGGP:E
MY5IYC,S!A@G Y'05[!YL9D,?F)O R5SR!ZXJNVJ:>EA]N>^MEL\9^T&91'UQ
M][.* &V5K*-&@M-1=;F7R!'.S#B0XPV1[UEZ=X+TG3)[*2+[5(M@6^QQ3SM(
MEON 4A >G P,YQSC&:W/M5N(TD\^+8XW*V\888SD'OQS3H9HKB!)H)$EBD4,
MCHP96!Z$$=10!S%S\/=!NC?ADNDBO9UN984N&6-9@P;S%7HK$CDCKD^M:,7A
MG3X/%%QX@B:Y2]N8U295G812;054E.A(!('U]:UI)8XD+R.J*!DEC@ 5B^)M
M=DT:#3TMDB>XU"]CLXC*V%4MD[CW. #P* +&L>';#7);.>Z$J7%E+YMO/#(4
M=&^HZ@]P<@^E59/!^FR:/?Z9YEX(]08M=RBX;S9L]07/(!Z8&!@D# -6]#_M
M@6LT>M-:RSQS%8Y[92JRQX!!VDG:025QD_=SWK1::-'"-(BNW(4L 30!#I]D
MNG6$%G'+))' @C0R$%@H& ,@#/ K+NO"6G7=UJT[R78.JQ"*YC6<[#A0NX+T
M#84#-;FY>>1QUYZ4;UP#N&#T.: .;M? VD6EWHES$USOT:W-M: R# 0\'=QR
M>!^5*O@G31:7<#W-_(;B\%]YKW!WQ3 YW1G^#TX[<=*=XAUZXTK5_#UI;K"T
M6I7I@E9B<A0C-\O;M6[!<P72,]O/',BL4+1N& 8'!''<'@B@"KI>D6^DBY,+
MRR274QGFDF;<SL0!^6 !CVIMMH\5KK-[J:7-R9;S8)8W<%,(,*%&/EZD\'DG
MFM$G R:8S$QOY10OCY<GC/;- &)-X8MU\2S>);:28:HUM]G"F0+$ZCD*PVGO
MWY->>Z?X4U-+8*;7Q+;ZU(S/))%J CM%E+;RP&2-N[G&#TKOO!&O3>(_"%EJ
M]WY2RW#2Y\L%5PLCJ, ^RBK7B6YU6WT5IM%-F+H2)E[M]L:Q[AO)/^[G% $.
MB>%K;1]5OM7$LSZAJ*1_;"6^1V4<$+CCJWYU3LOAYH%AJIOH8K@KYIF2T>8M
M;QN3G<L9X!SR/3M7127UI"9%FNH(WB56D#2 ; Q(4G/0$@@>N#4GVB'[1]G\
MZ/SBN_R]PW;?7'7'O0!S5I\/M!L]:FU*..X/G2&4VCS$VX<G.X1] <\_C3U\
M#:6NG:W8F:]>'6I&DO"\VYF)&#@D9 P /;'%=-39)$AC:25U1%&69C@ >I-
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MWGA.WM;NYO;$ZO<&WN+O;&)$\ASB(;@3#NX'RXZ]CSZW<:;8W5D+*XM()+4
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M +$8P4&.G'2@#RZYDT2=/!MKI<31:*-;D^S^8^%GC*.Y9><[-S%0".@]*W_
M_E0^+?&MG;E$MHK^(QPQD!$W0J6PHX&6SGWKL'TVPE$0DLK9Q",1!HE.P>W'
M'X4^&RM;:222"VABDD.79(PI8^Y'6@#$\=O-%X)U22&+SML69(\D%H\C>!@C
MG;G'-9'AS6/#&H>(HKOPTDLZ2V0BN9;4A;:W52642#M(26 ZG&>U=PRAE*L
M5(P0>]5[?3[.TA>&WM((8I,ETCC"AL]<@=: /'O#%WI2_#SP;;W\EO$YENI(
MI[HXAC(DD!.""KOM8X4D>O05EW-W#+\&9HQ<K.L/B/RXB& "K]HRN!V7;G '
M0>U>Y_V5I^V!?L-N%@D\V("( (_]X>AI!I.G>2\/V"V,3R&5D,0(+GJV/7WH
M \IOK'3K_P ??$:"Z@@EMVTB"0JP&-P0D-]<X.:-,-K;_P#"K]4B:)-1O(D@
MN[@$>9,GV<\.>I^91U]*]8_LVPS(?L5MF1=C_NE^9?0\<C@4T:1IH:-AIUH#
M%_JSY*_)SGCCCDDT 0Z7K^EZU<7T&G7B3RV$YM[E0"#'(.J\CGZCBL?XEHK_
M  T\1!U# 6,I&1G! X-:.D>'8-)U75-269Y;C490[[E50@'15P.G.23DDY-1
M>,],U+6O"M]I6EBU\^\C:$O<RLBQJ0?F&U6R0<<<=^: .3L-/TJ+5- N_#R0
M+J+Z9*;G[)MRZ&(;6DQU/F8P3SDFL2P_LEO 7A_[/'#;^+;>ZBMU2X)$YN5D
M43!\?,05W$@]%Q7J.A:1#I>GP V=I!>&)%N'MU&&8* ?FP"1QZ"K0TRP%\U\
M+*W^UMC,_EC?P,=>O0T >:ZUX9$'B77=$M-+C:T\268DA9(AMAG#!)78X^7"
MN']\$#YF -'3[#4]2\*:C)<6;IK_ (;LI-,@\HJI$A&YW3!QS'Y6#Z[N*]@,
M:&19"H+J"H;'(!QD?H/RI(X8HF=HXU0R-N<J,;CZGUH \CT&7PO<:G976GZD
M+R'[%-'?Q6T,=M%;Q%<LUQ@*<A@<9YR21W-:O@-= T7P'H'B;4I8(+D6$=HU
MV6.-I;Y5./J.M=[!I&FVJ3)!86T:SDF4+$ ').3GUJGK/AVUU309M(B$5G!,
MP+F*!3@9!.T$8#<=<'% &S7F&LZ=9:K\=(K&]A26";P_^\0G&2)F(Z<YX%>F
M11)!"D,:[8T4*H] .!3/LEM]J^U?9XOM&-OF[!OQZ9ZT >>K)"FJ?$Q(;C[)
MY5I%F8.3Y1^S,=XV_,,9SZY&>]8W@+4=(UWQCIMU9VNGV36>D>3)&+N"22=\
MKA@L;,?E /S-@_-]:]&\0^'8M:T+4K"VE6PGOX_+DNHH@6(SR#TW C(//0FL
M.Q\'W<VHVT^HV&AV*6<RRPOIB-YDFT$;6+ ;5(QD#.1D9]0#S_56M+;P3IFM
MV"I'J4/B%HEN_E,@!G<,H8<[<$_*?7I70>&]3T;0?B%\0+C5Y[:U9+F&96E
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MC\ZXSQ%X>\20Z)XUT6ST>6_AUFX>^M[J.>,;2P4&-E8@Y'EC&,YS0!Z!!KL
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MIWAA-#N[FYT75;>9IHG"1W$7G>9E"Q&X\X([8H ]?N+B*UMY+B=PD4:EW<]
M!U-8=MXST>YO[6S+SP27BE[,SP,@N5'4ID9XXZX/(JWXFTR;6?#&IZ9;NJ37
M5L\2,XR 2, FN2DEU7Q%-H5I=>&[RTETF]CN+JYG*^6A1#S%M/[S<"1P,#/8
MT ;$7Q"T">.RFCDN6MKR\>RBN/(;RQ*K;<,?X<G@9ZUK^(\_\(SJA5Y$9;65
ME:-RC A2001R.17D%CI^I6?PPTRVGTG4Q<#Q(MRT*V,S.L2S[BY4*2!CGGKV
MKV36K>6[T+4+:!=\LMM)&BY RQ4@#GWH XGX<^+K,>%O#>D:C<7 U&YM0(9)
MT8K.1DD*_0D #//I72CQAI1NHX@9S#)<&U6Z\H^29NFS=ZY&,XQGC-<5X,M-
M4N-!\):++H=W:R:).9;V>]B,:HRJZ@1?\]"V_P"\,KC/.2*9X1T^_P!)G/AB
M]\(++<07DEQ'JTT"M T;2EPP?!^<;B N<\#I0!?TCQ;9^'[SQ7<:M->&W36?
M+\S#RK$K!5&?[JC@?E@5TVK^-M%T6_FL[J69IK>(3W/E1%Q;Q$XWO_L_3. #
M7GGB#2M4F\'_ !#A32K]IKS5$:VC6W=FF4.AW* #E<*3FCQ7INNZ@^MV4ND:
MA);2:$#9-:1E1+*L9R)V4AF8' 6,YSD\=2 #LM3OQ)X]\'RVUW,;2]M[N4HL
MK!) (T*'8>"<,>P/-<WI-Q>^,?%NOA[O7;$VNH0I921ADCMT1 77;NVY;ON!
MZC@@XJWHD5VFM> +:32]3B^QZ5/Y\CV[".)G10$=N@;]VW!]5]:W/!0E75/$
MKSZ?=6WVS43=P230%!+"42,')&0<QL=IP0"#C!H Z#4M7M]*\B.59IKB<[88
M($WO)C&3CH ,C)) KG->\<VD?@[6;_3O/-Y9(\<D!B/F6\FTX+CL.,YSBG>)
MK*^L/%FE^*K.QFU"&TMIK:[MX,&41MAMZ*2-Y!7&T<G/'-<_J%A>W>A^+]7A
MT.]AEU^".VMK+ROWQ;:4#R*#A,YR22" .>U '3^#;+= FKPW>I_9KJUC0VE]
M([D2*6+2@LQQNR.F < ]ZMP^,-+GO%MXQ<E9)G@@F\K]W-(H.Y$/<C:PYP.#
MS6EHX9=&LD>-XWC@1&1E(*D* 1S7G.BZ1=VGC;S](T_4-,:6[:35+*[C9K(J
M1_K8'QMWGC@'(R0>!0!V*^,],?2[/4DCNVMKJY^REEBR89=_E[9 #E3NX[U+
MJOBW3=(EN$G%PZVH!NI(H2R6X.""Y^ASQG ZXKBK2+5;+0-1TQ=%U&:ZMO$,
M5W_J\)+&UVL@\MCP0%'/0+SD\&K,DNM>&/$NMV2>'9]4MM<N?/M;B)"T4;E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH RM/\.:9IFK7^J6UOMO+Y]\TA)/)"@X] =JYQUP/2M6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I7__
M !\6'_7P?_1;U=JG>JS3V) )"SDG'8>6] %RBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *SM0\PZAI@66-4\URR%"6;]VV,'.!C/.0<^U:-
M9U[&K:KISG.Y6DP1$2<%><MT4=.#U./2@#1HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LO4 K:WI2G&X&5A^\Q_!C[N>>OH<>HSSJ5GWJ.
MVIZ<P?"*TFY=P&3L.._/?MW[=P#0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LN^><:_I<:!S$RS-( @P,!<$MU'4\=\^U:E9EVRCQ!IB%
M6W&*<AA&"!C9D%NJ]>@ZX]J -.BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *S[J+=KFGRB,'9',-Y#?+G;QP,<X[D=.,]M"J=S$7U*RDWX5
M!)E,XR2!STYQSW'7O0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "L^[=1K&GH964LLI$8'#X ZGVST]_:M"JLSR#4+9%67RV5RS*!M&,8
M#'\3CZ&@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit101-iansconsultin008.jpg
<TEXT>
begin 644 exhibit101-iansconsultin008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:I:KJUAHFG2W^I7*6UK%]^1SP*\^G\?:[J^LZ=8^'HK!$U/3&N[=KH,S*ZN
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MEBA:--_.5SN;<O'44 >AT5Y5H?C7Q1<P>%-1O7T]M/UAOLKK&A\P3$,0W7
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M>ZUF?Q=IVC0Z[/%;W&A-<,ZPH'#JR#> 1P3D]<XR:J6GB;7KGP7H.J2_:;B
M74BZE+91@RM&A8 @#L2!G'/'% 'I;2(A4,ZJ6.%!.,GVIU>3O=7FK'P=.OB:
MY9;N\N85FMU49 #E=P9?O #:<]P:35/%.LVNJ7-W'J4\T5MK\5D8K>(&$0'
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MHH **** &N&*,%.&P<'WKRRP\)>)8[O2[R;3H?M=MJ[W%W,UV";E""%?'.
M>G7VKU6B@#SV]\&ZO=6'BZ%1:*^KW*36Y\P\   [N..G:K'_  CFMZ?KMQ=V
M,=O)%J&GK;3DRE&AD5<!AQR/IS76OJMM'K,6E,)/M,L)F7$9*[0<'+= ?:KM
M ',^!](U'1/!MIIFH!$NXE8$J^_DD\UQL_@?Q*\(DEM[*ZOQJ\5W+=M/AYXD
M)P,8PN >E>L44 <&?"FL+9>,8T-L)-9F\RW_ 'APN5"_-Q[51\4K#=:9I&BV
MFH6T7BJRDA6".*0,Z';AB0<?+MR>:]*JB-&TT:HVIBQM_MS*%-QL&_'IF@"6
MPLX]/L(+2/[D2!1[UQM_X0O[_6[;4DAM+._M[G>+^!L,\.>59<?,2/6N[HH
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M-,Q+?/A2O'YUJZ3HUW9>)]9U*9X3!>[/+5,[AM&.:WZ* .9NM"U!_'":[!+
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M:-YX@%RH4R%-VWG/2MRB@#D9/!D\WB2#5Y=4?]UIAL!&J8VD]7!SP?:J6E^
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MF+;_ !5UBTTRY&G*NG6\:PK'E)EPPSSW7*]/4YKTNF>5'YGF>6GF?WMHS^=
M'(:A\/K:72M)LM,NWT]].N3<K,B!F9V!#,<]SN)S70:WIDFK:#=Z9'<F W,)
MA:7;N(4C!X]QFM*B@#F;3PM<VNIZ/>#4RW]G61LRIC_URD#))SP<JI_"K_AS
M1#H.G26AN//WSR3;MN.78L1^9K7HH Y!_ X&J^(KR#49(X]<A\N>#8" =FS<
M#UZ$_G3X_!81O# -YN30(_+B'E_ZP>7Y9SS_ ':ZRB@#A+#X96MAJ[3)JM\V
MEF8SC3"_[D/G(_X"#VKI-?T/^VH[/9=RVLUI<I<1R1GN,Y!'<$$BM>B@#R#Q
MIX0_L?3]-6UEFFGO?$45Y<SHGS1Y?)*J.@4?RKNW\'6=[_;+:G(UVVJQK#*&
MX"(H^4*.V#SGUKHRH;&0#CU%+0!R.@>!8]*M[J'4-5O-62:$VZK=/D1Q'&5'
MUP/R%,\.> (?#U\MQ_:U_>K"K):0W$I9( ?0=S78T4 <.GPX@B\ MX1COY!:
MO+YC2[!NR)!(,?BM:U[X8DO]7T'5)M0?[3I&_:RH!YN\!7SZ948_&NBIJ+L7
M&XM[F@#CHOAU91:_-?\ V^\-C).;DZ;O_<>:3DL5^O./6NBUW2(=?T.\TJX9
ME@NHS'(5Z[3UQ6C10!SMKX3AMM5TO4!=RM+8:<=/ /21#CD^_P HJOIW@I=*
MTNRM++5+F*2S>9HY0!\PD.2K#H1T_*NJHH Y0>!+*&RTV*TN);:>QNFN_/0#
M=)(P(<D=/FR?I6?J'POL;_\ M('4KZ*.\O1?K'&^U8ILY+ #KGWKNZ* .>D\
M)6TM[K5V]S,9-6MTMYNF J A2!Z_,?SK-U'X<:=J&FZ7;B\O+>ZTV+R8;RWD
M*2%#U4D=0:[.B@#CM9^&^D:K9:=##+<V$VG[C!<6LA5P6^\2>I)ZD^M=%H^C
MVFAZ<EE9H0@)9W<[GD<]78GDL3U-7Z* .;NO!6F7<.O12/<!-;V_:@K_ -T8
M^7CC(J8>%+7^V-+U0W5TUQIMN;>'+#!4XW;ACDG _*MZB@""]M(;^QN+.X4M
M#/&T4@!(RK#!Y'UK+C\+:?$="**1_8H*V_3D&,QG/X'/U%;=% &"?"6GGQ)>
MZ[YEP+R\MOLLF'&WR^. ,=>,U';>#+"SL='LX+F]2'29#) !+]XY/W^/F')%
M=%10!R4WPZT.?7YM6=KT&=_,FM%N66WE;'!9 <'IGZU)+X"TR4:RIN]0"ZN<
MW0$XY/'W>,C@8X[5U-% $%I:BTLHK42R2+&NP/(06(]\ 5RP^&VA+H4^D![T
M027?VU9!.1)%/_?1A@@UV%% %"'2+>WT4:5#).D B,8<R%I,'J=S9R>3R:Q+
M;P#I=G9V-O:W>I0"R>1H7CN<-\Y!93QRN0#@\5U5% %/2],MM'TR#3[-66"%
M<+N.2><DD]R223]:N444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 AX!(&:\EO_'FO/;W>HV4\,,\
M&L+I:Z?+$)$VDXWG&&+=^& KUI\A&P,G' KR;2=$N+87UW'<^(+759[B:40_
MV<63<?NCS&C/R\#G=CZ4 ='>:CK:^/;'1C?1I%<Z3)*?*@"D2J<;LL6XR>G\
MZP=%\0>*=3TC2[(WTO\ :RZL\%])]G08A4\Y&, 8QSUYKK[3PY<SZUIGB'4+
MQAJ%O9^1)"J#8=PRV.^<U>M/#MK9^)+[6HR?.O(U1TP, CN/<]_I0!S%QJWB
M2^N[F]TJY79:7OD-9F)3&T:G#%G)!#=QV]JH:UKOB.2?Q7'9:O#:?V7%'=0
M0AV*[22ASV)[UT$W@&TDURYOHM1OH+2[<275A$P$4SCH3QD>X!YJ:3P3;2OK
M#27<I&J0^3*H10%4<#;]!0!KZ!>RZCX>TZ]GV^=<6T<K[1@9*@G%:-8-GX86
MRNM+EAU&\$=A;_9Q!O\ W<BXP"R],CUK>H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-,D6*[NT25L8B'S/@]]HYQ[T :-%5++4['4?,^Q7<-P8R!((W#%">QQT-6Z
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M0,0!N8#)/04 0Z=I\&EV$5G;!A%&#@LQ8DDDDDGJ2223[U:H!R,BB@ HHHH
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M\4 :-SJD']F7=S93P7#01,_R.& (!(SBN)L_&^L7?A_PMJ CM VIW1AN0<Y
MR0-@_#FL;PY+#8^+-;L;:>R6VET-)A#;O\I<<9;GEL'G&*9X=E@_X03P69'B
M$@U$A,L,_>;.* /8'=8T+NP55&2S'  JM'JFGS6KW,=];O G+R+*"J_4]JQ/
M']U:6O@^[-\91;R,D3>7)L/S, ,GL/7VKSA7T^4^.;%9-/,9MH6A@MY-Z?*/
MX0IR<>HH ]A.K:<)I83?6PDB3S)%,@RJ^I]!4T5W;3V@NHIXWMV&X2JP*D>N
M:\SN-(TL_$[P\DT,>+W1Y//#-CSV79M#>M9X$=EX+>UMQ_Q*8/$#I=*K$B*
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M\UK7[7$6A*K+'C.5)X/6@#>%I;+*)1;Q"0# <(,@?6EBMK>!W>&"*-W.79$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^('B,:'K6JC1],,6E3-$Z?:VW28ZD?+Q^->@ZAJ5II=L+B]E\J$N$W;21DG
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M=3@59)W,;/,"9!L/*DGYJ9X:UZUC^%N@6NH0Q7FEW=Q):WV]2WEQY)!( X/
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M]I$5Y]EN+24@"2"XB:-D;'(P>H]ZQ/$4<FO^)K+14N)[6WM1]JEGCBSF7^!
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M9=,E:-M/1(KO[.2BR G/SXP#C H Z[2+6ZLM*M[>^OI+ZZ1?WEQ(JJ7;OPH
M%7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRL<=%.[K[5-K$T>I>._"]QI4\LT*RS->F&1M@3RB4+C.,;L5WFX#N*-P'<4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1:/=1_Z1:2K+!..'C8'G!]".".E3ZSI::UI4^GRW,\$4ZE)&@VABIZCYE/\
M*@#+\(V=RUI)K>H!!?:H$F=$<LL28^1 2!G _6NCJEI.G#2=,@L%N;BY2!0B
M27!4OM'0$J ./I5V@#B?B*$>/0XKP@:;)J,:W&#\Q/.T8Q@KG&<U8^)D</\
MPK76]P4!+4M'VPPZ8]ZZ#5M'L-<T]['48!- Q!VDD$$="".0:S#X2@F6&*^U
M+4+^UA8,MM=-&T9(Z;L("V/<F@#'O+<S_".9I8G>>;3E>7"%F9@HY(R/3UK7
MU:" ^#Y;ET42QZ>563NH*<X.1_.K^MZ*FMZ8^GO>W=I!(NU_LCJC,OIDJ<#Z
M8J*X\/177ALZ'+?7I@:/RFFW+YK+TP3MQT]J .2GF\2'X:L/L&E?9O[/^_\
M;9-^W;UQY6,^V?QJC=I<-X/\ O:+"UTEW 8A,Q5"=IZD G]#7:CPM"/#*Z"-
M2U#[,J^7YA=#(4_NDE<8_#/O6<WP^M&L]/M#K6L>3I[K):J)HQL9>ASLR?QH
M 2R?5AK]W)XB2SBQ ([(P.2A)!W ,P!+<#C%>6:??7D?@6XTRXCCBT34=8N+
M>XO4_>20Y8=4(P >F<\5[!_PA]L]VMU=:EJ5W/&K"%YY$;R2>K* H ;W(-1Z
M3X$TK2-*OM+66ZN;*\9GDBN75@&;JPPHP30!O:?!%;:=;00/OACB5$;.<@#
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M]K7]F1VSRG2K;/VAB /WC^GXUTOA26^>RN1JT<$6J?:',Z0@ 8SA3]" ,9H
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M1ETV[DNX;?[4P79@QYQD<^O;K7*Z!/)X8\<PZ?<V$NF:;JELL5M'*\;;[B,
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ME&*2QF:*:V\S)X8#(;&#U% %F[\''^W6U;2=7N]*DE.ZYA@56CG;IN96!&<
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M'=:@JK=ZB'#7$V !RQ! R!T QS5/2_&>J7_AS2_$#:5$;"[&Z812$O"O.6Y
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M,*L"P)Y^3!Z=ZRM(\6^((/"^BZU>:O\ ;+B\U 6<MG+%$H(,A7<NQ0<@#W%
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M,GJM 'I-%8GA*?[5X=M[I+V:\@G+20S3C#E"> WO6W0 4444 %%%% !1110
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M$1L&'! ;!Z^E>E3:?97#L\UG;R.V S/$K$X.1G(['FI%MH$C\M((UC)+;0@
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MYKT*Y\1065E916:_;+J9HXDA0\X. S'CH!DGZ5O@*B  !5 P!T H!##(((-
M'G7AR5%NO'RDD%[QY$R#\R^4HR/49&*@;PY>WGA30-=T.00:WI]H$P^0)H\?
M-&P^HKTQ=H 5<  < =A2T >*6.D:C;>!_!VO6EK)<RZ3=2SW5NF"^QG?> .Y
M!/3K6W\1[JUUS2]*.E37#WDE[ I%N[JZQL06# =!CKFO3D5$!5%51DG &.3R
M:18HT=G6-%=OO,% )^M '#>(-%T?6;F;0=9@2"W@CCFL+F/<)$.2" _/(/;T
M-6_AN^J?\(]<0:G<RW0M[R6*VN91AI81C:Q_'(_"NO;;P&QR>,^M*6"]2!VY
MH Q/&&AGQ'X2U+2E<J]Q"P0@X^;J/PSBLS0/$L,/@RV:\MKF&\M;812VAB8R
M;U&W &.<X_6NNW+S\PX.#SWI Z'HZGZ&@#QG5=(NX/A["E]93I=7VM)>?9E4
MN4C:0'YMO3Y:W["UE\&>/;JZ:*6ZT;7")$N=A=K63'W2>H4UZ0&##*D$>QH)
M"@DD #J30 (ZNBNIRK#(-<O\1PTGP_UF%$=Y9;9D1$4LS''0 5TY=57<6 7U
M)XI0RE=P((]<T <G>LA^%TB1>:Y;3?+4%&+EMF,8QG.:YKP_X>TA?A-;&?3&
M6]%D5975R_F8/&*],^UVV,_:(L9Q]\4\RQK'YC2*$QG<3Q^= 'DLWE2>!O U
ME<VDT@AN[;[5&;9R8T .XGC(KIT73-$\461T+2Y9)]1(@N"D;+'%$O)<DCKV
MKM$=9%#(P93T(.0:8UQ DGEO-&K_ -TL ?RH E)P,UY1J'AVV\5^./$<,BW,
M7G64"VMWY+J%D4L2 2,>F:]2>ZMXW"//$K'D!G )HDN8(6"RS1H3T#,!F@#S
MF76[VZ^&VL:;J=E<+JUK"]NR0VKXF(X#)@8P?:J6B6^F:+X)T34(-#GEU^UB
M14B2VD5S(W!#''3UKU26>*!0TTJ1J3@%V 'ZTUKRU1 [7,(0G 8N,4 >?Z-<
MO;?%37[V[M[B*&>SMT1Q;N5+#.X9 Y(J[K_BB]FT?48[&PN/WTJV=M(;>3)W
M<.Y&.% /7'-=D;VT6-9&NH0C<!C(,'\:DBECF3?%(DB_WD8$4 >=^+=-N?#=
MKX?UC3S>7LNES)%]GCB+EXF7:W"C/3G\*Z+QE<K<> M4,44[M<V;K%&L#LY+
M*<#:!D&NC9U3&Y@N3@9/4^E.H Y;3[A8?AI:B2.X5TTQ(6C\A]X<1 $;<9Z^
MU<+8:#J5SX \'7]K;3B]T"599K.6%D=@&.X ,!DXY]Z]=^UVWG&'[1%YHZIO
M&X?A39+^SA($MW A(R T@&10!R7B^]N]?T#^R-$L[I[C4 $=Y8WA6"/^(L2!
M],"I8K6P3Q NBR6<SVHTH6K;K9VB(W?=W8VGCWKIEU*Q<,5O;8A1DD2KP/SJ
M6&ZM[E2T$\4JKU*.& _*@#A?#OAJ_P##7BP6<4DT^BQ6LALVD&XPEF!,>[/3
MC@8K+UK3U\0:)_:%YIMW%XHMI&6UGL[>2-OO_(=VW&" ,YKTR*]M;B0QPW,,
MCCJJ2 D?@*%O+5[@P+<PM,.L8<%A^'6@#@O%MD=1USP?#>6$UY%:RM)>YM7D
M108\9)VD'YJJ7FD0:-\7]*N]/T66"P%@ZS2VEDWEAR>,E1UQ7I$E[:PS+#+<
MPI*W1&D 8_A4] 'F_A?S;'QOXOO;FSOH[:\,3V\ALY2) JD'&%_2G_#?PII]
MOID-]?Z-Y6LP2R_O+B!E959V92,C&<'J.17=RZG802&.:^MHW'57E4$?@34L
M%S!=(7MYXYD!QNC<,,_A0!+7">+HKBX\;>&I8;&\FALIFEN)8X79$4C Z##'
MZ9-=HM]:/<&W2Z@:8=8Q("P_#K1<7MK:;?M-S##NZ>9(%S^= '$:=IC1_$,Z
MEI&ES:=HZ6CB[(@,*W4A(VD1\$D?-R5[U2\/:392Z3K$.NZ)<2B?4)KBW673
MY&;:V,,ORG:?R->@KJ5@\X@2]MFF)P(Q*I8_AFA]3L(Y'C>^ME=!EU:505^H
MSQ0!A&6^F\ S-?V,\%S);NBVT",\B@Y"# ).[&,U)X"MIK#P1I-A<P20W%M;
MK'+&Z,NU@.1R!GZBMC^U-/\ (\_[=:^3G;YGG+MSZ9S3/[:TK /]IV>"< ^>
MO^- '#:UX4O;CXEVLL*R_P!D7Z^??,L>0LL0P@+=LY/Y5)\._"=UHNH:F^HK
M(6M)6MK!F7Y?L['?\I(YY/)%=Y<WMK9VYN+FXBAA'_+1W 7\ZAAUC3;A-T.H
M6LB[2^5E4X4=3UZ4 <KI\4MOX^\2WEWIUV+.ZB@BCD^S,ZR[5(;H#QSWK-\1
M6FI:AX8@LK;2+B..WU:$VT2QL6\A&!+D8X[\'Z5WZ:G826[W$=[;M"GWI%D!
M5?J:DM[JWO(O-MIXYH\XW1L&'YB@#F=6:6;6K&]T?3KEK]B();B6%XXXX<Y;
M=D#)].O6DA\.0:WHNM:9J:7'DW5[)*&*F-N0NUE)],?I75R2)#&TDCJB*,LS
M'  I(I4FB66-PZ.,JRG((H Y3P)INKZ9#J4&L[Y)UN L=PY!\^,+A6X[XX-=
M=3)IHX(S)*X1!U8]!5$Z_I(@2<ZA;B%VVI(7 5CZ ]Z .>O[:Z;XHZ=J:VEP
MUG!82V\DJQ,0'9@0.G/UZ4>(;2YG\=Z!>QVD\MK:+*)W6(L!N7 ^M=->:K8Z
M?:+=7=S'# V,.YP#GI4%SXATBRN$@NM0@AE=0RK(VTD'OS0!R'BK1YW\:>%;
MK3M*D^QV$[2W+P0X505P.!U/TJ;P_#<6OB7Q5)?:7>?8M2F22&3R"0ZA-I!'
M4?B*[#^U;#^SVOQ>0FT7K,'!4?C3;'6-/U*TDNK*[CG@C)#2(<@$=>: ,[PG
M:3V6G26YM39V4<A2SMF&&2,=SSW.3[5OU3TW5;'6+8W&GW*7$(.W>G3-7* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *XZ]UO5HOB3:^'H[F%+.XTZ2Z#F#+*ZN% SGIBNQKS/Q#:
M6&L_%C3OM,4K6L%B]M-.A=%65FRJ;UQR1GB@#I/!GB.YUNRU1[\P9L+Z6V\^
M'B.55 .X?GS]*S?"/BN\U7Q3J=G??+!<1K>:8!WM\[ 3[DC=C_:J7Q';V7AG
MPH-$T:W>U6^D\I?*1G"!V =R3G'WN_K6%KN@:IX6U'0=:L+NZU)[1Q:O;1P
M'[,1\WW?3 /- '2:GKFH6_Q"LM$2[@@LKC3I;IF>(%@R,HZD],$FJ7A'Q'KN
MOQ>(K9VMI)+&Y,-G?1QXBF'KC/.*H>)=,M-?^(]@+VSG>Q72I89)?+8"*25@
M%!(Z$@FKG@R\O_#<\OA76HI=ENZII]ZL.(YHCG:"5X#<'K0!/=:MKT/Q"L-
M74+<VLUD\\CFW&\,#CCG&*4ZIX@T[7/#^FZE>P-)>23+,8;?".%R5()Z$C&1
M5:^227XPZ=?10W1MH+1[6:=8F\OS#RJD].]7O$V9_&7AHK!.R6,[RS2B%F1-
MZ%%RP& 230!4T[Q)J,OC3Q)I>H:K;6UGI_E-;LT(4X8$G))YQ@=*BU_Q5J&E
M^#[#5$O4GM+J\VRZA#!GR;5MQ$@7IG 49Z<U5TS2H9?B!XLO-4T:66VNS#!
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M/IMREI?K:&WD.SY_+C*L,;LCDT 0?"JZGU/PK_:5Y>7UQ=//+%(+JX+[-KG
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MJM[$D%MIJ.8$#[F>1QM)..@ _G0!E>$K6/Q1-J>LZN!=,E]-;6T;G*11H=N
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M?O9/% 'L1EC5]AD4-Z$\TKND:EG8*H[DX%>?:U:"7XTZ %C4H;"::4'."58
M-CU'%/\ B/?_ &[R_#5K.8KQH'U!G#  +%C:I_WF*_@#0!W[.J+N9@%]2<"D
M26.3/ENK8Z[3FN6T35H_%OPZBU"YBC+36K>;&.0LB@@C\"*J_"F*$?#[3)XX
M\2RQDRN>KL"1DF@#M&8*I9B !U)I@N(64L)HR%ZD,.*K:Q&)M$OXV (:WD'/
M^Z:\R^%^H:1!X$AM[RVN9II&<3N;=Y ^&..0.1Z4 >L)(DJ[HW5QZJ<TU9XG
ME>))$:1,;U!R5STR*X'X8WEMI_PP;4IF*Q1S7<LC-G.U97Q^@ K(\(:EY/CR
MWU%[G?%XIM6N!$S@F%U.408_Z9]?I0!ZA>:C9:<J->W<%NLC;$,L@7<WH,]Z
MFCECF7=%(KCIE3FO-_&L%]8^+X-9N],&N: L/ES6Y 9K-LCYU7OD &M_P!'I
M@TF\N-&NDFL+F[::- I5H<@91L]P<_AB@#IY+F")MLDT:-Z,X!IT<T4JEHY4
M<#J58'%>:_%"WA_X27P;(;<2-+J!CD4#F1=OW3ZBGZ/+#;?%RYL8(9-/LY=.
M(-K(-J3R[A\RCIPH/3UH ]!;4+)5+-=P  9),@XIS7MJFS=<PKO7<N7 W#U%
M>/>#196]AXTGN-%^W_9-1F*#8& 41J0@SVSZ>M6?&&CVNDZ;X#M(8Y9HQJ:K
MME;<Q5@6*9/;)Z>PH ]5_M.PW,OVVWW*N]AYHX7IGKTJ:">*YA2:"5)8G&5=
M&R"/8UR4.@:1?Z[,[:*+9[.':(]H59U<9PV.#@J/H:X[PAK5[X/EMH[M"?#F
MH3RJ78Y_LZ<.1LSW0\ =* /6K2_M+\2FTN8IQ$YCD,;AMKCJIQT/(XI7O;6*
MZ2UDN8EN)!E(F<!F'L.]<WX&BCBCUXQ(JH^LW+ J,!N0,_I^E9?Q0MGT^RT_
MQ?9VPEO-$N5F<#@O <AU_(_AUH [>&_L[F5HX+J&212051P2,'!XIMKJ-E>S
MW$-K=PS2V[;)DC<,8V]&QT->965RMA\77UU45-&U:V%L)@1@3J@?D=L@&NN\
M&6T=CHM_J<@1!?W<U\S*,?(Q^7_QT"@#I!<P-=-;"9#.J!VCW?,%/ ./3@U6
MO-9TS3YXH+R_MK>64A8TED"ER>@ /6O*]+\0P6WCBP\3F^D:U\0EK:6&3I
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MN#W]J /3-+UC3M;M?M6F7D-W!G;YD3;ES]:-3UG3]&B22_NHX!(=J!CRYQG
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MB:[F%O &ZO(02%'X _E5F21(HVDD=411EF8X %>4^/YO[9EU*6 77VC10K6
MB5N;A3N=@1Q]W"\^]:'C'Q!%K?PUTZ_M99%M-1N;>*<KP0C/AU/ISD&@#HIO
M'WAVWE=9KUDB0X-P8F\H_1\8-3WOC/0=.FNHKR^$)M<><S(VU<C(R<8K0N=(
ML+G19-*DA1;%X3%L4 !5(QQZ5R?Q-M8+;X6Z^8%'[R$.[]W.5&2>_ % &N?'
MGAP"4F_P(H!<,3&P_=DXW#CD9(_.M!_$>DQZ"NMO>(NG,H99SG!!. 1]:YG6
MK6!_A0;HPH;A-&5%DV_,%,:Y&?3BN;T]VDLOAC:3DFRF@!>,_<=Q$2H([^M
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MC.%9&92?;(/Y&MZ@#G_"6A7?AGPM:Z,989S:1;(I!D;N2?F';KVJ+PEX>O\
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MEHL45JEQ8:O(L5M>K,-F\C(!'7GM0!-XE\.76O:EH]S%>I;QZ9<B[5#'N+R
M$#)[#!/YT[7/#D^L:UI&HK>+ VER--$H3=O9E*D'VP:N:UJUUIL^GPVMC]K>
M[G\G:)0A3@L6YZ@ '-9ND^+)=2\6:OH+Z?Y,FEA#-+YNX-O4,NT8]"* (1X5
MU6/Q+J&NV^LQPW%XD<+1_9PRK&A..IZ\G]*I:E\.I-9TC4+34-8DDGO[R.YF
MG6(# C "(HZ # _6K<'CB:?1+?6TT2Y;3;EU6*19%+A6("NRYX4Y^H[UH?\
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M&H6\+)=7)!FD\QCYF,@9YYQDX]*6RT+3=.:X^R6RQ+<2-)+&"=C,W4E>F30
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M6L> [2+58$6*>S"S1N, #&/PKG?A%"DOAZ>^FD::[^T20>9(V6$:,0B_3 H
M[/6)M3ALX_[*@BFNGE5#YI(15[L<<XX_6N3B\1>,+N\U>SM++2GN--(!4NX\
MTD9 'IQQS7>UP_A9@?B#XL(((9H2"#U^6@"73?%6J7?Q#E\/7%K!##'8)=MR
M2X)P"OIU)JS'K6K2>.[W0B+=;:.S6ZBF"$GEBNUN<9X-<['!%<_'B_\ ,)V?
MV0@!5RN3N'&16O9?8[/XGW\2N0QTN,Y?D??;(W$_3B@"GI7B/Q9K7A^;5;1=
M)C$<LB".;>-P4X'.>"2*[;39[JZTJWFNX/L]T\0,D9YV-CD?G7FGA72[*^^'
M]TMQ??8W%W+*9&DX4++NR5)P1Q7I.DZA'J6E07L:LL4BY7>,''K0!P3^.?$%
MKX<U779+>QGMM,O)()XE#(S(I W#/(//0@5V=]KL-MX5EUM!^[%MY\:MU8D9
M5<>I) QZFN(\+Z!IWB,^($N;^>YL3K,["T6<^6RY!&1CD'KU(K:UJ%-8\5:5
MH=K) D.F 7TD9&58C*(N!Z=?P% &SX4UT>)?#5KJ07RY9%(EC(YCD!P5([8(
MZ5@)XC\02V_B6XBDTQDT>X:) 5<>8%4,VX]C@@<=ZK>&4?PQ\0]7T6XN5>WU
M1/M]JJ<)&P.V13D\$D@@<YYKG9M)N_$4?C%=-O)#J%MK+S+:M)\MS&%4!&']
MTX('TH ]"AU;5M<T?0]1T6*WBAOHUGG-R"3&C*#@ =^:Q=,\0^*=7TW5[JQB
ML)9;#49;5(&5E,J1G!.<\,>W:NA\*Z_I^O>'[:ZLPL"J@62W/RF!@.5([8K!
M^&DT9A\1Q!U+KK=TY7/.TOP?H: )=+\1:SJ$_BD.;9(]'F:&(+$2TA"!SGGW
M XJ/1O$>MZKX"@\0--817,H++!(FU&.X@)DMPQX ]S5'PU>6L5_\05EF0?Z<
M\FW@ED,*C(!Z]"*QO#46@?\ "M-,N9[\6UU YN$5Y""2DA;;Y9) S@CIQGB@
M#K[KQ;.?B%%X5B-O;$V7VDRS<L['.%49'3'-:_AJ_P!3OK*Y_M:&*.Y@N7A_
M<JP5U7HPW<\UR>M2:'XQNTT3Q#I[Z;?FSBNK:ZW8>!V!.U9./F4C..]:_P .
MGU#_ (1^6"]NI+V"WN'BL[R08:>$?=8^OU[T .L/$&I77Q'U70'$*V-G;QS(
M_ED.Y<#C.<$#GFH;?Q'JESX]UGP_YD"06-K'<))Y668MV/-9=E'97OQGUQ9#
M&W^@0 &.1U+$=<G@$\CH3QCOFJVE?9;'XP^)55U2)]-A"%W)#$ Y )- &QX;
M\2ZKKG@-?$%U/::?*Z.5\] (L@X4YW<*3CKS4NKZ[K5AKGA?31+9(^K>8+C>
MA_=E$5CLYYY)'/M7"^%;?PC??#&VT_6;];6ZVMN#2R*R,'W [2<'D+VQ6QXE
MU"+5?%?@9KF!HU9KDO''(=T<;H%C=C\I7./_ -= '5^&O$%]JFM^(=&O/LQF
MTN5$6X@SM<.NX9!Z$="*IZ)KVKZAX>U6^O;VRM9K*ZN+8.\6V$F-BH8DGH35
M+P5,?"6H7/A+5B!-YK2V5\4/^F1L2?F<]77.TY/;O6)I,/AV]\/>(+/4;XP2
M7NIW4J-EP=IDRK ' (.!Z@YZT =O>WVOVFC7FH3?9HOLU@)@JKNWRA"7'7[N
M< 5G?\)/JMGX=TOQ)>&!]+>U:XO]J8:+Y,IMYYRW'XBKNHZC-J'P[U&[N;86
MIGM)?)C+[F92IVYX'S$<XY^IJC#H[^)/@Y'I$4GE2W&FK$"RYVL ."..XQ0!
MIZ<WBC4-#AOIY+.SOI$,@L]A=!G[JLV<_7%6O">O_P#"1Z%'>R0^1<H[P7,.
M<^7*AVLH/<9%9^E>,K&+2K.#5-]IJPA19;$QMY@?'W57&6YZ>M9GA.\C\):)
M91:ZDMI>:YJ$TR0F,L(7D?(1F' ZCDXH [^N&T_QQ+=_$FXT,QK_ &8\++:7
M!7;YDT9Q*H)^]@\?A[UN^+M:?0?#ES>0C-R1Y< ()'F'H3CL.I^E<#X@\-7F
MA^#]/U>._P#M\^DR1W5O%';#=*['YP&'.&W'MV% &YXX\6ZMX3UK3I+6$:A9
MRI))=6<:?ODC4#,BG/09K9O]>::/PY=Z7=1-:ZA>K$YQN#(8W? (Z'* 5CW-
M_'J/Q$\,W4)N3!-8SX#(1&"2.#_M<'@]A6>/#%WX9\:Z/;6TK2>&[J_>Z2+!
M!M)Q%)\H/]UBY/X8H Z'3-6U+4?&OB/1VN5C@TT6S1,L8)/FH6(/T(INA>)K
MUO%M_P"%]92 7L$2W-O/"<+/$W&<'D$$$'Z5DZ3JMKIWQ)\8W5T98X+A;-8G
M\IB'*1L& XYP34FCZ-<:U\39_&<UM+;645DMI9>9PTPR2SE>H'/'YT ;_B!]
M9M(M0U"WO8HK2WLR\<7E[F:09)R?3  JEH=UKU_H^F:R]]"\$]HTEQ"8L%6*
M94J1[CD'U]JU_%$OD^%M3?:6/V=U"A=V21@#'?DBLSPE<);_  YL'F61!#9[
M9%*$,"!@C'6@"#X=ZWJ'B?P3%J=]=)]KG:6/*( (RKL@('?H#7-2^,M?C^#4
M?BI+I&OFN<']QE0GV@QXP.G '/J:F^%EE8KX&_XF-C-#/:W$SN)4=6"M(S*<
M?2N:E>X7]GR/1DL;LWK7)C:#R&W ?:3)G&.FW% 'J[1ZA%J]I#'KB2.6,TEK
M)$H+PCY6((YX++S7)Z=XNU/6WUZ)-0CT_6+2>2.UTJ:,;V50"I.>3NYZ>M:\
ME_I,>JVEYH]M++J3+]C13&X79(Z%BQ(X "9KEM8-CXI\,SW6KZ7/;^)K=Y5M
M9;:!Q)N5R(V5L<@C'6@#8U3Q/KJ>)O"%F5DT^WUB!A<))$"T4P7<%SV/7\JZ
M/27O/[?N[5M6^VPVT:B9'B"LDC<K@CJ,5Y[KCZJ?$'P\76K2XFFMH3-J<R1L
MRHQ3;@[1CKG\J[/2+JS'BMX]%M9Q%=KYM[+)$RHNQ=J!21RQ)_(&@!?&>I:E
MIFI>'$L;TPQZAJ2V<R^6&^4H[9&>_P HK)A\2ZP]]XST=KH,^BP+-;WBH,L3
M$'VL.G7^M2?$6:.75O"UN;>XF6WU6.YN#'"S*D01P22!ZL*W-?MK#2O".L26
MED5:ZMW4K!$6>1V4@9 Y/)H YJV\2:U#I7@N^_M 7EQK#6PNK0QC(CD +R+C
MD!<]3Q6_?ZU=7WCB'PUIURL"PVINKR90&=<D!$ /KR?H*XK2=+N-%T7POXLT
MRSN'N;*Q@T_5+0Q-O,6%,C*IZLI].M= 6%AXU_X2^V@O)=,U"S%M=J("7CD0
MCRSM(W8P6!Q0!=UC7KOPQXFTBTO+IKBPU>1K=79 &@E R#D<$'TH\.ZIJD'C
M+5M!UN^\Z10+FPP@ > \<X_B!&*J:U8GQQXD\/R6T-S'I^E7+W$\\L1CW,%
M15!Y/)YIGQ*L-1@FTO7]"A+:G#+]C8@$_NI?E.<=@2#GMB@!U[JNO0>&O&6M
M_;"B6GVC^SD\M< 1+][W^8,*@UOQ'K>B>%/#MZT[O'>R1-J-]Y0;[-$RY+8
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MXT>&]OM2>.35]2F\^[>+[@(&%5?8#%=)0 4444 %%%% !1110 4444 %%%%
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M%G*9@=2E3<R;0ISNZ]?K5F!;.ZMO$C:5KNHW%O;PM!(CW$C&.9!G<DI;=Z#
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M58-5MM5F@TR&VOYFD.W&Q5BW88=B2.!0![2\$,H(DB1P>NY0:>JJBA44*HZ
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M>!88;:)(([F6- (AQ^[.!GK^'2HO'>C66E3:'<6%HJS7GB.UFE . []/H.E
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MT&2WLI;%86FDGC+*P);&U6.1SBET[P=_8WC4:G82E=,>VF4VG&V&5WC8LO\
MO;3GZ5OPZUIUQ?\ V!+E/M>SS!"W#%?4 ]:K1>*-(FOKJQBNM]S:@&>)5)9,
M],C'?% &)XXTW6M3U'0CIFGK/%IUXM_*[S*FXJ"OEJ#W(8G)P..M=DA+(I92
MI(R5/;VJ"QOK?4;..[M)!)#(,JP[UECQ=HC?9<7@/VJ1HX/E/[QAG(''/0T
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M.@VNJZ68X@P$Y@DWC=GD?-C(S^E:-EX_BOGNQ%H&L;+.<P7+[(B(V'4X#DD
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MX8T^2QTY"ENT[S!3_"6.<#V'2@#EO"__ "&OB#_U_P#_ +02G_!TA?A7HY)
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MD,P'0''4?6@#,\#7MK=^"M*>WD4JELBNN1E"!@@XZ$$&L_6S:7UWX9GL9D2
MZE(%DC;!SMD!VCH<L#6R?"FB?:GN4L$AD<Y?R':,.?\ :52 ?Q%6+K0-*O/L
MWGV,3"UP8 !@1$="N.AH QD!T7Q9(UW>RW U-8X+:,_,R%0Y8D #"].:Q/A3
M+'#I7B:25U1%UVY+,QP!\J5V\6C:?#=&Z2W'V@H8_-9BS!3U&2>!59/"^BI#
M+"NGQ"*5B\D>3M=CU+#.">!UH Y7X?J;[Q9XPUV!&73[RZC2V?&%EV)M9AZC
M/?OFO0:9##%;PI#!&D42#"HB@ #T %/H **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>^2"3SQ"]P;477E_NO.SC9GU_2EN?'>E6FJQV<T=R(I)_LZ7?E_N3)C[N?\
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M6EN;BW*1H.I.16;)87Q\=^']2%G.;6TTR6&9]GW78*0/T-=L""2 02.OM2T
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M'L4@8ZX.2/:M?PAX=O\ 1-?\37=T(_(U*]-S!L?) QCD=CQ77TC$*I8] ,T
M<MJ]EK-IXN36]+M(;R.2P^QO$\FPHP<NK9[KR0>_2N5F^'.J:2NG:]H?V3_A
M(('EEO(I,F*Y,I&X GIC  ]A75+\0M";2+;4]]P+>ZO6L8,PD%I02,8[?=/7
M'2NJH Q_#]GJ5O;RW&K31F\N"&>& GRH<#[JYY^I[UQESX6\3V5AXBT/2ULI
M+#49)+NWN)F(9'D;+QL/KT->ET4 >?7'AWQ7I?B6XU303ILL.II&U_%>$_),
M!M+(0.F,<>U-N/"WBG2_$/\ :VC7EA<-?00P:@ES&0-Z#'G#'^S@8KT)W5$9
MW8*JC)). !6=<ZY:V\VFH!)*FH2&.&2)=R@[2V21T&!UH Y*W\+>((/&1UF5
MK2X"Z6]KO+E2\I^;.,?*N[CKTQ4"^$O$)T+PE:R+9?:-'U$74^V4[64!@ O'
M4[S^5>C44 >>1>%_%6CZY>VNBW=D-"OIC<%YU)FMG;&\)@8.3R,],UG^(? ?
MB6>Q\3:1ID]@VD:Q(UY^]W"9)CM) QQ@L@Y]Z]3KF;WQUI-C%'+)#?/#-=BS
MAECMF9)92Q4!3WR01F@#5L[&?_A'HM/O7C,WV?R9&B!V],<9]JX>P\%Z_;:%
MI:++9Q:GH$S1Z9("2);<@*RR>FX =/05T>H>-;+3[JTMI+2]\RXU"&P^>+8%
M>095N>H^E=-0!SVD:1J \1WFN:H\2RRV\=M#!"Q98T4EF.3W)/Z"NAHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K@O%$\VG?$;0;Z&.YN-UI<I]EC;B1@N5XZ ^]=[7*>)=,OV
M\1Z)K5C:FY%B9%EB5PK%7&,C/% #;7Q]87>C?:DMYA>^<;8V#<.)AU3/3\>E
M:7ASQ+;^(8;@+!);7=K)Y=Q;2<F-L9ZC@CGJ*XN\\'^(9+>3642VDU;^TFO5
MM7QL,>T*$/;..]=?X;M]5#W%WJ5M;68F"^7:0@$Q^NYAU- %36O&T>D7UU F
MGRW$5EL-W,'"B)6Z$ _>P,DXIM]XX^S:I=V%KI-S=RP60O5*L%$J$CIGIU[U
MC>(O#^NZCJ_B(I81W$-S:)'92/* JG^(;?7/>K@T/5UUZ6Y-JK6[Z(MD/G'$
MO4\>G&* .JT36+77]&MM4M"?(G3<-PP1V(/T(-8,_CN%&FNH+":XT>VD,5QJ
M". L; X/R]2 >IJ;P%H]YHO@JTTK48A'/#YB,%;((+$@C\#7/V7A76M*T+4O
M"L%M'-8WLLKI>%P!&KG)!4\D@4 ;K^-EDU&_LK'2[B[DLI;=)"C  K+SO'L!
MS6=I7B72-*T;5;NPM)SG5I+98GDYFN"0."?N@FKOA_2+_2/%FK2-9C[#=QPI
M%," ?W2;?F'?.?TKDY])U31_#][87$<$=UJ.N^?:'?DG<^>#_"1CK[T =#-X
MS2_@UW2M3T2[MY[&V:2YC256!C(.TJW'7Z55T'QA;V&B>&].TW1;N5+W3VFM
MD:<,0$&=A8]3[\5$W]I_:M4T>]TY#J&JV\@6Y6=79MJX4$<;5YXJ70O!^K:<
M_@]YA$3I-G);W"A^[KC(^E &HGCQ9_#MKJ-OI<TEW<7'V869<#9("<[GQ@ 8
MZUSWC+7T\1_#J\N/(:VGM+](98Q)O 8..C#&1@TDGA'7XM&L[=;9)A%K#7,M
MN)MHDB).#GVSG%-?P5KUUHOB'2WMK:)+K44NK5A(2N, GCMR,4 >F23BUTUK
MAE9A%"7*J,DX&<"N7T[QW]LN?)GTN2!I+,WD($P<L@ZAA@;6Z<<UT5W!=SZ'
M-!!((+M[<JC]=CE?\:\_TCPEKUI>Z?=?8K6%DL9;2?\ >Y8N>?,)[Y/\Z -6
MW^(CS2:%))HDT5CJQV"Z:88BDR0%VXR>G7BL3QWXC.M^';HVFFR2V%M?QP?;
M!,!^\5QD[<?=&<9S5N3P?K[>'?#5LCVXETRX\Z>(N?W@YX!Z9YHE\'Z_!X<O
M_#ULUO-:R3FYMYI3RF6W>61_6@#T*YN5L[":Y=2RPQ&0A1R0!GBN<\,^+9_$
M%VUK=:4++=;"YCQ<B4LA;;A@ "I]JV=5M[NZ\/W5O;D)=RV[(I#8 8KCK7(:
M+X8U73=>T*[73K.&"WL7@N=LS%E8X.?]HD^N: .*-M&/ 88 YA\2RJAW'@>9
M7M.I:G::-I4^HWTHBMK>/?(YYP!7"GP#JA\,/IAN+;SFU=K_ '<[=I;./K77
M^)-!@\2^'+S1[EF5+B(IN4X*GL?SH R8O%]\M_9PWNB"VMK]/]#N3=!E9\95
M'&W*DCOS7,>'M-E\3ZWK0UK1;=PNHG==I='S(2@!55^4$CZ$>XKH(_#FMWZ:
M%!JTEGY>ERB5FB!)F*C"\'I6CX8T.]T:ZU>2Z:W9+VZ-PGE%LKD8P<_2@"/5
MO$]YI/BG3M(;2HVM+X%8KUKK: X&=I7:?YUCV_Q)DEL-4DETF)+RQOELA;+=
ME_.8D#*GR_Z=NU;WC#P_+X@TVW2UE\B^MKA)[>?/^K8=3@Y!X)X(JO%X7>W\
M86NI0R'[)%9F)T)^_)GAB/7!/- 'G^E>(IO!^K^+]2ATK[9:G48OM@2<1FV4
MK][!!WY)Z#TKL+K7M*M?&0O9=-57_LDW0OB_S-'G[H7^I(K.N?AWJES8>+(#
M>6BOK<T<D9PV(POK6C>>![O4+Z#[1<P_8AI)T^:-2P9F/\0]LT 2Q^*-2U%8
M[2^T#[-;:A823QS)<&4*-I^5QL !(]":Y?P3XODT'2?#.ER:66TN_9K>.^63
M:5F&3M\LY../O9'L*ZS2=$\4V^G16&H:G820VT#0QF&-E,OR[5W]A@>E85O\
M-M4@T;P[8M?V9;2;][MWPV'!SP/SH ]-KC/[7UL>.M5@-M;O865HDB*+M@S
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M:/>7+V"&2UO88!(RNB31N<;E!&011<?#J\O(=2D?4H[>^FU,ZE:3P*?W+XP
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MWLNB$I=B(  Y&"%Z'&:2S\5ZGJOA[2MU^EG<W$\UM+-'$'D8Q@X*H?4CGTH
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M9OT]$BADC:!%>0#):19"#M/J,CTJ'2-;U_6=?N+*75UBV:3#=D6Z(ZI+O(<
M]P<8H ].K/UG6;;0[(7=TDS1F1(_W2%B"Q !/H,GK7!:!X@\3>)+#2]5M(9$
M62]Q=,TL0A$()4JHW;MW&>@IKWFH^)?!>IZK)J$D&W4S&( H*"*.8+L[=<9S
M0!W^MZQ;Z#H]SJ=TDK06Z[G$2;FQ]*L6-W'?V$%W$&$<T8D4-UP1GFLGQK9K
M?^"M8MV8*&M7.2N[H,]/PKCK4ZSHZ>%RFLW,]IJD8MY(#$I,/[O*LF!GCWH
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M;:A=1W%I),Z2;4.1+RRXQC\>M:B:Y*WBY]%:V B%L)UG#9W<X(QVK:R#T(H
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M^E;6LZ/9:]I4VFZA&9+>8#< <$$'((/8CUJCX@U>YTJ\TA(O)\J[NU@D\SJ
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MP'GS&/8$8QFKMGXHT2_N3;V^HPM+G"JV4\SW3=C>/=<B@"Q-H>EW.EIIDUA
M]D@ 2!D!5<=,#MBH?^$9T0Z=+IYTNU-I*=TD)C!5SZD=ZP-(\1Z=I::Y=:GX
MG2ZACU$QD.K 6Q; 6(<9/X9%;NG^*-%U..[>UU"(K9G%QYF8_+XSD[@./?I0
M!/\ V%I7VM;K^S[;[0L/D++Y8W"/IMSZ>U0CPOH(TLZ7_8]C]@+;_L_D+LW9
MSG&,9S51_%.FZGI.J'2;X-=6UL\@5HV1E^4E6"N 2/0]#5'X8ZE>:K\/].OM
M0N7N+F7S#)+(<D_.U '4VMI;64"P6L$<$2]$C4*!^ JFGA[1X]0-^FF6JW9D
M,IF$0W;SU;/K[U7M_%NB76J?V=#>[K@E@O[IPC;>NUR-K8P>A[56TG5['3_#
MIN[K7?[1A%Q(@NMNXR-O("*JCYB.@"@]* *FN>";6YLH;?2K'3HH!<_:+FTE
MBQ%=<'A\#KSG.#R*J67@"RFU6*^NM(TVQM1;/#)86Z[EF+$']X<!2!MX&._7
MM6Y_PF?AT:7-J3:I"EM =LOF J\9SC#(1N!SV(J6V\5:)=W]W91:A'Y]I&)9
M@X*A4/\ %D@ CW!XH D7PWHJ36LRZ7:"2U7;;OY0S$/1?04D?AK0X?L_EZ19
M)]G?S(=L"CRV]5XX-45\<Z!)'>-#=2R-:0^?)&MO)O,?.&4%?F7CJ,BJ^A^/
MM(U72]'N9I);>74P%B62WD53)C)4,1C]>: -=_#>B2PW43Z39M'=,'G0PKB5
M@<@L.YI7\.Z*ZS*VE69$Z*DH\E?G5?N@^H%4)?'/AV"#4)IM0$::?,L%SOB<
M%';H,8R<^HI[^,M%2R2Z:>4QR2O$@6W=G8KU(4#./?&.10!I2Z/IL^F+ILUA
M;26*J$6W>,% !T&.E3VMI;6-LEM:01P01C:D<:A54>P%,T_4+75+&*\LIEF@
MD&5<?YX/M5F@#D-#\)^1KFN7FJVEI.MY>_:K=BH8H-H7'/?Y0?QKH(]$TN'4
MFU*+3[9+UAAKA8P'(],]:OT4 4_[(T[[>;[[#;_:SUF\L;C^-<O/X.N9;W4'
MN(M*U.&[N//7[?$6:+C 4#!& *[2B@#"T'PM8Z+96:-%#/=VJLJ7)B"LNXDD
M+_=7GI6@=(TUI)I#86Q>=E:5C$,N5Z$^I&!5VB@"FVE:>\<T;6-N4G_UJF,8
M?KU]>II?[,L/M$5Q]C@\Z%/+CD\L;D7GY0>PY/'O5NB@"M#IUE;W4ES#:0QS
MR@*\B( S = 3[4Z:QM+BXCGFMHI)HLB-W0$KGK@]JGHH KV]C:6D:1V]M#$D
M>=BH@ 7/7'I3GM+:2)XWMXF1_OJ4&&^M344 116\$+%HH8T9L E5 )P,#^52
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5QOC07PO]/FMXI+NUBCE:YLH9MDK+@ .O(W%<]/>N
MRK/U'1+#5)HIKJ$M+$K+&ZN590V,C(/? H \^TK48-:\26NF/J-PNF'1 ]J9
M)"KM+O*N6]64 5-?&>>6WM+?49M3\G1Y/G+^6C-G:)2WKQCBNMU+P7X?U:"T
MAO=.CD2T&(<$J5'<9!S4LWA31+B2!Y+",^1"8(U!(4(3G;@<8S0!PUO<SZGJ
MG@8S7L[+?:;<B<13'8^(AS]<]ZP]+U;6+C1[2)K^;[-9>)39NYFPYA.0JDGK
MR17JUGX6T:P%C]FLE3["K+;?,3Y8;J!SWH3PKHD8 2PC4"X^U<9_UO\ >^M
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MDE. <'';O6-8V\>D:[X-AO&:-99KMH[:2-BT<<I^12,' [<X%>Q$ ]0#]:,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !111D>M !1110 44@8-T(/TIHEC,IB
M$B^8!DIGD#UQ0 ^BB@D#J<4 %%("#T(I: "BBB@ HHI@EC:5HA(AD49*!AD#
MZ4 /HICRQQLBO(BLYPH9@"Q]!ZT^@ HHHH **0LJD L 6X )ZTM !1110 44
M44 %%%% !1110 44UW2.-GD9511EF8X 'J:;#/#<PI-!*DL3C*O&P96'J".M
M $E%%% !1110 4444 %%%007EM=231P7$4KPMLE5&!*'K@^E $]%55U*R;47
MTY;J(WB()&@W?.%/?'I5J@ HHHH **** "BBB@ HK+E\1Z+#JR:5)JMFNH.<
M+;F8;\XSC'8X[=ZTF=45F9@%49)/84 .HJO97UKJ5HEW9SI/;R<I(AR&^E6*
M "BJFHZKI^D6_P!HU*]M[.'./,GD"+GZFJ,7B[PY/+%%#KVFR22L%C5;E"7)
MZ <\YH V:*R=1\3:)I%Y':7^IVUO<28VQNX!P> 3Z#W-.A\1Z1<:E_9\-_"]
MSN90BMG++]Y0>F1W% &I1102 ,DX% !151]3LX]3CTYIU%W(AD2+N5'4U;H
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MG.  23R:W6MM7\77&FWE[ITFEV-C/]I^RS,//FD7[H.,J%S^/TJUX=T:\/\
M;::UIT*P7MWYZ1F02 C X..X(H W]*M9+'2;6UEG:XDBC"M*_5R.YKG=8\1W
M]KX\TC1+>T,EO/%)+(4D4,V!P,$CCO5Y==ND\:#0FM;?[,;?S4E2?,@Q_>3'
M ]#6;KFB:H?'^CZ]86\5Q##$\$RM)M*AOXO>@"CIOBBVT"SU-GL;N2VAU9X)
MIE(VQ[F !^9LD<]LXJ?^TM(L?B!K%R+&X^VP:6D\MP9,K)%N.T(,_7FL74_"
M'B.]\.^)]-2R@#ZG?^? QN!@)G//H>.WK6C#X=\00^);K4$M+0Q2:-%8J)9
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MD>._&=Y9Q&29-(@D";L8;YN?_P!56Y_"OB 6=W8QM;&'^TTO8I2YW2+ORRL
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M\17LRRW\D MT$:;4C0')QDDDD^IH P_&7C75O#D]XUO8VRVME LY>X))N02
M53:1M(YY(--U#QS?_;+"*T2QLDN[+[2CWRLZRN>D:E6&#[GUZ58U_P "7&N:
MIJ\K:F$M=3LUMF1HMS0[>1L.>A/)S5B3P=<7?A\:->7UM-:-:+;NCVI;:P&-
MZ'=P>AY!Y% &KKFOQ^'O#$VL7R#]S&I9$)(+'  !QTR:P6\3ZUIUUI<6K-IH
M75OW=L\$,G[J4C*A@6^88[C;6U>>%;*_\'CPW<R326P@6'S21O\ EQANF,Y
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M^'KK2$N1;)<1^6TACWD#V&15&'PU?P^'K711JZ"W@5(V=+8J[HO49WG&?7%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!&+>!9VG6&,3,-K2!1
MN(]">M2444 %%%% !1110 4444 %%%% !1110 4444 4YM)TVXF::;3[225N
MKO"K,?Q(JTB+&@1%"J. %& *=10 5%<6MO=Q^7<P13)G.V1 PS]#4M% %>VL
M;2SS]EM8(,]?*C"Y_*K%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !11D44 %%%&1ZT %%)D>HHW+ZC\Z %HHHH **** "BBB@ HI"
M0H))  [FF13).NZ,[D[,.A^A[T 24444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9^NZK%H>@W^J3%=EK \OS' .!D#\:K:)K$G
MB'PG9ZK9&!)KJW61=V617(Y!P0< USOBAAXB\4VF@P+:W*6,9NKJWN)=JNS
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M[O\ 09$D,*L%:7GD*6X!'O75VL^JZWKNGW<^BW&FVUDCN_VET+N[*5VJ%8C
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MU10J2-)&3'@Y&X!N_M0!Z;I-M-9:/9VMQ(9)H841W)SN8#!.:N444 %%%(2
M"20 .YH 6HKFYBM('FF<*BC)K(F\0K/<R6NF)Y[1,4N+@\16Y S\Q[GV%1:7
M8/>7?VR]5IA$08I7R-[?W@O8>E &L%.H6X\Z,I$X5@A)#>O/I5I$5%"HH51T
M & *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !34D25 \;JZGH5.13J9'$D,82-%1!T51@4 /HHHH **** "BBB@
MHHHH R!K.SQ(^E2JJJT8:%\\LV"2/RK7KE;V'^SKF:]9F9X[])1AV(VR (05
M&3QR1Q_6NBOKN*PL+B[F;;%!&TC'V S0!QETLFL^/[JR<120Q6PAPR_<4D,^
M?4G"C\?>NY1%C1410J*,!0, "N&\$'[%X:DUJ]E5;K6+EKB+SNH#D;$]>@'
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M)#,DT*RH05;H10!)16?IFLVFK"0VWF#8[+\Z;=VTX)'MFK[+N0KDC(QD'!H
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MM%G&Z6V9<GV]:\W\:>,[[Q1X@L(/#VA7^JZ=I,PN+J-8BFZ<9VJV1T YQ[T
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M&/\ OQ-_C0!VYS@XZUQDVD67B33ETS:QB6=OMA0%58@G(X.,].YJ/[-\3?\
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MI6\.W\[RM<^(+QMX^41(L80YSQU[<<YI\6G^(_+'G:];A^<[+$8Z\=6]*?\
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MX?UBTOK*UM5O?-O4M8Y)$D&V4J1@.5Z@-C/XUR/Q@!.F:  VT_VS;8/I\XH
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MW=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3A9RO:(7-M.>-S* 6P>G /ZUVNC7.DV,5DDND74/VK4'^P?:8][Y(R90",Q
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MP^[",=5 /./QJZEU'J<T-[&\3AMRV(()!/0N?:M:PLH["V$2<DDL[?WF/)-
M%@ *    . !VI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=2<W>CV=U]ELK9QA Z#$C$#&X[N/FS[5I7*:=X)2\U=V:+3A#'$D"LSD/N(
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MZ[U"'9)+;1N'WAC)E<D\=*Z"@"M96OV6W2/Y % "HB@*@_NCVJS110 4444
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MVFWDUQ'>",RK%]EE)D4=2F%^?_@.:;X;FUP7>H6NLE75'#6LC-'YK1D?QJG
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MD= V[\Z -^+QBESKO]FVNEWT\7G"+[;&F8>GS-N] >*N3^);2#Q9:^'3%/\
M:KB!YU?;A-JXSSW/(KC8-)?P#KNA0Z)J5S=Z7J=R;>>TN)?-*E@7\U#V VG/
MUKH=7+?\+'\-C9'M^S7?SX^?.$XSZ4 :'B7Q+!X;MK666!I3<W,=NH#;54N<
M99CP!6W7GWQDF-OX%2955BE_;L%89!P_>O01TH **** "BBB@ HHHH ****
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M>QB2*VN=(N$3R3\IY4Y!^F>: /1_,3.-ZYQG&>WK2)+'*"8Y%<#J5.:\>O\
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MWG)\D32M:JV<K 7)C!S_ +./SH ZBBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH R9=%,WB6'5WN7*PP-"EN5&T9P2?7/%5-5
M\*1:IXDTS6OMD]O/IZLL:Q!<-NZ[L@\5T-% '$M\/O)LM5TZPUBYMM/U!_-,
M.U7,<A;<S*Q&0#Z>M7[WP>)]7.H6VI3V[S6OV2Z4*K"9,<'D<-[UT]% '&Z9
M\/+73;?P_&NI79.BL[P\)AR_WMWRU8UKP/!J>N-K-IJ5YIU[+#]GN&MRI$T?
MH0P.#C@$=*ZJB@#F&\&0)IZZ?:7US#8_9A:O;L%D5D&<G+ D,<]<TV_\#V=]
MI4FDM>7*:9($!MEV879MP%)7(^Z.]=310!GVFEFUU6ZO1>7#I.D:"W9OW<>T
M8RH]3WJ+5=*N[^ZM)[75[JP\@MO6':5E!'<,",CL<5JT4 4=*TJVTBU:&W#$
MR2-++(YRTCL<LQ/J3^%49_#C-KMQK%IJ=W:W-Q$D4B*$:,JI]&4D'KSFMRB@
M#DI_A[I4WAZ+2EGNU>"Y:\AN]X\U)R2=_3!Y)XQBI6\$VTVE7]G<:E?S3:@5
M-U=,R>8^W&  5VJ..@%=110!RNI>!K:_U&/48-7U6PO1"()9K295\]!QAU*D
M9P3@@#!.>U7;/PI9:?JEO?6D]S"T%I]D$0*E&7);)RI);))SFMVB@#D%^'6D
MKH4.EB[U$"WNGN[>Y694FAD8DDJ54#')X(/6I;CP!I%YIUQ;74U[-<SS)</?
MF;%P)5^ZP8  8[ # ]*ZJB@#'T/P]#H?GN+V^OKB<KYEQ>RAW(48 X & /:H
M-0\)VNI>*+'Q!)>7D=W8HT<*1LGE@-UR"I)S]:WZ* ,;Q!X;M/$26?VB>YMY
MK.83P36SA71\$=P0>#W%8EQ\,])N;?5X'O\ 4PFK2K-=XE3YG7G(^3C)[=/3
M%=I10!BZAX:MM3N=*GN+FZ+::_F1!64!FQC+?+SQZ8KF-9\ 0VGA[4;'1SJ,
MCW]X+D1I.B+#+D'>#MX48''->@T4 5WMY)=/^SM/)'(T84RQXW XY(R"/TJO
MI^CV]AHL>D[Y+BUCB$($Y!)0#&#@#M6A10!S.H> ]#U+PW:Z%-',MK9N'MGC
MDVR1,,X*L/3)J_I'ARQT?3IK)&GNDG_U\EW(97E^4+\Q/7@8Q6O10!B1^$M&
MCT;3M)^RAK33Y(YH%)P0Z<JQQC)SS[FMIAE2,D9'4=J6B@##T'PK9>&[:XM]
M.GNEBGD:5E=P<.QR2.*H6_P^T>VLA;1RWN1=_;4F,V9$FSDL&QW[CH:ZNB@#
M&T?PS8Z'J&H7MH]P9;]Q)<>9)N#.!C/3BK&F:)9:3:7%M;(WE7$TDTBL<Y9S
MEOPK1HH Y;1/A]H.@7ZW=G'<,T98PQS3ETA+<G8O09J=?!.C+I-KIFR<VMK=
M"[B4RG(E#;@V>O4D_C7144 <SX<\.-I6MZQJ7EB!;Z0'R@Y;)!/SG/0G/0>E
M:>KZ!I^M_9VO(F\VV?S()D;:\3=,@UIT4 9UKHMK;7_VXM-/=^4(1-,^XA,Y
MP.W7VI)-"LY=>BUIO,^VQ1&%'#<!"02N/0D UI44 %4=6TFSUNP:SOHR\197
M&#@JP.00>Q!J]10!EP^']-BTZ^L3 98+YG:Z$C%C*7&&R?<<55M?!VBVDAD2
MW=W^R&R5GD)*0GJ@]!P/RK>HH P](\(Z+H<D,EE:XD@C,4+.Y<QH3DA<].:M
MW&B6=SK-MJT@D-W;(R1,'("JV-PQ[X%:-% &9KF@:?XCL19:G$TMN'#^6&(!
M8="<>E:2KM4+DG QD]:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;1-777+J^UN]BN8H9W.G1QQA1%&PQS[@<?GZU?O/#EG?>(K+6;C+362D0J%
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M8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3<"Q4$9'44M !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@ DX&3U-+110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17&Q_$:P;
M7SH+Z7JBZJ$,AMA"I.P?Q9W8J8^/[ :)J&J_8-0\JPF\JXC\H>8OJV,\@4 =
M917'Z?\ $;2M4\,7/B"TM;Q[&"01XV+YC].0N??IUI=;^(%IX?@T^74-+U%%
MU *L 5%)\QNB'YN#T]N: .OHKD=<\?6OAZXTJWO],O1/J>U88T"L0Y(&QN<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC5@Q>:\7Y4<'.%"]L5V]_P##[1-2UJ'6+IM0:_@7;%.+Z4-&/08/ Y-6-/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[N(]4MPQ*R*)67<1_G%>@_#O5K3Q#9ZIK=BI%M>7A9"PP>% .1]10!VE%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%7!;DG)SSVI:** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)"@EB !R2
M: %HJ"TO;6^1WM+B*=$<HS1L& 8=1QWY%3T %%%% !15"YUK2[*8PW-_;Q2+
MU5Y "._-6+.]M=0MEN;.XCG@;.V2-MRG'O0!/1110 4444 %%5%U6P?4VTU;
MR$WJKO: .-X7UQZ<T7^IV.E0I-?W<-M&[B-6E8*"QZ#ZT 6Z*** "BBL_4M=
MTO2'B34+Z&W>4XC5VP6^@H T**I:?K&GZJ9A87D5QY+;9/+;.T^AJ[0 4456
MU#4+32K&6]OKA+>VB&Z25S@*/>@"S145K=07MK'<VTJRPRJ&1U.0P]14M !1
M110 44UW6-&=CA5&2:PHO&OAV?S#'JD)6.0Q.V>%<=B>U &_12(ZR(KHP96&
M00>"*6@ HHK.U'6[+2[RQM;EG$M[+Y4(5"06]SVH T:*H:UK%IH.DW&IWS.M
MM NYRB[CCZ5;@F2XMXIX\[)$#KGT(R* )**** "BBB@ HHHH **@DNXD>2,.
MK3)&9#$#\V/I5'P[K8\0:-'J M9K7>S*8IA\RE3C^E &K1110 4444 %%(QV
MJ6/89K(\-^((O$FF-?0P/"@E>,+(03\IQDXZ4 ;%%%% !1167I6K3ZE>ZE!+
MIL]HEG,(HY)>DX(SN7V[=Z -2BH;FZAL[=I[B18XEZL>U3=: "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVK0AV24A<D$G!)!] *W(_!$*^,8]>:Y_=VME]CL[54PL(/5LY.3^ _2J.B>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]0^2>XBTUD2\EB7(B9N@]S]*EE\;6(C<P6\\LT5O]JE@.%=(\9!/.,D<@9H
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MBJUC>QW^FV]]$&$<\2RJ".<$9%<E;?$>RN-0TZV:QGC34+J2UA9R-VY>Y7J
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M%0#'?/4UT@\27,.I0:?>Z>(KFYMVEMPLP979>J9[&@#HJ0D*"2< <DUPTWQ
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M8-"JJDE5 W')P.II: "N9\4:Q8Z=J6D0WEX85DG+%/++!AM(R2!\HY[UTU%
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MHVGBSPMY%I<3V>G6AMYYP5"CY H/)R>1Z5I>/]&N];\+O!81)-=0S1W$<+G
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M?".GZ5?F$W%K'Y9:%BRD9.#R!7'ZCX%UFY'C1(A;XULQ"W9I,!0O4MQ7IU%
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M=G?VH1YY3-S*61B).<@<#@57TKP'K^E7'@^[66SEGT:VGM[@/(V#OR 5..<
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M\=0N8YHWN"UJ$7!CBP,*?4YSS0!H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9FKZ[9Z(UBMWYF;VY6VBV+GYVZ9]!Q6G7#?$D.
M?^$9\LJ&_MJWY89'?- '<T5POAW4]=TOQI<>%]:OVU<26_VR"^$"Q>4N<%'5
M>.IX.>U=U0 5B:_XJT[PW)9IJ N0;R40PF*!I TA. N0.":VZXCXF?\ (/\
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M89U8/Q;B0C" ]"!@G!]:KWLO]L^+?$FEWU['9FTMHOLC3%N$*Y,J88#.[^5
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M#R0R1E3 B'+Y8 #D?GFJTL"CX=^+(H;.>*7^TY7$94ESEU(8<=^HQ0!ZV""
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M<G\* ,]O 7AAKJ2Y.DP^;)<K=,02 9%Z'&<>^.A-33>"_#EQ<7T\VD6SRWP
MN6*\OCI].@Z>E:>FZI8ZO:"ZT^ZBN(2<;HVS@]P?0^U<YXT\40V.B:K:Z?J
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M:=JJ^#+VYTZX+WUV'MU\W:(6V,?FQUXSQ0!WV!C&!BC:/05P^G_$=;ZYN?\
MB3W26=K<R0W%T6!6$(,[C]?2G:?\2;*ZU8:?<VWV>26(RVX659"X'.U@/N,1
MR >QH [5XTD1D=%96&&!'!'I6=HVC)HL$UM#,SVS2%XHF Q"#_"/:N0T_P"*
M,=U!I%U-I$T5IJ4TEO'() Q6520%(]\=:U+?QW"MAKEQJ5F;.32'"S1F0-NR
M,KSCO0!L:IH@U6[LWFNIDM;=M[6R8"3-VW>H'I6M7#V?Q#\^6:*:PB$YMC<6
MT,%T)3)@9*,0,*W&:73O'MS?)HET^DK#8ZQ'BWE:Y&1+SA",=\=: .WP/2C
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M*O.9%#B-< C"#GMS7LOD1>1Y'E)Y6W;LQ\N/3%,-E:F%(C;Q&-#E4V# /L*
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MAOPW9/ GG:?JSW<WSC'EEB>/?FMRX\&WNHS>,(9L11ZJ\;VTF0>4'&1]0*]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<9\4/$=UX:\$W5W8F9+IBJ))'&6V9/)SC ..F:[.N'^*]G>:EX)EL+"SN+J
MYGF0(D*,V,'))QR!0!?TR[@TFYF\W4M0N5N(O/CM)HF>2$ G>V,;@"3QG\.*
MO'Q9HHL].NQ>!H-1?R[9U0D.^"=O3@X!X/I6#<RW&A>,1KDMG=W&GWUA'!^X
MA:1XI%)(!4<C(;]*YYO#>H::ND7$=C=S_:?$C:I-&D1;[-$5(&1_">1D>YH
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M%!>RZD-1MI50L(G!S@@XSZ5<T7PEJ]EXTN/$=_JMM*US;B&:"&W*@XZ$$G-
M$GB_Q)J6D726MC'!$#;O/]HN!N5BO\  .<UD7/CR_.@^'M1_T:PCU!"]Q<SH
MS0QD9PN1TR1WK1\0>";W5O%9UFVU**&.2Q:RDBEA+[0<Y9>>O/Z4S2/!^M:5
MHFFZ8VI6=S;VL,D,L,D)"2*3E3WY% '/^(O$9TWQ#X+UO6?)#B&\+_9VW(24
MPN#Z'BO1=#?4I; 3ZE) TDIWHL(X53T&>YQWKDT^&L6S0;6>>*XLM-AN(I(W
M0CS1*"#@=@,\5!/X?\3Z#X:73K+6Y;B5+H-:".'+"(<^62>V.YH [/Q#?W.E
MZ#>7MI"LUQ%&6C1C@$^]<7;^--52?5[626UN'@TL7T$B(0 V.5;U&?2NM\1:
M))XB\*W&E/<&WEN(@ID SM;@_P Q6%_P@UV]W/<SZG&\D^E?V>X6':H/]X<]
M/:@#,L/&FM0Z[X9CU)[5['6;5Y"(T(:-E4'DD^]5M1UK5?$_AR'6;<P+ICZG
M$B0.OSA%DVELYZY'2MK_ (0&8WGA:9[^-ET2-XW'E_ZX-@?AP*JO\.+Y-.ET
MFRUX6VF?:Q=P1BW#-$0V[;DGIF@#L/$.JC1-!N]0PI,*94,< D\#]:Q6NO$N
MG17#7DUE*AL6ECE QB< DJ%ZE<?RK?U+3(M5T:?3;LEXYXC&[8Y/'6N4TKP'
MJ-K:/!J/B.>_\J!H+-GB $(*[=Q'\1QD=: ,W^W/$E_X0N==E2P?3IM-6:"*
M1-Q$N1D,.XZTR66\N?C'H2B[=(SI#R^6!\HSMR *Z:/PE*O@$^&&U$@B$P+=
M)$ 0O8[>F:ICP/=CQ'HNLC5V$]A:&UF(C&9AQ^72@#,TGQ5>OX?;8MO#=W.N
M36*.D8" "3&XCN<#\ZU]9U76]%TG5&$]D\T<B?9I+B0(%C8@98>HYQZU7_X5
MTO\ PCUYIG]J2"26_>_M[E8@&@D9MW'//-17GPYFU/PW+8W^NW$^I2O$[7S1
MC(\LY50O3&: ,Z'Q->ZM:^--)NW66*PM08I=FUF#1Y.1]>E=EX-V_P#"%Z-L
M^[]DCQGZ5B6_@"6&[UNY;6)'EU>T2"=VB!PXXW ?3C%=+HVD_P!EZ!;:5).;
MA8(?)\PKM++TZ#IQ0!R>GZ_J,OBC3[>:Y$OG3W,;B.+]TJ*"4 <]6XYQD563
MQ1K;>(5L+R[M]-N1=NHMYXSLG@P=IC;N<XS5JR^'%Q9SV++XBN_*L+AWMHUC
M4>7$V<QY[]<9J9?A\JWMG/=:Q<W-KI]Q)=6UNZ#*,P/&_J0,GB@#F[;Q;XJ;
MPY%KKW=LL=M?M:SPRQ[?M"[\!E/KS^E;-QK_ (DU75-<MM(B(;3YUAAQMV,=
MBL=^>?XNU8G@#P\GB/0KI+FZNH[&/4Y)&LRNW>X;(;)Y Z<>U=5J7P^BO/$4
MFJVNKWUA'<;?M=M;MA9R!C)/4'''% %:/5M?U]M;.FW*6TVFLD44+@!7E"@O
MO)S\O/:J%H]U>_%"_GBO//EBT2.2%492BN7(95..A(K9U7X>VNHZV-1@U*\L
MDD58[NW@;"W"*, -Z<<9%3OX%M4UR+4;&\FLHELQ9/;1 ;9(QG;DGG@F@#&\
M)>)=1NM:M['5[N>VOF1_.LKV((78=#"1PR^O.:VM;UR9O%VG^&;:9[=[F!YY
M9E W*HX 7.1G/M2:5X*%GJ-E?:CJEQJEQ8HR6KSHJF,-UZ=3]:T]<\/0:R8)
MQ-):WUL2UO=1?>C/T/!'L: /-O%NKZA<^&O&N@WUSYATR.-HY@ &E1\'#<8X
M]L5Z/X4@\KPQII:1I6-LA#.!D#:.!@=*R[OP%:7N@WNG2WLYGU!E-[>8'F3@
M'H>P&...E=%I5A_9>F6]B)FF6! BNX .T=,X]J +E%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU<:A+%J]E&9+>&*502A/S$@@D@]*Z8D#K7F=_=74_P 7]&DABC%RVAS.B,>
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M;&5KG[47@4F?;M\SCKCM0!H4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 U41!A%50?08IU%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<QXPT?6=6;2'T@V8:SO5N9!<R.NX $8&T'U[UT]% '"2^&O$4VM^)K]_[
M-*:G9K:VJ"5P4 !&7.S_ &B>/_KUSVKV.J:7-X0T2WO]/M=2T^PG=I;G?Y#\
M(H"L "3P>/3\*]+L=;L=1U/4-/MI"UQ8,J3C' ++N'UXJW/:6UT%%Q;Q3;>G
MF(&Q^= 'E-GI6N>(O#!T2VBT,)I^H0W$<]JT@MW )=D&5)+ ]3_M5U$WAK6+
MCQ7K.K.;)(KO2C80HLC$[@6(9OEX'S<XS78Q0Q01B.&-(T'144 #\!3Z /-K
M;P'K=MX,\*Z*LU@TVCZA'>3.9'"N$9B OR]3N[^E86N3R:MXAUBYL;W2+;?<
M)!+;ZM%(K2"-  <#[R[MQ&17LU0O:6TLHEDMXGD'1V0$C\: .#T72=8UGQ#H
M7C&=;6$IICV\L'S*2Q;(91CA3@'!YYJMIW@'Q!8^#[.Q^WV1U6RU0ZA#(V]H
MWZ\,2-V?F/->ET4 <'?^"]8N/&5WKL5[:$7.C2:>RNK AVP=W';*U+I7@_5+
M/3O"%K/=VO\ Q),^<8PQ\SY"BA<_7G-=O10!XD1()M:O(-2L1J?]I7-U;Z=/
M;%I2ZLVP?[Q &#CTKU6:Q3Q/X3%IK%F8?MMLOVBW8Y,;$ XSZ@_RK3^RV_G>
M=Y$7F_W]@W?G4M '#Z+X3\162(FH:^+M;(,MA\I'48#2_P!X@$X'2D3P'=VU
M[INI66IQ0:I;HZ75P(,_:P3_ !C/M77C4;1M4?31,INTB$S1CJ$)(!_,5:H
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M*7 D4G)SQMSGMZ5<GNK>U"FXGCB#'"[V"Y/XT 95EX5TW3]=OM7M_.%Q??\
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M N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[$\SH?[FZO7UL;1+QKM;6$7+C#3",;R/<]:6*RM8'E>*VAC:7_6%(P"_U]:
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M 4444 %%%!.!D]* "BD!#*&4@@C(([TM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M("3G(QS2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exhibit101-iansconsultin009.jpg
<TEXT>
begin 644 exhibit101-iansconsultin009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@N(Q));DC[DA8?\ ?+#^
MM3U%*%+Q90L0_! SCY3R?3_Z] $M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5'*^UXA@_,V._H3V^G>I*K71Q-:?+G,I'3./D:@"S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[D RVN0.)3C)Q_ W3
MUJQ4$Y826^T<>8=W7IM;T]\=: )Z*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JO<NR2VH'1I2#QGC8Q_I5BJMV"9K/Y"V)B<@?=^1^?Z?C0
M!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH :L:H7*C!<[F]SC']!3J** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JUV<36GRALS'DC./D;G_/K5FJEZP$]D"H;,Y )SQ^[?G_/K0!;HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKC=L(7.5.WD@^F1F@#DO!M_HFK>+(YCI']@^)+2REAN=,\H+F-GC.\,  P!
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M::6T%A9ZI)I\5RMG<[B;J9@=T,;[E"E2.IW9R.!3Y?!^ORZ!9Z-<S:-?6BV
MMIX[B)PHD&=LB=>0#[9P.E5=0^'FL7.EIHHU&SN]-%E;VJ37J$S6S1\,\8 Q
MDC'4YR!DG% &S/JLEMXYU>*'3K:6>#2$GC=%/G3?,WR%N@&1P,<Y]JR6\6:G
MJW@+6M2M-0L&9-/\V&XM[=U\F3Y@\;J68[EP,'C.>G%;$_A;4CXBO+VWOXXK
M>725L8G&?/60'(<L![GO5.T\#W\UUK=YJEQ91W.H6/V$?8(BB..?WLBMG+]
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M[@>A(.,XR.._>II/A_K.EV>ES>&]?%OJEG;_ &65[B/=#/%DMRHZ%2>*T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?,3,5!)0]UZD'TH Y+6/ $?]GZPVG7>K/>ZDD2'_ $[RPCJ !+TY/ +9R3C
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M4C&=H)R<9'3UH IZ_P"'M.\3:>MCJ<<CP+*LH$<K1D,IR#E2#P:@UWPII_B
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5_\ \?%A_P!?!_\
M1;U=JC?$_;-/!7Y?.8[L]#Y;8&/IG\J +U%%% !1110 4444 %%%% !1110
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MTA],L)'G=[*V9IP!,6B4F0#INXY_&D;2]/>U6U:QM6MU.Y8C"I0'U QC/)H
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M[>>&.;85MUED"B24CY5&>O->;:_H^J>#_#NB>([N]TZ[?0YS,[) ZM*LQ E
M;>1W!''\(Z5ZS=65I?(J7=K#<*IR!+&' /XTLUI;7%O]GGMXI8./W;H&7CIP
M>* /-?$":+XC^*?AN*ZN(I[*YTFYVHLV%FW%5VG!Y!!;CU'M1XBTV^\+>*$E
MTJ'&EZ[:II'EQ %H;@*5A;!/W=N[)YX'/:O1$TC38Y(I$T^T5XN(V6%04YSP
M<<<D_G5ID5BI902ARI(Z'&,C\"1^- 'G6N:79>']8^'NDV@6."WNWCC!/)Q'
MR?Q)_6N4U1[<?#/XD.&B$T'B"XDA8$;HVW1;67N#P<$>AKVR6TMIY8I9K>*2
M2$YC=T!*'U!/3H*A.DZ:R2H=/M2LK!I%,*X<CH3QR>30!Y)XZN;:ZU3QB6#6
M\EMH@B/GQ>8;@_>!C'.%!89<<@\\;:;XB,4EIJ>J6=Q#-)/IUO#>Z?<GFZC$
M8*FVD4[@V6(Z<MCIBO8Y;2VG8M+;Q2,4,9+H"2AZK]#Z4CV5I(T#/:PL8/\
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MV@>&-.6ZM9K658%7R9W#2(HX7<1_%@#/O6M110 4444 %%%% !1110 4444
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M?^$7T?6K2)8=?TF2)X+;8,%Y,1-'M4G@AC@ \X H [#2M7MM8BGDM5E"0SM
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M3P<'\JT)I8X(9)I7"1QJ6=CT ')->>:2NK>$+37[BWL=3OM.MQ%]ECOY4\X
M$^8 Y;F-1@C)]0*ZG4X4\7>";B.RGN+==1LR8I!F-UW#(SW'H?QH B3QKI;W
M\-DT=Y%/<QO):++ 4^TA>H3/?C@'%9GA[QPUUX:EU?6;2YM URT4,7D\L2Y1
M(EP3N?(P>V369X=@UJYO-'%YX(T_3+VU<O>WKQ1$;<,J^0RDG<>,],#/J*K7
MVCZQ<^#H/L>D3_;]'U]M06WE"Q_:E69V^0YYRKC!.,T =YI/B*PUFZO+2W:1
M+RR*BYMY4VO%NSMSVYVGH:U:P-!N]4U&]FOKK1AI5K)"@6.8J;B1^<EMI("@
M< $YY/3I6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !52]&9[+Y@,3GKW_=O5NJ5ZY6ZL%"\-,V6(! _=O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5&_'^E:>V3Q.PQV_P!6]7JHWT@%[I\>PG=*QW8X&(V[^O/Z&@"]
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[W'GV.?^>YQS
M_P!,WJY5*^!,]A@=)S_Z+>@"[1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9^H/.M]IH14\IIF\QBY##]V^ !CD=>XQ@=:T*JW<ACFLP #O
MF*G.>/D<_P!* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 52O7 N[%&C8@RL0XQ@$(W![\@G\C[5=JG>?\?-CE@%\UN,<D[&_IG_/4 N4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45YAXO\+G3O!F
MK:]>:I>?\)%$'N(+R"XD4*^[,<:1@[<'"K]W)SZUZ!HDEY-H6GR:@NV]>W1I
MP1@ARHSD=CGM0!?HHHH **\XL?$^L>.O%.KZ3I%PNFZ-ID@AN;V/#7$KG/$>
M<JO*D$D$X/&#6E:6-[X.U:6[U'Q+>W7AN*P;+:E*LCI-Y@))8*"PV] <]P*
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M22L: =,DAC@^E 'I]%>66&MZE!I?AWQ3-<W3R:WJXMY;6:X9HXX9G*QJB [
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MFQXVTW^T!;M!>+;M<FT6_,8^S&4?P[\^ORYQC=QUJ-_'6GIKJ:9]COF1[S[
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M35.PU[2=48+8ZE:W#GHJ2@L>,].O2@#COB-(L/B;P-(T;R!=6)*HI8_ZL\@
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M?L]0M8]JRF,2VDB@D1G)(P21DC@9/7'/J-9EIXBT>^O19VNHV\MP5++&K\L
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MF(V+GG8 , $G%=N!@8[>]<MI?AG4O#TES!I&HPC2Y7>2&SGA)%LS'.V,@C"
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M;G:QA9O.NE57^5&W (H."<X'?/&#SS:KJ.N>$O#$FI7ES)*GB=K;+2G=L ?
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M8@CD[4Z\?SS_ $K4\=ZU=Z7;Z196<DEN^J:A%9M=(H)A1NI!/ 8XP"0>3T-
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M(4;U0D''91D^M>C^#X=:M--N;/7=0AOKJWN"BR1MN(C*JRJQP"6 /4CGKWH
MZ&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG?#,]AR!^_/X_NWJY52\
M?;/9#GYIB.#_ -,W/]* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!STW@W2VU&YO[1[S3[BZ!^T&QN6A$IQC<R@XW8_BQ
MGOUJ2Z\(:)>:0NFRVA\E9%F$BR,LOFJ,"3>#N+\#DG-4-+UW5/%%Y<7&D>1:
MZ/;N\ FG3=)<2KD$J ?E0, .>3STXJ]X:U/5+R&_BUR&U@O+.Y,+_9R?+*[%
M96!;GD,/ITH D;PQ8R6^HQS27,SZA"(+B:27<YCQMVCLHP3T R23UYJ!?!FD
MK=Z-<XF,NCPF"T)?[J%2F#QS\IQ6Z)X2C.)4*I]YMPP/K4$.IV%Q&LD-Y;R(
MT0F!60$&,]&^A]: ,RS\):?9S6+F:\N%L6=[:.XG+K&S=2 >I ) SG&3C%5V
M\!:$ULUL8IQ;?;%O8X%F(2&16+9C ^X"220,9KH!=VYMQ<">,PGI(&&T_C1%
M=VT\T\44\;R6[;)D5@3&V V".QPP/XB@#'D\(:3-J>JW\L<KR:K;?9;M"_RR
M1[=N/4<$\@]ZA3P1I<6EZ?IR37X@L)EGAS=,S!UX7DYX Z 8'M70+/"_W)8V
MXSPP/%1K?6CF,+<PL9&*( X^9AG('OP?RH PKKP+HMX-;$JW&-:*&]"RD;]O
M3&.G6N1UGPI)%XNDNVTC6[R**S@@L[G3;Q8F55W;@Y+*2V<'/TKT]9XFW;94
M.S[V&'R_6EBECGB66)U>-QE64Y!'J* ,;PG87NG:&D%Y).WSEH8[B7S9(8SC
M:C/W(Y]?3/%6]1T6TU.ZL[N;S4N;,LUO-$Y5HRP ;V((&,'(K,\>:Q?^'_"%
M]J^G26RSVH5@MSPCY=01G(YP3@=S@52M?$NI6&OZ/I^L_9I(-9@+6DL"E725
M5#,CKG[N#PPSSP?6@#:MO#.F007L<L3W9OABZDNY#*THYPIST R< 8 K*LOA
MUH&GZ;>6,"W/E7<#6TADG+L(B,%%+9V@CTKJ%GB=MJRHQ] P-1S7]I!:37<M
MU"EM"I>65G 5 !DDGM0 RPT^+3]-AL(V>2"&,1(),$A , <#D8J&TT.QT_1C
MI5C$+6U(88A !^8DL>F,G)J>;4K&V,HFO((S"@DD#2 ;%.<$^@X/Y&G"_LVO
M19K=0FZ*&00AQNVYQG'IR* .>G^'V@76C6.F3Q7#QV (M)OM#"6$'L'!!QCC
M!XQ4UUX%\/W>@PZ.]F5MH9/.B=9&\U),Y+A\[MQ[G-;AO+5;L6IN(A<%=PB+
MC<1ZXJ.?5+"U*B>]MXRTBQ#?(!EVX5?J?2@#)B\%Z1!9V-O;B>)[*?[1%<+*
M3*7P5)9CG=D'!!X.!Z5I:/HUEH5C]CL(BD9=I7+,69W8Y9B3U)-5/^$GL#XQ
M'AE&#7@LGO)2&&(P'154^YWD_0>]:L=Q!*[)'-&[*<$*P)' /]10!CZOX2TK
M6M5M=4N4G2]ME*)-!.T1*$Y*-M/*GN*J6O@'1+&QL+.T%U##879O+4+.3Y3D
M8P,YRN"1@YZFNF>2.( R.J ]V.*02QF0QB12X&2N>1^% &'+X.TNY_M9;K[1
M<Q:K@W,4\N]"P  90?ND  #'H/04S3O!6CZ;J=MJ:?;9[ZVB:&.>YO)96"'J
M/F;&.V,5:GNKV77-*:QN[$Z7(DWVE6;,LC8&SR\<8!#9KCM7\;:QIWAKQKJ"
M^6;C1[P0VH: B/82F,G/S-\W/X>M 'HTL4<\+PRHLD<BE71AD,#P01W%<[I/
M@30M$NYKFQAF1G5E1#,Q2 -G/EKG"=2..@X'%;>FSO=:59W$F/,E@1VP.,E0
M37*>&_%T]UK_ (CLM8N+:&*RU$6EHW"!\J"%Y/+<T :#>!M)-CI5HCW<::6Y
MDM728AU;GDMU/4\=#WK%TKPXNK>)O%=Q?V^I6MM=7<( ,QC2[C2,1G*J>5)5
MN.,@C/6NVO-0L].C22]NH;='<(K2N%!8G  SW)JR"",CD4 <YK7@;0M=NK:Z
MN;>2*>W3RE>VD,1*<?*=O5>.E6?^$7TY=8L-2B,\4EA$8;>*.0B)%;[PV=.>
M,GKP/05=FU?3;>1DFO[:-UD2%@T@!#O]U3[GL*DO=0L].@\^]NH;>(D+OE<*
M,D@ 9/N1^= &!9> M(TZ 164M] 1>->^9'<L'\U@ V3W! &0<@XI;CP!X?N]
M)CT^XMI9?*F:X2Y:9O/61OO/YF<Y/]!Z5IW'B#3K?7;/1VG7[9=Q/.BC^XO5
ML].IQ6I0!SD/@?1K6*S2S6YM7M)C/'-%.WF,Y&"69L[LC@@\>U4K_P %QFYT
M9M/:9'L;J2Y^TR7!8AG8,Y*_QEN1VQFI[?Q5)>^/5T:U1&T]+2<R3D8)N(WC
M!0>P#]<8.>O%4M0U[Q%J7B6;3_##:0+>Q=8;TW\C+(7(#'RU4'("D<G&3GTS
M0!VU<G<?#K0;D.&^W(C7HOO+CO)%C64-N)" [1DYR<9Y/-=8,X&>M<UXXU^;
MP_X8N+^REMQ<QRPH%E^8?/(JD8'.<-Q0 Z?P3I%Q/K<KB<'6HUCO0),!U4$#
M''& 2./6FR>!M'D&G$->13:?%Y$$]O<M#)Y7]PLF,KP*Z*2:*+_62(G?YF H
M$T1D\L2IOZ[=PS^5 &?HF@:?X>M9+;3DE2*21I662=Y/F)).-Q..O;\:DU#2
M8=1N+6X::XAFM69HG@?:>1@@]01[&K,MY;0)OEN(D7>(\LX W$X"_4D@8J1'
M61=R,&4]P<B@#GY/!6COIT%E&MS L-R;M98+AXY?-.=S%P<\[C3)O 7AVXM-
M7MIK'S$U>19;LM(V7=?ND'/!'7CUYS3-9UZ[7Q98^'K":*&6XM)KEIG4-@J5
M"KU[DG/T%:.CZF\EC80:K<V2ZM,C;XH),AF0X?;ZX/7T- &9#\/M#@TF[TZ(
MW@2\PMQ,;EC-(@Z)O/(7V&._J:TD\-V:Z[;:R\MS+>6UN;:-I),@(>N1CDD@
M$GK6HD\4APDJ,<9P&!XIIN[8-&IN(MTA(0;Q\Q'8>O0T )>VD.H6%Q97 )AN
M(FBD ."58$']#6/;^$-+AE223S[EX[,V,9GDW&.$C!48QU &3U.*V(+RVNI)
MHX+B*5X&"2JC E"0& /IP0?QJ26:."-I)9%C1>2S' % '*1?#?0(+'3[6(Z@
M@TZ1GM9%O9 \6X895.>%([#^IH'PV\-IILEA%!<QP-="\3;<OF&49^:,D_)U
M.2.3GFNFCO[2596CNH76)S'(0X.QAU4^A]JD6XA>(2K-&8ST8,,'\: .=U3P
M#X?U>]M+V[MYVNK:-81,+A]\D8.=CG.7')SGGFKD/A>PMM4DO[5KBWD:U%H(
MX9=L:1C[NU.@([''%:5M?VEY:+=6US%-;M]V5'!4\XZ_6L^^U)K_ ,,W5[X?
MU"P:8Q,;>YE?= '']XCMD4 48_ >BQ:1:Z8HNO(MKPWJDSDLTI))+$_>Y)/-
M&J^ /#VLZN=2N[1C,^WSDCD*1S[>AD4<.>W/8 =*TK;6+6*QL!J&H60NI[99
M24D 63 &YDSU7)'/N*CU/Q-I>EWNF6<]RAN=2F\JWC4Y+8ZM]!0!4D\$:-+>
MZM=F.82:K:_8[D+)\OE;=NU1_#QZ>M-?P+HKP:5%MN4&EHT4!CG9&*-C*,5P
M2IP.*Z4'(R*B6ZMVE,2SQF0'!4,,C\* )    !@#H*P(/!NDP20DBXEA@N6N
MH()9BT<4C9)*@]LDD \ G.,\UCZEXFUB_P#%.L^'_#S6D=UIUC%,K7*Y$LSG
M(7(/"[1Z9R?:NIN);V/0)I2]M#?K;,=SL?*23;U)Z[0?TH Q9_ .D76@OHMS
M/?SV+W!N&66X+L7)W$[CSUR>O4FGWG@/1+]]0:<79%^RR31K=.J>8I4B0*#@
M/E5Y]JU;"\>'3["+5;JU_M%[97F\I\([!1O9,\[<G]15J.]M9H(IH[B)HI0#
M&X<8<'T/>@"BGA^V37%U<3W1NEMA:C=+E=G7IW.><GG-/T31+70+%K2S:9HV
ME>9FFD+L68Y8DGDY/-:'FQ[RF]=X&2N>0*CCNH)V989XW9>"%8''&?ZT 4M<
MT&Q\06L$%\)1]GG2Y@DAD,;QR+G# COR?SJ$>%M):UU&">V^TC4CF\:<[VF.
M-HSV&!T P!3/#ESJ<EK>G6+[3KB2.[D1&LR=J1@_*K9Z-@C-:L%Y;7-N+B"X
MBDA/_+16!7TZT 9GA_PKIGAJ.5; 3DR8W//.TK #H 6/ ^E7-7TJVUO39+"[
M,@B=D?,3E6#(X=2".A#*#5Q)$?.QU;'7!SBL#7=6O=.\0^'[>(QBQO)IH[IG
M4Y4+"SJ0>@Y7O0 ^Y\(:5>V>HV]VL\YU$*+F5Y2';;]W&, 8]A4=MX)T6WU&
M/4&BGN;E+,V1>ZG:7?$220VXG=]XCGMQVK7M=4L+VRBO+:]MYK:89CF20%7^
MA[U.]Q#'-%$\J+)+GRT+<O@9.!WXH Y:?PWI_AC35OM-TV^U Z=E[/3UN25C
MW<-Y88XX!.,YQSCK46C>'VU:/Q))K=DRV.MRJ5LIP Z((U4[MI(!)&<@YX%;
M'BOQ):^$_#UQJ]U&\JQ;52*/K(['"CVY/7T]>E96N7OBK1_"TVKB33Y;FV1I
M[BV\MMHC')"L#DLHS]2.V: +FD^!?#^CV4UK#9><LT9A=[EC(YC./DW'D+P.
M!QGFFZ+X#\/:#'*EM9M*)(VA/VJ0S8B(P8P&R I].];EOJ%M<6L-PLJJDT2R
MJ'.T[2,C(/3K4DEU;Q2QQ231I)("45F + #)(^@H I:)H=GX?T];*R\XQ+@
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MJRO!.&VRQ,O1E8=#CCCJ,CO4NG:-::9-=7$0>2ZNW#SW$K;I)". ">P X &
M/3DUB^)_$[Z9?Z':V$UO(]WJ\5C=(3N**R,Y[\' 'YUI^)M1FT[PUJEW930)
M>6UJ\T?FC(RJD\C/M0 ZS\.Z786>H6<-JOV?4)I9[F-_F5VD^_D'L?3WK.M/
M FBV=SI5RAO7FTO=]E>6[=RH*A=N2?N@#&T8')XYI-%U'6M3T_PQJ#2V26]W
M8)<7Z-D2,[1JPV#TR3FI#X@?6/#6J7FB3VD4\+2Q6T]R_P"Z++P';'(7/\J
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M,\88C\Z<UK;O,LS01-*@PKE 6 ]C0!XC=QZ)#\-+ZY@^P"6R\1EH6RN]5%X
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MO=-W10QS7,6HHV(94D?=MZ9W@MC&,<=>F0#T^#Q+9W&L7&EQ17#74%FEX1M
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MZ))$8]^=S C=YN#C'<\\#FDGTG6D\&^,;230+XRWFKO=PQH\+-+$[HWRX?J
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MIZM!$S):7U@8F1DSD"0,R^61NQD\'!Q5_5QXBC;2=??2X[B:RN)FEL+4AI1
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M6N@3-:8[3$GG_8:@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M85,LF.O(Y/<GM4FL>(=8U&]\)RQ^1!;S:T\#+')OCN556:.17!Y0@9Z=?IR
M>BIJ-G)J4FG)<QF\CC$KP@_,J$D D>F0:LUQ5]XE^P^*?$,45A9M<:=HXO#-
MP))0"QV,PY &#CZTNG>+=3DU#PQ'=V=K]DUVR$R21R_/'*(A(RD=".>H- ':
M45PR^.;^XTVUU"UTR(P3ZL=-97E.Z(;V3S" .?F"\#GYJZ[4-/BU73);&[W>
M5.FV41L5)'< ]10 MKJ5A?/(EG>VUP\1Q(L,JN4/H<'BN=OO#GA2ZUZ9YK@0
MZE<LIEAAU!XFD;'!**PR2!Z<XK'DTBRC^*6FRZ'8)!'IUE(E]+;?)$H(^2)E
M'&[G=CJ!U[5S O9+_P""WB/Q9ND34KRY-XLH8AX2DJ^6JD8QM  XQGG/4T >
MPI]ATJVM[96AMH<B*%&8*">RC/4^U2SW5O:A3<3Q0ACA3(X7)_&N3UT'4-)\
M)WEQM:8:C9S9V_Q,,''I]XU5^(*S6VI^'M6M4-Y=6=Q(8], &;K*$-M)X!49
M.3].] ';6]S!=PB:VFCFB;H\;AE/XBF7.H65FZI=7<$#."5$L@4L!U(R:YKX
M<M:2^&'N[2[,ZWEW-<R(01]GD=MS18/(VDXQ69XO?5_#WB=/%%GH_P#;=D;0
M6ES;1J#/; ,6WQ\9*G/(Y/ /04 =Y!<0W,(EMY8Y8FZ/&P8'\14E>5Z[J,*>
M ]'NO"MU$FFW6M1;U$93_67&6C XV@,2#QVKL#K]]=:YJ6EZ=:V\TFG6R/.[
MR$#SG!*QC STP<^XH Z2J5]JVGZ9+:QWUW%;O=R^3 LC8\Q\9P*YZQ\7W.J2
MZ+:V]BL%W?VTUQ,EPQ_<>60I7@<G<<?05Q?C_6;J?0_"]_KEG_9TMMX@"R[C
MP419/G'?! SB@#V*JEQJNG6EPEO<W]K#,_W(Y9E5F^@)R:KZ%J%UJFFK?7$$
M4,<Y+P*C[SY>?E+'IDC!P.F:XKXAHA\>_#XE5).H2@\=?D% 'I ((!!R#T-%
M<+J_BW5X+[Q196$%H)-%MX+M6ER1+&P9F7CH<(0#VS5FR\:OKD]E:Z/;QF>Z
MT@:I^_)&U6;:J\=]V>_:@#L:*XV#QI>R2:1:W&BSV=Y>023SQR(\GD!'V8.P
M$_,2"/:J-WXXU<:7I$R:8+.YNM<CTR6.ZC=04+,-Z9 .&"\>F: /0*KSWUK:
MW%O!//''+<L4A1C@R,!D@>IP,UYIXJ\;ZF?#7C2PA6"#4=)\N,R)DJ8YE."-
MW?(8<_6MZ6_?3G\%V\UO;2RW.Z%)9'9C&WDD@J><D@8.: .UHK@V\>7WV+6H
M8M.@FUJQU(6,%@LC SAB-K9(XRNYO0!3DT:MX]N[6ZU6.QTZ2[;2YUB:"&"6
M5[@^7N*@HI"'YAC/I[T =VS!5+,0% R2>@JC#KFDW+*L&J64K,VU0EPC$GT&
M#UJQ9W O;&"X\IX_-C#F.12&7(Z$'O7CPLGO_!7C73;'2)+^^N/$5ZEO'%\G
MED.I#;^BXQG&1GI0![ ;^T&H+8&YB^V-&91!N&_8" 6QZ9(_.K%<#$L]M\5=
M.68O).GAE_, ;.]A*F<^ISGGWJ?3?'DUYXCT72)K6V2?48)Y)8DFW/:/& 0C
MC&,D'IU% ';T5YI!X\U^\TN/5(K&T6WBUT:=<)&6EWQ$JF]6XQAF))([8]Z]
M+H **Y_Q'KUYHUWID<%I UM<NZW%U<3>7';@+E<GN6)"@>M<M'\49)?"^E:L
M]@EL+O4'LKF5V+16H5F&]B!D9P.H'6@#TFBJ&CWYU/3$N]UNZN\@1[>021NH
M=E5@PZY !_&N4\1^/KCP]-J@FLH MH\(@1Y6#W*,R*S  ' !?'/!/&: .ZHK
MA-9\7ZQ;:SXHL[*WM?)TBP@N4DE))9GWD@@>H&/;'O4&G?$.]O-;\+P2:="E
MIXAMFGBQ*2\(50?FXP<Y_#% 'H5%>?S^/KYM]_8Z=-=6$-VUN\$5I,\DD2R;
M&F1@NTD8)V?KQ3M0\9:M';>+[FUCM0GAZX4[) 3YT2Q"1QD=&.< ]O>@#OJJ
M:;JECJ]J;G3KJ.Y@#M'YD9R-P."*PK7Q4VK:Q;Z7IJ1?:%L8[Z[,I.(A)C8@
MQU8\GV 'K7%^!/$SZ1HMIIOV>-KV]U.]:2-=S>4B,2S *I+<X'3O0!ZY56'4
M;.YOKFQAN8Y+JV"F>)6RT8;.W/IG!_*N,LO'.I2V]G92Z84U:ZU!K*!KB.2"
M.>-4+M. R[@-HSM/.3C-2^%3<#XC^,4NIT:41V),48.P?NW^89[G'/\ NB@#
MN***X*;X@W-OK&GV,]C;Q27FHO9_9WG_ '\:#.V0J 1SC.,].F: .]IDLL<$
M+RRN$C12S,QP !R2:\^O/'&MPZ=KFH1V%FL>C:D+:6)Y"#-%P,JQ  ;+AL<Y
MVX&2:V=2U^;4;K7](TM8&?3+93<M,2=S2*Q"J!_LKR3W/L: -F+7]*FT,ZU'
M?1-IH4O]IS\FT'!/TR*TJ\NL8VN?!'@GPR(/,BU...:Z#L9 (4 E8'?G@MM7
M;T . ,5T$GB[49-*UW4[+3(I(-)N986C>1A)*L6/,*C'7&<#OCWH [&D9E12
MS$*H&22< "N0F\4:M=7[1:+IL=U%)IEOJ$#.^PD/)@HV>A*!B.V5YZBNDU/3
M8-6L6L[DL;=R#(@QB0 YVG(/!QS0 ^SU&QU%':QO;>Z5#AC!*KA3Z'!XH74+
M)KQK1;NW-RO6$2#>.,_=SGIS7%V>C06_Q+GO=%CBM+*RT[R+R*W4)')(0#&"
MHP"50#KG ('%<I',8O@SI_BR)5754U-;X2$*=SR77ELIP.5*L1@>@]* /8WN
MK>.X2W>>)9Y.4C+@,W4\#J>A_*FW%[:6907-U# 7.$$L@7<?;/6N9\06ME_P
ML#PC>%(Q?F2YB5NC-%Y#DCW ./INXZFL3XAW=SH_BK0=:L+4ZG=00W$9TR,9
MDDC8 EU'/W2 /QH ]%BFBN(EEAD22-AE71@0?H14-SJ-E9.$NKRW@9E+ 2RJ
MI('4\GIS6%\/H;6#P1IXLKM;JV?S)(Y%7: &D9MH';:21SZ5SOB>;4?"/BZ[
M\0IHDNM:7J,,4%RL W26GE@\[><J=V3@?P\T >BQ313QB2&1)$/1D8$?F*?7
MDNMZD+'P_P"$(O"VH!]*U'5 I+ H74DN%)XP 001CFNR7Q->:C/K<6BVT%RV
MD_NGWN5\V< EHUP.W R>Y]J .HJK-J-G;W]M8RW,:7=R&,,);YG"C+$#V%<U
MI'C1_$MQ:KHL%N\36"WEP9I3NB+DA$P!R<JV3[5AZOKD46J>#?$?B"V_LF:$
M7JS1RN/DS$<@'ODJN/K0!Z75&ZUO2;&;R;O4[*WEQG9+<(C?D33-$O+W4--B
MN[VVCMFF&](D?>54],GIG&.E<MK,MK#\6=)-Q;[P=)N#E8?,)_>)V )_I0!W
M$<B31B2-U=&Z,IR#^-.KRW2]6U7PCH=WJ5QICPVVI:XJ6EC</M:"*0X)XS@E
M@6Q[UU!\6S_VIXMLA:1_\2*WBGC8N?WV^-GP>.,;<?C0!U55=0U&RTFR>\U"
MZBMK:/[TDK!0*XNU\::W/%8WKZ5;K9ZM!9G3_P!Z2?,E0M(& &<+].GXXI?$
MFZU"]^'/B>#4;)+/[--;BWFWY6=?-C.X=P<Y7GOZ4 >DHZR(KH058 @CN*=7
M*:;XAO8O%<V@ZA'"V=-74+8V^20@8(RMD\MGD'W]LU!I'C>34/$.FZ7-;0QO
M>VLLK*DFY[>2,KF-^V[##CJ/Q% '945PVE_$ W]NETT-LL$*3OJ,0E/G6/E@
MGYXR-W.TC@59T[QA>WE_HD3Z1/\ 9]3B9GE2"4"U;8&4.64#!SMR#UH ZF[O
M;2PA\Z\NH;:(G;OFD"#/IDTEK?V=\F^TNX+A>N89 X_2N3^*]O'/\-]5,D7F
M"$),/FV[2KJ<_AZ=ZH26-SJ'Q#\.:AI%K-;6]K9N+VZ:WV))&>D7S $G/.0.
M.?4T =Q8ZI8:D9Q8W<-QY#^7*8F#!6ZXR.]6Z\>\(:W<^']+\4W5II[7C-XD
MFA*@[5B5I&!D8]E7OZ5MGXG2/HOB6[@L[>631KE(%>.8F.=6( 8''O0!Z-17
M-V'B.ZF\:3>'KJVB&-.34(IHV/*M(R;6!'7C/%7/$FL3Z)8V]Q!:"<274<,K
M,^U((V/SRN>RJ 2: -BBN%7X@L- ;5)+6W\E-4%B]RD^ZW6,MCSMP&<=!TZG
MKCFND\/ZG=:M937%S#;HHG9()+>821SQ#&V12.QS0!K4444 %%%% !1110 4
M444 %%%% !1110 4444 %5+R3;<62!@"TIX/4@(W_P!:K=4[U0;BQ/<3G_T6
M] %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZT
M44 <=IWA+4O#5U>#PYJ%M'87<K3FUO86D$4C=?+*L,*>N/4FG:KX,N-9L;66
M[U1O[7M;M;V"Y2/$<<@7;M"]=A'49R3SFNOK$UOQ ^DW$-K:Z7=ZE=RQ/,(;
M8H"$0J"3N8=V  ')H P[WP9J&L#4+_4KFQ_M>YTYM/A>*%_+@1P0YP6R2<^O
M84D7@K4X[WP=<?VC:$>'H#"R^2_[[,?E$CYOE^7Z\^W%==9WHO=+@OHX90)H
M5E6)QM<9&0I'8]JJZ7K]EK%[?VMIYIDL9!%<;XRFUR,[>>O!!_&@#A-0\-W?
MA;P+XQ:]U*VF7496NHR(F41LV 01DEAP#@<]:TU\(7NOW*:IJVHVQ>/3I+.Q
M^Q1LJ*)4PTAW$G=TQS_#[UVMW96E_#Y-Y:PW,6<[)HPZY]<&I(88K:%(8(DB
MB0;41%"JH] !TH XG0?!VL::_AN6?4;7=I-I):211P_+(A "L#UW?*I)Z=>.
M]5_^$ U1O#2:9)JULTPU@ZF9/(;;@N7V ;LCD]<]*]!HH X2\CTOQ7XYT:\T
MN>.=].,PO)HCQM1@!$^.IW_,H/'RL1FN[K!;Q)9+JS:5IEI-?74<N+I;55"V
M^>2SLQ SSG );G.*WJ .)/@J_O-;L+[4=0MG^P7KW4%Q!$R7)0LQ$+/NP4P0
M",<@8K;\4^'8_$VBM9&YDM)T=9K>ZBQYD$BG(93V]#[$CO3->\56NA3);"SO
M;^\=/-^S64.]Q&" 7/0 #/<Y/;-.;Q;H_P#PCB:['<-+92$+'L0[W8G 4+UW
M9XQ0!B'PQXKEAEN+CQ);-JGD_9H9DM66..,XWG;NY<D?>SQZ5-H_@ZZT'Q;<
MZCIMQ9P:7<PI'-9K$Y9V48$FXMC?V)QR/?FM*V\8Z5+;7LER\EC-8;/M=O=)
MMDA+@%1@9#9SP5)!I-)\7V.J:Q-I+6]Y97Z!I(X+N$QF:(''F+_LGT/([@4
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M))XXJA'\-;N#1K86NL_9M:M+V6[M[V.$8Q(V6C<=64CJ,BNFTSQ1'J7BW6-
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MBB@ HHHH **** "JMV<36G'68]L_P/\ E5JJ=Z!Y]CP3^_/3M^[>@"Y1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V1_+B=\9VJ3
MBG44 >71:CJM[\-E\=PZG?)J7D-=_9O-S;E0<>7Y>-I&T8SC=DYSTQ<CL?[2
M^+$=Q+=W\)FT*&Z\J*Z9 K"7!7:#]WU!XR3^'2#P5HHGD98IUMY'\Q[-;AQ
M9-P;?LSC.1T'!YR*OR:%82:XFM!'345A$'G+(>8MV[85Z8SSTS[T 7I[B"UA
M,UQ-'#$I +R,%49.!R?<@5Y-J$][INB_$V^M9)[:5=1C:&>,E#D)%G!'Y&O3
MM9T>RU[3)=/OXR\$F#\K%2K Y# CH00#44WA[2Y])O-+EMM]I>;C.C.Q+D@
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MY=QX=M6%S9CRO,S(YW+G)4'J.>AZFNKU/P3HFJZHNI313Q7101S/;W#Q?:4
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M!YP,8P?6O5K.<W5C;W!7:98U?;G.,C.*RIO!^AW%AJ=E/9&2WU.7SKM&E?\
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MK1:UO('D'DN/+;:P7& VY5.1R>1WQ7?+X6L$U34]266Y%UJ-LMM(XE_U:*"
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M#Y@LJA5!?)P.IK/\$W>GZ7X@TVUN_+_L^]MC+X;DDD!,43MDQ'OO.1@G/'%
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MUKGKZWTFX^,FGV;16C:=)H,C>3M41D>8&!QTQU- 'I\ES!%!Y\DT:0X!\QF
M7!Z<T^.1)8UDC=71AE64Y!'L:^?O#.H(?"?@J?7KVZ30XQ=123 +)''-N C\
MT,&&T#.,C@XKUSP-:Z7:Z3=#1KVZN["2Z:2.2;:$&57*Q!54",'H,=<T =/1
M110 4444 %%%% !1110 4444 %%%% !1110 5!<*#);9)&)"1@9S\K5/5.]Q
MY]CG'^O.,_\ 7-Z +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#'SMR6(&YB#@#)X)X%7?#^NVOB31+;5K*.>.WN%W()X]K8_4?D30!I!0"2
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MU8DC\()J5[?ZG*=&2*(P_:)&D:$C<&4<9;.5(ZDDD=A0!T!@B*!#$A0=%VC
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M)0I.1DDY.!P/PYVQ\):[;^ _!&EO8'[7I&JPW5V@FCPL:,Y)!W8/WAQ7J5%
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M9WGTY[S1HY(=#T^*:(Q2I;1J\9Q\I"@$<<5>HH **** "BBB@ HHHH ****
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MDENLL;X##!_C4GMQ_.MC_A(-:@\6:GH5X;3)TIM1LY(4/[H*^PJ^3\QR0<C
MZTVY\!W6H>'[^RU#79;G4;X1QRWYA"E8D8,$5 < $@Y_WC6M+X;>?Q4-<DND
MW'36T]HEB(RK.'+9SZCI0!2^&ANY? .D7%W.LCSP>:<#NQ)))R<YS76UQ^B^
M$-5T;3]-L$\22/:V-PKK&+95WP@,/+)SDY)!S[=*["@ HHHH **** "BBB@
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M7*$G!..5_6N L_$.N7^K?$?1-2U!KJST^SF^S*T<:E04;&2BC/'K7%7QD?\
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MN))@%7:R1O'MQ($8%2V)",D=!65>VFH7'QWOM/M;XQW<VA"(7I3#(^PX? &
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M5P"1SDDGC\,"L^W\6^)=*\5>*?#&K:Y)<WRVV_17%M"F]F^Y_" 3DJ#GC@T
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MAFEMX,-*(5W,J9 +8] .3[ UX_XS@OXM6^%CW6HR7HFU2&9Y)P/,\QY(F;&
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M1?-IT.OS)#<6SPQS(I\W82"5#8//\0XQTH ]JHKSO0?$^L6WQ8U/P?JMZ+^
MVHN[6<P+$T?W<QX48(PQY//'?-:?CG5]8TJYT<V=S'9Z7+.5U"[RAEC7C:L:
ML&W,<G@*3QQ0!V-%>1>'_&'B#6?#WCJ-M5E2YT&64VEX;:-9'51(0KH4V_P
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M7680^@2+)!="R0O(K+O\O;]T <#<03CWYKT?P?JT^O>#M(U6Z"B>[M4ED"C
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M9Y([.<SVD\D:DQMN+89<889+<'UKK-8U^TT::R@F666YOI?)MX8@"SM@GN0
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M?7C_ /"6[M6C/_"1+MD/D8\H8V\<\_*<?7FND\)Z)-X<\,V6CRW2W(M$\I)
MFW*#ID>M;5% !1110 4444 %%%% !1110 4444 %%%% !1110 5!<,1);C<!
MF0C!)&?E;C_/I4]5KB)6N;:4CYT9E!QG *G/?V'K0!9HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \K\=Z[X@M/%&HV-KJ;VT":-)<V,5JR>:TZ#=E@5.
M5^7!SV)[X(P?%NM7WB7]FS^U-1=)+MVA,DGE@;B)5&0!@ _0>M=WJ?PUL]3\
M6ZAK[ZC=J]]I\EC+ ?F3:Z;<@GD =<#'/XYJ3?"N"?P!9^#WUB?[%#,))9/)
M3?* <A1_=Y[CGCZT <K_ ,UU\%?(S?\ %.1]%SC_ %O/6ND^.=U=VWPPO!:'
M EFCBF/_ $S).?U J\WPY8^,=&\1KK4@GTRSCLUC-LI61%W9SSP3N/3I77ZG
MIEEK.FW&G:C;I<6EPA26)^C _P CZ$<@\B@#(\!P6=OX#T..P$8@^Q1M^[;(
MW%06Y]=Q-<W\0+Z;P-H%F/#[&TDU76HXI7),FSS-S.5#9 SM[>I/6M72/!-[
MX?CAL=(\1W-MI$3Y2T:WCD95)R5$AY]>QQ5K4_ NE:IH$6DS27)$-U]MCN'D
MWR"?).\D]>2>.!@XXH Y%/$6MVOB7QYX>?4YIH=-T[[993LJB2$F/?MSCYAE
ML?-DX%</IWCGQ=/X.T+7Y?$-T\\VM?8I(1%&$>/Y6Y 7)/)'7I7KL'@*&-=<
MN9M0DFU;6H#;W-[Y2J F-H"H.!Q@=><9KGK;X,6UOX9L]#_MN=H;2]>]1_LZ
MY,A4!<C/0$ X[]* *?C_ ,9ZEX?\;G3]0NKG3=*O+/9IUY!C8L^06:4'E@,X
MX(P#T).0NN>)?$%C\8/"FD6FJ,UA?6<4MS#\I1\E@Q7(SSM!ZYKI]:\ -K3Z
M@)=5Q;ZBJ+=P-:JZDJJKN3)RC'!Y'J/3-.U[X<V&L^(-"UJ&[FLKS2 L<;1@
M/OC7D*=W QD\X[_2@#C/"^OZSK7A#XCQ:K>RW<=DES#;M(%!"B.0$< >@KD-
M5:]C^ 'A=H=2GB@FOUMY8(RH5U)9AGC.04''2O5]+^&?]CZ5XDTZSUR?R-;+
MDF2!6>'<3N^;/S94D<_6HYOA5:W/P]L_"4^K3E+*Y6XM[I(55E()X*]&X9OS
M'I0!C^,[_7?"_C/P/I]KKM]=V]],\4ZW"Q%GVNO.50<XD(X'0?6J&HZ[XI-]
M\0[2QU_RH](5)[5& :=>-Q"Y'W,9!)!/W>1S79:U\/#K?B'0]5GUNX/]D2&6
M.-XE?S'8@L22>,[1P!@=A4-Q\.)I=0\23Q^()H8=?P+F-+<!D4< *^<CC(]\
MT <U-X]UV]^'/@K43<FSDU:_CM;^]C51L02&-FRPVJ6 )SCCZ5I>"K_Q%?\
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M@<-N[GZ M^?M1X<\*6GA;3]1M=,?9]LNY;H,RY\MGZ#D\@8'>@#RB\UK6_\
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MA0Z[=R6,S,(\Q(/*C8[BH'<ECG<>>PQ5I_AS&+[PY>0:O/'-H%NMO:EHE8%
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M=*O)K:*\5%5I$&WAN,9^8@X XQ]:Z?X(P21_"S2I7NYIEF\UEB<+MBQ*X(7
M!YZG)//3%3:'\,+;2]*UW2;O4Y+W3]8D:6>/R1&ZNQ&2'!SCCI48^%<0\!VG
MA4:]?+%:7/GPW$:A'0;MVT8]R3G.<F@#T*BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW+*LML
M&QEI2!]=C'U^M6*KW*!I[9C(5VR'"]F.UO\ Z] %BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *AF=EF@4<!F.3VZ'CKU[]^AJ:JUPX^U6L
M6 69F;D] %()Z^X]>M %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *K3QK]HMY HWABN[ SC:W'Y^E6:KW /GVS ,3O(."< ;3U[=AUH L
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:XE9;BUC5&.]
MV);:2% 4]^W./UJS5>Y<B:U56 +2'(/4C:W]<4 6**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4,[ 20 [>9"!G/]UNE356N
MF*S6@!/S2D'#8_@8\^O2@"S1110 4444 %%%% !1110 4444 %%%% !1110
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M/$ZQVUL\F K DDJ,#\:O?\([X_\ ^A^M?_!&G_QRC_A'?'__ $/UK_X(T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4,Y(D@P&YD.<9_NMUJ:JURBM<VK,"0KMM [-M/)Y],COUH LT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%$T[33B2-5
MC5@(F#9+# R2.W.1^% $M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !56X;;=VN44JS,NXGY@=I/ QTX/Z5:JK<0Q&\M)VC0S(61'
M.,J&7) ^NT?E0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***HZQJUIH6D7.IW
MTFRVMT+N>Y]A[GI0W8$KEZBN>L;SQ#J^F)?PK8V F7?#;W$+ROM/3<P=0I/H
M <>]);:MK;6VE&YT^TAGGF:.\5[C9Y8&0#&",MG X]#1;H%^IT5%5Y;^S@;;
M-=P1MD+AY #D]!R>IHN+^SLWC2YNX(&D.$660*6/MD\T 6**8)8R[()%+*,E
M<\@>M<MXPUV]TM-&GTVZA\FYU&*VF&P/N5FP<'/'<4=4@.LHJ">\M;9XTGN8
M8FD.$61PI8^@SUK)OO%VD:?XDM="N;N*.ZGB:7+R*JH!C .3U.>!0!NT5!+>
MVD$T<,UU#'++_JT>0!G^@/6F:A>0V5H\LUW!:\$+).P"@_B1G\Z +5%<QX"U
MN\\0>&1?WTL<LQN)8P\:A5*JQ P![5ORW]G!<I;S7<$<[_<B>0!F^@)R:+ 6
M**@FO;6VECBGN88I)#A$>0*6/L#UIDVI6%N9!->VT9B ,F^51L!Z$Y/% %JB
MHQ<0&W%P)HS"5W>9N&W'KGIBFQ7=M/;"XAN(I(#SYJ."OYCB@":BJ\=]:3.R
M174#LJAV"R D*>A/M[U#/K.G0:9/J)O(&M(%+/*DBE1CMG.,T/0-R]165H7B
M+3O$.CQ:G97$9A= [#>I,>1G#8/!^M9/C;Q!/IW@;4=9T.]MFEMEW*X E4G(
M!'7'>AZ;@M=CJZ*H0:M9,\-M)?6PO'0-Y)E4.<C/W<YJ>UO[.]:1;2[@G,9P
MXBD#[3[X/%#0D[JY8HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %5KB4+=6L99079B,]3A3P./?U'2K-4
MKIX$U"R+D^<Q=(P 2,;<GV'W1UH NT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M?\3]'O-<\!7UK8(9+A&CG6(=9-C!BOX@5V%%)JXT[&)X<U^PU?PY;7T,R(BQ
M 2JYVF)@/F# ],8/6N3\3:C9ZQJW@O4K4#RWU1TCE88+J%89'^R<9'X5VUUX
M?T6^N#<7>D6%Q,>LDMLCM^9&:6YT'1[TPF[TFQG, Q"9;=&\L>BY''X55[NY
M-K*WD<-I>@Z3J?Q.\4+>V4%PL8@D1)%!57QG<!ZY[T>'-4T/46UN#Q0UG_:<
M-\XDBO-NX(#^[V ]L8QCO7=6^AZ3:WSWUOI=E#=R9+SQVZ+(V>N6 R:?+I6G
M3WT=]+86LEY'PEP\*F1?HV,BDM+#>MS@;*XTRR^(?B^WO)+>""XLK:2*.8A%
MD78V2 >O)%<Y87$,OPQ\'!)D<IK:!@&!*_OWZ^E>QW&F:?=W45U<V-M-<0C$
M<LD2LZ?0D9'X52/A3PX8UC.@:645MZJ;.,@-Z].OO0M+?+\'<'K?^NECS7QY
MJ>GW%EXPM84BCN[9(V>6[F)D+#!7R5/0>X[YK5>XT^;XD^%KN>6V>*;19OWS
ME2KN"G?H37H$FD:9-.9Y-.M'F,?DF1H5+;/[N<?=]NE$FDZ;*MNLFGVKBV.8
M T*GRC_L\?+^%"T_KR:_4'K_ %Z?Y'E4.S7M0\5Z?K>O6NGW'V["QS0@S)$%
M7RVB<N./3 ZD^M;%CJ5LGQ%US3]?N8MD=G -/%V0%>/9\[#/&2W6N^FTO3KB
M]BO9["UENXAB.=X59T^C$9%+=:;8WTL4MW96UQ)"=T32Q*Y0^JDCC\*%LE_7
M8'NSCOA-+;-X->*WDB*QWLXVQD?*-YQP.G%86MROI.MZAJJ);:UI-UJ,<5Q;
MOE+FTF&%&P]2. <<=:].L],L-.\S[#8VUKYK;I/(B5-[>IP.333I&FG4/[0.
MG6GVW_GX\E?,_P"^L9I]4PZ-'E>5UW6O%^F:YKEKITINMJ1W$ \U8 J^6T3E
MQCN> >3[UI6NGZ.WQ1U:#4DM9X_[)MR3=*O[S[P+$'OCK7H<^EZ?=7D5Y<6%
MK-=0_P"JFDA5G3_=8C(_"N13P]-<_$^]U:_T*.>P>VBBM[B;RGV.F26"DDCK
MU'-)=%_6P/9O^MT<SISP>'M"M8KZ*5[*YUZ0:5'+.8X4C(.TOV*<$@'VI-%E
MM9/#7Q#L6GM)%CNYI(XHF&Q08E.4'IGOZUZS=V5IJ%N;>]M8;F X)CFC#J<=
M.#Q4$NBZ5.DR2Z992)/@2J\"D28X&[CG';-)JZ:[JWY?Y#3LT_._Y_YGG"6W
MA_P_\-M#U6?3M\US'9QRRQR&,RL<$>:_=,]0>,<5'H\\#ZUX^L_.LG$EM'*D
M%NP*$^4VXJ._;)KTR/1],BTYM.CTVS2Q88:V6!1&1[KC%/@TVPMI/,@LK:)]
M@CW1Q*IV#HN0.GM3G[S?G?\ $4?=MY'D4VHK:?"KPI]CN8(+5I+==2E5 XC3
M!P9%!!QN !R15OQ5I]G;^!O%]_;:U;WS7=O&98[1 D*$%0" &;#$>]>HQ:5I
MUO:RVL-A:QV\I)DB2%0CD]20!@YJ%O#^BOIXT]M(L#9 [A;&V3RP?7;C%#=[
MON$=+>1Q7C:--$D\.^,HH-QL9$ANRBY+02#;^.&(KK/#&EC3-(4O$B75RQGN
M"% )=CG!^F<?A5;5=.NIKO2M(LM.ABT1)!+<NA554(<K&$]"V#QQQ71T[[_U
M_6HDK67D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5#-'"9X)'1#(I*HQZC(Y _+]/:IJBE#%XMI  ?
MG)QD;3^= $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%*
M0'BS(%R_0_Q?*>/Z_A4M0S.J/ &SEGPO..=K'^0- $U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5#,"7@QV?GI_=;U_I4U03(K7-NP/SJ6
MP-Y&5QSQWYQ0!/1110 4444 %%%% !1110 4444 %%%% !112%@& YR>G% "
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,>38T8P3O;;QVX)_I3ZBEW;XMJY&_GV&TT 2T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:L^YA&3\S@#G ]!D9_#UH L4444 %%%% !1110 4444 %%%% !1110 4444
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MYAXR.< 5WE(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4Q_O)T^]W^AI],?/F1\C;D\8
MYSCUS]: 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 R42-"ZQ.J2%2$9EW!3V)&1GZ9%.7(4;B"<<D#%+10 4
M444 %%%% !1110 4444 %%%% !1110!SLG@'PA+(\DGAC2'=R69FLT))/4GB
MF_\ "O?!O_0K:/\ ^ 4?^%=)10!S?_"O?!O_ $*VC_\ @%'_ (4?\*]\&_\
M0K:/_P" 4?\ A7244 <W_P *]\&_]"MH_P#X!1_X4?\ "O?!O_0K:/\ ^ 4?
M^%=)10!S?_"O?!O_ $*VC_\ @%'_ (4?\*]\&_\ 0K:/_P" 4?\ A7244 <W
M_P *]\&_]"MH_P#X!1_X4?\ "O?!O_0K:/\ ^ 4?^%=)10!S?_"O?!O_ $*V
MC_\ @%'_ (4?\*]\&_\ 0K:/_P" 4?\ A7244 <W_P *]\&_]"MH_P#X!1_X
M5TE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55FCE;
M4;612?+1) XWL!D[<< X/0]0<=L<U:JK- 'U*UFYS&D@Z'OM_#MWH M4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6%!X8BM_%4_B!;ZZ-Q/&(I(CM\LH,X&-N>,^N:W:*/,/(**** "BBB@ HH
MHH S+W0X+_6K#4YIIRUCN,4(;]V6(QN(]0"0/K6G110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4+
MF?9K5A#EOWD<QP(\@XV]6S\O7I@Y_"K]4;A8SK%BS2 2".7:F5RP^7/49XXZ
M$=><\4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/N1%
M_;=@61S+Y<VQ@6PH^3.0!@]NI'MGFM"LVZNGCU_3;8'Y)HIV88/.W9CM[^M
M&E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9UT[#7M.07&
MQ6BF)AVY\S&SG/;']:T:R[N)6\1Z9(5B+)%. 6#;AG9TQ\N..<^V.] &I111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4IT4ZO9,?O+'*!^Z
M)Z[<_-C"_3O^%7:S[F&)M;L)6<"5(Y@B^9@D'9GY<?-T'.1CWS0!H4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5">YECURSM\0^3+%(V2&
M,FY=O0XP!SSDU?K)N[X)XHTVQ$B[I()Y&3S,' V ';GD<GG!Q[4 :U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5DWLDJ^)M*C5@(WAN"XY
MR2/+Q[=SUK6K'O?+'BK2LL-[07 52@.0/+S@YR/PZ]^E &Q1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %9=RKGQ+8,KJB"";>"V#)RN,#/.
M.<\<9'K6I6-=;(_%VG,6</-:S*%"\$*4/)S_ +7'![].X!LT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !63<%%\46(,P5WMI0L>T_/@KDY]
ML]..O?MK50E9!KMLICC+&%]K>7EEY&?F[ _K^% %^BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *S+K[/_PD6G[V G\F;RP5SD?)NP<<=NXS
MGOVTZR+J8_\ "5:?!L8C[-,Y8(2%Y0?>S@9].>G;N :]%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5E209\407#,@ M61%Q\Q.X9_#IU_"M
M6LN>7'B6TB+RC-O(RJ&PC'*YSS\Q''8XSUYH U**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $!SG@
MC'ZTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !69/$_\ PD=I*&41_9Y%(,F"3E>B
M]_J,>^>VG69/<6G_  D=G;/$'N_L\DD;XYC7*AN<]^.@[4 :=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 52EC1M7MY"KETB<*=HVC)&><9
MSP.]7:H,BG78W"G>+<@L%;INX!/3\.3]* +]%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5GO&IU^.1H9,K;D+*%^7EN5)'?IP?P[UH54\G.
MK^<0<"#:#YG'WO[N/US0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J$L1EUNVD\I,0PO^\93GYB!@'I_#S^%7ZI.$_MF$EX=_DMA21OQ
MD<CN10!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&8#K
MVTH//6VR&V'.TMTW9QU'3'XU?JF)?^)R8=Z_\>X;;@Y^\1G.<?I0!<HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J(D7^W6CQ)N^S!L[1MQ
MN/?KGVJ]5(0M_;9GVIM^S!-W.[.XG'IC]: +M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 51"G^W&;:<?9@-V./O'CI_7\*O5F?:HAXE^RD
MOYIM=P'DG;@-_?Q[],_A0!IT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5(%O[<89FV?9AQCY,[CWSU_#I5VLL*W_"5,VX;/L0&W'.=YH U
M**** "HY(8Y6C:1 QB;>A/\ "V",_D3^=244 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %4 9O\ A(&&&\C[*.<<;MY]O3WJ_5 1+_;[38;=]E"YYQC<
M3Z8_7- %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S@J_
M\)(S;AO^Q@8XZ;S[Y_3'O6C6:J?\5*[E3G[(H#8&,;SQZYH TJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-64?\)))$(X_P#CT5C(%.[[
MY&"?3VK2K-5A_P ))(I8!A:*0NP<C<>=V,_AGWH TJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K.5F_P"$B=#)\OV52(^/[QYZY_3\:T:S
MAL/B1\0C>+09E^;IO/R^GOZT :-%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 512V_XG<MT2<^0L:C:<8R3UZ5>JDDD?]M219_>^0K8'ID^W
M]?PH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !51(O^)M
M+,77/E*@7)SC).?2K=4U5SK#ON;8( NWG&=QY],T 7**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K,C5CXEF<@;1:JH.T9SN/?K^7%:=4X0
M_P#:MRV[]WL0;=O?GG- %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *IPE?[4NAE2VQ, 9R!SU[5<JM%N-_<$G@*@ #D^O49X_*@"S1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5XE47EPPSN(7.2<=#
M[8_*K%5HQ_Q,9B&.-BAE &,\\YZY_2@"S1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %01!OMEP2V00N!\W'7UX_+\:GJE;MG5+U<C@1_P (
M'8]^] %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IV[ Z
MG>#: 0(\D=3P:N54@0+J-VX#981Y)Z' /3B@"W1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5((V74KN0D;7$>!GT!JW5"U_P"0QJ'^[%_(
MT 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JA:Y_MC4.%
MQMBP03D\'K5^J5N5.JWP &X+'DX.>A[Y_H/QH NT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5&V!&KWYXY6+O[&KU4;8QG5[\*Q+A8MRD<
M#@XY[T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.M-G
M]MZEA\MMAW+@?+P<>_YUHU4@D#:C=IELJ(^O3D'I0!;HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "JT.?MUSD,!A,$DX/!Z#I^56:JP[?[0
MNL!=V$R0>3P>O- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *KQ+B]N&Q]X)S^!]_Z"K%011LMY<.0NU@N"!R<9ZGO0!/1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,417,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">746.3<span></span>
</td>
<td class="nump">938.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">889.5<span></span>
</td>
<td class="nump">1,067.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">909.3<span></span>
</td>
<td class="nump">1,091.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">157.8<span></span>
</td>
<td class="nump">229.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">134.1<span></span>
</td>
<td class="nump">292.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">529.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, zero shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 73.2 and 68.8 shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,509.9)<span></span>
</td>
<td class="num">(1,531.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,118.1<span></span>
</td>
<td class="nump">2,092.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">609.3<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 909.3<span></span>
</td>
<td class="nump">$ 1,091.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">68.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">68.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 76.5<span></span>
</td>
<td class="nump">$ 211.2<span></span>
</td>
<td class="nump">$ 101.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">159.4<span></span>
</td>
<td class="nump">178.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">93.9<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">233.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(71.5)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(131.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) income before income taxes</a></td>
<td class="num">(61.5)<span></span>
</td>
<td class="num">(35.0)<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="num">(104.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (61.2)<span></span>
</td>
<td class="num">$ (35.2)<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="num">$ (104.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) earnings per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (61.2)<span></span>
</td>
<td class="num">$ (35.2)<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="num">$ (104.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (61.7)<span></span>
</td>
<td class="num">$ (34.6)<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="num">$ (105.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 660.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (1,332.7)<span></span>
</td>
<td class="nump">$ 1,995.7<span></span>
</td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(104.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">600.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,437.3)<span></span>
</td>
<td class="nump">2,041.2<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">609.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,402.1)<span></span>
</td>
<td class="nump">2,016.1<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(35.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 600.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,437.3)<span></span>
</td>
<td class="nump">2,041.2<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">68.8<span></span>
</td>
<td class="nump">68.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 561.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,531.6)<span></span>
</td>
<td class="nump">2,092.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">73.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 609.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,509.9)<span></span>
</td>
<td class="nump">2,118.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">660.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,448.7)<span></span>
</td>
<td class="nump">2,107.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">73.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 609.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (1,509.9)<span></span>
</td>
<td class="nump">$ 2,118.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="num">$ (104.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Collaboration contract asset</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(17.6)<span></span>
</td>
<td class="num">(13.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(211.3)<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(184.3)<span></span>
</td>
<td class="num">(47.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(237.6)<span></span>
</td>
<td class="num">(440.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">437.5<span></span>
</td>
<td class="nump">326.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and leasehold improvements</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property, equipment and leaseholds improvements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">198.3<span></span>
</td>
<td class="num">(114.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares', window );">Proceeds from exercise of stock options and issuance of ESPP shares</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="num">(156.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">100.5<span></span>
</td>
<td class="nump">317.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">114.9<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its subsidiaries (&#8220;Arvinas&#8221; or the "Company&#8221;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2024 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2024, forming part of Arvinas&#8217; 2024 Annual Report on Form 10-K filed with the SEC on February&#160;11, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $861.2 million as of June&#160;30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Pronouncements and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Accounting Pronouncements and Significant Accounting Policies</a></td>
<td class="text">Summary of Accounting Pronouncements and Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recently adopted accounting pronouncements that have had a material impact on the Company's</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, "Disaggregation of Income Statement Expenses," which requires </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures of certain disaggregated income statement expense captions into specified categories within the footnotes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU No. 2024-03 will have on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the six months ended June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">Research Collaboration and License Agreements <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;Vepdegestrant (ARV-471) Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound vepdegestrant (the &#8220;Licensed Products&#8221;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company is eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with Accounting Standards Codification ("ASC") 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of June&#160;30, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $3.8&#160;million in non-refundable option payments if Pfizer exercises its option for such target protein. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive up to $225.0&#160;million in development milestone payments and up to $550.0&#160;million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were no sales-based milestone payments or royalties received through June&#160;30, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis License and Asset Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and has all research, development, manufacturing, and commercialization rights with respect to the Company&#8217;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the &#8220;HSR Termination&#8221;). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $150.0&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> being met, as well as tiered royalties based on worldwide net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, subject to reduction under certain circumstances as provided in the Novartis License Agreement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no development, regulatory or commercial milestone payments, or sales-based royalties received through June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company determined the fair value of the assets sold under </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Novartis Asset Agreement to be $20.0&#160;million, which was recognized at the time of sale as revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and the fair value of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novartis License Agreement to be $130.0&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis also reimbursed the Company for development costs incurred during the technology transfer period, which was recognized as revenue as costs were incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">luxdegalutamide (ARV-766)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to Novartis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $3.0&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $3.0&#160;million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license. The Company also received an additional $12.0 million from Bayer AG from inception through 2023. These payments were recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was eligible to receive up to $197.5&#160;million in development milestone payments and up to $490.0&#160;million in sales-based milestone payments for all designated target</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restated Genentech Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Restated Genentech Agreement&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period, which concluded during the first quarter of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $44.0&#160;million per target protein in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the six months ended June&#160;30, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(211.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(56.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from new collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">599.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $150.2&#160;million, an increase in operating expenses of $2.6&#160;million, an increase in net income of $147.6&#160;million, and an increase in basic and diluted earnings per share of $2.04 and $2.03, respectively, for the six months ended June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease in revenue and net income of $2.5&#160;million, respectively, and a decrease in basic and diluted earnings per share of $0.03 for the six months ended June&#160;30, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024 and the six months ended June&#160;30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June&#160;30, 2025 totaled $237.0 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">685.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">686.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">745.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">746.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">934.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">935.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">937.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">938.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">Property, Equipment and Leasehold Improvements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $0.8 million and $1.2 million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $1.5 million and $2.4 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right-of-Use Assets and Liabilities</a></td>
<td class="text">Right-of-Use Assets and Liabilities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at June&#160;30, 2025 totaled 6.9%. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than December 2029. The leases have a weighted average remaining term of approximately 4.4 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment, and in February 2025, the Company entered into a Ninth Amendment to its lease (collectively the &#8220;Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#8220;Building 5 Premises&#8221;). The Building 5 Lease Amendments extended the term of the original lease to December 31, 2029, and expanded the Building 5 Premises to include approximately 10,900 square feet of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional laboratory and office space in the first quarter of 2025, resulting in an increase in the Company's ROU assets of $1.5&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of June&#160;30, 2025, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the 2018 Assistance Agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of June&#160;30, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2025 and 2024, interest expense was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended and restated the Equity Distribution Agreement with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$262.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the six mo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nths </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;30, 2025, no shares were issued under this agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of June&#160;30, 2025, 3,601,429 shares remained available for purchase. During the six months ended June&#160;30, 2025 and 2024, the Company issued 86,008 and 34,515 shares of common stock, respectively, under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Fourth Amendment to the Company&#8217;s Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of June&#160;30, 2025, 1,855,723 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic restructuring plan initiated by the Company in the second quarter of 2025, as further discussed below in Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company modified the vesting terms of certain Restricted Stock Units previously granted to employees. The incremental impact of the modification was fully recognized during the three and six months ended June&#160;30, 2025 as a decrease to compensation expense </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $1.7&#160;million. There were no remaining unrecognized compensation expenses related to the modified awards at June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $10.4 million and $21.6 million, respectively, related to the issuance of incentive awards, including $0.2 million related to the 2018 ESPP in each period presented.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $25.4 million and $40.2 million, respectively, relating to the issuance of incentive awards, including $0.4 million related to the 2018 ESPP in each period presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, there was $60.5 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.6 years.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the six months ended June&#160;30, 2025 and 2024 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.1 - 80.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.9 - 75.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.5 - 5.7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.9% - 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.9% - 4.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.61 - $17.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$24.94 - $47.00</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,892,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,165,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled/ Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(503,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,553,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and exercisable </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,195,452&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and expected to vest </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during the six months ended June&#160;30, 2025 and 2024 was $12.54 and $28.08, respectively. There were no options exercised during the six months ended June&#160;30, 2025. The total intrinsic value of options exercised during the six months ended June&#160;30, 2024 was $3.5 million.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units ("RSUs")</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,311,291&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42.25&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,382,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(911,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(628,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,153,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSUs granted during the six months ended June&#160;30, 2025 and 2024 was $13.98 and $44.98, respectively. The total intrinsic value of RSUs released during the six months ended June&#160;30, 2025 and 2024 was $14.9 million and $11.4 million, respectively. The total fair value of RSUs vested during the six months ended June&#160;30, 2025 and 2024 was $42.4 million and $10.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025, the Company recognized income tax benefit of $0.3 million, resulting in an effective tax rate of 0.6%, as compared to income tax expense of $0.2 million, resulting in an effective tax rate of (0.6)%, in the same period for 2024. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June&#160;30, 2025 and the Company&#8217;s overall effective tax rate of 0.6% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June&#160;30, 2024 and the Company&#8217;s overall effective tax rate of (0.6)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2025, the Company recognized income tax benefit of $0.2 million, resulting in an effective tax rate of (0.9)%, as compared to income tax expense of $0.3 million resulting in an effective tax rate of (0.3)% in the same period for 2024. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June&#160;30, 2025 and the Company&#8217;s overall effective tax rate of (0.9)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June&#160;30, 2024 and the Company&#8217;s overall effective tax rate of (0.3)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; (the &#8220;OBBB Act&#8221;) was enacted into law. The OBBB Act includes changes to U.S. tax with multiple effective dates starting in 2025. These changes include provisions allowing accelerated tax deductions for qualified property and research expenditures. Although the Company does not expect the OBBB Act to have a material impact on its estimated annual effective tax rate in 2025, it continues to assess the impact of the OBBB Act on subsequent periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Earnings Per Common Share</a></td>
<td class="text">(Loss) Earnings Per Common Share <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted (loss) earnings per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(61.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104.6)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Number of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Loss) earnings per common share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and six months ended June&#160;30, 2024 gives effect to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants issued in November 2023 which allowed holders to acquire up </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,422,380 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a nominal exercise price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share. As of June&#160;30, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration and the Company issued 3,422,186 shares of common stock to the holders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three months ended June&#160;30, 2025 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three and six months ended June&#160;30, 2024 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three and Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 43.4% and 44.5% as of June&#160;30, 2025 and 2024, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss of Oerth Bio for the three months ended June&#160;30, 2025 and 2024 totaled $0.7 million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.8 million, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net lo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ss of Oerth Bio for the six months ended June&#160;30, 2025 and 2024 totaled $0.2 million and $1.5 million, res</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment was zero. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and six months ended June&#160;30, 2025 and 2024 were immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company entered into an Amended and Restated License Agreement (the &#8220;Amended License Agreement&#8221;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95&#160;million to Yale in June 2024, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Collaboration and License Agreements,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the agreements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company made another $5.0&#160;million payment to Yale in June 2025 on the first anniversary of signing, which was included in the company's accounts payable and accrued liabilities as of June 30, 2024. Thereafter, the Company will also pay to Yale (1) up to $15.0&#160;million if it secures approval of the first and second royalty products (as defined in the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#8220;collaboration products,&#8221; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#8220;meaningfully involved products.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement to pay to Yale a minimum license maintenance royalty totaling $0.1&#160;million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2&#160;million to $0.5&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Activity</a></td>
<td class="text">Restructuring Activity<div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#8217;s workforce by approximately 33% across all areas of the Company, as part of the Company&#8217;s decision to streamline operations across the organization and enable the efficient progression of the Company&#8217;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, the restructuring activities were substantially completed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Restructuring Charges</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company recognized restructuring charges of $1.0&#160;million, including $7.4&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, offset by a reversal of $6.4&#160;million of non-cash stock compensation and bonus expenses, of which $0.6&#160;million is reflected in research and development expenses and $0.4&#160;million is reflected in general and administrative expenses in the accompanying unaudited condensed consolidated financial statements. The Company's restructuring accrual totaled $2.2&#160;million as of June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are organized into one operating and reportable segment focused on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-806, targeting Kirsten rat sarcoma, or KRAS, G12D for mutated cancers, including pancreatic and colorectal cancers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also generated revenue through the sale of assets based on fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have intra-entity sales or transfers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the operating segment are the same as those described in the Company's </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the year ended December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 2,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Accounting Pronouncements and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as net income (loss). The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">211.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806 </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense<br/>(including stock-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(61.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(**)&#160;&#160;&#160;&#160;Includes primarily realized foreign exchange gains/ losses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $0.8 million and $1.2 million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $1.5 million and $2.4 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2024 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2024, forming part of Arvinas&#8217; 2024 Annual Report on Form 10-K filed with the SEC on February&#160;11, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div>The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recently adopted accounting pronouncements that have had a material impact on the Company's</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, "Disaggregation of Income Statement Expenses," which requires </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures of certain disaggregated income statement expense captions into specified categories within the footnotes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU No. 2024-03 will have on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the six months ended June&#160;30, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(211.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(56.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from new collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">599.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Transaction Price Allocated to Performance Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June&#160;30, 2025 totaled $237.0 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">685.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">686.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">745.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">746.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">934.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">935.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">937.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">938.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Leasehold Improvements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of June&#160;30, 2025, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Future Payments on Long-Term Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of June&#160;30, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the six months ended June&#160;30, 2025 and 2024 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.1 - 80.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.9 - 75.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.5 - 5.7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.9% - 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.9% - 4.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.61 - $17.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$24.94 - $47.00</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,892,330&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,165,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled/ Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(503,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,553,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and exercisable </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,195,452&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Vested and expected to vest </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Grant Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,311,291&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42.25&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,382,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(911,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(628,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,153,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted (Loss) Earnings per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted (loss) earnings per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(61.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104.6)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Number of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denominator adjustments for diluted EPS:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Loss) earnings per common share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three months ended June&#160;30, 2025 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss for the three and six months ended June&#160;30, 2024 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three and Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of reportable segment financial information</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">211.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806 </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense<br/>(including stock-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(61.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(**)&#160;&#160;&#160;&#160;Includes primarily realized foreign exchange gains/ losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">$ 861.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
<td class="nump">$ 154.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
<td class="nump">$ 160.3<span></span>
</td>
<td class="nump">$ 317.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">47 Months Ended</th>
<th class="th" colspan="1">62 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="nump">599,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="nump">599,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="nump">237,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,400,000<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,200,000<span></span>
</td>
<td class="nump">101,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,900,000)<span></span>
</td>
<td class="num">(125,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,300,000)<span></span>
</td>
<td class="num">(233,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61,200,000)<span></span>
</td>
<td class="num">$ (35,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="num">$ (104,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember', window );">Removal of Combination Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember', window );">Updated Research Timelines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract', window );">Collaboration agreement direct and incremental costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Payments To License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember', window );">Novartis Pharma AG | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RevenueRemainingPerformanceObligationContingentPayments', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct and incremental costs incurred to obtain the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DirectAndIncrementalCostsIncurredToObtainTheContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_RevenueRemainingPerformanceObligationContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_RevenueRemainingPerformanceObligationContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions', window );">Additions</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived', window );">Payments received</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Ending balance</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts payable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Beginning balance</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentAdditions', window );">Additions</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentPayments', window );">Payments made</a></td>
<td class="num">(24.8)<span></span>
</td>
<td class="num">(26.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Ending balance</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward', window );"><strong>Contract assets: Collaboration contract asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CapitalizedContractCostAmortizationDuringPeriod', window );">Amortization</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities: Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">448.2<span></span>
</td>
<td class="nump">549.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions to collaboration agreements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from balances held at the beginning of the period</a></td>
<td class="num">(211.2)<span></span>
</td>
<td class="num">(56.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration', window );">Revenue recognized from new collaborations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 237.0<span></span>
</td>
<td class="nump">$ 599.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CapitalizedContractCostAmortizationDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CapitalizedContractCostAmortizationDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Payable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Receivable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized From New Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 237.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 69.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 66.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 20.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 80.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Details) - Level 2 - Fair Value, Measurements, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 745.3<span></span>
</td>
<td class="nump">$ 937.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">746.3<span></span>
</td>
<td class="nump">938.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">685.6<span></span>
</td>
<td class="nump">934.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">686.6<span></span>
</td>
<td class="nump">935.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">59.7<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 59.7<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(26.7)<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Lease for laboratory and office space (in sq feet) | ft&#178;</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing for lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfIncrementalBorrowingForLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">11.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent', window );">General and administrative and commercial expenses</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative And Commercial, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current installments</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Decrease in compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants', window );">Inducement grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.54<span></span>
</td>
<td class="nump">$ 28.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">311,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance represented as percentage on outstanding common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,601,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,601,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,008<span></span>
</td>
<td class="nump">34,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants', window );">Number of inducement grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="nump">$ 44.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod', window );">Total intrinsic value of RSUs released</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">4,067,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,855,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,855,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares as percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">1,277,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember', window );">Piper Sandler and Cantor | At-the-Market Offering | Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percentage)</a></td>
<td class="nump">72.10%<span></span>
</td>
<td class="nump">72.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percentage)</a></td>
<td class="nump">80.10%<span></span>
</td>
<td class="nump">75.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (percentage)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percentage)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 24.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.70<span></span>
</td>
<td class="nump">$ 47.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Details) - 2018 Plan - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">7,892,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,165,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/ Forfeited (in shares)</a></td>
<td class="num">(503,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">9,553,958<span></span>
</td>
<td class="nump">7,892,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable, ending balance (in shares)</a></td>
<td class="nump">6,195,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">9,212,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 44.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/ Forfeited (in dollars per share)</a></td>
<td class="nump">44.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">37.31<span></span>
</td>
<td class="nump">$ 44.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">45.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 37.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in Years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Restricted Stock (Details) - RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="nump">$ 44.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,311,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,382,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(911,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled/ Forfeited (in shares)</a></td>
<td class="num">(628,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,153,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 42.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">43.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/ Forfeited (in dollars per share)</a></td>
<td class="nump">26.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate, percentage</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (61.2)<span></span>
</td>
<td class="num">$ (35.2)<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="num">$ (104.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Denominator adjustments for diluted EPS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Number of stock options and RSUs (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Denominator adjustments for diluted EPS (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_EarningsLossPerCommonShareEPSAbstract', window );"><strong>(Loss) earnings per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EarningsLossPerCommonShareEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings (Loss) Per Common Share, EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EarningsLossPerCommonShareEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Common Share - Additional Information (Details) - Pre-Funded Warrant - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to be purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,422,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="nump">3,422,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,200,000)<span></span>
</td>
<td class="num">$ (35,200,000)<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="num">$ (104,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage', window );">Future grant of incentive units to service providers percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (700,000)<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest, percentage</a></td>
<td class="nump">43.40%<span></span>
</td>
<td class="nump">44.50%<span></span>
</td>
<td class="nump">43.40%<span></span>
</td>
<td class="nump">44.50%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future grant of incentive units to service providers, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Yale University<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2013 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AnnualLicenseFeePayment', window );">Annual payment for license</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfLicensedProducts', window );">Number of licensed products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PaymentsForCollaboration', window );">Payments for collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Milestone Payment on First Anniversary of Signing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment the Company will make</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Milestone Payment Upon Approval of First and Second Royalty Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment the Company will make</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Success-Based Milestone Payments | License First Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Success-Based Milestone Payments | License Second Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AnnualLicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fee Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AnnualLicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Licensed Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PaymentsForCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PaymentsForCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_RequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_RequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activity (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring accrual</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember', window );">Stock Compensation And Bonus Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">$ (6.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization | $</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 76.5<span></span>
</td>
<td class="nump">$ 211.2<span></span>
</td>
<td class="nump">$ 101.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">159.4<span></span>
</td>
<td class="nump">178.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net (loss) income</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="num">(104.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">211.2<span></span>
</td>
<td class="nump">101.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific', window );">Non program-specific external expense</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related personnel expense (including stock-based compensation)</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expense</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">159.4<span></span>
</td>
<td class="nump">178.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expense, net</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net (loss) income</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="num">(104.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Vepdegestrant ARV-471</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-102</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-393</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-806</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Bavdegalutamide (ARV-110)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Luxdegalutamide (ARV-766)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Other programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Non-Program Specific</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchAndDevelopmentExpenseNonProgramSpecific</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Program Specific</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchAndDevelopmentExpenseProgramSpecific</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV471Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV471Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV102Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV102Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV393Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV393Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV806Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV806Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV766Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV766Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_OtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_OtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>198</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies</Role>
      <ShortName>Summary of Accounting Pronouncements and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Right-of-Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</Role>
      <ShortName>Right-of-Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - (Loss) Earnings Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LossEarningsPerCommonShare</Role>
      <ShortName>(Loss) Earnings Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Restructuring Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RestructuringActivity</Role>
      <ShortName>Restructuring Activity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables</Role>
      <ShortName>Right-of-Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LongTermDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/Equity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - (Loss) Earnings Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LossEarningsPerCommonShareTables</Role>
      <ShortName>(Loss) Earnings Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LossEarningsPerCommonShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SegmentInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails</Role>
      <ShortName>Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Equity - Summary of Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails</Role>
      <ShortName>Equity - Summary of Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/IncomeTaxes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - (Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails</Role>
      <ShortName>(Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - (Loss) Earnings Per Common Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails</Role>
      <ShortName>(Loss) Earnings Per Common Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - (Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>(Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsDetails</Role>
      <ShortName>Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/EquityMethodInvestments</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/CommitmentsandContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Restructuring Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RestructuringActivityDetails</Role>
      <ShortName>Restructuring Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RestructuringActivity</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arvn-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Segment Information - Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails</Role>
      <ShortName>Segment Information - Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="arvn-20250630.htm">arvn-20250630.htm</File>
    <File>arvn-20250630.xsd</File>
    <File>arvn-20250630_cal.xml</File>
    <File>arvn-20250630_def.xml</File>
    <File>arvn-20250630_lab.xml</File>
    <File>arvn-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arvn-20250630_g1.jpg</File>
    <File>arvn-20250630_g2.jpg</File>
    <File>arvn-20250630_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="649">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arvn-20250630.htm": {
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "arvn-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "arvn-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arvn-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 247,
   "keyCustom": 37,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 40,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 198,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 571,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 649,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.arvinas.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation",
     "longName": "9952156 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies",
     "shortName": "Summary of Accounting Pronouncements and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements",
     "longName": "9952158 - Disclosure - Research Collaboration and License Agreements",
     "shortName": "Research Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements",
     "longName": "9952159 - Disclosure - Marketable Securities and Fair Value Measurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements",
     "longName": "9952160 - Disclosure - Property, Equipment and Leasehold Improvements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilities",
     "longName": "9952161 - Disclosure - Right-of-Use Assets and Liabilities",
     "shortName": "Right-of-Use Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities",
     "longName": "9952162 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arvinas.com/role/LongTermDebt",
     "longName": "9952163 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arvinas.com/role/Equity",
     "longName": "9952164 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arvinas.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arvinas.com/role/LossEarningsPerCommonShare",
     "longName": "9952166 - Disclosure - (Loss) Earnings Per Common Share",
     "shortName": "(Loss) Earnings Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arvinas.com/role/EquityMethodInvestments",
     "longName": "9952167 - Disclosure - Equity Method Investments",
     "shortName": "Equity Method Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arvinas.com/role/CommitmentsandContingencies",
     "longName": "9952168 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arvinas.com/role/RestructuringActivity",
     "longName": "9952169 - Disclosure - Restructuring Activity",
     "shortName": "Restructuring Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arvinas.com/role/SegmentInformation",
     "longName": "9952170 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)",
     "shortName": "Summary of Accounting Pronouncements and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)",
     "shortName": "Summary of Accounting Pronouncements and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables",
     "longName": "9955513 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables",
     "longName": "9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables",
     "longName": "9955516 - Disclosure - Right-of-Use Assets and Liabilities (Tables)",
     "shortName": "Right-of-Use Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "longName": "9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arvinas.com/role/LongTermDebtTables",
     "longName": "9955518 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arvinas.com/role/EquityTables",
     "longName": "9955519 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arvinas.com/role/LossEarningsPerCommonShareTables",
     "longName": "9955520 - Disclosure - (Loss) Earnings Per Common Share (Tables)",
     "shortName": "(Loss) Earnings Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arvinas.com/role/SegmentInformationTables",
     "longName": "9955521 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails",
     "longName": "9955522 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails",
     "longName": "9955523 - Disclosure - Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)",
     "shortName": "Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-34",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
     "longName": "9955524 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails",
     "longName": "9955525 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "shortName": "Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails",
     "longName": "9955526 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
     "longName": "9955527 - Disclosure - Marketable Securities and Fair Value Measurements (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
     "longName": "9955528 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
     "longName": "9955529 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
     "longName": "9955530 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "shortName": "Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails",
     "longName": "9955531 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "shortName": "Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "longName": "9955532 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
     "longName": "9955533 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9955534 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "longName": "9955535 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Long Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
     "longName": "9955536 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:InterestExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails",
     "longName": "9955537 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
     "longName": "9955538 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
     "longName": "9955539 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails",
     "longName": "9955540 - Disclosure - Equity - Summary of Stock Option Activity (Details)",
     "shortName": "Equity - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-131",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
     "longName": "9955541 - Disclosure - Equity - Summary of Restricted Stock (Details)",
     "shortName": "Equity - Summary of Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arvinas.com/role/IncomeTaxesDetails",
     "longName": "9955542 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails",
     "longName": "9955543 - Disclosure - (Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details)",
     "shortName": "(Loss) Earnings Per Common Share - Schedule of Basic and Diluted (Loss) Earnings per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails",
     "longName": "9955544 - Disclosure - (Loss) Earnings Per Common Share - Additional Information (Details)",
     "shortName": "(Loss) Earnings Per Common Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-137",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails",
     "longName": "9955545 - Disclosure - (Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "shortName": "(Loss) Earnings Per Common Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
     "longName": "9955546 - Disclosure - Equity Method Investments (Details)",
     "shortName": "Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955547 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:PaymentsForRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:PaymentsForRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arvinas.com/role/RestructuringActivityDetails",
     "longName": "9955548 - Disclosure - Restructuring Activity (Details)",
     "shortName": "Restructuring Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9955549 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails",
     "longName": "9955550 - Disclosure - Segment Information - Financial Information (Details)",
     "shortName": "Segment Information - Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "arvn_ARV102Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV102Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-102",
        "label": "ARV-102 [Member]",
        "documentation": "ARV-102"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV110Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV110Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bavdegalutamide (ARV-110)",
        "label": "ARV-110 [Member]",
        "documentation": "ARV-110"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV393Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV393Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-393",
        "label": "ARV-393 [Member]",
        "documentation": "ARV-393"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV471Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV471Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vepdegestrant ARV-471",
        "label": "ARV-471 [Member]",
        "documentation": "ARV-471"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV766Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV766Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Luxdegalutamide (ARV-766)",
        "label": "ARV-766 [Member]",
        "documentation": "ARV-766"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV806Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ARV806Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-806",
        "label": "ARV-806 [Member]",
        "documentation": "ARV-806"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r39",
      "r1093"
     ]
    },
    "arvn_AccountsPayableContractBalancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccountsPayableContractBalancesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Payable, Contract Balances, Current",
        "documentation": "Accounts Payable, Contract Balances, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsPayableContractBalancesCurrentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccountsPayableContractBalancesCurrentAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Payable, Contract Balances, Current Additions",
        "documentation": "Accounts Payable, Contract Balances, Current Additions"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsPayableContractBalancesCurrentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccountsPayableContractBalancesCurrentPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments made",
        "label": "Accounts Payable, Contract Balances, Current Payments",
        "documentation": "Accounts Payable, Contract Balances, Current Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r819"
     ]
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments received",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of bond discounts/premiums",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccruedGeneralAndAdministrativeAndCommercialCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative and commercial expenses",
        "label": "Accrued General And Administrative And Commercial, Current",
        "documentation": "Accrued General And Administrative And Commercial, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r77"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r107",
      "r623"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r49",
      "r111",
      "r620",
      "r659",
      "r660",
      "r1105"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r16",
      "r463",
      "r466",
      "r530",
      "r655",
      "r656",
      "r961",
      "r962",
      "r963",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r819",
      "r1167"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1106",
      "r1170"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "documentation": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r866",
      "r876",
      "r908"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r869",
      "r879",
      "r911"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r904",
      "r912",
      "r916",
      "r924"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r418",
      "r419"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AnnualLicenseFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AnnualLicenseFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payment for license",
        "label": "Annual License Fee Payment",
        "documentation": "Annual License Fee Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per common share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r86",
      "r108",
      "r132",
      "r135",
      "r136",
      "r174",
      "r185",
      "r204",
      "r208",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r453",
      "r455",
      "r503",
      "r606",
      "r607",
      "r616",
      "r696",
      "r773",
      "r774",
      "r786",
      "r819",
      "r835",
      "r836",
      "r847",
      "r1058",
      "r1059",
      "r1123"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r112",
      "r132",
      "r135",
      "r136",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r453",
      "r455",
      "r503",
      "r819",
      "r1058",
      "r1059",
      "r1123"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At the market offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r261",
      "r615"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r261",
      "r477",
      "r496",
      "r497",
      "r498",
      "r499",
      "r602",
      "r752",
      "r806",
      "r809",
      "r816",
      "r1029",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "arvn_BayerAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "BayerAGMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer Collaboration Agreement",
        "label": "Bayer A G [Member]",
        "documentation": "Bayer AG."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_BayerCropScienceLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "BayerCropScienceLPMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer LP",
        "label": "Bayer Crop Science L P [Member]",
        "documentation": "Bayer CropScience LP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1010"
     ]
    },
    "stpr_CT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CT",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State of Connecticut",
        "label": "CONNECTICUT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of collaboration contract asset",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r265"
     ]
    },
    "arvn_CapitalizedContractCostAmortizationDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CapitalizedContractCostAmortizationDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization",
        "label": "Capitalized Contract Cost, Amortization During Period",
        "documentation": "Capitalized Contract Cost, Amortization During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized costs",
        "label": "Capitalized Contract Cost, Gross",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r105",
      "r755"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r74"
     ]
    },
    "arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities",
        "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r58",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r58"
     ]
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate by Type [Axis]",
        "label": "Effect of Change in Accounting Estimate, Type [Axis]",
        "documentation": "Information by type of effect from change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r153",
      "r606",
      "r608"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate, Type [Domain]",
        "label": "Effect of Change in Accounting Estimate, Type [Domain]",
        "documentation": "Type of effect from change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r153",
      "r606",
      "r608"
     ]
    },
    "arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable related to collaborations",
        "label": "Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]",
        "documentation": "Change in Accounts Payable, after Allowance for Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable related to collaborations",
        "label": "Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]",
        "documentation": "Change in Accounts Receivable, after Allowance for Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ChangeInCollaborationContractAssetAndOtherAssetsRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets: Collaboration contract asset",
        "label": "Change in Collaboration Contract Asset And Other Assets [Roll Forward]",
        "documentation": "Change in Collaboration Contract Asset And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities: Deferred revenue",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "documentation": "Change in Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r138",
      "r356"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to be purchased (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "arvn_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CollaborationContractAssetAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CollaborationContractAssetAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration contract asset and other assets",
        "label": "Collaboration Contract Asset And Other Assets",
        "documentation": "Collaboration contract asset and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r450",
      "r451"
     ]
    },
    "arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment the Company will make",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Milestones",
        "label": "Commercial Milestones [Member]",
        "documentation": "Commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r79",
      "r617",
      "r683"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r297",
      "r298",
      "r739",
      "r1049",
      "r1055"
     ]
    },
    "arvn_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840",
      "r842",
      "r843",
      "r844",
      "r845",
      "r1017",
      "r1018",
      "r1020",
      "r1106",
      "r1166",
      "r1170"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r684",
      "r702",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 73.2 and 68.8 shares issued and outstanding as of June\u00a030, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r345",
      "r351",
      "r619",
      "r819"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r114",
      "r116",
      "r121",
      "r604",
      "r629",
      "r630"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Balances",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract revenue receivable if milestones achieved",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r360",
      "r361",
      "r365"
     ]
    },
    "arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "documentation": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r365"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r365"
     ]
    },
    "arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to collaboration agreements",
        "label": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "documentation": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r365"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Revenue recognized from balances held at the beginning of the period",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from new collaborations",
        "label": "Contract with Customer, Liability, Revenue Recognized From New Collaboration",
        "documentation": "Contract with Customer, Liability, Revenue Recognized From New Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140",
      "r141",
      "r318",
      "r354",
      "r531",
      "r548",
      "r614",
      "r756",
      "r757",
      "r758",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r132",
      "r134",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r303",
      "r304",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r330",
      "r337",
      "r338",
      "r340",
      "r461",
      "r514"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r35",
      "r76",
      "r78",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1050",
      "r1051",
      "r1052",
      "r1118",
      "r1119",
      "r1132"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r514",
      "r515",
      "r782",
      "r783",
      "r817"
     ]
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument interest payments term (in months)",
        "label": "Debt Instrument Interest Payments Term",
        "documentation": "Debt instrument interest payments term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate",
        "terseLabel": "Debt instrument bearing interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r316"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r461",
      "r610",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1118",
      "r1119"
     ]
    },
    "arvn_DebtInstrumentLoanForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "DebtInstrumentLoanForgiveness",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan forgiveness",
        "label": "Debt Instrument Loan Forgiveness",
        "documentation": "Debt instrument loan forgiveness."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1050",
      "r1051",
      "r1052",
      "r1118",
      "r1119",
      "r1132"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r29",
      "r32",
      "r67",
      "r68",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r461",
      "r610",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r817",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1118",
      "r1119"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "DevelopmentMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Milestone Payments",
        "label": "Development Milestone Payments [Member]",
        "documentation": "Development milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_DirectAndIncrementalCostsIncurredToObtainTheContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "DirectAndIncrementalCostsIncurredToObtainTheContract",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement direct and incremental costs incurred",
        "label": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "documentation": "Direct and incremental costs incurred to obtain the contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r383",
      "r412",
      "r413",
      "r416",
      "r797"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "arvn_EarningsLossPerCommonShareEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "EarningsLossPerCommonShareEPSAbstract",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Loss) earnings per common share",
        "label": "Earnings (Loss) Per Common Share, EPS [Abstract]",
        "documentation": "Earnings (Loss) Per Common Share, EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) earnings per common share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r122",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r160",
      "r162",
      "r167",
      "r168",
      "r169",
      "r173",
      "r343",
      "r417",
      "r444",
      "r449",
      "r474",
      "r475",
      "r605",
      "r631",
      "r764"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r122",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r162",
      "r167",
      "r168",
      "r169",
      "r173",
      "r343",
      "r417",
      "r444",
      "r449",
      "r474",
      "r475",
      "r605",
      "r631",
      "r764"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) Earnings Per Common Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r798"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r424",
      "r434",
      "r798"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense not yet recognized, period of recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98",
      "r99",
      "r100",
      "r117",
      "r118",
      "r119",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r156",
      "r158",
      "r175",
      "r254",
      "r255",
      "r276",
      "r342",
      "r357",
      "r417",
      "r432",
      "r433",
      "r441",
      "r442",
      "r443",
      "r445",
      "r448",
      "r449",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r516",
      "r518",
      "r530",
      "r627",
      "r655",
      "r656",
      "r657",
      "r668",
      "r721"
     ]
    },
    "arvn_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Distribution Agreement",
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r440",
      "r503",
      "r934",
      "r935",
      "r936",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest, percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r503"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r196",
      "r208",
      "r247",
      "r949",
      "r1046"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r250",
      "r253",
      "r936"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r866",
      "r876",
      "r908"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r863",
      "r873",
      "r905"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r488",
      "r806"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r488",
      "r806"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r487",
      "r488",
      "r490",
      "r497",
      "r535",
      "r536",
      "r537",
      "r752",
      "r782",
      "r783",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r806",
      "r809",
      "r816"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r806",
      "r1111",
      "r1114"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r483",
      "r485",
      "r486",
      "r487",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r601",
      "r806",
      "r810"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r368",
      "r373",
      "r374",
      "r376",
      "r478",
      "r479",
      "r488",
      "r497",
      "r536",
      "r752",
      "r782",
      "r783",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r806",
      "r816"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r806",
      "r1111",
      "r1114"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r487",
      "r488",
      "r490",
      "r497",
      "r535",
      "r536",
      "r537",
      "r752",
      "r782",
      "r783",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r806",
      "r809",
      "r816"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1114"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r339",
      "r355",
      "r461",
      "r472",
      "r495",
      "r502",
      "r505",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r613",
      "r628",
      "r779",
      "r806",
      "r807",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r820",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future grant of incentive units to service providers percentage",
        "label": "Future Grant Of Incentive Units To Service Providers Percentage",
        "documentation": "Future grant of incentive units to service providers, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r705"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r81",
      "r85",
      "r606",
      "r608",
      "r625",
      "r760",
      "r762",
      "r763",
      "r768",
      "r773",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]",
        "documentation": "Income Statement And Statement Of Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r284",
      "r289",
      "r457",
      "r458",
      "r459",
      "r460",
      "r482",
      "r484",
      "r489",
      "r504",
      "r505",
      "r506",
      "r652",
      "r654",
      "r706",
      "r751",
      "r752",
      "r799",
      "r800",
      "r804",
      "r805",
      "r808",
      "r816",
      "r1099",
      "r1100",
      "r1137"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r289",
      "r457",
      "r458",
      "r459",
      "r460",
      "r482",
      "r484",
      "r489",
      "r504",
      "r505",
      "r506",
      "r652",
      "r654",
      "r706",
      "r751",
      "r752",
      "r799",
      "r800",
      "r804",
      "r805",
      "r808",
      "r816",
      "r1099",
      "r1100",
      "r1137"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r435",
      "r437",
      "r438",
      "r439",
      "r612",
      "r662",
      "r667",
      "r798"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/IncomeTaxesDetails",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit (expense)",
        "verboseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r95",
      "r132",
      "r157",
      "r158",
      "r174",
      "r193",
      "r208",
      "r423",
      "r424",
      "r436",
      "r632",
      "r760",
      "r762",
      "r763",
      "r798"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r128",
      "r430",
      "r431"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Collaboration contract asset",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance represented as percentage on outstanding common stock",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock options and RSUs (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r169",
      "r382"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r904",
      "r912",
      "r916",
      "r924"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r928"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r928"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r928"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r185",
      "r189",
      "r195",
      "r208",
      "r513",
      "r773",
      "r774",
      "r1169"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "verboseLabel": "Interest income, net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r188",
      "r208",
      "r773",
      "r965"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation and related personnel expense (including stock-based compensation)",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r762",
      "r964"
     ]
    },
    "arvn_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease for laboratory and office space (in sq feet)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r528"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r529"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1012",
      "r1016",
      "r1132"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1012",
      "r1016",
      "r1132"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1012",
      "r1016",
      "r1132"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1012",
      "r1016",
      "r1132"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1012",
      "r1016",
      "r1132"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets and Liabilities",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r35",
      "r36",
      "r38",
      "r39",
      "r40",
      "r41",
      "r132",
      "r135",
      "r136",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r454",
      "r455",
      "r456",
      "r503",
      "r682",
      "r767",
      "r786",
      "r847",
      "r1058",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r80",
      "r622",
      "r819",
      "r835",
      "r836",
      "r1011",
      "r1015",
      "r1047",
      "r1117"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r104",
      "r132",
      "r135",
      "r136",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r454",
      "r455",
      "r456",
      "r503",
      "r819",
      "r1058",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_LicenseFirstLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "LicenseFirstLicensedProductMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License First Licensed Product",
        "label": "License First Licensed Product [Member]",
        "documentation": "License First Licensed Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064"
     ]
    },
    "arvn_LicenseSecondLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "LicenseSecondLicensedProductMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Second Licensed Product",
        "label": "License Second Licensed Product [Member]",
        "documentation": "License Second Licensed Product"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r133",
      "r142",
      "r327",
      "r341",
      "r610",
      "r782",
      "r783",
      "r817",
      "r1134"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current installments",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r142",
      "r332",
      "r610"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r142",
      "r332",
      "r610"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r142",
      "r332",
      "r610"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1016"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term debt",
        "terseLabel": "Total long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "MaximumAggregateOfferingPriceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate offering price",
        "label": "Maximum Aggregate Offering Price Of Common Stock",
        "documentation": "Maximum aggregate offering price of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r407",
      "r408",
      "r409",
      "r420",
      "r481",
      "r564",
      "r651",
      "r653",
      "r661",
      "r674",
      "r675",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r749",
      "r750",
      "r778",
      "r787",
      "r796",
      "r799",
      "r801",
      "r802",
      "r809",
      "r810",
      "r814",
      "r815",
      "r830",
      "r1060",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "MilestonePaymentOnFirstAnniversaryOfSigningMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment on First Anniversary of Signing",
        "label": "Milestone Payment On First Anniversary Of Signing [Member]",
        "documentation": "Milestone Payment On First Anniversary Of Signing"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment Upon Approval of First and Second Royalty Products",
        "label": "Milestone Payment Upon Approval Of First And Second Royalty Products [Member]",
        "documentation": "Milestone Payment Upon Approval Of First And Second Royalty Products"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r407",
      "r408",
      "r409",
      "r420",
      "r481",
      "r564",
      "r651",
      "r653",
      "r661",
      "r674",
      "r675",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r749",
      "r750",
      "r778",
      "r787",
      "r796",
      "r799",
      "r801",
      "r802",
      "r809",
      "r810",
      "r814",
      "r830",
      "r1060",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "netLabel": "Net (loss) income",
        "verboseLabel": "Net loss",
        "terseLabel": "Segment net (loss) income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r61",
      "r82",
      "r100",
      "r102",
      "r113",
      "r115",
      "r119",
      "r132",
      "r135",
      "r136",
      "r139",
      "r146",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158",
      "r166",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r343",
      "r346",
      "r348",
      "r352",
      "r417",
      "r444",
      "r449",
      "r475",
      "r503",
      "r626",
      "r703",
      "r719",
      "r720",
      "r760",
      "r762",
      "r763",
      "r846",
      "r1058"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r904",
      "r912"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Grant Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "arvn_NovartisPharmaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "NovartisPharmaAGMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Pharma AG",
        "label": "Novartis Pharma AG [Member]",
        "documentation": "Novartis Pharma AG"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_NumberOfLicensedProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "NumberOfLicensedProducts",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of licensed products",
        "label": "Number of Licensed Products",
        "documentation": "Number of Licensed Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r1023"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r777",
      "r1023"
     ]
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oerth",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "documentation": "Oerth Bio LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "negatedLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r760",
      "r763",
      "r768",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r818"
     ]
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Payments To License Agreement",
        "label": "Option Payments To License Agreement [Member]",
        "documentation": "Option payments to license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities",
        "verboseLabel": "Issuance of common stock for pre-funded warrants (in shares)",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r73"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r803"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "arvn_OtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "OtherProgramsMember",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other programs",
        "label": "Other Programs [Member]",
        "documentation": "Other Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expense",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r868",
      "r878",
      "r910"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r871",
      "r881",
      "r913"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r871",
      "r881",
      "r913"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PaymentsForCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PaymentsForCollaboration",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for collaboration",
        "label": "Payments For Collaboration",
        "documentation": "Payments For Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, equipment and leasehold improvements",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "arvn_PercentageOfIncrementalBorrowingForLeasePayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PercentageOfIncrementalBorrowingForLeasePayments",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of incremental borrowing for lease payments",
        "label": "Percentage Of Incremental Borrowing For Lease Payments",
        "documentation": "Percentage of incremental borrowing for lease payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PercentageOfLiquidatedDamages",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of liquidated damages",
        "label": "Percentage Of Liquidated Damages",
        "documentation": "Percentage of liquidated damages."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PfizerIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PfizerIncorporationMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer, Inc.",
        "label": "Pfizer Incorporation [Member]",
        "documentation": "Pfizer, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PiperSandlerAndCantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PiperSandlerAndCantorMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Piper Sandler and Cantor",
        "label": "Piper Sandler And Cantor [Member]",
        "documentation": "Piper sandler and cantor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "arvn_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrant",
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r353"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r353"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r684",
      "r702",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, zero shares issued and outstanding as of June\u00a030, 2025 and December\u00a031, 2024, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r345",
      "r350",
      "r618",
      "r819"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options and issuance of ESPP shares",
        "label": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares",
        "documentation": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "documentation": "Proceeds from maturities of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property, equipment and leaseholds improvements",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r566",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r753",
      "r759",
      "r762",
      "r763",
      "r788",
      "r789",
      "r829",
      "r830",
      "r831",
      "r834",
      "r837",
      "r938",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1056",
      "r1057",
      "r1136",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r566",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r753",
      "r759",
      "r762",
      "r763",
      "r788",
      "r789",
      "r829",
      "r830",
      "r831",
      "r834",
      "r837",
      "r938",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1056",
      "r1057",
      "r1136",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Leasehold Improvements",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r90",
      "r93",
      "r94"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property, equipment and leasehold improvements",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r106",
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r528",
      "r611",
      "r624",
      "r819"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Equipment and Leasehold Improvements",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r528"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r299",
      "r300",
      "r301",
      "r302",
      "r367",
      "r377",
      "r407",
      "r408",
      "r409",
      "r416",
      "r420",
      "r481",
      "r538",
      "r547",
      "r564",
      "r651",
      "r653",
      "r661",
      "r674",
      "r675",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r749",
      "r750",
      "r778",
      "r787",
      "r796",
      "r799",
      "r801",
      "r802",
      "r809",
      "r810",
      "r814",
      "r815",
      "r830",
      "r840",
      "r1053",
      "r1060",
      "r1111",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r299",
      "r300",
      "r301",
      "r302",
      "r367",
      "r377",
      "r407",
      "r408",
      "r409",
      "r416",
      "r420",
      "r481",
      "r538",
      "r547",
      "r564",
      "r651",
      "r653",
      "r661",
      "r674",
      "r675",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r749",
      "r750",
      "r778",
      "r787",
      "r796",
      "r799",
      "r801",
      "r802",
      "r809",
      "r810",
      "r814",
      "r815",
      "r830",
      "r840",
      "r1053",
      "r1060",
      "r1111",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r863",
      "r873",
      "r905"
     ]
    },
    "arvn_RegulatoryAndSalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "RegulatoryAndSalesBasedMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory and Sales-Based Milestones",
        "label": "Regulatory And Sales Based Milestones [Member]",
        "documentation": "Regulatory and sales-based milestones."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "RegulatoryMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestone Related to Marketing Approvals",
        "label": "Regulatory Milestone Payments [Member]",
        "documentation": "Regulatory milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_RemovalOfCombinationTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "RemovalOfCombinationTrialsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Removal of Combination Trials",
        "label": "Removal Of Combination Trials [Member]",
        "documentation": "Removal Of Combination Trials"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r665"
     ]
    },
    "arvn_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140",
      "r141",
      "r318",
      "r354",
      "r531",
      "r548",
      "r614",
      "r756",
      "r757",
      "r758",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "arvn_RequiredMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "RequiredMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required milestone payments",
        "label": "Required Milestone Payments",
        "documentation": "Required Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r751",
      "r760",
      "r761",
      "r773",
      "r1131"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchAndDevelopmentExpenseNonProgramSpecific": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchAndDevelopmentExpenseNonProgramSpecific",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non program-specific external expense",
        "label": "Research And Development Expense, Non-Program Specific",
        "documentation": "Research And Development Expense, Non-Program Specific"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchAndDevelopmentExpenseProgramSpecific": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchAndDevelopmentExpenseProgramSpecific",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Program-specific external expense",
        "label": "Research And Development Expense, Program Specific",
        "documentation": "Research And Development Expense, Program Specific"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Collaboration And License Agreements [Abstract]",
        "documentation": "Research Collaboration And License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration And License Agreements [Line Items]",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "documentation": "Research collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration And License Agreements [Table]",
        "label": "Research Collaboration And License Agreements [Table]",
        "documentation": "Research collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchFundingPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ResearchFundingPaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Funding Payments",
        "label": "Research Funding Payments [Member]",
        "documentation": "Research funding payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r864",
      "r874",
      "r906"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r865",
      "r875",
      "r907"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r872",
      "r882",
      "r914"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1009"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Activity",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r291",
      "r296"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in workforce (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r123",
      "r126",
      "r292",
      "r293",
      "r761",
      "r1054"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r126",
      "r287",
      "r288",
      "r293",
      "r294",
      "r761"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring accrual",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r294"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r69",
      "r621",
      "r658",
      "r660",
      "r666",
      "r685",
      "r819"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r156",
      "r158",
      "r254",
      "r255",
      "r276",
      "r342",
      "r417",
      "r432",
      "r433",
      "r441",
      "r442",
      "r443",
      "r445",
      "r448",
      "r449",
      "r462",
      "r464",
      "r465",
      "r467",
      "r473",
      "r516",
      "r518",
      "r655",
      "r657",
      "r668",
      "r1170"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r174",
      "r186",
      "r187",
      "r202",
      "r208",
      "r211",
      "r213",
      "r215",
      "r362",
      "r363",
      "r364",
      "r566",
      "r760",
      "r763"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "arvn_RevenueRemainingPerformanceObligationContingentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "RevenueRemainingPerformanceObligationContingentPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payments",
        "label": "Revenue, Remaining Performance Obligation, Contingent Payments",
        "documentation": "Revenue, Remaining Performance Obligation, Contingent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transaction Price Allocated to Performance Obligations",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r120",
      "r132",
      "r135",
      "r136",
      "r174",
      "r186",
      "r187",
      "r202",
      "r208",
      "r211",
      "r213",
      "r215",
      "r252",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r503",
      "r606",
      "r608",
      "r773",
      "r803",
      "r835",
      "r836",
      "r1058"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r818"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "SalesBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Based Milestone Payments",
        "label": "Sales Based Milestone Payments [Member]",
        "documentation": "Sales-based milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Based Milestones",
        "label": "Sales Based Milestones [Member]",
        "documentation": "Sales-based milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r29",
      "r32",
      "r67",
      "r68",
      "r782",
      "r784",
      "r1012",
      "r1016",
      "r1118",
      "r1132"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted (Loss) Earnings per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r440",
      "r503",
      "r934",
      "r935",
      "r936",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r136",
      "r248",
      "r249",
      "r251",
      "r252",
      "r503"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Equity Method Investments [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r132",
      "r136",
      "r248",
      "r249",
      "r251",
      "r252",
      "r503"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Minimum Future Payments on Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r528"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r1135"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of reportable segment financial information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r416"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]",
        "documentation": "Supplemental cash flow information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r174",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r215",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r290",
      "r295",
      "r446",
      "r447",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r770",
      "r773",
      "r774",
      "r780",
      "r833",
      "r1136",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r213",
      "r214",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r606",
      "r607",
      "r608",
      "r609",
      "r671",
      "r672",
      "r673",
      "r725",
      "r727",
      "r730",
      "r732",
      "r734",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r754",
      "r765",
      "r788",
      "r790",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r840",
      "r1136",
      "r1138",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r174",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r198",
      "r200",
      "r201",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r769",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expense, net",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r200",
      "r201",
      "r208",
      "r773"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of RSUs released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/ Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/ Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of inducement grants (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, maximum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, minimum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares remained available for purchase (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Vested and exercisable, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/ Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in reserved shares of common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in reserved shares as percentage of outstanding common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in compensation expense",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cancelled/ Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accounting Pronouncements and Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r101",
      "r174",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r215",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278",
      "r290",
      "r295",
      "r446",
      "r447",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r770",
      "r773",
      "r774",
      "r780",
      "r833",
      "r1136",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r46",
      "r47",
      "r98",
      "r99",
      "r100",
      "r117",
      "r118",
      "r119",
      "r143",
      "r144",
      "r145",
      "r147",
      "r154",
      "r156",
      "r158",
      "r175",
      "r254",
      "r255",
      "r276",
      "r342",
      "r357",
      "r417",
      "r432",
      "r433",
      "r441",
      "r442",
      "r443",
      "r445",
      "r448",
      "r449",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r516",
      "r518",
      "r530",
      "r627",
      "r655",
      "r656",
      "r657",
      "r668",
      "r721"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r213",
      "r214",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r606",
      "r607",
      "r608",
      "r609",
      "r671",
      "r672",
      "r673",
      "r725",
      "r727",
      "r730",
      "r732",
      "r734",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r754",
      "r765",
      "r788",
      "r790",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r840",
      "r1136",
      "r1138",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r175",
      "r344",
      "r345",
      "r347",
      "r349",
      "r518",
      "r566",
      "r663",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r762",
      "r763",
      "r841",
      "r1168"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r175",
      "r216",
      "r344",
      "r345",
      "r347",
      "r349",
      "r518",
      "r566",
      "r663",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r762",
      "r763",
      "r841",
      "r1168"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r867",
      "r877",
      "r909"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "arvn_StockCompensationAndBonusExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "StockCompensationAndBonusExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Compensation And Bonus Expense",
        "label": "Stock Compensation And Bonus Expense [Member]",
        "documentation": "Stock Compensation And Bonus Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r69"
     ]
    },
    "arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r69",
      "r664",
      "r721",
      "r733"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity incentive plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r69"
     ]
    },
    "arvn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity incentive plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r42",
      "r43",
      "r69"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r62",
      "r686",
      "r702",
      "r722",
      "r723",
      "r819",
      "r847",
      "r1011",
      "r1014",
      "r1015",
      "r1047",
      "r1117",
      "r1170"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SuccessBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "SuccessBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success-Based Milestone Payments",
        "label": "Success-Based Milestone Payments [Member]",
        "documentation": "Success-Based Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental non-cash information:",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "documentation": "Supplemental non-cash information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r339",
      "r355",
      "r461",
      "r472",
      "r495",
      "r502",
      "r505",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r613",
      "r628",
      "r806",
      "r807",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r820",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1107",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Assistance Agreement",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "documentation": "Two thousand and eighteen assistance agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Plan",
        "verboseLabel": "2018 Plan",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "documentation": "Two thousand eighteen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r126",
      "r287",
      "r288",
      "r293",
      "r294",
      "r761"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "arvn_UpdatedResearchTimelinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "UpdatedResearchTimelinesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Updated Research Timelines",
        "label": "Updated Research Timelines [Member]",
        "documentation": "Updated Research Timelines"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements",
        "label": "Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member]",
        "documentation": "Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofAccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r176",
      "r178",
      "r179",
      "r180",
      "r606",
      "r608",
      "r766"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r481",
      "r547",
      "r749",
      "r750",
      "r809",
      "r1125",
      "r1127",
      "r1130"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Denominator adjustments for diluted EPS (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator adjustments for diluted EPS:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited",
      "http://www.arvinas.com/role/LossEarningsPerCommonShareScheduleofBasicandDilutedLossEarningsperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncomeunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_YaleUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20250630",
     "localname": "YaleUniversityMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yale University",
        "label": "Yale University [Member]",
        "documentation": "Yale University"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001655759-25-000139-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-25-000139-xbrl.zip
M4$L#!!0    ( "F*!EM2AEL<O'H! ',?$0 1    87)V;BTR,#(U,#8S,"YH
M=&WL?6MWXDB2Z/?]%;K,[D[5.89"XNVJYA[*=O5XMMKV&%?WSOTR)Y$2HRDA
M,7K89G[]C<B4> J00* 4SGU4&SU2F?&.R(C(+__W;6PI+]3U3,?^Y<]JI?IG
MA=JZ8YCV\R]_[O6O;F___'^[__'E_Y3+__OU\;MR[>C!F-J^<N52XE-#>37]
MD>*/J/*'X_XT7XCR8!%_Z+CC<IF_=N5,IJ[Y//(5K:HUHL>BN^ZE/M2&[:%.
MR\-&IUFNU]NDW!D8U7*+M#MZNU$?#E1R\7PY[+2(KJK5,E750;D^U/7RH*97
MRYV:T8+_[:BU5O7"N(2'.ZI!VH0.!O6J7NLTR4"MT[K6;C3UX4!CWQWYL&98
MM^U=FF^_E$:^/[G\].GU];7R-G"MBN,^?]*J:NV3:5NF37'=I=GC?MFC^M([
M\+OR[+PL//W)=XGM(1"(#V#%P1KE:KM<4Z-QJ&[,QF#?C :!&Y\03M&#GC]Q
MXY_$.TN/!E[YF9#)[.DA\09L+>&-I8=-SZEK:FO3XJNP>/Y$] )Q7^REI^&"
M:1.OHCMC-G*U6:M&#^-(YK:Q;<\GMDYG4_?=C4]W/L'=Z$& \,\MX^+M ?%F
MX[ZM/?]:8T^KG4[G$[L;/6I0,Q[.<&,)<F^>&3<B?%_]]+^_?>_K(SHFY=45
M>JZ_CABXN#CTYHDBP2Z08#P$MM&?5BU7M;*J+2+(6%EPN(KF)WZ3/7II$9 #
M)6J7?_1+W2\C2HSNES'UB8)OENF_ O/EE]*58_L@$\I/TPDL6.>_?BGY],W_
MQ*;^J?L?__$?7WS3MV@7":D<$<R73_SBET]\Z(%C3+M?#/-%\?RI17\I&:8W
ML<CTTG9L"A,PWR[Q0>KR/TW#H#;[$^[?@6!R39U__\U_I,-?2GH96,XF8QR)
MFI<]$%T&BJ]O%GDN*1Q"OY0 I)=#\XT:Y2&QD'I,X,YA66N6NNS"ET]+7TCQ
MP4A<?C,]G5A_I\3]!E>\V1=:I2Z"(JL//,#CCK'\B7:I^S=M_P_<V("AZ15\
MPB76K6W0M_^AT]G@G5*W"H3?;#1:C<[^'[D*7'<)2C>V<0WJ)?H.2)9N&<@7
M)&BJC[1KT5="&7CY2%^H'=!'X%'3!AT'$&-4 *QZ/[#,9\8P-V\3JH-R>S+'
M\,C]L ]7O2'1\1X'L;I$/*@2+HW '</'1]&<ZU6MU&VFFV[]I-.= J#GLZV5
MNBF!V\AQMO74LVWF.-M&W&P_+4LPEPXI,(%.O1C!BYKJTF.J!=:C,,UUZ8.X
M_:7DF>.)A7J&71NYN-PE&5MY\PR0P.Q[\X^$W_2<P&6_F,J^#&S39[/V1@1N
MEJ+K8TJ\P*5=_HO?_/)I^5[T&\=8&R^ .:P.%EH8ES_ZUVG' M#W<1*S,4%E
MF 9=?)3!F?B.N^=GU]['B]?4=H 0XH9-"IJE(3XMSW[;JNU@/*#N!HQ,X,]4
M,/3^-?37Q@)#ZQ)OI!IIXCI&H*\/AC1X&=Y,-S7ZC!HM?L#P9I(!0_YG8Z*^
MB:Y3IM&B7P!W^#TTJ:LP_J*QMOW5[?\L:[K5EV<S6!Y]PD1$] M,0M='O<:4
M?KFJPO]%[\WOS:9I+#S:+*.QM'PG^AU]Y-/2NN/!H D !FX;^^'*V@M B.[L
ML[*:<"M;Q-DA*ZN+M;)Z9(@=OK*& "M;9<KZZ9FR*1H8ZLG!4,\.#"T!P9!4
M1&<(AO:QP1"NAFM2_M. C[U-+%,W_=\HVAF*8<)=%A2<&<Q]'Y:$[]R VP\^
MH3.>@%=N^U[OS013,7H,KH,CU/<=_2<?Z\NGV$_,H#&;26H)6\M(#G4*#O)'
MZH,/0XT;XJ(GXQ4%[FJUX(#O&8:)KB"Q'HAIW-I79&+ZQ"H,_(]N%1\;_KH>
MC ,+=R+N_1%U\3F7CG"T%WIKZ\Z8%@87XIGFF2WMZ+;YN;"Y ,:H>G1WH_#*
M4 0L'=UU*K*5* *"CN[4G:-J%0%Q1W=#B\Q9QXEPJ47W>4_M@&4&^*)[OCDY
M8%G!7RN\ YR_ Y89+HKN#)]*\->S\PRUHSN]YR3XLP2\=,GSA7_1O>R\!7^6
MN!!A&_)(2RN\%YI+Y"V?_4^MZ)[GB2-O.6&IZ+[JZ2)O.2&H\#YM[I&W?!!7
M*[HS?$('+"NGMU9TI_?4#EAF@"^ZYYN3 Y89_ OO .?O@&6&"^$R7+-;FMRG
M/7E6<:WH3N^)=5IV@"^Z YN/3LL._D5W3?/7:=GAHO!>:%XY;SE41=6+[GF>
M/N<M#RP5W5<]:<Y;'@@JND][*F.WEIV>J1?=CSVIL9LEX N_@YN#L9LE_(ON
M6>=M[&:)"Q$J6(^T-.G3[KF#E$/I;+WH#O#I=]#SP%+17>.3[J#G@*!&T=UA
M(7;0\T"<<!ZRY_K +@%,TIT "*9W9$PYKE@[GX>A^6_J(D;<B>.RCEL[$).8
M5+ 9X?VPY[K$?F8DL_#9*\>RR"#\8._9I>R!HUI;0 VMK+JF".MF;X/Y(WU&
MCG3<:<\V^L2BWE?B4>,W$_[R@8EWZ3H!20V_^(A+Y9_!G[^1-W,<C M#2L)%
M#\04&'/BG='K YGB0\>-5V2):N'B%6*B>@_1) Z.A8N)% ;'QV/G);M076YX
M=Z+ ?$.XC @QZ>*D8EX$NA NN"4F79S*7Q!@#Z\A7 CM?9/$<6J=&\*%X#+'
M\H'LI[83LQ\\NK3=<% K4&%#;]N8X7["^J&'JO+)^6[J\#I-RA8"BH"<7/L,
M6;PI7"PP"25=TQ=J.1-&-"E-,$E%(16IK>RV/YN%C#7N[]])(CH&$<DHH^!A
MB7Q\C6;10I)WS@M<-;V'$7''I/=K%JS]P(_(N'?[U'T!NVEY)S.TI(Z<]5YM
M9,7I10M GA%&5_>?&SDP=-'BC.>*_ISD>='"B6>$_B,YD46+!IXG1ED_CHPP
M6K3(WU<RI>Y.1![FZW2RXYB6< &\3.";B7_S2#U*7'WT+;#Q?.F39%!DF K>
MDA&U7$@KIP!(ED)!1M$DX>Q%.$6+G)U0FQP@V [=&V083IS=C=N#6;A7K:*%
MRTY(#+F%3O.BA:(%VGZE6*=!]=%25+UG&]_^X@R'8V)_)X\.3/B[.39]P.)Q
MD=8JJTDW]]FC&1UP6;3PF%A(:Y2KG81(:V27D=$2+J@EN-6?+=$(:N1E&61K
M%2W(=F(,"Y>Y>R0R*%ID3D RP,I<ZNHFL4Y4O)$A_MM%BQP*91WDM.75%C8F
M>#5"_KBU>[J.*#3MYQO/-\>PT*]39*$EX3EV7HAU/P3V&9@V0^.3"TQTGFDG
M;6&C<2EP]F-B8'E[%%)_@L$L\RC23@2,Y10&\P'FQF9T/8*1;0<4V(>8V*[C
M@;I#QP7!I]/[@64^,T:Z>9M0'3 %&()'[H=]N.H-B8[W^A'X.&*_'&?@BN'@
M."%.6@Q]Q_W2C/P6 "B2ILTID'9VY-2,I,'[)J><8G%G1TXM24Y(3CE%"<^.
MG-J2G)"<A(U??@-7PT9?_1:6YP9S5W[>9XM[E?2K8QM]J@>NZ9N'-XJ9?9^8
M[N_$"L"X_HT2+W!9-.&;2_\54%N?+L]E]O#"H]XCSLD%,CG"E&9__@6 C";^
M]#O&=#?,ZM:>!+['GM *$_ 0+NZ9F#)_]']U7JAKXYUK.O E<9X=<0H7C964
M(09E=(2+TTJ%6F#*S/#,D8ZPP6BI4"5Q"AMUEY21,V4(E^0:@?7!=6 A_O3!
M@K7U; .[#K.<FK7MF.^\%Y#C3F?/%,:>$2ZM5'SP9TG]PF5RI@+_K P.Q"$=
M.99Q.YZXH,H+E7K3$2XQLR XR)(/A(U3IL+!_7!HZK1X2D#86)RPT,^2]H4+
M-L5EU9IVD;)JU>K1XS0)UG9 \DPMHP1VM2I<6 #):7:4QZ_4>7;)9&3J)/1J
M/'_B7EX]'>Y&821A->+ [,6G5^=IY 0>L0T4*>;SR*?4[GF>B02G)^Y<>!"U
M8XO)3F;4+IQ[_9Z1O-I)-&G=R@I%',;VPKK5VS*X^<$^UX BUQP$:9KK)B+(
M;4W?3 !O'XC%HB[0RQ6PHN-F%=#I!P//-$SB3K%2\7[(#H]:^'C/?QK1WXC[
MD_I@P] $L:3#%&UMN:KM,-$C; !!$EH^A"9 RK!:%3:NTGLEKK'NN]R,)Y8S
MI?3HQP]G:W<(&SK)!\Q":'YA0REYDWZV#J:P,9/\23\WJ2]<)$4@G.1S**6J
M"ILP@S'%%>-LP6F,/$:&FEMP&.%[+Q3?*8QV5H4,_>Q5KB^1.D.JD*&>O:+%
M!43J:O.?I'UD.MFU)%%584,[$D]+>!(V,B(.GHYDG*O"NO]' GV1#-$&]C,^
MO7.@"ANKD#3!>USGX)P(&RN1-)%7$$$5+K 38V#_01D%&+T7ZI+G\SQ00E4+
M'<[AQR*>)V8T88,ZPF FIW";5HB83[;A 6%PGA<W%B(DE&V<[]WC7+@@T#OB
M\[QDNW !I7?$YWGA7+A(UGGS^9$"DIIPP:?S9MUCH5&X>-&[X<9ZEF@L0HCG
M/+DQ4S0*&Q\2<H,MPY(UM29L $@<T.]O/F:W!UT3+APD.)YR<N=KPH5P=NB-
M1XJE$]@JDZ'HAVWZWF/_QYEB1[A@B^#;A">CCF.I-^$B+1+A HD#X6(RDCK6
MQ$&6;G]-N.B-*  7(41:$RXH,^NX:1'/NQ_^0; &U;]W'Y$!%VM!78JGH5,C
M?.*H#)%ET6]-N "*." 70D,)&QGIP0B&:06H>>9M/F_>="L I'QSG?&5,YX$
M/NO&?S^\(2[VZO<>J-L?$9=^G<8/D/?N4$XYK75APS GP7-N5F<NN!8VE'.F
M/)U33G)=W%#0V>(Y#[.U+FQ0Z8QE=UX\+6P\Z;QQG0M?"Q<=VM&1Z"N94O?*
M=29]W:2V3K\_'!H.8LW?8(E&@$V(>*^EWZ@_<HQ;^P5H >>]?I72E8G=4]<?
M?36=\ CA[R89F!:\=#4_;_B8'C/6C;:RBBC7A0LA222M(TFX2))DW?RCOW7A
M@EV2*O)//JH+%V(SJ'GYG3X3ZX;-)V^XBQ S:0@7'Q,923DY1PWA ELB(RFG
M'86&<%$ID9&4D^O9$"ZD=":&0Y;F9$.X6-"9("E+ZZY1M"#.WXE%?]CF"W4]
MAJ=L\GFVM=#^,1FZ +0',L4;WQRW!_\U$.\Z##/OK]^SC3OG!:9L>M$MV^AY
M'O5GCQSAF*)5<=S,0QP+&?,1BHA^,RT0)8Y-0S*ZM[^9K@<TPV=!W.G]L&\^
MV\?NB)^I[! NBK0/)GY,'+LWP9/$B'4_#+&"QP8[MO'H3(GE3Q]<QPCTG=PK
M%E7N76DE$($5+2!U? P>ZW2JI3Z2-0PU5QL)U,CJHX>I$>$B36>+[H5]A14,
M'L2P3>'"4 C%4'S?NWWJOH!EMGBB*C?4F-0/_S;"QT]A%?0#7:>>]Y7 9U?U
MDE#:IJ 2I2E<Q"T9/7+K0Q+D^1&D<-'%W%7<L6Q2(= M7)QR*5,)A$J 1V-=
M.<SG@6L@D#;U3:#8@=/63]"",X\-M*9PP<K$F.*"&_/-,(,-7F<12'CJJV,'
MWLT;7CI7K D7O8RP=FOKSIC.#@;][N@<*ZOI@I2X^@AP=0WL93GL..?SQIAP
MH<)4&/N5VB %+0SL&F-PSH U"2:$GC?.A(WSS;#U-?!,&PS7/A_"6Y",CW3B
MN#X96#2\>:9($BY6)C*2<LH :0H7X1(923EE@+2$"V*)C*2<,D!:18OL]!Y_
MK[?4K&(X(E)"3HJO)61(Y5U30D[:M25<M.7=4T)>*ERX:,Z[IX2\[ 3A(D2[
M*4&M:N=,"7G9"<)%GMX])>1E)P@7SWKWE)"7G2!<T.S=4T)>=H)PD;G=E%#K
MU,Z9$G*R$]K"A?_>/27D9">T"QAC/'-*R,E.:!<PQGCFE)"3G= N8(RQ76V>
M,R7D92<4,,9XYI20EYU0P!CCF5-"7G9" 6.,9TX)>=D)18PQJM5SIH2\[(0B
MQAC/FQ+RLA,*&&,\<TK(R4[H%##&>.:4D).=T"E@C+'5/&N+,2<[H5/ &..9
M4T).=D*G@#'&,Z>$O.R$ L88SYP2\K(3BA9CO/='U(7[SRX9']PY0F2"R,M<
M*%JH\=T01%Y60]$BCN^&(/(R'HH6>'PW!'%\&^*3^7;I4L\)7)UZ_.>($H--
MWC!?NE_@'T8GYD E'=4@;4('@WI5KW6:9*#6:5UK-YKZ<*#] TW0^3N>/[6
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M09?OS"(*8?O@ /"L_V=.N($9 JY6ZE:;#54]DBET?*#M5@T(LP\A$-!)G;A
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M9C:=,MK52KN938X]-I;;GM^?,#*0T)7>W^,6)5_W 81<JE3<-3-1URD%27)
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MZ&6@7/"DS3&QO%]*Y4:)19GPR?(S(9-+I(6>;>!_;N:$T/.OB.MB*Z7?B16
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M]?H7RNW=547IW5TK_1]?^[?7M[W'VYO^1J85:Q%7,S%TM2B&^C/A@R@*&Q+
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MI(!4DMA#2$TE;4%DR?F7NMQB(Q+J^:%;L+]I=<8YR#O2!6[M%P @YAUSNHY
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M."=)(M5.QFF5NDTPY=8/T1.3==YC*^GZ(?OO"PB).=?P3*-QVNZ#85-%X]K
M).W#>20U2L1OC;8/315-M:1?=9$X*,XDRZ*A8+MSI";2DF<DSP@8@=/6>@D>
M+0+7J;+^T54MAKT.Z1\M.4MREH#:: \_)R4_J1A[JZI-J:XD4Q67J=*IJZ0M
M4!(9>QVMU*W'=,"2VD@RCOB,DXIODE0][627&H^ZK1__(:*ZD0VCS[D[@JS"
ME#B1.)$X*2).4BGNM1J+W!O'=NK@=ZJ5IB#5S9+().,7!"=I&%] OF\(Q?>R
M8?0Y%83)8E")$XF3K*.E:Y4I>[8\[31+W5I#A):GDBPDJTJ<2)R<0GPF;6^P
M4WJV1)&>LA/8F3TE&T;+AM'[9ANOU5X>HV%TA[4TS2I/7\:E!+)4)$XD3MX7
M3K+<N,FDSVRG Y:E,'UF)=5(3BX(3C+<B<F"D;5J521&SK:_<"&\BH7FPL_$
MM&5S81G DCB1.)$XD3B1.,G#?=K1NNCDO5ZU*NOU>G#VBR0Q44ALAUV? X5I
M(E'8NVXI/&]><FA+8;Z^N *7=]ISN+:C<U:Z+B=:M<:ZG&25E9@IUL3NLG5$
MRA0C?W+?-EP9 :9(K!K7IRN##G=:M7Z$ML:2.25SGB%SILI-JJTU.SI6WQ:M
MVF!]6VJMF&W\?3LG2Q:6+'R&+)R*@]<Z+V7.N$W6(*:N9GTBA^1>R;UGR+WI
M%/!:?Z<#.M%H54P1KK2E?I4<*CDT(_VZUBIJ'[[$'KK5ZODH4!;5_<0BT5%P
M$_Z)YCTF[K-ILZ^K*WD;F$Y-74 !>W>V4#Y=6*1%)AZ]C/[X'"6JFS;#(GOI
M<SA\N/K&>MX'^QZ__?G5-/S1I0K AW4C[L-8=/CE\'8%;GU:OZZ!L]*NQ]ZJ
M5M38ZYN&:E4ZG?@[FT;:?+W1:)WMG%2M4FVG_?C1)P4W-#FII)-J;QTJW!&*
M;D:2&?BXM$GOY]C OA5I%#;,)39$,/4D5J"!,LSU%&(#'-@.A&+:"GS0 KGO
MK5EDLU5WDJR:B]&3K'OK_A??9=FXEG4,QNX<PV.N\[I7=JB@<.GI>C .+.)3
M0_DR<#]UK^G0U$U?D:!: ]6LZPB'%/8>*0.GL!]A"Q()MMT4QA(-0J@MIAOP
M2SSI0/F M:4?)3C7P/GD^!$!+EKT?^:7N&&_#+9X-:95MZBQ8R0[Q-C<W.*/
M!BWC")>=R7JZ]*D4Y#K$,57ZF^,J0+)*WWQ3?H.G1YYR W,S6!:%$IW)S-1G
M@DR*!2"G<WU$)$:>L)" 29.N=1,3GP_(>F-@*S\#N7::QTY]DE.>65'75*?C
M 77#S*C58YW29T:M]_U]5XE/.WHPITU\ZK#$I_68\<'-F'.-"V?3Q/Q]A'WW
M67>1^"@NJIM!(W--K1[ID"?).9)SQ-VQ3-K/Z/#, U5EAZW7XKJ%'G*XAN0O
MR5_":J:U9HN9<Y7&\GDZVN';D9*U)&L5B+62M*K::?35,CEL77*.Y)SB<$X6
M.3!JO=1M--5C'/LDQF'K6[JFB-D87A[\)+LI29Q(G$B<% LGJ6S>'0TP3G\
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M#3@18/-UU\S>8>3ID4Y"/Q<=),NQG\L^=<%MHH-W45B:96AI#LO[X7> Y!,
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M@(F0,>H,7 <['!H4U,+YIA?1@5-L/,K/^>:*RJ,+7XN4WN(7\8U_!L8S7]J
M,&D'D@&$C(-:QF+C@>(#QK]04,[@BA!<+&( WQX&S!#%QW0N5_BH#C(,"!T=
M!O(6P<] ;()@\)!)/<=&!W!]MB"I<5TF?>53 MIQ[&<'^6G C%R>:_-BXI1!
M0LS$705U2L#DHA=8L"J=R03#1$-L)H@6OY4E\X#3A-X;)[Q'T_MY!1K']/&O
M.2<U8FS\QKJ-OX6_<O:(<#D< S_LD*R7BM%BX2BH*['1 4*,,%$2$:[)3,%_
M,NYT0*/: 4I]Y$J7P<,S85*@%> FI_XX_\%DG AO1T\S5^,BY$X@[PME$/BH
M=(#'QR9W,RX8 ]F4^QS.@,D18H"P ?I5,#Z-,T?#!\PR-L;$ =L#(RN@]JW0
M4P21&#DXBA^V[P)M-K^&P/1BO\6[DS,;8X(.#WX*K4QF5CD&F)"*#N3 Y":,
M@$N%QQGK&R"<+#1PGF'05V4&$/9)T[9AL%"41%9I]&TOT)&GAP%:>3#D&(M9
M@4+_S27=\WQBH=4<U9['"?MPFIQJ87#X[2,FPR6 +4Y]-);F" /K;&DHQ7"8
MV>DO3RR$D,O-8P>&F($(IK()0J8/J@/,.S!5 B8!<4[<"_#I3* S:16][A'T
M%-"6TT<F/( WAL"R_%BS"N.W14+N*HEB3_EK:X>9=1=+L$8+$D$=@01D/%S=
M I=(]R&*T2^W05DM<L;\0#%P(+SP!9L^LQCYPMU9.H@W,_7@OZ O*,,25W?<
M!%V<*S<5*'<8P]%0%0)= ; !5#"2ZP3/HPB-D2KG$P>KP9]RIPT8$^ACLM1V
M 1!@D8'C+NA7 N(!-(W'>-)UT>?@3L.SB^Y)* C8H]CV9UX\O#IW8ULY6NRI
M!&SR2.-O3'_"VOXS@U1'5KR>) $K68OV6K59ZK:;:DR6M *D:S'?DBWEKX%-
M0].]NM&:7F*L-/'-IOCQ32UM?+-O/MOF$ 2X[:_$F  5,?&E5HR]TUJW=_K!
M>(PB&%VE>93DP75L^%M?\,@6OK_T9#B#G?'.Y"N]HZ\+*UR:R8Z86CMFS>T8
M&V^3]<'@$P,U;5M0-F="VHBU)(H(#<%PJ[V,>1A'441I[5R*QCP(N)[AL*#<
M9KI,NL1DJE9KX/\>PS$&4W >][$=C![Q)9)PB4L!RJ4E,O>4O8Q:@R@H_%T6
M6@1=HK/HQ5*()P+)Z4R)_5SZBC!VTK[DB>U<ME+G'9A2?P<[.:3C= OFFY(8
M6C2'4]%@P!."YKN22CD,IB$4D!1=.D(S":@V?+2LW/ 8B7)M>N3YV65&(!#O
M]4)T^4,_&  40$-H6K5<KW[,@9C+&!Z^P\;UZ&;RF"(RV'PO=@'A  #;("Y8
MC%\=^,\LZ/RMU_^ZL,FU2B?SUWY,D$/FVV;]'[/7[IP*^WRY6KM02BM0 VV]
MAH,0P-Y%27D=F?IH'A?;95EM"1J\DRR7YN8L%YFP4J2$E<V6G;;%[FMOV7;?
M())/ZJTO;L%A]408U#;F0H'ML#&!,%.Q450:G,PP\ RNKJ-XX*Z#'<\J)7WZ
M[+!]>XRHAWN?T;[?+%DN5GLS?S84,+.FM_@TB# 61J8LHHX:@.V$\1T77HKI
M+53),T::;>8H:H,Y@TV^#1QNI[HSU9+T_=8%WR.@Q(V,+$0WO,YW%&.F'P6&
MP,>V$#A@AB&D< 76=+XA%(Z$:W*I/W^&OZ<SLEIV]DTO"N'#.!3\ZX#'/-A6
M,+?A$&8+XI[/A=E\2*,LFGXLNZH(9@9+/%8^/#'+H)6C63 C,T!4+30+0-//
M-/P<C;5RM0-:^R@339D)>[MP#@^R]!RHB[;7Z4&Z;J90>Q2&\_@4?9CB@N1;
M"-='0DQ?E&$LZK9F)BVF-802;BZ:\ MA[!<82S<MDSUXL299YV,PVR=,0YI-
M$[Z.E4$7T260#ACPC.*(3..PP/\\1CF@&.%<7&HDKN'E ;7IT/1#*;CMB<U?
M.+*(KB<2L?L)0>2>+(5@?"Q1R$V^G5&V+ ,>Q\L$ .IZQ7]L1^&I.3-K8G6+
MR%M8\&(4)%RP8@1N1"B>^::,X>LC+\P!V1E$%C&JL'E#-,6&-P_*[PK:K_:C
M8F'3>;2T$Q/K[*Q'2WG;#5;^>+.R4S'_(KN_ZD@J!P2!^_J(&@&>6!6_&.81
MK(> U=A@[SZ?W07-F&]7$R83B,"A(/,MRWEEO,6<J[#I+6;D+FO#J%X[6>N5
M>?[,@D^1)+EM)B%\!^O%>?8-RRY[G6GN#>,L) HMUI;/-Q,32 ZV%M1KEPEE
M+" LW*.+8AZLQ)OM&DX\>AG]\3DJK#)MA@CVTN=PK#!0TE@O<&;TP6_/0PB5
M*@\CA'5CX9?#VQ6X]6G]>JM:454M]A;<B;V^:2A5JW0Z\;<V#;7Y>KW:S&Y2
MV]>WH]8NQT8*[?3J@C<[-)"Z7);5$FZL>FL- 0\HS%\OC#D)%+:V?T*>58!=
MOPS<3UUDV03KS>K()$'!4H\!2WT)+ 5L+I(@LC@[B N%]JI6.F8;YEP*V'<#
MA&F%Y!7L^RS\I!7N"5><<:^O=1NOYU\1U\6:E]_!9:4Q"2^JEE%/K^(TH'\'
M_)2R(\09\--1NGKMQ5 U;'A<CSGQ74R&*N!!EPFEZV-V7?'S;T![>HVR'#^X
MXM'/%,V"5'E<N_A$D[G8W$ UZ]31P)-("M)M)U439+66LS1<<[.89$C>?'A/
M#16&@E;: QYR@K8@>F1?.^HP@ @F*([AKV38-+6F-H_BQQR$0[']&\FODE_S
MZW)<4UL9=3G.F6%CVLRM59*LUP;'9O%U$F7QY;7G]KB^3\;[0N".FT5]GU>U
MZJQTF1>?^=B>!#[!#J(D+.V/;97[+!72H"R[-MH;\X#<HIIUGECS2CPL?]2I
M1:.V##9=Z,J G\5STO"8>M,..W\\NS2LH%](WV"A;C:([_!WU:H*=RV+/F,*
MLHO-*;Y_O\*O](+GP//95MK.-(R#BKPZXA=YU=(6>5W-:PY?:&]>83C/U(K9
M=HZI>E)CJIZ  "EQ@2ZN%@L;F07[G54U4J4781]SQN/KN38P'_]@S#2T%11L
M]$&VX.;)'%-/N:.ORJ,S)C9@:05!M61)?#-R7"?$;<G#;!5Q:ZL)7!;V.YT8
MP)P@<S"SYD/O\?=RO:5^7$'^#.$9)1;M@]T,9.NMK?PUL*8H=-2+S9*+;%H]
MEVD/0_BDR]M01149_-JL*.,#CAW>2@GAV1B+W8RXH%Z<,*LDA@F'DWEU7,MX
M-0W,?2C3-]T*6%4-4ZHL8R*L].<[84OE^K/B>Z1<8MI1&E5,D?ZL$!][""#V
ME)?EQ2TL.Y05!E8[L?'GK:1^S-I3I83-,LZP.HXU, *Z"B9#U\$'0!2578H5
MUCQ;A4P9XD /IJJ#;NPZK-+!/B*Z_P<0Q!7H,0< VL.:\?BFQRHHH6:C&G,D
M;+0MS]I-127QR^LT/86"-62&C0C"9<.26:<+>[&0/MT:M:4UMO=:8V>V1JV*
MW1C73\]4!F%%-S<M,&T/,1)B9J&QS2Q9=[%= ] 8*\HO\\< 6D MCDWG23MK
MA%91[H<+&4(QW[Q(":A=3G8Z8M# _*Q7MQ&#LMRS8F'1O//.++5XO?4'#S6E
M6UX]6SK K<ZXQ45TL+*&>/2RO. H/335:AJ+J[F]^[:ZG(>P>\,WUQG/Y8SC
M>CN#[M7Y&FOIO+Y&\Q23JI>ZMK,&]W5$+) 6\% L_.?L.9.R48^,(V;3YF06
M+&:@(_>$.M4;L>SW?P6\]Z-E14ITS/ML>?X6(72QV(YHUEWL#3OA\*S[&_8W
M&R"Z#7AA.?\&:TT[0'\./O?*M0$VJN,E6-AXT/*<F/GQIC-<!(2=5)C0G:O[
MN2T_9IU2+6QI1DP7WID=:+YY4:PY$GR'=U!B2=@N:W*V8ZUG1!]1_1?"9T'Z
M!O[(<2/PCAP+#9S8)J$ ^B5PK4OP"V7@.#_#5C1Q8UR@.0BV0&3ZL0((^.2F
M^7B*$_C8U6U]*%Y]L41:!N5^/N5&YX5B#K&]S\6,.A?R=9G5.0.)YUATM1D4
M"TF@/$E1:?%.:HE;LI;XQ#,X;2TQ<_SCP@'U--T#<Q)Y*!*F%V%A&?94&X7\
M'Z.+6&-;O&Y&.I/ULUM319O5RLP%8(TU08PHE.@C]IFYQ)U0-VS:*D[USO8^
MZ!BQ-4P7)3WO=[FI_QTVI9SRV,/!7C%KKH:AC/#+86V@&QVPQ^V6>?? L%Z"
M6?@7_. R%@*9U\L1X\7T'/>"^U.H7M*Y%QM.#6(]Q:[9)'NV<3N?XA7.\#9<
MQI-SS^8)>BKR0^)<J@;X'%K,KN2R>[W26#JVU<:58_#@.>L.7>KUKTH?E5H=
M3%T1JG3OF>75FW>GNZ9#RM#-H)9#>>YJ2,9YMIG>Q\ $3C-]Z*6]K0?=(@M$
M!,'  33$@,-A$T<CS1TTPFWE11:+^")<R;QU;M@>,$79DD)P!R8TB2,Y$(>N
MG 3^GG'@4Q(:#X*:6'/,;-PQ=GOX-^\P'/;HY]T7#5 2IN?SW9%Y-?1+&'3D
M8:&HP[ 1EC(SI<55#,-:L&^0,K%VRCGR'[H/&[9[LH[X'SVPO]!T06UM#>ZG
MV>!:BO@OAK<30B\NZ(W^U:S(/N$X^T>^6< _],D7(L6S^,Z>2KVS/22Z)9ZU
M+IA;I:[6WA$.!:RV%1Y6X&<XH#49>!M;"B_T=K9"I(;-A1%"(=C+41C2C<!/
M,/H"IL]R76I")$6-TF>P15N8"ZO_S]Z;-JF-9 O#?T7!3#]3O@]%([';\Q)1
MWGI\Q^WR4W;/C?MI0HBDT+20:"U5IG_]>\[)U(8D)($ 02EBHJ<,*)5Y\NQK
M1#"6XT,=$/;IC5#;?.P!++V"NW6H:[7YB#$"($P0."$#*XQCY)Q(F< 1PUHR
M!K*4SR.%*H;=0SSP40^JZ:UNYQ89B+A:&CJ.,2"?55<00<DM@O,[6_B7KR]\
MP+,?Z \A;QPU( Y: Q$HQ751SVO=+.8L.SO#W6K:0?Y(V(CN&MRI'[_Y<G=]
M4.BMY%U/@/4H@Q3>D[CMJ.\WQ4V.S&6?PRJG.VROVYH.4H.0B</FQ 2H#PSY
M"K$M!P_DQ+#8V8O[.-(S0X<"<&^=!+9M;52#/ UAD% U#@@.#7LGB,/TY-0X
M3!Y0L558<-XJHRYGUC._6$_H+G("Y8K&5Y%!%>8177Q>R=W:UHU('] ,W1-M
M"$<@*JF3K0 \W\.O6J^B3:QF%D_"\\$7Z*9;"R24U]8K;@_YEOC: _I3=RVQ
M=2VP ,G_X/NO2Q6(0+K[1;H)'FJ]"CQ[819*A%NV<=Z.A\-F<-3%=OY)T#K$
M\'Z E:4:G@OW BN0G34:#E_%X/DW!WO=6SAA@@\?P*>_/MQ_OWN'2]L6?$S$
MLP:BQ35>P58>;169$>XRF/U'Y\+F?1@'X>F/MIAG)GJ!J,:V<ODW)S:FX^[A
M]E\C7 /67V4J^ &LG78(1QTIW%GCL!T:7&#%,GC\%T1%3B;<3F^)9]Y4C=P9
M!"^<_8!BRM?NVUEH25-9TB$L,J@(7?#*1-@NS>00:"A$8(AW7#0B)1/&M%%3
MQR:03 )LT%4S< O?/>S0_C(XWY3Z.91]ZGRW@RUFD%_^JFXBW%)TQ41:>%;U
M2 _/B![Q#R"=VV^:Y;JW#Q8P1DNZ0X73QN!#K'EA,-]P-(S.-VRC)TBW_;%M
M6Y>9QH9C!O\_OCU(W\,,Z-"PO^.MD*+^_:W?BBPF6'TA%H;?B1BZ8=&4D.C4
MKF KOC,^*D]4C*;>@LG(VK[I'YCZPEH-.A)&1I.54TKS:A12E-+/8N;9IK16
MBNE"Q;32G69I[!*3?AQ_?E&6J,ODW]EKGLCTC5_&*.8.?^ S=Q[(!8!3,$+'
MP?T,=A.XR7D"W%>A:Q:[HS"EJ]>CE"XYXXIFX<B6(@E^&)N*\N&M=+^0!V]G
M^YU4U!&CJKFHHST*#].*%36A0DW#9&XX\JB!;MH>8\DZ %#/IUAD%KY?5=-M
MS5LY-..,1J**)GG!H.!L)M(Y ]SW-9Y/D5G92T]BS.08F#Z7PC BJ;Y;*8['
ML;%K:IA^WRT4*;7"SU"A09XBJ6]S.]O<BC_%2,\;S ! 7/=Q'@>AMTGUP;P0
M?$!DB-#O7TD863=X(V74NV+37B/Z'K^/#0G=T"GJO_N&&J@_4DX\JG+!<Z]X
MZMJ.PXER!NPHC"H*GQ\8ZF1$H@[7N$);F\;H,)UT,YY^LE+#YUB>EG&CPKG7
M(I$E&,&#^5MP)G%V*[(XVJBS5T'#Z2>_H"[ZFW#(*WH9<2RX9< /M0W_/2B@
M@69A;"+:8ZF-4QJJ9<*"]";<&)T#3!5UP?A.(U1'G<POF#A\-AB.C_2S'N<<
M!0[4)E,J(8.?8L_4H,=U.!1;-#5FW .!N(Z,;49;"O(04I3@NV_OI&%WF)Z>
M<CS(EFA$J5!5:V0XI&\_"+/:-R%2LU?.A!OQMN0Q[&!\6CLV)P\<1"(?Q,$L
M7*X:-/FNV_FNXR;?]=KS7?NI^:Z#>N>[$KWO9.; PH%!E[/:AWG]FX@?<DTY
MZ4WY\$,H)+@5^-_\N_JCM&,%X*[D^E7:D28 T>P]+@+1ST0Q?W2&TR]HVZ<W
M6<(!U$GF6R.QL4-EV >),C)GMY!HM_>G--I@FF1O;[P)<*1LOEUD@$,D=X?B
M90O4A>FA=C1!)W!W!OZX6!XY)CJ'V="ZN?9<=)(LK7G4U[?+O1=\1^D--M-7
M,\]VA!+@ZP:HK27KPL(L[&+'R@,FN=9P8;+:_=7]Y* @]ZTGMR->]>P7BO;V
MZ":*' 6KN@WFB@/2(WHP'P<CU.:CY<^M7ANJ2:II?$!]XTC*=-,! _ 1ZMH+
M&-*"*36O4AAF9)V'?9G69.P 7?H"&S/N?[$MIZ [/<)B1YAAEL-@TRL6P-AK
M:A%.5XMP4JP8%\"*%UVC<(!#YGSU"L\4@3Y1J4)S6?MM]E)RZ=ZJ&[CI"Z_4
MH$DD2E>>Q/DU8@4_W]TON_LQI5=J1),U=L(IZ+ $2$>I)D!([C)5KXFS6A+!
MP19QLB/"4%^0=QS3NE>BGY+++&.#09,P]4=;@BEM _G?M$2>$/^.CY"-)0QA
M1ATYH;%%@^^[YU^&091XNFUF]L).0)RNG=(PIURD9 >=W@1LU%%*6^MHQ4BL
M4@0/6JI:).X %@9@"*!]LSE&!Q4R) #1[U)-XX[2&7*X!SA+_PI%O!_XQ%F:
MB>*59UY<LF_=RF68.%\C3=9,R\6DO#C$BJ0=%2"RG3\A'2$(U<TC U=%DTQ9
MX6;]=75247=E3)6CJA.6C/1E(+E)&O,Y4<G(Z(0E(WVE->U/CEHR<H8AW;[4
MK)&VO*/]7P:=M-'/&4O@RM,K@FK'=="C:J7/;T75X!S>0&S0L)YO14]G\=E6
M)EE@V:" 2,N.<DZ<U+0]3;@4-9VB(JA?LEW<J'^*315M%Q=E8_G]XG:7,6T)
MM'8@3/VTG+GH6AWS[%^*>8:]NXG"?@$;WT2E\O*LLR^81U^DCAX4F)4((X@1
MSW3T^S5G8<) XX&[+,4G:K/M EY@LI$"%OR@S9OPXAL^=J1_6(L%Z)ZWGU7I
MP=*PT9 [[\ K+&"'Z!!K!<]A?155!5 T XMZGG3+<R)O5M,S>8";?@/=.0#0
M(&IX[3I EJD5FA$Y)I=3VN8:#:HKT>\/6M->?Y?!=1-I+U!>I<F)EI?:*DTH
MV642!= /_68!!H3WSGL.#%X%+0."6TUT#0 D$)4867>W;4NEA4FC'KUX6! S
MQ@QO'H\F+G0;&.D?GFJ+B0!DQ%V&U;55/5Z5%9 3+J]4,1Z!8MS/U8O70?E7
MH(WEV@4EFQ./\D(459YZW)H.E"*F3UKWXKCE4^Z0!_F/2AX2>W47,GEV)IYO
ME:R?HKI]W#V!VCCH5IN@?VC=>Y-:V9I.FM3*:T^M'*2F5@X#N[+PX)@,1GEG
MSH,23MIN<H#,(#$JIK8*QCOR_ ?![[!^/XB6B\!WV)74T7](*_AVZ8CDJ"3G
M(;F%9BMGS2H^;!C6L_.ZA'U*(ZQ"3D/SLBC,M';8:_^/-W/=61OJYK5NTN'H
MH3=B,<&>D#JWQF41S/G7(>%VNIQXQ=Q-\6;Q=0>^^CGY^7#4F4S2O^IVY-3/
MLY:204L:I#^2M53VY_WNL+I-]78NE3.K](QSF<=[U&#@_-F;.6*7350AM!@G
MR)!+C&L^;#8U%X(G@4*61X;.3+%FH%_JDH T7."\.P<27R=8^C&P5#2FMU[3
M>>G<HN.OKV?R L1P%$DLW._L11HEQ\F7QK$= TF/NK^*YM?78W1S.G]\RT"Z
MTO@KH1P<,AZ[II-;Z:#%)[>F':QF$UA+CU;/:6[BLXB'@$-\86[V@/6!@@/6
M1S49L+XG<18::]P@^24A>8Y'?3>6YSB#(MC?:TTIB4IY4Q,*J$AWH?<J@UIB
MME_OGZV@*.7.FTK&EXCU&6E U"HIB?%WZ 6[0P,>A?U'RWY',Y4_6XXC*"&
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MMN,)+S<F>AA ZL@[CIQDL,L'.<;&!;U192F55=Q139WT#3TV]%A-!L-.@AR
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MM=(]UN#K:L9T?M=7@(Q?V+/T8*U4$\AKOPK\]/KWBIK#U& ,,#EUCS@$^9K
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M9P"+IMHV]>AX4@V/M]VH$92P(TB@Y9(I4HZ%]G(ZPF3X.'+GM(;='$;R[DZ
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MR2]@)_2X-6 *KA*5FKSC<>24&-NP5BQDB-AT%S'&R5@V^/K.<9@;Q5J'X<.
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M*E6-.#!/%92X P7YZ$<0*)+<O?UGD*1$R7T\,_,]&$SHU!"Q*SF<VW6&XAT
M*]6!*<<IJBI9OB1]HY%@E.!X%V+/5U!9X&_-K_NEJ4,@Z$$[QA+*Z"\%GIW+
M>,G1\QG*5F&,LYCFD4T7W*P!2]JEHGK'\FS430.9C6EGO##P9X,G%& =/.H
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MK0*5CA@[4+JMZ:2RQA -NM0!7:KSP1?F/(K<<)YK1*4C^N<5I365>[5QT+\
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MF]C <84R]IYI;#5CME#(9%+(^O!F [[$A]G,!A!L^/<R_W[0D;XC<");1^T
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M;6G"RQ\W@9P!PH+?(,:", )T19$L3$<#9 QQ.<!HG5B(XR'VX_>$]7,VTPV
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M^$>!DX)9:%O]81=>:]V$"P^=S+9UW!W!OT$ 1=$<'\!_O^I:OQ"RC!@1\GB
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M,L,TP?F"L7$'-'^N+CW!2"BM1&X3I>G4Y6SF0LZHIF/A=JHR2//9T<J$A<N
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MHN) (!X" B# DTFSF9[(BN-R![#5UL(%;-H+L&,59;IT@<ZPN:$LFL9 .,-
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ME$ZPU1GZ%8)I1).*A:UT53?PXC!@9>2R<_'KYR^OLO[_1@TPZ.K7%'J.Y#@
M.:)78I;J]O7UEX]V5K++RFNV/US>EJ_AGG%*$_9I#_2\)A)^CT$J1)N(UJ"S
MY]MZ$4M0:\'!^!7F[;UM<;F1N*QYFC$S]^+=H&?@-2#DQ;O^F764.#,'-$Z'
M/Z.Y#"=G$^MH&8+&FOX)UN+$NA%N"(N\LF4X1Q:QE%")G6)&S6,>UYFU"T+H
M C[+YE5RG@0B[MNM1]NWR+57Y/+R<U"*8CI+U2>,REQ_MG1]D=_!2-=+E^@%
MT[T)U6PKZ3<S\%=:QKAL1X^9EQ-0C;:[Z#X%^/(@GEO$6!^K95'1S6]H?8E
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M^M1=!8 P4Y+5L@H^-P;50'"UWP6F3F0:1&V3&56DV%&EDCO=<*F-CNZ6AC[
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MXQ^*#"3<JW&%]I2ABT82?9H)IE5249VR-.50 <XXD__ 3D6QW$N#,C3Y)K#
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MHM ,[PPA <$L?[^@ B$:X*=8(QVH-FSG0#Y^)F7Q_%XBU4RB&3G%&I.OS7P
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M2Q=SC9"K-2AAL*CU)=GEZMABU<WG*NM#&JFF661&"<4%2HJCG4^O6//3<WK
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M2J'WVHCZ$?9=Y)';C+H.5??7!:-?R>'DU<J/$>EE8N- =.;H5.\^HF+?:^*
MV!)#_^Y502<L'TUFV@*/ <TIY!FO1L26*"UF3XM9)P>*E%@?)%_SSB/G5:;S
ME0+?LV*L''7<H\DK1>Q4[UQZ!HL$(LH'D,TV5>R<G^]:YYK)8K&7WMU.&R]F
M'H0R/N[(D>E<=*VS\[PX3L7ANI=^=E9PO0>?*P\<==#KGVW.E:^,XVFWR]K;
MD+X7>N8PHWUV%NXS0WCJ1.LB>+)D9N$EJLSQZZ;[*IE.2-RRK*%_=B@1FTP-
MW(0<; /P4S*R)MM4K0FI503>?-@M=I?FO%&9TH$)+U0[GKV#U S'PQ;]/*[
M*87%RF#N6N^JTRTVGXXZ^F)JR1)9*?;DLI5\J,XTL5G1P!A#UH_5UAW;C 0S
M"A,6QC0LY5PWK"F=XE5TU( !TI%OJ8Q;C2Q?" QE>3$=1_I#/""-R4IO@'>5
MM?\QV_B7: SW4W>5W'2#9T-GU .?<KTJ_E0:P]C/%N2(0\$[!G=* H6%&AF0
MJC%(UBQVE752%SXU>N(FYJJI0N8?\55^4W4-N#+%59@76QVFN1:ZS0^F]P?5
M1N1V*%O=PW%#0)7,PY/N6 ?4E*_>M. &^8!;MCA9D>4FLH/>8,C9OV*SN?BR
M?V:^?Z=8X.ALW[' <M$%G:%B^WL(U-D4.\R'##%!];;CANED8QB1=E891&P^
MJI>\<S)CE3"*<?W\EZJ<XUT)8^,CU(,NRW,VTSW/TVOTOO8'U EYU)Q;W5'O
M_44$J"=F6=&'I_5> 8O1N6SC"M4WL#XO-R6O9?<P"\$Z9&_3)JJMZ\U. J>0
M2*!=6%OIIRP8:?0*Z9YN16J"4RJ\0674BPL*..(P&(Q.('U(GS!:H#+_-%^&
M%YU+CPH>!;O1$3_Z+/N/_68DP-1+&E4EJU/<9$Z;7BZ[YBT2V9Y)$'?8:X.X
M3SF(^_C"--,;UQ&B;7R(C;_)<ZQ4<ZT62?T*[J'$D')]&*LY8YIX/L_',.-"
M%?FXI&NB=EC:222H)YE3M$MTXY!IR=&ATS'Q9ZX'0IS:8A06X)86#K<BK&>\
MENS,05%5X.+<HR>-U1@1/%S6?RBHRM)D\[#&Y3^#[8>WW.&4YY(H;5RO2A8P
M>QXR<WDNY[V6KZ @X#"QECA]U_C0BXT"*%5/$H3258@#L(K0UL&IW,NTUS\2
MJJI*]7.BW^O2POP6$758>IQ'-_!.'E!M3$&IF'O2')UK_:1&]M\2NA15$W+L
M F9[U%^E1B.I383-&6K]S-J1654;WKN>%12-1C/?=)2WR=1V9%L^N"HR^"2Z
M2/MJ;5IK9K])\Y$R3*4=-S+,N*4H*E:9;UUV\E0W4ADI-**!;]>^=3PPSECQ
MUB,GCM.%63ZK0FKH]I'#=UX5T[AKMUA9Y?Z6V_6OV>5QKW W6RBLTOGC7&,@
M)"F&7HK)\ML>@ U=HXX>F5,L*FWT&LL4,Y-O=?,[JN5R.&RG!AM-?<=;D"M)
M>^ZTYV?CR4URH%",WAF&2^6XR4*2\C:6_=8[J#+I=TK_W=Y3_-@#[G23X/>R
M2^=!F)+&H"_8NFXP&A?&(1%F4M(&SC55I>>F>.:A2L7."XY.VJEJPLH/[1 ,
M:%H [=(\_3OC] H'#B-9^[(.B!H?).B-\3;4.%8V5^5>M*INN'):6Q9:IOD2
M6E'6O295WD1N8$+=>!/5V(!TU3=;7W(.?8Z'A6OO#$[V=N^#K>X=:\0'QV\?
M.L,T?P^#09>:0I:F*)BC"Q3P0 (XW$U$SE7 LBV<?R!]S+DI"'(!!FT$',3G
M#L3 ;F+LJ.J#?G8-%KYK]GPNX:#J[PRJ00OG?<"YU$1:]A',V@66!QB:.("M
MI(W^V_E!AV1/JIA35AVV1>MSY2:<")IX:Z:CE=^0FZ%8/0%)U;55-+5>,]RQ
M1;*](!F+!N+?W#0 !4CJ8\I<(<\(F\[,A%C'1]B9(IM8$1_1O*D%UU[ Q;X)
M"3+IH4"[C+K6*TJ13'G[2:DZ\ZL%TW[ !!R/<C@[91'-EI34B*3%BQ,[X$^9
M_:KABV,1LV%SCN^'T]QBQ#DC]3W6OB:"AKGBC^46%,#E)*;<?*)&0GL[1;@9
MT!YVQQD/U5):NA +^G%E\@<Y49H'@P.D.%(].IR8DW501GEU*"ELLKUV$(N-
MMGJ&;-T=;_^KMP"&\$G<6I<AJ&:PXSM6YC[[L&B_#8NV8=%[Y@?):LE)E=SW
MPQC+)-TJ:B)\@TI)Y4B1&'9+!0#9^-&J$2>VJC/#.*2MW.LX9>6;6<2GYXC6
M<D:M$U$-@%P>:SQ4.J\<KXA1R2R&F1"2Q.D"?65_BKC@%JM[ATK93  C&12Q
M]]U:W$_CK[6W'23SIHP0IOU0Y/;AKX%J"[A6;]BCG+<Q@063WQIT.V]V")%(
MU%3B,<(T3(I*+V/Q1OWEK>O%2]]9O?$">AO]Z*U<3,I4E"@WH&S25&^6E\37
M^.M,V'1[+'"2"/[OJC?+K[OPU>ORYZ-1=S@>57[5Z_8K/Z];"G-U3ZM_4K=4
M_>>CWG&[J8??U'CM4J\)LQB[ (&1$O[R8O@BTY5(K7_3L_I  *_SCYV5'ALL
MO^.#Y3E/161G/-^/Z#[=-/RI/\+A3U(\?"7Q\'M(3/H]<<9)]/JO5 <%;$HS
M@\1]/G=R!8)RNQO9@"ZU+'S-9:#%^"!741N=+*N\>#E'+O+SB+*/9,)$_&H+
M])!B :5&KWL"C![CO9YKJ8T? %Z@J-[C22L)Y:E=V.A'.<=3NY 6@WX(@S9P
M6J5C!B$8X;47\QR?:B^NO;A&75Q9*9I.A7A<I6CSQ%3B2E^DRT9F;4XMV"'[
M?*3;Y<TV3+[N_/OB_ION]ZZ_;_?WP/M[:.MBVUS)^TB076M[U UP./JO5P5O
MN22[76ZH9S6!X50?_&61G^QT,/- 5/S3@!/UQUW9L.Q'C@;0LG8ZX@[46GB=
M2>TM6C45K08M6CT^$)X>6@W/NH,6K5JTVO.)1J/'XE9[LLT86X:-1!?4#ON]
M0:TE-MCMM)64T11$&G9/=\2C-?"\#_:TC>GTE #2[YZT &D40'K=80N1)D%D
MJ+IE/S1 ]N1.:;KL&YX-[R3[MM4*FX)'@^[X8%7S)PF0W65?"Y![!<@A^T2>
M)$ &W;/6[+M'T7?:.[:>A=W7FAD- TAO9S]A"Y![9K7'+4":!)!'L\.?@=GW
MLW-3GI?4[_?J\W.?DE;5>RRMJE5S6\O\0 "RJ\NM!<C]!@#;^-^]W>UO=<,#
MGX5EB TO^H.WK>[;)*"<[2P06X"T5/+<@-(?/I83Y1F8B)]Y^*5L:?%,[,)=
MDV-:K;>!7+<%2FNL/R> /"J5[-,^'(P;6<3W-4RXN^'Z4KX?L1:-2J]^KLSK
M<+!P,+IK:NEVAW\ Q7GS1NZJ4C\!^(YZ=PTA-P:^+13_>GSG1( 6B@V"XLE=
M@]7W!\4#[&RTI?S_A).>[D7Z'YJFV>^W"8(-@\BPM<::!9'!N(V=-@PB9SM+
MRV89QPV4B?\(LLD-NH_Q)E'X "U3VM_O^??/(-)Q43?MQY@4)C$;^WH>&?/(
M:F8&/8\TNL%I=]1*NB9!9'B\<\YL"Y'[M=3'+42:!9&3T8%K@TT6I9PTL&G6
MQ+/(JQNU;02:!9!'2Q9J 5+#B7=6'UN W*^R\A32Z1J=1)#>Q6VRA?;U!&):
MP\%=NT$\?F1R3SKT4X#B[IGK+10;!\63EA:? !1/[YS/W* L@8.)B+" W]7T
MW3)?0TZ] Z/?<L,49^@1-'X 21OB,-B^5>L^+Z2)U'I\^H,Y/3]T)8]D1K7H
MWZ*_K'@<_F!B8HO^+?H?+OKWQV=W]8:U^-_B_^'C_\GI7;O\/A;^M^/>VCEY
M[<4=Q%/MQ;47UU[<03S57MR/7-SKQ '-1PTWK![/>+PL3F<\5<JQ%[@B2-YT
M\).'4O\&/9P5_U^O6/DK__<C9=N*V I$8D7"6TS2*!;D4TU"<K/.HG!A?9G!
MZR)K"5^F#G^7S(55-PCR F?3@V[(2;_GUY&@);OYZ9!KYEN:]S4\?N#KNJSS
M,CO3Q+OQ$@^NRXF$A<.Y(\?'RPC3R)JD,2P5Q]8B=(7?M?XER"T]A=N:.PD]
MLLE_'5NWGN\#/@:)%Z0"5_:":22<6%AQ.HD3N&8XGK^R9F%$$( _84V!>&G-
MTB2%;3FPBLBM 7]WTREO(0RN0TRNGL*Y4?&V$KRPV IGUHT)3=N2@YOX+\.S
M(6U:MO6VZ1_F.X!@IB%H\^;1+*0#1 $N\*<]3.%[SW42$7>MVHO6UZ%RQ>$%
MN=W1_<=S^*]KB3]2NI);+YDK1 5(3(7UMQ0^'L )!KU!WZ;[ I-&(!2%A7O
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M8T62P_46B$-,7T=;I6S+Y2\LG  U:K*1%(:;-!$)I0?"38,N3G^;6=_$RA+
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M:G%1;3ZMTU9V-(?OHJQL;P]G/1SRNDH1RQIA#[><=0\V\6=R.7X,X%"'47'
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MZ7#8K+-<HD65T=\[]%R W;:RW@?7. X2C3RI,1B +;-9!N4V"D4#^_,=(.1
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M7Z68)$!>ZP(=)D4T-4CR034E/XQ+>*+,++;\W;928$PXTZQ1<L8&?5&[\8[
MV;QVB0C>PO5"@,'/*0CBDC.T%5IG.J7U0,[A8(#L!B.\\[R:3P!*2599P4SM
M@2RN5ZJ2WZO8=K%YOA;(:5MC%UQQ>L](X3B*!G7-9L#-(%$ =,(O-V*AX,V2
MEY6N"G6PE(Y%VC*(IFBD%"!T M6EINDB6['[I%6,;P[H_ND?9_GF3P^E3&O1
M&LT#(H%<N$YS%>;:CJ>D:LD)40-CB;(%CE*M_S(*-@-7JQEB.2]F3".G62%\
MG,=&]CDD;N$WRS-S5J96\X_8!J2)QDQ'T1@D0 E!JC*'GEU&%+' RO5@PV_+
MQ]%+L&E_3*68Q?#=!7O+I3%^&AD/8^J*0RTE064,S31(#3T,L Z4$*6Q73?+
M+-W;?]'=%V[I3O"7[;WGW6V?:[K_HM_=M;_2TENTBZ_Y[S9YWN9?_3H-.*$S
M&KYV29Y3F'ILG\"$-TBHX4:OL[O=Z^[)>/RV=?!=9A7'YAR][O,%.,P#Q_5X
MR;(W-N<]RQD68P51ZE.D9I<DS5X8=:GS*X26V6*S?Z.]#Y;YRALW32-N2UE(
MK'3DBKP(;_SV+HJXKO@M;J 8U:,2CO*]:6KW=$L(*LUK*\QL^R@IU#E-*-6+
MCA! ><6I?G\N2B;9"#[&5W1S-LM"9>R-R40D+8;T*21XN%O&C=#W),YZO\3S
MBNH/@.UK #A?;1DM; :MIBWPL6Z TO7@70GD($4Q9$H+J5]07Z+:2_RME/S7
M7.YD98K@L2SUUDO?422EU-U5Y,R7O$(;+#^_Z:24;:(XC<3K*F((+FO\,P$[
M',&+X*?;RVN5XZ'!CPL4(/N-[!X..4MKZY2K[CQMI%D^"TQ94ZI!=>$%T#C=
MD,/L6K/, TD*O9[7#QJ2%SXM#XP.(JID1- H.02FZ_TQB9!SV S3S%(,VB05
MP/=EMOS,G+W.O#O:J V8&=MET25%2I@Y4A0=Q^# L"'IN8'?)1GR^R13_D47
MM[NN]WY_[+D_RYCF2V)KO2/EDOFF/7<E\Y0NT!J/\8*2@/(/-0XSHD;,[2PT
M/TJB>F>=J'[LB>I7YW#NTM'&)!Z6+_>V:^I_H_]\5?0_XB7W7JV,X>VO7'^[
MNPLKY4?O&&<6*DJ..D/)%79Q*S.$>)-@$ED0*O2BB6U+7&A3R;1N[,GDP30N
M0ZBH2@;!FY/_V7SWYJ2_$<#)+4H"A.6*:P(&]>GDX^>#0QA;&1L-#62B4,?H
M=>?@F@T8SON3DU_[\FG%7_$-CWI]^'[//<GCO5CP:;^>')P&/_?Z1P0SJTKB
M4<'I%J]N7%NZ/B9+/29BANM;OVU3;?X!N_4>?SC: &$^_'RP@18^YJ=*<T[B
MXM5Z-^]E-R$5,],'$]H"0<QS%KQ)1^"R@8U*FDCO>&-5&;'(6C7IX8E5/&"]
MU_>SU]BNFE G@_"<S/C$Q9U:!&"M:.]INXHX_N)7Q#(.#5W?QG@:N4P>T97%
M0M2LE_6VWM.V3J$RRC7S0I./4QU"?V9))K0AF<<E58(H\MYQDG.N_DL\<T@P
M3C-(E=;4 5H@SMQQ0M6Q@,8!H>DP7 Q5>X VI^C@, \=OR. S\,JQ3"6X#K]
MZ+6@(3OBD%\"&8GC4C,_4B7W!$IHB832#SPXA.;:*EA=&:T)!M[UZE+QP)^9
MK>:N)66  %%0&-+U3\),KF))])R'$T6:A)*:G]41QO%P"!T#U])SC]*CD]]A
MGD-;AZGS<4NCN:(-ZGOB2".E7Z+57!ZAY-VG)$<UD<9R.J.9 M_$59JPXI:%
MK:$!+&R]/;F\-_&[+VNVHZ2, &REY%4@:XK\ A53L,0@;8X=>6X7'F:*$>.]
M'W64G)-0$B9G8ED)I ^D#C&QC,D6)LOI, 2<(T6;!8+FS?!3\/BHJ:D$Q9(Z
M/[T%_GO=#3@W@):L!/RIO&3(I!7(RY/.%%(TUF7GNE5JC796:YLAM2U!(P,-
MX3F\I 3S\B;6.89RXA<8M>NLKYODLQ^P3+UVK; POU89+9=516M_BWI^[!P(
MAL-!7-F*C?HMWIFG[ 8,3TYI9]V0!@C&J+;3\7^(@"L2?&'"IAR3^308GVB)
M0EZP8_^ND-F-^;=N\.;"6*UT0J*6#]D6:36L=U$51!VB:J7\[!YDN27#3*58
M4DX<%@F3-RO28V[!1DCQJ4:336(&S$;Q>2ZH5B@ CFOY^5J513)';IN'4'/&
M>-9.P*$"OY&(U;1SQ5[ZU+#Q93ND#6?>59A!9QGD"X>+_B).VZLP#FS;& :I
M-,Y,,5JSO$)Z$7K/0&%YS!6S#9UF"!ZI6LT\%C#*S4&3>,[_$/KX& "3BA)F
M/JWKY7+KV]7(P*_%BEQ!> TZ@M)?T.L&S@6'2'C4H11ZK$NZ8U_XLKS1.]"X
M]^N\A ?>^\+EV;U,^7S2O3%GCJ<OC0?*\=;)+U6,!Z<&.C$@3@R3[$%KPHRK
MY>D/5V3/KF%-]Y-'$H3&EQ&S2@I+.YKYE*YI7!F)B!E*DUPXUH&.#])OKT'4
M4]!XD?D9A+4F!2TQ.S)# -X)W&3><-UTFO@_O6)-NHX8<]'R$F6P-.4E+^=Q
MSC[1P-PA$8$2QC0J?\ '>V:7%U5RF$P=3$)0R-50$&YL4T?:6/!/0\"@3H7F
MF0!2DDG/;1%W#PMG\3L=B^JF1]TV<*AY%+9.=#"&I*BUI.N[V#"U-C02L'^A
M,8WX/JH:=66VND@/NL-/SU5)-#6<L[U,B.9BKE6<5P]UJ6\7!QFZYIYIV2D6
M'@4(6_SF09\&P>+Q.9E0<+?@50$["O0;D\ERKJ?FT)6^G%0=4^L%!9\C4&\.
M>K^HLS=S"+<M&W I-J*C%C"VXI JF1J>@PQ1T(ATV?;0CP*]VEU#KQX=].J^
M"G'$0(<JE4%8&(T"_\6Z '/CVUI2.KHXK\*UU,6*'6LA6#CW7U[L];I]5["#
MALQJA)1QNE!7PVT(MX16[[4P$'F1&&L6@(V)*OLLGJ"C;J&C"R]:R"RP]3'0
M+<; ](J(E"JVW\3$=0/R(*UR"2DDKEPJTDN-*]H9?#X.)T-&GK] HPGK*XB%
M"9F![>6-^V<O:4<^A=DV[AYZF6=@DW&I!KG+XB?+T!S75I%EJ70/;(C8<7""
MKRS[;349A4^&X4U=_V"=%&I'Z"ZE /8Q9'3N/J3.)+D([^JH)I.Z0?/-L9$-
MWAW"$ZV;I]R[6TS5_6#[5PR,%NI<MXTW@6E9I[7-/9USG!V]WWH[E[2=UAGK
MS*VVIW7-7G7:-TH<@7-H)Q+7B;=JT93F((IFQ%QO\I+/+ &V7&3;K^ATNX6.
M\*>A>66.V_2SV1]CPP[&:_VYK+U ==F1A!-%Z$HI#_?HT(4\OBW1O]Z296X)
M!<(X#3AL#YIX!'+VX'QKR+)S?5 5/R&T'M(8IR$\NQ:(I0G$7&FB;4>$T=1K
MH(GKO5NUPVRLT?.03N0PF5C7(L\*),R'\PLTQF6-.$KRT?(%HF,6JZ89_L,A
M5+*EAK&0),R:/[XA68_!)$RF!-Y:B\(R1*$&/W"(/R_-HF'!\R!"LEO/$H!\
MC5,R7B$A[.-.%,MK&@S#BRQW07_2(!SQSY K"9MV(,<V<I5UM#8 'RJ;A1,H
MT%:C(=/<,B0JXG!;[N?!BO*&:^N*'H"/"5-T#.-)AD19+WG3-M=2-8?7_BIW
M)JBU*V#T6<&=K3:@IT8U19U"P3CI-V5!2Y:<E)HBA5_,:XFB2%%(VKB9HW>R
M) W$.B!$<6;<H4OM%5[:J#UG2UDUBRYRC#8-/><;"TUUGW(!(\D#/60JNA@4
MOE._YZNT<'>I *0BL\/V2K7WJ,#[K4L99?A*EX\\T^\%K,!%:,Z%:A8P$XY=
M>_:^.V58:"27QR>886(SN< &7Y'9DEI.G[ZM45QVN.:15=&4*D15(2.O)Y_A
M48@"T(J,XZ2<%G9*B%-N(.B)I4O$GDGQ"#/<*9![6D<P=J T"70+^4Y169X4
MFI($;^9ABW[8_/%P\"P.>X*]HJ \@3/J7=80[( A$T =6 #,_$$4-O6!H[ !
M_![UIK04D8I[0VDZ[ZLJA&]D<9KE#CHXP;<X@U6U=AMAFP>8P!<C%N,LB[C)
M!Q[YAXUO$A2J"+ILDNHO@KD<H$?*$YW*P.,XS 9TB.?B5SY+_7RL+.&KRK5N
M-@=,;Q5RTH6L[^W9)\971[B*\D-$=!G6P%0I)9J4"=,L%4,+OIZ3CPENMTWR
MX,*($"CE;F_8&E649K_#?DB$JRHWV.B)@E].#W?V^L%3(/Y/LJHP>GQ2?8WB
M43BI2K.Y41P\A=#]\[V]9S""#^8R,\=#[FVA5VH"6E-/H@O]+.2Q(?H_P'%8
M0F@;MN0D V*/$L2>_S?FWH34EX4LJ##X- :0VW;MI;36=U\_TKYDJY%NQ4$F
MZ3VLC.*S&(2V22"T;,,K'GT_H'M@MH<56BYL% $H/H;%JQ,B8MHBA V"3^:8
M:"PP*#*^0ESQ'2@54H&<=6Z\6"X2O"'TX1=+C3"R<H<(RD?KH@9;TU')-6+(
MZH,R#KP[F!XS&WGFU)3*\IHY$\?.\V9LM%?<4ZMJEEQ;MR/=T6 ;Q5I3Y8VM
M,-7K+K*V>\M:N[,DGA"QIF>PLRC9MB8,KV-#7Q5HV%V%<_##P[[VUK"O1P/[
M6@G=T&3((=:4V)%8D6-^XDKGQ)JF.727^+."*!N>7%@/!RE%8VO>LQ&*6B\8
MU^'PF)]$4=6"#5$R=&V;8F2 ]0V9])B[^90,627<$S3>1E<(2P" HA;*T&#B
M<OE0?"";Q',X_OE(FYLQMN29F_$#(-M<D!5=(;8DT]Q.-,N+6>.3P&C:!$PS
M9FF,+I(BRUT)PSQ5+>'9\.:B'!KRSV9)6CH^"FR#.4YBK]DR]FC..U1D GRS
MQ1QG9LF-,[%I;D?&C(Y@9AX"<OMG959GF!ASS+)I/("=781'&-PL(';AXKBQ
M^23SO9C3B$MYEF1^,!S.6%09ZVMF): ZGY<!N[Y-"\OO*;XDDTD<64)SZNNB
M5IN<+NQ268()8A0%U'-"=:%+HW?JM;O6EZ>&'O"2HO:..G\[R0R$/[A%$+BZ
M*+K<YTCZOM*(XA#JQH9<+E63.@BR\=_-FDY1;3IL/S=4<,_&!U;8:PG,* @\
M(UZ3;25;,,E]L^%0T?I(!^D$NEIC65,MSVQ'IIKQV//X6,J,4:I/XD%>)2[!
M$DM*SYU@+43B5'7JN?PZMXVN:>">+TXVH94;WBL8W8=@LZY+@A"VM%!CNA,;
M/X?&'D!![/BB\XMDX)+,\R+E-M!3JJX<-^;^31S UISKKI+D^HO-A;HI'P4]
MB=$O!150/^(>1Y3KFNC%SME+F\T3C?]2F6]9GO%:P :#/N,PR6FYL7LDM6*G
M@3?K>S@PM-L5KB7 G#$^S9=2DC/O/_PAAZN>[X6;/=UV/:G=2](H-ZY=3IVK
M;Z=Z95Y*W2"N6A(W3@02M3AU#:M D\<*Y># : BOITD,/(O%.#F')4]'L=]G
M7JE2-+EXN-*+$(;E?L_57U==R1EH*@Z,)C'R3U]D4"MDNR\B.P"CWE-,(R7P
M96@N9TT#6+R$"B9Y+#1VU?=,&ME1?!,)Y4/HW: ;*>=4DP@_F/F+=O>Z(3JC
M%='G2$QCC$LT)KV!C9,\5NJG=E(A1.\HW;G\$)-95'EESB$UDNF("M=4[WA#
MA;:AE7U46LM4&24S#C'@GPSBFH U;J37\Y*B,04 U40]J9:F1I%]2;-+<V&/
M8I^(7O798DYZ.?9DV\F"BSA ;,HU]W.# 2\%XE[=X+?FL=HN< ,,5"ORB!E7
MW*(HF95BX@"*Z;ID3,TV,$8*\:&USJ>Y_Q?-"!L+2'<9=VB$/8#"4X_LIN6,
M%VZ"Y%;-,"ZYO<U_+;6"UX_!:T7C6H&/S??F/ANS-K!;A16NW*?-O,D<4"[.
MI;VV%X_+FYE?05I#7X(NN=-Q\LB)'Y<&*F9%&;MHF'1YIT.-)H:].]%M8.R1
M2M,VN0RH<;WFDNS>\'0&3+\AO?7<*>'!V_--EQGDA;@Q_+5-1Q^PJ'&C/E"T
M'7$G.$) '<JH2&K.5(+=N:GKR4E2I\>E7AN@'%CBS,TS83L3RHF"A0Y\*IK8
M1C**KNX9@J47250QGQ&AR=AOLJ75$,6+2G05&MT4#P#BF5M\WW>"40LHA(D%
MM(FGX[&>-<:Q';QD[%+,;/92#&&U!Z$2=!7GR="4M6;5%78 ZUMXK2O[UMK6
M]2SW[A(Y"H]+U#]>GRU1%#5-MCCOC;8_W ZY&Z]S$S^(3'^+97;"I?SR<8:U
M\G47QVU/$Z:E1G+$XR2/)R% EF<PH44%0N1^:X[#X OD#5)TWD&7QE1PCM<1
M)-3G.AI+5AU:Y4+D(3#33#,D<Z+S!2^F," C.?"(<[F3@W'0/SEBQ/9&"33E
M96V45^2A'DGBB6R!<3)!4 6%3HQ_D3$7Q'AVEB<1RG$=Y2@N%*TWHIQ*+*B5
M;F34BQ@V](-9TW<AX)7&1DTRUU6!O:-P4ZGY6(-@R6' FZ)V%IP,^T:)Z@D-
MNPHM9FT8C#OXA0UJONG!X30S$YP+G#D4*=JWMD>OA:"V@DY#4/)%Z5#F$K;S
M0!L^FD4H]RR0A4@VK'N%Z5PYXF9FT-$]Y\:#MBNUO;&DE#?*+/H/ET;N4&DP
M#,<KYC^G!<?YV54"@SRN 5C,RS<AI8U1M]K?8,D'9K.A3HEX>\A_A=9SM4[0
M]9VB6*;P&CN5Y^,]W8ZAZ)GWHL\@ W,.MG*""K+F0!HF$]Y!)RI@J5*9,JX*
MBDM=4^L@48/61@7UPR="GZ\3H>M$Z#+O*M33Y4S3HE\=P;@JUJD9;WP#F\Q\
M8 -,1N)B6A -NHWL+GMNG1<D0?J(9DZHMDC"?0/R:Z9>CN&0M-7KTD5U;;K9
M?1;49 &8+C 9$M3OV*!7:G2NI&";CW"KN S$X5%W7^T<LEF'S+;\;PC(X_V*
M]V+EFC?CA4P],RE=A =,7B'TH_0"VEO0_QZ0$Y:#J%<$Q4O7""6.&%INY;)J
MH:YJN&6N3'7BM=-P2&K'@)',OH/&80SKIPGZGZVE!>-?2[YG%D1T'W(4&0R@
M\&LP"2\972U4GWZT*:,:L?P<UM2BVLP&@ZWC*Q/OM#M;S>+V'TN8D%4"E#O;
MA!I&2B2#)>MJ_FK6K,(2E+S"SV66)!H5H0WEQZF17Z)=,VX=QF,H7;J:"I'=
MSN96K3I8WR &6CE"B,FK<II8V>)022&.MXU$X_+F"-G!A4X4]SRE5(HQ_B4[
MF_ =50\'@?5\G YI%X(3&X(X !UB/GA\<M"ACKC4;8UJW<)+;!]<C8S'P-W7
M)2WV,8V#U\DH>!V'QH@V=ZCYR:@(>=['UZ]?TP\M#[6I0DJ=FO?#G_%:!6?,
MN(DP(?1!BCK=01CT_FJF-@#..OB46;>,P\]2PX5$OQ!3-)[2&%%$9S/.T)CW
MEM"&+++JCM8+AN$_ERJZ<(>8OU^:Q0X +D6^"7.C7_'LX&GF&"<AC B7TA J
M6@&/^0S=&1RN0(>O>!30G7_EE![6365I/'/GT-:S/E5WF?=P[V&E46C#9QV?
MY]&X?,:^-GJ^@%=1 @M6IRHZ',JV"\0' 7N%P07%<_1@7'CEP44&#CW,2,+J
M<UM$6R"2@]<=^,B.8=R7"%L&@$$K:URQFRM%?-E0\*C4?A;C&U#7!RE4.M2E
M?FM2J+HU"M)RHDYBFE<DZAK//KZ)5HHWSH]2<"'A'-H ^KTS=;>\$;?P3E'Y
MJ/O<ZF14;A?_62'2&./G+AFV FH:10@*]H$TEN]]LM?\749=XA0KY01(K @N
M0%_EZ)'=8S0,C"=@#HEH4+2(0MGJ6*I**4P1F1NS@&J&=EITU88Y>$K\IF6.
MS:LS/K D$I%#]KNL6#C-\E+5"D.5D=&U-WO=,QKP6996!3'%#Q*I,I#9\24N
M6A_GGXH7!*LWS,WM#4'!KKE5+ O*J$HBA"^YM<<;1F]"1\6TS)-L3?W$6/(%
M7U2V<HC6H& 4#O"?CHTUD@B!':(%[$N9RVY2"K6AI;G.  UFSE4Z?ZS,7\DR
M3&]FVM60'J@Y7 TQ-[DRP[T$+87B5087(6)OT$B2MM7FB=0G(VM>)O9?K-I$
M"\ MT<,!+S:#4(]B*@D[@0#F6PRT/>S"1%1 ,!F*&HJJB21C>$ M'4YB:GR5
M@ITV#7I;&[_:,"?400=D$A\9589QZ>T>\DWN!$_N5MNV^EJM6 *O1OM:'(%7
M2*_"OS9GF9#G9F$#>)V2>^K;X\WY\]6XFW!MND] 1P RYPS;UZ#<)VB&883
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MK^ZNOIZ]_#[IO'U.F1O.9+/8#'[)QFGP+C/[!8R_7(!X:VKG6]&4-^6'^=:
MW+W9<K@/5^W!O1$RW6#LX"!!) Y;UV)HXA#[S\ZAN!_,;)Y> 45_UJ##FL.%
MO7LLMUU?,.L+9J4NF(,TRN/+X#1,OMSCQ?+M]\<]+&:+:[ *"[GB"X4.,5U"
M\Z!^N* ^0[>1*C<_!=CI[>D550#/FI9YK>K7JGZMZN</':CZH_#"Z-1?N\'[
M+)LFQ4JH^YZGZU==T>-2KLPR/H3%^K?1U$&3$W(P&!C=AVP]<@'4-?[\1QI4
M_EQF],[38O>; =O=:L^ ;9YET<S\S[B<3G[Z?U!+ P04    "  IB@9;!PK
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M163KES?L0K$)*RV&I:R-P7I)%X$S6>VP@L^"H1;$4I['=!&EBTCFET:L$-M
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MPS0]F>AY?GI4\[C^W;^<)(44\F-ATG(X64J%>MB*2D;3JQP16F_JWP+G&_
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M7,Z<=[MN"<^&!7757/N1V?( [_55^U+A'C(JL\SHE!*>/!!I47(?HR(4MZS
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M,6K]('KS:?P>RK]OOCTTUZ<A$SB)RQ')PN3B+Y4J"D(3F[UEFD-FOMJL[-.
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MV8H!325+]'!R?3_UM@.:GM*K3R$Q>G?+K#'Q'FKMW]@ZZJ!4EH1*9XE,1I/
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MT$?_]O6B'*:$R 3$(F'"GN5O/&Q02:B['6\G/;=.Z5Q->J5U&&@#&"JL-PG
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M6 QN!5L$#S0[Q" C!N&HU00]89HE2:4=P>T9RIW\:.,9NLJ92,/8')4UB'U
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MU9X-F:@\3;,C5F'M[)"6#\&^54S U6?\L<%T!&]*&C*@$S)[)-Q/@,:R $P
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MO:<<.*G0"6:CGZ.86(WZ;/%VX0>B5#B5,LL[R-$^\#1'!^8W>9#:*M6!7]P
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M@Q1HQN.[P+,4DQ;T:515/0D3)9&B5^'SP%]6L4] 63B]QT''(@GZ14CB15)
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MF5CE)1%!\51(K?.97OS@Y)GOEV)AP#9,9-HK*R0#T(7@6<'FTROGUXIHJG-
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M@@@J4;698CL&522^0N>"V3IJ*22@,%9*_8C(_>N6?NN\E-*N\W\4.=-U/"1
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ML[\M9G[J;E$],XN2CLC'EIISP'!E_TM*LL97\6IE]H;!?*V1/2YH.W]1B5E
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MX3<+(&_EHQ=&93>1T8%BC\>\V3,%<UPS=*I/W+S^5S#U.LO-1+8.+P: BP&
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MQ*6W>2=IKL^U\"[S5 4?N!NF/U%IC?Z?(U%GRSSF**N(70HC/>%1R_^K?SG
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M ML\3#8O49^J@,.P?<?$W_J<F=%F^AQGMC,VSI"T+ NHF974T']/:[+;^QC
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M[S"&6];K3!80L)T(-J@';M>4U4-(\E3J/K!\':5IL*Q_0V\1C7@PI8$;>B>
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M!)9O5 %)<FAL^^6581:1T=&(3NBHV8JO/#?\41*&NR??FZO@M'&:B32I_B<
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MDVS_? *6.I@Q>9V%6NU*Q&A$&JEVLX1R-!J[)ZNH3 ]@/KO 7=[6@0<'I;B
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MI?++0;XT@VJPI?ZXO^SOW[,41OQA1!J&PU1=KU#%7UW$":VSUM:.NN&J-=I
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MM\='CMZ.'%FIJ]&W* WJZ%2(C?W^[>V)XO;#%WP>_>P,0;%.++5Q 9O"+ES
MIP34KX5.?Z(UF_*IA)%4 EMOB1WTN%RSU TC.@QF*$?:CA++71?LV!@Z* :T
M7\V[$%'YTUZ]B5?Q]JUWOWT:N\I>+)SZ"-,8!M-WXWK]2&1D;+#G_;AC/LZO
M#)Y]4_3^G'8G\ODKPX,&SU;NGR"&K([?5]5+#?Z=1@OLV@@P97V#J28)0V_=
M!WO_<N'O'#4X%PQ].$/(V1W5)4]I?V<I]O^''?8,RY0$8EQ<,Q=C,J$W>KB
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M.KZL9.Z&W,'+O(5H:XXL?VD+<"U2%CT7)D;IJ0H!,<SJK9"57E(3%&5+]MK
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M+7&*%;K69\@5.-)5+J!5E;WE[-#QX(EU"@X/X5$(:H[^R]I!6K&@D*S!5[R
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M@5WA2 _4WL#*-ALGT3Y-#9% 50?<]0$Q@DI/)VKD9%;,]VD!:O"$X0X+T<%
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M3^.#]D2J!3'F_EP:O7(^1[@:4W>#T_JVH_A,^+*)0,QK.1LZ8A_11T!NUXQ
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M/!8)ZY)S8(#;<-0(HLDK^R]:,W0KO>A,N<-R3E\N[ODB>'\F/J#,DC25^+J
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MYWMHAE7:_9]8O5%OIX\<.*LZX2-^YTVJZ2<9V]8JV]_?>]R %!?9&8[5$;B
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M;-6: "S>IH%O-U9OIW'"^G56B75@VZ3:$2F5CWMVPE3P9-''2J]Q4<0R%$Q
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MP"#.+W#@'Z>%$ *O7PAA[28LY/F#04OD<,HX&,!(""E"U]%Z'9%83BS>VX&
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M9^#S9Q.75EWM##1Z^(+G.P\_+5B+JXL%G!"BF)J"8[BG9GA8AH]>K.KT &K
ME0F+<G,-X $3CO>SKP;937$(GV+/>VTKR'DXYA#@K2>NVCI'IU;NOKIY3&_8
MQVM(Q6L8'?8.W71"O'97@>:Z[GQ-5V+22&:4W8OF;R>M:9_*F%*Y][^,ON8_
M%VBX8]?H8=Y/I2P4\/NSNQ(U(Q339?3N]PY?.Q]H4;8^9"QG1T=[*J$1CIUA
M($T$!XPD=IU[+L' *)L2"?TA[@'RQ\%<+>.)6>W/A/).L!6KT7Z;YC]6.[AJ
M=^G,?LT>NGRR2?Q%/FR[[[.3FGV +$<?\&5OA[7[A>">1J+\F/A30R9\.;OQ
M[NW7;F4XGR(K[*Y\<NX62?(G9K- ;QPMRL^HLAT,*3!89MIU:E[1W!1P95BK
M<K_[KOPHQ"VEINLU&6\($7@^T6"W:N0P6Z$TPV NJWAG_/B0NUBJZ!T%W^#,
MD'A(7\^P-NET-14^!>(OEB=QV.=1N8M"<C*_6H ('L6*89QI(HX\Z;8JCZ%4
M\DY/RTFI[;4'6=%5@=LFFF(F",X'VXX_>'GCX7YMDG0N="/&!;'%"[O9A=W]
M=(0=4/FVW_.X[422_.;V1]VWS\8?E_YI;43)\9+;JA:3]>PPZ3.18D+'UIC8
MZYM,.\+P[+48=UCI">^?WMF>9M-4A10=!?J#1.CA**=J6Y8;(YP^A5L].;"+
M?57^".NGI>?BB>R8UX->"P]&#V1X'#A6Y'KR\A]1.E_W0P\>W@)K#.CVKO A
M"$J7:/9B/<YM$[B?#$QM<VG8<T&[$++Z!K!I>,K[:,,LR(Z-.HZT+;>:?*TQ
MBS"VDKL'@:TF/'PW:/,=\P%:9XQWUSM#/S\?JF16W#YOZQ8_TT;U[IQ^^X=(
MRFGCFR*?UT!LOM'D!?L]H-M13MXAK[!;"<E>+KMSC8>\S4RFRJ^HJY__-D-?
MU6=@J!M$EM:<I!5#2:J/B*OGJ9%<KKF, X"U_!BB<LH[LR3D@.62B%R%MO:F
MQ>+6H/P)GKKI^%+R(&,9[2KW/>:P>LX;4W0:#?<S&%JC(D4G?,C8"]]:=>J]
MN^F6#/Y!C^\O#7[XDK\"X2P#YN)=[(O+V-YD@9GH9RA'"J3OIPLPXE.(-7Z8
M[4'YC@"F_N[,?3"2PS@3F3$S V,> [-+Q]](]K<S;^E8746 F+G+EF< O*;'
M;O=4,]>,2<;L[OA!R2W)S[U]^LD>B85]N8^>>]68NR!;!/#LF!,_\$J2K@O4
MT&0ZM76,N@@5J17TG6D %4;0,4Q./B@%2PN$$ E'E=7>7 -R->]*_V)PH7H=
MHMCU)?O,4%F#JC008WK76\*X,[K$#OFXP+#A=:#:V1O;+GSX+%9=&7_AGFGP
M#I!PBH9E\7&B]:=<5BK3ZG,Z/W'5(N!XQLZ:(]YS6FZWR+0)QX=T&E6WUGJ9
M69>W^T)S71=Z%_O<&W]E$[X(7<7?1&?COKBX/6L,[#+DYO<\V=+@U^$M6W#)
M!8FX,V\V$%8X^?WY:'9Q.M\OB9#L_@5(Y2H'V7\FJ &A:IU51CF >OUAP0U/
M&2?C/+L+3V4;CS7<2[[=].KFDMGM]9(A0_!I'%T%-MB*'\9M(@U';Q\SK(PY
M=%//RSF)<4?:SX%],/H\(FTK27_]'OGP'$'GP%86L1ZS;JK"ST"++1:;><I?
MLI\4@7<*#E'^(_?U<'26>^9A*>#"3#_YE!T1)*M>N-5  AT:Q=N?#0J =P-3
M"0>^V60HI$@_,AW;7V)2:C52EWOO\#N]!*S5#]%=^ ,#0LC2<>X\3Z_Q[8>V
M5*N/=JJU_E3']&XO^>$AU<T K)Y6ZIJ0 ^1<\':=J-J[IL>NS[Y6/[PNV>#Z
M2X6U\2+]J497Q_"W:*M*B&$TUC/T=YG L+==&K&;,2[!,L\KTBXFEX8N1JK=
MW[MK-M'WP[8,,:^6!1QU4^T==#M!!HB]GNW9\N;*>.:%RM)/,0KE\*G XZOV
M6HJ^^-2\>7 ^]X0Y8QNK]DL9=B><OKM=S_((SRVK1"T28/0.5P64'[6_^>G*
MO91C:N4$:S)!,] RUC-RE%K6B/L>=+>DTZ0QFUE/:TY4_=+7@>C%TA7Q="$$
M$D0T9$N%DQ[Y,Y#<[6Q_D?M',^/J(F5?7XEX-V=Q:BVLJ?=KO54I_YF&OF@]
M5BHL H</TE,9;#[E[W+'DYW5[7A#>I]EB^PAW7/M]X[7^4TXAH:R:XU2.78_
M#.3LJ9-J09'F73%O?3A[2GM?GJ=\6?19(K&&'[:$RG*OH:Y48'I#OE@O@DSI
M6C?/;5U!/<_Y^C>+<Q_5X#9JK)#MASJ,K9X/MYOS-JA@&-TM_+U6'$D=GZ2X
M40QG*@FKV82B<0_SH"P2"2H[B99FKQ-DYO278@^TIA^(*GH5?#$J+^S<UR^M
M(MI6+?X&6_C/51:0#V>G[%I:%L(BF;QS!/D?TUU7NGJQK5>R/"Z]=BK)'QNY
M7A<Z14*+HTXETQ%U3+&@7,U !RV&<XKVYR,L;-)EZ3W.F<>D]4U#F*18*O0"
M.RP")1HZZ*W(-6]'P=X;X#3?9N_P#7TSDK4YR,CWP>:7^G?V#A6$P'T)I>:A
MN #!5&9$0L[TSQ&V,G[,WYE@;G47VFL^.)#)WK=(]\9&\B[J89#N",9MPU7M
MWVKT1U8_HCW+4G/H!V68\FGD*GXQQPSP&JQV&("JD\:,*T.L99/YAT>5#I[?
MKW_K//P"2**?Y .ZV3S##O0A#_16MB[J9$7);'U!QX<M.HIJCX[NTD$]@R@A
MS4X_,"X4F^-D%7T"8'33K;T(DR&&<KU;79GZ\7UV%_Z8^^/R%9U;QL\PXCA-
M-5_+6'@R#!FM;V"CFWGBV)AO:=L(GNFV29E6T!IYCI]0=>"=H,MNK':#IHJ'
MWZ;=NHRXOOSO_'?$9(GKJ4W4J*]W#XXKJWXF%C-KC0W6]J'.L0O+AY37JV@&
MYRN4M3TZVIZ;_B[N2>S([?,'7C ^ZXEEMFF ,D]JL"&=[3H\I(&69'NPCV:[
MEP;&J]VKW[AVC9I2ZIQ$T8XDTIH]:YZA#+C#A0_]N6J.*!U[T[->=[P*WA=\
MB8$7!QLN7BOE4ZM+AP>*T3_].JGL,037N]YJLMM'B\;ZB>'ZQ[X1[!)\(VZN
MVL0>KN5\W,3<.>&X]SO5XD<!/M(KF'[UT/'4Q\[2NG;'4R]=FR&?]&KA:7*U
M -&AL3JL/&(\/BB7]"5#1IQ#U?:^%K\<4JM ?5UR/C$L25+D^Z4R[<7M2HPX
M>BKT*7:C/]=!R2:^O5;F2(I9SHZBNH_G'34MOP^=WK6Z?"EB] W+AF'!6J1W
M1^NY[ S/!O HV:&OJ*G&*N!5!P.YZ9OMH-JG55I?7Z'H3[[-M?IYZC7FE)U
M %*5LR,\[]'K&ZP\VXP5AV@Y^X@"TY"E;4$TCNK'3YBP,O263VR19*>A2%##
M3$RC$.X?:%>T;0("#2^M71MQ)@;8=4,V)K(>6J3ZZ.T/GI,'_:6>K_<05(R"
MKW$$'II?\:LV?K9]RD=@E_ ]:F9F?9].H7(=%*\4-@_?&J1LP8HBZ+!WI,AG
M=2^J V-V(4_2__"6CMYG*Z.AZXPZO^,8V3>%!H1S+P>MJ4O*4""V,0T.I3M9
ME\9K^Z46A+YJ\W;QWU.1?V?GX0VM-1O3G-PE)<H4RE&,1644#@-XJ0>%VJ<.
ME)F;E2TQRIISCU?9<O5Y!UCB-4@1(!(!XM3>[JK+65D<ZUL:(I(5:LK)MYW6
M7=L\+GZ X).#)\8((1]Q]P1; ,51:R+[$:4O0*W/?FJ+FUR%9D?]O6,ST9O.
MDMX-?+ZMXSF'C<;*:HB'.VX$3#.O]'BN1FR8(-[HV,FPU$@O_;P^/+%G<,FT
M<6.PG$VV)PT/JRT0I4M%HO8/,N -"865KC<'VU&&@7)=)^P^2L+=#)P^K=&!
M+.RYK6S'B[[$">VO/H%)%_ WOV^*C(^*_VB"T/6:HN8D6_V,./BFG*SQYSY?
M9:\OA.-=:"B01$)\5\UJQ]O#:#O8V);SXY=65M)]K^"9H#]ETP7O47>[13+?
MA9<PU_4:1^;5[PI)DGMQG8RQ'G^U/&AE7/8Z6[OI]@59;*"@&2,K2D)NGI3?
MDVR6;$H\]V33)PXLOBUWJYV2WO$T-^FF,=$B ^K5G <HW;> V1#(W7Y,OVXO
M:3[(H)?A[]]Z^EH<VI'0J)#0XN_?A_,V+WP0'V$9>-UPA]61_Z&;EF$ B>6C
M&I409$F[V)&T6_Q\IX1E5=M/O(1BYH?K3C>NK'.TU]F2-H\[GX^1"JH\SX(^
M82[P[R[X,?8UP+6&1CI?[/LI%K%!(1X"V6[\/ED%=S2%3XFPL#13=7L]:J#$
M?X'2N3.L*A*46J.UC+CO+RZ.D'V)^3C_X@?RS;4U-0+;/YQ7K]G=TQ<T^OX*
MNCE@&Z [%!:&W^+&8 51+; 6VT-CKQ<%ZF9^'@A\?DU6Y^KP*]R5C^S2AYC
MM[;U>1050;:GZLUIQ>>&_AH*;D&//P D1'*4W+"D:+A@?Y#5%_4OHD^KS#/=
MU<VRAV(O=>PK]=@AM_UUC[/;I^R#ADK2_A5<!H9_ -7]/B):EVO81F8%\ X
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MO[7AZYJV<B=+QZ8[A-Q#N+2C-!K.9=QK8\QE^@9]V= *TRP"0Z-CQD "W16
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MQ\P*&0\I=[,>:V>R^@]]#Z%:: :+OC1J_6"F^U!V<2K.S3A-P6A2Y'^>";6
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MI'LQ_ZH!1<T&RF7(S!:$>CQ8W_4XV0,2J3R$]]7(Q5WY,1W4%^Y:/9:QJ&S
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M<Z;&^/</@510QYWY67K'ZYFE\1V=Z5JV@XT_C[J[!&:C@!KY<!007@^,E2%
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M!%ME[GGC%B[. J]0$#.Q4@X;B@;*B=E:ICQ(E@VJ41?]G*"JYE.Y<$/H8#7
M?XM@PM>]N_5&3X&C"DL;2KP_+TW4GF=Q;;?GK(H9$\@,$G@S9_[DKIS;OIQ%
MK*E:%I[%"/<;N:]7[*.?PY[^]*214E+"+!.OMT,KND;+7ZOU,E9IUU^7:$2L
M)OY0UED"LK9A=F+!3S8#WZ2(Y>IORH)X.Q3PWQ=1?NEQM3-0JOVLQNWB="QK
MH[?Z1IS'-&]?X29*UG0:]3A(^O(A@\![R'<Y2:<Y30:B"8:MI\F$?_Q^S@_A
M85Y$&<15I=/SZ8?W5 H>YW=BE'D129Z,FC20Q*5H\Q+;5-8!]//AU&UM%W.Q
MQ' *J-;NOMBT64P?@J,E$G:VO(2KA@)*"6FH7EP] &\3-<NSL7&O3NZ/9HV(
MC6[)+2((LB:M7#OZ+[4=7"HC[Z[9Q$U+81:7BDCQT))5ES6?4+]0V=%Q^Z:\
M45;WA[0.0ZAZ*DS]QT)?'WQZGNFJ[N''I13N)(,#;-#VIU:C6ZE4+YEH!E_4
M7I%7A(K37IAZ5[@A7NDV6M^7/HKWLY_^?L;QW!3*9P&U^,)[IRT_=ZM2$$>T
M>TH: @OU&1,@C[$C0;L)O)&$YBLZR7';_-H"+1M:GR;#WSXS>JU\C7U(SI^O
MCV<H7BU*?V!A<$RNY9M1EB@#I^.SA*EPEV37DI1B7\Y,SRAD&IL#7%UB^G"^
M]:>H/==J96/K5/O+GH<_A3JEF??%WV;BK=3ZB (82=UO7X-&M&N'.0E*"Y!W
MEB</SD^IH *\+WRX/ZT%+1$B/Z+?-XY9[<(;D','!_ %2O!ASGZ>8?[K0Q:M
M'2R"T59VNXV7*LDZ!6;<^(QEM;YZ26/5;"/D/(WIOE$P6H8]-UNJ!G'S^SOT
MIEZ&XVD6*N8V3O&];+KALR:-AJK-__Y&]W:*-FJH(@+[5H[.*ZM<M[.W41Q:
M[IMA8#YUY?)8JV9'RLQ;6Z&6K]/7L4OQI#C8?%RY6HDDF@.[4\W),VE_(&,N
M;;M39_Y#"Y!$=5@U9<OM8JX!.PMXY<KSE*=B#K1V=SA>B7?[B@^7U*J[86,?
M#PI,TRB5Z\_51'R(*,NN?0?4;GUTA-(,]^&X)K%^W?]FC:"/:ZW>#(2T3^QY
MBK?'6K6D76SXM@68#D!:XMT)3N0A\GB0>JCD^0,CJK0$IXEBB,]<6G,ZEAY\
M$8'SP,%P&MF":5'@SAUW\V5"IH.?].'(.__.^NN8CQEXYUX\RBR^603)#\9$
M=O!W/0M7X_CH6Q>XR%I/ 3WQ_^CR'48OEO9:IB&J',;(/9WFXU*@";/(&)LT
M?4@!>71<,T^^H$$M[RGN)C_<OX%>=]M?><G:SKM4OPX>7,LB93/[W@INU<)#
M.KW@FALM ^2I2$='LE4\>@"*,J$-]+]CMC8M"3V#3VH<\-0SA&A['6<=W43%
MW7'4V 51_=A;\=8+A*0R#;IRC'DH5@Q^3FQ=VFF^Y7C]V1/]H?VW7.S!5."0
MXIU&!38*Z*T?%O6D5URMILC6S^,WZ$:*BTY";K7.8X]&_638.780^.;>%W_T
M[M9^7BZTMHA]PC^YRU\9H/!SZ_HC68/%OFRSLCV7K;U](RY7QT]D5M"+D+9N
MG8V]AGSDTC:K4] SSJL,IBTOH;=)]!O.=LF?II&94)LL;<?%#DN:O\^<2<V,
M])Q5H"4:]OF?P]]&-9H*!NT\PIY*<I+H$+;A3/K::?#([M1 \BS]7;FK\WEX
MGR9_#LS,#[? >8<4F/G+XK4!,R378UF)Y!;00_O/W^B/?1]W254VC*^(7%?W
MAVA,D62"3712IM/\&^*+>FSZR3RF!G@KHR&B^5Q'U.D(+NHXR12')SJ<UY W
M0,S+B]]75!AB9RF@L'HNK,Y2@B,%1"O.RG'!5N1DH(YD=,U;Z0G.[Z<6M9%=
M,7=<8DWE<U;]N0&!WQ#BS1/EE^\9WW1'C#9]>DWK:^HL9W",V.2Q9\=G?5X%
MB+Y:2Z,A@SVM#$LQN%?G/9J:^:,-NK*1+WG6+77.=F[<?1SVVB7YU03\J1O,
M/;5AI"T^@[#' D:?OXX1"B,JDP(TB9R'Z0/^7;B>/0I()H<T;=:Q7Q;.G@+Q
M:(+1R1GDV1P&919[7B)0:2 &IG&L46A/!]_MRW?4\ZJ,PY-3/ZV:@6=N >O,
M@O4)I( X[\-6\.N]"E?PP8UZIG18@:!WJ A8RY58:V=5\=12_GYENP(6ZI\S
M5UYUO/HA=VQ5/X>4G#W$30%ES>R(?UO66G5OV(:P:0: K=6@5SUYFZLGK-&Y
M,RMQ7>Z'$.,MD9;%^(>T7QTG5 BU/D-%FJBAN/A9#AI(4=:DB>WT=1W&*P(%
M6S&J%T1J,%(G7B5[7-4+G[+>9V?%<\Z5L-A@2]4B+J"4AC(5]S_'=]*IP";?
MERB\T9D($9(3G3-[72_AI^ SQ:&$X/._'E[3&'/LG?!J>/)NV]5M/B_NSN%V
ML;3XEH/559>;B)^I^^J'Z /(FG=+3ROMQ15_1NQ1=\^Q*>M8&_=VEZL\))Z@
M18,*]*4;<_ING"?FRQ78B'>Q5A$\Y6E/,$(XQC W.\'G@S#X7.4D\_' #IWS
M(K3^*>MA^!0LI&F&WI\./TQ[H=T-1@,/;1>8@\?<O,]RV:XC0,T\V9QY2Z?!
M"K#PJED#&V);5R&'2PC!3V&"47D=HN,3##J"-VBN?$%S6C>QRUCFR%2D07<H
M("'%#I6<-+/MHY=85J[<S'C?(T%*;UB(74_;VQ(BAWH3MTOZ2]X9GF>_A=E>
MV=?D<A]_,S^L]R9@K;@P*_]:^.S^J=I<,G/F#_ NXP@%M$7D(%H&*/!EU ]2
M0$$W,9JDDW *B$ !45- +)G_[[E??$[H]1F'G$AF<YN<Z-=<3OF6EKP@D$P,
M!*TY-H)SB_KNV#0O1'>OS#-2J5,"'63$S;GW/C(7H3B9FC:'W!B:XPA*W,*U
M1-<-E@RY-_%DK,Q33;V_+<@<*>(2.=I>HO?YO(DV^:$\+7F" EHY7E' ]/2H
M%>O^[]?,'8)^H77JZ//7AJW2OQQW_?F_G\[[WS_GS<Y30)UZY(9%\D>X_K\*
M\[]M^SJ;701KNT(!D>L6**!>=9._7"76>RP#< E7FLAU*.!+)>!+(>*K0O#Z
M-)AT0F?\%]K"_E5[%\#5="F@*&""2D+ N[:/3X[_/H1"DEJSH6Z$VTM(GJV[
MNZ1DS^)XDXMC=%W3 DWI:T7S.*U7:;7RUE3W0EN@K)YN3$\L1\KA)N*OS81K
MHQ@+]?/HB3/7^4\WF4>'QH"9K)],C1KFP'/KAHCW(%*Z:R+[PN]5/$>DW;[+
MA4?2@&RZSAK?PZK49+K=[EBC/54;,X SQW251-L=-H04[ZKP[J!Z-\79AF]/
MA!U;?$O-PEOOM6[ZB@(ZLQ\$+ELZNOLQ2I5P7N2 WL2O6N@65ZN[J,-WJ'F7
M@0)?WZG/P]3Z RW;3;@@..&)5P:_52=?,AHIO1K*&+DBJ2M^"T)-OC1S/HG5
MIV]>@&ML\K=G02ATGY=SFTQ&Q08C[NK@MF>38N0\>6JO3IIW8*"S]ETQBL8N
MV;?__"(U9VQD^;$2)7.A"#EY7IS[E,<C*/J&4IP0)]CVVFQ(/30M5<%X1QU
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M_F^79!,9WUX \"-.B@CW[D[C1N_>6.H?<\@4,7Z@>$-E1/KE=?U-%F;J_B\
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M%Q'=S'C(YPIG>9M(O$+V4Y(OULKUV&)-MTU)]:NON')O:O'YW%@"@,/.2!]
M_?N<.\L3FL?-5R@YO;DY7O.OG#YM-5-5<IK3 5W\-K=S;D7E\P-\GNK.PRE
MELKYFY,"9'5Q'1H)%"![T9'%Y7__&4T/_B,]>$B=/8KRD#9O+I<#)P7M%.+V
M]1(H:/>J)9?+WY4]J=<^3D_WZKMM!<@J)'NH\E0SLHTGBX+8_^=;1&@ 3JD-
M"3NEML\G@//]?U%;_NII[[8\U[;DP!1J<^YTZ3!/;O7AGMB;&'9 PY)K!E-!
M#4E5D=TN3 #VA3>V"2&&E0LO&'7&LP+N7*5,QF@5.=E!&0J4N0F&1XA0H*PE
MXJ$<^=TW^L2N:YQ<E ?B5'3D!F4H6.<BN)DJ0L&ZCF =.?+"';&D 8&4Z:P
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MM+7BT:;+<3VO(.L:$>&X?5U;6Z@^X6J+-6_,H8)X<)[(B#;H]O-.U1[MF<=
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MCZCF43**_-J/M+5?1@YLVW^$"8S(\%T@WVXDSB39'#KWKEV@;TG<%U[0F&Z
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M_3N7MJ)[4&MMQ$("^W2?:;?"3'[&9&'5!8^53V20>&SA"B=P]\:T95ZBGY_
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M<^\>^[?'^/;]QKG?^>ZX9R;SC[QKL=9\RWS>]YES0IPA+@$8[^D:Z +(R,@
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M).>1,P$T ></"^*O _Y#>C., W(/G=4]X:)F@@SE[X[9@\X2 ?55R(:#!E3
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MCK_7JVN2^6-E\K$'\&'MF-]<A?:#EIB^KBF1/.0F\C;/@[X/F8$.79\!:4#
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MH<D]A58I\+! GGY45;@F:X?\!H%C A**7. ;-8ZR"'UH KKTSJ.HX5&<9%M
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M<W@(LU=[-+W0$N=<.&#4Y^!4EMM0\UB>Z2L V4TPNI:SG?BO.&P7-?S\4[<
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M\E*O6/6]!([K9ORR,&?\/GM\>G\/ICTD[Z%@R_VX?6+=T;7B&9BW4-ETJ->
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MYN8&<$> */?9Z]_%0K3JO,7,BYE#.V^?$+IS"M6H3O<!91RH'?5&2&@35J<
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MUJ\R-CF,[K_^]X(\=QMPAPYQJ'U$'L14YB]7V?[3$/^_4&(Z#R5?VZ,F .F
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M#:+S\?L-]6M8 G9SU;O"XNMLP!#PPKHF$$/&S+=7R9)?K83?@7EO)C0W:T=
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MQ2FDDZH=NV3DNMQ%0L"C9MU>M%TZ#:9'!\#YJ/G'G#.8?,RJM85;$&3U*CH
MO_S/76NP43=O9SI@!.'G4JX8Y587)"$]4Z$_Y8-H!G$&=((HA'@:6<$_&G&
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M#?'2[H5UN\(IP&^MKP*4?Y@<Y/^;D_O_->+_ 8UX:]7+_F?>0T"N1]O?X$B
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M;,\;QWGE2@:\X[!T;O[$-K@#O@P;>3H"U> @QG4VS4J.-MC-F1&\OUQ;@W!
M8JU6M;/.J+AFQYE+O_C=Q_2">T%=AP[X\IC&)9V,FQH0M"7KMJ.N$A$?71JD
M!/IS--3:DJ+L\_@#OTGN<'.YVCGQF9H9G^L OGCVF X0(X,15DZS:ZAX.H"!
M^.=X$4Y.#)$FCBTW.RS] 2$X45' =FD],0#.A7)('#CJSK[_POJZ6+*(=O]-
M^?AW9XLLR<@[Q.R)T 8Q(L<#&_,IL\'=O[QJ8G6FC'AK('1CL!<!70PMV31^
M&>NM(]>0KT1@,;8].+H'(2X7S-5X^KLNM=HR-XZ?5R.50!"B:<]#K7H&,V=T
MS+[IIKXPP8V(.6^VQEB96^Q4SV;0 8^0#5_V*"S/,E V1.[PAK_4PS@39H>7
M">/KB"7TTMA6I#UL7,%LTRMHC#+8R>,U5EAG_XS*1UO+BJA%B62F3[BU010;
M^0/^V$JT8L_TY2Y7<6>XR-H>/1K;XWV])R._]-MRT+(LT9Z-ZU?NVXWMR&>]
M7A%)T!V([91_'Z,INBA^!$4'^*RH54<H%+%8#BE\F2H1?C2>'<?/!*^&JLY'
M9;O%,%E?+3T([;^IBJ]<PV\%^XXGX8&A8 ;%$_A&*VOBUQ$P*&QWJN^A7];(
M5G_ZFY=A<S$)99X(1:Y+;*YF((GU\V5P_HD&@WDDKY,YIB1*H5&XS1N+,9^]
M,@3NK(Y;_2BG?U(KLX$I\>W=-0[AMJ;0P:\H2DJ<&[S PH'LM=E 9?RQY0("
M;_\^4BJC&.-=E)OK3F]6%EI3D0_*C>1\*%7^$3'RE7?LN@5.PX\7G)D1+Q/:
MP(+_4G]!ZS'?_\'>>T8U^35[P[&"(@(BO3=!6J1+%Y$N($5:"*AT8HCT  %4
M>A<0$! 0Z4) I(2:T)$FTJ4&0I.>4 .$\/#_\JYUW^=9SWG>#V>M]ZSW?)@/
MU[6NM??LN6;O^<W,VC.K[5@:3,3!593+H\:QC'F!SO'+JI^&IA]5\;U&!!9_
MN#'?X1U58QN"8:+.B6E2K?C+->D3QYB53UQ?[?2TG&%ZR==T1)>?R!_-UV&?
MV"#'Q\*;H5.;O'<,GB0--QS<,X]NW#]>"ZYO5-4,S-% )! \NPRA98BGD$$6
M"*M<1Y;"-C.)?J%1V0KB'L <SHB2L! 1MBFKJN[A4]![R^*1^S $=Q0/W428
M$USGCKJMQI-Q9S*O<]I8.0HKE!L&$8?N#/%47@Z@MCV_EPLP"=,'BDS]CGY6
M!>(GY!O3$V!S35M@T^(9#):T>9*W<2*RS!5-4P%6)\2 580)C,G?X"^K>_:+
MI;>,+:!E*[*UN[I/A1'U*=,A[&U/-L*N??Y!'#$A&+:;$/+4\.65Y:XN17\;
MQ M>>ROKX@YQHS/Z[@Q+E?TX2UJ_9\>?GCMH&O>&% ANEV(V3LA-'P.7,G9)
M5K;?2(B* ^CS,1F0&(UAQJE1$^K[CW>^>I[>PMWL=F/ID8! R!)8KF.JA>BR
M>)I%T7UB>N+7.&3V$P[K]B1^W7F:OG-'_L^L=4=Y%._K#L-FCQ_NX2)F04 X
MN PA0NAN0Y81$Y[]]FH6U)^ \C9, -WNU?HR43W<RS 14:^=D8_[]$4QTLAT
M0OP<,-YF<XB=." 'JQ8B_!9C@!%HCD";$ZK2CE.-YGRS6J$*I3U]20U6WBHA
M_JKX_!?VA^7132IS8,%N6UK2I2]$B"G8L\V&XP?LSD"0]WT9>G>^X]3#1S.*
MC;J2;OE]$O+OY''-;3$NP7)'8BJG1;O?&Z9[@A3(9O_X6&UULP$+;LDXFL@Y
M5D)3\IS5AO\M.49"8/J075WT\W:M!\)Z0JH/6JWIYQJ%[R,Y)@Y^N]1X-81=
M /#_YX;><V]]6:S5B/C^:8U/34/8?(I=8MZKV (+"F,6@QM+M%IV9L7Y8V.?
M1EQF6>8X\>2L!>7;W9K#8GS?1T1?6HAM?>42=<X#T!"4L@_R-!CT:[<[&+HA
MP51>";0D7?Q17$5A8Z;Q;V@1ZGO-',8QKA"@U.BS#:R&_MJTJ_4K[XK6T_(^
M\^*8:@#_$W+7_-<@T[]6 7YT[:[Y1_)0MC3ZGR '5:DJ[3F@38QZ-5+T-<S;
M&D3&36GQFO7_)90#?JV8Q!J-B6\!F__4=0Y,!IN-'KB*M#11$:HV[R ,&S,[
M?B >XVU#MWC0,;:U(/-LK0?5R=,BCRK5[S_[UO+V@;UPO_9B;<2B]^<IL? O
M2E*XJX%6"R^&7MN'7ZL?\X@33+_#@O%Z=[=>[KKH+:>K;UTZR;;QV(G!EPT>
M!MCQ'C+3!,ID:$TD8I@L:K6>85/)Z\RZY#^>_"8US8;K@>91B>@[*YZ/B;E3
MZ[UMAG)]@*S^1A"+,2)XZ+6T[=W9]1.#RJ^V1#<]>(57S,^%@%1(W-?I/N<"
M^"?M_KM<4H"0NF*6"V<B9QR3O;'#Q(^IV" H4^D,;4I3RU*K/OV!&BD3F["7
MK4T4-=*L_\5@"J#X_;R7@(D*9I<Y!U 281J8[WCQ2H:M\6:7 NM)5SU(@W2J
MQ<2R0P-=HT)/J+VOQHLGF6\T_*]C%C7P@^VSAIU6J9F>+S*"<F1S57(\""P?
M-,/Z[;NV,^NZ>_OEUYU3$ST#@+N&!UQ5R>YZOF0?!5V17M*5/.)&A\*],%R<
M2=<1(PJU04V:NJH0F.=2^7A> D71=ZKV(H+3*>>H:ZL@2+THF) TK3VQO\&A
MUV[#/5(]H&7$^KRPWOOJ?8A8NQMEHQ*V6KB*Y[E/Y/V'\E.]79]9$15!V(D9
M0[&#F 8R9F%0[6M3CLE9GG2@-#'>:&&0#KR6S88.X+ S#9^B@SI5E]L++)LE
M J#=O>8.-_6$EST;<< 8GP;#R.G'P]4<=IT-GV4AQ>#.K_Q7K1XM14YI9EB,
M5FUY%(=]#A5TDTBO^A%X#E@X!_ V?TZNLIW8GYAKS)IE6)W"=NGIJYR0)Y[B
MMYMQYB/<>G%/U]X\SGEA;BC!J)%MD9Y_?\_//>*-1,JUCZQ3$=UQK,H!ZD/[
M8$$+PO-#5 &U:ZM7Y*M)L9(7<FD9VN,JE*KR1C\!J3QZ1M#IDPVRX?:KI=0+
MI&>X9^NW9FI\O_>]IG*<F Y%%Q9OLG/,'\1P#O@^?PX8]H/LO<)<N#W_VT*=
M- 4MP5=/$SIR;AMV0N4.=?#3]T[ULB1=Q(D_3Y4@,/[Z_=X2+F.1)F)KX(+J
M%/V";6><8'NV1$+G5'D"/..L/(<S4Z9^)"]<.FHA[O.K%V;W5>P7);V6S%O&
M@^\J.14%.YTE=TYM51QZT4 <EM9-!"=?OG:+5Y+[&>&Z; [8XDS)NI :(R3H
M3D/VJOJX##7C"CQCSK+ZM.C=4ERD:.RS]Z8?)&G8;Y9H[ > 2=,-Q\X8VJ*P
MC]8. V50F $F<(OL-,U5@VK?B>94(.;.(T$+!>45Q7"7Z@#OH?)]G?XW5K7,
ME7-EC.PEAEG1[Q](=8GTDR0KN$CTI]UZ@B>=A%">'YZ_^A![-C3Y)#,"*F+?
M=C,0V,5*SLQ?2-MDS/A,4 L9]7-M]>L99$BFB?8N#:89_-)9BNW.'7Q0E_94
M+XUQ6/?!E6K+*="['I9Y4P58TC-#S9&]85?;@KB2H8\O*7OGMFIW]8,P8@$Y
MT'4NNH2VGZKV<?XZB%*>@@$(7.\E(DJCR<WP.W4C^;(P9DM@ 60[V;A $XU0
MM!.%^"V> QAZO)DCK]TOTC33,% 4H<5HR1 <2W%9$/#WD3)O,9L+4/9CQ$["
M8AILW50YE=ME)O#J\97J-W5_E86[HY3<<:HL,GGPD [6PKKQ:./9&I%)\5O"
M[A\R_VRQWZ;X@ES<_B6U.1WTN=?L= +77[( EF,*1!V85Y&"KP:VGT+@,.V)
M)C]OAJ-VZE>S]N$_P8AGH7,S5FOC"Q,#CK5/=G->N5UUH\BQ-E<\50#!G1;$
M<CJS;!>.$IBZ)2V(NOKJ6X9Y T7()H*\_>,D"?';OSU44G;1)812'&-]X8S+
M5%J"DGZQR]&-Y0$7[S)KO;O1_J5\\E<#Z*S)R3BHW2,4!C4B ]I2H'Y,#_5C
M*&CO0$EP5OZ\^W8]N,%#Y*;7LH'X_2,2#*,'%/&;,6[K];+3-72S;2W:&&E.
ML]O.B4ME%2\Y%44\(:Q&,+P:(D&]"UQ79MW)"=ZKPM8=[C/:^3D^,O/8:RH<
M%UB;784YX=;TG\EI8H@602QK8#S_PU?KVA3WT_0J;I:7]&'!F0]IN@O@W^!]
M'71$1\/;A?4EP(BEY(%  ;<EQMAC"O<819V?% \'+]<JL1&DGN&5)-4+NP_M
MZ\.U@0(UZ5O;XD8_!6[]5 \]-A>Z/1+RP=-@KB^]3:[1#(R$B 6*_87HW3S+
MX<O*FF[$V!HTG*T.G126X$\-\:_/ 71>6ZSMAM_'$):>3C$P2DO(@T[(9>[:
MF@>#2CK0%:T&37M.NR2#98 C*@8WU"2 M^WB%,)'M/<%R&O%6PVK$G41RM2=
M*\FNAY7U47D?M"/1+__D'@'XF=MIM2*)YHL340BJPW22G##1_^3OMT'9CP-0
M]DH11E/G#Z&OJ&C9XUKN2('-(DY-7&T8B/X(^5P73^>)/,O EQ<HR@Q>(#KT
M^K[XC%(][-..!V5;RCQK9+V&JOO?))!O&/E4^;19#KW;5@#15T8<'B$#%<#B
MC<"T4I(5WCPBB'6:9$P AI&D\F8@XRA6)4^7"3,Z&Y"SB"=%IKR>W_.\XX*;
M;U,4KZ2 FR9,%BMHUEC#?A7@<NB<)=8:YD+PIT_J0O0BU/7V1Q"3]_0BP"I^
M1ARO;"3NBW#ZTNI&'QMJ$-=P-+<WS!7&/ZT:C!_0]GUS-3-1HI\K9?\^%\K<
MHRIQ_[W%=:7H5-4$LF"(=0SH/<["N^^A?GE6";(_Q[GZ[?M;#D>.1N^#R&\L
ML@]N/Q=S,S]"*H^7U4R#CHZWT87(N^N%XSN@YE<'P[-B>],^Y+=XVS"2"$'$
M=/P@X191%P1UY*)4%VC>KEJX=GKK*,>%]JQ<3/;/C,@->I%=S;]Q;+5S-07E
M?X/NYI@0RHN\%YR]2L\!%$0G WM:(B]S:')O?UK:6N'@8;#" XF0AU.?O]L
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M V"%+=PH.7$.\+# L=U57M(WP"\#27V_E=S%BCOK0^L2<\2(YTT)QA9F!VY
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MQT-.H][ Z-1Q)@_U_.E'/Z;9X)Z7M!>?[T;U"%T?UN&W3P8]^#M%T9%*3"S
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M+,)J_CXV[EKM\PB]I:":^L>>Q<9#V2>Z'"("!+:BCFMMJ],DTR#D^\ >@7/
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M&'8TD*B[T9F&EAM2$1'LJ!LGS4R2% FR(8'B*<Q>SCT=Y97+5ZIN"7_>+[O
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MX7ER[H'3T2,?_X*S9I\U ._6U]JZW2:;HZ[>JW\?&!;R_;<E;%$"3B5?)LR
MI&X8..4Q\5IWS#?K@/RM;XUA=%2<SN<)M>*GIEEL2B7[T:;V?*]E$;K;S@+V
M6J>P'/W$)1U=_N+@"ZXRF]L;HJ<.G)A74'4.^PN>BB@8QG$X/]_?9DMO<P/J
MM.+@)T1)!G!BYEAPMN;(?V5#8&>_N#&G\*0X5Z\J^>"AHFH5 \L9<L\9.;GE
M#@<@<]1!N2 +6E$TT)%2!-FM-HL(Q-;#%W\JNDXK:)YNK.7D82ZNHHP:)-E
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MBA"@Z/-'L) 979877)E9L)C1(<\+9F4!LC-ZEWF+@K\S^-]*WFGRJ&&5%41
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MO,G[X8!AN!P8W"\S3Q4KV]YG-Z1,<Q]=!02KW_M]9]?X@X/]G=_ P'Z9^3V
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MHKIJX*N=^FS#'D6$#OQ:"'-0N+SM ('*M7[("U<_NGP-J^&P%*F8ZQ;G]-U
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MBJEJ1OIOK) E6Y4\.7@_@MCQ] C\7O-48QHVV89!4N,4?!M1>?X@(BK/G)A
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M^HL\I,C[9ZV664)<@:79RWY^NX@ NX6+:I9GT?5HGIR_$&CYC&YX6:N!_M#
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M).*AR>IGS\KD2V1'4QK?\LTQ6R3/@%AO)9T'.#-ET/*T %NNVK#,8AN7>5R
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ME*<PBB/AA6;"74^37.@,Q%F(*>,$&RF)<9)S[=67N[WZQ=[VLUPC53]LZ5V
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M3B:GZ=S[,O&YRTU3-U@E97\N5ROA9LH_+CV<\HB'LHB6T"(HSKG,;J702VG
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M/(6V\!.8!3B'J8\\@CR>Y)Z1MCA-:F(-L2.\*PIMNN^H@9>>&G"#@MG4MP3
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M@*DC=3HEI[.JXQD@?ZK.YR!IWL+FK6"C>?QRRU?J]!]>/RZCG%*<IC[TB6P
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M%X2OIVZPZ+))D1O6A!-A8:89M[OY'0,+T+, >AZVF_?N ;+(BG 'U)GI#^<
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M"=T[*<])O91O<E+H 9?D]#WFIRI>EU_XBE.QGGWD6-;O,#B_=>S>B>=HET4
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MC0%YIL3,1[!M1W?!F'BOZJNR;O#J_RON7Y>,+RDG>43\!&8L$/9NX%/Q6Y;
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MC,RL"0=%E4YV-F\..IMO11*_*J%^@-))ML_AI:LD&?/]KU$0R?9Q.*M]9,V
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M RO7FW^*S=Z9;DJ2E0CMC_3G@D66^'E*@@BQQ-<Y^P'5%YXIDDD8\C!,(T9
M\<]YV9]X-SZH7!5M \1BO?&>Q:87H.FZ-^B\@7+/G??3LE"?)&4%'.$[\U?
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M'9<G6\CKRH$RH#BO)V0.P0N7!O"HQ6WF]=??<!JT%8O,CR@-9(YXSG73HRQ
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M6ZX=XS)LHIQ("S,U8$$MNJN=$>:"MFK'*\[<3^V,0"\;J9W[(#Q4<2?6NFN
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ML?"_>%/D35;8#W^<FCIIZI*-+31UQM6.OJ<8^.G'WWJ3)P$^VR@<!FZ<2R2
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MVO2HZ6\_V+MJ YNO?N[YV1)1N^%^_1'D[3URG>$ RS\]"<6PPKI" 7@;:0R
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M[3KCWI9?=<WTKE1:L#:/[!U9K03_^;GKH-M^L%J$>2IQSGSD4S]#.*8ARDC
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M6*2^DSGR28O<@Y_)LRC?E>NG;VPI%*>?[MJN9V$J:2A9HF<61,K-# *41XE
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MH3=U]N.P6%9!YS-+SA9V'A:I'W@>^:1EMF-5B4W537")LXA1)CEB:2J4#Z;
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MR\7YZDPCF>O'=;E9_KL^(R^4JXN)2)522U]ME4+X*$^QCX(H2' BPE#F1M?
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M6%)BD: P"SG""6.(<)RHLU:<)FF<ESD'84@<H3.I5>C!:ZJ6LGVMW#&5@4V
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MMS(/-+TTX3@KF6L4CSTZKP/7<4S<H[@<1U^ NWR^K.JYCM,T-_)[S:_K6I?
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MCJWO\;Q]5O_ZK_\U_$3]0=4QZ;_^U_\'4$L#!!0    ( "F*!EM.&AUQS(X
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M>Y?=#A']9S$/$.;8-0UGZ;0K2W?Q,,WG:/2&<N0<5"WI\N0]@PBY)!,C/[2
M\J&5MWOGUW':LHE(F\'BWWZ](\>W],'>3_8)X_,59OK-:C&;YMJ:X7F8U9X#
M%&GA>G4Z#Z=Y2I_>Y&3;1_W;?WV;9_][LG-@8X#3%7P.X>MD4RE73Y1WY351
M-D]3.E869T\!+W%(0/'%9((@U@RG\A&\+!:$L2(;-$GJQU*$):SB!B/GBYYM
M1YRM5Q>?7.W+7>C:U^I<K/%LM2+Y7G(93>&%FP!:)HJRM&00"DHHQ83$74XQ
M/W:[O@^7-RD8I^W 8$BXL$@-Q#WB$763^G/+>B6/J )G/@#YWAE4EF2AM2A
MQZS3PK'B^&-.R_Z8N47(N- Y1+/W@N00,7> E1=A]>79/-?_O/JOT^FW,"-F
M5L_6+\)R^6,Z__R?87:*$PK@LY-: H_%@1*Z0&0DL$R?Z2!L$3PUQLY6A/6
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M@.9=^12^3WR).4A-3!6A*085A0YI+B#IJ"6S14G7^I#;D<1QDP)#H6U -76
MPKM2F_"H=) 4AT1;J\RTC?0[$IYS3J$LQ?#<&FAWJ1@W,3 0E@X4=@>9I:=B
MVPGWT@6%M:U3G9/)0@$?7('$6!&)U11K.')MYS@3:\?*51ZNEF8P&ZW+TON-
M9K[@>IK(![K!5O.62S?7.G+_I4<8/68S)E."#+$HT*+(>HU"Y@RS TS1:6&U
MM>ZQOOV]-F.ZF2HA6;];;I;-FV#X/2XW;7'I1-">U_>%ID0/"C%!++2%95 Y
M*A483ZHQ]]M1-G;^JC%R'L]D-5%/!P[93:[.&B^_6:U.,4^\CSS5\AXCL;;*
M$TB!<G(4'CN6C5'*Q-9GZ\/4C)WP.BJX]E9#IX"ZWLE;DCLK$SF?AJO:EL%X
MB($9$,1)*<R*\&C#]%:HVK5_^H#IKQ&@M:]".L#7M23Q@S:8XEXCC*?8I@A9
MZQP9.$D<"JMBC@F#XJV+B;<@:^SLV, X:ZV8OK!VPR1;U"S4ML*(.=;6,IK8
M2 6R]-HQF7W2K4_&!T@9.P=V/$SMK8 ><73=_@H*EF6T%!R74F]#!3F,LGBP
MQA;K*6*.IO65T,'31 ;,A!T;4?NJXF=J#GTIU=6BG%<ITM^&6AYT+;M<\\IG
M&>;V_:/WIV"P%$<CH1R8^-AT:#A;X)*@34[M<A_<<P-PN1-<]%ZH'$ Z6\>X
MAAH;8 ;FD5F."96.3^GK( H.M8RWU[UDS J1:_-1[TVM$[$.G&*T,:7W+!0O
ME6K=U.$!4L;):AP/%K<-9 N-='#D?L!O.#_%U:0P3G3Z0/&,I,,B&P<Q8J3P
MF1=$F:,VCPWSVZ_BXFSM<1-B311YIZAB#ZEV@(;+TOSSIGY7?5.R#2YRFT&@
MJCUO(L4F]58,L[ I.U%T:MWC]4%BQLUQ#8&7-G+O $ ?2!=$0.VB_9+VP&RQ
MZ=9VSM4D1L&"CP9BLK7Y3LBU>: %P:,W01FO?.LK[$<)&M?P-%+Z'=/32@,=
MP.DO."<9S6H3B7PRG4^K?.IP[0MVC$7&D\P@"XE'&>(II&1(4$IH%$KYT'JH
MPA,DC6N;AH%42RUT *H[0IH8(X/PW$#(=3Z[9+0K#$/(*1CG DN6M[XJO$/$
MN-GU88!SF*0[J*NY9."JHFRBHTO,<%'[C&I0SG@Z\6,"5Y$NK> B-N]3?I>,
M<>$RJ ^TIZQ[@$NM1/Q],5_<9.6B0_:%E+@-TNH@ZE3.>@A[!<$Z 5D'GT/F
MQ&?KNHSM*!OWYF404+772 \GV*-<383R3*E4P&+MZ&]U@IAE?:^O42GN0VQ>
MZ/XX12/[V0-@8">8[:20#N#U9OX-5YNGL6=LO)G3=],G$TW[CF=B029#CEX,
MM9D(;<=D!(O*\RQ-Z_OBAV@9V<\>'E)-E- !F![>%888\#&33*3(%#8H1[%H
M<-7,%R:2R;9YR_/#+-1PWO?P<&JCA@Y\K"OO\#7)\>S=_BDQ=74U]1S+8GF>
MZO\4ON/JU7>2'^EP.@_+'V_(NUC57B.U@=)B-MO(XWQK^:B"YT&"39IBG<3J
M,"51 (MC3GL,Z%HWI1V0G7%K'H;PYGK1?3?;@%@\W\;/<8YE2N(U69<H$2)/
M%#$QK2":F(&V<<Q&:!Z;/YQ]@)1Q"R2&@]]A,M\=.OX,.G/\7&_C/[4[F'%]
M+=)VAB/71'FRLN;P%(/ ?(1@"EKO$I;F*; ;!(S;&V0(M.POWP[,R\5K\(N*
MQ$N),)M%DB0'QA3Y($:3H\#(5M*?:A\X(6QI[;0]1,NX#\B&@$P3J7?@\]_F
MXWE83=.$"RX"$M4Y1/)A?72T!="0U8PFN"R5M:TKVN\E9-QL1!L=/P&<W07>
M1<O&VVR\G,Y.Z<R;Z)0$E]*1@K$.RZUC<XM/( O]!1:?56S=5.\!4L9-.QP%
M._L(O0OT_ WK<"_,S^A+PV?\_?0DXO)=N5.^>L[@R^DJS1:K4PH7:EAP*<M2
M&$<2)K 4299((8&+GD-,*(11FNGFS[G:4+X5-OW/=!Z.H-$.3L]MN3XS\LK6
M%N**$W.6Y!O00W#TNQ1LRLH&05'(2'#MX+0= T%[@GAW=?:+U7-QWGTY4*3+
MF%0 PW/M5.9$O?_W8)7*.CHEVH^*WY'$<4_X?O':1*4=(/9::?AY-?BMEPRW
M:L2%32KJHH"Y4I\5<SK)ZM!9STIVEJ-4L75";4<2QT'L>)7W0VJP X#>S!M)
M&YFLC:JR3194?7\<C*;S( 6FE,$44NN2V=WS<L=H5M%>U8_FZW:1^P$YW76[
M>I G.J"]7RPW6ENOE]-XNJZSV3XMSAK57(K/DO,ALQ%@8B+Q"5=(?/0+[51C
MO.=*-"^G;41Z-VTO!H?I&+KNP"H^Q/:S;V$ZJPR6Q7(59O@1T^GRK.-6_C^G
M9P446XAEHHL009G:YBO7.QRTX&CK0W68O-,FRMCZZG=@ECHHNCHV3+?<*F-@
MIH,M=(\D+MMC.J%\3K) *)&..\D=>-0.LM AR&(5-N]B^@@YW72:&=R:M]+)
MS]0<\/J#\A=?POPSKJ;SN\T1AWU<O]7"1WE3O[L(VO<0?*3_90Y)>.DYY!("
M*)\R.$0.+&AFK<U>R=8UGUL1UBP/\*G:] F3RE%(2K:\^$*;.$D(.FC8/%_2
MJ8Z#'"S,WU#03:#5" L/1NV[R[N#L_.2^C.)5+.]F-?]^^S[=#5AG.4L&$)R
M#D$5K2'8J$A,7A ?)439.FYZE*!.L+2'IA\"S<%B[P!#MWAXN3@)T_E$:\-]
M$A98%L2$009." %)%62AO@XPK3/B]Q+2"68.5_3MZ^V#I=X!=*YU8_H-:SY^
M$H.2R1D--N@ZHMBGRD !E)I+[5U2<L!N6&=$C%Q(<[AB'^YYM8>4.X#)[5DN
MYUP8I7EP(8%AA2QPL:+&T+2;DK:U$5R*S=L\WD_)R-4SS0'30-X=H.:!P2T7
MS)!7EZ,Q4*P)M45]'24M XAH363H,-G6$P0?)6C<W$![#+63?@]0>GHJRSEC
M//L42AVP$4HDKU!*\(E[,%Y(86-EMW6^=6OBQGT&/0#$!M%*!W"[]!K?DA7>
M5$!,;,A>>Z\A8W45>9V"YY,':5"E%!1RT?KM\UTJ.KF-:AA_[2?@#B!"\%[6
M,>,O\>R_;^Y)LWU8S&:O%\L_PC)/M.7.&6?!F_H,+*8 $56=4B#JO0,K3K<N
MI]N1Q$X"M3T1<?=)U6#JZ0!]CW;1S05-YIJV8\RA&ML(3B*"B3$PK;5GJC74
M#FYH/&07QN& L$MOXUVTLC?"ON)RNJBW ,LV!2#WC):R:,GP2P>2>P$JT"GN
MD'%0VA@NE75>M>[GN>>,KR$[-1X-4P=JH!LD7=V KSXM'HA--ILFALV=UDE]
M";O1Z <DME?3-7[$Y;=IJL,,B+(/F!:?YYMO.1]JK; (P9%.BVQ!><<A:F8A
MLFS)51&!-^]8/#1/H_?B.AK*NT)'!^?[S9I!VM+:Y2 @2B?.'"'/O*W/[R3S
MVFCTK:^!=J_5'+)]U]%PN+_<1Z_5W CE;#S'R],E>1QG.^',$;EXO'ES[TP8
MJBRE+6#-9E?8"%[K!#)I^H1A)EP,<9;O1N;H_4:.>]@/J,,.+-L#+&ZL] ,<
M%N68EIR#"6DST4^"XU$",L:%*M9+V?J5[NY4CMZ59&R0MM+@B!C=/#UY= _^
M+2R7@9R45]]QF:;$YD1E'8HAUD(H)$G%' 11FZ@5+@P7MAB\U=_D@0D@NZT[
M>EN3P>$VM#(ZL(5#UQ%C]C(%J8"\7]IVM-=HVQF$X+BS1F(0[6<K=%![/F1K
MEJ-9V9ZPT447AD>3:U9(IU-@@,[66ZR4P#&*\32W/EE1M+;=S7 ;LF-"'RG/
M7;1R8*+JU3P/E?#T7)<0E 6G0@85*!1TJ7#(43$L0FI16M\H[YGPY.R? 5('
MJJ ID([]:B&LOKR>+?Y8#?Q&X>XRQWF1\ 1[[=\?7*YX-;N21<XB(=,Z3*!D
MM!!3UL C"]X)HVWS-/%C]#1(%-;O?+]<?)N2Y)[_^"O)_\W\<N;!L[2>?CMS
M#RY?OF6>*18+D#W:.@,XD0]0!R"((@U7JF@Q0$?&':GLY#+Z4 3=DU\<4ET=
MQ#0W,ZB1V22-XF"MR74LBR<3GA4@ER8(Q5).K2=2=-1E8&AM/YJ\WD7THR>O
M;]S_U,N;>9K.\ 9#GQ:[RE(H*[)B!HSVK#ZC)?>S9 9%:E6,3P5%:_ -P<>X
M=]U'QO#H0.C A+Y$6CE-SU0\S\].:AC_C[-,:A8A6NEK-W%+AT\.Y!,;P4 4
M*XVGN(HW?Y[Q"#GCFM?QL;(81G$=8/!9HD!OP\<U)FJSKE5:G-;G4_/\?HDG
MT].3U=5 D=4D6>N28!HDB1M(8 (BJP/<E9;>Y3I?I'5QT'Z4CFM4NT/N$=1]
M:(/Z-AGW"_F]K5F,#[4AW;M"HGVV6N'Z.N\70TQ2=BE;+T!X3D(5*D)$30<:
M_3'%.G;)M.Y?L2N-XU8)=0?E057<@64^KX::_F.39]G(Z\5B=8.S"4LNLF02
MV.P<*$\L.48L!:4=^619.M$ZR;$%6>.6$74'U-:*[ ";#US_8RD>,];W(84"
M B8YN.QU30E+49P)OGT&O<-*HNX0V$!='8#N[MW$I;S.M]A59,J8TU)HR*%.
M"2["@?,B0/0^9U=44K)UZG-[ZL:M(.H.G .IM4O DON]<;-)[CC]MGE=5XIU
M4;H"Q:L BLL"GN<,V@B%+"K._/!0O4M7;X]YVF#B2>@=J* N8I][A%=K3*Y8
M6DV\+=+6IG Q<U6;TSH(B8(ZVNXL9<%#:=ZM[VFJ>GOK<R3(':2<3@'W?HE?
MPS2_/*?H8@[I_.SY^"9"6TTR#R(GP< $52_[$<%I;\!Z:YRG/8?-B]+WH[2W
MYSE' F9S)78*UHN@[&_3]9<7Y!N1%W3&W<041@BRY" [J4$Y+H DB6!C\$ID
MG6@[#H[0!\GK[;7.D6#91EW]C-%\V EY'W[4$Z'>,*2T/"4"IR%.9QO7>Y)R
MEL11A/KP Y0OGC8>A7&18KJ"4=C8?*S$?I3V]JKGR)YD,R5V&=#<3,)>L/9C
MXI"E5#.LEDNL3Y>))TY;T2"B$9B<YT=P,.\GKK<7/,?R,QNHJDL,WG<@7+$G
M4451!].G5!M@2:> 9&A!Q*28"BYI-\X9OAL>C_C$9\1S?#^U=8#*[:MG)H85
MY#P;*"*S>I>*$!1:P&),"EI&FUKWP]N>NG%#G>/7T0VAM ZF;S_ V=F5_@,I
MW)2*T2:"4"J!(G[ &2F!>2Z*L%A2;OV&;'<J.^F+=J1JX5;JZL ^DA=\T?0C
M_=?I=(F_A>7?<?-2[>IAVR1FQ85- DJ0A5P1VF^>8R:1%E4"\N1E:PQN15B7
MU<7-T+$86E6CYGTVSXM)=@DQKUZ3<'\+ZW,FWI7[6>.!26$]I#J\6J&FG6P#
M@T)G@",%<'[[\O"!E]Z[K-IE\6]KB VKBQ[-'#%+WL3ZQ_M9V$RWK._<OM8?
MF3"FK$6ER'LN&91.]#LM).VB)"Q]<R1G>VA;]R!U7;J!1S-X;9361;;[^F;[
M&&;XKCS,7 [<.$V;RYA X5T@+SI8%<%8FUD47EK3NGIG!_+&S78?&Y(#J:T#
M$[F])"=1LI0B&@A:D/'/0H'+.D%VW"@1DD]#M$/;DKIQT]I'QN- 2NLW4GX]
MG8=YNE^03%N/R1C(H1CR28A-KS,#R[AC)?M@FP_<V9W*;B8@'B52;J6N#NSC
M!_QZ[H^\*V\7\\^?<'GR$N-Z8F4JOI"=9R[60:8I NTF#^B,E4JH7$QKA_$A
M6KJ,AYMAX,Z,E@8*&?^Z^4[L==%-ZWQ@W[NO57_U 5!MPT62I+]X=?)UMOB!
M>*WMRR1%[AD9<_)Y-8DRL Q.1 4B:\YIZWHE;MWL;1$=[T=+ES%S:QB.H;<.
MS.#VTIV4J*-.K,Y.#K6,'7D=*FE VAR25<&FYD]EMZ>NRTAZ*%,YD-(Z<!,K
M6_7_:]CUC0*R38DP26R:R#C7OZ#]=_.#:S]YULOP[@UHFIW6]EFOOJ?-!-\/
M9.A?E8*D!!6D*O4NRX5:%R)"@"!Y JM),D8XDYJWTS@NA^-&\X.YIQW#Y&??
M1). 6;*2:F]9ZRE^-0J"*1F*$UY%5V34S2?,'T+PN F"/B&^DQ*[&6EQ(,N!
M2Y0&05LM@)A,X.L(T( L80HL)-UZH-CPN!VL/*Y7W.Z@Q%XZ7)Y^_3K;B#+,
M+D3Y9EX6RY,S95X(M9CB!<^>CH[Z]#B@ Z=SG9B10I26*<F;/]K=CK1Q"^,&
M0^(0BND@8CM[/_HI?,=5'>="L< D&^>CY@Z8KR,+4LC@O7&@5=;"<\=+\QZ,
M=ZD8N</@$,J^6UMYB.2;8:=M$]7?:VT +LKST]5TCJM5F.?G835=+<K[:PO<
M9&*[OJE;?G.+5JG[,-&H.^J[Y><P/^\O<=6H]:QCU?7%WY7S^#S,KGJX7N)2
M%>ES41:,D_4Q(BNU7TH"6;RVWF2TS:? -2'\4&MVH;"7N$K+Z=?SY3>Z>W=#
M=Y](7<_I7_Y]4G*R&#0"%YY\VZA)5)M.23''6&+$$EN_Y-Z=RG&MX?$Q>=M6
M#JS73FWIQ].3D[#\L2CGKY+J@(WE8DZ_36>R);OT<?IY/BW35.L+KGZ*-)1J
M&G,/,WOXHBTL<&/6&QGGN\M<HEMS-!$% UDQK8R0X# R$%%@P(2^-"_$?IB:
M@X.0QR1[M<7069M33.3],'OVLB2$A"!TX=YP6Y1N7>FQ'64C-[YL@Y([ 4A[
MI71J]RB@1R+JRXO%C,"Y6&Z^CS;\VVG:O&7_O,0S(["/?=O^RUO8L3U9.=!>
M;6X?[UWZV3U+7Z*3QYP+YQEJ81$HG0VXY#SH[!P3' 4WZ2GQ[K?TX=-G+A?Z
MAL_JW*G/FP5JA\S98D7._-4&D0I%<);75C"ZIM\->.EI@Z24N?=6V9 ;6ZT=
MR!O'=!T!,'='TPRCLDYMVGUU\F0'7H?I<C.:[S<,E>>]S=I.W]_"LNW/4"-G
M['*E*\1<"S9,85:R!%QBI(-66T),"!"M<#HCVLQ;/]=\C)Y#[=M]WWWMR*<P
M)T8? (4M%%E908=_(*^">51(>T2QUK[GHP2-ZWXUP\5MB]5."9W:J(MJ]<LJ
M]>JHU-OL.N[IS<G7Y>+;_@9J^R]O89WV9*61:7JP[/\2AP&+\IY'D,K4NJ[L
MP$EF *5GQNB QK9.T#U)5(-7*_<O<-^1[C (%#4ND5R RI%<A^@5*(Y%"L&=
MB*WK G:A;UP3UA8_]SQ3&49/G9JU39/QQ663\=4F_+IJ=+1/#/GX-S8)''<@
MNI'5VMC'JZ,2A7:><0W1,%6G^AD(B2.=E\8GH1&3DXUWZ$T*#K5';Y$DAS<;
MZ%P[L)E4CD4O(!LM:P^*.I?8^LU;Z(1&N:+;\_<81>/:G .T?]O -!1\IR;E
M5INP<&\'M3T,RU;?V\*\[,Y *]?H;,'516>U,+O"7$83I"87VM9VO4HE.M2<
M<D#BP9)0T%'7^BKN$7(:S.AYLI7<?2>NBD:D7-O)$;M0^S6 MU@@)I8="\PF
MW[HP?D]21W:2&B'IGF$[@^NM4[-VX[78'N;K[FNS \W4PP0U,D?UBZ^4>?7J
M5LKD0BQ@7.V/RS.=@SK2Z>>R%(&CXZ)U^NA^2@X?5A?O=>N-B8(.=@9>56?>
M, (K<HH?H@@E)2FQ^22P!T@9UX@TT/_=,7.'B[Q3^W ^['P/RW!]3/J!-N$^
M(EI9@TNUO2O79ZY\P%E]SEGG_ZPV#_-BG<IRT8'DZCI$.:7)/P;&L@?E9:03
M@(X!3"AC(=R(%%IOJH,H/MBZ;+OZ\^NK7ZO18=86)Q HHK#U_@C!)6E!F$@;
MD*6D4^LB^P-)'ME:'0^?=ZS:$57=J?6[5K"[CPF\_L];V,$'R6ED#"^__Y[S
M,;AZ)C(%U@M>KU$B!&X+,"5DHB!>*CM &_.'R&E6 W_?L5VBMKKD %XBL2J#
M I^]!V?(%2 W0&O7NES@,7I&G_#3!!,/UL(?JH%.34>=S_4J+.?3^>?Z8)0,
MZ,EBOC&7^X59#WY;FZ!K.V(;V9EK2VT6N2J6*TEJI0K!2"'4_I3UKA;!4IPM
MF,V%3H[&.^\A6@ZU,+>_]UII2\U3Y.(!)2%<.9[!J9H;98ESEXOBOG6D^2 Q
MX]J6)CBX;5C:"+Y3JW(6"?V&ZR_U ?K5\.R]X[.[7]4N8'N"S%;&Y/ZUGLWS
M_[.8SM?_27^X40^")D>9M %32KV+"!Y\I&C?"%.XMI*'W+J$>4<2#S8]]R]W
M;X;"2DFPYR!=G2P:L@3'78)<0@K)2^M\<X.[-74C&Z<!<77'9@VCL4Z-6'4O
MINN+-QUUO 39:YSO^WSEL:]K8<RV)K>10;NVWK-;Z]WC@R<4(1G#@!54=%0Z
M#<';#"G$8B6F$&+K#-1.!!Y>Y[W%8M??0K"D=- @;.+UC$_@L/[1&/1:&"R\
M^:#UG2@<UZ@-AZV[Q=Z#Z:U3L[9I2G&::J/TRPY:>V7.[_^B1F]3GB*QD1&[
MN5+MV+%)&M[3QRQ9DT11 ;20=3"EH#"?G'V(I>20N$[)MBX!V)JXPWN$/K'0
MO?5WK*CL+ /O:L<U&04%/\Z XH7^REFOL+5/M@^=XQJR8?!UMZ7HP/KKU)1]
MQ,_5<E_K?[&/';OG6YH\%'Z"N$86['R9#_AUL=RTSKX E)/HM%,"K/(:5%0)
M8C 2&$&)E>I_\]8&ZR%:#G[U>^M[[\W%YBQTO;7.S%%<DZ6$D C3*7J6T5MO
MFA>%;D'6R,UB6F#CSFO?QLKHU;8<^LY_U%8'?;4\&*OU@2G2(B9%@8&L78NB
MJX4M%"(HQA@*5*)YV>9PK0_.>XK<6N#'V:]76X_VG7,Q6^ ^$*=,>P@\)9 ^
M9Q6"%T&TKES8CK)N6Q_L@I([[5_:*Z6#UFM_K=W 7ZW64_);<#7AS@J;N0")
M2-9<:@>1C@LP7(C@BBXEMKX)NDG!N(W9!X+. 4+N "(O%F3\Z\#=3:G-=/7W
M%T3#=%U_-XE%*N]-@6AJ,T/+%#@LQ)DO12<Z_+EIC9='R!FW8_I X&DE_@Z0
M]#O^\9!?<;\Q]>1#>J3X.!E+_/E$.\4;<F-+CM(GZUAJ_4!S5QK';4<^$.8&
M550'0#QOVOM44]_;7=8W3$]X<%9&Z0 W4]-XCN"-0L"2?"H^%(5#=&7>E]YQ
MFXD/912/I<!_UI#UT^;9TB@!Z_G2782K]XEA^&"5CFU?)-8))HKP[K6 B#$!
M4]:$XI//HG7!QX!]^M(7S*=UT.3]FVXCXFL/;Z/ST:4 S)3:KLG7OB?)@I:2
M)6FY"<W+[7>CL-O@=1?4W,GD#:>D#H[S*^Z>.@&N6(S9*Q9<HCC=4A 6-@^K
M9 $K,' M2YTY.1@.MR:SVW"X#1B'45>G9_;6;1CW/YMW7>*HW24'.&OW;!EH
M,NJDR=_,@A=0*!G!F&7@5CM;WR!99I\2]5@])N>;[_G;=/WEQ>EJO3C!Y:8W
MR[.KUBP_;AGSI(POQ6:0.GAR=XTC;JT%[E3,,82HFC<7WX/,GZKGY"X NB>?
M,Z@*.SB//^ WG)^293P)TUKY_AZ7FYOQ.F$RSJ:?-P)^]?TK5LO_:7I"/_*N
M?*1/5X4$4SNHWV1?9V-D%B1?%%7<W(#G(0,F+EQ&EKRPC1'<F(5QSO$1T#VF
MZCL]]W=I4KK_T;_'*L?NP#I@L/UHOTU3Y\J;5, 95<Z&/@1A @0NN-("?7*M
M1V(.V8>U]G:X$O:S;V$ZJX)]O5A^)*_YUO[)A4O.=(!B9*KI6(KD0B[D1A>/
MO@A?;.NVK+O0UW&7UEU0<U_[C4%4U*F)V[K3Z?[V;=<ECMK =4#+]G0;SIP#
ML\Y00.PUA>)6;8#*H&1IA9"*LW"T+J:#MW&]]G82C?*:-@MR9D!YSL"G(,@[
MU@I-M-JDUL,'GZ:J]Y:MNV!EZY:M^^FD4U/V>,_3 U(SVWSO\$U;![14MYIW
M\F2E*H9#4%X2%FK,ZG2"8%%Y^HM4<FNSU+IU*WU;[2ESZ[P.,F;D&$!HM*"$
MJ*,62VTJ8RQY!127R-8U+P^0TE6SUEWT?;=9Z^&B'C'OL8FSK[+:3PSN/'^R
M\6EQWI/VEC?(750F!,C>D]M9BPA#%!*,)1<1(QE6M]W\FS;TC'L!T0!B8^FF
M@S3<?2V0+S.,O]7QHG<SC<&9(+V3$$U],RXI#G%!1>#!$8]%9-,\6;P'F>,6
M^C4U?,.JJ%,G:YO.S_N[6CM\^[':6 \9(#[2@EA*YS *!BQD)"_<>8C2*)!:
M1\S.R^2;3_@8KIGUE15_0,!7>X3S$I*T"7AQ&13Y"Q"\<""YL\SYPHQIG?;:
MGKI^6U;O@I>';_6;:J=3"W:]*?3^ENJ>;VG=L7I R_- WV*94U!:\9K # 0B
M.IH\XPXR"X$S5#:+(5+.[1M]7"&Z?O^;>7UY?:NC:'W\:+)44!3#.N 9P67R
M#35+C*%-);G6O4Z>IJK+;M:[H.)AT])$$1VXYE<<G3MY9"3?E3O[]EK]D^9!
M%AV LU1?>M06_\DDL,:2RZ<%RV6X VT[&L<-%0>%W0!*ZO1<.^O[M?^)=N/?
MMVO<-^0I=E@_ZQRUM#XI$&@L*$0+%)TIX-83[C+G)K:N31FWW_JU7,KM5MO/
M_@C+_'%-6^'=UTK0JEZNGEF U>KTY.RSVWN&\V20>^#*Q?H8,H)C18!#^E]E
MDI>Q>3.'IAS\U-W8=T'OP^;QZ$#HZ@2_XOZZ JYS?]'7ZG88I$5Q2F;(R.FX
M,"Y 1#JJ6(DQ!1YBB*WK4@ZG>N13OB^X#ZCP#B#^^V+3^!/S59G^ALD-_P_Q
MF(PT7DD#I2@'RFD-Y/M88.BUY4DSJ5NW.]R'SG$SR"/">'"E=NK8/MQ0_I#T
MS1/?.6PG_ &=X@?[H$OIHW'> PN^FK#"("J?(09M79):EN:EV$/UP[\RZ+=7
MJ*U>TK-Y?CF=G=;;P%M67$2351W:'JP!I;D!YQF)(%K:>,Q&.Z#'NA.IG?;2
MWP5##Y_"PRFM@Z/W6C)]OI[FRM+TV[42ZU??T^R4MOEKDGH]0$[/U'I7*M>:
M0"K%M&,*R/=@H')R=&@H!)^9R2%'SV\7%K2\$FG$Q;C>Y\"('D75G1[7=UMJ
M'M"QX*'O&J;WYX#'\H-='KV.AB5?XV9;)YM1!!VRQ=I2BJ-A.J;<>A;68!U
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MAN3)Q8\ZBF0W48PSCH2A0&."@Z!J17[6$EP.%EC))99,!RC;[H'M<<>1W"K
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MC% &T$>G8<E56P0EM8N6-H[)IA9:" W!*PK]E;=%.:XM:UU3?7B[BJ$#DR&
ML%.SBEVTTF\X<LG/GIYKH!-#)PF2HZTG!AGV3)XK#RSJ3/(PVWIWS6GK(B@9
M$*4]J+1WTWGYGCTM/L^K:SS),09NR<_U6M,1%*6G72MS'5)%Q)&;X\0Q<CP/
M4]A%W#*V<3U,;YW<K>S&86W_\3O^<6-73IQ55AH,$(2OM<"<@PO2@7)6.Z>L
MQK1E%<W!M'01THQJ3MNKK'?S.4DV&*>C!\WKH[2<;>TE:$#)[!-7N@2ENO,\
MAVF4UH]QW$DK3:/ID1[V79L.]GY)?UGO85,UU.O%O0UJCO+@;V^BCOH0L(WH
MQGD@R)4SKE9G%U4XV<^D(&C%P:88F$TN8=YV!/F1'@CNU$:I]J!(U=N8GM"/
MO"L?Z=-5.=/56:MU76RPW 70K@H %1TJS@B0C.),<HA,]%O-?&K=#^M)RG^J
MEX6[P&RO?EEM%=V!SW PUYM\QDLR0YNQ.)E93'180M2N]F!72,>99Z!2-B$$
M[L3MA\#CP_P&!^,.D!D#@ZVWP?Z ^&?8#F\OFT 4%;1 X4!*8^N 4@Y>%@:8
M/6-):.1IJUF?Q]P*;W>:83+88)Q_AFVP'Q!^EBTPR2@PHPETTB8*B-%*""D'
MD(%;7Y\$)#U0=[P&_3W[M=][HF:OUI^[J/!GP>5CLCTKEN 3C-:@Y@Z"S)MJ
MB0+1"03!9<A>*Z<9Z\TPG]/^DYOE(Z*[-1":;8"V>9??PO+O%.73:?<1T^ER
MNI[B*LSSZS!=_F>8G>)O&%:G9^-&#LFD[+-,B]S(P>P=F.VX@-SE@B^GJS1;
MU#6O!9WT\U&)#!BK8VLY@TB.!Q2*.;-0TI?F]4J/T7.HG;W\[K.:HDV\?9:M
MG-;A@1N!YW?S#U4AM0:-?N#WQ7QY\<?: ^]\O)PV: V3]1J]9C3Y)FO*:H+3
M8MW]R<36'5&;$3^N']$,;[=MYSC*[<![N&3\^8_+W_Z/*2YK?NG'6SI19IMP
M-2*3PJ(#%FO5G,,,44H)/D>=4G2,/AH*LH]2U@D>CPN;A\#;3H<](?/Z87:7
MO_-QL$5GHH$Q<")33*L$;7YE$)+,7 6KG2BMNX/L1& G.&V(D(= V%Q=/6'Q
MS?SKZ7JUD9@X'QALC"W"F0Q")0G*) &>/$0@/J)7A8?D6L^*?X2<3G#6'@0/
MP>U C?0$KN<_KHGM]1+_ZQ3GZ<=F9UHOF32*]B.C:$P54W>F,9 *LTBG@W-B
M,) ]3-:X87=WAV\3[?4$R/L8.M^[,6NO.>,08JJU:D;5X4P9N/8J<*$<3\<X
M;V^1U8GU:P6%+8[80_32*=16ESOVW)X')U!SKR'YVN:D%D<Z1 \I")1&!I1Z
M,./W"%V=@*T5&+;QYP[13 ]HF\[#/$W#[,U\M5Z>5I8VF]*A=0I# (LB@_*H
MP055?RE*\L(QJ^8 NY^4<2JC.SM1&VBI [!MRM)HY2K&C[C\-DV;A/L]W*T^
MT5>N[O^K"U?9"^VMI\C,U-+P(AD$QA-DR\F_M<+9V/INIB7](YO*%H!:=*+=
M#I#]8K'\6JO.\/FB,G]Q 7%^)ECDQ?A$QP&+H3;$JS4N,0$KRB9I$AT,[5^?
M/$+0N-@;#R=WRJU;*:T#!/[UXU\6WW YK\)YB7%]AQ]ELG28,UA5'R[R:"$(
MC1"Y= Z9L:*XQB!\BJ9Q@^5N<-A4=1U L87/='7_GYBWD38;!%[[=@>,M7=%
MA*P,>I6"]:GU8Y2F#(SS@JHS_W4T1'2P'9Y]"]-9%>'KQ?)CF.'-+7[>J:6V
M;UFM-XQ.M%0N>DQ0-IWJ92FTTY.$[)D1#J,HO'5E]*XT=A+H'Q].MUN_#ZG;
M_;&[6(?9,;";TNG)Z:P^+-H,</XKR?BL%]%?Z$Q\CF6QQ#JV/A?O4V9T.%HE
MB&D*+8(U"J3@.LF07 ZMIVTW(?SG3^8?!>4#H*!_L_T@T[4Y[!730=D<A;8@
MC:JO@64!5[0!EY.LXZM-X:U+^YL0_O-GW<:%_OXHZ*+KVFVVKUB^*8 )3YH%
ME45]1E>GZI@ /D0&A;'H4"GZ0_,1-%O2]O,[WL- N(DN.RUR?K]<?,7E^L>K
M_SJ=?JWQ='T=79O@?%G,\IN3KTL*M,]&I:8OF$]GN"A;_Y,#BJ*/05:+(NJC
MBZ]1T?4%$>]G85X;'5X2<U4)Z[BTV24@K83:F+UVZD .!&P1= F"V=:5UT\2
M=:B1OE#"N_+@4F>A>\D9N=4:0K (*HH$WFE>7R]DZW,V,L?&S&]+V[B!9%O<
MW#:\@^BG \_X06Z>_ZB)TLU%DK08O1(*D(5-\Q,'CE&PZUPI4=.'/(IC[;<K
MLL9%VS!X6 RKG)[Q5ADZS[]GVI6*,00C!*MUNN0J!5;JCDTA:HG<'0UO5V1U
M:MWVA<*V4-M3+V/W.'][UCEDL;QR9LXO8+264B>; )/,H(3()*6LP44K5$DH
M=2E/^8"/+]$I4O;5Y**Y6#NP0_>ZM1=E7XJ'*)T%RY6FV,DGB%X',.0V>!,*
M!MGZENH1<L9-7 Z%IM9ZZ !2[TJ9)KR]+QQSJ7A10$9F05G-P+.,X*TQB0NC
M0VA]57\O(>,F 8>&T>&R[P! #PKI*G?DC%:6I5(+$NK;#Q'!U4;LQ4E?C%4E
MZ-:FZ6FJQK50XWKB^ZFF9[!MDM^3K(B5H@0X4P<A&E7=2!106$ITE%/ S%JG
M&1ZGJ%.G:D_];PNOW971 ;2NW:2\1"(B3<]FU^#7&9[W\KL^T^9!YHEO29N3
M3'?6(56^:<<&RX"AR2':R*(NC4'8BO9.O;8V<!U%P5W<I3W(2AV1$P//13(%
M,=?&8X$.F*B-(/<U>.>,L,H?+6^Q[02CXWM\ UO,7171K#!GI,NOBW$0M9!U
MTP_I;"<.?[WUZ,)'O<#:7@1'NZ)R)GKI @>N4GU[00ZG]U)!+ED9;G+M-O"S
M75%=-_6W+/R$=K#6VM*."[INY6C!)5G %U]2MA3+^=28WT?(Z=17W L=MPU?
M*RWL;?>^X3(N!KSV_S#]_&6]*']=G5=;A!O5%JW-W0&K->D"WXC91H9M8UZO
M6D[I8IFJL]"#\IYP:K#F3QR(H#/3*")Y:4,D0ILU-7N+)%5\>S9!:966TZ]7
M;6)#9M(R;L$R0TZ"%PC.4U 5,GD/.LC 3.L(]Q%RQC59!^C];D*WC<A'C&-7
MR_7D0QT5LKE54U@81J+7HR9CS7T&Q\EVNZS0<!Z]W@XG]*W7,$)_NL+'C07'
M1D(C]2T.E64/ +AXLY71JV(E%&E+#51JQQUIP)7@N!%8>&@&@3&O$ ]0UFUU
M[R&YD17^VW0^/3D]N7@Q&C22-Z: %U]?2 D.T3L*(3,BXUY[:[9RX)]0^8U%
M1U;Z/BI;M)!?!RG+^\W>5:K"2YZ--1J$#5AOI!0$23(B&QA#)&F5V+KD\ F2
MQDTPMCXFAM##V"4H[W&9JDX^X[NRF>.YR6',GB^6R\4?T_GGUXOEAM'WX<?9
MV$Z>:^FW*F"P7H!ZRVK-M@4ABHK9NZ)NVYP'*E-V7;E'EV-/G2^.I8 .C-:[
MKUB'(\T_;[CX&]98$O,S"M")Y<L^Z9N__(3+$S[)SF81@P>=A *5:^?S0CM3
MH _%9>=HC=:U"#O2V*-9.PR*1]%6!VA\&^;YXVG\/YC6GQ9_62Y.S[.UJXFV
MRI-/4:?_&&)DTQ+3!P?2.,[(K>"$FM:'YT/$C'LI,B2^VLB_ R!M<F+O+G-B
M[^*:M@;F-_-7W]-F@B?9[9N;Z6JNIK9<ET)<.E<SJ[E@=3LY,/)&,=1Q<*9U
M'OH <L=]U38D&(^EPTZ?KCV>UGVQ./FZF%>/8U$VO->I)?.JA8'2V$\M.'PF
M>R>6ATEF^TQ!B+896)WXHAAR\(0KD([^K)A4VK1^O=TVF7USO]0V%!,TS%K+
M(F@6:8O6=D6!HX&4M+ N&>=\ZQSV72K&CA[VUO+C'MK. OXI;='5X\^/IU_)
MT)R%2"_"ZLOKV>*/:]=.'W!V-G3X3."#V:I#"1K>EC45V3"V3IJZ"TP&)TMM
M>L<M4/ :(6,0W"<TT;<>P=/&UIW-:2=1O@_33#["LQ/R8]<KBMYGI[GZ#]?:
M];XK-QR'Z77^E539Q  I1PD4NQ<(%,E#<9Y%)EG2)3X%TS:D=&4<=X'%C4S*
M<37200QR\RBX3! Q;SG37$!23-?CP$'(L@!C//.DM(K8NB#U?DI&',]]9"P\
M>D;OI9BQ\\+73XW?%_,JS[N'QJ?%K;T;62PF!9)7('=FT^P\%E9(:(9%81&9
M\EN9M+V6'SLMU\:,#2_Y#DS7(:&W-P+)TQ6@2BW\0-I+P;-41R=3U&]*D;9U
MIF[H],DP1O (2&J84=E%K3]Y%/-;6)^W0%J4^\4Q/4KPLA,=QXQ9]A?0,*$*
MTX2_H 4PD>LX:JT@D#7?C-PH(<6D6=]IF;,TZ@-;[\)!.;O?(8-4&T^O4IC]
M+PS+"6V>$J*B+1GJ+\8R""$G<EV,UY8979J/G=R?VJXBF5U0<W^-P> *Z\ 5
MV(K3EZ?X.VWM3W_@[!O^MIBOOZPF0;,DDY?@-*-3P]0:\NPX8,;"F648@AD#
MF/?0VI5G.C@L#U763P3*NN$^_;&84#RHHK41=-"ZMDOTX$V20)P5GK4+NKE/
MNB.)8]\I'QV"^ZCF9T,>00DGGFFM$VH01E*D&8,C>X\(EFF,R!7)>%3L52+'
MOD0>!WT[J^<GP]_KQ2FY&YEGLNX,)(6)H*3>Q&T9C#$BVBPE8NN&O+O2N!7Z
M]#\9^G96SD\$O@D)S 85ZYPP09M*H8"(-94JI#:9S'MD[>^.MJ-M*["9?R*P
M[:2,#D9,/,K77^>9(JEZ8X#YU?=$/WIV?S"Q/$C&K8"@79W+'A0XY@U@3,$)
MG3&688KK=R1T*_C9GQU^3=341;..A]*AV:5@O!?58ZV66WH()GM QTB8K""R
MUD6"AV2PW4^ J!:B[C3S_"QM-L.*S')]WA+FF3Y9GF)NDU#>Y>M;Y(GW9J=5
M[XRS=>L0A<W"87:%0&,ME]9QT#QR4,)%<,9FL(ZL2TA)Z-C:]7B$G 9ML*Y+
M^L7ILF[*29%%)NLE"(J/Z\LX2T<Z[;KH=$!N EK??,K&O92,W"6C$0[NZ4UU
MJ-0[\-;O[LES1LY&BZ3S/UP(#.MS$&-JE;:BH]G6!_OD)T(B@ROIHZ1+ZXN$
MW2@<N1W:<%@;2DMC%ZF<L_:!%$5$?"&&7N(WG"TVC6S.B[<O]E9U#9RS' 0F
M.NFU#>0X( ?G32HR:R:VK+;;8=%QC=>0BE\<00L=6+A7Y!PM?B">UTK<%27M
M3):)#0O(E07%7 !G@ZC/X7C)W&H*/AH;M2>)&M>.'0%VPZBG [R=R^[-G#SA
M.L?MBA%,N?!@'01R$&CC^ @QI0(R!4S1,V3M)UH^1,RX5TE'Q%<;=?2#J_?+
M1<'5:M.LZS5><<-L#JH("4;4 %A[!J%D#=IZ(J:@]'R %K:/4#3N=='Q$=9"
M,9TX8W_!.2[#K'JQ^60ZGU8AK:??D#YXL3@YP64=9W_!GS<B>"\#,&TIX/&.
M053.$EQ,DIGQD'7:Q2G;9?%Q+X6.[)P-II4^C-OU8/K9?<FB"]:T%"EC(H<S
MQ0Q*Z43^@$\45TFFHDW9-Q]TL0-Y(S=#/DZRHYE^.FV*_'8Q_UQ[8VQFG5Y6
MM%[_](!$[/9?WB(-NR<KC9*PF^^?KM)L49_K7#V>C73X86WQQM&!RIE#E!A!
MBV"DR:98U3HU>3\EA[<JCNLW<_JNTQHHOYF31<35^@-%,A_7-9RYZ@PTB:D8
M75BH^XW<S91EM<@>C%&:J6(XDZV]_^VI&S?+T0 E=[L7#Z*8ALV,#[C\OK9Y
M)R:X(I)WD$+V=?XR!^^4@I*8]IH+8TSS.^W_O[TO:VXK1]9\G_^">[$O+Q.A
M\M+C";?EL%4UT4\*K#*G*=)-4J[R_/I)D-1&<3D\Q!$@E;LC%"J*!G+Y &0F
M$ID/YJ\;IQ@ .+V%VT)6Q /:;T]CA@5+@GK$:&Z7AS%!-E*"HI=.,B*%*E^-
MXBD9=:VB@6'21]1-Y"T\9.+>8;G40&IB+B&L67XV2QURF-M<VH)B$BE3KG0H
M83LE=4,( Z.FI\ ;35YXR%GITOF=QRYM+S][6?P=D!.<V4A"0B1A!\>0,\@%
M&0$N23B-.76LM,?['.;RJHJK3DRR9!W86P(C3JQ"6A..8B+1XD U,:5WFRUD
M-&D 'Z/W_0;P\:)N("CTF(5EJ7"J,--:!*0=7Y8*AR,V&(94H(D'2B7LP8."
MI7[A_),5NQ<H1TNY.9Q\LM=WC5X-H5HYBY($B7!*(S) .L)8.>*<I%27MGUW
MT=(29H[7\5[(]!1X[;N.BS^G%]^F-_G]>NZ=M*R2&R=G\_EHOK 3'\^N9C$^
MZ/$++I\5TC(D=0*!*:W %]0@-6<,YT83Q[NU<S]RXI:0TU?5TV>2>^7.#LO0
MTK*;:IQ>S>SW;R-OQ\O5EF("]P '\ 5AH7%)&#+<:Q2=)5QJJP/IE#=WH,O#
M3@+JAVE*'%GE9%P;*/%JDX7ULDJ14VXU13AQCK@W%OQ,F9"(1 0G7%2LDS5\
M""B["*C7&J208J>EI5P3*HOOL\LW%Y>&.:G XL]MQ%G.@(+=SSN&B(YY]W78
MRWWIZO/H_^MJ^N._\W K4.3?'@!B-4U%U9=1U+2_U)JS8C_>5<<.DGICJ$?1
M!HNXBQQ93!U2UN%DO<WVVZ!&[,>C.L$,&L0=SN_I)^_F8//>@@&U>D7'@4[*
M4D2YLC#831[X"#X@')U/C')G\+"N\CTM+9FP/16]%SP]I5[; ]H0S-1.WL,\
MHQ]Q$N?S2T4$23;!64MT/G5SE\:D$Z*1!^V]$"YL!!UW^#M[IVG),#T-&H5%
MVMS6LO<./=<;=#@:%#%/B*?@D9-2PV&=;$@Z,H_YH)O-R<D-SW1N#;']%--,
M6QO2+5NW90KRK<RE<EP")QA)D6_D=7Y99V!%81<(;*U,D,TLFDZ[TK:YZM\^
M#K@UG2S<VEAYV'/MX^@_-Z.0@?_67L,G\\L8<8A*1>2MI8A'RY&1-F43,5AN
M'+=$=8+)WFGJIA\71T@YD39P>-T"?/UX[3+0!.XB!TN,Y1).&'ZSF GD*<^%
MZY*AIO0=Z@8)=8O*#'$,G2+C%Y#'\*"6[:KE[/N;Q<WLKA8\S#-D0O 1<PZ7
M)]R7\6'S(0A/%%PIC:17#C:@E#L'<X8"QXDKC'U4I5^A#Y,/\5".]_62O\3O
M:TF?I\^ST<2/OMOQ]CJQ$K- '0:/ MN<TY\2TEPJ!!:>=9QYE7CQ^JDGTEP_
M&' BHO8E=0VNQ 9.UB/X_3!Y4D16,AV"-@YAF7*=># CG -FHXC)6$6EE\4K
M79Y"</T 13VXGJB^EX;5VVJS4;$ %HQ$428./&IP@Q)+X!49!CXS+$U:%:)-
M5 .NC<P^RGJ1@%P6H/5<&DE#0!XKB;A@%CD!AX64@J0DK>2A=/_%?I36#YI4
M!^71"FL,EI=4*QL"IHBX_(!S^5"9<84TT]BSX),S0^Y_]:,J T+H*.$V^CKV
MW7]N1HN?I;/\.XQ:PL\]EOA2GNP=I,Y3[E$<)_.''9QR#]CYUV^ 4&?G,=QZ
MVG?PL\EQ:V5"V'HXY7BN54)91%X(*UP23.#B#V9/HOC4#>DV!'&>EG/\EN=X
M2,79;)9[42WG_.WG_7?6=)S]:6=AE2- 2?"66X=L)+!RHP:+E1.!8DR)*B(9
M3[BPZ(H17]E7?C[,;FZ9==1?.2OPS;(6\@R4L_B9,VV7R6\N86)UP(AIQ7-,
ME2,3&$$6CB/",?%NL^9=KX3 ;7/715\E"$P+ZJ,RGL!(O9GY;R"4NYSJ39;6
M:78Q:*YAA2)I\IM&S43.HY+(*1"9I@'[;B\^#X"L,T'U4A%/U_ET: 54OWD=
M?8^SKW82QG&6:P_9"7QYG:QO(V,\&HH2X[G[I)3Y!AD$1P5+1%&P=[M=S^^9
MI!XX!M+G= #A-N!3?KUQ\U$8V=G/KW:YC2^F_M_+]:0=%<'0B))RX!QC*I$E
M$J/HA8])<L9"Z?N;G<34C>_6/>3*:JH%R-V3GQ?C>;H \<W!&,W>W3JCG.8G
MM8$@'"7/ERT,::H#LBHFPY45BI>NEW*8JLJ65AGU;X*JK"YJGWIGBXMO\9]V
M]N^X.$\P_6ARM=Z6'= MG=1(*)*S.GENMLP,2I'I8+TS-(A.9][.*2K#H[ B
MI\6EVL#.<UO&>"FF-0M<*F*77>-@;T8\"(UT4O"#)]"[3T'JTD&;+614/N"&
M 4\IL3> G OXWGEZ<- O=UZI.0O.)U QX;G7*LG'N48>?LUUJ%+4I3N4;"6D
M[B5C&^;1Z1IJ &8/1;6J3VOO/WFP*.?K580C]8Z"GZ&)R,6L##@;$2?X3W"%
M,4A,Q-*914>26/=4+ "*S1JK VJHMO6TNG5YFVL6C]S-4D<;S_RE]"I)88!\
MK7)3,(Q,HAJ%D%]]BAQ*[A8Y.#A5Y8X>0VIY.IC(&]C!/H_MY"XD9QR1VMF(
M+!/+A\$R%^W$B'$G$V<>4%'Z=>/#^>NF.;1Q+/;61T-86IN@2J;@([@8P+%&
MG$G@0T:,J* ,BY2T]*7O"!]34+E%6F]-[H!$#['6/J$>E*6YK4FS="H^3/*;
MF-&/F'E;;YR:46^XULB"$YI%I& +9<"7T48RRX4TW5H>'#%I&PCIH]@=Q7^*
M2KGV35O>;E<&H,$I&B,0MC'ELDAP4@>+D8X>8\DC8]UZ21VZ2;N=L&ZR5/T[
MVGZ2;P$N:Y130UD2+"(BB 7&8TZHQA0%:IPPQ&?KKQ1@JM^?]5/6IKI[2*ZR
MPO]I_\K/J-:$)VXL850B;C+AW 1 ?3YKM0X,!.)#-]OU@,H?35I9Z7U4-BTA
MO]J*7[V?NRUEI['5#!.D132(6T*0B4XA@UUTUL00=(E<GD>3U@G_%E-\;_E5
M5OS_B4OS)IS]B#-[)P8K(O:6)123CXB3P)!-,B!FJ=,DXLB[M<\] ("MD]>)
MY)8"PNGR;,#K7-D[\.7E&>BM44IY HX6A[TL)8X,410Y$@P)46B72A?V>D1
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MZ3YGXX=\82A,A]=+"YOK\M)I/K^)X>W-DB5@;!J6DIQ_BG\N_S2_3))K@5-
M@>=*=S:7'V<RH>!DTEXQFFSI#,YNE#5^\ ^#R0&5UP D'ZRF-_;[:&''*X;
MJ(FS'S&\G\Y69=@R>[E1RJ7Q3&'#07S8Y@+WP*7+1I.*3D:#+<6Q= [,T416
MSA^M"]1A55K[U/XP\;,(@OLPZ<;<E[A6?PQG\P>U1B?G-XO<^B? 2GYXI(!G
M2&40 KE <RGU9)'+J95>8AIQ2"&F;AF! Q-:.1>LHGW0$@(:V,%[J^+33790
MUR['_.R''8VS"P'R^P?\V\6E!P>5&NR1<<DCSJ)$UN6^L]@P$;F-F):NKCX4
M+Y7S52H;+BT I(6%LL^ >Q1$_+Q^;YV#1/-+YP1F5GI$EQ5%9&+("A,0G)K$
M"$\UM<7C&?U(K7RWUK!]7DB]+:"XKY3/OR\3_,\7W^+L]@B=OXWK7SY,5N*Z
MQ#:*P)5'D2J+N/82:44-8B:ZE"R3,I8NPS8P2Y5#>R]T\Q\ +B]Y]3SL4O#
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MKR@S.$[VE8WKK;06:KHOUW!0CBL.5"8?@&CN"3*4*<0"=SIH'8(L4>7YN!8
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M(320C)MPBS8%M?+NF$S$"PX[KF.P"Q-BD*5<(&&-QQISGG3I>JU;":G8K&H
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MER[2DH/Y^A8HMTPA 8.9G$+.DQ(2:6L3 F\).QHY=KY$Y8>=!-0[+4[7Z5.
MG"C@VF[G.JBX]*;7OX<U9^M]T3CJG+4:*0^&%!<)7*N@'%+&"0PN4+*J6W[/
MP:FJ ^-474X'$VPC,%D%6[:S@[G//1XI<))S,'7(I>)H0EYJ104A*78L!7)X
MKGIFQW! *27:VDC9<R!_O$O5C<P*091'0D00EDL<.><="@"%J'G,96I/S1G\
M>-2+,O%RK)-AQ%P;-[<QM_?3V9OI&/ZZ?HUYR2EP$8A!+"JPRX.EX(N!5T99
M]%8JHBC!G;"R:X8VTP)[:G%:6J2U<?& \A_Q05AXU5<-I';NQJ,KNPH&;P1P
M+[&50H)#B$SD^?&:)<AH%Y$GX" *I@+MO,_TIZ+-U)X"^'HVU=3&X-ED<F/'
MMQ9=O.-!J\",T :))#3PP"*<^9(CK8UBVH,YH+NE4>R8H,V8>@'DE!!H;5#<
M=C#=,-GFERG1Z(DDB)K<F#HJB8SW8 D*"]LMYS3Y;AV^=\W09KBE "R*B+0V
M+K[$_]R,9EMN$R\ULP9\.X*B=!BXX"H7K0#_3Q,#(K%*Z=0)&#NG:-/4+8",
M,D)M()7T@4VVRED ^5S:P)+1P(,VN;,<3^#?19%09+GFNB!&J](/R+;1T0D]
M\F6AIYC<&WW=N>S7 GODLOWKF0=++)>:Z_^N<^]X)5YT=B>XT%O.QQ-.PI<X
MMHL8UE./'M0=CUP(PYQ%A@$2N 6WW.0'#<PSSR.A7G1+F3BVS5 7XLJ5!]HQ
MY9OI_+:ZC53"::5@'?A\$Z:,@M.6<\2)-G#T*L=CZ>9=1Y!7-T%X&#3MKA%4
M5EL-'("/&,IL+)F:Q]F/U74,Y=9@%@0*)N7N(AK#[@PN@(^1<7 &9&"#]/K:
M35(K!8$*0V%;XZ]">FD 9JLG)H^8N@W4>ZZ44 %)EG+I. )6!+.YE)>/%)Q-
M+U/IJBP[B6EH+SM5Y5O??9TJ_P: =-=B,?Z(,SOQMTDG0C@1= #K,^9J(]@!
M&P9<4FT=YH$%)TWI+ML[2&GA+=?)BM[5V/($J=<.!"P;*.;66G$R7ZEC$GZ;
M3F[F[_[*']VR9*Q(Q'(#:XMZ<&!U=D*,1)E3X(EB9KK%J+O-5_<U2UFT#"7F
M!K:=54VKKZ"994C]8_X'F;>\+T<NX92/&D6<\UN]%\@J2Y (S!A8 E+Q5'CK
MV4-.*\7KAC6/2NFC76BMUZ'@ED6L#+(4@Y"P5<CY:!'.-6\9X]ZJTO;W7H+J
MGF[%U-X-3CUTT "@LLT(!'R#1?<6SNOQ]/NR[O>C[1?CY*CU$7B 'UPPDUDB
M2&HFG18)/.(!8BN'R&H27'U \-29*ZJ1!D#VCS@!2W"<7S^'Z]%DE*,L^=[Y
M,5/>Q<1QI,CKQ',6%ISW FOD@TS&\N#"WNY#?6#6B;"ZA^1P0"NOE0:@ML<O
MOK^,R 4IL,R-6W0PB)L8D#$$I.9!:I0&CDUI(ZP+7:W4?*T6K.JGH=90]UAB
MM_?BGZ?ST3*;YMUX!*LM__ESG(VF85TQ^9)KSH7GN80*IXA+<(^-@*4,VSS5
M+%J2-GW)H6XPCB&[V2A83RSM ^LS*+8U++_Y9F=7^;;5:4H(U;DM%<@PB,R#
MTF!P)&R9\-X7+X>]C8ZZ1_'SHJV/Z%N#SUHZERY7?[<\Y=Y "HP(<+=<=!)1
M;VC4BKNH2W<9WT9'W0/V>>'31_2-YDE\C5?9]/TP2=/9]4I=(2SW7#M^\.$)
MF1-'SE BE^(4I@IE5ZQ)^!*_3V<Y9^?N^MMZ$[5T$5&*P:@+S"$+GB;RC F'
M'36VVSOT8Y((=M!R<E>']2E]_CUF[V9RM9YH?DD$T6#%1B0$Y;F@)D$VY: R
M]4G9$'7$I9V G<14OJ8N@8,GO1V*"+Z! ^V6D95XLOMSQXG&D1OB<J'>54W6
MB)R4&O'D!)=&:$<[U</N :&GU%2.Y0^)H1-%WP"(WD:8V8]N[[C.KK.4_M_J
M18\ R'MG.&(N9S(J<!*<L@HL *:Y3Y*!MUT817O(J1R$& )&I83_8LRC]_"%
M"3 \F'6T;X)AC*/.+ UM&XFHD@#,H."4RXDU#@ST$!!6'IPQ[A2)Q1LP#F0;
MW4?\-F=X(.3??J[_N(K\X42BQW+9J"< ^T+G4O4>86*T52(*C$M'J7J0V:@]
M=0QV=J>5#J.L!@[)NTN.WV[FX!#/Y[>G_?+*%KSB*)-,R!F"8:=F"FEO,8K$
M"!:X2MZ7OMS>2U KJ:4#P6$3?L5TTP+05K2O[]"<-H8&HQ'.#UFY<@%I":M2
M$D*P5\ 8*_V"YQ$!E8%43K&;D.DMY=K9?T_\C=N:M)2;Q$5 20:V+)6,M/81
M*1V#S\%8L_G(9.<CP*T3-'%L]='7M+#PVJB_];C6%-$6_ ]%$0D^(0XN"'B<
MP(XC05"+F8Z\TS8Q5(VV9TC3&_:H*2+Y-I"SI<:0(RQ:+B0"H.<'D)(C1Q5#
M*BBM,+'6*%H./LU7;CM*IYTJMQTCX-H'S-F7/[@BMQLC3C:Z!,N$2/CA8,\U
M4CCDDI,D<(UM[%9SX.&HU=5]JH:F)<35@)X)IK?5::E2) '&A9<XI\IPI(F5
M*,+VJ 1)SNEN73 >CMIB.;53]-Q/7 WHF1FV)EQ'9BPX^D@8DU\K $H=>/Y(
M)&M9PO WWEG/=Z/6"<L.I^=^XFI SQK+->&62@Y[44*:.2#<Y,Q(JCQ2^8TP
M3YJES:2&W7J^&[5.?9CA]-Q/7 WH&;R<V]Y,7IJ@@T<^"9S[4Q!D$L7(BB@5
MUUH)0SOOV[>CUJGV,N"^W4M<#>A9R5N BL2((3G)V>981W9[+<OLZ\1-9(P^
MB0/MUO/=J'7JL@RGYW[BJJWG\\6W. .!7,WL]6UGF&"4L5I;A(U28%]8CJQW
MN1FJ5))&J;WLUE%VR^"=M*Y>B-9/%5X[ =]M@8N/=ZEW3"3A%6<HL@@N*28B
M5]8T2.2BSB'HJ'SQJZT.=+7R*N"9[AE*:ZH!]'V)/^+D)LXO?<"Y$6I$)I*(
M.-<,Z20XRNX,CC3 GEGZ[OAV[B9"RP6U^B3UM8>(>T/C1YRY:3%P^.G$C\:K
M])3W(+K;M31=V/'\8OIF.IE/QZ.P+%5T>Y.LDS%168:DRTY3SA6V8((A(JPE
ME/O ;:<^$$<AJ0>A;26E#0"[H957VW+:^QIU;11\_1[]*(W\I0[2&TUS5WF1
M'X-%AEP">8:HI28V.BU<)Y/JF%EKOT :' '3YU!'TSC[-)UL\N8=]088 +>2
MPZK-2]=Y:U ,D@KE#7<=.U8<.7'M%TCMH.U$I31@EWW,!=#O'_6M^;JT,0KN
MN4=.X]Q%C@$_AFDDL3#,:R85*?WZ83LEM9\K/1?6"NJC"9-NZ3#O73N70@K+
ME(M@=*3LC%N+G!(488YI5$D#:Z5SC@Y35;=M\//CK;">&MC1]C,3B7;4"I"0
MDOFFQ8J<@4,1X\)XR;E2F\7MAZWC4B<&7@]OY;33'VJ9M^>HZ7*I"/9"8X>\
M%B*'APUR660,/G?@A1O7+5VJ7#67.J'X>G KJ:$FSM5-=WZY?V<G_NQZ>C-9
M7"9%->;>(V-X $/!2:2)BDC&!(PEQGSQ_>T 277N >I!KJ2&&CA.5[67+NQ?
MZR7S&ZRH-%I<!N^2$T8C<*ES)5/+D=%)(0H<!!P)$V&8.GM/2.D$,/UZ %9"
M(TWL91\F/^)\L7KDEEGZ, '8PB>77#(:<@$(;O,/$6"Q!&P0!:O 4BVU*_Z^
M;!<M;3T%+1Z\+:*")L#T*:Y9^#B=SR]%(IYP+E%0\(,;CX'\!(+A@7,=!4ZT
MM.7UB("Z;N3@L.DO[/KOAY=CSZ/_KZOIC_^./JR&/_O3SL)%+EYU]78T]^/I
M_&:V0?2VA\*/4/-PT!5@?+C'R?89CGPIW)OX$Y\$PU27JUFNEU/<P:BW.':/
MV',C>#C@/R??1WG0"V#[-_CCOXN0^734*M<N!W5QNUH[2:2BB?F(OKCX-@V%
M];4Q9I5KBW[:VBZ-1G3U&:9=S*XGX?W87A71U.,1JYA<O?2T51*-:"FO^#>3
M>9B54]/&D%5LG-Z[WU-9-**H_S7]\YZ^LCO@CJ&KQ)Q[*6Z_;"HK\.Y,'5W'
ML&Q2?OW]#SL^>;GM&[=*_/8HU7602@L+;_X&S.1X,;TC-Z=M%EQ]!\:O$A0]
M?@EVDU*S^AQ(C74BCH6TUXC2/DS"Z,<HW-CQ\G7_*8K:&*JN4[9?YM-# JB]
ME,;C>[IN'W*<M(BV#5A-0SMD/NTF@ 9N8U;K'[Y\8-'T"6 ^'KNNL]QI%>T5
M2@/*^OH-F/W-SG.M_ ?MW68S.[E:EAN:__;S_COK#M]+9NXYFH3/8SOY9*_C
MNH1%X;O;(4BLFHR\'0R;=[0#:J8!X-UUG\RM!<^_9]X.;N4G-?1\,D_=ES9#
M:G=7H\]=HFX #DO:SK[?%X#],KKZMIA_/?OR=1!8')ZO[HN89X1'9]'7MONV
M';I@"&4.RSM1MP-W@8$9S,;H[49MR*4%U?T^";/QSZNOT=_,1HM1G)]=+T[7
MV]91.VWMN+[6]HFD!96]^VOF/\]&OL#ZNA^JDW(:N)%\PGP+&OD'G "+MW81
MW]O1[ \[OBF@FBUC=M)1 _>0N\5165F/5_;/?_Y[L832FV^3J\_^M&WOP-"=
M5%?W:K*;<%I-PWDW6]X7#)2"\W3T(NDW!X@ND'J3DTQ_Q-G/\_1DKB=@Z(7[
M3A.<L&37H]Y.<WIP?NN U>**Q^CGX6+=)Y;*FVQNI+:NBIW/@).#]-O&JZ:O
MO7*?=A+"W_KZ9!#KI*M2?EV<_+HX.4HWGZ:33W%:0BF/1ZIWT;A/UM,#C#=T
MKD08<MDN.#<R@@^+'3!/!JZVJ?6U#+J(J?:6=W6U6#-U<K3I\5#5$D#[:FN[
M*"KKYY:@B1W_G(_F97*;=@Y:+1GT1-M[IW@J:^_KXM^?9_Y\=C&?O9LO1JO7
M.R6SY#M-4"U3M*]6CQ%;90V?WRQ@CX=S?')5<"O=/6JUU-&^NCPHH'8.P$_3
MQ;_BW4D=2Z5Q=YF@6B9I@</RH-@J:_@]##J=Q%M.2UR([ABR6D9I7RWN%TU;
M>GM[$R^FZ]?RP&=^#>N7IO6IF^TQ\U2[["ZDX2Y";%#M?XRFXZ68S]/_FE['
M-[D&Q^SG1_OG$+K?.UF]B_.2".@BSP9A !S_Y\:.<XG&-?47]J]UY8R3DR5Z
M35COJKXD'+K*M2U(P#8VMI,UP1^NO^>:+," &XU'BY]E;+=^,];+#2@$BN,D
MVXX'5M+$VS-LO02" DY8F[;>%@(+^]&;PW928E.QKL,R:NA68!KGX!=^B?^Y
M&<WN]I4RF_(1TW12<E.AK^-EV&H6T.<?0V4 /1ZY2/;/'F(+9/Y\MC__F'^.
MLV4!IXF/I1-_NHQ_PKH&X9R>ZW,W2+4+UR.T\'!%;G)?^T+HK^AO<O73-[!-
M7$UG/T].'=D^8CTU;<I[VI'YVH'D\7B3O%$LE$2R>^!ZV5=[53$]3BZ55?<Y
M3@OHZ7Z4FCDEAV4]W<-X_20?(.E3$75LCE7O+?212MDAA%^YBL]YTOS*3_R5
MGWB<;L+_S66BP1\_=7D\'JE:&M6^U;&5V=H*&(_OR"JS-#:'JW>L;Q7WM OO
MM95R=;58OEJ:S"=_6%B\7V^NKU=QJ_EB<N'&[Z>SL^]C-_[7K(3.CIZMIJ6V
M2V/3 N)K0.V99F!Q_O6'?S-?%-+NUD%K6G8=E;A/&+6=G])ZZJVC81;:(>E/
MNXFB$2U]GLV**VISS'KKJ8>N=@BD=I3N/XN?9W_.PCR36$!5V\:K5V&YT[:W
M1P2M*&=@<^28>>K%\?:H:9LV7XP-\HBQ=W_Y\1584%^^SQ;A*0NE5VBWZ>H]
MTCQ2YT=+L++J_S5[-PGO<[F+\W3'Q#]FDTSXFQ^S\*]9ODL/DZNS2?A]\F.^
M" 4 T'O2-I;^<?J=EA-V9:QD]^K#9$W_)J6;_("Q\:]9B?.\_ZQM;!J]T7*R
MN"O#Y0]@\.KM8BO>@0_X\QWL"\#D^-FJ&85EX-%;O.WL(F?S\[1FXSPM$7S'
M1F%T])ZTVC//XGM(+V'73F.^)7Q%[R0\/3=7&]_[<5CR]F8Z"?.W,_BE%'(*
MD5#M86D9')551&54O?T1POQ\=K[X-GL'%,X_A_/)'3>?%OGS/^=?TMAGMBX6
MXRR@W-BC%*1*S%_M<6L9/!540>VF.-'FO+B3KS(?CE/MT-EWD;F%T=J!WC6U
M97*EGXY6+]OBM/3+UIZ=O)E^C>/H%S&L,73RBY/M(]:[_^^GK[URJ9U>!J2$
MNURL\Y1&'L9]/RFSU@Z/7F\+[*?+SO*JO6?&./O';'KS_<-\?E-0H_O&K6;[
M]MU'#\NH]H[Z+=?N#W>$EM+BOG&K69Q]=]?#,JJ^%J<7TX4=EWB^MSE6M2HI
MO=?<5EG4U]"97]S8\?CG9SL*A12U;<AJ]5#ZZVN/9&KG5.4K=Z!PZ346VAIW
MC5FMS$E/Q1V036VS\S:A_^S'5;&]<>>@]2J4]+4R#XBG(>TM*7NP0Y14XK:Q
MZY47*:#+/<)J82N]([7XAKISY'J%04[95P\)JGJ>S\UH\3.W-EF)$MR;ZV4+
MM[>C!,1$X+:4=H^<JEZ=D)[J[B?*VF[CQC;SQWQYB"R;OWV;CD'*7Q:E/,GC
MIJI78J1W[*Z/*)O3_Z>X^##QT^M",?1.$]2K-%),U[O%UIR&GP29A]+TGHDZ
M:;RIV%$/,5;6_);M)W.^#GZ547K7.3KINZ7HTY'":VZ1GR^^Q=G ZWO[')U4
MW5+@ZDCAU5[5UMV,[>SC:+XH>-6]>]1.ZFPIG'500+45^'1G.342LF/(3MD*
M+06S]HNF>N3_=O,OK\!#8W?29$NAK(["JGYL;IAPI^IQZX"=E-=2)&.?6&J7
M.LTG<^:HD,*VC==)7RU%'O8(I858<9'V6 \'ZJ2@EL(%V\10_32;GIQS=SM&
M)WVTY,QO,-]&OO#)ZC@V\9&VY&\WF.\XG?S#VN]KPM[&N9^-EO'\0@F/AX?O
MI,26/.GN(JM^+H51ILN..:8_[KDK=8]Y:/1.FFW)J>XLL-K'VF0^^6V2%ODM
M2K%$UAUC=DHN;\F]/B"<ZE?1]\^(RMTY;Q^SD^I:\J</"*?5,O8?)O,1"/-B
M9I<M#&>SG(";R_-O/!@ZL:;]GFF*%+CORD:!:O=/IGH"BYY58W<.>THH\VZX
MWW)+E-/KW&\=L&))U4.Z>!2\W".,VB'G.]).?I2X,50UW>R5]E:M-/1,\6P\
MWK*7E*F[NGO@!G2UIP3K08'\*N%=:PW]*N?]JYSW<1&MQ6Q\$6?7\_-T,0N
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MP#&/8 G!AN+8K!?:91HC+W K48],HR07J!-1LA"N$B),$I=D&&3")^$V2>8
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MP"@5!$N-$LD0;3$JD<*="9@\-%)(KB4Y('V^=K2>DJ;<4 YU:]"XA.M(3QE
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M,D<E%^:^R1,/A:KW\OG4MGLN]C]02P,$%     @ *8H&6YD0KQ&-!   <A(
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MW*C6Q-3JE:+%B @5F2GXMU>7:XP(\#@;*)$SDC+EC*\3MH)!9/-E1%!%.\$
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M-C,P7V-A;"YX;6Q02P$"% ,4    "  IB@9;@A2U58I'  !N.@, %0
M        @ $TJ0$ 87)V;BTR,#(U,#8S,%]D968N>&UL4$L! A0#%     @
M*8H&6X=.)'JB%0( -V@" !0              ( !\? ! &%R=FXM,C R-3 V
M,S!?9S$N:G!G4$L! A0#%     @ *8H&6TCO^B4Y!@  V 8  !0
M     ( !Q08$ &%R=FXM,C R-3 V,S!?9S(N:G!G4$L! A0#%     @ *8H&
M6VQN4)%E5@$ V:D! !0              ( !, T$ &%R=FXM,C R-3 V,S!?
M9S,N:G!G4$L! A0#%     @ *8H&6\BUVDS4_0  818* !4
M ( !QV,% &%R=FXM,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( "F*!EM.
M&AUQS(X  )BU!@ 5              "  <YA!@!A<G9N+3(P,C4P-C,P7W!R
M92YX;6Q02P$"% ,4    "  IB@9;)[L 8B (  "W)P  &@
M@ '-\ 8 87)V;BTR,#(U,#8S,'@Q,'%E>#,Q,2YH=&U02P$"% ,4    "  I
MB@9;#080-R (  !8*   &@              @ $E^08 87)V;BTR,#(U,#8S
M,'@Q,'%E>#,Q,BYH=&U02P$"% ,4    "  IB@9;;:)>L)T$   >$P  &@
M            @ %] 0< 87)V;BTR,#(U,#8S,'@Q,'%E>#,R,2YH=&U02P$"
M% ,4    "  IB@9;F1"O$8T$  !R$@  &@              @ %2!@< 87)V
M;BTR,#(U,#8S,'@Q,'%E>#,R,BYH=&U02P$"% ,4    "  IB@9;A:%P39D!
M  "3"P  '               @ $7"P< 97AH:6)I=#$P,2UI86YS8V]N<W5L
==&EN+FAT;5!+!08     #@ . +H#  #J# <    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>arvn-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2024-08-12</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2024-08-12</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:RemovalOfCombinationTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentOnFirstAnniversaryOfSigningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-07-05</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">arvn:StockCompensationAndBonusExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>arvn:product</measure>
    </unit>
    <unit id="segment">
        <measure>arvn:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001655759</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-83" id="f-402">P6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-84" id="f-403">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-85" id="f-404">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-86" id="f-405">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">73417595</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-31" unitRef="usd">114900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-32" unitRef="usd">100500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-5" id="f-33" unitRef="usd">746300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-5" id="f-34" unitRef="usd">938900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-5" id="f-35" unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-36" unitRef="usd">5700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-3" decimals="-5" id="f-37" unitRef="usd">10600000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-5" id="f-38" unitRef="usd">8000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-5" id="f-39" unitRef="usd">17200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-5" id="f-40" unitRef="usd">14200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-5" id="f-41" unitRef="usd">889500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-5" id="f-42" unitRef="usd">1067300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-43" unitRef="usd">6100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-44" unitRef="usd">7000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-5" id="f-45" unitRef="usd">9300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-5" id="f-46" unitRef="usd">9000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-3" decimals="-5" id="f-47" unitRef="usd">4400000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-4" decimals="-5" id="f-48" unitRef="usd">8100000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:Assets contextRef="c-3" decimals="-5" id="f-49" unitRef="usd">909300000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-5" id="f-50" unitRef="usd">1091400000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-51" unitRef="usd">53100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-52" unitRef="usd">71800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-5" id="f-53" unitRef="usd">102900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-5" id="f-54" unitRef="usd">156200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-5" id="f-55" unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-5" id="f-56" unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-57" unitRef="usd">157800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-58" unitRef="usd">229800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-5" id="f-59" unitRef="usd">134100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-60" unitRef="usd">292000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-5" id="f-61" unitRef="usd">500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-62" unitRef="usd">600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-5" id="f-63" unitRef="usd">7600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-64" unitRef="usd">7300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-5" id="f-65" unitRef="usd">300000000.0</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-5" id="f-66" unitRef="usd">529700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-68" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-70"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-5" id="f-71" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-5" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-5" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-5" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-5" id="f-75" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-5" id="f-76" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-5" id="f-79" unitRef="shares">73200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-5" id="f-80" unitRef="shares">73200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-5" id="f-81" unitRef="shares">68800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-5" id="f-82" unitRef="shares">68800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-5" id="f-83" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-5" id="f-84" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-85" unitRef="usd">-1509900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-86" unitRef="usd">-1531600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-5" id="f-87" unitRef="usd">2118100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-5" id="f-88" unitRef="usd">2092200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-5" id="f-89" unitRef="usd">1000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-5" id="f-90" unitRef="usd">1000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-91" unitRef="usd">609300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-92" unitRef="usd">561700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-5" id="f-93" unitRef="usd">909300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-5" id="f-94" unitRef="usd">1091400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-95" unitRef="usd">22400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-96" unitRef="usd">76500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-97" unitRef="usd">211200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-98" unitRef="usd">101800000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-5" id="f-99" unitRef="usd">68600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-5" id="f-100" unitRef="usd">93700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-101" unitRef="usd">159400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-5" id="f-102" unitRef="usd">178000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-5" id="f-103" unitRef="usd">25300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-5" id="f-104" unitRef="usd">31300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-105" unitRef="usd">51900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-5" id="f-106" unitRef="usd">55600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-5" id="f-107" unitRef="usd">93900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-5" id="f-108" unitRef="usd">125000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-5" id="f-109" unitRef="usd">211300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-5" id="f-110" unitRef="usd">233600000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-5" id="f-111" unitRef="usd">-71500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-5" id="f-112" unitRef="usd">-48500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-113" unitRef="usd">-100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-5" id="f-114" unitRef="usd">-131800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-5" id="f-115" unitRef="usd">-300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-5" id="f-116" unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-117" unitRef="usd">-400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-5" id="f-118" unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-5" id="f-119" unitRef="usd">10300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-6" decimals="-5" id="f-120" unitRef="usd">13600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-121" unitRef="usd">22000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-5" id="f-122" unitRef="usd">27600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-5" id="f-123" unitRef="usd">10000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-5" id="f-124" unitRef="usd">13500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-125" unitRef="usd">21600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-5" id="f-126" unitRef="usd">27500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-5" id="f-127" unitRef="usd">-61500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-5" id="f-128" unitRef="usd">-35000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">21500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-5" id="f-130" unitRef="usd">-104300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-131" unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-5" id="f-132" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-134" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-135" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-5" id="f-136" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-138" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-5" id="f-147" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-5" id="f-148" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-149" unitRef="shares">72800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-150" unitRef="shares">71700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-5" id="f-151" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-5" id="f-152" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-153" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-154" unitRef="shares">71700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-155" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-5" id="f-156" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-157" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-158" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-159" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-5" id="f-160" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-161" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-5" id="f-162" unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-5" id="f-163" unitRef="usd">-61700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-5" id="f-164" unitRef="usd">-34600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-165" unitRef="usd">21700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-5" id="f-166" unitRef="usd">-105300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="-5" id="f-167" unitRef="shares">73000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-5" id="f-168" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-5" id="f-169" unitRef="usd">-1448700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-5" id="f-170" unitRef="usd">2107200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-5" id="f-171" unitRef="usd">1500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-5" id="f-172" unitRef="usd">660100000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-5" id="f-173" unitRef="usd">10400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-5" id="f-174" unitRef="usd">10400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-5" id="f-175" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-176" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-15" decimals="-5" id="f-177" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-5" id="f-178" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-5" id="f-179" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-5" id="f-180" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-181" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-17" decimals="-5" id="f-182" unitRef="shares">73200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-5" id="f-183" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-184" unitRef="usd">-1509900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-185" unitRef="usd">2118100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-5" id="f-186" unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-187" unitRef="usd">609300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-5" id="f-188" unitRef="shares">68300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-5" id="f-189" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-5" id="f-190" unitRef="usd">-1402100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-5" id="f-191" unitRef="usd">2016100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-5" id="f-192" unitRef="usd">-4400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-5" id="f-193" unitRef="usd">609700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-5" id="f-194" unitRef="usd">21600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-5" id="f-195" unitRef="usd">21600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-196" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-5" id="f-197" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-28" decimals="-5" id="f-198" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-26" decimals="-5" id="f-199" unitRef="usd">3500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-6" decimals="-5" id="f-200" unitRef="usd">3500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-29" decimals="-5" id="f-201" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-5" id="f-202" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-203" unitRef="shares">68600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-5" id="f-204" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-205" unitRef="usd">-1437300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-206" unitRef="usd">2041200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-207" unitRef="usd">-3800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-5" id="f-208" unitRef="usd">600200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-35" decimals="-5" id="f-209" unitRef="shares">68800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-5" id="f-210" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-5" id="f-211" unitRef="usd">-1531600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-5" id="f-212" unitRef="usd">2092200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-5" id="f-213" unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-214" unitRef="usd">561700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-5" id="f-215" unitRef="usd">25400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-216" unitRef="usd">25400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="-5" id="f-217" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-218" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-41" decimals="-5" id="f-219" unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-5" id="f-220" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-5" id="f-221" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <arvn:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c-41" decimals="-5" id="f-222" unitRef="shares">3400000</arvn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-17" decimals="-5" id="f-223" unitRef="shares">73200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-5" id="f-224" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-225" unitRef="usd">-1509900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-226" unitRef="usd">2118100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-5" id="f-227" unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-228" unitRef="usd">609300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-229" unitRef="shares">68000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-5" id="f-230" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-5" id="f-231" unitRef="usd">-1332700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-232" unitRef="usd">1995700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-5" id="f-233" unitRef="usd">-3100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-5" id="f-234" unitRef="usd">660000000.0</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-47" decimals="-5" id="f-235" unitRef="usd">40200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-5" id="f-236" unitRef="usd">40200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-5" id="f-237" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-238" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-49" decimals="-5" id="f-239" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-47" decimals="-5" id="f-240" unitRef="usd">5300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-7" decimals="-5" id="f-241" unitRef="usd">5300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-50" decimals="-5" id="f-242" unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-5" id="f-243" unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-244" unitRef="shares">68600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-5" id="f-245" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-246" unitRef="usd">-1437300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-247" unitRef="usd">2041200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-248" unitRef="usd">-3800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-5" id="f-249" unitRef="usd">600200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-250" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-251" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-252" unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-253" unitRef="usd">2400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-5" id="f-254" unitRef="usd">7300000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-5" id="f-255" unitRef="usd">11200000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-5" id="f-256" unitRef="usd">1200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-5" id="f-257" unitRef="usd">1000000.0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-1" decimals="-5" id="f-258" unitRef="usd">3700000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-7" decimals="-5" id="f-259" unitRef="usd">1700000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-260" unitRef="usd">25300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-5" id="f-261" unitRef="usd">40200000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-262" unitRef="usd">-5200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-5" id="f-263" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-5" id="f-264" unitRef="usd">2600000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-7" decimals="-5" id="f-265" unitRef="usd">2800000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-5" id="f-266" unitRef="usd">3100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-5" id="f-267" unitRef="usd">6000000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-5" id="f-268" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-7" decimals="-5" id="f-269" unitRef="usd">3000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-5" id="f-270" unitRef="usd">-17600000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-7" decimals="-5" id="f-271" unitRef="usd">-13900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-272" unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-5" id="f-273" unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-274" unitRef="usd">-211300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-5" id="f-275" unitRef="usd">50000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-276" unitRef="usd">-184300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-5" id="f-277" unitRef="usd">-47200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-5" id="f-278" unitRef="usd">237600000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-5" id="f-279" unitRef="usd">440400000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-280" unitRef="usd">437500000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities contextRef="c-7" decimals="-5" id="f-281" unitRef="usd">326400000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-282" unitRef="usd">1600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-5" id="f-283" unitRef="usd">800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-284" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-7" decimals="-5" id="f-285" unitRef="usd">100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-286" unitRef="usd">198300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-5" id="f-287" unitRef="usd">-114700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-288" unitRef="usd">100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-5" id="f-289" unitRef="usd">300000</us-gaap:RepaymentsOfLongTermDebt>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares contextRef="c-1" decimals="-5" id="f-290" unitRef="usd">500000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares contextRef="c-7" decimals="-5" id="f-291" unitRef="usd">5300000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-292" unitRef="usd">400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-5" id="f-293" unitRef="usd">5000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-294" unitRef="usd">14400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-5" id="f-295" unitRef="usd">-156900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-296" unitRef="usd">100500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-5" id="f-297" unitRef="usd">317200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-298" unitRef="usd">114900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-5" id="f-299" unitRef="usd">160300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-5" id="f-300" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-5" id="f-301" unitRef="usd">1500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-302">Nature of Business and Basis of Presentation&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its subsidiaries (&#x201c;Arvinas&#x201d; or the "Company&#x201d;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2024 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2024, forming part of Arvinas&#x2019; 2024 Annual Report on Form 10-K filed with the SEC on February&#160;11, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $861.2 million as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2024 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2024, forming part of Arvinas&#x2019; 2024 Annual Report on Form 10-K filed with the SEC on February&#160;11, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-304">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-305">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</us-gaap:ConcentrationRiskCreditRisk>
    <arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities contextRef="c-3" decimals="-5" id="f-306" unitRef="usd">861200000</arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-307">Summary of Accounting Pronouncements and Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recently adopted accounting pronouncements that have had a material impact on the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2024, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03, "Disaggregation of Income Statement Expenses," which requires &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disclosures of certain disaggregated income statement expense captions into specified categories within the footnotes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU No. 2024-03 will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2023, the FASB issued ASU No. 2023-09, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes to the Company&#x2019;s significant accounting policies during the six months ended June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;154.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recently adopted accounting pronouncements that have had a material impact on the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2024, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03, "Disaggregation of Income Statement Expenses," which requires &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disclosures of certain disaggregated income statement expense captions into specified categories within the footnotes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU No. 2024-03 will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2023, the FASB issued ASU No. 2023-09, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2023-09 will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-309">Cash, Cash Equivalents and Restricted Cash&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;154.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-310">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June&#160;30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;154.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-312" unitRef="usd">114900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-34" decimals="-5" id="f-313" unitRef="usd">154800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-5" id="f-314" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-34" decimals="-5" id="f-315" unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-316" unitRef="usd">114900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-5" id="f-317" unitRef="usd">160300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-318">Research Collaboration and License Agreements &lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vepdegestrant (ARV-471) Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) (the &#x201c;Vepdegestrant (ARV-471) Collaboration Agreement&#x201d;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#x2019;s proprietary compound vepdegestrant (the &#x201c;Licensed Products&#x201d;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company is eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Pfizer share equally all development costs for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with Accounting Standards Codification ("ASC") 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471) Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Research Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#x201c;Pfizer Research Collaboration Agreement&#x201d;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of June&#160;30, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $3.8&#160;million in non-refundable option payments if Pfizer exercises its option for such target protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also entitled to receive up to $225.0&#160;million in development milestone payments and up to $550.0&#160;million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were no sales-based milestone payments or royalties received through June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis License and Asset Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;luxdegalutamide (ARV-766)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and has all research, development, manufacturing, and commercialization rights with respect to the Company&#x2019;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the &#x201c;HSR Termination&#x201d;). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $150.0&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;luxdegalutamide (ARV-766)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; being met, as well as tiered royalties based on worldwide net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;luxdegalutamide (ARV-766)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, subject to reduction under certain circumstances as provided in the Novartis License Agreement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no development, regulatory or commercial milestone payments, or sales-based royalties received through June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. The Company determined the fair value of the assets sold under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the Novartis Asset Agreement to be $20.0&#160;million, which was recognized at the time of sale as revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and the fair value of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Novartis License Agreement to be $130.0&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis also reimbursed the Company for development costs incurred during the technology transfer period, which was recognized as revenue as costs were incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;luxdegalutamide (ARV-766)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $3.0&#160;million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $3.0&#160;million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis License Agreement and the Novartis Asset Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was amortized as general and administrative expense over the total estimated period of performance under the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis License Agreement and the Novartis Asset Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#x201c;Bayer Collaboration Agreement&#x201d;) setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license. The Company also received an additional $12.0 million from Bayer AG from inception through 2023. These payments were recognized over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was eligible to receive up to $197.5&#160;million in development milestone payments and up to $490.0&#160;million in sales-based milestone payments for all designated target&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; proteins&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restated Genentech Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#x201c;Restated Genentech Agreement&#x201d;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period, which concluded during the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible to receive up to $44.0&#160;million per target protein in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances for the six months ended June&#160;30, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(211.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from new collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;599.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#x2019;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $150.2&#160;million, an increase in operating expenses of $2.6&#160;million, an increase in net income of $147.6&#160;million, and an increase in basic and diluted earnings per share of $2.04 and $2.03, respectively, for the six months ended June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease in revenue and net income of $2.5&#160;million, respectively, and a decrease in basic and diluted earnings per share of $0.03 for the six months ended June&#160;30, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2025 and 2024 and the six months ended June&#160;30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June&#160;30, 2025 totaled $237.0 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-51" decimals="-5" id="f-319" unitRef="usd">650000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-52" decimals="-8" id="f-320" unitRef="usd">1400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-53" decimals="-5" id="f-321" unitRef="usd">400000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-54" decimals="-8" id="f-322" unitRef="usd">1000000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-55" decimals="INF" id="f-323" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators contextRef="c-56" decimals="INF" id="f-324" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <arvn:DirectAndIncrementalCostsIncurredToObtainTheContract contextRef="c-57" decimals="-5" id="f-325" unitRef="usd">12900000</arvn:DirectAndIncrementalCostsIncurredToObtainTheContract>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-58" decimals="-5" id="f-326" unitRef="usd">12900000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ProceedsFromCollaborators contextRef="c-59" decimals="-5" id="f-327" unitRef="usd">28000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-60" decimals="-5" id="f-328" unitRef="usd">3800000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-61" decimals="-5" id="f-329" unitRef="usd">225000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-62" decimals="-5" id="f-330" unitRef="usd">550000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-63" decimals="INF" id="f-331" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerLiability contextRef="c-64" decimals="-5" id="f-332" unitRef="usd">150000000</us-gaap:ContractWithCustomerLiability>
    <arvn:RevenueRemainingPerformanceObligationContingentPayments contextRef="c-64" decimals="-7" id="f-333" unitRef="usd">1010000000.00</arvn:RevenueRemainingPerformanceObligationContingentPayments>
    <us-gaap:ProceedsFromCollaborators contextRef="c-65" decimals="INF" id="f-334" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-66" decimals="-5" id="f-335" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-67" decimals="-5" id="f-336" unitRef="usd">130000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CapitalizedContractCostGross contextRef="c-68" decimals="-5" id="f-337" unitRef="usd">3000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="c-68" decimals="-5" id="f-338" unitRef="usd">3000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-69" decimals="-5" id="f-339" unitRef="usd">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-70" decimals="-5" id="f-340" unitRef="usd">12000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-71" decimals="-5" id="f-341" unitRef="usd">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-72" decimals="-5" id="f-342" unitRef="usd">490000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-73" decimals="INF" id="f-343" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators contextRef="c-74" decimals="INF" id="f-344" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators contextRef="c-75" decimals="-5" id="f-345" unitRef="usd">34500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators contextRef="c-76" decimals="-5" id="f-346" unitRef="usd">11000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-77" decimals="-5" id="f-347" unitRef="usd">44000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-78" decimals="-5" id="f-348" unitRef="usd">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-79" decimals="-5" id="f-349" unitRef="usd">60000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-80" decimals="INF" id="f-350" unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances for the six months ended June&#160;30, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(211.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from new collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;599.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-352" unitRef="usd">5700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-46" decimals="-5" id="f-353" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions contextRef="c-1" decimals="-5" id="f-354" unitRef="usd">100000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions contextRef="c-7" decimals="-5" id="f-355" unitRef="usd">1800000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived contextRef="c-1" decimals="-5" id="f-356" unitRef="usd">5300000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived contextRef="c-7" decimals="-5" id="f-357" unitRef="usd">0</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-5" id="f-358" unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-34" decimals="-5" id="f-359" unitRef="usd">1800000</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-4" decimals="-5" id="f-360" unitRef="usd">5400000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-46" decimals="-5" id="f-361" unitRef="usd">13100000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrentAdditions contextRef="c-1" decimals="-5" id="f-362" unitRef="usd">29500000</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentAdditions contextRef="c-7" decimals="-5" id="f-363" unitRef="usd">29200000</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentPayments contextRef="c-1" decimals="-5" id="f-364" unitRef="usd">24800000</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrentPayments contextRef="c-7" decimals="-5" id="f-365" unitRef="usd">26100000</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-3" decimals="-5" id="f-366" unitRef="usd">10100000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-34" decimals="-5" id="f-367" unitRef="usd">16200000</arvn:AccountsPayableContractBalancesCurrent>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-4" decimals="-5" id="f-368" unitRef="usd">7800000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-46" decimals="-5" id="f-369" unitRef="usd">9400000</us-gaap:ContractWithCustomerAssetNet>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-1" decimals="-5" id="f-370" unitRef="usd">0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-7" decimals="-5" id="f-371" unitRef="usd">3000000.0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod contextRef="c-1" decimals="-5" id="f-372" unitRef="usd">3700000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod contextRef="c-7" decimals="-5" id="f-373" unitRef="usd">1700000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-3" decimals="-5" id="f-374" unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-34" decimals="-5" id="f-375" unitRef="usd">10700000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-5" id="f-376" unitRef="usd">448200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-46" decimals="-5" id="f-377" unitRef="usd">549200000</us-gaap:ContractWithCustomerLiability>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-1" decimals="-5" id="f-378" unitRef="usd">0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-7" decimals="-5" id="f-379" unitRef="usd">130000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-380" unitRef="usd">211200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-5" id="f-381" unitRef="usd">56300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration contextRef="c-1" decimals="-5" id="f-382" unitRef="usd">0</arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration contextRef="c-7" decimals="-5" id="f-383" unitRef="usd">-23700000</arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-5" id="f-384" unitRef="usd">237000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-34" decimals="-5" id="f-385" unitRef="usd">599200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues contextRef="c-81" decimals="-5" id="f-386" unitRef="usd">150200000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-81" decimals="-5" id="f-387" unitRef="usd">2600000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss contextRef="c-81" decimals="-5" id="f-388" unitRef="usd">147600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-81"
      decimals="2"
      id="f-389"
      unitRef="usdPerShare">2.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-81"
      decimals="2"
      id="f-390"
      unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues contextRef="c-82" decimals="-5" id="f-391" unitRef="usd">-2500000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-82" decimals="-5" id="f-392" unitRef="usd">-2500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-82"
      decimals="2"
      id="f-393"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-82"
      decimals="2"
      id="f-394"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="c-1" id="f-395">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June&#160;30, 2025 totaled $237.0 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-3" decimals="-5" id="f-396" unitRef="usd">237000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-83" decimals="-5" id="f-397" unitRef="usd">69600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-84" decimals="-5" id="f-398" unitRef="usd">66600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-85" decimals="-5" id="f-399" unitRef="usd">20300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-86" decimals="-5" id="f-400" unitRef="usd">80500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-3" decimals="-5" id="f-401" unitRef="usd">237000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-406">Marketable Securities and Fair Value Measurements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;685.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;686.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;745.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;746.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;934.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;935.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;937.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;938.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;685.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;686.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;745.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;746.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;934.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;935.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;937.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;938.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-87" decimals="-5" id="f-408" unitRef="usd">685600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-87" decimals="-5" id="f-409" unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-5" id="f-410" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-5" id="f-411" unitRef="usd">686600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-88" decimals="-5" id="f-412" unitRef="usd">59700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-88" decimals="-5" id="f-413" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-5" id="f-414" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-5" id="f-415" unitRef="usd">59700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-89" decimals="-5" id="f-416" unitRef="usd">745300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-5" id="f-417" unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-5" id="f-418" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-5" id="f-419" unitRef="usd">746300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="-5" id="f-420" unitRef="usd">934400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="-5" id="f-421" unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-5" id="f-422" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-5" id="f-423" unitRef="usd">935400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-91" decimals="-5" id="f-424" unitRef="usd">3500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-91" decimals="-5" id="f-425" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-91" decimals="-5" id="f-426" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-5" id="f-427" unitRef="usd">3500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="-5" id="f-428" unitRef="usd">937900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="-5" id="f-429" unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="-5" id="f-430" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-5" id="f-431" unitRef="usd">938900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-432">Property, Equipment and Leasehold Improvements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $0.8 million and $1.2 million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $1.5 million and $2.4 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-433">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-93" decimals="-5" id="f-434" unitRef="usd">20800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-94" decimals="-5" id="f-435" unitRef="usd">20600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-5" id="f-436" unitRef="usd">9000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-5" id="f-437" unitRef="usd">9300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-5" id="f-438" unitRef="usd">3000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-5" id="f-439" unitRef="usd">2700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-5" id="f-440" unitRef="usd">32800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-441" unitRef="usd">32600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-5" id="f-442" unitRef="usd">26700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-443" unitRef="usd">25600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-444" unitRef="usd">6100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-445" unitRef="usd">7000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-5" id="f-446" unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-5" id="f-447" unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-448" unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-449" unitRef="usd">2400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-450">Right-of-Use Assets and Liabilities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at June&#160;30, 2025 totaled 6.9%. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than December 2029. The leases have a weighted average remaining term of approximately 4.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment, and in February 2025, the Company entered into a Ninth Amendment to its lease (collectively the &#x201c;Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#x201c;Building 5 Premises&#x201d;). The Building 5 Lease Amendments extended the term of the original lease to December 31, 2029, and expanded the Building 5 Premises to include approximately 10,900 square feet of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additional laboratory and office space in the first quarter of 2025, resulting in an increase in the Company's ROU assets of $1.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of June&#160;30, 2025, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments contextRef="c-99" decimals="3" id="f-451" unitRef="number">0.069</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-452">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-5" id="f-454" unitRef="usd">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-5" id="f-455" unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-456" unitRef="usd">1500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-5" id="f-457" unitRef="usd">1000000.0</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-459" unitRef="usd">1000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-5" id="f-460" unitRef="usd">1000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-100" decimals="-5" id="f-461" unitRef="usd">1500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-5" id="f-462" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-12" decimals="-2" id="f-463" unitRef="sqft">10900</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-100" decimals="-5" id="f-464" unitRef="usd">1500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of June&#160;30, 2025, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-5" id="f-466" unitRef="usd">1300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-5" id="f-467" unitRef="usd">2300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-5" id="f-468" unitRef="usd">2400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-5" id="f-469" unitRef="usd">2500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-5" id="f-470" unitRef="usd">2600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-5" id="f-471" unitRef="usd">11100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-5" id="f-472" unitRef="usd">1700000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-5" id="f-473" unitRef="usd">9400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-474">Accounts Payable and Accrued Liabilities &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative and commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative and commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-5" id="f-476" unitRef="usd">16600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-5" id="f-477" unitRef="usd">13400000</us-gaap:AccountsPayableCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-3" decimals="-5" id="f-478" unitRef="usd">16200000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-5" id="f-479" unitRef="usd">25900000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-480" unitRef="usd">10500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-481" unitRef="usd">22400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-3" decimals="-5" id="f-482" unitRef="usd">3300000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-5" id="f-483" unitRef="usd">3200000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-5" id="f-484" unitRef="usd">3300000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-5" id="f-485" unitRef="usd">1800000</us-gaap:AccruedProfessionalFeesCurrent>
    <arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent contextRef="c-3" decimals="-5" id="f-486" unitRef="usd">3200000</arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent>
    <arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent contextRef="c-4" decimals="-5" id="f-487" unitRef="usd">5100000</arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-488" unitRef="usd">53100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-489" unitRef="usd">71800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-490">Long-Term Debt&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the 2018 Assistance Agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of June&#160;30, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2025 and 2024, interest expense was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-491">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-3" decimals="INF" id="f-492" unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-5" id="f-493" unitRef="usd">700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-5" id="f-494" unitRef="usd">800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-5" id="f-495" unitRef="usd">200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-5" id="f-496" unitRef="usd">200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-5" id="f-497" unitRef="usd">500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-498" unitRef="usd">600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-101" decimals="-5" id="f-499" unitRef="usd">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:DebtInstrumentLoanForgiveness contextRef="c-102" decimals="-5" id="f-500" unitRef="usd">1000000.0</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-101"
      decimals="INF"
      id="f-501"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm contextRef="c-102" id="f-502">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-101" decimals="-5" id="f-503" unitRef="usd">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="c-102"
      decimals="INF"
      id="f-504"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of June&#160;30, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-5" id="f-506" unitRef="usd">100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-5" id="f-507" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-5" id="f-508" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-3" decimals="-5" id="f-509" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-5" id="f-510" unitRef="usd">700000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-5" id="f-511" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-5" id="f-512" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-5" id="f-513" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-514" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-515">Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company amended and restated the Equity Distribution Agreement with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Piper Sandler &amp;amp; Company (&#x201c;Piper Sandler&#x201d;) and Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as agents,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$262.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the common stock registered under a universal shelf registration statement pursuant to one or more &#x201c;at-the-market&#x201d; offerings. During the six mo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nths &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; June&#160;30, 2025, no shares were issued under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#x201c;2018 ESPP&#x201d;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#x2019;s common stock. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1 of each year. As of June&#160;30, 2025, 3,601,429 shares remained available for purchase. During the six months ended June&#160;30, 2025 and 2024, the Company issued 86,008 and 34,515 shares of common stock, respectively, under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s stockholders approved, the 2018 Stock Incentive Plan (the &#x201c;2018 Plan&#x201d;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Fourth Amendment to the Company&#x2019;s Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#x2019;s common stock, 4% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the year or an amount determined by the Company&#x2019;s board of directors. As of June&#160;30, 2025, 1,855,723 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the strategic restructuring plan initiated by the Company in the second quarter of 2025, as further discussed below in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Activity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company modified the vesting terms of certain Restricted Stock Units previously granted to employees. The incremental impact of the modification was fully recognized during the three and six months ended June&#160;30, 2025 as a decrease to compensation expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $1.7&#160;million. There were no remaining unrecognized compensation expenses related to the modified awards at June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $10.4 million and $21.6 million, respectively, related to the issuance of incentive awards, including $0.2 million related to the 2018 ESPP in each period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2025 and 2024, the Company recognized compensation expense of $25.4 million and $40.2 million, respectively, relating to the issuance of incentive awards, including $0.4 million related to the 2018 ESPP in each period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, there was $60.5 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the six months ended June&#160;30, 2025 and 2024 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.1 - 80.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.9 - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.5 - 5.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9% - 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.61 - $17.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$24.94 - $47.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,892,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,165,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(503,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,553,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Vested and exercisable &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,195,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Vested and expected to vest &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of options granted during the six months ended June&#160;30, 2025 and 2024 was $12.54 and $28.08, respectively. There were no options exercised during the six months ended June&#160;30, 2025. The total intrinsic value of options exercised during the six months ended June&#160;30, 2024 was $3.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units ("RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,382,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(911,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(628,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,153,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of RSUs granted during the six months ended June&#160;30, 2025 and 2024 was $13.98 and $44.98, respectively. The total intrinsic value of RSUs released during the six months ended June&#160;30, 2025 and 2024 was $14.9 million and $11.4 million, respectively. The total fair value of RSUs vested during the six months ended June&#160;30, 2025 and 2024 was $42.4 million and $10.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <arvn:MaximumAggregateOfferingPriceOfCommonStock contextRef="c-103" decimals="-5" id="f-516" unitRef="usd">262800000</arvn:MaximumAggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-104"
      decimals="INF"
      id="f-517"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-105"
      decimals="INF"
      id="f-518"
      unitRef="shares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock contextRef="c-106" decimals="2" id="f-519" unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-107"
      decimals="INF"
      id="f-520"
      unitRef="shares">3601429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-108"
      decimals="INF"
      id="f-521"
      unitRef="shares">86008</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-109"
      decimals="INF"
      id="f-522"
      unitRef="shares">34515</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-110"
      decimals="INF"
      id="f-523"
      unitRef="shares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-111"
      decimals="INF"
      id="f-524"
      unitRef="shares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="c-112"
      decimals="INF"
      id="f-525"
      unitRef="shares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-113" decimals="2" id="f-526" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-114"
      decimals="INF"
      id="f-527"
      unitRef="shares">1855723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-1" decimals="-5" id="f-528" unitRef="usd">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-5" decimals="-5" id="f-529" unitRef="usd">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-5" id="f-530" unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-5" id="f-531" unitRef="usd">21600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-5" id="f-532" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-5" id="f-533" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-534" unitRef="usd">25400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-5" id="f-535" unitRef="usd">40200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-5" id="f-536" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-537" unitRef="usd">60500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-118" id="f-538">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the six months ended June&#160;30, 2025 and 2024 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.1 - 80.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.9 - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.5 - 5.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9% - 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.61 - $17.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$24.94 - $47.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-119" decimals="3" id="f-540" unitRef="number">0.721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-119" decimals="3" id="f-541" unitRef="number">0.801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-120" decimals="3" id="f-542" unitRef="number">0.729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-120" decimals="3" id="f-543" unitRef="number">0.756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-121" id="f-544">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-122" id="f-545">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-123" id="f-546">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-124" id="f-547">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-119" decimals="3" id="f-548" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-119" decimals="3" id="f-549" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-120" decimals="3" id="f-550" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-120" decimals="3" id="f-551" unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-119" decimals="2" id="f-552" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-120" decimals="2" id="f-553" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-126"
      decimals="2"
      id="f-555"
      unitRef="usdPerShare">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">24.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-128"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">47.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-558">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,892,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,165,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(503,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,553,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Vested and exercisable &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,195,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Vested and expected to vest &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants contextRef="c-1" decimals="INF" id="f-559" unitRef="shares">255611</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-129"
      decimals="INF"
      id="f-560"
      unitRef="shares">7892330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-129"
      decimals="2"
      id="f-561"
      unitRef="usdPerShare">44.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-130" id="f-562">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-129" decimals="-5" id="f-563" unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-131"
      decimals="INF"
      id="f-564"
      unitRef="shares">2165498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-131"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">12.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-131"
      decimals="INF"
      id="f-566"
      unitRef="shares">503870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-131"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">44.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-114"
      decimals="INF"
      id="f-568"
      unitRef="shares">9553958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-114"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">37.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-131" id="f-570">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-114" decimals="-5" id="f-571" unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-114"
      decimals="INF"
      id="f-572"
      unitRef="shares">6195452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-114"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">45.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-131" id="f-574">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-114" decimals="-5" id="f-575" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-114"
      decimals="INF"
      id="f-576"
      unitRef="shares">9212437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-114"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">37.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-131" id="f-578">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-114" decimals="-5" id="f-579" unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">12.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">28.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-582" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-7" decimals="-5" id="f-583" unitRef="usd">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity during the six months ended June&#160;30, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,382,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(911,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(628,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,153,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants
      contextRef="c-132"
      decimals="INF"
      id="f-585"
      unitRef="shares">170365</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-133"
      decimals="INF"
      id="f-586"
      unitRef="shares">2311291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-133"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">42.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-134"
      decimals="INF"
      id="f-588"
      unitRef="shares">3382825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-134"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-134"
      decimals="INF"
      id="f-590"
      unitRef="shares">911874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-134"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">43.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-134"
      decimals="INF"
      id="f-592"
      unitRef="shares">628701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-134"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">26.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-135"
      decimals="INF"
      id="f-594"
      unitRef="shares">4153541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-135"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">21.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-132"
      decimals="2"
      id="f-596"
      unitRef="usdPerShare">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-136"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">44.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod contextRef="c-132" decimals="-5" id="f-598" unitRef="usd">14900000</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod contextRef="c-136" decimals="-5" id="f-599" unitRef="usd">11400000</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-132" decimals="-5" id="f-600" unitRef="usd">42400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-136" decimals="-5" id="f-601" unitRef="usd">10200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-602">Income Taxes &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2025, the Company recognized income tax benefit of $0.3 million, resulting in an effective tax rate of 0.6%, as compared to income tax expense of $0.2 million, resulting in an effective tax rate of (0.6)%, in the same period for 2024. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June&#160;30, 2025 and the Company&#x2019;s overall effective tax rate of 0.6% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June&#160;30, 2024 and the Company&#x2019;s overall effective tax rate of (0.6)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June&#160;30, 2025, the Company recognized income tax benefit of $0.2 million, resulting in an effective tax rate of (0.9)%, as compared to income tax expense of $0.3 million resulting in an effective tax rate of (0.3)% in the same period for 2024. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June&#160;30, 2025 and the Company&#x2019;s overall effective tax rate of (0.9)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June&#160;30, 2024 and the Company&#x2019;s overall effective tax rate of (0.3)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the &#x201c;One Big Beautiful Bill Act&#x201d; (the &#x201c;OBBB Act&#x201d;) was enacted into law. The OBBB Act includes changes to U.S. tax with multiple effective dates starting in 2025. These changes include provisions allowing accelerated tax deductions for qualified property and research expenditures. Although the Company does not expect the OBBB Act to have a material impact on its estimated annual effective tax rate in 2025, it continues to assess the impact of the OBBB Act on subsequent periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-603" unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-604" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-5" id="f-605" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-606" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="INF" id="f-607" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-608" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="INF" id="f-609" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-610" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-611" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-612" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-613" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-614" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-615" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-616" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="INF" id="f-617" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-618" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-619">(Loss) Earnings Per Common Share &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) earnings per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Denominator adjustments for diluted EPS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Number of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Denominator adjustments for diluted EPS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(Loss) earnings per common share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and six months ended June&#160;30, 2024 gives effect to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pre-funded warrants issued in November 2023 which allowed holders to acquire up &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,422,380 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock at a nominal exercise price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share. As of June&#160;30, 2025, all outstanding&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pre-funded warrants had been cashless exercised for no consideration and the Company issued 3,422,186 shares of common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss for the three months ended June&#160;30, 2025 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss for the three and six months ended June&#160;30, 2024 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three and Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted (loss) earnings per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Denominator adjustments for diluted EPS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Number of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Denominator adjustments for diluted EPS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(Loss) earnings per common share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-621" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-5" id="f-622" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-623" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-624" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-5" id="f-625" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-5" id="f-626" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-627" unitRef="shares">72800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-628" unitRef="shares">71700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-5" id="f-629" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-6" decimals="-5" id="f-630" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-631" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="-5" id="f-632" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="-5" id="f-633" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-6" decimals="-5" id="f-634" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-5" id="f-635" unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-7" decimals="-5" id="f-636" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-5" id="f-637" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-5" id="f-638" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-639" unitRef="shares">73000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-640" unitRef="shares">71700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-641"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-642"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-643"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-644"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-645"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-646"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-137"
      decimals="INF"
      id="f-649"
      unitRef="shares">3422380</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-137"
      decimals="INF"
      id="f-650"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c-138"
      decimals="INF"
      id="f-651"
      unitRef="shares">3422186</arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-652">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss for the three months ended June&#160;30, 2025 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss for the three and six months ended June&#160;30, 2024 and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three and Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-139"
      decimals="-5"
      id="f-653"
      unitRef="shares">9600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-140"
      decimals="-5"
      id="f-654"
      unitRef="shares">4200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-655" unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-141"
      decimals="-5"
      id="f-656"
      unitRef="shares">8300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-142"
      decimals="-5"
      id="f-657"
      unitRef="shares">8300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-143"
      decimals="-5"
      id="f-658"
      unitRef="shares">2400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-144"
      decimals="-5"
      id="f-659"
      unitRef="shares">2400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-5" id="f-660" unitRef="shares">10700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-5" id="f-661" unitRef="shares">10700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-662">Equity Method Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company and Bayer CropScience LP (&#x201c;Bayer LP&#x201d;) formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 43.4% and 44.5% as of June&#160;30, 2025 and 2024, respectively, as a result of vested incentive units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss of Oerth Bio for the three months ended June&#160;30, 2025 and 2024 totaled $0.7 million&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $0.8 million, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net lo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ss of Oerth Bio for the six months ended June&#160;30, 2025 and 2024 totaled $0.2 million and $1.5 million, res&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carrying value of t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he investment was zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and six months ended June&#160;30, 2025 and 2024 were immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-145" decimals="2" id="f-663" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage contextRef="c-146" decimals="2" id="f-664" unitRef="number">0.15</arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-147" decimals="3" id="f-665" unitRef="number">0.434</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-148" decimals="3" id="f-666" unitRef="number">0.445</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NetIncomeLoss contextRef="c-149" decimals="-5" id="f-667" unitRef="usd">-700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-150" decimals="-5" id="f-668" unitRef="usd">-800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-151" decimals="-5" id="f-669" unitRef="usd">-200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-152" decimals="-5" id="f-670" unitRef="usd">-1500000</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestments contextRef="c-153" decimals="INF" id="f-671" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-154" decimals="INF" id="f-672" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-673">Commitments and Contingencies&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical and Preclinical Development and Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Yale University License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Company entered into an Amended and Restated License Agreement (the &#x201c;Amended License Agreement&#x201d;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95&#160;million to Yale in June 2024, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research Collaboration and License Agreements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Company made another $5.0&#160;million payment to Yale in June 2025 on the first anniversary of signing, which was included in the company's accounts payable and accrued liabilities as of June 30, 2024. Thereafter, the Company will also pay to Yale (1) up to $15.0&#160;million if it secures approval of the first and second royalty products (as defined in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#x201c;collaboration products,&#x201d; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#x201c;meaningfully involved products.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirement to pay to Yale a minimum license maintenance royalty totaling $0.1&#160;million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2&#160;million to $0.5&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <arvn:PaymentsForCollaboration contextRef="c-155" decimals="-4" id="f-674" unitRef="usd">14950000</arvn:PaymentsForCollaboration>
    <arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-156" decimals="-5" id="f-675" unitRef="usd">5000000</arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-157" decimals="-5" id="f-676" unitRef="usd">15000000</arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <arvn:AnnualLicenseFeePayment contextRef="c-158" decimals="-5" id="f-677" unitRef="usd">100000</arvn:AnnualLicenseFeePayment>
    <arvn:NumberOfLicensedProducts
      contextRef="c-159"
      decimals="INF"
      id="f-678"
      unitRef="product">2</arvn:NumberOfLicensedProducts>
    <arvn:RequiredMilestonePayments contextRef="c-160" decimals="-5" id="f-679" unitRef="usd">3000000</arvn:RequiredMilestonePayments>
    <arvn:RequiredMilestonePayments contextRef="c-161" decimals="-5" id="f-680" unitRef="usd">1500000</arvn:RequiredMilestonePayments>
    <us-gaap:PaymentsForRoyalties contextRef="c-158" decimals="-5" id="f-681" unitRef="usd">200000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-162" decimals="-5" id="f-682" unitRef="usd">500000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-683">Restructuring Activity&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#x2019;s workforce by approximately 33% across all areas of the Company, as part of the Company&#x2019;s decision to streamline operations across the organization and enable the efficient progression of the Company&#x2019;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, the restructuring activities were substantially completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Components of Restructuring Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company recognized restructuring charges of $1.0&#160;million, including $7.4&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, offset by a reversal of $6.4&#160;million of non-cash stock compensation and bonus expenses, of which $0.6&#160;million is reflected in research and development expenses and $0.4&#160;million is reflected in general and administrative expenses in the accompanying unaudited condensed consolidated financial statements. The Company's restructuring accrual totaled $2.2&#160;million as of June 30, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-5" decimals="2" id="f-684" unitRef="number">0.33</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges contextRef="c-5" decimals="-5" id="f-685" unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-163" decimals="-5" id="f-686" unitRef="usd">7400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-164" decimals="-5" id="f-687" unitRef="usd">-6400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-165" decimals="-5" id="f-688" unitRef="usd">600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-5" id="f-689" unitRef="usd">400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-3" decimals="-5" id="f-690" unitRef="usd">2200000</us-gaap:RestructuringReserve>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-691">Segment Information&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations are organized into one operating and reportable segment focused on &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the discovery, development and commercialization of therapies that degrade disease-causing proteins. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ARV-806, targeting Kirsten rat sarcoma, or KRAS, G12D for mutated cancers, including pancreatic and colorectal cancers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also generated revenue through the sale of assets based on fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have intra-entity sales or transfers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the operating segment are the same as those described in the Company's &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual Report on Form 10-K for the year ended December&#160;31, 2024 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Note 2,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Summary of Accounting Pronouncements and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as net income (loss). The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the reportable segment's financial information: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vepdegestrant (ARV-471) (*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-806 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bavdegalutamide (ARV-110)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Luxdegalutamide (ARV-766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non program-specific external expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Compensation and related personnel expense&lt;br/&gt;(including stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;178.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other segment expense, net (**)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Plus:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(**)&#160;&#160;&#160;&#160;Includes primarily realized foreign exchange gains/ losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $0.8 million and $1.2 million, respectively. During the six months ended June&#160;30, 2025 and 2024, the Company recognized depreciation and amortization expense of $1.5 million and $2.4 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-692"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-693"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-694">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the reportable segment's financial information: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vepdegestrant (ARV-471) (*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-806 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bavdegalutamide (ARV-110)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Luxdegalutamide (ARV-766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non program-specific external expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Compensation and related personnel expense&lt;br/&gt;(including stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;178.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other segment expense, net (**)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Plus:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(**)&#160;&#160;&#160;&#160;Includes primarily realized foreign exchange gains/ losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-167" decimals="-5" id="f-695" unitRef="usd">22400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-168" decimals="-5" id="f-696" unitRef="usd">76500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-169" decimals="-5" id="f-697" unitRef="usd">211200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-5" id="f-698" unitRef="usd">101800000</us-gaap:Revenues>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-171" decimals="-5" id="f-699" unitRef="usd">15100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-172" decimals="-5" id="f-700" unitRef="usd">25100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-173" decimals="-5" id="f-701" unitRef="usd">39200000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-174" decimals="-5" id="f-702" unitRef="usd">44100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-175" decimals="-5" id="f-703" unitRef="usd">3800000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-176" decimals="-5" id="f-704" unitRef="usd">1700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-177" decimals="-5" id="f-705" unitRef="usd">10300000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-178" decimals="-5" id="f-706" unitRef="usd">3000000.0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-179" decimals="-5" id="f-707" unitRef="usd">2500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-180" decimals="-5" id="f-708" unitRef="usd">1700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-181" decimals="-5" id="f-709" unitRef="usd">5100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-182" decimals="-5" id="f-710" unitRef="usd">2900000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-183" decimals="-5" id="f-711" unitRef="usd">1700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-184" decimals="-5" id="f-712" unitRef="usd">200000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-185" decimals="-5" id="f-713" unitRef="usd">2600000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-186" decimals="-5" id="f-714" unitRef="usd">300000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-187" decimals="-5" id="f-715" unitRef="usd">900000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-188" decimals="-5" id="f-716" unitRef="usd">2500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-189" decimals="-5" id="f-717" unitRef="usd">2000000.0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-190" decimals="-5" id="f-718" unitRef="usd">4100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-191" decimals="-5" id="f-719" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-192" decimals="-5" id="f-720" unitRef="usd">9500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-193" decimals="-5" id="f-721" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-194" decimals="-5" id="f-722" unitRef="usd">13200000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-195" decimals="-5" id="f-723" unitRef="usd">800000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-196" decimals="-5" id="f-724" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-197" decimals="-5" id="f-725" unitRef="usd">2500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-198" decimals="-5" id="f-726" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-167" decimals="-5" id="f-727" unitRef="usd">11100000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-168" decimals="-5" id="f-728" unitRef="usd">13500000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-169" decimals="-5" id="f-729" unitRef="usd">25000000.0</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-170" decimals="-5" id="f-730" unitRef="usd">29600000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <us-gaap:LaborAndRelatedExpense contextRef="c-167" decimals="-5" id="f-731" unitRef="usd">28400000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-168" decimals="-5" id="f-732" unitRef="usd">36300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-169" decimals="-5" id="f-733" unitRef="usd">65300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-170" decimals="-5" id="f-734" unitRef="usd">74600000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-167" decimals="-5" id="f-735" unitRef="usd">4300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-168" decimals="-5" id="f-736" unitRef="usd">3200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-169" decimals="-5" id="f-737" unitRef="usd">7400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-170" decimals="-5" id="f-738" unitRef="usd">6200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-167" decimals="-5" id="f-739" unitRef="usd">68600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-168" decimals="-5" id="f-740" unitRef="usd">93700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-169" decimals="-5" id="f-741" unitRef="usd">159400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-170" decimals="-5" id="f-742" unitRef="usd">178000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-167" decimals="-5" id="f-743" unitRef="usd">25300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-168" decimals="-5" id="f-744" unitRef="usd">31300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-169" decimals="-5" id="f-745" unitRef="usd">51900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-170" decimals="-5" id="f-746" unitRef="usd">55600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-167" decimals="-5" id="f-747" unitRef="usd">300000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-168" decimals="-5" id="f-748" unitRef="usd">100000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-169" decimals="-5" id="f-749" unitRef="usd">400000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-170" decimals="-5" id="f-750" unitRef="usd">100000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-167" decimals="-5" id="f-751" unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-168" decimals="-5" id="f-752" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-169" decimals="-5" id="f-753" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-170" decimals="-5" id="f-754" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:InvestmentIncomeInterest contextRef="c-167" decimals="-5" id="f-755" unitRef="usd">10300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-168" decimals="-5" id="f-756" unitRef="usd">13600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-169" decimals="-5" id="f-757" unitRef="usd">22000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-170" decimals="-5" id="f-758" unitRef="usd">27600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss contextRef="c-167" decimals="-5" id="f-759" unitRef="usd">-61200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-168" decimals="-5" id="f-760" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-169" decimals="-5" id="f-761" unitRef="usd">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-170" decimals="-5" id="f-762" unitRef="usd">-104600000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-5" id="f-763" unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-5" id="f-764" unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-765" unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-766" unitRef="usd">2400000</us-gaap:DepreciationAndAmortization>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-767">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-768">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-769">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-770">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
